<SEC-DOCUMENT>0001193125-21-036239.txt : 20210210
<SEC-HEADER>0001193125-21-036239.hdr.sgml : 20210210
<ACCEPTANCE-DATETIME>20210210160502
ACCESSION NUMBER:		0001193125-21-036239
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		153
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210210
DATE AS OF CHANGE:		20210210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		21613756

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d102112d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:teva="http://www.tevapharm.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 10-K</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2020To12_31_2020">false</ix:nonNumeric><ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" id="hidden17703734" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis">2021-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" id="hidden17703735" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis">2022-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" id="hidden17703736" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis">2023-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" id="hidden17703737" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsNoExpirationMemberusgaapTaxCreditCarryforwardAxis">2030-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" id="hidden17703738" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis">2029-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="hidden17703740" contextRef="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis">2008 2009 2010 2011</ix:nonNumeric><ix:nonNumeric name="teva:CreditTermsToCustomers" id="hidden17702468" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">P30D</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2020To12_31_2020">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2020To12_31_2020">0000818686</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="hidden17704910" contextRef="P01_01_2020To12_31_2020">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressCountry" id="hidden17711877" contextRef="P01_01_2020To12_31_2020">IL</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="PAsOn12_31_2020">us-gaap:OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="PAsOn12_31_2019">us-gaap:OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:footnote id="FN_64427" xml:lang="en-US">Represents an amount less than 0.5 million.</ix:footnote ><ix:footnote id="FN_64429" xml:lang="en-US">Mainly MCPS conversion.</ix:footnote ><ix:footnote id="FN_64453" xml:lang="en-US">Following the adoption of ASU 2016-01, the Company recorded a $ 5 million opening balance reclassification from accumulated other comprehensive income to retained earnings. </ix:footnote ><ix:footnote id="FN_64426" xml:lang="en-US">Mandatory convertible preferred shares.</ix:footnote ><ix:footnote id="FN_64452" xml:lang="en-US">During the third quarter of 2020, Teva recorded a gain of $134 million under share in profits of associated companies, net, reflecting the difference between the book value of Teva&#8217;s investment in American Well and its fair value as of the date it completed its initial public offering in September 2020. The investment was reclassified from &#8220;investment in associated companies&#8221; to &#8220;investment in marketable securities,&#8221; since Teva no longer had significant influence in American Well. This represented a transfer into Level 3 measurement within fair value hierarchy. By December 31, 2020, Teva recorded an additional gain of $80 million under financial expenses, net, reflecting the revaluation gain of this security as of December 31, 2020 and transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate. Due to management&#8217;s intention and ability to sell this security in the next twelve months, the balance as of December 31, 2020 was reclassified to short term investments.</ix:footnote ><ix:footnote id="FN_64451" xml:lang="en-US">Accumulated goodwill impairment as of December 31, 2020, December 31, 2019 and December 31, 2018 was approximately $25.6 billion, $21.0 billion and $21.0 billion, respectively.</ix:footnote ><ix:footnote id="FN_64423" xml:lang="en-US">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</ix:footnote ><ix:footnote id="FN_64449" xml:lang="en-US">In July 2020, Teva repaid at maturity &#8364;1,010 million of its 0.375% senior notes.</ix:footnote ><ix:footnote id="FN_64450" xml:lang="en-US">In March 2020, Teva repaid at maturity $700 million of its 2.25% senior notes. </ix:footnote ><ix:footnote id="FN_64437" xml:lang="en-US">Mainly related to the divestment of several activities in our International Markets segment. </ix:footnote ><ix:footnote id="FN_64461" xml:lang="en-US">Including $514 million convertible notes. See note 9a.</ix:footnote ><ix:footnote id="FN_64439" xml:lang="en-US">Including impairments related to exit and disposal activities </ix:footnote ><ix:footnote id="FN_64455" xml:lang="en-US">Includes adjustments for foreign currency translation.</ix:footnote ><ix:footnote id="FN_64456" xml:lang="en-US">In 2020, Income from investments comprised mainly of revaluation gain of Teva&#8217;s investment in American Well Corporation (&#8220;American Well&#8221;). See note 20. </ix:footnote ><ix:footnote id="FN_64436" xml:lang="en-US">In 2018, Other, net comprised mainly of a make-whole payment of $46 million following early redemption of senior notes during 2018. </ix:footnote ><ix:footnote id="FN_64458" xml:lang="en-US">In 2020 and 2018, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.</ix:footnote ><ix:footnote id="FN_64441" xml:lang="en-US">The decrease in deferred tax liability is mainly due to impairment and amortization.</ix:footnote ><ix:footnote id="FN_64459" xml:lang="en-US">The amounts are shown after reduction for unrecognized tax benefits of $ 63 million and $115 million as of December 31, 2020 and 2019, respectively. This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: 2021-2022&#8212;$79 million; 2023-2029&#8212;$663 million; 2030 and thereafter&#8212;$171 million. The remaining balance&#8212;$1,327 million&#8212;can be utilized with no expiration date.</ix:footnote ><ix:footnote id="FN_64425" xml:lang="en-US">Comparative figures are based on prior hedge accounting standard.</ix:footnote ><ix:footnote id="FN_64430" xml:lang="en-US">In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva&#8217;s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3 million. </ix:footnote ><ix:footnote id="FN_64428" xml:lang="en-US">With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588 million in cross-currency swap agreements against its outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </ix:footnote ><ix:footnote id="FN_64431" xml:lang="en-US">In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500 million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </ix:footnote ><ix:footnote id="FN_64457" xml:lang="en-US">Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $56 million gain in 2020, $14 million gain in 2019 and $26 million gain in 2018. </ix:footnote ><ix:footnote id="FN_64433" xml:lang="en-US">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the British pound, the Russian ruble and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. [The [positive] impact from these derivatives recognized under revenues was $1 million, $14 million and ($4) million, partially offset by $0 million, $X million and $X million negative impact recognized under cost of sales in the years ended December 31, 2020, 2019 and 2018, respectively]. [To be updated] The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </ix:footnote ><ix:footnote id="FN_64432" xml:lang="en-US">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </ix:footnote ><ix:footnote id="FN_64438" xml:lang="en-US">Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. </ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="teva-20201231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="teva-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2015" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2015-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2019To09_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-07-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2014To12_31_2014" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2014-01-01</xbrli:startDate> <xbrli:endDate>2014-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2015" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2015-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2009" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2009-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_21_2017To08_21_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-08-21</xbrli:startDate> <xbrli:endDate>2017-08-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_17_2018To12_17_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-12-17</xbrli:startDate> <xbrli:endDate>2018-12-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2005" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2005-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2008" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2008-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2013To04_30_2013" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-04-01</xbrli:startDate> <xbrli:endDate>2013-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2013To09_30_2013" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-09-01</xbrli:startDate> <xbrli:endDate>2013-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2010To12_31_2010" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2010-12-01</xbrli:startDate> <xbrli:endDate>2010-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2012To08_31_2012" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2012-08-01</xbrli:startDate> <xbrli:endDate>2012-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2009To11_30_2009" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2009-11-01</xbrli:startDate> <xbrli:endDate>2009-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2015To07_31_2015" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2015-07-01</xbrli:startDate> <xbrli:endDate>2015-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_StockOptionsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:StockOptionsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:RestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:OmnibusLongTermShareIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsExpirationPeriodOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsExpirationPeriodOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsNoExpirationMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsNoExpirationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:ProAirMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:QVARMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >teva:StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis_HedgingOfRevenuesTwoThousandAndTwentyOneMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:CostOfSalesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >teva:HedgingOfRevenuesTwoThousandAndTwentyOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EagleTransactionMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:EagleTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_Amendment69ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:Amendment69ToInvestmentLawMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:BuildingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AlvotechMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AlvotechMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" >teva:DevelopmentZoneaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:SpecialPreferredTechnologicalEnterpriseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AustedoMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AustedoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_LenalidomideProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:LenalidomideProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_LenalidomideProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:LenalidomideProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:JP</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" >us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:SpecialPreferredTechnologicalEnterpriseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2020TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OtherDebentures2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2020OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:FairValueHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:FairValueHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:CashFlowHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:CashFlowHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:ActavisGenericsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:IL</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SettlementOnAccountOfProductLiabilityMembersrtLitigationCaseAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:SettlementOnAccountOfProductLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RevaluationOfAssetsMemberusgaapFreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" >us-gaap:RevaluationOfAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_StockOptionsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:StockOptionsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:RestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:OmnibusLongTermShareIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:ProAirMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:QVARMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >teva:StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2005To2007MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >teva:TaxYear2005To2007Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_EagleTransactionMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:EagleTransactionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DiscontinuedBusinessMemberTEVADiscontinuationOfBusinessAxis_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:DiscontinuationOfBusinessAxis" >teva:DiscontinuedBusinessMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:JP</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_LenalidomideProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:LenalidomideProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_LenalidomideProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:LenalidomideProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:FairValueHedgingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:FairValueHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:CashFlowHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:CashFlowHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:ActavisGenericsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:IL</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:OtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:DistributionServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_StockOptionsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:StockOptionsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:RestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:OmnibusLongTermShareIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AjovyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AustedoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:BendekaAndTreandaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:ProAirMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:QVARMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:NorthAmericaSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:RespiratoryProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:EuropeSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:GenericsMediciansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:COPAXONEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:OtherProductsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis" >us-gaap:OtherRestructuringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >teva:StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_RegeneronMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RegeneronMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_JPsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:JP</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CorporateMemberusgaapStatementBusinessSegmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis" >us-gaap:CorporateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >teva:EosinophilicEsophagitisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >teva:EosinophilicEsophagitisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis" >teva:EosinophilicEsophagitisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:FairValueHedgingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:CashFlowHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis" >us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:IL</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetRevenuesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:NetRevenuesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AlderMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-08</xbrli:startDate> <xbrli:endDate>2018-01-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_AlderMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AlderMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:OtsukaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-05-12</xbrli:startDate> <xbrli:endDate>2017-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:OtsukaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CelltrionMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:CelltrionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RegeneronMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-07-01</xbrli:startDate> <xbrli:endDate>2016-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2016To09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-07-01</xbrli:startDate> <xbrli:endDate>2016-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2016To09_30_2016_RimsaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RimsaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-09-01</xbrli:startDate> <xbrli:endDate>2016-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RegeneronMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-09-01</xbrli:startDate> <xbrli:endDate>2016-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2015_TevaMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >teva:TevaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2015-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DemandDepositsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" >teva:ExercisePriceRangeSixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_Customer1MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >teva:Customer1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_Customer2MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >teva:Customer2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ILsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:IL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HRsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:HR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DEsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:DE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CZsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CZ</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_HUsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:HU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_IEMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:IEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsExpirationPeriodOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsNoExpirationMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsNoExpirationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsIndefiniteMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:TaxCarryforwardsAndDeductionsIndefiniteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeniornotesandconvertibleseniordebenturesmemberMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniornotesandconvertibleseniordebenturesmemberMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TradeNamesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >teva:SeniorNotesAndLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >teva:SeniorNotesAndLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_JanssenAndMillenniumMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >teva:JanssenAndMillenniumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2020OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2020TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OtherDebentures2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeniorNotesDue2020MemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2020Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >teva:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MaximumMembersrtRangeAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >teva:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ModafinilSettlementAgreementMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:ModafinilSettlementAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DemandDepositsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:DemandDepositsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_Customer1MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >teva:Customer1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_Customer2MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >teva:Customer2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ILsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:IL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_HRsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:HR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DEsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:DE</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CZsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CZ</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_HUsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:HU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_IEMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:IEMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:EquitySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_InterestRateSwapMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:InterestRateSwapMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeniornotesandconvertibleseniordebenturesmemberMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >teva:SeniornotesandconvertibleseniordebenturesmemberMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TradeNamesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >teva:ProductRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SubsidiarySeniorNotesDue2021TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:ShortCreditAgreement2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_SwapMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:SwapMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:NondesignatedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >teva:SeniorNotesAndLoansMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2020OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2021TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2020TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherDebentures2026MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >teva:OtherDebentures2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To09_30_2020_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_RegeneronMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RegeneronMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis" >us-gaap:CashFlowHedgingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis" >us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >teva:FinancialExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_Customer1MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >teva:Customer1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_Customer2MembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >teva:Customer2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_27_2018To06_27_2018_JanssenAndMillenniumMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >teva:JanssenAndMillenniumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-06-27</xbrli:startDate> <xbrli:endDate>2018-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2009_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >teva:AndroGelRateAtOnePercentageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2009-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2019To05_31_2019_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-05-01</xbrli:startDate> <xbrli:endDate>2019-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:NationwideSettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-21</xbrli:startDate> <xbrli:endDate>2019-10-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:LitigationCaseAxis" >teva:OpioidLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-21</xbrli:startDate> <xbrli:endDate>2019-10-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To03_31_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >teva:PgtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_02_2016To08_02_2016_ActavisMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:ActavisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-08-02</xbrli:startDate> <xbrli:endDate>2016-08-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_03_2016To10_03_2016_AndaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:AndaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-10-03</xbrli:startDate> <xbrli:endDate>2016-10-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2018To01_31_2018_AllerganPlcMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >teva:AllerganPlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-31</xbrli:startDate> <xbrli:endDate>2018-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_03_2016To03_03_2016_RimsaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >teva:RimsaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-03-03</xbrli:startDate> <xbrli:endDate>2016-03-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2018To09_30_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >teva:PgtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-01</xbrli:startDate> <xbrli:endDate>2018-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2016To12_31_2016_Amendment68ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:Amendment68ToInvestmentLawMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" >teva:DevelopmentZoneaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2016To12_31_2016_Amendment68ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:Amendment68ToInvestmentLawMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2016To12_31_2016_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredEnterpriseMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:PreferredEnterpriseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2016To12_31_2016_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredEnterpriseMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:PreferredEnterpriseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" >teva:DevelopmentZoneaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2016To12_31_2016_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-01</xbrli:startDate> <xbrli:endDate>2016-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To01_01_2017_Amendment73ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >teva:Amendment73ToInvestmentLawMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" >teva:DevelopmentZoneaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-01-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheAExtensionMemberusgaapLineOfCreditFacilityAxis_TracheAMemberTEVATrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:TrancheAxis" >teva:TracheAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >teva:TracheAExtensionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2010_TwoThousandTenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:TwoThousandTenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2010-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_03_2015_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2015-09-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_18_2016To04_18_2016_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-04-18</xbrli:startDate> <xbrli:endDate>2016-04-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_18_2016_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-04-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2018To12_17_2018_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-01-01</xbrli:startDate> <xbrli:endDate>2018-12-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_13_2017_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-07-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_13_2017To07_13_2017_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-07-13</xbrli:startDate> <xbrli:endDate>2017-07-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheAExtensionMemberusgaapLineOfCreditFacilityAxis_TracheAMemberTEVATrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:TrancheAxis" >teva:TracheAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >teva:TracheAExtensionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheBMemberTEVATrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="teva:TrancheAxis" >teva:TracheBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_01_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_11_2020_TwoThousandTwentyPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:TwoThousandTwentyPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:RestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:RestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_OtherCountriesMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:OtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:RestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:EmployeeTerminationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis" >teva:OtherExitAndDisposalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:RebatesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ChargebacksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ReturnsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_InternationalMarketsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >teva:InternationalMarketsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EuropeMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:EuropeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >srt:NorthAmericaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_PreferredStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_RestrictedStockUnitsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >teva:RestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis" >us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:TreasuryStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CAD" > <xbrli:measure>iso4217:CAD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR" > <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_ILS" > <xbrli:measure>iso4217:ILS</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CHF" > <xbrli:measure>iso4217:CHF</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Segment" > <xbrli:measure>teva:Segment</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Lawsuit" > <xbrli:measure>teva:Lawsuit</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CHF_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:CHF</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Employee" > <xbrli:measure>teva:Employee</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Number" > <xbrli:measure>teva:Number</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Y" > <xbrli:measure>utr:Y</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_17701953" toRefs="FN_64427"/><ix:relationship fromRefs="Fact_17701954" toRefs="FN_64429"/><ix:relationship fromRefs="Fact_17701975" toRefs="FN_64429"/><ix:relationship fromRefs="Fact_17701976" toRefs="FN_64429"/><ix:relationship fromRefs="Fact_17701977" toRefs="FN_64429"/><ix:relationship fromRefs="Fact_17701992" toRefs="FN_64453"/><ix:relationship fromRefs="Fact_17701993" toRefs="FN_64453"/><ix:relationship fromRefs="Fact_17701996" toRefs="FN_64426"/><ix:relationship fromRefs="Fact_17702197" toRefs="FN_64426"/><ix:relationship fromRefs="Fact_17702257" toRefs="FN_64426"/><ix:relationship fromRefs="Fact_17702405" toRefs="FN_64452"/><ix:relationship fromRefs="Fact_17702408" toRefs="FN_64452"/><ix:relationship fromRefs="Fact_17702679" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702680" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702681" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702682" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702683" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702690" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702691" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702692" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702693" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702694" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17702754" toRefs="FN_64423"/><ix:relationship fromRefs="Fact_17702755" toRefs="FN_64423"/><ix:relationship fromRefs="Fact_17702766" toRefs="FN_64423"/><ix:relationship fromRefs="Fact_17702767" toRefs="FN_64423"/><ix:relationship fromRefs="Fact_17702857" toRefs="FN_64449"/><ix:relationship fromRefs="Fact_17702859" toRefs="FN_64449"/><ix:relationship fromRefs="Fact_17702929" toRefs="FN_64450"/><ix:relationship fromRefs="Fact_17702931" toRefs="FN_64450"/><ix:relationship fromRefs="Fact_17703027" toRefs="FN_64437"/><ix:relationship fromRefs="Fact_17703028" toRefs="FN_64437"/><ix:relationship fromRefs="Fact_17703029" toRefs="FN_64437"/><ix:relationship fromRefs="Fact_17703057" toRefs="FN_64461"/><ix:relationship fromRefs="Fact_17703133" toRefs="FN_64439"/><ix:relationship fromRefs="Fact_17703138" toRefs="FN_64439"/><ix:relationship fromRefs="Fact_17703188" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17703189" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17703190" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17703191" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17703192" toRefs="FN_64451"/><ix:relationship fromRefs="Fact_17703207" toRefs="FN_64450"/><ix:relationship fromRefs="Fact_17703224" toRefs="FN_64449"/><ix:relationship fromRefs="Fact_17703225" toRefs="FN_64439"/><ix:relationship fromRefs="Fact_17703264" toRefs="FN_64455"/><ix:relationship fromRefs="Fact_17703265" toRefs="FN_64455"/><ix:relationship fromRefs="Fact_17703266" toRefs="FN_64455"/><ix:relationship fromRefs="Fact_17703578" toRefs="FN_64456"/><ix:relationship fromRefs="Fact_17703579" toRefs="FN_64456"/><ix:relationship fromRefs="Fact_17703580" toRefs="FN_64456"/><ix:relationship fromRefs="Fact_17703585" toRefs="FN_64436"/><ix:relationship fromRefs="Fact_17703586" toRefs="FN_64436"/><ix:relationship fromRefs="Fact_17703660" toRefs="FN_64458"/><ix:relationship fromRefs="Fact_17703661" toRefs="FN_64458"/><ix:relationship fromRefs="Fact_17703662" toRefs="FN_64458"/><ix:relationship fromRefs="Fact_17703679" toRefs="FN_64441"/><ix:relationship fromRefs="Fact_17703680" toRefs="FN_64441"/><ix:relationship fromRefs="Fact_17703681" toRefs="FN_64459"/><ix:relationship fromRefs="Fact_17703682" toRefs="FN_64459"/><ix:relationship fromRefs="Fact_17704196" toRefs="FN_64425"/><ix:relationship fromRefs="Fact_17704196" toRefs="FN_64430"/><ix:relationship fromRefs="Fact_17704197" toRefs="FN_64425"/><ix:relationship fromRefs="Fact_17704197" toRefs="FN_64428"/><ix:relationship fromRefs="Fact_17704198" toRefs="FN_64425"/><ix:relationship fromRefs="Fact_17704205" toRefs="FN_64425"/><ix:relationship fromRefs="Fact_17704205" toRefs="FN_64430"/><ix:relationship fromRefs="Fact_17704206" toRefs="FN_64425"/><ix:relationship fromRefs="Fact_17704206" toRefs="FN_64428"/><ix:relationship fromRefs="Fact_17704207" toRefs="FN_64425"/><ix:relationship fromRefs="Fact_17704211" toRefs="FN_64430"/><ix:relationship fromRefs="Fact_17704212" toRefs="FN_64430"/><ix:relationship fromRefs="Fact_17704215" toRefs="FN_64430"/><ix:relationship fromRefs="Fact_17704216" toRefs="FN_64430"/><ix:relationship fromRefs="Fact_17704217" toRefs="FN_64428"/><ix:relationship fromRefs="Fact_17704218" toRefs="FN_64428"/><ix:relationship fromRefs="Fact_17704338" toRefs="FN_64453"/><ix:relationship fromRefs="Fact_17704339" toRefs="FN_64453"/><ix:relationship fromRefs="Fact_17704356" toRefs="FN_64425"/><ix:relationship fromRefs="Fact_17704356" toRefs="FN_64431"/><ix:relationship fromRefs="Fact_17704357" toRefs="FN_64431"/><ix:relationship fromRefs="Fact_17704358" toRefs="FN_64431"/><ix:relationship fromRefs="Fact_17704359" toRefs="FN_64431"/><ix:relationship fromRefs="Fact_17704360" toRefs="FN_64431"/><ix:relationship fromRefs="Fact_17704361" toRefs="FN_64428"/><ix:relationship fromRefs="Fact_17704362" toRefs="FN_64428"/><ix:relationship fromRefs="Fact_17704366" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704367" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704368" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704369" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704370" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704555" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704556" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704557" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704558" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704559" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704560" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704561" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704562" toRefs="FN_64457"/><ix:relationship fromRefs="Fact_17704579" toRefs="FN_64452"/><ix:relationship fromRefs="Fact_17704583" toRefs="FN_64455"/><ix:relationship fromRefs="Fact_17704584" toRefs="FN_64455"/><ix:relationship fromRefs="Fact_17704585" toRefs="FN_64455"/><ix:relationship fromRefs="Fact_17704867" toRefs="FN_64433"/><ix:relationship fromRefs="Fact_17704944" toRefs="FN_64432"/><ix:relationship fromRefs="Fact_17704947" toRefs="FN_64433"/><ix:relationship fromRefs="Fact_17704949" toRefs="FN_64432"/><ix:relationship fromRefs="Fact_17704950" toRefs="FN_64432"/><ix:relationship fromRefs="Fact_17705017" toRefs="FN_64438"/><ix:relationship fromRefs="Fact_17705018" toRefs="FN_64438"/><ix:relationship fromRefs="Fact_17705078" toRefs="FN_64429"/><ix:relationship fromRefs="Fact_17705079" toRefs="FN_64426"/><ix:relationship fromRefs="Fact_17705080" toRefs="FN_64429"/><ix:relationship fromRefs="Fact_17705081" toRefs="FN_64429"/><ix:relationship fromRefs="Fact_17705082" toRefs="FN_64429"/><ix:relationship fromRefs="Fact_17705120" toRefs="FN_64433"/></ix:resources></ix:header></div><div style="font-size: 13.28px;margin-top: 0em;margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2020To12_31_2020">10-K</ix:nonNumeric></div> </div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Mark One) </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2020To12_31_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2020To12_31_2020" format="ixt:datemonthdayyearen"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2020To12_31_2020" format="ixt:datemonthdayen">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2020To12_31_2020">2020</ix:nonNumeric></ix:nonNumeric> </div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 11pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission file number <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2020To12_31_2020">001-16174</ix:nonNumeric></div></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 20pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 20pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2020To12_31_2020">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</ix:nonNumeric></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><span style="-sec-ix-hidden:hidden17704910">No</span>t Applicable</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2020To12_31_2020">5 Basel Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2020To12_31_2020">Petach Tikva</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden17711877">ISRAEL</span>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2020To12_31_2020">4951033</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address of principal executive offices and Zip Code) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2020To12_31_2020">+972 (3)</ix:nonNumeric><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2020To12_31_2020">914-8213</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Registrant&#8217;s telephone number, including area code) </div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading Symbol(s)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange on which registered</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">American Depositary Shares, each representing one <ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2020To12_31_2020">Ordinary Share</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2020To12_31_2020">TEVA</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Act: </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None </div></div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2020To12_31_2020">No</ix:nonNumeric>&#160;&#160;&#9746; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#167;232-405</div> of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2020To12_31_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 15%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 61%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 19%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td>
<td colspan="2" style="height: 1.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2020To12_31_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric> </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2020To12_31_2020" format="ixt:booleanfalse">&#9746;</ix:nonNumeric></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;">The aggregate market value of the voting common equity held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> of the registrant, computed by reference to the closing price at which the American Depositary Shares were last sold on the New York Stock Exchange, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter (June 30, 2020), was approximately $<ix:nonFraction name="dei:EntityPublicFloat" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">11.83</ix:nonFraction>&#160;billion. Teva Pharmaceutical Industries Limited has no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> common equity. For purpose of this calculation only, this amount excludes ordinary shares and American Depositary Shares held by directors and executive officers and by each person who owns or may be deemed to own 10% or more of the registrant&#8217;s common equity at June&#160;30, 2020. </div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,096,511,852</ix:nonFraction> ordinary shares outstanding. </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Portions of the registrant&#8217;s definitive proxy statement for its annual meeting of shareholders to be filed within 120 days after the close of the registrant&#8217;s fiscal year are incorporated by reference into Part III of this Annual Report on Form 10-K.&#160;</div> </div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 87%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_1">Introduction and Use of Certain Terms</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_2">Forward-Looking Statements</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PART I</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_3">Business</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_4">Risk Factors</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">24</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1B.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_5">Unresolved Staff Comments</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">47</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_6">Properties</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_7">Legal Proceedings</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_8">Mine Safety Disclosures</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PART&#160;II</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;5.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;"><a href="#toc102112_9">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_10">Selected Financial Data</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">50</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 7.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_11">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">52</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;7A.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_12">Quantitative and Qualitative Disclosures about Market Risk</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">82</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;8.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_13">Financial Statements and Supplementary Data</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">85</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 9.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">169</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 9A.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_15">Controls and Procedures</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">169</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 9B.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_16">Other Information</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">170</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PART&#160;III</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 10.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_17">Directors, Executive Officers and Corporate Governance</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">170</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 11.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_18">Executive Compensation</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">170</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 12.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="display:inline;"><a href="#toc102112_19">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">170</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 13.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_20">Certain Relationships and Related Transactions, and Director Independence</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">170</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 14.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_21">Principal Accounting Fees and Services</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">170</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PART IV</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 15.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc102112_22">Exhibits, Financial Statement Schedules</a></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">171</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 16.</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><a href="#toc102112_23">Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span> Summary</a></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="display:inline;">176</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INTRODUCTION AND USE OF CERTAIN TERMS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Unless otherwise indicated, all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Teva&#8221; refer to Teva Pharmaceutical Industries Limited and its subsidiaries, and references to &#8220;revenues&#8221; refer to net revenues. References to &#8220;U.S. dollars,&#8221; &#8220;dollars,&#8221; &#8220;U.S. $&#8221; and &#8220;$&#8221; are to the lawful currency of the United States of America, and references to &#8220;NIS&#8221; are to new Israeli shekels. References to &#8220;ADS(s)&#8221; are to Teva&#8217;s American Depositary Share(s). References to &#8220;MS&#8221; are to multiple sclerosis. Market data, including both sales and share data, is based on information provided by IQVIA, a provider of market research to the pharmaceutical industry, unless otherwise stated. References to &#8220;R&amp;D&#8221; are to Research and Development, references to &#8220;IPR&amp;D&#8221; are to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> R&amp;D, references to &#8220;S&amp;M&#8221; are to Selling and Marketing and references to &#8220;G&amp;A&#8221; are to General and Administrative. Some amounts in this report may not add up due to rounding. All percentages have been calculated using unrounded amounts. This report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> contains many of the trademarks and trade names used by Teva in the United States and internationally to distinguish its products and services. Any third-party trademarks mentioned in this report are the property of their respective owners. </div> <div id="toc102112_2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to historical information, this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> and the reports and documents incorporated by reference in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management&#8217;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221; &#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe&#8221; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.&#160;Important factors that could cause or contribute to such differences include risks relating to: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, AJOVY<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and COPAXONE<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our business and operations in general, including: uncertainty regarding the magnitude, duration, and geographic reach of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice (&#8220;DOJ&#8221;) criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption sanctions and trade control laws; and environmental risks; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">and other factors discussed in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> including in the sections captioned &#8220;Risk Factors.&#8221; Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I </div></div></div> <div id="toc102112_3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;1. BUSINESS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. Our mission is to be a global leader in generics, specialty medicines and biopharmaceuticals, improving the lives of patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Our key strengths include our world-leading generic medicines expertise and portfolio, focused specialty medicines portfolio and global infrastructure and scale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva was incorporated in Israel on February&#160;13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Business Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We operate our business through three segments: North America, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, specialty and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> (&#8220;OTC&#8221;) products. This structure enables strong alignment and integration between operations, commercial regions, R&amp;D and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to these three segments, we have other activities, primarily the sale of active pharmaceutical ingredients (&#8220;API&#8221;) to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For information regarding our major customers, see note 19 to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Below is an overview of our three business segments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our North America segment includes the United States and Canada. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are the leading generic pharmaceutical company in the United States. We market over 500 generic prescription products in more than 1,500 dosage strengths, packaging sizes and forms, including oral solid dosage forms, injectable products, inhaled products, liquids, ointments and creams. Most of our generic sales in the United States are made to retail drug chains, mail order distributors and wholesalers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our wholesale and retail selling efforts are supported by participation in key pharmaceutical conferences as well as focused advertising in professional journals and on leading pharmacy websites. We continue to strengthen consumer awareness of the benefits of generic medicines through partnerships and digital marketing programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our specialty portfolio in North America focuses on three main areas: central nervous system (&#8220;CNS&#8221;) and pain, respiratory and oncology. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our CNS portfolio includes AJOVY<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> for the preventive treatment of migraine in adults, AUSTEDO<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> for the treatment of neurodegenerative and movement disorders &#8211; chorea associated with Huntington disease and tardive dyskinesia and COPAXONE<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, which is still among the leading products for the treatment of multiple sclerosis (&#8220;MS&#8221;) in North America since it launched nearly 25 years ago. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are committed to maintaining a leading presence in the respiratory market by delivering a range of medicines for the treatment of asthma and chronic obstructive pulmonary disease (&#8220;COPD&#8221;), including ProAir<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, QVAR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and our newly launched digital inhaler portfolio. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We maintain a meaningful presence in oncology medicines, including both specialty and generic medicines (including biosimilars). In 2019, we launched TRUXIMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, our first oncology biosimilar product in the United States. BENDEKA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> is a liquid, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-volume</div> (50 mL) and short-time <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-minute</div> infusion formulation of bendamustine hydrochloride that we licensed from Eagle Pharmaceuticals, Inc. (&#8220;Eagle&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda, our distribution business in the United States, distributes generic, specialty and OTC pharmaceutical products from various third party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the secondary distribution market by maintaining high inventory levels for a broad offering of products, competitive pricing and offering next day delivery throughout the United States. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Europe segment includes the European Union and certain other European countries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are the leading generic pharmaceutical company in Europe. We are among the top three generic pharmaceutical companies in a number of European Union markets, including some of the largest markets in the European Union. No single country in Europe represents more than 25% of our total European generic revenues, and therefore we are not highly dependent on any single country that could be affected by pricing reforms or changes in regulations and public policy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Despite their diversity and highly fragmented nature, the European markets share many characteristics that allow us to leverage our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pan-European</div> presence and broad portfolio. Global customers are important partners in </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">our generic business and are expanding across Europe, although customer consolidation is lower than in the United States. We are one of a few generic pharmaceutical companies with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pan-European</div> footprint. Most competitors focus on a select few markets or business lines. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our OTC portfolio in Europe includes global brands such as SUDOCREM<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> as well as local and regional brands such as NasenDuo<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in Germany and Flegamina<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in Poland. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our specialty portfolio in Europe focuses on three main areas: CNS and pain (including migraine), respiratory and oncology. Our leading product, COPAXONE, continues to be among the leading products for the treatment of MS, though new treatments are being introduced to various markets in the European Union. AJOVY was granted EU marketing authorization in 2019 and, as of December&#160;31, 2020, we have launched AJOVY in most European countries. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments. These markets comprise more than 35 countries, covering a substantial portion of the global pharmaceutical market. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our key international markets are Japan, Russia and Israel. In Japan, we operate a majority of our business through a business venture with Takeda Pharmaceutical Companies Limited (&#8220;Takeda&#8221;), in which we own a 51% stake and Takeda owns the remaining 49%. On February&#160;1, 2021, we completed the sale of the majority of the generic and operational assets of our business venture in Japan. Countries in our International Markets segment include highly regulated, pure generic markets, such as Israel, branded generics oriented markets, such as Russia and certain Latin America markets, and hybrid markets, such as Japan. Each market&#8217;s strategy is built upon differentiation and filling the unmet needs of that market. Our integrated sales force enables us to extract synergies across our branded generic, OTC and specialty medicines product offerings and across various channels (e.g., retail, institutional). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our specialty portfolio in our International Markets segment focuses on three main areas: CNS and pain, respiratory and oncology. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Product Portfolio and Business Offering </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product and service portfolio includes generic medicines, biopharmaceuticals, specialty medicines, OTC products, a distribution business, API and contract manufacturing. Each region manages the entire range of products and services offered in its region and our global marketing and portfolio function optimizes our pipeline and product lifecycle across therapeutic areas. In most markets in which we operate, we use an integrated and comprehensive marketing model, offering a broad portfolio of products, including specialty, generic and OTC products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Generic Medicines </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic medicines are the chemical and therapeutic equivalents of originator medicines and are typically more affordable in comparison to the originator&#8217;s products. Generics are required to meet similar governmental requirements as their brand-name equivalents, such as those relating to manufacturing processes and health authorities&#8217; inspections, and must receive regulatory approval prior to their sale in any given country. Generic medicines may be manufactured and marketed if relevant patents on their brand-name equivalents (and any additional government-mandated market exclusivity periods) have expired or have been challenged or otherwise circumvented. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop, manufacture and sell generic medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. We offer a broad range of basic chemical entities, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">as well as specialized product families, such as sterile products, hormones, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our generics business has a wide-reaching commercial presence. We are the leading generic pharmaceutical company in the United States and have a top three leadership position in many countries, including some of the key European markets. We have a robust product portfolio, comprehensive R&amp;D capabilities and product pipeline and a global operational network, which enables us to execute key generic launches to further expand our product pipeline and diversify our revenue stream. We use these capabilities to help overcome price erosion in our generics business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When considering whether to develop a generic medicine, we take into account a number of factors, including our overall strategy, regional and local patient and customer needs, R&amp;D and manufacturing capabilities, regulatory considerations, commercial factors and the intellectual property landscape. We will challenge patents when appropriate if we believe they are either invalid or would not be infringed by our generic version. We may seek alliances to acquire rights to products we do not have in our portfolio, to share development costs or litigation risks, or to resolve patent and regulatory barriers to entry. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Between 2017 and 2019, we substantially optimized our global generics portfolio, particularly in the United States, through product discontinuation and price adjustments, with a focus on increasing profitability. This resulted in the restructuring and optimization of our manufacturing and supply network, including the closure or divestment of a significant number of manufacturing plants around the world. We are continuing our ongoing efforts to consolidate our manufacturing and supply network. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In markets such as the United States, the United Kingdom, Canada, the Netherlands and Israel, generic medicines may be substituted by the pharmacist for their brand name equivalent or prescribed by International Nonproprietary Name (&#8220;INN&#8221;). In these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> &#8220;pure generic&#8221; markets, physicians and patients have little control over the choice of generic manufacturer, and consequently generic medicines are not actively marketed or promoted to physicians or consumers. Instead, the relationship between the manufacturer and pharmacy chains and distributors, health funds and other health insurers is critical. Many of these markets have automatic substitution models when generics are available as alternatives to brands. In Russia, Turkey, Ukraine, Kazakhstan and certain Latin American and European countries, generic medicines are generally sold under brand names alongside the originator brand. These markets are referred to as &#8220;branded generic&#8221; markets and are generally &#8220;out of pocket&#8221; markets in which consumers can pay for a particular branded generic medicine (as opposed to government or privately funded medical health insurance), often at the recommendation of their physician. Branded generic products are actively promoted and a sales force is necessary to create and maintain brand awareness. Other markets, such as Germany, Japan, France, Italy and Spain, are hybrid markets with elements of both approaches. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our position in the generics market is supported by our global R&amp;D function, as well as our API R&amp;D and manufacturing activities, which provide significant vertical integration for our products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For information about our product launches and pipeline of generic medicines in North America and Europe, see &#8220;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Segment Information&#8212;North America Segment&#8221; and &#8220;Item 7&#8212;Management&#8217;s Discussions and Analysis of Financial Condition and Results of Operations&#8212;Segment Information&#8212;Europe Segment.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biologic medicines are large and complex medicines produced by or made from living cells or organisms, often produced using cutting-edge biotechnological methods. Biosimilars are highly similar to the reference biologic, in both structure and function (e.g., pharmacodynamics, pharmacokinetics, safety, efficacy and immunogenicity) and, for any approved uses, have no clinically meaningful differences from the reference product in terms of safety, purity, and potency. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2019 and February 2020, we launched TRUXIMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (rituximab-abbs), a biosimilar to Rituxan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (rituximab), in the United States and in Canada, respectively. It is our first oncology biosimilar product in the United States and is the first rituximab biosimilar to be approved in the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2020 and March 2020, we launched HERZUMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (trastuzumab-pkrb), a biosimilar to Herceptin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (trastuzumab), in Canada and the United States, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, a Biologics License Application (&#8220;BLA&#8221;) was accepted for review by the FDA and a Marketing Authorization Application was accepted for review by the European Medicines Agency (&#8220;EMA&#8221;) for a proposed biosimilar to Humira<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (adalimumab) that is under development by Alvotech. For further information regarding our partnership with Alvotech, see &#8220;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212; Alvotech Partnership.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have additional biosimilar products in development in various stages of clinical trials and regulatory review. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Specialty Medicines </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our specialty medicines business, which is focused on delivering innovative solutions to patients and providers via medicines, devices and services in key regions and markets around the world, includes our core therapeutic areas of CNS (with a strong emphasis on MS, neurodegenerative disorders, neuropsychiatry, movement disorders and pain care including migraine) and respiratory medicines (with a focus on asthma and COPD). We also have specialty products in oncology and selected other areas. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We deploy medical and sales and marketing professionals within specific therapeutic areas who seek to address the needs of patients and healthcare professionals. We tailor our patient support, payer relations and medical affairs activities to the distinct characteristics of each therapeutic area and medicine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The U.S. market is the most significant market in our specialty business. In Europe and International Markets, we leverage existing synergies between our specialty business and our generics and OTC businesses. Our specialty presence in International Markets is mainly built on our CNS, pain, respiratory and oncology medicines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have built specialized &#8220;Patient Support Programs&#8221; to help patients adhere to their treatments, improve patient outcomes and, in certain markets, to ensure timely delivery of medicines and assist in securing reimbursement. These programs reflect the importance we place on supporting patients and ensuring better medical outcomes for them. Patient Support Programs are currently operated in many countries around the world in multiple therapeutic areas. We believe that it is important to provide a range of services and solutions tailored to meet the needs of patients according to their specific condition and local market requirements. We believe this capability provides an important competitive advantage in the specialty medicines market. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Below is a description of our key specialty products: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CNS (including Movement Disorders, Pain and Migraine) </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CNS and pain</div></div> portfolio includes AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease, AJOVY for the preventive treatment of migraine and COPAXONE for the treatment of relapsing forms of MS. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO (deutetrabenazine) is a deuterated form of a small molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of a specific </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">neurotransmitter, dopamine, in the brain. The FDA granted Deutetrabenazine New Chemical Entity exclusivity until April 2022 and Orphan Drug exclusivity for the treatment of chorea associated with Huntington disease until April 2024. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO was launched in the U.S. in 2017. It is indicated for the treatment of chorea associated with Huntington disease and for the treatment of tardive dyskinesia in adults, which is a debilitating, often irreversible movement disorder caused by certain medications used to treat mental health or gastrointestinal conditions. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO launched in China for the treatment of chorea associated with Huntington disease and for the treatment of tardive dyskinesia in early 2021. We continue with additional submissions in various other countries around the world. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO is protected in the United States by five Orange Book patents expiring between 2031 and 2033 and in Europe by two patents expiring in 2029. The first date for expected generic ANDA filings on AUSTEDO is in April 2021. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY (fremanezumab-vfrm) injection is a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (&#8220;CGRP&#8221;) and it is indicated for the preventive treatment of migraine in adults. AJOVY was launched in the U.S. in 2018. AJOVY was approved in Canada in April&#160;2020. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2019, AJOVY was granted a marketing authorization in the European Union by the EMA in a centralized process and began receiving marketing authorizations in various countries in our International Markets segment. By the end of 2020, we launched AJOVY in most European countries and in certain International Markets countries. We are moving forward with plans to launch in other countries around the world. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;27, 2020, the FDA approved an auto-injector device for AJOVY in the U.S., which became commercially available in April 2020. We have also received approval from the EMA for AJOVY&#8217;s auto-injector submission in the EU in October 2019, and we commenced launch in March 2020. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY is protected by patents expiring in 2026 in Europe and in 2027 in the United States. Applications for patent term extensions have been submitted in various markets around the world, and certain extensions in Europe and other countries have already been granted until 2031. Additional patents relating to the use of AJOVY in the treatment of migraine have also been issued in the United States and will expire in 2035 and 2037. Such patents are also pending in other countries. AJOVY will also be protected by regulatory exclusivity of 12 years from marketing approval in the United States and 10 years from marketing approval in Europe. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that Eli Lilly&#160;&amp; Co.&#8217;s (&#8220;Lilly&#8221;) marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents. Lilly then submitted IPR (inter partes review) petitions to the Patent Trial and Appeal Board, challenging the validity of the nine patents asserted against it in the litigation. The litigation in the district court was stayed pending resolution of the IPR petitions. On February&#160;18, 2020, the Patent Trial and Appeal Board issued decisions on the first six IPRs, finding the six composition of matter patents invalid as being obvious. On April&#160;21, 2020, we filed notices of appeal in connection with these decisions. On March&#160;31, 2020 the Patent Trial and Appeal Board issued a decision upholding the three method of treatment patents and, on June&#160;1, 2020, Lilly filed notices of appeal in connection with the decisions on these three patents. The litigation stay ended following the issuance of the most recent IPR decisions, and the parties are proceeding with the litigation. In addition, in 2018 we entered into separate agreements with Alder Biopharmaceuticals, Inc. and Lilly, resolving the European Patent Office oppositions that they filed against our AJOVY patents. The settlement agreement with Lilly also resolved Lilly&#8217;s action to revoke the patent protecting AJOVY in the United Kingdom. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE (glatiramer acetate injection) is one of the leading MS therapies in the United States (according to IQVIA data as of late 2020). COPAXONE is indicated for the treatment of patients with relapsing forms of MS (&#8220;RMS&#8221;), including the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (&#8220;RRMS&#8221;), including in patients who have experienced a first clinical episode and have MRI features consistent with MS. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE is believed to have a unique mechanism of action that works with the immune system, unlike many therapies that are believed to rely on general immune suppression or cell sequestration to exert their effect. COPAXONE provides a proven mix of efficacy, safety and tolerability. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One European patent protecting COPAXONE 40 mg/mL was found invalid by the Board of Appeal of the European Patent Office in September 2020. Two additional patents expiring in 2030 are currently under opposition at the European Patent Office. In certain countries, Teva remains in litigation against generic companies on an additional COPAXONE 40 mg/mL patent that expires in 2030. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market for MS treatments continues to develop, particularly with the approval of generic versions of COPAXONE. Oral treatments for MS, such as Tecfidera<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, Gilenya<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and Aubagio<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, continue to present significant and increasing competition. COPAXONE also continues to face competition from existing injectable products, as well as from monoclonal antibodies, such as Ocrevus<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Oncology </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our specialty <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">oncology</div></div> portfolio includes BENDEKA / TREANDA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, GRANIX<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and TRISENOX<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in the United States and LONQUEX<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, TEVAGRASTIM<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>/RATIOGRASTIM<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and TRISENOX<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> outside the United States. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA and TREANDA </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">BENDEKA (bendamustine hydrochloride) injection and TREANDA (bendamustine hydrochloride) for injection are approved in the United States for the treatment of patients with Chronic Lymphocytic Leukemia (&#8220;CLL&#8221;) and patients with indolent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> Non-Hodgkin&#8217;s Lymphoma (&#8220;NHL&#8221;) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. We launched BENDEKA in the United States in January 2016. It is a liquid, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-volume</div> (50 mL) and short-time <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-minute</div> infusion formulation of bendamustine hydrochloride that we licensed from Eagle. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">BENDEKA faces direct competition from Belrapzo<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>(a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ready-to-dilute</div></div> bendamustine hydrochloride product from Eagle). Other competitors to BENDEKA include combination therapies such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">R-CHOP</div> (a combination of cyclophosphamide, vincristine, doxorubicin and prednisone in combination with rituximab) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVP-R</div> (a combination of cyclophosphamide, vincristine and prednisolone in combination with rituximab) for the treatment of NHL, as well as a combination of fludarabine, doxorubicin and rituximab for the treatment of CLL and newer targeted oral therapies, such as ibrutinib, idelilisib and venetoclax. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Eagle prevailed in its suit against the FDA to obtain seven years of orphan drug exclusivity in the United States for BENDEKA. On March&#160;13, 2020, this decision was upheld in the appellate court. As things currently stand, drug applications referencing BENDEKA, TREANDA or any other bendamustine product will not be approved by the FDA until the orphan drug exclusivity expires in December 2022. In April 2019, we signed an amendment to the license agreement with Eagle extending the royalty term applicable to the United States to the full period for which we sell BENDEKA and increased the royalty rate. In consideration, Eagle agreed to assume a portion of BENDEKA-related patent litigation expenses. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are 15 patents listed in the U.S. Orange Book for BENDEKA with expiry dates in 2026 and 2031. In September 2019, a patent infringement action against four of six ANDA filers for generic versions of BENDEKA was tried in the United States District Court for the District of Delaware. On April&#160;27, 2020, the District Court upheld the validity of all of the asserted patents and found that all four ANDA filers infringe at least one of the patents. Three of the four ANDA filers have appealed the district court decision, but barring an adverse appellate decision, these ANDA filers should be enjoined until the patents expire in 2031. The litigation against the fifth ANDA filer was dismissed after the withdrawal of its patent challenge, and the case against the sixth ANDA filer is in the early stages of litigation. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in July 2018, Teva and Eagle filed suit against Hospira, Inc. (&#8220;Hospira&#8221;) related to its 505(b)(2) new drug application (&#8220;NDA&#8221;) referencing BENDEKA in the U.S. District Court for the District of Delaware. On December&#160;16, 2019, the Delaware District Court dismissed the case against Hospira on all but one of the asserted patents, which expires in 2031. Trial against Hospira on that patent is scheduled to begin on November&#160;15, 2021. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the settlement with Eagle regarding its bendamustine 505(b)(2) NDA, between 2015 and 2020, we reached final settlements with 22 ANDA filers for generic versions of the lyophilized form of TREANDA and one 505(b)(2) NDA filer for a generic version of the liquid form of TREANDA, providing for the launch of generic versions of TREANDA prior to patent expiration. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Respiratory </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">respiratory</div></div> portfolio includes our legacy products, ProAir and QVAR, as well as our new digital inhalers with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">built-in</div> sensors: ProAir<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Digihaler<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, AirDuo<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Digihaler<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and ArmonAir<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Digihaler<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>. Our portfolio also includes BRALTUS<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, CINQAIR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>/CINQAERO<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, DuoResp<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Spiromax<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and AirDuo<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> RespiClick<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>/ ArmonAir<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> RespiClick<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are committed to maintaining a leading presence in the respiratory market by delivering a range of medicines for the treatment of asthma and COPD. Our portfolio is centered on optimizing respiratory treatment for patients and healthcare providers through the development and commercialization of innovative delivery systems and therapies that help address unmet needs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key areas of focus for our respiratory R&amp;D is the development of differentiated respiratory therapies for patients using innovative delivery systems to deliver chemical and biological therapies. Our device strategy is intended to result in &#8220;device consistency,&#8221; allowing physicians to choose the device that best matches a patient&#8217;s needs both in terms of ease of use and effectiveness of delivery of the prescribed molecule, and includes three main types of devices: (i)&#160;Digihaler, which captures and shares objective inhaler use data; (ii)&#160;a breath-actuated inhaler (&#8220;BAI&#8221;) used in QVAR RediHaler<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>; and (iii)&#160;RespiClick (U.S.) or Spiromax (EU), a novel inhalation-driven multi-dose dry powder inhaler (&#8220;MDPI&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our legacy products include ProAir and QVAR: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ProAir HFA</div></div> (albuterol sulfate) is an inhalation aerosol with dose counter and is indicated for patients four years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. ProAir HFA is among the leading quick relief inhalers in the United States. In January 2019, we launched our own ProAir authorized generic in the United States following the launch of a generic version of Ventolin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>HFA, another albuterol inhaler. Generic versions of ProAir were launched in 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ProAir RespiClick</div></div> (albuterol sulfate) inhalation powder is a breath-actuated, multi-dose, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">dry-powder,</div> short-acting beta-agonist inhaler for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients four years of age and older. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">QVAR</div></div> (beclomethasone dipropionate HFA) is indicated as a maintenance treatment for asthma as a prophylactic therapy in patients five years of age or older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for systemic corticosteroids. Three generic manufacturers have filed ANDAs for the metered-dose inhaler (&#8220;MDI&#8221;)&#160;presentation of QVAR. We are currently asserting our patents against two of those ANDA filers in the New Jersey District Court. No trial date has been set for these pending lawsuits. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">QVAR RediHaler</div></div> (beclomethasone dipropionate HFA) inhalation aerosol, a BAI, is indicated for the maintenance treatment of asthma as a prophylactic therapy in patients four years of age and older. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Digihaler portfolio consists of ProAir Digihaler, ArmonAir Digihaler<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>and AirDuo Digihaler that capture objective inhaler use data that may help health care professionals and patients make more informed treatment decisions that may improve health outcomes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ProAir Digihaler</div></div> (albuterol sulfate 117 mcg) inhalation powder was launched in the U.S. in July 2020. It is the first and only digital rescue inhaler with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">built-in</div> sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ArmonAir Digihaler</div></div> (fluticasone propionate MDPI U.S.) was launched in the U.S. in September 2020. It is a formulation of long acting inhaled corticosteroid (&#8220;ICS&#8221;) using our MDPI device, indicated for maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AirDuo Digihaler</div></div> (fluticasone propionate and salmeterol inhalation powder) was launched in the U.S. in September 2020. It is the first and only digital maintenance inhaler with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">built-in</div> sensors which connects to a companion mobile application and provides inhaler use information to people with asthma. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional products in our respiratory portfolio include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BRALTUS</div></div> (tiotropium bromide) is a long-acting muscarinic antagonist, indicated for adult patients with COPD, delivered via the Zonda<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> inhaler. It was launched in Europe in August 2016. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CINQAIR/CINQAERO</div></div> (reslizumab) injection is a humanized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">interleukin-5</div> antagonist monoclonal antibody for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">add-on</div> maintenance treatment of adult patients with severe asthma and with an eosinophilic phenotype. This biologic treatment was launched in the U.S. and in certain European countries in 2016 and in Canada in 2017. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AirDuo RespiClick</div></div> (fluticasone propionate and salmeterol inhalation powder) (and its authorized generic) is a combination of an inhaled corticosteroid and a long acting beta-agonist bronchodilator, approved in the United States for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an ICS or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist combination. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Below is a description of key products in our specialty pipeline: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 22%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 21%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 27%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 27%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 2</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 3</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Submission</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Novel Biologics</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fremanezumab</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fibromyalgia</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fremanezumab</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional indication</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-48574</div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fasinumab</div></div></div></div><br/>Osteoarthritic Pain</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(March 2016) <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TEV-53275</div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Small Molecules</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deutetrabenazine</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dyskinesia in Cerebral Palsy</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(September&#160;2019)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risperidone LAI</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Schizophrenia <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Digital Respiratory</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Digihaler<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(budesonide and formoterol fumarate dihydrate)</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(EU)</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">QVAR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> Digihaler<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(beclomethasone dipropionate HFA)</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S.)</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Developed in collaboration with Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;). Results for two phase 3 clinical trials, FACT OA1 and FACT OA2, were released on August&#160;5, 2020, indicating that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-primary</div> endpoints for fasinumab 1 mg monthly were achieved. Fasinumab 1 mg monthly demonstrated significant improvements in pain and physical function over placebo at week 16 and week 24, respectively. Fasinumab 1 mg monthly also showed nominally significant benefits in physical function in two trials and pain in one trial, when compared to the maximum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> prescription doses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-steroidal</div> anti-inflammatory drugs for osteoarthritis. The FACT OA1 trial included an additional treatment arm, fasinumab 1 mg every two months, which showed numerical benefit over placebo, but did not reach statistical significance. In initial safety analyses from the phase 3 trials, there was an increase in arthropathies reported with fasinumab. In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-group</div> of patients from one phase 3 long-term safety trial, there was an increase in joint replacement with fasinumab 1 mg monthly treatment during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-drug</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period, although this increase was not seen in the other trials to date. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Active treatment of patients with fasinumab, which only involved dosing in an optional second-year extension phase of one trial, has been discontinued following a recommendation from the fasinumab program&#8217;s Independent Data Monitoring Committee that the program should be terminated, based on available evidence obtained to date. The core efficacy data has already been obtained to support potential fasinumab regulatory filings. Long-term safety data continues to be gathered, and is expected to be reported in 2021, along with a decision on the program. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2021, we announced positive results for a phase 3 clinical trial designed to evaluate the efficacy of risperidone LAI. No new safety signals were identified that are inconsistent with the known safety profile of other risperidone formulations. The second phase 3 study evaluating long-term safety and tolerability is ongoing. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2020, development of the following projects was discontinued: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the U.S., which was being developed under a partnership agreement with Nuvelution Pharma, Inc.; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fremanezumab (anti CGRP) for post-traumatic headache. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We produce approximately 350 APIs for our own use and for sale to third parties in many therapeutic areas. APIs used in pharmaceutical products are subject to regulatory oversight by health authorities. We utilize a variety of production technologies, including chemical synthesis, semi-synthetic fermentation, enzymatic synthesis, high potency manufacturing, plant extract technology and peptide synthesis. Our advanced technology and expertise in the field of solid state particle technology enable us to meet specifications for particle size distribution, bulk density, specific surface area and polymorphism, as well as other characteristics. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We provide contract manufacturing services related to products divested in connection with the sale of certain business lines, as well as other miscellaneous items. Our other activities are not included in our North America, Europe and International Markets segments described above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our R&amp;D activities span the breadth of our business, including generic medicines (finished goods and API), biosimilars, specialty medicines and OTC medicines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of our R&amp;D activities are concentrated under one global group with overall responsibility for generics, biosimilars and specialty, enabling better focus and efficiency. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A strong focus for Teva is the development of new generic medicines. We develop generic products for our North America, Europe and International Markets segments. Our focus is on developing complex formulations with complex technologies, which have higher barriers to entry. Generic R&amp;D activities, which are carried out in development centers located around the world, include product formulation, analytical method development, stability testing, management of bioequivalence, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bio-analytical</div> studies, other clinical studies and registration of generic drugs in all of the markets where we operate. We also operate several clinics where most of our bioequivalent studies are performed as well as most of our phase 1 studies for specialty and biosimilar products. We have more than 1,160 generic products in our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> global pipeline, which includes products in all stages of the approval process: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-submission,</div> post-submission and after tentative approval. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our generic R&amp;D supports our OTC business in developing OTC products, as well as in overseeing the work performed by contract developers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our current R&amp;D capabilities include solid oral dosage forms (such as tablets and capsules), inhalation, semi-solid and liquid formulations (such as ointments and creams), sterile formulations and other dosage forms, and delivery systems, such as matrix systems, special coating systems for sustained release products, orally disintegrating systems, sterile systems, such as vials, syringes, blow-fill-seal systems, long-acting release injectable, transdermal patches, oral thin film, drug device combinations and nasal delivery systems. In addition, we are in the process of developing multiple <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-rated</div> respiratory programs and devices for our long active injectable pipeline. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We pursue biosimilar pipeline projects in other therapeutic and disease areas that leverage our global R&amp;D and commercial areas of expertise. Biosimilar development activities, such as analytical method development, testing for analytical biosimilarity, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> work, clinical studies and regulatory strategy, are conducted in Teva&#8217;s various global development sites. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our specialty R&amp;D product pipeline is focused on biologic and select small molecule products. Specialty development activities include preclinical assessment (including toxicology, pharmacokinetics, pharmacodynamics and pharmacology studies), clinical development (including pharmacology and the design, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">execution and analysis of global safety and efficacy trials), as well as regulatory strategy to deliver registration of our pipeline products. We develop novel specialty products in our core therapeutic and disease focus areas. We have CNS projects in areas such as migraine, pain, movement disorders/neurodegeneration and neuropsychiatry. Our respiratory projects are focused on asthma and COPD and include both novel compounds and delivery systems designed to address unmet patient needs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our API R&amp;D division focuses on the development of processes for the manufacturing of APIs, including intermediates, chemicals and fermentation products, for both our generic and proprietary drugs. Our facilities include two large development centers in India and Croatia, focusing on synthetic products, and three centers with specific expertise: a center in Hungary specializing in fermentation and semi-synthetic products, a center in Israel for oligonucleotides and a center in the Czech Republic for high-potency APIs. Our substantial investment in API R&amp;D generates a steady flow of API products, supporting the timely introduction of generic products to market in compliance with increasing regulatory requirements. The API R&amp;D division also seeks methods to continuously reduce API production costs, enabling us to improve our cost structure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">While our focus is on internal growth that leverages our R&amp;D capabilities, we have entered into, and expect to pursue, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing,</div> acquisition and partnership opportunities to supplement and expand our existing specialty and biosimilar pipeline (e.g., the transactions with Celltrion, Regeneron and Alvotech). In parallel, we evaluate and expand the development scope of our existing R&amp;D pipeline products as well as our existing products for submission in additional markets. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate our business globally and believe that our global infrastructure provides us with the following capabilities and advantages: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">global R&amp;D facilities that enable us to have a broad global generic pipeline and product line, as well as a focused pipeline of specialty products; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pharmaceutical manufacturing facilities approved by the FDA, EMA and other regulatory authorities located around the world, which offer a broad range of production technologies and the ability to concentrate production in order to achieve high quality and economies of scale; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">API manufacturing capabilities that offer a stable, high-quality supply of key APIs, vertically integrated with our pharmaceutical operations; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">high-volume, technologically advanced distribution facilities that allow us to deliver new products to our customers quickly and efficiently, providing a cost-effective, safe and reliable supply. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These capabilities provide us with the means to respond on a global scale to a wide range of therapeutic and commercial requirements of patients, customers and healthcare providers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmaceutical Production </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate 46 finished dosage and packaging pharmaceutical plants in 22 countries. These plants manufacture solid dosage forms, sterile injectables, liquids, semi-solids, inhalers, transdermal patches and other medical devices. In 2020, we produced approximately 68&#160;billion tablets and capsules and approximately 646&#160;million sterile units. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our primary manufacturing technologies, solid dosage forms, injectable and blow-fill-seal, are available in North America, Europe, Latin America, India and Israel. The manufacturing sites located in Israel, Germany, Hungary, Croatia, Bulgaria, India, Spain, Poland and the Czech Republic make up the majority of our production capacity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We use several external contract manufacturers to achieve operational and cost benefits. We continue to strengthen our third party operations unit to strategically work with our supplier base in order to meet cost, supply security and quality targets on a sustainable basis in alignment with our global procurement organization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our policy is to maintain multiple supply sources for APIs to appropriately mitigate risk in our supply chain to the extent possible. However, our ability to do so may be limited by regulatory and other requirements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Between 2017 and 2019, we closed or divested a significant number of manufacturing plants in the United States, Europe, Israel and Japan in connection with a restructuring plan. We are continuing our ongoing efforts to consolidate our manufacturing and supply network. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Raw Materials for Pharmaceutical Production </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In general, we purchase our raw materials and supplies required for the production of our products in the open market. For some products, we purchase such raw materials and supplies from one source (the only source available to us) or a single source (the only approved source among many available to us), thereby requiring us to obtain such raw materials and supplies from that particular source. We attempt, if possible, to mitigate our raw material supply risks through inventory management and alternative sourcing strategies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We source a large portion of our APIs from our own manufacturing facilities. Additional APIs are purchased from suppliers located in Europe, Asia and the United States. We have implemented a supplier audit program to ensure that our suppliers meet our high standards and are able to fulfill the requirements of our global operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently have 15 API production facilities, producing approximately 350 APIs in various therapeutic areas. Our API intellectual property portfolio includes hundreds of granted patents and pending applications worldwide. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have expertise in a variety of production technologies, including chemical synthesis, semi-synthetic fermentation, enzymatic synthesis, high-potency manufacturing, plant extract technology, peptides synthesis, vitamin D derivatives synthesis and prostaglandins synthesis. Our advanced technology and expertise in the field of solid state particle technology enable us to meet specifications for particle size distribution, bulk density, specific surface area and polymorphism, as well as other characteristics. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our API facilities are required to comply with applicable current Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements under U.S., European, Japanese and other applicable quality standards. Our API plants are regularly inspected by the FDA, European agencies and other authorities, as applicable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents and Other Intellectual Property Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We rely on a combination of patents, trademarks, copyrights, trade secrets and other proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and regulatory exclusivities, as well as contractual protections, to establish and protect our intellectual property rights. We own or license numerous patents covering our products in the United States and other countries. We have also developed many brand names and own many trademarks covering our products. We consider the overall protection of our intellectual property rights to be of material value and act to protect these rights from infringement. We license or assign certain intellectual property rights to third parties in connection with certain business transactions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Environment, Health and Safety </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are committed to business practices that promote socially and environmentally responsible economic growth. During 2020, we continued to make significant progress on our multi-year plan towards our long-term environment, health and safety (&#8220;EHS&#8221;) goal referred to as &#8220;Target Zero&#8221;: zero incidents, zero injuries and zero releases. Among other things, in 2020, we: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continued the implementation of our global EHS management system, which promotes proactive compliance with applicable EHS requirements, establishes EHS standards throughout our global operations and helps drive continuous improvement in our EHS performance; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provided EHS regulatory monitoring tools in all countries where we have significant operations; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">proactively evaluated EHS compliance through self-evaluation and an internal and external audit program, addressing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-conformities</div> through appropriate corrective and preventative action. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Please see the section entitled &#8220;Environmental Sustainability&#8221; from our Teva 2019 ESG Progress Report (which is located on our website) for more detailed information regarding our environmental goals. Nothing on our website, including our 2019 ESG Progress Report or sections thereof, shall be deemed incorporated by reference into this Annual Report or any other filing with the Securities and Exchange Commission. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quality </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are committed not only to complying with quality requirements but to developing and leveraging quality as a competitive advantage. In 2020, we successfully completed numerous inspections by various regulatory agencies of our finished dosage pharmaceutical and API plants and we actively engaged in discussions with authorities to mitigate drug shortages and participated in several industry-wide task forces. We continue to focus on maintaining a solid and sustainable quality compliance foundation, as well as making quality a priority to foster continuous compliance. We seek to ensure that quality is an embedded part of our corporate culture and is reflected in all of our daily operations, delivering reliable and high quality products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For information regarding significant regulatory events, see note 15 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of generic medicines have benefitted from increasing awareness and acceptance on the part of healthcare insurers and institutions, consumers, physicians and pharmacists around the world. Factors contributing to this increased awareness are the passage of legislation permitting or encouraging generic substitution and the publication by regulatory authorities of lists of equivalent pharmaceuticals, which provide physicians and pharmacists with generic alternatives. In addition, various government agencies and many private managed care or insurance programs encourage the substitution of brand-name pharmaceuticals with generic products as a cost-savings measure in the purchase of, or reimbursement for, prescription pharmaceuticals. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, we are subject to competition in the generic drug market from domestic and international generic drug manufacturers and brand-name pharmaceutical companies through introduction of next-generation medicines, authorized generics, existing brand equivalents and manufacturers of therapeutically similar drugs. An increase in FDA approvals for existing generic products is increasing the competition on our base generic products. Price competition from additional generic versions of the same product typically results in margin pressures, which is causing some generics companies to increase focus on portfolio efficiency. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The European market continues to be ever more competitive, especially in terms of pricing, higher quality standards, customer service and portfolio relevance. We are one of only a few companies with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pan-European</div> footprint, while most of our European competitors focus on a limited number of selected markets or business lines. Our leadership position in Europe allows us to be a reliable partner to fulfill the needs of patients, physicians, pharmacies, customers and payers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In our International Markets, our global scale and broad portfolio give us a significant competitive advantage over local competitors, allowing us to optimize our offerings through a combination of high quality medicines and unique <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">go-to-market</div></div> approaches. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, in significant markets such as Japan and Russia, governments have issued or are in process of issuing regulations designed to increase generic penetration. Specifically, in Japan, ongoing regulatory pricing reductions and generic competition to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-patented</div> products have negatively affected our sales in Japan. These conditions result in intense competition in the generic market, with generic companies competing for advantage based on pricing, time to market, reputation and customer service. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The biosimilars business is also highly competitive and continues to evolve as intellectual property protections for biological products continue to expire in the United States. While we believe that our biologics knowledge and experience provide us with competitive advantages, we anticipate significant competition in the biosimilar space. Risks related to commercialization of our prospective biosimilars include the number of competitors, potential for steeper than anticipated price erosion, and intellectual property challenges that may impact timely commercialization. There is also a risk of lower or slower uptake due to various factors that may differ among biosimilars such as competitive practices, physician hesitancy to prescribe biosimilars for certain therapeutic areas, and level of financial incentives (payer or government). We anticipate that the downward pressure on uptake may ease in the future as physicians and payers become increasingly aware of the benefits of biosimilars and more comfortable prescribing them. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our specialty medicines business faces intense competition from both specialty and generic pharmaceutical companies. The specialty business may continue to be affected by price reforms and changes in the political landscape, following recent public debate in the United States. We believe that our primary competitive advantages include our commercial marketing teams, global R&amp;D capabilities, the body of scientific evidence substantiating the safety and efficacy of our various medicines, our patient-centric solutions, physician and patient experience with our medicines and our medical capabilities, which are tailored to our product offerings, regional and local markets and the needs of our stakeholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Human Capital Management </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our People </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our employees are the heart of our Company. In the highly competitive pharmaceutical industry, it is imperative that we attract, develop and retain top talent on an ongoing basis. To do this, we seek to make Teva an inclusive, diverse and safe workplace, with meaningful compensation, benefits and wellness programs, and offering training and leadership development programs that foster career growth. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Human Resources and Compensation Committee, Compliance Committee and Board play key roles in overseeing culture and talent at Teva and devote time throughout the year to human capital strategy and execution in such areas as: inclusion and diversity, Company culture, employee engagement, training and development, recruiting and turnover, leadership development and succession planning. Management regularly updates the Board on internal metrics in these areas. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, Teva&#8217;s work force consisted of 40,216 employees. As a global company, we have employees in 60 countries around the world, representing a wide range of nationalities. In certain countries, we are party to collective bargaining agreements with certain groups of employees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents our workforce headcount by employment type: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Full-time</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Part-time</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,158</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">621</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,497</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,785</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total full time equivalent</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,717</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,535</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents our workforce headcount by geographic area (excluding contractors): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,752</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets (excluding Israel)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Israel</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,843</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total (excluding contractors)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">38,372</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">39,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">41,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inclusion and Diversity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inclusion and diversity are essential to our ability to innovate and grow our business. It is our desire to create and sustain an inclusive and diverse work environment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees identifying as female represent 45% of our global employee population, 47% of managers, and 23% of top executives, as of December&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We seek to underscore our inclusive and diverse culture through employee resource groups and training, among other things. For instance, in the U.S., the Teva Inclusion Network is made up of nine employee resource groups (&#8220;ERGs&#8221;), which have a key role in creating a culture of inclusion and bring together employees with shared characteristics and life experiences to foster opportunities for networking, mentoring, collaboration, community outreach, career development, leadership training and cultural exchanges. Currently, our ERGs include groups for women, men, African Americans, Hispanics/Latinos, Asian Americans, employees with disabilities, military veterans, pride and parenting stages. We also train and offer educational resources to our employees on unconscious bias. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Health and Safety </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that every person has the right to a safe and healthy work environment, and we believe all injuries, illnesses and safety incidents are preventable. We aspire toward Target Zero: Zero Incidents, Zero Injuries and Zero Releases (spills and accidental discharges). We also ensure our employees are properly trained on the safety precautions implemented across our Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Since the start of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, we have operated conscientiously, focusing on the health, safety and well-being of our employees as a top priority. We have reduced the number of employees in our facilities to enable social distancing by introducing virtual solutions and flexible work arrangements. We adhere to PPE and hygiene instructions to protect our people, their families and the communities where we operate and live. We handle suspected and confirmed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> cases with the highest safety measures and with full respect for our employees&#8217; privacy. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Career Growth, Training and Development </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We invest in employee career growth and development at Teva in order to remain competitive in our industry. Our programs also benefit employees individually by providing them with the resources they need to enhance their professional and management abilities, develop leadership skills and achieve their career aspirations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We maintain a range of learning resources to support employees of all levels in developing skills and contributing to Teva&#8217;s strategy, ultimately driving business performance. Much of our employee training is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-role,</div> amplified by global online training and locally-tailored training modules to meet different challenges, help gain new leadership and essential skills and ensure compliance with our policies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to measure our success at promoting talent from inside our organization, we track the proportion of positions filled with internal candidates and other related statistics. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To continue our employee training and development during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, many of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> programs have been modified to be virtual. In addition, we equipped our managers with information and tools on effective management in times of disruption and provided employees with online resources to address the challenges of working remotely, including with respect to maintaining their well-being. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation, Benefits and Wellness </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commitment to our employees starts with compensation and benefit programs that show how we value their contributions by providing a full complement of competitive compensation, health and retirement programs for them and their families. In addition to salaries, we offer variable pay in the form of bonuses and stock-based compensation for eligible employees. We have one global annual bonus design for all eligible employees, demonstrating our One Teva culture. We offer benefits that vary by country and are designed to be competitive in the marketplace. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Through practical tools and local programs, we also address the physical, financial, social and emotional needs of our employees and their families. We offer programs and initiatives that promote healthy diets, physical activity and mental well-being. For example, we provide annual medical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">check-ups</div> and examinations for employees across many of our markets. In addition, we enhanced our well-being programs in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Engagement and Satisfaction </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">To understand whether our human capital strategies are effective and are resonating with our employees, and where we can improve, we conduct an annual employee survey. In 2019, 82% of our employees completed the survey. In 2020, in the midst of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, 86% participated. The 2020 employee survey served as one of the ways we sought to monitor employee morale during this time. Results of the survey show that employee engagement levels are high. Employees are feeling connected with Teva&#8217;s mission and values. They feel pride in Teva&#8217;s positive impact on society and have trust in Teva&#8217;s future. Management reviews the survey results closely to determine areas for improvement and creates action plans to address any gaps. Survey results are communicated to employees though global communications and town halls and shared with our Board of Directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also created an initiative to recognize and celebrate Teva heroes&#8212;those who have gone above and beyond during this challenging time to deliver on Teva&#8217;s mission and provide medicines to our patients around the world. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Please see the section entitled &#8220;Our People&#8221; from our Teva 2019 ESG Progress Report (which is located on our website) for more detailed information regarding our Human Capital programs and initiatives. Nothing on our website, including our 2019 ESG Progress Report or sections thereof, shall be deemed incorporated by reference into this Annual Report or any other filing with the Securities and Exchange Commission. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Food and Drug Administration and the Drug Enforcement Administration </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All pharmaceutical manufacturers selling products in the United States are subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration (&#8220;DEA&#8221;), and, to a lesser extent, by state and local governments. The Federal Food, Drug, and Cosmetic Act, the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Controlled Substances Act (&#8220;CSA&#8221;) and other federal and state statutes and regulations govern or influence the development, manufacture, testing, safety, efficacy, labeling, approval, storage, distribution, recordkeeping, advertising, promotion, sale, import and export of our products. Our facilities are periodically inspected by the FDA, which has extensive enforcement powers over the activities of pharmaceutical manufacturers. Noncompliance with applicable requirements may result in fines, criminal penalties, civil injunction against shipment of products, recall and seizure of products, total or partial suspension of production, sale or import of products, refusal of the government to enter into supply contracts or to approve NDAs, ANDAs or BLAs and criminal prosecution by the U.S. Department of Justice (&#8220;DOJ&#8221;). The FDA also has the authority to deny or revoke approvals of marketing applications and the power to halt the operations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-complying</div> manufacturers. Any failure to comply with applicable FDA policies and regulations could have a material adverse effect on our operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">FDA approval is required before any &#8220;new drug&#8221; (including generic versions of previously approved drugs) may be marketed, including new strengths, dosage forms and formulations of previously approved drugs. Applications for FDA approval must contain information relating to bioequivalence (for generics), safety, toxicity and efficacy (for new drugs), product formulation, raw material suppliers, stability, manufacturing processes, packaging, labeling and quality control. FDA procedures generally require that commercial manufacturing equipment be used to produce test batches for FDA approval. The FDA also requires validation of manufacturing processes so that a company may market new products. The FDA conducts <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> and post-approval reviews and plant inspections to implement these requirements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal CSA and its implementing regulations establish a closed system of controlled substance distribution for legitimate handlers. The CSA imposes registration, security, recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements upon legitimate handlers under the oversight of the DEA. The DEA categorizes controlled substances into one of five schedules&#8212;Schedule I, II, III, IV, or V&#8212;with varying qualifications for listing in each schedule. Facilities that manufacture, distribute, conduct chemical analysis, import or export any controlled substance must register annually with the DEA. The DEA inspects all registered facilities to review security, record keeping and reporting and handling prior to issuing a controlled substance registration and periodically thereafter. Failure to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action, such as civil penalties, refusal to renew necessary registrations or the initiation of proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal prosecution. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Drug Price Competition and Patent Term Restoration Act (the &#8220;Hatch-Waxman Act&#8221;) established the procedures for obtaining FDA approval for generic forms of brand-name drugs. This act also provides market exclusivity provisions that can delay the approval of certain NDAs and ANDAs. One such provision allows a five-year period of data exclusivity for NDAs containing new chemical entities and a three-year period of market exclusivity for NDAs (including different dosage forms) containing new clinical trial(s) essential to the approval of the application. The Orphan Drug Act grants seven years of exclusive marketing rights to a specific drug for a specific orphan indication. The term &#8220;orphan drug&#8221; refers, generally, to a drug that treats a rare disease affecting fewer than 200,000 Americans. Market exclusivity provisions are distinct from patent protections and apply equally to patented and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-patented</div> drug products. Another provision of the Hatch-Waxman Act extends certain patents for up to five years as compensation for the reduction of effective life of the patent which resulted from time spent in clinical trials and time spent by the FDA reviewing a drug application. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Hatch-Waxman Act, any company submitting an ANDA or an NDA under Section&#160;505(b)(2) of the Food, Drug, and Cosmetic Act (i.e., an NDA that, similar to an ANDA, relies, in whole or in part, on FDA&#8217;s prior approval of another company&#8217;s drug product; also known as a &#8220;505(b)(2) application&#8221;) must make certain certifications with respect to the patent status of the drug for which it is seeking approval. In the event that such applicant plans to challenge the validity or enforceability of an existing listed patent or asserts that the proposed product does not infringe an existing listed patent, it files a &#8220;Paragraph IV&#8221; certification. In the case of ANDAs, the Hatch-Waxman Act provides for a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">180-day</div> period of generic exclusivity for the first company to </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submit an ANDA with a Paragraph IV certification. This filing triggers a regulatory process in which the FDA is required to delay the final approval of subsequently filed ANDAs containing Paragraph IV certifications until 180 days after the first commercial marketing. For both ANDAs and 505(b)(2) applications, when litigation is brought by the patent holder, in response to this Paragraph IV certification, the FDA generally may not approve the ANDA or 505(b)(2) application until the earlier of 30 months or a court decision finding the patent invalid, not infringed or unenforceable. Submission of an ANDA or a 505(b)(2) application with a Paragraph IV certification can result in protracted and expensive patent litigation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Products manufactured outside the United States and marketed in the United States are subject to all of the above regulations, as well as to FDA, DEA and United States customs regulations at the port of entry. Products marketed outside the United States that are manufactured in the United States are additionally subject to various export statutes and regulations, as well as regulation by the country in which the products are to be sold. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our products also include biopharmaceutical products that are comparable to brand-name biologics, but that are not approved as biosimilar versions of such brand-name products. While regulations are still being developed by the FDA relating to the Biologics Price Competition and Innovation Act of 2009, which created a statutory pathway for the approval of biosimilar versions of brand-name biological products and a process to resolve patent disputes, the FDA has issued guidance to provide a roadmap for development of biosimilar products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2017, the FDA user fee reauthorization legislation, known as the FDA Reauthorization Act of 2017 (&#8220;FDARA&#8221;) was enacted in the United States. The agreements for pharmaceuticals, biosimilars and medical devices were negotiated with industry representatives over the course of 2016 to establish the amounts regulated companies would pay the FDA to support the product review process at the agency. Various fees must be paid by these manufacturers at different times, such as annually and with the submission of different types of applications. In return for this additional funding, the FDA has entered into agreements with each of the affected industries (known as the &#8220;user fee agreements&#8221;) that commit the agency to interacting with manufacturers and reviewing applications such as NDAs, ANDAs and BLAs in certain ways, and taking action on those applications at certain times. The agency is obligated to set specific timelines to communicate with companies, meet with company product sponsors during the review process and take action on their applications. On the generics side, FDARA established a new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">180-day</div> exclusivity for certain generic drugs that are no longer protected by exclusivity or patents, as well as new programs for enhanced and priority review of certain generic drug applications. On the branded side, this was the sixth agreement between the industry and the FDA. The user fee agreement for biosimilars was reauthorized for the second time as well. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Patient Protection and Affordable Care Act and Certain Government Programs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) from 2010 represented the most significant health care reform in the United States in over thirty years. It was passed to require individuals to have health insurance and to control the rate of growth in healthcare spending through, among other things, stronger prevention and wellness measures, increased access to primary care, changes in healthcare delivery systems and the creation of health insurance exchanges. Enrollment in the health insurance exchanges began in October 2013. However, the individual mandate was subsequently repealed by Congress in the tax reform bill signed into law in December 2017. In December 2018, a U.S. federal district court ruled that the ACA is unconstitutional, but such decision has been stayed, pending resolution by the Supreme Court following oral arguments on November&#160;10, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA requires the pharmaceutical industry to share in the costs of reform, by, among other things, increasing Medicaid rebates and expanding Medicaid rebates to cover Medicaid managed care programs. The ACA also included funding of pharmaceutical costs for Medicare patients in excess of the prescription drug coverage limit and below the catastrophic coverage threshold. Commencing 2019, under the ACA, pharmaceutical companies were obligated to fund 70% of the patient obligation for branded prescription pharmaceuticals in this gap, or &#8220;donut hole.&#8221; Additionally, an excise tax was levied against certain branded pharmaceutical products. The tax is specified by statute to be approximately $2.8&#160;billion in 2019 and each year </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thereafter. The tax is to be apportioned to qualifying pharmaceutical companies based on an allocation of their governmental programs as a portion of total pharmaceutical government programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) administer the Medicaid drug rebate program, in which pharmaceutical manufacturers pay quarterly rebates to each state Medicaid agency. Generally, for generic drugs marketed under ANDAs, manufacturers (including Teva) are required to rebate 13% of the average manufacturer price, and for products marketed under NDAs or BLAs, manufacturers are required to rebate the greater of 23.1% of the average manufacturer price or the difference between such price and the commercial best price during a specified period. An additional rebate for products marketed under ANDAs, NDAs or BLAs is payable if the average manufacturer price increases at a rate higher than inflation and other methodologies apply to new formulations of existing drugs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Various state Medicaid programs have implemented voluntary supplemental drug rebate programs that may provide states with additional manufacturer rebates in exchange for preferred status on a state&#8217;s formulary or for patient populations that are not included in the traditional Medicaid drug benefit coverage. In addition, a number of states, including New York, have enacted legislation that requires entities to pay assessments or taxes on the sale or distribution of opioid medications in order to address the misuse of prescription opioid medications. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In Europe, marketing authorizations for pharmaceutical products may be obtained either through a centralized procedure involving the EMA, a mutual recognition procedure which requires submission of applications in other member states following approval by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> reference member state, a decentralized procedure that entails simultaneous submission of applications to chosen member states or occasionally through a local national procedure. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2020, we continued to register products in the European Union, primarily using the decentralized procedure (simultaneous submission of applications to chosen member states). We continue to use, on occasion, the mutual recognition and centralized procedures. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The European pharmaceutical industry is highly regulated and much of the legislative and regulatory framework is driven by the European Parliament and the European Commission. This has many benefits, including the potential to harmonize standards across the complex European market, but it also has the potential to create complexities affecting the entire European market. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The medicines regulatory framework of the European Union requires that medicinal products, including generic versions of previously approved products and new strengths, dosage forms and formulations of previously approved products, receive a marketing authorization before they can be placed on the market in the European Union. Authorizations are granted after a favorable assessment of quality, safety and efficacy by the respective health authorities. In order to obtain authorization, application must be made to the EMA or to the competent authority of the member state concerned. Besides various formal requirements, the application must contain the results of pharmaceutical (physico-chemical, biological or microbiological) tests, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> (toxicological and pharmacological) tests and clinical trials. All of these tests must have been conducted in accordance with relevant European regulations and must allow the reviewer to evaluate the quality, safety and efficacy of the medicinal product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to control expenditures on pharmaceuticals, most member states of the European Union regulate the pricing of such products and in some cases limit the range of different forms of a drug available for prescription by national health services. These controls can result in considerable price differences among member states. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to patent protection, exclusivity provisions in the European Union may prevent companies from applying for marketing approval for a generic product for eight years (or ten years for orphan medicinal products) from the date of the first marketing authorization of the original product in the European Union. Further, the generic product will be barred from market entry (marketing exclusivity) for a further two years, with the possibility of extending the market exclusivity by one additional year under certain circumstances. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The term of certain pharmaceutical patents may be extended in the European Union by up to five years upon grant of Supplementary Patent Certificates (&#8220;SPC&#8221;). The purpose of this extension is to increase effective patent life (i.e., the period between grant of a marketing authorization and patent expiry) to 15 years. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subject to the respective pediatric regulation, the holder of an SPC may obtain a further patent term extension of up to six months under certain conditions. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> period cannot be claimed if the license holder claims a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> extension of the period of marketing exclusivity based on the grounds that a new pediatric indication brings a significant clinical benefit in comparison with other existing therapies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In July 2019, the SPC Manufacturing Waiver Regulation came into force in the European Union (subject to certain conditions) allowing products manufactured prior to SPC expiry to be exempt from SPC infringement if such products are manufactured for export to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-European</div> Union markets or for launch in the European Union upon expiry of the SPC. This waiver will apply from July&#160;2, 2022 to all SPCs that come into effect after July&#160;1, 2019 or, if the SPC was applied for after July&#160;1, 2019, from the date the SPC comes into effect. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan designated products, which receive, under certain conditions, a blanket period of ten years of market exclusivity, may receive an additional two years of exclusivity instead of an extension of the SPC if the requirements of the pediatric regulation are met. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The legislation also allows for R&amp;D work during the patent term for the purpose of developing and submitting registration dossiers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2016, the United Kingdom conducted a referendum and voted to leave the European Union, also known as &#8220;Brexit.&#8221; On March&#160;29, 2017, the United Kingdom government invoked Article 50 of the Lisbon Treaty to exit the European Union. On January&#160;31, 2020, the United Kingdom left the European Union, and entered a transition period of 11 months. On December&#160;24, 2020, the United Kingdom and European Union agreed on a new Trade and Cooperation Agreement and on December&#160;31, 2020, the United Kingdom formally left the transition period. The Trade and Cooperation Agreement is comprehensive, but does not cover all areas of regulation pertinent to the pharmaceutical industry, so certain complexities remain. We continue to have processes and contingencies in place to minimize their impact, and to maintain our ability to supply medicines to patients in the United Kingdom, and to supply medicines made in the United Kingdom to other markets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, the European Commission published a &#8220;Pharmaceutical strategy for Europe,&#8221; which sets out a suite of policies that will shape the future European regulatory environment. These wide-ranging policies represent a multi-year program aimed, through review and revision of existing legislation, to provide a flexible regulatory system that, amongst other things, will lead to accelerated availability of medicines and promote sustainability of that system. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to regulations in the United States and Europe, we, and our partners, are subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales, marketing and distribution of our products. Such regulations may be similar or, in some cases, more stringent than those applicable in the United States and Europe. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether or not we, or our partners, obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketing of such product in those countries. The requirements and processes governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In addition, we, and our partners, may be subject to foreign laws and regulations and other compliance requirements, including, without limitation, anti-kickback laws, false claims laws and other fraud and abuse laws, as well as laws and regulations requiring transparency of pricing and marketing information and governing the privacy and security of health information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we, or our partners, fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Miscellaneous Regulatory Matters </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to various national, regional and local laws of general applicability, such as laws regulating working conditions. We are also subject to country specific data protection laws and regulations applicable to the collection and processing of personal data around the world. In addition, we are subject to various national, regional and local environmental protection laws and regulations, including those governing the emission of material into the environment. We are also subject to various national, regional and local laws regulating how we interact with healthcare professionals and representatives of government that impact our promotional and other commercial activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Data exclusivity provisions exist in many countries around the world and may be introduced in additional countries in the future, although their application is not uniform. In general, these exclusivity provisions prevent the approval and/or submission of generic drug applications to the health authorities for a fixed period of time following the first approval of the brand-name product in that country. As these exclusivity provisions operate independently of patent exclusivity, they may prevent the submission of generic drug applications for some products even after the patent protection has expired. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On 16&#160;July 2020, the Court of Justice of the European Union invalidated Decision 2016/1250 on the adequacy of the protection provided by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-US</div> Data Privacy Shield (&#8220;Schrems II&#8221;). The General Data Protection Regulation (the &#8220;GDPR&#8221;) provides that the transfer of personal data to a country outside the European Economic Area (&#8220;EEA&#8221;) may, in principle, take place only if the third country ensures an adequate level of data protection, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-U.S.</div> Privacy Shield was previously approved by the European Commission to provide such adequate level of data protection. However, in the view of the Court, U.S. law and practice are not circumscribed in a way that satisfies requirements that are essentially equivalent to those required under EU law, and therefore the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-U.S.</div> Privacy Shield cannot be considered to ensure an adequate level of data protection. As a practical result of the ruling and ensuing guidance from the European Data Protection Board, companies must now verify, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis, and in collaboration with the data importers, whether the law of the importer&#8217;s country ensures a level of protection for the personal data that is essentially equivalent to the EEA&#8217;s protections. If not, data exporters will need to assess whether they can implement supplementary measures to help ensure the requisite level of protection. As a result, companies are now required to conduct and document comprehensive data transfer assessments before allowing any personal data to flow from the EU to outside the EU, and if supplementary measures cannot address an adequate level of protection, then such transfers shall be restricted. Teva is preparing for these new developments by aligning our data mapping documentation with these new requirements and Teva will continue to closely monitor further guidance from authorities on how to adequately address data transfers going forward. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2015, the European Commission adopted regulations providing detailed rules for the safety features appearing on the packaging of medicinal products for human use. This legislation, part of the Falsified Medicines Directive (&#8220;FMD&#8221;), is intended to prevent counterfeit medicines entering into the supply chain and will allow wholesale distributors and others who supply medicines to the public to verify the authenticity of the medicine at the level of the individual pack. The safety features comprise a unique identifier and a tamper-</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evident seal on the outer packaging, which are to be applied to certain categories of medicines. FMD is effective as of February 2019. Teva&#8217;s packaging sites, distribution centers and contract manufacturing operators (&#8220;CMOs&#8221;) for the European market comply with this new requirement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2013, the federal Drug Supply Chain Security Act (the &#8220;DSCSA&#8221;) became effective in the United States, mandating an industry-wide, national serialization system for pharmaceutical packaging with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">phase-in</div> process. By November 2018, all manufacturers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-packagers</div> were required to mark each prescription drug package with a unique serialized code. Teva&#8217;s packing sites, distribution centers and CMOs for the U.S. market comply with the new requirements. In addition, under the DSCSA, Teva is required by November 2023, to provide to downstream trading partners, serial number specific transaction details. This will require additional modification to the packing sites, distribution centers and CMOs for the U.S. market. Subsequently, in February 2019, the EU enacted the Falsified Medicines Directive (&#8220;FMD&#8221;), traceability requirements for drug products, which Teva complies with as well. Other countries are following suit with variations of two main requirements: (i)&#160;to be able to associate the unit data with the uniquely-identified shipping package, or (ii)&#160;to report the data for tracking and tracing of products, reimbursements and other purposes. Certain countries, such as Russia, China, Korea, Turkey, Argentina, Brazil and India (for exported products), already have laws mandating serialization and aggregation and we are working to comply with these requirements. Other countries, including India (domestic market), Indonesia, Kazakhstan, Malaysia, Taiwan, Ukraine and other Latin American countries are currently considering mandating similar requirements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Available Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our main corporate website address is http://www.tevapharm.com. Copies of our Quarterly Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and Current Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed or furnished to the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), and any amendments to the foregoing, will be provided without charge to any shareholder submitting a written request to our company secretary at our principal executive offices or by sending an email to TevaIR@tevapharm.com. All of our SEC filings are also available on our website at http://www.tevapharm.com, as soon as reasonably practicable after having been electronically filed or furnished to the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov. The information on our website is not, and will not be deemed, a part of this Report or incorporated into any other filings we make with the SEC. We also file our annual reports and other information with the Israeli Securities Authority through its fair disclosure electronic system called MAGNA. You may review these filings on the website of the MAGNA system operated by the Israeli Securities Authority at www.magna.isa.gov.il or on the website of the Tel Aviv Stock Exchange (the &#8220;TASE&#8221;) at www.tase.co.il. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc102112_4" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RISK FACTORS </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business faces significant risks. You should carefully consider all of the information set forth in this Annual Report and in our other filings with the SEC, including the following risk factors which we face and which are faced by our industry. Our business, financial condition and results of operations could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements as a result of certain factors including the risks described below and elsewhere in this report and our other SEC filings. For a summary of the risk factors included in this Item 1A and for further details on our forward-looking statements, see &#8220;Forward-Looking Statements and Summary of Risk Factors&#8221; on page 1. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks related to our ability to successfully compete in the marketplace </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales of our generic medicines comprise a significant portion of our business, and we are subject to the significant risks associated with the generic pharmaceutical business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, total revenues from sales of our generic medicines in all our business segments were $9,316&#160;million, or 55% of our total revenues. Generic pharmaceuticals are, as a general matter, less profitable </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">than specialty pharmaceuticals, and have faced price erosion in each of our business segments, placing even greater importance on our ability to continually introduce new products. We have become more dependent on sales of our generics medicines and are increasingly subject to market and regulatory factors and other risks affecting generic pharmaceuticals worldwide. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During 2020, our business was impacted by increased volatility in demand and fluctuations in overall prescription volumes due in large part to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The effects of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may continue in 2021. Due to the volume of our generic portfolio and global nature of our supply chain, we have experienced supply discontinuities due to regulatory actions and approval delays, which had an impact on our ability to timely meet demand in certain instances.&#160;These adverse market forces have a direct impact on our overall performance. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also expect to continue to experience significant adverse challenges in the U.S. generics market deriving from limitations on our ability to influence generic medicine pricing in the long term and a decrease in value from future launches and growth. These and other challenges have required us to recognize significant goodwill impairments in past years. If we experience further difficulty in this market, this may continue to adversely affect our revenues and profits from our North America business segment or cause us to recognize one or more goodwill impairments relating to this reporting unit. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales of our generic products may be adversely affected by the continuing consolidation of our customer base and commercial alliances among our customers. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant portion of our sales are made to relatively few U.S. retail drug chains, wholesalers, managed care purchasing organizations, mail order distributors and hospitals. These customers have undergone significant consolidation and formed various commercial alliances in recent years, which may continue to increase the pricing pressures that we face in the United States. Additionally, the emergence of large buying groups, and the prevalence and influence of managed care organizations and similar institutions, have increased pressure on price, as well as terms and conditions required to do business. Certain of these Group Purchasing Organizations (&#8220;GPOs&#8221;) have been making aggressive requests for pricing proposals and established commercial alliances resulting in greater bargaining power. Due to such consolidation and subsequent changes in these commercial alliances, there are four large GPOs that account for approximately 85% of generics purchases in the United States. We expect the trend of increased pricing pressures from our customers and price erosion in the U.S. generics market to continue. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The traditional model for distribution of pharmaceutical products is also undergoing disruption as a result of the entry or potential entry of new competitors and significant mergers among key industry participants. For example, in 2020, Amazon.com launched its pharmaceutical distribution business. In November 2020, Mylan and Pfizer&#8217;s Upjohn completed a merger of their businesses by forming Viatris Inc., and, in November 2018, CVS Health and Aetna completed a merger which created a vertically integrated organization with increased control over the physician and pharmacy networks and, ultimately, over which medicines are sold to patients. In addition, several major hospital systems in the United States announced a plan to form a nonprofit company that will provide U.S. hospitals with a number of generic drugs. These changes to the traditional supply chain could lead to our customers having increased negotiation leverage and to additional pricing pressure and price erosion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our net sales may also be affected by fluctuations in the buying patterns of retail chains, mail order distributors, wholesalers and other trade buyers, whether resulting from seasonality, pricing, wholesaler buying decisions or other factors. Our business was also impacted by increased volatility in demand due in large part to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and fluctuations in overall market prescription volumes. In addition, since a significant portion of our U.S. revenues is derived from relatively few key customers, any financial difficulties experienced by a single key customer, or any delay in receiving payments from such a customer, could have a material adverse effect on our business, financial condition and results of operations. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our revenues and profits from generic products may decline as a result of competition from other pharmaceutical companies and changes in regulatory policy. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our generic drugs face intense competition. Prices of generic drugs may, and often do, decline, sometimes dramatically, especially as additional generic pharmaceutical companies (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-cost</div> generic producers based in China and India) receive approvals and enter the market for a given product and competition intensifies. Consequently, our ability to sustain our sales and profitability on any given product over time is affected by the number of companies selling such product, including new market entrants, and the timing of their approvals. The goals established under the Generic Drug User Fee Act, and increased funding of the FDA&#8217;s Office of Generic Drugs, have led to more and faster generic approvals, and consequently increased competition for some of our products. The FDA has stated that it has established new steps to enhance competition, promote access and lower drug prices and is approving record-breaking numbers of generic applications. While these FDA improvements are expected to benefit Teva&#8217;s generic product pipeline, they will also benefit competitors that seek to launch products in established generic markets where Teva currently offers products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, brand pharmaceutical companies continue to manage products in a challenging environment through marketing agreements with payers, pharmacy benefits managers and generic manufacturers. For example, brand companies often sell or license their own generic versions of their products, either directly or through other generic pharmaceutical companies <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(so-called</div> &#8220;authorized generics&#8221;). No significant regulatory approvals are required for authorized generics, and brand companies do not face any other significant barriers to entry into such market. Brand companies may seek to delay introductions of generic equivalents through a variety of commercial and regulatory tactics. Many pharmaceutical companies increasingly have used state and federal legislative and regulatory means to delay generic (including biosimilar) competition. These efforts have included pursuing new patents for existing products to extend patent protection; selling the brand product as their own generic equivalent (an authorized generic); using the Citizen Petition process to request amendments to FDA standards or otherwise delay generic (or biosimilar) drug approvals; seeking changes to U.S. Pharmacopeia, an organization which publishes industry recognized compendia of drug standards; using the legislative and regulatory process to have drugs reclassified or rescheduled; attaching patent extension amendments to unrelated federal legislation; and entering into agreements with pharmacy benefit management companies to block the dispensing of generic (including biosimilar) products. These actions may increase the costs and risks of our efforts to introduce generic products and may delay or prevent such introduction altogether. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the U.S. Congress and various state legislatures in the United States have passed, or have proposed passing, legislation that could have an adverse impact on pharmaceutical manufacturers&#8217; ability to (i)&#160;settle litigation initiated pursuant to the federal Hatch-Waxman Act and Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;) and (ii)&#160;secure the full benefit of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-to-file</div></div> regulatory approval status secured under the federal Hatch-Waxman Act. Hatch-Waxman and BPCIA create various pathways for generic drug manufacturers to secure accelerated approvals of their abbreviated new drug applications and abbreviated biologics license applications.&#160;The new laws and proposals from the federal and state governments could change Hatch-Waxman and BPCIA, as well as impact the ability of generic manufacturers to accelerate the launch of their new generic and biosimilar products, and the ability of brand manufacturers to protect their investments in the intellectual property associated with their branded specialty and innovative biologic products.&#160;Teva continues to monitor these legislative developments and advocate for policies that support both innovation and access to high quality medicines for patients. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have experienced, and may continue to experience, delays in launches of our new generic products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we believe we have one of the most extensive pipelines of generic products in the industry, in recent years we were unable to successfully execute a number of generic launches and these challenges may continue in the foreseeable future. As a result of these unsuccessful launches, we may not be able to realize the economic benefits anticipated in connection with planned launches. If we cannot execute timely launches of new products, we may not be able to offset the increasing price erosion on existing products in the United States </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">resulting from pricing pressures and accelerated generics approvals for competing products. Such unsuccessful launches can be caused by many factors, including the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, delays in regulatory approvals, lack of operational or clinical readiness or patent litigation. Failure or delays to execute launches of new generic products could have a material adverse effect on our business, financial condition and results of operations. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products may adversely affect our revenues and profits</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our ability to achieve continued growth and profitability through sales of generic pharmaceuticals is dependent on our continued success in challenging patents, developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> products or developing products with increased complexity to provide opportunities with U.S. market exclusivity or limited competition. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To the extent that we succeed in being the first to market a generic version of a product, and particularly if we are the only company authorized to sell during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">180-day</div> period of exclusivity in the U.S. market, as provided under the Hatch-Waxman Act, our sales, profits and profitability can be substantially increased in the period following the introduction of such product and prior to a competitor&#8217;s introduction of an equivalent product. Even after the exclusivity period ends, there is often continuing benefit from having the first generic product in the market. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">However, the number of generic manufacturers targeting significant new generic opportunities with exclusivity under the Hatch-Waxman Act, or which are complex to develop, continues to increase. Additionally, many of the smaller generic manufacturers have increased their capabilities, level of sophistication and development resources in recent years. The FDA has also been limiting the availability of exclusivity periods for new products, which reduces the economic benefit from being <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-to-file</div></div> for generic approvals. The failure to maintain our industry-leading performance in the United States on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-to-file</div></div> opportunities and to develop and commercialize high complexity generic products could adversely affect our sales and profitability. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">180-day</div> market exclusivity period is triggered by commercial marketing of the generic product. However, the exclusivity period can be forfeited by our failure to obtain tentative or final approval of our product within a specified statutory period or to launch a product following final court decisions that are no longer subject to appeal holding the applicable patents to be invalid, unenforceable or not infringed. The Hatch-Waxman Act also contains other forfeiture provisions that may deprive the first &#8220;Paragraph IV&#8221; filer of exclusivity if certain conditions are met, some of which may be outside our control. Accordingly, we may face the risk that our exclusivity period is forfeited before we are able to commercialize a product. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be unable to take advantage of the increasing number of high-value biopharmaceutical opportunities. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We aim to be a global leader in biopharmaceuticals. TRUXIMA, our first oncology biosimilar product in the United States, launched in November 2019 and is the first rituximab biosimilar to be approved in the United States. HERZUMA, a biosimilar to Herceptin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (trastuzumab), was launched in the United States in March 2020. In August 2020, we entered into a partnership agreement with a biopharmaceutical company, Alvotech, for the exclusive commercialization in the U.S. of five biosimilar product candidates. We are developing a product pipeline and manufacturing capabilities for biosimilar products, which are expected to make up an increasing proportion of the high-value generic opportunities in the coming years. The development, manufacture and commercialization of biopharmaceutical products require specialized expertise and are very costly and subject to complex regulation, which is still evolving. Due to the complex process required to develop biosimilars, obstacles and delays may arise that increase the cost of development or force us to abandon a potential product in which we may have invested substantial amounts of time and resources. We are behind many of our competitors in developing biopharmaceuticals and will require significant investments and collaborations with third parties to benefit from these opportunities. Failure to develop and commercialize biopharmaceuticals could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our specialty pharmaceutical products face intense competition from companies that have greater resources and capabilities. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face intense competition to our specialty pharmaceutical products. Many of our competitors are larger and/or have substantially more experience in the development, acquisition and marketing of branded, innovative and consumer-oriented products. They may be able to respond more quickly to new or emerging market preferences or to devote greater resources to the development and marketing of new products and/or technologies than we can. As a result, any products and/or innovations that we develop may become obsolete or noncompetitive before we can recover the expenses incurred in connection with their development. In addition, we must demonstrate the benefits of our products relative to competing products that are often more familiar or otherwise better established to physicians, patients and third-party payers. If competitors introduce new products or new variations on their existing products, our marketed products, even those protected by patents, may be replaced in the marketplace or we may be required to lower our prices. For example: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future success depends on our ability to maximize the growth and commercial success of AUSTEDO. If our revenues derived from AUSTEDO do not increase as expected, it may have an adverse effect on our results of operations. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY faces strong competition from two products that were introduced into the market around the same time and are competing for market share in the same space, as well as from other emerging competing therapies. Our auto-injector for AJOVY launched in April 2020, but we may still be at a competitive disadvantage in our ability to sell and market this product compared to competing products that launched earlier with an auto-injector due to our late entry into the market. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE faces increasing competition from generic versions in the U.S. and competing glatiramer acetate products in Europe, as well as from orally-administered therapies. Following the approval of generic competition, COPAXONE&#8217;s revenues and profitability have decreased. We expect this trend to continue in the future, which may have a significant effect on our financial results and cash flow. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, our specialty products require much greater use of a direct sales force than does our core generics business. Our ability to realize significant revenues from direct marketing and sales activities depends on our ability to attract and retain qualified sales personnel. Competition for qualified sales personnel is intense. We may also need to enter into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion,</div> contract sales force or other such arrangements with third parties, for example, where our own direct sales force is not large enough or sufficiently well-aligned to achieve maximum market penetration. Any failure to attract or retain qualified sales personnel or to enter into third-party arrangements on favorable terms could prevent us from successfully maintaining current sales levels or commercializing new innovative and specialty products. Furthermore, due to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the ability to promote our new specialty products, primarily AJOVY and AUSTEDO, has been impacted by less physician visits by patients and less physician interactions with our sales personnel as well as the reluctance of physicians to introduce new medication at a time when access to patients may be restricted. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If generic or biosimilar products that compete with any of our specialty products are approved and sold, sales of our specialty products will be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to COPAXONE, certain of our other leading specialty medicines also face patent challenges and impending patent expirations. For example, in January 2019, we launched our own ProAir authorized generic in the United States following the launch of a generic version of Ventolin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> HFA, another albuterol inhaler. Generic versions of ProAir were launched in 2020. Eagle has launched a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ready-to-dilute</div></div> bendamustine hydrochloride in June 2018, which directly competes with BENDEKA, in addition to the ANDAs and NDAs that have been filed by competitors in connection with TREANDA and BENDEKA. The first date for expected generic ANDA filings on AUSTEDO is in April 2021.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic equivalents and biosimilars for branded pharmaceutical products are typically sold at lower costs than the branded products. After the introduction of a competing generic product, a significant percentage of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prescriptions previously written for the branded product are often written for the generic version. Legislation enacted in most U.S. states allows or, in some instances mandates, that a pharmacist dispense an available generic equivalent when filling a prescription for a branded product in the absence of specific instructions from the prescribing physician. Pursuant to the provisions of the Hatch Waxman Act, manufacturers of branded products often bring lawsuits to enforce their patent rights against generic products released prior to the expiration of branded products&#8217; patents, but it is possible for generic manufacturers to offer generic products while such litigation is pending. As a result, branded products typically experience a significant loss in revenues following the introduction of a competing generic product, even if subject to an existing patent. Our specialty products are or may become subject to competition from generic equivalents because our patent protection expired or may expire soon. In addition, we may not be successful in our efforts to extend the proprietary protection afforded our specialty products through the development and commercialization of proprietary product improvements and new and enhanced dosage forms. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investments in our pipeline of specialty and other products may not achieve expected results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We must invest significant resources to develop specialty medicines and biosimilars, both through our own efforts and through collaborations with, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> or acquisition of products from, third parties. We have entered into, and expect to pursue, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing,</div> acquisition and partnership opportunities to supplement and expand our existing specialty and biosimilar pipeline (e.g., the transactions with Celltrion, Regeneron and Alvotech). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The development of specialty medicines involves processes and expertise different from those used in the development of generic medicines, which increase the risk of failure. For example, the time from discovery to commercial launch of a specialty medicine can be 15 years or more and involves multiple stages, including intensive preclinical and clinical testing and highly complex, lengthy and expensive approval processes, which vary from country to country. The longer it takes to develop a new product, the less time that remains to recover development costs and generate profits. Specialty medicines currently in development include fasinumab for osteoarthritic pain, AUSTEDO for dyskinesia&#160;in cerebral&#160;palsy, AJOVY for fibromyalgia and risperidone LAI for schizophrenia. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During each stage, we may encounter obstacles that delay the development process and increase expenses, potentially forcing us to abandon a potential product in which we may have invested substantial amounts of time and resources. These obstacles may include preclinical failures, difficulty enrolling patients in clinical trials, delays in completing formulation and other work needed to support an application for approval, adverse reactions or other safety concerns arising during clinical testing, insufficient clinical trial data to support the safety or efficacy of the product candidate and delays or failure to obtain the required regulatory approvals for the product candidate or the facilities in which it is manufactured. For example, in 2020, the development of AUSTEDO for Tourette syndrome and the development of AJOVY for post-traumatic headache were both discontinued. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When we enter into partnerships and joint ventures with third parties, such as our collaborations with Celltrion, Otsuka, Regeneron and Alvotech, we face the risk that some of these third parties may fail to perform their obligations or fail to reach the levels of success that we are relying on to meet our revenue and profit goals. There is a trend in the specialty pharmaceutical industry of seeking to &#8220;outsource&#8221; drug development by acquiring companies with promising drug candidates and we face substantial competition from historically innovative companies, as well as companies with greater financial resources than us, for such acquisition targets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our success depends on our ability to develop and commercialize additional pharmaceutical products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our financial results depend upon our ability to develop and commercialize additional generic, specialty and biosimilar products in a timely manner, particularly in light of the increasing generic competition to COPAXONE, generic and other competition to our respiratory products, such as ProAir, and patent challenges and impending patent expirations facing certain of our other specialty medicines, such as BENDEKA and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TREANDA. Commercialization requires that we successfully develop, test and manufacture pharmaceutical products. All of our products must receive regulatory approval and meet (and continue to comply with) regulatory and safety standards; if health or safety concerns arise with respect to a product, we may be forced to withdraw it from the market. Developing and commercializing additional pharmaceutical products is also subject to difficulties relating to the availability, on commercially reasonable terms, of raw materials, including API and other key ingredients; preclusion from commercialization by the proprietary rights of others; the costs of manufacture and commercialization; costly legal actions brought by our competitors that may delay or prevent development or commercialization of a new product; and delays and costs associated with the approval process of the FDA and other U.S. and international regulatory agencies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The development and commercialization process, particularly with respect to specialty and biosimilar medicines, as well as the complex generic medicines that we increasingly focus on, is both time-consuming and costly, and involves a high degree of business risk. Our products currently under development, including fasinumab for osteoarthritic pain, AUSTEDO for dyskinesia&#160;in cerebral&#160;palsy, AJOVY for fibromyalgia and risperidone LAI for schizophrenia, if and when fully developed and tested, may not perform as we expect. Necessary regulatory approvals may not be obtained in a timely manner, if at all, and we may not be able to produce and market such products successfully and profitably. Delays in any part of the process or our inability to obtain regulatory approval of our products could adversely affect our operating results by restricting or delaying our introduction of new products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We depend on the effectiveness of our patents, confidentiality agreements and other measures to protect our intellectual property rights. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The success of our specialty medicines business depends substantially on our ability to obtain patents and to defend our intellectual property rights. If we fail to protect our intellectual property adequately, competitors may manufacture and market products identical or similar to ours. We have been issued numerous patents covering our specialty medicines, and have filed, and expect to continue to file, patent applications seeking to protect newly developed technologies and products in various countries, including the United States. Currently pending patent applications may not result in issued patents or be approved on a timely basis or at all. Any existing or future patents issued to or licensed by us may not provide us with any competitive advantages for our products or may be challenged or circumvented by competitors or governments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efforts to defend the validity of our patents are expensive and time-consuming, and there can be no assurance that such efforts will be successful. Our ability to enforce our patents also depends on the laws of individual countries and each country&#8217;s practices regarding the enforcement of intellectual property rights. The loss of patent protection or regulatory exclusivity on specialty medicines could materially impact our business, results of operations, financial condition and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also rely on trade secrets, unpatented proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> trademarks, regulatory exclusivity and continuing technological innovation that we seek to protect, in part by confidentiality agreements with licensees, suppliers, employees and consultants. These measures may not provide adequate protection for our unpatented technology. If these agreements are breached, it is possible that we will not have adequate remedies. Disputes may arise concerning the ownership of intellectual property or the applicability of confidentiality agreements. Furthermore, our trade secrets and proprietary technology may otherwise become known or be independently developed by our competitors or we may not be able to maintain the confidentiality of information relating to such products. If we are unable to adequately protect our technology, trade secrets or proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> or enforce our intellectual property rights, our results of operations, financial condition and cash flows could suffer. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks related to our substantial indebtedness </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have substantial debt of $25,919&#160;million as of December&#160;31, 2020, which has increased our expenses and restricts our ability to incur additional indebtedness or engage in other transactions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our consolidated debt was $25,919&#160;million at December&#160;31, 2020, compared to $26,908&#160;million at December&#160;31, 2019. If we are unable to meet our debt service obligations and other financial obligations, we could be forced to restructure or refinance our indebtedness and other financial transactions, seek additional debt or equity capital or sell our assets. We might then be unable to obtain such financing or capital or sell our assets on satisfactory terms, if at all. Any refinancing of our indebtedness could be at significantly higher interest rates, incur significant transaction fees or include more restrictive covenants. See &#8220;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity&#8221; and note 9 to our consolidated financial statements for a detailed discussion of our outstanding indebtedness. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may have lower-than-anticipated cash flows in the future, which could further reduce our available cash. Although we believe that we will have access to cash sufficient to meet our business objectives and capital needs, this reduced availability of cash could constrain our ability to grow our business. We may have lower-than-anticipated net income in the future. Our revolving credit facility (&#8220;RCF&#8221;) contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time. We borrowed up to &#8364;270&#160;million from our RCF during 2020, which has since been fully repaid. As of December&#160;31, 2020 and as of the date of this Annual Report, we did not have any outstanding debt under the revolving credit facility. Under specified circumstances, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with any of the covenants and the unavailability of any waiver, amendment or other modification thereto, we will not be able to borrow under the RCF. Additionally, violations of the covenants, under certain circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes is outstanding, could lead to an event of default under our senior notes due to cross acceleration provisions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, we were in compliance with all applicable financial ratios. We continue to take steps to reduce our debt levels and improve profitability to ensure continual compliance with the financial maintenance covenants. If such covenants will not be met, we believe we will be able to renegotiate and amend the covenants, or refinance the debt with different repayment terms to address such situation as circumstances warrant. Although we have successfully negotiated amendments to our loan agreements in the past, we cannot guarantee that we will be able to amend such agreements on terms satisfactory to us, or at all, if required to maintain compliance in the future. If we experience lower than required earnings and cash flows to continue to maintain compliance and efforts could not be successfully completed on commercially acceptable terms, we may curtail additional planned spending, may divest additional assets in order to generate enough cash to meet our debt requirements and all other financial obligations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This substantial level of debt and lower levels of cash flow and earnings have severely impacted our business and resulted in a restructuring plan between 2017 and 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our substantial net debt could also have other important consequences to our business, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">making it more difficult for us to satisfy our obligations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limiting our ability to borrow additional funds and increasing the cost of any such borrowing; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increasing our vulnerability to, and reducing our flexibility to respond to, general adverse economic and industry conditions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">placing us at a competitive disadvantage as compared to our competitors, to the extent that they are not as highly leveraged; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restricting us from pursuing certain business opportunities. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, if the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has a significant impact on our business and financial results for an extended period of time, our credit losses, liquidity and cash resources could be negatively impacted. We may be required to draw down funds from our RCF or pursue additional sources of financing to fund our operations, such as secured financing. If we seek secured financing in excess of the limitation in our debt instruments, we may have to secure our current outstanding debt as well. Capital and credit markets have been disrupted by the crisis and foreign exchanges have experienced increased volatility. As a result, access to additional financing may be challenging and is largely dependent upon evolving market conditions and other factors. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may need to raise additional funds in the future, which may not be available on acceptable terms or at all. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may consider issuing additional debt or equity securities in the future to refinance existing debt or for general corporate purposes, including to fund potential acquisitions or investments. If we issue ordinary equity, convertible preferred equity or convertible debt securities to raise additional funds, our existing shareholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing shareholders. If we incur additional debt, it may increase our leverage relative to our earnings or to our equity capitalization, requiring us to pay additional interest and potentially lowering our credit ratings. We may not be able to market such issuances on favorable terms, or at all, in which case, we may not be able to develop or enhance our products, execute our business plan, take advantage of future opportunities or respond to competitive pressures or unanticipated customer requirements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If our credit ratings are further downgraded by leading rating agencies, we may not be able to raise debt or borrow funds in amounts or on terms that are favorable to us, if at all. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our credit ratings impact the cost and availability of future borrowings and, accordingly, our cost of capital. Our ratings at any time will reflect each rating organization&#8217;s then opinion of our financial strength, operating performance and ability to meet our debt obligations. In November 2017, Fitch Ratings Inc. (&#8220;Fitch&#8221;) downgraded our rating to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-investment</div> grade, from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BBB-</div> to BB, with a negative outlook. On January&#160;12, 2018, Moody&#8217;s Investor Service, Inc. (&#8220;Moody&#8217;s&#8221;) downgraded our rating to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-investment</div> grade from Baa3 to Ba2, with a stable outlook. On August&#160;16, 2019, Moody&#8217;s revised our rating outlook to negative. On September&#160;3, 2020, Standard and Poor&#8217;s Financial Services LLC (&#8220;Standard and Poor&#8217;s&#8221;) downgraded our rating from BB to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-</div> due to rising litigation risks, but removed our rating outlook from CreditWatch back to stable, reflecting recent stabilization of our revenue and EBITDA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The downgrade of our ratings to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-investment</div> grade by Fitch, Moody&#8217;s and Standard&#160;&amp; Poor&#8217;s limits our ability to borrow at interest rates consistent with the interest rates that were available to us prior to such downgrades. This may limit our ability to sell additional debt securities or borrow money in the amounts, at the times or interest rates, or upon the terms and conditions that would have been available to us if our previous credit ratings had been maintained. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional risks related to our business and operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, could adversely affect our business, results of operations and financial condition. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. The virus has spread globally to multiple countries and regions, including to the United States, certain European countries, Israel, India and Latin America, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">where we currently manufacture most of our products and conduct our clinical trials. The potential closure of our facilities in these or other areas in which we operate, or other protectionist measures or restrictions inhibiting our employees&#8217; ability to access our facilities, may materially affect our operations, including potentially interrupting our manufacturing, supply chain, clinical trial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> launch activities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may also affect our employees as well as employees and operations at third-party manufacturers or suppliers that may result in delays or disruptions in manufacturing and supply. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has also led to a new working environment, which may affect employee wellbeing and engagement, causing stress and fear of returning to work at the office. This in turn may result in lower productivity and motivation among employees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2020, we did not experience significant impacts or delays from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our business operations. We have experienced minimal delays in clinical trials due to cessation or slow-downs of recruitment for patient studies and suspended regulatory inspections, delays in regulatory approvals of new products due to reduced capacity or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-prioritization</div> of regulatory agencies and delays in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> launch activities. In addition, we experienced slightly lower demand due to less physician and hospital activity in certain regions and for certain medicines in the second half of 2020 resulting from the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. While we expect to be able to continue our operations and to satisfy the demand for our products, while protecting the health and safety of our employees and customers, the uncertainty surrounding the full economic implications of the pandemic may result in a period of business disruption. Any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> related disruption could have a material adverse impact on our business and our results of operation and financial condition. Changes in patient behavior resulting in less visits to physicians and medical facilities, or increased layoffs in the U.S. employment market, which may affect healthcare benefits coverage, have caused a decline or slower growth in the number of patients diagnosed with diseases for which we produce treatments, and if this trend continues or worsens, our revenues could be adversely affected. In addition, a recession or market correction resulting from the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could materially affect our business, the value of our shares and our access to the capital and credit markets including our liquidity and cash resources. The new working environment, with many employees working remotely, has exposed many companies to cyber-attacks and data security breaches. If such breach were to occur, it may have a material adverse effect on our business, operations and reputation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have taken precautionary measures, and may take additional measures, intended to minimize the risk of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic to our employees and operations. The extent of the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our operational and financial performance, including our ability to execute our business strategies in the expected time frame or at all, will depend on future developments, such as the duration and spread of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and long-term impact on the world&#8217;s economy, all of which are uncertain and cannot be predicted. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Implementation of ongoing optimization efforts may adversely affect our business, financial condition and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may face wrongful termination, discrimination or other legal claims from employees affected by ongoing changes in our workforce. We may incur substantial costs defending against such claims, regardless of their merits, and such claims may significantly increase our severance costs. Additionally, we may see variances in the estimated severance costs depending on the category of employees and locations in which severance is incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the proposed divestiture of any facility in connection with our ongoing plant optimization, we may not be able to divest such facility at a favorable price or in a timely manner. Any divestiture that we are unable to complete may cause additional costs associated with retaining the facility or closing and disposing of the impacted businesses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any workforce reduction and site consolidation may result in the loss of numerous long-term employees, the loss of institutional knowledge and expertise, the reallocation of certain job responsibilities and the disruption of business continuity, all of which could negatively affect operational efficiencies and our ability to achieve growth and profitability through the development and sale of new pharmaceutical products. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot guarantee that, following such efficiency measures, our business will be more efficient or effective. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our continued success depends on our ability to attract, hire and retain highly skilled key personnel. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the size, complexity and global reach of our business and our multiple areas of focus, we are especially reliant upon our ability to recruit and retain highly qualified management and other key employees. Our ability to attract and retain such employees may be diminished by the financial, legal and regulatory challenges we have faced in recent years. In addition, the success of our R&amp;D activity depends on our ability to attract and retain sufficient numbers of skilled scientific personnel, which may be limited due to our R&amp;D spending and programs. Any difficulty in recruiting, hiring, retaining and motivating talented and skilled members of our organization may delay or prevent the achievement of major business objectives. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturing or quality control problems may damage our reputation for quality production, demand costly remedial activities and negatively impact our financial results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a pharmaceutical company, we are subject to substantial regulation by various governmental authorities. For instance, we must comply with requirements of the FDA, EMA and other healthcare regulators with respect to the manufacture, labeling, sale, distribution, marketing, advertising, promotion and development of pharmaceutical products. Failure to strictly and promptly comply with these regulations and requirements may damage our reputation and lead to financial penalties, compliance expenditures associated with remediation efforts, the recall or seizure of products, total or partial suspension of production and/or distribution, suspension of the applicable regulator&#8217;s review of our submissions, enforcement actions, injunctions and criminal prosecution. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We must register our facilities, whether located in the United States or elsewhere, with the FDA for products sold in the United States, and with other regulators outside the United States for products sold outside of the United States. Our products must be produced in a manner consistent with cGMP, or similar quality and compliance standards in each territory in which we manufacture. In addition, the FDA and other agencies periodically inspect our manufacturing facilities. Following an inspection, an agency may issue a notice listing conditions that are believed to violate cGMP or other regulations, or a warning letter for violations of &#8220;regulatory significance&#8221; that may result in enforcement action if not promptly and adequately corrected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In recent years, regulatory agencies around the world have increased their scrutiny of pharmaceutical manufacturers. This has resulted in requests for product recalls, temporary plant shutdowns to address specific issues and other remedial actions. Our manufacturing facilities, as well as those of our vendors and manufacturing partners, have also been the subject of increased regulatory oversight, leading to increased expenditures required to ensure compliance with new or more stringent production and quality control regulations. For information regarding significant regulatory events, see note 15 to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These regulatory actions also adversely affected our ability to supply various products around the world and to obtain approvals for new products manufactured at the affected facilities. If any regulatory body were to require one or more of our significant manufacturing facilities to cease or limit production, our business and reputation could be adversely affected. In addition, because regulatory approval to manufacture a drug is site-specific, the delay and cost of remedial actions or obtaining approval to manufacture at a different facility could also have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The manufacture of our products is highly complex, and an interruption in our supply chain or problems with internal or third party information technology systems could adversely affect our results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our products are either manufactured at our own facilities or obtained through supply agreements with third parties. Many of our products are the result of complex manufacturing processes, and some require highly </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">specialized raw materials. Problems may arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with or shortages of raw materials, natural disasters, and environmental factors. For some of our key raw materials, we have only a single, external source of supply, and alternate sources of supply may not be readily available. If our supply of certain raw materials or finished products is interrupted from time to time, or proves insufficient to meet demand, our cash flows and results of operations could be adversely impacted. Moreover, the streamlining of our manufacturing network may result in our product supply becoming more dependent on a smaller number of specific manufacturing plants. Our inability to timely manufacture any of our key products may result in claims and penalties from customers and could have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In recent years, medicine shortages have become an increasingly widespread problem around the world and particularly in Europe. We are working diligently across our supply chain to ensure continuous and stable supply. Many European countries are implementing legal and regulatory measures, such as mandatory stockpiling and high penalties in order to prevent supply disruptions. Such measures may lead to substantial monetary losses in case we experience long-term supply disruptions in the relevant territories. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also rely on complex shipping arrangements to and from the various facilities of our supply chain. Customs clearance and shipping by land, air or sea routes rely on and may be affected by factors that are not in our full control or are hard to predict. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we rely on complex information technology systems, including Internet-based systems, to support our supply-chain processes as well as internal and external communications. The size and complexity of our systems make them potentially vulnerable to breakdown or interruption, whether due to computer viruses, lack of system upgrades or other causes that may result in the loss of key information or the impairment of production and other supply chain processes. Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and results of operation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant disruptions of our information technology systems could adversely affect our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely extensively on information technology systems in order to conduct business, including some systems that are managed by third-party service providers. These systems include, but are not limited to, programs and processes relating to internal and external communications, ordering and managing materials from suppliers, converting materials to finished products, shipping products to customers, processing transactions, summarizing and reporting results of operations, and complying with regulatory, legal or tax requirements. These information technology systems could be damaged or cease to function properly due to the poor performance or failure of third-party service providers, catastrophic events, power outages, network outages, failed upgrades or other similar events. If our business continuity plans do not effectively resolve such issues on a timely basis, we may suffer significant interruptions in conducting our business, which may adversely impact our business, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, our systems and networks have been, and are expected to continue to be, the target of advanced cyber-attacks which may pose a risk to the security of our systems and the confidentiality, availability and integrity of our data, as well as disrupt our operations or damage our facilities or those of third parties. As cybersecurity threats rapidly evolve in sophistication and become more prevalent, we are continually increasing our attention to these threats. We assess potential threats and vulnerabilities and make investments seeking to address them, including ongoing monitoring and updating of networks and systems, increasing specialized information security skills, deploying employee security training and updating our security policies. However, because the techniques, tools and tactics used in cyber-attacks frequently change and may be difficult to detect for periods of time, we may face difficulties in anticipating and implementing adequate preventative measures or fully mitigating harms after such an attack. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compromise information security. We outsource administration of certain functions to vendors that could be targets of cyber-attacks. Any theft, loss and/or fraudulent use of customer, employee or proprietary data as a result of a cyber-attack targeting us or one of our third-party service providers could subject us to significant litigation, liability and costs, as well as adversely impact our reputation with customers and regulators, among others. A significant cyber-attack on our information technology systems may lead to substantial interruptions in our business, legal claims and liability, regulatory investigations and penalties, and reputational damage, which could have a material adverse effect on our business, financial condition and results of operations. While we maintain insurance coverage that is designed to address certain aspects of cyber risks, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise in the event we experience a cybersecurity incident, data security breach or disruption, unauthorized access or failure of systems. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A significant data security breach could adversely affect our business and reputation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of our business, we collect and store sensitive data in our data centers and on our networks, including intellectual property, proprietary business information (both ours and that of our customers, suppliers and business partners) and personally identifiable information of our employees. We are subject to laws and regulations governing the collection, use and transmission of personal information, including health information. As the legislative and regulatory landscape for data privacy and protection continues to evolve around the world, there has been an increasing focus on privacy and data protection issues that may affect our business, including the U.S.&#8217;s federal Health Insurance Portability and Accountability Act of 1996, as amended (&#8220;HIPAA&#8221;), the EU&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;), California Consumer Privacy Act (&#8220;CCPA&#8221;) and other laws and regulations governing the collection, use, disclosure and transmission of data in other jurisdictions. Although Teva is not HIPAA-regulated, we do business with customers who are, and increased focus on compliance with HIPAA and state laws that govern the privacy and security of medical data may impact our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA mandates the adoption of specific standards for electronic transactions and code sets that are used to transmit certain types of health information. To protect the information transmitted using the mandated standards and the patient information used in the daily operations of a covered entity, HIPAA also sets forth federal rules protecting the privacy and security of protected health information (&#8220;PHI&#8221;). The law provides both criminal and civil fines and penalties for covered entities that fail to comply with HIPAA. Under HIPAA, covered entities must establish administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of electronic PHI maintained or transmitted by them or by others on their behalf. Covered entities we engage are in material compliance with the privacy, security and National Provider Identifier requirements of HIPAA and state laws that regulate the privacy and security of medical data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act imposed certain of the HIPAA privacy and security requirements directly upon business associates of covered entities and significantly increased the monetary penalties for violations of HIPAA. Regulations also require business associates to notify covered entities, who in turn must notify affected individuals and government authorities, of data security breaches involving unsecured PHI. Since the passage of the HITECH Act, enforcement of HIPAA violations has increased. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have procedures in place to detect and respond to data security incidents. If our efforts to protect the security of information about our customers, suppliers and employees are unsuccessful, a significant data security breach may result in costly government enforcement actions, private litigation and negative publicity resulting in reputation or brand damage with customers, and our business, financial condition, results of operations or prospects could suffer. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because our facilities are located throughout the world, we are subject to varying intellectual property laws that may adversely affect our ability to manufacture our products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to intellectual property laws in all countries where we have manufacturing facilities. Modifications of such laws or court decisions regarding such laws may adversely affect us and may impact our ability to produce and export products manufactured in any such country in a timely fashion. Additionally, the existence of third-party patents in such countries, with the attendant risk of litigation, may cause us to move production to a different country (potentially leading to significant production delays) or otherwise adversely affect our ability to export certain products from such countries. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have significant operations globally, including in countries that may be adversely affected by political or economic instability, major hostilities or acts of terrorism, which exposes us to risks and challenges associated with conducting business internationally. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a global pharmaceutical company with worldwide operations. Although approximately 51% of our sales are in the United States and Western Europe, an increasing portion of our sales and operational network are located in other regions, such as Latin America, Central and Eastern Europe and Asia, which may be more susceptible to political and economic instability. Other countries and regions, such as the United States and Western Europe, also face potential instability due to political and other developments. In addition, in the United States, the executive administration has discussed, and in some cases implemented, changes with respect to certain trade policies, tariffs and other government regulations affecting trade between the United States and other countries. As a company that manufactures most of its products outside the United States, a &#8220;border adjustment tax&#8221; or other restriction on trade, if enacted, may have a material adverse effect on our business, financial condition and results of operations. In addition, given that a significant portion of our business is conducted in the European Union, including the U.K., the formal change in the relationship between the U.K. and the European Union caused by the U.K. referendum to leave the European Union, referred to as &#8220;Brexit,&#8221; may pose certain implications to our research, commercial and general business operations in the U.K. and the European Union, including the approval and supply of our products. On December&#160;24, 2020, the United Kingdom and European Union agreed on a new Trade and Cooperation Agreement and on December&#160;31, 2020, the United Kingdom formally left the transition period. The Trade and Cooperation Agreement is comprehensive, but does not cover all areas of regulation pertinent to the pharmaceutical industry, so certain complexities remain. This finalization of the long-term relationship between the United Kingdom and the European Union will dictate how the European Union will be impacted and may result in an impact on our business operations in Europe. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant portions of our operations are conducted outside the markets in which our products are sold, and accordingly we often import a substantial number of products into such markets. We may, therefore, be denied access to our customers or suppliers or denied the ability to ship products from any of our sites as a result of a closing of the borders of the countries in which we sell our products, or in which our operations are located, due to economic, legislative, political and military conditions, including hostilities and acts of terror, in such countries. In addition, certain countries have put regulations in place requiring local manufacturing of goods, while foreign-made products are subject to pricing penalties or even bans from participation in public procurement auctions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face additional risks inherent in conducting business internationally, including compliance with laws and regulations of many jurisdictions that apply to our international operations. These laws and regulations include data privacy requirements, labor relations laws, tax laws, competition regulations, import and trade restrictions, economic sanctions, export requirements, the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), the UK Bribery Act 2010 and other local laws that prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. Given the high level of complexity of these laws, there is a risk that some provisions may be breached by us, for example through fraudulent or negligent behavior of individual employees (or third parties acting on our behalf), our failure to comply with certain formal documentation requirements, or otherwise. Actions by our employees, or by third-party intermediaries acting on our behalf, in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">violation of such laws, whether carried out in the United States or elsewhere in connection with the conduct of our business have exposed us, and may further expose us, to significant liability for violations of the FCPA or other anti-corruption laws. In 2016, we paid a monetary fine for FCPA violations and entered into a three year deferred prosecution agreement with the DOJ, which included retaining an independent compliance monitor. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violation could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our ability to attract and retain employees, our business, our financial condition and our results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our corporate headquarters and a sizable portion of our manufacturing activities are located in Israel. Our Israeli operations are dependent upon materials imported from outside Israel. Accordingly, our operations could be materially and adversely affected by acts of terrorism or if major hostilities were to occur in the Middle East or trade between Israel and its present trading partners were materially impaired, including as a result of acts of terrorism in the United States or elsewhere. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to extensive pharmaceutical regulation, which can be costly and subject our business to disruption, delays and potential penalties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are subject to extensive regulation by the FDA and various other U.S. federal and state authorities, the EMA and other foreign regulatory authorities. The process of obtaining regulatory approvals to market a drug or medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, future products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues and substantial additional costs. For example, in the last three years, we experienced delays in obtaining anticipated approvals for various generic and specialty products, and during 2020 the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic caused some delays in approvals due to travel and work restrictions. We may continue to experience similar delays. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, no assurance can be given that we will remain in compliance with applicable FDA and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns. Our facilities are subject to ongoing regulation, including periodic inspection by the FDA and other regulatory authorities, and we must incur expense and expend effort to ensure compliance with these complex regulations. In addition, we are subject to regulations in various jurisdictions, including the Federal Drug Supply Chain Security Act in the U.S., the Falsified Medicines Directive in the EU and many other such regulations in other countries that require us to develop electronic systems to serialize, track, trace and authenticate units of our products through the supply chain and distribution system. Compliance with these regulations may result in increased expenses for us or impose greater administrative burdens on our organization, and failure to meet these requirements could result in fines or other penalties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to comply with all applicable regulatory requirements may subject us to operating restrictions and criminal prosecution, monetary penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, shutdown of production, revocation of approvals or the inability to obtain future approvals, or exclusion from future participation in government healthcare programs. Any of these events could disrupt our business and have a material adverse effect on our revenues, profitability and financial condition. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare reforms, and related reductions in pharmaceutical pricing, reimbursement and coverage, by governmental authorities and third-party payers may adversely affect our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The continuing increase in expenditures for healthcare has been the subject of considerable government attention almost everywhere we conduct business. Both private health insurance funds and government health authorities continue to seek ways to reduce or contain healthcare costs, including by reducing or eliminating coverage for certain products and lowering reimbursement levels. The focus on reducing or containing healthcare costs has been increased by controversies, political debate and publicity about prices for pharmaceutical products that some consider excessive, including Congressional and other inquiries into drug pricing, including with respect to our specialty medicines, which could have a material adverse effect on our reputation. In most of the countries and regions where we operate, including the United States, Western Europe, Israel, Russia, Japan, certain countries in Central and Eastern Europe and several countries in Latin America, pharmaceutical prices are subject to new government policies designed to reduce healthcare costs, and may be subject to additional regulatory efforts, funding restrictions, legislative proposals, policy interpretations, investigations and legal proceedings regarding pricing practices. These changes frequently adversely affect pricing and profitability and may cause delays in market entry. Certain U.S. states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints under the Medicaid program, and some jurisdictions have implemented or are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates and a reduction in demand for our products. We cannot predict which additional measures may be adopted or the impact of current and additional measures on the marketing, pricing and demand for our products, which could have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Significant developments that may adversely affect pricing in the United States include Medicare reforms by Congress and regulatory changes to Medicare Part B (physician administered drugs) and Medicare Part D (prescription drug benefit), additional changes to the Affordable Care Act (&#8220;ACA&#8221;) under the Biden Administration and trends in the practices of managed care groups and institutional and governmental purchasers, including the impact of consolidation of our customers. In particular, additional pressure to reduce health care costs in states is critical as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic strained state healthcare budgets and swelled Medicaid rolls due to economic downturns and job loss.&#160;Many new Medicaid recipients were previously covered under employer-sponsored plans. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The branded pharmaceutical industry faces uncertainty regarding whether the Interim Final Rule (IFR) published on November&#160;27, 2020 by the CMS will survive pending court challenges. Originally set to be effective January&#160;1, 2021, the IFR imposes a mandatory Most Favored Nation (MFN) pricing model on fifty single-source drugs and biologics (including biosimilars) reimbursed by Medicare Part&#160;B, to be administered by the Centers for Medicare and Medicaid Innovation.&#160;PhRMA, the Biotechnology Industry Organization (BIO), a biotechnology company, and several patient support groups filed litigation to enjoin the implementation process and allow for more thoughtful deliberations over the imposition of drug price control proposals.&#160;On December 28, 2020, the court in the BIO case imposed a preliminary injunction on implementation of the IFR pending completion of regulatory notice-and-comment requirements by CMS. Subsequently, on January 13, 2021 the DOJ and PhRMA agreed to stay their litigation (which sought a similar national injunction of IFR implementation) until a final rule based on the IFR is published in the Federal Register. As a result, while the IFR as published will not go into effect, CMS could propose pricing changes similar to the IFR in the future, albeit with more notice and opportunity for stakeholders to participate in the regulatory process. There is likely to be consideration of Medicare Part D reform as well, which could impact pricing policies, such as direct price negotiation between the U.S. Department of Health and Human Services and manufacturers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries may result in increased pricing pressure by influencing the reimbursement policies of third-party payers. Healthcare reform legislation has increased the number of patients who have insurance coverage for our </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">products, but provisions such as the assessment of a branded pharmaceutical manufacturer fee and an increase in the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs may have an adverse effect on us. It is uncertain how current and future reforms in these areas will influence the future of our business operations and financial condition. In addition, &#8220;tender systems&#8221; for generic pharmaceuticals have been implemented (by both public and private entities) in a number of significant markets in which we operate, including in some European markets, in an effort to lower prices. Under such tender systems, manufacturers submit bids that establish prices for generic pharmaceutical products. These measures impact marketing practices and reimbursement of drugs and may further increase pressure on reimbursement margins. Certain other countries may consider the implementation of a tender system. Failing to win tenders or our withdrawal from participating in tenders, or the implementation of similar systems in other markets leading to further price declines, could have a material adverse effect on our business, financial position and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A significant portion of our revenues is derived from sales to a limited number of customers. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant portion of our revenues is derived from sales to a limited number of customers. If we were to experience a significant reduction in or loss of business with one or more such customers, or if one or more such customers were to experience difficulty in paying us on a timely basis, our business, financial condition and results of operations could be materially adversely affected. For a description of our revenue from our main customers, see note 19 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to find or successfully bid for suitable acquisition targets or licensing opportunities, or consummate and integrate future acquisitions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We may evaluate or pursue potential acquisitions, strategic alliances and licenses, among other transactions, as part of our business strategy. Relying on acquisitions, licensing agreements and other transactions as sources of new specialty, biosimilar and other products, or as a means of growth, involves risks that could adversely affect our future revenues and operating results. We may not be successful in seeking or consummating appropriate opportunities to enable us to execute our business strategy. We may not be able to pursue relevant acquisitions and licensing opportunities due to financial capacity constraints, and we may not be able to obtain necessary regulatory approvals, including those of competition authorities, and as a result, or for other reasons, we may fail to consummate an announced acquisition. We may fail to integrate acquisitions successfully into our existing business, and could incur or assume significant debt and unknown or contingent liabilities, including, among others, patent infringement or product liability claims. In addition, partners for which we may enter into licensing or other collaboration agreements may not be able to perform their responsibilities challenging the ability to monetize opportunities related to them.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may decide to sell assets, which could adversely affect our prospects and opportunities for growth. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We may from time to time consider selling certain assets if we determine that such assets are not critical to our strategy or we believe the opportunity to monetize the asset is attractive or for various other reasons, including for the reduction of indebtedness. We closed or divested a significant number of manufacturing plants and R&amp;D facilities between 2017 and 2019 in connection with our restructuring plan and may close or divest additional plants and facilities as part of our ongoing efficiency measures and plant rationalization process. We have explored and may continue to explore the sale of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-core</div> assets. We may fail to identify appropriate opportunities to divest assets on terms acceptable to us or may fail to transition employees and continuing operations from disposed businesses efficiently. If divestiture opportunities are found, consummation of any such divestiture may be subject to closing conditions, including obtaining necessary regulatory approvals, including those of competition authorities, and as a result, or for other reasons, we may fail to consummate an announced divestiture. Although our expectation is to engage in asset sales only if they advance or otherwise support our overall strategy, any such sale could reduce the size or scope of our business, the durability of our manufacturing network, our market share in particular markets or our opportunities with respect to certain markets. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance, regulatory and litigation risks </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our operations are subject to complex legal and regulatory environments. If we fail to comply with applicable laws and regulations we may suffer legal consequences that may have a material effect on our business, operations or reputation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate around the world in complex legal and regulatory environments. Any failure to comply with applicable laws, rules and regulations may result in civil and/or criminal legal proceedings and lead to fines, damages, mandated compliance programs and other sanctions and remedies that may materially affect our business and operations as well as our reputation. In addition, as rules and regulations change or as interpretations of those rules and regulations evolve, our prior conduct or that of companies we have acquired may be investigated. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Examples of rules and regulations impacting our operations include rules and regulations applicable to the sales and marketing of our products, competition laws, trade control laws, anti-bribery laws, privacy laws, compliance with cGMP, labor laws, safety and laws regarding manufacturing practices, product labeling, advertising and post marketing reporting including adverse event reports and field alerts due to manufacturing quality concerns, tax and financial reporting laws and environmental laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are currently subject to several governmental and civil proceedings and litigations relating to our pricing and marketing practices, intellectual property, product liability, competition matters, opioids, securities disclosure and corporate governance and environmental matters. These investigations and litigations are costly and involve a significant diversion of management attention. Such proceedings are unpredictable and may develop over lengthy periods of time. An adverse resolution of these proceedings may result in large monetary fines, damages, additional litigation, such as securities and derivative actions, and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> sanctions and remedies, such as mandated compliance agreements, which can be expensive and disruptive to operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Public concern over the abuse of&#160;opioid&#160;medications, including increased legal and regulatory action, could negatively affect our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain governmental and regulatory agencies are focused on the abuse of opioid medications in the United States. U.S. federal, state and local governmental and regulatory agencies are conducting investigations of us, other pharmaceutical manufacturers and other supply chain participants with regard to the manufacture, sale, marketing and distribution of opioid medications. A number of state attorneys general, including a coordinated multistate effort, are investigating our sales and marketing of opioids, and we have received subpoenas from the DOJ seeking documents relating to the manufacture, marketing and sale of opioid medications. In addition, we are currently litigating civil claims and administrative actions brought by various states and political subdivisions as well as private claimants, against various manufacturers, distributors and retail pharmacies throughout the United States in connection with our manufacture, sale and distribution of opioids. Also, several jurisdictions and consumers in Canada have initiated litigation regarding opioids alleging similar claims as those in the United States, and we may be sued in other jurisdictions globally for similar claims as well. For further information, including on a nation-wide framework agreement we entered into with a group of attorney generals, see &#8220;Opioids Litigation&#8221; in note 12 to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the costs and potential consequences associated with defending the governmental investigations and legal proceedings, legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not able to predict. For example, a number of states, including New York, have enacted legislation that requires the payment of assessments or taxes on the sale or distribution of opioid medications in those states. If other state or local jurisdictions successfully enact similar legislation and we are not able to mitigate the impact on our business through operational changes or commercial arrangements, such legislation in the aggregate may have a material adverse effect on our business, financial condition and results of operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, we utilize controlled substances in certain of our current products and products in development, and therefore must meet the requirements of the Controlled Substances Act of 1970 and related regulations administered by the DEA in the U.S., as well as the requirements of similar laws and regulations in other countries where we operate, relating to the manufacture, shipment, storage, sale, and use of controlled substances. While we are committed to compliance and have robust compliance systems in place, risk associated with these laws and regulations cannot be entirely eliminated by policies and procedures. The DEA and other regulatory agencies also set annual procurement quotas that limit the availability of the controlled substances used in certain of our current products and products in development, and quota levels may impact our ability to meet commercial demand or complete clinical trials. In addition, prescription drug abuse and the diversion of opioids and other controlled substances are the frequent subject of public attention, which presents significant reputational risk. The occurrence of any of the above risks could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or share price. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The pharmaceutical sector is facing increased government scrutiny from competition and pricing authorities around the world, which may expose us to significant damages and commercial restrictions that can materially and adversely affect our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are required to comply with competition laws in the territories where we do business around the world. Compliance with these laws has been the subject of increasing focus and activity by regulatory authorities, both in the United States and Europe, in recent years. Alleged actions by our employees, in violation of such laws, or evolving interpretations of competition law as applicable to certain practices, have exposed us, and may further expose us, to investigations and legal proceedings, which may result in significant liability for violations of competition laws, which may have a material adverse effect on our reputation, business, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to a DOJ civil investigation and a criminal indictment charging Teva USA with criminal felony Sherman Act violations, that, if resulting in a conviction or guilty plea, could have a material adverse effect on our business, including monetary penalties, debarment from federally funded health care programs and reputational harm. In addition, we are a party to numerous civil claims brought by state officials and private plaintiffs alleging that Teva, together with other pharmaceutical manufacturers, engaged in conspiracies to fix prices and/or allocate market share of generic products in the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have been involved in numerous litigations involving challenges to the validity or enforceability of listed patents (including our own), and therefore settling patent litigations has been and will likely continue to be an important part of our business. We have been facing increased scrutiny of our patent settlements, including from the U.S. Federal Trade Commission (&#8220;FTC&#8221;) and the European Commission. Accordingly, we may receive formal or informal requests from competition law authorities around the world for information about a particular settlement agreement, and there is a risk that governmental authorities, customers, other downstream purchasers or others may commence actions against us alleging violations of antitrust laws. We are currently defendants in antitrust actions brought by U.S. states, the European Commission and private plaintiffs involving numerous settlement agreements and, since 2015, we are subject to a consent decree with the FTC, which imposes on us certain injunctive reliefs with respect to our ability to enter into patent settlements in the United States. The U.S. Congress and certain state legislatures in the United States have also passed, or proposed passing, legislation that could adversely impact our ability to settle patent litigations. For example, the State of California has enacted legislation that prohibits, with certain exceptions and safe harbors, various types of patent litigation settlements, and imposes substantial monetary penalties on companies and individuals who do not comply. Such legislation creates a risk of significant potential exposure for settling patent litigations and, in turn, makes it more difficult to settle in the first place, which could have a material adverse effect on our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following calls in recent years from policy makers and other stakeholders in many countries for governmental intervention against the high prices of certain pharmaceutical products, we are currently, and may in the future be, subject to governmental investigations, claims or other legal or regulatory actions regarding our </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pricing and/or other alleged exclusionary practices. These include U.S. Congressional investigations regarding both our specialty and generic medicines, the European Commission&#8217;s inquiry into COPAXONE and the U.K. Competition and Markets Authority inquiry regarding hydrocortisone. Also, in September 2020, the U.S. House Committee on Oversight and Reform held a hearing focused on pricing of branded medications, which focused in part on historic pricing of COPAXONE in the U.S. It is not possible to predict the ultimate outcome of any such investigations, claims or proceedings or what other investigations or lawsuits or regulatory responses may result from such assertions, which could have a material adverse effect on our reputation, business, financial condition and results of operations. See note 12 to our consolidated financial statements for more information on our material investigations, proceedings and litigations relating to competition law and governmental investigations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third parties may claim that we infringe their proprietary rights and may prevent us from manufacturing and selling some of our products, and we have sold and may in the future elect to sell products prior to the final resolution of outstanding patent litigation, and, as a result, we could be subject to liability for damages in the United States, Europe and other markets where we do business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our ability to introduce new products depends in large part upon the success of our challenges to patent rights held by third parties or our ability to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> products. Based upon a variety of legal and commercial factors, we may elect to sell a product even though patent litigation is still pending, either before any court decision is rendered or while an appeal of a lower court decision is pending. The outcome of such patent litigation could, in certain cases, materially adversely affect our business. For example, we launched a generic version of Protonix<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (pantoprazole) despite pending litigation with the company that sells the brand versions, which we eventually settled in 2013 for $1.6&#160;billion. For further details, see note 12 to our consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we sell products prior to a final court decision, whether in the United States, Europe or elsewhere, and such decision is adverse to us, we could be required to cease selling the infringing products, causing us to lose future sales revenue from such products and to face substantial liabilities for patent infringement, in the form of either payment for the innovator&#8217;s lost profits or a royalty on our sales of the infringing products. These damages may be significant, and could materially adversely affect our business. In the United States, in the event of a finding of willful infringement, the damages assessed may be up to three times the profits lost by the patent owner. Because of the discount pricing typically involved with generic pharmaceutical products, patented brand products generally realize a significantly higher profit margin than generic pharmaceutical products. As a result, the damages assessed may be significantly higher than our profits. In addition, even if we do not suffer damages, we may incur significant legal and related expenses in the course of successfully defending against infringement claims. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be susceptible to significant product liability claims that are not covered by insurance. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business inherently exposes us to claims for injuries allegedly resulting from the use of our products. As our portfolio of available products expands, particularly with new specialty products, we may experience increases in product liability claims asserted against us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva maintains an insurance program, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both approaches, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. Teva sells, and will continue to sell, pharmaceutical products that are not covered by its product liability insurance. In addition, it may be subject to claims for which insurance coverage is denied, as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in the markets in which it operates. For details regarding our current material product liability cases, see note 12 to our consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any failure to comply with the complex reporting and payment obligations under the Medicare and Medicaid programs may result in further litigation or sanctions, in addition to those that we have announced in previous years. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The U.S. laws and regulations regarding Medicare and/or Medicaid reimbursement and rebates and other governmental programs are complex. Some of the applicable laws may impose liability even in the absence of specific intent to defraud. The subjective decisions and complex methodologies used in making calculations under these programs are subject to review and challenge, and it is possible that such reviews could result in material changes. A number of state attorney generals and others have filed lawsuits alleging that we and other pharmaceutical companies reported inflated average wholesale prices, leading to excessive payments by Medicare and/or Medicaid for prescription drugs. In addition, the U.S. government has alleged violations of the federal Anti-Kickback Statute, and related causes of action under the federal False Claims Act and state law in connection with Teva&#8217;s donations to patient assistance programs. Such allegations could, if proven or settled, result in additional monetary penalties (beyond the lawsuits we have already settled) and possible exclusion from Medicare, Medicaid and other programs. In addition, we are notified from time to time of governmental investigations regarding drug reimbursement or pricing issues. See &#8220;Government Investigations and Litigation Relating to Pricing and Marketing&#8221; in note 12 to our consolidated financial statements. Certain parts of Medicare benefits are under scrutiny, as the U.S. Congress looks for ways to reduce government spending on prescription medicines. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanctions and other trade control laws create the potential for significant liabilities, penalties and reputational harm. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As a company with global operations, we may be subject to national laws as well as international treaties and conventions controlling imports, exports, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-export,</div> transfer and diversion of goods (including finished goods, materials, APIs, packaging materials, other products and machines), services and technology. These include import and customs laws, export controls, trade embargoes and economic sanctions, restrictions on sales to parties that are listed on (or are owned or controlled by one or more parties listed on) denied party watch lists and anti-boycott measures (collectively &#8220;Customs and Trade Controls&#8221;). Applicable Customs and Trade Controls are administered by Israel&#8217;s Ministry of Finance, the U.S. Treasury&#8217;s Office of Foreign Assets Control (OFAC), the U.S. Department of Commerce, other U.S. agencies and multiple other agencies of other jurisdictions around the world where we do business. Customs and Trade Controls relate to a number of aspects of our business, including most notably the sales of finished goods and API as well as the licensing of our intellectual property. Compliance with Customs and Trade Controls has been the subject of increasing focus and activity by regulatory authorities, both in the United States and elsewhere, in recent years, and requirements under applicable Customs and Trade Controls in general, change frequently. Although we have policies and procedures designed to address compliance with Customs and Trade Controls, actions by our employees, by third-party intermediaries (such as distributors and wholesalers) or others acting on our behalf in violation of relevant laws and regulations may expose us to liability and penalties for violations of Customs and Trade Controls and accordingly may have a material adverse effect on our reputation and our business, financial condition and results of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our failure to comply with applicable environmental laws and regulations worldwide could adversely impact our business and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to laws and regulations concerning the environment, safety matters, regulation of chemicals and product safety in the countries where we manufacture and sell our products or otherwise operate our business. These requirements include regulation of the handling, manufacture, transportation, storage, use and disposal of materials, including the discharge of pollutants into the environment. If we fail to comply with these laws and regulations, we may be subject to enforcement proceedings including fines and penalties. In the normal course of our business, we are also exposed to risks relating to possible releases of hazardous substances into the environment, which could cause environmental or property damage or personal injuries, and which could require remediation of contaminated soil and groundwater. Under certain laws, we may be required to remediate </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contamination at certain of our properties, regardless of whether the contamination was caused by us or by previous occupants or users of the property. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional financial risks </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because we have substantial international operations, our sales and profits may be adversely affected by currency fluctuations and restrictions as well as credit risks. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, approximately 48% of revenues were denominated in currencies other than the U.S. dollar. As a result, we are subject to significant foreign currency risks, including repatriation restrictions in certain countries, and may face heightened risks as we enter new markets. An increasing proportion of our sales, particularly in Latin America, Central and Eastern European countries and Asia, are recorded in local currencies, which exposes us to the direct risk of devaluations, hyperinflation or exchange rate fluctuations. Exchange rate movements during 2020 in comparison with 2019, including hedging effects, negatively impacted overall revenues by $33&#160;million and operating income (loss) by $56&#160;million. The imposition of price controls or restrictions on the conversion of foreign currencies could also have a material adverse effect on our financial results. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In particular, although the majority of our net sales and operating costs is recorded in, or linked to, the U.S. dollar, our reporting currency, in 2020 we incurred a substantial amount of operating costs in currencies other than the U.S. dollar. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, fluctuations in exchange rates between the currencies in which such costs are incurred and the U.S. dollar may have a material adverse effect on our results of operations, the value of balance sheet items denominated in foreign currencies and our financial condition. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We use derivative financial instruments and &#8220;hedging&#8221; techniques to manage our balance sheet and operating income net exposure to currency exchange rate fluctuations in the major foreign currencies in which we operate. However, not all of our potential exposure is covered, and some elements of our consolidated financial statements, such as our equity position, are not fully protected against foreign currency exposures. Therefore, our exposure to exchange rate fluctuations could have a material adverse effect on our financial results. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our intangible assets may continue to lead to significant impairments in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We regularly review our long-lived assets, including identifiable intangible assets, goodwill and property, plant and equipment, for impairment. Goodwill and acquired indefinite life intangible assets are subject to impairment review on an annual basis and whenever potential impairment indicators are present. Other long-lived assets are reviewed when there is an indication that impairment may have occurred. The amount of goodwill, identifiable intangible assets and property, plant and equipment on our consolidated balance sheet may increase following acquisitions or other collaboration agreements. Changes in market conditions or other changes in the future outlook of value may lead to further impairments in the future. In addition, the potential divestment of assets, including the closure or divestment of manufacturing plants and R&amp;D facilities, headquarters and other office locations, may lead to additional impairments. Future events or decisions may lead to asset impairments and/or related charges. For assets that are not impaired, we may adjust the remaining useful lives. Certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> impairments may result from a change in our strategic goals, business direction or other factors relating to the overall business environment. Any significant impairment could have a material adverse effect on our results of operations. See notes 6 and 7 in our consolidated financial statements, for descriptions of impairments of intangible assets and goodwill in recent periods. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our tax liabilities could be larger than anticipated. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to tax in many jurisdictions, and significant judgment is required in determining our provision for income taxes. Likewise, we are subject to audit by tax authorities in many jurisdictions. In such </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">audits, our interpretation of tax legislation may be challenged and tax authorities in various jurisdictions may disagree with, and subsequently challenge, the amount of profits taxed in such jurisdictions under our inter-company agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we believe our estimates are reasonable, the ultimate outcome of such audits and related litigation could be different from our provision for taxes and may have a material adverse effect on our consolidated financial statements and cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The base erosion and profit shifting (&#8220;BEPS&#8221;) project undertaken by the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) may have adverse consequences to our tax liabilities. The BEPS project contemplates changes to numerous international tax principles, as well as national tax incentives, and these changes, when adopted by individual countries, could adversely affect our provision for income taxes. The first wave of BEPS recommendations is being implemented by countries in specific national tax laws, and the OECD is currently working on further initiatives that may further change current international tax principles. It remains difficult to predict the magnitude of the effect of such new rules on our financial results. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The termination or expiration of governmental programs or tax benefits, or a change in our business, could adversely affect our overall effective tax rate. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our tax expenses and the resulting effective tax rate reflected in our consolidated financial statements may increase over time as a result of changes in corporate income tax rates, other changes in the tax laws of the various countries in which we operate or changes in our product mix or the mix of countries where we generate profit. We have benefited, and currently benefit, from a variety of Israeli and other government programs and tax benefits that generally carry conditions that we must meet in order to be eligible to obtain such benefits. If we fail to meet the conditions upon which certain favorable tax treatment is based, we would not be able to claim future tax benefits and could be required to refund tax benefits already received. Additionally, some of these programs and the related tax benefits are available to us for a limited number of years, and these benefits expire from time to time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of the following could have a material effect on our overall effective tax rate: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">some government programs may be discontinued, or the applicable tax rates may increase; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be unable to meet the requirements for continuing to qualify for some programs and the restructuring plan may lead to the loss of certain tax benefits we currently receive; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">these programs and tax benefits may be unavailable at their current levels; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon expiration of a particular benefit, we may not be eligible to participate in a new program or qualify for a new tax benefit that would offset the loss of the expiring tax benefit; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to refund previously recognized tax benefits if we are found to be in violation of the stipulated conditions. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity ownership risks </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shareholder rights and responsibilities as a shareholder are governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The rights and responsibilities of the holders of our ordinary shares are governed by our articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders of U.S. corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising his or her rights and performing his or her obligations towards the company and other shareholders, and to refrain from abusing his or her power in the company, including, among other things, in voting at a general meeting of shareholders on matters such as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law available to assist in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provisions of Israeli law and our articles of association may delay, prevent or make difficult an acquisition of us, prevent a change of control and negatively impact our share price. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Israeli corporate law regulates acquisitions of shares through tender offers and mergers, requires special approvals for transactions involving directors, officers or significant shareholders, and regulates other matters that may be relevant to these types of transactions. Furthermore, Israeli tax considerations may make potential acquisition transactions unappealing to us or to some of our shareholders. For example, Israeli tax law may subject a shareholder who exchanges his or her ordinary shares for shares in a foreign corporation to taxation before disposition of the investment in the foreign corporation. These provisions of Israeli law may delay, prevent or make difficult an acquisition of our company, which could prevent a change of control and, therefore, depress the price of our shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our articles of association contain certain provisions that may make it more difficult to acquire us, such as provisions that provide for a classified board of directors and that our Board of Directors may issue preferred shares. These provisions may have the effect of delaying or deterring a change in control of us, thereby limiting the opportunity for shareholders to receive a premium for their shares and possibly affecting the price that some investors are willing to pay for our securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ADSs and ordinary shares are traded on different markets and this may result in price variations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ADSs have been traded in the United States since 1982, and since 2012 on the New York Stock Exchange (the &#8220;NYSE&#8221;), and our ordinary shares have been listed on the TASE since 1951. Trading in our securities on these markets takes place in different currencies (our ADSs are traded in U.S. dollars and our ordinary shares are traded in New Israeli Shekels), and at different times (resulting from different time zones, different trading days and different public holidays in the United States and Israel). As a result, the trading prices of our securities on these two markets may differ due to these factors. In addition, any decrease in the price of our securities on one of these markets could cause a decrease in the trading price of our securities on the other market. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">It may be difficult to enforce a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Israeli</div> judgment against us, our officers and our directors. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are incorporated in Israel. Certain of our executive officers and directors and our outside auditors are not residents of the United States, and a substantial portion of our assets and the assets of these persons are located outside the United States. Therefore, it may be difficult for an investor, or any other person or entity, to enforce against us or any of those persons in an Israeli court a U.S. court judgment based on the civil liability provisions of the U.S. federal securities laws. It may also be difficult to effect service of process on these persons in the United States. Additionally, it may be difficult for an investor, or any other person or entity, to enforce civil liabilities under U.S. federal securities laws in original actions filed in Israel. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="toc102112_5" style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ITEM&#160;1B.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNRESOLVED STAFF COMMENTS </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;2. PROPERTIES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We own or lease 86 manufacturing and R&amp;D facilities, occupying approximately 25.2&#160;million square feet. As of December&#160;31, 2020, our manufacturing and R&amp;D facilities are used by our business segments as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Segment</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Facilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Square&#160;Feet</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Worldwide Total Manufacturing and R&amp;D Facilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the manufacturing facilities discussed above, we maintain numerous office, distribution and warehouse facilities around the world. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We generally seek to own our manufacturing and R&amp;D facilities, although some, principally in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> locations, are leased. Office, distribution and warehouse facilities are often leased. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are committed to maintaining all of our properties in good operating condition and repair, and the facilities are well utilized. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In Israel, our principal executive offices and corporate headquarters recently relocated from Petach-Tikva to Tel Aviv-Jaffa. Our executive offices in Petach-Tikva are leased until December 2021 and we have an operating lease for the office space in Tel Aviv-Jaffa for an initial term of twelve and a half years, with an option for three extensions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In North America, our principal executive offices are our U.S. headquarters in Parsippany, New Jersey. In Europe, our principal executive offices are in Amsterdam, the Netherlands. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are continuing the ongoing review and optimization of our manufacturing and supply network, which may include closures and/or divestment of manufacturing plants around the world. </div></div> <div id="toc102112_7" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;3.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>LEGAL PROCEEDINGS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information pertaining to legal proceedings can be found in &#8220;Item 8&#8212;Financial Statements&#8212;Note&#160;12b.&#8212;Contingencies&#8221; and is incorporated by reference herein. </div></div> <div id="toc102112_8" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;4. MINE SAFETY DISCLOSURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div id="toc102112_9" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM 5. MARKET FOR THE COMPANY&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">American Depositary Shares (&#8220;ADSs&#8221;) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ADSs, which have been traded in the United States since 1982, were admitted to trade on the Nasdaq National Market in October 1987 and were subsequently traded on the Nasdaq Global Select Market. On May&#160;30, 2012, we transferred the listing of our ADSs to the New York Stock Exchange (the &#8220;NYSE&#8221;). The ADSs are </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">quoted under the symbol &#8220;TEVA.&#8221; Citibank, N.A. serves as depositary for the ADSs. Each ADS represents one ordinary share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Various other stock exchanges quote derivatives and options on our ADSs under the symbol &#8220;TEVA.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ordinary shares have been listed on the Tel Aviv Stock Exchange (&#8220;TASE&#8221;) since 1951. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of record holders of ADSs at December&#160;31,&#160;2020&#160;was&#160;2,747. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of record holders of ordinary shares at December&#160;31,&#160;2020&#160;was&#160;185. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of record holders is based upon the actual number of holders registered on our books at such date and does not include holders of shares in &#8220;street names&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not paid dividends on our ordinary shares or ADSs since December 2017. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unregistered Sales of Equity Securities and Use of Proceeds </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Graph </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set forth below is a performance graph comparing the cumulative total return (assuming reinvestment of dividends), in U.S. dollars, for the calendar years ended December&#160;31, 2016, 2017, 2018, 2019 and 2020, of $100 invested on December&#160;31, 2015 in the Company&#8217;s ADSs, the Standard&#160;&amp; Poor&#8217;s 500 Index and the Dow Jones U.S.&#160;Pharmaceuticals Index. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g102112g01r43.jpg" style="width: 601px; height: 218px;"/><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">$100 invested on December&#160;31, 2015 in stock or index&#8212;including reinvestment of dividends. Indexes calculated on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-end</div> basis. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_10" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;6. SELECTED FINANCIAL DATA </div></div></div> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Data </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2018&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2017&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2016&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;dollars&#160;in&#160;millions,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Statement Data:&#160;<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(a)</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net&#160;revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,887</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,811</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,726</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,077</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling and marketing expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,498</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,614</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,916</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,502</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,991</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">900</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other asset impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">479</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">423</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">987</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,836</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,208</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(76</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(291</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,199</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(769</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,572</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(443</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17,484</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">822</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">959</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">895</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18,379</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(278</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in (profits) losses of associated companies, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,099</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,449</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">311</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(109</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(322</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(184</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(999</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,150</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">329</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued dividends on preferred shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(999</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,399</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16,525</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings (loss) per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic ($)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted ($)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares (in millions):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">955</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a discussion of items that affected the comparability of results for the years 2020 and 2019, refer to &#8220;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance Sheet Data </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As at December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2016</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial assets (cash, cash equivalents and investment in securities)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,846</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,949</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,923</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,232</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,640</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,624</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,846</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,917</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Working capital (operating assets minus liabilities)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">662</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(186</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(384</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,640</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,683</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70,615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term debt, including current maturities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,188</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,646</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net of current maturities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,731</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,562</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,829</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,919</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,908</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,916</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,475</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,794</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,745</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_11" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. Our mission is to be a global leader in generics, specialty medicines and biopharmaceuticals, improving the lives of patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Our key strengths include our world-leading generic medicines expertise and portfolio, focused specialty medicines portfolio and global infrastructure and scale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva was incorporated in Israel on February&#160;13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Business Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate our business through three segments: North America, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, specialty and OTC products. This structure enables strong alignment and integration between operations, commercial regions, R&amp;D and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to these three segments, we have other activities, primarily the sale of API to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a leading global pharmaceutical company, Teva provides essential medicines to millions of patients around the world every day.&#160;Our priorities remain focused on the health and well-being of our employees and on our responsibility to continue to provide our medicines to the nearly 200&#160;million patients who depend on us every day.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our industry plays a critical role, particularly during such challenging times. We are working with governments to do all they can, in partnership with our industry, to maintain the development, production, supply and distribution of high quality medicines for patients worldwide during this unprecedented global health crisis. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Continuity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The supply chain supporting our key products &#8211; specialty, generics and API &#8211; remains largely uninterrupted, and with adequate product inventory across our network. Additionally,&#160;based on analysis of potential scenarios, we currently have inventory and redundancy plans in place to address potential shortfalls, if any. We are closely monitoring the evolving situation in our key manufacturing locations and commercial markets as well as key products, and are accordingly adapting our business continuity plans. All our facilities that research, manufacture, order, pack, distribute and provide critical customer and patient services are currently functioning to meet demand for essential medicines for patients throughout the world. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Teva has worked since the early days of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic to support efforts of governments and health services to curb the impact of the virus. Our global manufacturing network has been tirelessly focused on securing and scaling production of both API and finished doses for potential treatments that were proven essential or may prove essential in treating the condition nearly everywhere Teva does business. Teva will continue to work with governments and international organizations throughout the world to support emerging needs related to this crisis, while doing everything possible to also continue to supply our vast portfolio of medicines to patients. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">R&amp;D and New Launches </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We do not expect a material impact on our ongoing clinical research programs and product launches as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; however, we have experienced minimal delays in clinical trials due to cessation or slow-downs of recruitment for patient studies and suspended regulatory inspections, delays in regulatory approvals of new products due to reduced capacity or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-prioritization</div> of regulatory agencies and delays in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercial</div> launch activities. We may experience further delays if the pandemic continues for an extended period of time. All of our new product launches have been risk-assessed based on upcoming manufacturing and regulatory inspections. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Workforce Policy and Measures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our employees across all aspects of our business are safeguarding the continuity of our activities and we are committed to supporting their efforts while caring for their personal health and safety. We are enacting appropriate measures to ensure the safe supply and transport of our medicines and APIs, and have established measures intended to ensure our sites remain open, allowing us to maintain our business, R&amp;D and manufacturing operations. We have reduced the number of people in our facilities to enable social distancing. By doing our part to reduce physical proximity to one another, we hope to better protect our overall workforce, and ultimately, the communities in which we live. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As we work through this health crisis, we continue to adapt our strategy for returning to usual operations at all organizational levels as events develop, under guiding principles to protect our business and maximize organizational productivity and efficiency, while simultaneously ensuring a safe workplace. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trends </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are still not experiencing material delays in development, production and distribution of medicines or disruptions in our supply chains; however, longer term effects cannot be predicted at this time and would depend on the duration and severity of the pandemic and the restrictive measures put in place to control its impact. In the first quarter of 2020, we experienced increasing demand for certain medicines, as would be expected during a global crisis of this nature. We saw a compensating effect with lower demand for certain medicines during the second quarter of 2020 and continuing slightly lower demand due to less physician and hospital activity in certain regions and for certain medicines in the second half of 2020. Although no one can predict future demand for pharmaceutical products, market dynamics or the scope or duration of the financial and other challenges arising from the pandemic, it is possible that we will continue to see variable demand in 2021, but we do not currently anticipate a material negative impact on our 2021 financial results due to the ongoing global pandemic. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Highlights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant highlights of 2020 included: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our revenues in 2020 were $16,659&#160;million, a decrease of 1% in both U.S. dollar and local currency terms, compared to 2019, mainly due to a decline in revenues from certain oncology products, COPAXONE and certain respiratory products, partially offset by higher revenues from AUSTEDO and AJOVY. The decline in revenues was also affected by reduced demand for certain products resulting from the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our North America segment generated revenues of $8,447&#160;million and profit of $2,421&#160;million in 2020. Revenues decreased by 1% compared to 2019, mainly due to a decline in revenues from COPAXONE, BENDEKA/TREANDA and certain other specialty products, partially offset by higher revenues from AUSTEDO, AJOVY and our U.S. generics business. Our North America segment has experienced some reductions in volume due to less physician and hospital activity during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, but has also experienced increase in demand for certain products related to the treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">and its symptoms. In addition, the ability to promote our new specialty products, primarily AJOVY and AUSTEDO, has been impacted by less physician visits by patients and less physician interactions by our sales personnel. Profit increased by 7%, mainly due to higher gross profit margin and lower R&amp;D expenses. </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our Europe segment generated revenues of $4,757&#160;million and profit of $1,331&#160;million in 2020. Revenues decreased by 1%, or 2% in local currency terms compared to 2019, mainly due to price declines for our oncology products as a result of generic competition and a decline in COPAXONE revenues due to competing glatiramer acetate products, partially offset by the launch of AJOVY. Revenues from generic products were flat, due to a decline in doctor and hospital visits by patients resulting in fewer prescriptions during the second half of 2020 due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, partially offset by new generic product launches. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic caused significant fluctuations in customer stocking throughout 2020, which mostly offset each other by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end.</div> Profit increased by 1%, mainly due to lower S&amp;M expenses. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our International Markets segment generated revenues of $2,154&#160;million and profit of $474&#160;million in 2020. Revenues decreased by 4%, or flat in local currency terms compared to 2019, with higher revenues in most markets offsetting the lower sales in Japan and loss of revenues from divested businesses in Israel. Revenues in 2020 were also impacted by reduced demand for certain products and higher demand for other products, resulting from the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has led to a decline in doctor and hospital visits by patients resulting in fewer prescriptions during 2020. Profit increased by 2%, mainly due to higher revenues in most markets and lower S&amp;M expenses, partially offset by lower sales in Japan. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenues from other activities in 2020 were $1,302&#160;million, flat compared to 2019. In local currency terms, revenues decreased by 1%. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of identifiable intangible assets were $1,502&#160;million and $1,639&#160;million in the years ended December&#160;31, 2020 and 2019, respectively. See note 6 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded a goodwill impairment charge of $4,628&#160;million related to our North America reporting unit in the year ended December&#160;31, 2020. See note 7 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded expenses of $479&#160;million for other asset impairments, restructuring and other items in 2020, compared to expenses of $423&#160;million in 2019. See note 15 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, we recorded an expense of $60&#160;million in legal settlements and loss contingencies, compared to $1,178&#160;million in 2019. See note 11 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss was $3,572&#160;million in 2020, compared to an operating loss of $443&#160;million in 2019. The increase in operating loss in 2020 was mainly due to goodwill impairment charges, partially offset by lower provisions in connection with legal settlements and loss contingencies, as well as higher profit in our North America segment. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses were $834&#160;million in 2020, compared to $822&#160;million in 2019. Financial expenses in 2020 were mainly comprised of interest expenses of $963&#160;million, partially offset by gains on revaluations of marketable securities of $85&#160;million (see note 20 to our consolidated financial statements) as well as a gain of $26&#160;million resulting from our hedging and derivatives activities. Financial expenses in 2019 were mainly comprised of interest expenses of $881&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In 2020, we recognized a tax benefit of $168&#160;million, or 4%, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $4,406&#160;million. In 2019, we recognized a tax benefit of $278&#160;million, or 22%, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $1,265&#160;million. Our tax rate for 2020 was lower than in 2019, mainly due to goodwill impairments that did not have a corresponding tax effect. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange rate movements during 2020, including hedging effects, in comparison with 2019, negatively impacted revenues by $33&#160;million and operating income (loss) by $56&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, our debt was $25,919&#160;million, compared to $26,908&#160;million as of December&#160;31, 2019. This decrease was mainly due to senior notes repaid at maturity with cash generated during the year, partially offset by exchange rate fluctuations. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow generated from operating activities was $1,216&#160;million in 2020, compared to $748&#160;million in 2019. This increase was mainly due to higher profit in our North America segment during 2020. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2020, we generated free cash flow of $2,110&#160;million, which we define as comprising $1,216&#160;million in cash flow generated from operating activities, $1,405&#160;million in beneficial interest collected in exchange for securitized accounts receivables and $67&#160;million in proceeds from sale of property, plant and equipment and intangible assets, partially offset by $578&#160;million in cash used for capital investments. The increase in 2020 compared to 2019, resulted mainly from higher cash flow generated from operating activities, partially offset by less cash generated from sales of assets and higher capital investments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alvotech Partnership </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, we entered into a partnership agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this partnership contains biosimilar candidates addressing multiple therapeutic areas. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. We paid an upfront payment in the third quarter of 2020 that was recorded as R&amp;D expenses. During the fourth quarter of 2020, we accrued additional amounts due to the high probability that additional milestone payments will be paid in 2021. Additional development and commercial milestone payments of up to $450&#160;million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The discussion that follows includes a comparison of our results of operations and liquidity and capital resources for fiscal years 2020 and 2019. For a comparison of our results of operations and financial condition for fiscal years 2019 and 2018, see &#8220;Item 7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of our 2019 Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> filed with the SEC on February&#160;21, 2020. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment Information </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our North America segment for the past two years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions&#160;/&#160;%&#160;of&#160;Segment&#160;Revenues)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">652</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">439</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,252</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our North America segment includes the United States and Canada. Revenues from our North America segment in 2020 were $8,447&#160;million, a decrease of $95&#160;million, or 1%, compared to 2019, mainly due to a decline in revenues from COPAXONE, BENDEKA/TREANDA and certain other specialty products, partially offset by higher revenues from AUSTEDO, AJOVY and our U.S. generics business. Our North America segment has experienced some reductions in volume due to less physician and hospital activity during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, but has also experienced increase in demand for certain products related to the treatment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and its symptoms. In addition, the ability to promote our new specialty products, primarily AJOVY and AUSTEDO, has been impacted by less physician visits by patients and less physician interactions by our sales personnel. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our North America segment by major products and activities for the past two years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019-2020</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">884</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProAir*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">241</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QVAR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Does not include revenues from the ProAir authorized generic, which are included under generic products. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Generic products </div></div>revenues in our North America segment (including biosimilars) in 2020 increased by 1% to $4,010&#160;million, compared to 2019, mainly due to higher revenues from TRUXIMA (the biosimilar to Rituxan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), our ProAir authorized generic and new generic product launches, partially offset by lower revenues from other generic products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Among the most significant generic products we sold in North America in 2020 were TRUXIMA, albuterol sulfate inhalation aerosol (our ProAir<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>authorized generic), emtricitabine and tenofovir disoproxil fumarate tablets (the generic equivalent of Truvada<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), epinephrine injectable solution (the generic equivalent of EpiPen<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and EpiPen Jr.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) and lidocaine transdermal patch (the generic equivalent of Lidoderm Patch<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on our generic products, including biosimilars, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Generic Medicines.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, we led the U.S. generics market in total prescriptions and new prescriptions, with approximately 348&#160;million total prescriptions (based on trailing twelve months), representing 9.6% of total U.S. generic prescriptions according to IQVIA data. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AJOVY </div></div>revenues in our North America segment in 2020 increased by 45% to $134&#160;million, compared to 2019, mainly due to growth in volume. In 2020, AJOVY&#8217;s exit market share in the United Stated in terms of total number of prescriptions was 20%, compared to 17% in 2019. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on AJOVY, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8212;AJOVY.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AUSTEDO </div></div>revenues in our North America segment in 2020 increased by 55% to $637&#160;million, compared to 2019. This increase was mainly due to growth in volume. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on AUSTEDO, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8212;AUSTEDO.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BENDEKA </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> TREANDA</div></div> combined revenues in our North America segment in 2020 decreased by 16% to $415&#160;million, compared to 2019, mainly due to the emergence of alternative novel therapies and continued competition from Belrapzo<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>(a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ready-to-dilute</div></div> bendamustine hydrochloride product from Eagle). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on BENDEKA and TREANDA, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8212;Oncology.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COPAXONE</div></div> revenues in our North America segment in 2020 decreased by 13% to $884&#160;million, compared to 2019, mainly due to generic competition in the United States. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on COPAXONE, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8212;COPAXONE.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ProAir</div></div> (HFA and RespiClick) revenues in our North America segment in 2020 decreased by 12% to $241&#160;million, compared to 2019. In January 2019, we launched our own ProAir authorized generic in the United States, following the launch of a generic version of Ventolin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> HFA, another albuterol inhaler. Revenues from our ProAir authorized generic are included in &#8220;generic products&#8221; above. In 2020, ProAir was the fourth largest short-acting beta-agonist in the market, with an exit market share of 10.2% in terms of total number of prescriptions for albuterol inhalers, compared to 23.3% in 2019. The exit market share including our ProAir authorized generic is 40.1%, making our overall albuterol product the largest in the market, compared to 45.8% in 2019. Generic versions of ProAir were launched in 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on ProAir and our Digihaler portfolio, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8212;Respiratory.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">QVAR</div></div> revenues in our North America segment in 2020 decreased by 28% to $179&#160;million, compared to 2019. This decrease was mainly due to lower volume. In 2020, QVAR maintained its second-place position in the inhaled corticosteroids category in the United&#160;States, with an exit market share of 17.4% in terms of total number of prescriptions, compared to 20.5% in 2019. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Anda</div></div> revenues from third parties in our North America segment in 2020 decreased by 2% to $1,462&#160;million, compared to 2019. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Launches and Pipeline </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, we launched the generic version of the following branded products and biosimilars in the United States: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Brand<br/>Name</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Launch<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Annual&#160;U.S.<br/>Branded&#160;Sales&#160;at&#160;Time<br/>of Launch<br/>(U.S.&#160;$ in millions<br/>(IQVIA))&#160;<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Doxepin tablets, 3 mg&#160;&amp; 6 mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Silenor<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">January</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HERZUMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (trastuzumab-pkrb) for injection, 150 mg/vial&#160;&amp; 420 mg/vial <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Herceptin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">March</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferasirox Tablets, 180mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Jadenu<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Romidepsin Injection, 27.5mg/5.5 mL (5mg/mL) <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">April</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vigabatrin for Oral Solution, USP, 500mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Sabril<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">May</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Everolimus Tablets, 2.5mg, 5mg&#160;&amp; 7.5mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Anfinitor<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">June</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Imiquimod Cream 3.75% <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Zyclara<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">July</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sildenafil for Oral Suspension</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Revatio<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PEG-3350,</div> Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">MoviPrep<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">August</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tobramycin Inhalation Solution, USP</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Bethkis<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">September</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dimethyl Fumarate Delayed-Release Capsules</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Tecfidera<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">September</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Atripla<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">September</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200mg/300mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Truvada<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">September</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Methylphenidate Hydrochloride Extended-Release Capsules</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Aptensio<br/>XR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">October</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alvimopan Capsules</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Entereg<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Colchicine Tablets, USP</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Colcrys<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">December</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The figures presented are for the twelve months ended in the calendar quarter immediately prior to our launch or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-launch.</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biosimilar. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approved via 505(b)(2) regulatory pathway; not equivalent to a brand product. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Authorized generic. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, our generic products pipeline in the United States includes 213 product applications awaiting FDA approval, including 75 tentative approvals. This total reflects all pending ANDAs, supplements for product line extensions and tentatively approved applications and includes some instances where more than one application was submitted for the same reference product. Excluding overlaps, the branded products underlying these pending applications had U.S. sales for the twelve months ended September&#160;30, 2020 exceeding $110&#160;billion, according to IQVIA. Approximately 70% of pending applications include a paragraph IV patent challenge and we believe we are first to file with respect to 80 of these products, or 104 products including final approvals where launch is pending a settlement agreement or court decision. Collectively, these first to file opportunities represent over $78&#160;billion in U.S. brand sales for the twelve months ended September&#160;30, 2020, according to IQVIA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">IQVIA reported brand sales are one of the many indicators of future potential value of a launch, but equally important are the mix and timing of competition, as well as cost effectiveness. The potential advantages of being the first filer with respect to some of these products may be subject to forfeiture, shared exclusivity or competition from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> &#8220;authorized generics,&#8221; which may ultimately affect the value derived. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In 2020, we received tentative approvals for generic equivalents of the products listed in the table below, excluding overlapping applications. A &#8220;tentative approval&#8221; indicates that the FDA has substantially completed its review of an application and final approval is expected once the relevant patent expires, a court decision is reached, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> regulatory stay lapses or a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">180-day</div> exclusivity period awarded to another manufacturer either expires or is forfeited. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Brand&#160;Name</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;U.S.&#160;Annual&#160;Branded<br/>Market (U.S.&#160;$<br/>in&#160;millions&#160;(IQVIA))*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eliglustat Capsules, 84mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Cerdela<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Icosapent Capsules, 500mg&#160;&amp; 1000mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Vascepa<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Macitenta Tablets, 10mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Opsumit<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">590</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pemetrexed Disodium Injection, 100mg vial</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Alimta<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Apixaban Tablets, 2.5 mg and 5 mg</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Eliquisr<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">11,445</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pirfenidone Tablets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Esbriet<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Micafungin for Injection</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Mycamine<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the twelve months ended in the calendar quarter immediately prior to the receipt of tentative approval. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our specialty product pipeline, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8221; above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our North America segment in 2020 was $4,489&#160;million, an increase of 3% compared to $4,350&#160;million in 2019. This increase was mainly due to higher revenues from AUSTEDO, partially offset by lower revenues from COPAXONE. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin for our North America segment in 2020 increased to 53.1%, compared to 50.9% in 2019. This increase was mainly due to higher revenues from AUSTEDO and a favorable mix of generic products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our North America segment in 2020 were $622&#160;million, a decrease of 5% compared to $652&#160;million in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our R&amp;D expenses in 2020, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses relating to our North America segment in 2020 were $1,013&#160;million, a decrease of 1% compared to $1,021&#160;million in 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our North America segment in 2020 were $443&#160;million, an increase of 1% compared to $439&#160;million in 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Other Income </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income from our North America segment in 2020 was $10&#160;million, compared to $14&#160;million in 2019. Other income in 2020 was mainly comprised of Section&#160;8 recoveries in Canada. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our North America segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our North America segment in 2020 was $2,421&#160;million, an increase of 7% compared to $2,252&#160;million in 2019. This increase was mainly due to higher gross profit margin and lower R&amp;D expenses, as discussed above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our Europe segment for the past two years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions / % of Segment Revenues)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,704</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">247</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">890</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our Europe segment includes the European Union and certain other European countries. Revenues from our Europe segment in 2020 were $4,757&#160;million, a decrease of $38&#160;million, or 1%, compared to 2019. In local currency terms, revenues decreased by 2%, mainly due to price declines for our oncology products as a result of generic competition and a decline in COPAXONE revenues due to competing glatiramer acetate products, partially offset by the launch of AJOVY. Revenues from generic products were flat, due to a decline in doctor and hospital visits by patients resulting in fewer prescriptions during the second half of 2020 due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, partially offset by new generic product launches. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic caused significant fluctuations in customer stocking throughout 2020, which mostly offset each other by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our Europe segment by major products and activities for the past two years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019-2020</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">852</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">432</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">353</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">536</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Generic products</div></div> revenues in our Europe segment in 2020, including OTC products, increased by 1% to $3,513&#160;million, compared to 2019. In local currency terms, revenues were flat, due to a decline in doctor and hospital visits by patients resulting in fewer prescriptions during the second half of 2020 due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, partially offset by new generic product launches. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic caused significant fluctuations in customer stocking throughout 2020, which mostly offset each other by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AJOVY</div></div> revenues in our Europe segment in 2020 were $31&#160;million, compared to $3&#160;million in 2019, mainly due to launches and reimbursements in additional European countries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on AJOVY, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8212;AJOVY.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COPAXONE</div></div> revenues in our Europe segment in 2020 decreased by 7% to $400&#160;million, compared to 2019. In local currency terms, revenues decreased by 9%, mainly due to price reductions resulting from competing glatiramer acetate products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on COPAXONE, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8212;COPAXONE.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Respiratory products</div></div> revenues in our Europe segment in 2020 were $353&#160;million, flat compared to $354&#160;million in 2019. In local currency terms, revenues decreased by 1%. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Launches and Pipeline </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, our generic products pipeline in Europe included 500 generic approvals relating to 71 compounds in 149 formulations, no EMA approvals received. In addition, approximately 1,105 marketing authorization applications pending approval in 37 European countries, relating to 133 compounds in 270 formulations. No applications are pending with the EMA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our specialty product pipeline, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8221; above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our Europe segment in 2020 was $2,666&#160;million, a decrease of 1% compared to $2,704&#160;million in 2019. This decrease was mainly due to lower revenues from COPAXONE and other specialty products, partially offset by the launch of AJOVY. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit margin for our Europe segment in 2020 decreased to 56.0%, compared to 56.4% in 2019. This decrease was mainly due to the change in product mix. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our Europe segment in 2020 were $247&#160;million, a decrease of 6% compared to $262&#160;million in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our R&amp;D expenses in 2020, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">S&amp;M expenses relating to our Europe segment in 2020 were $830&#160;million, a decrease of 7% compared to $890&#160;million in 2019. This decrease was mainly due to lower marketing and travel costs attributed to restrictions related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our Europe segment in 2020 were $261&#160;million, an increase of 9% compared to $239&#160;million in 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit of our Europe segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our Europe segment in 2020 was $1,331&#160;million, an increase of 1% compared to $1,318&#160;million in 2019. The increase was mainly due to lower S&amp;M expenses, as described above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets Segment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues, expenses and profit for our International Markets segment for the past two years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions / % of Segment Revenues)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">427</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#167;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit does not include amortization and certain other items. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than 0.5%. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments. The International Markets segment includes more than 35 countries, covering a substantial portion of the global pharmaceutical market. Our key international markets are Japan, Russia and Israel. The countries in our International Markets segment include highly regulated, pure generic markets, such as Israel, branded generics oriented markets, such as Russia and certain Latin American markets, and hybrid markets, such as Japan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Revenues from our International Markets segment in 2020 were $2,154&#160;million, a decrease of $92&#160;million, or 4%, compared to 2019. In local currency terms, revenues were flat compared to 2019, with higher revenues in most markets offsetting the lower sales in Japan and loss of revenues from divested businesses in Israel. Revenues in 2020 were also impacted by reduced demand for certain products and higher demand for other products, resulting from the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has led to a decline in doctor and hospital visits by patients resulting in fewer prescriptions during 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues by Major Products and Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents revenues for our International Markets segment by major products and activities for the past two years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019-2020</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,792</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Generic products</div></div> revenues in our International Markets segment in 2020, which include OTC products, decreased by 5% to $1,792&#160;million, compared to 2019. In local currency terms, revenues were flat, mainly due to lower revenues in Japan resulting from regulatory price reductions and generic competition to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-patented</div> products, offset by higher revenues in most other markets. Revenues in 2020 were also impacted by reduced demand for certain products and higher demand for other products, resulting from the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has led to a decline in doctor and hospital visits by patients resulting in fewer prescriptions during 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">COPAXONE</div></div> revenues in our International Markets segment in 2020 decreased by 16% to $53&#160;million, compared to 2019. In local currency terms, revenues decreased by 4%. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on COPAXONE, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8212;COPAXONE.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AJOVY.</div></div> On May&#160;12, 2017, we entered into a license and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. (&#8220;Otsuka&#8221;) providing Otsuka with an exclusive license to conduct phase 2 and 3 clinical trials for AJOVY in Japan and, once approved, to commercialize the product in Japan. On July&#160;29, 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan. As a result, Otsuka paid Teva a milestone payment of $15&#160;million in the third quarter of 2020, which was recorded as revenue under &#8220;Other&#8221; in the table above. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Gross Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit from our International Markets segment in 2020 was $1,096&#160;million, a decrease of 6% compared to $1,167&#160;million in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Gross profit margin for our International Markets segment in 2020 decreased to 50.9%, compared to 51.9% in 2019. This decrease was mainly due to lower revenues in Japan resulting from regulatory price reductions and generic competition to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-patented</div> products. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets R&amp;D Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses relating to our International Markets segment in 2020 were $70&#160;million, a decrease of 20% compared to $88&#160;million in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our R&amp;D expenses in 2020, see &#8220;&#8212;Teva Consolidated Results&#8212;Research and Development (R&amp;D) Expenses&#8221; below. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets S&amp;M Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">S&amp;M expenses relating to our International Markets segment in 2020 were $427&#160;million, a decrease of 11% compared to $481&#160;million in 2019. This decrease was mainly due to lower marketing and travel costs attributed to restrictions related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets G&amp;A Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses relating to our International Markets segment in 2020 were $136&#160;million, flat compared to $138&#160;million in 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">International Markets Profit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit of our International Markets segment consists of gross profit less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit from our International Markets segment in 2020 was $474&#160;million, an increase of 2% compared to $464&#160;million in 2019. This increase was mainly due to higher revenues in most markets and lower S&amp;M expenses, partially offset by lower sales in Japan, as discussed above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our North America, Europe or International Markets segments described above. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenues from other activities in 2020 were $1,302&#160;million, flat compared to 2019. In local currency terms, revenues decreased by 1%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">API sales to third parties in 2020 were $774&#160;million, an increase of 3% in both U.S. dollar and local currency terms. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva Consolidated Results </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Revenues in 2020 were $16,659&#160;million, a decrease of 1%, in both U.S. dollar and local currency terms, compared to 2019, mainly due to a decline in revenues from certain oncology products, COPAXONE and certain respiratory products, partially offset by higher revenues from AUSTEDO and AJOVY. The decline in revenues was also affected by reduced demand for certain products resulting from the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. See &#8220;&#8212;North America Revenues,&#8221; &#8220;&#8212;Europe Revenues,&#8221; &#8220;&#8212;International Markets Revenues&#8221; and &#8220;&#8212;Other Activities&#8221; above. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange rate movements during 2020, including hedging effects, negatively impacted revenues by $33&#160;million, compared to 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Profit </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit in 2020 was $7,726&#160;million, an increase of 3% compared to 2019. This increase was mainly a result of the factors discussed above under &#8220;&#8212;North America Gross Profit,&#8221; &#8220;&#8212;Europe Gross Profit&#8221; and &#8220;&#8212;International Markets Gross Profit.&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit as a percentage of revenues was 46.4% in 2020, compared to 44.6% in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This increase in gross profit as a percentage of revenues was mainly due to higher profitability in North America, resulting from higher revenues from AUSTEDO and AJOVY, higher gross profit margin in our U.S. generics business, partially offset by a decline in COPAXONE revenues due to generic competition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling and Marketing (S&amp;M) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses in 2020 were $2,498&#160;million, a decrease of 4% compared to 2019. Our S&amp;M expenses were primarily the result of the factors discussed above under &#8220;&#8212;North America Segment&#8212; S&amp;M Expenses,&#8221; &#8220;&#8212;Europe Segment&#8212; S&amp;M Expenses&#8221; and &#8220;&#8212;International Markets Segment&#8212; S&amp;M Expenses.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses as a percentage of revenues were 15.0% in 2020, compared to 15.5% in 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development (R&amp;D) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our R&amp;D activities for generic products in each of our segments include both (i)&#160;direct expenses relating to product formulation, analytical method development, stability testing, management of bioequivalence and other clinical studies and regulatory filings; and (ii)&#160;indirect expenses, such as costs of internal administration, infrastructure and personnel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our R&amp;D activities for specialty and biosimilar products in each of our segments include costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, clinical trials and product registration costs. These expenditures are reported net of contributions received from collaboration partners. Our spending takes place throughout the development process, including (i)&#160;early-stage projects in both discovery and preclinical phases; (ii)&#160;middle-stage projects in clinical programs up to phase 3; (iii) late-stage projects in phase 3 programs, including where a new drug application is currently pending approval; (iv)&#160;post-approval studies for marketed products; and (v)&#160;indirect expenses, such as costs of internal administration, infrastructure and personnel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net R&amp;D expenses for 2020 were $997&#160;million, a decrease of 1% compared to 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, our R&amp;D expenses were primarily related to specialty product candidates in the pain, neuropsychiatry and respiratory therapeutic areas, with additional activities in selected other areas and generic products including biosimilars. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our lower R&amp;D expenses in 2020, compared to 2019, resulted primarily from project milestone timing and pipeline optimization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses as a percentage of revenues were 6.0% in both 2020 and 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and Administrative (G&amp;A) Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses in 2020 were $1,173&#160;million, a decrease of 2% compared to 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses as a percentage of revenues were 7.0% in 2020, flat compared to 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable Intangible Asset Impairments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded expenses of $1,502&#160;million for identifiable intangible asset impairments in 2020, compared to expenses of $1,639&#160;million in 2019. See note 6 to our consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill Impairment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded a goodwill impairment charge of $4,628&#160;million related to our North America reporting unit in the year ended December&#160;31, 2020. No goodwill impairment charge was recorded in 2019. See note 7 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Asset Impairments, Restructuring and Other Items </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recorded expenses of $479&#160;million for other asset impairments, restructuring and other items in 2020, compared to expenses of $423&#160;million in 2019. For further details, as well as a description of significant regulatory and other events, see note 15 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Settlements and Loss Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, we recorded&#160;an expense of $60&#160;million in legal settlements and loss contingencies, compared to $1,178&#160;million in 2019. The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). The expenses in 2019 were mainly related to an estimated provision recorded in connection with potential settlement of the opioid cases. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Income </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income in 2020 was $40&#160;million, compared to $76&#160;million in 2019. See note 16 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Income (Loss) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss was $3,572&#160;million in 2020, compared to operating loss of $443&#160;million in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss as a percentage of revenues was 21.4% in 2020, compared to 2.6% in 2019. The increase in operating loss in 2020 was mainly due to goodwill impairment charges, partially offset by lower provisions in connection with legal settlements and loss contingencies, as well as higher profit in our North America segment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Expenses, Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses were $834&#160;million in 2020, compared to $822&#160;million in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses in 2020 were mainly comprised of interest expenses of $963&#160;million, partially offset by gains on revaluations of marketable securities of $85&#160;million (see note 20 to our consolidated financial statements) as well as a gain of $26&#160;million resulting from our hedging and derivatives activities. Financial expenses in 2019 were mainly comprised of interest expenses of $881&#160;million. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents a reconciliation of our segment profits to Teva&#8217;s consolidated operating income (loss) and to consolidated income (loss) before income taxes for the past two years: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,252</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit (loss) of other activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,142</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other asset impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">479</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">423</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible asset impairments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,502</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on divestitures, net of divestitures related costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other R&amp;D expenses (income)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs related to regulatory actions taken in facilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">252</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,572</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(443</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">822</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Rate </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2020, we recognized a tax benefit of $168&#160;million, or 4%, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $4,406&#160;million. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2019, we recognized a tax benefit of $278&#160;million, or 22%, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss of $1,265&#160;million. Our tax rate for 2020 was lower than in 2019, mainly due to goodwill impairments that did not have a corresponding tax effect. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The statutory Israeli corporate tax rate was 23% in 2020. Our tax rate differs from the Israeli statutory tax rate mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits in Israel and other countries, as well as infrequent or nonrecurring items with no corresponding tax effect, or with a tax rate that is different from the Israeli tax rate. </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share In (Profits) Losses of Associated Companies, Net </div></div></div> </div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in profits of associated companies, net was $138&#160;million in 2020, compared to share in losses of $13&#160;million in 2019. Our share in profits of associated companies, net in 2020 was mainly due to a gain of $134&#160;million reflecting the difference between the book value of our investment in American Well Corporation and its fair value as of the date it completed its initial public offering in September 2020 (see note 20 to our consolidated financial statements). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) Attributable to Teva </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $3,990 million&#160;in 2020, compared to a net loss of $999&#160;million in 2019. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted Shares Outstanding and Earnings (Loss) Per Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average diluted shares outstanding used for the fully diluted share calculation for 2020 and 2019 was 1,095&#160;million and 1,091&#160;million shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted loss per share for the twelve months ended December&#160;31, 2020 and 2019, no account was taken of the potential dilution that could occur upon the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs granted under employee stock compensation plans and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted loss per share was $3.64 for the year ended December&#160;31, 2020, compared to diluted loss per share of $0.91 for the year ended December&#160;31, 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Count for Market Capitalization </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We calculate share amounts using the outstanding number of shares (i.e., excluding treasury shares) plus shares that would be outstanding upon the exercise of options and vesting of RSUs and performance share units (&#8220;PSUs&#8221;) and the conversion of our convertible senior debentures, in each case, at period end. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,117&#160;million and 1,108&#160;million, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impact of Currency Fluctuations on Results of Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, approximately 48% of our revenues were denominated in currencies other than the U.S. dollar. Since our results are reported in U.S. dollars, we are subject to significant foreign currency risks. Accordingly, changes in the rate of exchange between the U.S. dollar and local currencies in the markets in which we operate (primarily the euro, Israeli shekel, Japanese yen, British pound, Russian ruble, Canadian dollar, Swiss franc, Indian rupee and Polish zloty) impact our results. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2020, the following main currencies relevant to our operations decreased in value against the U.S. dollar (each on an annual average compared to annual average basis): the Argentinian peso by 33%, the Brazilian real by 23%, the Turkish lira by 18%, the Chilean peso by 11% and the Russian ruble by 10%. The following main currencies relevant to our operations increased in value against the U.S. dollar: the Swiss franc by 6%, the Israeli shekel by 4%, the Swedish krona by 3%, the Japanese yen by 2% and the euro by 2%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, exchange rate movements during 2020, including hedging effects, negatively impacted overall revenues by $33&#160;million and negatively impacted our operating income by $56&#160;million in comparison with 2019. In 2020, the positive hedging impact recognized under revenues was $15&#160;million, partially offset by a positive impact of $1&#160;million recognized under cost of sales, in comparison with 2019. Hedging transactions against future projected revenues and expenses are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. See note 10 to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Commencing in the third quarter of 2018, the cumulative inflation in Argentina exceeded 100% or more over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-year</div> period. Although this triggered highly inflationary accounting treatment, it did not have a material impact on our results of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total balance sheet assets were $50,640&#160;million as of December&#160;31, 2020, compared to $57,470&#160;million as of December&#160;31, 2019. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our working capital balance, which includes accounts receivables net of SR&amp;A, inventories, prepaid expenses and other current assets, accounts payables, employee-related obligations, accrued expenses and other current liabilities, was $662&#160;million as of December&#160;31, 2020, compared to $74&#160;million as of December&#160;31, 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash investment in property, plant and equipment in 2020 was $578&#160;million, compared to $525&#160;million in 2019. Depreciation was $537&#160;million in 2020, compared to $609&#160;million in 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents and short-term and long-term investments, as of December&#160;31, 2020, were $2,478&#160;million, compared to $2,033&#160;million as of December&#160;31, 2019. This increase was mainly due to cash flow generated during the year, partially offset by debt repayments as discussed below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cash on hand that is not used for ongoing operations is generally invested in bank deposits, as well as liquid securities that bear fixed and floating rates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our principal sources of short-term liquidity are our cash on hand, existing cash investments, liquid securities and available credit facilities, primarily our $2.3&#160;billion unsecured syndicated revolving credit facility entered into in April 2019 (&#8220;RCF&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The RCF agreement provides for two separate tranches, a $1.15&#160;billion tranche A and a $1.15&#160;billion tranche B. Loans and letters of credit will be available from time to time under each tranche for Teva&#8217;s general corporate purposes. Tranche A has a maturity date of April&#160;8, 2022, with two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> extension options, of which $1.065&#160;billion were extended to April&#160;8, 2023. Tranche B has a maturity date of April&#160;8, 2024. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time. The net debt to EBITDA ratio limit is 5.75x in the fourth quarter of 2020 and declines to 5.50x in the first and second quarters of 2021, 5.00x in the third and fourth quarters of 2021, and continues to gradually decline over the remaining term of the RCF. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The RCF can be used for general corporate purposes, including repaying existing debt. As of December&#160;31, 2020 and as of the date of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> no amounts were outstanding under the RCF. Based on current and forecasted results, we expect that we will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under specified circumstances, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, we will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes is outstanding, could lead to an event of default under our senior notes due to cross acceleration provisions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that we will continue to have sufficient cash resources to support our debt service payments and all other financial obligations within one year from the date that the financial statements are issued. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 Debt Balance and Movements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of December&#160;31, 2020, our debt was $25,919&#160;million, compared to $26,908&#160;million as of December&#160;31, 2019.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>This decrease was mainly due to senior notes repaid at maturity with cash generated during the year, partially offset by exchange rate fluctuations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, we repaid at maturity our $700&#160;million 2.25% senior notes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2020, we repaid at maturity our &#8364;1,010&#160;million 0.375% senior notes. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2020 we borrowed up to &#8364;270&#160;million from our RCF, which was fully repaid before year end. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our debt as of December&#160;31, 2020 was effectively denominated in the following currencies: 65% in U.S. dollars, 32% in euros and 3% in Swiss francs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The portion of total debt classified as short-term as of December&#160;31, 2020 was 12%, compared to 9% as of December&#160;31, 2019, due to a reclassification of upcoming maturities in 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our financial leverage was 70% as of December&#160;31, 2020, compared to 64% as of December&#160;31, 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our average debt maturity was approximately 5.8 years as of December&#160;31, 2020, compared to 6.4 years as of December&#160;31, 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;1, 2021, $491&#160;million of our 0.25% convertible senior debentures, due 2026 were redeemed by holders. See note 9 of our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019 Debt Balance and Movements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the first quarter of 2019, we repurchased and canceled approximately $126&#160;million principal amount of our $1,700&#160;million 1.7% senior notes due July 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the second quarter of 2019, we repurchased and canceled approximately $18&#160;million principal amount of our $1,574&#160;million 1.7% senior notes due July 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2019, we repaid at maturity our $1,556&#160;million 1.7% senior notes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2019, we completed debt issuances for an aggregate principal amount of $2,102&#160;million, comprised of $1,000&#160;million principal amount of 7.125% senior notes due 2025, and &#8364;1,000&#160;million principal amount of 6.0% senior notes due 2025. See note 9 to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2019, we completed a debt tender offer, which resulted in a debt decrease of $1,525&#160;million from our 2.2% $3,000&#160;million senior notes due in July 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, we partially redeemed &#8364;650&#160;million of our 0.375% &#8364;1,660&#160;million senior notes due in July 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During 2019, we borrowed up to $500&#160;million from our RCF, which was fully repaid before 2019 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Equity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity was $11,061&#160;million as of December&#160;31, 2020, compared to $15,063&#160;million as of December&#160;31, 2019. This decrease was mainly due to a net loss of $4,099&#160;million (primarily due to the goodwill impairment charge), partially offset by $129&#160;million stock-based compensation expenses and $57&#160;million in unrealized profit associated with hedging activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Exchange rate fluctuations affected our balance sheet, as approximately 56% of our net assets (including both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> and monetary assets) were in currencies other than the U.S. dollar. When compared to December&#160;31, 2019, changes in currency rates had a negative impact of $69&#160;million on our equity as of December&#160;31, 2020, mainly due to the change in value against the U.S. dollar of: the Russian ruble by 20%, the euro by 9%, the Chilean peso by 6%, the Mexican peso by 5%, the Japanese yen by 5%, the British pound by 4%, the Polish zloty by 2% and the Canadian dollar by 2%. All comparisons are on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> basis. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flow </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We seek to continually improve the efficiency of our working capital management. From time to time, as part of our cash management activities, we may make decisions in our commercial and supply chain activities which may drive an acceleration of receivable payments from customers or deceleration of payments to vendors, having the effect of increasing or decreasing cash from operations in an individual period. Such decisions had no material impact on our 2020 operating cash flow measurement, but may impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">quarter-to-quarter</div></div> results. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow generated from operating activities in 2020 was $1,216&#160;million, compared to $748&#160;million in 2019. The increase was mainly due to higher profit in our North America segment during 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2020, we generated free cash flow of $2,110&#160;million, which we define as comprising $1,216&#160;million in cash flow generated from operating activities, $1,405&#160;million in beneficial interest collected in exchange for securitized accounts receivables and $67&#160;million in proceeds from sale of property, plant and equipment and intangible assets, partially offset by $578&#160;million in cash used for capital investments. During 2019, we generated free cash flow of $2,053&#160;million, comprised of $748&#160;million in cash flow generated from operating activities, $1,487&#160;million in beneficial interest collected in exchange for securitized accounts receivables and $343&#160;million in proceeds from sale of property, plant and equipment and intangible assets, partially offset by $525&#160;million in cash used for capital investments. The increase in 2020 resulted mainly from higher cash flow generated from operating activities, partially offset by less cash generated from sales of assets and higher capital investments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not paid dividends on our ordinary shares or ADSs since December 2017. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to financing obligations under short-term debt and long-term senior notes and loans, debentures and convertible debentures, our major contractual obligations and commercial commitments include royalty payments, contingent payments pursuant to acquisition agreements and participation in joint ventures associated with R&amp;D activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, we entered into a partnership agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this partnership contains biosimilar candidates addressing multiple therapeutic areas. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. We paid an upfront payment in the third quarter of 2020 that was recorded as R&amp;D expenses. During the fourth quarter of 2020, we accrued additional amounts due to the high probability that additional milestone payments will be paid in 2021. Additional development and commercial milestone payments of up to $450&#160;million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2016, we entered into an agreement to develop and commercialize Regeneron&#8217;s pain medication product, fasinumab. We paid Regeneron $250&#160;million upfront and will share with Regeneron in the global commercial rights of this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&amp;D costs of approximately $1.0&#160;billion. Additional payments for achievement of development milestones in an aggregate amount of $120&#160;million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $2,230&#160;million, as well as future royalties. For information regarding fasinumab phase 3 clinical trial results, see &#8220;Item 1&#8212;Business&#8212;Our Product Portfolio and Business Offering&#8212;Specialty Medicines&#8221; above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2016, we entered into an exclusive partnership with Celltrion to commercialize TRUXIMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and HERZUMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, two of Celltrion&#8217;s biosimilar products in development for the U.S. and Canadian markets. We paid </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Celltrion $160&#160;million, of which we received an aggregate credit of $60&#160;million as of December&#160;31, 2020. We share the profit from the commercialization of these products with Celltrion. These two products, TRUXIMA and HERZUMA, were approved by the FDA in November and December 2018, respectively and were launched in the United States in November 2019 and March 2020, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are committed to pay royalties to owners of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> partners in alliances and certain other arrangements, and to parties that financed R&amp;D at a wide range of rates as a percentage of sales of certain products, as defined in the agreements. In some cases, the royalty period is not defined; in other cases, royalties will be paid over various periods not exceeding 20 years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with certain development, supply and marketing, and research and collaboration or services agreements, we are required to indemnify, in unspecified amounts, the parties to such agreements against third-party claims relating to (i)&#160;infringement or violation of intellectual property or other rights of such third party; or (ii)&#160;damages to users of the related products. Except as described in our financial statements, we are not aware of any material pending action that may result in the counterparties to these agreements claiming such indemnification. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Supplemental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Income Data </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We utilize certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures to evaluate performance, in conjunction with other performance metrics. The following are examples of how we utilize the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our management and Board of Directors use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures to evaluate our operational performance, to compare against work plans and budgets, and ultimately to evaluate the performance of management; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our annual budgets are prepared on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> basis; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">senior management&#8217;s annual compensation is derived, in part, using these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures. While qualitative factors and judgment also affect annual bonuses, the principal quantitative element in the determination of such bonuses is performance targets tied to the work plan, which is based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> presentation set forth below. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> financial measures have no standardized meaning and accordingly have limitations in their usefulness to investors. We provide such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> data because management believes that such data provide useful information to investors. However, investors are cautioned that, unlike financial measures prepared in accordance with U.S. GAAP, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures may not be comparable with the calculation of similar measures for other companies. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures are presented solely to permit investors to more fully understand how management assesses our performance. The limitations of using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures as performance measures are that they provide a view of our results of operations without including all events during a period and may not provide a comparable view of our performance to other companies in the pharmaceutical industry. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Investors should consider <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In arriving at our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> presentation, we exclude items that either have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> impact on the income statement or which, in the judgment of our management, are items that, either as a result of their nature or size, could, were they not singled out, potentially cause investors to extrapolate future performance from an improper base. In addition, we also exclude equity compensation expenses to facilitate a better understanding of our financial results, since we believe that such exclusion is important for understanding the trends in our financial results and that these expenses do not affect our business operations. While not all inclusive, examples of these items include: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amortization of purchased intangible assets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">legal settlements and/or loss contingencies, due to the difficulty in predicting their timing and scope; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impairments of long-lived assets, including intangibles, property, plant and equipment and goodwill; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restructuring expenses, including severance, retention costs, contract cancellation costs and certain accelerated depreciation expenses primarily related to the rationalization of our plants or to certain other strategic activities, such as the realignment of R&amp;D focus or other similar activities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">acquisition- or divestment- related items, including changes in contingent consideration, integration costs, banker and other professional fees, inventory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> R&amp;D acquired in development arrangements; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expenses related to our equity compensation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> financing costs and valuation gains or losses; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unusual tax items; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other awards or settlement amounts, either paid or received; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as impacts due to changes in accounting, significant costs for remediation of plants, such as inventory write-offs or related consulting costs, or other unusual events; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">corresponding tax effects of the foregoing items. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The following tables present supplemental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> data, in U.S. dollar, which we believe facilitates an understanding of the factors affecting our business. In these tables, we exclude the following amounts: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="54" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31, 2020</div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. $ and shares in millions, except per share amounts)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">GAAP</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="46" style="vertical-align: bottom;;text-align:center;">Excluded for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measurement</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div><br/>GAAP</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amortization<br/>of&#160;purchased<br/>intangible<br/>assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Legal<br/>settlements<br/>and&#160;loss<br/>contingencies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Goodwill<br/>impairment</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Impairment<br/>of&#160;long-<br/>lived assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/>R&amp;D<br/>expenses</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Restructuring<br/>costs</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Costs<br/>related&#160;to<br/>regulatory<br/>actions<br/>taken&#160;in<br/>facilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Equity<br/>compensation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Contingent<br/>consideration</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Gain&#160;on<br/>sale&#160;of<br/>business</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div><br/>GAAP<br/>items</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/>items</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">COGS</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">941</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,498</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">126</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other asset impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">479</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">416</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(81</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,502</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,502</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(85</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in profits (losses) of associated companies, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(109</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(177</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reconciled items</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">37</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(81</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,140</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS&#8212;Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS&#8212;Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> diluted weighted average number of shares was 1,099&#160;million for the year ended December&#160;31, 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="50" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div> <div style="text-align: left; font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. $ and shares in millions, except per share amounts)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">GAAP</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="42" style="vertical-align: bottom;;text-align:center;">Excluded for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measurement</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div><br/>GAAP</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amortization<br/>of&#160;purchased<br/>intangible<br/>assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Legal<br/>settlements<br/>and&#160;loss<br/>contingencies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Impairment<br/>of&#160;long-<br/>lived assets</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/>R&amp;D<br/>expenses</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Restructuring<br/>costs</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Costs<br/>related&#160;to<br/>regulatory<br/>actions<br/>taken&#160;in<br/>facilities</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Equity<br/>compensation</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Contingent<br/>consideration</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on<br/>sale&#160;of</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">business</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div><br/>GAAP<br/>items</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Other<br/>items</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">COGS</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">973</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,614</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(76</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(50</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other asset impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">423</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">822</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(278</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(875</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in profits (losses) of associated companies, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss) attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(82</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reconciled items</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(50</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(959</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS&#8212;Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.41</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">EPS&#8212;Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> diluted weighted average number of shares was 1,094&#160;million for the year ended December&#160;31, 2019. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Tax Rate </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes for 2020 were $577&#160;million on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $3,470&#160;million. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> income taxes in 2019 were $597&#160;million on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income of $3,317&#160;million. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> tax rate for 2020 was 17%, compared to 18% in 2019. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trend Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following factors are expected to have a significant effect on our 2021 results: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">variable demand for certain products in certain markets and changes in physician and hospital activity due to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. For further details, see &#8220;&#8212;The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic&#8212;Trends&#8221; above; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continued success of our specialty products AUSTEDO and AJOVY; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">success of clinical trials and approval of our specialty product fasinumab, which is under development by Regeneron; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ability to successfully execute key generic launches in a timely manner; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ability to successfully develop and launch new biosimiliar products; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a decrease in sales of COPAXONE following the launches of generic versions to the product, and the possibility of additional generic competition in the future; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a decrease in sales of other specialty products due to potential loss of exclusivity or generic competition; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we expect continued competition for our generic products where multiple similar generic products have been launched, resulting in pricing pressure in the generics markets. We do, however, also see certain generic segments in which opportunities exist to grow our business, our portfolio of new drug applications and our portfolio of approved complex products; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our disciplined cash management and debt repayment schedule; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our high debt levels and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-investment</div> grade credit rating may increase the cost of any new borrowing; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continued impact of currency fluctuations on revenues and operating income, as well as on various balance sheet and statements of income line items; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ongoing evaluation of opportunities to further optimize our manufacturing and supply network to achieve additional operational efficiencies, which may affect our business and operations; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continued efforts towards achieving our long-term financial goals. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For additional information, please see &#8220;Item 1&#8212;Business&#8221; and elsewhere in this Item 7. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated Contractual Obligations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our material contractual obligations and commitments as of December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Payments Due by Period</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less&#160;than<br/>1 year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-3&#160;years</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5&#160;years</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">More&#160;than<br/>5 years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt obligations, including estimated interest*</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,254</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,902</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase obligations (including purchase orders)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">33,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt obligations mainly include senior notes and convertible senior debentures as disclosed in note 9 to our consolidated financial statements. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total gross amount of unrecognized tax benefits for uncertain tax positions was $888&#160;million at December&#160;31, 2020. Payment of these obligations would result from settlements with tax authorities. Due to the difficulty in determining the timing and magnitude of settlements, these obligations are not included in the table above. Correspondingly, it is difficult to ascertain whether we will pay any significant amount related to these obligations within the next year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have committed to make potential future milestone payments to third parties under various agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, we may be required to pay such amounts. As of December&#160;31, 2020, if all milestones and targets, for compounds in phase 2 and more advanced stages of development, are achieved, the total contingent payments could reach an aggregate amount of up to $509&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have committed to pay royalties to owners of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> partners in alliances and other certain arrangements and to parties that financed research and development, at a wide range of rates as a percentage of sales or of the gross margin of certain products, as defined in the underlying agreements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the uncertainty of the timing of these payments, these amounts, and the amounts described in the previous paragraph, are not included in the table above. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Arrangements </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Except for securitization transactions, which are disclosed in note 10 f to our consolidated financial statements, we do not have any material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a description of our significant accounting policies, see note 1 to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions in certain circumstances that affect the amounts reported in the accompanying consolidated financial statements and related footnotes. Actual results may differ from these estimates. We base our judgments on our experience and on various assumptions that we believe to be reasonable under the circumstances. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of our policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and complex judgment, involving critical accounting estimates and assumptions impacting our consolidated financial statements. We have applied our policies and critical accounting estimates consistently across our businesses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The significant accounting estimates relate to the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition and SR&amp;A in the United States </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable Intangible Assets </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring Costs </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition and SR&amp;A in the United States </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our gross product revenues are subject to a variety of deductions which are generally estimated and recorded in the same period that the revenues are recognized, and primarily represent chargebacks, rebates and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sales allowances to wholesalers, retailers and government agencies with respect to our pharmaceutical products. Those deductions represent estimates of rebates and discounts related to gross sales for the reporting period and, as such, knowledge and judgment of market conditions and practice are required when estimating the impact of these revenue deductions on gross sales for a reporting period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historically, our changes of estimates reflecting actual results or updated expectations, have not been material to our overall business. Product-specific rebates, however, may have a significant impact on year-over-year individual product growth trends. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate predictors of our future experience, our results could be materially affected. The sensitivity of our estimates can vary by program, type of customer and geographic location. However, estimates associated with governmental allowances, U.S. Medicaid and other performance-based contract rebates are most at risk for material adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this time lag, in any given quarter, our adjustments to actual can incorporate revisions of several prior quarters. See also &#8220;Revenue recognition&#8221; in note 1 to the consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The provision for income tax is calculated based on our assumptions as to our entitlement to various benefits under the applicable tax laws in the jurisdictions in which we operate. The entitlement to such benefits depends upon our compliance with the terms and conditions set out in these laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting for uncertainty in income taxes requires that it be more likely than not that the tax benefits recognized in the financial statements be sustained based on technical merits. The amount of benefits recorded for these positions is measured as the largest benefit more likely than not to be sustained. Significant judgment is required in making these determinations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the determination of the appropriate valuation allowances, we have considered the most recent projections of future business results and prudent tax planning alternatives that may allow us to realize the deferred tax assets. Taxes which would apply in the event of disposal of investments in subsidiaries have not been taken into account in computing deferred taxes, as it is our intention to hold these investments rather than realize them. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Deferred taxes have not been provided for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> income, as the Company intends to permanently reinvest these profits and does not currently foresee a need to distribute dividends out of these earnings. Furthermore, we do not expect our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Israeli</div> subsidiaries to distribute taxable dividends in the foreseeable future, as their earnings and excess cash are used to pay down the group&#8217;s external liabilities, while we expect to have sufficient resources in the Israeli companies to fund our cash needs in Israel. In addition, the Company announced a suspension of dividend distribution on ordinary shares and ADSs in 2017. An assessment of the tax that would have been payable had the Company&#8217;s foreign subsidiaries distributed their income to the Company is not practicable because of the multiple levels of corporate ownership and multiple tax jurisdictions involved in each hypothetical dividend distribution. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a discussion of the valuation allowance, deferred tax and valuation allowance estimates see notes&#160;1 and 13 to our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Tax Cuts and Jobs Act </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We accounted for the tax effects of the Tax Cuts and Jobs Act, enacted on December&#160;22, 2017, on a provisional basis in our 2017 consolidated financial statements. We completed our accounting analysis in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fourth quarter of 2018, within the one year measurement period from the enactment date. See note 13 to our consolidated financial statements for additional information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, in large part as a result of the nature of its business, Teva is frequently subject to litigation, governmental investigations and other legal proceedings. Except for income tax contingencies or contingent consideration acquired in a business combination, Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. When accruing these costs, Teva will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, Teva accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts at the gross amount that is expected to be collected when they are considered virtually certain to occur. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva reviews the adequacy of the accruals on a periodic basis and may determine to alter its provisions at any time in the future if it believes it would be appropriate to do so. As such accruals are based on management&#8217;s judgment as to the probability of losses and, where applicable, actuarially determined estimates, accruals may materially differ from actual verdicts, settlements or other agreements made with regards to such contingencies. Litigation outcomes and contingencies are unpredictable and excessive verdicts can occur. Accordingly, management&#8217;s assessments involve complex judgments concerning future events and often rely heavily on estimates and assumptions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the acquiree, over the assigned fair values of the identifiable net assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least annually, in the second quarter of the fiscal year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We perform an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The provisions of the accounting standard for goodwill allow us to first assess qualitative factors to determine whether it is necessary to perform the next goodwill impairment quantitative test. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Examples of events or circumstances that may be indicative of impairment include, but are not limited to: macroeconomic and industry conditions, overall financial performance and adverse changes in legal, regulatory, market share and other relevant entity specific events. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimates the fair values of all reporting units using a discounted cash flow model which utilizes Level&#160;3 unobservable inputs. Key estimates include the revenue growth rates and operating margins taking into consideration industry and market conditions, terminal growth rate and the discount rate. The discount rate used is based on the WACC, adjusted for the relevant risk associated with country-specific and business-specific characteristics. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill, to those reporting units. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When necessary, we record charges for impairments of goodwill for the amount by which the carrying amount exceeds the fair value of these assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See note 7 and note 19 to our consolidated financial statements for further details on the goodwill impairments recognized in 2020 and 2018, and Teva&#8217;s operating and reporting segments. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the FDA or the equivalent agencies in other countries. These assets are amortized using mainly the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing expenses when separable </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of identifiable intangible assets amounted to $1,502&#160;million and $1,639&#160;million in the years ended December&#160;31, 2020 and 2019, respectively. See note 6 to our consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of acquired identifiable intangible assets is determined using an income approach. This method starts with a forecast of all expected future net cash flows associated with the asset and then adjusts the forecast to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset&#8217;s estimated life, calculates the undiscounted value of the asset&#8217;s or asset group&#8217;s cash flows and then calculates, if required, the discounted value of cash flow by applying an appropriate discount rate to the undiscounted cash flow streams. Teva then compares such value against the asset&#8217;s or asset group&#8217;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of carrying value over fair value based on the discounted cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Examples of events or circumstances that may be indicative of impairment include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A projection or forecast that indicates losses or reduced profits associated with an asset. This could result, for example, from a change in the competitive landscape modifying our assumptions about market share or pricing prospectively, a government reimbursement program that results in an inability to sustain projected product revenues and profitability, or lack of acceptance of a product by patients, physicians or payers limiting our projected growth. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights by a competitor would likely result in generic competition earlier than expected. And conversely, a lost challenge of patent rights in connection with our generic file would likely result in delayed entry. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A significant adverse change in the extent or manner in which an asset is used. For example, restrictions imposed by the FDA or other regulatory authorities could affect our ability to manufacture or sell a product. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For IPR&amp;D projects, this could result from, among other things, a change in outlook affecting assumptions around competition or timing of entry such as approval success or the related timing of approval, clinical trial data results, other delays in the projected launch dates or additional expenditures required to commercialize the product. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The more significant estimates and assumptions inherent in the estimate of the fair value of identifiable intangible assets include (i)&#160;assumptions associated with forecasting product profitability, including sales and cost to sell projections, (ii)&#160;tax rates which seek to incorporate the geographic diversity of the projected cash flows, (iii)&#160;expected impact of competitive, legal and/or regulatory forces on the projections and the impact of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">technological risk, R&amp;D expenditure for ongoing support of product rights or continued development of IPR&amp;D, and (iv)&#160;estimated useful lives and IPR&amp;D expected launch dates. Additionally, for IPR&amp;D assets the risk of failure has been factored into the fair value measure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While all intangible assets other than goodwill can face events and circumstances that can lead to impairment, in general, intangible assets other than goodwill that are most at risk of impairment include IPR&amp;D assets and newly acquired or recently impaired indefinite-lived brand assets. IPR&amp;D assets are high-risk assets, as R&amp;D is an inherently risky activity. Consequently, IPR&amp;D assets could be determined to be no longer commercially viable. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value annually or when triggering events are present. As such, immediately after acquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment charge. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restructuring Costs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring costs have been recorded in connection with Teva&#8217;s restructuring plan between the years 2017 and 2019 and ongoing expenses associated with other network consolidation impacts. Following these actions and in anticipation of ongoing efficiency measures in our business, Teva&#8217;s management has made estimates and judgments regarding future plans, mainly related to employee termination benefit costs, potential closures or divestments of manufacturing plants, headquarters and other office locations. In connection with these actions, management also assesses the recoverability of long-lived assets employed in the business. In certain instances, asset lives have been shortened based on changes in the expected useful lives of the affected assets. Asset-related impairments and severance and other related costs are reflected within asset impairments, restructuring and others. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See note 1 to our consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_12" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The objective of our financial risk management measures is to minimize the impact of risks arising from foreign exchange and interest rate fluctuations. To reduce these risks, we take various operational measures in order to achieve a natural hedge and may enter, from time to time, into financial derivative instruments. Our derivative transactions are executed through global banks. We believe that due to our diversified derivatives portfolio, the credit risk associated with any of these banks is minimal. No derivative instruments are entered into for trading purposes. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Rate Risk Management </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We operate our business worldwide and, as such, we are subject to foreign exchange risks on our results of operations, our monetary assets and liabilities and our foreign subsidiaries&#8217; net assets. For further information on currencies in which we operate, see &#8220;Item 7&#8212; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;Impact of Currency Fluctuations on Results of Operations.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We generally prefer to borrow in U.S. dollars; however, from time to time we borrow funds in other currencies, such as the euro, Swiss franc, Japanese yen and new Israeli shekel, in order to benefit from same currency revenues in relation to same currency costs and same currency assets in relation to same currency liabilities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flow Exposure </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenues were $16,659&#160;million in 2020. Of these revenues, approximately 48% of our revenues were denominated in currencies other than the U.S. dollar, 21% in euros, 5% in Japanese yen and the rest in other currencies, none of which accounted for more than 4% of total revenues in 2020. In most currencies, we record corresponding expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In certain currencies, primarily the euro, our revenues generally exceed our expenses. Conversely, in other currencies, primarily the new Israeli shekel and the Indian rupee, our expenses generally exceed our revenues. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We enter into financial derivatives to hedge part of those currencies which do not have a sufficient natural hedge, in order to reduce the impact of foreign exchange fluctuations on our operating results. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, we hedged part of our expected operating results for 2021 in currencies other than the U.S. dollar, primarily the euro, British pound, Swiss franc, Polish zloty, Japanese yen, Russian ruble and other European and Latin American currencies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In certain cases, we may hedge exposure arising from a specific transaction, executed in a currency other than the functional currency, by entering into forward contracts and/or by using plain-vanilla and exotic option strategies. We generally limit the term of hedging transactions to a maximum of fifteen months. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Balance Sheet Exposure </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to our monetary assets and liabilities, the exposure arises when the monetary assets and/or liabilities are denominated in currencies other than the functional currency of our subsidiaries. We strive to limit our exposure through natural hedging. Most of the remaining exposure is hedged by entering into financial derivative instruments. To the extent possible, the hedging activity is carried out on a consolidated level. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents exposures exceeding $50&#160;million in absolute values: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 20%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="4" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net exposure as of</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2020</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability/Asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD/CHF</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD/EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD/JPY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BGN/EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HRK/USD</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAD/EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PLN/EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD/MXN</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INR/USD</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD/GBP</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Outstanding Foreign Exchange Hedging Transactions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, we had long and short forwards and currency option contracts with a corresponding notional amount of approximately $2.4&#160;billion and $0.5&#160;billion, respectively. As of December&#160;31, 2019, we had long and short forwards and currency option contracts with corresponding notional amounts of approximately $2.7&#160;billion and $1.1&#160;billion, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents the net notional and fair values of the financial derivatives entered into as of December&#160;31, 2020 in order to reduce currency exposure arising from our cash flow and balance sheet exposures. The table below presents only currency paired with hedged net notional values exceeding $50&#160;million. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency (sold)</div></div></div> </td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cross<br/>Currency<br/>(bought)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Notional&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020&#160;Weighted<br/>Average Cross<br/>Currency&#160;Prices&#160;or<br/>Strike Prices</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CHF</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">503</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">JPY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">104.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">INR</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">75.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GBP</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">133</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">PLN</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">CAD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">101</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MXN</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20.52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAD</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">101</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PLN</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">GBP</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">445</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">RUB</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NIS</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RUB</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">EUR</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">381</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">JPY</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">106.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CHF</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GBP</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">USD</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EUR</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">GBP</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents Net Notional Value of less than $50&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Subsidiaries Net Assets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under certain market conditions, we may hedge against possible fluctuations in foreign subsidiaries&#8217; net assets (&#8220;net investment hedge&#8221;). In these cases, we may use cross currency swaps and forward contracts. During 2017, we entered into a cross currency swap agreement, to hedge $1&#160;billion of our subsidiaries&#8217; euro denominated net assets. In the first quarter of 2020, these cross currency swap agreements expired. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest Rate Risk Management </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to interest rate risk on our investments and on our borrowings. We manage interest rate risk in the aggregate, while focusing on our immediate and intermediate liquidity needs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We raise capital through various debt instruments including senior notes that bear a fixed or variable interest rate, syndicated bank loans that bear a fixed or floating interest rate and convertible debentures that bear a fixed and floating interest rate. In some cases, as described below, we have swapped from a fixed to a floating interest rate (&#8220;fair value hedge&#8221;), from a floating to a fixed interest rate and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#8220;cash flow hedge&#8221;), reducing overall interest expenses or hedging risks associated with interest rate fluctuations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In certain cases, we may hedge, in whole or in part, against exposure arising from a specific transaction, such as debt issuances related to an acquisition or debt refinancing, by entering into forward and interest rate swap contracts and/or by using options. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents the aggregate outstanding debt by currencies and maturities as of December&#160;31, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest Rate<br/>Ranges</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026 &amp;<br/>thereafter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="34" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed Rate:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,286</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">853</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,996</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Euro</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,408</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">861</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,595</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CHF</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD convertible debentures*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Floating Rate:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,089</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">9,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less debt issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">25,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Classified under short-term debt. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_13" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEAR ENDED DECEMBER&#160;31, 2020 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_50">Report of Independent Registered Public Accounting Firm</a></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Financial Statements:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_51">Balance Sheets</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_52">Statements of Income (Loss)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_53">Statements of Comprehensive Income (Loss)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_54">Statements of Changes in Equity</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_55">Statements of Cash Flows</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_56">Notes to Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx102112_50" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Shareholders of TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opinions on the Financial Statements and Internal Control over Financial Reporting </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have audited the accompanying consolidated balance sheets of Teva Pharmaceutical Industries Limited and its subsidiaries<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>(the &#8220;Company&#8221;) as of December 31, 2020 and 2019,<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and the related consolidated statements of income (loss), of comprehensive income (loss), of changes in equity and of cash flows for each of the three years in the period ended December 31, 2020, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended December 31, 2020 appearing under Item 15(a) (collectively referred to as the &#8220;consolidated financial statements&#8221;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control - Integrated Framework</div></div> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In our opinion, the consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">, </div></div>and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control - Integrated Framework</div></div> (2013) issued by the COSO. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in Accounting Principle </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1(cc) to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinions </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the Report of Teva Management on Internal Control over Financial Reporting appearing under<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>financial statements and on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Definition and Limitations of Internal Control over Financial Reporting </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Critical Audit Matters </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill Impairment Assessment &#8211; North America reporting unit </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Notes 1 and 7 to the consolidated financial statements, the Company&#8217;s consolidated goodwill balance and goodwill balance for the North America reporting unit was $20,624 million and $6,473 million, respectively, as of December 31, 2020. As disclosed by management, goodwill is assigned to reporting units and tested for impairment at least annually, in the second quarter of the fiscal year, and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. During the second quarter of 2020, management noted that market concerns regarding the uncertainty related to the opioid and price fixing litigation risks were impacting its market capitalization. Teva conducted a quantitative analysis of the North America reporting unit as part of its annual goodwill impairment test and utilized the assistance of an independent valuation expert. No goodwill impairment charge was recorded during the second quarter of 2020. During the third quarter of 2020, management noted factors that led to an assessment of the North America reporting unit for impairment, including a 25% reduction in the Company&#8217;s market capitalization from the second quarter of 2020 to the third quarter of 2020 and recent developments that indicate the timeframe for resolution of the opioids litigation will take significantly longer than previously expected which introduces greater uncertainty to a favorable resolution, resulting in an impairment charge of $4,628 million. Management determines the fair value of its reporting units using the income approach. Within the income approach, the method used is the discounted cash flow method. For each of the second and third quarter impairment assessments, management started with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applied a discount rate to arrive at a net present value amount. As disclosed by management, key estimates include the revenue growth rates and operating </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">margins taking into consideration industry and market conditions, terminal growth rate and the discount rate. Market conditions include estimates related to the timeframe and resolution of the opioids and price fixing litigation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal considerations for our determination that performing procedures relating to the goodwill impairment assessments for the North America reporting unit is a critical audit matter are (i) the significant judgment by management when determining the fair value measurement of the reporting unit; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s significant assumptions related to revenue growth rates, discount rate, estimates related to the timeframe and resolution of the opioids and price fixing litigation and terminal growth rate; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s goodwill impairment assessment, including controls over the valuation of the North America reporting unit. These procedures also included, among others, (i) testing management&#8217;s process for determining the fair value estimate; (ii) evaluating the appropriateness of the discounted cash flow model; (iii) testing the completeness, accuracy and relevance of underlying data used in the model; and (iv) evaluating the significant assumptions used by management related to the revenue growth rates, discount rate, estimates related to the timeframe and resolution of the opioids and price fixing litigation and terminal growth rate. Evaluating management&#8217;s assumptions related to revenue growth rates and terminal growth rate involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the reporting unit, (ii) the consistency with external market and industry data, and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Evaluating management&#8217;s assumption related to estimates related to the timeframe and resolution of the opioids and price fixing litigation involved obtaining and evaluating letters of audit inquiry with internal and external legal counsel and discussing the status of significant known actual and potential litigation with the Company&#8217;s internal and external legal counsel. Professionals with specialized skill and knowledge were used to assist in the evaluation of management&#8217;s discounted cash flow model and the discount rate assumption. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Reserves and Allowances (&#8220;SR&amp;A&#8221;) - Rebates, Chargebacks and Medicaid in the United States </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Notes 1 and 3 to the consolidated financial statements, the amount of consideration to which the Company expects to be entitled varies as a result of rebates, chargebacks, and other SR&amp;A that the Company offers to its customers and their customers. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. As of December 31, 2020, consolidated SR&amp;A for rebates, chargebacks and Medicaid were $3,990 million. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers. Provisions are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Provisions for rebates are estimated based on the specific terms in each agreement based on historical trends and expected sales. Provisions for Medicaid are based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal considerations for our determination that performing procedures relating to SR&amp;A for rebates, chargebacks and Medicaid in the United States is a critical audit matter are (i) the significant judgment by management due to the significant measurement uncertainty involved in developing the reserves, as the reserves are based on assumptions developed using contractual and mandated terms with customers, historical experience, and projected market conditions in the US; and (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s significant assumptions, including wholesaler inventory levels and expected chargeback levels. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to SR&amp;A for rebates, chargebacks and Medicaid in the United States, including controls over the assumptions used by management to estimate the reserves. These procedures also included, among others, (i) developing independent estimates of the reserves using third party information, the contractual or mandated terms of the specific rebate or chargeback programs, and the historical trends of payments and comparing the independent estimates to management&#8217;s estimates; (ii) evaluating the reasonableness of significant assumptions used by management, including wholesaler inventory levels and expected chargeback levels; and (iii) testing the completeness, accuracy, and relevance of underlying data used to estimate the reserves, including testing actual claims processed by the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Opioid and Price Fixing and Market Allocation Litigation in the United States </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Notes 1, 11 and 12 to the consolidated financial statements, management evaluates litigation contingencies and records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Such contingencies include those related to opioid and price fixing and market allocation litigation in the United States. As of December 31, 2020, the Company&#8217;s consolidated provision for legal settlements and loss contingencies was $1,625 million, which included an estimated settlement provision recorded in connection with the remaining opioid cases. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal considerations for our determination that performing procedures relating to opioid and price fixing and market allocation litigation in the United States is a critical audit matter are the significant judgment by management when assessing the likelihood of a loss being incurred and when determining whether a reasonable estimate of the loss or range of loss for each claim can be made, which in turn led to high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s assessment of the loss contingencies associated with these legal matters. In addition, the audit effort involved the use of professionals with specialized skill and knowledge. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s evaluation of the loss contingencies relating to opioid and price fixing and market allocation litigation in the United States, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as financial statement disclosures. These procedures also included, among others, obtaining and evaluating the letters of audit inquiry with internal and external legal counsel; discussing the status of significant known actual and potential litigation with the Company&#8217;s internal legal counsel; evaluating the reasonableness of management&#8217;s assessment regarding whether a loss is probable and whether the amount of loss can be reasonably estimated; testing the completeness, accuracy, and relevance of underlying data used to estimate loss amounts; and evaluating the sufficiency of the Company&#8217;s litigation contingency disclosures. Professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of the factual investigation performed by management and their advisors with respect to price fixing and market allocation allegations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Kesselman &amp; Kesselman </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kesselman &amp; Kesselman </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certified Public Accountants (Isr.) </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A member of PricewaterhouseCoopers International Limited </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tel Aviv, Israel </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February 10, 2021 </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since at least 1976. We have not been able to determine the specific year we began serving as the auditor of the company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="tx102112_51" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="8" style="vertical-align: top; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">ASSETS</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 0em; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="8" style="vertical-align: top; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Current assets:</div></div></div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 0em; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;;display:inline;">Accounts receivables, net of allowance for credit losses of $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></div><div style="line-height: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;million and $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">135</ix:nonFraction></div><div style="line-height: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;million as of December&#160;31, 2020 and December&#160;31, 2019</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">945</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Total current assets</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Deferred income taxes</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Other non-current assets</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">591</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Property, plant and equipment, net</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Operating lease right-of-use assets</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">559</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Identifiable intangible assets, net</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,923</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Goodwill</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">24,846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Total assets</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">50,640</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">57,470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 40%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 0%;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">LIABILITIES AND EQUITY</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Current liabilities:</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term debt</div></div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; width: 0%;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; width: 0%;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; width: 1%;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; width: 0%;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales reserves and allowances</div></div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="teva:SalesReservesAndAllowances" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="teva:SalesReservesAndAllowances" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payables</div></div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,718</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee-related obligations</div></div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">685</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">693</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="teva:AccruedExpenses" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="teva:AccruedExpenses" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">889</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Total current liabilities</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13,164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13,674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Long-term liabilities:</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">964</ix:nonFraction><div style="font-size:9pt;;display:inline;"> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other taxes and long-term liabilities</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,640</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and loans</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22,731</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">24,562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">479</ix:nonFraction><div style="font-size:9pt;;display:inline;"> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Total long-term liabilities</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">26,414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">28,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Commitments and contingencies</div></div>, see note 12</div></div></td>
<td style="vertical-align: bottom; width: 1%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Total liabilities</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">39,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">42,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 40%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 0%;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;;font-weight:bold;display:inline;">Equity:</div></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;<div style="font-weight:bold;display:inline;width:100%;">Teva shareholders&#8217; equity:</div></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares of NIS <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_CHF_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_CHF_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.10</ix:nonFraction></ix:nonFraction> <div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;;display:inline;">par value per share; December 31, 2020 and December 31, 2019: authorized&#160;</div> <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2,495</ix:nonFraction></ix:nonFraction> million<div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;;display:inline;">&#160;</div>shares; issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,202</ix:nonFraction>&#160;million shares and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,198</ix:nonFraction>&#160;million shares, respectively</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional paid-in capital</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">27,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">27,312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10,946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive loss</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif;;display:inline;">Treasury shares as of December 31, 2020 and December 31, 2019</div>: <ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction></ix:nonFraction>&#160;million ordinary shares</div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10,026</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Non-controlling interests</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Total equity</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 1%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 40%; line-height: 9pt; font-size: 9pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 9pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 9pt; font-size: 9pt;;font-weight:bold;display:inline;">Total liabilities and equity</div></div></div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; width: 0%;"><div style="font-size:9pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">50,640</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; width: 0%;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; width: 1%;"><div style="font-size:9pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; width: 0%;"><div style="font-size:9pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; white-space: nowrap; width: 0%;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">57,470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%; line-height: 9pt; font-size: 9pt;"><div style="font-size:9pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">90</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx102112_52" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF INCOME (LOSS) </div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions, except share and per share data) </div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net&#160;revenues</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16,887</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">18,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of sales</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9,351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7,726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling and marketing expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,614</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairments</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,502</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,639</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IntangibleAssetsImpairments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other asset impairments, restructuring and other items</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">987</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating (loss) income</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,572</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,406</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes (benefit)</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share in (profits) losses of associated companies<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to non-controlling interests</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued dividends on preferred shares</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">&#8212;<div style="display:inline;">&#160;</div><div style="display:inline;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings (loss) per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">$</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares (in millions):</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">91</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx102112_53" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions) </div></div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss), net of tax:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Currency translation adjustment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">713</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain (loss) on derivative financial instruments, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain (loss) on available-for-sale securities, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></div></div> </td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain (loss) on defined benefit plans, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other comprehensive income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total comprehensive income (loss)</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) attributable to non-controlling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive income (loss) attributable to Teva</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">92</div></div> </div> </div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="tx102112_54" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 100%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="30" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Teva shareholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> shares (in<br/> millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stated<br/> value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MCPS**</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in&#160;capital</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/> earnings<br/> (accumulated<br/> deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> other<br/> comprehensive<br/> income (loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury<br/> shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Teva<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share-holders&#8217;</div><br/> equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-</div><br/> controlling<br/> interests</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="34" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. dollars in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January&#160;1, 2018</div></div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17701996">3,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">23,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">17,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">18,745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes during 2018:</div></div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cumulative effect of new accounting standard****</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17701993">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17701992">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; padding: 0px; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">611</ix:nonFraction></div></div></td>
<td style="background: rgb(204, 238, 255); padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">611</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;">)<div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2018To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;">)<div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Treasury Shares</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; text-align: right; white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, sans-serif; white-space: nowrap;;text-align:right;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(<ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></div></div></td>
<td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"><div style="margin:0in 0in 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2018To12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; padding: 0px; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; padding: 0px; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of shares***</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17701954">72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17705078">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2018To12_31_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17705079">3,880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17705080">3,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17705081">52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17705082">52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends to preferred shareholders</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; text-align: right; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" contextRef="P01_01_2018To12_31_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17702197">249</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DividendsPreferredStockCash" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; padding: 0px; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; padding: 0px; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Transactions with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:TransactionsWithNonControllingInterests" contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:TransactionsWithNonControllingInterests" contextRef="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:TransactionsWithNonControllingInterests" contextRef="P01_01_2018To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:TransactionsWithNonControllingInterests" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2018</div></div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">27,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);">)<div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); border-top: 0.75pt solid black;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes during 2019:</div></div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; padding: 0px; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2019To12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Shares</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Treasury Shares</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">*</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size:8pt;;display:inline;">)</div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2019To12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17701975">119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17701976">119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17701977">119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Transactions with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:TransactionsWithNonControllingInterests" contextRef="P01_01_2019To12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:TransactionsWithNonControllingInterests" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 34%; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherEquity" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);">)<div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherEquity" contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);">)<div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherEquity" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 34%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 34%; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;"><div style="font-size: 8pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">Balance at December&#160;31, 2019</div></div></div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,198</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">27,312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); text-align: right; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); text-align: right; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;width:100%;">Changes during 2020:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 2%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 2%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; width: 2%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="font-size: 8pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 34%; line-height: 8pt; font-size: 8pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;">Net income (loss)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 2%; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; white-space: nowrap; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 2%; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap; width: 2%; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; white-space: nowrap; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; white-space: nowrap; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; white-space: nowrap; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; white-space: nowrap; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap; line-height: 8pt;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,990</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;">)</div>&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="font-size: 8pt; margin-bottom: 0px; margin-top: 0px; white-space: nowrap; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap; line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; white-space: nowrap; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="font-size: 8pt; margin-bottom: 0px; margin-top: 0px; text-align: right; white-space: nowrap; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap; line-height: 8pt;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,990</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;">)</div>&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="font-size: 8pt; margin-bottom: 0px; margin-top: 0px; text-align: right; white-space: nowrap; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap; line-height: 8pt;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">109</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;">)</div>&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="font-size: 8pt; margin-bottom: 0px; margin-top: 0px; text-align: right; white-space: nowrap; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap; line-height: 8pt;;display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,099</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); line-height: 8pt; font-size: 8pt;"><div style="margin-bottom: 0px; margin-top: 0px; font-size: 8pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;">)</div>&#160;</div></div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Shares</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17701953">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 2%;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 8pt; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap; width: 2%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); text-align: right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 34%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Transactions with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:TransactionsWithNonControllingInterests" contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:TransactionsWithNonControllingInterests" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 34%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 34%; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 10pt;;display:inline;">Balance at December&#160;31, 2020</div></div></div></div></td>
<td style="vertical-align: bottom; width: 2%; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash" id="Fact_17702257">&#8212;</ix:nonFraction><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">27,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10,946</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_TreasuryStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10,026</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);;width:1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8pt; font-size: 8pt; background-color: rgb(204, 238, 255);"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 34%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million.&#160;&#160;&#160;&#160; </div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatory convertible preferred shares.&#160;&#160;&#160;&#160; </div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">***</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Mainly MCPS conversion.&#160;&#160;&#160;&#160; </div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">****</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Following the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-01,</div> the Company recorded a $ <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>&#160;million opening balance reclassification from accumulated other comprehensive income to retained earnings. </div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="tx102112_55" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities:</div></div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net income (loss)</div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash provided by operations:</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Impairment of <div style="letter-spacing: 0px; top: 0px;;display:inline;">goodwill,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>long-lived assets and assets held for sale</div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,778</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,722</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in operating assets and liabilities</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,823</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net and uncertain tax positions</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:DeferredIncomeTaxesNetAndUncertainTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:DeferredIncomeTaxesNetAndUncertainTaxPositions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">985</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:DeferredIncomeTaxesNetAndUncertainTaxPositions" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">837</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other items</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development in process</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net loss (gain) from investments and from sale of long lived assets</div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ProfitFromSaleOfLongLivedAssetsAndInvestment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ProfitFromSaleOfLongLivedAssetsAndInvestment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ProfitFromSaleOfLongLivedAssetsAndInvestment" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities</div></div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">748</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,446</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities:</div></div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beneficial interest collected in exchange for securitized trade receivables</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,405</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,735</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sales of long-lived assets and investments</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property, plant and equipment</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">525</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of investments and other assets</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investing activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by investing activities</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,866</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of senior notes and loans and other long<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>term liabilities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,871</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,944</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7,446</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from senior notes and loans, net of issuance costs</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="margin-left: 0in; line-height: normal; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,083</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,434</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from short term debt</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Repayment of short term debt</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">502</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other financing activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Tax withholding payments made on shares and dividends</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">Net cash used in financing activities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#160;(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,885</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation adjustment on cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance of cash and cash equivalents at beginning of year</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,782</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">963</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance of cash and cash equivalents at end of year</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255);;width:2%;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,177</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255);"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255);"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,975</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255);"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255); width: 2%;"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255);"><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 11pt; font-size: 11pt; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,782</ix:nonFraction><div style="font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. dollars in millions) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information:</div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash financing and investing activities:</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beneficial interest obtained in exchange for securitized trade receivables</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,397</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of mandatory convertible preferred shares into ordinary shares</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,880</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid during the year for:</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Interest</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">840</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes, net of refunds</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">709</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">552</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in operating assets and liabilities: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,416</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,437</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Trade payables, accrued expenses, employee-related obligations and other liabilities</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables net of sales reserves and allowances</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">293</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,823</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts may not add up due to rounding. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9<div style="display:inline;">5</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx102112_56" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704595"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1&#8212;Significant accounting policies: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:GeneralOptionsAccountingPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704596">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva Pharmaceutical Industries Limited (the &#8220;Parent Company&#8221;), headquartered in Israel, together with its subsidiaries and associated companies (the &#8220;Company,&#8221; &#8220;Teva&#8221; or the &#8220;Group&#8221;), is engaged in the development, manufacturing, marketing and distribution of generics, specialty medicines and biopharmaceuticals. The majority of the Group&#8217;s revenues are in the United States and Europe. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of presentation and use of estimate<div style="display:inline;">s</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In preparing the Company&#8217;s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of intangible assets and goodwill; assessing sales reserves and allowances in the United States, and contingent consideration; assessing compliance with debt covenants; uncertain tax positions, valuation allowances, contingencies, inventory valuation and restructuring. The inputs into Teva&#8217;s judgments and estimates also consider the economic implications of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&amp;D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva&#8217;s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic within its financial statements may change in future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Functional currency </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A major part of the Group&#8217;s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income (loss) in the consolidated statements of comprehensive income (loss). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). </div></div></ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_17704595" continuedAt="TextSelectionAppend_17704595_1"><ix:continuation id="TextSelection_17704596"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of consolidation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and VIEs for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders&#8217; interests are shown as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, are carried on the equity basis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated. </div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704599">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New accounting pronouncements </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently adopted accounting pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-04</div> &#8220;Reference Rate Reform (Topic 848)&#8212;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no impact to the Company&#8217;s consolidated financial statements for the period ended December&#160;31, 2020 as a result of adopting this standard update. The Company is continuing to evaluate the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities and has started initial negotiations to transform the facility base rate of its securitization program. However, it is not expected to have a material impact on the consolidated financial results. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In April 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-04</div> &#8220;Codification Improvements to Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825).&#8221; This ASU provides clarifications of three topics related to financial instruments accounting. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> &#8220;Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606.&#8221; The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i)&#160;addresses when the participant should be considered a customer in the context of a unit of account, (ii)&#160;adds <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">unit-of-account</div></div> guidance in ASC 808 to align with guidance in ASC 606 and (iii)&#160;precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> &#8220;Intangibles&#8212;Goodwill and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other&#8212;Internal-use</div> software (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40):</div> Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.&#8221; This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software. Teva applied the guidance prospectively to all implementation costs incurred after the date of adoption. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_1" continuedAt="TextSelectionAppend_17704595_2"><ix:continuation id="TextSelection_17704599" continuedAt="TextSelectionAppend_17704599_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> &#8220;Fair Value Measurement (Topic 820)&#8212;Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement.&#8221; This guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level&#160;3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. Certain disclosures required by this guidance must be applied on a retrospective basis and others on a prospective basis. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Upon adoption of the standard, there was no immediate impact to the Company&#8217;s financial position, results of operations or cash flows. On an ongoing basis, the Company will contemplate forward-looking economic conditions in recording lifetime expected credit losses for the Company&#8217;s financial assets measured at cost, such as the Company&#8217;s trade receivables and certain short-term investments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> &#8220;Debt &#8211; Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> &#8220;Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes&#8221; (the &#8220;update&#8221;). The amendments in this update simplify the accounting for income taxes by removing the following exceptions in ASC 740: (1) exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items; (2)&#160;exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment; (3)&#160;exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary; and (4)&#160;exception to the general methodology for calculating income taxes in an interim period when a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss exceeds the anticipated loss for the year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the update also simplifies the accounting for income taxes in certain topics as follows: (1)&#160;requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-income-based</div> tax; (2)&#160;requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; (3)&#160;specifying that an entity can elect (rather than be required to) allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; and (4)&#160;requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2020. The </div> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_2" continuedAt="TextSelectionAppend_17704595_3"><ix:continuation id="TextSelectionAppend_17704599_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company reviewed the above topics, noting that Items (1)&#160;and (4) of this paragraph are expected to be relevant, but not material. The adoption of this guidance will not have a significant impact on the Company&#8217;s consolidated financial statements. </div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:AcquisitionTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s consolidated financial statements include the operations of acquired businesses from the date of the acquisition&#8217;s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> at each reporting period, with any adjustments in fair value recognized in earnings under other assets impairments, restructuring and other items. </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:CollaborativeArrangementAccountingPolicy" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative arrangements: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative agreements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues are recorded on a net basis. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:EquityAndCostMethodInvestmentPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity investments: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-01</div> &#8220;Financial Instruments&#8212;Recognition and Measurement of Financial Assets and Financial Liabilities&#8221; to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months. </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704604">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">f.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurement: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_3" continuedAt="TextSelectionAppend_17704595_4"><ix:continuation id="TextSelection_17704604"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. </div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704605">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">g.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in debt securities: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Investment in securities consists of debt securities classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s investment in debt securities accounting policy until December&#160;31, 2019, prior to the adoption of the new Current Expected Credit Losses (&#8220;CECL&#8221;) standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gains of available for sale debt securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for debt securities are included in financial expenses, net. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s investment in debt securities accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unrealized gains and losses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are excluded from earnings and reported net of the related tax effect in the accumulated other comprehensive income component of shareholders&#8217; equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The CECL methodology, which became effective January&#160;1, 2020, requires the Company to estimate lifetime expected credit losses for all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position. </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">100</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_4" continuedAt="TextSelectionAppend_17704595_5"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><ix:continuation id="TextSelection_17704605">Comparative information continues to be reported in accordance with the methodology in effect for prior periods. When estimating a security&#8217;s probability of default and the recovery rate, the Company assesses the security&#8217;s credit indicators, including credit ratings. If the assessment indicates that an expected credit loss exists, the Company determines the portion of the unrealized loss attributable to credit deterioration and records an allowance for the expected credit loss through the Consolidated Statements of Income. Unrealized gains and any portion of a security&#8217;s unrealized loss attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax.</ix:continuation> </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">h.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:AccountsReceivablesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">i.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s accounts receivables accounting policy until December&#160;31, 2019, prior to the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables are stated at their net realizable value. The allowance against gross accounts receivables reflects the best estimate of losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. An allowance for doubtful debts is reflected in net accounts receivables. Accounts receivables are written off after all reasonable means to collect the full amount have been exhausted. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s accounts receivables accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Write-off</div> activity and recoveries for the periods presented were not material. </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">j.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of credit risks: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of Teva&#8217;s cash and cash equivalents (which, along with investment in securities, totaled $<ix:nonFraction name="teva:CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,478</ix:nonFraction>&#160;million at December&#160;31, 2020) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately <ix:nonFraction name="teva:PercentageOfConsolidatedSalesInNorthAmerica" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>% of Teva&#8217;s consolidated revenues in 2020. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">101</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_5" continuedAt="TextSelectionAppend_17704595_6"><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">k.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Inventories acquired in a business combination are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stepped-up</div> to their estimated fair value and amortized to cost of sales as that inventory is sold. </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704609">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">l.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva&#8217;s long-lived, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are comprised mainly of goodwill, identifiable intangible assets, property, plant and equipment, and operating lease ROU assets. All long-lived assets are monitored for impairment indicators throughout the year. Impairment testing for goodwill and all indefinite-lived intangible assets is performed at least annually. When necessary, charges for impairments of long-lived assets, other than goodwill, are recorded for the amount by which the fair value is less than the carrying value of these assets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the acquiree, over the assigned fair values of the identifiable net assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has historically performed its annual goodwill assessment during the fourth quarter of each year. During the second quarter of 2020, the Company decided to change the date of its annual impairment assessment from October&#160;1 to June 30. The change was made to more closely align the impairment assessment date with the Company&#8217;s long-term planning and forecasting process. See note 7. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The goodwill impairment test is performed according to the following principles: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value is recognized. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company&#8217;s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company&#8217;s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Identifiable intangible assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">102</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_6" continuedAt="TextSelectionAppend_17704595_7"><ix:continuation id="TextSelection_17704609"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (&#8220;S&amp;M&#8221;) expenses when separable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite life intangible assets are mainly comprised of IPR&amp;D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. Teva determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset&#8217;s estimated life, calculates the undiscounted value of the asset&#8217;s or asset group&#8217;s cash flows and compares such value against the asset&#8217;s or asset group&#8217;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company&#8217;s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i)&#160;for IPR&amp;D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii)&#160;for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, plant and equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">40</ix:nonNumeric> years; machinery and equipment, mainly between <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">15</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">20</ix:nonNumeric> years; and other assets, between <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years. </div>&#160;</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For property, plant and equipment and lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, whenever impairment indicators are identified, Teva reconsiders the asset&#8217;s estimated life, calculates the undiscounted value of the asset&#8217;s cash flows and compares such value against the asset&#8217;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See note 8 and note 1 cc for further discussion. </div></div> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_7" continuedAt="TextSelectionAppend_17704595_8"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">m.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:TreasurySharesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treasury shares: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treasury shares are presented as a reduction of Teva shareholders&#8217; equity and carried at their cost to Teva, under treasury shares. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">o.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (&#8220;RSUs&#8221;) and performance share units (&#8220;PSUs&#8221;). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704613">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">p.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Deferred income taxes are determined utilizing the &#8220;asset and liability&#8221; method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_8" continuedAt="TextSelectionAppend_17704595_9"><ix:continuation id="TextSelection_17704613"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax has not been provided on the following items: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company&#8217;s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amounts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> income generated from the Company&#8217;s current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 13 f. </div> </td> </tr> </table> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:IncomeTaxesUncertaintiesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">q.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncertain tax positions: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> its tax positions based on developments in its tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of Teva&#8217;s ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704615">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">r.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives and hedging: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company&#8217;s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative instruments are recognized on the balance sheet at their fair value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net in the statements of income in the period that the changes in fair value occur. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For derivative instruments that are designated as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-investment</div> hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income. The effective portion is determined by looking into changes in spot exchange rate. The change in fair value attributable to changes other than those due to fluctuations in the spot exchange rate are excluded from the assessment of hedge effectiveness and are recognized in the statement of income under financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_9" continuedAt="TextSelectionAppend_17704595_10"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_17704615">Derivative instruments that do not qualify for hedge accounting are recognized on the Balance Sheet at their fair value, with changes in the fair value recognized as a component of financial expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.</ix:continuation> </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704616">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">s.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (&#8220;SR&amp;A&#8221;) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&amp;A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&amp;A components and how they are estimated, see &#8220;Variable Consideration&#8221; below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&amp;M expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> year or less, based on the practical expedient. The Company&#8217;s credit terms to customers are, on average, between <span style="-sec-ix-hidden:hidden17702468">thirty</span> and <ix:nonNumeric name="teva:CreditTermsToCustomers" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">ninety days</ix:nonNumeric>. </div>&#160;</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&amp;M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of revenue streams </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_10" continuedAt="TextSelectionAppend_17704595_11"><ix:continuation id="TextSelection_17704616" continuedAt="TextSelectionAppend_17704616_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements performance obligations generally include intellectual property (&#8220;IP&#8221;) rights, certain R&amp;D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct&#8212;i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company&#8217;s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s IP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Revenues from licensing arrangements included royalty income of $<ix:nonFraction name="us-gaap:RoyaltyIncomeNonoperating" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:RoyaltyIncomeNonoperating" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:RoyaltyIncomeNonoperating" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction> million for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specifies goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenues are primarily comprised of contract manufacturing services, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets and liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities are mainly comprised of deferred revenues which were immaterial as of December&#160;31, 2020 and 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration mainly includes SR&amp;A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. </div></div> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_11" continuedAt="TextSelectionAppend_17704595_12"><ix:continuation id="TextSelectionAppend_17704616_1" continuedAt="TextSelectionAppend_17704616_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rebates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-established</div> volumes or the attainment of revenue milestones for a specified period, the customer receives a rebate. Since rebates are contractually agreed upon, they are estimated based on the specific terms in each agreement based on historical trends and expected sales. Externally obtained inventory levels and expected sales usage by contract are evaluated in relation to estimates made for rebates payable to indirect customers and managed care agreements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid and Other Governmental Rebates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer&#8217;s price for generic products dispensed and &#8220;best price&#8221; for specialty products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chargebacks </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva&#8217;s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva&#8217;s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a &#8220;chargeback&#8221;) to the wholesaler for the difference between the invoice price to the wholesaler and the customer&#8217;s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers and, therefore, will not necessarily fluctuate in proportion to an increase or decrease in sales. Provisions for estimating chargebacks are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Teva considers current and expected price competition when evaluating the provision for chargebacks. Chargeback provisions are compared to externally obtained distribution channel reports for reasonableness. The Company regularly monitors the provision for chargebacks and makes adjustments when the Company believes that actual chargebacks may differ from estimated provisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Promotional Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other promotional or incentive arrangements are periodically offered to customers, specifically related to the launch of products or other targeted promotions. Provisions are made in the period for which the Company can estimate the incentive earned by the customer, in accordance with the contractual terms. The Company regularly monitors the provision for other promotional arrangements and makes adjustments when it believes that the actual provision may differ from the estimated provisions. </div></div> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_12" continuedAt="TextSelectionAppend_17704595_13"><ix:continuation id="TextSelectionAppend_17704616_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shelf Stock Adjustments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers&#8217; existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. Teva regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns primarily relate to customer returns of expired products which, the customer has the right to return up to one year following the expiration date. Such returned products are destroyed and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recoded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, The Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies or packaging and any changes to customer terms, for determining the overall expected levels of returns. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prompt Pay Discounts </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prompt pay discounts are offered to most customers to encourage timely payment. Discounts are estimated at the time of invoice based on historical discounts in relation to sales. Prompt pay discounts are almost always utilized by customers. As a result, the actual discounts do not vary significantly from the estimated amount. </div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">t.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses are charged to statement of income (loss) as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Upfront fees received in connection with cooperation agreements are deferred and recognized over the period of the applicable agreements as a reduction of research and development expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are delivered or the services are performed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred. </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:CostOfShippingAndHandlingPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">u.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs, which are included in S&amp;M expenses, were $<ix:nonFraction name="teva:ShippingHandlingAndTransportationCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction> million, $<ix:nonFraction name="teva:ShippingHandlingAndTransportationCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction> million and $<ix:nonFraction name="teva:ShippingHandlingAndTransportationCost" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction> million for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, respectively. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_13" continuedAt="TextSelectionAppend_17704595_14"><ix:nonNumeric name="us-gaap:AdvertisingCostsPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">v.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs are expensed as incurred. Advertising costs for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> were $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction> million, respectively. </div> </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:RestructuringTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">w.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual termination benefits are provided to employees when employment is terminated due to an event specified in the provisions of an existing plan or agreement. A liability is recorded and the expense is recognized when it is probable that employees will be entitled to the benefits and the amount is reasonably estimable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Special termination benefits arise when the Company offers, for a short period of time, to provide certain additional benefits to employees electing voluntary termination. A liability is recorded and the expense is recognized in the period the employees irrevocably accept the offer and the amount of the termination liability is reasonably estimable. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">x.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment reporting: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s business includes three reporting segments based on three geographical areas: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment, which includes the United States and Canada. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment, which includes the European Union and certain other European countries. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment, which includes all countries in which Teva operates other than those in the North America and Europe segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each business segment manages the entire product portfolio in its region, including generics, specialty and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> (&#8220;OTC&#8221;) products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704622">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">y.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share are computed by dividing the net income attributable to ordinary shareholders by the weighted average number of ordinary shares (including fully vested RSUs and PSUs) outstanding during the year, net of treasury shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans and one series of convertible senior debentures, using the treasury stock method; (ii)&#160;the conversion of the remaining convertible senior debentures using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;if-converted&#8221;</div> method, by </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_14" continuedAt="TextSelectionAppend_17704595_15"><ix:continuation id="TextSelection_17704622"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">adding to net income interest expense on the debentures and amortization of issuance costs, net of tax benefits, and by adding the weighted average number of shares issuable upon assumed conversion of the debentures; and (iii)&#160;until December&#160;17, 2018, the conversion of the mandatory convertible preferred shares (&#8220;MCPS&#8221;) using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;if-converted&#8221;</div> method by adding to net income attributable to ordinary shareholders the dividends on the preferred shares and by adding the weighted average number of shares issuable upon assumed conversion of the mandatory convertible preferred shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;17</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, the mandatory convertible preferred shares automatically converted into ordinary shares. As a result of this conversion, Teva issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P12_17_2018To12_17_2018" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">70.6</ix:nonFraction>&#160;million ADSs. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">See note 14</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:SecuritizationTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">z.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securitization </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva accounts for transfers of certain of its trade receivable as sales when it has surrendered control over the related assets in accordance with ASC Topic 860 &#8220;Transfer and Servicing&#8221; of Financial Assets. Whether control has been relinquished requires, among other things, an evaluation of relevant legal considerations and an assessment of the nature and extent of the Company&#8217;s continuing involvement with the assets transferred. Assets obtained and liabilities incurred in connection with transfers reported as sales are initially recognized in the balance sheet at fair value. Refer to note 10 f. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:DivestituresTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">aa.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Divestitures </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company nets the proceeds on the divestitures of products with the carrying amount of the related assets and records gain or loss on sale within other income. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when it is probable that a significant reversal of income will not occur, or in the case of a business, when such payments are realizable. For divestures of businesses, including divestitures of products that qualify as a business, the Company reflects the relative fair value of goodwill associated with the businesses in the determination of gain or loss on sale. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">bb.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt instruments </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Debt instruments are initially recognized at the fair value of the consideration received. Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liability. They are subsequently recognized at amortized cost using the effective interest method. Debt may be considered extinguished when it has been modified and the terms of the new debt instruments and old debt instruments are &#8220;substantially different&#8221; (as defined in the debt modification guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div> &#8220;Debt&#8212;Modifications and Extinguishments&#8221;). The Company classifies the current portion of long term debt as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities on the Balance Sheet when it has the intent and ability to refinance the obligation on a long-term basis, in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div> &#8220;Debt&#8221;. </div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17705180">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">cc.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s lease accounting policy until December&#160;31, 2018, prior to the adoption of the new lease standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva leases real estate, cars and equipment for use in its operations, which are classified as operating leases. In addition to rent, the leases may require Teva to pay directly for fees, insurance, maintenance and other operating expenses. Rental expense for the year ended December&#160;31, 2018 was $<ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">175</ix:nonFraction>&#160;million. The Company also has capital leases for properties. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704595_15" continuedAt="TextSelectionAppend_17704595_16"><ix:continuation id="TextSelection_17705180"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s lease accounting policy from January&#160;1, 2019, following the adoption of the new lease standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva adopted the new accounting standard ASC 842 &#8220;Leases&#8221; and all the related amendments on January&#160;1, 2019 and used the effective date as Teva&#8217;s date of initial application. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseDescription" contextRef="P01_01_2020To12_31_2020">Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">842-10-25-2.</div></div></div> If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva&#8217;s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.</ix:nonNumeric></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets, other current liabilities and operating lease liabilities in the consolidated balance sheets. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated balance sheets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets represent Teva&#8217;s right to use an underlying asset for the lease term and lease liabilities represent Teva&#8217;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Teva uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For finance leases, Teva recognizes interest on the lease liability separately from amortization of the ROU assets in the statement of comprehensive income. For operating leases, lease expenses are recognized on a straight-line basis over the lease term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The new standard also provides practical expedients for an entity&#8217;s ongoing accounting. Teva elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, Teva does not recognize ROU assets or lease liabilities, including ROU assets or lease liabilities for existing short-term leases of assets in transition, but recognizes lease expenses over the lease term on a straight line basis. Teva also elected the practical expedient to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for all of Teva&#8217;s leases, other than leases of real estate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease terms will include options to extend or terminate the lease when it is reasonably certain that Teva will either exercise or not exercise the option to renew or terminate the lease. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s lease agreements have remaining lease terms ranging from <ix:nonNumeric name="teva:OperatingLeaseRemainingLeaseTerm" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">1</ix:nonNumeric> year to <ix:nonNumeric name="teva:OperatingLeaseRemainingLeaseTerm" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">78</ix:nonNumeric> years. Some of these agreements include options to extend the leases for up to </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> years and some include options to terminate the leases immediately. Certain leases also include options to purchase the leased property. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of Teva&#8217;s vehicle lease agreements include rental payments based on the actual usage of the vehicles and other lease agreements include rental payments adjusted periodically for inflation. Teva&#8217;s lease agreements do not contain any material residual value guarantees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The new lease standard has no impact on Teva&#8217;s debt-covenant compliance under its RCF. </div></div> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">12</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_17704595_16">Teva rents out or subleases certain assets to third parties, which has an immaterial impact on Teva&#8217;s consolidated financial statements.</ix:continuation> </div></div> <ix:nonNumeric name="teva:CertainTransactionsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704626"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2&#8212;Certain transactions: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business acquisitions: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics and Anda acquisitions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;2, 2016, Teva consummated its acquisition of Allergan plc&#8217;s (&#8220;Allergan&#8221;) worldwide generic pharmaceuticals business (&#8220;Actavis Generics&#8221;). At closing, Teva transferred to Allergan consideration of approximately $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P08_02_2016To08_02_2016_ActavisMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">33.4</ix:nonFraction> billion in cash and approximately <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P08_02_2016To08_02_2016_ActavisMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">100.3</ix:nonFraction>&#160;million Teva shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;3, 2016, Teva consummated the acquisition of Anda Inc. (&#8220;Anda&#8221;), a medicines distribution business in the United States, from Allergan, for cash consideration of $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P10_03_2016To10_03_2016_AndaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> million. This transaction was related to the Actavis Generics acquisition and, as such, the purchase price accounting and related disclosures were treated on a combined basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The final cash consideration for the Actavis Generics acquisition was subject to certain net working capital adjustments. On January&#160;31, 2018, Teva and Allergan entered into a settlement agreement and mutual releases for which Allergan made a one-time payment of $<ix:nonFraction name="teva:OneTimeMilestonePaymentReceived" contextRef="P01_31_2018To01_31_2018_AllerganPlcMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">703</ix:nonFraction> million to Teva to settle the working capital adjustments under the Master Purchase Agreement, dated July&#160;26, 2015. As the measurement period has ended, this amount was recorded as a gain under legal settlements and loss contingencies in the first quarter of 2018. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rimsa </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;3, 2016, Teva completed the acquisition of Representaciones e Investigaciones M&#233;dicas, S.A. de C.V. (&#8220;Rimsa&#8221;), a pharmaceutical manufacturing and distribution company in Mexico, for $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P03_03_2016To03_03_2016_RimsaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.3</ix:nonFraction>&#160;billion, in a cash free, debt free set of transactions. Teva financed the transaction using cash on hand. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the closing of the acquisition, Teva identified issues concerning Rimsa&#8217;s pre-acquisition quality, manufacturing and other practices, at which point Teva began an assessment of the extent and cost of remediation required to return its products to the market. In September 2016, <ix:nonFraction name="teva:NumberOfLawsuitsFiled" contextRef="P09_01_2016To09_30_2016_RimsaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_Lawsuit" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> lawsuits were filed: a pre-emptive suit by the Rimsa sellers against Teva and Teva&#8217;s lawsuit alleging fraud and breach of contract against the Rimsa sellers. The Rimsa sellers subsequently dismissed their lawsuit and the dismissal was approved by court order on December&#160;20, 2016. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On February&#160;15, 2018, Teva and the Rimsa sellers entered into a settlement agreement and mutual releases with respect to Teva&#8217;s breach of contract claim, pursuant to which the Rimsa sellers made a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payment to Teva. Teva&#8217;s breach of contract claim was subsequently dismissed by the court. As the measurement period has ended, this payment was recorded as a gain under legal settlements and loss contingencies in the first quarter of 2018. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other significant agreements: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#8217;s most significant agreements of this nature are summarized below. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_17704626" continuedAt="TextSelectionAppend_17704626_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alvotech Partnership </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, Teva entered into a partnership agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this partnership contains biosimilar candidates addressing multiple therapeutic areas. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva paid an upfront payment in the third quarter of 2020 that w<div style="letter-spacing: 0px; top: 0px;;display:inline;">as</div>&#160;recorded as R&amp;D expenses. During the fourth quarter of 2020, Teva accrued additional amounts due to the high probability that additional milestone payments will be paid in 2021. Additional development and commercial milestone payments of up <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">to</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_01_2020To12_31_2020_AlvotechMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">450</ix:nonFraction> million, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilar</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">s.&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eli Lilly and Alder BioPharmaceuticals </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, Teva entered into an agreeme<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div>t with Eli Lilly, resolving the European Patent Office opposition they had filed against Teva&#8217;s AJOVY<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> patents. The settlement agreement with Lilly also resolved Lilly&#8217;s action to revoke the patent protecting AJOVY in the United Kingdom. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;8, 2018, Teva signed a global license agreement with Alder BioPharmaceuticals (&#8220;Alder&#8221;). The agreement validates Teva&#8217;s intellectual property and resolves Alder&#8217;s opposition to Teva&#8217;s European patent with respect to anti-calcitonin gene-related peptide (CGRP) antibodies, including the withdrawal of Alder&#8217;s appeal before&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">the European Patent Office. Under the terms of the agreement, Alder will receive a non-exclusive license to Teva&#8217;s anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the United States and worldwide, excluding Japan and Korea. Teva received a</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">upfront payment that was recognized as revenue during the first quarter of 2018, and a&#160;</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="teva:MilestonePayment" contextRef="P01_01_2020To03_31_2020_AlderMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million milestone payment in March 2020 that was recognized as revenue in the first quarter of 2020. The agreement stipulates additional commercial milestone payments to Teva of up to</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million, as well as future royalties.</div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PGT Healthcare Partnership </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Teva terminated its joint venture with the Procter&#160;&amp; Gamble Company (&#8220;P&amp;G&#8221;), PGT Healthcare partnership (&#8220;PGT&#8221;), which the two companies established in 2011 to market OTC medicines. Teva will continue to maintain its OTC business on an independent basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the separation, Teva transferred to P&amp;G the shares it held in New Chapter Inc. and ownership rights in an OTC plant located in India. Teva provides certain services to P&amp;G after the separation for a transition period.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the first quarter of 2018, Teva classified the plant in India as an asset held for sale and recorded an impairment of</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2018To03_31_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million under other assets impairments, restructuring and other items. In addition, Teva recorded a write-down of</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P01_01_2018To03_31_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million of its investment in New Chapter Inc. under share in losses of associated companies.&#160;</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">During September 2018, Teva and P&amp;G completed the final net asset distribution as part of the dissolution and Teva recorded a gain of&#160;</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:ProfitFromSaleOfLongLivedAssetsAndInvestment" contextRef="P09_01_2018To09_30_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million to reflect the cash payment received from P&amp;G under the dissolution agreement.&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;19, 2017, Teva entered into a partnership agreement with Nuvelution Pharma, Inc. (&#8220;Nuvelution&#8221;) for development of AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704626_1" continuedAt="TextSelectionAppend_17704626_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States. There are no further plans in this indication following clinical trial results received in February 2020, which failed to meet their primary endpoints. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Otsuka </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#8220;Otsuka&#8221;), providing Otsuka with an exclusive license to conduct phase 2 and 3 clinical trials for AJOVY in Japan and, if approved, to commercialize the product in Japan. Otsuka paid Teva an upfront payment of $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction>&#160;million in consideration for the transaction. Results for these trials were received in January 2020 indicating that primary and secondary endpoints were achieved and that no clinically significant adverse events were observed in subjects. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $<ix:nonFraction name="teva:MilestonePayment" contextRef="P07_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>&#160;million, which was recognized as revenue in the third quarter of 2020. Teva may receive additional milestone payments upon achievement of certain commercial and revenue targets. Otsuka will also pay Teva royalties on AJOVY sales in Japan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Celltrion </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2016, Teva and Celltrion, Inc. (&#8220;Celltrion&#8221;) entered into a collaborative agreement to commercialize TRUXIMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and HERZUMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, two biosimilar products for the U.S. and Canadian markets. Teva paid Celltrion $<ix:nonFraction name="teva:TotalAssociatedCost" contextRef="PAsOn09_30_2020_CelltrionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction>&#160;million, of which Teva received an aggregate credit of $<ix:nonFraction name="teva:RefundablePayment" contextRef="PAsOn09_30_2020_CelltrionMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>&#160;million as of December&#160;31, 2020. Teva and Celltrion share the profit from the commercialization of these products. These two products, TRUXIMA and HERZUMA, were approved by the FDA in November and December 2018, respectively and were launched in the United States in November 2019 and March 2020, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regeneron </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;) entered into a collaborative agreement to develop and commercialize Regeneron&#8217;s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&amp;D costs of approximately $<ix:nonFraction name="teva:ResearchAndDevelopmentCosts" contextRef="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction>&#160;billion. Teva made an upfront payment of $<ix:nonFraction name="teva:UpfrontPayments" contextRef="P07_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>&#160;million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_01_2017To12_31_2017_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P01_01_2018To12_31_2018_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction></ix:nonFraction>&#160;million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $<ix:nonFraction name="teva:CollaborativeAgreementMilestonePayments" contextRef="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,230</ix:nonFraction>&#160;million, as well as future royalties. </div></div> </ix:continuation></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704626_2" continuedAt="TextSelectionAppend_17704626_3">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and Liabilities Held For Sale: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain assets of Teva&#8217;s business venture in Japan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva operates its business in Japan, which is part of Teva&#8217;s International Market segment, through a business venture with The Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), in which Teva owns a</div> <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn11_30_2015_TevaMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">51</ix:nonFraction>% <div style="letter-spacing: 0px; top: 0px;;display:inline;">stake and Takeda owns the remaining</div> <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn11_30_2015_TevaMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2020, Teva and Takeda entered into a purchase agreement to sell the majority of the business venture&#8217;s generic and operational assets. This transaction was completed on February&#160;1, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is accounting for the business venture assets and liabilities under the purchase agreement as held for sale and determined that the fair value less cost to sell did not exceed the carrying value, resulting in an impairment charge of</div>&#160;$<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million in other assets impairments, restructuring and other items recognized in 2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704626_3"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determined that the sale of this portion of the Teva-Takeda business venture does not constitute a strategic shift for Teva, and does not and will not have a major effect on its operations and financial results. Accordingly, the operations associated with the transactions are not reported as discontinued operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale include the Teva-Takeda business venture assets that are held for sale, the anticipated sale of certain OTC assets and other manufacturing assets that are expected to be sold within the next year. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below summarizes all Teva assets included as held for sale as of December&#160;31, 2020 and December&#160;31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 76%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net and others</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments of assets held for sale to fair value</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">(<ix:nonFraction name="us-gaap:AssetsFairValueAdjustment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">(<ix:nonFraction name="us-gaap:AssetsFairValueAdjustment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704633"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3&#8212;Revenue from contracts with customers: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregation of revenue </div></div></div> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;activities</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,902</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,736</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,946</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">772</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14,354</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,462</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,495</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#167;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">169</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">527</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">680</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,447</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,757</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,154</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,302</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16,659</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 0.5%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 0.5%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 0.5%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 0.5%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div> </td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">activities</div></div></div> </td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,941</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,770</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,045</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#167;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">545</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,304</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16,887</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 2%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 2%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 2%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 2%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">activities</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7,838</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15,881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,347</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9,297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,366</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">18,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $1&#160;million. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration mainly includes SR&amp;A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. For description of the nature of each deduction and how provisions are estimated see note 1. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_17704633"><ix:nonNumeric name="teva:SalesReservesAndAllowancesCurrentTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR&amp;A to U.S. customers comprised approximately <ix:nonFraction name="teva:SalesReservesAndAllowancesToCustomersPercentage" contextRef="P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">79</ix:nonFraction>% of the Company&#8217;s total SR&amp;A as of December&#160;31, 2020, with the remaining balance primarily in Canada and Germany. The changes in SR&amp;A for third-party sales for the period ended December&#160;31, 2019 and 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="26" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> reserves<br/> included in<br/> Sales<br/> Reserves<br/> and<br/> Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at January 1, 2019</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,361</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">638</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,886</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year period</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2019To12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">383</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,552</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">976</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9,565</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16,767</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">17,150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">17</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">17,134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">17,605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2019</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%; border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,342</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year period</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2020To12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14,415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14,806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 2%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">184</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,614</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15,309</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ValuationAllowancesAndReservesForeignCurrencyTranslation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 39%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2020</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">828</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 39%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4&#8212;Inventories: </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories, net of reserves, consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,378</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,504</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw and packaging materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,231</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Products in process</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">583</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials in transit and payments on account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherInventoryInTransit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherInventoryInTransit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-size: 10pt;;text-align:right;">$<ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,403</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,422</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5&#8212;Property, plant and equipment: </div></div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net, consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;"><ix:nonFraction name="us-gaap:BuildingsAndImprovementsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:BuildingsAndImprovementsGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and other assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,197</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets under construction and payments on account</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;"><ix:nonFraction name="teva:AssetsUnderConstructionAndPaymentsOnAccount" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:AssetsUnderConstructionAndPaymentsOnAccount" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">672</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Land</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"><ix:nonFraction name="us-gaap:Land" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Land" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">323</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less&#8212;accumulated depreciatio<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">$<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,436</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expenses were $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">537</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">609</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">676</ix:nonFraction> million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. During the years ended December&#160;31, 2020, 2019 and 2018, Teva had impairments of <div style="letter-spacing: 0px; top: 0px;;display:inline;">property</div>, plant and equipment in the amount of $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">416</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> million, respectively. <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">See note </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">15</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704643"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6&#8212;Identifiable intangible assets: </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount<br/> net of impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Product rights</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">19,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">19,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12,094</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10,640</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7,556</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9,023</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trade names</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">In-process research and development (IPR&amp;D)</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">911</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,735</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160; </div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">911</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,735</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">21,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">21,998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12,259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,923</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product rights and trade names </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">10</ix:nonNumeric> years. Amortization of intangible assets amounted to $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,020</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,113</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,166</ix:nonFraction> million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the estimated aggregate amortization of intangible assets for the years 2021 to 2025 is as follows: 2021&#8212;$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">812</ix:nonFraction> million; 2022&#8212;$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">764</ix:nonFraction> million; 2023&#8212;$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">744</ix:nonFraction> million; 2024&#8212;$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction> million&#160;and 2025&#8212;$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">723</ix:nonFraction> million. These estimates do not include the impact of IPR&amp;D that is expected to be successfully completed and reclassified to product rights.</div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_17704643" continuedAt="TextSelectionAppend_17704643_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s IPR&amp;D are assets that have not yet been approved in major markets. Teva&#8217;s IPR&amp;D is comprised mainly of various generic products from the Actavis Generics acquisition of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="PAsOn12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">877</ix:nonFraction>&#160;million. IPR&amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Impairment of identifiable intangible assets amounted to $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,502</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,639</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction> million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. These amounts are recorded<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">in the statement of income (loss) under intangible assets impairment.&#160;</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in 2020 mainly consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">797</ix:nonFraction>&#160;million, mainly due to: (i) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_LenalidomideProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction>&#160;million related to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States; (ii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020_LenalidomideProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction>&#160;million related to lenalidomide (generic equivalent of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revlimid&#174;),&#160;</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">due to modified competition assumptions as a result of settlements between the innovator and other generic filers; (iii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020_AustedoMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction>&#160;million related to AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the United States following clinical trial results, received in February 2020, which failed to meet their primary endpoints; and&#160;</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million, mainly due to: (i) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">398</ix:nonFraction> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States; (ii) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million in Japan in connection with ongoing regulatory pricing reductions and generic competition; and (iii) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million related to a change in the assumptions regarding competition for the expected relaunch of metformin tablets. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in 2019 mainly consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction> million, mainly due to: (i) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">647</ix:nonFraction> million due to updated market assumptions regarding price and volume of certain products acquired from Actavis Generics and primarily marketed in the United States, (ii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonFraction> million related to a decrease in future expected sales in Japan as a result of generic competition, and (iii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019_DiscontinuedBusinessMemberTEVADiscontinuationOfBusinessAxis_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction> million related to the discontinuation of certain products from Actavis Generics&#8217; portfolio in several international markets; and</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">681</ix:nonFraction>&#160;million, due to: (i) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_LenalidomideProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">497</ix:nonFraction>&#160;million related to various generic pipeline products acquired from Actavis Generics due to development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date or discount rate) in the United States (ii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019_LenalidomideProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction>&#160;million related to lenalidomide (generic equivalent of REVLIMID<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), due to modified competition assumptions as a result of settlements between the innovator and other generic filers, and (iii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction>&#160;million related to a change in assumptions concerning the future European market share of a number of pipeline products acquired from Actavis Generics. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in 2018 mainly consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,068</ix:nonFraction>&#160;million, mainly due to: (i) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">412</ix:nonFraction>&#160;million in connection with updated market assumptions regarding price and volume of products acquired from Actavis Generics currently marketed in the United States and supply constraints; (ii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">290</ix:nonFraction>&#160;million in certain international markets, due to a loss of several tenders and termination of products manufacturing lines; and (iii) $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_JPsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction>&#160;million in Japan in connection with ongoing regulatory pricing reductions and generic competition. </div></div> </td> </tr> </table> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><ix:continuation id="TextSelectionAppend_17704643_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2018To12_31_2018_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">923</ix:nonFraction>&#160;million, mainly related to revaluation of generic products acquired from Actavis Generics due to development progress and changes in other key valuation indications (e.g., market size, legal landscape, launch date or discount rate). </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value measurement of the impaired intangible assets in 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> is<div style="letter-spacing: 0px; top: 0px;;display:inline;"> based</div> on significant unobservable inputs in the market and thus represents a Level&#160;3</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> measurement within the fair value hierarchy. The discount rate applied ranged from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:numdotdecimal">7.5</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:numdotdecimal">9</ix:nonFraction>%. A probability of success factor of <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:numdotdecimal">80</ix:nonFraction>% was used in the</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">majority of </div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">fair value calculation</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">s</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> to reflect</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> inherent regulatory and commercial risk of IPR&amp;D. </div></div></div></div> </ix:continuation><ix:nonNumeric name="us-gaap:GoodwillDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704653"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7&#8212;Goodwill: </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfGoodwillTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 0.5%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 0.5%;"></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 201</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(1)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702679">11,098</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2018_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702680">8,653</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2018_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702681">2,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2018_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702682">2,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702683">24,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwil</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">l </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">disposal</div><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:3%;">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019 (1)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703192">11,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703191">8,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703190">2,532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703189">2,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703188">24,846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwill reclassified as assets held for sale</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(<ix:nonFraction name="teva:GoodwillReclassification" contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:GoodwillReclassification" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:GoodwillReclassification" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:3%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of <div style="letter-spacing: 0px; top: 0px;;display:inline;">December </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">31</div>, 2020 (1)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702690">6,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702691">9,102</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702692">2,362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702693">2,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702694">20,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accumulated goodwill impairment as of December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018 was approximately $<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">25.6</ix:nonFraction>&#160;billion, $<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">21.0</ix:nonFraction>&#160;billion and $<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">21.0</ix:nonFraction>&#160;billion, respectively. </div></div></div></div></td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva&#8217;s production and sale of APIs to third parties (&#8220;Teva API&#8221;) and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. The Teva API and Medis reporting units are included under &#8220;Other&#8221; in the above table. See note 19 for additional segment information. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#8217;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#8220;WACC&#8221;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#8217;s assumptions, Teva may recognize an impairment of goodwill allocated to its reporting units in the future. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">2<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_17704653" continuedAt="TextSelectionAppend_17704653_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">First Quarter Developments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the first quarter of 2020, management assessed developments that occurred during the quarter, including expected effects of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its business, to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. As part of this assessment, management also considered the sensitivity of its conclusions as they relate to changes in the estimates and assumptions used in the latest forecast available for each period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of March&#160;31, 2020 and, therefore, no quantitative assessment was performed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Second Quarter Developments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Company policy, the Company has historically performed its annual goodwill assessment during the fourth quarter of each year. During the second quarter of 2020, the Company changed its annual impairment assessment date from October&#160;1 to June&#160;30 to more closely align the impairment assessment date with the Company&#8217;s long-term planning and forecasting process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the second quarter of 2020, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test and utilized the assistance of an independent valuation expert. No goodwill impairment charge was recorded during the second quarter of 2020.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the aforementioned analysis, Teva analyzed the aggregated fair value of its reporting units compared to its market capitalization as part of its annual goodwill impairment test, in order to assess the reasonableness of the results of its cash flow projections used for its goodwill impairment analysis. Management noted differences between the market capitalization and management&#8217;s internal projections as of the end of the second quarter. As of June&#160;30, 2020, those differences were believed to be attributable to the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management noted a portion of the difference can be attributed to sales projections of AJOVY and AUSTEDO in the International Markets reporting unit. Management continues to believe that the majority of analysts do not focus on these brands in preparing their financial models and, as a result, have not attributed value to the launch potential in this reporting unit. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management noted an additional difference can be attributed to sales projections of AUSTEDO in the North America reporting unit, resulting in higher fair value as analyzed by management compared to Teva&#8217;s market capitalization. Management continues to believe that it has more accurate information based on its knowledge of the market and its growth and therefore no adjustment was incorporated to the fair value. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management noted that market concerns regarding the uncertainty related to the opioid and price fixing litigation risks are impacting its market capitalization. Management believes that these concerns led to an acute reaction, which resulted in a decline in Teva&#8217;s share price. Management believed developments in the opioids case would clarify the outlook with regards to the opioid litigation, when the proposed settlement framework is finalized, which was expected in the near term. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if management was to adjust the fair value of the North America reporting unit for any one of the uncertainties noted, the estimated fair value would still exceed its carrying amount. Management also noted that negative results related to all the uncertainties noted may lead to a material goodwill impairment charge. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">22</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_17704653_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third Quarter Developments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of 2020, Teva&#8217;s share price experienced further decline. Teva analyzed its aggregated internal valuation of its reporting units compared to its market capitalization as part of its goodwill impairment test. Management believed there are similar reconciling factors to those referenced in the second quarter with additional declines occurring due to increased uncertainty related to certain litigation actions in the third quarter and the related uncertainties it added to the existing concerns around financial strength. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of 2020, management noted the following factors that led to an assessment of the North America reporting unit for impairment: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; padding-top: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company noted a <ix:nonFraction name="teva:PercentageDecreaseInTheMarketCapitalization" contextRef="P01_01_2020To09_30_2020_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% reduction in its market capitalization from the second quarter of 2020 to the third quarter of 2020. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">With respect to the opioids litigation, as discussions continue with the group of Attorneys General regarding the nationwide framework and trial dates are postponed largely due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, a resolution of this matter is taking longer than anticipated. Accordingly, the Company was and is currently unable to predict the timing of any final settlement or whether the settlement will be finalized based upon the current settlement framework. </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;25, 2020, the Company was indicted by the U.S. Department of Justice for alleged violations of the Sherman Act. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;18, 2020, the Company was sued by the U.S. Department of Justice alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is committed to its projected cash flow targets and management&#8217;s views on the litigation exposures have not changed. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">However, the developments indicated&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">the timeframe for resolution will take significantly longer than previously expected which introduces greater uncertainty to a favorable resolution. In addition, management </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">believed&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">that analysts </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">were&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">unlikely to modify their projections until the Company </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">could&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> demonstrate progression on the resolution with respect to some or all of the above legal matters. As such, for purposes of testing the goodwill in the North America reporting unit under ASC 350</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, management incorporated these factors into its valuation of the North America reporting unit, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">which resulted&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in an impairment charge of $<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,628</ix:nonFraction> million. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fourth Quarter Developments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the fourth quarter of 2020, management assessed developments during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of December&#160;31, 2020 and, therefore, no quantitative assessment was performed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the goodwill impairment charge recorded in the third quarter of 2020 to the North America reporting unit, the carrying value of the North America reporting unit equaled its fair value as of September&#160;30, 2020. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to the North America reporting unit in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The other reporting units all have fair value in excess of <ix:nonFraction name="teva:PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" contextRef="PAsOn12_31_2020_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% over their book values as of December&#160;31, 2020. </div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704655"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8&#8212;Leases: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva adopted the new accounting standard ASC 842 &#8220;Leases&#8221; and all the related amendments on January&#160;1, 2019 and used the effective date as Teva&#8217;s date of initial application. </div></div> <ix:nonNumeric name="teva:ComponentsOfLeaseExpenseTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease cost for the year ended December&#160;31, 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 16%;"></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost:</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed payments and variable payments that depend on an index or rate</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">166</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease payments not included in the lease liability</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 16%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$<ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$<ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="teva:SupplementalCashFlowInformationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to operating leases was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 16%;"></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for lease obligations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-cash):</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%; padding-bottom: 2.2pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom; width: 16%; padding-bottom: 2.2pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;"><ix:nonFraction name="teva:OperatingLeasesNonCash" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 2.2pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;"><ix:nonFraction name="teva:OperatingLeasesNonCash" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;">&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="teva:SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental balance sheet information related to operating leases was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 18%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease ROU assets</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:OperatingLeaseLiabilityOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:OperatingLeaseLiabilityOther" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">595</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">553</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020" format="ixt-sec:duryear">7.5</ix:nonNumeric>&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2019" format="ixt-sec:duryear">7.5</ix:nonNumeric>&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">5.2</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">6.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_17704655"><ix:nonNumeric name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2025 and thereafter</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">302</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease payments</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">722</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:OperatingLeasesImputedInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">595</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At the end of the third quarter of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, after obtaining the right to use the building, Teva began transitioning its corporate headquarters to a consolidated site in Tel-Aviv, Israel. Teva has an operating lease for the office space in Tel Aviv for an initial term of twelve and a half years, with an option for three extensions. Teva estimates that the reasonably certain holding period of the lease for accounting purposes is twelve and a half years. As of September 30,&#160;</div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, <div style="letter-spacing: 0px; top: 0px;;display:inline;">upon initial recognition,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>Teva booked&#160;&#160;$</div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2020_MinimumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million as operating lease right-of-use and $</div><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn09_30_2020_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million as operating lease liability.&#160;</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, Teva&#8217;s total finance lease assets and finance lease liabilities were</div>&#160;$<ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. The difference between those amounts is mainly due to prepaid payments.</div> </div></div> </ix:continuation><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704660"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9&#8212;Debt obligations: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShortTermDebtTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term debt: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> interest rate as of<br/> December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible debentures</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 7%; text-align: center;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>%</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">2026</ix:nonNumeric></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn12_31_2019_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="5" style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current maturities of long-term liabilities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,674</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,831</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td colspan="5" style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total short term debt</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,188</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,345</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible senior debentures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>% convertible senior debentures, due 2026, principal amount as of December&#160;31, 2020 and 2019 were $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2020_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2019_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">514</ix:nonFraction></ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. These convertible senior debentures include a &#8220;net share settlement&#8221; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#8220;net share settlement&#8221; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. Holders of the convertible debentures were able to cause Teva to redeem the debentures on February 1, 2021, and $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn02_01_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction> million of the convertible debentures were redeemed on such date.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_17704660" continuedAt="TextSelectionAppend_17704660_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:LongTermDebtExcludingConvertibleDebtTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 100%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> interest rate as of<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,010</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million (1)</div></div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal" id="Fact_17703224">0.38</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis" id="Fact_17702857">2020</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702859">1,131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,500</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.13</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">2024</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,839</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,300</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.25</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">2023</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,595</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">900</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.50</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.63</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">2028</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">916</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">833</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">700</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.25</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">2022</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">861</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">700</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.88</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">2027</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">860</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction>&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.00</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,230</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,120</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction>&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">7.13</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,500</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.15</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">2026</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,494</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,475</ix:nonFraction>&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.20</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis">2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,000</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.80</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">2023</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,000</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.10</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">2046</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,986</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,985</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.00</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">2024</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.75</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">2028</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">844</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.95</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">2022</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">853</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">856</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">789</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.15</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">2036</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">783</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">700</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million (2)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal" id="Fact_17703207">2.25</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis" id="Fact_17702929">2020</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702931">700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">613</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.65</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis">2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">616</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">618</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.65</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis">2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">587</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_CHF" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">2022</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">361</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_CHF" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction>&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right; padding-bottom: 0.45pt;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.00</ix:nonFraction></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">2025</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">25,490</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">26,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term debt</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.08</ix:nonFraction> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"><ix:nonNumeric name="teva:DebtInstrumentMaturityYear" contextRef="P01_01_2020To12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis">2026</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2019_OtherDebentures2026MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current maturities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less debt issuance costs</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes and loans</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22,731</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"><ix:nonFraction name="us-gaap:LongTermNotesAndLoans" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">24,562</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In July&#160;</div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, Teva repaid at maturity &#8364;</div><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn07_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">1,010</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million of its</div>&#160;<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn07_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="5" scale="-2" format="ixt:numdotdecimal">0.375</ix:nonFraction>% <div style="letter-spacing: 0px; top: 0px;;display:inline;">senior notes.</div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March&#160;</div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, Teva repaid at maturity $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">700</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of its</div>&#160;<ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn03_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.25</ix:nonFraction>% <div style="letter-spacing: 0px; top: 0px;;display:inline;">senior notes.&#160;</div> </div></div></td></tr></table> </ix:nonNumeric></ix:continuation></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17704660_1" continuedAt="TextSelectionAppend_17704660_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts (as defined), if any. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term debt as of December&#160;31, 2020 is effectively denominated in the following currencies: U.S. dollar <ix:nonFraction name="teva:LongTermDebtCurrencyPortionUSD" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%, euro <ix:nonFraction name="teva:LongTermDebtCurrencyPortionEUR" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">37</ix:nonFraction>% and Swiss franc <ix:nonFraction name="teva:LongTermDebtCurrencyPortionCHF" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.3</ix:nonFraction> billion<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">unsecured syndicated</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;revolving credit facility</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">entered into in April 2019</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;(&#8220;RCF&#8221;).</div></div></div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">12<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div></div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA <div style="letter-spacing: 0px; top: 0px;;display:inline;">PHARMACEUTICAL</div> INDUSTRIES <div style="letter-spacing: 0px; top: 0px;;display:inline;">LIMITED</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(<div style="letter-spacing: 0px; top: 0px;;display:inline;">Continued</div>) </div></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17704660_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The RCF agreement provides for two separate tranches, a</div> $<ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="PAsOn04_30_2019" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.15</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">billion tranche A and a</div>&#160;$<ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="PAsOn11_30_2015" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.15</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">billion tranche B. Loans and letters of credit will be available from time to time under each tranche for Teva&#8217;s general corporate purposes. Tranche A has a maturity date of April 8, 2022, with two one-year extension options, of which $<ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="PAsOn04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheAExtensionMemberusgaapLineOfCreditFacilityAxis_TracheAMemberTEVATrancheAxis" unitRef="Unit_USD" decimals="-6" scale="9" format="ixt:numdotdecimal">1.065</ix:nonFraction> billion was extended to <ix:nonNumeric name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="P04_01_2019To04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheAExtensionMemberusgaapLineOfCreditFacilityAxis_TracheAMemberTEVATrancheAxis" format="ixt:datemonthdayyearen">April 8, 2023</ix:nonNumeric>. Tranche B has a maturity date of <ix:nonNumeric name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="P04_01_2019To04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheBMemberTEVATrancheAxis" format="ixt:datemonthdayyearen">April 8, 2024</ix:nonNumeric>.&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time.</div> <ix:nonNumeric name="us-gaap:DebtInstrumentCovenantDescription" contextRef="P01_01_2020To12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">The net debt to EBITDA ratio limit was 5.75x through December 31, 2020, gradually declines to 5.50x in the first and second quarters of 2021, 5.00x in the third and fourth quarters of 2021, and continues to gradually decline over the remaining term of the RCF.</ix:nonNumeric> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The RCF can be used for general corporate purposes, including repaying existing debt. As of December&#160;31, 2020, and as of the date of this Annual Report on Form 10-K, <ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date these financial statements are issued. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes is outstanding, could lead to an event of default under the Company&#8217;s senior notes due to cross acceleration provisions.&#160;</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that these financial statements are issued.</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the required annual principal payments of long-term debt, excluding debt issuance cost, including convertible senior debentures, starting from the year 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>, are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,591</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,089</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">202<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,735</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">2026 and thereafter *</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="teva:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703057">9,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="teva:LongTermDebtaExcludeIssuanceCost" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">23,330</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2020_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">514</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million convertible notes. See note 9a. </div></div></div> </td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="text-align: left;"><ix:nonNumeric name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704684"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="/* background-color: rgb(255, 255, 255); */letter-spacing: 0px;top: 0px;;display:inline;">NOTE 10&#8212;Derivative instruments and hedging <div style="letter-spacing: 0px; top: 0px;;display:inline;">activities</div>:</div></div></div></div></div></ix:nonNumeric></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_17704684" continuedAt="TextSelectionAppend_17704684_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange risk management: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, approximately <ix:nonFraction name="teva:RevenuesOtherThanUsd" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>% of Teva&#8217;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is <div style="letter-spacing: 0px; top: 0px;;display:inline;">subject </div>to significant foreign currency risks. </div></div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">12<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div></div></div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704684_1" continuedAt="TextSelectionAppend_17704684_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company enters into forward exchange contracts, purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: the euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar, the Polish zloty, the Indian rupee and other European and Latin American currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#8220;net investment hedge&#8221;) and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest risk management: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company raises capital through various debt instruments, including straight notes that bear a fixed or variable interest rate, bank loans and convertible debentures. In some cases, the Company has swapped from a fixed to a floating interest rate (&#8220;fair value hedge&#8221;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#8220;cash flow hedge&#8221;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative instrument disclosure: </div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-currency swap<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net investment hedge</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeNotionalAmount" contextRef="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative instrument outstanding: </div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification and fair values of derivative instruments: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">$</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn12_31_2020_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="PAsOn12_31_2019_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; padding: 0pt; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal; text-align: left; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Cross-currency swaps<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">, </div>net investment<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>hedge</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn12_31_2020_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_SwapMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction>)</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn12_31_2020_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn12_31_2019_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704684_2" continuedAt="TextSelectionAppend_17704684_3"> <ix:nonNumeric name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives designated in fair value or cash flow hedging relationships: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other comprehensive<br/> income&#160;(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018**&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018**&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">834</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2017To12_31_2017_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704207">959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704198">585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cross-currency swaps&#8212;cash flow hedge (1)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash" id="Fact_17704362">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704218">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2017To12_31_2017_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704206">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash" id="Fact_17704361">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704217">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704197">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cross-currency swaps<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net investment hedge (2)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704212">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704216">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2017To12_31_2017_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704205">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704211">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704215">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704196">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Interest rate swaps&#8212;fair value hedge (3)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash" id="Fact_17704360">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704359">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash" id="Fact_17704358">&#8212;</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash" id="Fact_17704357">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash" id="Fact_17704356">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetRevenuesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparative figures are based on prior hedge accounting standard. </div></div> </td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704770"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16,887</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">18,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (4)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704950">130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704949">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704944">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts&#160; (5)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:zerodash" id="Fact_17704867">&#8212;</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2019To12_31_2019_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704947">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2018To12_31_2018_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17705120">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>&#160;million in cross-currency swap agreements against its </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outstanding <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.65</ix:nonFraction>% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $<ix:nonFraction name="teva:CashReceivedOnSettlementOfPosition" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $<ix:nonFraction name="teva:CashReceivedOnSettlementOfPosition" contextRef="PAsOn12_31_2020_SeniorNotesDue2020MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>&#160;</div> million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva&#8217;s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">float-for-float</div></div> interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $<ix:nonFraction name="teva:CashReceivedOnSettlementOfPosition" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>&#160;million. <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn12_31_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction>% senior notes due 2023 with respect to $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn12_31_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>&#160;million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $<ix:nonFraction name="teva:SettlementGainPosition" contextRef="PAsOn12_31_2020_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div></div> </td> </tr> </table> </ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704684_3" continuedAt="TextSelectionAppend_17704684_4"> <ix:continuation id="TextSelection_17704770">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. During 2019 and 2020, Teva entered into hedging instruments to hedge part of the projected 2020 operating results. In 2020, Teva recognized a gain of $<ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2020To12_31_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction>&#160;million in relation with the 2020 hedging program. During the second half of 2020, Teva entered into hedging instruments to hedge part of the projected operating results for 2021. As part of the economic hedge treatment, Teva recorded a loss of $<ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2020To12_31_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis_HedgingOfRevenuesTwoThousandAndTwentyOneMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction>&#160;million in relation to the 2021 hedging instruments in the second half of 2020, while the positive foreign exchange impact on the underlying revenues and expenses, may occur upon their maturity in 2021. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div></div> </td> </tr> </table> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortizations due to terminated derivative instruments: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward starting interest rate swaps and treasury lock agreements </div></div></div> <div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;margin-left: 0%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position of $<ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">493</ix:nonFraction>&#160;million, which was recorded in other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to these forward starting interest rate swaps and treasury lock agreements, losses of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million, </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million and </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million were recognized under financial expenses, net for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value hedge </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.95</ix:nonFraction>% senior notes due 2022 with respect to $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">844</ix:nonFraction>&#160;million notional amount and its <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.65</ix:nonFraction>% senior notes due 2021 with respect to $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">450</ix:nonFraction>&#160;million notional amount. Settlement of these transactions resulted in a gain position of $<ix:nonFraction name="us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" contextRef="P07_01_2016To09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction>&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2019, Teva terminated $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>&#160;million interest rate swap agreements designated as a fair value hedge relating to its <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction>% senior notes due 2023 with respect to $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,000</ix:nonFraction>&#160;million notional amount. Settlement of these transactions resulted in cash proceeds of $<ix:nonFraction name="teva:CashReceivedOnSettlementOfPosition" contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704684_4" continuedAt="TextSelectionAppend_17704684_5"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow hedge </div></div></div> <div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;margin-left: 0%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fourth quarter of 2019, Teva terminated $<ix:nonFraction name="teva:NotionalAmountHedgeDebt" contextRef="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million cross-currency swap agreements against its </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outstanding <ix:nonFraction name="teva:PreviouslyHedgeDebtRate" contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.65</ix:nonFraction>% </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">senior notes maturing in November 2021. Settlement of these transactions resulted in cash proceeds of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="teva:CashReceivedOnSettlementOfPosition" contextRef="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">With respect to the interest rate swap and cross-currency swap agreements,&#160;gains of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="teva:InterestRateSwapGain" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million, $<ix:nonFraction name="teva:InterestRateSwapGain" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction> million and $<ix:nonFraction name="teva:InterestRateSwapGain" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million were recognized under financial expenses, net for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">f.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securitization: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2011, Teva established a trade receivables securitization program to sell trade receivables to BNP Paribas Bank (&#8220;BNP&#8221;). Under the program Teva (on a consolidated basis) receives an initial cash purchase price and the right to receive a deferred purchase price (&#8220;DPP&#8221;), according to the purchase price for the receivables sold by it. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On an individual seller basis, each Teva subsidiary sells receivables to BNP for an amount equal to their nominal amount. BNP then immediately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-sells</div> such receivables to a bankruptcy-remote special-purpose entity (&#8220;SPE&#8221;), for an amount equal to the nominal amount of such trade receivables. The SPE then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-sells</div> such receivables to a conduit sponsored by BNP (&#8220;the conduit&#8221;) for an initial cash purchase price (equal to the nominal amount of such receivables less a discount) and the right to receive a DPP. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The SPE is a VIE for which Teva is considered to be the primary beneficiary. The SPE&#8217;s sole business consists of the purchase of receivables from Teva subsidiaries and the subsequent transfer of such receivables to the conduit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the SPE is included in Teva&#8217;s consolidated financial statements, it is a separate legal entity with separate creditors. The conduit and other designated creditors of the SPE are entitled, both before and upon the SPE&#8217;s liquidation, to be paid out of the SPE&#8217;s assets prior to the DPP payable to Teva. The assets of the SPE are not available to pay creditors of Teva or its subsidiaries.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This program expires on August&#160;21, 2021 but can be renewed with consent from the parties to the program up to August&#160;20, 2022 or any other date agreed between the parties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Once sold to BNP, the relevant Teva subsidiary as seller has no retained interests in the receivables sold and they are unavailable to the relevant seller should the relevant seller become insolvent. The conduit has all the rights in the securitized trade receivables, including the right to pledge or dispose of such receivables. Consequently, receivables sold under this agreement are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-recognized</div> from Teva&#8217;s consolidated balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The portion of the purchase price for the receivables which is not paid in cash by the conduit is a DPP asset. The conduit pays the SPE the DPP from collections received by the conduit from the securitized trade receivables (after paying senior costs and expenses, including the conduit&#8217;s debt service obligations), which the SPE then pays to Teva.The DPP asset represents a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The DPP asset is included in other current assets on Teva&#8217;s consolidated balance sheet. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva has collection and administrative responsibilities for the sold receivables. The fair value of these servicing arrangements as well as the fees earned was immaterial. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">31</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued)</div></div></div> <ix:continuation id="TextSelectionAppend_17704684_5"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">DPP asset as of December&#160;31, 2020 and 2019 was </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="teva:DeferredPurchaseAsset" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction> million and $<ix:nonFraction name="teva:DeferredPurchaseAsset" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, the balance of Teva&#8217;s securitized assets sold were </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:AccountsReceivableFromSecuritization" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">734</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AccountsReceivableFromSecuritization" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">690</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <ix:nonNumeric name="teva:ScheduleOfAccountReceivableFromSecuritization" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the sold receivables outstanding balance net of DPP asset under the outstanding securitization program: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;and&#160;for&#160;the&#160;year&#160;ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sold receivables at the beginning of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableFromSecuritization" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableFromSecuritization" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromAccountsReceivableSecuritization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromAccountsReceivableSecuritization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash collections (remitted to the owner of the receivables)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfAccountsReceivableSecuritization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfAccountsReceivableSecuritization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,849</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of currency exchange rate changes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:EffectOfExchangeRateOnAccountsReceivableFromSecuritization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:EffectOfExchangeRateOnAccountsReceivableFromSecuritization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sold receivables at the end of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableFromSecuritization" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableFromSecuritization" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:LegalMattersAndContingenciesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11&#8212;Legal settlements and loss contingencies: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies for 2020 amounted to expenses of $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>&#160;million, compared to expenses of $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,178</ix:nonFraction>&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in 2019&#160;</div></div>and an income of $<ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,208</ix:nonFraction>&#160;million in &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">2018.</div>&#160;<ix:nonNumeric name="teva:RestructuringExpenseAndIncome" contextRef="P01_01_2020To12_31_2020_SettlementOnAccountOfProductLiabilityMembersrtLitigationCaseAxis_USsrtStatementGeographicalAxis">The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). The expenses in 2019 were mainly related to an estimated provision recorded in connection with potential settlement of the opioid cases.</ix:nonNumeric> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, Teva&#8217;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,625</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,580</ix:nonFraction>&#160;million, respectively. </div></div></ix:nonNumeric></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704857"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 12&#8212;Commitments and contingencies:</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalty commitments: </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company is committed to pay royalties to owners of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> partners in alliances and other certain arrangements and to parties that financed research and development, at a wide range of rates as a percentage of sales or of the gross margin of certain products, as defined in the underlying agreements. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until September&#160;30, 2018, royalty expenses were reported in cost of goods sold if related to the acquisition of a product, and if not, such expenses were included in S&amp;M expenses. Commencing October&#160;1, 2018, royalty expenses are retroactively reported entirely under cost of goods sold. Royalty expenses in each of the years ended December&#160;31, 2020, 2019 and 2018 were $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">505</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction> million, respectively. </div>&#160;</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone commitments: </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva has committed to make potential future milestone payments to third parties under various agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events,</div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">32</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_17704857" continuedAt="TextSelectionAppend_17704857_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is unclear when, if ever, Teva may be required to pay such amounts. As of December&#160;31, 2020, if all milestones and targets, for compounds in phase 2 and more advanced stages of development, are achieved, the total contingent payments could reach an aggregate amount of up to $<ix:nonFraction name="teva:MilestoneContingentPayments" contextRef="PAsOn12_31_2020_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">509</ix:nonFraction>&#160;million. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of the cases described below, management&#8217;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#8217;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters that the Company has determined no longer meet the materiality threshold for disclosure. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#8217;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA (formerly IMS Health Inc.) data. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property Litigation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva seeks to develop generic versions of patent-protected pharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#8217;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#8217;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic version even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_17704857_1" continuedAt="TextSelectionAppend_17704857_2"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act. For example, Teva could be sued for patent infringement after commencing sales of a product. In addition, for biosimilar products, Teva could be sued according to the &#8220;patent dance&#8221; procedures of the Biologics Price Competition and Innovation Act (BPCIA). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#8217;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#8217;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In July 2014, GlaxoSmithKline (&#8220;GSK&#8221;) sued Teva in Delaware federal court for infringement of a patent expiring in June 2015 directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#8217;s Coreg<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#8217;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $<ix:nonFraction name="teva:DamagesAssessment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">235.5</ix:nonFraction>&#160;million, not including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> or post-judgment interest or a multiplier for willfulness. Following post-trial motions filed by the parties, on March&#160;28, 2018, the district court issued an opinion overturning the jury verdict and instead found no induced infringement by Teva, thereby finding that Teva did not owe any damages; the district court also denied Teva&#8217;s motion seeking to overturn the jury verdict with respect to invalidity. The provision that was originally included in the financial statements following the damages verdict in this matter in 2017 was reversed in 2018, following the opinion overturning the verdict as the exposure was no longer considered probable. On October&#160;2, 2020, the Court of Appeals for the Federal Circuit overturned the lower court&#8217;s ruling and reinstated the jury verdict in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-to-one</div></div> decision. On December&#160;2, 2020, <div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva filed a request for panel and en banc review. On February 9, 2021, the Federal Circuit granted panel rehearing. In its February 9, 2021 order, the Court vacated the October 2, 2020 judgment and scheduled oral argument for February 23, 2021. The Court will hear oral argument only on the issue of whether there is enough evidence to support the jury&#8217;s verdict of induced infringement during the time period from January 8, 2008 through April 30, 2011 (the &#8220;skinny label&#8221; period). If further appeals are decided against Teva, the case would be remanded to the district court for it to consider Teva&#8217;s other legal and equitable defenses that have not yet been considered by the district court.&#160;</div> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">In 2014, Teva Canada succeeded in its challenge of the bortezomib (the generic equivalent of Velcade&#174;) product and mannitol ester patents under the Patented Medicines (Notice Of Compliance) Regulations (&#8220;PM (NOC)&#8221;). At the time of Teva&#8217;s launch in 2015, annual sales of Velcade were approximately</div></div>&#160;<ix:nonFraction name="teva:AnnualSalesOfVelcade" contextRef="P01_01_2014To12_31_2014" unitRef="Unit_CAD" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million Canadian dollars. Additionally, Teva commenced an action under Section 8 of PM (NOC) to recover damages for being kept off of the market during the PM (NOC) proceedings. Janssen and Millennium filed a counterclaim for infringement of the same two patents as well as a patent covering a process to prepare bortezomib. The product patent expired in October 2015; the other patents expire in January 2022 and March 2025. In 2017, Teva entered into an agreement with Janssen and Millennium which limited the damages payable by either party depending on the outcome of the infringement/impeachment action. As a result, the most Janssen and Millennium could have recovered is</div> <ix:nonFraction name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="PAsOn12_31_2020_JanssenAndMillenniumMembersrtCounterpartyNameAxis" unitRef="Unit_CAD" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million Canadian dollars plus post-judgment interest. In June 2018, the court ruled that Janssen and Millennium pay Teva</div> <ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" contextRef="P06_27_2018To06_27_2018_JanssenAndMillenniumMembersrtCounterpartyNameAxis" unitRef="Unit_CAD" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million Canadian dollars in Section 8 damages. Janssen and</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Millennium filed an appeal, which was denied by the appellate court on November&#160;4, 2019. On January&#160;3, 2020, Janssen and </div></div></div></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134 </div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc" style="/* margin-left: calc(-48.56vw + 48.9%); */">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_17704857_2" continuedAt="TextSelectionAppend_17704857_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Millennium applied for leave to appeal to the Canadian Supreme Court. On May&#160;8, 2020, the Canadian Supreme Court denied Janssen and Millennium&#8217;s application. This matter is now closed.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Liability Litigation </div></div></div></div></ix:continuation></div></div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17704857_3" continuedAt="TextSelectionAppend_17704857_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both approaches, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (API) supplied by multiple API manufacturers. Teva&#8217;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#8220;MDL&#8221;) pending in the United States District Courts. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring claims. Defendants&#8217; motions to dismiss in the valsartan, losartan and irbesartan MDL were denied in part and granted in part, allowing plaintiffs to file amended complaints.&#160;On December&#160;31, 2020, the court in the ranitidine MDL granted the generic defendants&#8217; motion to dismiss on the grounds of preemption and deficient pleading, allowing plaintiffs to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-plead</div> certain claims. Certain plaintiffs appealed the decision. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#8217;s, as well as other generic manufacturers&#8217; metformin products. A motion to dismiss in that consolidated action is pending. Similar lawsuits are pending in Canada and Germany.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition Matters </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#8217;s patent challenges have resulted in litigation relating to Teva&#8217;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva and its subsidiaries have increasingly been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases, which are usually direct and indirect purchasers of pharmaceutical products, and often assert claims on behalf of classes of all direct and indirect purchasers, typically allege that (1)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (2)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These class action cases seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and</div></div></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135 </div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17704857_4" continuedAt="TextSelectionAppend_17704857_5"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">what the generic price allegedly would have been and disgorgement of profits, which are automatically tripled under the relevant statutes, plus attorneys&#8217; fees and costs. The alleged damages generally depend on the size of </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the branded market and the length of the alleged delay, and can be substantial&#8212;potentially measured in multiples of the annual brand sales&#8212;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#8217;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#8220;FTC&#8221;) v. Actavis, Inc. (the &#8220;AndroGel case&#8221;), that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva&#8217;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#8217;s currently pending antitrust litigations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning in April 2006, certain subsidiaries of Teva were named in a class action lawsuit filed in the U.S. District Court for the Eastern District of Pennsylvania with allegations that the settlement agreements entered into between Cephalon, Inc., now a Teva subsidiary (&#8220;Cephalon&#8221;), and various generic pharmaceutical companies in late 2005 and early 2006 to resolve patent litigation involving certain finished modafinil products (marketed as PROVIGIL<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) were unlawful because they had the effect of excluding generic competition. The cases also allege that Cephalon improperly asserted its PROVIGIL patent against the generic pharmaceutical companies. Separately, Apotex challenged Cephalon&#8217;s PROVIGIL patent and, in October 2011, the court found the patent to be invalid and unenforceable based on inequitable conduct. Teva has either settled or reached agreements in principle to settle with all plaintiffs in such cases, except for an action brought by the State of Louisiana. The settlement with the State of California that was reached in 2019 received final court approval in June 2020. All settlements entered into in connection with the above proceeding are covered by the settlement fund explained below. </div></div><div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 12pt;margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In May 2015, Cephalon entered into a consent decree with the FTC (the &#8220;Modafinil Consent Decree&#8221;) under which the FTC dismissed its claims against Cephalon in the FTC Modafinil Action in exchange for payment of</div>&#160;$<ix:nonFraction name="teva:ModafinilPayment" contextRef="PAsOn05_31_2015" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">billion (less set-offs for prior settlements) by Cephalon and Teva into a settlement fund. Under the Modafinil Consent Decree, Teva also agreed to certain injunctive relief with respect to the types of settlement agreements Teva may enter into to resolve patent litigation in the United States for a period of ten years. The remaining balance of the settlement fund after consideration of the settlement with the State of California noted above is approximately</div>&#160;$<ix:nonFraction name="teva:ModafinilPaymentRemainingBalance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million. In February 2019, in connection with the settlement of other unrelated FTC antitrust lawsuits, as described below, Teva and the FTC agreed to amend certain non-financial provisions of the Modafinil Consent Decree and to restart its ten-year term.&#160;</div> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the European Commission issued a Statement of Objections and a Supplementary Statement of Objection in July 2017 and June 2020, respectively, and a final decision against both Cephalon and Teva in November 2020, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling &#8364;<ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2020_ModafinilSettlementAgreementMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">60.5</ix:nonFraction>&#160;million on Teva and Cephalon. Teva and Cephalon&#160;filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva and its affiliates have been named as defendants in lawsuits that allege that multiple patent litigation settlement agreements relating to AndroGel<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> 1% (testosterone gel) violate the antitrust laws. The first of these lawsuits (the &#8220;Georgia AndroGel Litigation&#8221;) was filed in January 2009 in California federal court, and later transferred to Georgia federal court, with the FTC and the State of California, and later private plaintiffs, </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES <div style="letter-spacing: 0px; top: 0px;;display:inline;">LIMITED</div> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_17704857_5" continuedAt="TextSelectionAppend_17704857_6"><div style="color: rgb(0, 0, 0);font-family: 'Times New Roman';font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: left;text-indent: 0px;text-transform: none;white-space: normal;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;/* background-color: rgb(255, 255, 255); */text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;margin-top: 0pt;margin-bottom: 0pt;font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">challenging a September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#8220;Watson&#8221;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#8220;Solvay&#8221;). The second lawsuit (the &#8220;Philadelphia AndroGel Litigation&#8221;) was filed by the F</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">T<div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>&#160;in September 2014 in federal court in Philadelphia, challenging Teva&#8217;s December 2011 patent litigation settlement with AbbVie. The FTC stipulated to dismiss Teva from both litigations, in exchange for Teva&#8217;s agreement to amend the Modafinil Consent Decree, as described above. On July 16, 2018, the direct purchaser plaintiffs&#8217; motion for class certification in the Georgia AndroGel Litigation was denied and Teva later settled with most of the retailer plaintiffs in the Georgia AndroGel Litigation as well as the three direct purchasers that had sought class certification. These settlement amounts were paid in full. In addition, on January 7, 2021, Teva settled all claims with the remaining retailer plaintiff in the Georgia AndroGel Litigation and thus no claims remain in the Georgia AndroGel Litigation. In August 2019, certain other direct-purchaser plaintiffs (who would have been members of the direct purchaser class in the Georgia AndroGel Litigation, had it been certified) filed their own claims in the federal court in Philadelphia (where the Philadelphia AndroGel Litigation has been pending), challenging (in one complaint) both the September 2006 settlement between Watson and Solvay, and the December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AndroGel<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> 1% were approximately<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn01_31_2009" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million at the time of the earlier Watson/Solvay settlement and approximately</div> $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn01_31_2009_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million at the time Actavis launched its generic version of AndroGel<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> 1% in November 2015. A provision for these matters was included in the financial statements. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving extended release venlafaxine (generic Effexor XR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) entered into in November 2005. The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In October 2014, the court granted Teva&#8217;s motion to dismiss in the direct purchaser cases, after which the parties agreed that the court&#8217;s reasoning applied equally to the indirect purchaser cases. Plaintiffs appealed and, in August 2017, the Third Circuit reversed the district court&#8217;s decision and remanded for further proceedings. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> were approximately</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:AnnualSalesOfEffexor" contextRef="P08_21_2017To08_21_2017" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.6</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion at the time of settlement and at the time Teva launched its generic version of Effexor XR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in July 2010. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) entered into in February 2005. The plaintiffs claim that the settlement agreement unlawfully delayed generic entry and seek unspecified damages. In December 2012, the court dismissed the case, but in June 2015, the U.S. Court of Appeals for the Third Circuit reversed and remanded for further proceedings. In December 2018, the district court granted the direct-purchaser plaintiffs&#8217; motion for class certification, but on April&#160;22, 2020, the Third Circuit reversed that ruling and remanded for further class certification proceedings. The district court&#8217;s decision on the direct purchaser plaintiffs&#8217; renewed motion for class certification remains pending. Annual sales of Lamictal<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> were approximately<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="teva:AnnualSalesOfLamictal" contextRef="PAsOn02_28_2005" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">950</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million at the time of the settlement and approximately</div>&#160;$<ix:nonFraction name="teva:AnnualSalesOfLamictal" contextRef="PAsOn07_31_2008" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.3</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion at the time Teva launched its generic version of Lamictal<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in July 2008. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (extended release niacin) sued Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005, to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#8217; class. In August 2019, the district court certified the direct-purchaser class, but in June 2020, the </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_17704857_6" continuedAt="TextSelectionAppend_17704857_7"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">court denied the indirect purchasers&#8217; motion for class certification without prejudice. On September&#160;4, 2020, the indirect purchasers filed a renewed motion for class certification, which remains pending. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, which has since been amended, alleging violations of state law. Defendants moved to strike the District Attorney&#8217;s claims for restitution and civil penalties to the extent not limited to alleged activity occurring in Orange County. The Superior Court denied that motion. The Court of Appeals subsequently reversed the decision and in June 2020, the California Supreme Court reversed the Court of Appeals&#8217; decision, allowing the District Attorney&#8217;s claims to proceed. Annual sales of Niaspan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> were approximately</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $<ix:nonFraction name="teva:AnnualSalesOfNiaspan" contextRef="P04_01_2013To04_30_2013" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">416</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million at the time of the settlement and approximately&#160;</div>$<ix:nonFraction name="teva:AnnualSalesOfNiaspan" contextRef="P09_01_2013To09_30_2013" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction>&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion at the time Teva launched its generic version of Niaspan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in September 2013.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Beginning in 2013, several putative class actions were filed against Actavis, Inc. and certain of its affiliates, alleging that Watson&#8217;s 2012 patent lawsuit settlement with Endo Pharmaceuticals Inc. relating to Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (lidocaine transdermal patches) violated the antitrust laws. The cases were consolidated as a multidistrict litigation in federal court in California and were settled in 2018. The FTC also filed suit to challenge the Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> settlement, although in February&#160;2019, the FTC dismissed its claims against Actavis and Allergan, in exchange for Teva&#8217;s agreement to amend the Modafinil Consent Decree, as described above. In July 2019, Teva also settled a complaint brought by the State of California. On September&#160;16, 2019, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers</div> Blue Cross Blue Shield of Michigan and Blue Care Network of Michigan (collectively &#8220;BCBSM&#8221;) filed their own lawsuit against Watson, and other defendants, in Michigan state court relating to the Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> settlement. Defendants moved to dismiss that lawsuit on June&#160;5, 2020, and those motions were granted in part and denied in part on October&#160;16, 2020. In January 2021, Watson and BCBSM reached an agreement in principle to settle the lawsuit. On January&#160;24, 2020, the State of Mississippi filed a complaint against Teva and Watson in Mississippi state court relating to the Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> settlement, which it subsequently amended on June&#160;12, 2020. Teva and Watson have moved to dismiss that amended complaint, and their motion remains pending. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers</div> for, and direct-purchasers of, Actos<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers&#8217;</div> lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#8217; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#8217;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#8217; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#8217;s settlement, annual sales of Actos<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and Actoplus Met were approximately</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div><ix:nonFraction name="teva:AnnualSalesOfActos" contextRef="P12_01_2010To12_31_2010" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">3.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion and approximately</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div><ix:nonFraction name="teva:AnnualSalesOfActoplus" contextRef="P12_01_2010To12_31_2010" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. At the time Teva launched its authorized generic version of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actos<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actoplus Met in August 2012, annual sales of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actos<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actoplus Met were approximately&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $</div><ix:nonFraction name="teva:AnnualSalesOfActos" contextRef="P08_01_2012To08_31_2012" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion and approximately</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div><ix:nonFraction name="teva:AnnualSalesOfActoplus" contextRef="P08_01_2012To08_31_2012" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">430</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2015, a purported class of end payers for Namenda IR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (memantine hydrochloride) filed a lawsuit against Forest Laboratories, LLC (&#8220;Forest&#8221;), the innovator, and several generic manufacturers, including Teva, alleging, among other things, that the settlement agreements between Forest and the generic manufacturers to resolve patent litigation over Namenda IR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> violated the antitrust laws. Teva reached a settlement agreement with these plaintiffs in July 2020, which received preliminary approval on October&#160;13, 2020 and is awaiting final court approval. Annual sales of Namenda IR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> at the time of the patent litigation settlement were approximately<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="teva:AnnualSalesOfNamenda" contextRef="P11_01_2009To11_30_2009" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion and approximately</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div><ix:nonFraction name="teva:AnnualSalesOfNamenda" contextRef="P07_01_2015To07_31_2015" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">550</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million at the time other manufacturers first launched generic versions of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Namenda IR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in July<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2015.&#160;</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">PHARMACEUTICAL </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">INDUSTRIES </div>LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px; display: inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px; display: inline;"><div style="text-indent: 4%; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"><div style="top: 0px; letter-spacing: 0px; display: inline;"></div></div></div></div><ix:continuation id="TextSelectionAppend_17704857_7" continuedAt="TextSelectionAppend_17704857_8"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">In January 2019, generic manufacturer Cipla Limited filed a lawsuit against Amgen, which was later amended to include Teva as a defendant, in Delaware federal court, alleging, among other things, that a January&#160;2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), violated the antitrust laws. On August&#160;14, 2020, Cipla Limited agreed to dismiss its claims against Teva, with prejudice, and those claims have since been dismissed. Putative classes of direct-purchaser and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payer</div> plaintiffs have also filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva related to the January&#160;2, 2019 settlement. On July&#160;22, 2020, a magistrate judge recommended that plaintiffs&#8217; claims be dismissed and on November&#160;30, 2020, the district court overruled the magistrate judge&#8217;s recommendation, denied Teva&#8217;s motion to dismiss in part, and instructed plaintiffs to file an amended complaint. Annual sales of Sensipar<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesOfSensipar" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion at the time Teva launched its generic version of Sensipar<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in December 2018, and at the time of the January&#160;2, 2019 settlement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;16, 2016, the U.K. Competition and Markets Authority (&#8220;CMA&#8221;) issued a statement of objections (a provisional finding of breach of the Competition Act) in respect of certain allegations against Allergan, Actavis UK and certain Auden Mckenzie entities alleging competition law breaches in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. On March&#160;3, 2017 and February&#160;28, 2019, the CMA issued second and third statements of objections in respect of certain additional allegations relating to the same products and covering part of the same time periods as in the first statement of objections. On February&#160;12, 2020, the CMA issued a Supplementary Statement of Objections effectively combining the three previously issued statements referenced above and a Statement of Draft Penalty Calculation was issued on October&#160;28, 2020. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to the December&#160;16, 2016 and March&#160;3, 2017 statements of objections, and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. A liability for this matter has been recorded in the financial statements. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the European Commission commenced an inspection of Teva and subsequently requested information for purposes of investigating whether Teva may have abused a dominant position in the Multiple Sclerosis field, dating back to at least 2014. No formal proceedings have been initiated. Annual sales of COPAXONE<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in the European Economic Area for the past year were approximately $<ix:nonFraction name="teva:AnnualSalesOfCopaxone" contextRef="P01_01_2014To12_31_2014" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction>&#160;million. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> retailer purchasers of Bystolic<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> violated the antitrust laws. The cases have been coordinated and remain in their preliminary stages, pending a decision regarding potential transfer. Annual sales of Bystolic<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in the United States were approximately $<ix:nonFraction name="teva:AnnualSalesAtTimeOfSettlement" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">700</ix:nonFraction>&#160;million at the time of Watson&#8217;s 2013 settlement with Forest. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Investigations and Litigation Relating to Pricing and Marketing </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#8220;DOJ&#8221;) Antitrust Division seeking documents and other information relating to the marketing and </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">TEVA </div>PHARMACEUTICAL INDUSTRIES <div style="letter-spacing: 0px; top: 0px;;display:inline;">LIMITED</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704857_8" continuedAt="TextSelectionAppend_17704857_9"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three count indictment charging T<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div>va USA with criminal felony Sherman Act violations. See No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-cr-200</div></div> (E.D. Pa.). The indictment alleges Teva USA participated in a conspiracy with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs, including Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-Cream,</div> Gel, and Ointment), Warfarin, Etodolac (IR), Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. A tentative trial date is yet to be scheduled. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#8217;s busi<div style="display:inline;">n</div>ess, including monetary penalties and debarment from federally funded health care programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#8217;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed yet another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA in a similar complaint relating to dermatological generics products. In the various complaints described above, the states seek a finding that the defendants&#8217; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#8220;Pennsylvania MDL&#8221;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#8217; general November&#160;1, 2019 complaint, referenced above, along with three complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. Teva moved the court to reconsider that ruling, and the motion was granted on February&#160;9, 2021. As a result, the attorneys&#8217; general November&#160;1, 2019 amended complaint is not expected to be among the bellwether complaints in the Pennsylvania MDL. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva and Actavis. The plaintiffs generally </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">40</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">TEVA </div>PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704857_9" continuedAt="TextSelectionAppend_17704857_10"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the <div style="letter-spacing: 0px; top: 0px;;display:inline;">court </div>denied certain of the defendants&#8217; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#8217; motions to dismiss as to certain state law claims. On July&#160;18, 2019, and again on May&#160;6, 2020, certain individual plaintiffs commenced a civil action in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaint has been filed in either action and the July&#160;18, 2019 case has been placed in deferred status. On November&#160;13, 2019, and again on August&#160;24, 2020, certain counties in New York commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. On December&#160;15, 2020, several additional New York counties filed suit in New York state court raising similar allegations. On March&#160;1, 2020, Harris County in Texas filed a complaint against several generic manufacturers including Teva and Actavis in the District Court for the Southern District of Texas, which has been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2017, Teva received a subpoena from the U.S. Attorney&#8217;s office in Boston, Massachusetts requesting documents related to Teva&#8217;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#8217;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. It is alleged that Teva caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On October&#160;19, 2020, Teva filed a motion to dismiss the complaint, which remains pending. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2016, Teva resolved certain claims under the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) with the SEC and the DOJ. The settlement included a fine, disgorgement and prejudgment interest, a three-year deferred prosecution agreement (&#8220;DPA&#8221;) for Teva and the retention of an independent compliance monitor for a period of three years. In February 2020 the term of the monitorship provided for by the DPA and Teva&#8217;s consent judgement with the SEC expired and on March&#160;4, 2020, following Teva&#8217;s certification to the SEC and the DOJ confirming that Teva had complied with its disclosure obligations under the DPA, the DOJ filed a motion to dismiss the information filed against Teva at the time the DPA was entered into. On July&#160;21, 2020, the information was dismissed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opioids Litigation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Since May 2014, more than 3,000 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#8220;MDL Opioid Proceeding&#8221;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were recently transferred back to federal district court for additional discovery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-trial</div> proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14-cv-04361</div></div> (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">18-cv-07591-CRB</div></div></div> (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law, generally contend that the defendants </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704857_10" continuedAt="TextSelectionAppend_17704857_11"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">allegedly engaged in improper marketing and distribution of opioids, including ACTIQ<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and FENTORA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>. The complaints also assert claims related to Teva&#8217;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#8217; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-economic</div> damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Absent resolutions, trials are expected to proceed in several states in 2021, unless postponed as a result of the COVID-19 pandemic. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Teva settled the Oklahoma litigation brought by the Oklahoma Attorney General (State of Oklahoma, ex. rel. Mike Hunter, Attorney General of Oklahoma vs. Purdue Pharma L.P., et. al.) for</div> $<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P05_01_2019To05_31_2019_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million. The settlement did not include any admission of violation of law for any of the claims or allegations made. As the Company demonstrated a willingness to settle part of the litigation, for accounting purposes, management considered a portion of opioid-related cases as probable and, as such, recorded an estimated provision in the second quarter of 2019. Given the relatively early stage of the cases, management viewed no amount within the range to be the most likely outcome. Therefore, management recorded a provision for the reasonably estimable minimum amount in the assessed range for such opioid-related cases in accordance with Accounting Standards Codification 450 &#8220;Accounting for Contingencies.&#8221;&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;21, 2019, Teva reached a settlement with the two plaintiffs in the MDL Opioid Proceeding that was scheduled for trial for the Track One case, Cuyahoga and Summit Counties of Ohio. Under the terms of the settlement, Teva will provide the two counties with opioid treatment medication, buprenorphine naloxone (sublingual tablets), known by the brand name Suboxone<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, with a value of $<ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction>&#160;million at wholesale acquisition cost and distributed over <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedDistributionPeriod" contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric> to help in the care and treatment of people suffering from addiction, and a cash payment in the amount of $<ix:nonFraction name="teva:LitigationSettlementAmountAwardedCashAmount" contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>&#160;million, to be paid in <ix:nonFraction name="teva:LitigationSettlementAmountAwardedNumberOfInstallments" contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis" unitRef="Unit_Number" decimals="0" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> payments over <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod" contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. </div></div> <div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 12pt;margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Also on October 21, 2019, Teva and certain other defendants reached an agreement in principle with a group of Attorneys General from North Carolina, Pennsylvania, Tennessee and Texas for a nationwide settlement framework (the &#8220;framework&#8221;). The framework is designed to provide a mechanism by which the Company attempts to seek resolution of remaining potential and pending opioid claims by both the U.S. states and political subdivisions (i.e., counties, tribes and other plaintiffs) thereof. Under this framework, Teva would provide buprenorphine naloxone (sublingual tablets) with an estimated value of up to approximately</div>&#160;$<ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:numdotdecimal">23</ix:nonFraction>&#160;billion at wholesale acquisition cost over a <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedDistributionPeriod" contextRef="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis" format="ixt-sec:durwordsen">ten year</ix:nonNumeric> period. In addition, Teva would also provide cash payments of up to $<ix:nonFraction name="teva:LitigationSettlementAmountAwardedCashAmount" contextRef="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>&#160;million over a <ix:nonNumeric name="teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod" contextRef="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis" format="ixt-sec:durwordsen">ten year</ix:nonNumeric> period.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of January 2021, the Company continues to negotiate the terms and conditions of the framework. The Company cannot predict if the framework will be finalized with its current terms and obligations. The Company considered a range of potential settlement outcomes. The current provision remains a reasonable estimate of the ultimate costs if the nationwide settlement framework is finalized based on recent discussions. However, if not finalized for the entirety of the cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and adverse effect on Teva&#8217;s reputation, business, results of operations and cash flows.</div></div></div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="margin-bottom: 0px; margin-top: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">42</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704857_11" continuedAt="TextSelectionAppend_17704857_12"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Separately, on April&#160;27, 2018, Teva received subpoena requests from the United States Attorney&#8217;s office in the Western District of Virginia and the Civil Division seeking documents relating to the manufacture, marketing and sale of branded opioids. In August 2019, Teva received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Teva received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. Following a Statement of Changes and Notice of Hearing filed by the NYDFS, a hearing is currently scheduled to take place in June 2021. Currently, Teva cannot predict how the nationwide settlement framework agreement (if finalized) will affect these investigations and administrative actions. In addition, a number of state attorneys general, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids. Other states are conducting their own investigations outside of the multistate group. Teva is cooperating with these ongoing investigations and cannot predict their outcome at this time. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, several jurisdictions and consumers in Canada have initiated litigation regarding opioids alleging similar claims as those in the United States. The cases in Canada may be consolidated and are in their early stages. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder Litigation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#8220;Ontario Teachers Securities Litigation&#8221;). On December&#160;13, 2019, the lead plaintiff in that action filed an amended complaint, purportedly on behalf of purchasers of Teva&#8217;s securities between February&#160;6, 2014 and May&#160;10, 2019. The amended complaint asserts that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#8217;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. The amended complaint seeks unspecified damages, legal fees, interest, and costs. In July 2017, August 2017, and June 2019, other putative securities class actions were filed in other federal courts based on similar allegations, and those cases have been transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and October 2020, twenty complaints were filed against Teva and certain of its current and former officers and directors seeking unspecified compensatory damages, legal fees, costs and expenses. The similar claims in these complaints have been brought on behalf of plaintiffs, in various forums across the country, who have indicated that they intend to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> of the plaintiffs&#8217; class if one is certified in the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases for pretrial purposes. The case is now in discovery. Pursuant to that consolidation order, plaintiffs in several of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases filed amended complaints on May&#160;28, 2020. On January&#160;22, 2021, the Court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> plaintiffs&#8217; claims arising from statements made prior to the five year statute of repose, but denied Teva&#8217;s motion to dismiss their claims under Israeli laws. The Ontario Teachers Securities Litigation plaintiffs filed a Motion for Class&#160;Certification and Appointment of Class&#160;Representatives and Class&#160;Counsel on June&#160;19, 2020, which the defendants opposed. That motion is pending. Motions to approve securities class actions were also filed in the Tel Aviv District Court in Israel with similar allegations to those made in the Ontario Teachers Securities Litigation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers alleging, among other things, violations of </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704857_12" continuedAt="TextSelectionAppend_17704857_13"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;10(b) of the Securities and Exchange Act of 1934 and SEC Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b-5.</div> The complaint, purportedly filed on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020, alleges that Teva and certain of its former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#8217;s commercial success and the sustainability of its revenues and resulted in the above referenced August 2020 False Claims Act complaint filed by the DOJ. The securities class action complaint seeks unspecified damages, legal fees, interest, and costs. The case is in its preliminary stages. Motions for the appointment of lead plaintiff and selection of counsel were filed in late November 2020 and remain pending. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Motions to approve derivative actions against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness with respect to the acquisition of the Rimsa business, the acquisition of Actavis Generics and the patent settlement relating to Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>. Motions for document disclosure prior to initiating derivative actions were filed with respect to several U.S. and EU settlement agreements, opioids, the U.S. price-fixing investigations and allegations related to the DOJ&#8217;s complaint regarding Copaxone patient assistance program in the U.S. In October 2020, Teva filed a notice with the Tel Aviv District Court to settle the derivative proceeding with regard to the acquisition of Actavis Generics and two related actions, including the derivative proceedings related to allegations in connection with the Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> patent settlement agreement. Various motions were filed in Israel to approve a derivative action, discovery and a class action related to claims regarding Teva&#8217;s above-mentioned FCPA resolution with the SEC and DOJ. The parties have reached a settlement which was approved by the Tel Aviv District Court on April&#160;6, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Environmental Matters </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#8217;s facilities or former facilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#8217;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and natural resource damages have not yet been determined, and for others Teva&#8217;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#8217;s facilities may result in the imposition of significant penalties (in amounts not </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES <div style="letter-spacing: 0px; top: 0px;;display:inline;">LIMITED</div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_17704857_13"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expected to materially adversely affect Teva&#8217;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implem<div style="display:inline;">e</div>nted. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Matters </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#8217;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (reslizumab) for the treatment of eosinophilic esophagitis (&#8220;EE&#8221;). The plaintiffs claim damages of at least $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction>&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million) and Europe ($<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_EuropeMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million). Defendants moved to dismiss the complaint and on December&#160;28, 2018, the court granted the motion in part and dismissed all of plaintiffs&#8217; claims, except for their claim against Cephalon for breach of contract.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;Trial in this matter is currently scheduled for October 2021<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704668"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 13&#8212;Income taxes: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 8pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent Company and its Israeli subsidiaries</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">947</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,022</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-Israeli subsidiaries</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,353</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,406</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In Israel</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outside Israel</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">885</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_17704668" continuedAt="TextSelectionAppend_17704668_1"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (Loss) before income taxes</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(4,406</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory tax rate in Israel</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">23.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">23.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">23.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Theoretical provision for income taxes</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Increase (decrease) in the provision for income taxes due to:</div> </div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-left: 0in; text-indent: 0in; width: 66%;"><div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">The Parent Company and its Israeli subsidiaries - Mainly tax benefits arising from reduced tax rates under benefit programs</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Non-Israeli subsidiaries, including impairments *</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703660">1,369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17703661">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703662">381</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Tax Cuts and Jobs Act effect</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:Ustaxcutsandjobsacteffect" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase (decrease) in other uncertain tax positions&#8212;net</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingencies" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">341</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingencies" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingencies" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective consolidated income taxes</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In 2020 and 2018, income before income taxes includes goodwill impairment in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Israeli</div> subsidiaries that did<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have a corresponding tax effect. </div></td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The effective tax rate is the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Israeli</div> subsidiaries that have tax rates different than Teva&#8217;s average tax rates, the impact of impairment, restructuring and legal settlement charges and adjustments to valuation allowances on deferred tax assets on such subsidiaries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Teva released a valuation allowance on its deferred tax assets in one jurisdiction and recorded a valuation allowance in another jurisdiction, with both adjustments reflecting changes in the business forecasts of profitability in these jurisdictions. The net effect of these adjustments did not materially impact Teva&#8217;s effective tax rate for 2020. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704672">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Long-term deferred tax assets (liabilities), net:</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory related</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales reserves and allowances</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">198</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for legal settlements</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets (*)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703679">1,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703680">1,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carryforward losses and deductions and credits (**)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703681">2,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703682">1,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred interest</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsDeferredInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">527</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsDeferredInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for employee related obligations</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsLiabilitiesGrossNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:DeferredTaxAssetsLiabilitiesGrossNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance&#8212;in respect of carryforward losses and deductions that may not be utilized&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">269</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(*)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The decrease in deferred tax liability is mainly due to impairment and amortization. </div></div></td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_17704668_1" continuedAt="TextSelectionAppend_17704668_2"><ix:continuation id="TextSelection_17704672">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(**)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts are shown after reduction for unrecognized tax benefits of $ <ix:nonFraction name="teva:DeferredTaxAssetUnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction>&#160;million and $<ix:nonFraction name="teva:DeferredTaxAssetUnrecognizedTaxBenefits" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction> million as of December&#160;31, <div style="letter-spacing: 0px; top: 0px;;display:inline;">2020</div> and <div style="letter-spacing: 0px; top: 0px;;display:inline;">2019</div>, respectively. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 0%;line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703734">2021</span></div>-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703735">2022</span></div>&#8212;$<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction> million; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703736">2023</span></div>-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703738">2029</span></div>&#8212;$<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">663</ix:nonFraction> million; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703737">2030</span> </div>and thereafter&#8212;$<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsNoExpirationMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction> million. The remaining balance&#8212;$<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsIndefiniteMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,327</ix:nonFraction> million&#8212;can be utilized with no expiration date. </div></div></td></tr></table> </ix:continuation><ix:nonNumeric name="teva:ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The deferred income taxes are reflected in the balance sheets among: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term assets&#8212;deferred income taxes</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term liabilities&#8212;deferred income taxes</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">964</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">269</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncertain tax positions: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity of Teva&#8217;s gross unrecognized tax benefits: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at the beginning of the year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,223</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,034</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase <div style="letter-spacing: 0px; top: 0px;;display:inline;">(decrease)&#160;</div>related to prior year tax positions, net</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to current year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:UnrecognizedTaxBenefitsIncreasesDecreasesOther" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 70%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at the end of the year</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,223</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncertain tax positions, mainly of a long-term nature, <div style="letter-spacing: 0px; top: 0px;;display:inline;">include</div> accrued potential penalties and interest of $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million as of December&#160;31, 2020, 2019 and 2018, respectively. The total amount of interest and penalties reflected in the consolidated statements of income was a net increase of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction> million, $</div><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction> million <div style="letter-spacing: 0px; top: 0px;;display:inline;">and $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction> million&#160;</div>for the <div style="letter-spacing: 0px; top: 0px;;display:inline;">years</div> ended December&#160;31, 2020,&#160;2019 and 2018<div style="letter-spacing: 0px; top: 0px;;display:inline;">, respectively</div>. Substantially all the above uncertain tax benefits, if recognized, would reduce Teva&#8217;s annual effective tax rate. Teva does not expect uncertain tax positions to change significantly over the next 12 months, except in the case of settlements with tax authorities, the likelihood and timing of which is difficult to estimate. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax assessments: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva files income tax returns in various jurisdictions with varying statutes of limitations. Teva and its subsidiaries in Israel have received final tax assessments through tax year 2007. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2013, Teva settled the 2005-2007 income tax assessment with the Israeli tax authorities, paying $<ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2019To12_31_2019_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2005To2007MemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction> million. No further taxes are due in relation to these years. Certain guidelines which were set pursuant to the agreement reached in relation to the 2005-2007 assessment have been implemented in the audit of tax years <span style="-sec-ix-hidden:hidden17703740">2008-2011</span>, and are reflected in the provisions. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_17704668_2" continuedAt="TextSelectionAppend_17704668_3"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Israeli tax authorities issued tax assessment decrees for 2008-2012 and 2013-2016, challenging the Company&#8217;s positions on several issues. Teva has protested the 2008-2012 and 2013-2016 decrees before the Central District Court in Israel. The Company believes it has adequately provided for these items, however, adverse results could be material. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, Teva has one tax issue in dispute for the 2009-2011 audit cycle, which is currently in litigation. The 2012-2014 audit cycle is ongoing, with an assessment report expected to be received in 2021. Additionally, Teva&#8217;s U.S. subsidiaries have multiple audit cycles open. The Company believes it has adequately provided for these items and that any adverse results would have an immaterial impact on Teva&#8217;s financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in <div style="letter-spacing: 0px; top: 0px;;display:inline;">March 2021</div>. A final and binding decision against Teva in this case may lead to an impairment in the amount of $<ix:nonFraction name="teva:ExpectedImpairmentOfIncomeTaxBenefit" contextRef="P07_01_2020To07_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonFraction> million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s subsidiaries in Europe have received final tax assessments mainly through tax year 2014. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">f.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of taxation: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and its subsidiaries are subject to tax in many jurisdictions, and estimation is required in recording the assets and liabilities related to income taxes. The Company believes that its accruals for tax liabilities are adequate for all open years. The Company considers various factors in making these assessments, including past history, recent interpretations of tax law, and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these assessments can involve a series of complex judgments regarding future events. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentives Applicable until 2013 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the incentives regime applicable to the Company until 2013, industrial projects of Teva and certain of its Israeli subsidiaries were eligible for &#8220;Approved Enterprise&#8221; status. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the projects in Israel have been granted Approved Enterprise status under the &#8220;alternative&#8221; tax benefit track which offered tax exemption on undistributed income for a period of two to ten years, depending on the location of the enterprise. Upon distribution of such exempt income, the distributing company is subject to corporate tax at the rate ordinarily applicable to the Approved Enterprise&#8217;s income. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment 69 to the Investment Law </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Amendment 69 to the Investment Law (&#8220;Amendment 69&#8221;), a company that elected by November&#160;11, 2013 to pay a corporate tax rate as set forth in that amendment (rather than the tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company up until December&#160;31, 2011 is entitled to distribute a dividend from such income without being required to pay additional corporate tax with respect to such dividend. A company that has so elected must make certain qualified investments in Israel over the five-year period commencing in 2013. Teva invested the entire required amount in 2013. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2013, Teva applied the provisions of Amendment 69 to certain exempt profits Teva accrued prior to 2012. Consequently, Teva paid $<ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2020To12_31_2020_Amendment69ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">577</ix:nonFraction> million in corporate tax on exempt income of $<ix:nonFraction name="us-gaap:DividendIncomeSecuritiesOperatingTaxExempt" contextRef="P01_01_2020To12_31_2020_Amendment69ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">9.4</ix:nonFraction> billion. Part of this income was distributed as dividends during 2013-2018, while the remainder is available to be distributed as dividends in future years with no additional corporate tax liability. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_17704668_3" continuedAt="TextSelectionAppend_17704668_4"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentives Applicable starting 2014: The Incentives Regime &#8211; Amendment 68 to the Investment Law </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Amendment 68 to the Investment Law, which Teva started applying in 2014, upon an irrevocable election made by a company, a uniform corporate tax rate will apply to all qualifying industrial income of such company (&#8220;Preferred Enterprise&#8221;), as opposed to the previous law&#8217;s incentives, which were limited to income from Approved<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Enterprises during the benefits period. Under the law, when the election is made, the uniform tax rate for 2014 until 2016 was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2016To12_31_2016_Amendment68ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>% in areas in Israel designated as Development Zone A and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2016To12_31_2016_Amendment68ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction>% elsewhere in Israel. The uniform tax rate for Development Zone A, as of January&#160;1, 2017, is <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2017To01_01_2017_Amendment73ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction>% (as part of changes enacted in Amendment 73, as described below). The profits of these &#8220;Preferred Enterprise&#8221; will be freely distributable as dividends, subject to a <ix:nonFraction name="teva:WithholdingTaxPercentageOnDividends" contextRef="P01_01_2016To12_31_2016_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredEnterpriseMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>% or lower withholding tax, under an applicable tax treaty. Certain &#8220;Special Preferred Enterprises&#8221;&#160;that meet more stringent criteria (significant investment, R&amp;D or employment thresholds) will enjoy further reduced tax rates of <ix:nonFraction name="teva:WithholdingTaxPercentageOnDividends" contextRef="P01_01_2016To12_31_2016_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredEnterpriseMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>% in Zone A and <ix:nonFraction name="teva:WithholdingTaxPercentageOnDividends" contextRef="P01_01_2016To12_31_2016_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>% elsewhere. In order to be classified as a &#8220;Special Preferred Enterprises,&#8221; the approval of three governmental authorities in Israel is required. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The New Technological Enterprise Incentives Regime &#8211; Amendment 73 to the Investment Law </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since 2017, a portion of the Company&#8217;s taxable income in Israel is entitled to a preferred 6% tax rate under Amendment 73 to the Investment Law as it pertains to Special Preferred Technological Enterprises. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The new incentives regime applies to &#8220;Preferred Technological Enterprises&#8221; or &#8220;Special Preferred Technological Enterprises.&#8221; A &#8220;Preferred Technological Enterprise&#8221; is an enterprise that meet certain conditions, including, inter alia: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of at least <ix:nonFraction name="teva:MinimumPercentageOfInvestmentIncome" contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>% of income, or at least NIS <ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" unitRef="Unit_ILS" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction>&#160;million (approximately $<ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction> million) in R&amp;D activities; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the following: </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At least <ix:nonFraction name="teva:MinimumPercentageOfWorkforce" contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>% of the workforce (or at least <ix:nonFraction name="teva:MinimumNumberOfEmployeesEmployed" contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" unitRef="Unit_Employee" decimals="INF" scale="0" format="ixt:numdotdecimal">200</ix:nonFraction> employees) are employed in R&amp;D; </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A venture capital investment approximately equivalent to at least $<ix:nonFraction name="teva:VentureCapitalInvestments" contextRef="PAsOn12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction> million was previously made in the company; or </div></div></td></tr></table> </ix:continuation></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <ix:continuation id="TextSelectionAppend_17704668_4" continuedAt="TextSelectionAppend_17704668_5">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">c.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Growth in sales or workforce by an average of <ix:nonFraction name="teva:AverageGrowthRateInSalesOrWorkforce" contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% over the <ix:nonNumeric name="teva:AverageGrowthPrecedingPeriodInSalesOrWorkforce" contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric> preceding the tax year. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A &#8220;Special Preferred Technological Enterprise&#8221; is an enterprise that meets, inter alia conditions 1 and 2 above, and in addition has total annual consolidated revenues above NIS <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_ILS" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion (approximately $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.9</ix:nonFraction> billion). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Technological Enterprises are subject to a corporate tax rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction>% on their income derived from intellectual property in areas in Israel designated as Zone A and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>% elsewhere, while Special Preferred Technological Enterprises are subject to <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>% on such income. The withholding tax on dividends from these enterprises is <ix:nonFraction name="teva:WithholdingTaxPercentageOnDividends" contextRef="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>% to foreign companies (or a lower rate under a tax treaty, if applicable). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income not eligible for Preferred Technological Enterprise benefits is taxed at the regular corporate tax rate, which is <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%, or the preferred tax rate, as the case may be. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Parent Company and its Israeli subsidiaries elected to compute their taxable income in accordance with Income Tax Regulations (Rules for Accounting for Foreign Investors Companies and Certain Partnerships and Setting their Taxable Income), 1986. Accordingly, the taxable income or loss is calculated in U.S. dollars. Applying these regulations reduces the effect of U.S. dollar&#8212;NIS exchange rate on the Company&#8217;s Israeli taxable income<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_17704668_5"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Israeli</div> subsidiaries are taxed according to the tax laws in their respective country of residence. Certain manufacturing subsidiaries operate in several jurisdictions outside Israel, some of which benefit from tax incentives such as reduced tax rates, investment tax credits and accelerated deductions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Tax reform </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the &#8220;Act&#8221;), which among other provisions, reduced the U.S. corporate tax rate from <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>% to <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%, effective January&#160;1, 2018, and imposed a one-time deemed repatriation tax based on the post-1986 earnings and profits of the Company&#8217;s U.S. owned foreign subsidiaries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The one-time deemed repatriation tax is based on the post-1986 earnings and profits for which the Company has previously deferred from U.S. income taxes and is payable over 8 years. The year ended December&#160;31, 2017 included a $<ix:nonFraction name="us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction> million provisional estimate for Teva&#8217;s one-time deemed repatriation taxes liability. During 2018, Teva completed its analysis of the impacts of the Act and recorded an additional expense of $<ix:nonFraction name="us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction> million, pursuant to guidance issued by the U.S. Department of Treasury and revisions to the Company&#8217;s estimates since the assessment date. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17705199"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 14&#8212;Equity: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares and ADSs </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, Teva had approximately <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-8" scale="9" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction></ix:nonFraction>&#160;billion ordinary shares issued. Teva ordinary shares are traded on the Tel-Aviv Stock Exchange and on the New York Stock Exchange, in the form of American Depositary Shares (&#8220;ADSs&#8221;), each of which represents one ordinary share<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatory convertible preferred shares </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;17, 2018, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s</div> </div>mandatory convertible preferred shares automatically converted into ordinary shares at a ratio of <ix:nonNumeric name="us-gaap:ConvertiblePreferredStockTermsOfConversion" contextRef="P12_17_2018To12_17_2018">1 mandatory convertible preferred share to 16 ADSs, and all of the accumulated and unpaid dividends on the mandatory convertible preferred shares were paid in ADSs, at a ratio of 3.0262</ix:nonNumeric> ADSs per mandatory convertible preferred share, all in accordance with the conversion mechanism set forth in the terms of the mandatory convertible preferred shares.</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>As a result of this conversion, Teva issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P12_17_2018To12_17_2018" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">70.6</ix:nonFraction> million ADSs. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation plans </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation plans are comprised of stock options, RSUs, PSUs, and other equity-based awards to employees, officers, directors and consultants of the Company and its affiliates. The purpose of the plans is to (a)&#160;attract, retain, motivate, and reward such individuals, and (b)&#160;promote the creation of long-term value for shareholders of the Company by closely aligning the interests of such individuals with those of the shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;29, 2010, the Teva 2010 Long-Term Equity-Based Incentive Plan was approved by Teva&#8217;s shareholders, under which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn06_29_2010_TwoThousandTenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. The 2010 Plan expired on June&#160;28, 2015 (except with respect to awards outstanding on that date), and no additional awards under the 2010&#160;Plan may be made.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;3, 2015, the Teva 2015 Long-Term Equity-Based Incentive Plan was approved by Teva&#8217;s shareholders, under which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn09_03_2015_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">43.7</ix:nonFraction>&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:continuation id="TextSelection_17705199" continuedAt="TextSelectionAppend_17705199_1"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;18, 2016, Teva&#8217;s shareholders approved an increase of an additional <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="P04_18_2016To04_18_2016_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">33.3</ix:nonFraction>&#160;million equivalent share units to the share reserve of Teva&#8217;s 2015 Long-Term Equity-Based Incentive Plan, so that <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn04_18_2016_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction>&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, are approved for grant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;13, 2017, Teva&#8217;s shareholders approved an increase of an additional <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="P07_13_2017To07_13_2017_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million equivalent share units to the share reserve of Teva&#8217;s 2015 Long-Term Equity-Based Incentive Plan, so </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn07_13_2017_TwoThousandFifteenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction>&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, are approved for grant.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2015 Plan expired on June&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div>, 2020 (except with respect to awards outstanding on that date), and no additional awards under the 2015&#160;Plan may be made. </div></div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_17705199_1" continuedAt="TextSelectionAppend_17705199_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;11, 2020, the Teva 2020 Long-Term Equity-Based Incentive Plan was approved by Teva&#8217;s shareholders and became effective on July&#160;1, 2020. Under the plan, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn06_11_2020_TwoThousandTwentyPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction>&#160;million shares, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares remain available for future awards under the 2020 Long-Term Equity-Based Incentive Plan. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the past, Teva had various employee stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards granted under such prior plans continue in accordance with the terms of the respective plans. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2020To12_31_2020">The vesting period of the outstanding options and RSUs is generally from 1 to 4 years from the date of grant. The vesting period of PSUs is generally 3 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for ten years.</ix:nonNumeric> </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><ix:continuation id="TextSelectionAppend_17705199_2" continuedAt="TextSelectionAppend_17705199_3">Status of options</ix:continuation> </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_17705199_3" continuedAt="TextSelectionAppend_17705199_4"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the status of the options granted by Teva as of December&#160;31, 2020, 2019 and 2018, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">40,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">37.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">48,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2017" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">43,121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2017" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">44.32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes during the year:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">12,401</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">19.12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.99</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">17.01</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">40.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">8,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">42.12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">39.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">49.35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">50.65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">35,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">37.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">40,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">37.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">48,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance exercisable at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">28,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">40.56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">26,601</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">43.41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">24,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">46.89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">151 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_17705199_4" continuedAt="TextSelectionAppend_17705199_5"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average fair value of options granted during <div style="letter-spacing: 0px; top: 0px;;display:inline;">these</div> years was generally estimated by using the Black-Scholes option-pricing model as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">7.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_17705199_5" continuedAt="TextSelectionAppend_17705199_6"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of these options was estimated on the date of grant, based on the following weighted average assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">2.6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2018To12_31_2018" format="ixt-sec:durwordsen">5 years</ix:nonNumeric></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td> </tr> </table> </ix:continuation></ix:nonNumeric> <ix:continuation id="TextSelectionAppend_17705199_6" continuedAt="TextSelectionAppend_17705199_7"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected term was estimated based on the weighted average period for which the options granted are expected to be outstanding, taking into consideration the current vesting of options and the historical exercise patterns of existing options. The expected volatility assumption used is based on a blend of the historical and implied volatility of the Company&#8217;s stock. The risk-free interest rate used is based on the yield of U.S. Treasuries with a maturity closest to the expected term of the options granted.</div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17705199_7" continuedAt="TextSelectionAppend_17705199_8"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables summarize information as of December&#160;31, 2020 regarding the number of ordinary shares issuable upon (1)&#160;outstanding options and (2)&#160;vested options: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(1) Number of ordinary shares issuable upon exercise of outstanding options</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of exercise prices</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;end&#160;of<br/> period&#160;(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> remaining life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lower than $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">15.01</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">11.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">6.84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">15.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">25.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">18.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">7.12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">25.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">35.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,221</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">34.61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">6.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">35.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">45.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">40.66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">1.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">45.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">55.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">51.06</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">4.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">55.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">65.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,223</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">59.26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">4.30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">35,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">37.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">5.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(2) Number of ordinary shares issuable upon exercise of vested options</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of exercise prices</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;end&#160;of<br/> period&#160;(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> remaining life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lower than $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">15.01</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">11.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">6.84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">15.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">25.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,431</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">18.81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">7.09</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">25.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">35.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">34.61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">6.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">35.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">45.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">40.66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">1.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">45.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">55.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">51.06</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">4.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">55.01</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">65.00</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,197</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">59.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">4.30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">28,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">40.56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" contextRef="PAsOn12_31_2020" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:numdotdecimal">4.65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">152 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <ix:continuation id="TextSelectionAppend_17705199_8" continuedAt="TextSelectionAppend_17705199_9"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company&#8217;s closing stock price of $ <ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">9.65</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>on December&#160;31, 2020, less the weighted average exercise price in each range. This represents the potential amount receivable by the option holders had all option holders exercised their options as of such date. As of December&#160;31, 2020, there were no exercisable options that were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-the-money.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total intrinsic value of options exercised during the years ended December&#160;31,&#160;2019 and 2018 was immaterial, based on the Company&#8217;s average stock price of&#160;$<ix:nonFraction name="teva:AverageSharePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">11.50</ix:nonFraction> and $<ix:nonFraction name="teva:AverageSharePrice" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">20.92</ix:nonFraction>, for the years then ended, respectively.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;No options were exercised during 2020.</div> </div></div> </ix:continuation></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><ix:continuation id="TextSelectionAppend_17705199_9" continuedAt="TextSelectionAppend_17705199_10">Status of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs</ix:continuation> </div></div></div></div> <ix:continuation id="TextSelectionAppend_17705199_10" continuedAt="TextSelectionAppend_17705199_11"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes information about the number of RSUs and PSUs <div style="letter-spacing: 0px; top: 0px;;display:inline;">granted</div>&#160;and outstanding: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; padding: 0px; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.49</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">20.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2017_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2017_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">27.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,848</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">11.42</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">9,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">15.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">18.80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">19.49</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">30.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">37.30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">18.18</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,294</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">18.74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">32.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">20,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.81</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">20.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses compensation costs are based on the grant-date fair value. For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded stock-based compensation costs as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee stock options</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_StockOptionsPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_StockOptionsPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_StockOptionsPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs and PSUs</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2018To12_31_2018_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax effect on stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2020To12_31_2020_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2019To12_31_2019_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P01_01_2018To12_31_2018_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net effect</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="P01_01_2020To12_31_2020_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="P01_01_2019To12_31_2019_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="P01_01_2018To12_31_2018_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the total unrecognized compensation cost before tax on employee stock options and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div>/PSUs amounted to $<ix:nonFraction name="teva:UnrecognizedCompensationCostOptions" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million and $<ix:nonFraction name="teva:UnrecognizedCompensationCostRsus" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million, respectively. This cost is expected to be recognized over a weighted average period of approximately <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">1.1</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>years and <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">2.5</ix:nonNumeric> years, respectively. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva has not paid dividends on Teva ordinary shares or ADSs since December 2017. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <ix:continuation id="TextSelectionAppend_17705199_11"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive los<div style="display:inline;">s</div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704849">The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:</ix:nonNumeric> </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:continuation id="TextSelection_17704849" continuedAt="TextSelectionAppend_17704849_1">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Unrealized Gains/(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-</div><br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-sale</div><br/> securities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial<br/> gains/(losses)<br/> and prior<br/> service<br/> (costs)/credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 53%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2017_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2017_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2017_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2017_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Cumulative effect of new accounting standard**</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" contextRef="P01_01_2018To12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704338">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704339">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">729</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">639</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">729</ix:nonFraction></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704555">739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704556">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704557">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704558">611</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,878</ix:nonFraction></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">504</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704559">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704560">1</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704561">84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704562">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704366">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704367">125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704368">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704369">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17704370">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">363</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">117</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,399</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div> <ix:continuation id="TextSelectionAppend_17704849_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction> million gain in <div style="letter-spacing: 0px; top: 0px;;display:inline;">2020</div>, $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2018To12_31_2018_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction> million gain in <div style="letter-spacing: 0px; top: 0px;;display:inline;">2019</div> and $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2017To12_31_2017_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million gain in 2018. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the adoption of ASU 2016-01, the Company recorded a $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million opening balance reclassification from accumulated other comprehensive income to retained earnings. </div></div> </td> </tr> </table> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:OtherExpensesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704798"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 15&#8212;Other assets impairments, restructuring and other items: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of long-lived tangible assets <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703138">416</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703225">139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703133">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration (see note 2)</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:ImpairmentAndRestructuring" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">987</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including impairments related to exit and disposal activities. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following Teva&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> restructuring plan, described below, and its ongoing plant rationalization efforts, the Company may change its current plans with respect to any given asset and/or the assumptions underlying such plans. Consequently, additional impairments may be recorded in the future. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of tangible assets for the years ended December&#160;31, 2020, 2019 and 2018 were </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">416</ix:nonFraction> million<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction> million&#160;and $<ix:nonFraction name="us-gaap:TangibleAssetImpairmentCharges" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. The impairment for the year ended December&#160;31, 2020 was mainly related to the <div style="letter-spacing: 0px; top: 0px;;display:inline;">sale of&#160;</div> certain assets from Teva&#8217;s business venture in Japan<div style="letter-spacing: 0px; top: 0px;;display:inline;">, which was completed on February 1, 2021, as well as&#160;</div>plant rationalization. See note 2. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Teva recorded an income of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million for contingent consideration, compared to an expense of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million in 2019 and 2018 respectively. The income in 2020 was mainly related to a change in the future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), which was part of the Actavis Generics acquisition, partially offset by the change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">expense</div> in 2019 <div style="letter-spacing: 0px; top: 0px;;display:inline;">was</div> mainly related to a change in the estimated future royalty payments from Eagle in connection with bendamustine sales and an increase in the expected future royalty payments to Eagle due to the orphan drug status granted to BENDEKA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, offset by the change in future royalty payments in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), which was part of the Actavis Generics acquisition. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restructuring </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Teva recorded $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction> </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million of restructuring expenses, compared to </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonFraction> million in 2019 and $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">488</ix:nonFraction> million in 2018. The expenses in 2020 were primarily related to <div style="letter-spacing: 0px; top: 0px;;display:inline;">residual expenses</div>&#160;of the restructuring plan announced in 2017<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">and other network consolidation impacts.</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2017, Teva announced a comprehensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> restructuring plan intended to reduce its cost base by $<ix:nonFraction name="teva:RestructuringPlanCostReduction" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:numdotdecimal">3</ix:nonFraction>&#160;billion, unify and simplify its organization and improve business performance, profitability, cash flow generation and productivity. This plan achieved its goals, including a total cost base reduction of $<ix:nonFraction name="teva:RestructuringPlanCostReduction" contextRef="P01_01_2017To12_31_2017" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:numdotdecimal">3</ix:nonFraction>&#160;billion by the end of 2019. Teva is continuing to evaluate opportunities to further optimize its manufacturing and supply network to achieve additional operational efficiencies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <ix:continuation id="TextSelection_17704798" continuedAt="TextSelectionAppend_17704798_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:ScheduleOfRestructuringChargesTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide the components of costs associated with Teva&#8217;s restructuring plan, including other costs associated with Teva&#8217;s restructuring plan and recorded under different items: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2020</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2019</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2018</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">410</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">488</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee<br/> termination&#160;costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions )</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January 1, 2019</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2018_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2018_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2019To12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2019To12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2019To12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703264">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2019To12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703265">62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703266">217</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2020To12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;">(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2020To12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(<ix:nonFraction name="teva:RestructuringAccrualProvision" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr>
<td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2020To12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704583">164</ix:nonFraction></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2020To12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704584">49</ix:nonFraction></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:UtilizationAndOther" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704585">213</ix:nonFraction></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December 31, 2020</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction></div></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes adjustments for foreign currency translation. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant regulatory and other events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, the FDA completed an inspection of Teva&#8217;s manufacturing plant in Davie, Florida in the United States, and issued a Form FDA-483 to the site. In October 2018, the FDA notified Teva that the inspection of the site is classified as &#8220;official action indicated&#8221; (OAI). On February 5, 2019, Teva received a warning letter from the FDA that contained four additional enumerated concerns related to production, quality control and investigations at this site. Teva has been working diligently to address the FDA&#8217;s concerns in a manner consistent with current good manufacturing practice (cGMP) requirements as quickly and as thoroughly as possible. An FDA follow up inspection occurred in January 2020, resulting in some follow up findings and Teva received a letter from the FDA dated April 24, 2020 notifying it that the site continues to be classified as OAI. If Teva is unable to remediate the findings to the FDA&#8217;s satisfaction, Teva may face additional consequences. These would potentially include delays in FDA approval for future products from the site, financial implications due to loss of revenues, impairments, inventory write-offs, customer penalties, idle capacity charges, costs of additional remediation and possible FDA enforcement action. Teva expects to generate approximately</div> $<ix:nonFraction name="teva:ExpectedRevenueFromFacility" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction> &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million in revenues from this site in 2021, assuming remediation or enforcement does not cause any unscheduled slowdown or stoppage at the facility, however, delays in FDA approvals of future products from the site may occur.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#8220;Huahai&#8221;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <ix:continuation id="TextSelectionAppend_17704798_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#8217;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2020, Teva&#8217;s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva has completed partial remediation of this issue and has restarted limited supply from its Goa facilities. The impact to Teva&#8217;s financial results for the twelve months ended December&#160;31, 2020 was immaterial, however, if the full remediation takes longer than expected there may be further loss of sales, customer penalties or impairments to related assets. </div></div> </ix:continuation><ix:nonNumeric name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 16&#8212;Other income: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:ScheduleOfOtherIncomeTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td style="width: 1%;"></td>
<td style="width: 4.5%;"></td>
<td style="width: 1%;"></td>
<td style="width: 4.5%; vertical-align: bottom;"></td>
<td style="width: 1%;"></td>
<td style="width: 4.5%;"></td>
<td style="width: 1%;"></td>
<td style="width: 5.5%; vertical-align: bottom;"></td>
<td style="width: 1%;"></td>
<td style="width: 4.5%;"></td>
<td style="width: 0.5%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on divestitures, net of divestitures related costs (1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703027">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703028">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703029">67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;8 and similar payments (2)</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap; width: 4.5%;;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212; </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="teva:PatentedMedicinesRegulationsAndSimilarPayments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17705017">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="teva:PatentedMedicinesRegulationsAndSimilarPayments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17705018">195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain (loss) on sale of assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="teva:OtherOperatingIncomeNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="teva:OtherOperatingIncomeNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="teva:OtherOperatingIncomeNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mainly related to the divestment of several activities in the International Markets segment. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. </div></div> </td> </tr> </table> </ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="teva:FinancialExpensesNetTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 17&#8212;Financial expenses, net: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:FinancialExpensesNetTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width:0.5%;"></td>
<td style="width:3%;"></td>
<td style="width:1%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width:0.5%;"></td>
<td style="width:3%;"></td>
<td style="width:1%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width:0.5%;"></td>
<td style="width:3%;"></td>
<td style="width:0.5%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December,&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses and other bank charges</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">920</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from investments (1)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(<ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703578">104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(<ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703579">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(<ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703580">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Foreign exchange (gains) losses, net</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(<ix:nonFraction name="teva:ForeignCurrencyTransactionGainLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(<ix:nonFraction name="teva:ForeignCurrencyTransactionGainLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="teva:ForeignCurrencyTransactionGainLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net (2)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;;width:3%;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(<ix:nonFraction name="teva:OtherFinancialIncomeExpenseNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17703585">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="teva:OtherFinancialIncomeExpenseNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal" id="Fact_17703586">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total finance expense, net</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="teva:FinanceIncomeExpensesNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="teva:FinanceIncomeExpensesNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><ix:nonFraction name="teva:FinanceIncomeExpensesNet" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Income from investments comprised mainly of revaluation gain of Teva&#8217;s investment in American Well Corporation (&#8220;American Well&#8221;). See note 20. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2018, Other, net comprised mainly of a make-whole payment of $<ix:nonFraction name="teva:PaymentForRedemptionOfSeniorNotes" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction> million following early redemption of senior notes during 2018. </div></div> </td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 18&#8212;Earnings (loss) per share: </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December&#160;31, 2020, 2019 and 2018 are as follows: </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December, 31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions,&#160;except&#160;share&#160;data)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) used for the computation of <div style="letter-spacing: 0px; top: 0px;;display:inline;">basic and&#160;</div>diluted <div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,399</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares used in the computation of basic<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares used in the computation of diluted <div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#8217;s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested restricted share units (&#8220;RSUs&#8221;)) during the period, net of treasury shares. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In computing diluted loss per share for the years ended December 31, 2020, 2019 and 2018, no account was taken of the potential dilution that could occur upon the exercise of employee stock options, RSUs and PSUs, amounting to</div>&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonFraction>&#160;million, <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction>&#160;million and <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2018To12_31_2018_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction>&#160;million weighted average shares, respectively, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in computing diluted loss per share for the period between January 1, 2018 and December 17, 2018, no account was taken of the potential dilution of the mandatory convertible preferred shares amounting to</div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2018To12_17_2018_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction>&#160;million&#160;since they had an anti-dilutive effect on loss per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss per share was $<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.64</ix:nonFraction> for the year ended December&#160;31, 2020, compared to basic and diluted loss per share of $<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.91</ix:nonFraction> and $<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.35</ix:nonFraction> for the years ended December&#160;31, 2019 and December&#160;31, 2018, respectively. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704806"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 19&#8212;Segments: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva operates its business and reports its financial results in <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> segments: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment, which includes the United States and Canada. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment, which includes the European Union and certain other European countries. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment, which includes all countries other than those in the North America and Europe segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to these three segments, Teva has other sources of revenues included in other activities, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their <div style="letter-spacing: 0px; top: 0px;;display:inline;">performance</div>. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_17704806" continuedAt="TextSelectionAppend_17704806_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit is comprised of gross profit for the segment less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#8217;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s CEO may review its strategy and organizational structure. Any changes in strategy may lead to a reevaluation of the Company&#8217;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 7. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment information: </div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704852"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">622</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">427</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 52%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A <div style="letter-spacing: 0px; top: 0px;;display:inline;">expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,331</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,542</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,795</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,246</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,350</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,704</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,167</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">652</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,021</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">481</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">439</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">239</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,252</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,318</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:nonNumeric></ix:continuation> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17704806_1" continuedAt="TextSelectionAppend_17704806_2"><ix:continuation id="TextSelection_17704852"> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9,297</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,186</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,422</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,979</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,884</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,254</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">713</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">283</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">96</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,154</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,003</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">484</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">209</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:OtherOperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,837</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,273</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">498</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> </ix:continuation></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">159 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><ix:continuation id="TextSelectionAppend_17704806_2" continuedAt="TextSelectionAppend_17704806_3">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,421</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,252</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,837</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,331</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,318</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,273</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">498</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,225</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,034</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_CorporateMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,608</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit (loss) of other activities</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,388</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,142</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,723</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,020</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,113</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,166</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; white-space: nowrap; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Other asset impairments, restructuring and other items</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">479</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">423</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:ImpairmentsRestructuringAndOthers" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">987</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,628</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212; &#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,027</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible asset impairments</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,502</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,639</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on divestitures, net of divestitures related costs</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">66</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other R&amp;D expenses (income)</div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:PurchaseOfResearchAndDevelopmentInProcess" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:PurchaseOfResearchAndDevelopmentInProcess" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:PurchaseOfResearchAndDevelopmentInProcess" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs related to regulatory actions taken in facilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:CostsRelatedToRegulatoryActionsTakenInFacilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:CostsRelatedToRegulatoryActionsTakenInFacilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:CostsRelatedToRegulatoryActionsTakenInFacilities" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,178</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:LegalSettlementsAndLossContingencies" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,208</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">219</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">252</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="teva:OtherUnallocatedAmounts" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,572</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">443</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,637</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">834</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">822</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">959</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,406</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,265</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P01_01_2018To12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,596</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div> <ix:continuation id="TextSelectionAppend_17704806_3" continuedAt="TextSelectionAppend_17704806_4">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment revenues by major products and activities:</div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present revenues by major products and activities for each segment for the year ended December&#160;31, 2020, 2019 and 2018: </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704808"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,963</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProAir*</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QVAR</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,347</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">546</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">708</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">8,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">9,297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Does not include revenues from the ProAir authorized generic, which are included under generic products. </div></div> </td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">160 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES <div style="letter-spacing: 0px; top: 0px;;display:inline;">LIMITED</div> </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <ix:continuation id="TextSelectionAppend_17704806_4" continuedAt="TextSelectionAppend_17704806_5"><ix:continuation id="TextSelection_17704808"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,593</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;">&#160;<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;">&#160;<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; text-align: right; padding: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">353</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">402</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 70%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 70%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,792</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,022</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">309</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,246</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva revenues from external customers attributed to Israel were less than <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2018To12_31_2018_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the consolidated revenues in the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div> </ix:continuation></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17704806_5" continuedAt="TextSelectionAppend_17704806_6"> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental data&#8212;major customers: </div></div></div> </td> </tr> </table> <ix:nonNumeric name="teva:SalesPercentageByTherapeuticCategoryTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the percentage of consolidated third party net sales to Teva&#8217;s major customers during the years ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage&#160;of&#160;Third&#160;Party&#160;Net&#160;Sales</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">McKesson Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:NetSalesPresent" contextRef="PAsOn12_31_2020_Customer1MembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:NetSalesPresent" contextRef="PAsOn12_31_2019_Customer1MembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:NetSalesPresent" contextRef="PAsOn12_31_2018_Customer1MembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AmerisourceBergen Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:NetSalesPresent" contextRef="PAsOn12_31_2020_Customer2MembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:NetSalesPresent" contextRef="PAsOn12_31_2019_Customer2MembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:NetSalesPresent" contextRef="PAsOn12_31_2018_Customer2MembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">161 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES <div style="letter-spacing: 0px; top: 0px;;display:inline;">LIMITED</div> </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <ix:continuation id="TextSelectionAppend_17704806_6"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of Teva&#8217;s revenues from these customers were in the North America segment. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment&#8212;by geographical location were as follows: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Israel</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_ILsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,611</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_ILsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Croatia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_HRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">539</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_HRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Germany</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_DEsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_DEsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">665</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Czech republic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_CZsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_CZsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hungary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_HUsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_HUsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ireland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_IEMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">267</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_IEMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019_OtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property, plant and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,296</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">6,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">162 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704850"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 20 &#8212;Fair value measurement: </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704779"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial items carried at fair value as of December&#160;31, 2020 and 2019 are classified in the tables below in one of the three categories described in note 1f: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_DemandDepositsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,810</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Equity securities*</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702405">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17704579">259</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702408">284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, mainly debt securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2020_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Asset derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn12_31_2020_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liabilities derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Contingent consideration**</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702754">268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702755">268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_17704850" continuedAt="TextSelectionAppend_17704850_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_17704779" continuedAt="TextSelectionAppend_17704779_1">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2019_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2019_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2019_DemandDepositsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, mainly debt securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Asset derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeAssets" contextRef="PAsOn12_31_2019_InterestRateSwapMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liability derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2019_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liabilities derivatives&#8212;interest rate and cross-currency swaps</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Contingent consideration**</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702766">460</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal" id="Fact_17702767">460</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,019</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of 2020, Teva recorded a gain of $<ix:nonFraction name="us-gaap:GainLossOnSaleOfEquityInvestments" contextRef="P01_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction>&#160;million under share in profits of associated companies, net, reflecting the difference between the book value of Teva&#8217;s investment in American Well&#160;and its fair value as of the date it completed its initial public offering in September 2020. The investment was reclassified from &#8220;investment in associated companies&#8221; to &#8220;investment in marketable securities,&#8221; since Teva no longer ha<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div>&#160;significant influence in American Well. <div style="letter-spacing: 0px; top: 0px;;display:inline;">This represented a transfer into Level 3 measurement within fair value hierarchy. By&#160;</div>December&#160;31,&#160;2020,&#160;Teva recorded an&#160;additional&#160;gain&#160;of&#160;$<ix:nonFraction name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" contextRef="P01_01_2020To12_31_2020_RevaluationOfAssetsMemberusgaapFreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million under financial expenses, net, reflecting the revaluation gain of this security as of December 31, 2020 and transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate.&#160;</div></div></div></div> </td> </tr> </table> </ix:continuation></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">163 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <ix:continuation id="TextSelectionAppend_17704850_1" continuedAt="TextSelectionAppend_17704850_2"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:continuation id="TextSelectionAppend_17704779_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Due to management&#8217;s intention and ability to sell this security in the next twelve months, the balance as of December&#160;31, 2020 was reclassified to short term investments. </div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">**</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></div> </td> </tr> </table> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor ranging from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MaximumMembersrtRangeAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;D. The discount rate applied ranged from <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction>% to <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">8.0</ix:nonFraction>%. The weighted average discount rate, calculated based on the relative fair value of Teva&#8217;s contingent consideration liabilities, was <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_WeightedAverageMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.7</ix:nonFraction>%. <div style="letter-spacing: 0px; top: 0px;;display:inline;">The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities.&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17704850_2" continuedAt="TextSelectionAppend_17704850_3"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The fair value measurement of the investment in equity securities is based on a discount rate for fair value measurement, related to restriction of sale of shares, and thus represents a Level 2 measurement within the fair value hierarchy. The discount rate applied for the fair value measurement at December 31, 2020 was</div>&#160;<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>%.</div></div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Transfer into Level 3- equity securities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revaluation of equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revaluation of debt securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Reclassification to Level 2- equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">259</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;">Adjustments to provisions for contingent consideration:</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Actavis Generics transaction</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" contextRef="P01_01_2020To12_31_2020_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">156</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" contextRef="P01_01_2019To12_31_2019_ActavisGenericsMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Eagle transactio<div style="display:inline;">n</div></div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" contextRef="P01_01_2020To12_31_2020_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">75</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" contextRef="P01_01_2019To12_31_2019_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">151</ix:nonFraction></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;">Settlement of contingent consideration:</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Eagle transaction</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2020To12_31_2020_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P01_01_2019To12_31_2019_EagleTransactionMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Teva&#8217;s financial instruments consist mainly of cash and cash equivalents, investments in securities, current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> receivables, short-term credit, accounts payable and accruals, loans and senior notes, convertible senior debentures and derivatives. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The fair value of the financial instruments included in working capital and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> receivables approximates their carrying value. The fair value of long-term bank loans mostly approximates their carrying value, since they bear interest at rates close to the prevailing market rates.</div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">164 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <ix:continuation id="TextSelectionAppend_17704850_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments not measured at fair value </div></div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value consist of senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value:&#160;&#160;&#160;&#160; </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes included under long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22,684</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2019_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">22,686</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2020_SeniornotesandconvertibleseniordebenturesmemberMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2019_SeniornotesandconvertibleseniordebenturesmemberMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">25,891</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">25,004</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; margin-left: 13%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices. </div></div> </td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;"></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:LongTermEmployeeRelatedObligationsTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true" continuedAt="TextSelection_17704851"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 21&#8212;Long-term employee-related obligations: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="teva:LongTermEmployeeRelatedObligationsTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term employee-related obligations consisted of the following: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued severance obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:AccruedSeverancePayNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:AccruedSeverancePayNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined benefit plans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:EmployeeRelatedObligationsNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="teva:EmployeeRelatedObligationsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, Teva had $<ix:nonFraction name="teva:LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction> million and $<ix:nonFraction name="teva:LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, deposited in funds managed by financial institutions and earmarked by management to cover severance pay liability. Such deposits are not considered to be &#8220;plan assets&#8221; and are therefore included in other non-current assets.&#160;</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the change resulted from actuarial updates, as well as from exiting from several defined benefit plans in several countries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to expense an approximate contribution of $<ix:nonFraction name="teva:DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction> million in 2021 to pension funds and insurance companies in connection with its severance and pension pay obligations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The main terms of the different arrangements with employees are described in below. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Terms of arrangements: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Israel </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Parent Company and its Israeli subsidiaries make ongoing deposits into employee pension plans to fund their severance liabilities. Generally, employees that joined the Company after 2005, have signed an arrangement, pursuant to which such deposits are made in lieu of the Company&#8217;s severance liability. Therefore, no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who were employed by the Parent Company and its Israeli subsidiaries prior to that date, as well as employees who have special contractual arrangements, are provided for in the financial statements based upon the number of years of service and the latest monthly salary of such employees. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">165 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <ix:continuation id="TextSelection_17704851" continuedAt="TextSelectionAppend_17704851_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of the employees in the Company&#8217;s European subsidiaries are entitled to a retirement grant when they leave the Company. In the consolidated financial statements, the liability of the European subsidiaries is accrued, based on the length of service and remuneration of each employee at the balance sheet date. Other employees in Europe are entitled to a pension according to a defined benefit scheme providing benefits based on final or average pensionable pay or according to a hybrid pension scheme that provides retirement benefits on a defined benefit and a defined contribution basis. Independent certified actuaries value these schemes and determine the rates of contribution payable. Pension costs for the defined benefit section of the scheme are accounted for on the basis of charging the expected cost of providing pensions over the period during which the subsidiaries benefit from the employees&#8217; services. The Company uses December&#160;31 as the measurement date for defined benefit plans. </div></div> </ix:continuation></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_17704851_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s North American subsidiaries mainly provide various defined contribution plans for the benefit of their employees. Under these plans, contributions are based on specified percentages of pay. Additionally, a multi-employer plan is maintained in accordance with various union agreements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Latin America </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The majority of the employees in Latin America are entitled to severance under local law. The severance payments are calculated based on service term and employee remuneration, and accruals are maintained to reflect these amounts. In some Latin American countries it is Teva&#8217;s practice to offer retirement health benefits to qualifying employees. Based on the specific plan requirements, benefits accruals are maintained to reflect the estimated amounts or adjusted if future plans are modified. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to pay the following future minimum benefits to its employees: $<ix:nonFraction name="teva:FutureExpectedDomesticMinimumBenefitPaymentsYearOne" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction> million in 2021; $<ix:nonFraction name="teva:FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million in 2022; $<ix:nonFraction name="teva:FutureExpectedDomesticMinimumBenefitPaymentsYearThree" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million in 2023; $<ix:nonFraction name="teva:FutureExpectedDomesticMinimumBenefitPaymentsYearFour" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction> million in 2024; $<ix:nonFraction name="teva:FutureExpectedDomesticMinimumBenefitPaymentsYearFive" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million in 2025 and $<ix:nonFraction name="teva:FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">million in the aggregate between 2026 to 2030. These amounts do not include amounts that may be paid to employees who cease working with the Company before their normal retirement age.</div></div></div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">166 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements&#8212;(Continued) </div></div></div></div> <ix:nonNumeric name="teva:SelectedQuarterlyFinancialDataTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 22&#8212;Selected quarterly financial data (unaudited): </div></div></div> <ix:nonNumeric name="teva:SelectedQuarterlyFinancialDataTableTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents selected unaudited quarterly financial data for 2020 and 2019:</div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2020</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">4th&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">3rd&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2nd&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">1st&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">U.S $ in millions (except per share amounts)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,454</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">3,870</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,357</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,048</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,763</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,340</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.06</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P10_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.06</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2019</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">4th quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">3rd quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2nd quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">1st quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">U.S $ in millions (except per share amounts)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,093</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,177</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4,149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,856</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">671</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P10_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA PHARMACEUTICAL INDUSTRIES LIMITED </div></div></div> <div id="tx102112_58" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCHEDULE II&#8212;VALUATION AND QUALIFYING ACCOUNTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Years Ended December 31, 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(U.S. $ in millions) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" contextRef="P01_01_2020To12_31_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Column A</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Column&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Column C</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Column D</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Column&#160;E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at<br/>beginning<br/>of period</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charged&#160;to&#160;costs<br/>and&#160;expenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charged&#160;to&#160;other<br/>accounts</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;end<br/>of&#160;period</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for doubtful accounts:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="P01_01_2020To12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="P01_01_2020To12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="P01_01_2019To12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2017_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="P01_01_2018To12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="P01_01_2018To12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2018To12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance in respect of carryforward tax losses and deductions that may not be utilized:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="P01_01_2020To12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">670</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2020To12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">2,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="P01_01_2019To12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2019To12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2017_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="P01_01_2018To12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="P01_01_2018To12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="P01_01_2018To12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="PAsOn12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">1,633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_14" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not Applicable. </div></div> <div id="toc102112_15" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;9A. CONTROLS AND PROCEDURES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disclosure Controls and Procedures </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva maintains &#8220;disclosure controls and procedures&#8221; (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Securities Exchange Act of 1934, as amended) that are designed to provide reasonable assurance that information required to be disclosed in Teva&#8217;s reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to Teva&#8217;s management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After evaluating the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, Teva&#8217;s disclosure controls and procedures were effective at the reasonable assurance level. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Teva Management on Internal Control over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(f)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(f)</div> under the Exchange Act, as amended. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our management assessed the effectiveness of Teva&#8217;s internal control over financial reporting as of December&#160;31, 2020. In making this assessment, it used the criteria established in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Internal Control&#8212;Integrated Framework</div></div> (2013)&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on such assessment, management has concluded that, as of December&#160;31, 2020, Teva&#8217;s internal control over financial reporting was effective. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attestation Report of the Registered Public Accounting Firm </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our internal control over financial reporting as of December&#160;31, 2020 has been audited by Kesselman&#160;&amp; Kesselman, an independent registered public accounting firm in Israel and a member of PricewaterhouseCoopers International Limited (&#8220;PwC&#8221;), as stated in their report which is included under &#8220;Item 8&#8212;Financial Statements.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Control over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2020, there were no changes in internal control over financial reporting that materially affected or are reasonably likely to materially affect Teva&#8217;s internal control over financial reporting. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">169 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;9B. OTHER INFORMATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART III </div></div></div> <div id="toc102112_17" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reference is made to Teva&#8217;s 2021 Proxy Statement, which will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year ended December&#160;31, 2020, with respect to Teva&#8217;s directors, executive officers and corporate governance, which is incorporated herein by reference and made a part hereof in response to the information required by Item 10. </div></div> <div id="toc102112_18" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;11. EXECUTIVE COMPENSATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reference is made to Teva&#8217;s 2021 Proxy Statement, which will be filed no later than 120 days after the close of Teva&#8217;s fiscal year ended December&#160;31, 2020, with respect to Teva&#8217;s executive compensation, which is incorporated herein by reference and made a part hereof in response to the information required by Item 11. </div></div> <div id="toc102112_19" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reference is made to Teva&#8217;s 2021 Proxy Statement, which will be filed no later than 120 days after the close of Teva&#8217;s fiscal year ended December&#160;31, 2020, with respect to the security ownership of certain beneficial owners and management and related stockholder matters of Teva, which is incorporated herein by reference and made a part hereof in response to the information required by Item 12. </div></div> <div id="toc102112_20" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reference is made to Teva&#8217;s 2021 Proxy Statement, which will be filed no later than 120 days after the close of Teva&#8217;s fiscal year ended December&#160;31, 2020, with respect to certain relationships and related transactions, and director independence of Teva, which is incorporated herein by reference and made a part hereof in response to the information required by Item 13. </div></div> <div id="toc102112_21" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reference is made to Teva&#8217;s 2021 Proxy Statement, which will be filed no later than 120 days after the close of Teva&#8217;s fiscal year ended December&#160;31, 2020, with respect to principal accountant fees and services provided to Teva, which is incorporated herein by reference and made a part hereof in response to the information required by Item 14. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">170 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc102112_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART IV </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The following financial statements are filed as part of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K:</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_50">Report of Independent Registered Public Accounting Firm </a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Financial Statements:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_51">Balance Sheets</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_52">Statements of Income (Loss)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_53">Statements of Comprehensive Income (Loss)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_54">Statements of Changes in Equity</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_55">Statements of Cash Flows</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_56">Notes to Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statement Schedule:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx102112_58">Schedule II&#8212;Valuation and Qualifying Accounts </a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The information called for by this Item is incorporated herein by reference to the Exhibit Index in this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K.</div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 93%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Memorandum of Association (1)(2)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518349399/d656228dex31.htm">Amendment to Memorandum of Association (1)(3) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520164664/d933868dex31.htm">Articles of Association (1)(4) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518342203/d664508dex41.htm">Second Amended and Restated Deposit Agreement, dated as of December&#160;4, 2018, among Teva Pharmaceutical Industries Limited, Citibank, N.A., as depositary, and the holders from time to time of shares (5) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312506016240/dex41.htm">Senior Indenture, dated as of January&#160;31, 2006, by and among Teva Pharmaceutical Finance Company LLC, Teva Pharmaceutical Industries Limited and The Bank of New York, as trustee (6) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312506016240/dex42.htm">First Supplemental Senior Indenture, dated as of January&#160;31, 2006, by and among Teva Pharmaceutical Finance Company LLC, Teva Pharmaceutical Industries Limited and The Bank of New York, as trustee, including the form of 0.25% Convertible Senior Debentures due 2026 (7) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312506016240/dex43.htm">Second Supplemental Senior Indenture, dated as of January&#160;31, 2006, by and among Teva Pharmaceutical Finance Company LLC, Teva Pharmaceutical Industries Limited and The Bank of New York, as trustee, including the form of 6.150% Senior Notes due 2036 (8) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.5</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312510106539/dex41.htm">Third Supplemental Senior Indenture, dated as of March&#160;16, 2010, by and among Teva Pharmaceutical Finance Company LLC, Teva Pharmaceutical Industries Limited and The Bank of New York, as trustee, relating to Teva&#8217;s 0.25% Convertible Senior Debentures due 2026 (9) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.6</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex41.htm">Senior Indenture, dated as of November&#160;10, 2011, by and among Teva Pharmaceutical Finance IV, LLC, Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee (10) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.7</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312512506295/d455114dex42.htm">Second Supplemental Senior Indenture, dated as of December&#160;18, 2012, by and among Teva Pharmaceutical Finance IV, B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 2.950% Senior Notes due 2022 (11) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.8</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex43.htm">Senior Indenture, dated as of November&#160;10, 2011, by and among Teva Pharmaceutical Finance Company B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee (12) </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">171 </div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 92%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.9</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex44.htm">First Supplemental Senior Indenture, dated as of November&#160;10, 2011, by and among Teva Pharmaceutical Finance Company B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 3.650% Senior Notes due 2021 (13) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312512506295/d455114dex44.htm">Second Supplemental Senior Indenture, dated as of December&#160;18, 2012, by and among Teva Pharmaceutical Finance Company LLC, Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 2.250% Senior Notes due 2020 (14) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.11</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex45.htm">Senior Indenture, dated as of November&#160;10, 2011, by and among Teva Pharmaceutical Finance IV B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee (15) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.12</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312511306761/d252883dex46.htm">First Supplemental Senior Indenture, dated as of November&#160;10, 2011, by and among Teva Pharmaceutical Finance IV B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 3.650% Senior Notes due 2021(16) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.13</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312515113855/d899515dex41.htm">Senior Indenture, dated as of March&#160;31, 2015, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Finance Netherlands II B.V. and The Bank of New York Mellon, as trustee (17) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.14</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312515113855/d899515dex42.htm">Supplemental Senior Indenture, dated as of March&#160;31, 2015, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Finance Netherlands II B.V., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London branch, as principal paying agent, including the form of 1.250% Senior Notes due 2023 and the form of 1.875% Senior Notes due 2027 (18) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.15</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312516656602/d220765dex42.htm">Second Supplemental Senior Indenture, dated as of July&#160;25, 2016, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Finance Netherlands II B.V., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London branch, as principal paying agent, including the form of 0.375% Senior Notes due 2020, the form of 1.125% Senior Notes due 2024 and the form of 1.625% Senior Notes due 2028 (19) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312516653824/d334267dex41.htm">Senior Indenture, dated as of July&#160;21, 2016, by and among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee (20) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.17</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312516653824/d334267dex42.htm">First Supplemental Senior Indenture, dated as of July&#160;21, 2016, by and among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of 2.200% Senior Notes due 2021, the form of 2.800% Senior Notes due 2023, the form of 3.150% Senior Notes due 2026 and the form of 4.100% Senior Notes due 2046 (21) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.18</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex42.htm">Permanent Global Certificate, dated as of July&#160;28, 2016, and the Terms of the CHF 350,000,000 0.500&#160;per cent Notes due 2022 (22) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.19</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex43.htm">Permanent Global Certificate, dated as of July&#160;28, 2016, and the Terms of the CHF 350,000,000 1.000&#160;per cent Notes due 2025 (23) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex45.htm">Guarantee, dated as of July&#160;28, 2016, by Teva Pharmaceutical Industries Limited (relating to the 2022 Notes) (24) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.21</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312516661692/d202899dex46.htm">Guarantee, dated as of July&#160;28, 2016, by Teva Pharmaceutical Industries Limited (relating to the 2025 Notes) (25) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.22</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex41.htm">Senior Indenture, dated as of March&#160;14, 2018, by and among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and the Bank of New York Mellon, as trustee (26) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.23</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex42.htm">First Supplemental Senior Indenture, dated as of March&#160;14, 2018, by and among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and the Bank of New York Mellon, as trustee, including the form of 6.000% Senior Notes due 2024 and the form of 6.750% Senior Notes due 2028 (27) </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">172 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 92%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.24</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex45.htm">Senior Indenture, dated as of March&#160;14, 2018, by and among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and the Bank of New York Mellon, as trustee (28) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.25</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518082582/d550834dex46.htm">First Supplemental Senior Indenture, dated as of March&#160;14, 2018, by and among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and the Bank of New York Mellon, as trustee, including the form of 3.250% Senior Notes due 2022 and the form of 4.500% Senior Notes due 2025 (29) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.26</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312519299994/d839912dex42.htm">Second Supplemental Senior Indenture, dated as of November&#160;25, 2019, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent, including the form of the 6.000% Senior Notes due 2025 (30) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.29</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312519299994/d839912dex46.htm">Second Supplemental Senior Indenture, dated as of November&#160;25, 2019, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of the 7.125% Senior Notes due 2025&#160;(31) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.30</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520044221/d852939dex433.htm">Description of Securities Registered Pursuant to Section&#160;12 of the Securities Exchange Act of 1934&#160;(32)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.31</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Other long-term debt instruments: The registrant hereby undertakes to provide the Securities and Exchange Commission with copies upon request.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312519102327/d728714dex101.htm">Senior Unsecured Revolving Credit Agreement, dated as of April&#160;8, 2019, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Finance Netherlands II B.V., Bank of America, N.A. and the lenders party thereto (33) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1020.htm">Employment Agreement, dated September&#160;7, 2017, between Teva Pharmaceutical Industries Limited and K&#229;re Schultz (34) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520164664/d933868dex101.htm">Amendment No.&#160;1 to Employment Agreement, dated as of June&#160;9, 2020, between Teva Pharmaceutical Industries Limited and K&#229;re Schultz (35) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1032.htm">Employment Agreement, dated as of June&#160;18, 2017, between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir (36) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.5</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312519043564/d613675dex1026.htm">Amendment to Employment Agreement between Teva Pharmaceuticals USA, Inc. and Hafrun Fridriksdottir, dated as of January&#160;4, 2019 (37) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.6</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520044221/d852939dex1010.htm">Employment Agreement, dated as of May&#160;6, 2018, between Teva Pharmaceuticals USA Inc. and Brendan O&#8217;Grady (38) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.7</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d102112dex107.htm">Employment Agreement, dated as of March&#160;12, 2020, between Teva Pharmaceutical Industries Limited and Eric Drap&#233; * </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.8</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d102112dex108.htm">Employment Agreement, dated as of May&#160;30, 2013, between Teva Sante and Eric Drap&#233;* </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.9</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d102112dex109.htm">Transfer Agreement of Employment Contract, dated as of March&#160;20, 2020, between Teva Sante, Teva Pharmaceutical Industries Limited and Eric Drap&#233; * </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520044221/d852939dex1013.htm">Employment Agreement, dated as of November&#160;6, 2019, between Teva Pharmaceutical Industries Limited and Eli Kalif (39) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.11</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520044221/d852939dex1032.htm">Amendment to Employment Agreement between Teva Pharmaceutical Industries Limited and Eli Kalif, dated as of February&#160;6, 2020 (40)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.12</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312517198533/d281982d6k.htm#toc281982_31">Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (41) </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">173 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.13</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1049.htm">Teva Pharmaceuticals USA, Inc. Supplemental Deferred Compensation Plan (42) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.14</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1050.htm">Teva Pharmaceuticals USA, Inc. Defined Contribution Supplemental Executive Retirement Plan (43) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.15</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1051.htm">Form of Indemnification and Release Agreement (44) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1052.htm">Form Director Award Agreement (45) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.17</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1053.htm">Hafrun Fridriksdottir Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016 grants (46) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.18</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1054.htm">K&#229;re Schultz Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to November&#160;3, 2017 grant (47) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.19</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1056.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016 grants made to Hafrun Fridriksdottir (48) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1061.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016 grants made to Eric Drap&#233; (49) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.21</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1060.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2017 grants made to Hafrun Fridriksdottir, Eric Drap&#233; and K&#229;re Schultz (50) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.22</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520114316/d838062ddef14a.htm#toc838062_18">Teva Pharmaceutical Industries Limited 2020 Long-Term Equity-Based Incentive Plan (51)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.23</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1063.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2018 grants made to K&#229;re Schultz, Hafrun Fridriksdottir, Eric Drap&#233; and Brendan O&#8217;Grady (52) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.24</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex1064.htm">Form Bonus Letter Agreement (53) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.25</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520286828/d175316dex102.htm">Form Award Agreement under Teva&#8217;s 2020 Long-Term Equity-Based Incentive Plan (54)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.26</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520044221/d852939dex1030.htm">Form Award Agreement under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan applicable to selected 2016 grants and 2017 grants made to Brendan O&#8217;Grady (55) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.27</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520044221/d852939dex1031.htm">Form Award Agreement (RSUs and PSUs) under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (56) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.28</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520286828/d175316dex103.htm">Teva Pharmaceutical Industries Limited Israeli Subplan of Teva&#8217;s 2020 Long-Term Equity-Based Incentive Plan (57) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">18</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/818686/000119312520210627/d938521dex18.htm">Kesselman&#160;&amp; Kesselman Preferability Letter dated August&#160;5, 2020 (58)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">21</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d102112dex21.htm">Subsidiaries of the Registrant *</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d102112dex23.htm">Consent of Kesselman&#160;&amp; Kesselman, independent registered public accountants * </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d102112dex311.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 * </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d102112dex312.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 * </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">32</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d102112dex32.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 * </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Instance Document (The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document)</td> </tr> </table> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">174 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td style="width: 88%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Labels Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed herewith </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">English translation or summary from Hebrew original, which is the official version. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 3.1 to Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1(Reg.</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;33-15736).</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">3.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 3.1 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on December&#160;14, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">4.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 3.1 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on June&#160;9, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">5.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.1 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on December&#160;4, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">6.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.1 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on January&#160;31, 2006. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">7.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.2 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on January&#160;31, 2006. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">8.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.3 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on January&#160;31, 2006. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">9.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.1 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on May&#160;4, 2010. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">10.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.1 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on November&#160;10, 2011. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">11.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.2 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on December&#160;18, 2012. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">12.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.3 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on November&#160;10, 2011. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">13.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.4 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on November&#160;10, 2011. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">14.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.4 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on December&#160;18, 2012. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">15.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.5 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on November&#160;10, 2011. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">16.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.6 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on November&#160;10, 2011. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">17.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.1 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on March&#160;31, 2015. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">18.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.2 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on March&#160;31, 2015. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">19.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.2 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on July&#160;25, 2016. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">20.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.1 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on July&#160;21, 2016. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">21.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.2 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on July&#160;21, 2016. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">22.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.2 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on July&#160;28, 2016. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">23.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.3 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on July&#160;28, 2016. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">24.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.5 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on July&#160;28, 2016. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">25.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.6 to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-K</div> filed on July&#160;28, 2016. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">26.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.1 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on March&#160;14, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">27.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.2 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on March&#160;14, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">28.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.5 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on March&#160;14, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">29.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.6 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on March&#160;14, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">30.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.2 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on November&#160;25, 2019. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">31.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.6 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on November&#160;25, 2019. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">32.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 4.33 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;21, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">33.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.1 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on April&#160;10, 2019. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">34.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.20 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">35.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.1 to Current Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed on June&#160;9, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">36.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.32 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">37.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.26 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;19, 2019. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">38.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.10 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;21, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">39.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.13 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;21, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">40.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.32 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;21, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">41.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated by reference to Exhibit A to Proxy Statement filed on June&#160;8, 2017. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">175 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">42.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.49 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">43.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.50 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">44.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.51 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">45.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.52 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">46.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.53 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">47.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.54 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">48.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.56 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">49.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.61 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">50.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.60 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">51.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated by reference to Exhibit Appendix A to our Definitive Proxy Statement filed on April&#160;22, 2020. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">52.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.63 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">53.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.64 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;12, 2018. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">54.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> filed on November&#160;5, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">55.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.30 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;21, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">56.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.31 to Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed on February&#160;21, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">57.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 10.3 to Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> filed on November&#160;5, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">58.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Incorporated by reference to Exhibit 18 to Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> filed on August&#160;5, 2020. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div id="toc102112_23" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">ITEM&#160;16. FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> SUMMARY </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">176 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 81%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TEVA&#160;PHARMACEUTICAL&#160;INDUSTRIES&#160;LIMITED</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ K&#229;re Schultz</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Name:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">K&#229;re Schultz</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Title:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">President and Chief Executive Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Dated:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">POWER OF ATTORNEY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">KNOW ALL PERSONS BY THESE PRESENT, that each of the undersigned directors and/or officers of Teva Pharmaceutical Industries Limited, a corporation organized under the laws of Israel, hereby constitutes and appoints K&#229;re Schultz, Eli Kalif, David M. Stark and Deborah A. Griffin, and each of them, his or her true and lawful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorneys-in-fact</div></div> and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign, execute and deliver with the U.S. Securities and Exchange Commission any and all amendments to this annual report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> with all exhibits thereto, and other documents in connection therewith, granting unto said <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorneys-in-fact</div></div> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorneys-in-fact</div></div> and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 3%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 28%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Dr.&#160;Sol&#160;J. Barer</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Sol&#160;J. Barer</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Chairman of the Board of Directors</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ K&#229;re Schultz</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">K&#229;re Schultz</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">President and Chief Executive Officer and Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Eli Kalif</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eli Kalif</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Executive Vice President, Chief Financial Officer<br/>(Principal Financial Officer)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Deborah A. Griffin</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deborah A. Griffin</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Senior Vice President, Chief Accounting Officer <br/>(Principal Accounting Officer)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Rosemary A. Crane</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rosemary A. Crane</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Amir Elstein</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amir Elstein</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">177 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 3%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 28%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Jean-Michel Halfon</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jean-Michel Halfon</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Abbas Hussain</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Abbas Hussain</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Gerald M. Lieberman</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gerald M. Lieberman</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Roberto A. Mignone</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roberto A. Mignone</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Dr.&#160;Perry&#160;D. Nisen</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Perry&#160;D. Nisen</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Nechemia (Chemi) J. Peres</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nechemia (Chemi) J. Peres</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Prof. Ronit Satchi-Fainaro</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prof. Ronit Satchi-Fainaro</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Janet Vergis</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Janet Vergis</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">February&#160;10, 2021</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>d102112dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EMPLOYMENT AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
Employment Agreement (this &#147;<B>Agreement</B>&#148;) is entered on March&nbsp;12, 2020, and is made by and between <B>TEVA PHARMACEUTICAL INDUSTRIES LTD</B>., an Israeli corporation located at 5 Basel Street, Petach Tikva, Israel, Company <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">No.&nbsp;52-001395-4</FONT></FONT> (the &#147;<B>Company</B>&#148;, &#147;<B>Teva</B>&#148;), and Eric Drap&eacute; (&#147;<B>Executive</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the Company wishes to employ Executive as Executive Vice President &#150; Teva Global Operations (&#147;<B>EVP TGO</B>&#148;), and Executive
wishes to be so employed; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the parties have agreed on the terms pursuant to which Executive shall serve as EVP TGO, and wish to set
forth such terms in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term; Positions and Duties; Location </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company agrees to employ Executive, and Executive agrees to serve the Company and its affiliates, subject
to the terms and conditions of this Agreement, for the period commencing on March&nbsp;1,2020 (the &#147;<B>Effective Date</B>&#148;) and until the termination of this Agreement pursuant to Section&nbsp;7 of this Agreement (the
&#147;<B>Term</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive shall report directly to the President and Chief Executive Officer of Teva (&#147;<B>CEO</B>&#148;).
Executive shall have all of the duties, authorities and responsibilities customarily exercised by an individual serving as the Executive Vice President &#150; Global Operations of a company the size and nature of the Company. In addition, the
Executive shall have such additional executive duties and responsibilities as may be assigned to him by the CEO. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Executive shall devote his full business time, attention, and efforts to the performance of his duties
under this Agreement and shall not engage in any other business or occupation during the Term, including, without limitation, any activity that (a)&nbsp;conflicts with the interests of the Company or its affiliates, (b)&nbsp;interferes with the
proper and efficient performance of his duties for the Company or (c)&nbsp;interferes with the exercise of his judgment in the Company&#146;s or its affiliates&#146; best interests. Notwithstanding the foregoing, nothing herein shall preclude the
Executive from: (i)&nbsp;serving, with the prior written consent of the CEO, as a member of the board of directors or advisory boards (or their equivalents in the case of a <FONT STYLE="white-space:nowrap">non-corporate</FONT> entity) of <FONT
STYLE="white-space:nowrap">non-competing</FONT> businesses and charitable organizations; (ii)&nbsp;engaging in charitable activities and community affairs; (iii)&nbsp;speaking at meetings of business, charitable and civic organizations; or
(iv)&nbsp;managing his personal investments and affairs; provided, however, that the activities set out in clauses (i), (ii), (iii) and (iv)&nbsp;shall be limited by the Executive so as not to be in contradiction to any Company policy and/or
materially interfere, individually or in the aggregate, with the performance of his duties and responsibilities hereunder or create a potential business or fiduciary conflict. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the Term, and as part of Executive&#146;s position, Executive may be required to serve as a director,
officer or committee member of the Company and its subsidiaries and affiliates (collectively, the &#147;<B>Company Group</B>&#148;), and the fulfillment of such position shall not constitute an employer-employee relationship between Executive and
any such entity (other than the Company), and notwithstanding any such position, Executive shall only be considered to be an employee of the Company and shall not be entitled to receive any additional compensation for serving in such additional
position. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive&#146;s principal place of employment shall be at the Company&#146;s principal offices in Israel.
However, Executive acknowledges and agrees that he shall be required to travel abroad extensively on Company business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive acknowledges and agrees that no collective and/or special bargaining agreement that might apply to
the Company&#146;s employees shall apply to Executive in his capacity as an employee of the Company, unless required by applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement and all compensation and benefits payable hereunder are subject to the Company&#146;s
compensation plans and policies applicable to senior officers or any successor compensation plans or policies, including the Company&#146;s Compensation Policy for Executive Officers and Directors adopted by the shareholders at the 2019 annual
general meeting of shareholders (the &#147;<B>Compensation Policy</B>&#148;) and nothing herein shall derogate in any way from the Company&#146;s rights thereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Base Salary </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Executive&#146;s gross annual base salary shall be 620,500 EUR (the &#147;<B>Annual Salary</B>&#148;). The
Annual Salary shall be divided by 12 and converted to local currency in accordance with Company practice, and each such 1/12 shall constitute Executive&#146;s monthly salary (the &#147;<B>Monthly Salary</B>&#148;). The Annual Salary shall be
reviewed, from time to time, by the Human Resources&nbsp;&amp; Compensation Committee of the Company&#146;s Board of Directors (the &#147;<B>Compensation Committee</B>&#148;) and/or the Board of Directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive hereby acknowledges and agrees that in light of his position and areas of responsibility, which
require a special degree of trust, and since he is part of the Company&#146;s senior management, the provisions of the Hours of Work and Rest Law, 5711-1951, shall not apply to his employment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is hereby agreed that only the Monthly Salary payable to Executive pursuant to Section&nbsp;2.1 shall
constitute the basis for the calculation of all social benefits granted to Executive pursuant to this Agreement (including Pension Contributions and Severance Contributions (as such terms are defined in Sections 6.1 and 6.5) and for any other
purpose or benefit plan for which deductions are calculated based on a percentage of Executive&#146;s salary. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereby acknowledge and agree that the compensation terms set forth in this Agreement constitute
fair consideration to Executive, given, inter alia, his managerial responsibilities and obligations towards the Company and that the Executive shall not be entitled to receive any other payment or compensation of any kind beyond the Monthly Salary
and the other payments and benefits specified in this Agreement unless otherwise agreed between the Company and the Executive in writing and approved as required by applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall pay or reimburse Executive for all reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses incurred by Executive in performing his duties under this Agreement, subject to presentation of appropriate supporting documentation and in accordance with the expense
reimbursement policy of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Bonus </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For each fiscal year that ends during the Term, the Executive shall be eligible to be considered for an annual
bonus under the Company&#146;s annual cash bonus plan in accordance with the Compensation Policy (the&nbsp;&#147;<B>Annual Bonus</B>&#148;) and subject to the sole discretion of the CEO, the Compensation Committee and the Board of Directors, with a
target amount equal to 100% of Executive&#146;s Annual Salary. If payable, the Annual Bonus shall be paid to the Executive at the same time as annual bonuses are generally payable to other similarly situated senior executives of the Company, subject
to the Executive&#146;s continuous employment through the payment date. . </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Equity Awards </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Equity-based Awards.</U> During the Term, the Executive shall be considered for equity-based
compensation awards under the terms of Teva&#146;s 2015 Long Term Equity-Based Incentive Plan (the &#147;<B>2015 Plan</B>&#148;), or any successor equity compensation plan(s), at the sole discretion of the CEO, the Compensation Committee and the
Board of Directors. Any such awards shall be granted on such terms and conditions as may be determined by the Compensation Committee and the Board of Directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Executive Benefits </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General</U>. During the Term, Executive (and, to the extent eligible, his dependents) shall be entitled to
participate in any and all health, medical, dental, group insurance, welfare, fringe benefits, perquisites and other employee benefit plans, programs and arrangements, and for the avoidance of doubt excluding study fund, that are generally available
from time to time to similarly situated senior executives of the Company and their dependents (the &#147;<B>Executive Benefits</B>&#148;). Nothing contained herein shall be construed to limit the Company&#146;s ability to amend, suspend, or
terminate any employee benefit plan or policy at any time without providing the Executive notice, and the right to do so is expressly reserved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Relocation. From January&nbsp;1, 2020 until the third anniversary thereafter, Executive shall be provided
relocation benefits as set forth in the Company&#146;s Long Term International Assignment Policy (the<B> &#147;Relocation Policy</B>&#148;), as shall be amended from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Changes to Relocation Policy</U>. The Executive acknowledges, agrees and understands that the Relocation
Policy does not form part of this Agreement and the Company reserves the right to amend, suspend, or terminate the Relocation Policy at any time without providing the Executive notice, and the right to do so is expressly reserved. Notwithstanding
the foregoing, in the event of any conflict between the Relocation Policy and this Agreement, the terms of this Agreement shall prevail. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Vacation</U>. Executive shall be entitled to twenty three and a half (23.5) paid vacation working days per
calendar year during the Term, which shall accrue in accordance with Company policy. Executive shall be required to utilize at least five (5)&nbsp;consecutive vacation days every calendar year, and may accumulate the remaining vacation days up to 47
days in total and in accordance with Company policy which may be revised from time to time. Any accumulated vacation days above 47 days shall be forfeited by the Company with no consideration. The dates of Executive&#146;s annual vacation shall be
coordinated in advance with the CEO. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sick Leave</U>. Executive shall be entitled to twenty two (22)&nbsp;paid sick working days per calendar year
during the Term (without any reduction in the compensation or benefits payable hereunder), which may accumulate during the Term in accordance with the Company&#146;s practice or policy, as in effect from time to time but in no event shall exceed
twelve (12)&nbsp;months. The sick pay shall include the Monthly Salary and all other amounts and benefits to which Executive is entitled under this Agreement, as if Executive worked at the Company during the period of his illness (in respect of
period for which he is entitled to receive payment as aforesaid), less any amount that Executive is entitled to receive with respect to the aforementioned period of his illness, including from any Israeli pension fund; <U>provided</U> that Executive
provides the Company with medical confirmation of his illness. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Recreation Pay</U>. Executive shall be entitled to fifteen (15)&nbsp;paid recreation days per calendar year
during the Term. The amount of recreation pay per recreation day, the payment conditions and any other conditions governing recreation pay shall be in accordance with applicable Law and the Company&#146;s policy in effect at the applicable time with
respect to its employees generally. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Car.</U> The Company shall furnish the Executive with a car owned or leased by Teva, and which the Executive
shall use during the Term. Subject to the provisions of any applicable Law, and the Company&#146;s policy on the matter, the Company shall bear all costs relating to the use and maintenance of the car. The Executive undertakes to use the car in a
reasonable manner. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pension Insurance </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to approval of the Compensation Committee and the Board (if applicable), the Company shall reimburse
Executive on a monthly basis an amount equal to the required monthly French contribution, to be paid by the Executive to French social security, to enable Executive&#146;s continued social security coverage (the &#147;<B>Pension
Contribution</B>&#148;). By signing this Agreement Executive declares that he is covered by a sufficient loss of ability to work insurance in France. In no event shall the Pension Contribution be less than 7.5% of the Executive Monthly Salary.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive declares and warrants that the Pension Contribution pursuant to Section&nbsp;6.1 is in lieu of the
Company&#146;s obligation under applicable Law to insure the Executive under a pension plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since the Pension Contribution payment as aforementioned is done pursuant to Executive&#146;s request, and for
his benefit, neither Executive nor his successors, heirs and assigns shall have a cause of action with respect to any matter regarding the Company&#146;s obligation to insure Executive under a pension plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is hereby acknowledged and agreed that the Pension Contribution payment shall not be deemed part of the
Executive&#146;s Monthly Salary for any purpose, including without derogating from the foregoing, for the purpose of payment of severance and any other entitlement calculated as a percentage of Executive&#146;s Monthly Salary, and this
Section&nbsp;6 shall not impose on the Company any additional current or future cost or expense, directly or indirectly. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition, the Company shall contribute and deposit, on a monthly basis, 8.33% of the Monthly Salary on
account of severance contribution to an interest-bearing bank account in Israel that shall be opened for such purpose, in accordance with applicable Law (such contributions and all earnings thereon, the &#147;<B>Severance Contribution</B>&#148;).
The Severance Contribution is to be paid out along with the last salary payment. For the avoidance of doubt, the Severance Payment and any severance entitlements payable under applicable Law (whether arising during or after the Term) shall be
reduced (but not below $0) by the amount of the Severance Contribution. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of Employment </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General</U>. Executive&#146;s employment with the Company shall terminate upon the earliest to occur of
(a)&nbsp;Executive&#146;s death, (b)&nbsp;a termination by reason of a Disability (as defined in Section&nbsp;7.8.5), (c)&nbsp;a termination by the Company with or without Cause (as defined in Section&nbsp;7.8.3), and (d)&nbsp;a termination by
Executive with or without Good Reason (as defined in Section&nbsp;7.8.6).<I> </I>The date on which employee-employer relations cease to exist between the parties shall be referred to in this Agreement as the &#147;<B>Date of Termination</B>.&#148;
Upon any termination of Executive&#146;s employment for any reason, except as may otherwise be requested by the Company in writing and agreed upon in writing by Executive, Executive shall be deemed to have resigned, effective immediately, from any
and all directorships, committee memberships, and any other positions Executive holds with any member of the Company Group. If for any reason this Section&nbsp;7.1 is deemed to be insufficient to effectuate the resignations contemplated by the
immediately preceding sentence, then Executive shall without incurring any costs on him, upon the Company&#146;s request, execute any documents or instruments that the Company may deem necessary or desirable to effectuate such resignations. In
addition, Executive hereby designates the Secretary or any Assistant Secretary of the Company to execute any such documents or instruments as Executive&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to effectuate such resignations if execution by the Secretary or any Assistant Secretary of the Company is deemed by the Company to be a more expedient
means to effectuate such resignation or resignations. In addition, Executive undertakes to cooperate with the Company to ensure the orderly transition of position and provide any other assistance that may be required by the Company in connection
with the Executive&#146;s duties and responsibilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination Due to Death or Disability</U>. Executive&#146;s employment shall terminate automatically upon
his death. The Company may terminate Executive&#146;s employment immediately upon the occurrence of a Disability, such termination to be effective upon Executive&#146;s receipt of written notice of such termination and subject to applicable
proceedings pursuant to applicable Law. Upon Executive&#146;s death or in the event that Executive&#146;s employment is terminated due to his Disability, Executive or his estate or his Beneficiaries (as defined in Section&nbsp;7.8.2), as the case
may be, shall be entitled to: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Accrued Obligations (as defined in Section&nbsp;7.8.1); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any portion of the severance payment required to be paid pursuant to applicable Law, which shall be paid in
accordance with the requirements of applicable Law; <U>provided</U>, <U>however</U>, that such payment shall be reduced (but not below $0) by the amount of the Severance Contribution. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions of this Section&nbsp;7.2, the payments and benefits described in this Section&nbsp;7.2 (other than
the components of the Accrued Obligations and any portion of the Severance Payment required to be paid pursuant to applicable Law) (a)&nbsp;are subject to Executive&#146;s or his estate or his Beneficiaries, as the case may be, execution and <FONT
STYLE="white-space:nowrap">non-revocation</FONT> of the Release of Claims in accordance with Section&nbsp;7.6 and (b)&nbsp;shall immediately terminate, and the Company shall have no further obligations to Executive with respect thereto, in the event
that Executive breaches any provision of Sections 9, 10, 11, 12 and/or 13. In addition, in the event Executive breaches any provision of Sections 9, 10, 11, 12 and/or 13, Executive shall repay to the Company all payments and benefits which were made
and/or paid by the Company pursuant to Section&nbsp;7.2 (other than the components of the Accrued Obligations and the portion of the Severance Payment required to be paid pursuant to applicable Law). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination by the Company for Cause.</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may terminate Executive&#146;s employment at any time and without any advance notice, in the event
of Cause, subject to applicable proceedings pursuant to applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that the Company terminates Executive&#146;s employment for Cause, he shall be entitled only to
those components of the Accrued Obligations required to be paid by applicable Law, and subject to applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following such termination of Executive&#146;s employment by the Company for Cause, except as set forth in this
Section&nbsp;7.3, Executive shall have no further rights to any compensation or any benefits under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination by the Company without Cause</U>. The Company may terminate Executive&#146;s employment at any
time without Cause, effective six (6)&nbsp;months following the date of Executive&#146;s receipt of notice of such termination (the &#147;<B>Company </B><B>Notice Period</B>&#148;); <U>provided</U>, <U>however,</U> that the Company may, in its sole
and absolute discretion and by written notice, waive the services of the Executive during the Company Notice Period or in respect of any part of such period, and at the Company&#146;s sole discretion accelerate the effective date of such termination
of employee-employer relationship (such accelerated date shall constitute the Termination Date), all on the condition that the Company pay the Executive the Monthly Salary and all additional compensation and benefits to which the Executive is
entitled in respect of the Notice Period without regard to any such Company waiver. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">In the event that Executive&#146;s employment is terminated by the Company without Cause
(other than due to death or Disability), Executive shall be entitled to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Accrued Obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Severance Payment (as defined in Section&nbsp;7.8.10); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Non-Compete</FONT> Payment (as defined in Section&nbsp;7.8.7); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Executive&#146;s employment is terminated by the Company without Cause within one (1)&nbsp;year following a
Change in Control event (as defined in the Compensation Policy as in effect on the date hereof), the CIC Amount (as defined in Section&nbsp;7.8.4). </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the payments and benefits described in this Section&nbsp;7.4 (other than the components of the Accrued
Obligations and the portion of the Severance Payment required to be paid pursuant to applicable Law) (a)&nbsp;are subject to Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of the Release of Claims in accordance
with Section&nbsp;7.6 and (b)&nbsp;shall immediately terminate, and the Company shall have no further obligations to Executive with respect thereto, in the event that Executive breaches any provision of Sections 9, 10, 11, 12 and/or 13. In addition,
in the event Executive breaches any provision of Sections 9, 10, 11, 12 and/or 13, Executive shall repay to the Company all payments and benefits which were made and/or paid by the Company pursuant to this Section&nbsp;7.4 (other than the components
of the Accrued Obligations and the portion of the Severance Payment required to be paid pursuant to applicable Law). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination by Executive with or without Good Reason. </U>Executive may terminate his employment with or
without Good Reason by providing the Company six (6)&nbsp;months&#146; prior written notice of such termination (the &#147;<B>Executive Notice Period</B>&#148;); provided, however, that the Company may, in its sole and absolute discretion, by
written notice, waive the services of the Executive during the Executive Notice Period or in respect of any part of such period, and at Company&#146;s sole discretion accelerate the effective date of such termination of employee-employer
relationship (such accelerated date shall constitute the Termination Date) and still have it treated as a termination without Good Reason. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">In the event of a termination of employment by Executive for Good Reason, Executive shall
be entitled to the same payments and benefits as provided in Sections 7.4.1, 7.4.2 and 7.4.3, subject to the same conditions on payment and benefits as described in Section&nbsp;7.4 (including execution and
<FONT STYLE="white-space:nowrap">non-revocation</FONT> of the Release of Claims in accordance with Section&nbsp;7.6 and compliance with Sections 9, 10, 11, 12 and 13). Notwithstanding the above, the Company may terminate the employment of Executive
without Cause in accordance with Section&nbsp;7.4 after receipt of the &#147;Good Reason Notice&#148; (as defined in Section&nbsp;7.8.6). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">In the event of a termination of employment by Executive without Good Reason, Executive shall only be entitled to the (i)&nbsp;Accrued
Obligations; (ii)&nbsp;Severance Contributions accumulated in the bank; and (iii)&nbsp;the <FONT STYLE="white-space:nowrap">Non-Compete</FONT> Payment, subject to the same conditions on payment and benefits as described in Section&nbsp;7.4
(including execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of the Release of Claims in accordance with Section&nbsp;7.6 and compliance with Sections 9, 10, 11, 12 and 13). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Release</U>. Notwithstanding any provision in this Agreement to the contrary, the payment of any amount or
provision of any benefit pursuant to Section&nbsp;7 (other than the components of the Accrued Obligations and those components of the Severance Payment required to be paid pursuant to applicable Law) (collectively, the &#147;<B>Severance
Benefits</B>&#148;) shall be conditioned upon Executive&#146;s execution, delivery to the Company, and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of the Release of Claims (as defined in Section&nbsp;7.8.9) within thirty (30)&nbsp;days
following the Date of Termination. If Executive fails to execute the Release of Claims in such a timely manner, Executive shall not be entitled to any of the Severance Benefits. For the avoidance of doubt, in the event of a termination due to
Executive&#146;s death or Disability or Executive&#146;s death or Disability following a notice of termination of employment without Cause or for Good Reason, Executive&#146;s obligations herein to execute the Release of Claims may be satisfied on
his behalf by his estate or a person having legal power of attorney over his affairs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Full Settlement</U>. The payments and benefits provided under this Section&nbsp;7 shall be in full
satisfaction of all obligations of the Company Group to Executive under this Agreement or any other agreement, plan, arrangement or policy of the Company Group in connection with his termination of employment. For the avoidance of doubt,
Executive&#146;s sole and exclusive remedy upon a termination of employment shall be receipt of the payments and benefits specified in this Section&nbsp;7. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. For purposes of this Agreement, the following terms have the following meanings:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Accrued Obligations</B>&#148; means (a)&nbsp;any unpaid Monthly Salary earned through the Date of
Termination, and any unused vacation days and recreation days accrued in accordance with Company policy and this Agreement through the Date of Termination, which amounts shall be paid on the next regular payroll date immediately following the Date
of Termination, (b)&nbsp;any other payment to which Executive is entitled under the applicable terms of any applicable plan, program, agreement, corporate governance document or arrangement of the Company, including Company reimbursement of any
unreimbursed business expenses and rights to any Company indemnification as set forth in Section&nbsp;8. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Beneficiaries</B>&#148; means, subject to applicable Law, the executors of Executive&#146;s estate,
the Executive&#146;s legal heirs and with respect to the Pension Contributions those beneficiaries whom the Executive stipulated in a written notice to any applicable pension providers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Cause</B>&#148; means (A)&nbsp;the Executive&#146;s indictment for, conviction of or pleading of
guilty or nolo contendere to, (i)&nbsp;a felony or (ii)&nbsp;any crime involving moral turpitude; (B)&nbsp;the Executive&#146;s embezzlement, dishonesty, misappropriation of Company property, breach of fiduciary duty or fraud with regard to the
Company or any of its assets or businesses; (C)&nbsp;the Executive&#146;s willful misconduct or gross negligence in the performance of the Executive&#146;s duties or continual failure to perform the material duties of his position; (D)&nbsp;the
Executive&#146;s material violation of a Company rule or regulation; (E)&nbsp;the Executive&#146;s breach of a material provision of this Agreement; or (F)&nbsp;circumstances entitling the Company under any applicable law to terminate the employment
of the Executive without payment of severance pay. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>CIC Amount</B>&#148; means one and a half (1.5) million USD converted into local currency at the Date
of Termination and in accordance with the Company&#146;s practice and polices. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Disability</B>&#148; means that Executive, due to a physical or mental disability, has been
substantially unable to perform his duties under this Agreement for a continuous period of ninety (90)&nbsp;days or longer, as determined by a physician selected by the Company and reasonably acceptable to Executive. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Good Reason</B>&#148; means a termination by Executive if (a)&nbsp;any of the following events occurs
without Executive&#146;s express prior written consent, (b)&nbsp;Executive notifies the Company in writing that such event has occurred, describing such event in reasonable detail and demanding cure, within ninety (90)&nbsp;days after Executive
learns of the occurrence of such event (the &#147;<B>Good Reason Notice</B>&#148;), (c)&nbsp;such event is not substantially cured within thirty (30)&nbsp;days after Executive delivers the Good Reason Notice to the Company, and (d)&nbsp;the Date of
Termination occurs within one hundred twenty (120)&nbsp;days after the failure of the Company to so cure: (A)&nbsp;the Company&#146;s breach of a material provision of this Agreement, (B)&nbsp;a material diminution in the Executive&#146;s duties or
responsibilities that is inconsistent with the Executive&#146;s position as described herein, or (C)&nbsp;a material reduction in the Executive&#146;s Annual Salary. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">&#147;Non-Compete</FONT> Payment&#148;</B> means the payment defined in
Section&nbsp;14. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Law</B>&#148; means any Israeli law, rule or regulation, and the regulations of any securities
exchange on which the Company&#146;s securities are listed, or any applicable judgment, order, writ, decree, permit or license of any governmental authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Release of Claims</B>&#148; means the release of claims in favor of the Company Group substantially in
the form attached hereto as <B><U>Exhibit A</U></B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Severance</B> <B>Payment</B>&#148; means an amount equal to fifteen (15)&nbsp;times of the
then-current Monthly Salary deduced by the amounts accumulated pursuant to Section&nbsp;6.5 as a result of the Severance Contributions. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In accordance with and subject to the provisions of Israeli law and the applicable provisions of the Company&#146;s Articles of Association and
the Compensation Policy, the Indemnification and Release Agreement between Executive and the Company, dated October&nbsp;2, 2019, shall continue to apply in full force and effect in accordance with its terms, and is incorporated by reference to this
Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality and Disclosure of Information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Executive shall execute the Confidentiality, Disclosure of Information and Assignment of Inventions Agreement attached hereto as <B><U>Exhibit
B</U></B><B> </B>concurrently with the execution of this Agreement and agrees to abide by the terms thereof, which shall be deemed incorporated into this Section&nbsp;9. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Competition</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">By signing this Agreement, the Executive hereby acknowledges and agrees that, in his capacity as Executive Vice President - Teva Global
Operations the Executive will have a great deal of exposure and access to a broad variety of commercially valuable proprietary information of the Company Group, including, by way of illustration, confidential information regarding the Company
Group&#146;s current and future products and strategies, costs and other financial information, R&amp;D and marketing plans and strategies, etc. As a result of the Executive&#146;s knowledge of the above information and in consideration for the
benefits offered by the Company under this Agreement, including, but not limited to, the <FONT STYLE="white-space:nowrap">Non-Compete</FONT> Payment, the Executive affirms and recognizes his continuing obligations with respect to the use and
disclosure of confidential and proprietary information of the Company Group pursuant to the Company Group&#146;s policies and the terms and conditions of this Agreement, and hereby agrees that, during the Term and for the six (6)&nbsp;months
following the Date of Termination, the Executive shall not, directly or indirectly (whether as an officer, director, owner, employee, partner, consultant or other direct or indirect service provider) engage, directly or indirectly, anywhere in the
world, in any activity, business or any other engagement in the pharmaceutical industry, which competes with the business of any member of the Company Group as of the Date of Termination (including any business that any member of the Company Group
is actively planning to enter as of the Date of Termination), except with the Company&#146;s prior written approval. Notwithstanding anything to the contrary contained in this Section&nbsp;10, the foregoing shall not prevent Executive from acquiring
for his own personal investment not more than 1% of the outstanding voting securities of any publicly-traded corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Executive herby agrees that during the Term and for the six (6)&nbsp;months following the Date of Termination, the Executive shall not,
directly or indirectly, (i)&nbsp;solicit or induce, or in any manner attempt to solicit or induce, any person employed by, or as agent of, the Company Group to terminate such person&#146;s contract of employment or agency, as the case may be, with
the Company Group, or (ii)&nbsp;divert, or attempt to divert, any person, concern or entity from doing business with the Company Group, or attempt to induce any such person, concern or entity to cease being a customer or supplier of the Company
Group. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">It is hereby agreed and clarified that, when determining the above <FONT STYLE="white-space:nowrap">non-solicitation</FONT>
undertaking, the parties took into account the entire consideration provided to Executive pursuant to this Agreement, which is being made in consideration, <I>inter alia</I>, for such undertaking. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Disparagement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">During the Term and at all times thereafter, the Executive agrees not to (i)&nbsp;make any disparaging or defamatory comments regarding any
member of the Company Group or any of its current or former directors, officers, employees or products or (ii)&nbsp;make any negative or disparaging comments concerning any aspect of the Executive&#146;s relationship with any member of the Teva
Group or any conduct or events relating to any termination of the Executive&#146;s employment with the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Nothing herein shall
prevent Executive from testifying truthfully in any legal proceeding, to any governmental or regulatory body or as may otherwise be required by applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">It is hereby agreed and clarified that, when determining the above <FONT STYLE="white-space:nowrap">non-disparagement</FONT> undertaking, the
parties took into account the entire consideration provided to Executive pursuant to this Agreement, which is being made in consideration, <I>inter alia</I>, for such undertaking. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cooperation. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">During the Term and at all times thereafter, Executive agrees to cooperate with the Company and its attorneys in connection with any matter
related to the period he was employed by the Company and/or his services to any other member of the Company Group, including but not limited to any threatened, pending, and/or subsequent litigation, government investigation, or other formal inquiry
against any member of the Company Group, and shall make himself available upon reasonable notice to prepare for and appear at deposition, hearing, arbitration, mediation, or trial in connection with any such matters. Such cooperation will include
willingness to be interviewed by representatives of the Company and to participate in legal proceedings by deposition or testimony. To the extent reasonably practicable, the Company shall coordinate with Executive to minimize scheduling conflicts
with Executive&#146;s business and personal commitments. The Company shall reimburse Executive for any reasonable <FONT STYLE="white-space:nowrap">pre-approved</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including travel expenses) incurred in connection with providing such assistance and subject to any terms and limitation in the Indemnification
and Release Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Compete,</FONT>
<FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> and No Disparagement Payments. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In consideration for
Executive&#146;s undertaking set forth in Sections 9, 10, 11, 12 and 13, and subject to compliance therewith, following the Date of Termination and subject to the provisions of Section&nbsp;7, Executive shall receive an amount equal to three
(3)&nbsp;times the Monthly Salary in effect immediately prior to the Date of Termination, to be paid in six (6)&nbsp;equal monthly installments (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Compete</FONT> Payment</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event that Executive&#146;s employment is terminated by the Company for Cause, Executive shall remain
subject to Sections 9, 10, 11, 12 and 13, and any other <FONT STYLE="white-space:nowrap">non-compete</FONT> obligations, but the Company shall not be required to pay the<B> </B><FONT STYLE="white-space:nowrap">Non-Compete</FONT> Payment and the
entire compensation paid to the Executive pursuant to this Agreement shall constitute as consideration for the Executive&#146;s undertaking set forth in Sections 9, 10, 11, 12 and 13. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">No-Hedging</FONT> Policy;
<FONT STYLE="white-space:nowrap">No-Pledging</FONT> Policy; Stock Ownership Guidelines. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Executive acknowledges and
agrees to adhere to the Company&#146;s <FONT STYLE="white-space:nowrap">No-Hedging</FONT> Policy, <FONT STYLE="white-space:nowrap">No-Pledging</FONT> Policy and Stock Ownership Guidelines applicable to executive officers of the Company, as each may
be amended from time to time in the Company&#146;s sole discretion </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return of Car, Equipment and Documents </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">As of no later than the Date of Termination, or earlier than that if required by the Company, Executive shall return to the Company the car,
cell phone (or other hand-held device), laptop, credit card(s) and any other company equipment, if any, provided to Executive, and any other confidential or proprietary information of the Company that is in Executive&#146;s possession;
<U>provided</U>, <U>however</U>, that nothing in this Agreement or elsewhere shall prevent Executive from retaining and utilizing documents relating to his personal benefits, personal contact list, and the like; and such other records and documents
as may reasonably be approved by the CEO (such approval not to be unreasonably withheld or delayed). Executive shall confirm such return in writing to the Company promptly upon Company&#146;s written request, together with confirmation that
Executive no longer has any Company property or confidential or proprietary information of the Company in his possession or control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignability; Binding Nature </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement shall inure to the benefit of, and be binding on, the parties and each of their respective successors, heirs (in
Executive&#146;s case) and assigns. No rights or obligations of the Company under this Agreement may be assigned or transferred by the Company except that such rights and obligations may be assigned or transferred pursuant to a merger or
consolidation, or the sale or liquidation of all or substantially all of the business and assets of the Company; <U>provided</U> that the assignee or transferee is the successor to all or substantially all of the business and assets of the Company
and such assignee or transferee contractually assumes the liabilities, obligations and duties of the Company, as contained in this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tax Payments; Clawback </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Tax and Social Security Payments</U>. Executive hereby acknowledges and agrees that the payments and
benefits granted to him under this Agreement shall be subject to income tax deductions and other mandatory tax deductions which the Company is required to deduct and/or withhold by applicable Law, and further represents that, except as specifically
set forth in this Agreement, nothing in this Agreement shall be construed as imposing on the Company the obligation to pay taxes or any other obligatory payment imposed on Executive due to any payment or benefit, except that the Company shall pay
taxes related to the use of car pursuant to Section&nbsp;5.7. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Clawback</U>. All payments made pursuant to this Agreement are subject to the &#147;clawback&#148;
provisions in the Compensation Policy as may be amended from time to time. By signing this Agreement, Executive grants the Company a power of attorney to deduct from the Monthly Salary and/or any other payments due to Executive by the Company, any
amounts owed by him, in accordance with applicable Law and any Company clawback provisions in the Compensation Policy. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Executive represents that (a)&nbsp;he has provided to the Company complete and accurate information regarding the terms of all contracts,
arrangements, agreements, policies or understandings applicable to Executive, with prior employers or otherwise, which include post-employment covenants including those relating to competition or solicitation of third parties and (b)&nbsp;he is not
subject to (or has been released from all restrictive covenants under) any contract, arrangement, agreement, policy or understanding that in any way impacts his ability to enter into or fully perform his obligations under this Agreement. Executive
and the Company each represent and warrant (i)&nbsp;that such party is not otherwise unable to enter into and fully perform such party&#146;s obligations under this Agreement; and (ii)&nbsp;that, upon the execution and delivery of this Agreement by
both parties, this Agreement shall be such party&#146;s valid and binding obligation, enforceable against such party in accordance with its terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or
similar laws affecting the enforcement of creditors&#146; rights generally, or otherwise as may be limited by applicable Laws. Notwithstanding any portion of this Agreement to the contrary, if any of Executive&#146;s representations under this
Section&nbsp;19 prove to be inaccurate, the Company may immediately declare this Agreement null and void and Executive&#146;s employment with the Company shall terminate immediately without obligation of any sort by the Company, including pursuant
to any equity or other award previously issued to Executive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any notice or other communication required or permitted to be delivered under this Agreement shall be (a)&nbsp;in writing; (b)&nbsp;delivered
personally, by email received by the intended receiver of such email, by facsimile, by courier service or by certified or registered mail, first class postage prepaid and return receipt requested; (c)&nbsp;deemed to have been received on the date of
delivery or, if so mailed, on the third business day after the mailing thereof; and (d)&nbsp;addressed as follows (or to such other address as the party entitled to notice shall hereafter designate in accordance with the terms hereof): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If to the Company: to the Company&#146;s headquarters, Attn: CEO; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If to Executive: to the last address on file with the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>Miscellaneous</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement</U>. As of the Effective Date, this Agreement shall constitute the entire agreement between
the parties with respect to the subject matter hereof, and this Agreement (including the agreements attached hereto as Exhibits) shall supersede all prior representations, agreements and understandings (including any prior course of dealings), both
written and oral, between the parties with respect to the subject matter hereof, except that any confidentiality and/or assignment of invention agreements by and between Executive and a company member of the Company Group shall continue to apply and
in the event of a conflict between this Agreement and such agreement(s), the stricter arrangement shall apply. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment or Waiver</U>. No provision in this Agreement may be amended unless such amendment is set forth in
writing that expressly refers to the provision of this Agreement that is being amended and that is signed by Executive and by an authorized officer of the Company. No waiver by either party of any breach of any condition or provision contained in
this Agreement shall be deemed a waiver of any similar or dissimilar condition or provision at the same or any prior or subsequent time. To be effective, any waiver must be set forth in writing signed by the waiving party and must specifically refer
to the condition(s) or provision(s) of this Agreement being waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inconsistencies</U>. Subject to applicable Law, in the event of any inconsistency between any provision of
this Agreement and any provision of any applicable plan, program, agreement, corporate governance document or arrangement of the Company or its affiliates, the provisions of this Agreement shall control unless Executive and the Company otherwise
agree in a writing that expressly refers to the provision of this Agreement whose control they are waiving. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Headings; Construction</U>. The headings of the sections and
<FONT STYLE="white-space:nowrap">sub-sections</FONT> contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement. For purposes of this Agreement,
the term &#147;including&#148; shall mean &#147;including, without limitation.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Survivorship</U>. The provisions of this Agreement that by their terms call for performance subsequent to
the termination of either Executive&#146;s employment or this Agreement (including the terms of Sections 7 through 14, 18 and Section&nbsp;20) shall survive such termination in accordance with their applicable terms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law; Severability</U>. This Agreement shall be governed by the laws of the State of Israel,
without regard to its conflict of laws rules. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under Law but the invalidity or unenforceability of any
provision or portion of any provision of this Agreement in any jurisdiction shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of this Agreement, including that
provision or portion of any provision, in any other jurisdiction. In addition, should a court or arbitrator determine that any provision or portion of any provision of this Agreement, is not reasonable or valid, either in period of time,
geographical area, or otherwise, the parties agree that such provision should be interpreted and enforced to the maximum extent which such court or arbitrator deems reasonable or valid. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which shall be
deemed an original, but all such counterparts shall together constitute one and the same instrument. Signatures delivered by facsimile shall be effective for all purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Board Approvals</U>. Any reference made in this Agreement to an approval required of the Board or a
committee of the Board shall also include any approval of the Board or any committee of the Board as may be required by Law, the Compensation Policy or the Company&#146;s corporate documents. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#151; </B>Signature page follows &#150; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Agreement in one or more
counterparts as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEVA PHARMACEUTICAL INDUSTRIES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Sabag</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Sabag</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">K&aring;re Schultz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">K&aring;re Schultz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President&nbsp;&amp; CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric Drap&eacute;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Eric Drap&eacute;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Dated: March&nbsp;12, 2020</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Employment Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Release Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Release
Agreement (this &#147;<B>Release Agreement</B>&#148;) is dated as of [_____________] and is entered into by Eric Drap&eacute; (&#147;<B>Executive</B>&#148;, &#147;<B>Me</B>&#148; or &#147;<B>I</B>&#148;) and <B>TEVA PHARMACEUTICAL INDUSTRIES
LTD.</B> (the &#147;<B>Company</B>&#148;) in connection with the termination of Executive&#146;s employment with the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. General Release.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In consideration for the receipt of those payments that are in excess of the amounts required to be paid to Me by Law (as detailed
in the settlement of account attached hereto), I, on behalf of myself and my family, agents, representatives, heirs, executors, trustees, administrators, attorneys, successors and assigns (the &#147;<B>Releasors</B>&#148;), hereby irrevocably and
unconditionally (i)&nbsp;represent and warrant that I have received in a timely manner full and complete payment of all amounts due to Me under my employment agreement with the Company or under any applicable law and/or in connection with the
termination of my employment, both at law and pursuant to the terms of the employment agreement, and (ii)&nbsp;release, settle, cancel, acquit, discharge and acknowledge to be fully satisfied, and covenant not to sue the Company and each of its
respective past and/or present subsidiaries, affiliates, successors and assigns, and each of their respective predecessors, and past and/or present stockholders, partners, members, directors, managers, officers, employees, agents or other
representatives, and employee benefit plans of the Company or its affiliates, including, but not limited to, trustees and administrators of these plans, in each case, in their individual and/or representative capacities (collectively, the
&#147;<B>Releasees</B>&#148;) from any and all claims, contractual or otherwise, demands, costs, rights, causes of action, charges, debts, liens, promises, obligations, complaints, losses, damages and all liability of whatever kind and nature,
whether known or unknown, and hereby waive any and all rights that I, he, she or it may have, from the beginning of time up to and including the time of signing this Release Agreement, in respect of my employment or separation from employment with
the Company, or is in any way connected with or related to any applicable compensatory or benefit plan, program, policy or arrangement, including, but not limited to, any claims relating to salaries, benefits, bonuses, compensation, fringe benefits,
social benefits according to any law or agreement, amounts of pension fund, overtime, severance pay, sick pay, recreation payments, vacation payments, prior notice payments, options or other securities, reimbursement of expenses and/or any other
payments or benefits due to Me by any of the Releasees, or claims under any policy, agreement, understanding or promise, written or oral, formal or informal, between the Company and any of its affiliates and myself, now or hereafter recognized,
including claims for wrongful discharge, slander and defamation, as well as all claims for counsel fees and costs; <U>provided</U> that such released claims shall not include any claims to enforce my rights under, or with respect to, any
post-termination obligations of the Company expressly undertaken by the Company under my employment agreement with the Company (including vested accrued benefits and compensation under the Company&#146;s employee benefit plans and arrangements as
set forth in Section&nbsp;7 to the Employment Agreement), rights as a shareholder of the Company and rights to indemnification and liability insurance coverage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Releasors agree not to bring any action, suit or proceeding whatsoever (including
the initiation of governmental proceedings or investigations of any type) against any of the Releasees hereto for any matter or circumstance concerning which the Releasors have released the Releasees under this Release Agreement. Further, the
Releasors agree not to encourage any other person or suggest to any other person that he, she or it institute any legal action against the Releasees, and I hereby declare, confirm and undertake that, if the Releasors or anyone else in their name
should deliver a claim as mentioned above, I shall reimburse the Releasees and anyone else on their behalf to the full extent of the sum of the legal expenses and legal fees incurred by them as a result of any such claim; and in the event that
Releasors prevail in such legal action, then the Releasees shall reimburse such sum to Me or the Releasors. The Releasors hereby agree to waive the right to any relief (monetary or otherwise) in any action, suit or proceeding I may bring in
violation of this Release Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) This Release Agreement shall constitute a dismissal and compromise notice for the purposes of
Section&nbsp;29 of the Severance Pay Law 5713-1963. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Legal Advice, Reliance.</B> I represent and acknowledge that (a)&nbsp;I have been given
adequate time to consider this Release Agreement and have been advised to discuss all aspects of this Release Agreement with my private attorney, (b)&nbsp;I have carefully read and fully understand all the provisions of this Release Agreement,
(c)&nbsp;I have voluntarily entered into this Release Agreement, without duress or coercion, and (d)&nbsp;I have not heretofore assigned or transferred or purported to assign or transfer, to any person or entity, any of the claims described in
Section&nbsp;1(a), any portion thereof or any interest therein. I understand that if I request additional time to review the terms of this Release Agreement, a reasonable extension of time shall be granted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Miscellaneous. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Violation of
Law</U>. I agree and acknowledge that this Release Agreement is not and shall not be construed to be an admission by the Company of any violation of any applicable laws of Israel, or of any duty owed by the Company to Me. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Governing Law; Severability</U>. This Release Agreement shall be governed by the laws of the State of Israel, without regard to its
conflict of laws rules. In the event that any one or more of the provisions of this Release Agreement is held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be
affected or impaired thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Counterparts</U>. This Release Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ACCEPTED AND AGREED:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEVA PHARMACEUTICAL INDUSTRIES LTD</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidentiality, Disclosure of Information and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Assignment of Inventions Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To:
Teva Pharmaceutical Industries<B> </B>Ltd. and its subsidiaries and affiliates (the &#147;<B>Company</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Proprietary Information, <FONT
STYLE="white-space:nowrap">Non-Disclosure</FONT> and Assignment of Inventions Agreement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned (&#147;<B>Executive</B>&#148;)
hereby acknowledges that he has had and will have access to, certain proprietary information, inventions, commercial secrets and other confidential information of the Company and may participate in the development, planning or marketing of the
Company&#146;s products, in connection with Executive&#146;s employment under the Employment Agreement entered into between the Company and Executive dated March&nbsp;12, 2020 (hereinafter, the &#147;<B>Employment Agreement</B>&#148;) and any other
confidentiality and/or assignment of inventions obligations and agreements by and between Executive and a company member of the Company Group. In relation to such confidential information Executive hereby undertakes as follows, in full knowledge
that the force of this undertaking is in no way dependent upon the force of the Employment Agreement, is entirely independent from said agreement, does not in any way constitute a concurrent obligation with the obligations defined in the Employment
Agreement and has been a material part of the consideration of his engagement by the Company: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Proprietary Information and <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> </U>
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive acknowledges and agrees that he has had and will have access to or be involved in the planning,
making or development of, confidential and proprietary information concerning the business and financial activities of the Company or its property, business, dealings, clients, suppliers, people or entities that come into contact with them, their
operational methods, research or manufacturing process, plans and strategies, business plans, research projects, employees, marketing plans, supplier lists, customers, data, trade secrets, test results, formulas, processes, data and <FONT
STYLE="white-space:nowrap">know-how,</FONT> improvements, inventions, patents, application for patents, copyrights, trademarks, engineering specifications, product designs, technical information discoveries, studies, techniques, specifications,
computer programs (in source and object code), databases, products (actual or planned) and information contained in computers, preservation of information methods, disks, diskettes, drawings, plans, communications, prospectuses, reports, prices,
calculations, fees, work conditions in the Company or other agreement conditions which relate to the Company and documents of the Company. All such information, whether in documentary, written, oral or digital format, and whether received by
Executive as a result of his employment with the Company or brought to his attention in any other manner, shall be deemed to be and referred to as &#147;<B>Proprietary Information</B>.&#148; For purposes of this Confidentiality, Disclosure of
Information and Assignment of Inventions Agreement, the term &#147;Company&#148; shall include all entities within the Company Group (as defined in the Employment Agreement). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;Proprietary Information&#148; shall be deemed to include any and all proprietary
information disclosed by or on behalf of the Company irrespective of form, but excluding information that (i)&nbsp;was known to Executive prior to his association with the Company and can be so proven by Executive by documentary evidence;
(ii)&nbsp;shall have appeared in any printed publication or patent of a third party or shall have become a part of the public knowledge except as a result of a breach of this Agreement by Executive; or (iii)&nbsp;shall have been received by
Executive from a third party having no obligation to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">In addition, the term &#147;Proprietary Information&#148; shall include
information regarding salaries, bonuses and benefits paid or granted to Executive by the Company under the Agreement to which this <B><U>Exhibit B</U></B> is attached. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive agrees and declares that all Proprietary Information and rights in connection therewith are, and
shall be, the sole property of the Company and its assignees. At all times, both during the term of his engagement with the Company and thereafter Executive will keep in strict confidence and trust all Proprietary Information, and Executive will not
copy, transmit, reproduce, summarize, quote, publish and/or make any commercial or other use or disclose directly or indirectly any Proprietary Information or anything relating to it without the prior written consent of the Company, except as may be
necessary in the ordinary course of performing Executive&#146;s duties in his engagement with the Company and in the best interests of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive recognizes that the Company received and will receive confidential or proprietary information from
third parties subject to a duty on the Company&#146;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. At all times, both during the term of his engagement with the Company and thereafter,
Executive undertakes to hold and maintain all such information in strict confidence, and not to use or disclose any of such information without the prior written consent of the Company, except as may be necessary to perform his duties as an
Executive of the Company and consistent with the Company&#146;s agreement with such third party. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Assignment of Inventions</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive understands that the Company has been and is engaged, involved or associated in a continuous program
of investment, research, development, production or marketing in connection with its business and that, as an essential part of his engagement with the Company, he may make new contributions to and create
<FONT STYLE="white-space:nowrap">know-how</FONT> of value for the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of his engagement, Executive undertakes and covenants that he will promptly disclose in
confidence to the Company all inventions, improvements, ideas, themes, designs, original works of authorship, formulas, concepts, techniques, forecasts, test results and documentation, discoveries, models, drawings, tooling, schematics and other
diagrams, instructional material, notes, records, algorithms, operating procedures methods, systems, processes, compositions of matter, computer software programs, databases, mask works, and trade secrets, whether or not patentable, copyrightable or
protectable as trade secrets or under any other intellectual property right, that are made or conceived or first reduced to practice or created by him, either alone or jointly with others, in the course of his engagement with the Company and due to
his engagement with the Company (&#147;<B>Inventions</B>&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive agrees and represents, that all Inventions will be the sole and exclusive property of the Company
and/or its assignees and undertakes to act with respect to such Inventions in accordance with the Company&#146;s applicable corporate policy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the extent relevant, Executive agrees to keep and maintain adequate and current written records of all
Inventions made by him (solely or jointly with others) during the term of his engagement. The records will be in the form of notes, sketches, drawings and any other format that may be specified by the Company. The records will be available to and
remain the sole property of the Company at all times and will be returned to the Company upon the termination of Executive&#146;s employment or earlier at the request of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive hereby irrevocably transfers and assigns to the Company and/or its assignees and shall in the future
take all reasonable steps (including by way of illustration only, signing all appropriate documents) to assign to Company and/or its assignees without additional consideration to Executive (other than Executive&#146;s salary and other benefits to
which he is entitled to as an employee of the Company (including without limitation, without any compensation or royalties in accordance with Sections 132 or 134 of the Patent Law of 1967 (the &#147;<B>Patent Law</B>&#148;)): (a) all worldwide
patents, patent applications, copyrights, mask works, trade secrets and other intellectual property rights, titles and interests, in any Invention, including, without limitation, service inventions under Section&nbsp;134 of the Patent Law, and
hereby further acknowledges and shall in the future acknowledge Company&#146;s full and exclusive ownership in all such Inventions; and (b)&nbsp;any and all Moral Rights (as defined below) that he may have in or with respect to any Invention.
Executive also hereby forever waives and agrees never to assert any and all Moral Rights he may have in or with respect to any Invention, even after termination of his engagement with the Company. &#147;<B>Moral Rights</B>&#148; mean any rights of
paternity or integrity, any right to claim authorship of an invention, to object to any distortion, mutilation or other modification of, or other derogatory action in relation to, any Invention, whether or not such would be prejudicial to his honor
or reputation, and any similar right, existing under judicial or statutory law of any jurisdiction whatsoever, or under any treaty, regardless of whether or not such right is denominated or generally referred to as a &#147;moral right.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive expressly waives all economic rights in the Inventions including without limitation any rights to
royalties from any intellectual property right (specifically including patent rights under Section&nbsp;134 of the Patent Law) and any right to receive any payment or other consideration whatsoever. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive agrees to assist the Company in every reasonable way to obtain and enforce, for the benefit of the
Company and/or its assignees exclusive and absolute title, right, interest, patents, copyrights, mask work rights, and other legal protections for the Inventions in any and all countries. Executive will execute any documents that may be reasonably
requested of him for use in obtaining or enforcing such patents, copyrights, mask work rights, trade secrets and other legal protections. Executive&#146;s obligations under this Section&nbsp;2.7 will survive the termination of his engagement with
the Company; <U>provided</U> that the Company will compensate him at a reasonable rate after such termination for time or expenses actually spent by him at the Company&#146;s request on such assistance. After the termination of Executive&#146;s
engagement with the Company, any assistance requested by the Company or any of its assignees pursuant to this Section&nbsp;2.7 shall take into account Executive&#146;s obligations towards third parties. Executive hereby irrevocably appoints the
Company and/or its duly authorized officers and agents (including, without limitation, the chairman of the Board) as his <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to execute documents on his
behalf for this purpose and agrees that, if the Company is unable because of Executive&#146;s unavailability, mental or physical incapacity, or for any other reason, to secure Executive&#146;s signature for the purpose of applying for or pursuing
any application for any Israeli or foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company in this Section&nbsp;2, to act for and on Executive&#146;s behalf to execute and file any such applications
and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by Executive. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive hereby acknowledge and agrees that the salary and other benefits provided to him under his Employment
Agreement constitute appropriate, full and fair consideration in connection with his employment with the Company, including, without limitation, with respect to this Agreement and including with respect to Executive&#146;s undertakings under this
Section&nbsp;2, and with respect to any Inventions created, conceived or reduced to practice or that may be created, conceived or reduced to practice by Executive, either alone or jointly with others, in the course of his employment with the
Company, all of which are assigned to the Company in accordance with this Agreement, and Executive hereby unconditionally and irrevocably waives any right that he may have to receive any additional payment or other consideration whatsoever to which
Executive may be entitled with respect to any Invention pursuant to any applicable law, in any jurisdiction, including (but not limited to) pursuant to Section&nbsp;134 of the Patent Law, or any provision that may supersede it. In the event that for
any reason such right cannot be waived, Executive hereby assigns and transfers to the Company any such right Executive may have to receive any additional payment or other consideration whatsoever with respect to any Invention pursuant to any
applicable law, including the Patent Law, in any jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive acknowledges that the Company has entered into the Employment Agreement in reliance on his
undertaking set forth in this Section&nbsp;2, and that given his access to information regarding the Company, the provisions of this Section&nbsp;2 are reasonable and necessary to protect the Company&#146;s business and rights.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any one or more of the terms contained in this Proprietary Information, Assignment of Inventions and <FONT
STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement shall for any reason be held to be excessively broad with regard to time, geographic scope or activity, the term shall be construed in a manner to enable it to be enforced to the extent
compatible with applicable law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Survivorship.</U> The provisions of Sections 1 and 2 shall survive termination or expiration of the
Employment Agreement and shall be and remain in full force and effect at all times thereafter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law</U>. This Agreement shall be governed by and construed according to the laws of the State of
Israel. Any dispute arising under or relating to this Agreement or any transactions contemplated herein shall be resolved in accordance with Section&nbsp;20.6 of the Employment Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Injunctive Relief</U>. Any breach of this Agreement may cause irreparable harm to the Company, for which
damages would not be an adequate remedy, and therefore, the Company will be entitled to injunctive relief from any court of competent jurisdiction as such court so determines, restraining any violation or further violation of this Agreement by
Executive. The Company&#146;s right to injunctive relief shall be cumulative and in addition to any other remedies provided by law or equity and without any requirement to post bond. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Executive has signed this Proprietary Information,
<FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> and Assignment of Inventions Agreement as of March&nbsp;1, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYEE</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ACCEPTED AND AGREED:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEVA PHARMACEUTICAL INDUSTRIES LTD</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>d102112dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g102112page186a.jpg" ALT="LOGO">
 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTRAT DE TRAVAIL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A DUREE INDETERMINEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>NTRE</SMALL> <SMALL>LES</SMALL> <SMALL>SOUSSIGNES</SMALL> : </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>La soci&eacute;t&eacute; TEVA SANTE, </B>soci&eacute;t&eacute; par actions simplifi&eacute;e au capital de 109.599.592 Euros dont le si&egrave;ge social est
sis 110 Esplanade du G&eacute;n&eacute;ral de Gaulle, Paris La D&eacute;fense Cedex (92931), France, immatricul&eacute;e sous le num&eacute;ro 401 972 476 au RCS de Nanterre, repr&eacute;sent&eacute;e par Sima de Cayron, agissant en sa
qualit&eacute; de Directeur des Ressources Humaines, d&ucirc;ment habilit&eacute; &agrave; cet effet, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Ci-apr&egrave;s</FONT> d&eacute;nomm&eacute;e &laquo; <B>la Soci&eacute;t&eacute; &raquo;,</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D&#146;une part, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>T</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Monsieur Eric Drap&eacute;, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">N&eacute; le Mai 30,1961
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Demeurant 4 Place de l&#146;Eglise, 92210 Saint-Cloud, France </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">de nationalit&eacute; fran&ccedil;aise </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">N&deg; de
s&eacute;curit&eacute; sociale : 1610569384234 11 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Ci-apr&egrave;s</FONT> d&eacute;nomm&eacute;e le &laquo;
<B>Salari&eacute; &raquo;,</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D&#146;autre part, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensemble d&eacute;nomm&eacute;es les &laquo; <B>Parties &raquo;.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A titre purement informatif, la convention collective applicable actuellement appliqu&eacute;e aux cadres de la Soci&eacute;t&eacute; est, sous r&eacute;serve
de modification ult&eacute;rieure, la Convention Collective Nationale de l&#146;Industrie Pharmaceutique (la &laquo; Convention Collective &raquo;).
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INDEFINITE TERM EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Translation for Information Purposes Only </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B<SMALL>ETWEEN</SMALL> <SMALL>THE</SMALL> <SMALL>UNDERSIGNED</SMALL>: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEVA SANTE, </B>a simplified joint stock company (SAS) with a share capital of 109,599,592 Euros and registered office located in 110 Esplanade du
G&eacute;n&eacute;ral de Gaulle, Paris La D&eacute;fense Cedex (92931), France, registered under the number 401 972 476 RCS Nanterre, represented by Sima de Cayron, in his capacity as HR Director, duly authorized thereto, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hereafter referred to as the <B>&#147;Company&#148;,</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of
the first part, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>ND</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Eric
Drap&eacute;, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Born on May&nbsp;30,1961 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Residing at 4
Place de l&#146;Eglise, 92210 Saint-Cloud, France </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">French national, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Social security number 1610569384234 11 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hereafter referred to
as the <B>&#147;Employee&#148;,</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the other part, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together hereafter referred to as the <B>&#147;Parties&#148;.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purely information purposes, it is reminded that the collective bargaining agreement which is currently applied to the Executives unless future
modification - is the <I>Convention Collective Nationale de l&#146;industrie pharmaceutique</I> (the &#147;CBA&#148; or the &#147;Collective Bargaining Agreement&#148;).
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Teva </B><B>Sant&#233;
</B><B>SAS</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Si&#232;ge </B><B>Social </B>: C&#156;ur D&#233;fense &#150; 110 Esplanade du G&#233;n&#233;ral de Gaulle &#150; 92931
La D&#233;fense Cedex </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">T&#232;l. 01.55.91.78.00 | Fax. 01.55.91.78.01 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Soci&#233;t&#233; par actions simplifi&#233;e au capital de 109 599 592&#128; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">RCS Nanterre 401 972 476 | APE 2120Z | TVA intracommunautaire FR 54 401 972 476 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Soci&eacute;t&eacute; remettra un exemplaire du r&egrave;glement int&eacute;rieur le cas
&eacute;ch&eacute;ant, et met &agrave; la disposition de la Salari&eacute;e la Convention Collective ainsi que les accords collectifs applicables dans l&#146;entreprise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 1 &#150; E<SMALL>NGAGEMENT</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; est engag&eacute; en qualit&eacute; de <B>Senior Vice President</B><B></B><B>&nbsp;&amp; Head of Sterile and Respiratory Operations (Europe
and Israel).</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le pr&eacute;sent contrat prend effet le 26<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Ao&ucirc;t 2013 au plus tard, sous
r&eacute;serve des r&eacute;sultats de la visite m&eacute;dicale d&#146;embauche d&eacute;cidant de l&#146;aptitude du Salari&eacute; &agrave; tenir cet emploi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le pr&eacute;sent contrat est conclu sans p&eacute;riode d&#146;essai. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; accepte cet engagement et d&eacute;clare formellement n&#146;&ecirc;tre li&eacute; &agrave; aucune autre entreprise et &ecirc;tre libre de
tout engagement en vigueur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 2 &#150; F<SMALL>ONCTION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lari&eacute; est engag&eacute; en qualit&eacute; de <B>Senior Vice President</B><B></B><B>&nbsp;&amp; Head of Sterile and Respiratory Operations (Europe et
Israel) </B>avec le statut de <B>Cadre, Groupe XI </B>de la Convention Collective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A ce titre, le Salari&eacute; aura notamment les fonctions
d&eacute;crites en Annexe A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compte tenu de la nature de ses fonctions, les attributions du Salari&eacute; sont susceptibles d&#146;&eacute;voluer.
Ainsi, le Salari&eacute; peut &eacute;galement, sur demande de la Soci&eacute;t&eacute;, se voir confier des t&acirc;ches suppl&eacute;mentaires ou compl&eacute;mentaires, conform&eacute;ment &agrave; ses fonctions et qualifications, sans que cela
ne conduise &agrave; une augmentation de la r&eacute;mun&eacute;ration pr&eacute;vue dans le contrat. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; rendra compte au Pr&eacute;sident
et CEO Teva Global Op&eacute;rations ou &agrave; toute autre personne qui pourrait leur &ecirc;tre substitu&eacute;e par la Soci&eacute;t&eacute;.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide the Employee with a copy of the internal rules and regulations, if applicable. The CBA
and collective agreements applicable to the Company will be at the Employee&#146;s disposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 1 &#150; H<SMALL>IRING</SMALL>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee is hired in the position of <B>Senior Vice President</B><B></B><B>&nbsp;&amp; Head of Sterile and Respiratory Operations (Europe and
Israel).</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The present contract shall start on 26<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> August 2013 at the latest. However, it shall
be confirmed only after the Employee&#146;s mandatory medical exam, stating that he is physically able to perform his role. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The present contract is not
subject to any probationary period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee accepts this appointment and expressly declares that he is not bound by any other agreement with any
other company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 2 &#150; P<SMALL>OSITION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee is employed as <B>Senior Vice President</B><B></B><B>&nbsp;&amp; Head of Sterile and Respiratory Operations (Europe and Israel) </B>with executive
status, <B>Group XI </B>of the Collective Bargaining Agreement currently applied by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this respect, the Employee will perform the duties
described in the attached Appendix A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the scope of his functions, the duties of the Employee may change. The Employee may be required to perform
additional or complementary tasks, according to his function and qualification, without any corresponding increase in the level of remuneration set out in the contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee reports to the President and CEO Teva Global Operations or to any other person that the Company may substitute in their place.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 3 &#150; L<SMALL>IEU</SMALL> <SMALL>DE</SMALL> <SMALL>TRAVAIL</SMALL>
<SMALL>ET</SMALL> <SMALL>MOBILIT&Eacute;</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A titre informatif, il est indiqu&eacute; que le Salari&eacute; est rattach&eacute; au si&egrave;ge
social de la Soci&eacute;t&eacute; actuellemment situ&eacute; 110 Esplanade du G&eacute;n&eacute;ral de Gaulle, Paris La D&eacute;fense Cedex (92931), France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dans le cadre de ses fonctions, le Salari&eacute; sera amen&eacute; &agrave; effectuer de fr&eacute;quents d&eacute;placements de plus ou moins longue
dur&eacute;e en Europe, notamment aux <FONT STYLE="white-space:nowrap">Pays-Bas,</FONT> au Royaume Uni, en Croatie, en Hongrie, en Irlande, et dans d&#146;autres pays, notamment en Russie, en Isra&euml;l et aux Etats Unis, ce que le Salari&eacute;
accepte express&eacute;ment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Les conditions des d&eacute;placements du Salari&eacute; se feront conform&eacute;ment &agrave; la politique des
d&eacute;placements professionnels en vigueur dans la Soci&eacute;t&eacute; au moment des d&eacute;placements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 4 &#150;
R<SMALL>EMUNERATION</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1 R&eacute;mun&eacute;ration fixe </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; per&ccedil;oit un salaire annuel brut forfaitaire de <B>420.000 euros </B>(quatre cent vingt mille euros) payable en 12
&eacute;ch&eacute;ances mensuelles &eacute;gales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compte tenu de sa qualit&eacute; de cadre dirigeant au sens de l&#146;article L. <FONT
STYLE="white-space:nowrap">3111-2</FONT> du code du travail, il est express&eacute;ment pr&eacute;cis&eacute; que cette r&eacute;mun&eacute;ration forfaitaire de base couvrira l&#146;int&eacute;gralit&eacute; du temps consacr&eacute; par le
Salari&eacute; &agrave; l&#146;exercice de sa fonction sans limitation de dur&eacute;e. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La r&eacute;mun&eacute;ration fixe sera revue pour la
premi&egrave;re fois au cours du premier trimestre 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2 R&eacute;mun&eacute;ration variable </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">En suppl&eacute;ment de son salaire fixe, le Salari&eacute; pourra percevoir une r&eacute;mun&eacute;ration variable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Les objectifs et les conditions de versement de la r&eacute;mun&eacute;ration variable sont d&eacute;finis unilat&eacute;ralement par la Soci&eacute;t&eacute;
et peuvent &ecirc;tre modifi&eacute;s &agrave; sa seule discr&eacute;tion, &eacute;tant pr&eacute;cis&eacute; que ces modifications seront port&eacute;es &agrave; la connaissance du Salari&eacute; au d&eacute;but de la p&eacute;riode ouvrant droit
&agrave; r&eacute;mun&eacute;ration variable. </P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 3 &#150; P<SMALL>LACE</SMALL> <SMALL>OF</SMALL> <SMALL>WORK</SMALL> <SMALL>AND</SMALL>
<SMALL>MOBILITY</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information purposes only, it is indicated that the Employee will be attached to the Company&#146;s registered office
currently located in 110 Esplanade du G&eacute;n&eacute;ral de Gaulle, Paris La D&eacute;fense Cedex (92931), France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within the scope of his duties, the
Employee will be required to undertake travel of variable duration in Europe, notably the Netherlands, UK, Croatia, Hungary, Ireland,&nbsp;&nbsp;&nbsp;&nbsp;, and other countries, in particular to Russia, Israel and the USA, which the Employee
expressly agrees to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Travel conditions and arrangements shall be made in accordance with the Company&#146;s policy in force at the time of the travel.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 4 &#150; R<SMALL>EMUNERATION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1 Base salary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee shall receive a yearly gross
remuneration of <B>420,000 Euros </B>(four hundred twenty thousand Euros), paid in 12 equal installments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the Employee&#146;s &#147;cadre
dirigeant&#148; status (article L. <FONT STYLE="white-space:nowrap">3111-2</FONT> French Labour Code), this basic remuneration is a lump sum compensation, set in consideration of the Employee&#146;s total working time without any limit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The base salary will be reviewed for the first time during the first quarter of 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2 Variable remuneration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to his fixed
salary, the Employee may be eligible to variable remuneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The targets and the conditions of payment of of the variable remuneration are determined
solely by the Company and may change at its sole discretion. Such amendments shall be communicated to the Employee upon the start of period giving rise to the right to variable remuneration.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sous r&eacute;serve de l&#146;atteinte des objectifs fix&eacute;s, le Salari&eacute; pourra
b&eacute;n&eacute;ficier d&#146;une r&eacute;mun&eacute;ration annuelle sur objectifs laquelle pourra atteindre 50% du salaire de base lorsque le Salari&eacute; aura atteint 100% des objectifs. Si le Salari&eacute; r&eacute;alise plus de 100% des
objectifs, le montant du bonus annuel pourra d&eacute;passer 50% du salaire de base, &agrave; la discr&eacute;tion de la Soci&eacute;t&eacute;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3
Bonus exceptionnel </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; pourra &eacute;galement percevoir un bonus exceptionnel d&#146;un montant total de 425.000 euros bruts
r&eacute;parti entre trois &eacute;ch&eacute;ances &eacute;gales d&#146;un montant de 141.667 euros bruts en d&eacute;cembre 2013, d&eacute;cembre 2014 et d&eacute;cembre 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le droit &agrave; chacune de ces sommes est soumis &agrave; une condition de pr&eacute;sence du Salari&eacute; dans la Soci&eacute;t&eacute; au moment de son
versement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 5 &#150; D<SMALL>UREE</SMALL> <SMALL>DU</SMALL> <SMALL>TRAVAIL</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compte tenu de la nature de sa fonction, de son degr&eacute; d&#146;autonomie, de l&#146;&eacute;tendue de ses responsabilit&eacute;s dont l&#146;importance
implique une grande ind&eacute;pendance dans l&#146;organisation de son emploi du temps ainsi que de son niveau de r&eacute;mun&eacute;ration se situant dans les niveaux les plus &eacute;lev&eacute;s des syst&egrave;mes de r&eacute;mun&eacute;ration
de la soci&eacute;t&eacute;, le Salari&eacute; est consid&eacute;r&eacute; comme un cadre dirigeant au sens de l&#146;article L. <FONT STYLE="white-space:nowrap">3111-2</FONT> du code du travail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">En cons&eacute;quence, la r&eacute;glementation relative &agrave; la dur&eacute;e du travail et aux temps de repos ne lui sera pas applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 6 &#150; F<SMALL>RAIS</SMALL> P<SMALL>ROFESSIONNELS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Les frais professionnels et notamment les frais de d&eacute;placements raisonnablement engag&eacute;s par le Salari&eacute; lui seront rembours&eacute;s sur
pr&eacute;sentation de justificatifs et conform&eacute;ment aux r&egrave;gles en vigueur au sein de la Soci&eacute;t&eacute;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 7
&#150; V<SMALL>EHICULE</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Soci&eacute;t&eacute; met un v&eacute;hicule &agrave; la disposition du Salari&eacute; &agrave; des fins
professionnelles, conform&eacute;ment aux usages en vigueur au sein de la Soci&eacute;t&eacute;.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the achievement of the objectives set out, the Employee may be entitled to an annual variable
remuneration of 50% of base salary at the maximum when 100% of targets are reached. Above 100% of targets reached by the Employee, the amount of the annual bonus could be higher than 50% of base salary at the Company&#146;s discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3 Exceptional bonus </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee will also be entitled
to an exceptional bonus of 425,000 Euros gross split over three equal installments of 141,667 Euros gross in December 2013, December 2014 and December 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The right to each of these sums is subject to the presence of the Employee within the Company at the time it is due to be paid. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 5 &#150; W<SMALL>ORKING</SMALL> T<SMALL>IME</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the nature of his position, his level of autonomy, the importance of his duties which implies a large independence in the organization of his work
schedule, as well as the level of his remuneration, which is one of the highest in the Company, the Employee is considered as a top executive (&#147;cadre dirigeant&#148;) according to the article <FONT STYLE="white-space:nowrap">L.3111-2</FONT> of
the French Labor Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a consequence, the Employee is not subject to working hours or mandatory <FONT STYLE="white-space:nowrap">time-off</FONT>
provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 6 &#150; P<SMALL>ROFESSIONAL</SMALL> <SMALL>EXPENSES</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reasonable professional expenses, such as travel expenses, incurred by the Employee are reimbursed upon presentation of supporting documents and according to
the procedures in force within the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 7 &#150; V<SMALL>EHICLE</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides the Employee with a car for professional use, in accordance with the Company&#146;s car policy in force.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Soci&eacute;t&eacute; se r&eacute;serve le droit d&#146;attribuer le v&eacute;hicule de son choix au
Salari&eacute;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; est autoris&eacute; &agrave; utiliser &agrave; des fins personnelles le v&eacute;hicule qui lui est confi&eacute;.
L&#146;utilisation personnelle du v&eacute;hicule constitue un avantage en nature dont il est tenu compte tant sur le plan fiscal que sur le plan social, et qui donne lieu au paiement de cotisations sociales. Cet avantage en nature figure sur le
bulletin de paie du Salari&eacute;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Les frais d&#146;entretien de la voiture sont &agrave; la charge de la Soci&eacute;t&eacute;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">En cas d&#146;accident, le Salari&eacute; doit informer dans les 48 heures la Soci&eacute;t&eacute; ainsi que la compagnie d&#146;assurance en
pr&eacute;cisant les circonstances de l&#146;accident. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cette mise &agrave; disposition du v&eacute;hicule peut &ecirc;tre remise en cause &agrave; tout
moment par la Soci&eacute;t&eacute; en fonction des n&eacute;cessit&eacute;s du service sous r&eacute;serve du respect d&#146;un pr&eacute;avis raisonnable et sans que cela ne constitue une modification du contrat. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 8 &#150; A<SMALL>VANTAGES</SMALL> <SMALL>SOCIAUX</SMALL> <SMALL>ET</SMALL> <SMALL>SITUATION</SMALL> <SMALL>AU</SMALL>
<SMALL>REGARD</SMALL> <SMALL>DE</SMALL> <SMALL>LA</SMALL> CCN <SMALL>DE</SMALL> <SMALL>RETRAITE</SMALL> <SMALL>ET</SMALL> <SMALL>DE</SMALL> <SMALL>PREVOYANCE</SMALL> <SMALL>DES</SMALL> <SMALL>CADRES</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; sera affili&eacute; aux r&eacute;gimes sociaux (retraite, mutuelle et pr&eacute;voyance) en vigueur au sein de la Soci&eacute;t&eacute; en
faveur des salari&eacute;s de sa cat&eacute;gorie. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toutes variations des taux de cotisations impos&eacute;es par les Caisses, dans le cadre de
l&#146;&eacute;volution des dispositions l&eacute;gales, r&eacute;glementaires et conventionnelles, seront d&#146;application obligatoire, le Salari&eacute; ne pouvant s&#146;y opposer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; rel&egrave;vera de l&#146;article 4 de la Convention Collective Nationale de retraite et de pr&eacute;voyance des cadres du 14 mars 1947.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reserves the right to provide the Employee with the car it may choose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee is authorized to use the car provided to his for private purpose. The personal use of the car constitutes a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">benefit-in-kind,</FONT></FONT> which generates tax issues and gives place to the payment of social security contributions. This
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">benefit-in-kind</FONT></FONT> is mentioned on the Employee&#146;s pay statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenses of servicing of the car are the responsibility of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of accident, the Employee has to inform in the 48 hours the Company as well as the insurance company by specifying the circumstances of the
accident. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This provision of the car could be called into question at any time by the Company according to the business interests, subject to the respect
of a reasonable notice. This shall not constitute a modification of the contract. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 8 &#150; S<SMALL>OCIAL</SMALL>
<SMALL>BENEFITS</SMALL> <SMALL>AND</SMALL> <SMALL>SITUATION</SMALL> <SMALL>REGARDING</SMALL> <SMALL>THE</SMALL> CBA <SMALL>FOR</SMALL> <SMALL>PENSION</SMALL> <SMALL>AND</SMALL> <SMALL>WELFARE</SMALL> <SMALL>BENEFITS</SMALL> <SMALL>FOR</SMALL>
<SMALL>EXECUTIVES</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee shall be registered with the social schemes (retirement, health and welfare scheme) entered into by the Company
in favour of employees of the same category. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All changes of rates imposed by the Social security entity, in the context of changing legal provisions,
regulations and agreements, will become mandatory, the Employee cannot oppose them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee shall benefit from Article 4 of the national collective
bargaining agreement regarding pension and welfare benefits for executives dated March&nbsp;14,1947. </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 9 &#150; C<SMALL>ONGES</SMALL> P<SMALL>AYES</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; b&eacute;n&eacute;ficiera du nombre de jours de cong&eacute;s pay&eacute;s d&eacute;termin&eacute; en application des dispositions
l&eacute;gales et conventionnelles en vigueur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Les dates des cong&eacute;s sont fix&eacute;es conform&eacute;ment aux dispositions l&eacute;gales en
tenant compte des exigences et n&eacute;cessit&eacute;s de service et souhaits du Salari&eacute;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sauf accord &eacute;crit de la Soci&eacute;t&eacute;,
aucun report de cong&eacute;s pay&eacute;s ne sera autoris&eacute; d&#146;une ann&eacute;e sur l&#146;autre. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 10 &#150;
O<SMALL>BLIGATIONS</SMALL> <SMALL>GENERALES</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; s&#146;engage &agrave; accomplir ses fonctions avec loyaut&eacute; et soin, et
&agrave; prot&eacute;ger au mieux les int&eacute;r&ecirc;ts de la Soci&eacute;t&eacute;, &agrave; tout moment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Il s&#146;engage, pendant toute la
dur&eacute;e du pr&eacute;sent contrat, &agrave; se conformer aux r&egrave;gles r&eacute;gissant le fonctionnement interne de <FONT STYLE="white-space:nowrap">celle-ci,</FONT> y compris aux r&egrave;gles &eacute;dict&eacute;es au niveau du groupe,
&agrave; condition que ces instructions et r&egrave;gles ne soient pas en opposition avec les lois applicables. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 11 &#150;
E<SMALL>XCLUSIVITE</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pendant la dur&eacute;e du Contrat, le Salari&eacute; s&#146;engage &agrave; consacrer l&#146;int&eacute;gralit&eacute; de
son activit&eacute; professionnelle &agrave; l&#146;ex&eacute;cution de ses fonctions au sein de la Soci&eacute;t&eacute;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus
pr&eacute;cis&eacute;ment, le Salari&eacute; s&#146;interdit, pour son propre compte ou pour le compte d&#146;une autre personne physique ou morale, &agrave; quelque titre que ce soit (notamment, sans, que cette liste soit limitative, en tant
qu&#146;administrateur, g&eacute;rant, salari&eacute;, consultant, actionnaire ou associ&eacute;), d&#146;&ecirc;tre directement ou indirectement engag&eacute;, concern&eacute; ou int&eacute;ress&eacute; dans aucun autre commerce, industrie,
activit&eacute; professionnelle ou emploi quel qu&#146;il soit sans l&#146;autorisation pr&eacute;alable expresse &eacute;crite de la Soci&eacute;t&eacute;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">De m&ecirc;me, le Salari&eacute; s&#146;interdit de s&#146;int&eacute;resser directement ou indirectement, de quelque mani&egrave;re que ce soit, &agrave;
toute soci&eacute;t&eacute; ou entreprise ayant une activit&eacute; concurrente ou compl&eacute;mentaire &agrave; celle de la Soci&eacute;t&eacute;, et ce pendant toute la dur&eacute;e de son contrat de travail.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 9 &#150; P<SMALL>AID</SMALL> H<SMALL>OLIDAY</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee shall be entitled to the number of days holiday provided by French law and the provisions of the applicable collective bargaining agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The period of leave is determined in accordance with statutory provisions, taking into account both the Employee&#146;s obligation to ensure the effective
performance of his duties and wishes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for with the written consent of the Company, the Employee&#146;s holiday entitlement shall not be carried
forward from one year to the next. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 10 &#150; G<SMALL>ENERAL</SMALL> <SMALL>OBLIGATIONS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee undertakes to carry out employment duties with loyalty and care, and to protect the Company&#146;s interests, as best as possible, at any and all
times. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee undertakes, during the term of this contract, to comply with the internal rules of the Company, including the rules implemented at
the group level, provided that these instructions and rules do not conflict with the applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 11 &#150;
E<SMALL>XCLUSIVITY</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the duration of the Contract, the Employee shall devote all of the Employee&#146;s working time to the performance of
employment duties within the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More specifically, the Employee undertakes that he will not, either individually, or on behalf of any other
individual or corporate entity, in any capacity whatsoever (particularly, but without limitation, as director, manager, employee, consultant, shareholder or partner) become directly or indirectly involved, concerned or interested in any other
business, industry, professional activity or employment of any kind without the prior written consent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee also agrees not to
have any direct or indirect interest, in whatever way, in any company or firm whose activity is in competition or complementary to the Company&#146;s activity, while he is employed by the Company.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 12 &#150; D<SMALL>ISCRETION</SMALL>
<SMALL>ET</SMALL>&nbsp;<SMALL>CONFIDENTIALITE</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sous r&eacute;serve de ce qui sera strictement n&eacute;cessaire pour les besoins des missions
qui lui sont confi&eacute;es au sein de la Soci&eacute;t&eacute;, le Salari&eacute; s&#146;engage &agrave; ne pas divulguer, communiquer, ni utiliser directement ou indirectement les informations confidentielles de toute nature dont il aura eu
connaissance dans le cadre ou &agrave; l&#146;occasion de ses fonctions concernant les affaires et activit&eacute;s de la Soci&eacute;t&eacute;, de leurs actionnaires, clients, fournisseurs, salari&eacute;s ou mandataires sociaux, et ce aussi bien
pendant la dur&eacute;e du pr&eacute;sent contrat qu&#146;apr&egrave;s la rupture de <FONT STYLE="white-space:nowrap">celui-ci,</FONT> sans limitation de dur&eacute;e. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On entend par information confidentielle, sans que cette liste soit limitative, inventions, savoir-faire, secrets commerciaux, cahiers de laboratoire,
mat&eacute;riaux biologiques, dessins et concepts (d&#146;ing&eacute;nierie), listes de prix, donn&eacute;es financi&egrave;res, budgets, clients, ventes aux clients, propositions des clients, pr&eacute;visions des ventes, m&eacute;thodes
op&eacute;rationnelles, vendeurs, fournisseurs, sous-traitants et partenaires (ainsi que leurs conditions de vente), acheteurs, toute proposition li&eacute;e &agrave; l&#146;acquisition ou &agrave; la vente de toute soci&eacute;t&eacute; ou
entreprise g&eacute;r&eacute;e par Teva, toute proposition li&eacute;e &agrave; l&#146;expansion ou &agrave; la r&eacute;duction des activit&eacute;s (affaires-, recherche et d&eacute;veloppement-, construction-,technique-,ventes-et production-),
projets et processus, appareils, concepts, compositions, formules, d&eacute;veloppements, recherches, techniques, am&eacute;liorations, proc&eacute;dures, id&eacute;es, mat&eacute;riel informatique, logiciels, m&eacute;thodes de comptabilit&eacute;,
approches commerciales, projets marketing, informations sur le personnel et l&#146;emploi (y compris les d&eacute;tails sur les salari&eacute;s et les directeurs, le niveau de r&eacute;mun&eacute;ration et les avantages qui leur sont
attribu&eacute;s) ; obtenus, d&eacute;velopp&eacute;s, modifi&eacute;s, utilis&eacute;s, g&eacute;n&eacute;r&eacute;s et/ou employ&eacute;s par ou pour le compte de Teva. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toute violation de la pr&eacute;sente clause rendra le Salari&eacute; automatiquement redevable d&#146;une p&eacute;nalit&eacute; fixe &eacute;gale aux
salaires bruts per&ccedil;us effectivement pendant les <B>six (6)</B><B></B><B>&nbsp;mois </B>pr&eacute;c&eacute;dant le d&eacute;part de la personne sollicit&eacute;e, sans que cela ne porte pr&eacute;judice aux droits que se r&eacute;serve la
Soci&eacute;t&eacute; de poursuivre le Salari&eacute; en r&eacute;paration du pr&eacute;judice mat&eacute;riel et moral.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 12 &#150; D<SMALL>ISCRETION</SMALL>
<SMALL>AND</SMALL>&nbsp;<SMALL>CONFIDENTIALITY</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless strictly necessary to the carrying out of the Employee&#146;s duties assigned within the
Company, the Employee undertakes not to communicate, disclose or use directly or indirectly confidential information of any kind which he would have gained in the course of, or due to, his position relating to the businesses or activities of the
Company; of their shareholders, clients, retailers, employees, corporate officers, and so during the execution and upon the termination of the contract, under the conditions defined below, unless he is obliged to do so by the law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of this clause, confidential information includes, but will not be limited to, any inventions,
<FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, laboratory notebooks, biological materials, (engineering) designs and drawings, price lists, pricing methodologies, pricing policies, licenses, contract information, financial
forecasts, financial data, budgets, customers, customer sales, customer proposals, sale forecasts, methods of operation, vendors, suppliers&nbsp;&amp; contractors&nbsp;&amp; Partners (and their terms of business), purchasers, any proposals relating
to the acquisition or disposal of any company owned or business operated by Teva, any proposals relating to the expansion or contracting of activities, (business-research&nbsp;&amp; development-, construction-, technical-, sales-and production-)
plans&nbsp;&amp; processes, apparatus, designs, compositions, formula, developments, research, techniques, improvements, procedures, ideas, computer hardware, computer software, methods of accounting, manners of doing business, marketing plans,
personnel and employment matters (including details of employees and directors, the level of remuneration and benefits paid to them); all as acquired, developed, amended, used, generated and/or utilised by or on behalf of Teva. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that this clause is breached the Employee will automatically be liable to the payment of a fixed penalty equal to the gross salary received for
the <B>six (6)</B><B></B><B>&nbsp;months </B>preceding the departure of the solicited person, without prejudice to the Company&#146;s right to file an action against the Employee to obtain full remedy of the prejudice suffered.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 13 &#150; P<SMALL>ROPRIETE</SMALL> <SMALL>INTELLECTUELLE</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">L Salari&eacute; devra informer sans d&eacute;lai la Soci&eacute;t&eacute; de toute id&eacute;e ou invention qu&#146;il aurait pu cr&eacute;er ou
d&eacute;velopper et qui pourrait &ecirc;tre effectivement ou potentiellement int&eacute;ressante pour l&#146;activit&eacute; de la Soci&eacute;t&eacute;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sous r&eacute;serve des droits d&eacute;tenus et qui seront d&eacute;velopp&eacute;s par les partenaires de la Soci&eacute;t&eacute;, le Salari&eacute;
reconna&icirc;t que toute marque, dessins, droits, brevets, bases de donn&eacute;es ou tout autre &eacute;l&eacute;ment de propri&eacute;t&eacute; intellectuelle, qu&#146;ils soient existants ou futurs, qui pourraient &ecirc;tre cr&eacute;es pendant
l&#146;ex&eacute;cution normale du contrat de travail ou en utilisant les outils, &eacute;quipement ou savoir-faire mis &agrave; la disposition du Salari&eacute; pendant la relation contractuelle, demeureront la propri&eacute;t&eacute; exclusive de
la Soci&eacute;t&eacute; ou de toute autre entit&eacute; qu&#146;elle d&eacute;signera &agrave; cet effet, et si cela lui &eacute;tait demand&eacute; (soit pendant l&#146;ex&eacute;cution du contrat de travail, soit apr&egrave;s) il effectuera
toutes les formalit&eacute;s n&eacute;cessaires afin de transf&eacute;rer les droits susmentionn&eacute;s aupr&egrave;s de la Soci&eacute;t&eacute; qui en serait le propri&eacute;taire et utilisateur unique. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 14 &#150; M<SMALL>ATERIELS</SMALL> <SMALL>ET</SMALL> D<SMALL>OCUMENTS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tous documents, biens, mat&eacute;riels et supports d&#146;information de toute nature que la Soci&eacute;t&eacute; conf&iacute;e au Salari&eacute; demeurent
la propri&eacute;t&eacute; exclusive de la Soci&eacute;t&eacute;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Soci&eacute;t&eacute; met notamment &agrave; la disposition du Salari&eacute; un
ordinateur portable et un t&eacute;l&eacute;phone portable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; s&#146;interdit d&#146;en faire un usage autre que professionnel ainsi que
d&#146;en faire des copies sur tout support de quelque nature que ce soit pour son usage personnel, sauf autorisation expresse et pr&eacute;alable de la Soci&eacute;t&eacute;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; s&#146;engage &agrave; restituer &agrave; tout moment &agrave; la demande de la Soci&eacute;t&eacute; ou lors de la rupture du Contrat, les
&eacute;l&eacute;ments susvis&eacute;s, et plus g&eacute;n&eacute;ralement tout &eacute;crit ou tout enregistrement r&eacute;alis&eacute; par lui sur tout support de quelque nature que ce soit relatifs &agrave; l&#146;activit&eacute; de la
Soci&eacute;t&eacute; ou dont il aurait eu connaissance dans le cadre de l&#146;ex&eacute;cution du Contrat et qui proviendrait de la Soci&eacute;t&eacute;. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 13 &#150; I<SMALL>NTELLECTUAL</SMALL> <SMALL>PROPERTY</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee shall promptly disclose to the Company any idea or invention created or developed by him which is actually or potentially relevant to the business
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights held and developed by the Company&#146;s partners, the Employee acknowledges that all trade marks, registered
designs, design rights, copyright, database rights and all other intellectual property rights, whether in existence now or coming into existence at any time in the future, will, on creation either during the normal course of employment or by using
materials, tools or knowledge made available through his employment, vest in and be the exclusive property of the Company which the Company shall nominate and if required to do so (whether during or after the termination of his employment), he will
execute all instruments and do all things necessary to vest ownership in the above rights in the Company as sole beneficial owner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 14 &#150; M<SMALL>ATERIAL</SMALL> <SMALL>AND</SMALL> D<SMALL>OCUMENTS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All documents, goods, materials and equipment of any kind provided by the Company to the Employee remain the property of the Company and must be returned upon
request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company notably provides the Employee with a laptop and mobile phone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee agrees not to make use of such items for any purpose other than that of the business and not to make copies of any description for personal use
without the prior express authorisation of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee undertakes at any time, upon request by the Company or upon termination of the
Contract, to return to the Company any of the above mentioned items and, more generally, any written document or recording by him of any nature relating to the business of the Company, or of which he would have had knowledge of during the course of
the Contract and whose author would be the Company. </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 15 &#150; L<SMALL>OYAUTE</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Il est rappel&eacute; aux Parties que les relations contractuelles sont bas&eacute;es sur une confiance r&eacute;ciproque. La confiance par essence implique la
bonne foi, laquelle s&#146;exprime au travers de la loyaut&eacute;. A ce titre, les Parties sont tenues l&#146;une envers l&#146;autre par cette obligation de loyaut&eacute;, qui perdure <FONT STYLE="white-space:nowrap">au-del&agrave;</FONT> de la
rupture du contrat de travail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 16 &#150;
N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-</FONT><SMALL>SOLLICITATION</SMALL> <SMALL>DES</SMALL> <SMALL>SALARIES</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pendant toute la
dur&eacute;e du contrat et pendant <B>six (6)</B><B></B><B>&nbsp;mois </B>&agrave; l&#146;issue du d&eacute;part effectif du Salari&eacute;, ce dernier devra s&#146;abstenir d&#146;embaucher ou de solliciter - directement ou indirectement -
d&#146;encourager ou de faciliter le d&eacute;bauchage de tout salari&eacute; de la Soci&eacute;t&eacute; pour son propre compte ou pour le compte de son nouvel employeur ou de toute autre soci&eacute;t&eacute;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toute violation de la pr&eacute;sente clause rendra le Salari&eacute; automatiquement redevable d&#146;une p&eacute;nalit&eacute; fixe &eacute;gale aux
salaires bruts per&ccedil;us effectivement pendant les <B>six (6)</B><B></B><B>&nbsp;mois </B>pr&eacute;c&eacute;dant le d&eacute;part de la personne sollicit&eacute;e, sans que cela ne porte pr&eacute;judice aux droits que se r&eacute;serve la
Soci&eacute;t&eacute; de poursuivre le Salari&eacute; en r&eacute;paration du pr&eacute;judice mat&eacute;riel et moral. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 17
&#150; C<SMALL>LAUSE</SMALL> <SMALL>DE</SMALL> N<SMALL>ON</SMALL>-<SMALL>CONCURRENCE</SMALL> E<SMALL>T</SMALL> <SMALL>DE</SMALL> <SMALL>NON</SMALL><FONT STYLE="white-space:nowrap">-</FONT><SMALL>SOLLICITATION</SMALL>
<SMALL>DE</SMALL>&nbsp;<SMALL>CLIENTELE</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compte tenu du caract&egrave;re extr&ecirc;ment sensible du savoir-faire et des informations
techniques et commerciales auxquels le Salari&eacute; a acc&egrave;s dans l&#146;exercice de ses fonctions, de la nature particuli&egrave;rement concurrentielle des activit&eacute;s de la Soci&eacute;t&eacute;, des fonctions du Salari&eacute; ainsi
que des responsabilit&eacute;s qui lui sont confi&eacute;es, les Parties conviennent d&#146;une obligation de <FONT STYLE="white-space:nowrap">non-concurrence</FONT> et de <FONT STYLE="white-space:nowrap">non-sollicitation</FONT> de client&egrave;le
qui a vocation &agrave; prendre effet &agrave; l&#146;issue de la relation de travail, <FONT STYLE="white-space:nowrap">c&#146;est-&agrave;-dire</FONT> &agrave; la date du d&eacute;part effectif du Salari&eacute;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pass&eacute;e la pr&eacute;sente relation contractuelle de travail, les Parties conviennent, dans le seul but de prot&eacute;ger les int&eacute;r&ecirc;ts
l&eacute;gitimes de la Soci&eacute;t&eacute;, que le Salari&eacute; s&#146;interdit d&#146;exercer, directement ou indirectement, une activit&eacute; concurrente &agrave; celle de la Soci&eacute;t&eacute; et plus particuli&egrave;rement toute
activit&eacute; dans le secteur de la fabrication, du d&eacute;veloppement, du marketing, de la promotion et de la commercialisation de tous produits et dispositifs pharmaceutiques, m&eacute;dicaux et v&eacute;t&eacute;rinaires.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 15 &#150; L<SMALL>OYALTY</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties are aware that contractual relationships are based on mutual trust. Trust includes by nature good faith, which is expressed by loyalty. The parties
have to respect this loyalty obligation which continues to exist even after the termination of the employment contract. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 16
&#150; N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-</FONT><SMALL>SOLICITATION</SMALL> <SMALL>OF</SMALL>&nbsp;<SMALL>EMPLOYEES</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During
the whole duration of the contract and for <B>six (6)</B><B></B><B>&nbsp;months </B>after effective departure of the Employee, the Employee shall not hire or solicit - directly or indirectly - encourage or facilitate the poaching of any employee of
the Company on his behalf or on the behalf of his new employer or any other company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that this clause is breached, the Employee will
automatically be liable to the payment of a fixed penalty equal to the gross salary received for the <B>six (6)</B><B></B><B>&nbsp;months </B>preceding the departure of the solicited person, without prejudice to the Company&#146;s right to file an
action against the Employee to obtain full remedy of the prejudice suffered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 17 &#150; N<SMALL>ON</SMALL><FONT
STYLE="white-space:nowrap">-</FONT><SMALL>COMPETE</SMALL> <SMALL>AND</SMALL> <SMALL>NON</SMALL>-<SMALL>POACHING</SMALL> <SMALL>OF</SMALL> <SMALL>CLIENTS</SMALL> C<SMALL>LAUSE</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Considering the extreme sensitiveness of the <FONT STYLE="white-space:nowrap">know-how</FONT> and technical and commercial information to which the Employee
has access in the framework of his functions, the extremely competitive nature of the activities of the Company, the functions and responsibilities of the Employee, the Parties agree that a non-competition obligation and a <FONT
STYLE="white-space:nowrap">non-poaching</FONT> obligation regarding clients will take effect at the end of the employment relationship, i.e. on the date of the effective departure of the Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After this employment contract has terminated, in order to protect the legitimate interests of the Company, the Parties agree that the Employee undertakes not
to directly or indirectly carry out any activity that would compete with that of the Company and, in particular, any activity which is related to manufacturing, development, marketing, promoting and distributing of any pharmaceutical, medical and
veterinary products and devices. </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; s&#146;engage &agrave; s&#146;abstenir de solliciter, de d&eacute;marcher les clients de la
Soci&eacute;t&eacute;, de les d&eacute;tourner ou tenter de les d&eacute;tourner, ni directement ni indirectement, &agrave; son profit ou &agrave; celui d&#146;un tiers, et de leur apporter son concours sous quelque forme que ce soit, pour son
propre compte ou pour le compte d&#146;un tiers, ni directement, ni indirectement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Par client de la Soci&eacute;t&eacute;, la pr&eacute;sente clause vise
toute personne physique ou morale en contact avec la Soci&eacute;t&eacute; ou pour lesquelles le Salari&eacute; a &eacute;t&eacute; amen&eacute; &agrave; travailler &agrave; titre permanent ou occasionnel dans le cadre de ses fonctions en France et
en Europe au sein de la Soci&eacute;t&eacute;. La qualit&eacute; de client est &eacute;tendue aux filiales et sous-filiales des personnes morales directement clientes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cette interdiction est limit&eacute;e &agrave; une dur&eacute;e de <B>six (6)</B><B></B><B>&nbsp;mois </B>&agrave; compter de la date du d&eacute;part
effectif du Salari&eacute;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cette interdiction porte sur le territoire suivant : <B>France, <FONT STYLE="white-space:nowrap">Pays-Bas,</FONT> <FONT
STYLE="white-space:nowrap">Royaume-Uni,</FONT> l&#146;Irlande, la Croatie, la Hongrie, et l&#146;Allemagne</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le Salari&eacute; reconna&icirc;t que les
conditions d&#146;application de l&#146;obligation de non concurrence telles qu&#146;elles sont expos&eacute;es <FONT STYLE="white-space:nowrap">ci-</FONT> dessus ne l&#146;emp&ecirc;chent pas d&#146;exercer une activit&eacute; conforme &agrave; son
exp&eacute;rience et &agrave; sa formation et ne portent pas atteinte &agrave; sa libert&eacute; de travail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">En cas d&#146;application de la clause de <FONT
STYLE="white-space:nowrap">non-</FONT> concurrence, il sera vers&eacute; au Salari&eacute; pendant toute la dur&eacute;e d&#146;application de la clause, une indemnit&eacute; mensuelle d&#146;un montant brut correspondant &agrave; <B>50%</B> de la
r&eacute;mun&eacute;ration moyenne mensuelle brute de base per&ccedil;ue au titre des douze derniers mois de pr&eacute;sence du Salari&eacute; au sein de la Soci&eacute;t&eacute;.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee undertakes to refrain from solliciting, approaching the clients of the Company, poaching or
tempting to poach clients, either directly or indirectly - either individually or on behalf of any third party, and from bring them his support in any way, on his behalf or behalf of any third party, either directly or indirectly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Client of the Company mentioned in the present clause refers to any individual or corporate entity in contact with the Company or for which the Employee has
worked permanently or occasionally in relation to his functions in France and in Europe within the Company. Client also refers to subsidiaries and subsubsidiaries of corporate entities which are direct clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prohibition on competition will remain binding for a period of <B>six (6)</B><B></B><B>&nbsp;months, </B>starting on the date of effective departure of
the Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prohibition applies to the following territories: <B>France, Netherlands, UK, Ireland, Croatia, Hungary, and Germany</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Employee acknowledges that the conditions in which the above <FONT STYLE="white-space:nowrap">non-compete</FONT> provision applies will not prevent him
from carrying out an activity that corresponds to his training and experience, and will not impact his freedom to work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the <FONT
STYLE="white-space:nowrap">non-competition</FONT> clause is implemented, the Employee will receive a gross monthly indemnity for a gross amount which corresponds to <B>50%</B> of the average monthly gross base salary paid to the Employee for the 12
last months of presence of the Employee within the Company. </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La pr&eacute;sente clause de <FONT STYLE="white-space:nowrap">non-concurrence</FONT> pourra &ecirc;tre
lev&eacute;e dans le cadre de la rupture du contrat de travail, que <FONT STYLE="white-space:nowrap">celle-ci</FONT> soit &agrave; l&#146;initiative de la Soci&eacute;t&eacute; ou du Salari&eacute;, conform&eacute;ment aux dispositions de la
Convention Collective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toute violation des dispositions de la pr&eacute;sente clause lib&egrave;re la Soci&eacute;t&eacute; du versement de
l&#146;indemnit&eacute; de <FONT STYLE="white-space:nowrap">non-concurrence</FONT> et rend le Salari&eacute; redevable des sommes re&ccedil;ues &agrave; ce titre ainsi que des cotisations sociales acquitt&eacute;es par la Soci&eacute;t&eacute; et
qui ne lui seraient pas rembours&eacute;es. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Par ailleurs, en cas de violation de cette interdiction, le Salari&eacute; s&#146;expose au paiement, par
manquement constat&eacute;, d&#146;une indemnit&eacute; forfaitaire &eacute;gale &agrave; la r&eacute;mun&eacute;ration de ses <B>six (6)</B><B></B><B>&nbsp;derniers mois </B>d&#146;activit&eacute; sans pr&eacute;judice du droit pour la
Soci&eacute;t&eacute; de faire cesser ladite violation par tout moyen et de demander r&eacute;paration de l&#146;entier pr&eacute;judice subi. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 18 &#150; P<SMALL>REAVIS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chacune des Parties pourra rompre le pr&eacute;sent contrat de travail en respectant une p&eacute;riode de pr&eacute;avis de <B>12 mois.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cependant, cette p&eacute;riode de pr&eacute;avis ne sera pas due en cas de licenciement pour faute grave ou lourde du Salari&eacute;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 19 &#150; P<SMALL>ROTECTION</SMALL> <SMALL>DES</SMALL> <SMALL>DONNEES</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La Soci&eacute;t&eacute; traite les donn&eacute;es personnelles du Salari&eacute; pour les finalit&eacute;s li&eacute;es &agrave; l&#146;ex&eacute;cution de
son contrat de travail et le fonctionnement de la Soci&eacute;t&eacute;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conform&eacute;ment &agrave; la l&eacute;gislation fran&ccedil;aise en vigueur,
le Salari&eacute; pourra exercer son droit d&#146;acc&egrave;s et de rectification de ses donn&eacute;es personnelles collect&eacute;es par la Soci&eacute;t&eacute;, en application des dispositions de la loi n&deg;
<FONT STYLE="white-space:nowrap">78-17</FONT> du 6 janvier 1978 modifi&eacute;e. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 20 &#150; D<SMALL>ROIT</SMALL>
<SMALL>APPLICABLE</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le contrat est soumis au Droit fran&ccedil;ais. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Si l&#146;une des dispositions du contrat devait &ecirc;tre d&eacute;clar&eacute;e invalide, la validit&eacute; des autres clauses ne serait pas pour autant
affect&eacute;e </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fait &agrave; Paris </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Le 30 Mai 2013
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It will be possible to renounce to the present clause upon termination of the contract, either at the
Company&#146;s initiative or at the Employee&#146;s, in compliance with the provisions of the CBA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that this clause is breached, the Company
will be released from paying the non-compete indemnity and the Employee will be liable for any sums paid in this respect and which have not been reimbursed. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the Employee will be liable for the payment, in the case of each breach, of an <FONT STYLE="white-space:nowrap">all-inclusive</FONT> contractual
indemnity equal to the remuneration of his last <B>six (6)</B><B></B><B>&nbsp;months </B>of activity, without prejudice to the Company&#146;s right to obtain the cessation of the breach by all available means, and to fully remedy any loss suffered.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 18 &#150; N<SMALL>OTICE</SMALL> P<SMALL>ERIOD</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each party shall have the right to terminate this employment contract by giving a <B><FONT STYLE="white-space:nowrap">12-month</FONT> </B>notice period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, this notice period will not be due in case of dismissal for gross or serious misconduct. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 19 &#150; D<SMALL>ATA</SMALL> <SMALL>PROTECTION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall process personal data relating to the Employee for the purpose of performance of this contract and the business of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In line with French legislation currently in force, the Employee may exercise all rights to access and modify his personal data held by the Company in
compliance with the law n&deg; <FONT STYLE="white-space:nowrap">78-17</FONT> of January&nbsp;6, 1978, as modified. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>RTICLE</SMALL> 20 &#150;
G<SMALL>OVERNING</SMALL> <SMALL>LAW</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contract is governed by French Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any provision of the contract become invalid, the validity of the other provisions shall not be affected thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signed in Paris </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May 30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>, 2013 </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fait &aacute; Paris,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">le 30 Mai 2013</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">En deux (2)&nbsp;exemplaires originaux</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">dont un pour chaque
partie</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signed in Paris,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May 30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>, 2013</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In two (2)&nbsp;originals, one for each party</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Le Salari&eacute;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Monsieur Eric Drap&eacute;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Employee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Mr Eric Drap&eacute;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&laquo;Bon pour accord&raquo;</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>/s/
</B>Eric Drap&eacute;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&laquo; Read and Approved &raquo;</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>/s/
</B>Eric Drap&eacute;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEVA SANTE (*)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Repr&eacute;sent&eacute;e par Sima de Cayron, agissant en sa qualit&eacute; de Directeur des Ressources Humaines</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TEVA SANTE (*)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Represented by Sima de Cayron, in his capacity as HR Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&laquo;Bon pour accord&raquo;</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>/s/
Sima de Cayron</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<I>Read and Approved</I>&#148;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Sima
de Cayron</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><I>(*)&#8194;&#8201;&#8202;Parapher le bas de chaque page et, sur la derni&egrave;re page, faire
pr&eacute;c&eacute;der la siganture de la mention manuscrite &laquo;Bon pour accord&raquo;</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><I>(*)&#8194;&#8201;&#8202;Initial the bottom of each page and, on the last page, write by hand
&#147;Read and Approved&#148; before the signature</I></P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>4
<FILENAME>d102112dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g102112g0203043727908.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVENTION DE TRANSFERT DU</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTRAT DE TRAVAIL</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">(Ci-apr&egrave;s</FONT> la &#147;<B>Convention</B>&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSFER AGREEMENT OF THE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT CONTRACT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Hereinafter the &#147;<B>Agreement</B>&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ENTRE LES SOUSIGNEES :</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>BETWEEN THE UNDERSIGNED:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">La soci&eacute;t&eacute; <B>TEVA SANTE</B>, soci&eacute;t&eacute; par actions simplifi&eacute;e dont le si&egrave;ge social est sis 110
Esplanade du General de Gaulle, Paris La D&eacute;fense Cedex (92931), France, immatricul&eacute;e sous le num&eacute;ro 401 972 476 au RCS de Nanterre,</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Repr&eacute;sent&eacute;e par Karima ZERHOUNI agissant en sa qualit&eacute; de Directeur des Ressources Humaines, d&ucirc;ment habilit&eacute; aux fins des
pr&eacute;sentes.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company <B>TEVA SANTE</B>, a simplified joint stock company (SAS) and registered office located 110 Esplanade du General de Gaulle, Paris
La D&eacute;fense Cedex (92931), France, registered with the Nanterre register of companies under number 401 972 476,</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Represented by Karima ZERHOUNI as Human Resources Director, duly appointed for the purpose hereof.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Ci-apr&egrave;s</FONT> d&eacute;nomm&eacute;e &#147;<B>TEVA</B><B></B><B>&nbsp;SANTE</B>&#148;;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hereinafter referred to as &#147;<B>TEVA SANTE</B>&#148;;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ET</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">La soci&eacute;t&eacute; <B>TEVA PHARMACEUTICAL INDUSTRIES LTD</B>, soci&eacute;t&eacute; de droit Isra&eacute;lien, dont le si&egrave;ge social est 5 Basel
Street, Petach Tikwa, Israel, soci&eacute;t&eacute; enregistr&eacute;e sous le num&eacute;ro <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">52-001395-4,</FONT></FONT> repr&eacute;sent&eacute;e par Mark Sabag et Ephie
Nissenfeld.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AND</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The company <B>TEVA PHARMACEUTICAL INDUSTRIES LTD</B>, with registered address located at 5 Basel Street, Petach Tikwa, Israel, Company <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">No.&nbsp;52-001395-4,</FONT></FONT> represented by Mark Sabag and Ephie Nissenfeld.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Ci-apr&egrave;s</FONT> d&eacute;nomm&eacute;e &#147;<B>TEVA PHARMACEUTICAL</B>&#148;;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hereinafter referred to as &#147;<B>TEVA PHARMACEUTICAL</B>&#148;;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ET</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Monsieur <B>Eric Drap&eacute;</B>, n&eacute; le 30 mai 1961 &agrave; Lyon (France), demeurant 4 Place de l&#146;Eglise &agrave; Saint-Cloud (92210)&nbsp;en
France, de nationalit&eacute; fran&ccedil;aise. N&deg; de s&eacute;curit&eacute; sociale : 1610569384234 11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AND</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mr.<B>&nbsp;Eric Drap&eacute;</B>, born on 30&nbsp;May 1961 in Lyon (France), residing at 4 Place de l&#146;Eglise, Saint-Cloud (92210)&nbsp;in France, French
national. Social security number: 1610569384234 11</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Ci-apr&egrave;s</FONT> d&eacute;nomm&eacute; &#147;<B>Monsieur Drap&eacute;</B>&#148; ou le &#147;<B>Salari&eacute;</B>&#148;;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hereinafter referred to as Mr.&nbsp;&#148;<B>Drap&eacute;</B>&#148; or the &#147;<B>Employee</B>&#148;;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Ci-apr&egrave;s</FONT> d&eacute;sign&eacute;es collectivement les &#147;<B>Parties</B>&#148; et individuellement une &#147;<B>Partie</B>&#148;.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hereinafter collectively referred as to the &#147;<B>Parties</B>&#148; and individually one &#147;<B>Party</B>&#148;.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>IL EST PREALABLEMENT RAPPELE CE QUI SUIT:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>THE FOLLOWING PROVISIONS ARE HEREBY REMINDED :</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Le Salari&eacute; a &eacute;t&eacute; embauch&eacute; &agrave; compter du 26 ao&ucirc;t 2013 par contrat &agrave; dur&eacute;e ind&eacute;termin&eacute;e conclu le 30 mai 2013, en qualit&eacute; de &#147;<I>Senior Vice
President</I><I></I><I>&nbsp;&amp; Head of Sterile and Respiratory Operations (Europe and Israel)</I>&#148; (le &#147;<B>Contrat de travail</B>&#148;).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Employee has been hired as from 26&nbsp;August 2013 under an indefinite term employment contract concluded on 30&nbsp;May&nbsp;2013, as <I>&#147;Senior Vice President</I><I></I><I>&nbsp;&amp; Head of Sterile and Respiratory
Operations (Europe and Israel)&#148;</I> (the &#147;<B>Employment contract</B>&#148;).</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g102112g0203043727908.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Il a &eacute;t&eacute; propos&eacute; au Salari&eacute; d&#146;occuper le poste de <I>Executive Vice President &#150; Global Operations</I> au sein de TEVA PHARMACEUTICAL. Le Salari&eacute; s&#146;est ainsi vu proposer un transfert
volontaire de son Contrat de travail &agrave; TEVA PHARMACEUTICAL.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Employee has been offered to hold the position of Executive Vice President &#150; Global Operations within TEVA PHARMACEUTICAL. A voluntary transfer of his Employment contract within TEVA PHARMACEUTICAL has therefore been
offered to the Employee.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">La pr&eacute;sente Convention emporte ainsi novation du Contrat de travail et fixe les termes et conditions de la poursuite du Contrat de travail au sein de TEVA PHARMACEUTICAL et, par suite, la disparition des relations
contractuelles entre TEVA SANTE et le Salari&eacute;.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">This Agreement thus entails the novation of the Employment contract and lays down the terms and conditions for the continuation of the Employment contract with TEVA PHARMACEUTICAL and, consequently, the termination of any
contractual relationship between TEVA SANTE and the Employee.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">C&#146;est dans ce contexte qu&#146;intervient la signature de la pr&eacute;sente Convention tripartite de transfert.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The signing of this tripartite transfer Agreement is made in this context.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Le Contrat de travail transf&eacute;r&eacute; est annex&eacute; &agrave; la pr&eacute;sente Convention.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The transferred Employment contract is attached to this Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>IL A ETE CONVENU CE QUI SUIT :</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>THE FOLLOWING PROVISIONS ARE HEREBY AGREED UPON:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Article 1&nbsp;: Cessation des relations contractuelles entre TEVA SANTE et le Salari&eacute;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Article 1 : Ending of the contractual relationships between TEVA SANTE and the Employee</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TEVA SANTE et le Salari&eacute; sont convenus de la fin des relations contractuelles les unissant.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TEVA SANTE and the Employee agreed on the ending of any contractual relationship between them.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">En cons&eacute;quence, le Salari&eacute; cessera d&eacute;finitivement de faire partie des effectifs de TEVA SANTE, &agrave; compter du 1 Mars 2020 <FONT STYLE="white-space:nowrap">(ci-apr&egrave;s</FONT> d&eacute;nomm&eacute;e la
&#147;<B>Date de Transfert</B>&#148;, sans aucune p&eacute;riode de pr&eacute;avis. Il cessera donc d&#146;&ecirc;tre r&eacute;mun&eacute;r&eacute; par TEVA SANTE &agrave; compter de cette Date.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consequently, as from March&nbsp;1, 2020 (hereinafter referred to as the &#147;<B>Date of Transfer</B>&#148;), the Employee will no longer be part of the headcount of TEVA SANTE, without any notice period. He will therefore no
longer be paid by TEVA SANTE as from this Date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dans la mesure o&ugrave; il s&#146;agit d&#146;un transfert de contrat de travail, les Parties conviennent qu&#146;aucune somme ne sera vers&eacute;e au Salari&eacute; au titre de la cessation de ses relations contractuelles avec
TEVA SANTE, qui ne saurait &ecirc;tre assimil&eacute;e ni &agrave; une d&eacute;mission du Salari&eacute; de TEVA SANTE, ni &agrave; un licenciement par <FONT STYLE="white-space:nowrap">celle-ci,</FONT> ni &agrave; une rupture conventionnelle.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As it is a transfer of employment contract, the Parties expressly agree that there will be no payment made to the Employee as for the termination of his contractual relationships with TEVA SANTE, which does not amount to resignation
from the Employee with TEVA SANTE, nor to a dismissal or a termination by mutual agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">La pr&eacute;sente Convention tripartite de transfert est en cons&eacute;quence exclusive de toute indemnit&eacute; de rupture et de tout pr&eacute;avis &agrave; la charge aussi bien de TEVA SANTE que du Salari&eacute;.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consequently, this tripartite transfer Agreement does not entail the payment of any severance payment and does not give rise to any notice period from either TEVA SANTE or the
Employee.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g102112g0203043727908.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Elle a uniquement pour effet de permettre d&#146;un commun accord la poursuite du Contrat de travail entre le Salari&eacute; et TEVA PHARMACEUTICAL, la soci&eacute;t&eacute; TEVA PHARMACEUTICAL devenant &agrave; compter de la Date
de Transfert son nouvel employeur.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It only has the effect of allowing, by mutual agreement, the continuation of the Employment contract between the Employee and TEVA PHARMACEUTICAL, which becomes his new employer as of the Transfer Date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TEVA SANTE versera au Salari&eacute; son salaire ainsi que l&#146;ensemble des droits acquis et &eacute;chus jusqu&#146;&agrave; la Date de Transfert.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">TEVA SANTE will pay the Employee his salary as well as all the rights acquired and expired until the Transfer Date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A compter de la Date de Transfert, TEVA PHARMACEUTICAL sera seule responsable du versement des salaires et autres droits acquis par le Salari&eacute; post&eacute;rieurement &agrave; la Date de Transfert.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As from the Transfer Date, TEVA PHARMACEUTICAL will be solely responsible and liable for the payment of wages and other rights acquired by the Employee after the Transfer Date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Il est pr&eacute;cis&eacute; que les droits &agrave; cong&eacute;s pay&eacute;s acquis et non pris par le Salari&eacute; aupr&egrave;s de TEVA SANTE &agrave; la Date de Transfert, dans la limite de 47 jours de cong&eacute;s
pay&eacute;s, seront transf&eacute;r&eacute;s &agrave; TEVA PHARMACEUTICAL et pourront &ecirc;tre pris suivant les modalit&eacute;s en vigueur au sein de TEVA PHARMACEUTICAL. <FONT STYLE="white-space:nowrap">Au-del&agrave;</FONT> de la limite de ces
47 jours, les cong&eacute;s pay&eacute;s acquis et non pris par le Salari&eacute; seront pay&eacute;s au Salari&eacute; par TEVA SANTE.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It is specified that the entitlement to 47 days paid holidays acquired and not taken by the Employee within TEVA PHARMACEUTICAL on the Transfer Date, will be transferred to TEVA PHARMACEUTICAL and may be taken according to the
procedures in force within TEVA PHARMACEUTICAL. To the extent the Employee acquired more than 47 days of paid holidays, such acquired paid holidays in excess of the 47 days will be paid to the Employee by TEVA SANTE.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Article 2&nbsp;: Transfert du Contrat de travail du Salari&eacute; au sein de TEVA PHARMACEUTICAL</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Article 2 : Transfer of the Employment contract of the Employee within TEVA PHARMACEUTICAL</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Par la pr&eacute;sente Convention, les Parties d&eacute;cident d&#146;un commun accord du transfert d&eacute;finitif du Contrat de travail du Salari&eacute; au sein de TEVA PHARMACEUTICAL.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By this Agreement, the Parties agree by mutual agreement of the definitive transfer of the Employment contract of the Employee within TEVA PHARMACEUTICAL.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ce transfert d&eacute;finitif du Contrat de travail op&egrave;re ainsi une novation de Contrat de travail du Salari&eacute; par substitution de la soci&eacute;t&eacute; TEVA PHARMACEUTICAL &agrave; TEVA SANTE en sa qualit&eacute;
d&#146;employeur et conclusion d&#146;un nouveau contrat de travail entre les parties.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The definitive transfer of this Employment contract entails the novation of the Employment contract of the Employee by substituting TEVA PHARMACEUTICAL to TEVA SANTE as an employer and entering into a new employment
contract.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A la Date de Transfert, TEVA PHARMACEUTICAL deviendra l&#146;unique employeur du Salari&eacute;.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">At the Transfer Date, TEVA PHARMACEUTICAL will become the sole employer of the Employee.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Article 3 : Nouvelles clauses contractuelles</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Article 3 : New contractual clauses</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A compter de la Date de transfert, le Contrat de travail du Salari&eacute; sera modifi&eacute;, l&#146;ensemble de ses clauses &eacute;tant remplac&eacute; par les termes de l&#146;accord sign&eacute; entre Monsieur Drap&eacute; et
TEVA PHARMACEUTICAL le Mars 20, 2020, annex&eacute; &agrave; la pr&eacute;sente Convention.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As from the Transfer date, the Employment contract shall be modified, with all of its clauses being replaced by the terms of the agreement signed between Mr.&nbsp;Drap&eacute; and TEVA PHARMACEUTICAL on March&nbsp;12, 2020<B>,</B>
which will be attached to this Agreement.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g102112g0203043727908.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Le Contrat de travail sera ainsi soumis &agrave; compter du 1 Mars 2020, au droit isra&eacute;lien, applicable &agrave; l&#146;accord pr&eacute;cit&eacute;.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As from March&nbsp;1, 2020, the Employment contract shall thus be subject to Israelite law, applicable to the aforementioned agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Article 4 : Lev&eacute;e de la clause de <FONT STYLE="white-space:nowrap">non-concurrence</FONT> et <FONT STYLE="white-space:nowrap">non-sollicitation</FONT> de client&egrave;le applicable au sein de TEVA SANTE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Article 4: Waiving of the <FONT STYLE="white-space:nowrap">non-compete</FONT> and <FONT STYLE="white-space:nowrap">non-poaching</FONT> of clients commitment applicable within TEVA SANTE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dans le cadre de la pr&eacute;sente Convention, TEVA SANTE lib&egrave;re le Salari&eacute; de l&#146;interdiction de <FONT
STYLE="white-space:nowrap">non-sollicitation</FONT> de client&egrave;le pr&eacute;vue &agrave; l&#146;article 17 de son Contrat de travail conclu avec TEVA SANTE.</P> <P STYLE="font-size:20pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">La pr&eacute;sente renonciation d&eacute;charge TEVA SANTE de tout paiement de la contrepartie financi&egrave;re qui d&eacute;pendait de l&#146;application de
clause.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the framework of this Agreement, TEVA SANTE releases the Employee from his <FONT STYLE="white-space:nowrap">non-compete</FONT> and <FONT
STYLE="white-space:nowrap">non-poaching</FONT> commitment provided for by Article 17 of his Employment contract concluded with TEVA SANTE.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">This waiver releases TEVA SANTE from paying any financial indemnity relating to the application of this Article.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Article 5 : Transfert de donn&eacute;es</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Article 5 : Data transfer</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">En signant cette Convention de transfert de son Contrat de travail, le Salari&eacute; accepte que les &eacute;l&eacute;ments de son dossier soient transmis par la soci&eacute;t&eacute; TEVA SANTE &agrave; la TEVA PHARMACEUTICAL afin
de permettre la poursuite de son emploi au sein de cette derni&egrave;re.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By signing this transfer Agreement of his Employment contract, the Employee agrees that his file will be provided by TEVA SANTE to TEVA PHARMACEUTICAL in order to enable the continuation of his employment within TEVA
PHARMACEUTICAL.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">En tant que nouvel employeur, et en cons&eacute;quence du transfert du Contrat de travail, TEVA PHARMACEUTICAL aura acc&egrave;s &agrave; certaines des donn&eacute;es personnelles du Salari&eacute; (pouvant inclure des
donn&eacute;es personnelles &laquo; sensibles &raquo;) afin de respecter ses diverses obligations. Les cat&eacute;gories de donn&eacute;es personnelles peuvent notamment inclure : les coordonn&eacute;es du Salari&eacute;, le d&eacute;tail de sa
r&eacute;mun&eacute;ration et toute autre information li&eacute;e &agrave; la poursuite de son emploi.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As a new employer, and as a result of the transfer of the Employment contract, TEVA PHARMACEUTICAL will have access to some of the Employee&#146;s personal data (which may include &#147;sensitive&#148; personal data) in order to
meet its various obligations. Personal data may in particular include: contact details of the Employee, information regarding his remuneration and any other information related to the continuation of his employment.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Concernant les donn&eacute;es personnelles qui pourraient &ecirc;tre transf&eacute;r&eacute;es et trait&eacute;es par TEVA PHARMACEUTICAL pendant toute la dur&eacute;e de l&#146;emploi du Salari&eacute;, conform&eacute;ment &agrave;
la loi Informatique et Libert&eacute;s n&deg; <FONT STYLE="white-space:nowrap">78-17</FONT> du 6 janvier 1978, modifi&eacute;e en 2018, et le R&egrave;glement g&eacute;n&eacute;ral sur la protection des donn&eacute;es (UE) 679/2016, le
Salari&eacute; b&eacute;n&eacute;ficie d&#146;un droit d&#146;acc&egrave;s et de rectification aux informations qui le concernent.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Regarding the personal data that could be transferred and processed by TEVA PHARMACEUTICAL during the performance of the employment of the Employee, in accordance with the Data Protection Act
<FONT STYLE="white-space:nowrap">No.&nbsp;78-17</FONT> of 6&nbsp;January 1978, amended in 2018, and the General Data Protection Regulation (EU) 679/2016, the Employee has the right to access and rectify the information concerning
him.</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g102112g0203043727908.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">En paraphant la pr&eacute;sente page, le Salari&eacute; marque son accord explicite aux transferts et traitements des donn&eacute;es personnelles sensibles le concernant.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By initiating this page, the Employee expressly agrees to the transfer and processing of sensitive personal data concerning him.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Article 6 : Information du salari&eacute;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Article 6 : Employee information</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Le Salari&eacute; reconna&icirc;t avoir re&ccedil;u toute l&#146;information n&eacute;cessaire et avoir b&eacute;n&eacute;fici&eacute; d&#146;un temps de r&eacute;flexion suffisant pour prendre sa d&eacute;cision en connaissance de
cause avant de signer la pr&eacute;sente Convention.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Employee acknowledges having received all the necessary information and has had sufficient time to make an informed decision before signing this Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Article 7&nbsp;: Langue</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Article 7 : Language</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">La version d&eacute;finitive de la pr&eacute;sente Convention qui lie les Parties est la version fran&ccedil;aise, la version anglaise de l&#146;accord n&#146;&eacute;tant fournie qu&#146;&agrave; titre d&#146;information. En cas de
contradiction entre les versions fran&ccedil;aises et anglaises, la version fran&ccedil;aise pr&eacute;vaudra.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The definitive version of this Agreement that binds the Parties is the French language version, the English version being provided for information purposes only. In the event of a contradiction between the two versions, the French
version shall prevail.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Article 8&nbsp;: Loi applicable &#150; Tribunaux comp&eacute;tents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Article 8 : Governing law &#150; Competent Courts</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">La pr&eacute;sente Convention est soumise &agrave; la loi fran&ccedil;aise et tout litige s&#146;y rapportant sera de la comp&eacute;tence exclusive des tribunaux fran&ccedil;ais.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">This Agreement is governed by French law and any dispute relating hereto shall be subject to the exclusive jurisdiction of the French courts.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Annexe &#150; Contrat de travail du Salari&eacute; conclu avec TEVA PHARMACEUTICAL</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><I></I><B><I>Annex &#150; Employment contract of the Employee concluded with TEVA PHARMACEUTICAL</I></B><I></I><B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fait en trois exemplaires originaux</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In three originals,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Paris, le Mars 20, 2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In Paris, on March&nbsp;20, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Pour la soci&eacute;t&eacute; TEVA SANTE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Karima ZERHOUNI</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">/s/ Karima ZERHOUNI</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Directeur des Ressources Humaines</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director of Human Resources</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Pour la soci&eacute;t&eacute; TEVA PHARMACEUTICAL INDUSTRIES</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Eric Drap&eacute;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Eric Drap&eacute;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Eric
Drap&eacute;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>M. Eric Drap&eacute;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Chaque page doit &ecirc;tre paraph&eacute;e et les signatures <FONT STYLE="white-space:nowrap">ci-dessus</FONT> doivent
&ecirc;tre pr&eacute;c&eacute;d&eacute;es de la mention manuscrite suivante :&laquo; Lu et approuv&eacute; &raquo; ) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Each page must be initialed
and the signatures are to be preceded by the handwritten comment: &#147;READ AND AGREED&#148;) </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g102112g0203043727908.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Annexe &#150; Contrat de travail du Salari&eacute; au sein de TEVA PHARMACEUTICAL
INDUSTRIES </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>[Employment contract of Mr.&nbsp;Drap&eacute; concluded within TEVA PHARMACEUTICAL INDUSTRIES TO BE ATTACHED] </I></B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>5
<FILENAME>d102112dex21.htm
<DESCRIPTION>EX-21
<TEXT>
<HTML><HEAD>
<TITLE>EX-21</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a list of subsidiaries of the Company as of December&nbsp;31, 2020, omitting some subsidiaries which, considered in the
aggregate, would not constitute a significant subsidiary. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Jurisdiction of Organization</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Actavis Group PTC ehf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Iceland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Actavis Pharma Holding ehf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Iceland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IVAX UK Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mepha Schweiz AG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merckle GmbH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Germany</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Norton (Waterford) Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ireland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Orvet UK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PLIVA HRVATSKA d.o.o.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Croatia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plus Chemicals, branch of Teva Pharmaceuticals International GmbH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ratiopharm GmbH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Germany</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva API B.V.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Netherlands</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Canada Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Canada</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Capital Services Switzerland GmbH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Czech Industries s.r.o</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Czech Republic</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Finance Services II B.V.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Curacao</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Italia S.r.l</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Italy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Limited Liability Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Russia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Pharma S.L.U</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Spain</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Pharmaceuticals Europe B.V.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Netherlands</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Pharmaceutical Finance Netherlands III B.V</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Netherlands</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Pharmaceuticals International GmbH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Switzerland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Pharmaceuticals USA, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Pharm. Works Private Ltd. Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hungary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Sant&eacute; SAS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">France</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva Takeda Pharma Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Japan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Teva UK Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>6
<FILENAME>d102112dex23.htm
<DESCRIPTION>EX-23
<TEXT>
<HTML><HEAD>
<TITLE>EX-23</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Registration Statements on Form<B> </B>S-8 (Nos. 333-168331,
<FONT STYLE="white-space:nowrap">333-206753,</FONT> <FONT STYLE="white-space:nowrap">333-212851,</FONT> <FONT STYLE="white-space:nowrap">333-214077,</FONT> <FONT STYLE="white-space:nowrap">333-220382</FONT> and 333-241003) and Form S-3 (No.
333-222767) of Teva Pharmaceutical Industries Limited of our report dated February 10, 2021 relating to the financial statements and financial statement schedule and the effectiveness of internal control over financial reporting, which appears in
this Form 10-K. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kesselman &amp; Kesselman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certified Public Accountants (Isr.)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A member
of PricewaterhouseCoopers International Limited</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel-Aviv, Israel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">February 10, 2021</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>d102112dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I,
K&aring;re Schultz, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Teva Pharmaceutical
Industries Limited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this report any change in the company&#146;s internal control over financial reporting that
occurred during the company&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;10, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K&aring;re Schultz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K&aring;re Schultz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>d102112dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I,
Eli Kalif, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Teva Pharmaceutical
Industries Limited; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the company and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed in this report any change in the company&#146;s internal control over financial reporting that
occurred during the company&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the company&#146;s auditors and the audit committee of the company&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the company&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;10, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Eli Kalif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>9
<FILENAME>d102112dex32.htm
<DESCRIPTION>EX-32
<TEXT>
<HTML><HEAD>
<TITLE>EX-32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION OF THE CEO AND CFO PURSUANT TO SECTION 906 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FINANCIAL OFFICER </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Teva Pharmaceutical Industries Limited (the &#147;Company&#148;) on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the period ended December&nbsp;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), we, K&aring;re Schultz, President and Chief Executive Officer of the
Company, and Eli Kalif, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February&nbsp;10, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K&aring;re Schultz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K&aring;re Schultz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Eli Kalif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>teva-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-February-2021 [01:05:18] {AM}-->
<schema targetNamespace="http://www.tevapharm.com/20201231" elementFormDefault="qualified" xmlns:teva="http://www.tevapharm.com/20201231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.tevapharm.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" id="ConsolidatedStatementsOfIncomeLoss">
<link:definition>1004 - Statement - Consolidated Statements of Income (Loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" id="ConsolidatedStatementsOfComprehensiveIncomeLoss">
<link:definition>1005 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" id="ConsolidatedStatementsOfChangesInEquity">
<link:definition>1006 - Statement - Consolidated Statements of Changes in Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" id="ConsolidatedStatementsOfChangesInEquityParenthetical">
<link:definition>1007 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1008 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactions" id="CertainTransactions">
<link:definition>1010 - Disclosure - Certain transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" id="RevenueFromContractsWithCustomers">
<link:definition>1011 - Disclosure - Revenue from contracts with customers</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Inventories" id="Inventories">
<link:definition>1012 - Disclosure - Inventories</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
<link:definition>1013 - Disclosure - Property, Plant and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" id="IdentifiableIntangibleAssets">
<link:definition>1014 - Disclosure - Identifiable Intangible Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Goodwill" id="Goodwill">
<link:definition>1015 - Disclosure - Goodwill</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Leases" id="Leases">
<link:definition>1016 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligations" id="DebtObligations">
<link:definition>1017 - Disclosure - Debt obligations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" id="DerivativeInstrumentsAndHedgingActivities">
<link:definition>1018 - Disclosure - Derivative instruments and hedging activities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" id="LegalSettlementsAndLossContingencies">
<link:definition>1019 - Disclosure - Legal Settlements and Loss Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1020 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1021 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Equity" id="Equity">
<link:definition>1022 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" id="OtherAssetsImpairmentsRestructuringAndOtherItems">
<link:definition>1023 - Disclosure - Other assets impairments, restructuring and other items</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherIncome" id="OtherIncome">
<link:definition>1024 - Disclosure - Other income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FinancialExpensesNet" id="FinancialExpensesNet">
<link:definition>1025 - Disclosure - Financial expenses, net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
<link:definition>1026 - Disclosure - Earnings (Loss) per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/Segments" id="Segments">
<link:definition>1027 - Disclosure - Segments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurement" id="FairValueMeasurement">
<link:definition>1028 - Disclosure - Fair value measurement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations" id="LongTermEmployeeRelatedObligations">
<link:definition>1029 - Disclosure - Long-term Employee-related Obligations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited" id="SelectedQuarterlyFinancialDataUnaudited">
<link:definition>1030 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts" id="ScheduleOfValuationAndQualifyingAccounts">
<link:definition>1031 - Disclosure - Schedule of Valuation and Qualifying Accounts</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition>1032 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" id="CertainTransactionsTables">
<link:definition>1033 - Disclosure - Certain transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" id="RevenueFromContractsWithCustomersTables">
<link:definition>1034 - Disclosure - Revenue from contracts with customers (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/InventoriesTables" id="InventoriesTables">
<link:definition>1035 - Disclosure - Inventories (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
<link:definition>1036 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" id="IdentifiableIntangibleAssetsTables">
<link:definition>1037 - Disclosure - Identifiable Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillTables" id="GoodwillTables">
<link:definition>1038 - Disclosure - Goodwill (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LeasesTables" id="LeasesTables">
<link:definition>1039 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsTables" id="DebtObligationsTables">
<link:definition>1040 - Disclosure - Debt obligations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" id="DerivativeInstrumentsAndHedgingActivitiesTables">
<link:definition>1041 - Disclosure - Derivative instruments and hedging activities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1042 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquityTables" id="EquityTables">
<link:definition>1043 - Disclosure - Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" id="OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<link:definition>1044 - Disclosure - Other assets impairments, restructuring and other items (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherIncomeTables" id="OtherIncomeTables">
<link:definition>1045 - Disclosure - Other income (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FinancialExpensesNetTables" id="FinancialExpensesNetTables">
<link:definition>1046 - Disclosure - Financial expenses-net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EarningsLossPerShareTables" id="EarningsLossPerShareTables">
<link:definition>1047 - Disclosure - Earnings (Loss) per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsTables" id="SegmentsTables">
<link:definition>1048 - Disclosure - Segments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1049 - Disclosure - Fair Value Measurement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables" id="LongTermEmployeeRelatedObligationsTables">
<link:definition>1050 - Disclosure - Long-term Employee-related Obligations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables" id="SelectedQuarterlyFinancialDataUnauditedTables">
<link:definition>1051 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" id="SignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1052 - Disclosure - Significant Accounting Policies - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail" id="CertainTransactionsBusinessTransactionsAdditionalInformationDetail">
<link:definition>1053 - Disclosure - Certain Transactions - Business Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" id="CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<link:definition>1054 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail" id="CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail">
<link:definition>1055 - Disclosure - Certain Transactions - Assets and Liabilities Held For Sale - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" id="CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail">
<link:definition>1056 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" id="RevenueFromContractsWithCustomersAdditionalInformationDetail">
<link:definition>1057 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" id="RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<link:definition>1058 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" id="RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<link:definition>1059 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" id="InventoriesSummaryOfInventoriesDetail">
<link:definition>1060 - Disclosure - Inventories - Summary of Inventories (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail" id="PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail">
<link:definition>1061 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" id="PropertyPlantAndEquipmentAdditionalInformationDetail">
<link:definition>1062 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" id="IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<link:definition>1063 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" id="IdentifiableIntangibleAssetsAdditionalInformationDetail">
<link:definition>1064 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" id="GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<link:definition>1065 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" id="GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<link:definition>1066 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" id="GoodwillAdditionalInformationDetail">
<link:definition>1067 - Disclosure - Goodwill - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail" id="LeasesComponentsOfLeaseExpenseDetail">
<link:definition>1068 - Disclosure - Leases - Components of Lease Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail" id="LeasesSupplementalCashFlowInformationRelatedToLeasesDetail">
<link:definition>1069 - Disclosure - Leases - Supplemental cash flow information related to leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail" id="LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<link:definition>1070 - Disclosure - Leases - Supplemental Balance Sheet Information Related To Leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" id="LeasesMaturitiesOfLeaseLiabilitiesDetail">
<link:definition>1071 - Disclosure - Leases -  Maturities of lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1072 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" id="DebtObligationsScheduleOfShortTermDebtDetail">
<link:definition>1073 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" id="DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<link:definition>1074 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" id="DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<link:definition>1075 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail" id="DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail">
<link:definition>1076 - Disclosure - Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail" id="DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail">
<link:definition>1077 - Disclosure - Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" id="DebtObligationsAdditionalInformationDetail">
<link:definition>1078 - Disclosure - Debt Obligations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail" id="DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail">
<link:definition>1079 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" id="DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<link:definition>1080 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails" id="DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails">
<link:definition>1081 - Disclosure - Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" id="DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails">
<link:definition>1082 - Disclosure - Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail" id="DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail">
<link:definition>1083 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" id="DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<link:definition>1084 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" id="LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<link:definition>1085 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail" id="CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail">
<link:definition>1086 - Disclosure - Commitments and Contingencies - Commitments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesContingenciesAdditionalInformationDetail">
<link:definition>1087 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail" id="IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail">
<link:definition>1088 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail" id="IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail">
<link:definition>1089 - Disclosure - Income Taxes - Schedule of the Provision for Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" id="IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail">
<link:definition>1090 - Disclosure - Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" id="IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail">
<link:definition>1091 - Disclosure - Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail" id="IncomeTaxesScheduleOfDeferedIncomeTaxesDetail">
<link:definition>1092 - Disclosure - Income Taxes - Schedule of Defered Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail" id="IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail">
<link:definition>1093 - Disclosure - Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1094 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail">
<link:definition>1095 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail">
<link:definition>1096 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquityAdditionalInformationDetail" id="EquityAdditionalInformationDetail">
<link:definition>1097 - Disclosure - Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail" id="EquitySummaryOfStockOptionActivityDetail">
<link:definition>1098 - Disclosure - Equity - Summary of Stock Option Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail" id="EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail">
<link:definition>1099 - Disclosure - Equity - Summary of Weighted Average Fair Value of Options Granted (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail" id="EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail">
<link:definition>1100 - Disclosure - Equity - Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail" id="EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail">
<link:definition>1101 - Disclosure - Equity - Schedule of Ordinary Shares Issued Upon Outstanding Options (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail" id="EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail">
<link:definition>1102 - Disclosure - Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail" id="EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail">
<link:definition>1103 - Disclosure - Equity - Schedule of Number of RSUs Issued and Outstanding (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail" id="EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail">
<link:definition>1104 - Disclosure - Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" id="EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail">
<link:definition>1105 - Disclosure - Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" id="EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail">
<link:definition>1106 - Disclosure - Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<link:definition>1107 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<link:definition>1108 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<link:definition>1109 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" id="OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<link:definition>1110 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail" id="OtherIncomeScheduleOfOtherIncomeDetail">
<link:definition>1111 - Disclosure - Other Income - Schedule of Other Income (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail" id="FinancialExpensesNetScheduleOfFinancialExpensesDetail">
<link:definition>1112 - Disclosure - Financial expenses, net - Schedule of Financial Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail" id="FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail">
<link:definition>1113 - Disclosure - Financial expenses, net - Schedule of Financial Expenses (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" id="EarningsLossPerShareScheduleOfEarningsPerShareDetail">
<link:definition>1114 - Disclosure - Earnings (Loss) per Share - Schedule of Earnings per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" id="EarningsLossPerShareAdditionalInformationDetail">
<link:definition>1115 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" id="SegmentsSummaryOfSegmentProfitDetail">
<link:definition>1116 - Disclosure - Segments - Summary of Segment Profit (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" id="SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<link:definition>1117 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" id="SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<link:definition>1118 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail" id="SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail">
<link:definition>1119 - Disclosure - Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail" id="SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail">
<link:definition>1120 - Disclosure - Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" id="SegmentsAdditionalInformationDetail">
<link:definition>1121 - Disclosure - Segments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" id="FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<link:definition>1122 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" id="FairValueMeasurementAdditionalInformationDetail">
<link:definition>1123 - Disclosure - Fair value measurement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" id="FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<link:definition>1124 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" id="FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<link:definition>1125 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail" id="LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail">
<link:definition>1126 - Disclosure - Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail" id="LongTermEmployeeRelatedObligationsAdditionalInformationDetail">
<link:definition>1127 - Disclosure - Long-term Employee-related Obligations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail" id="SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail">
<link:definition>1128 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail" id="ScheduleIiValuationAndQualifyingAccountsDetail">
<link:definition>1129 - Disclosure - Schedule II Valuation and Qualifying Accounts (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="teva-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SalesReservesAndAllowances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_SalesReservesAndAllowances" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IntangibleAssetsImpairments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_IntangibleAssetsImpairments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ImpairmentsRestructuringAndOthers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentsRestructuringAndOthers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LegalSettlementsAndLossContingencies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LegalSettlementsAndLossContingencies" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransactionsWithNonControllingInterests" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_TransactionsWithNonControllingInterests" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentsRelatedToTaxWithholdingForSharesAndDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentToAcquireMarketableSecuritiesAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredIncomeTaxesNetAndUncertainTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProfitFromSaleOfLongLivedAssetsAndInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashPaidDuringTheYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CashPaidDuringTheYearForAbstract" substitutionGroup="xbrli:item" />
<element name="CertainTransactionsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CertainTransactionsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="OtherExpensesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherExpensesTextBlock" substitutionGroup="xbrli:item" />
<element name="FinancialExpensesNetTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FinancialExpensesNetTextBlock" substitutionGroup="xbrli:item" />
<element name="LongTermEmployeeRelatedObligationsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LongTermEmployeeRelatedObligationsTextBlock" substitutionGroup="xbrli:item" />
<element name="SelectedQuarterlyFinancialDataTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SelectedQuarterlyFinancialDataTextBlock" substitutionGroup="xbrli:item" />
<element name="AcquisitionTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AcquisitionTextBlock" substitutionGroup="xbrli:item" />
<element name="IncomeTaxesUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_IncomeTaxesUncertaintiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CostOfShippingAndHandlingPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CostOfShippingAndHandlingPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EquityAndCostMethodInvestmentPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_EquityAndCostMethodInvestmentPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="GeneralOptionsAccountingPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_GeneralOptionsAccountingPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DivestituresTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DivestituresTextBlock" substitutionGroup="xbrli:item" />
<element name="RestructuringTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RestructuringTextBlock" substitutionGroup="xbrli:item" />
<element name="SecuritizationTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SecuritizationTextBlock" substitutionGroup="xbrli:item" />
<element name="TreasurySharesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_TreasurySharesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AccountsReceivablesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AccountsReceivablesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SalesReservesAndAllowancesCurrentTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SalesReservesAndAllowancesCurrentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" substitutionGroup="xbrli:item" />
<element name="SupplementalCashFlowInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SupplementalCashFlowInformationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ComponentsOfLeaseExpenseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ComponentsOfLeaseExpenseTableTextBlock" substitutionGroup="xbrli:item" />
<element name="LongTermDebtExcludingConvertibleDebtTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccountReceivableFromSecuritization" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfAccountReceivableFromSecuritization" substitutionGroup="xbrli:item" />
<element name="DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfRestructuringChargesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfRestructuringChargesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfOtherIncomeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfOtherIncomeTableTextBlock" substitutionGroup="xbrli:item" />
<element name="FinancialExpensesNetTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FinancialExpensesNetTableTextBlock" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SalesPercentageByTherapeuticCategoryTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SalesPercentageByTherapeuticCategoryTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" substitutionGroup="xbrli:item" />
<element name="LongTermEmployeeRelatedObligationsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LongTermEmployeeRelatedObligationsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SelectedQuarterlyFinancialDataTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SelectedQuarterlyFinancialDataTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfConsolidatedSalesInNorthAmerica" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PercentageOfConsolidatedSalesInNorthAmerica" substitutionGroup="xbrli:item" />
<element name="CreditTermsToCustomers" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CreditTermsToCustomers" substitutionGroup="xbrli:item" />
<element name="ShippingHandlingAndTransportationCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ShippingHandlingAndTransportationCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLeaseRemainingLeaseTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OperatingLeaseRemainingLeaseTerm" substitutionGroup="xbrli:item" />
<element name="OneTimeMilestonePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OneTimeMilestonePaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ActavisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ActavisMember" substitutionGroup="xbrli:item" />
<element name="AndaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AndaMember" substitutionGroup="xbrli:item" />
<element name="AllerganPlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AllerganPlcMember" substitutionGroup="xbrli:item" />
<element name="CelltrionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CelltrionMember" substitutionGroup="xbrli:item" />
<element name="AlderMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AlderMember" substitutionGroup="xbrli:item" />
<element name="RegeneronMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RegeneronMember" substitutionGroup="xbrli:item" />
<element name="RimsaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RimsaMember" substitutionGroup="xbrli:item" />
<element name="OtsukaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtsukaMember" substitutionGroup="xbrli:item" />
<element name="AlvotechMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AlvotechMember" substitutionGroup="xbrli:item" />
<element name="CollaborativeAgreementMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CollaborativeAgreementMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RefundablePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_RefundablePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TotalAssociatedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_TotalAssociatedCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UpfrontPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfLawsuitsFiled" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_NumberOfLawsuitsFiled" substitutionGroup="xbrli:item" />
<element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_MilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PgtMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PgtMember" substitutionGroup="xbrli:item" />
<element name="TevaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TevaMember" substitutionGroup="xbrli:item" />
<element name="RevenueRecognitionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueRecognitionTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RevenueRecognitionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueRecognitionLineItems" substitutionGroup="xbrli:item" />
<element name="SalesReservesAndAllowancesToCustomersPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_SalesReservesAndAllowancesToCustomersPercentage" substitutionGroup="xbrli:item" />
<element name="InternationalMarketsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InternationalMarketsMember" substitutionGroup="xbrli:item" />
<element name="OtherActivitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherActivitiesMember" substitutionGroup="xbrli:item" />
<element name="ValuationAllowancesAndReservesForeignCurrencyTranslation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ValuationAllowancesAndReservesRelatedToPriorPeriodSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MedicaidAndOtherGovernmentalAllowancesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MedicaidAndOtherGovernmentalAllowancesMember" substitutionGroup="xbrli:item" />
<element name="OtherSalesReservesAndAllowancesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherSalesReservesAndAllowancesMember" substitutionGroup="xbrli:item" />
<element name="RebatesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RebatesMember" substitutionGroup="xbrli:item" />
<element name="ReservesIncludedInAccountsReceivableNetMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ReservesIncludedInAccountsReceivableNetMember" substitutionGroup="xbrli:item" />
<element name="ReturnsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ReturnsMember" substitutionGroup="xbrli:item" />
<element name="ChargebacksMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ChargebacksMember" substitutionGroup="xbrli:item" />
<element name="TotalReservesIncludedInSalesReservesAndAllowancesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" substitutionGroup="xbrli:item" />
<element name="InventoriesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InventoriesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="InventoriesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_InventoriesLineItems" substitutionGroup="xbrli:item" />
<element name="AssetsUnderConstructionAndPaymentsOnAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AssetsUnderConstructionAndPaymentsOnAccount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProductRightsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ProductRightsMember" substitutionGroup="xbrli:item" />
<element name="AustedoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AustedoMember" substitutionGroup="xbrli:item" />
<element name="DiscontinuationOfBusinessAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DiscontinuationOfBusinessAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DiscontinuationOfBusinessDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DiscontinuationOfBusinessDomain" substitutionGroup="xbrli:item" />
<element name="DiscontinuedBusinessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DiscontinuedBusinessMember" substitutionGroup="xbrli:item" />
<element name="LenalidomideProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_LenalidomideProductMember" substitutionGroup="xbrli:item" />
<element name="ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" substitutionGroup="xbrli:item" />
<element name="GoodwillReclassification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_GoodwillReclassification" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherCountriesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherCountriesMember" substitutionGroup="xbrli:item" />
<element name="OtherMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherMember" substitutionGroup="xbrli:item" />
<element name="PercentageDecreaseInTheMarketCapitalization" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PercentageDecreaseInTheMarketCapitalization" substitutionGroup="xbrli:item" />
<element name="PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OperatingLeaseCostAbstract" substitutionGroup="xbrli:item" />
<element name="FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLeasesNonCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OperatingLeasesNonCash" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OperatingLeasesAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseLiabilityOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_OperatingLeaseLiabilityOther" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeasesImputedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_OperatingLeasesImputedInterest" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentMaturityYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DebtInstrumentMaturityYear" substitutionGroup="xbrli:item" />
<element name="ShortCreditAgreement2026Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ShortCreditAgreement2026Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2020OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2020OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2020TwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2020TwoMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2021OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2021OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2028Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2028Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2028OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2028OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2036Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2036Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2046Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2046Member" substitutionGroup="xbrli:item" />
<element name="OtherDebentures2026Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherDebentures2026Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2021ThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2021ThreeMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2027Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2027Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025ThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025ThreeMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025TwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025TwoMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2021TwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2021TwoMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2022OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2022OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2022ThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2022ThreeMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2022TwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2022TwoMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2023OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2023OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2024Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2024Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2024OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2024OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2025Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2025Member" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2026OneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2026OneMember" substitutionGroup="xbrli:item" />
<element name="SubsidiarySeniorNotesDue2023TwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SubsidiarySeniorNotesDue2023TwoMember" substitutionGroup="xbrli:item" />
<element name="LongTermDebtMaturityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_LongTermDebtMaturityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LongTermDebtMaturityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_LongTermDebtMaturityLineItems" substitutionGroup="xbrli:item" />
<element name="LongTermDebtaExcludeIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtaExcludeIssuanceCost" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermDebtCurrencyPortionCHF" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionCHF" substitutionGroup="xbrli:item" />
<element name="LongTermDebtCurrencyPortionEUR" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionEUR" substitutionGroup="xbrli:item" />
<element name="LongTermDebtCurrencyPortionUSD" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermDebtCurrencyPortionUSD" substitutionGroup="xbrli:item" />
<element name="TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TrancheDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TrancheDomain" substitutionGroup="xbrli:item" />
<element name="TracheAMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TracheAMember" substitutionGroup="xbrli:item" />
<element name="TracheBMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TracheBMember" substitutionGroup="xbrli:item" />
<element name="TracheAExtensionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TracheAExtensionMember" substitutionGroup="xbrli:item" />
<element name="SeniorNotesAndLoansMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesAndLoansMember" substitutionGroup="xbrli:item" />
<element name="FinancialExpensesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FinancialExpensesMember" substitutionGroup="xbrli:item" />
<element name="NetRevenuesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NetRevenuesMember" substitutionGroup="xbrli:item" />
<element name="EffectOfExchangeRateOnAccountsReceivableFromSecuritization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SeniorNotesDue2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesDue2021Member" substitutionGroup="xbrli:item" />
<element name="SeniorNotesDue2022Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesDue2022Member" substitutionGroup="xbrli:item" />
<element name="SeniorNotesDue2023TwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesDue2023TwoMember" substitutionGroup="xbrli:item" />
<element name="SeniorNotesDue2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniorNotesDue2020Member" substitutionGroup="xbrli:item" />
<element name="HedgingOfRevenuesTwoThousandAndTwentyOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" substitutionGroup="xbrli:item" />
<element name="DeferredPurchaseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_DeferredPurchaseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InterestRateSwapGain" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_InterestRateSwapGain" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenuesOtherThanUsd" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_RevenuesOtherThanUsd" substitutionGroup="xbrli:item" />
<element name="SettlementGainPosition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_SettlementGainPosition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashReceivedOnSettlementOfPosition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_CashReceivedOnSettlementOfPosition" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NotionalAmountHedgeDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_NotionalAmountHedgeDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreviouslyHedgeDebtRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_PreviouslyHedgeDebtRate" substitutionGroup="xbrli:item" />
<element name="SettlementOnAccountOfProductLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SettlementOnAccountOfProductLiabilityMember" substitutionGroup="xbrli:item" />
<element name="RestructuringExpenseAndIncome" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RestructuringExpenseAndIncome" substitutionGroup="xbrli:item" />
<element name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CommitmentAndContingenciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_CommitmentAndContingenciesLineItems" substitutionGroup="xbrli:item" />
<element name="MilestoneContingentPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_MilestoneContingentPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfVelcade" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfVelcade" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DamagesAssessment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DamagesAssessment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesAtTimeOfSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AnnualSalesAtTimeOfSettlement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AnnualSalesOfActoplus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfActoplus" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfNamenda" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfNamenda" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfNiaspan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfNiaspan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfActos" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfActos" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfEffexor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfEffexor" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnnualSalesOfLamictal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AnnualSalesOfLamictal" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ModafinilPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_ModafinilPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ModafinilPaymentRemainingBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_ModafinilPaymentRemainingBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LitigationSettlementAmountAwardedDistributionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementAmountAwardedDistributionPeriod" substitutionGroup="xbrli:item" />
<element name="AnnualSalesOfSensipar" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfSensipar" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LitigationSettlementAmountAwardedCashAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementAmountAwardedCashAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LitigationSettlementAmountAwardedNumberOfInstallments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementAmountAwardedNumberOfInstallments" substitutionGroup="xbrli:item" />
<element name="LitigationSettlementAmountAwardedCashAmountDistributionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" substitutionGroup="xbrli:item" />
<element name="AnnualSalesOfCopaxone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AnnualSalesOfCopaxone" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="JanssenAndMillenniumMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_JanssenAndMillenniumMember" substitutionGroup="xbrli:item" />
<element name="EosinophilicEsophagitisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EosinophilicEsophagitisMember" substitutionGroup="xbrli:item" />
<element name="AndroGelRateAtOnePercentageMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AndroGelRateAtOnePercentageMember" substitutionGroup="xbrli:item" />
<element name="NationwideSettlementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NationwideSettlementMember" substitutionGroup="xbrli:item" />
<element name="OpioidLitigationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OpioidLitigationMember" substitutionGroup="xbrli:item" />
<element name="ModafinilSettlementAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ModafinilSettlementAgreementMember" substitutionGroup="xbrli:item" />
<element name="IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" substitutionGroup="xbrli:item" />
<element name="Ustaxcutsandjobsacteffect" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_Ustaxcutsandjobsacteffect" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" substitutionGroup="xbrli:item" />
<element name="ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DeferredTaxAssetsLiabilitiesNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DeferredTaxAssetsLiabilitiesNetLineItems" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsDeferredInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DeferredTaxAssetsDeferredInterest" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsLiabilitiesGrossNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetUnrecognizedTaxBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DeferredTaxAssetUnrecognizedTaxBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IncomeTaxTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IncomeTaxLineItems" substitutionGroup="xbrli:item" />
<element name="AverageGrowthRateInSalesOrWorkforce" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AverageGrowthRateInSalesOrWorkforce" substitutionGroup="xbrli:item" />
<element name="AverageGrowthPrecedingPeriodInSalesOrWorkforce" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" substitutionGroup="xbrli:item" />
<element name="MinimumNumberOfEmployeesEmployed" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_MinimumNumberOfEmployeesEmployed" substitutionGroup="xbrli:item" />
<element name="MinimumPercentageOfInvestmentIncome" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_MinimumPercentageOfInvestmentIncome" substitutionGroup="xbrli:item" />
<element name="MinimumPercentageOfWorkforce" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_MinimumPercentageOfWorkforce" substitutionGroup="xbrli:item" />
<element name="VentureCapitalInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_VentureCapitalInvestments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WithholdingTaxPercentageOnDividends" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_WithholdingTaxPercentageOnDividends" substitutionGroup="xbrli:item" />
<element name="ExpectedImpairmentOfIncomeTaxBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ExpectedImpairmentOfIncomeTaxBenefit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DevelopmentZoneaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_DevelopmentZoneaMember" substitutionGroup="xbrli:item" />
<element name="TaxYear2005To2007Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TaxYear2005To2007Member" substitutionGroup="xbrli:item" />
<element name="Amendment68ToInvestmentLawMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_Amendment68ToInvestmentLawMember" substitutionGroup="xbrli:item" />
<element name="Amendment69ToInvestmentLawMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_Amendment69ToInvestmentLawMember" substitutionGroup="xbrli:item" />
<element name="Amendment73ToInvestmentLawMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_Amendment73ToInvestmentLawMember" substitutionGroup="xbrli:item" />
<element name="PreferredEnterpriseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PreferredEnterpriseMember" substitutionGroup="xbrli:item" />
<element name="PreferredTechnologicalEnterprisesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_PreferredTechnologicalEnterprisesMember" substitutionGroup="xbrli:item" />
<element name="SpecialPreferredTechnologicalEnterpriseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SpecialPreferredTechnologicalEnterpriseMember" substitutionGroup="xbrli:item" />
<element name="TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" substitutionGroup="xbrli:item" />
<element name="TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" substitutionGroup="xbrli:item" />
<element name="TaxCarryforwardsAndDeductionsIndefiniteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TaxCarryforwardsAndDeductionsIndefiniteMember" substitutionGroup="xbrli:item" />
<element name="TaxCarryforwardsAndDeductionsNoExpirationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TaxCarryforwardsAndDeductionsNoExpirationMember" substitutionGroup="xbrli:item" />
<element name="UnrecognizedTaxBenefitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_UnrecognizedTaxBenefitsAbstract" substitutionGroup="xbrli:item" />
<element name="ScheduleOfUnrecognizedTaxBenefitsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfUnrecognizedTaxBenefitsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfUnrecognizedTaxBenefitsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" substitutionGroup="xbrli:item" />
<element name="UnrecognizedTaxBenefitsIncreasesDecreasesOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AverageSharePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AverageSharePrice" substitutionGroup="xbrli:item" />
<element name="UnrecognizedCompensationCostRsus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_UnrecognizedCompensationCostRsus" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnrecognizedCompensationCostOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_UnrecognizedCompensationCostOptions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TwoThousandFifteenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TwoThousandFifteenPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TwoThousandTenPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_TwoThousandTwentyPlanMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExercisePriceRangeFiveMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExercisePriceRangeFourMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExercisePriceRangeSixMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExercisePriceRangeThreeMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExercisePriceRangeOneMember" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExercisePriceRangeTwoMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" substitutionGroup="xbrli:item" />
<element name="RestrictedStockUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="OmnibusLongTermShareIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OmnibusLongTermShareIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="StockOptionsPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_StockOptionsPlanMember" substitutionGroup="xbrli:item" />
<element name="RestructuringAndImpairmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentAbstract" substitutionGroup="xbrli:item" />
<element name="RestructuringAndImpairmentCostsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentCostsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RestructuringAndImpairmentCostsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAndImpairmentCostsLineItems" substitutionGroup="xbrli:item" />
<element name="ImpairmentAndRestructuring" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ImpairmentAndRestructuring" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LegalSettlementsLossContingenciesImpairmentsOtherExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestructuringPlanCostReduction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RestructuringPlanCostReduction" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExpectedRevenueFromFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ExpectedRevenueFromFacility" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExitAndDisposalAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExitAndDisposalAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ExitAndDisposalDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExitAndDisposalDomain" substitutionGroup="xbrli:item" />
<element name="EmployeeTerminationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EmployeeTerminationMember" substitutionGroup="xbrli:item" />
<element name="OtherExitAndDisposalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherExitAndDisposalMember" substitutionGroup="xbrli:item" />
<element name="RestructuringAccrualProvision" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_RestructuringAccrualProvision" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UtilizationAndOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_UtilizationAndOther" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherIncomeExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherIncomeExpenseTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="OtherincomeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherincomeLineItems" substitutionGroup="xbrli:item" />
<element name="PatentedMedicinesRegulationsAndSimilarPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PatentedMedicinesRegulationsAndSimilarPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherOperatingIncomeNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherOperatingIncomeNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FinancialExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_FinancialExpensesNetAbstract" substitutionGroup="xbrli:item" />
<element name="ExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExpensesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ExpensesLineItems" substitutionGroup="xbrli:item" />
<element name="FinanceIncomeExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FinanceIncomeExpensesNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ForeignCurrencyTransactionGainLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_ForeignCurrencyTransactionGainLoss" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherFinancialIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherFinancialIncomeExpenseNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentForRedemptionOfSeniorNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_PaymentForRedemptionOfSeniorNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="EuropeSegmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EuropeSegmentMember" substitutionGroup="xbrli:item" />
<element name="NorthAmericaSegmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_NorthAmericaSegmentMember" substitutionGroup="xbrli:item" />
<element name="OtherOperatingIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherOperatingIncomeExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmountsAllocatedToSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AmountsAllocatedToSegmentsAbstract" substitutionGroup="xbrli:item" />
<element name="AmountsNotAllocatedToSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AmountsNotAllocatedToSegmentsAbstract" substitutionGroup="xbrli:item" />
<element name="CostsRelatedToRegulatoryActionsTakenInFacilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_CostsRelatedToRegulatoryActionsTakenInFacilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PurchaseOfResearchAndDevelopmentInProcess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_PurchaseOfResearchAndDevelopmentInProcess" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherUnallocatedAmounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_OtherUnallocatedAmounts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SegmentsAndOtherActivitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SegmentsAndOtherActivitiesMember" substitutionGroup="xbrli:item" />
<element name="GenericsMediciansMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_GenericsMediciansMember" substitutionGroup="xbrli:item" />
<element name="COPAXONEMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_COPAXONEMember" substitutionGroup="xbrli:item" />
<element name="QVARMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_QVARMember" substitutionGroup="xbrli:item" />
<element name="RespiratoryProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RespiratoryProductMember" substitutionGroup="xbrli:item" />
<element name="OtherProductsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OtherProductsMember" substitutionGroup="xbrli:item" />
<element name="ProAirMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ProAirMember" substitutionGroup="xbrli:item" />
<element name="AjovyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_AjovyMember" substitutionGroup="xbrli:item" />
<element name="BendekaAndTreandaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_BendekaAndTreandaMember" substitutionGroup="xbrli:item" />
<element name="RevenueTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="RevenueTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_RevenueTypeDomain" substitutionGroup="xbrli:item" />
<element name="Customer1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_Customer1Member" substitutionGroup="xbrli:item" />
<element name="Customer2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_Customer2Member" substitutionGroup="xbrli:item" />
<element name="NetSalesPresent" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_NetSalesPresent" substitutionGroup="xbrli:item" />
<element name="IEMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_IEMember" substitutionGroup="xbrli:item" />
<element name="OptionsAndForwardContractsDerivativeLiabilitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputProbabilityOfSuccessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_MeasurementInputProbabilityOfSuccessMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EagleTransactionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EagleTransactionMember" substitutionGroup="xbrli:item" />
<element name="ActavisGenericsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ActavisGenericsMember" substitutionGroup="xbrli:item" />
<element name="SeniornotesandconvertibleseniordebenturesmemberMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SeniornotesandconvertibleseniordebenturesmemberMember" substitutionGroup="xbrli:item" />
<element name="EmployeeRelatedObligationsNoncurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_EmployeeRelatedObligationsNoncurrentAbstract" substitutionGroup="xbrli:item" />
<element name="AccruedSeverancePayNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_AccruedSeverancePayNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EmployeeRelatedObligationsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_EmployeeRelatedObligationsNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FutureExpectedDomesticMinimumBenefitPaymentsYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FutureExpectedDomesticMinimumBenefitPaymentsYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FutureExpectedDomesticMinimumBenefitPaymentsYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FutureExpectedDomesticMinimumBenefitPaymentsYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SelectedQuarterlyFinancialInformationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SelectedQuarterlyFinancialInformationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SelectedQuarterlyFinancialInformationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_SelectedQuarterlyFinancialInformationLineItems" substitutionGroup="xbrli:item" />
<element name="ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>teva-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-February-2021 [01:05:17] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesComponentsOfLeaseExpenseDetail" roleURI="http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail" roleURI="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfDeferedIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" roleURI="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherIncomeScheduleOfOtherIncomeDetail" roleURI="http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNetScheduleOfFinancialExpensesDetail" roleURI="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingAndMarketingExpense" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_TEVA_IntangibleAssetsImpairments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_IntangibleAssetsImpairments" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_TEVA_LegalSettlementsAndLossContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_LegalSettlementsAndLossContingencies" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GoodwillImpairmentLoss" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_TEVA_ImpairmentsRestructuringAndOthers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_TEVA_ImpairmentsRestructuringAndOthers" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" use="optional" order="20" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AssetImpairmentCharges" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationAndAmortization" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_TEVA_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TEVA_DeferredIncomeTaxesNetAndUncertainTaxPositions" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_TEVA_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TEVA_ProfitFromSaleOfLongLivedAssetsAndInvestment" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_TEVA_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TEVA_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_TEVA_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_TEVA_PaymentToAcquireMarketableSecuritiesAndOtherAssets" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" xlink:label="loc_TEVA_PaymentsRelatedToTaxWithholdingForSharesAndDividend" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TEVA_PaymentsRelatedToTaxWithholdingForSharesAndDividend" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt" use="optional" order="24" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:label="loc_TEVA_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" xlink:label="loc_TEVA_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:to="loc_TEVA_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" xlink:label="loc_TEVA_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:to="loc_TEVA_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="28" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_OtherInventoryInTransit" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_TEVA_ImpairmentAndRestructuring" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_ImpairmentAndRestructuring" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherIncome" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PatentedMedicinesRegulationsAndSimilarPayments" xlink:label="loc_TEVA_PatentedMedicinesRegulationsAndSimilarPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherIncome" xlink:to="loc_TEVA_PatentedMedicinesRegulationsAndSimilarPayments" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherIncome" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherOperatingIncomeNet" xlink:label="loc_TEVA_OtherOperatingIncomeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherIncome" xlink:to="loc_TEVA_OtherOperatingIncomeNet" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_Land" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AssetsUnderConstructionAndPaymentsOnAccount" xlink:label="loc_TEVA_AssetsUnderConstructionAndPaymentsOnAccount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_TEVA_AssetsUnderConstructionAndPaymentsOnAccount" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_MachineryAndEquipmentGross" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="7" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtaExcludeIssuanceCost" xlink:label="loc_TEVA_LongTermDebtaExcludeIssuanceCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_LongTermDebtaExcludeIssuanceCost" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_LongTermDebtaExcludeIssuanceCost" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_LongTermDebtaExcludeIssuanceCost" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="loc_TEVA_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_LongTermDebtaExcludeIssuanceCost" xlink:to="loc_TEVA_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:label="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" xlink:label="loc_TEVA_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_TEVA_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsDeferredInterest" xlink:label="loc_TEVA_DeferredTaxAssetsDeferredInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_TEVA_DeferredTaxAssetsDeferredInterest" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" xlink:label="loc_TEVA_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_TEVA_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" xlink:label="loc_TEVA_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="loc_TEVA_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeRelatedObligationsNoncurrent" xlink:label="loc_TEVA_EmployeeRelatedObligationsNoncurrent" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccruedSeverancePayNoncurrent" xlink:label="loc_TEVA_AccruedSeverancePayNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_EmployeeRelatedObligationsNoncurrent" xlink:to="loc_TEVA_AccruedSeverancePayNoncurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_EmployeeRelatedObligationsNoncurrent" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinanceIncomeExpensesNet" xlink:label="loc_TEVA_FinanceIncomeExpensesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_FinanceIncomeExpensesNet" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_FinanceIncomeExpensesNet" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ForeignCurrencyTransactionGainLoss" xlink:label="loc_TEVA_ForeignCurrencyTransactionGainLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_FinanceIncomeExpensesNet" xlink:to="loc_TEVA_ForeignCurrencyTransactionGainLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherFinancialIncomeExpenseNet" xlink:label="loc_TEVA_OtherFinancialIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_TEVA_FinanceIncomeExpensesNet" xlink:to="loc_TEVA_OtherFinancialIncomeExpenseNet" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" use="optional" order="8" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" use="optional" order="4" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="13" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DebtCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_TEVA_SalesReservesAndAllowances" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_TEVA_SalesReservesAndAllowances" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccruedExpenses" xlink:label="loc_TEVA_AccruedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_TEVA_AccruedExpenses" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_LongTermNotesAndLoans" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" use="optional" order="34" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="35" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" xlink:label="loc_TEVA_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_TEVA_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_VariableLeaseCost" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_ShortTermLeaseCost" use="optional" order="3" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>teva-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-February-2021 [01:05:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfChangesInEquityParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SignificantAccountingPolicies" roleURI="http://www.tevapharm.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactions" roleURI="http://www.tevapharm.com/role/CertainTransactions" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomers" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Inventories" roleURI="http://www.tevapharm.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipment" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipment" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssets" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Goodwill" roleURI="http://www.tevapharm.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Leases" roleURI="http://www.tevapharm.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligations" roleURI="http://www.tevapharm.com/role/DebtObligations" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivities" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LegalSettlementsAndLossContingencies" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CommitmentsAndContingencies" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxes" roleURI="http://www.tevapharm.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Equity" roleURI="http://www.tevapharm.com/role/Equity" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItems" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherIncome" roleURI="http://www.tevapharm.com/role/OtherIncome" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNet" roleURI="http://www.tevapharm.com/role/FinancialExpensesNet" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EarningsLossPerShare" roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Segments" roleURI="http://www.tevapharm.com/role/Segments" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurement" roleURI="http://www.tevapharm.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligations" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ScheduleOfValuationAndQualifyingAccounts" roleURI="http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsTables" roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomersTables" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#InventoriesTables" roleURI="http://www.tevapharm.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipmentTables" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssetsTables" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#GoodwillTables" roleURI="http://www.tevapharm.com/role/GoodwillTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesTables" roleURI="http://www.tevapharm.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsTables" roleURI="http://www.tevapharm.com/role/DebtObligationsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesTables" roleURI="http://www.tevapharm.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityTables" roleURI="http://www.tevapharm.com/role/EquityTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsTables" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherIncomeTables" roleURI="http://www.tevapharm.com/role/OtherIncomeTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNetTables" roleURI="http://www.tevapharm.com/role/FinancialExpensesNetTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EarningsLossPerShareTables" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsTables" roleURI="http://www.tevapharm.com/role/SegmentsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementTables" roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligationsTables" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsBusinessTransactionsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsOtherTransactionsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomersAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipmentAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#GoodwillAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesComponentsOfLeaseExpenseDetail" roleURI="http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesSupplementalCashFlowInformationRelatedToLeasesDetail" roleURI="http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesMaturitiesOfLeaseLiabilitiesDetail" roleURI="http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsScheduleOfShortTermDebtDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail" roleURI="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail" roleURI="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LegalSettlementsAndLossContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfDeferedIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/EquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquitySummaryOfStockOptionActivityDetail" roleURI="http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail" roleURI="http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail" roleURI="http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail" roleURI="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail" roleURI="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail" roleURI="http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail" roleURI="http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" roleURI="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" roleURI="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherIncomeScheduleOfOtherIncomeDetail" roleURI="http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNetScheduleOfFinancialExpensesDetail" roleURI="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail" roleURI="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EarningsLossPerShareScheduleOfEarningsPerShareDetail" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EarningsLossPerShareAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsSummaryOfSegmentProfitDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligationsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail" roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ScheduleIiValuationAndQualifyingAccountsDetail" roleURI="http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CoverPage" roleURI="http://www.tevapharm.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_AssetsAbstract_27" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_AssetsCurrentAbstract_28" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_InventoryNet_44" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_OtherAssetsCurrent_46" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_45" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Goodwill_40" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Assets_41" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_37" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_38" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommitmentsAndContingencies_50" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_31" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_DebtCurrent_55" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_57" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_AccruedExpenses_59" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_60" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_SalesReservesAndAllowances_56" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_Liabilities_51" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_66" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LongTermNotesAndLoans_65" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_CommonStockValue_68" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AdditionalPaidInCapital_69" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_StockholdersEquity_73" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_TreasuryStockValue_72" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_StatementTable_34" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_dei_LegalEntityAxis_29" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49_default" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_84" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_84" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesIssued_85" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_StatementTable_78" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_dei_LegalEntityAxis_76" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_86" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_TreasuryStockShares_86" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_91" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_102" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_104" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GrossProfit_99" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_98" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_94" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasic_94" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_95" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_95" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ProfitLoss_113" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_111" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_IntangibleAssetsImpairments_103" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLoss_115" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_117" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_109" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OperatingIncomeLoss_108" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_555939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_555939" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_SellingAndMarketingExpense_101" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_StatementTable_92" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_dei_LegalEntityAxis_90" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_408527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_408527" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_412170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_412170" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_124" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_128" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_720056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_720056" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ProfitLoss_132" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_StatementTable_125" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_dei_LegalEntityAxis_122" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_141" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_DividendsPreferredStockCash_163" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherEquity" xlink:label="loc_teva_OtherEquity_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_teva_OtherEquity_166" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StatementTable_142" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_140" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_NoncontrollingInterestMember_150" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_CommonStockMember_143" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_ParentMember_149" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_PreferredStockMember_144" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_TreasuryStockMember_148" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xlink:label="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning_153" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_154" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TransactionsWithNonControllingInterests" xlink:label="loc_teva_TransactionsWithNonControllingInterests_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_teva_TransactionsWithNonControllingInterests_165" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_157" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_720066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_ProfitLoss_720066" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_176" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StatementTable_177" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_171" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472725" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_171" xlink:to="loc_us-gaap_CommonStockMember_178" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_srt_RangeAxis_173" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_174" xlink:to="loc_srt_MaximumMember_180" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_581610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_581610" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_190" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" xlink:label="loc_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories_206" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" xlink:label="loc_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt_205" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_207" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_204" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:label="loc_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation_209" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_211" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_213" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" xlink:label="loc_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend_406864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend_406864" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_506169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_506169" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_809430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_809430" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_223" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_DepreciationAndAmortization_194" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_AssetImpairmentCharges_193" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_412174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_ShareBasedCompensation_412174" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_764481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_764481" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_ProfitLoss_229" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_StatementTable_191" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_dei_LegalEntityAxis_186" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_236" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" xlink:to="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashPaidDuringTheYearForAbstract" xlink:label="loc_teva_CashPaidDuringTheYearForAbstract_584943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_teva_CashPaidDuringTheYearForAbstract_584943" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CashPaidDuringTheYearForAbstract_584943" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_241" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CashPaidDuringTheYearForAbstract_584943" xlink:to="loc_us-gaap_InterestPaidNet_240" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1654" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1654" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1657" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1654" xlink:to="loc_us-gaap_StatementTable_1655" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1655" xlink:to="loc_dei_LegalEntityAxis_1653" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1653" xlink:to="loc_dei_EntityDomain_1656" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1653" xlink:to="loc_dei_EntityDomain_1656_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1696" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock_1699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_teva_CertainTransactionsDisclosureTextBlock_1699" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_us-gaap_StatementTable_1697" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_dei_LegalEntityAxis_1695" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1797" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_StatementTable_1798" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_dei_LegalEntityAxis_1796" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Inventories">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1741" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1744" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_StatementTable_1742" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_dei_LegalEntityAxis_1740" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1755" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1755" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1758" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1755" xlink:to="loc_us-gaap_StatementTable_1756" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1756" xlink:to="loc_dei_LegalEntityAxis_1754" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1754" xlink:to="loc_dei_EntityDomain_1757" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1757_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1754" xlink:to="loc_dei_EntityDomain_1757_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1783" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_StatementTable_1784" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_dei_LegalEntityAxis_1782" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Goodwill">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1769" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_1772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_1772" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_StatementTable_1770" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_dei_LegalEntityAxis_1768" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_389988" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_389985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_389988" xlink:to="loc_us-gaap_StatementTable_389985" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_389986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_389985" xlink:to="loc_dei_LegalEntityAxis_389986" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_389987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_389986" xlink:to="loc_dei_EntityDomain_389987" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_389987_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_389986" xlink:to="loc_dei_EntityDomain_389987_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_389991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_389988" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_389991" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1826" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_StatementTable_1827" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_dei_LegalEntityAxis_1825" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1829" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1903" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_StatementTable_1904" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_dei_LegalEntityAxis_1902" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1949" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_StatementTable_1950" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_dei_LegalEntityAxis_1948" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1856" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_StatementTable_1857" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_dei_LegalEntityAxis_1855" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1884" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_StatementTable_1885" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_dei_LegalEntityAxis_1883" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1863" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1863" xlink:to="loc_us-gaap_StatementTable_1864" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1864" xlink:to="loc_dei_LegalEntityAxis_1862" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1862" xlink:to="loc_dei_EntityDomain_1865" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1865_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1862" xlink:to="loc_dei_EntityDomain_1865_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_556529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1863" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_556529" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1933" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock_1936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_teva_OtherExpensesTextBlock_1936" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_us-gaap_StatementTable_1934" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_dei_LegalEntityAxis_1932" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1842" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1842" xlink:to="loc_us-gaap_StatementTable_1843" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1843" xlink:to="loc_dei_LegalEntityAxis_1841" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1841" xlink:to="loc_dei_EntityDomain_1844" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1844_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1841" xlink:to="loc_dei_EntityDomain_1844_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_1845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1842" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_1845" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1919" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1919" xlink:to="loc_us-gaap_StatementTable_1920" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1920" xlink:to="loc_dei_LegalEntityAxis_1918" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1918" xlink:to="loc_dei_EntityDomain_1921" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1921_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1918" xlink:to="loc_dei_EntityDomain_1921_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetTextBlock" xlink:label="loc_teva_FinancialExpensesNetTextBlock_1922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1919" xlink:to="loc_teva_FinancialExpensesNetTextBlock_1922" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1974" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_StatementTable_1975" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_dei_LegalEntityAxis_1973" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1977" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Segments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1956" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_StatementTable_1957" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_dei_LegalEntityAxis_1955" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1713" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_StatementTable_1711" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_dei_LegalEntityAxis_1709" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1812" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermEmployeeRelatedObligationsTextBlock" xlink:label="loc_teva_LongTermEmployeeRelatedObligationsTextBlock_1815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1812" xlink:to="loc_teva_LongTermEmployeeRelatedObligationsTextBlock_1815" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1812" xlink:to="loc_us-gaap_StatementTable_1813" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1813" xlink:to="loc_dei_LegalEntityAxis_1811" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1811" xlink:to="loc_dei_EntityDomain_1814" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1814_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1811" xlink:to="loc_dei_EntityDomain_1814_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1988" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialDataTextBlock" xlink:label="loc_teva_SelectedQuarterlyFinancialDataTextBlock_1991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1988" xlink:to="loc_teva_SelectedQuarterlyFinancialDataTextBlock_1991" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1988" xlink:to="loc_us-gaap_StatementTable_1989" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1989" xlink:to="loc_dei_LegalEntityAxis_1987" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1987" xlink:to="loc_dei_EntityDomain_1990" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1990_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1987" xlink:to="loc_dei_EntityDomain_1990_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2002" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2002" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2005" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2002" xlink:to="loc_us-gaap_StatementTable_2003" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2003" xlink:to="loc_dei_LegalEntityAxis_2001" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2001" xlink:to="loc_dei_EntityDomain_2004" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2004_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2001" xlink:to="loc_dei_EntityDomain_2004_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1661" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AcquisitionTextBlock" xlink:label="loc_teva_AcquisitionTextBlock_1666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_AcquisitionTextBlock_1666" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1685" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1671" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1667" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1676" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1673" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxesUncertaintiesPolicyTextBlock" xlink:label="loc_teva_IncomeTaxesUncertaintiesPolicyTextBlock_1680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_IncomeTaxesUncertaintiesPolicyTextBlock_1680" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1679" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CostOfShippingAndHandlingPolicyTextBlock" xlink:label="loc_teva_CostOfShippingAndHandlingPolicyTextBlock_1684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_CostOfShippingAndHandlingPolicyTextBlock_1684" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_1692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_DebtPolicyTextBlock_1692" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1688" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EquityAndCostMethodInvestmentPolicyTextBlock" xlink:label="loc_teva_EquityAndCostMethodInvestmentPolicyTextBlock_1668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_EquityAndCostMethodInvestmentPolicyTextBlock_1668" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1669" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GeneralOptionsAccountingPolicyPolicyTextBlock" xlink:label="loc_teva_GeneralOptionsAccountingPolicyPolicyTextBlock_1664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_GeneralOptionsAccountingPolicyPolicyTextBlock_1664" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1675" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock_1682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock_1682" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_1681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_1681" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DivestituresTextBlock" xlink:label="loc_teva_DivestituresTextBlock_1690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_DivestituresTextBlock_1690" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1678" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_1674" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1670" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1683" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringTextBlock" xlink:label="loc_teva_RestructuringTextBlock_1686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_RestructuringTextBlock_1686" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SecuritizationTextBlock" xlink:label="loc_teva_SecuritizationTextBlock_1689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_SecuritizationTextBlock_1689" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1687" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_StatementTable_1662" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_dei_LegalEntityAxis_1660" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TreasurySharesPolicyTextBlock" xlink:label="loc_teva_TreasurySharesPolicyTextBlock_1677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_TreasurySharesPolicyTextBlock_1677" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_556086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_556086" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccountsReceivablesPolicyTextBlock" xlink:label="loc_teva_AccountsReceivablesPolicyTextBlock_572410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_AccountsReceivablesPolicyTextBlock_572410" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1703" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_us-gaap_StatementTable_1704" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_dei_LegalEntityAxis_1702" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1804" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_StatementTable_1805" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_dei_LegalEntityAxis_1803" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806_default" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1748" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_StatementTable_1749" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_dei_LegalEntityAxis_1747" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1762" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1762" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1765" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1762" xlink:to="loc_us-gaap_StatementTable_1763" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1763" xlink:to="loc_dei_LegalEntityAxis_1761" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1761" xlink:to="loc_dei_EntityDomain_1764" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1764_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1761" xlink:to="loc_dei_EntityDomain_1764_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1790" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_StatementTable_1791" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_dei_LegalEntityAxis_1789" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1776" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_StatementTable_1777" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_dei_LegalEntityAxis_1775" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_389999" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_389996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_us-gaap_StatementTable_389996" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_389997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_389996" xlink:to="loc_dei_LegalEntityAxis_389997" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_389998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_389997" xlink:to="loc_dei_EntityDomain_389998" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_389998_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_389997" xlink:to="loc_dei_EntityDomain_389998_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" xlink:label="loc_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock_390017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock_390017" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SupplementalCashFlowInformationTableTextBlock" xlink:label="loc_teva_SupplementalCashFlowInformationTableTextBlock_390273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_teva_SupplementalCashFlowInformationTableTextBlock_390273" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ComponentsOfLeaseExpenseTableTextBlock" xlink:label="loc_teva_ComponentsOfLeaseExpenseTableTextBlock_390276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_teva_ComponentsOfLeaseExpenseTableTextBlock_390276" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_390009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_390009" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1833" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xlink:label="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock_1837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock_1837" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_StatementTable_1834" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_dei_LegalEntityAxis_1832" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_556360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_556360" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1910" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_StatementTable_1911" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_dei_LegalEntityAxis_1909" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_390224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_390224" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_406869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_406869" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1913" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfAccountReceivableFromSecuritization" xlink:label="loc_teva_ScheduleOfAccountReceivableFromSecuritization_557012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_teva_ScheduleOfAccountReceivableFromSecuritization_557012" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1891" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock_1895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock_1895" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" xlink:label="loc_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock_1898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock_1898" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1897" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1896" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1894" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1899" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_StatementTable_1892" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1892" xlink:to="loc_dei_LegalEntityAxis_1890" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1890" xlink:to="loc_dei_EntityDomain_1893" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1893_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1890" xlink:to="loc_dei_EntityDomain_1893_default" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1870" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1878" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1876" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1879" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1875" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1874" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_1877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_1877" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1880" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1873" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_StatementTable_1871" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1871" xlink:to="loc_dei_LegalEntityAxis_1869" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1869" xlink:to="loc_dei_EntityDomain_1872" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1872_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1869" xlink:to="loc_dei_EntityDomain_1872_default" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1940" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_StatementTable_1941" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_dei_LegalEntityAxis_1939" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherIncomeTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1849" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfOtherIncomeTableTextBlock" xlink:label="loc_teva_ScheduleOfOtherIncomeTableTextBlock_1852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1849" xlink:to="loc_teva_ScheduleOfOtherIncomeTableTextBlock_1852" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1849" xlink:to="loc_us-gaap_StatementTable_1850" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1850" xlink:to="loc_dei_LegalEntityAxis_1848" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1848" xlink:to="loc_dei_EntityDomain_1851" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1851_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1848" xlink:to="loc_dei_EntityDomain_1851_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNetTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1926" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetTableTextBlock" xlink:label="loc_teva_FinancialExpensesNetTableTextBlock_1929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1926" xlink:to="loc_teva_FinancialExpensesNetTableTextBlock_1929" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1926" xlink:to="loc_us-gaap_StatementTable_1927" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1927" xlink:to="loc_dei_LegalEntityAxis_1925" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1925" xlink:to="loc_dei_EntityDomain_1928" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1928_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1925" xlink:to="loc_dei_EntityDomain_1928_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1981" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1981" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1984" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1981" xlink:to="loc_us-gaap_StatementTable_1982" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1982" xlink:to="loc_dei_LegalEntityAxis_1980" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1980" xlink:to="loc_dei_EntityDomain_1983" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1983_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1980" xlink:to="loc_dei_EntityDomain_1983_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1963" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" xlink:label="loc_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock_1970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock_1970" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesPercentageByTherapeuticCategoryTableTextBlock" xlink:label="loc_teva_SalesPercentageByTherapeuticCategoryTableTextBlock_1969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_SalesPercentageByTherapeuticCategoryTableTextBlock_1969" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_StatementTable_1964" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_dei_LegalEntityAxis_1962" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965_default" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1717" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_StatementTable_1718" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_dei_LegalEntityAxis_1716" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1819" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermEmployeeRelatedObligationsTableTextBlock" xlink:label="loc_teva_LongTermEmployeeRelatedObligationsTableTextBlock_1822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1819" xlink:to="loc_teva_LongTermEmployeeRelatedObligationsTableTextBlock_1822" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1819" xlink:to="loc_us-gaap_StatementTable_1820" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1820" xlink:to="loc_dei_LegalEntityAxis_1818" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1818" xlink:to="loc_dei_EntityDomain_1821" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1821_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1818" xlink:to="loc_dei_EntityDomain_1821_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1995" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialDataTableTextBlock" xlink:label="loc_teva_SelectedQuarterlyFinancialDataTableTextBlock_1998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1995" xlink:to="loc_teva_SelectedQuarterlyFinancialDataTableTextBlock_1998" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1995" xlink:to="loc_us-gaap_StatementTable_1996" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1996" xlink:to="loc_dei_LegalEntityAxis_1994" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1994" xlink:to="loc_dei_EntityDomain_1997" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1997_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1994" xlink:to="loc_dei_EntityDomain_1997_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SignificantAccountingPoliciesLineItems" xlink:label="loc_teva_SignificantAccountingPoliciesLineItems_245" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" xlink:label="loc_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions_262" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_AdvertisingExpense_267" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageOfConsolidatedSalesInNorthAmerica" xlink:label="loc_teva_PercentageOfConsolidatedSalesInNorthAmerica_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_PercentageOfConsolidatedSalesInNorthAmerica_263" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CreditTermsToCustomers" xlink:label="loc_teva_CreditTermsToCustomers_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_CreditTermsToCustomers_265" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_264" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_244" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_244" xlink:to="loc_us-gaap_TypeOfAdoptionMember_256" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_256_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_244" xlink:to="loc_us-gaap_TypeOfAdoptionMember_256_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_255" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_255" xlink:to="loc_us-gaap_EquityComponentDomain_246" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_246_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_255" xlink:to="loc_us-gaap_EquityComponentDomain_246_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_247" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_247" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_248" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_248_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_247" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_248_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_dei_LegalEntityAxis_249" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_249" xlink:to="loc_dei_EntityDomain_274" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_274_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_249" xlink:to="loc_dei_EntityDomain_274_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_250" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_250" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_250" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" xlink:to="loc_us-gaap_BuildingMember_275" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" xlink:to="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_277" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_276" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_srt_RangeAxis_252" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_252" xlink:to="loc_srt_RangeMember_253" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_253_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_252" xlink:to="loc_srt_RangeMember_253_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_253" xlink:to="loc_srt_MinimumMember_278" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_253" xlink:to="loc_srt_MaximumMember_279" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShippingHandlingAndTransportationCost" xlink:label="loc_teva_ShippingHandlingAndTransportationCost_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_ShippingHandlingAndTransportationCost_266" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_268" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_556063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_556063" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseRemainingLeaseTerm" xlink:label="loc_teva_OperatingLeaseRemainingLeaseTerm_556067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_OperatingLeaseRemainingLeaseTerm_556067" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription_556082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescription_556082" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_572119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_572119" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_287" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OneTimeMilestonePaymentReceived" xlink:label="loc_teva_OneTimeMilestonePaymentReceived_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_287" xlink:to="loc_teva_OneTimeMilestonePaymentReceived_296" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_287" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_294" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_287" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_286" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_286" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_286" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ActavisMember" xlink:label="loc_teva_ActavisMember_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285" xlink:to="loc_teva_ActavisMember_292" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285" xlink:to="loc_teva_AndaMember_293" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_dei_LegalEntityAxis_289" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_297" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_297_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_srt_CounterpartyNameAxis_288" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_288" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_290" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_290_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_288" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_290_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AllerganPlcMember" xlink:label="loc_teva_AllerganPlcMember_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_290" xlink:to="loc_teva_AllerganPlcMember_298" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_504335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_504335" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_504336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_504335" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_504336" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_504336_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_504335" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_504336_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_504332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_srt_StatementGeographicalAxis_504332" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_504333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_504332" xlink:to="loc_srt_SegmentGeographicalDomain_504333" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_504333_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_504332" xlink:to="loc_srt_SegmentGeographicalDomain_504333_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_287" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_295" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_CollaborativeAgreementMilestonePayments_327" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_us-gaap_GainLossOnInvestments_329" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_328" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_330" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RefundablePayment" xlink:label="loc_teva_RefundablePayment_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_RefundablePayment_333" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_302" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CelltrionMember" xlink:label="loc_teva_CelltrionMember_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_CelltrionMember_317" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AlderMember" xlink:label="loc_teva_AlderMember_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlderMember_313" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RegeneronMember" xlink:label="loc_teva_RegeneronMember_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_RegeneronMember_318" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RimsaMember" xlink:label="loc_teva_RimsaMember_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_RimsaMember_312" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_OtsukaMember_314" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember_758265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlvotechMember_758265" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_CounterpartyNameAxis_303" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_dei_LegalEntityAxis_304" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_ProductOrServiceAxis_307" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PgtMember" xlink:label="loc_teva_PgtMember_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_309" xlink:to="loc_teva_PgtMember_338" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_758271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_LeaseContractualTermAxis_758271" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_RangeAxis_765341" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_758266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_758266" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ResearchAndDevelopmentCosts" xlink:label="loc_teva_ResearchAndDevelopmentCosts_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_ResearchAndDevelopmentCosts_335" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TotalAssociatedCost" xlink:label="loc_teva_TotalAssociatedCost_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_TotalAssociatedCost_334" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_UpfrontPayments_326" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NumberOfLawsuitsFiled" xlink:label="loc_teva_NumberOfLawsuitsFiled_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_NumberOfLawsuitsFiled_321" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_320" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment_572506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_MilestonePayment_572506" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_718596" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_718593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_718596" xlink:to="loc_us-gaap_StatementTable_718593" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_718594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_718593" xlink:to="loc_us-gaap_StatementClassOfStockAxis_718594" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_718595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_718594" xlink:to="loc_us-gaap_ClassOfStockDomain_718595" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_718595_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_718594" xlink:to="loc_us-gaap_ClassOfStockDomain_718595_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_718600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_718593" xlink:to="loc_srt_OwnershipAxis_718600" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_718601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_718600" xlink:to="loc_srt_OwnershipDomain_718601" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_718601_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_718600" xlink:to="loc_srt_OwnershipDomain_718601_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TevaMember" xlink:label="loc_teva_TevaMember_718602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_718601" xlink:to="loc_teva_TevaMember_718602" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_718597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_718596" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_718597" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_718598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_718596" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_718598" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_718599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_718596" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_718599" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_607" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_RevenueRecognitionTable_608" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_srt_StatementGeographicalAxis_610" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_609" xlink:to="loc_country_US_617" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_dei_LegalEntityAxis_604" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_620" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_621" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_ProductOrServiceAxis_623" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_DistributionServiceMember_633" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_LicenseMember_632" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_634" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductMember_631" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_dei_LegalEntityAxis_622" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_627" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_InternationalMarketsMember_635" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_OtherActivitiesMember_636" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_StatementGeographicalAxis_628" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_EuropeMember_638" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_NorthAmericaMember_637" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_642" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_RevenueRecognitionTable_643" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_dei_LegalEntityAxis_641" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_OtherSalesReservesAndAllowancesMember_658" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_RebatesMember_654" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReturnsMember_657" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ChargebacksMember_656" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems_452" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_teva_InventoriesTable_453" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_dei_LegalEntityAxis_454" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryNet_459" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit_458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_OtherInventoryInTransit_458" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_473" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_468" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_Land_471" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_467" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_472" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_474" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_469" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_465" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_465" xlink:to="loc_dei_LegalEntityAxis_463" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_463" xlink:to="loc_dei_EntityDomain_466" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_466_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_463" xlink:to="loc_dei_EntityDomain_466_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AssetsUnderConstructionAndPaymentsOnAccount" xlink:label="loc_teva_AssetsUnderConstructionAndPaymentsOnAccount_581605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_teva_AssetsUnderConstructionAndPaymentsOnAccount_581605" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_492" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_492" xlink:to="loc_us-gaap_Depreciation_495" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_492" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xlink:to="loc_dei_LegalEntityAxis_491" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_491" xlink:to="loc_dei_EntityDomain_494" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_494_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_491" xlink:to="loc_dei_EntityDomain_494_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_492" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_496" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_teva_ProductRightsMember_567" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_TradeNamesMember_568" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_594" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_589" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_588" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_593" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_592" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_590" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_591" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_574" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ActavisMember" xlink:label="loc_teva_ActavisMember_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" xlink:to="loc_teva_ActavisMember_582" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" xlink:to="loc_teva_AustedoMember_584" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_teva_ProductRightsMember_598" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis_581599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_DiscontinuationOfBusinessAxis_581599" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuedBusinessMember" xlink:label="loc_teva_DiscontinuedBusinessMember_581601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DiscontinuationOfBusinessDomain_581600" xlink:to="loc_teva_DiscontinuedBusinessMember_581601" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_408202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_ProductOrServiceAxis_408202" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LenalidomideProductMember" xlink:label="loc_teva_LenalidomideProductMember_408205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_408203" xlink:to="loc_teva_LenalidomideProductMember_408205" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_dei_LegalEntityAxis_578" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_764554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_764554" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_StatementGeographicalAxis_581" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:label="loc_country_JP_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_580" xlink:to="loc_country_JP_601" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_580" xlink:to="loc_teva_InternationalMarketsMember_600" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_764548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_RangeAxis_764548" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_764550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MinimumMember_764550" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_764551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MaximumMember_764551" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" use="optional" order="48" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_499" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_506" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_509" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_501" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_391588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_ConsolidationItemsAxis_391588" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_504" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_StatementGeographicalAxis_505" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_EuropeMember_519" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_InternationalMarketsMember_520" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_NorthAmericaMember_518" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_OtherCountriesMember_521" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_dei_LegalEntityAxis_500" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GoodwillReclassification" xlink:label="loc_teva_GoodwillReclassification_556229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_teva_GoodwillReclassification_556229" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_816238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_816238" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_524" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_526" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_dei_LegalEntityAxis_525" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_531" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_536" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_539" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementGeographicalAxis_540" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_538" xlink:to="loc_srt_NorthAmericaMember_556" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherMember" xlink:label="loc_teva_OtherMember_764540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_538" xlink:to="loc_teva_OtherMember_764540" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_RangeAxis_533" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_dei_LegalEntityAxis_532" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_556283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementScenarioAxis_556283" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_718483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_718483" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" xlink:label="loc_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill_581567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill_581567" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageDecreaseInTheMarketCapitalization" xlink:label="loc_teva_PercentageDecreaseInTheMarketCapitalization_764541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_teva_PercentageDecreaseInTheMarketCapitalization_764541" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_821784" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_821781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_821784" xlink:to="loc_us-gaap_StatementTable_821781" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_821782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_821781" xlink:to="loc_dei_LegalEntityAxis_821782" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_821783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_821782" xlink:to="loc_dei_EntityDomain_821783" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_821783_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_821782" xlink:to="loc_dei_EntityDomain_821783_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseCostAbstract" xlink:label="loc_teva_OperatingLeaseCostAbstract_821789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_821784" xlink:to="loc_teva_OperatingLeaseCostAbstract_821789" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" xlink:label="loc_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate_821792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeaseCostAbstract_821789" xlink:to="loc_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate_821792" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_821794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeaseCostAbstract_821789" xlink:to="loc_us-gaap_VariableLeaseCost_821794" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_821796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeaseCostAbstract_821789" xlink:to="loc_us-gaap_ShortTermLeaseCost_821796" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_821797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeaseCostAbstract_821789" xlink:to="loc_us-gaap_LeaseCost_821797" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390196" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" xlink:label="loc_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract_391682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390196" xlink:to="loc_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract_391682" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesNonCash" xlink:label="loc_teva_OperatingLeasesNonCash_391689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract_391682" xlink:to="loc_teva_OperatingLeasesNonCash_391689" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" xlink:label="loc_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract_390197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390196" xlink:to="loc_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract_390197" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_390199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract_390197" xlink:to="loc_us-gaap_OperatingLeasePayments_390199" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390196" xlink:to="loc_us-gaap_StatementTable_390193" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_801291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390193" xlink:to="loc_dei_LegalEntityAxis_801291" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_801292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_801291" xlink:to="loc_dei_EntityDomain_801292" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_801292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_801291" xlink:to="loc_dei_EntityDomain_801292_default" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390098" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesAbstract" xlink:label="loc_teva_OperatingLeasesAbstract_390099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390098" xlink:to="loc_teva_OperatingLeasesAbstract_390099" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_390100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_390100" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseLiabilityOther" xlink:label="loc_teva_OperatingLeaseLiabilityOther_390102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_teva_OperatingLeaseLiabilityOther_390102" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_390103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_390103" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_390104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseLiability_390104" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_390144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_390144" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_390151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_390151" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_820573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390098" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_820573" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390098" xlink:to="loc_us-gaap_StatementTable_390095" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390095" xlink:to="loc_dei_LegalEntityAxis_390096" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390096" xlink:to="loc_dei_EntityDomain_390097" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390097_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390096" xlink:to="loc_dei_EntityDomain_390097_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_390154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390095" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_390154" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_390155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_390154" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_390155" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_390155_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_390154" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_390155_default" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390045" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_StatementTable_390042" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390042" xlink:to="loc_dei_LegalEntityAxis_390043" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_390043" xlink:to="loc_dei_EntityDomain_390044" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390044_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_390043" xlink:to="loc_dei_EntityDomain_390044_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesImputedInterest" xlink:label="loc_teva_OperatingLeasesImputedInterest_390062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_teva_OperatingLeasesImputedInterest_390062" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_390064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_OperatingLeaseLiability_390064" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_390050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_390050" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_390051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_390051" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_390053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_390053" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_390054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_390054" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="loc_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_390056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_390056" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_390060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_390060" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390349" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_StatementTable_390346" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_390431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390346" xlink:to="loc_srt_RangeAxis_390431" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_390432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_390431" xlink:to="loc_srt_RangeMember_390432" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_390432_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_390431" xlink:to="loc_srt_RangeMember_390432_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_390434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_390432" xlink:to="loc_srt_MinimumMember_390434" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_390433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_390432" xlink:to="loc_srt_MaximumMember_390433" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_515069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390346" xlink:to="loc_srt_StatementGeographicalAxis_515069" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_515070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_515069" xlink:to="loc_srt_SegmentGeographicalDomain_515070" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_515070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_515069" xlink:to="loc_srt_SegmentGeographicalDomain_515070_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390346" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515072" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515072" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515073" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515073_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515072" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515073_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_809731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_809731" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_412011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_412011" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_412012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_FinanceLeaseLiability_412012" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_809732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_OperatingLeaseLiability_809732" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_688" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_teva_DebtInstrumentMaturityYear_698" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtCurrent_701" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentTable_690" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentAxis_687" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689" xlink:to="loc_teva_ShortCreditAgreement2026Member_704" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_504448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_CreditFacilityAxis_504448" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_srt_CurrencyAxis_686" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_dei_LegalEntityAxis_691" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_VariableRateAxis_692" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_LongTermDebtCurrent_700" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_ShortTermBorrowings_699" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_762" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_teva_DebtInstrumentMaturityYear_772" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_769" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DebtInstrumentTable_764" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentAxis_761" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020OneMember_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2020OneMember_782" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020TwoMember_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2020TwoMember_800" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021OneMember_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021OneMember_791" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_787" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_799" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_794" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_OtherDebentures2026Member_814" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember_802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember_802" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2027Member_789" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_572585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_572585" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_801" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_798" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_783" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_786" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_dei_LegalEntityAxis_765" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_VariableRateAxis_766" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_srt_CurrencyAxis_760" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermDebtCurrent_778" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermNotesAndLoans_781" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_SeniorNotes_775" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_820" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentTable_822" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentAxis_819" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_841" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_844" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_826" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_848" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_829" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2027Member_832" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_830" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020OneMember_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2020OneMember_825" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020TwoMember_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2020TwoMember_843" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021OneMember_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021OneMember_834" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember_845" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_842" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_837" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_824" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturityLineItems" xlink:label="loc_teva_LongTermDebtMaturityLineItems_860" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_865" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtaExcludeIssuanceCost" xlink:label="loc_teva_LongTermDebtaExcludeIssuanceCost_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_teva_LongTermDebtaExcludeIssuanceCost_868" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_866" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_864" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturityTable" xlink:label="loc_teva_LongTermDebtMaturityTable_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_teva_LongTermDebtMaturityTable_861" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_LongTermDebtMaturityTable_861" xlink:to="loc_dei_LegalEntityAxis_859" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_862" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_862_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_862_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="loc_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_867" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_808808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_808808" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_816467" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_816461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_816467" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_816461" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_816462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_816461" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_816462" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_816463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_816462" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_816463" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_816463_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_816462" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_816463_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_816465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_816463" xlink:to="loc_us-gaap_ConvertibleDebtMember_816465" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_816468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_816467" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_816468" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_722" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_732" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentTable_724" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_CreditFacilityAxis_719" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_728" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentAxis_721" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_dei_LegalEntityAxis_725" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_726" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_727" xlink:to="loc_us-gaap_ConvertibleDebtMember_756" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_408262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_408262" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_408266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_408264" xlink:to="loc_us-gaap_SeniorNotesMember_408266" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis_682383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_TrancheAxis_682383" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheAMember" xlink:label="loc_teva_TracheAMember_682385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_TrancheDomain_682384" xlink:to="loc_teva_TracheAMember_682385" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheBMember" xlink:label="loc_teva_TracheBMember_682386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_TrancheDomain_682384" xlink:to="loc_teva_TracheBMember_682386" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_466637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_466637" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_682892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_682892" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheAExtensionMember" xlink:label="loc_teva_TracheAExtensionMember_682894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" xlink:to="loc_teva_TracheAExtensionMember_682894" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_srt_RangeAxis_765345" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaap_LinesOfCreditCurrent_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LinesOfCreditCurrent_729" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_SeniorNotes_733" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionCHF_741" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionEUR_740" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionUSD_739" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_390546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_390546" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_466634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_466634" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_466635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCredit_466635" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_682388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_682388" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1318" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1318" xlink:to="loc_us-gaap_DerivativeTable_1319" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1317" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1317" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1322" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1322_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1317" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1322_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1322" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1330" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1316" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1316" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1315" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1315_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1316" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1315_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1315" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_1324" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_1320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_us-gaap_HedgingDesignationAxis_1320" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1320" xlink:to="loc_us-gaap_HedgingDesignationDomain_1321" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1321_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1320" xlink:to="loc_us-gaap_HedgingDesignationDomain_1321_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1321" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1327" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_dei_LegalEntityAxis_1323" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1323" xlink:to="loc_dei_EntityDomain_1331" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1331_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1323" xlink:to="loc_dei_EntityDomain_1331_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1318" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1326" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1339" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeTable_1340" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_408399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1343" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_408399" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_1350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_1350" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1348" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SwapMember" xlink:label="loc_us-gaap_SwapMember_1349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_SwapMember_1349" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1334" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1347" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesAndLoansMember" xlink:label="loc_teva_SeniorNotesAndLoansMember_1346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_teva_SeniorNotesAndLoansMember_1346" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1345" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_390198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_390198" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_dei_LegalEntityAxis_1344" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_HedgingDesignationAxis_1341" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_NondesignatedMember_1354" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1353" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_390277" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_390269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_390277" xlink:to="loc_us-gaap_DerivativeTable_390269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_390270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_390270" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_390271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_390270" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_390271" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_390271_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_390270" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_390271_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390330" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390330" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390338" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390338_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390330" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390338_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember_390351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390338" xlink:to="loc_teva_FinancialExpensesMember_390351" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_390379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_390379" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_390380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_390379" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_390380" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_390380_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_390379" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_390380_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_390381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_390380" xlink:to="loc_us-gaap_OtherComprehensiveIncomeMember_390381" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_391806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_391806" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_391807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_391806" xlink:to="loc_us-gaap_HedgingRelationshipDomain_391807" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_391807_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_391806" xlink:to="loc_us-gaap_HedgingRelationshipDomain_391807_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_391809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_391807" xlink:to="loc_us-gaap_CashFlowHedgingMember_391809" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_391810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_391807" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_391810" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_391811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_391807" xlink:to="loc_us-gaap_FairValueHedgingMember_391811" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_412059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_HedgingDesignationAxis_412059" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_412060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_412059" xlink:to="loc_us-gaap_HedgingDesignationDomain_412060" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_412060_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_412059" xlink:to="loc_us-gaap_HedgingDesignationDomain_412060_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_412062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_412060" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_412062" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_391805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_390277" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_391805" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_390516" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_390515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_DerivativeTable_390515" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390519" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember_406886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_NetRevenuesMember_406886" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember_406916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_FinancialExpensesMember_406916" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_406887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_HedgingDesignationAxis_406887" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_406890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NondesignatedMember_406890" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1360" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization_1363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_us-gaap_AccountsReceivableFromSecuritization_1363" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_us-gaap_DerivativeTable_1361" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1361" xlink:to="loc_dei_LegalEntityAxis_1362" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1362" xlink:to="loc_dei_EntityDomain_1368" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1368_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1362" xlink:to="loc_dei_EntityDomain_1368_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" xlink:label="loc_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization_1366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization_1366" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromAccountsReceivableSecuritization" xlink:label="loc_us-gaap_ProceedsFromAccountsReceivableSecuritization_1364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_us-gaap_ProceedsFromAccountsReceivableSecuritization_1364" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfAccountsReceivableSecuritization" xlink:label="loc_us-gaap_RepaymentsOfAccountsReceivableSecuritization_1365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_us-gaap_RepaymentsOfAccountsReceivableSecuritization_1365" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1285" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredPurchaseAsset" xlink:label="loc_teva_DeferredPurchaseAsset_1308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_DeferredPurchaseAsset_1308" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization_1309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_AccountsReceivableFromSecuritization_1309" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_1301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_1301" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeTable_1286" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1288" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_688628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1289" xlink:to="loc_us-gaap_CostOfSalesMember_688628" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember_817875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1289" xlink:to="loc_teva_NetRevenuesMember_817875" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2021Member" xlink:label="loc_teva_SeniorNotesDue2021Member_1297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2021Member_1297" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2022Member" xlink:label="loc_teva_SeniorNotesDue2022Member_1294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2022Member_1294" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2023TwoMember" xlink:label="loc_teva_SeniorNotesDue2023TwoMember_1291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2023TwoMember_1291" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_581630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_581630" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2020Member" xlink:label="loc_teva_SeniorNotesDue2020Member_412070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2020Member_412070" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" xlink:label="loc_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember_817880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1287" xlink:to="loc_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember_817880" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_558657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_HedgingDesignationAxis_558657" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_558659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_558658" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_558659" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_817883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_558658" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_817883" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_dei_LegalEntityAxis_1290" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_817877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_srt_RangeAxis_817877" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InterestRateSwapGain" xlink:label="loc_teva_InterestRateSwapGain_391830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_InterestRateSwapGain_391830" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd_1298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_RevenuesOtherThanUsd_1298" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SettlementGainPosition" xlink:label="loc_teva_SettlementGainPosition_1305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_SettlementGainPosition_1305" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashReceivedOnSettlementOfPosition" xlink:label="loc_teva_CashReceivedOnSettlementOfPosition_581646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_CashReceivedOnSettlementOfPosition_581646" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NotionalAmountHedgeDebt" xlink:label="loc_teva_NotionalAmountHedgeDebt_1300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_NotionalAmountHedgeDebt_1300" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreviouslyHedgeDebtRate" xlink:label="loc_teva_PreviouslyHedgeDebtRate_1304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_PreviouslyHedgeDebtRate_1304" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_688630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_688630" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_718504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_718504" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_817874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_817874" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1458" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingenciesTable_1459" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_LitigationCaseAxis_471102" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SettlementOnAccountOfProductLiabilityMember" xlink:label="loc_teva_SettlementOnAccountOfProductLiabilityMember_720064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471103" xlink:to="loc_teva_SettlementOnAccountOfProductLiabilityMember_720064" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_dei_LegalEntityAxis_1457" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_720032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_StatementGeographicalAxis_720032" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_720035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_720033" xlink:to="loc_country_US_720035" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LitigationSettlementExpense_1461" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_577495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_577495" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringExpenseAndIncome" xlink:label="loc_teva_RestructuringExpenseAndIncome_720065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_teva_RestructuringExpenseAndIncome_720065" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems_882" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_882" xlink:to="loc_us-gaap_RoyaltyExpense_894" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_882" xlink:to="loc_teva_CommitmentAndContingenciesTable_883" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_883" xlink:to="loc_srt_RangeAxis_885" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_885" xlink:to="loc_srt_RangeMember_886" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_886_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_885" xlink:to="loc_srt_RangeMember_886_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_886" xlink:to="loc_srt_MaximumMember_897" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_883" xlink:to="loc_dei_LegalEntityAxis_884" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_884" xlink:to="loc_dei_EntityDomain_896" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_896_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_884" xlink:to="loc_dei_EntityDomain_896_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MilestoneContingentPayments" xlink:label="loc_teva_MilestoneContingentPayments_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_882" xlink:to="loc_teva_MilestoneContingentPayments_895" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems_900" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfVelcade" xlink:label="loc_teva_AnnualSalesOfVelcade_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfVelcade_912" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_CommitmentAndContingenciesTable_901" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_CounterpartyNameAxis_902" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_JanssenAndMillenniumMember" xlink:label="loc_teva_JanssenAndMillenniumMember_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" xlink:to="loc_teva_JanssenAndMillenniumMember_939" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_dei_LegalEntityAxis_903" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_903" xlink:to="loc_dei_EntityDomain_935" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_935_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_903" xlink:to="loc_dei_EntityDomain_935_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_905" xlink:to="loc_teva_EosinophilicEsophagitisMember_936" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_StatementGeographicalAxis_910" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_srt_EuropeMember_941" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_country_US_940" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_ProductOrServiceAxis_906" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_AndroGelRateAtOnePercentageMember_937" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_LitigationCaseAxis_471076" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember_515110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_NationwideSettlementMember_515110" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OpioidLitigationMember" xlink:label="loc_teva_OpioidLitigationMember_471080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_OpioidLitigationMember_471080" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilSettlementAgreementMember" xlink:label="loc_teva_ModafinilSettlementAgreementMember_818713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_ModafinilSettlementAgreementMember_818713" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515106" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_DamagesAssessment_911" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTimeOfSettlement_919" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActoplus_926" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfNamenda" xlink:label="loc_teva_AnnualSalesOfNamenda_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNamenda_928" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNiaspan_922" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActos_925" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_914" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfEffexor_920" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfLamictal_921" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_913" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilPayment" xlink:label="loc_teva_ModafinilPayment_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_ModafinilPayment_917" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_933" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_934" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilPaymentRemainingBalance" xlink:label="loc_teva_ModafinilPaymentRemainingBalance_515099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_ModafinilPaymentRemainingBalance_515099" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar_471045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfSensipar_471045" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedCashAmount" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmount_515111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedCashAmount_515111" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedNumberOfInstallments" xlink:label="loc_teva_LitigationSettlementAmountAwardedNumberOfInstallments_515112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedNumberOfInstallments_515112" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod_515113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod_515113" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone_720069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfCopaxone_720069" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" use="optional" order="53" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1140" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1140" xlink:to="loc_dei_LegalEntityAxis_1141" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1141" xlink:to="loc_dei_EntityDomain_1145" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1145_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1141" xlink:to="loc_dei_EntityDomain_1145_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1142" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1143" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1144" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1154" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1155" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1151" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_1152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_1152" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1149" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1149" xlink:to="loc_dei_LegalEntityAxis_1150" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1150" xlink:to="loc_dei_EntityDomain_1157" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1157_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1150" xlink:to="loc_dei_EntityDomain_1157_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1153" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1164" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1161" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1161" xlink:to="loc_dei_LegalEntityAxis_1162" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1162" xlink:to="loc_dei_EntityDomain_1172" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1172_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1162" xlink:to="loc_dei_EntityDomain_1172_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1163" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1165" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1171" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1167" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1168" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_1170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_1170" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Ustaxcutsandjobsacteffect" xlink:label="loc_teva_Ustaxcutsandjobsacteffect_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_teva_Ustaxcutsandjobsacteffect_1169" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1175" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1175" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1176" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1176" xlink:to="loc_dei_LegalEntityAxis_1177" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1177" xlink:to="loc_dei_EntityDomain_1179" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1179_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1177" xlink:to="loc_dei_EntityDomain_1179_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1175" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1178" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetLineItems" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent_1189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent_1189" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsDeferredInterest" xlink:label="loc_teva_DeferredTaxAssetsDeferredInterest_1191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsDeferredInterest_1191" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1185" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent_1194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent_1194" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent_1193" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" xlink:label="loc_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent_1192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent_1192" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_1187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_1187" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_1186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_1186" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1195" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1196" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_1188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_1188" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1190" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xlink:label="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1184" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1184" xlink:to="loc_dei_LegalEntityAxis_1183" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1183" xlink:to="loc_dei_EntityDomain_1197" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1197_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1183" xlink:to="loc_dei_EntityDomain_1197_default" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetLineItems" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1200" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetUnrecognizedTaxBenefits" xlink:label="loc_teva_DeferredTaxAssetUnrecognizedTaxBenefits_1203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1200" xlink:to="loc_teva_DeferredTaxAssetUnrecognizedTaxBenefits_1203" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xlink:label="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1200" xlink:to="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1202" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1202" xlink:to="loc_dei_LegalEntityAxis_1201" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1201" xlink:to="loc_dei_EntityDomain_1204" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1204_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1201" xlink:to="loc_dei_EntityDomain_1204_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems_1209" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageGrowthRateInSalesOrWorkforce" xlink:label="loc_teva_AverageGrowthRateInSalesOrWorkforce_1236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_AverageGrowthRateInSalesOrWorkforce_1236" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendIncomeSecuritiesOperatingTaxExempt" xlink:label="loc_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt_1228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt_1228" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" xlink:label="loc_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce_1237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce_1237" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1239" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_1226" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_IncomeTaxTable_1210" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_dei_LegalEntityAxis_1211" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DevelopmentZoneaMember" xlink:label="loc_teva_DevelopmentZoneaMember_1243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" xlink:to="loc_teva_DevelopmentZoneaMember_1243" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_1244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_1244" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" xlink:to="loc_us-gaap_IsraelTaxAuthorityMember_1220" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_RangeAxis_1214" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1215" xlink:to="loc_srt_MaximumMember_1246" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1215" xlink:to="loc_srt_MinimumMember_1245" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxPeriodAxis_1218" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxYear2005To2007Member" xlink:label="loc_teva_TaxYear2005To2007Member_1257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1219" xlink:to="loc_teva_TaxYear2005To2007Member_1257" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1216" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment68ToInvestmentLawMember" xlink:label="loc_teva_Amendment68ToInvestmentLawMember_1252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_Amendment68ToInvestmentLawMember_1252" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment69ToInvestmentLawMember" xlink:label="loc_teva_Amendment69ToInvestmentLawMember_1251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_Amendment69ToInvestmentLawMember_1251" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment73ToInvestmentLawMember" xlink:label="loc_teva_Amendment73ToInvestmentLawMember_1253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_Amendment73ToInvestmentLawMember_1253" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreferredEnterpriseMember" xlink:label="loc_teva_PreferredEnterpriseMember_1254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_PreferredEnterpriseMember_1254" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreferredTechnologicalEnterprisesMember" xlink:label="loc_teva_PreferredTechnologicalEnterprisesMember_1255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_PreferredTechnologicalEnterprisesMember_1255" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SpecialPreferredTechnologicalEnterpriseMember" xlink:label="loc_teva_SpecialPreferredTechnologicalEnterpriseMember_1256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_SpecialPreferredTechnologicalEnterpriseMember_1256" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember_1247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember_1247" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember_1248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember_1248" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsIndefiniteMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsIndefiniteMember_1250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_TaxCarryforwardsAndDeductionsIndefiniteMember_1250" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsNoExpirationMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsNoExpirationMember_1249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_TaxCarryforwardsAndDeductionsNoExpirationMember_1249" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_581719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_581719" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_673833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_StatementScenarioAxis_673833" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxesPaid_1227" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1225" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_InvestmentIncomeNet_1232" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1238" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumNumberOfEmployeesEmployed" xlink:label="loc_teva_MinimumNumberOfEmployeesEmployed_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_MinimumNumberOfEmployeesEmployed_1234" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumPercentageOfInvestmentIncome" xlink:label="loc_teva_MinimumPercentageOfInvestmentIncome_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_MinimumPercentageOfInvestmentIncome_1231" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumPercentageOfWorkforce" xlink:label="loc_teva_MinimumPercentageOfWorkforce_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_MinimumPercentageOfWorkforce_1233" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1224" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_VentureCapitalInvestments" xlink:label="loc_teva_VentureCapitalInvestments_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_VentureCapitalInvestments_1235" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_WithholdingTaxPercentageOnDividends" xlink:label="loc_teva_WithholdingTaxPercentageOnDividends_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_WithholdingTaxPercentageOnDividends_1230" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1222" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_1221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_1221" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1223" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit_801122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit_801122" use="optional" order="62" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetLineItems" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1265" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1264" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1263" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xlink:label="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" xlink:to="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1262" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1262" xlink:to="loc_dei_LegalEntityAxis_1261" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1261" xlink:to="loc_dei_EntityDomain_1266" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1266_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1261" xlink:to="loc_dei_EntityDomain_1266_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" xlink:label="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" xlink:label="loc_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther_1278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther_1278" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1275" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfUnrecognizedTaxBenefitsTable" xlink:label="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable_1271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable_1271" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable_1271" xlink:to="loc_dei_LegalEntityAxis_1269" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1269" xlink:to="loc_dei_EntityDomain_1272" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1269" xlink:to="loc_dei_EntityDomain_1272_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1273" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1276" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="loc_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_1274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_1274" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_944" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_969" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageSharePrice" xlink:label="loc_teva_AverageSharePrice_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_teva_AverageSharePrice_971" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_964" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_950" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_950" xlink:to="loc_dei_LegalEntityAxis_945" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_945" xlink:to="loc_dei_EntityDomain_979" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_979_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_945" xlink:to="loc_dei_EntityDomain_979_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_950" xlink:to="loc_us-gaap_PlanNameAxis_946" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_946" xlink:to="loc_us-gaap_PlanNameDomain_947" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_947_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_946" xlink:to="loc_us-gaap_PlanNameDomain_947_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandFifteenPlanMember" xlink:label="loc_teva_TwoThousandFifteenPlanMember_981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_947" xlink:to="loc_teva_TwoThousandFifteenPlanMember_981" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandTenPlanMember" xlink:label="loc_teva_TwoThousandTenPlanMember_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_947" xlink:to="loc_teva_TwoThousandTenPlanMember_980" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandTwentyPlanMember" xlink:label="loc_teva_TwoThousandTwentyPlanMember_818708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_947" xlink:to="loc_teva_TwoThousandTwentyPlanMember_818708" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_950" xlink:to="loc_srt_TitleOfIndividualAxis_951" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_951" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_952" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_952_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_951" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_952_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_970" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_976" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_968" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_967" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedCompensationCostRsus" xlink:label="loc_teva_UnrecognizedCompensationCostRsus_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_teva_UnrecognizedCompensationCostRsus_975" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_583146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_583146" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_959" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_SharePrice_955" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_SharesOutstanding_953" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedCompensationCostOptions" xlink:label="loc_teva_UnrecognizedCompensationCostOptions_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_teva_UnrecognizedCompensationCostOptions_974" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_994" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_992" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_991" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1004" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_995" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1001" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_999" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_988" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_988" xlink:to="loc_dei_LegalEntityAxis_987" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_987" xlink:to="loc_dei_EntityDomain_990" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_990_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_987" xlink:to="loc_dei_EntityDomain_990_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1000" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1002" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_993" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_997" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_998" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1009" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1009" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1008" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1008" xlink:to="loc_dei_LegalEntityAxis_1007" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1007" xlink:to="loc_dei_EntityDomain_1010" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1010_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1007" xlink:to="loc_dei_EntityDomain_1010_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1009" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1011" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1015" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1015" xlink:to="loc_dei_LegalEntityAxis_1014" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1014" xlink:to="loc_dei_EntityDomain_1017" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1017_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1014" xlink:to="loc_dei_EntityDomain_1017_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1020" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1021" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1019" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" xlink:to="loc_dei_LegalEntityAxis_1024" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1024" xlink:to="loc_dei_EntityDomain_1029" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1024" xlink:to="loc_dei_EntityDomain_1029_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1026" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1026" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1026" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFiveMember" xlink:label="loc_teva_ExercisePriceRangeFiveMember_1034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeFiveMember_1034" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFourMember" xlink:label="loc_teva_ExercisePriceRangeFourMember_1033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeFourMember_1033" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeSixMember" xlink:label="loc_teva_ExercisePriceRangeSixMember_1035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeSixMember_1035" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeThreeMember" xlink:label="loc_teva_ExercisePriceRangeThreeMember_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeThreeMember_1032" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeOneMember" xlink:label="loc_teva_ExercisePriceRangeOneMember_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeOneMember_1030" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeTwoMember" xlink:label="loc_teva_ExercisePriceRangeTwoMember_1031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeTwoMember_1031" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1041" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1037" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010_1038" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010_1039" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1042" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" xlink:to="loc_dei_LegalEntityAxis_1045" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1045" xlink:to="loc_dei_EntityDomain_1050" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1050_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1045" xlink:to="loc_dei_EntityDomain_1050_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1047" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1047" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1047" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeThreeMember" xlink:label="loc_teva_ExercisePriceRangeThreeMember_1052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeThreeMember_1052" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeTwoMember" xlink:label="loc_teva_ExercisePriceRangeTwoMember_1051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeTwoMember_1051" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFiveMember" xlink:label="loc_teva_ExercisePriceRangeFiveMember_1054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeFiveMember_1054" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFourMember" xlink:label="loc_teva_ExercisePriceRangeFourMember_1053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeFourMember_1053" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeSixMember" xlink:label="loc_teva_ExercisePriceRangeSixMember_1055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeSixMember_1055" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeOneMember" xlink:label="loc_teva_ExercisePriceRangeOneMember_572234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeOneMember_572234" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010_1058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010_1058" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010_1059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010_1059" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1057" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1062" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1061" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1090" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1083" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1088" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" xlink:to="loc_dei_LegalEntityAxis_1075" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1075" xlink:to="loc_dei_EntityDomain_1080" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1080_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1075" xlink:to="loc_dei_EntityDomain_1080_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" xlink:to="loc_us-gaap_PlanNameAxis_1076" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1076" xlink:to="loc_us-gaap_PlanNameDomain_1077" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1077_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1076" xlink:to="loc_us-gaap_PlanNameDomain_1077_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestrictedStockUnitsMember" xlink:label="loc_teva_RestrictedStockUnitsMember_1081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1077" xlink:to="loc_teva_RestrictedStockUnitsMember_1081" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1085" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1089" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1082" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1087" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1084" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1103" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1105" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1104" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" xlink:to="loc_us-gaap_PlanNameAxis_1095" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1095" xlink:to="loc_us-gaap_PlanNameDomain_1096" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1096_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1095" xlink:to="loc_us-gaap_PlanNameDomain_1096_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestrictedStockUnitsMember" xlink:label="loc_teva_RestrictedStockUnitsMember_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1096" xlink:to="loc_teva_RestrictedStockUnitsMember_1101" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OmnibusLongTermShareIncentivePlanMember" xlink:label="loc_teva_OmnibusLongTermShareIncentivePlanMember_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1096" xlink:to="loc_teva_OmnibusLongTermShareIncentivePlanMember_1102" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_StockOptionsPlanMember" xlink:label="loc_teva_StockOptionsPlanMember_1100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1096" xlink:to="loc_teva_StockOptionsPlanMember_1100" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" xlink:to="loc_dei_LegalEntityAxis_1094" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1094" xlink:to="loc_dei_EntityDomain_1099" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1099_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1094" xlink:to="loc_dei_EntityDomain_1099_default" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" xlink:to="loc_dei_LegalEntityAxis_1111" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1111" xlink:to="loc_dei_EntityDomain_1126" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1126_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1111" xlink:to="loc_dei_EntityDomain_1126_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1112" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1112" xlink:to="loc_us-gaap_EquityComponentDomain_1110" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1110_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1112" xlink:to="loc_us-gaap_EquityComponentDomain_1110_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1125" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1124" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1123" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1122" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_1121" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1113" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_1115" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1119" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_1118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_1118" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xlink:label="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning_1114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning_1114" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_1116" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_801129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_801129" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1129" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1129" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" xlink:to="loc_dei_LegalEntityAxis_1132" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1132" xlink:to="loc_dei_EntityDomain_1136" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1136_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1132" xlink:to="loc_dei_EntityDomain_1136_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1133" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1133" xlink:to="loc_us-gaap_EquityComponentDomain_1131" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1131_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1133" xlink:to="loc_us-gaap_EquityComponentDomain_1131_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_1135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1131" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_1135" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_582305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_582305" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_582306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_582305" xlink:to="loc_us-gaap_TypeOfAdoptionMember_582306" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_582306_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_582305" xlink:to="loc_us-gaap_TypeOfAdoptionMember_582306_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_582307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_582306" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_582307" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_1134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1129" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_1134" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring_1401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_ImpairmentAndRestructuring_1401" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1393" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_dei_LegalEntityAxis_1391" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_RestructuringCharges_1398" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_RestructuringCharges_1421" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_1419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_1419" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringPlanCostReduction" xlink:label="loc_teva_RestructuringPlanCostReduction_581689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_teva_RestructuringPlanCostReduction_581689" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1412" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_dei_LegalEntityAxis_1406" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_ProductOrServiceAxis_1407" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1404" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementGeographicalAxis_1414" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_515346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementScenarioAxis_515346" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpectedRevenueFromFacility" xlink:label="loc_teva_ExpectedRevenueFromFacility_572186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_teva_ExpectedRevenueFromFacility_572186" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_RestructuringCharges_1438" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_dei_LegalEntityAxis_1432" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1433" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_1439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_EmployeeSeveranceMember_1439" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_OtherRestructuringMember_1440" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390248" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250_default" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1451" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision_1452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_RestructuringAccrualProvision_1452" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis_1443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_teva_ExitAndDisposalAxis_1443" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_EmployeeTerminationMember_1448" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_OtherExitAndDisposalMember_1449" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_dei_LegalEntityAxis_1445" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_UtilizationAndOther_1453" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherincomeLineItems" xlink:label="loc_teva_OtherincomeLineItems_873" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PatentedMedicinesRegulationsAndSimilarPayments" xlink:label="loc_teva_PatentedMedicinesRegulationsAndSimilarPayments_406930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_teva_PatentedMedicinesRegulationsAndSimilarPayments_406930" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_us-gaap_OtherIncome_879" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherIncomeExpenseTable" xlink:label="loc_teva_OtherIncomeExpenseTable_872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_teva_OtherIncomeExpenseTable_872" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_OtherIncomeExpenseTable_872" xlink:to="loc_dei_LegalEntityAxis_871" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_871" xlink:to="loc_dei_EntityDomain_874" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_874_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_871" xlink:to="loc_dei_EntityDomain_874_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_875" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets_877" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherOperatingIncomeNet" xlink:label="loc_teva_OtherOperatingIncomeNet_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_teva_OtherOperatingIncomeNet_878" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesLineItems" xlink:label="loc_teva_ExpensesLineItems_1371" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinanceIncomeExpensesNet" xlink:label="loc_teva_FinanceIncomeExpensesNet_1380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_teva_FinanceIncomeExpensesNet_1380" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesTable" xlink:label="loc_teva_ExpensesTable_1372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_teva_ExpensesTable_1372" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_ExpensesTable_1372" xlink:to="loc_dei_LegalEntityAxis_1373" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1373" xlink:to="loc_dei_EntityDomain_1381" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1381_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1373" xlink:to="loc_dei_EntityDomain_1381_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ForeignCurrencyTransactionGainLoss" xlink:label="loc_teva_ForeignCurrencyTransactionGainLoss_1377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_teva_ForeignCurrencyTransactionGainLoss_1377" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_us-gaap_InterestExpense_1375" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_1376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_1376" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherFinancialIncomeExpenseNet" xlink:label="loc_teva_OtherFinancialIncomeExpenseNet_1378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_teva_OtherFinancialIncomeExpenseNet_1378" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesLineItems" xlink:label="loc_teva_ExpensesLineItems_1384" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentForRedemptionOfSeniorNotes" xlink:label="loc_teva_PaymentForRedemptionOfSeniorNotes_1387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_ExpensesLineItems_1384" xlink:to="loc_teva_PaymentForRedemptionOfSeniorNotes_1387" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesTable" xlink:label="loc_teva_ExpensesTable_1385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_ExpensesLineItems_1384" xlink:to="loc_teva_ExpensesTable_1385" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_ExpensesTable_1385" xlink:to="loc_dei_LegalEntityAxis_1386" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1386" xlink:to="loc_dei_EntityDomain_1388" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1386" xlink:to="loc_dei_EntityDomain_1388_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1581" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1581" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1584" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1581" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1583" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1583" xlink:to="loc_dei_LegalEntityAxis_1582" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1582" xlink:to="loc_dei_EntityDomain_1589" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1589_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1582" xlink:to="loc_dei_EntityDomain_1589_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1581" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1588" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1581" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1585" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1601" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="loc_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember_1600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" xlink:to="loc_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember_1600" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_dei_LegalEntityAxis_1595" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_688342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_688342" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_OperatingIncomeLoss_1497" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense_1496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_teva_OtherOperatingIncomeExpense_1496" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1495" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GrossProfit_1492" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_dei_LegalEntityAxis_1482" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1486" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_InternationalMarketsMember_1490" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_EuropeSegmentMember_1489" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_NorthAmericaSegmentMember_1488" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1494" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" xlink:to="loc_us-gaap_OperatingIncomeLoss_1507" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_1508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_AdjustmentForAmortization_1508" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CostsRelatedToRegulatoryActionsTakenInFacilities" xlink:label="loc_teva_CostsRelatedToRegulatoryActionsTakenInFacilities_1515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_CostsRelatedToRegulatoryActionsTakenInFacilities_1515" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1510" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_1509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_1509" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PurchaseOfResearchAndDevelopmentInProcess" xlink:label="loc_teva_PurchaseOfResearchAndDevelopmentInProcess_1514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_PurchaseOfResearchAndDevelopmentInProcess_1514" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_1516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_1516" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts_1517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_OtherUnallocatedAmounts_1517" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1512" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1525" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_dei_LegalEntityAxis_1502" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1506" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1523" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_InternationalMarketsMember_1521" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember_1522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_CorporateMember_1522" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_EuropeSegmentMember_1520" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_NorthAmericaSegmentMember_1519" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember_1524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_SegmentsAndOtherActivitiesMember_1524" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_1530" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_1533" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1535" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_InternationalMarketsMember_1550" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_NorthAmericaSegmentMember_1548" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_EuropeSegmentMember_1549" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_dei_LegalEntityAxis_1529" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_srt_ProductOrServiceAxis_1531" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember_1538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_GenericsMediciansMember_1538" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember_1539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_COPAXONEMember_1539" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember_1546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AndaMember_1546" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember_1543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AustedoMember_1543" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_QVARMember" xlink:label="loc_teva_QVARMember_1542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_QVARMember_1542" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember_1545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_RespiratoryProductMember_1545" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember_1547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_OtherProductsMember_1547" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProAirMember" xlink:label="loc_teva_ProAirMember_1541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_ProAirMember_1541" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember_408213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AjovyMember_408213" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember_1540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_BendekaAndTreandaMember_1540" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis_558204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_teva_RevenueTypeAxis_558204" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211_default" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1556" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetSalesPresent" xlink:label="loc_teva_NetSalesPresent_1561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1556" xlink:to="loc_teva_NetSalesPresent_1561" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1556" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_1554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" xlink:to="loc_srt_MajorCustomersAxis_1554" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1554" xlink:to="loc_srt_NameOfMajorCustomerDomain_1555" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1554" xlink:to="loc_srt_NameOfMajorCustomerDomain_1555_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Customer1Member" xlink:label="loc_teva_Customer1Member_1559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1555" xlink:to="loc_teva_Customer1Member_1559" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Customer2Member" xlink:label="loc_teva_Customer2Member_1560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1555" xlink:to="loc_teva_Customer2Member_1560" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" xlink:to="loc_dei_LegalEntityAxis_1553" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1553" xlink:to="loc_dei_EntityDomain_1558" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1558_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1553" xlink:to="loc_dei_EntityDomain_1558_default" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1565" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1565" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" xlink:to="loc_srt_StatementGeographicalAxis_1568" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1568" xlink:to="loc_srt_SegmentGeographicalDomain_1567" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1567_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1568" xlink:to="loc_srt_SegmentGeographicalDomain_1567_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_1572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_US_1572" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HR" xlink:label="loc_country_HR_1573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_HR_1573" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HU" xlink:label="loc_country_HU_1576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_HU_1576" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_country_IL_1571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_IL_1571" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CZ" xlink:label="loc_country_CZ_1578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_CZ_1578" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:label="loc_country_DE_1574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_DE_1574" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember_1577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_teva_OtherCountriesMember_1577" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IEMember" xlink:label="loc_teva_IEMember_809515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_teva_IEMember_809515" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" xlink:to="loc_dei_LegalEntityAxis_1564" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1564" xlink:to="loc_dei_EntityDomain_1569" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1569_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1564" xlink:to="loc_dei_EntityDomain_1569_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1565" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1570" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1472" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_556480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_556480" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_NumberOfReportableSegments_1478" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_dei_LegalEntityAxis_1469" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" xlink:to="loc_us-gaap_SalesRevenueNetMember_1474" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1468" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1475" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_srt_StatementGeographicalAxis_1473" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_country_IL_1477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1471" xlink:to="loc_country_IL_1477" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeAssets_370" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeLiabilities_371" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_373" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_369" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_362" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" xlink:to="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FinancialInstrumentAxis_365" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_385" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_InterestRateSwapMember_384" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_dei_LegalEntityAxis_366" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_360" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember_375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_DemandDepositsMember_375" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_MoneyMarketFundsMember_374" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_377" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_EquitySecuritiesMember_376" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_380" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_382" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_381" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_682372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_srt_RangeAxis_682372" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_682374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MaximumMember_682374" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_682375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MinimumMember_682375" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_688250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_WeightedAverageMember_688250" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_682378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_682378" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_682382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_682382" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevaluationOfAssetsMember" xlink:label="loc_us-gaap_RevaluationOfAssetsMember_764535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" xlink:to="loc_us-gaap_RevaluationOfAssetsMember_764535" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_764538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_GainLossOnSaleOfEquityInvestments_764538" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_764539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_764539" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_389" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_392" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_EagleTransactionMember_406" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_ActavisGenericsMember_404" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_dei_LegalEntityAxis_394" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_720077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_720077" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_764522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_764522" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_764523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_764523" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_815485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_815485" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_DebtInstrumentFairValue_415" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_dei_LegalEntityAxis_412" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_413" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_us-gaap_SeniorNotesMember_417" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniornotesandconvertibleseniordebenturesmemberMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesmemberMember_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniornotesandconvertibleseniordebenturesmemberMember_418" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_666" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccruedSeverancePayNoncurrent" xlink:label="loc_teva_AccruedSeverancePayNoncurrent_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" xlink:to="loc_teva_AccruedSeverancePayNoncurrent_665" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeRelatedObligationsNoncurrent" xlink:label="loc_teva_EmployeeRelatedObligationsNoncurrent_667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" xlink:to="loc_teva_EmployeeRelatedObligationsNoncurrent_667" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_664" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_664" xlink:to="loc_dei_LegalEntityAxis_663" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_663" xlink:to="loc_dei_EntityDomain_668" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_668_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_663" xlink:to="loc_dei_EntityDomain_668_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" xlink:label="loc_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear_675" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_673" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_673" xlink:to="loc_dei_LegalEntityAxis_672" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_672" xlink:to="loc_dei_EntityDomain_682" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_682_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_672" xlink:to="loc_dei_EntityDomain_682_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive_680" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour_679" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne_676" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen_681" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree_678" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo_677" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" xlink:label="loc_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations_674" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialInformationLineItems" xlink:label="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_ProfitLoss_1615" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_GrossProfit_1614" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1606" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1606" xlink:to="loc_us-gaap_EarningsPerShareBasic_1610" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1606" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1611" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_NetIncomeLoss_1616" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1617" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1613" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialInformationTable" xlink:label="loc_teva_SelectedQuarterlyFinancialInformationTable_1609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_teva_SelectedQuarterlyFinancialInformationTable_1609" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationTable_1609" xlink:to="loc_dei_LegalEntityAxis_1607" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1607" xlink:to="loc_dei_EntityDomain_1612" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1612_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1607" xlink:to="loc_dei_EntityDomain_1612_default" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1649" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1646" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_1647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_1647" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1648" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" xlink:to="loc_dei_LegalEntityAxis_1638" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1638" xlink:to="loc_dei_EntityDomain_1643" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1643_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1638" xlink:to="loc_dei_EntityDomain_1643_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1640" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1640" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1640" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_1644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_1644" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" xlink:label="loc_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember_1645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639" xlink:to="loc_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember_1645" use="optional" order="13" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>teva-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-February-2021 [01:05:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCountry" xml:lang="en-US">Entity Address, Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Smaller Reporting Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets held for sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivables, net of allowance for credit losses of $126 million and $135 million as of December 31, 2020 and December 31, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Identifiable intangible assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other&#160;non-current&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, plant and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease ROU assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies, see note 12</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Short-term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Total short term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AccruedExpenses" xlink:to="lab_teva_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AccruedExpenses" xml:lang="en-US">Accrued expenses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">Sales Reserves And Allowances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">Sales reserves and allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowances" xlink:to="lab_teva_SalesReservesAndAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowances" xml:lang="en-US">The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Long-term liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other taxes and long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Notes and Loans, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Senior notes and loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermNotesAndLoans" xml:lang="en-US">Total senior notes and loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesAndLoans" xlink:to="lab_us-gaap_LongTermNotesAndLoans" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Teva shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Ordinary shares of NIS 0.10 par value per share; December 31, 2020 and December 31, 2019: authorized 2,495 million shares; issued 1,202 million shares and 1,198 million shares, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional&#160;paid-in&#160;capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' equity attributable to Teva shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury shares as of December 31, 2020 and December 31, 2019: 106 million ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Ordinary shares, authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Ordinary shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">G&amp;A expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill impairment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (loss) before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of Goods and Services Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings (loss) per share attributable to ordinary shareholders:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings per share attributable to ordinary shareholders:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Share in (profits) losses of associated companies, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income taxes (benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Effective consolidated income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible Assets Impairments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible assets impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IntangibleAssetsImpairments" xlink:to="lab_teva_IntangibleAssetsImpairments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IntangibleAssetsImpairments" xml:lang="en-US">Intangible Assets Impairments</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to Teva</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to Teva</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net loss attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net income (loss) attributable to ordinary shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net income (loss) attributable to ordinary shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Financial expenses, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Financial expenses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating (loss) income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Segment profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Segments profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Consolidated operating income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other Operating Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and development expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">R&amp;D expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xml:lang="en-US">Accrued dividends on preferred shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Net revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Annual revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and marketing expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">S&amp;M expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted average number of shares (in millions):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of shares used in the computation of diluted earnings (loss) per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of shares used in the computation of basic earnings (loss) per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Impairments Restructuring And Others</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Other asset impairments, restructuring and other items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Other asset impairments, restructuring and other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentsRestructuringAndOthers" xlink:to="lab_teva_ImpairmentsRestructuringAndOthers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentsRestructuringAndOthers" xml:lang="en-US">Impairments restructuring and others.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">Legal Settlements And Loss Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">Legal settlements and loss contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LegalSettlementsAndLossContingencies" xlink:to="lab_teva_LegalSettlementsAndLossContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LegalSettlementsAndLossContingencies" xml:lang="en-US">The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive income (loss), net of tax:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xml:lang="en-US">Unrealized gain (loss) on derivative financial instruments, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized gain (loss) on&#160;available-for-sale&#160;securities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xml:lang="en-US">Unrealized gain (loss) on defined benefit plans, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Total other comprehensive income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive income (loss) attributable to Teva</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive income (loss) attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Non-controlling Interests [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Ordinary Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ParentMember" xml:lang="en-US">Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ParentMember" xml:lang="en-US">Total Teva Shareholders' Equity [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">MCPS [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xml:lang="en-US">Dividends, Preferred Stock, Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xml:lang="en-US">Dividends to preferred shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash" xlink:to="lab_us-gaap_DividendsPreferredStockCash" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherEquity" xlink:label="loc_teva_OtherEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherEquity" xml:lang="en-US">Other Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherEquity" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherEquity" xlink:to="lab_teva_OtherEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherEquity" xml:lang="en-US">Other Equity</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xlink:label="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xml:lang="en-US">Reclassification From Accumulated Other Comprehensive Income To Retained Earning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xml:lang="en-US">Cumulative effect of new accounting standard</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xml:lang="en-US">Cumulative effect of new accounting standard</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xlink:to="lab_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xml:lang="en-US">Reclassification From Accumulated Other Comprehensive Income To Retained Earning</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Beginning balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Ending balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Shares, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TransactionsWithNonControllingInterests" xlink:label="loc_teva_TransactionsWithNonControllingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TransactionsWithNonControllingInterests" xml:lang="en-US">Transactions With Non Controlling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TransactionsWithNonControllingInterests" xml:lang="en-US">Transactions with non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TransactionsWithNonControllingInterests" xlink:to="lab_teva_TransactionsWithNonControllingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TransactionsWithNonControllingInterests" xml:lang="en-US">Transactions With Non Controlling Interests</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Issuance of Treasury Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Shares, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of options by employees and vested RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Foreign currency translation attributable to non-controlling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net change in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Balance of cash and cash equivalents at beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Balance of cash and cash equivalents at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Translation adjustment on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Net change in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" xlink:label="loc_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" xml:lang="en-US">Increase Decrease In Certain Current Assets Excluding Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" xml:lang="en-US">Trade receivables net of sales reserves and allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" xlink:to="lab_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" xml:lang="en-US">The net change during the period in accounts receivable and current assets not separately reported.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" xlink:label="loc_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" xml:lang="en-US">Increase Decrease In Certain Current Liabilities Excluding Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" xml:lang="en-US">Trade payables, accrued expenses, employee-related obligations and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" xlink:to="lab_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" xml:lang="en-US">The net change during the period in sales reserves and allowances, accounts payable, and other current liabilities not separately reported.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:label="loc_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xml:lang="en-US">Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xml:lang="en-US">Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:to="lab_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xml:lang="en-US">The net change during the reporting period in the amounts of the current assets and current liabilities that are reported in the supplemental disclosure of information section of the Consolidated Statements of Cash Flows.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash used in financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayments of Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xml:lang="en-US">Repayment of senior notes and loans and other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US">Other financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xml:lang="en-US">Repayments of Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xml:lang="en-US">Repayment of short term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" xlink:label="loc_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" xml:lang="en-US">Payments Related To Tax Withholding For Shares And Dividend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" xml:lang="en-US">Tax withholding payments made on shares and dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" xlink:to="lab_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" xml:lang="en-US">Amount of cash outflow to satisfy income tax withholding obligation for shares and dividends.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Proceeds from senior notes and loans, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from short term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Other investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">Payment To Acquire Marketable Securities And Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">Purchases of investments and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:to="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xml:lang="en-US">The cash outflow from purchase of available for sales securities and other assets.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Proceeds from beneficial interest in exchange for securitized trade receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial interest collected in exchange for securitized trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:to="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Proceeds from beneficial interest in exchange for securitized trade receivables</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from sales of long-lived assets and investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred Income Taxes Net And Uncertain Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred income taxes, net and uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:to="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xml:lang="en-US">Deferred income taxes net and uncertain tax positions.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Impairment of goodwill, long-lived assets and assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Increase (Decrease) in Operating Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Net change in operating assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Profit From Sale Of Long Lived Assets And Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Net loss (gain) from investments and from sale of long lived assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Net (gain) loss from sale of long-lived assets and investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:to="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xml:lang="en-US">Profit from sale of long lived assets and investment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and development in process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Non-cash&#160;financing and investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of mandatory convertible preferred shares into ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial interest obtained in exchange for securitized trade receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:to="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xml:lang="en-US">Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashPaidDuringTheYearForAbstract" xlink:label="loc_teva_CashPaidDuringTheYearForAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CashPaidDuringTheYearForAbstract" xml:lang="en-US">Cash paid during the year for [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CashPaidDuringTheYearForAbstract" xml:lang="en-US">Cash paid during the year for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CashPaidDuringTheYearForAbstract" xlink:to="lab_teva_CashPaidDuringTheYearForAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CashPaidDuringTheYearForAbstract" xml:lang="en-US">Cash paid during the year for.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income Taxes Paid, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income taxes, net of refunds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">Certain Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">Certain transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CertainTransactionsDisclosureTextBlock" xlink:to="lab_teva_CertainTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CertainTransactionsDisclosureTextBlock" xml:lang="en-US">This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from contracts with customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xml:lang="en-US">Goodwill Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xml:lang="en-US">Legal Settlements and Loss Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="loc_us-gaap_FederalHomeLoanBanksAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalHomeLoanBanksAbstract" xml:lang="en-US">Federal Home Loan Banks [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalHomeLoanBanksAbstract" xlink:to="lab_us-gaap_FederalHomeLoanBanksAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other Expenses [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other assets impairments, restructuring and other items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherExpensesTextBlock" xlink:to="lab_teva_OtherExpensesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherExpensesTextBlock" xml:lang="en-US">Other Expenses [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xml:lang="en-US">Other Operating Income and Expense [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetTextBlock" xlink:label="loc_teva_FinancialExpensesNetTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FinancialExpensesNetTextBlock" xml:lang="en-US">Financial Expenses Net [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FinancialExpensesNetTextBlock" xml:lang="en-US">Financial expenses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FinancialExpensesNetTextBlock" xlink:to="lab_teva_FinancialExpensesNetTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FinancialExpensesNetTextBlock" xml:lang="en-US">Financial Expenses Net [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings (Loss) per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermEmployeeRelatedObligationsTextBlock" xlink:label="loc_teva_LongTermEmployeeRelatedObligationsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermEmployeeRelatedObligationsTextBlock" xml:lang="en-US">Long Term Employee Related Obligations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermEmployeeRelatedObligationsTextBlock" xml:lang="en-US">Long-term Employee-related Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermEmployeeRelatedObligationsTextBlock" xlink:to="lab_teva_LongTermEmployeeRelatedObligationsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermEmployeeRelatedObligationsTextBlock" xml:lang="en-US">Long Term Employee Related Obligations [Text Block]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialDataTextBlock" xlink:label="loc_teva_SelectedQuarterlyFinancialDataTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SelectedQuarterlyFinancialDataTextBlock" xml:lang="en-US">Selected Quarterly Financial Data [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SelectedQuarterlyFinancialDataTextBlock" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SelectedQuarterlyFinancialDataTextBlock" xlink:to="lab_teva_SelectedQuarterlyFinancialDataTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SelectedQuarterlyFinancialDataTextBlock" xml:lang="en-US">Selected Quarterly Financial Data [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AcquisitionTextBlock" xlink:label="loc_teva_AcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AcquisitionTextBlock" xml:lang="en-US">Acquisition [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AcquisitionTextBlock" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AcquisitionTextBlock" xlink:to="lab_teva_AcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AcquisitionTextBlock" xml:lang="en-US">Acquisition [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xml:lang="en-US">Collaborative arrangements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of credit risks</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxesUncertaintiesPolicyTextBlock" xlink:label="loc_teva_IncomeTaxesUncertaintiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeTaxesUncertaintiesPolicyTextBlock" xml:lang="en-US">Income Taxes Uncertainties Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeTaxesUncertaintiesPolicyTextBlock" xml:lang="en-US">Uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeTaxesUncertaintiesPolicyTextBlock" xlink:to="lab_teva_IncomeTaxesUncertaintiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeTaxesUncertaintiesPolicyTextBlock" xml:lang="en-US">Describes an entity's accounting policy for tax positions taken in the Company's tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of contingencies related to income taxes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CostOfShippingAndHandlingPolicyTextBlock" xlink:label="loc_teva_CostOfShippingAndHandlingPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CostOfShippingAndHandlingPolicyTextBlock" xml:lang="en-US">Cost of Shipping and Handling [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CostOfShippingAndHandlingPolicyTextBlock" xml:lang="en-US">Shipping and handling costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CostOfShippingAndHandlingPolicyTextBlock" xlink:to="lab_teva_CostOfShippingAndHandlingPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CostOfShippingAndHandlingPolicyTextBlock" xml:lang="en-US">Cost of shipping and handling policy.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EquityAndCostMethodInvestmentPolicyTextBlock" xlink:label="loc_teva_EquityAndCostMethodInvestmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EquityAndCostMethodInvestmentPolicyTextBlock" xml:lang="en-US">Equity And Cost Method Investment Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EquityAndCostMethodInvestmentPolicyTextBlock" xml:lang="en-US">Equity investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EquityAndCostMethodInvestmentPolicyTextBlock" xlink:to="lab_teva_EquityAndCostMethodInvestmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EquityAndCostMethodInvestmentPolicyTextBlock" xml:lang="en-US">This element describes an entity's application of the equity method of accounting to investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The description provided may include a description of how equity method or cost investments are assessed for impairment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GeneralOptionsAccountingPolicyPolicyTextBlock" xlink:label="loc_teva_GeneralOptionsAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_GeneralOptionsAccountingPolicyPolicyTextBlock" xml:lang="en-US">General Options Accounting Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_GeneralOptionsAccountingPolicyPolicyTextBlock" xml:lang="en-US">General</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_GeneralOptionsAccountingPolicyPolicyTextBlock" xlink:to="lab_teva_GeneralOptionsAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_GeneralOptionsAccountingPolicyPolicyTextBlock" xml:lang="en-US">General options accounting policy.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Long-lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" xml:lang="en-US">Revenue, Remaining Performance Obligation, Provision for Loss [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" xml:lang="en-US">Revenue recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives and hedging</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DivestituresTextBlock" xlink:label="loc_teva_DivestituresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DivestituresTextBlock" xml:lang="en-US">Divestitures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DivestituresTextBlock" xml:lang="en-US">Divestitures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DivestituresTextBlock" xlink:to="lab_teva_DivestituresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DivestituresTextBlock" xml:lang="en-US">Divestitures [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Investment in debt securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New accounting pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringTextBlock" xlink:label="loc_teva_RestructuringTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringTextBlock" xml:lang="en-US">Restructuring [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringTextBlock" xml:lang="en-US">Restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringTextBlock" xlink:to="lab_teva_RestructuringTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringTextBlock" xml:lang="en-US">Restructuring [Text Block]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SecuritizationTextBlock" xlink:label="loc_teva_SecuritizationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SecuritizationTextBlock" xml:lang="en-US">Securitization [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SecuritizationTextBlock" xml:lang="en-US">Securitization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SecuritizationTextBlock" xlink:to="lab_teva_SecuritizationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SecuritizationTextBlock" xml:lang="en-US">Securitization [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment reporting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TreasurySharesPolicyTextBlock" xlink:label="loc_teva_TreasurySharesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TreasurySharesPolicyTextBlock" xml:lang="en-US">Treasury Shares [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TreasurySharesPolicyTextBlock" xml:lang="en-US">Treasury shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TreasurySharesPolicyTextBlock" xlink:to="lab_teva_TreasurySharesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TreasurySharesPolicyTextBlock" xml:lang="en-US">Describes how the entity's previously issued shares that were reacquired by the entity are presented in the balance sheet.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccountsReceivablesPolicyTextBlock" xlink:label="loc_teva_AccountsReceivablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AccountsReceivablesPolicyTextBlock" xml:lang="en-US">Accounts Receivables [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AccountsReceivablesPolicyTextBlock" xml:lang="en-US">Accounts receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AccountsReceivablesPolicyTextBlock" xlink:to="lab_teva_AccountsReceivablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AccountsReceivablesPolicyTextBlock" xml:lang="en-US">Accounts Receivables [Text Block]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Summary of Major Classes of Assets and Liabilities Included as Held for Sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:to="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xml:lang="en-US">Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Summary of disaggregates revenues by major revenue streams</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Sales Reserves And Allowances Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Summary of Sales Reserves and Allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:to="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowancesCurrentTableTextBlock" xml:lang="en-US">Tabular disclosure of sales reserves and allowances current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Summary of Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of Property, Plant and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Summary of Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xml:lang="en-US">Summary of Changes in the Carrying Amount of Goodwill by Segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" xlink:label="loc_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" xml:lang="en-US">Supplemental Balance Sheet Information Related To Leases Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" xml:lang="en-US">Supplemental Balance Sheet Information Related To Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" xlink:to="lab_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" xml:lang="en-US">Tabular disclosure of supplemental balance sheet information related to leases.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SupplementalCashFlowInformationTableTextBlock" xlink:label="loc_teva_SupplementalCashFlowInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SupplementalCashFlowInformationTableTextBlock" xml:lang="en-US">Supplemental cash flow information related to leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SupplementalCashFlowInformationTableTextBlock" xml:lang="en-US">Supplemental cash flow information related to leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SupplementalCashFlowInformationTableTextBlock" xlink:to="lab_teva_SupplementalCashFlowInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SupplementalCashFlowInformationTableTextBlock" xml:lang="en-US">na</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ComponentsOfLeaseExpenseTableTextBlock" xlink:label="loc_teva_ComponentsOfLeaseExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ComponentsOfLeaseExpenseTableTextBlock" xml:lang="en-US">Components Of Lease Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ComponentsOfLeaseExpenseTableTextBlock" xml:lang="en-US">Components Of Lease Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ComponentsOfLeaseExpenseTableTextBlock" xlink:to="lab_teva_ComponentsOfLeaseExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ComponentsOfLeaseExpenseTableTextBlock" xml:lang="en-US">na</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Maturities of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xlink:label="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xml:lang="en-US">Long Term Debt Excluding Convertible Debt Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xml:lang="en-US">Schedule of Senior Notes and Loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xlink:to="lab_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xml:lang="en-US">A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xml:lang="en-US">Schedule of Short-term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xml:lang="en-US">Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xml:lang="en-US">Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xml:lang="en-US">Summary of Classification and Fair Values of Derivative Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfAccountReceivableFromSecuritization" xlink:label="loc_teva_ScheduleOfAccountReceivableFromSecuritization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfAccountReceivableFromSecuritization" xml:lang="en-US">Schedule Of Account Receivable From Securitization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfAccountReceivableFromSecuritization" xml:lang="en-US">Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfAccountReceivableFromSecuritization" xlink:to="lab_teva_ScheduleOfAccountReceivableFromSecuritization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfAccountReceivableFromSecuritization" xml:lang="en-US">Schedule of account receivable from securitization.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Domestic And Foreign Income Tax Expense Benefit Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of the Provision for Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Domestic And Foreign Income Tax Expense Benefit Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" xlink:label="loc_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities By Report Caption [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities By Report Caption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" xlink:to="lab_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" xml:lang="en-US">Schedule of deferred tax assets and liabilities by report caption.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss) (Net of Tax)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income Before Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Schedule of the Number of RSUs Issued and Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Schedule of Ordinary Shares Issued Upon Outstanding Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xml:lang="en-US">Summary of Weighted Average Fair Value of Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xml:lang="en-US">Schedule of Ordinary Shares Issued Upon Vested Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss) (Net of Tax)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xml:lang="en-US">Summary of Restructuring Accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Schedule of Restructuring Charges [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Summary of Restructuring Plan Including Costs Related to Exit and Disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:to="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfRestructuringChargesTableTextBlock" xml:lang="en-US">Schedule of Restructuring Charges [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xml:lang="en-US">Schedule of Other Assets Impairments, Restructuring and Other Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfOtherIncomeTableTextBlock" xlink:label="loc_teva_ScheduleOfOtherIncomeTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfOtherIncomeTableTextBlock" xml:lang="en-US">Schedule Of Other Income Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfOtherIncomeTableTextBlock" xml:lang="en-US">Schedule of Other Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfOtherIncomeTableTextBlock" xlink:to="lab_teva_ScheduleOfOtherIncomeTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfOtherIncomeTableTextBlock" xml:lang="en-US">Schedule Of Other Income Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetTableTextBlock" xlink:label="loc_teva_FinancialExpensesNetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FinancialExpensesNetTableTextBlock" xml:lang="en-US">Financial Expenses Net Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FinancialExpensesNetTableTextBlock" xml:lang="en-US">Schedule of Financial Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FinancialExpensesNetTableTextBlock" xlink:to="lab_teva_FinancialExpensesNetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FinancialExpensesNetTableTextBlock" xml:lang="en-US">Financial Expenses Net Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" xlink:label="loc_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" xml:lang="en-US">Property Plant And Equipment By Geographic Area Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" xml:lang="en-US">Schedule of Property, Plant and Equipment by Geographic Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" xlink:to="lab_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" xml:lang="en-US">A schedule indicating where long-lived tangible assets are located.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US">Summary of Segment Profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesPercentageByTherapeuticCategoryTableTextBlock" xlink:label="loc_teva_SalesPercentageByTherapeuticCategoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesPercentageByTherapeuticCategoryTableTextBlock" xml:lang="en-US">Sales Percentage By Therapeutic Category Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesPercentageByTherapeuticCategoryTableTextBlock" xml:lang="en-US">Schedule of Sales Percentage by Therapeutic Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesPercentageByTherapeuticCategoryTableTextBlock" xlink:to="lab_teva_SalesPercentageByTherapeuticCategoryTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesPercentageByTherapeuticCategoryTableTextBlock" xml:lang="en-US">A schedule of net sales by therapeutic category, stated as a percentage of total sales.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule Of Consolidated Income Before Income Tax [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule Of Consolidated Income Before Income Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:to="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xml:lang="en-US">Schedule of consolidated income before income tax.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Schedule of Net Sales by Product Line</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Summary of Financial Instrument Measured on a Basis Other Than Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Summary of Financial Items Carried at Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermEmployeeRelatedObligationsTableTextBlock" xlink:label="loc_teva_LongTermEmployeeRelatedObligationsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermEmployeeRelatedObligationsTableTextBlock" xml:lang="en-US">Long Term Employee Related Obligations Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermEmployeeRelatedObligationsTableTextBlock" xml:lang="en-US">Schedule of Long Term Employee Related Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermEmployeeRelatedObligationsTableTextBlock" xlink:to="lab_teva_LongTermEmployeeRelatedObligationsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermEmployeeRelatedObligationsTableTextBlock" xml:lang="en-US">Long Term Employee Related Obligations Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialDataTableTextBlock" xlink:label="loc_teva_SelectedQuarterlyFinancialDataTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SelectedQuarterlyFinancialDataTableTextBlock" xml:lang="en-US">Selected Quarterly Financial Data Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SelectedQuarterlyFinancialDataTableTextBlock" xml:lang="en-US">Selected Quarterly Financial Data</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SelectedQuarterlyFinancialDataTableTextBlock" xlink:to="lab_teva_SelectedQuarterlyFinancialDataTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SelectedQuarterlyFinancialDataTableTextBlock" xml:lang="en-US">Selected Quarterly Financial Data Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SignificantAccountingPoliciesLineItems" xlink:label="loc_teva_SignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems" xlink:to="lab_teva_SignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" xlink:label="loc_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" xml:lang="en-US">Cash Deposited With Financially Sound European Us And Israeli Banks And Financial Institutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" xml:lang="en-US">Cash deposited with financially sound European us and Israeli banks and financial institutions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" xlink:to="lab_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" xml:lang="en-US">Cash deposited with financially sound european us and israeli banks and financial institutions.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageOfConsolidatedSalesInNorthAmerica" xlink:label="loc_teva_PercentageOfConsolidatedSalesInNorthAmerica" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PercentageOfConsolidatedSalesInNorthAmerica" xml:lang="en-US">Percentage Of Consolidated Sales In North America</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PercentageOfConsolidatedSalesInNorthAmerica" xml:lang="en-US">Percentage of consolidated sales in North America</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PercentageOfConsolidatedSalesInNorthAmerica" xlink:to="lab_teva_PercentageOfConsolidatedSalesInNorthAmerica" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PercentageOfConsolidatedSalesInNorthAmerica" xml:lang="en-US">The percentage that sales to external customers in North America are to consolidated net sales for the reporting period.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CreditTermsToCustomers" xlink:label="loc_teva_CreditTermsToCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CreditTermsToCustomers" xml:lang="en-US">Credit Terms to Customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CreditTermsToCustomers" xml:lang="en-US">Credit terms to customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CreditTermsToCustomers" xlink:to="lab_teva_CreditTermsToCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CreditTermsToCustomers" xml:lang="en-US">Credit terms to customers.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property plant and equipment useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShippingHandlingAndTransportationCost" xlink:label="loc_teva_ShippingHandlingAndTransportationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ShippingHandlingAndTransportationCost" xml:lang="en-US">Shipping, Handling and Transportation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ShippingHandlingAndTransportationCost" xml:lang="en-US">Shipping and handling costs, which are included in selling and marketing expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ShippingHandlingAndTransportationCost" xlink:to="lab_teva_ShippingHandlingAndTransportationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ShippingHandlingAndTransportationCost" xml:lang="en-US">Shipping, handling and transportation cost.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Ordinary shares issued upon mandatory conversion of preferred shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Share issued due to conversion of convertible preferred shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating leases rent expense net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseRemainingLeaseTerm" xlink:label="loc_teva_OperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Operating Lease Remaining Lease Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OperatingLeaseRemainingLeaseTerm" xlink:to="lab_teva_OperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescription" xml:lang="en-US">Lessee, Operating Lease, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescription" xml:lang="en-US">Operating Lease description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescription" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescription" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xml:lang="en-US">Royalty Income, Nonoperating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xml:lang="en-US">Royalty income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BuildingMember" xml:lang="en-US">Building [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BuildingMember" xml:lang="en-US">Building [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xml:lang="en-US">Other Capitalized Property Plant and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xml:lang="en-US">Other Capitalized Property Plant and Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xml:lang="en-US">Other Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xml:lang="en-US">Other Machinery and Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OneTimeMilestonePaymentReceived" xlink:label="loc_teva_OneTimeMilestonePaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OneTimeMilestonePaymentReceived" xml:lang="en-US">One Time Milestone Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OneTimeMilestonePaymentReceived" xml:lang="en-US">Allergan one time payment to Teva</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OneTimeMilestonePaymentReceived" xlink:to="lab_teva_OneTimeMilestonePaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OneTimeMilestonePaymentReceived" xml:lang="en-US">One Time Milestone Payment Received</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Cash consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Shares issued as consideration for the acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ActavisMember" xlink:label="loc_teva_ActavisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ActavisMember" xml:lang="en-US">Actavis [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ActavisMember" xml:lang="en-US">Actavis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ActavisMember" xlink:to="lab_teva_ActavisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ActavisMember" xml:lang="en-US">Actavis [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AndaMember" xlink:to="lab_teva_AndaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AndaMember" xml:lang="en-US">Anda [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AllerganPlcMember" xlink:label="loc_teva_AllerganPlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AllerganPlcMember" xml:lang="en-US">Allergan Plc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AllerganPlcMember" xml:lang="en-US">Allergan plc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AllerganPlcMember" xlink:to="lab_teva_AllerganPlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AllerganPlcMember" xml:lang="en-US">Allergan Plc.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionsTable" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CelltrionMember" xlink:label="loc_teva_CelltrionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CelltrionMember" xml:lang="en-US">Celltrion [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CelltrionMember" xml:lang="en-US">Celltrion [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CelltrionMember" xlink:to="lab_teva_CelltrionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CelltrionMember" xml:lang="en-US">Celltrion [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AlderMember" xlink:label="loc_teva_AlderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AlderMember" xml:lang="en-US">Alder [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AlderMember" xml:lang="en-US">Alder [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AlderMember" xlink:to="lab_teva_AlderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AlderMember" xml:lang="en-US">Alder [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RegeneronMember" xlink:label="loc_teva_RegeneronMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RegeneronMember" xml:lang="en-US">Regeneron [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RegeneronMember" xml:lang="en-US">Regeneron [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RegeneronMember" xlink:to="lab_teva_RegeneronMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RegeneronMember" xml:lang="en-US">Regeneron [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RimsaMember" xlink:label="loc_teva_RimsaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RimsaMember" xml:lang="en-US">Rimsa [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RimsaMember" xml:lang="en-US">Rimsa [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RimsaMember" xlink:to="lab_teva_RimsaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RimsaMember" xml:lang="en-US">Rimsa [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtsukaMember" xlink:to="lab_teva_OtsukaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtsukaMember" xml:lang="en-US">Otsuka [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AlvotechMember" xlink:to="lab_teva_AlvotechMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AlvotechMember" xml:lang="en-US">Alvotech.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xml:lang="en-US">Noncash or Part Noncash Acquisitions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative Agreement Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative agreement milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CollaborativeAgreementMilestonePayments" xlink:to="lab_teva_CollaborativeAgreementMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CollaborativeAgreementMilestonePayments" xml:lang="en-US">Collaborative Agreement Milestone Payments</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Write-down of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RefundablePayment" xlink:label="loc_teva_RefundablePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RefundablePayment" xml:lang="en-US">Refundable Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RefundablePayment" xml:lang="en-US">Refundable payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RefundablePayment" xlink:to="lab_teva_RefundablePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RefundablePayment" xml:lang="en-US">Refundable Payment</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ResearchAndDevelopmentCosts" xlink:label="loc_teva_ResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ResearchAndDevelopmentCosts" xml:lang="en-US">Research And Development Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ResearchAndDevelopmentCosts" xml:lang="en-US">Research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ResearchAndDevelopmentCosts" xlink:to="lab_teva_ResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ResearchAndDevelopmentCosts" xml:lang="en-US">Research And Development Costs</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TotalAssociatedCost" xlink:label="loc_teva_TotalAssociatedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TotalAssociatedCost" xml:lang="en-US">Total Associated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TotalAssociatedCost" xml:lang="en-US">Total associated cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TotalAssociatedCost" xlink:to="lab_teva_TotalAssociatedCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TotalAssociatedCost" xml:lang="en-US">Total Associated Cost</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UpfrontPayments" xlink:to="lab_teva_UpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UpfrontPayments" xml:lang="en-US">Upfront payments</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NumberOfLawsuitsFiled" xlink:label="loc_teva_NumberOfLawsuitsFiled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NumberOfLawsuitsFiled" xml:lang="en-US">Number Of Lawsuits Filed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NumberOfLawsuitsFiled" xml:lang="en-US">Number of lawsuits filed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NumberOfLawsuitsFiled" xlink:to="lab_teva_NumberOfLawsuitsFiled" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NumberOfLawsuitsFiled" xml:lang="en-US">Number Of Lawsuits Filed</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MilestonePayment" xlink:to="lab_teva_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MilestonePayment" xml:lang="en-US">Milestone payment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PgtMember" xlink:label="loc_teva_PgtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PgtMember" xml:lang="en-US">Pgt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PgtMember" xml:lang="en-US">PGT Healthcare Partnership [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PgtMember" xlink:to="lab_teva_PgtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PgtMember" xml:lang="en-US">Pgt [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment Ownership Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Minority Interest Ownership Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xml:lang="en-US">Impairment charge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TevaMember" xlink:label="loc_teva_TevaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TevaMember" xml:lang="en-US">Teva [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TevaMember" xml:lang="en-US">Teva [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TevaMember" xlink:to="lab_teva_TevaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TevaMember" xml:lang="en-US">Teva Member</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xml:lang="en-US">Property, plant and equipment, net and others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xml:lang="en-US">Assets, Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueAdjustment" xml:lang="en-US">Adjustments of assets held for sale to fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueAdjustment" xlink:to="lab_us-gaap_AssetsFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xml:lang="en-US">Revenue Recognition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueRecognitionTable" xlink:to="lab_teva_RevenueRecognitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueRecognitionLineItems" xlink:to="lab_teva_RevenueRecognitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Sales Reserves and Allowances to Customers Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Percentage sales reserves and allowances to U.S. customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:to="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SalesReservesAndAllowancesToCustomersPercentage" xml:lang="en-US">Sales reserves and allowances to customers percentage.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DistributionServiceMember" xml:lang="en-US">Distribution Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DistributionServiceMember" xml:lang="en-US">Distribution [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionServiceMember" xlink:to="lab_us-gaap_DistributionServiceMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">Licensing Arrangements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Product and Service, Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Sale of Goods [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International Markets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International Markets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InternationalMarketsMember" xlink:to="lab_teva_InternationalMarketsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InternationalMarketsMember" xml:lang="en-US">International markets.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other Activities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other activities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherActivitiesMember" xlink:to="lab_teva_OtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherActivitiesMember" xml:lang="en-US">Other Activities [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NorthAmericaMember" xml:lang="en-US">North America [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_NorthAmericaMember" xml:lang="en-US">North America [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">Balance at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US">Balance at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xml:lang="en-US">Credits and payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xml:lang="en-US">Deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Valuation Allowances And Reserves Foreign Currency Translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:to="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xml:lang="en-US">Valuation allowances and reserves foreign currency translation.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Valuation Allowances And Reserves Related To Current Period Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Provisions related to sales made in current year period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:to="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xml:lang="en-US">Valuation allowances and reserves related to current period sales.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Valuation Allowances And Reserves Related To Prior Period Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Provisions related to sales made in prior periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:to="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xml:lang="en-US">Valuation allowances and reserves related to prior period sales.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid And Other Governmental Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid and Other Governmental Allowances [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:to="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MedicaidAndOtherGovernmentalAllowancesMember" xml:lang="en-US">Medicaid and other governmental allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other Sales Reserves And Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherSalesReservesAndAllowancesMember" xlink:to="lab_teva_OtherSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherSalesReservesAndAllowancesMember" xml:lang="en-US">Other sales reserves and allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RebatesMember" xlink:to="lab_teva_RebatesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RebatesMember" xml:lang="en-US">Rebates.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves Included In Accounts Receivable Net [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves Included in Accounts Receivable, Net [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ReservesIncludedInAccountsReceivableNetMember" xlink:to="lab_teva_ReservesIncludedInAccountsReceivableNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ReservesIncludedInAccountsReceivableNetMember" xml:lang="en-US">Reserves included in accounts receivable net.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ReturnsMember" xlink:to="lab_teva_ReturnsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ReturnsMember" xml:lang="en-US">Returns.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ChargebacksMember" xlink:to="lab_teva_ChargebacksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ChargebacksMember" xml:lang="en-US">Chargebacks.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total Reserves Included In Sales Reserves And Allowances [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total Reserves Included in Sales Reserves and Allowances [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:to="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xml:lang="en-US">Total reserves included in sales reserves and allowances.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InventoriesTable" xlink:to="lab_teva_InventoriesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InventoriesTable" xml:lang="en-US">Inventories [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InventoriesLineItems" xlink:to="lab_teva_InventoriesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InventoriesLineItems" xml:lang="en-US">Inventories [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Finished products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Raw and packaging materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Products in process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherInventoryInTransit" xml:lang="en-US">Other Inventory, in Transit, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherInventoryInTransit" xml:lang="en-US">Materials in transit and payments on account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryInTransit" xlink:to="lab_us-gaap_OtherInventoryInTransit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less&#8212;accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xml:lang="en-US">Buildings and Improvements, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xml:lang="en-US">Buildings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Land" xml:lang="en-US">Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Land" xml:lang="en-US">Land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xml:lang="en-US">Machinery and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xml:lang="en-US">Machinery and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xml:lang="en-US">Property, Plant and Equipment, Other, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xml:lang="en-US">Computer equipment and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOther" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AssetsUnderConstructionAndPaymentsOnAccount" xlink:label="loc_teva_AssetsUnderConstructionAndPaymentsOnAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AssetsUnderConstructionAndPaymentsOnAccount" xml:lang="en-US">Assets Under Construction And Payments On Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AssetsUnderConstructionAndPaymentsOnAccount" xml:lang="en-US">Assets under construction and payments on account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AssetsUnderConstructionAndPaymentsOnAccount" xlink:to="lab_teva_AssetsUnderConstructionAndPaymentsOnAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AssetsUnderConstructionAndPaymentsOnAccount" xml:lang="en-US">Assets under construction and payments on account.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense for the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xml:lang="en-US">Tangible Asset Impairment Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xml:lang="en-US">Impairment charge during the year on property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xml:lang="en-US">Impairments of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount net of impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Product Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Identifiable product rights [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProductRightsMember" xlink:to="lab_teva_ProductRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProductRightsMember" xml:lang="en-US">Product Rights [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade Names [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade Names [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development (IPR&amp;D) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xml:lang="en-US">In Process Research and Development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">Austedo [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">AUSTEDO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AustedoMember" xlink:to="lab_teva_AustedoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AustedoMember" xml:lang="en-US">Austedo [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business combination recognized identifiable assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Amortization of intangible assets useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of intangible assets excluding goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Intangible asset impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DiscontinuationOfBusinessAxis" xml:lang="en-US">Discontinuation Of Business [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DiscontinuationOfBusinessAxis" xlink:to="lab_teva_DiscontinuationOfBusinessAxis" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DiscontinuationOfBusinessDomain" xml:lang="en-US">Discontinuation Of Business [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DiscontinuationOfBusinessDomain" xlink:to="lab_teva_DiscontinuationOfBusinessDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuedBusinessMember" xlink:label="loc_teva_DiscontinuedBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DiscontinuedBusinessMember" xml:lang="en-US">Discontinued Business [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DiscontinuedBusinessMember" xml:lang="en-US">Discontinued business [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DiscontinuedBusinessMember" xlink:to="lab_teva_DiscontinuedBusinessMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LenalidomideProductMember" xlink:label="loc_teva_LenalidomideProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LenalidomideProductMember" xml:lang="en-US">Lenalidomide Product [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LenalidomideProductMember" xlink:to="lab_teva_LenalidomideProductMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:to="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:to="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xml:lang="en-US">Impairment Of Intangible Assets Reasons For Impairment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:label="loc_country_JP" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_JP" xml:lang="en-US">JAPAN</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_JP" xml:lang="en-US">Japan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillRollForward" xml:lang="en-US">Goodwill [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xml:lang="en-US">Schedule of Goodwill [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xml:lang="en-US">Schedule of Goodwill [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsAxis" xml:lang="en-US">Consolidation Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsDomain" xml:lang="en-US">Consolidation Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillLineItems" xml:lang="en-US">Goodwill [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillLineItems" xml:lang="en-US">Goodwill [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xml:lang="en-US">Translation differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GoodwillReclassification" xlink:label="loc_teva_GoodwillReclassification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_GoodwillReclassification" xml:lang="en-US">Goodwill Reclassification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_GoodwillReclassification" xml:lang="en-US">Goodwill reclassified as assets to held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_GoodwillReclassification" xlink:to="lab_teva_GoodwillReclassification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_GoodwillReclassification" xml:lang="en-US">Goodwill reclassification.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xml:lang="en-US">Goodwill disposal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other Countries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherCountriesMember" xlink:to="lab_teva_OtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherCountriesMember" xml:lang="en-US">Other countries.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xml:lang="en-US">Accumulated goodwill impairment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherMember" xlink:label="loc_teva_OtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherMember" xml:lang="en-US">Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherMember" xlink:to="lab_teva_OtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherMember" xml:lang="en-US">Other [Member].</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageDecreaseInTheMarketCapitalization" xlink:label="loc_teva_PercentageDecreaseInTheMarketCapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PercentageDecreaseInTheMarketCapitalization" xml:lang="en-US">Percentage Decrease In The Market Capitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PercentageDecreaseInTheMarketCapitalization" xml:lang="en-US">Reduction in its market capitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PercentageDecreaseInTheMarketCapitalization" xlink:to="lab_teva_PercentageDecreaseInTheMarketCapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PercentageDecreaseInTheMarketCapitalization" xml:lang="en-US">Percentage decrease in the market capitalization.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" xlink:label="loc_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" xml:lang="en-US">Percentage Difference Between Fair Value And Carrying Value In Respect Of Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" xml:lang="en-US">Percentage difference between fair value and carrying value in respect of goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" xlink:to="lab_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" xml:lang="en-US">Difference In the value of goodwill in percentage terms between the carrying value and the faitr value</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseCostAbstract" xlink:label="loc_teva_OperatingLeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OperatingLeaseCostAbstract" xml:lang="en-US">Operating Lease Cost [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_OperatingLeaseCostAbstract" xml:lang="en-US">Operating lease cost:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OperatingLeaseCostAbstract" xlink:to="lab_teva_OperatingLeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" xlink:label="loc_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" xml:lang="en-US">Fixed Payments And Variable Payments Depend On An Index Or Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" xml:lang="en-US">Fixed payments and variable payments that depend on an index or rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" xlink:to="lab_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" xml:lang="en-US">Represents the amount of fixed payments and variable payments depend on an index or rate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease payments not included in the lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" xlink:label="loc_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations Noncash [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations (non-cash):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" xlink:to="lab_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesNonCash" xlink:label="loc_teva_OperatingLeasesNonCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OperatingLeasesNonCash" xml:lang="en-US">Operating Leases Non Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_OperatingLeasesNonCash" xml:lang="en-US">Operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OperatingLeasesNonCash" xlink:to="lab_teva_OperatingLeasesNonCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OperatingLeasesNonCash" xml:lang="en-US">Represents the amount of operating leases non cash amount.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" xlink:label="loc_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" xml:lang="en-US">Cash Paid for Amounts Measurement of Lease Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash flows from operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesAbstract" xlink:label="loc_teva_OperatingLeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OperatingLeasesAbstract" xml:lang="en-US">Operating leases [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OperatingLeasesAbstract" xml:lang="en-US">Operating leases:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OperatingLeasesAbstract" xlink:to="lab_teva_OperatingLeasesAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseLiabilityOther" xlink:label="loc_teva_OperatingLeaseLiabilityOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OperatingLeaseLiabilityOther" xml:lang="en-US">Operating Lease Liability Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OperatingLeaseLiabilityOther" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OperatingLeaseLiabilityOther" xlink:to="lab_teva_OperatingLeaseLiabilityOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OperatingLeaseLiabilityOther" xml:lang="en-US">It represent of operating other current liabilties</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term Operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate Operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesImputedInterest" xlink:label="loc_teva_OperatingLeasesImputedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OperatingLeasesImputedInterest" xml:lang="en-US">Operating Leases Imputed Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OperatingLeasesImputedInterest" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OperatingLeasesImputedInterest" xlink:to="lab_teva_OperatingLeasesImputedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OperatingLeasesImputedInterest" xml:lang="en-US">Represents imputed interest.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="loc_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And Thereafter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xml:lang="en-US">2025 and thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:to="lab_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xml:lang="en-US">Lessee operating lease liability payments due year five and thereafter.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total operating lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Finance Lease, Right-of-Use Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance Lease, Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Weighted average interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Debt Instrument Maturity Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DebtInstrumentMaturityYear" xlink:to="lab_teva_DebtInstrumentMaturityYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DebtInstrumentMaturityYear" xml:lang="en-US">Debt Instrument Maturity Year</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current maturities of long-term liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less current maturities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Short Credit Agreement 2026 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Convertible senior debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ShortCreditAgreement2026Member" xlink:to="lab_teva_ShortCreditAgreement2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ShortCreditAgreement2026Member" xml:lang="en-US">Short credit agreement 2026.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CurrencyAxis" xml:lang="en-US">Currency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_AllCurrenciesDomain" xml:lang="en-US">All Currencies [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2020OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2020 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_teva_SubsidiarySeniorNotesDue2020OneMember" xml:lang="en-US">Senior notes EUR 1,010 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2020OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2020OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2020OneMember" xml:lang="en-US">Subsidiary senior notes due 2020 one.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2020TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2020 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2020TwoMember" xml:lang="en-US">Senior notes USD 700 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2020TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2020TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2020TwoMember" xml:lang="en-US">Subsidiary senior notes due 2020 two.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2021 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021OneMember" xml:lang="en-US">Senior notes USD 1,475 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2021OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2021OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021OneMember" xml:lang="en-US">Subsidiary senior notes due 2021 one.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Subsidiary Senior Notes Due 2028 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Senior notes EUR 750 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2028Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2028Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028Member" xml:lang="en-US">Subsidiary senior notes due 2028.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2028 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Senior notes USD 1,250 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2028OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2028OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2028OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2028 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Subsidiary Senior Notes Due 2036 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Senior notes USD 789 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2036Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2036Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2036Member" xml:lang="en-US">Subsidiary senior notes due 2036.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Subsidiary Senior Notes Due 2046 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Senior notes USD 2,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2046Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2046Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2046Member" xml:lang="en-US">Subsidiary senior notes due 2046.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other Debentures 2026 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other Debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherDebentures2026Member" xlink:to="lab_teva_OtherDebentures2026Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherDebentures2026Member" xml:lang="en-US">Other debentures 2026.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2021 Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021ThreeMember" xml:lang="en-US">Senior notes USD 588 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2021ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021ThreeMember" xml:lang="en-US">Subsidiary senior notes due 2021 three.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2027Member" xml:lang="en-US">Subsidiary Senior Notes Due 2027 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2027Member" xml:lang="en-US">Senior notes EUR 700 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2027Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2027Member" xml:lang="en-US">Subsidiary senior notes due 2027.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Senior notes EUR 1,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025ThreeMember" xml:lang="en-US">Senior notes CHF 350 Million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025ThreeMember" xml:lang="en-US">Subsidiary senior notes due 2025 three.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2025 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Senior notes USD 1,000 million [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Senior notes USD 1,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025TwoMember" xml:lang="en-US">Subsidiary senior notes due 2025 two.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2021 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021TwoMember" xml:lang="en-US">Senior notes USD 613 million [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021TwoMember" xml:lang="en-US">Senior Notes Due 2021 Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2021TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2021TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2021TwoMember" xml:lang="en-US">Subsidiary senior notes due 2021 two.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Senior notes EUR 700 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2022OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2022OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022OneMember" xml:lang="en-US">Subsidiary senior notes due 2022 one.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Senior notes CHF 350 Million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022ThreeMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 Three [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2022 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022TwoMember" xml:lang="en-US">Senior notes USD 844 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2022TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2022TwoMember" xml:lang="en-US">Subsidiary senior notes due 2022 two.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2023 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Senior notes EUR 1,300 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2023OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2023OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023OneMember" xml:lang="en-US">Subsidiary senior notes due 2023 one.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Subsidiary Senior Notes Due 2024 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Senior notes EUR 1,500 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2024Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024Member" xml:lang="en-US">Subsidiary senior notes due 2024.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2024 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Senior notes USD 1,250 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2024OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2024OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2024OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2024 One [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Subsidiary Senior Notes Due 2025 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Senior notes EUR 900 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2025Member" xlink:to="lab_teva_SubsidiarySeniorNotesDue2025Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2025Member" xml:lang="en-US">Subsidiary Senior Notes Due 2025 Member</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Subsidiary Senior Notes Due 2026 One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Senior notes USD 3,500 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2026OneMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2026OneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2026OneMember" xml:lang="en-US">Subsidiary senior notes due 2026 one.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Subsidiary Senior Notes Due 2023 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Senior notes USD 3,000 million [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:to="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SubsidiarySeniorNotesDue2023TwoMember" xml:lang="en-US">Subsidiary senior notes due 2023 two.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Less debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Senior Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Total senior notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturityTable" xlink:label="loc_teva_LongTermDebtMaturityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtMaturityTable" xml:lang="en-US">Long Term Debt Maturity [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtMaturityTable" xml:lang="en-US">Long Term Debt Maturity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtMaturityTable" xlink:to="lab_teva_LongTermDebtMaturityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtMaturityTable" xml:lang="en-US">Long Term Debt Maturity [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturityLineItems" xlink:label="loc_teva_LongTermDebtMaturityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtMaturityLineItems" xml:lang="en-US">Long Term Debt Maturity [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtMaturityLineItems" xml:lang="en-US">Long Term Debt Maturity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtMaturityLineItems" xlink:to="lab_teva_LongTermDebtMaturityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtMaturityLineItems" xml:lang="en-US">Long Term Debt Maturity [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtaExcludeIssuanceCost" xlink:label="loc_teva_LongTermDebtaExcludeIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtaExcludeIssuanceCost" xml:lang="en-US">Long Term Debta Exclude Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_teva_LongTermDebtaExcludeIssuanceCost" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtaExcludeIssuanceCost" xlink:to="lab_teva_LongTermDebtaExcludeIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtaExcludeIssuanceCost" xml:lang="en-US">Long Term Debta Exclude Issuance Cost</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="loc_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xml:lang="en-US">2026 and thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:to="lab_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Principal amount currently outstanding on the debt instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaap_LinesOfCreditCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xml:lang="en-US">Line of Credit, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xml:lang="en-US">Revolving credit facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long Term Debt Currency Portion C H F</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long term debt currency portion CHF</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionCHF" xlink:to="lab_teva_LongTermDebtCurrencyPortionCHF" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionCHF" xml:lang="en-US">Long term debt currency portion C H F.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long Term Debt Currency Portion E U R</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long term debt currency portion EUR</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionEUR" xlink:to="lab_teva_LongTermDebtCurrencyPortionEUR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionEUR" xml:lang="en-US">Long term debt currency portion E U R.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long Term Debt Currency Portion U S D</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long term debt currency portion USD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermDebtCurrencyPortionUSD" xlink:to="lab_teva_LongTermDebtCurrencyPortionUSD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermDebtCurrencyPortionUSD" xml:lang="en-US">Long term debt currency portion U S D.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCovenantDescription" xml:lang="en-US">Debt Instrument, Covenant Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantDescription" xlink:to="lab_us-gaap_DebtInstrumentCovenantDescription" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long Term Debt Payable Under Revolving Credit Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xml:lang="en-US">Line of Credit Facility, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xml:lang="en-US">Line of credit facility, expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationDate1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Senior Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Senior Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TrancheAxis" xml:lang="en-US">Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TrancheAxis" xlink:to="lab_teva_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TrancheAxis" xml:lang="en-US">Tranche.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TrancheDomain" xml:lang="en-US">Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TrancheDomain" xlink:to="lab_teva_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TrancheDomain" xml:lang="en-US">Tranche.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheAMember" xlink:label="loc_teva_TracheAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TracheAMember" xml:lang="en-US">Trache A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TracheAMember" xml:lang="en-US">Trache A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TracheAMember" xlink:to="lab_teva_TracheAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TracheAMember" xml:lang="en-US">Trache A.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheBMember" xlink:label="loc_teva_TracheBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TracheBMember" xml:lang="en-US">Trache B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TracheBMember" xml:lang="en-US">Trache B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TracheBMember" xlink:to="lab_teva_TracheBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TracheBMember" xml:lang="en-US">Trache B.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US">Lender Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheAExtensionMember" xlink:label="loc_teva_TracheAExtensionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TracheAExtensionMember" xml:lang="en-US">Trache A Extension [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TracheAExtensionMember" xlink:to="lab_teva_TracheAExtensionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xml:lang="en-US">Derivative Instrument Detail [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xml:lang="en-US">Hedging Relationship [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xml:lang="en-US">Hedging Relationship [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xml:lang="en-US">Hedging Relationship [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xml:lang="en-US">Hedging Relationship [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xml:lang="en-US">Net Investment Hedging [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xml:lang="en-US">Net Investment Hedge [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xml:lang="en-US">Derivative, Notional Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xml:lang="en-US">Notional amounts of hedge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xml:lang="en-US">Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xml:lang="en-US">Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingDesignationAxis" xml:lang="en-US">Hedging Designation [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingDesignationAxis" xml:lang="en-US">Hedging Designation [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HedgingDesignationDomain" xml:lang="en-US">Hedging Designation [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HedgingDesignationDomain" xml:lang="en-US">Hedging Designation [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xml:lang="en-US">Designated as Hedging Instrument [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xml:lang="en-US">Designated as Hedging Instrument [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xml:lang="en-US">Foreign Exchange Contract [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xml:lang="en-US">Foreign Exchange Contract [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SwapMember" xlink:label="loc_us-gaap_SwapMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SwapMember" xml:lang="en-US">Swap [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SwapMember" xml:lang="en-US">Swap [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SwapMember" xlink:to="lab_us-gaap_SwapMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other Current Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other Current Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesAndLoansMember" xlink:label="loc_teva_SeniorNotesAndLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesAndLoansMember" xml:lang="en-US">Senior Notes And Loans [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesAndLoansMember" xml:lang="en-US">Accounts Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesAndLoansMember" xlink:to="lab_teva_SeniorNotesAndLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesAndLoansMember" xml:lang="en-US">Senior notes and loans.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Noncurrent Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Non-current Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xml:lang="en-US">Other Current Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xml:lang="en-US">Asset derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Liability derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NondesignatedMember" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NondesignatedMember" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FinancialExpensesMember" xml:lang="en-US">Financial expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FinancialExpensesMember" xml:lang="en-US">Financial expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FinancialExpensesMember" xlink:to="lab_teva_FinancialExpensesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationAxis" xml:lang="en-US">Other Comprehensive Income Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationDomain" xml:lang="en-US">Other Comprehensive Income Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeMember" xml:lang="en-US">Other Comprehensive Income (Loss) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeMember" xml:lang="en-US">Other Comprehensive Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_OtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowHedgingMember" xml:lang="en-US">Cash Flow Hedging [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueHedgingMember" xml:lang="en-US">Fair Value Hedging [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NetRevenuesMember" xml:lang="en-US">Net Revenues [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NetRevenuesMember" xml:lang="en-US">Net Revenues [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NetRevenuesMember" xlink:to="lab_teva_NetRevenuesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xml:lang="en-US">Not Designated as Hedging Instrument, Trading [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xml:lang="en-US">Not Designated as Hedging Instrument, Trading [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:to="lab_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xml:lang="en-US">Not Designated as Hedging Instrument, Economic Hedge [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xml:lang="en-US">Not Designated as Hedging Instrument, Economic Hedge [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:to="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableFromSecuritization" xml:lang="en-US">Accounts Receivable from Securitization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AccountsReceivableFromSecuritization" xml:lang="en-US">Sold receivables at the end of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AccountsReceivableFromSecuritization" xml:lang="en-US">Sold receivables at the beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableFromSecuritization" xml:lang="en-US">Sold receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableFromSecuritization" xlink:to="lab_us-gaap_AccountsReceivableFromSecuritization" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" xlink:label="loc_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" xml:lang="en-US">Effect Of Exchange Rate On Accounts Receivable From Securitization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" xml:lang="en-US">Effect of currency exchange rate changes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" xlink:to="lab_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" xml:lang="en-US">Effect of exchange rate on accounts receivable from securitization.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromAccountsReceivableSecuritization" xlink:label="loc_us-gaap_ProceedsFromAccountsReceivableSecuritization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromAccountsReceivableSecuritization" xml:lang="en-US">Proceeds from Accounts Receivable Securitization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromAccountsReceivableSecuritization" xml:lang="en-US">Proceeds from sale of receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromAccountsReceivableSecuritization" xlink:to="lab_us-gaap_ProceedsFromAccountsReceivableSecuritization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfAccountsReceivableSecuritization" xlink:label="loc_us-gaap_RepaymentsOfAccountsReceivableSecuritization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfAccountsReceivableSecuritization" xml:lang="en-US">Repayments of Accounts Receivable Securitization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfAccountsReceivableSecuritization" xml:lang="en-US">Cash collections (remitted to the owner of the receivables)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfAccountsReceivableSecuritization" xlink:to="lab_us-gaap_RepaymentsOfAccountsReceivableSecuritization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesMember" xml:lang="en-US">Cost of sales [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2021Member" xlink:label="loc_teva_SeniorNotesDue2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesDue2021Member" xml:lang="en-US">Senior Notes Due 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesDue2021Member" xml:lang="en-US">Senior Notes Due 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesDue2021Member" xlink:to="lab_teva_SeniorNotesDue2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesDue2021Member" xml:lang="en-US">Senior Notes Due 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2022Member" xlink:label="loc_teva_SeniorNotesDue2022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesDue2022Member" xml:lang="en-US">Senior Notes Due 2022 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesDue2022Member" xml:lang="en-US">Senior Notes Due 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesDue2022Member" xlink:to="lab_teva_SeniorNotesDue2022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesDue2022Member" xml:lang="en-US">Senior notes due 2022.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2023TwoMember" xlink:label="loc_teva_SeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesDue2023TwoMember" xml:lang="en-US">Senior Notes Due 2023 Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesDue2023TwoMember" xml:lang="en-US">Senior Notes Due 2023 Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesDue2023TwoMember" xlink:to="lab_teva_SeniorNotesDue2023TwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesDue2023TwoMember" xml:lang="en-US">Senior notes due 2023 two.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2020Member" xlink:label="loc_teva_SeniorNotesDue2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniorNotesDue2020Member" xml:lang="en-US">Senior Notes Due 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniorNotesDue2020Member" xml:lang="en-US">Senior Notes Due 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniorNotesDue2020Member" xlink:to="lab_teva_SeniorNotesDue2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniorNotesDue2020Member" xml:lang="en-US">Senior Notes Due 2020</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" xlink:label="loc_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" xml:lang="en-US">Hedging Of Revenues Two Thousand And Twenty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" xml:lang="en-US">Hedging Of Revenues 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" xlink:to="lab_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredPurchaseAsset" xlink:label="loc_teva_DeferredPurchaseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredPurchaseAsset" xml:lang="en-US">Deferred Purchase Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DeferredPurchaseAsset" xml:lang="en-US">Deferred purchase asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredPurchaseAsset" xlink:to="lab_teva_DeferredPurchaseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredPurchaseAsset" xml:lang="en-US">Deferred Purchase Asset</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward starting interest rate swaps and treasury lock agreements losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:to="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xml:lang="en-US">Forward starting interest rate swaps and treasury lock agreements losses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Derivative, Loss on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Teva other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossOnDerivative" xlink:to="lab_us-gaap_DerivativeLossOnDerivative" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InterestRateSwapGain" xlink:label="loc_teva_InterestRateSwapGain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_InterestRateSwapGain" xml:lang="en-US">Interest Rate Swap Gain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_InterestRateSwapGain" xlink:to="lab_teva_InterestRateSwapGain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_InterestRateSwapGain" xml:lang="en-US">Interest rate swap gain.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues Other Than Usd</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues other than USD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenuesOtherThanUsd" xlink:to="lab_teva_RevenuesOtherThanUsd" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RevenuesOtherThanUsd" xml:lang="en-US">Revenues other than US Dollar.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SettlementGainPosition" xlink:label="loc_teva_SettlementGainPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SettlementGainPosition" xml:lang="en-US">Settlement Gain Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SettlementGainPosition" xml:lang="en-US">Settlement gain position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SettlementGainPosition" xlink:to="lab_teva_SettlementGainPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SettlementGainPosition" xml:lang="en-US">Settlement gain position.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashReceivedOnSettlementOfPosition" xlink:label="loc_teva_CashReceivedOnSettlementOfPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CashReceivedOnSettlementOfPosition" xml:lang="en-US">Cash Received On Settlement Of Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CashReceivedOnSettlementOfPosition" xml:lang="en-US">Cash received on settlement of position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CashReceivedOnSettlementOfPosition" xlink:to="lab_teva_CashReceivedOnSettlementOfPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CashReceivedOnSettlementOfPosition" xml:lang="en-US">Notional amount hedge debt.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NotionalAmountHedgeDebt" xlink:label="loc_teva_NotionalAmountHedgeDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NotionalAmountHedgeDebt" xml:lang="en-US">Notional Amount Hedge Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NotionalAmountHedgeDebt" xml:lang="en-US">Notional amount hedge debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NotionalAmountHedgeDebt" xlink:to="lab_teva_NotionalAmountHedgeDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NotionalAmountHedgeDebt" xml:lang="en-US">Notional amount hedge debt.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreviouslyHedgeDebtRate" xlink:label="loc_teva_PreviouslyHedgeDebtRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PreviouslyHedgeDebtRate" xml:lang="en-US">Previously Hedge Debt Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PreviouslyHedgeDebtRate" xml:lang="en-US">Previously hedge debt rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PreviouslyHedgeDebtRate" xlink:to="lab_teva_PreviouslyHedgeDebtRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PreviouslyHedgeDebtRate" xml:lang="en-US">Previously hedge debt rate.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Derivative, Gain on Derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainOnDerivative" xlink:to="lab_us-gaap_DerivativeGainOnDerivative" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xml:lang="en-US">Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xml:lang="en-US">Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:to="lab_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_LitigationCaseAxis" xml:lang="en-US">Litigation Case [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_LitigationCaseTypeDomain" xml:lang="en-US">Litigation Case [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SettlementOnAccountOfProductLiabilityMember" xlink:label="loc_teva_SettlementOnAccountOfProductLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SettlementOnAccountOfProductLiabilityMember" xml:lang="en-US">Settlement On Account Of Product Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SettlementOnAccountOfProductLiabilityMember" xlink:to="lab_teva_SettlementOnAccountOfProductLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SettlementOnAccountOfProductLiabilityMember" xml:lang="en-US">Settlement On Account Of Product Liability.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss Contingency Accrual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Accrued amount for legal settlements and loss contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Generic modafinil, and imposed fines amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation Settlement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Legal settlements and loss contingencies, expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xml:lang="en-US">Legal settlements, income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringExpenseAndIncome" xlink:label="loc_teva_RestructuringExpenseAndIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringExpenseAndIncome" xml:lang="en-US">Restructuring expense and income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringExpenseAndIncome" xml:lang="en-US">Restructuring expense and income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringExpenseAndIncome" xlink:to="lab_teva_RestructuringExpenseAndIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringExpenseAndIncome" xml:lang="en-US">Restructuring expense and income</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CommitmentAndContingenciesTable" xlink:to="lab_teva_CommitmentAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CommitmentAndContingenciesTable" xml:lang="en-US">Commitment And Contingencies [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CommitmentAndContingenciesLineItems" xlink:to="lab_teva_CommitmentAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CommitmentAndContingenciesLineItems" xml:lang="en-US">Commitment And Contingencies [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MilestoneContingentPayments" xlink:label="loc_teva_MilestoneContingentPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MilestoneContingentPayments" xml:lang="en-US">Milestone Contingent Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MilestoneContingentPayments" xml:lang="en-US">Milestone contingent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MilestoneContingentPayments" xlink:to="lab_teva_MilestoneContingentPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MilestoneContingentPayments" xml:lang="en-US">Milestone Contingent Payments</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfVelcade" xlink:label="loc_teva_AnnualSalesOfVelcade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfVelcade" xml:lang="en-US">Annual Sales Of Velcade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfVelcade" xml:lang="en-US">Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfVelcade" xlink:to="lab_teva_AnnualSalesOfVelcade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfVelcade" xml:lang="en-US">Annual Sales Of Velcade</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages Assessment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages assessment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DamagesAssessment" xlink:to="lab_teva_DamagesAssessment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DamagesAssessment" xml:lang="en-US">Damages assessment.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual Sales At Time Of Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual sales at the time of settlement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesAtTimeOfSettlement" xlink:to="lab_teva_AnnualSalesAtTimeOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesAtTimeOfSettlement" xml:lang="en-US">Annual sales at time of settlement.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual Sales Of Actoplus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual sales of Acto plus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfActoplus" xlink:to="lab_teva_AnnualSalesOfActoplus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfActoplus" xml:lang="en-US">Annual sales of Acto plus.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfNamenda" xlink:label="loc_teva_AnnualSalesOfNamenda" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfNamenda" xml:lang="en-US">Annual Sales Of Namenda</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfNamenda" xml:lang="en-US">Annual sales of Namenda</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfNamenda" xlink:to="lab_teva_AnnualSalesOfNamenda" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfNamenda" xml:lang="en-US">Annual sales of Namenda.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual Sales Of Niaspan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual sales of Niaspan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfNiaspan" xlink:to="lab_teva_AnnualSalesOfNiaspan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfNiaspan" xml:lang="en-US">Annual sales of Niaspan.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual Sales Of Actos</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual sales of Actos</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfActos" xlink:to="lab_teva_AnnualSalesOfActos" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfActos" xml:lang="en-US">Annual sales of Actos.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xml:lang="en-US">Litigation settlement awarded from other party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xml:lang="en-US">Litigation settlement amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual Sales Of Effexor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual sales of Effexor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfEffexor" xlink:to="lab_teva_AnnualSalesOfEffexor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfEffexor" xml:lang="en-US">Annual sales of effexor.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual Sales Of Lamictal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual sales of Lamictal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfLamictal" xlink:to="lab_teva_AnnualSalesOfLamictal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfLamictal" xml:lang="en-US">Annual sales of Lamictal.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xml:lang="en-US">Maximum damages payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilPayment" xlink:label="loc_teva_ModafinilPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ModafinilPayment" xml:lang="en-US">Modafinil Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ModafinilPayment" xml:lang="en-US">Modafinil payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ModafinilPayment" xlink:to="lab_teva_ModafinilPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ModafinilPayment" xml:lang="en-US">Modafinil payment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xml:lang="en-US">Loss Contingency, Damages Paid, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xml:lang="en-US">Loss contingency payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Damage claimed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilPaymentRemainingBalance" xlink:label="loc_teva_ModafinilPaymentRemainingBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ModafinilPaymentRemainingBalance" xml:lang="en-US">Modafinil payment Remaining Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ModafinilPaymentRemainingBalance" xml:lang="en-US">Modafinil payment remaining balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ModafinilPaymentRemainingBalance" xlink:to="lab_teva_ModafinilPaymentRemainingBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ModafinilPaymentRemainingBalance" xml:lang="en-US">Modafinil payment remaining balance.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation Settlement Amount Awarded Distribution Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded distribution period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:to="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountAwardedDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded distribution period.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfSensipar" xml:lang="en-US">Annual Sales Of Sensipar</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfSensipar" xlink:to="lab_teva_AnnualSalesOfSensipar" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfSensipar" xml:lang="en-US">Represents Annual Sales Of Sensipar.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedCashAmount" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmount" xml:lang="en-US">Litigation Settlement Amount Awarded Cash Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmount" xml:lang="en-US">Litigation settlement amount awarded cash amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountAwardedCashAmount" xlink:to="lab_teva_LitigationSettlementAmountAwardedCashAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmount" xml:lang="en-US">Litigation settlement amount awarded cash amount.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedNumberOfInstallments" xlink:label="loc_teva_LitigationSettlementAmountAwardedNumberOfInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountAwardedNumberOfInstallments" xml:lang="en-US">Litigation Settlement Amount Awarded Number Of Installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountAwardedNumberOfInstallments" xml:lang="en-US">Litigation settlement amount awarded number of installments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountAwardedNumberOfInstallments" xlink:to="lab_teva_LitigationSettlementAmountAwardedNumberOfInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountAwardedNumberOfInstallments" xml:lang="en-US">Litigation settlement amount awarded number of installments.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xml:lang="en-US">Litigation Settlement Amount Awarded Cash Amount Distribution Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded cash amount distribution period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xlink:to="lab_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xml:lang="en-US">Litigation settlement amount awarded cash amount distribution period.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual Sales Of Copaxone</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual sales of Copaxone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AnnualSalesOfCopaxone" xlink:to="lab_teva_AnnualSalesOfCopaxone" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AnnualSalesOfCopaxone" xml:lang="en-US">Annual Sales Of Copaxone.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_JanssenAndMillenniumMember" xlink:label="loc_teva_JanssenAndMillenniumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_JanssenAndMillenniumMember" xml:lang="en-US">Janssen and Millennium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_JanssenAndMillenniumMember" xml:lang="en-US">Janssen and Millennium [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_JanssenAndMillenniumMember" xlink:to="lab_teva_JanssenAndMillenniumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_JanssenAndMillenniumMember" xml:lang="en-US">Janssen and Millennium [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EosinophilicEsophagitisMember" xlink:to="lab_teva_EosinophilicEsophagitisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EosinophilicEsophagitisMember" xml:lang="en-US">Eosinophilic Esophagitis [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">Andro Gel Rate At One Percentage [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">AndroGel Rate at 1% [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AndroGelRateAtOnePercentageMember" xlink:to="lab_teva_AndroGelRateAtOnePercentageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AndroGelRateAtOnePercentageMember" xml:lang="en-US">Andro gel rate at one percentage.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NationwideSettlementMember" xml:lang="en-US">Nationwide Settlement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NationwideSettlementMember" xlink:to="lab_teva_NationwideSettlementMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OpioidLitigationMember" xlink:label="loc_teva_OpioidLitigationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OpioidLitigationMember" xml:lang="en-US">Opioid Litigation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OpioidLitigationMember" xlink:to="lab_teva_OpioidLitigationMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilSettlementAgreementMember" xlink:label="loc_teva_ModafinilSettlementAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ModafinilSettlementAgreementMember" xml:lang="en-US">Modafinil Settlement Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ModafinilSettlementAgreementMember" xlink:to="lab_teva_ModafinilSettlementAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ModafinilSettlementAgreementMember" xml:lang="en-US">Modafinil settlement agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xml:lang="en-US">Income Before Income Taxes And Income Tax Expense Benefit [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xml:lang="en-US">Income Before Income Taxes And Income Tax Expense Benefit [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:to="lab_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xml:lang="en-US">Income Before Income Taxes And Income Tax Expense Benefit [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xml:lang="en-US">Income Before Income Taxes And Income Tax Expense Benefit [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xml:lang="en-US">Income Before Income Taxes And Income Tax Expense Benefit [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:to="lab_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xml:lang="en-US">Income before income taxes and income tax expense benefit.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Parent Company and its Israeli subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Non-Israeli subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">In Israel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US">Outside Israel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory tax rate in Israel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Theoretical provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xml:lang="en-US">Increase (decrease) in the provision for income taxes due to:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">The Parent Company and its Israeli subsidiaries- Mainly tax benefits arising from reduced tax rates under benefit programs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Non-Israeli subsidiaries, including impairments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xml:lang="en-US">Increase (decrease) in other uncertain tax positions-net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Ustaxcutsandjobsacteffect" xlink:label="loc_teva_Ustaxcutsandjobsacteffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_Ustaxcutsandjobsacteffect" xml:lang="en-US">US Tax Cuts and Jobs Act Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_Ustaxcutsandjobsacteffect" xml:lang="en-US">U.S. Tax Cuts and Jobs Act effect</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_Ustaxcutsandjobsacteffect" xlink:to="lab_teva_Ustaxcutsandjobsacteffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_Ustaxcutsandjobsacteffect" xml:lang="en-US">US tax cuts and jobs act effect.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Income before income taxes includes goodwill impairment tax effect</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" xml:lang="en-US">Deferred Tax Assets Liabilities Net Noncurrent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" xlink:to="lab_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" xml:lang="en-US">Deferred tax assets, net, noncurrent, classification.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xlink:label="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xml:lang="en-US">Schedule Of Computation Of Deferred Tax Assets Liabilities Net [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xml:lang="en-US">Schedule Of Computation Of Deferred Tax Assets Liabilities Net [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xlink:to="lab_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xml:lang="en-US">Schedule Of Computation Of Deferred Tax Assets Liabilities Net [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetLineItems" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesNetLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities Net [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesNetLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities Net [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems" xlink:to="lab_teva_DeferredTaxAssetsLiabilitiesNetLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesNetLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities Net [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" xml:lang="en-US">Deferred Tax Assets Carryforward Losses And Deductions Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" xml:lang="en-US">Carryforward losses and deductions and credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" xlink:to="lab_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" xml:lang="en-US">Deferred tax assets carryforward losses and deductions noncurrent.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsDeferredInterest" xlink:label="loc_teva_DeferredTaxAssetsDeferredInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredTaxAssetsDeferredInterest" xml:lang="en-US">Deferred Tax Assets Deferred Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DeferredTaxAssetsDeferredInterest" xml:lang="en-US">Deferred interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredTaxAssetsDeferredInterest" xlink:to="lab_teva_DeferredTaxAssetsDeferredInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredTaxAssetsDeferredInterest" xml:lang="en-US">Deferred Tax Assets Deferred Interest</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Deferred Tax Assets, Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Inventory related</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xml:lang="en-US">Deferred Tax Assets Liabilities Gross Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xml:lang="en-US">Long-term deferred tax assets (liabilities)-gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:to="lab_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xml:lang="en-US">The amount of deferred tax assets liabilities gross noncurrent.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" xml:lang="en-US">Deferred Tax Assets Liabilities Other Net Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" xlink:to="lab_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" xml:lang="en-US">Deferred tax assets liabilities other net noncurrent.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" xlink:label="loc_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Non Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" xml:lang="en-US">Provisions for employee related obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" xlink:to="lab_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Non Current</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xml:lang="en-US">Provision for legal settlements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xml:lang="en-US">Sales reserves and allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance&#8212;in respect of carryforward losses and deductions that may not be utilized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred tax assets liabilities net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetUnrecognizedTaxBenefits" xlink:label="loc_teva_DeferredTaxAssetUnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DeferredTaxAssetUnrecognizedTaxBenefits" xml:lang="en-US">Deferred Tax Asset Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DeferredTaxAssetUnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DeferredTaxAssetUnrecognizedTaxBenefits" xlink:to="lab_teva_DeferredTaxAssetUnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DeferredTaxAssetUnrecognizedTaxBenefits" xml:lang="en-US">Deferred Tax Asset Unrecognized Tax Benefits</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeTaxTable" xlink:to="lab_teva_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IncomeTaxLineItems" xlink:to="lab_teva_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageGrowthRateInSalesOrWorkforce" xlink:label="loc_teva_AverageGrowthRateInSalesOrWorkforce" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AverageGrowthRateInSalesOrWorkforce" xml:lang="en-US">Average growth rate in sales or workforce</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AverageGrowthRateInSalesOrWorkforce" xml:lang="en-US">Average growth rate in sales or workforce</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AverageGrowthRateInSalesOrWorkforce" xlink:to="lab_teva_AverageGrowthRateInSalesOrWorkforce" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AverageGrowthRateInSalesOrWorkforce" xml:lang="en-US">Average growth rate in sales or workforce.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendIncomeSecuritiesOperatingTaxExempt" xlink:label="loc_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt" xml:lang="en-US">Dividend Income, Securities, Operating, Tax Exempt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt" xml:lang="en-US">Exempt Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt" xlink:to="lab_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" xlink:label="loc_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" xml:lang="en-US">Average growth preceding period in sales or workforce</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" xml:lang="en-US">Average growth preceding period in sales or workforce</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" xlink:to="lab_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" xml:lang="en-US">Average growth preceding period in sales or workforce.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xml:lang="en-US">Income Tax Examination, Year under Examination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xml:lang="en-US">Income tax audit period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Payment of corporate tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income tax settlement amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment Income, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Minimum investment income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumNumberOfEmployeesEmployed" xlink:label="loc_teva_MinimumNumberOfEmployeesEmployed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MinimumNumberOfEmployeesEmployed" xml:lang="en-US">Minimum number of employees employed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MinimumNumberOfEmployeesEmployed" xml:lang="en-US">Minimum number of employees employed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MinimumNumberOfEmployeesEmployed" xlink:to="lab_teva_MinimumNumberOfEmployeesEmployed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MinimumNumberOfEmployeesEmployed" xml:lang="en-US">Minimum number of employees employed.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumPercentageOfInvestmentIncome" xlink:label="loc_teva_MinimumPercentageOfInvestmentIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MinimumPercentageOfInvestmentIncome" xml:lang="en-US">Minimum percentage of investment income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MinimumPercentageOfInvestmentIncome" xml:lang="en-US">Minimum percentage of investment income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MinimumPercentageOfInvestmentIncome" xlink:to="lab_teva_MinimumPercentageOfInvestmentIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MinimumPercentageOfInvestmentIncome" xml:lang="en-US">Minimum percentage of investment income.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumPercentageOfWorkforce" xlink:label="loc_teva_MinimumPercentageOfWorkforce" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MinimumPercentageOfWorkforce" xml:lang="en-US">Minimum percentage of workforce</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MinimumPercentageOfWorkforce" xml:lang="en-US">Minimum percentage of workforce</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MinimumPercentageOfWorkforce" xlink:to="lab_teva_MinimumPercentageOfWorkforce" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MinimumPercentageOfWorkforce" xml:lang="en-US">Minimum percentage of workforce.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_VentureCapitalInvestments" xlink:label="loc_teva_VentureCapitalInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_VentureCapitalInvestments" xml:lang="en-US">Venture Capital Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_VentureCapitalInvestments" xml:lang="en-US">Venture capital investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_VentureCapitalInvestments" xlink:to="lab_teva_VentureCapitalInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_VentureCapitalInvestments" xml:lang="en-US">Venture Capital Investments</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_WithholdingTaxPercentageOnDividends" xlink:label="loc_teva_WithholdingTaxPercentageOnDividends" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_WithholdingTaxPercentageOnDividends" xml:lang="en-US">Withholding tax percentage on dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_WithholdingTaxPercentageOnDividends" xml:lang="en-US">Withholding tax percentage on dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_WithholdingTaxPercentageOnDividends" xlink:to="lab_teva_WithholdingTaxPercentageOnDividends" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_WithholdingTaxPercentageOnDividends" xml:lang="en-US">Withholding tax percentage on dividends.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax effect of unspecified carryforward losses and deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xml:lang="en-US">Expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="lab_us-gaap_TaxCreditCarryforwardExpirationDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Balance of accrued potential penalties and interest in unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected Impairment OF Income Tax Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected impairment of income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:to="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExpectedImpairmentOfIncomeTaxBenefit" xml:lang="en-US">Expected impairment of income tax benefit.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xml:lang="en-US">Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Liability, Income Tax Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xml:lang="en-US">Provisional estimate for one-time deemed repatriation tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DevelopmentZoneaMember" xlink:label="loc_teva_DevelopmentZoneaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DevelopmentZoneaMember" xml:lang="en-US">Development Zone A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DevelopmentZoneaMember" xml:lang="en-US">Development Zonea [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DevelopmentZoneaMember" xlink:to="lab_teva_DevelopmentZoneaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DevelopmentZoneaMember" xml:lang="en-US">Development Zone A.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xml:lang="en-US">Research and Development Arrangement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xml:lang="en-US">Research and Development Arrangement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IsraelTaxAuthorityMember" xml:lang="en-US">Israel Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IsraelTaxAuthorityMember" xml:lang="en-US">Israel Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IsraelTaxAuthorityMember" xlink:to="lab_us-gaap_IsraelTaxAuthorityMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxYear2005To2007Member" xlink:label="loc_teva_TaxYear2005To2007Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TaxYear2005To2007Member" xml:lang="en-US">Tax Year 2005 To 2007 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TaxYear2005To2007Member" xml:lang="en-US">Tax Year 2005 To 2007 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TaxYear2005To2007Member" xlink:to="lab_teva_TaxYear2005To2007Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TaxYear2005To2007Member" xml:lang="en-US">Tax year 2005 to 2007.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment68ToInvestmentLawMember" xlink:label="loc_teva_Amendment68ToInvestmentLawMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_Amendment68ToInvestmentLawMember" xml:lang="en-US">Amendment 68 to Investment Law [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_Amendment68ToInvestmentLawMember" xml:lang="en-US">Amendment 68 to Investment Law [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_Amendment68ToInvestmentLawMember" xlink:to="lab_teva_Amendment68ToInvestmentLawMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_Amendment68ToInvestmentLawMember" xml:lang="en-US">Amendment 68 to Investment Law [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment69ToInvestmentLawMember" xlink:label="loc_teva_Amendment69ToInvestmentLawMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_Amendment69ToInvestmentLawMember" xml:lang="en-US">Amendment 69 to Investment Law [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_Amendment69ToInvestmentLawMember" xml:lang="en-US">Amendment 69 to Investment Law [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_Amendment69ToInvestmentLawMember" xlink:to="lab_teva_Amendment69ToInvestmentLawMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_Amendment69ToInvestmentLawMember" xml:lang="en-US">Amendment 69 to Investment Law [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment73ToInvestmentLawMember" xlink:label="loc_teva_Amendment73ToInvestmentLawMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_Amendment73ToInvestmentLawMember" xml:lang="en-US">Amendment 73 to Investment Law [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_Amendment73ToInvestmentLawMember" xml:lang="en-US">Amendment 73 to Investment Law [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_Amendment73ToInvestmentLawMember" xlink:to="lab_teva_Amendment73ToInvestmentLawMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_Amendment73ToInvestmentLawMember" xml:lang="en-US">Amendment 73 to Investment Law [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreferredEnterpriseMember" xlink:label="loc_teva_PreferredEnterpriseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PreferredEnterpriseMember" xml:lang="en-US">Preferred Enterprise [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PreferredEnterpriseMember" xml:lang="en-US">Preferred Enterprise [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PreferredEnterpriseMember" xlink:to="lab_teva_PreferredEnterpriseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PreferredEnterpriseMember" xml:lang="en-US">Preferred Enterprise [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreferredTechnologicalEnterprisesMember" xlink:label="loc_teva_PreferredTechnologicalEnterprisesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PreferredTechnologicalEnterprisesMember" xml:lang="en-US">Preferred Technological Enterprises [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PreferredTechnologicalEnterprisesMember" xml:lang="en-US">Preferred Technological Enterprises [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PreferredTechnologicalEnterprisesMember" xlink:to="lab_teva_PreferredTechnologicalEnterprisesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PreferredTechnologicalEnterprisesMember" xml:lang="en-US">Preferred Technological Enterprises [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SpecialPreferredTechnologicalEnterpriseMember" xlink:label="loc_teva_SpecialPreferredTechnologicalEnterpriseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SpecialPreferredTechnologicalEnterpriseMember" xml:lang="en-US">Special Preferred Technological Enterprise [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SpecialPreferredTechnologicalEnterpriseMember" xml:lang="en-US">Special Preferred Technological Enterprise [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SpecialPreferredTechnologicalEnterpriseMember" xlink:to="lab_teva_SpecialPreferredTechnologicalEnterpriseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SpecialPreferredTechnologicalEnterpriseMember" xml:lang="en-US">Special Preferred Technological Enterprise [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" xml:lang="en-US">Tax Carryforwards And Deductions Expiration Period One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" xml:lang="en-US">Tax Carryforwards And Deductions Expiration Period One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" xlink:to="lab_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" xml:lang="en-US">Tax carryforwards and deductions expiration period one.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" xml:lang="en-US">Tax Carryforwards And Deductions Expiration Period Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" xml:lang="en-US">Tax Carryforwards And Deductions Expiration Period Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" xlink:to="lab_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" xml:lang="en-US">Tax carryforwards and deductions expiration period two.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsIndefiniteMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsIndefiniteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsIndefiniteMember" xml:lang="en-US">Tax Carryforwards And Deductions Indefinite [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsIndefiniteMember" xml:lang="en-US">Tax Carryforwards And Deductions Indefinite [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TaxCarryforwardsAndDeductionsIndefiniteMember" xlink:to="lab_teva_TaxCarryforwardsAndDeductionsIndefiniteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsIndefiniteMember" xml:lang="en-US">Tax carryforwards and deductions indefinite.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsNoExpirationMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsNoExpirationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsNoExpirationMember" xml:lang="en-US">Tax Carryforwards And Deductions No Expiration [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsNoExpirationMember" xml:lang="en-US">Tax Carryforwards And Deductions No Expiration [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TaxCarryforwardsAndDeductionsNoExpirationMember" xlink:to="lab_teva_TaxCarryforwardsAndDeductionsNoExpirationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TaxCarryforwardsAndDeductionsNoExpirationMember" xml:lang="en-US">Tax carryforwards and deductions no expiration.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Long-term liabilities-deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Long-term assets-deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedTaxBenefitsAbstract" xlink:label="loc_teva_UnrecognizedTaxBenefitsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnrecognizedTaxBenefitsAbstract" xml:lang="en-US">Unrecognized Tax Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnrecognizedTaxBenefitsAbstract" xlink:to="lab_teva_UnrecognizedTaxBenefitsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UnrecognizedTaxBenefitsAbstract" xml:lang="en-US">Unrecognized Tax Benefits [Abstract]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfUnrecognizedTaxBenefitsTable" xlink:label="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfUnrecognizedTaxBenefitsTable" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfUnrecognizedTaxBenefitsTable" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable" xlink:to="lab_teva_ScheduleOfUnrecognizedTaxBenefitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfUnrecognizedTaxBenefitsTable" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" xlink:label="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" xlink:to="lab_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" xlink:label="loc_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" xml:lang="en-US">Unrecognized Tax Benefits Increases Decreases Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" xlink:to="lab_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" xml:lang="en-US">Unrecognized tax benefits increases decreases other.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Increase related to current year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at the beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at the end of the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xml:lang="en-US">Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="loc_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Increase (decrease) related to prior year tax positions, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of shares available for future awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageSharePrice" xlink:label="loc_teva_AverageSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AverageSharePrice" xml:lang="en-US">Average Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AverageSharePrice" xml:lang="en-US">Company average share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AverageSharePrice" xlink:to="lab_teva_AverageSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AverageSharePrice" xml:lang="en-US">Average share price.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" xml:lang="en-US">Convertible preferred stock terms of conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Vesting period, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share based compensation arrangements expected over weighted average period for RSU/PSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US">Number of additional shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of shares exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Balance at end of period (in thousands) Number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedCompensationCostRsus" xlink:label="loc_teva_UnrecognizedCompensationCostRsus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnrecognizedCompensationCostRsus" xml:lang="en-US">Unrecognized Compensation Cost Rsus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UnrecognizedCompensationCostRsus" xml:lang="en-US">Total unrecognized compensation cost before tax on employee stock RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnrecognizedCompensationCostRsus" xlink:to="lab_teva_UnrecognizedCompensationCostRsus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UnrecognizedCompensationCostRsus" xml:lang="en-US">Unrecognized compensation cost rsus.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share based compensation arrangements expected over weighted average period for options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ordinary shares issuance ADSs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedCompensationCostOptions" xlink:label="loc_teva_UnrecognizedCompensationCostOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UnrecognizedCompensationCostOptions" xml:lang="en-US">Unrecognized Compensation Cost Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UnrecognizedCompensationCostOptions" xml:lang="en-US">Total unrecognized compensation cost before tax on employee stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UnrecognizedCompensationCostOptions" xlink:to="lab_teva_UnrecognizedCompensationCostOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UnrecognizedCompensationCostOptions" xml:lang="en-US">Unrecognized compensation cost options.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandFifteenPlanMember" xlink:label="loc_teva_TwoThousandFifteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TwoThousandFifteenPlanMember" xml:lang="en-US">Two Thousand Fifteen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TwoThousandFifteenPlanMember" xml:lang="en-US">2015 Long-Term Equity-Based Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TwoThousandFifteenPlanMember" xlink:to="lab_teva_TwoThousandFifteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TwoThousandFifteenPlanMember" xml:lang="en-US">Two thousand fifteen plan.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandTenPlanMember" xlink:label="loc_teva_TwoThousandTenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TwoThousandTenPlanMember" xml:lang="en-US">Two Thousand Ten Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TwoThousandTenPlanMember" xml:lang="en-US">2010 Long-Term Equity-Based Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TwoThousandTenPlanMember" xlink:to="lab_teva_TwoThousandTenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TwoThousandTenPlanMember" xml:lang="en-US">Two thousand ten plan.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandTwentyPlanMember" xlink:label="loc_teva_TwoThousandTwentyPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_TwoThousandTwentyPlanMember" xml:lang="en-US">Two Thousand Twenty Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_TwoThousandTwentyPlanMember" xml:lang="en-US">2020 Long-Term Equity-Based Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_TwoThousandTwentyPlanMember" xlink:to="lab_teva_TwoThousandTwentyPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_TwoThousandTwentyPlanMember" xml:lang="en-US">Two thousand twenty plan.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance outstanding at begining of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance outstanding at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Balance exercisable at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Balance exercisable at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance outstanding at begining of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance outstanding at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFiveMember" xlink:label="loc_teva_ExercisePriceRangeFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExercisePriceRangeFiveMember" xml:lang="en-US">Exercise Price Range Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExercisePriceRangeFiveMember" xml:lang="en-US">$45.01 - $55.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExercisePriceRangeFiveMember" xlink:to="lab_teva_ExercisePriceRangeFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExercisePriceRangeFiveMember" xml:lang="en-US">Fifth range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFourMember" xlink:label="loc_teva_ExercisePriceRangeFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExercisePriceRangeFourMember" xml:lang="en-US">Exercise Price Range Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExercisePriceRangeFourMember" xml:lang="en-US">$35.01 - $45.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExercisePriceRangeFourMember" xlink:to="lab_teva_ExercisePriceRangeFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExercisePriceRangeFourMember" xml:lang="en-US">Fourth range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeSixMember" xlink:label="loc_teva_ExercisePriceRangeSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExercisePriceRangeSixMember" xml:lang="en-US">Exercise Price Range Six [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExercisePriceRangeSixMember" xml:lang="en-US">$55.01 - $65.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExercisePriceRangeSixMember" xlink:to="lab_teva_ExercisePriceRangeSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExercisePriceRangeSixMember" xml:lang="en-US">Sixth range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeThreeMember" xlink:label="loc_teva_ExercisePriceRangeThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExercisePriceRangeThreeMember" xml:lang="en-US">Exercise Price Range Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExercisePriceRangeThreeMember" xml:lang="en-US">$25.01 - $35.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExercisePriceRangeThreeMember" xlink:to="lab_teva_ExercisePriceRangeThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExercisePriceRangeThreeMember" xml:lang="en-US">Third range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeOneMember" xlink:label="loc_teva_ExercisePriceRangeOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExercisePriceRangeOneMember" xml:lang="en-US">Exercise Price Range One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExercisePriceRangeOneMember" xml:lang="en-US">Lower than $15.01 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExercisePriceRangeOneMember" xlink:to="lab_teva_ExercisePriceRangeOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExercisePriceRangeOneMember" xml:lang="en-US">First range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeTwoMember" xlink:label="loc_teva_ExercisePriceRangeTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExercisePriceRangeTwoMember" xml:lang="en-US">Exercise Price Range Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExercisePriceRangeTwoMember" xml:lang="en-US">$15.01 - $25.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExercisePriceRangeTwoMember" xlink:to="lab_teva_ExercisePriceRangeTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExercisePriceRangeTwoMember" xml:lang="en-US">Second range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Range of exercise prices, lower limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Balance at end of period (in thousands) Number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance 2010</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" xml:lang="en-US">Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" xlink:to="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" xml:lang="en-US">The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term 2010</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" xml:lang="en-US">Weighted average remaining life Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" xlink:to="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" xml:lang="en-US">The weighted-average period remaining as of the balance-sheet date until option expiration pertaining to the outstanding stock options for all option plans in the customized range of exercise prices, which may be expressed in a variety of ways (for example, years, months).</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Range of exercise prices, upper limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price 2010</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" xml:lang="en-US">Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" xlink:to="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" xml:lang="en-US">Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term 2010</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" xml:lang="en-US">Weighted average remaining life Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" xlink:to="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" xml:lang="en-US">The weighted average remaining life of the exercisable stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestrictedStockUnitsMember" xlink:label="loc_teva_RestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestrictedStockUnitsMember" xml:lang="en-US">Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestrictedStockUnitsMember" xml:lang="en-US">Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestrictedStockUnitsMember" xlink:to="lab_teva_RestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestrictedStockUnitsMember" xml:lang="en-US">Share-based compensation arrangement under which unregistered shares are granted and issuable to employees, and which vest pursuant to terms of the arrangements.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Balance outstanding at end of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Balance outstanding at beginning of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value per share - RSUs at beginning year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value per share - RSUs at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OmnibusLongTermShareIncentivePlanMember" xlink:label="loc_teva_OmnibusLongTermShareIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OmnibusLongTermShareIncentivePlanMember" xml:lang="en-US">Omnibus Long Term Share Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OmnibusLongTermShareIncentivePlanMember" xml:lang="en-US">Omnibus Long Term Share Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OmnibusLongTermShareIncentivePlanMember" xlink:to="lab_teva_OmnibusLongTermShareIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OmnibusLongTermShareIncentivePlanMember" xml:lang="en-US">Omnibus Long Term Share Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_StockOptionsPlanMember" xlink:label="loc_teva_StockOptionsPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_StockOptionsPlanMember" xml:lang="en-US">Stock Options Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_StockOptionsPlanMember" xml:lang="en-US">Stock Options Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_StockOptionsPlanMember" xlink:to="lab_teva_StockOptionsPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_StockOptionsPlanMember" xml:lang="en-US">Stock Options Plan [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xml:lang="en-US">Net effect</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xml:lang="en-US">Tax effect on stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xml:lang="en-US">Other comprehensive income/(loss) before reclassifications</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Net other comprehensive income (loss) after tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xml:lang="en-US">Corresponding income tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xml:lang="en-US">Amounts reclassified to the statements of income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xml:lang="en-US">Net other comprehensive income (loss) before tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xml:lang="en-US">Benefit Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xml:lang="en-US">Derivative Financial Instruments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xml:lang="en-US">Available-for-sale Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xml:lang="en-US">Foreign Currency Translation Adjustments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xml:lang="en-US">Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentAbstract" xml:lang="en-US">Restructuring And Impairment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentAbstract" xlink:to="lab_teva_RestructuringAndImpairmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentAbstract" xml:lang="en-US">Restructuring and impairment.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable" xlink:to="lab_teva_RestructuringAndImpairmentCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentCostsTable" xml:lang="en-US">Restructuring And Impairment Costs [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring And Impairment Costs [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring and Impairment Costs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems" xlink:to="lab_teva_RestructuringAndImpairmentCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAndImpairmentCostsLineItems" xml:lang="en-US">Restructuring and impairment costs.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Impairment And Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ImpairmentAndRestructuring" xlink:to="lab_teva_ImpairmentAndRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ImpairmentAndRestructuring" xml:lang="en-US">Impairment and restructuring.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Contingent consideration (see note 2)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xml:lang="en-US">Business combination contingent consideration arrangements change in amount of contingent consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairments of long-lived tangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Legal Settlements Loss Contingencies Impairments Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:to="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xml:lang="en-US">Legal settlements loss contingencies impairments other expenses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringPlanCostReduction" xlink:label="loc_teva_RestructuringPlanCostReduction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringPlanCostReduction" xml:lang="en-US">Restructuring Plan Cost Reduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RestructuringPlanCostReduction" xml:lang="en-US">Restructuring plan cost reduction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringPlanCostReduction" xlink:to="lab_teva_RestructuringPlanCostReduction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringPlanCostReduction" xml:lang="en-US">Restructuring Plan Cost Reduction.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpectedRevenueFromFacility" xlink:label="loc_teva_ExpectedRevenueFromFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExpectedRevenueFromFacility" xml:lang="en-US">Expected Revenue From Facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExpectedRevenueFromFacility" xml:lang="en-US">Expected revenue from Florida manufacturing plant in 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExpectedRevenueFromFacility" xlink:to="lab_teva_ExpectedRevenueFromFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExpectedRevenueFromFacility" xml:lang="en-US">Expected Revenue From Facility</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">Restructuring and Related Activities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xml:lang="en-US">Employee Severance [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xml:lang="en-US">Employee termination [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other Restructuring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExitAndDisposalAxis" xlink:to="lab_teva_ExitAndDisposalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExitAndDisposalAxis" xml:lang="en-US">Exit And Disposal [Axis]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExitAndDisposalDomain" xlink:to="lab_teva_ExitAndDisposalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExitAndDisposalDomain" xml:lang="en-US">Exit And Disposal [Domain]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee Termination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee termination costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EmployeeTerminationMember" xlink:to="lab_teva_EmployeeTerminationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EmployeeTerminationMember" xml:lang="en-US">Employee termination.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other Exit And Disposal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other Exit and Disposal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherExitAndDisposalMember" xlink:to="lab_teva_OtherExitAndDisposalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherExitAndDisposalMember" xml:lang="en-US">Other exit and disposal.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Restructuring Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Ending balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_RestructuringReserve" xml:lang="en-US">Beginning balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Restructuring Accrual Provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RestructuringAccrualProvision" xlink:to="lab_teva_RestructuringAccrualProvision" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RestructuringAccrualProvision" xml:lang="en-US">Restructuring Accrual Provision</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization And Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_UtilizationAndOther" xlink:to="lab_teva_UtilizationAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_UtilizationAndOther" xml:lang="en-US">Utilization and other.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceAbstract" xlink:label="loc_us-gaap_InsuranceAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InsuranceAbstract" xml:lang="en-US">Insurance [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherIncomeExpenseTable" xlink:label="loc_teva_OtherIncomeExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherIncomeExpenseTable" xml:lang="en-US">Other Income Expense [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherIncomeExpenseTable" xml:lang="en-US">Other Income Expense [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherIncomeExpenseTable" xlink:to="lab_teva_OtherIncomeExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherIncomeExpenseTable" xml:lang="en-US">Other Income Expense [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherincomeLineItems" xlink:label="loc_teva_OtherincomeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherincomeLineItems" xml:lang="en-US">Otherincome [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherincomeLineItems" xml:lang="en-US">Other Income [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherincomeLineItems" xlink:to="lab_teva_OtherincomeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherincomeLineItems" xml:lang="en-US">Other Income.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PatentedMedicinesRegulationsAndSimilarPayments" xlink:label="loc_teva_PatentedMedicinesRegulationsAndSimilarPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PatentedMedicinesRegulationsAndSimilarPayments" xml:lang="en-US">Patented Medicines Regulations And Similar Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_PatentedMedicinesRegulationsAndSimilarPayments" xml:lang="en-US">Section 8 and similar payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PatentedMedicinesRegulationsAndSimilarPayments" xlink:to="lab_teva_PatentedMedicinesRegulationsAndSimilarPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PatentedMedicinesRegulationsAndSimilarPayments" xml:lang="en-US">Patented Medicines Regulations and Similar Payments</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Other Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherIncome" xml:lang="en-US">Total other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain (Loss) on Disposition of Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain on divestitures, net of divestitures related costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnSalesOfAssets" xml:lang="en-US">Gain (Loss) on Disposition of Assets for Financial Service Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnSalesOfAssets" xml:lang="en-US">Gain (loss) on sale of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnSalesOfAssets" xlink:to="lab_us-gaap_GainsLossesOnSalesOfAssets" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherOperatingIncomeNet" xlink:label="loc_teva_OtherOperatingIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherOperatingIncomeNet" xml:lang="en-US">Other Operating Income Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherOperatingIncomeNet" xml:lang="en-US">Other, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherOperatingIncomeNet" xlink:to="lab_teva_OtherOperatingIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherOperatingIncomeNet" xml:lang="en-US">Other Operating Income Net</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetAbstract" xlink:label="loc_teva_FinancialExpensesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FinancialExpensesNetAbstract" xml:lang="en-US">Financial Expenses Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FinancialExpensesNetAbstract" xlink:to="lab_teva_FinancialExpensesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FinancialExpensesNetAbstract" xml:lang="en-US">Financial Expenses Net [Abstract]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesTable" xlink:label="loc_teva_ExpensesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExpensesTable" xml:lang="en-US">Expenses [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExpensesTable" xml:lang="en-US">Expenses [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExpensesTable" xlink:to="lab_teva_ExpensesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExpensesTable" xml:lang="en-US">Expenses [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesLineItems" xlink:label="loc_teva_ExpensesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ExpensesLineItems" xml:lang="en-US">Expenses [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ExpensesLineItems" xml:lang="en-US">Expenses [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ExpensesLineItems" xlink:to="lab_teva_ExpensesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ExpensesLineItems" xml:lang="en-US">Expenses [Line Items]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinanceIncomeExpensesNet" xlink:label="loc_teva_FinanceIncomeExpensesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FinanceIncomeExpensesNet" xml:lang="en-US">Finance Income Expenses Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_teva_FinanceIncomeExpensesNet" xml:lang="en-US">Total finance expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FinanceIncomeExpensesNet" xlink:to="lab_teva_FinanceIncomeExpensesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FinanceIncomeExpensesNet" xml:lang="en-US">Finance income expenses net.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ForeignCurrencyTransactionGainLoss" xlink:label="loc_teva_ForeignCurrencyTransactionGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ForeignCurrencyTransactionGainLoss" xml:lang="en-US">Foreign Currency Transaction Gain Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_ForeignCurrencyTransactionGainLoss" xml:lang="en-US">Foreign exchange (gains) losses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ForeignCurrencyTransactionGainLoss" xlink:to="lab_teva_ForeignCurrencyTransactionGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ForeignCurrencyTransactionGainLoss" xml:lang="en-US">The aggregate of net unrealized foreign currency transaction gains (losses) and net realized foreign currency transaction gains (losses) relating to debt repayments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expenses and other bank charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xml:lang="en-US">Investment Income, Nonoperating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xml:lang="en-US">Income from investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherFinancialIncomeExpenseNet" xlink:label="loc_teva_OtherFinancialIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherFinancialIncomeExpenseNet" xml:lang="en-US">Other Financial Income Expense Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_teva_OtherFinancialIncomeExpenseNet" xml:lang="en-US">Other, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherFinancialIncomeExpenseNet" xlink:to="lab_teva_OtherFinancialIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherFinancialIncomeExpenseNet" xml:lang="en-US">Other financial income expense net.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentForRedemptionOfSeniorNotes" xlink:label="loc_teva_PaymentForRedemptionOfSeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PaymentForRedemptionOfSeniorNotes" xml:lang="en-US">Payment For Redemption Of Senior Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_PaymentForRedemptionOfSeniorNotes" xml:lang="en-US">Payment for redemption of senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PaymentForRedemptionOfSeniorNotes" xlink:to="lab_teva_PaymentForRedemptionOfSeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PaymentForRedemptionOfSeniorNotes" xml:lang="en-US">Payment for redemption of senior notes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net income (loss) used for the computation of basic and diluted earnings (loss) per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="loc_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" xml:lang="en-US">Stock Option Restricted Stock Units And Performance Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" xml:lang="en-US">Stock Option Restricted Stock Units And Performance Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:to="lab_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" xml:lang="en-US">Stock option restricted stock units and performance stock units.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Weighted average shares with anti-dilutive effect on earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EuropeSegmentMember" xlink:to="lab_teva_EuropeSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EuropeSegmentMember" xml:lang="en-US">Europe segment.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NorthAmericaSegmentMember" xlink:to="lab_teva_NorthAmericaSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NorthAmericaSegmentMember" xml:lang="en-US">North America segment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other Operating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other (income) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherOperatingIncomeExpense" xlink:to="lab_teva_OtherOperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherOperatingIncomeExpense" xml:lang="en-US">Other Operating Income (Expense)</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts Allocated To Segments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts allocated to segments:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract" xlink:to="lab_teva_AmountsAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AmountsAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts allocated to segments.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts Not Allocated To Segments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts not allocated to segments:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract" xlink:to="lab_teva_AmountsNotAllocatedToSegmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AmountsNotAllocatedToSegmentsAbstract" xml:lang="en-US">Amounts not allocated to segments.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CostsRelatedToRegulatoryActionsTakenInFacilities" xlink:label="loc_teva_CostsRelatedToRegulatoryActionsTakenInFacilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_CostsRelatedToRegulatoryActionsTakenInFacilities" xml:lang="en-US">Costs Related To Regulatory Actions Taken In Facilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_CostsRelatedToRegulatoryActionsTakenInFacilities" xml:lang="en-US">Costs related to regulatory actions taken in facilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_CostsRelatedToRegulatoryActionsTakenInFacilities" xlink:to="lab_teva_CostsRelatedToRegulatoryActionsTakenInFacilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_CostsRelatedToRegulatoryActionsTakenInFacilities" xml:lang="en-US">Costs related to regulatory actions taken in facilities.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PurchaseOfResearchAndDevelopmentInProcess" xlink:label="loc_teva_PurchaseOfResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_PurchaseOfResearchAndDevelopmentInProcess" xml:lang="en-US">Purchase Of Research And Development In Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_PurchaseOfResearchAndDevelopmentInProcess" xml:lang="en-US">Other R&amp;D expenses (income)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_PurchaseOfResearchAndDevelopmentInProcess" xlink:to="lab_teva_PurchaseOfResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_PurchaseOfResearchAndDevelopmentInProcess" xml:lang="en-US">Purchase of research and development in process.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other Unallocated Amounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other unallocated amounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherUnallocatedAmounts" xlink:to="lab_teva_OtherUnallocatedAmounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherUnallocatedAmounts" xml:lang="en-US">Other unallocated amounts.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xml:lang="en-US">Gain on divestitures, net of divestitures related costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xml:lang="en-US">Other Segments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xml:lang="en-US">Other Segments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateMember" xml:lang="en-US">Corporate Segment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateMember" xml:lang="en-US">Corporate Segment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateMember" xlink:to="lab_us-gaap_CorporateMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments And Other Activities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments and Other Activities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SegmentsAndOtherActivitiesMember" xlink:to="lab_teva_SegmentsAndOtherActivitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SegmentsAndOtherActivitiesMember" xml:lang="en-US">Segments and other activities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule of Product Information [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule of Product Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generics Medicians [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generic products [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_GenericsMediciansMember" xlink:to="lab_teva_GenericsMediciansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_GenericsMediciansMember" xml:lang="en-US">Generics Medicians.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_COPAXONEMember" xlink:to="lab_teva_COPAXONEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_COPAXONEMember" xml:lang="en-US">COPAXONE.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_QVARMember" xlink:label="loc_teva_QVARMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_QVARMember" xml:lang="en-US">QVAR [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_QVARMember" xml:lang="en-US">QVAR [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_QVARMember" xlink:to="lab_teva_QVARMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_QVARMember" xml:lang="en-US">QVAR.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory Product [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RespiratoryProductMember" xlink:to="lab_teva_RespiratoryProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_RespiratoryProductMember" xml:lang="en-US">Respiratory product.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OtherProductsMember" xlink:to="lab_teva_OtherProductsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OtherProductsMember" xml:lang="en-US">Other Products [Member]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProAirMember" xlink:label="loc_teva_ProAirMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ProAirMember" xml:lang="en-US">Pro Air [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ProAirMember" xml:lang="en-US">ProAir [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ProAirMember" xlink:to="lab_teva_ProAirMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ProAirMember" xml:lang="en-US">Pro air.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AjovyMember" xml:lang="en-US">AJOVY [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AjovyMember" xlink:to="lab_teva_AjovyMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA and TREANDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA and TREANDA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_BendekaAndTreandaMember" xlink:to="lab_teva_BendekaAndTreandaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_BendekaAndTreandaMember" xml:lang="en-US">BENDEKA and TREANDA.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueTypeAxis" xml:lang="en-US">Revenue Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueTypeAxis" xlink:to="lab_teva_RevenueTypeAxis" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_RevenueTypeDomain" xml:lang="en-US">Revenue Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_RevenueTypeDomain" xlink:to="lab_teva_RevenueTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Customer1Member" xlink:label="loc_teva_Customer1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_Customer1Member" xml:lang="en-US">Customer 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_Customer1Member" xml:lang="en-US">McKesson Corporation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_Customer1Member" xlink:to="lab_teva_Customer1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_Customer1Member" xml:lang="en-US">Customer 1.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Customer2Member" xlink:label="loc_teva_Customer2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_Customer2Member" xml:lang="en-US">Customer 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_Customer2Member" xml:lang="en-US">AmerisourceBergen Corporation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_Customer2Member" xlink:to="lab_teva_Customer2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_Customer2Member" xml:lang="en-US">Customer 2.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetSalesPresent" xlink:label="loc_teva_NetSalesPresent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_NetSalesPresent" xml:lang="en-US">Net Sales Present</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_NetSalesPresent" xml:lang="en-US">Third party net sales present</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_NetSalesPresent" xlink:to="lab_teva_NetSalesPresent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_NetSalesPresent" xml:lang="en-US">Net sales present.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xml:lang="en-US">Segments, Geographical Areas [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HR" xlink:label="loc_country_HR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_HR" xml:lang="en-US">CROATIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_HR" xml:lang="en-US">Croatia [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_HR" xlink:to="lab_country_HR" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HU" xlink:label="loc_country_HU" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_HU" xml:lang="en-US">HUNGARY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_HU" xml:lang="en-US">Hungary [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_HU" xlink:to="lab_country_HU" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_country_IL" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL" xml:lang="en-US">ISRAEL</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_IL" xml:lang="en-US">Israel [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_IL" xml:lang="en-US">Israel [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL" xlink:to="lab_country_IL" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CZ" xlink:label="loc_country_CZ" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CZ" xml:lang="en-US">CZECH REPUBLIC</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CZ" xml:lang="en-US">Czech republic [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CZ" xlink:to="lab_country_CZ" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:label="loc_country_DE" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_DE" xml:lang="en-US">GERMANY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_DE" xml:lang="en-US">Germany [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IEMember" xlink:label="loc_teva_IEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_IEMember" xml:lang="en-US">I E [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_IEMember" xml:lang="en-US">Ireland [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_IEMember" xlink:to="lab_teva_IEMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_IEMember" xml:lang="en-US">Ireland.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Sales Revenue, Net [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Sales Revenue, Net [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Revenues from external customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Options And Forward Contracts Derivative Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Liabilities Derivatives Options and Forward Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:to="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xml:lang="en-US">Options and forward contracts derivative liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestRateSwapMember" xml:lang="en-US">Interest Rate Swap [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestRateSwapMember" xml:lang="en-US">Asset Derivatives - Options and Forward Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeAssets" xml:lang="en-US">Derivative Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeAssets" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investment in securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DemandDepositsMember" xml:lang="en-US">Demand Deposits [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DemandDepositsMember" xml:lang="en-US">Cash, Deposits and Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Markets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xml:lang="en-US">Other Debt Obligations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xml:lang="en-US">Other, Mainly Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquitySecuritiesMember" xml:lang="en-US">Equity Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquitySecuritiesMember" xml:lang="en-US">Equity Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfEquityInvestments" xml:lang="en-US">Gain (Loss) on Sale of Equity Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfEquityInvestments" xml:lang="en-US">Gain&#160;under share&#160;in&#160;profits&#160;of&#160;associated&#160;companies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfEquityInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfEquityInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xml:lang="en-US">Gain under financial expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement Input Probability Of Success [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement input probability of success [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_MeasurementInputProbabilityOfSuccessMember" xlink:to="lab_teva_MeasurementInputProbabilityOfSuccessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_MeasurementInputProbabilityOfSuccessMember" xml:lang="en-US">Measurement input probability of success.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement input, discount rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xml:lang="en-US">Fresh-Start Adjustments [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xml:lang="en-US">Fresh-Start Adjustments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:to="lab_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" xml:lang="en-US">Type of Fresh-Start Adjustment [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" xml:lang="en-US">Type of Fresh-Start Adjustment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:to="lab_us-gaap_TypeOfFreshStartAdjustmentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevaluationOfAssetsMember" xlink:label="loc_us-gaap_RevaluationOfAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevaluationOfAssetsMember" xml:lang="en-US">Revaluation of Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevaluationOfAssetsMember" xml:lang="en-US">Revaluation of Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevaluationOfAssetsMember" xlink:to="lab_us-gaap_RevaluationOfAssetsMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Arising During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Actavis Generics transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:to="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Adjustments to provisions for contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:to="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair value at the end of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair value at the beginning of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Settlement of contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Revaluation of debt securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xml:lang="en-US">Transfer into Level&#160;3- equity securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US">Revaluation of equity securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xml:lang="en-US">Reclassification to Level&#160;2- equity securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle Transaction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle Transaction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EagleTransactionMember" xlink:to="lab_teva_EagleTransactionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EagleTransactionMember" xml:lang="en-US">Eagle transaction.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ActavisGenericsMember" xlink:to="lab_teva_ActavisGenericsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ActavisGenericsMember" xml:lang="en-US">Actavis Generics [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniornotesandconvertibleseniordebenturesmemberMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesmemberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesmemberMember" xml:lang="en-US">Seniornotesandconvertibleseniordebenturesmember [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesmemberMember" xml:lang="en-US">Senior Notes and Convertible Senior Debentures Included Under Short-Term Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SeniornotesandconvertibleseniordebenturesmemberMember" xlink:to="lab_teva_SeniornotesandconvertibleseniordebenturesmemberMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SeniornotesandconvertibleseniordebenturesmemberMember" xml:lang="en-US">Senior notes and convertible senior debentures.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeRelatedObligationsNoncurrentAbstract" xlink:label="loc_teva_EmployeeRelatedObligationsNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EmployeeRelatedObligationsNoncurrentAbstract" xml:lang="en-US">Employee Related Obligations Noncurrent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EmployeeRelatedObligationsNoncurrentAbstract" xlink:to="lab_teva_EmployeeRelatedObligationsNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EmployeeRelatedObligationsNoncurrentAbstract" xml:lang="en-US">Employee related obligations non-current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xml:lang="en-US">Defined benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccruedSeverancePayNoncurrent" xlink:label="loc_teva_AccruedSeverancePayNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_AccruedSeverancePayNoncurrent" xml:lang="en-US">Accrued Severance Pay Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_AccruedSeverancePayNoncurrent" xml:lang="en-US">Accrued severance obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_AccruedSeverancePayNoncurrent" xlink:to="lab_teva_AccruedSeverancePayNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_AccruedSeverancePayNoncurrent" xml:lang="en-US">Accrued severance pay non-current.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeRelatedObligationsNoncurrent" xlink:label="loc_teva_EmployeeRelatedObligationsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_EmployeeRelatedObligationsNoncurrent" xml:lang="en-US">Employee Related Obligations Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_teva_EmployeeRelatedObligationsNoncurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_EmployeeRelatedObligationsNoncurrent" xlink:to="lab_teva_EmployeeRelatedObligationsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_EmployeeRelatedObligationsNoncurrent" xml:lang="en-US">Employee related obligations non-current.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" xlink:label="loc_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" xml:lang="en-US">Defined Benefit Plan Estimated Future Discretionary Employer Contributions In Next Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" xml:lang="en-US">Expected contributions to pension funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" xlink:to="lab_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" xml:lang="en-US">Defined benefit plan estimated future discretionary employer contributions in next fiscal year.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" xml:lang="en-US">Future Expected Domestic Minimum Benefit Payments Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" xlink:to="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" xml:lang="en-US">Future expected domestic minimum benefit payments year five.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" xml:lang="en-US">Future Expected Domestic Minimum Benefit Payments Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" xlink:to="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" xml:lang="en-US">Future expected domestic minimum benefit payments year four.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" xml:lang="en-US">Future Expected Domestic Minimum Benefit Payments Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" xlink:to="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" xml:lang="en-US">Future expected domestic minimum benefit payments year one.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" xml:lang="en-US">Future Expected Domestic Minimum Benefit Payments Years Six Through Ten</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" xml:lang="en-US">2026 to 2030</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" xlink:to="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" xml:lang="en-US">Future expected domestic minimum benefit payments years six through ten.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" xml:lang="en-US">Future Expected Domestic Minimum Benefit Payments Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" xlink:to="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" xml:lang="en-US">Future expected domestic minimum benefit payments year three.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" xml:lang="en-US">Future Expected Domestic Minimum Benefit Payments Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" xlink:to="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" xml:lang="en-US">Future expected domestic minimum benefit payments year two.</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" xlink:label="loc_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" xml:lang="en-US">Long Term Investments Earmarked For Domestic Severance Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" xml:lang="en-US">Long-term investments earmarked for severance pay liabilities in Israel</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" xlink:to="lab_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" xml:lang="en-US">Long-term investments earmarked for domestic severance obligations.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialInformationTable" xlink:label="loc_teva_SelectedQuarterlyFinancialInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SelectedQuarterlyFinancialInformationTable" xml:lang="en-US">Selected Quarterly Financial Information [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SelectedQuarterlyFinancialInformationTable" xml:lang="en-US">Selected Quarterly Financial Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationTable" xlink:to="lab_teva_SelectedQuarterlyFinancialInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SelectedQuarterlyFinancialInformationTable" xml:lang="en-US">Selected Quarterly Financial Information [Table]</label>
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialInformationLineItems" xlink:label="loc_teva_SelectedQuarterlyFinancialInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_SelectedQuarterlyFinancialInformationLineItems" xml:lang="en-US">Selected Quarterly Financial Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_SelectedQuarterlyFinancialInformationLineItems" xml:lang="en-US">Selected Quarterly Financial Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems" xlink:to="lab_teva_SelectedQuarterlyFinancialInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_SelectedQuarterlyFinancialInformationLineItems" xml:lang="en-US">Selected Quarterly Financial Information [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xml:lang="en-US">Charged to costs and expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xml:lang="en-US">Charged to other accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xml:lang="en-US">Allowance For Doubtful Accounts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" xlink:label="loc_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" xml:lang="en-US">Valuation Allowance Tax Carryforward Losses And Deductions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" xml:lang="en-US">Valuation Allowance in Tax Carryforward Losses And Deductions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" xlink:to="lab_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" xml:lang="en-US">Valuation allowance tax carryforward losses and deductions.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>teva-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 11-February-2021 [01:05:17] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CoverPage" roleURI="http://www.tevapharm.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfChangesInEquity" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfChangesInEquityParenthetical" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SignificantAccountingPolicies" roleURI="http://www.tevapharm.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactions" roleURI="http://www.tevapharm.com/role/CertainTransactions" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomers" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Inventories" roleURI="http://www.tevapharm.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipment" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipment" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssets" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Goodwill" roleURI="http://www.tevapharm.com/role/Goodwill" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Leases" roleURI="http://www.tevapharm.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligations" roleURI="http://www.tevapharm.com/role/DebtObligations" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivities" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LegalSettlementsAndLossContingencies" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CommitmentsAndContingencies" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxes" roleURI="http://www.tevapharm.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Equity" roleURI="http://www.tevapharm.com/role/Equity" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItems" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherIncome" roleURI="http://www.tevapharm.com/role/OtherIncome" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNet" roleURI="http://www.tevapharm.com/role/FinancialExpensesNet" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EarningsLossPerShare" roleURI="http://www.tevapharm.com/role/EarningsLossPerShare" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#Segments" roleURI="http://www.tevapharm.com/role/Segments" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurement" roleURI="http://www.tevapharm.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligations" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ScheduleOfValuationAndQualifyingAccounts" roleURI="http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsTables" roleURI="http://www.tevapharm.com/role/CertainTransactionsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomersTables" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#InventoriesTables" roleURI="http://www.tevapharm.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipmentTables" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssetsTables" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#GoodwillTables" roleURI="http://www.tevapharm.com/role/GoodwillTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesTables" roleURI="http://www.tevapharm.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsTables" roleURI="http://www.tevapharm.com/role/DebtObligationsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesTables" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesTables" roleURI="http://www.tevapharm.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityTables" roleURI="http://www.tevapharm.com/role/EquityTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsTables" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherIncomeTables" roleURI="http://www.tevapharm.com/role/OtherIncomeTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNetTables" roleURI="http://www.tevapharm.com/role/FinancialExpensesNetTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EarningsLossPerShareTables" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsTables" roleURI="http://www.tevapharm.com/role/SegmentsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementTables" roleURI="http://www.tevapharm.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligationsTables" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsBusinessTransactionsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsOtherTransactionsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" roleURI="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomersAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" roleURI="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#InventoriesSummaryOfInventoriesDetail" roleURI="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#PropertyPlantAndEquipmentAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IdentifiableIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" roleURI="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#GoodwillAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesComponentsOfLeaseExpenseDetail" roleURI="http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesSupplementalCashFlowInformationRelatedToLeasesDetail" roleURI="http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesMaturitiesOfLeaseLiabilitiesDetail" roleURI="http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsScheduleOfShortTermDebtDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail" roleURI="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail" roleURI="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DebtObligationsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LegalSettlementsAndLossContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfDeferedIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" roleURI="http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/EquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquitySummaryOfStockOptionActivityDetail" roleURI="http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail" roleURI="http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail" roleURI="http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail" roleURI="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail" roleURI="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail" roleURI="http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail" roleURI="http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" roleURI="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" roleURI="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" roleURI="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#OtherIncomeScheduleOfOtherIncomeDetail" roleURI="http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNetScheduleOfFinancialExpensesDetail" roleURI="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail" roleURI="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EarningsLossPerShareScheduleOfEarningsPerShareDetail" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#EarningsLossPerShareAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsSummaryOfSegmentProfitDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" roleURI="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail" roleURI="http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SegmentsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" roleURI="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#LongTermEmployeeRelatedObligationsAdditionalInformationDetail" roleURI="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail" roleURI="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail" />
<roleRef xlink:type="simple" xlink:href="teva-20201231.xsd#ScheduleIiValuationAndQualifyingAccountsDetail" roleURI="http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187796" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_486714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentType_486714" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_507077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_AmendmentFlag_507077" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_507079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentFiscalYearFocus_507079" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_486701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentTransitionReport_486701" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_486682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentPeriodEndDate_486682" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_507080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentFiscalPeriodFocus_507080" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_558705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_DocumentAnnualReport_558705" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_486687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityRegistrantName_486687" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_507081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCentralIndexKey_507081" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_507082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_CurrentFiscalYearEndDate_507082" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_486685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCurrentReportingStatus_486685" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_486688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityInteractiveDataCurrent_486688" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_486689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_486689" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_486709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_Security12bTitle_486709" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_486710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_TradingSymbol_486710" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_486711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_SecurityExchangeName_486711" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_486690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityFileNumber_486690" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_486691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityIncorporationStateCountryCode_486691" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_486692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityTaxIdentificationNumber_486692" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_486693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressAddressLine1_486693" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_486694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressCityOrTown_486694" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_486695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressPostalZipCode_486695" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_486708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityAddressCountry_486708" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_486698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_CityAreaCode_486698" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_486699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_LocalPhoneNumber_486699" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_486715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityFilerCategory_486715" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_555878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntitySmallBusiness_555878" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_486704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityEmergingGrowthCompany_486704" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_486702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityShellCompany_486702" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_555876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_555876" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_555883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityVoluntaryFilers_555883" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_555879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_EntityPublicFloat_555879" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_815478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187796" xlink:to="loc_dei_IcfrAuditorAttestationFlag_815478" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="loc_us-gaap_StatementTable_34" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_dei_LegalEntityAxis_29" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_29" xlink:to="loc_dei_EntityDomain_49" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34" xlink:to="loc_us-gaap_StatementLineItems_33" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_AssetsAbstract_27" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_AssetsCurrentAbstract_28" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_InventoryNet_44" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_45" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_OtherAssetsCurrent_46" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_47" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_28" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_36" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_37" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_38" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_389976" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_39" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Goodwill_40" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27" xlink:to="loc_us-gaap_Assets_41" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_31" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_DebtCurrent_55" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowances" xlink:label="loc_teva_SalesReservesAndAllowances_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_SalesReservesAndAllowances_56" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_57" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_58" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccruedExpenses" xlink:label="loc_teva_AccruedExpenses_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_teva_AccruedExpenses_59" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_60" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_31" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_63" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LongTermNotesAndLoans_65" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_389981" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_32" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_66" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommitmentsAndContingencies_50" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_Liabilities_51" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityAbstract_35" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_CommonStockValue_68" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AdditionalPaidInCapital_69" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_71" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_TreasuryStockValue_72" use="optional" order="43" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_35" xlink:to="loc_us-gaap_StockholdersEquity_73" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_75" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_75" xlink:to="loc_us-gaap_StatementTable_78" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_dei_LegalEntityAxis_76" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_79" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_78" xlink:to="loc_us-gaap_StatementLineItems_77" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_688255" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_83" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_84" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_CommonStockSharesIssued_85" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_77" xlink:to="loc_us-gaap_TreasuryStockShares_86" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_88" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88" xlink:to="loc_us-gaap_StatementTable_92" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_dei_LegalEntityAxis_90" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_90" xlink:to="loc_dei_EntityDomain_96" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_us-gaap_StatementLineItems_91" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_98" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GrossProfit_99" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_100" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_SellingAndMarketingExpense_101" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_102" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IntangibleAssetsImpairments" xlink:label="loc_teva_IntangibleAssetsImpairments_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_IntangibleAssetsImpairments_103" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_104" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_408527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_408527" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_412170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_412170" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_107" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_OperatingIncomeLoss_108" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_109" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_110" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_111" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_112" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_ProfitLoss_113" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_114" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLoss_115" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_555939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_555939" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_117" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_EarningsPerShareAbstract_89" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareBasic_94" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_95" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_118" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_93" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_119" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_121" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_121" xlink:to="loc_us-gaap_StatementTable_125" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_dei_LegalEntityAxis_122" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_122" xlink:to="loc_dei_EntityDomain_126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementLineItems_124" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ProfitLoss_132" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_127" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_128" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_720056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_720056" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_123" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax_720057" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_131" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_133" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_134" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_135" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_137" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_137" xlink:to="loc_us-gaap_StatementTable_142" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_140" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_140" xlink:to="loc_us-gaap_EquityComponentDomain_138" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_CommonStockMember_143" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_PreferredStockMember_144" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_147" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_TreasuryStockMember_148" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_ParentMember_149" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_138" xlink:to="loc_us-gaap_NoncontrollingInterestMember_150" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_142" xlink:to="loc_us-gaap_StatementLineItems_141" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_152" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_154" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xlink:label="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning_153" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_720066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_ProfitLoss_720066" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_155" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_760310" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_158" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_157" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_162" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_DividendsPreferredStockCash_163" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TransactionsWithNonControllingInterests" xlink:label="loc_teva_TransactionsWithNonControllingInterests_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_teva_TransactionsWithNonControllingInterests_165" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherEquity" xlink:label="loc_teva_OtherEquity_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_teva_OtherEquity_166" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_167" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_SharesIssued_168" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_170" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_170" xlink:to="loc_us-gaap_StatementTable_177" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_srt_RangeAxis_173" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_173" xlink:to="loc_srt_RangeMember_174" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_174" xlink:to="loc_srt_MaximumMember_180" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_175" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_175" xlink:to="loc_us-gaap_EquityComponentDomain_171" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_171" xlink:to="loc_us-gaap_CommonStockMember_178" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_171" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_472725" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_472727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_472726" xlink:to="loc_us-gaap_TypeOfAdoptionMember_472727" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_177" xlink:to="loc_us-gaap_StatementLineItems_176" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_181" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_581610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_581610" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_183" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_183" xlink:to="loc_us-gaap_StatementTable_191" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_dei_LegalEntityAxis_186" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_186" xlink:to="loc_dei_EntityDomain_210" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_us-gaap_StatementLineItems_190" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_ProfitLoss_229" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_AssetImpairmentCharges_193" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_DepreciationAndAmortization_194" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_195" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredIncomeTaxesNetAndUncertainTaxPositions" xlink:label="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions_196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_412174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_ShareBasedCompensation_412174" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_515089" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_764481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_764481" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_184" xlink:to="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_200" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_189" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_230" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables_222" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_223" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_224" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets" xlink:label="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets_225" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_226" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_188" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_228" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_211" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_506169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_506169" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_809430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_809430" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_213" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_214" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend" xlink:label="loc_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend_406864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend_406864" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_187" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_221" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_231" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_232" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_234" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables" xlink:label="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" xlink:to="loc_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables_235" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_192" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_236" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashPaidDuringTheYearForAbstract" xlink:label="loc_teva_CashPaidDuringTheYearForAbstract_584943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_teva_CashPaidDuringTheYearForAbstract_584943" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CashPaidDuringTheYearForAbstract_584943" xlink:to="loc_us-gaap_InterestPaidNet_240" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CashPaidDuringTheYearForAbstract_584943" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_241" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_190" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_204" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt" xlink:label="loc_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt_205" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories" xlink:label="loc_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories_206" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_207" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation" xlink:label="loc_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_185" xlink:to="loc_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation_209" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1652" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1652" xlink:to="loc_us-gaap_StatementTable_1655" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1655" xlink:to="loc_dei_LegalEntityAxis_1653" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1653" xlink:to="loc_dei_EntityDomain_1656" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1655" xlink:to="loc_us-gaap_StatementLineItems_1654" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1654" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1657" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1694" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1694" xlink:to="loc_us-gaap_StatementTable_1697" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_dei_LegalEntityAxis_1695" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1695" xlink:to="loc_dei_EntityDomain_1698" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1697" xlink:to="loc_us-gaap_StatementLineItems_1696" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CertainTransactionsDisclosureTextBlock" xlink:label="loc_teva_CertainTransactionsDisclosureTextBlock_1699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1696" xlink:to="loc_teva_CertainTransactionsDisclosureTextBlock_1699" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomers">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1795" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1795" xlink:to="loc_us-gaap_StatementTable_1798" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_dei_LegalEntityAxis_1796" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1796" xlink:to="loc_dei_EntityDomain_1799" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1798" xlink:to="loc_us-gaap_StatementLineItems_1797" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1797" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1800" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Inventories">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1739" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1739" xlink:to="loc_us-gaap_StatementTable_1742" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_dei_LegalEntityAxis_1740" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1740" xlink:to="loc_dei_EntityDomain_1743" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1742" xlink:to="loc_us-gaap_StatementLineItems_1741" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1741" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1744" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1753" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1753" xlink:to="loc_us-gaap_StatementTable_1756" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1756" xlink:to="loc_dei_LegalEntityAxis_1754" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1754" xlink:to="loc_dei_EntityDomain_1757" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1756" xlink:to="loc_us-gaap_StatementLineItems_1755" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1755" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1758" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1781" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1781" xlink:to="loc_us-gaap_StatementTable_1784" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_dei_LegalEntityAxis_1782" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1782" xlink:to="loc_dei_EntityDomain_1785" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1784" xlink:to="loc_us-gaap_StatementLineItems_1783" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1783" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1786" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Goodwill">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1767" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1767" xlink:to="loc_us-gaap_StatementTable_1770" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_dei_LegalEntityAxis_1768" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1768" xlink:to="loc_dei_EntityDomain_1771" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1770" xlink:to="loc_us-gaap_StatementLineItems_1769" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_1772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1769" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_1772" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_389983" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_389985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_389983" xlink:to="loc_us-gaap_StatementTable_389985" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_389986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_389985" xlink:to="loc_dei_LegalEntityAxis_389986" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_389987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_389986" xlink:to="loc_dei_EntityDomain_389987" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_389988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_389985" xlink:to="loc_us-gaap_StatementLineItems_389988" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_389991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_389988" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_389991" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1824" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1824" xlink:to="loc_us-gaap_StatementTable_1827" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_dei_LegalEntityAxis_1825" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1825" xlink:to="loc_dei_EntityDomain_1828" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1827" xlink:to="loc_us-gaap_StatementLineItems_1826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1826" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1829" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1901" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1901" xlink:to="loc_us-gaap_StatementTable_1904" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_dei_LegalEntityAxis_1902" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1902" xlink:to="loc_dei_EntityDomain_1905" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1904" xlink:to="loc_us-gaap_StatementLineItems_1903" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1903" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1906" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1947" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1947" xlink:to="loc_us-gaap_StatementTable_1950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_dei_LegalEntityAxis_1948" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1948" xlink:to="loc_dei_EntityDomain_1951" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1950" xlink:to="loc_us-gaap_StatementLineItems_1949" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1949" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1952" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1854" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1854" xlink:to="loc_us-gaap_StatementTable_1857" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_dei_LegalEntityAxis_1855" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1855" xlink:to="loc_dei_EntityDomain_1858" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1857" xlink:to="loc_us-gaap_StatementLineItems_1856" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1856" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1859" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1882" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1882" xlink:to="loc_us-gaap_StatementTable_1885" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_dei_LegalEntityAxis_1883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1883" xlink:to="loc_dei_EntityDomain_1886" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1885" xlink:to="loc_us-gaap_StatementLineItems_1884" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1884" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1887" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Equity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="loc_us-gaap_FederalHomeLoanBanksAbstract_1861" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalHomeLoanBanksAbstract_1861" xlink:to="loc_us-gaap_StatementTable_1864" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1864" xlink:to="loc_dei_LegalEntityAxis_1862" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1862" xlink:to="loc_dei_EntityDomain_1865" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1864" xlink:to="loc_us-gaap_StatementLineItems_1863" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_556529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1863" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_556529" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1931" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1931" xlink:to="loc_us-gaap_StatementTable_1934" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_dei_LegalEntityAxis_1932" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1932" xlink:to="loc_dei_EntityDomain_1935" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1934" xlink:to="loc_us-gaap_StatementLineItems_1933" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherExpensesTextBlock" xlink:label="loc_teva_OtherExpensesTextBlock_1936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1933" xlink:to="loc_teva_OtherExpensesTextBlock_1936" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1840" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1840" xlink:to="loc_us-gaap_StatementTable_1843" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1843" xlink:to="loc_dei_LegalEntityAxis_1841" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1841" xlink:to="loc_dei_EntityDomain_1844" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1843" xlink:to="loc_us-gaap_StatementLineItems_1842" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_1845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1842" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_1845" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1917" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1917" xlink:to="loc_us-gaap_StatementTable_1920" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1920" xlink:to="loc_dei_LegalEntityAxis_1918" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1918" xlink:to="loc_dei_EntityDomain_1921" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1920" xlink:to="loc_us-gaap_StatementLineItems_1919" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetTextBlock" xlink:label="loc_teva_FinancialExpensesNetTextBlock_1922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1919" xlink:to="loc_teva_FinancialExpensesNetTextBlock_1922" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1972" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1972" xlink:to="loc_us-gaap_StatementTable_1975" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_dei_LegalEntityAxis_1973" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1973" xlink:to="loc_dei_EntityDomain_1976" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1975" xlink:to="loc_us-gaap_StatementLineItems_1974" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1974" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1977" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/Segments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1954" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1954" xlink:to="loc_us-gaap_StatementTable_1957" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_dei_LegalEntityAxis_1955" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1955" xlink:to="loc_dei_EntityDomain_1958" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1957" xlink:to="loc_us-gaap_StatementLineItems_1956" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1956" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1959" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1708" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1708" xlink:to="loc_us-gaap_StatementTable_1711" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_dei_LegalEntityAxis_1709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1709" xlink:to="loc_dei_EntityDomain_1712" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1711" xlink:to="loc_us-gaap_StatementLineItems_1710" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1710" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1713" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1810" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1810" xlink:to="loc_us-gaap_StatementTable_1813" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1813" xlink:to="loc_dei_LegalEntityAxis_1811" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1811" xlink:to="loc_dei_EntityDomain_1814" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1813" xlink:to="loc_us-gaap_StatementLineItems_1812" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermEmployeeRelatedObligationsTextBlock" xlink:label="loc_teva_LongTermEmployeeRelatedObligationsTextBlock_1815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1812" xlink:to="loc_teva_LongTermEmployeeRelatedObligationsTextBlock_1815" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1986" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1986" xlink:to="loc_us-gaap_StatementTable_1989" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1989" xlink:to="loc_dei_LegalEntityAxis_1987" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1987" xlink:to="loc_dei_EntityDomain_1990" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1989" xlink:to="loc_us-gaap_StatementLineItems_1988" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialDataTextBlock" xlink:label="loc_teva_SelectedQuarterlyFinancialDataTextBlock_1991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1988" xlink:to="loc_teva_SelectedQuarterlyFinancialDataTextBlock_1991" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_2000" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_2000" xlink:to="loc_us-gaap_StatementTable_2003" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2003" xlink:to="loc_dei_LegalEntityAxis_2001" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2001" xlink:to="loc_dei_EntityDomain_2004" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2003" xlink:to="loc_us-gaap_StatementLineItems_2002" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2002" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2005" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1659" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1659" xlink:to="loc_us-gaap_StatementTable_1662" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_dei_LegalEntityAxis_1660" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1660" xlink:to="loc_dei_EntityDomain_1663" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1662" xlink:to="loc_us-gaap_StatementLineItems_1661" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GeneralOptionsAccountingPolicyPolicyTextBlock" xlink:label="loc_teva_GeneralOptionsAccountingPolicyPolicyTextBlock_1664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_GeneralOptionsAccountingPolicyPolicyTextBlock_1664" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1665" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AcquisitionTextBlock" xlink:label="loc_teva_AcquisitionTextBlock_1666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_AcquisitionTextBlock_1666" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_1667" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EquityAndCostMethodInvestmentPolicyTextBlock" xlink:label="loc_teva_EquityAndCostMethodInvestmentPolicyTextBlock_1668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_EquityAndCostMethodInvestmentPolicyTextBlock_1668" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1669" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1670" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1671" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccountsReceivablesPolicyTextBlock" xlink:label="loc_teva_AccountsReceivablesPolicyTextBlock_572410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_AccountsReceivablesPolicyTextBlock_572410" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1673" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_1674" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1675" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1676" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TreasurySharesPolicyTextBlock" xlink:label="loc_teva_TreasurySharesPolicyTextBlock_1677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_TreasurySharesPolicyTextBlock_1677" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1678" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1679" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxesUncertaintiesPolicyTextBlock" xlink:label="loc_teva_IncomeTaxesUncertaintiesPolicyTextBlock_1680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_IncomeTaxesUncertaintiesPolicyTextBlock_1680" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_1681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_1681" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock_1682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock_1682" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1683" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CostOfShippingAndHandlingPolicyTextBlock" xlink:label="loc_teva_CostOfShippingAndHandlingPolicyTextBlock_1684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_CostOfShippingAndHandlingPolicyTextBlock_1684" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_1685" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringTextBlock" xlink:label="loc_teva_RestructuringTextBlock_1686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_RestructuringTextBlock_1686" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1687" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1688" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SecuritizationTextBlock" xlink:label="loc_teva_SecuritizationTextBlock_1689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_SecuritizationTextBlock_1689" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DivestituresTextBlock" xlink:label="loc_teva_DivestituresTextBlock_1690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_teva_DivestituresTextBlock_1690" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_1692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_DebtPolicyTextBlock_1692" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_556086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1661" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_556086" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1701" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1701" xlink:to="loc_us-gaap_StatementTable_1704" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_dei_LegalEntityAxis_1702" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1702" xlink:to="loc_dei_EntityDomain_1705" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1704" xlink:to="loc_us-gaap_StatementLineItems_1703" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock" xlink:label="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1703" xlink:to="loc_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock_1706" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1802" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1802" xlink:to="loc_us-gaap_StatementTable_1805" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_dei_LegalEntityAxis_1803" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1803" xlink:to="loc_dei_EntityDomain_1806" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1805" xlink:to="loc_us-gaap_StatementLineItems_1804" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1807" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowancesCurrentTableTextBlock" xlink:label="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1804" xlink:to="loc_teva_SalesReservesAndAllowancesCurrentTableTextBlock_1808" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1746" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1746" xlink:to="loc_us-gaap_StatementTable_1749" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_dei_LegalEntityAxis_1747" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1747" xlink:to="loc_dei_EntityDomain_1750" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1749" xlink:to="loc_us-gaap_StatementLineItems_1748" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1748" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1751" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1760" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1760" xlink:to="loc_us-gaap_StatementTable_1763" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1763" xlink:to="loc_dei_LegalEntityAxis_1761" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1761" xlink:to="loc_dei_EntityDomain_1764" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1763" xlink:to="loc_us-gaap_StatementLineItems_1762" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1762" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1765" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1788" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1788" xlink:to="loc_us-gaap_StatementTable_1791" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_dei_LegalEntityAxis_1789" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1789" xlink:to="loc_dei_EntityDomain_1792" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1791" xlink:to="loc_us-gaap_StatementLineItems_1790" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1790" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1793" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1774" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1774" xlink:to="loc_us-gaap_StatementTable_1777" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_dei_LegalEntityAxis_1775" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1775" xlink:to="loc_dei_EntityDomain_1778" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1777" xlink:to="loc_us-gaap_StatementLineItems_1776" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1776" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1779" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_389994" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_389996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_389994" xlink:to="loc_us-gaap_StatementTable_389996" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_389997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_389996" xlink:to="loc_dei_LegalEntityAxis_389997" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_389998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_389997" xlink:to="loc_dei_EntityDomain_389998" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_389999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_389996" xlink:to="loc_us-gaap_StatementLineItems_389999" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ComponentsOfLeaseExpenseTableTextBlock" xlink:label="loc_teva_ComponentsOfLeaseExpenseTableTextBlock_390276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_teva_ComponentsOfLeaseExpenseTableTextBlock_390276" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SupplementalCashFlowInformationTableTextBlock" xlink:label="loc_teva_SupplementalCashFlowInformationTableTextBlock_390273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_teva_SupplementalCashFlowInformationTableTextBlock_390273" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock" xlink:label="loc_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock_390017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock_390017" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_390009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_389999" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_390009" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1831" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1831" xlink:to="loc_us-gaap_StatementTable_1834" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_dei_LegalEntityAxis_1832" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1832" xlink:to="loc_dei_EntityDomain_1835" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1834" xlink:to="loc_us-gaap_StatementLineItems_1833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_1836" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtExcludingConvertibleDebtTableTextBlock" xlink:label="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock_1837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock_1837" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_556360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1833" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_556360" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1908" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1908" xlink:to="loc_us-gaap_StatementTable_1911" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_dei_LegalEntityAxis_1909" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1909" xlink:to="loc_dei_EntityDomain_1912" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1911" xlink:to="loc_us-gaap_StatementLineItems_1910" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1913" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1914" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_406869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_406869" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_390224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_390224" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfAccountReceivableFromSecuritization" xlink:label="loc_teva_ScheduleOfAccountReceivableFromSecuritization_557012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1910" xlink:to="loc_teva_ScheduleOfAccountReceivableFromSecuritization_557012" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1889" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1889" xlink:to="loc_us-gaap_StatementTable_1892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1892" xlink:to="loc_dei_LegalEntityAxis_1890" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1890" xlink:to="loc_dei_EntityDomain_1893" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1892" xlink:to="loc_us-gaap_StatementLineItems_1891" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1894" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock_1895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock_1895" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1896" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1897" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock" xlink:label="loc_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock_1898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock_1898" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1891" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1899" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="loc_us-gaap_FederalHomeLoanBanksAbstract_1868" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalHomeLoanBanksAbstract_1868" xlink:to="loc_us-gaap_StatementTable_1871" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1871" xlink:to="loc_dei_LegalEntityAxis_1869" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1869" xlink:to="loc_dei_EntityDomain_1872" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1871" xlink:to="loc_us-gaap_StatementLineItems_1870" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1873" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1874" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1875" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1876" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_1877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_1877" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1878" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1879" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1870" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1880" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1938" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1938" xlink:to="loc_us-gaap_StatementTable_1941" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_dei_LegalEntityAxis_1939" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1939" xlink:to="loc_dei_EntityDomain_1942" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1941" xlink:to="loc_us-gaap_StatementLineItems_1940" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_1943" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfRestructuringChargesTableTextBlock" xlink:label="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_teva_ScheduleOfRestructuringChargesTableTextBlock_1944" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1940" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1945" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherIncomeTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1847" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1847" xlink:to="loc_us-gaap_StatementTable_1850" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1850" xlink:to="loc_dei_LegalEntityAxis_1848" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1848" xlink:to="loc_dei_EntityDomain_1851" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1850" xlink:to="loc_us-gaap_StatementLineItems_1849" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfOtherIncomeTableTextBlock" xlink:label="loc_teva_ScheduleOfOtherIncomeTableTextBlock_1852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1849" xlink:to="loc_teva_ScheduleOfOtherIncomeTableTextBlock_1852" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNetTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1924" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1924" xlink:to="loc_us-gaap_StatementTable_1927" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1927" xlink:to="loc_dei_LegalEntityAxis_1925" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1925" xlink:to="loc_dei_EntityDomain_1928" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1927" xlink:to="loc_us-gaap_StatementLineItems_1926" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetTableTextBlock" xlink:label="loc_teva_FinancialExpensesNetTableTextBlock_1929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1926" xlink:to="loc_teva_FinancialExpensesNetTableTextBlock_1929" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1979" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1979" xlink:to="loc_us-gaap_StatementTable_1982" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1982" xlink:to="loc_dei_LegalEntityAxis_1980" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1980" xlink:to="loc_dei_EntityDomain_1983" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1982" xlink:to="loc_us-gaap_StatementLineItems_1981" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1981" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1984" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1961" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1961" xlink:to="loc_us-gaap_StatementTable_1964" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_dei_LegalEntityAxis_1962" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1962" xlink:to="loc_dei_EntityDomain_1965" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1964" xlink:to="loc_us-gaap_StatementLineItems_1963" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_1966" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock" xlink:label="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock_1967" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_1968" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesPercentageByTherapeuticCategoryTableTextBlock" xlink:label="loc_teva_SalesPercentageByTherapeuticCategoryTableTextBlock_1969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_SalesPercentageByTherapeuticCategoryTableTextBlock_1969" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock" xlink:label="loc_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock_1970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1963" xlink:to="loc_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock_1970" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1715" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1715" xlink:to="loc_us-gaap_StatementTable_1718" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_dei_LegalEntityAxis_1716" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1716" xlink:to="loc_dei_EntityDomain_1719" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1718" xlink:to="loc_us-gaap_StatementLineItems_1717" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1721" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1717" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1722" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1817" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1817" xlink:to="loc_us-gaap_StatementTable_1820" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1820" xlink:to="loc_dei_LegalEntityAxis_1818" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1818" xlink:to="loc_dei_EntityDomain_1821" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1820" xlink:to="loc_us-gaap_StatementLineItems_1819" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermEmployeeRelatedObligationsTableTextBlock" xlink:label="loc_teva_LongTermEmployeeRelatedObligationsTableTextBlock_1822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1819" xlink:to="loc_teva_LongTermEmployeeRelatedObligationsTableTextBlock_1822" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_1993" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_1993" xlink:to="loc_us-gaap_StatementTable_1996" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1996" xlink:to="loc_dei_LegalEntityAxis_1994" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1994" xlink:to="loc_dei_EntityDomain_1997" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1996" xlink:to="loc_us-gaap_StatementLineItems_1995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialDataTableTextBlock" xlink:label="loc_teva_SelectedQuarterlyFinancialDataTableTextBlock_1998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1995" xlink:to="loc_teva_SelectedQuarterlyFinancialDataTableTextBlock_1998" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_243" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_243" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_dei_LegalEntityAxis_249" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_249" xlink:to="loc_dei_EntityDomain_274" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_srt_RangeAxis_252" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_252" xlink:to="loc_srt_RangeMember_253" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_253" xlink:to="loc_srt_MinimumMember_278" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_253" xlink:to="loc_srt_MaximumMember_279" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_250" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_250" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" xlink:to="loc_us-gaap_BuildingMember_275" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_276" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_251" xlink:to="loc_us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember_277" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_247" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_247" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_248" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_244" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_244" xlink:to="loc_us-gaap_TypeOfAdoptionMember_256" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_255" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_255" xlink:to="loc_us-gaap_EquityComponentDomain_246" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SignificantAccountingPoliciesLineItems" xlink:label="loc_teva_SignificantAccountingPoliciesLineItems_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_254" xlink:to="loc_teva_SignificantAccountingPoliciesLineItems_245" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions" xlink:label="loc_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions_262" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageOfConsolidatedSalesInNorthAmerica" xlink:label="loc_teva_PercentageOfConsolidatedSalesInNorthAmerica_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_PercentageOfConsolidatedSalesInNorthAmerica_263" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_264" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CreditTermsToCustomers" xlink:label="loc_teva_CreditTermsToCustomers_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_CreditTermsToCustomers_265" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShippingHandlingAndTransportationCost" xlink:label="loc_teva_ShippingHandlingAndTransportationCost_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_ShippingHandlingAndTransportationCost_266" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_AdvertisingExpense_267" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_268" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_556063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_556063" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseRemainingLeaseTerm" xlink:label="loc_teva_OperatingLeaseRemainingLeaseTerm_556067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_teva_OperatingLeaseRemainingLeaseTerm_556067" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription_556082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescription_556082" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_572119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SignificantAccountingPoliciesLineItems_245" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_572119" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_284" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_284" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_dei_LegalEntityAxis_289" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_289" xlink:to="loc_dei_EntityDomain_297" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_286" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_286" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ActavisMember" xlink:label="loc_teva_ActavisMember_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285" xlink:to="loc_teva_ActavisMember_292" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_285" xlink:to="loc_teva_AndaMember_293" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_srt_CounterpartyNameAxis_288" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_288" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_290" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AllerganPlcMember" xlink:label="loc_teva_AllerganPlcMember_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_290" xlink:to="loc_teva_AllerganPlcMember_298" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_504332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_srt_StatementGeographicalAxis_504332" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_504333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_504332" xlink:to="loc_srt_SegmentGeographicalDomain_504333" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_504335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_504335" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_504336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_504335" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_504336" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_291" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_287" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_287" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_294" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_287" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_295" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OneTimeMilestonePaymentReceived" xlink:label="loc_teva_OneTimeMilestonePaymentReceived_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_287" xlink:to="loc_teva_OneTimeMilestonePaymentReceived_296" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_300" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsTable" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_300" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_dei_LegalEntityAxis_304" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_304" xlink:to="loc_dei_EntityDomain_319" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_302" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_302" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RimsaMember" xlink:label="loc_teva_RimsaMember_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_RimsaMember_312" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AlderMember" xlink:label="loc_teva_AlderMember_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlderMember_313" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtsukaMember" xlink:label="loc_teva_OtsukaMember_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_OtsukaMember_314" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CelltrionMember" xlink:label="loc_teva_CelltrionMember_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_CelltrionMember_317" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RegeneronMember" xlink:label="loc_teva_RegeneronMember_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_RegeneronMember_318" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AlvotechMember" xlink:label="loc_teva_AlvotechMember_758265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_301" xlink:to="loc_teva_AlvotechMember_758265" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_ProductOrServiceAxis_307" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_307" xlink:to="loc_srt_ProductsAndServicesDomain_308" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_CounterpartyNameAxis_303" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_303" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_311" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_310" xlink:to="loc_us-gaap_RelatedPartyDomain_309" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PgtMember" xlink:label="loc_teva_PgtMember_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_309" xlink:to="loc_teva_PgtMember_338" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_758266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_758266" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_758267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_758266" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_758267" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_758271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_LeaseContractualTermAxis_758271" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_758272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_758271" xlink:to="loc_us-gaap_LeaseContractualTermDomain_758272" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_srt_RangeAxis_765341" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_765341" xlink:to="loc_srt_RangeMember_765342" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionsLineItems" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsTable_306" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_320" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NumberOfLawsuitsFiled" xlink:label="loc_teva_NumberOfLawsuitsFiled_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_NumberOfLawsuitsFiled_321" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UpfrontPayments" xlink:label="loc_teva_UpfrontPayments_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_UpfrontPayments_326" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MilestonePayment" xlink:label="loc_teva_MilestonePayment_572506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_MilestonePayment_572506" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CollaborativeAgreementMilestonePayments" xlink:label="loc_teva_CollaborativeAgreementMilestonePayments_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_CollaborativeAgreementMilestonePayments_327" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_328" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_us-gaap_GainLossOnInvestments_329" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProfitFromSaleOfLongLivedAssetsAndInvestment" xlink:label="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment_330" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RefundablePayment" xlink:label="loc_teva_RefundablePayment_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_RefundablePayment_333" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TotalAssociatedCost" xlink:label="loc_teva_TotalAssociatedCost_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_TotalAssociatedCost_334" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ResearchAndDevelopmentCosts" xlink:label="loc_teva_ResearchAndDevelopmentCosts_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems_305" xlink:to="loc_teva_ResearchAndDevelopmentCosts_335" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_718590" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_718593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_718590" xlink:to="loc_us-gaap_StatementTable_718593" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_718594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_718593" xlink:to="loc_us-gaap_StatementClassOfStockAxis_718594" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_718595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_718594" xlink:to="loc_us-gaap_ClassOfStockDomain_718595" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_718600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_718593" xlink:to="loc_srt_OwnershipAxis_718600" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_718601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_718600" xlink:to="loc_srt_OwnershipDomain_718601" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TevaMember" xlink:label="loc_teva_TevaMember_718602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_718601" xlink:to="loc_teva_TevaMember_718602" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_718596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_718593" xlink:to="loc_us-gaap_StatementLineItems_718596" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_718597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_718596" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_718597" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_718598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_718596" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_718598" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_718599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_718596" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_718599" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_340" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_348" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_350" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="loc_us-gaap_AssetsFairValueAdjustment_718560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_AssetsFairValueAdjustment_718560" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_340" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_351" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_603" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_603" xlink:to="loc_teva_RevenueRecognitionTable_608" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_dei_LegalEntityAxis_604" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_604" xlink:to="loc_dei_EntityDomain_611" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_srt_StatementGeographicalAxis_610" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_610" xlink:to="loc_srt_SegmentGeographicalDomain_609" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_609" xlink:to="loc_country_US_617" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_608" xlink:to="loc_teva_RevenueRecognitionLineItems_607" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SalesReservesAndAllowancesToCustomersPercentage" xlink:label="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_607" xlink:to="loc_teva_SalesReservesAndAllowancesToCustomersPercentage_616" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_619" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_619" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_621" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_dei_LegalEntityAxis_622" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_622" xlink:to="loc_dei_EntityDomain_630" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_StatementGeographicalAxis_628" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_628" xlink:to="loc_srt_SegmentGeographicalDomain_626" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_NorthAmericaMember_637" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_626" xlink:to="loc_srt_EuropeMember_638" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_627" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_627" xlink:to="loc_us-gaap_SegmentDomain_625" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_InternationalMarketsMember_635" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherActivitiesMember" xlink:label="loc_teva_OtherActivitiesMember_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_625" xlink:to="loc_teva_OtherActivitiesMember_636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_srt_ProductOrServiceAxis_623" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_623" xlink:to="loc_srt_ProductsAndServicesDomain_624" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductMember_631" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_LicenseMember_632" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DistributionServiceMember" xlink:label="loc_us-gaap_DistributionServiceMember_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_DistributionServiceMember_633" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_624" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_634" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_621" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_620" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_620" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_629" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_640" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionTable" xlink:label="loc_teva_RevenueRecognitionTable_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_640" xlink:to="loc_teva_RevenueRecognitionTable_643" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_dei_LegalEntityAxis_641" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_641" xlink:to="loc_dei_EntityDomain_646" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_645" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReservesIncludedInAccountsReceivableNetMember" xlink:label="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReservesIncludedInAccountsReceivableNetMember_653" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RebatesMember" xlink:label="loc_teva_RebatesMember_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_RebatesMember_654" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MedicaidAndOtherGovernmentalAllowancesMember" xlink:label="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_MedicaidAndOtherGovernmentalAllowancesMember_655" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ChargebacksMember" xlink:label="loc_teva_ChargebacksMember_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ChargebacksMember_656" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReturnsMember" xlink:label="loc_teva_ReturnsMember_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_ReturnsMember_657" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherSalesReservesAndAllowancesMember" xlink:label="loc_teva_OtherSalesReservesAndAllowancesMember_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_OtherSalesReservesAndAllowancesMember_658" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TotalReservesIncludedInSalesReservesAndAllowancesMember" xlink:label="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_644" xlink:to="loc_teva_TotalReservesIncludedInSalesReservesAndAllowancesMember_659" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueRecognitionLineItems" xlink:label="loc_teva_RevenueRecognitionLineItems_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionTable_643" xlink:to="loc_teva_RevenueRecognitionLineItems_642" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales_648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales" xlink:label="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales_649" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_650" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowancesAndReservesForeignCurrencyTranslation" xlink:label="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation_651" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueRecognitionLineItems_642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_652" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_451" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InventoriesTable" xlink:label="loc_teva_InventoriesTable_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_451" xlink:to="loc_teva_InventoriesTable_453" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_dei_LegalEntityAxis_454" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_454" xlink:to="loc_dei_EntityDomain_460" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InventoriesLineItems" xlink:label="loc_teva_InventoriesLineItems_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesTable_453" xlink:to="loc_teva_InventoriesLineItems_452" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_455" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_456" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_457" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryInTransit" xlink:label="loc_us-gaap_OtherInventoryInTransit_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_OtherInventoryInTransit_458" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_InventoriesLineItems_452" xlink:to="loc_us-gaap_InventoryNet_459" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_462" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_462" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_465" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_465" xlink:to="loc_dei_LegalEntityAxis_463" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_463" xlink:to="loc_dei_EntityDomain_466" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_465" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_467" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_468" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_469" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AssetsUnderConstructionAndPaymentsOnAccount" xlink:label="loc_teva_AssetsUnderConstructionAndPaymentsOnAccount_581605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_teva_AssetsUnderConstructionAndPaymentsOnAccount_581605" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_Land_471" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_472" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_473" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_474" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_490" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_490" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xlink:to="loc_dei_LegalEntityAxis_491" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_491" xlink:to="loc_dei_EntityDomain_494" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_492" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_492" xlink:to="loc_us-gaap_Depreciation_495" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_492" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_496" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_558" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_558" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_559" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_teva_ProductRightsMember_567" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_TradeNamesMember_568" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_561" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_569" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_564" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_565" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_560" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_566" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_572" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_572" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_dei_LegalEntityAxis_578" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_599" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_StatementGeographicalAxis_581" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_581" xlink:to="loc_srt_SegmentGeographicalDomain_580" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_580" xlink:to="loc_teva_InternationalMarketsMember_600" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:label="loc_country_JP_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_580" xlink:to="loc_country_JP_601" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_574" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_574" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ActavisMember" xlink:label="loc_teva_ActavisMember_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" xlink:to="loc_teva_ActavisMember_582" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_573" xlink:to="loc_teva_AustedoMember_584" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_575" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_597" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProductRightsMember" xlink:label="loc_teva_ProductRightsMember_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_577" xlink:to="loc_teva_ProductRightsMember_598" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_408202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_ProductOrServiceAxis_408202" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_408203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_408202" xlink:to="loc_srt_ProductsAndServicesDomain_408203" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LenalidomideProductMember" xlink:label="loc_teva_LenalidomideProductMember_408205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_408203" xlink:to="loc_teva_LenalidomideProductMember_408205" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuationOfBusinessAxis" xlink:label="loc_teva_DiscontinuationOfBusinessAxis_581599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_DiscontinuationOfBusinessAxis_581599" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuationOfBusinessDomain" xlink:label="loc_teva_DiscontinuationOfBusinessDomain_581600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DiscontinuationOfBusinessAxis_581599" xlink:to="loc_teva_DiscontinuationOfBusinessDomain_581600" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DiscontinuedBusinessMember" xlink:label="loc_teva_DiscontinuedBusinessMember_581601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DiscontinuationOfBusinessDomain_581600" xlink:to="loc_teva_DiscontinuedBusinessMember_581601" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_764548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_srt_RangeAxis_764548" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_764549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_764548" xlink:to="loc_srt_RangeMember_764549" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_764550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MinimumMember_764550" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_764551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_764549" xlink:to="loc_srt_MaximumMember_764551" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_764554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_764554" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_764555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_764554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_764555" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain" xlink:label="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis_764580" xlink:to="loc_teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain_764582" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_587" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_588" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_589" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_590" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_591" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_592" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_593" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_594" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_596" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_576" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_764546" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_498" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_498" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_501" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_dei_LegalEntityAxis_500" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_500" xlink:to="loc_dei_EntityDomain_514" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_391588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_ConsolidationItemsAxis_391588" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_391589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_391588" xlink:to="loc_srt_ConsolidationItemsDomain_391589" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_srt_StatementGeographicalAxis_505" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_505" xlink:to="loc_srt_SegmentGeographicalDomain_503" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_NorthAmericaMember_518" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_srt_EuropeMember_519" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_InternationalMarketsMember_520" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_503" xlink:to="loc_teva_OtherCountriesMember_521" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_504" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_504" xlink:to="loc_us-gaap_SegmentDomain_502" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_501" xlink:to="loc_us-gaap_GoodwillLineItems_499" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_506" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GoodwillReclassification" xlink:label="loc_teva_GoodwillReclassification_556229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_teva_GoodwillReclassification_556229" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_816238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_816238" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_509" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_511" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_499" xlink:to="loc_us-gaap_Goodwill_512" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_523" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_523" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_526" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_dei_LegalEntityAxis_525" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_525" xlink:to="loc_dei_EntityDomain_528" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_526" xlink:to="loc_us-gaap_GoodwillLineItems_524" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_524" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_527" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_530" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_530" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_536" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_dei_LegalEntityAxis_532" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_532" xlink:to="loc_dei_EntityDomain_545" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_539" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_539" xlink:to="loc_us-gaap_SegmentDomain_537" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementGeographicalAxis_540" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_540" xlink:to="loc_srt_SegmentGeographicalDomain_538" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NorthAmericaMember" xlink:label="loc_srt_NorthAmericaMember_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_538" xlink:to="loc_srt_NorthAmericaMember_556" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherMember" xlink:label="loc_teva_OtherMember_764540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_538" xlink:to="loc_teva_OtherMember_764540" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_RangeAxis_533" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_533" xlink:to="loc_srt_RangeMember_534" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_556283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_srt_StatementScenarioAxis_556283" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_556284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_556283" xlink:to="loc_srt_ScenarioUnspecifiedDomain_556284" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_536" xlink:to="loc_us-gaap_GoodwillLineItems_531" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill" xlink:label="loc_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill_581567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill_581567" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_718483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_718483" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PercentageDecreaseInTheMarketCapitalization" xlink:label="loc_teva_PercentageDecreaseInTheMarketCapitalization_764541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_531" xlink:to="loc_teva_PercentageDecreaseInTheMarketCapitalization_764541" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_821779" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_821781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_821779" xlink:to="loc_us-gaap_StatementTable_821781" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_821782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_821781" xlink:to="loc_dei_LegalEntityAxis_821782" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_821783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_821782" xlink:to="loc_dei_EntityDomain_821783" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_821784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_821781" xlink:to="loc_us-gaap_StatementLineItems_821784" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseCostAbstract" xlink:label="loc_teva_OperatingLeaseCostAbstract_821789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_821784" xlink:to="loc_teva_OperatingLeaseCostAbstract_821789" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate" xlink:label="loc_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate_821792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeaseCostAbstract_821789" xlink:to="loc_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate_821792" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_821794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeaseCostAbstract_821789" xlink:to="loc_us-gaap_VariableLeaseCost_821794" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_821796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeaseCostAbstract_821789" xlink:to="loc_us-gaap_ShortTermLeaseCost_821796" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_821797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeaseCostAbstract_821789" xlink:to="loc_us-gaap_LeaseCost_821797" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_390191" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_390191" xlink:to="loc_us-gaap_StatementTable_390193" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_801291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390193" xlink:to="loc_dei_LegalEntityAxis_801291" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_801292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_801291" xlink:to="loc_dei_EntityDomain_801292" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390193" xlink:to="loc_us-gaap_StatementLineItems_390196" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract" xlink:label="loc_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract_390197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390196" xlink:to="loc_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract_390197" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_390199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract_390197" xlink:to="loc_us-gaap_OperatingLeasePayments_390199" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract" xlink:label="loc_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract_391682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390196" xlink:to="loc_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract_391682" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesNonCash" xlink:label="loc_teva_OperatingLeasesNonCash_391689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract_391682" xlink:to="loc_teva_OperatingLeasesNonCash_391689" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_390093" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_390093" xlink:to="loc_us-gaap_StatementTable_390095" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390095" xlink:to="loc_dei_LegalEntityAxis_390096" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390096" xlink:to="loc_dei_EntityDomain_390097" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_390154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390095" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_390154" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_390155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_390154" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_390155" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390095" xlink:to="loc_us-gaap_StatementLineItems_390098" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesAbstract" xlink:label="loc_teva_OperatingLeasesAbstract_390099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390098" xlink:to="loc_teva_OperatingLeasesAbstract_390099" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_390100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_390100" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeaseLiabilityOther" xlink:label="loc_teva_OperatingLeaseLiabilityOther_390102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_teva_OperatingLeaseLiabilityOther_390102" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_390103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_390103" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_390104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseLiability_390104" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_390144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_390144" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_390151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OperatingLeasesAbstract_390099" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_390151" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_820573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390098" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_820573" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_390040" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_390040" xlink:to="loc_us-gaap_StatementTable_390042" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_390043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390042" xlink:to="loc_dei_LegalEntityAxis_390043" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_390044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_390043" xlink:to="loc_dei_EntityDomain_390044" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390042" xlink:to="loc_us-gaap_StatementLineItems_390045" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_390050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_390050" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_390051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_390051" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_390053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_390053" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_390054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_390054" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="loc_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_390056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_390056" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_390060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_390060" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OperatingLeasesImputedInterest" xlink:label="loc_teva_OperatingLeasesImputedInterest_390062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_teva_OperatingLeasesImputedInterest_390062" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_390064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390045" xlink:to="loc_us-gaap_OperatingLeaseLiability_390064" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_390344" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_390344" xlink:to="loc_us-gaap_StatementTable_390346" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_390431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390346" xlink:to="loc_srt_RangeAxis_390431" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_390432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_390431" xlink:to="loc_srt_RangeMember_390432" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_390433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_390432" xlink:to="loc_srt_MaximumMember_390433" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_390434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_390432" xlink:to="loc_srt_MinimumMember_390434" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_515069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390346" xlink:to="loc_srt_StatementGeographicalAxis_515069" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_515070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_515069" xlink:to="loc_srt_SegmentGeographicalDomain_515070" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390346" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515072" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515072" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515073" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390346" xlink:to="loc_us-gaap_StatementLineItems_390349" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_412011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_412011" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_412012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_FinanceLeaseLiability_412012" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_809731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_809731" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_809732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390349" xlink:to="loc_us-gaap_OperatingLeaseLiability_809732" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_684" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_684" xlink:to="loc_us-gaap_DebtInstrumentTable_690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_dei_LegalEntityAxis_691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_691" xlink:to="loc_dei_EntityDomain_705" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentAxis_687" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShortCreditAgreement2026Member" xlink:label="loc_teva_ShortCreditAgreement2026Member_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689" xlink:to="loc_teva_ShortCreditAgreement2026Member_704" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_VariableRateAxis_692" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_692" xlink:to="loc_us-gaap_VariableRateDomain_693" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_srt_CurrencyAxis_686" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_686" xlink:to="loc_currency_AllCurrenciesDomain_685" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_504448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_CreditFacilityAxis_504448" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_504449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_504448" xlink:to="loc_us-gaap_CreditFacilityDomain_504449" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_690" xlink:to="loc_us-gaap_DebtInstrumentLineItems_688" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_695" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_teva_DebtInstrumentMaturityYear_698" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_ShortTermBorrowings_699" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_LongTermDebtCurrent_700" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_688" xlink:to="loc_us-gaap_DebtCurrent_701" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_758" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_758" xlink:to="loc_us-gaap_DebtInstrumentTable_764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_dei_LegalEntityAxis_765" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_765" xlink:to="loc_dei_EntityDomain_815" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentAxis_761" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_761" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_763" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherDebentures2026Member" xlink:label="loc_teva_OtherDebentures2026Member_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_OtherDebentures2026Member_814" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020OneMember_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2020OneMember_782" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_783" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_784" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_786" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_787" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_788" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2027Member_789" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_790" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_673253" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_794" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_796" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_797" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572204" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572603" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021OneMember_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021OneMember_791" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_798" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_799" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020TwoMember_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2020TwoMember_800" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_801" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember_802" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_804" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_572585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_763" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_572585" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_VariableRateAxis_766" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_766" xlink:to="loc_us-gaap_VariableRateDomain_767" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_srt_CurrencyAxis_760" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_760" xlink:to="loc_currency_AllCurrenciesDomain_759" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_764" xlink:to="loc_us-gaap_DebtInstrumentLineItems_762" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_769" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DebtInstrumentMaturityYear" xlink:label="loc_teva_DebtInstrumentMaturityYear_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_teva_DebtInstrumentMaturityYear_772" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_SeniorNotes_775" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermDebtCurrent_778" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_780" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesAndLoans" xlink:label="loc_us-gaap_LongTermNotesAndLoans_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_762" xlink:to="loc_us-gaap_LongTermNotesAndLoans_781" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_818" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_818" xlink:to="loc_us-gaap_DebtInstrumentTable_822" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentAxis_819" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_819" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_821" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020OneMember_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2020OneMember_825" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024Member_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024Member_826" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023OneMember_827" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025Member_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025Member_829" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028Member_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028Member_830" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022OneMember_831" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2027Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2027Member_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2027Member_832" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025OneMember_572208" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025TwoMember_572210" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2026OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2026OneMember_833" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021OneMember_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021OneMember_834" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2023TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2023TwoMember_835" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2046Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2046Member_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2046Member_837" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2024OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2024OneMember_839" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2028OneMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2028OneMember_840" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022TwoMember_841" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2036Member" xlink:label="loc_teva_SubsidiarySeniorNotesDue2036Member_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2036Member_842" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2020TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2020TwoMember_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2020TwoMember_843" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_844" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021ThreeMember_845" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2022ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2022ThreeMember_847" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2025ThreeMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_821" xlink:to="loc_teva_SubsidiarySeniorNotesDue2025ThreeMember_848" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_822" xlink:to="loc_us-gaap_DebtInstrumentLineItems_820" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_824" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_858" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturityTable" xlink:label="loc_teva_LongTermDebtMaturityTable_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_858" xlink:to="loc_teva_LongTermDebtMaturityTable_861" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_LongTermDebtMaturityTable_861" xlink:to="loc_dei_LegalEntityAxis_859" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_862" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturityLineItems" xlink:label="loc_teva_LongTermDebtMaturityLineItems_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_LongTermDebtMaturityTable_861" xlink:to="loc_teva_LongTermDebtMaturityLineItems_860" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_864" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_865" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_866" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_808808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_808808" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="loc_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_867" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtaExcludeIssuanceCost" xlink:label="loc_teva_LongTermDebtaExcludeIssuanceCost_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_LongTermDebtMaturityLineItems_860" xlink:to="loc_teva_LongTermDebtaExcludeIssuanceCost_868" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_816455" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_816461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_816455" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_816461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_816462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_816461" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_816462" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_816463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_816462" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_816463" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_816465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_816463" xlink:to="loc_us-gaap_ConvertibleDebtMember_816465" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_816467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_816461" xlink:to="loc_us-gaap_ShortTermDebtLineItems_816467" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_816468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_816467" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_816468" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_718" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_718" xlink:to="loc_us-gaap_DebtInstrumentTable_724" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_dei_LegalEntityAxis_725" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_725" xlink:to="loc_dei_EntityDomain_755" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_CreditFacilityAxis_719" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_719" xlink:to="loc_us-gaap_CreditFacilityDomain_720" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_720" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_728" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_726" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_726" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_727" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_727" xlink:to="loc_us-gaap_ConvertibleDebtMember_756" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentAxis_721" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_721" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_723" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_408262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_408262" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_408264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_408262" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_408264" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_408266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_408264" xlink:to="loc_us-gaap_SeniorNotesMember_408266" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_466637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_466637" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_466638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_466637" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_466638" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TrancheAxis" xlink:label="loc_teva_TrancheAxis_682383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_teva_TrancheAxis_682383" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TrancheDomain" xlink:label="loc_teva_TrancheDomain_682384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_TrancheAxis_682383" xlink:to="loc_teva_TrancheDomain_682384" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheAMember" xlink:label="loc_teva_TracheAMember_682385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_TrancheDomain_682384" xlink:to="loc_teva_TracheAMember_682385" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheBMember" xlink:label="loc_teva_TracheBMember_682386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_TrancheDomain_682384" xlink:to="loc_teva_TracheBMember_682386" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_682892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_682892" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_682892" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TracheAExtensionMember" xlink:label="loc_teva_TracheAExtensionMember_682894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_682893" xlink:to="loc_teva_TracheAExtensionMember_682894" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_srt_RangeAxis_765345" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_765346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_765345" xlink:to="loc_srt_RangeMember_765346" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_724" xlink:to="loc_us-gaap_DebtInstrumentLineItems_722" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaap_LinesOfCreditCurrent_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LinesOfCreditCurrent_729" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_732" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_SeniorNotes_733" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_390546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_390546" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_735" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionUSD" xlink:label="loc_teva_LongTermDebtCurrencyPortionUSD_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionUSD_739" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionEUR" xlink:label="loc_teva_LongTermDebtCurrencyPortionEUR_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionEUR_740" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermDebtCurrencyPortionCHF" xlink:label="loc_teva_LongTermDebtCurrencyPortionCHF_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_teva_LongTermDebtCurrencyPortionCHF_741" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_466634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_466634" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_466635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCredit_466635" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_682388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_682388" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_722" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_682881" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_1314" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1314" xlink:to="loc_us-gaap_DerivativeTable_1319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_dei_LegalEntityAxis_1323" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1323" xlink:to="loc_dei_EntityDomain_1331" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1316" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1316" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1315" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1315" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_1324" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_1320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_us-gaap_HedgingDesignationAxis_1320" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1320" xlink:to="loc_us-gaap_HedgingDesignationDomain_1321" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1321" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1327" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1317" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1317" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1322" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1322" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1330" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1319" xlink:to="loc_us-gaap_DerivativeLineItems_1318" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1318" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1326" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_1333" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1333" xlink:to="loc_us-gaap_DerivativeTable_1340" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_dei_LegalEntityAxis_1344" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1344" xlink:to="loc_dei_EntityDomain_1357" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_HedgingDesignationAxis_1341" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1341" xlink:to="loc_us-gaap_HedgingDesignationDomain_1342" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1353" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1342" xlink:to="loc_us-gaap_NondesignatedMember_1354" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1336" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_ForeignExchangeContractMember_1348" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SwapMember" xlink:label="loc_us-gaap_SwapMember_1349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_SwapMember_1349" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_1350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1336" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_1350" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1334" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1334" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1335" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_1345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_1345" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesAndLoansMember" xlink:label="loc_teva_SeniorNotesAndLoansMember_1346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_teva_SeniorNotesAndLoansMember_1346" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1347" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_390198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1335" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_390198" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1338" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1343" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_408399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1343" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_408399" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1340" xlink:to="loc_us-gaap_DerivativeLineItems_1339" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_1351" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1339" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_1352" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_390263" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_390269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_390263" xlink:to="loc_us-gaap_DerivativeTable_390269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_390270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_390270" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_390271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_390270" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_390271" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390330" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390330" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390338" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember_390351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390338" xlink:to="loc_teva_FinancialExpensesMember_390351" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_390379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_390379" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_390380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_390379" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_390380" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_390381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_390380" xlink:to="loc_us-gaap_OtherComprehensiveIncomeMember_390381" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_391806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_391806" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_391807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_391806" xlink:to="loc_us-gaap_HedgingRelationshipDomain_391807" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_391809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_391807" xlink:to="loc_us-gaap_CashFlowHedgingMember_391809" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_391810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_391807" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_391810" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_391811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_391807" xlink:to="loc_us-gaap_FairValueHedgingMember_391811" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_412059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_HedgingDesignationAxis_412059" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_412060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_412059" xlink:to="loc_us-gaap_HedgingDesignationDomain_412060" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_412062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_412060" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_412062" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_390277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390269" xlink:to="loc_us-gaap_DerivativeLineItems_390277" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_391805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_390277" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_391805" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentDetailAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_390514" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_390515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_390514" xlink:to="loc_us-gaap_DerivativeTable_390515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390519" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390519" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390520" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember_406886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_NetRevenuesMember_406886" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesMember" xlink:label="loc_teva_FinancialExpensesMember_406916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_390520" xlink:to="loc_teva_FinancialExpensesMember_406916" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_406887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_HedgingDesignationAxis_406887" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_406888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_406887" xlink:to="loc_us-gaap_HedgingDesignationDomain_406888" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_406890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NondesignatedMember_406890" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotDesignatedAsHedgingInstrumentTradingMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentTradingMember_406891" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_406888" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_466838" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_682287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_682286" xlink:to="loc_us-gaap_HedgingRelationshipDomain_682287" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_390516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_390515" xlink:to="loc_us-gaap_DerivativeLineItems_390516" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_390516" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_406900" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1359" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1359" xlink:to="loc_us-gaap_DerivativeTable_1361" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1361" xlink:to="loc_dei_LegalEntityAxis_1362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1362" xlink:to="loc_dei_EntityDomain_1368" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1361" xlink:to="loc_us-gaap_DerivativeLineItems_1360" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization_1363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_us-gaap_AccountsReceivableFromSecuritization_1363" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromAccountsReceivableSecuritization" xlink:label="loc_us-gaap_ProceedsFromAccountsReceivableSecuritization_1364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_us-gaap_ProceedsFromAccountsReceivableSecuritization_1364" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfAccountsReceivableSecuritization" xlink:label="loc_us-gaap_RepaymentsOfAccountsReceivableSecuritization_1365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_us-gaap_RepaymentsOfAccountsReceivableSecuritization_1365" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization" xlink:label="loc_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization_1366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization_1366" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization_1367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1360" xlink:to="loc_us-gaap_AccountsReceivableFromSecuritization_1367" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1281" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1281" xlink:to="loc_us-gaap_DerivativeTable_1286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_dei_LegalEntityAxis_1290" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1290" xlink:to="loc_dei_EntityDomain_1312" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1283" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1282" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2023TwoMember" xlink:label="loc_teva_SeniorNotesDue2023TwoMember_1291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2023TwoMember_1291" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2022Member" xlink:label="loc_teva_SeniorNotesDue2022Member_1294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2022Member_1294" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2021Member" xlink:label="loc_teva_SeniorNotesDue2021Member_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2021Member_1297" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniorNotesDue2020Member" xlink:label="loc_teva_SeniorNotesDue2020Member_412070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SeniorNotesDue2020Member_412070" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SubsidiarySeniorNotesDue2021TwoMember" xlink:label="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_581630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1282" xlink:to="loc_teva_SubsidiarySeniorNotesDue2021TwoMember_581630" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1288" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1288" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1289" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_688628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1289" xlink:to="loc_us-gaap_CostOfSalesMember_688628" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetRevenuesMember" xlink:label="loc_teva_NetRevenuesMember_817875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1289" xlink:to="loc_teva_NetRevenuesMember_817875" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1284" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1287" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember" xlink:label="loc_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember_817880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1287" xlink:to="loc_teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember_817880" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_558657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_HedgingDesignationAxis_558657" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_558658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_558657" xlink:to="loc_us-gaap_HedgingDesignationDomain_558658" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_558659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_558658" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_558659" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_817883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_558658" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_817883" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_817877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_srt_RangeAxis_817877" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_817878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_817877" xlink:to="loc_srt_RangeMember_817878" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_1285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1286" xlink:to="loc_us-gaap_DerivativeLineItems_1285" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenuesOtherThanUsd" xlink:label="loc_teva_RevenuesOtherThanUsd_1298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_RevenuesOtherThanUsd_1298" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NotionalAmountHedgeDebt" xlink:label="loc_teva_NotionalAmountHedgeDebt_1300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_NotionalAmountHedgeDebt_1300" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_1301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_1301" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses" xlink:label="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses_1303" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreviouslyHedgeDebtRate" xlink:label="loc_teva_PreviouslyHedgeDebtRate_1304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_PreviouslyHedgeDebtRate_1304" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SettlementGainPosition" xlink:label="loc_teva_SettlementGainPosition_1305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_SettlementGainPosition_1305" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InterestRateSwapGain" xlink:label="loc_teva_InterestRateSwapGain_391830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_InterestRateSwapGain_391830" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredPurchaseAsset" xlink:label="loc_teva_DeferredPurchaseAsset_1308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_DeferredPurchaseAsset_1308" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableFromSecuritization" xlink:label="loc_us-gaap_AccountsReceivableFromSecuritization_1309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_AccountsReceivableFromSecuritization_1309" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CashReceivedOnSettlementOfPosition" xlink:label="loc_teva_CashReceivedOnSettlementOfPosition_581646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_teva_CashReceivedOnSettlementOfPosition_581646" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_688630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_688630" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss" xlink:label="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_718504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss_718504" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_817874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1285" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_817874" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1456" xlink:to="loc_us-gaap_LossContingenciesTable_1459" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_dei_LegalEntityAxis_1457" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1457" xlink:to="loc_dei_EntityDomain_1460" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_LitigationCaseAxis_471102" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_471102" xlink:to="loc_srt_LitigationCaseTypeDomain_471103" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SettlementOnAccountOfProductLiabilityMember" xlink:label="loc_teva_SettlementOnAccountOfProductLiabilityMember_720064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471103" xlink:to="loc_teva_SettlementOnAccountOfProductLiabilityMember_720064" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_720032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_srt_StatementGeographicalAxis_720032" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_720033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_720032" xlink:to="loc_srt_SegmentGeographicalDomain_720033" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_720035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_720033" xlink:to="loc_country_US_720035" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1459" xlink:to="loc_us-gaap_LossContingenciesLineItems_1458" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LitigationSettlementExpense_1461" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_577495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_577495" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1462" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringExpenseAndIncome" xlink:label="loc_teva_RestructuringExpenseAndIncome_720065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1458" xlink:to="loc_teva_RestructuringExpenseAndIncome_720065" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_881" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_881" xlink:to="loc_teva_CommitmentAndContingenciesTable_883" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_883" xlink:to="loc_dei_LegalEntityAxis_884" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_884" xlink:to="loc_dei_EntityDomain_896" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_883" xlink:to="loc_srt_RangeAxis_885" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_885" xlink:to="loc_srt_RangeMember_886" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_886" xlink:to="loc_srt_MaximumMember_897" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_883" xlink:to="loc_teva_CommitmentAndContingenciesLineItems_882" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_882" xlink:to="loc_us-gaap_RoyaltyExpense_894" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MilestoneContingentPayments" xlink:label="loc_teva_MilestoneContingentPayments_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_882" xlink:to="loc_teva_MilestoneContingentPayments_895" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_899" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesTable" xlink:label="loc_teva_CommitmentAndContingenciesTable_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_899" xlink:to="loc_teva_CommitmentAndContingenciesTable_901" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_dei_LegalEntityAxis_903" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_903" xlink:to="loc_dei_EntityDomain_935" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_ProductOrServiceAxis_906" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_906" xlink:to="loc_srt_ProductsAndServicesDomain_907" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AndroGelRateAtOnePercentageMember" xlink:label="loc_teva_AndroGelRateAtOnePercentageMember_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_907" xlink:to="loc_teva_AndroGelRateAtOnePercentageMember_937" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_CounterpartyNameAxis_902" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_902" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_JanssenAndMillenniumMember" xlink:label="loc_teva_JanssenAndMillenniumMember_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_908" xlink:to="loc_teva_JanssenAndMillenniumMember_939" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_904" xlink:to="loc_us-gaap_LossContingencyNatureDomain_905" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EosinophilicEsophagitisMember" xlink:label="loc_teva_EosinophilicEsophagitisMember_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_905" xlink:to="loc_teva_EosinophilicEsophagitisMember_936" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_StatementGeographicalAxis_910" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_910" xlink:to="loc_srt_SegmentGeographicalDomain_909" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_country_US_940" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_909" xlink:to="loc_srt_EuropeMember_941" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_471076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_srt_LitigationCaseAxis_471076" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_471078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_471076" xlink:to="loc_srt_LitigationCaseTypeDomain_471078" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OpioidLitigationMember" xlink:label="loc_teva_OpioidLitigationMember_471080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_OpioidLitigationMember_471080" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NationwideSettlementMember" xlink:label="loc_teva_NationwideSettlementMember_515110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_NationwideSettlementMember_515110" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilSettlementAgreementMember" xlink:label="loc_teva_ModafinilSettlementAgreementMember_818713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_471078" xlink:to="loc_teva_ModafinilSettlementAgreementMember_818713" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515106" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_515107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515106" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_515107" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CommitmentAndContingenciesLineItems" xlink:label="loc_teva_CommitmentAndContingenciesLineItems_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesTable_901" xlink:to="loc_teva_CommitmentAndContingenciesLineItems_900" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DamagesAssessment" xlink:label="loc_teva_DamagesAssessment_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_DamagesAssessment_911" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfVelcade" xlink:label="loc_teva_AnnualSalesOfVelcade_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfVelcade_912" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilPayment" xlink:label="loc_teva_ModafinilPayment_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_ModafinilPayment_917" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesAtTimeOfSettlement" xlink:label="loc_teva_AnnualSalesAtTimeOfSettlement_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesAtTimeOfSettlement_919" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfEffexor" xlink:label="loc_teva_AnnualSalesOfEffexor_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfEffexor_920" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfLamictal" xlink:label="loc_teva_AnnualSalesOfLamictal_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfLamictal_921" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfNiaspan" xlink:label="loc_teva_AnnualSalesOfNiaspan_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNiaspan_922" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfActos" xlink:label="loc_teva_AnnualSalesOfActos_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActos_925" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfActoplus" xlink:label="loc_teva_AnnualSalesOfActoplus_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfActoplus_926" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfNamenda" xlink:label="loc_teva_AnnualSalesOfNamenda_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfNamenda_928" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_913" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_914" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_932" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_933" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_934" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfSensipar" xlink:label="loc_teva_AnnualSalesOfSensipar_471045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfSensipar_471045" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ModafinilPaymentRemainingBalance" xlink:label="loc_teva_ModafinilPaymentRemainingBalance_515099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_ModafinilPaymentRemainingBalance_515099" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedDistributionPeriod_515103" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedCashAmount" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmount_515111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedCashAmount_515111" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedNumberOfInstallments" xlink:label="loc_teva_LitigationSettlementAmountAwardedNumberOfInstallments_515112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedNumberOfInstallments_515112" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod" xlink:label="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod_515113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod_515113" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AnnualSalesOfCopaxone" xlink:label="loc_teva_AnnualSalesOfCopaxone_720069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_teva_AnnualSalesOfCopaxone_720069" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_CommitmentAndContingenciesLineItems_900" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_818712" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_1138" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_1138" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1140" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1140" xlink:to="loc_dei_LegalEntityAxis_1141" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1141" xlink:to="loc_dei_EntityDomain_1145" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1140" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1142" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1143" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1139" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1144" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_1147" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_1147" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1149" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1149" xlink:to="loc_dei_LegalEntityAxis_1150" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1150" xlink:to="loc_dei_EntityDomain_1157" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1149" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1151" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_1152" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1153" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1154" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1155" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1148" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1156" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1159" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1159" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1161" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1161" xlink:to="loc_dei_LegalEntityAxis_1162" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1162" xlink:to="loc_dei_EntityDomain_1172" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1161" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1163" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1164" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1165" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1160" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1167" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1168" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Ustaxcutsandjobsacteffect" xlink:label="loc_teva_Ustaxcutsandjobsacteffect_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_teva_Ustaxcutsandjobsacteffect_1169" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_1170" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_1166" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1171" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1174" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1174" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1176" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1176" xlink:to="loc_dei_LegalEntityAxis_1177" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1177" xlink:to="loc_dei_EntityDomain_1179" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems" xlink:label="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable_1176" xlink:to="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1175" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems_1175" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1178" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract_1181" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xlink:label="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract_1181" xlink:to="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1184" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1184" xlink:to="loc_dei_LegalEntityAxis_1183" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1183" xlink:to="loc_dei_EntityDomain_1197" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetLineItems" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1184" xlink:to="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1185" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_1186" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_1187" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_1188" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent_1189" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1190" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsDeferredInterest" xlink:label="loc_teva_DeferredTaxAssetsDeferredInterest_1191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsDeferredInterest_1191" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent" xlink:label="loc_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent_1192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent_1192" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent_1193" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent_1194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent_1194" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1195" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1182" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1196" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract_1199" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xlink:label="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract_1199" xlink:to="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1202" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1202" xlink:to="loc_dei_LegalEntityAxis_1201" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1201" xlink:to="loc_dei_EntityDomain_1204" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetLineItems" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1202" xlink:to="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1200" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetUnrecognizedTaxBenefits" xlink:label="loc_teva_DeferredTaxAssetUnrecognizedTaxBenefits_1203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1200" xlink:to="loc_teva_DeferredTaxAssetUnrecognizedTaxBenefits_1203" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1206" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxTable" xlink:label="loc_teva_IncomeTaxTable_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1206" xlink:to="loc_teva_IncomeTaxTable_1210" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_dei_LegalEntityAxis_1211" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1211" xlink:to="loc_dei_EntityDomain_1242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_RangeAxis_1214" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1214" xlink:to="loc_srt_RangeMember_1215" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1215" xlink:to="loc_srt_MinimumMember_1245" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1215" xlink:to="loc_srt_MaximumMember_1246" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1216" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1216" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember_1247" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember_1248" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsNoExpirationMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsNoExpirationMember_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_TaxCarryforwardsAndDeductionsNoExpirationMember_1249" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxCarryforwardsAndDeductionsIndefiniteMember" xlink:label="loc_teva_TaxCarryforwardsAndDeductionsIndefiniteMember_1250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_TaxCarryforwardsAndDeductionsIndefiniteMember_1250" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment69ToInvestmentLawMember" xlink:label="loc_teva_Amendment69ToInvestmentLawMember_1251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_Amendment69ToInvestmentLawMember_1251" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment68ToInvestmentLawMember" xlink:label="loc_teva_Amendment68ToInvestmentLawMember_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_Amendment68ToInvestmentLawMember_1252" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Amendment73ToInvestmentLawMember" xlink:label="loc_teva_Amendment73ToInvestmentLawMember_1253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_Amendment73ToInvestmentLawMember_1253" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreferredEnterpriseMember" xlink:label="loc_teva_PreferredEnterpriseMember_1254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_PreferredEnterpriseMember_1254" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PreferredTechnologicalEnterprisesMember" xlink:label="loc_teva_PreferredTechnologicalEnterprisesMember_1255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_PreferredTechnologicalEnterprisesMember_1255" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SpecialPreferredTechnologicalEnterpriseMember" xlink:label="loc_teva_SpecialPreferredTechnologicalEnterpriseMember_1256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1217" xlink:to="loc_teva_SpecialPreferredTechnologicalEnterpriseMember_1256" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1207" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaap_IsraelTaxAuthorityMember_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1208" xlink:to="loc_us-gaap_IsraelTaxAuthorityMember_1220" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_TaxPeriodAxis_1218" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1218" xlink:to="loc_us-gaap_TaxPeriodDomain_1219" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TaxYear2005To2007Member" xlink:label="loc_teva_TaxYear2005To2007Member_1257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1219" xlink:to="loc_teva_TaxYear2005To2007Member_1257" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1212" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DevelopmentZoneaMember" xlink:label="loc_teva_DevelopmentZoneaMember_1243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" xlink:to="loc_teva_DevelopmentZoneaMember_1243" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_1244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1213" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_1244" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_581719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_581719" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_581720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_581719" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_581720" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_673833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_srt_StatementScenarioAxis_673833" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_673834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_673833" xlink:to="loc_srt_ScenarioUnspecifiedDomain_673834" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IncomeTaxLineItems" xlink:label="loc_teva_IncomeTaxLineItems_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxTable_1210" xlink:to="loc_teva_IncomeTaxLineItems_1209" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_1221" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1222" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1223" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1224" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1225" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_1226" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_IncomeTaxesPaid_1227" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendIncomeSecuritiesOperatingTaxExempt" xlink:label="loc_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt_1228" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1229" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_WithholdingTaxPercentageOnDividends" xlink:label="loc_teva_WithholdingTaxPercentageOnDividends_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_WithholdingTaxPercentageOnDividends_1230" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumPercentageOfInvestmentIncome" xlink:label="loc_teva_MinimumPercentageOfInvestmentIncome_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_MinimumPercentageOfInvestmentIncome_1231" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_InvestmentIncomeNet_1232" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumPercentageOfWorkforce" xlink:label="loc_teva_MinimumPercentageOfWorkforce_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_MinimumPercentageOfWorkforce_1233" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MinimumNumberOfEmployeesEmployed" xlink:label="loc_teva_MinimumNumberOfEmployeesEmployed_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_MinimumNumberOfEmployeesEmployed_1234" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_VentureCapitalInvestments" xlink:label="loc_teva_VentureCapitalInvestments_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_VentureCapitalInvestments_1235" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageGrowthRateInSalesOrWorkforce" xlink:label="loc_teva_AverageGrowthRateInSalesOrWorkforce_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_AverageGrowthRateInSalesOrWorkforce_1236" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce" xlink:label="loc_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce_1237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce_1237" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1238" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1239" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpectedImpairmentOfIncomeTaxBenefit" xlink:label="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_teva_ExpectedImpairmentOfIncomeTaxBenefit_581718" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit_801122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_IncomeTaxLineItems_1209" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit_801122" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract_1259" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable" xlink:label="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract_1259" xlink:to="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1262" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1262" xlink:to="loc_dei_LegalEntityAxis_1261" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1261" xlink:to="loc_dei_EntityDomain_1266" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DeferredTaxAssetsLiabilitiesNetLineItems" xlink:label="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable_1262" xlink:to="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1263" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1264" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_DeferredTaxAssetsLiabilitiesNetLineItems_1260" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1265" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedTaxBenefitsAbstract" xlink:label="loc_teva_UnrecognizedTaxBenefitsAbstract_1268" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfUnrecognizedTaxBenefitsTable" xlink:label="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable_1271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_UnrecognizedTaxBenefitsAbstract_1268" xlink:to="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable_1271" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable_1271" xlink:to="loc_dei_LegalEntityAxis_1269" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1269" xlink:to="loc_dei_EntityDomain_1272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ScheduleOfUnrecognizedTaxBenefitsLineItems" xlink:label="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsTable_1271" xlink:to="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1273" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="loc_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_1274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_1274" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1275" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1276" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther" xlink:label="loc_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther_1278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther_1278" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems_1270" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1279" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_943" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_943" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_950" xlink:to="loc_dei_LegalEntityAxis_945" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_945" xlink:to="loc_dei_EntityDomain_979" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_950" xlink:to="loc_srt_TitleOfIndividualAxis_951" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_951" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_952" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_950" xlink:to="loc_us-gaap_PlanNameAxis_946" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_946" xlink:to="loc_us-gaap_PlanNameDomain_947" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandTenPlanMember" xlink:label="loc_teva_TwoThousandTenPlanMember_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_947" xlink:to="loc_teva_TwoThousandTenPlanMember_980" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandFifteenPlanMember" xlink:label="loc_teva_TwoThousandFifteenPlanMember_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_947" xlink:to="loc_teva_TwoThousandFifteenPlanMember_981" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_TwoThousandTwentyPlanMember" xlink:label="loc_teva_TwoThousandTwentyPlanMember_818708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_947" xlink:to="loc_teva_TwoThousandTwentyPlanMember_818708" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_950" xlink:to="loc_us-gaap_ClassOfStockLineItems_944" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_SharesOutstanding_953" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_SharePrice_955" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_959" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_964" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_967" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_968" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_969" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_970" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AverageSharePrice" xlink:label="loc_teva_AverageSharePrice_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_teva_AverageSharePrice_971" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedCompensationCostOptions" xlink:label="loc_teva_UnrecognizedCompensationCostOptions_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_teva_UnrecognizedCompensationCostOptions_974" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UnrecognizedCompensationCostRsus" xlink:label="loc_teva_UnrecognizedCompensationCostRsus_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_teva_UnrecognizedCompensationCostRsus_975" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_583146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_583146" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_976" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_986" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_986" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_988" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_988" xlink:to="loc_dei_LegalEntityAxis_987" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_987" xlink:to="loc_dei_EntityDomain_990" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_991" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_992" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_993" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_994" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_995" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_996" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_997" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_998" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_999" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1000" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1001" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1002" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1003" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1004" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1006" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1006" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1008" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1008" xlink:to="loc_dei_LegalEntityAxis_1007" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1007" xlink:to="loc_dei_EntityDomain_1010" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1008" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1009" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1009" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1011" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1013" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1013" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1015" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1015" xlink:to="loc_dei_LegalEntityAxis_1014" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1014" xlink:to="loc_dei_EntityDomain_1017" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1015" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1019" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1020" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1016" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1021" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1023" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" xlink:to="loc_dei_LegalEntityAxis_1024" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1024" xlink:to="loc_dei_EntityDomain_1029" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1026" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1026" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeOneMember" xlink:label="loc_teva_ExercisePriceRangeOneMember_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeOneMember_1030" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeTwoMember" xlink:label="loc_teva_ExercisePriceRangeTwoMember_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeTwoMember_1031" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeThreeMember" xlink:label="loc_teva_ExercisePriceRangeThreeMember_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeThreeMember_1032" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFourMember" xlink:label="loc_teva_ExercisePriceRangeFourMember_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeFourMember_1033" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFiveMember" xlink:label="loc_teva_ExercisePriceRangeFiveMember_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeFiveMember_1034" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeSixMember" xlink:label="loc_teva_ExercisePriceRangeSixMember_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1027" xlink:to="loc_teva_ExercisePriceRangeSixMember_1035" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1025" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1037" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010_1038" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010_1039" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1041" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1028" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1042" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1044" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1044" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" xlink:to="loc_dei_LegalEntityAxis_1045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1045" xlink:to="loc_dei_EntityDomain_1050" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1047" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1047" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeOneMember" xlink:label="loc_teva_ExercisePriceRangeOneMember_572234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeOneMember_572234" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeTwoMember" xlink:label="loc_teva_ExercisePriceRangeTwoMember_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeTwoMember_1051" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeThreeMember" xlink:label="loc_teva_ExercisePriceRangeThreeMember_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeThreeMember_1052" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFourMember" xlink:label="loc_teva_ExercisePriceRangeFourMember_1053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeFourMember_1053" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeFiveMember" xlink:label="loc_teva_ExercisePriceRangeFiveMember_1054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeFiveMember_1054" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExercisePriceRangeSixMember" xlink:label="loc_teva_ExercisePriceRangeSixMember_1055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1048" xlink:to="loc_teva_ExercisePriceRangeSixMember_1055" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1046" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1057" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010_1058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010_1058" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010" xlink:label="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010_1059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010_1059" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1061" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_1049" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1062" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1074" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1074" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" xlink:to="loc_dei_LegalEntityAxis_1075" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1075" xlink:to="loc_dei_EntityDomain_1080" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" xlink:to="loc_us-gaap_PlanNameAxis_1076" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1076" xlink:to="loc_us-gaap_PlanNameDomain_1077" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestrictedStockUnitsMember" xlink:label="loc_teva_RestrictedStockUnitsMember_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1077" xlink:to="loc_teva_RestrictedStockUnitsMember_1081" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1078" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1082" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1083" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1084" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1085" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1086" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1087" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1088" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1089" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1090" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1091" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1093" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1093" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" xlink:to="loc_dei_LegalEntityAxis_1094" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1094" xlink:to="loc_dei_EntityDomain_1099" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" xlink:to="loc_us-gaap_PlanNameAxis_1095" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1095" xlink:to="loc_us-gaap_PlanNameDomain_1096" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_StockOptionsPlanMember" xlink:label="loc_teva_StockOptionsPlanMember_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1096" xlink:to="loc_teva_StockOptionsPlanMember_1100" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestrictedStockUnitsMember" xlink:label="loc_teva_RestrictedStockUnitsMember_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1096" xlink:to="loc_teva_RestrictedStockUnitsMember_1101" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OmnibusLongTermShareIncentivePlanMember" xlink:label="loc_teva_OmnibusLongTermShareIncentivePlanMember_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1096" xlink:to="loc_teva_OmnibusLongTermShareIncentivePlanMember_1102" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1097" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1103" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1104" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1098" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1105" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1107" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1107" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" xlink:to="loc_dei_LegalEntityAxis_1111" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1111" xlink:to="loc_dei_EntityDomain_1126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1112" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1112" xlink:to="loc_us-gaap_EquityComponentDomain_1110" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_1121" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1122" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1123" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1124" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1110" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1125" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1109" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1113" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning" xlink:label="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning_1114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning_1114" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_1115" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_1116" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_801129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_801129" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_1118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_1118" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1119" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1108" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1120" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1128" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1128" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" xlink:to="loc_dei_LegalEntityAxis_1132" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1132" xlink:to="loc_dei_EntityDomain_1136" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1133" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1133" xlink:to="loc_us-gaap_EquityComponentDomain_1131" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_1135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1131" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_1135" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_582305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_582305" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_582306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_582305" xlink:to="loc_us-gaap_TypeOfAdoptionMember_582306" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_582307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_582306" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_582307" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1130" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1129" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1129" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_1134" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract_1390" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentAbstract_1390" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1393" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_dei_LegalEntityAxis_1391" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1391" xlink:to="loc_dei_EntityDomain_1394" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1393" xlink:to="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1395" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1396" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_us-gaap_RestructuringCharges_1398" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses" xlink:label="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses_1400" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentAndRestructuring" xlink:label="loc_teva_ImpairmentAndRestructuring_1401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1392" xlink:to="loc_teva_ImpairmentAndRestructuring_1401" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentAbstract" xlink:label="loc_teva_RestructuringAndImpairmentAbstract_1403" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsTable" xlink:label="loc_teva_RestructuringAndImpairmentCostsTable_1412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentAbstract_1403" xlink:to="loc_teva_RestructuringAndImpairmentCostsTable_1412" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_dei_LegalEntityAxis_1406" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1406" xlink:to="loc_dei_EntityDomain_1416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_ProductOrServiceAxis_1407" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1407" xlink:to="loc_srt_ProductsAndServicesDomain_1408" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1405" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementGeographicalAxis_1414" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1414" xlink:to="loc_srt_SegmentGeographicalDomain_1413" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_515346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_srt_StatementScenarioAxis_515346" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_515347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_515346" xlink:to="loc_srt_ScenarioUnspecifiedDomain_515347" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAndImpairmentCostsLineItems" xlink:label="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsTable_1412" xlink:to="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_1419" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_758336" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_us-gaap_RestructuringCharges_1421" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpectedRevenueFromFacility" xlink:label="loc_teva_ExpectedRevenueFromFacility_572186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_teva_ExpectedRevenueFromFacility_572186" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringPlanCostReduction" xlink:label="loc_teva_RestructuringPlanCostReduction_581689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RestructuringAndImpairmentCostsLineItems_1411" xlink:to="loc_teva_RestructuringPlanCostReduction_581689" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1431" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1431" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_dei_LegalEntityAxis_1432" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1432" xlink:to="loc_dei_EntityDomain_1437" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1433" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1433" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1436" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_1439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_EmployeeSeveranceMember_1439" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1436" xlink:to="loc_us-gaap_OtherRestructuringMember_1440" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_390248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_390248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_390250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_390248" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_390250" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1435" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1434" xlink:to="loc_us-gaap_RestructuringCharges_1438" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1442" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1442" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_dei_LegalEntityAxis_1445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1445" xlink:to="loc_dei_EntityDomain_1450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExitAndDisposalAxis" xlink:label="loc_teva_ExitAndDisposalAxis_1443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_teva_ExitAndDisposalAxis_1443" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExitAndDisposalDomain" xlink:label="loc_teva_ExitAndDisposalDomain_1444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalAxis_1443" xlink:to="loc_teva_ExitAndDisposalDomain_1444" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeTerminationMember" xlink:label="loc_teva_EmployeeTerminationMember_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_EmployeeTerminationMember_1448" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherExitAndDisposalMember" xlink:label="loc_teva_OtherExitAndDisposalMember_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExitAndDisposalDomain_1444" xlink:to="loc_teva_OtherExitAndDisposalMember_1449" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1447" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1451" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RestructuringAccrualProvision" xlink:label="loc_teva_RestructuringAccrualProvision_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_RestructuringAccrualProvision_1452" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_UtilizationAndOther" xlink:label="loc_teva_UtilizationAndOther_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_teva_UtilizationAndOther_1453" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1446" xlink:to="loc_us-gaap_RestructuringReserve_1454" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceAbstract" xlink:label="loc_us-gaap_InsuranceAbstract_870" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherIncomeExpenseTable" xlink:label="loc_teva_OtherIncomeExpenseTable_872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_870" xlink:to="loc_teva_OtherIncomeExpenseTable_872" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OtherIncomeExpenseTable_872" xlink:to="loc_dei_LegalEntityAxis_871" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_871" xlink:to="loc_dei_EntityDomain_874" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherincomeLineItems" xlink:label="loc_teva_OtherincomeLineItems_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OtherIncomeExpenseTable_872" xlink:to="loc_teva_OtherincomeLineItems_873" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_875" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PatentedMedicinesRegulationsAndSimilarPayments" xlink:label="loc_teva_PatentedMedicinesRegulationsAndSimilarPayments_406930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_teva_PatentedMedicinesRegulationsAndSimilarPayments_406930" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaap_GainsLossesOnSalesOfAssets_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_us-gaap_GainsLossesOnSalesOfAssets_877" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherOperatingIncomeNet" xlink:label="loc_teva_OtherOperatingIncomeNet_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_teva_OtherOperatingIncomeNet_878" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_OtherincomeLineItems_873" xlink:to="loc_us-gaap_OtherIncome_879" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetAbstract" xlink:label="loc_teva_FinancialExpensesNetAbstract_1370" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesTable" xlink:label="loc_teva_ExpensesTable_1372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_FinancialExpensesNetAbstract_1370" xlink:to="loc_teva_ExpensesTable_1372" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesTable_1372" xlink:to="loc_dei_LegalEntityAxis_1373" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1373" xlink:to="loc_dei_EntityDomain_1381" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesLineItems" xlink:label="loc_teva_ExpensesLineItems_1371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesTable_1372" xlink:to="loc_teva_ExpensesLineItems_1371" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_us-gaap_InterestExpense_1375" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_1376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_1376" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ForeignCurrencyTransactionGainLoss" xlink:label="loc_teva_ForeignCurrencyTransactionGainLoss_1377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_teva_ForeignCurrencyTransactionGainLoss_1377" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherFinancialIncomeExpenseNet" xlink:label="loc_teva_OtherFinancialIncomeExpenseNet_1378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_teva_OtherFinancialIncomeExpenseNet_1378" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinanceIncomeExpensesNet" xlink:label="loc_teva_FinanceIncomeExpensesNet_1380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesLineItems_1371" xlink:to="loc_teva_FinanceIncomeExpensesNet_1380" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FinancialExpensesNetAbstract" xlink:label="loc_teva_FinancialExpensesNetAbstract_1383" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesTable" xlink:label="loc_teva_ExpensesTable_1385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_FinancialExpensesNetAbstract_1383" xlink:to="loc_teva_ExpensesTable_1385" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesTable_1385" xlink:to="loc_dei_LegalEntityAxis_1386" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1386" xlink:to="loc_dei_EntityDomain_1388" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ExpensesLineItems" xlink:label="loc_teva_ExpensesLineItems_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesTable_1385" xlink:to="loc_teva_ExpensesLineItems_1384" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PaymentForRedemptionOfSeniorNotes" xlink:label="loc_teva_PaymentForRedemptionOfSeniorNotes_1387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_ExpensesLineItems_1384" xlink:to="loc_teva_PaymentForRedemptionOfSeniorNotes_1387" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1580" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1580" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1583" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1583" xlink:to="loc_dei_LegalEntityAxis_1582" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1582" xlink:to="loc_dei_EntityDomain_1589" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1583" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1581" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1581" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1584" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1581" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1585" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1581" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1588" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1591" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1591" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_dei_LegalEntityAxis_1595" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1595" xlink:to="loc_dei_EntityDomain_1603" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember" xlink:label="loc_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember_1600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" xlink:to="loc_teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember_1600" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1594" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1601" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1596" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1597" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_688342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1593" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_688342" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1481" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1481" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_dei_LegalEntityAxis_1482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1482" xlink:to="loc_dei_EntityDomain_1487" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1486" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1486" xlink:to="loc_us-gaap_SegmentDomain_1484" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_NorthAmericaSegmentMember_1488" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_EuropeSegmentMember_1489" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1484" xlink:to="loc_teva_InternationalMarketsMember_1490" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1483" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GrossProfit_1492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1493" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1494" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1495" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherOperatingIncomeExpense" xlink:label="loc_teva_OtherOperatingIncomeExpense_1496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_teva_OtherOperatingIncomeExpense_1496" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1485" xlink:to="loc_us-gaap_OperatingIncomeLoss_1497" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1499" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_1499" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_dei_LegalEntityAxis_1502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1502" xlink:to="loc_dei_EntityDomain_1518" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1506" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1506" xlink:to="loc_us-gaap_SegmentDomain_1504" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_NorthAmericaSegmentMember_1519" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_EuropeSegmentMember_1520" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_InternationalMarketsMember_1521" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaap_CorporateMember_1522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_CorporateMember_1522" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1523" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SegmentsAndOtherActivitiesMember" xlink:label="loc_teva_SegmentsAndOtherActivitiesMember_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1504" xlink:to="loc_teva_SegmentsAndOtherActivitiesMember_1524" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_1503" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AmountsAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsAllocatedToSegmentsAbstract_1500" xlink:to="loc_us-gaap_OperatingIncomeLoss_1507" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AmountsNotAllocatedToSegmentsAbstract" xlink:label="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_1508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_AdjustmentForAmortization_1508" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ImpairmentsRestructuringAndOthers" xlink:label="loc_teva_ImpairmentsRestructuringAndOthers_1509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_ImpairmentsRestructuringAndOthers_1509" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1511" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1510" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1512" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_PurchaseOfResearchAndDevelopmentInProcess" xlink:label="loc_teva_PurchaseOfResearchAndDevelopmentInProcess_1514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_PurchaseOfResearchAndDevelopmentInProcess_1514" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_CostsRelatedToRegulatoryActionsTakenInFacilities" xlink:label="loc_teva_CostsRelatedToRegulatoryActionsTakenInFacilities_1515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_CostsRelatedToRegulatoryActionsTakenInFacilities_1515" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LegalSettlementsAndLossContingencies" xlink:label="loc_teva_LegalSettlementsAndLossContingencies_1516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_LegalSettlementsAndLossContingencies_1516" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherUnallocatedAmounts" xlink:label="loc_teva_OtherUnallocatedAmounts_1517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_AmountsNotAllocatedToSegmentsAbstract_1501" xlink:to="loc_teva_OtherUnallocatedAmounts_1517" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_390232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_OperatingIncomeLoss_390232" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1525" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1526" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1528" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1528" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_1533" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_dei_LegalEntityAxis_1529" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1529" xlink:to="loc_dei_EntityDomain_1536" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_srt_ProductOrServiceAxis_1531" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1531" xlink:to="loc_srt_ProductsAndServicesDomain_1532" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_GenericsMediciansMember" xlink:label="loc_teva_GenericsMediciansMember_1538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_GenericsMediciansMember_1538" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_COPAXONEMember" xlink:label="loc_teva_COPAXONEMember_1539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_COPAXONEMember_1539" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_BendekaAndTreandaMember" xlink:label="loc_teva_BendekaAndTreandaMember_1540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_BendekaAndTreandaMember_1540" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ProAirMember" xlink:label="loc_teva_ProAirMember_1541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_ProAirMember_1541" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_QVARMember" xlink:label="loc_teva_QVARMember_1542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_QVARMember_1542" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AjovyMember" xlink:label="loc_teva_AjovyMember_408213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AjovyMember_408213" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AustedoMember" xlink:label="loc_teva_AustedoMember_1543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AustedoMember_1543" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RespiratoryProductMember" xlink:label="loc_teva_RespiratoryProductMember_1545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_RespiratoryProductMember_1545" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AndaMember" xlink:label="loc_teva_AndaMember_1546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_AndaMember_1546" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherProductsMember" xlink:label="loc_teva_OtherProductsMember_1547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1532" xlink:to="loc_teva_OtherProductsMember_1547" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1535" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1535" xlink:to="loc_us-gaap_SegmentDomain_1534" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NorthAmericaSegmentMember" xlink:label="loc_teva_NorthAmericaSegmentMember_1548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_NorthAmericaSegmentMember_1548" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EuropeSegmentMember" xlink:label="loc_teva_EuropeSegmentMember_1549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_EuropeSegmentMember_1549" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_InternationalMarketsMember" xlink:label="loc_teva_InternationalMarketsMember_1550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1534" xlink:to="loc_teva_InternationalMarketsMember_1550" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueTypeAxis" xlink:label="loc_teva_RevenueTypeAxis_558204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_teva_RevenueTypeAxis_558204" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_RevenueTypeDomain" xlink:label="loc_teva_RevenueTypeDomain_558211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_RevenueTypeAxis_558204" xlink:to="loc_teva_RevenueTypeDomain_558211" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_1530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_1533" xlink:to="loc_us-gaap_ProductInformationLineItems_1530" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_1530" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1537" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1552" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1552" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" xlink:to="loc_dei_LegalEntityAxis_1553" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1553" xlink:to="loc_dei_EntityDomain_1558" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_1554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" xlink:to="loc_srt_MajorCustomersAxis_1554" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1554" xlink:to="loc_srt_NameOfMajorCustomerDomain_1555" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Customer1Member" xlink:label="loc_teva_Customer1Member_1559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1555" xlink:to="loc_teva_Customer1Member_1559" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_Customer2Member" xlink:label="loc_teva_Customer2Member_1560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1555" xlink:to="loc_teva_Customer2Member_1560" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1557" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1556" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_NetSalesPresent" xlink:label="loc_teva_NetSalesPresent_1561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1556" xlink:to="loc_teva_NetSalesPresent_1561" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_1563" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_1563" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" xlink:to="loc_dei_LegalEntityAxis_1564" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1564" xlink:to="loc_dei_EntityDomain_1569" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" xlink:to="loc_srt_StatementGeographicalAxis_1568" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1568" xlink:to="loc_srt_SegmentGeographicalDomain_1567" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_country_IL_1571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_IL_1571" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_1572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_US_1572" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HR" xlink:label="loc_country_HR_1573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_HR_1573" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE" xlink:label="loc_country_DE_1574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_DE_1574" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CZ" xlink:label="loc_country_CZ_1578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_CZ_1578" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_HU" xlink:label="loc_country_HU_1576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_country_HU_1576" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_IEMember" xlink:label="loc_teva_IEMember_809515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_teva_IEMember_809515" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OtherCountriesMember" xlink:label="loc_teva_OtherCountriesMember_1577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1567" xlink:to="loc_teva_OtherCountriesMember_1577" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1566" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1565" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1565" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1570" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1464" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1464" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_dei_LegalEntityAxis_1469" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1469" xlink:to="loc_dei_EntityDomain_1476" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_srt_StatementGeographicalAxis_1473" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1473" xlink:to="loc_srt_SegmentGeographicalDomain_1471" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_country_IL_1477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1471" xlink:to="loc_country_IL_1477" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1466" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1465" xlink:to="loc_us-gaap_SalesRevenueNetMember_1474" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1467" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1468" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1468" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1475" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1470" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1472" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_1478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_NumberOfReportableSegments_1478" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_556480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1472" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_556480" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_356" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_356" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_dei_LegalEntityAxis_366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_383" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_361" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_380" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_381" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_364" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_382" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_360" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_360" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_MoneyMarketFundsMember_374" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DemandDepositsMember" xlink:label="loc_us-gaap_DemandDepositsMember_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_DemandDepositsMember_375" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_EquitySecuritiesMember_376" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDebtSecuritiesMember" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_359" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_377" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_362" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_362" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_OptionsAndForwardContractsDerivativeLiabilitiesMember" xlink:label="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_363" xlink:to="loc_teva_OptionsAndForwardContractsDerivativeLiabilitiesMember_379" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FinancialInstrumentAxis_365" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_365" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_InterestRateSwapMember_384" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CrossCurrencyInterestRateContractMember" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_367" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_385" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_358" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_368" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_369" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeAssets_370" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_DerivativeLiabilities_371" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_372" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_373" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_682369" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_682369" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_682372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_srt_RangeAxis_682372" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_682373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_682372" xlink:to="loc_srt_RangeMember_682373" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_682374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MaximumMember_682374" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_682375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_MinimumMember_682375" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_688250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_682373" xlink:to="loc_srt_WeightedAverageMember_688250" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_682378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_682378" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_682379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_682378" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_682379" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_MeasurementInputProbabilityOfSuccessMember" xlink:label="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_teva_MeasurementInputProbabilityOfSuccessMember_682380" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_682382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_682379" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_682382" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis" xlink:label="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfFreshStartAdjustmentDomain" xlink:label="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis_764533" xlink:to="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevaluationOfAssetsMember" xlink:label="loc_us-gaap_RevaluationOfAssetsMember_764535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfFreshStartAdjustmentDomain_764534" xlink:to="loc_us-gaap_RevaluationOfAssetsMember_764535" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682370" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_682381" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_764538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_GainLossOnSaleOfEquityInvestments_764538" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_764539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682371" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_764539" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_387" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_387" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_dei_LegalEntityAxis_394" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_394" xlink:to="loc_dei_EntityDomain_407" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_392" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_392" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_393" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ActavisGenericsMember" xlink:label="loc_teva_ActavisGenericsMember_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_ActavisGenericsMember_404" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EagleTransactionMember" xlink:label="loc_teva_EagleTransactionMember_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_393" xlink:to="loc_teva_EagleTransactionMember_406" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_389" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_389" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_388" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_391" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_397" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_764522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_764522" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_764523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_764523" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_720077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_720077" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_815485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_815485" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease_401" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod" xlink:label="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod_400" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_402" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_390" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_403" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_409" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_409" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_dei_LegalEntityAxis_412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_412" xlink:to="loc_dei_EntityDomain_416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_413" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_413" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_414" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_us-gaap_SeniorNotesMember_417" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SeniornotesandconvertibleseniordebenturesmemberMember" xlink:label="loc_teva_SeniornotesandconvertibleseniordebenturesmemberMember_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_414" xlink:to="loc_teva_SeniornotesandconvertibleseniordebenturesmemberMember_418" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_411" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_410" xlink:to="loc_us-gaap_DebtInstrumentFairValue_415" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeRelatedObligationsNoncurrentAbstract" xlink:label="loc_teva_EmployeeRelatedObligationsNoncurrentAbstract_661" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_EmployeeRelatedObligationsNoncurrentAbstract_661" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_664" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_664" xlink:to="loc_dei_LegalEntityAxis_663" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_663" xlink:to="loc_dei_EntityDomain_668" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_664" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_AccruedSeverancePayNoncurrent" xlink:label="loc_teva_AccruedSeverancePayNoncurrent_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" xlink:to="loc_teva_AccruedSeverancePayNoncurrent_665" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_666" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeRelatedObligationsNoncurrent" xlink:label="loc_teva_EmployeeRelatedObligationsNoncurrent_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_662" xlink:to="loc_teva_EmployeeRelatedObligationsNoncurrent_667" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_EmployeeRelatedObligationsNoncurrentAbstract" xlink:label="loc_teva_EmployeeRelatedObligationsNoncurrentAbstract_670" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_EmployeeRelatedObligationsNoncurrentAbstract_670" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_673" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_673" xlink:to="loc_dei_LegalEntityAxis_672" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_672" xlink:to="loc_dei_EntityDomain_682" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_673" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations" xlink:label="loc_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations_674" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear" xlink:label="loc_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear_675" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne_676" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo_677" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree_678" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour_679" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive_680" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen" xlink:label="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_671" xlink:to="loc_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen_681" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_1605" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialInformationTable" xlink:label="loc_teva_SelectedQuarterlyFinancialInformationTable_1609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_1605" xlink:to="loc_teva_SelectedQuarterlyFinancialInformationTable_1609" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationTable_1609" xlink:to="loc_dei_LegalEntityAxis_1607" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1607" xlink:to="loc_dei_EntityDomain_1612" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_SelectedQuarterlyFinancialInformationLineItems" xlink:label="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationTable_1609" xlink:to="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1613" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_GrossProfit_1614" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_ProfitLoss_1615" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_NetIncomeLoss_1616" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1617" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_teva_SelectedQuarterlyFinancialInformationLineItems_1608" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1606" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1606" xlink:to="loc_us-gaap_EarningsPerShareBasic_1610" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1606" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1611" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_1637" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_1637" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" xlink:to="loc_dei_LegalEntityAxis_1638" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1638" xlink:to="loc_dei_EntityDomain_1643" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1640" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1640" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForCreditLossMember" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_1644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_1644" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="teva-20201231.xsd#teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember" xlink:label="loc_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember_1645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1639" xlink:to="loc_teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember_1645" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1642" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1646" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_1647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_1647" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1648" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_1649" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_1641" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1650" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g102112g01r43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g102112g01r43.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MKV80UA:(<)O>VX[3:=[UD=L/#NRJ^+CV1>7_ &GC_@,S_4(.0G\_Z]R]@T,
M8 P!@# & , 8 P!@# & 0"'V[7O\"_\ E&L$=\/'LR_@HP!@# & , 8 P!@#
M & , 8! +_:55_&Y7\-'\JMBX=T1WP\>S+^0HP!@# & , 8 P!@# & , 8!
M,_U^K?C[O\.6'*K8N'=$=\/'LR_D*, 8 P!@# & , 8 P!@# & 0++]G1OQ^
MJ?Q2'P1V^</VB_@HP!@# & , 8 P#PI24ZVI2M)2G6][4K>M:UK7[][WOTUK
M6O[][P#EZV^:OBM3)PT41[;339<IU(;Q-L/S]XAU,P-ZJ5;U(BTBR">9P+:1
MJ1AJ'M1$CJT1@\4.*:?+%Y,$;'?E-BP],IK2GS?N8H/\G>N7B6#URWPX[=+#
MI[7(YE>S?9Y]1X)JLT<4X'V9[16 -F)F;1T*I.M3BC%5&C @LM9B8)]#F@P*
M>-L<@(U>7&NE!7JGYVVV11RO1>M<"XZU7.M&#5PI?'.?V7JL;I7&VDU==9I$
MB^=/(TZ91[9(?B7!-KLP*CDV7(1D'' 1ALP)*)EPIHW3-Q77]2>NJ^#U B+Y
MH4ZOU+R%\C+AR:Z6J_4^W]AZ\;8<9.VUJNLRXYFE<I9Y?RVU  J*VPFI +70
MS@ZLI*V'0QMM1XFN0$W5$GN[NO7Z1DQ3P^\3!7+ZIRD?XQ>/L7F-0O%5LE6Y
M\CCG/54VO615G#I<L@>MN5Y8F!8GM;5N0=C1&RTA:EK?F.+6M6Q&W>7+:ES5
MRU,G5> , 8 P" .^W+%_B)_R2LKMAX=V17Q<>R/*_P"T\?\  9G^H0<A/Y_U
M[E[!H8 P!@# & , 8 P!@# & , @$/MVO?X%_P#*-8([X>/9E_!1@# & , 8
M P!@# & , 8 P" 7^TJK^-ROX:/Y5;%P[HCOAX]F7\A1@# & , 8 P!@# &
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MKMAX=V17Q<>R/<O^T\?\!F?ZA!R$_G_7N7L&A@# & , 8 P!@# & , 8 P"
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MJ1-F^LV2E+R4.K3L0V7@# & , @67[.C?C]4_BD/@CM\X?M%_!1@# & , 8
MP!@# & , 8 P"!9?LZ-^/U3^*0^".WSA^T7\%& 8O/I%+*I*H)U"KD4'98X@
M;1/ "9B3$\0Y'=$S2J9$1S1"6+=B17!TF7IYZ$Y&CKC+:4RWM*7J(6A0=KM?
MD+%N/@@[S@-*$A5NC(3BPZ6UQG&TBU+85L>E#D*&M&HFV=)7$C*3K2F&MH$A
M:*EMQZ!WVY8O\1/^25E=L/#NPKXN/9'E?]IX_P" S/\ 4(.0G\_Z]R]@T, 8
M P!@# & , 8 P!@# & 0"'V[7O\  O\ Y1K!'?#Q[,OX*, 8 P!@# & , 8
MP!@# & :AZ%U?EM$NO(J?=^E4&G6WH]J(BN>5:U7&NUZQWPI&KI5N2-I@0N1
MB$[1/CN3X+;\,)%G2&ES8B%MI5)9TNK/>NZ$-Q";ARX5E#J]#;V0# & , 8
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M& , 8 P!@# & , 8 P!@# (%E^SHWX_5/XI#X([?.'[1?P48 P!@# & , 8
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M @#OMRQ?XB?\DK*[8>'=D5\7'LCRO^T\?\!F?ZA!R$_G_7N7L&A@# & , 8
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M,YIYF5TWQ,YY'G<;C04R ')>K=&+UWOSRHFY]DBRCW5J,)L?)X*$34CZI,!
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MX>?L3N?*?J1$[=4W_B1,T'TL&Z= GK&PR;Y7T&"N /KGQTHBR;5JNO-!BBV
M,V2,#$'&"AF.\,4)B35%QJ)39>YUBC5>%:K>)6]4FJ>5_?(B=\Y1,^)?9L[\
M15A ';0*;+5NUA'G059^.MG)TEDP#@NC=0$5XPZN.21#EO,1/A$:.\Q(BN/W
M9>F<75W'E#:5*WF+Y7/J&]UXT7T%W Z=2G-V((8LH-#Q\?#=)U^ON%VCIF*U
M,>CNN#0Z@!O9.7[&F82!4]V0MMN,ZM,V<2R=XM2=)M(VEK?M/AF0C^E<Y+I&
MK%7^DDT&1\XL(6/M0*:DJ*&.3FB1,:J-/=U.'CW1A)N=-B[=C1'!\Y#[K:HC
M^FT/1\GG;G*$K5<S!.C]DY]2R/(_C>PCE,7F_LU\/+AS8LJ-IR:!LL%DD^^T
MZII E)C<$-(G;7[B/.(QFW%Z]'-)J3>U1T7=$;7XUS[-=S.YW2N=#'&F2%\I
ML-]\04/QX\BS!FI,D&$9GR#)B+&5-T_)&"F!1-TC-8;<C0T#IRI#C>HK_NY#
MT=XL[NRXLLK5:WRU,59[YR29L9H5;V3_ ,=5DW< ZZT)/65HK7J]LR@K-'O@
M19!B4XR]7C$6/ :=41(3(>X0^)*E/QF7J\.)3*B*.8I,>4-I:WK9[_!^6.RP
M"&ARPM ZT88+54Q:X4EOGQ8+'V@1LRA "8Y:]U[XKLYAX,MD,(+:@JE?&(>4
M\]%@$69>2-ZO%T_FDRN$B=SY>Q\P>6>@=$(Z@."^(V>-&(5(L<]]:+51P;HR
MQQ-F$"J88A#C=BFL32[D :M9@>P4#CHAR,\](=D0Y\./82G\DVG%$W*I5-QO
MY"72FMW;3GT/#93O!'X$XW3^9UIJ342DB:T4NMAL,X5>O4NV$&(:%U$5"+5G
MU:"22Q5)$822W-(Q80UQR"Q)FS\=7?10USH[Y:6'Y:)4ULZZ75@V%[G/^"*(
M7WGP'2Z@1@DH]?H)<FXW=I.RC8\^+('+@EM(,6VZ'?4!G"9$@C(B3VW"L9B:
MQ\#?CH[YM6T:B^^1^6JLYIGER]O0CG5[EZBZ.=NNCR=5"=72+%? T:ML3#<[
M9!/RUC.ZKA0F--P69<1(Z$T2=!L/#&)#XV4I^6AY*RPJ\U;?QI7.1#S;MDDM
M:_7((XL%>U'T:N?5;$ANH3*9+9)](LT.(4@S]S=2RY"!7I8.!NT+:G+89LD.
M-#*PVH\/X#(C.1D.8G<KS;I6:;K"-[M%^O'>>QC@O(67(SSU(&E7HM3?HJ'[
M#))V9YZI2E2E2PDYZPSB;A*++^&R4RU$%2I$IMSW3[SC:&T(;3UBLTI7X&RM
M,H^/<[F8"^?T,)J)H-2JD)U $H P?BVN!X/P,&A3JT!HNXT-K; I*WWUI'M>
MS$TMYU6F?:<7M1MN[;SJ\]1"5DE\&6(0AM"6VT);;0G24(0G24(3K7II*4IU
MK24ZU]6M:UK6M?NR%/U@# (%E^SHWX_5/XI#X([?.'[1?P48 P!@# & , 8
MP!@# & , @67[.C?C]4_BD/@CM\X?M%_!1@# & 0!WVY8O\ $3_DE97;#P[L
MBOBX]D>5_P!IX_X#,_U"#D)_/^O<O8-# .<.M^(OCEVXDU8N@<KKTFZQ5>\'
M=(K:I]%ZB*>2CV6GAG2Z1,K]WAJ9WZ*;:;._!MJ3KWC#B?5.[+6?CD(\;^9I
M_P"8/RTY+_M>"^4R^D@8^O5CF7EZ W?$;2K_ 'V!_;Z*FL]-'>RG6DQY-M'=
M.=;WZ+>;D*TYIY3-:U7BW*"5R:?'LUW3XCZ8E\YEZL>4OB_U;E<*/_6NG<J8
M<\C>-)8;_H.DYQ;GHQ'3*M!4YKV_:MO*Q,>,VK7OR"M)TZXA73^'1_OX8EV:
M^55>5\\SIOE7<>.=R#;L''NGT?I(IO2/A4BGV06;=&N+^K48Q!AR7)X6:G>M
MI<@EHT.8TO6T.L(5K>L--7":=C:F0HP!@'PRA8R<ZP]-'0)CT;:U1G942/(=
MCJ<3[#BF''FUK:VXC^@O;>T[6G^BKUU]6!"T]];,*5R/E>WPLE/-Z,U)K;Q"
M17I,>JA(T@$^63I)5X0_'A-.C7"6M:^'+AK95+VE*G]K4E.]676KK>M^.I(5
M**EB"-X'R<)\FD@JLL U3W"[U=C ;!9PT(>X=]/C16X PS%@SM2%:2M"",>6
MW%<0AR(AA:$JU=IN9<S>4F39PZ:YO.AX&\8%A?DTV(O76H<6L*,*C0Y'2+"=
M8*:,:5[2+ JS/FY)IL:M6EAFYDA:1NT)0SKW.W&EQXIFBK%DE$:1:<RQ:KIO
M?7@<F7[AGD"SVWD]FJMY(6L/SR._% F[Q<!$6RS8]BF2=],07A!N<,BYBI-8
M?&AZPIOX)J+.#1215)-7LMHVL6'9::B;I)Q2T?EK><I2N9:>TG,Z2^>5)2:I
MQ.M!O)9T7Y-K)==Z\>?KR3.GW9UA!CD6/9C3NM;L,6MU@'%E?%"7MI"_!&H*
MH?L,N.JDOM(>UB;T2G=:-);^9F<R[._%S_7Z [B%1A_)Q<TUTBQ2:LV:;'2[
M'U*_DWY6CWOTSMFT*L+48_MMJ0ZP.T9CS4B6=H0-3%]TUM#:=52NB7&\3U+L
MVJZ:MZ1[XH>1O N0"MUM<>D#Y#M1;-,UR26F%CLL6W8OA'QVAJ8;($)3VB.I
M<E$C<EY_>VGW6D[2VO:,;3K6\=";.'3UEX/R3EE>:#,@^;T02W76R#0#4"I@
MHR@K19;KA5 IQJ"ER DFX\\LAJ*IKX:MUQ4GWNUJWLVW=MS>6ZEA:+EK<RX>
M#""6H[ H.+&,1$N)BLCQ\2&U&2\O:W4QVXS+:&4NKWM;FFTITM>]J5K>]^N0
M0M%[_P!?,J8*, 8 P!@# & , @%_M*J_C<K^&C^56Q<.Z([X>/9E_(48 P!@
M# & , 8 P!@# /ED084O?K*AQ9._=.L>LB.T]OW+[:VGV?5Q"M^Z>:<<;=;_
M -QQM:T+UM*E:V!CKU"HTA<=<BF5-]<0?/$Q5O5T.ZN,**MS&B@R.I<-6V1Y
M)HB0;GPF]IC3&YTQ$AIQ,E_2[+U?,D+19];\\SF3L7A]R/HY6E+VS.I$. '/
M<^B":$(H @5'KQ^+8SI5$2*2I!I4";)G/2EHECG8BHNYQ&1#0Q.GRY;VL.)I
M/G5N\I:Z&7A3:RRIP;.E*]SRD5:"%@A*I6H"  M0<8]"KH$:[%@/*DNS&(S8
MH; B0F2$J;.F38HZ-#A/2I\UW45'PAQ.\MMS5UJZOOW-))12V>9F24I0G24)
MTE*=:2E*=:2E*=:]-:UK7IK6M:^K6M:]-:_=D*>< 8 P!@# & , 8 P!@# (
M%E^SHWX_5/XI#X([?.'[1?P48 P!@# & , 8 P!@# & , @67[.C?C]4_BD/
M@CM\X?M%_!1@# & 8V)>0\<LWL:=U[IX8RKWK#['JMN'OVMM^_;;]\UOU_H/
MM>VPY]?NW%>F_2NV'AW9%?%Q[(]R_P"T\?\  9G^H0<A/Y_U[E[!H8 P!@#
M.9.J^''C?V(SJVVSF0H;T)K:W(?5*#,*\RZO D[]-MR8_2.?SJY;W%,.:2ZW
M'F%I<%2];T]$=;<=;74VN&EUR9&D[KSS-5_,GYC<D_VG$O)D9V2N1];U'YOY
M<UW18HEG?]-3 WO',88&WQW$[U[IB3<Z5T:3[M?K(DO+;]M9M/)+A\9!)K.>
M->-:=X'TT;#S;_R_E1XV==X<PS_6NC5" OR!XDAK_<U,D7;E\"9;*U#<=UO6
MWKYSFHL1T*;7(D)0K:](T:=]WWKHI$ZIKK]9;W!U1S/L/*>S@46?DG1Z3TD
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M/9E_(48 P!@# & , 8 P!@# & , @67[.C?C]4_BD/@CM\X?M%_!1@# & ,
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M0'A'4'::>I7BQ#FU6CUF[C!]:/V*S.WJ=8W>F!]_$&KU8N1%E.;8K>X,RM!
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MYM=4_B.[^O@?)O\ :/BOZ$7KGAK<&D_N6;X5V2GS'=:_^IT-W>RQ&MJ_OVF
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MN_36M[WZ)LX=2M_5_=I.M[WO]VM:WO?U:P1V^</VB]@HP!@# & , 8 P!@#
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M3\RDQ80!\;7R#! 5M^9,<)H@2CE?.B<I4XST2?OQODFZ5R7%MTZ>Y1VSD-C
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MDN+0]/V5QD^D>3...>5%=ZF[U=@A7Y-43Q^N<^MEF-(*-6"IO!^A4'YPHS,
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MLPVI-;9.M$)LQNL-3I 6$<D++/((:_\ )X]]]X#WW_AU> H3M7Y:/YQ7K ^
MF"J6U4Q=O#" S9$;-BA4B(5HC""D4P!?+176V2GP8I!(BY4YKV9L*1#<<C*
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M[7WXLS$ZEXTPJ/>K'T:GVINCV&^VFB'>E0J'3:X J]Z&443;X+8@B"(MV!4
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M#YY>O_>MTG\\VC]4P!\\O7_O6Z3^>;1^J8 ^>7K_ -ZW2?SS:/U3 'SR]?\
MO6Z3^>;1^J8 ^>7K_P!ZW2?SS:/U3 'SR]?^];I/YYM'ZI@#YY>O_>MTG\\V
MC]4P!\\O7_O6Z3^>;1^J8 ^>7K_WK=)_/-H_5, ?/+U_[UND_GFT?JF /GEZ
M_P#>MTG\\VC]4P!\\O7_ +UND_GFT?JF /GEZ_\ >MTG\\VC]4P!\\O7_O6Z
M3^>;1^J8 ^>7K_WK=)_/-H_5, ?/+U_[UND_GFT?JF /GEZ_]ZW2?SS:/U3
M'SR]?^];I/YYM'ZI@#YY>O\ WK=)_/-H_5, ?/+U_P"];I/YYM'ZI@#YY>O_
M 'K=)_/-H_5, ?/+U_[UND_GFT?JF /GEZ_]ZW2?SS:/U3 'SR]?^];I/YYM
M'ZI@'6_@=>+K=_,#Q^ 72WVBW G.AB9[@6SV L?$KG"4ODA4U8XK+EPU2QA&
C+&(#Y*F=O0YL=B5&6V^RVXF8K/@_HN&ZXK[/]H&<#N, _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g102112g0203043727908.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g102112g0203043727908.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ %H# 2(  A$! Q$!_\0
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)<[K3E)6N?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g102112page186a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g102112page186a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MNI VH7&<;R,>BUHJ4>QG[:?<O?*6+?[1QQ[_ /ZJY4=Y&V-^02./IGT_K0
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MV92&9!/&0#WIVL)D,CKUQGOS5)$2&;QZ-QQS3L2]!?- .#VXY-%A<R0--G!
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M/;FIL5<D\T 9ZD>M*Q2D,>3T.1W-%A.1"TA/2J2(<A@?/TIBO< QSUX^M A
M['.>..E  K8&.G/% $@<G)W''I05S"_,1D]/:EL!(L9Q_%FBY=B9 0#CG)R!
M4-HJ),JU#9I:Y(B\XZ9_"DV-*P\,1\O//3-(8PGL"<>E *Q'+ 6(]AZ]:<9$
MN)1DB?=@C@=\UNI:&$HV()&!4XY]!Z4T9L\[UM)([R0%6 SFO7I-..A\]B(M
M5&VC' ///'ZBMS$;GGDYH(%[<' H :<Y!!-!2%&<D'% ^@A ^E D-P3W- ,3
M!Z=A0)!@\ T#%R0<<4 +M)YSQ0 <D8'6@!>GTH %[^E R16*GOB@-B49(!S^
M% FA69\Y'!I,B[0]9?N\G(J;7#<L&_?:$ZXH42G4TL0-(TAZG/\ *JM8F]Q.
M2,$TQB E(R0V>U "H[\=3]:D-C1LIY0^.@QFLI1-Z-1W.EM+@@8R<8KEG$]6
MG.Z-2!RP '0]:YI:'7%E_. ,9%9&]["F7/?&:+$N1$SD'C)XZU2)<A4D/&XX
M(H8TV3QLV[KGV(J'L4FVPEPH..*2*>AF2WHA<C=6\8'/*K88-311@G\Q5^S?
M8SE7<78ZAF*E]V2N\GGIUKQT>^Q6;:<'H/7_ #_G% &=K6C0:]IPL[F65(A,
MLNZ,C/RGCKVS33L9U*<9JS9D2^!;.:)HYM4U*2-Q\P:8$'\"/\XJU4<=D<ZP
MNEG(4>";6-0HU/4T Z#S@,?I3]K+L)8115N8#X+M_+/_ !-=37/?[1T/Y4*H
MWI8:PB6TR(^!;,R13'4]0,L8^5S+EE!!X!QGU_*G[62TL)X2/60\^#8F96_M
MK5.F,?:.W7M2]J_Y0^IQ_G&1^!K=))676-261\*[^<-S8Z9(^OZU7M7_ "D_
M4E_.2+X+B$BO_;.J'U!G]C[8J?:O^4/JD7ISC(/ MG#E8=4U*,9+%4F Y/?@
M>U-UI-6L..$4&_>-70=$M]!:[6"::8W+B1VF()! QUJ)2<E9G11H^RU-7+ *
M#C!.,D9YJ3:]R+43C0=4W'_EW?M_LG^N:JG\:,ZO\.1XI;RO$B?-@8QQ7U,E
M=GQ%[&U;7"W2JF[[HY%825CIA)3T96U6>-T$<?(7O3I$5JD2C!;O_K5Z)S6Y
MSV<M47+5(Y"JRCECC%8R+B7EL(D5E5 ,]*GVAT>Q,A[1Q<;5'4XK=2.1QDF=
M/H6G&&)C-C>3^E<>(J'I82E;4W@$4A0.E<=[ZGH[$J8)R34L:)@N2-IRHXXY
MI%HE1L\K@CL!4LN)*,!<EN.M2RAZX')QC'6I&B;?@;F."?>D4.4A1G//O2*'
MEU4<YQ]*DH9*P*;<_-UQWIQ%(Y^_MHYV8%02/S%=M*=M#@K0C/1'#7VFSQW3
ML4")GANU>E"=XGAUL.XR9/I&C"^E9FD_=J>0.]15KJ&@\/A75>ITD.E);8\H
ME1_.N+VK;U/45!0T1:1-S J!CUQ0S4;*X3'H34@/B<;,&A@/)V*<GG-2 I)&
M2.PH*$^8,1G!'M0 \,00,\XH%S#Q)MQD]O2@KF'!\@!>E ^8C+!RV#QGH* O
M<=GN/NT"8S=N (Z8_"@0@(Y.<"@"0Y'RD#'44#0@; ZXH&2#ID>E2!;B 48J
M)&T8EL1J5 '>LN8VY1 I#\9&.?>@?*2J"&V\@#_/\JD:5A3M*X!YZ<'_ #[4
M )DC<.<CL*8R)R=^X=J9FMQ%(&-O 'OZ4#&R#<,<_6FC-JY0FC^;!Q]:W6QA
M*)S^MZ>L\$C(.6'-==&I;0\_%4[QN<)-"T#;7&#GI7HGCD>SJWH*H.4%7D>A
M%2'*-((R ,BF@M8:-N<\BF(4;<Y- QK8!XZ4"8@7T(S0)"E<GD8(H*# SG\*
M Y;"D #.* &@8(YH%$D4#9GMWH+Y1%(S@C@GGVJ1+1BDAN^<=Z:%/<DCQ@$_
MD*&)$F[YN.GK2*5NHQE4ME#QZTT$DGL';.<4S-Q'KM"YSS0RN6R)%X_E4B0A
MSG!]:!2';'9_Z4 O>-.VM]I"\+@5A*1V1I<IL6RDH.>E<\CLI&Q;?*OI[USR
M.Z)<:7"8Z>]9)7-&[%8S$G'0=/K5M6(3N6$PQ! Q2&3",$\#CZ4F:+8L1H%<
M @^N*AEQW"<;U/MS26@Y&)=632.< XKJC(X:D2@UITR,\>M=<9:&=:/OOY?D
MCNLD[\#C<>?QKYQ'TC%_BQV^N/:@"GJJ6DEO%%>.466953#E27.[ _G45*2J
M1LRH5W0ES(B71+(L,"?(./\ 7-UKE^I4TK-OY&_UF4/=*]MIFFWL7VFUDE>,
MLR[A,_W@V"/S!%'U.ET<OO".+DT3?V'9JO\ RV SC_6MQ^M"P4%LY?\ @3#Z
MW*6HT:'9[LDW XZB9O\ &G]4C_-+_P "#ZW(:=&LMPB,T^[&X*)VSM&.>O2C
MZI'^:7_@0?6I#FT:TCBD=Y+@(@)8B9CP._7TI?4X]Y?^!,)8J4?>%32;&6..
M5)9V20!D/G-@@CCO2^HT_P":7_@3#ZW(4:):*%.)_P#OZW!Q]:/J=-?:E_X$
M'UN1;M+*.RW>09"K'.7<G&/3/2NBC25+9M^NIE4J^T6I,VU0O) ZDD?Y]:V,
MQFI?\B[J>22/L\G_ * :NG\:,ZO\.1X<F?*7..GY5]3+<^(3M<G@+Q@.<J#P
M#V-0PMU-BU1&M78@%CQVJ);HW@H<C[AY:11[>H/:C8DMVU@FR-R"#GBL92.R
M%**BI#Y+"XGNU$?RQJ.F*/:1C$<Z,I2-=+!4105'J2>M<_,=<*7*6$39G  !
M&>*DT)=_88J6 _HV>,"D]@6Y;7:0"<$#J*R-D*,YSQ["@9(JDD=/4?Y_&DRH
MDRC:>?PJ2T2*2N 0-QI%#\;7P./Z_P">:DH.,$#OWQU'_P"J@9#++@8 .!Z?
MY]:J*,Y2,N13U'7TK<Y7N59K9)H]K@%1Q51G*.Q$H1EN+;V\5J,11@+CTISF
MYN[%""@K(M%6<J<8[$5!9&L9+D8IIV$U<AFC!&3T!XJXN[(DK(;$PVGC'/<5
M3V)6Y*0W3'/O69H+@[A@4 )@[B. >E #L8],^E  << 8)]/2@ )P>,8^E #M
MV,YY[?2@!"<KQT% #0W&>U  #U&,"@"11QDX_F*  ' P2 : '[P1QC-246(F
M;=C'3KGBHD:Q+B'/R#UYQ^IK(W)N06*#T_.I*'*!VP$ _P _I2*0IVD?, 1W
MH$R*3=A_Z52)97D4YSU&.*N)$BL=ZX(Y'8GO_D5=KF;=B2&0N"&Y-'+8<978
MDJE\,1^?:@4BC<QA@PZCI6T3&1QOB2P,;+(BC:..F*]"A(\?%T_>YCFF4],5
MTG&OA$^?' '% +8&#;\;>V:!/FZ";02.E-$N_4 /FQBF%[#203Z"@+W$(Y&T
M8I,%?H.P0??WI(?O# .Y JA#CSR !4E<PX_?^[0 T<\8P* '8.TD;>/>@!,
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M@<DJ!CU]:DZ-B#4@%\/:H>H,$A_\<JZ7\6)E6_AR/$8\")01U%?5O8^)B[7
MLI&W)]J0F[DB2E<;>M)H$6H92S DU#V%'<ZZR(DC7(SQQFN&H>W0^!&DL:JO
M QFN<Z"5L, .F?RH*(Y,%,8Q]::)*QD7=W'I5/<5[%B*3<1GL<BI8)W)P^"!
MG']14,I.Q.C[F )PW:I9I>Y90A%X SVJ6:Q''._ []:0V2I@+QC/TK-E1)."
M01CC&:18[R\= -OYT 5G7=NR0%]36BT,Y%*8#..".U:HQD5@F!G/'>F96N6(
M8MW)  I-V+C$L"'!!)_QJ;W-$K$4@PV1C/:FA2*QQG+?E5$,CV;23USTIH@
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M2#F(#.2<=NM4D9.1&3@''U]Q56)O<CW%4X/ H2$V,+8P>IJK$W&%L)D'GTH
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M'T$XQTH$&"&! H%J! SDCF@+B' Y Z4#$(]L#TH ?SMP.*!B8.WGI04A#C
M6@AZ"CCI0*X8 .,$F@!P(##Y2*!!R#TZT -).: &D\=2* $)P0<4 M!RL.>.
M: L*I^;[O'UH"Z0]2 < 8'?FF.]T6(9VC7 _//:H:3!-QV SL7R,_C0EH%WN
M:NG7V'"G[OH:RE&YT4:C3.CBF&P$ #/KVKDDFF>K&2:T)P^3QUJ&G8M2+,+C
MH>M0:IH>YW 8XJ; 1^9^E:I*QC*33.I! D<@8R2?3'^37BH^CL.) QR3GE?Y
MT!80/EL].W7OG% ;"C"@[3U[8Z_Y- @SC(S^'Y]J 0;PN<Y')!XZT#L- &""
M<#H<C\*!#@3@ YQCGV_R:"AV%/T'(H)&GDX'3'Z?YQ0.P%\A3C)Z'VZ_UH$-
M]<#!!Z^_7K0%QQ?E"!DXX_"@"IK!QX9U4YS_ *-+V_V*NC_&B9UE^ZD>)1\1
MKG.,=37U74^(4=+B* #UIHFR>YJZ)!YERQW8(&<5A4G96-J%-.5S>%OB7=*V
M?05S\R.YTT]RP!R,=:S:N;>19B8@9]>U38NY('4A001QQ4ZEW'_+C!Y&>YI@
M]1H&'SG(!H)M89DYY/'- #T)!!SBDV-.Q/$1A03]:AHT)]QC(P>OK2*3)1,=
MOL?UI6'<M0L&&0<5E(UB.\T[L=..*5BKCO,.2,]J=@N(' 7!YQQ2L%R-I5P.
MV?0]/\XJDB;E>1\KG)R/RJC-O4B:3;@=1]:I(AC Q&,G\<T]A#"^T\]^M-"9
M S9P<G\Z8AC >O>FA,0#''4U1(A(Z4 "@D]<8IW%8<.>O2D,D5!C).,>] ]!
M2 ,<X Z4#' 94'(R/UJ6,< =N<Y]J0$9.2/\XH 3)#<&@!P)+@<GB@$2IP<@
MG/O2N4/!Z\\^](!2QZCKWI6'<D5ONCVI%7)8W/&212L4G8G20^6QYQSQ6;6I
MJI:$BR9SD=^!G_/O4M%*1)&PVE2<D<8]J5BDR0OT/.[ODTK6'<,Y.3P!S]*+
M F!?#=/J?_KT6'=#MPW'<?\ Z]*S"Z(RZ\DY)]*JQ-T1N^T?*1GN:+,BZ(BX
MX _G6FH:#0..<C/IVIDZ$,@![?A5(AE.:(.NUN1G&*N+:U1G*":U.?U/2+8(
M\GEX8]Q771K2O9GGU\-!JZW.6_LV1E)3)P<8-=W.CR_9/J5983%(5;KC\J:D
M*UM&,VXY XIW)>FQ(5Z;2![47*:T(V7D47)Y1VPXSDT7&U87RBX+<DCBBXDK
MB-WSG HN.VMAN&Z#ITHN.U@"D# )HN1),-FTXYY/4FA"2%VD,2*86%VG!.[G
MT]*"FE;08<C! .?2@BPA'(H&D(5!'&2?2@&NPAZ<F@=A,8^Z<_TI7'RH4''7
MK3%9#U);*]*5Q6)$7C!)%(:7<>,+V-%QI*]B6-BO"T)"=XO0V[>_980,YQTS
M6,H(ZZ=9Q5B]!>@X ;//6L)0Z'1&M=FG!,6 .ZL7&QV)KH63*I7((Q46-+D?
MF'M6BV.>3U.U-J^6.02>G:O#N?3A]E?LW/UQBBX#39R%=H9>N:+BL.:V<L,$
M =S1<+"&TDYPP />BX6L#6KEAR O?GM1<8TVLA) (4?G1<5A#:2[CA@,GUZ<
M?XT7&2_9V&1D=>!1<5A/LK@CD8':BXP^ROGE@>,47%8!:R!3A@6/>BX6%%LX
M[C-%PL5[^PDN-(O;.-@))XF12> "5Q54YJ%129G5A*5-QB>?0?#G5%P))8"
MH'WS_A7M/,:5]F?-1RNNM+B#X<:H"?WMN1GCYS_A1_:-/L#RJL^IHVW@S58%
M^4VX8#&0YY_2LGC*;-J>75H*Q*GA36=RF1X"!V\P_P"%+ZW2-%@J]RR/#6I
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BQ]M3[F_U:LNGXC!I.HD?\>I&/]M?\:U5:G;<YW1J-['_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d102112d10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:teva="http://www.tevapharm.com/20201231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="teva-20201231.xsd" xlink:type="simple"/>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="P10_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2019To09_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P10_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2014To12_31_2014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2009-01-31</instant>
        </period>
    </context>
    <context id="P08_21_2017To08_21_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2017-08-21</startDate>
            <endDate>2017-08-21</endDate>
        </period>
    </context>
    <context id="P12_17_2018To12_17_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2018-12-17</startDate>
            <endDate>2018-12-17</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2005-02-28</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2008-07-31</instant>
        </period>
    </context>
    <context id="P04_01_2013To04_30_2013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2013-04-01</startDate>
            <endDate>2013-04-30</endDate>
        </period>
    </context>
    <context id="P09_01_2013To09_30_2013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="P12_01_2010To12_31_2010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2010-12-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="P08_01_2012To08_31_2012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2012-08-01</startDate>
            <endDate>2012-08-31</endDate>
        </period>
    </context>
    <context id="P11_01_2009To11_30_2009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2009-11-01</startDate>
            <endDate>2009-11-30</endDate>
        </period>
    </context>
    <context id="P07_01_2015To07_31_2015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_StockOptionsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:StockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:OmnibusLongTermShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsExpirationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsExpirationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsNoExpirationMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsNoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:ProAirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:QVARMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">teva:StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis_HedgingOfRevenuesTwoThousandAndTwentyOneMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">teva:HedgingOfRevenuesTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EagleTransactionMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:EagleTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_Amendment69ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:Amendment69ToInvestmentLawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AlvotechMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AlvotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">teva:DevelopmentZoneaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:SpecialPreferredTechnologicalEnterpriseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AustedoMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_LenalidomideProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:LenalidomideProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_LenalidomideProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:LenalidomideProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:SpecialPreferredTechnologicalEnterpriseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2020TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OtherDebentures2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2020OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ActavisGenericsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:ActavisGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SettlementOnAccountOfProductLiabilityMembersrtLitigationCaseAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:SettlementOnAccountOfProductLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RevaluationOfAssetsMemberusgaapFreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis">us-gaap:RevaluationOfAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_StockOptionsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:StockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:OmnibusLongTermShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:ProAirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:QVARMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">teva:StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2005To2007MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">teva:TaxYear2005To2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_EagleTransactionMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:EagleTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DiscontinuedBusinessMemberTEVADiscontinuationOfBusinessAxis_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:DiscontinuationOfBusinessAxis">teva:DiscontinuedBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_LenalidomideProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:LenalidomideProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_LenalidomideProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:LenalidomideProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ActavisGenericsMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:ActavisGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:OtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:DistributionServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_StockOptionsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:StockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:OmnibusLongTermShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AjovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AustedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:BendekaAndTreandaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:ProAirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:QVARMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:NorthAmericaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:RespiratoryProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:EuropeSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:GenericsMediciansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:COPAXONEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">teva:StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_RegeneronMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_JPsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">teva:SegmentsAndOtherActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CorporateMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">teva:EosinophilicEsophagitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">teva:EosinophilicEsophagitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">teva:EosinophilicEsophagitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherComprehensiveIncomeLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentTradingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetRevenuesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:NetRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AlderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-08</startDate>
            <endDate>2018-01-08</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_AlderMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AlderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:OtsukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-12</startDate>
            <endDate>2017-05-12</endDate>
        </period>
    </context>
    <context id="P07_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:OtsukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CelltrionMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:CelltrionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="P07_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2016To09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2016To09_30_2016_RimsaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RimsaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2015_TevaMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">teva:TevaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DemandDepositsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">teva:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_Customer1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">teva:Customer1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_Customer2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">teva:Customer2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ILsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DEsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CZsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_HUsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_IEMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:IEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsExpirationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsNoExpirationMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsNoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsIndefiniteMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:TaxCarryforwardsAndDeductionsIndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeniornotesandconvertibleseniordebenturesmemberMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniornotesandconvertibleseniordebenturesmemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">teva:SeniorNotesAndLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">teva:SeniorNotesAndLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:PreferredTechnologicalEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_JanssenAndMillenniumMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">teva:JanssenAndMillenniumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2020OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2020TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OtherDebentures2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeniorNotesDue2020MemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">teva:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MaximumMembersrtRangeAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">teva:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ModafinilSettlementAgreementMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:ModafinilSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DemandDepositsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_Customer1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">teva:Customer1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_Customer2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">teva:Customer2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ILsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_HRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DEsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CZsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CZ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_HUsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_IEMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:IEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_InterestRateSwapMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeniornotesandconvertibleseniordebenturesmemberMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">teva:SeniornotesandconvertibleseniordebenturesmemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">teva:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">teva:OptionsAndForwardContractsDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SubsidiarySeniorNotesDue2021TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:ShortCreditAgreement2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_SwapMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:SwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">teva:SeniorNotesAndLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2026OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2023OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2020OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2021TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2020TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2022TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2028OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2024OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025ThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:SubsidiarySeniorNotesDue2025OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherDebentures2026MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">teva:OtherDebentures2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To09_30_2020_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_RegeneronMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RegeneronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">teva:FinancialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_Customer1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">teva:Customer1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_Customer2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">teva:Customer2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="P06_27_2018To06_27_2018_JanssenAndMillenniumMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">teva:JanssenAndMillenniumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-27</startDate>
            <endDate>2018-06-27</endDate>
        </period>
    </context>
    <context id="PAsOn01_31_2009_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">teva:AndroGelRateAtOnePercentageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-01-31</instant>
        </period>
    </context>
    <context id="P05_01_2019To05_31_2019_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:NationwideSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-21</endDate>
        </period>
    </context>
    <context id="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">teva:OpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-21</endDate>
        </period>
    </context>
    <context id="P01_01_2018To03_31_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">teva:PgtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">teva:SeniorNotesDue2023TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="P08_02_2016To08_02_2016_ActavisMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:ActavisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-02</startDate>
            <endDate>2016-08-02</endDate>
        </period>
    </context>
    <context id="P10_03_2016To10_03_2016_AndaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:AndaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-03</startDate>
            <endDate>2016-10-03</endDate>
        </period>
    </context>
    <context id="P01_31_2018To01_31_2018_AllerganPlcMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">teva:AllerganPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-31</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="P03_03_2016To03_03_2016_RimsaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">teva:RimsaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-03</startDate>
            <endDate>2016-03-03</endDate>
        </period>
    </context>
    <context id="P09_01_2018To09_30_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">teva:PgtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2016To12_31_2016_Amendment68ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">teva:DevelopmentZoneaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:Amendment68ToInvestmentLawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2016To12_31_2016_Amendment68ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:Amendment68ToInvestmentLawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2016To12_31_2016_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredEnterpriseMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:PreferredEnterpriseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2016To12_31_2016_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredEnterpriseMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">teva:DevelopmentZoneaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:PreferredEnterpriseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2016To12_31_2016_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2017To01_01_2017_Amendment73ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">teva:DevelopmentZoneaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">teva:Amendment73ToInvestmentLawMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheAExtensionMemberusgaapLineOfCreditFacilityAxis_TracheAMemberTEVATrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">teva:TracheAExtensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:TrancheAxis">teva:TracheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="PAsOn06_29_2010_TwoThousandTenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-06-29</instant>
        </period>
    </context>
    <context id="PAsOn09_03_2015_TwoThousandFifteenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-03</instant>
        </period>
    </context>
    <context id="P04_18_2016To04_18_2016_TwoThousandFifteenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-18</startDate>
            <endDate>2016-04-18</endDate>
        </period>
    </context>
    <context id="PAsOn04_18_2016_TwoThousandFifteenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-18</instant>
        </period>
    </context>
    <context id="P01_01_2018To12_17_2018_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-17</endDate>
        </period>
    </context>
    <context id="PAsOn07_13_2017_TwoThousandFifteenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-13</instant>
        </period>
    </context>
    <context id="P07_13_2017To07_13_2017_TwoThousandFifteenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-13</startDate>
            <endDate>2017-07-13</endDate>
        </period>
    </context>
    <context id="P04_01_2019To04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheAExtensionMemberusgaapLineOfCreditFacilityAxis_TracheAMemberTEVATrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">teva:TracheAExtensionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:TrancheAxis">teva:TracheAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheBMemberTEVATrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="teva:TrancheAxis">teva:TracheBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn07_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn02_01_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="PAsOn06_11_2020_TwoThousandTwentyPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_OtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:EmployeeTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="teva:ExitAndDisposalAxis">teva:OtherExitAndDisposalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReservesIncludedInAccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:MedicaidAndOtherGovernmentalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:OtherSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:TotalReservesIncludedInSalesReservesAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_InternationalMarketsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">teva:InternationalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EuropeMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_RestrictedStockUnitsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">teva:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">teva:ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_ILS">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="Unit_CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Segment">
        <measure>teva:Segment</measure>
    </unit>
    <unit id="Unit_Lawsuit">
        <measure>teva:Lawsuit</measure>
    </unit>
    <unit id="Unit_CHF_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:CHF</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Employee">
        <measure>teva:Employee</measure>
    </unit>
    <unit id="Unit_Number">
        <measure>teva:Number</measure>
    </unit>
    <unit id="Unit_Y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2020To12_31_2020">false</dei:AmendmentFlag>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis"
      id="hidden17703734">2021-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis"
      id="hidden17703735">2022-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis"
      id="hidden17703736">2023-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsNoExpirationMemberusgaapTaxCreditCarryforwardAxis"
      id="hidden17703737">2030-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis"
      id="hidden17703738">2029-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis"
      id="hidden17703740">2008 2009 2010 2011</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <teva:CreditTermsToCustomers
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis"
      id="hidden17702468">P30D</teva:CreditTermsToCustomers>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2020To12_31_2020">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2020To12_31_2020">0000818686</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2020To12_31_2020" id="hidden17704910">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressCountry contextRef="P01_01_2020To12_31_2020" id="hidden17711877">IL</dei:EntityAddressCountry>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2020">us-gaap:OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2019">us-gaap:OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="P01_01_2020To12_31_2020">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="P01_01_2020To12_31_2020">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2020To12_31_2020">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2020To12_31_2020">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2020To12_31_2020">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2020To12_31_2020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2020To12_31_2020">001-16174</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2020To12_31_2020">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2020To12_31_2020">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2020To12_31_2020">5 Basel Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2020To12_31_2020">Petach Tikva</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2020To12_31_2020">4951033</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2020To12_31_2020">+972 (3)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2020To12_31_2020">914-8213</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2020To12_31_2020">Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2020To12_31_2020">TEVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2020To12_31_2020">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2020To12_31_2020">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2020To12_31_2020">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2020To12_31_2020">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2020To12_31_2020">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2020To12_31_2020">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2020To12_31_2020">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="P01_01_2020To12_31_2020">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="PAsOn06_30_2020"
      decimals="-7"
      unitRef="Unit_USD">11830000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">1096511852</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2177000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1975000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">126000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">135000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4581000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">5676000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4403000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4422000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">945000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">870000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">710000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">434000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">189000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">13005000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">13464000000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">695000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">386000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">538000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">591000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">6296000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6436000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">559000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">514000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">8923000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">11232000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">20624000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">24846000000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">50640000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">57470000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">3188000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2345000000</us-gaap:DebtCurrent>
    <teva:SalesReservesAndAllowances
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4824000000</teva:SalesReservesAndAllowances>
    <teva:SalesReservesAndAllowances
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6159000000</teva:SalesReservesAndAllowances>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1756000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1718000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">685000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">693000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <teva:AccruedExpenses
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1780000000</teva:AccruedExpenses>
    <teva:AccruedExpenses
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1869000000</teva:AccruedExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">933000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">889000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">13164000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">13674000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">964000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1096000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2240000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2640000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">22731000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">24562000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">479000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">435000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">26414000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">28733000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">39579000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">42407000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_CHF_per_Share">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_CHF_per_Share">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_shares">2495000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">2495000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">1202000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_shares">1198000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">27443000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">27312000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-10946000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-6956000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-2399000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-2312000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_shares">106000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">106000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4128000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4128000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">10026000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">13972000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1035000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1091000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">11061000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">15063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">50640000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">57470000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">16659000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">16887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">18271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">8933000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">9351000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">9975000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">7726000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">7537000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">8296000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">997000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1010000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1213000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2498000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2614000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">2916000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1173000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1192000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1298000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:IntangibleAssetsImpairments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1502000000</teva:IntangibleAssetsImpairments>
    <teva:IntangibleAssetsImpairments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1639000000</teva:IntangibleAssetsImpairments>
    <teva:IntangibleAssetsImpairments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1991000000</teva:IntangibleAssetsImpairments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4628000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">3027000000</us-gaap:GoodwillImpairmentLoss>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">479000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">423000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">987000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">60000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1178000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-1208000000</teva:LegalSettlementsAndLossContingencies>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">40000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">76000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">291000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-3572000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-443000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-1637000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-834000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-822000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-959000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4406000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1265000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2596000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-168000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-278000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-195000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">138000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-13000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-71000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4099000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1000000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2472000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-109000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-322000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-3990000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-999000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2150000000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">249000000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-3990000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-999000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2399000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">1095000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_shares">1091000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_shares">1021000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">1095000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_shares">1091000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_shares">1021000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4099000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1000000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2472000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-69000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">97000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-713000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-57000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-84000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-115000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-18000000</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-20000000</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">13000000</us-gaap:OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-30000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">160000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-585000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4129000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-840000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-3057000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-53000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">12000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-296000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4076000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-852000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2761000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1124000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">54000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17701996"
      unitRef="Unit_USD">3631000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">23479000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-3803000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1853000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4149000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">17359000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1386000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2017"
      decimals="-6"
      unitRef="Unit_USD">18745000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning
      contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17701993"
      unitRef="Unit_USD">-5000000</teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning>
    <teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17701992"
      unitRef="Unit_USD">5000000</teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2150000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2150000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-322000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2472000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-611000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-611000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2018To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">26000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-585000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-3000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2018To12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">155000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">155000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">155000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17701954"
      unitRef="Unit_shares">72000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17705078"
      unitRef="Unit_USD">2000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2018To12_31_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17705079"
      unitRef="Unit_USD">-3880000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17705080"
      unitRef="Unit_USD">3826000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      id="Fact_17705081"
      unitRef="Unit_USD">-52000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      id="Fact_17705082"
      unitRef="Unit_USD">-52000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DividendsPreferredStockCash
      contextRef="P01_01_2018To12_31_2018_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17702197"
      unitRef="Unit_USD">-249000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">249000000</us-gaap:DividendsPreferredStockCash>
    <teva:TransactionsWithNonControllingInterests
      contextRef="P01_01_2018To12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</teva:TransactionsWithNonControllingInterests>
    <teva:TransactionsWithNonControllingInterests
      contextRef="P01_01_2018To12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</teva:TransactionsWithNonControllingInterests>
    <teva:TransactionsWithNonControllingInterests
      contextRef="P01_01_2018To12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-3000000</teva:TransactionsWithNonControllingInterests>
    <teva:TransactionsWithNonControllingInterests
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:TransactionsWithNonControllingInterests>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1196000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27210000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-5958000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2459000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4142000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">14707000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1087000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">15794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-999000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-999000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1000000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">147000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">147000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2019To12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">160000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2019To12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17701975"
      unitRef="Unit_USD">119000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17701976"
      unitRef="Unit_USD">119000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      id="Fact_17701977"
      unitRef="Unit_USD">119000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <teva:TransactionsWithNonControllingInterests
      contextRef="P01_01_2019To12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:TransactionsWithNonControllingInterests>
    <teva:TransactionsWithNonControllingInterests
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:TransactionsWithNonControllingInterests>
    <teva:OtherEquity
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:OtherEquity>
    <teva:OtherEquity
      contextRef="P01_01_2019To12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:OtherEquity>
    <teva:OtherEquity
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:OtherEquity>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1198000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27312000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-6956000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2312000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">13972000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1091000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">15063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-3990000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-3990000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-109000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4099000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-30000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17701953"
      unitRef="Unit_shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <teva:TransactionsWithNonControllingInterests
      contextRef="P01_01_2020To12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2000000</teva:TransactionsWithNonControllingInterests>
    <teva:TransactionsWithNonControllingInterests
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-2000000</teva:TransactionsWithNonControllingInterests>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_shares">1202000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17702257"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">27443000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-10946000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2399000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_TreasuryStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10026000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1035000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">11061000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2018To12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4099000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1000000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2472000000</us-gaap:ProfitLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">6546000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1778000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">5621000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1557000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1722000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1842000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2188000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">896000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1823000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <teva:DeferredIncomeTaxesNetAndUncertainTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-696000000</teva:DeferredIncomeTaxesNetAndUncertainTaxPositions>
    <teva:DeferredIncomeTaxesNetAndUncertainTaxPositions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-985000000</teva:DeferredIncomeTaxesNetAndUncertainTaxPositions>
    <teva:DeferredIncomeTaxesNetAndUncertainTaxPositions
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-837000000</teva:DeferredIncomeTaxesNetAndUncertainTaxPositions>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">119000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">155000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">100000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">28000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-135000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">80000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">114000000</us-gaap:ResearchAndDevelopmentInProcess>
    <teva:ProfitFromSaleOfLongLivedAssetsAndInvestment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">213000000</teva:ProfitFromSaleOfLongLivedAssetsAndInvestment>
    <teva:ProfitFromSaleOfLongLivedAssetsAndInvestment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">18000000</teva:ProfitFromSaleOfLongLivedAssetsAndInvestment>
    <teva:ProfitFromSaleOfLongLivedAssetsAndInvestment
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">19000000</teva:ProfitFromSaleOfLongLivedAssetsAndInvestment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1216000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">748000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">2446000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1405000000</teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables>
    <teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1487000000</teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables>
    <teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1735000000</teva:ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">67000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">343000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">890000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">578000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">525000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">651000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">55000000</teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets>
    <teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">8000000</teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets>
    <teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">119000000</teva:PaymentToAcquireMarketableSecuritiesAndOtherAssets>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-24000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-58000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-11000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">863000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1355000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1866000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1871000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">3944000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">7446000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2083000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">4434000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">550000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">500000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">559000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">502000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">260000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-5000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-11000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-57000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend>
    <teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">52000000</teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend>
    <teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">22000000</teva:PaymentsRelatedToTaxWithholdingForSharesAndDividend>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-1885000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1926000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-3351000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">8000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-142000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">202000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">193000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">819000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1975000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1782000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2017"
      decimals="-6"
      unitRef="Unit_USD">963000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2177000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1975000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1782000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1397000000</teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables>
    <teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1511000000</teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables>
    <teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1716000000</teva:BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">3880000000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">846000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">840000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">815000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">709000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">552000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">420000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-1473000000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1416000000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-1437000000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-463000000</teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt>
    <teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">643000000</teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt>
    <teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-500000000</teva:IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt>
    <teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-293000000</teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories>
    <teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-394000000</teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories>
    <teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">88000000</teva:IncreaseDecreaseInCertainCurrentAssetsExcludingInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">41000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">271000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">26000000</us-gaap:IncreaseDecreaseInInventories>
    <teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-2188000000</teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation>
    <teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-896000000</teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation>
    <teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-1823000000</teva:NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 1&#x2014;Significant accounting policies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva Pharmaceutical Industries Limited (the &#x201c;Parent Company&#x201d;), headquartered in Israel, together with its subsidiaries and associated companies (the &#x201c;Company,&#x201d; &#x201c;Teva&#x201d; or the &#x201c;Group&#x201d;), is engaged in the development, manufacturing, marketing and distribution of generics, specialty medicines and biopharmaceuticals. The majority of the Group&#x2019;s revenues are in the United States and Europe. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of presentation and use of estimate&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In preparing the Company&#x2019;s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of intangible assets and goodwill; assessing sales reserves and allowances in the United States, and contingent consideration; assessing compliance with debt covenants; uncertain tax positions, valuation allowances, contingencies, inventory valuation and restructuring. The inputs into Teva&#x2019;s judgments and estimates also consider the economic implications of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&amp;amp;D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva&#x2019;s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic within its financial statements may change in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Functional currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A major part of the Group&#x2019;s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (&#x201c;dollar&#x201d; or &#x201c;$&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end&lt;/div&gt; exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income (loss) in the consolidated statements of comprehensive income (loss). &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and VIEs for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders&#x2019; interests are shown as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, are carried on the equity basis. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In March 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-04&lt;/div&gt; &#x201c;Reference Rate Reform (Topic 848)&#x2014;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#x201d; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no impact to the Company&#x2019;s consolidated financial statements for the period ended December&#160;31, 2020 as a result of adopting this standard update. The Company is continuing to evaluate the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities and has started initial negotiations to transform the facility base rate of its securitization program. However, it is not expected to have a material impact on the consolidated financial results. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In April 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-04&lt;/div&gt; &#x201c;Codification Improvements to Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825).&#x201d; This ASU provides clarifications of three topics related to financial instruments accounting. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In November 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&lt;/div&gt; &#x201c;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606.&#x201d; The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i)&#160;addresses when the participant should be considered a customer in the context of a unit of account, (ii)&#160;adds &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;unit-of-account&lt;/div&gt;&lt;/div&gt; guidance in ASC 808 to align with guidance in ASC 606 and (iii)&#160;precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&lt;/div&gt; &#x201c;Intangibles&#x2014;Goodwill and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other&#x2014;Internal-use&lt;/div&gt; software (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;350-40):&lt;/div&gt; Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.&#x201d; This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;internal-use&lt;/div&gt; software. Teva applied the guidance prospectively to all implementation costs incurred after the date of adoption. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In August 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; &#x201c;Fair Value Measurement (Topic 820)&#x2014;Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement.&#x201d; This guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level&#160;3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. Certain disclosures required by this guidance must be applied on a retrospective basis and others on a prospective basis. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; &#x201c;Financial Instruments&#x2014;Credit Losses&#x2014;Measurement of Credit Losses on Financial Instruments.&#x201d; This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Upon adoption of the standard, there was no immediate impact to the Company&#x2019;s financial position, results of operations or cash flows. On an ongoing basis, the Company will contemplate forward-looking economic conditions in recording lifetime expected credit losses for the Company&#x2019;s financial assets measured at cost, such as the Company&#x2019;s trade receivables and certain short-term investments. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently issued accounting pronouncements, not yet adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; &#x201c;Debt &#x2013; Debt with Conversion and Other Options &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Subtopic&#160;470-20)&lt;/div&gt; and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; &#x201c;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes&#x201d; (the &#x201c;update&#x201d;). The amendments in this update simplify the accounting for income taxes by removing the following exceptions in ASC 740: (1) exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items; (2)&#160;exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment; (3)&#160;exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary; and (4)&#160;exception to the general methodology for calculating income taxes in an interim period when a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt;&lt;/div&gt; loss exceeds the anticipated loss for the year. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition, the update also simplifies the accounting for income taxes in certain topics as follows: (1)&#160;requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-income-based&lt;/div&gt; tax; (2)&#160;requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; (3)&#160;specifying that an entity can elect (rather than be required to) allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; and (4)&#160;requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2020. The &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company reviewed the above topics, noting that Items (1)&#160;and (4) of this paragraph are expected to be relevant, but not material. The adoption of this guidance will not have a significant impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s consolidated financial statements include the operations of acquired businesses from the date of the acquisition&#x2019;s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in process research and development (&#x201c;IPR&amp;amp;D&#x201d;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&amp;amp;D is expensed. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; at each reporting period, with any adjustments in fair value recognized in earnings under other assets impairments, restructuring and other items. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaborative arrangements: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaborative agreements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues are recorded on a net basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity investments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-01&lt;/div&gt; &#x201c;Financial Instruments&#x2014;Recognition and Measurement of Financial Assets and Financial Liabilities&#x201d; to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;f.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value measurement: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;g.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in debt securities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Investment in securities consists of debt securities classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s investment in debt securities accounting policy until December&#160;31, 2019, prior to the adoption of the new Current Expected Credit Losses (&#x201c;CECL&#x201d;) standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrealized gains of available for sale debt securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for debt securities are included in financial expenses, net. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s investment in debt securities accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Unrealized gains and losses for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are excluded from earnings and reported net of the related tax effect in the accumulated other comprehensive income component of shareholders&#x2019; equity. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The CECL methodology, which became effective January&#160;1, 2020, requires the Company to estimate lifetime expected credit losses for all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities in an unrealized loss position. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Comparative information continues to be reported in accordance with the methodology in effect for prior periods. When estimating a security&#x2019;s probability of default and the recovery rate, the Company assesses the security&#x2019;s credit indicators, including credit ratings. If the assessment indicates that an expected credit loss exists, the Company determines the portion of the unrealized loss attributable to credit deterioration and records an allowance for the expected credit loss through the Consolidated Statements of Income. Unrealized gains and any portion of a security&#x2019;s unrealized loss attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-credit&lt;/div&gt; losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;h.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;i.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivables: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s accounts receivables accounting policy until December&#160;31, 2019, prior to the adoption of the new CECL standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivables are stated at their net realizable value. The allowance against gross accounts receivables reflects the best estimate of losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. An allowance for doubtful debts is reflected in net accounts receivables. Accounts receivables are written off after all reasonable means to collect the full amount have been exhausted. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s accounts receivables accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write-off&lt;/div&gt; activity and recoveries for the periods presented were not material. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;j.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of credit risks: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of Teva&#x2019;s cash and cash equivalents (which, along with investment in securities, totaled $2,478&#160;million at December&#160;31, 2020) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 48% of Teva&#x2019;s consolidated revenues in 2020. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;k.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Inventories acquired in a business combination are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stepped-up&lt;/div&gt; to their estimated fair value and amortized to cost of sales as that inventory is sold. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;l.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Teva&#x2019;s long-lived, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets are comprised mainly of goodwill, identifiable intangible assets, property, plant and equipment, and operating lease ROU assets. All long-lived assets are monitored for impairment indicators throughout the year. Impairment testing for goodwill and all indefinite-lived intangible assets is performed at least annually. When necessary, charges for impairments of long-lived assets, other than goodwill, are recorded for the amount by which the fair value is less than the carrying value of these assets. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest in the acquiree, over the assigned fair values of the identifiable net assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has historically performed its annual goodwill assessment during the fourth quarter of each year. During the second quarter of 2020, the Company decided to change the date of its annual impairment assessment from October&#160;1 to June 30. The change was made to more closely align the impairment assessment date with the Company&#x2019;s long-term planning and forecasting process. See note 7. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The goodwill impairment test is performed according to the following principles: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value is recognized. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company&#x2019;s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company&#x2019;s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Identifiable intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (&#x201c;S&amp;amp;M&#x201d;) expenses when separable. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indefinite life intangible assets are mainly comprised of IPR&amp;amp;D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. Teva determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset&#x2019;s estimated life, calculates the undiscounted value of the asset&#x2019;s or asset group&#x2019;s cash flows and compares such value against the asset&#x2019;s or asset group&#x2019;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company&#x2019;s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i)&#160;for IPR&amp;amp;D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii)&#160;for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property, plant and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly between 15 to 20 years; and other assets, between 5 to 10 years. &lt;/div&gt;&#160;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For property, plant and equipment and lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, whenever impairment indicators are identified, Teva reconsiders the asset&#x2019;s estimated life, calculates the undiscounted value of the asset&#x2019;s cash flows and compares such value against the asset&#x2019;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (ROU) assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;See note 8 and note 1 cc for further discussion. &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;m.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury shares: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury shares are presented as a reduction of Teva shareholders&#x2019; equity and carried at their cost to Teva, under treasury shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;o.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (&#x201c;RSUs&#x201d;) and performance share units (&#x201c;PSUs&#x201d;). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;p.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Deferred income taxes are determined utilizing the &#x201c;asset and liability&#x201d; method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax has not been provided on the following items: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company&#x2019;s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Amounts of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-exempt&lt;/div&gt; income generated from the Company&#x2019;s current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 13 f. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;q.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Uncertain tax positions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; its tax positions based on developments in its tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of Teva&#x2019;s ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;r.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives and hedging: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company&#x2019;s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative instruments are recognized on the balance sheet at their fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net in the statements of income in the period that the changes in fair value occur. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For derivative instruments that are designated as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net-investment&lt;/div&gt; hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income. The effective portion is determined by looking into changes in spot exchange rate. The change in fair value attributable to changes other than those due to fluctuations in the spot exchange rate are excluded from the assessment of hedge effectiveness and are recognized in the statement of income under financial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;expenses&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net.&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative instruments that do not qualify for hedge accounting are recognized on the Balance Sheet at their fair value, with changes in the fair value recognized as a component of financial expenses&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;s.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue recognition: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (&#x201c;SR&amp;amp;A&#x201d;) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&amp;amp;A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&amp;amp;A components and how they are estimated, see &#x201c;Variable Consideration&#x201d; below. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&amp;amp;M expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; year or less, based on the practical expedient. The Company&#x2019;s credit terms to customers are, on average, between &lt;span style="-sec-ix-hidden:hidden17702468"&gt;thirty&lt;/span&gt; and ninety days. &lt;/div&gt;&#160;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&amp;amp;M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nature of revenue streams &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements performance obligations generally include intellectual property (&#x201c;IP&#x201d;) rights, certain R&amp;amp;D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct&#x2014;i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company&#x2019;s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s IP. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Revenues from licensing arrangements included royalty income of $129 million, $147 million and $165 million for the years ended December&#160;31&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2020&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2019&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and 2018&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specifies goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenues are primarily comprised of contract manufacturing services, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets and liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities are mainly comprised of deferred revenues which were immaterial as of December&#160;31, 2020 and 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable consideration mainly includes SR&amp;amp;A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rebates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-established&lt;/div&gt; volumes or the attainment of revenue milestones for a specified period, the customer receives a rebate. Since rebates are contractually agreed upon, they are estimated based on the specific terms in each agreement based on historical trends and expected sales. Externally obtained inventory levels and expected sales usage by contract are evaluated in relation to estimates made for rebates payable to indirect customers and managed care agreements. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Medicaid and Other Governmental Rebates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer&#x2019;s price for generic products dispensed and &#x201c;best price&#x201d; for specialty products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva&#x2019;s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva&#x2019;s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a &#x201c;chargeback&#x201d;) to the wholesaler for the difference between the invoice price to the wholesaler and the customer&#x2019;s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers and, therefore, will not necessarily fluctuate in proportion to an increase or decrease in sales. Provisions for estimating chargebacks are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Teva considers current and expected price competition when evaluating the provision for chargebacks. Chargeback provisions are compared to externally obtained distribution channel reports for reasonableness. The Company regularly monitors the provision for chargebacks and makes adjustments when the Company believes that actual chargebacks may differ from estimated provisions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Promotional Arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other promotional or incentive arrangements are periodically offered to customers, specifically related to the launch of products or other targeted promotions. Provisions are made in the period for which the Company can estimate the incentive earned by the customer, in accordance with the contractual terms. The Company regularly monitors the provision for other promotional arrangements and makes adjustments when it believes that the actual provision may differ from the estimated provisions. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shelf Stock Adjustments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers&#x2019; existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. Teva regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Returns primarily relate to customer returns of expired products which, the customer has the right to return up to one year following the expiration date. Such returned products are destroyed and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recoded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, The Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies or packaging and any changes to customer terms, for determining the overall expected levels of returns. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prompt Pay Discounts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prompt pay discounts are offered to most customers to encourage timely payment. Discounts are estimated at the time of invoice based on historical discounts in relation to sales. Prompt pay discounts are almost always utilized by customers. As a result, the actual discounts do not vary significantly from the estimated amount. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;t.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses are charged to statement of income (loss) as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Upfront fees received in connection with cooperation agreements are deferred and recognized over the period of the applicable agreements as a reduction of research and development expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are delivered or the services are performed. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Research and development &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;u.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shipping and handling costs: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shipping and handling costs, which are included in S&amp;amp;M expenses, were $124 million, $138 million and $159 million for the years ended December&#160;31&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2020&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2019&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and 2018&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively. &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;v.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advertising costs: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advertising costs are expensed as incurred. Advertising costs for the years ended December&#160;31&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2020&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2019&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and 2018&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; were $225 million, $213&#160;million and $256 million, respectively. &lt;/div&gt; &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;w.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Costs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual termination benefits are provided to employees when employment is terminated due to an event specified in the provisions of an existing plan or agreement. A liability is recorded and the expense is recognized when it is probable that employees will be entitled to the benefits and the amount is reasonably estimable. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Special termination benefits arise when the Company offers, for a short period of time, to provide certain additional benefits to employees electing voluntary termination. A liability is recorded and the expense is recognized in the period the employees irrevocably accept the offer and the amount of the termination liability is reasonably estimable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;x.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment reporting: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s business includes three reporting segments based on three geographical areas: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America segment, which includes the United States and Canada. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe segment, which includes the European Union and certain other European countries. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(c)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets segment, which includes all countries in which Teva operates other than those in the North America and Europe segments. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Each business segment manages the entire product portfolio in its region, including generics, specialty and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;over-the-counter&lt;/div&gt;&lt;/div&gt; (&#x201c;OTC&#x201d;) products. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;y.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic earnings per share are computed by dividing the net income attributable to ordinary shareholders by the weighted average number of ordinary shares (including fully vested RSUs and PSUs) outstanding during the year, net of treasury shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; RSUs and PSUs granted under employee stock compensation plans and one series of convertible senior debentures, using the treasury stock method; (ii)&#160;the conversion of the remaining convertible senior debentures using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;if-converted&#x201d;&lt;/div&gt; method, by &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;adding to net income interest expense on the debentures and amortization of issuance costs, net of tax benefits, and by adding the weighted average number of shares issuable upon assumed conversion of the debentures; and (iii)&#160;until December&#160;17, 2018, the conversion of the mandatory convertible preferred shares (&#x201c;MCPS&#x201d;) using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;if-converted&#x201d;&lt;/div&gt; method by adding to net income attributable to ordinary shareholders the dividends on the preferred shares and by adding the weighted average number of shares issuable upon assumed conversion of the mandatory convertible preferred shares. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;17&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2018&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the mandatory convertible preferred shares automatically converted into ordinary shares. As a result of this conversion, Teva issued 70.6&#160;million ADSs. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;See note 14&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;z.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Securitization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva accounts for transfers of certain of its trade receivable as sales when it has surrendered control over the related assets in accordance with ASC Topic 860 &#x201c;Transfer and Servicing&#x201d; of Financial Assets. Whether control has been relinquished requires, among other things, an evaluation of relevant legal considerations and an assessment of the nature and extent of the Company&#x2019;s continuing involvement with the assets transferred. Assets obtained and liabilities incurred in connection with transfers reported as sales are initially recognized in the balance sheet at fair value. Refer to note 10 f. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;aa.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Divestitures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company nets the proceeds on the divestitures of products with the carrying amount of the related assets and records gain or loss on sale within other income. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when it is probable that a significant reversal of income will not occur, or in the case of a business, when such payments are realizable. For divestures of businesses, including divestitures of products that qualify as a business, the Company reflects the relative fair value of goodwill associated with the businesses in the determination of gain or loss on sale. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;bb.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Debt instruments are initially recognized at the fair value of the consideration received. Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liability. They are subsequently recognized at amortized cost using the effective interest method. Debt may be considered extinguished when it has been modified and the terms of the new debt instruments and old debt instruments are &#x201c;substantially different&#x201d; (as defined in the debt modification guidance in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-50&lt;/div&gt; &#x201c;Debt&#x2014;Modifications and Extinguishments&#x201d;). The Company classifies the current portion of long term debt as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities on the Balance Sheet when it has the intent and ability to refinance the obligation on a long-term basis, in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-50&lt;/div&gt; &#x201c;Debt&#x201d;. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;cc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s lease accounting policy until December&#160;31, 2018, prior to the adoption of the new lease standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva leases real estate, cars and equipment for use in its operations, which are classified as operating leases. In addition to rent, the leases may require Teva to pay directly for fees, insurance, maintenance and other operating expenses. Rental expense for the year ended December&#160;31, 2018 was $175&#160;million. The Company also has capital leases for properties. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s lease accounting policy from January&#160;1, 2019, following the adoption of the new lease standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva adopted the new accounting standard ASC 842 &#x201c;Leases&#x201d; and all the related amendments on January&#160;1, 2019 and used the effective date as Teva&#x2019;s date of initial application. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;842-10-25-2.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva&#x2019;s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Operating leases are included in operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets, other current liabilities and operating lease liabilities in the consolidated balance sheets. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated balance sheets. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ROU assets represent Teva&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent Teva&#x2019;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Teva uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For finance leases, Teva recognizes interest on the lease liability separately from amortization of the ROU assets in the statement of comprehensive income. For operating leases, lease expenses are recognized on a straight-line basis over the lease term. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The new standard also provides practical expedients for an entity&#x2019;s ongoing accounting. Teva elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, Teva does not recognize ROU assets or lease liabilities, including ROU assets or lease liabilities for existing short-term leases of assets in transition, but recognizes lease expenses over the lease term on a straight line basis. Teva also elected the practical expedient to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for all of Teva&#x2019;s leases, other than leases of real estate. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease terms will include options to extend or terminate the lease when it is reasonably certain that Teva will either exercise or not exercise the option to renew or terminate the lease. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s lease agreements have remaining lease terms ranging from 1 year to 78 years. Some of these agreements include options to extend the leases for up to &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; years and some include options to terminate the leases immediately. Certain leases also include options to purchase the leased property. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Some of Teva&#x2019;s vehicle lease agreements include rental payments based on the actual usage of the vehicles and other lease agreements include rental payments adjusted periodically for inflation. Teva&#x2019;s lease agreements do not contain any material residual value guarantees. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The new lease standard has no impact on Teva&#x2019;s debt-covenant compliance under its RCF. &lt;/div&gt;&lt;/div&gt; Teva rents out or subleases certain assets to third parties, which has an immaterial impact on Teva&#x2019;s consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <teva:GeneralOptionsAccountingPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva Pharmaceutical Industries Limited (the &#x201c;Parent Company&#x201d;), headquartered in Israel, together with its subsidiaries and associated companies (the &#x201c;Company,&#x201d; &#x201c;Teva&#x201d; or the &#x201c;Group&#x201d;), is engaged in the development, manufacturing, marketing and distribution of generics, specialty medicines and biopharmaceuticals. The majority of the Group&#x2019;s revenues are in the United States and Europe. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of presentation and use of estimate&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In preparing the Company&#x2019;s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of intangible assets and goodwill; assessing sales reserves and allowances in the United States, and contingent consideration; assessing compliance with debt covenants; uncertain tax positions, valuation allowances, contingencies, inventory valuation and restructuring. The inputs into Teva&#x2019;s judgments and estimates also consider the economic implications of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&amp;amp;D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva&#x2019;s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic within its financial statements may change in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Functional currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A major part of the Group&#x2019;s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (&#x201c;dollar&#x201d; or &#x201c;$&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-end&lt;/div&gt; exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income (loss) in the consolidated statements of comprehensive income (loss). &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and VIEs for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders&#x2019; interests are shown as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interests&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, are carried on the equity basis. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated. &lt;/div&gt;&lt;/div&gt; </teva:GeneralOptionsAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently adopted accounting pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In March 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-04&lt;/div&gt; &#x201c;Reference Rate Reform (Topic 848)&#x2014;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#x201d; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no impact to the Company&#x2019;s consolidated financial statements for the period ended December&#160;31, 2020 as a result of adopting this standard update. The Company is continuing to evaluate the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities and has started initial negotiations to transform the facility base rate of its securitization program. However, it is not expected to have a material impact on the consolidated financial results. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In April 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-04&lt;/div&gt; &#x201c;Codification Improvements to Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825).&#x201d; This ASU provides clarifications of three topics related to financial instruments accounting. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In November 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-18&lt;/div&gt; &#x201c;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606.&#x201d; The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i)&#160;addresses when the participant should be considered a customer in the context of a unit of account, (ii)&#160;adds &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;unit-of-account&lt;/div&gt;&lt;/div&gt; guidance in ASC 808 to align with guidance in ASC 606 and (iii)&#160;precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-15&lt;/div&gt; &#x201c;Intangibles&#x2014;Goodwill and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other&#x2014;Internal-use&lt;/div&gt; software (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;350-40):&lt;/div&gt; Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.&#x201d; This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;internal-use&lt;/div&gt; software. Teva applied the guidance prospectively to all implementation costs incurred after the date of adoption. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In August 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-13&lt;/div&gt; &#x201c;Fair Value Measurement (Topic 820)&#x2014;Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement.&#x201d; This guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level&#160;3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. Certain disclosures required by this guidance must be applied on a retrospective basis and others on a prospective basis. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; &#x201c;Financial Instruments&#x2014;Credit Losses&#x2014;Measurement of Credit Losses on Financial Instruments.&#x201d; This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Upon adoption of the standard, there was no immediate impact to the Company&#x2019;s financial position, results of operations or cash flows. On an ongoing basis, the Company will contemplate forward-looking economic conditions in recording lifetime expected credit losses for the Company&#x2019;s financial assets measured at cost, such as the Company&#x2019;s trade receivables and certain short-term investments. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently issued accounting pronouncements, not yet adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; &#x201c;Debt &#x2013; Debt with Conversion and Other Options &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Subtopic&#160;470-20)&lt;/div&gt; and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; &#x201c;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes&#x201d; (the &#x201c;update&#x201d;). The amendments in this update simplify the accounting for income taxes by removing the following exceptions in ASC 740: (1) exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items; (2)&#160;exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment; (3)&#160;exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary; and (4)&#160;exception to the general methodology for calculating income taxes in an interim period when a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt;&lt;/div&gt; loss exceeds the anticipated loss for the year. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition, the update also simplifies the accounting for income taxes in certain topics as follows: (1)&#160;requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-income-based&lt;/div&gt; tax; (2)&#160;requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; (3)&#160;specifying that an entity can elect (rather than be required to) allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; and (4)&#160;requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2020. The &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company reviewed the above topics, noting that Items (1)&#160;and (4) of this paragraph are expected to be relevant, but not material. The adoption of this guidance will not have a significant impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <teva:AcquisitionTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s consolidated financial statements include the operations of acquired businesses from the date of the acquisition&#x2019;s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in process research and development (&#x201c;IPR&amp;amp;D&#x201d;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&amp;amp;D is expensed. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; at each reporting period, with any adjustments in fair value recognized in earnings under other assets impairments, restructuring and other items. &lt;/div&gt;</teva:AcquisitionTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaborative arrangements: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaborative agreements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues are recorded on a net basis. &lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <teva:EquityAndCostMethodInvestmentPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity investments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-01&lt;/div&gt; &#x201c;Financial Instruments&#x2014;Recognition and Measurement of Financial Assets and Financial Liabilities&#x201d; to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months. &lt;/div&gt;</teva:EquityAndCostMethodInvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;f.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value measurement: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;g.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in debt securities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Investment in securities consists of debt securities classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s investment in debt securities accounting policy until December&#160;31, 2019, prior to the adoption of the new Current Expected Credit Losses (&#x201c;CECL&#x201d;) standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrealized gains of available for sale debt securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for debt securities are included in financial expenses, net. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s investment in debt securities accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Unrealized gains and losses for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are excluded from earnings and reported net of the related tax effect in the accumulated other comprehensive income component of shareholders&#x2019; equity. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The CECL methodology, which became effective January&#160;1, 2020, requires the Company to estimate lifetime expected credit losses for all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities in an unrealized loss position. &lt;/div&gt;Comparative information continues to be reported in accordance with the methodology in effect for prior periods. When estimating a security&#x2019;s probability of default and the recovery rate, the Company assesses the security&#x2019;s credit indicators, including credit ratings. If the assessment indicates that an expected credit loss exists, the Company determines the portion of the unrealized loss attributable to credit deterioration and records an allowance for the expected credit loss through the Consolidated Statements of Income. Unrealized gains and any portion of a security&#x2019;s unrealized loss attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-credit&lt;/div&gt; losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;h.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <teva:AccountsReceivablesPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;i.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivables: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s accounts receivables accounting policy until December&#160;31, 2019, prior to the adoption of the new CECL standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivables are stated at their net realizable value. The allowance against gross accounts receivables reflects the best estimate of losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. An allowance for doubtful debts is reflected in net accounts receivables. Accounts receivables are written off after all reasonable means to collect the full amount have been exhausted. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s accounts receivables accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Write-off&lt;/div&gt; activity and recoveries for the periods presented were not material. &lt;/div&gt;</teva:AccountsReceivablesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;j.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentration of credit risks: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of Teva&#x2019;s cash and cash equivalents (which, along with investment in securities, totaled $2,478&#160;million at December&#160;31, 2020) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 48% of Teva&#x2019;s consolidated revenues in 2020. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <teva:CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2478000000</teva:CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions>
    <teva:PercentageOfConsolidatedSalesInNorthAmerica
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.48</teva:PercentageOfConsolidatedSalesInNorthAmerica>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;k.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Inventories acquired in a business combination are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stepped-up&lt;/div&gt; to their estimated fair value and amortized to cost of sales as that inventory is sold. &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;l.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Teva&#x2019;s long-lived, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets are comprised mainly of goodwill, identifiable intangible assets, property, plant and equipment, and operating lease ROU assets. All long-lived assets are monitored for impairment indicators throughout the year. Impairment testing for goodwill and all indefinite-lived intangible assets is performed at least annually. When necessary, charges for impairments of long-lived assets, other than goodwill, are recorded for the amount by which the fair value is less than the carrying value of these assets. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-controlling&lt;/div&gt; interest in the acquiree, over the assigned fair values of the identifiable net assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has historically performed its annual goodwill assessment during the fourth quarter of each year. During the second quarter of 2020, the Company decided to change the date of its annual impairment assessment from October&#160;1 to June 30. The change was made to more closely align the impairment assessment date with the Company&#x2019;s long-term planning and forecasting process. See note 7. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The goodwill impairment test is performed according to the following principles: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value is recognized. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company&#x2019;s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company&#x2019;s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Identifiable intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (&#x201c;S&amp;amp;M&#x201d;) expenses when separable. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indefinite life intangible assets are mainly comprised of IPR&amp;amp;D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. Teva determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset&#x2019;s estimated life, calculates the undiscounted value of the asset&#x2019;s or asset group&#x2019;s cash flows and compares such value against the asset&#x2019;s or asset group&#x2019;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company&#x2019;s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i)&#160;for IPR&amp;amp;D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii)&#160;for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property, plant and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly between 15 to 20 years; and other assets, between 5 to 10 years. &lt;/div&gt;&#160;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For property, plant and equipment and lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, whenever impairment indicators are identified, Teva reconsiders the asset&#x2019;s estimated life, calculates the undiscounted value of the asset&#x2019;s cash flows and compares such value against the asset&#x2019;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (ROU) assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;See note 8 and note 1 cc for further discussion. &lt;/div&gt;&lt;/div&gt; </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_BuildingMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis_OtherCapitalizedPropertyPlantAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;m.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <teva:TreasurySharesPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;n.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury shares: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury shares are presented as a reduction of Teva shareholders&#x2019; equity and carried at their cost to Teva, under treasury shares. &lt;/div&gt;&lt;/div&gt;</teva:TreasurySharesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;o.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (&#x201c;RSUs&#x201d;) and performance share units (&#x201c;PSUs&#x201d;). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;p.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Deferred income taxes are determined utilizing the &#x201c;asset and liability&#x201d; method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current.&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax has not been provided on the following items: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;1.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company&#x2019;s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;2.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Amounts of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-exempt&lt;/div&gt; income generated from the Company&#x2019;s current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 13 f. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <teva:IncomeTaxesUncertaintiesPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;q.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Uncertain tax positions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; its tax positions based on developments in its tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of Teva&#x2019;s ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss. &lt;/div&gt;&lt;/div&gt;</teva:IncomeTaxesUncertaintiesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;r.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives and hedging: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company&#x2019;s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative instruments are recognized on the balance sheet at their fair value. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net in the statements of income in the period that the changes in fair value occur. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For derivative instruments that are designated as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net-investment&lt;/div&gt; hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income. The effective portion is determined by looking into changes in spot exchange rate. The change in fair value attributable to changes other than those due to fluctuations in the spot exchange rate are excluded from the assessment of hedge effectiveness and are recognized in the statement of income under financial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;expenses&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net.&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. &lt;/div&gt;&lt;/div&gt;Derivative instruments that do not qualify for hedge accounting are recognized on the Balance Sheet at their fair value, with changes in the fair value recognized as a component of financial expenses&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;s.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue recognition: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (&#x201c;SR&amp;amp;A&#x201d;) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&amp;amp;A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&amp;amp;A components and how they are estimated, see &#x201c;Variable Consideration&#x201d; below. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&amp;amp;M expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; year or less, based on the practical expedient. The Company&#x2019;s credit terms to customers are, on average, between &lt;span style="-sec-ix-hidden:hidden17702468"&gt;thirty&lt;/span&gt; and ninety days. &lt;/div&gt;&#160;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&amp;amp;M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nature of revenue streams &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements performance obligations generally include intellectual property (&#x201c;IP&#x201d;) rights, certain R&amp;amp;D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct&#x2014;i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company&#x2019;s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s IP. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Revenues from licensing arrangements included royalty income of $129 million, $147 million and $165 million for the years ended December&#160;31&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2020&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2019&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and 2018&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specifies goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenues are primarily comprised of contract manufacturing services, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets and liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contract liabilities are mainly comprised of deferred revenues which were immaterial as of December&#160;31, 2020 and 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable consideration mainly includes SR&amp;amp;A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rebates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-established&lt;/div&gt; volumes or the attainment of revenue milestones for a specified period, the customer receives a rebate. Since rebates are contractually agreed upon, they are estimated based on the specific terms in each agreement based on historical trends and expected sales. Externally obtained inventory levels and expected sales usage by contract are evaluated in relation to estimates made for rebates payable to indirect customers and managed care agreements. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Medicaid and Other Governmental Rebates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer&#x2019;s price for generic products dispensed and &#x201c;best price&#x201d; for specialty products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva&#x2019;s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva&#x2019;s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a &#x201c;chargeback&#x201d;) to the wholesaler for the difference between the invoice price to the wholesaler and the customer&#x2019;s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers and, therefore, will not necessarily fluctuate in proportion to an increase or decrease in sales. Provisions for estimating chargebacks are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Teva considers current and expected price competition when evaluating the provision for chargebacks. Chargeback provisions are compared to externally obtained distribution channel reports for reasonableness. The Company regularly monitors the provision for chargebacks and makes adjustments when the Company believes that actual chargebacks may differ from estimated provisions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Promotional Arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other promotional or incentive arrangements are periodically offered to customers, specifically related to the launch of products or other targeted promotions. Provisions are made in the period for which the Company can estimate the incentive earned by the customer, in accordance with the contractual terms. The Company regularly monitors the provision for other promotional arrangements and makes adjustments when it believes that the actual provision may differ from the estimated provisions. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shelf Stock Adjustments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers&#x2019; existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. Teva regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Returns primarily relate to customer returns of expired products which, the customer has the right to return up to one year following the expiration date. Such returned products are destroyed and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recoded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, The Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies or packaging and any changes to customer terms, for determining the overall expected levels of returns. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prompt Pay Discounts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prompt pay discounts are offered to most customers to encourage timely payment. Discounts are estimated at the time of invoice based on historical discounts in relation to sales. Prompt pay discounts are almost always utilized by customers. As a result, the actual discounts do not vary significantly from the estimated amount. &lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock>
    <teva:CreditTermsToCustomers contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">P90D</teva:CreditTermsToCustomers>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">147000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;t.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses are charged to statement of income (loss) as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Upfront fees received in connection with cooperation agreements are deferred and recognized over the period of the applicable agreements as a reduction of research and development expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are delivered or the services are performed. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Research and development &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <teva:CostOfShippingAndHandlingPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;u.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shipping and handling costs: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shipping and handling costs, which are included in S&amp;amp;M expenses, were $124 million, $138 million and $159 million for the years ended December&#160;31&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2020&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2019&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and 2018&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively. &lt;/div&gt;&lt;/div&gt;</teva:CostOfShippingAndHandlingPolicyTextBlock>
    <teva:ShippingHandlingAndTransportationCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">124000000</teva:ShippingHandlingAndTransportationCost>
    <teva:ShippingHandlingAndTransportationCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">138000000</teva:ShippingHandlingAndTransportationCost>
    <teva:ShippingHandlingAndTransportationCost
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">159000000</teva:ShippingHandlingAndTransportationCost>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;v.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advertising costs: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advertising costs are expensed as incurred. Advertising costs for the years ended December&#160;31&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2020&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2019&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and 2018&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; were $225 million, $213&#160;million and $256 million, respectively. &lt;/div&gt; &lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">225000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">213000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">256000000</us-gaap:AdvertisingExpense>
    <teva:RestructuringTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;w.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Costs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contractual termination benefits are provided to employees when employment is terminated due to an event specified in the provisions of an existing plan or agreement. A liability is recorded and the expense is recognized when it is probable that employees will be entitled to the benefits and the amount is reasonably estimable. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Special termination benefits arise when the Company offers, for a short period of time, to provide certain additional benefits to employees electing voluntary termination. A liability is recorded and the expense is recognized in the period the employees irrevocably accept the offer and the amount of the termination liability is reasonably estimable. &lt;/div&gt;&lt;/div&gt;</teva:RestructuringTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;x.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment reporting: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s business includes three reporting segments based on three geographical areas: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America segment, which includes the United States and Canada. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe segment, which includes the European Union and certain other European countries. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(c)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets segment, which includes all countries in which Teva operates other than those in the North America and Europe segments. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Each business segment manages the entire product portfolio in its region, including generics, specialty and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;over-the-counter&lt;/div&gt;&lt;/div&gt; (&#x201c;OTC&#x201d;) products. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;y.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic earnings per share are computed by dividing the net income attributable to ordinary shareholders by the weighted average number of ordinary shares (including fully vested RSUs and PSUs) outstanding during the year, net of treasury shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; RSUs and PSUs granted under employee stock compensation plans and one series of convertible senior debentures, using the treasury stock method; (ii)&#160;the conversion of the remaining convertible senior debentures using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;if-converted&#x201d;&lt;/div&gt; method, by &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;adding to net income interest expense on the debentures and amortization of issuance costs, net of tax benefits, and by adding the weighted average number of shares issuable upon assumed conversion of the debentures; and (iii)&#160;until December&#160;17, 2018, the conversion of the mandatory convertible preferred shares (&#x201c;MCPS&#x201d;) using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;if-converted&#x201d;&lt;/div&gt; method by adding to net income attributable to ordinary shareholders the dividends on the preferred shares and by adding the weighted average number of shares issuable upon assumed conversion of the mandatory convertible preferred shares. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;17&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2018&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the mandatory convertible preferred shares automatically converted into ordinary shares. As a result of this conversion, Teva issued 70.6&#160;million ADSs. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;See note 14&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P12_17_2018To12_17_2018"
      decimals="-5"
      unitRef="Unit_shares">70600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <teva:SecuritizationTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;z.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Securitization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva accounts for transfers of certain of its trade receivable as sales when it has surrendered control over the related assets in accordance with ASC Topic 860 &#x201c;Transfer and Servicing&#x201d; of Financial Assets. Whether control has been relinquished requires, among other things, an evaluation of relevant legal considerations and an assessment of the nature and extent of the Company&#x2019;s continuing involvement with the assets transferred. Assets obtained and liabilities incurred in connection with transfers reported as sales are initially recognized in the balance sheet at fair value. Refer to note 10 f. &lt;/div&gt;&lt;/div&gt;</teva:SecuritizationTextBlock>
    <teva:DivestituresTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;aa.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Divestitures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company nets the proceeds on the divestitures of products with the carrying amount of the related assets and records gain or loss on sale within other income. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when it is probable that a significant reversal of income will not occur, or in the case of a business, when such payments are realizable. For divestures of businesses, including divestitures of products that qualify as a business, the Company reflects the relative fair value of goodwill associated with the businesses in the determination of gain or loss on sale. &lt;/div&gt;&lt;/div&gt;</teva:DivestituresTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;bb.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Debt instruments are initially recognized at the fair value of the consideration received. Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liability. They are subsequently recognized at amortized cost using the effective interest method. Debt may be considered extinguished when it has been modified and the terms of the new debt instruments and old debt instruments are &#x201c;substantially different&#x201d; (as defined in the debt modification guidance in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-50&lt;/div&gt; &#x201c;Debt&#x2014;Modifications and Extinguishments&#x201d;). The Company classifies the current portion of long term debt as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities on the Balance Sheet when it has the intent and ability to refinance the obligation on a long-term basis, in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-50&lt;/div&gt; &#x201c;Debt&#x201d;. &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;cc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s lease accounting policy until December&#160;31, 2018, prior to the adoption of the new lease standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva leases real estate, cars and equipment for use in its operations, which are classified as operating leases. In addition to rent, the leases may require Teva to pay directly for fees, insurance, maintenance and other operating expenses. Rental expense for the year ended December&#160;31, 2018 was $175&#160;million. The Company also has capital leases for properties. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Company&#x2019;s lease accounting policy from January&#160;1, 2019, following the adoption of the new lease standard &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva adopted the new accounting standard ASC 842 &#x201c;Leases&#x201d; and all the related amendments on January&#160;1, 2019 and used the effective date as Teva&#x2019;s date of initial application. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;842-10-25-2.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva&#x2019;s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Operating leases are included in operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets, other current liabilities and operating lease liabilities in the consolidated balance sheets. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated balance sheets. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ROU assets represent Teva&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent Teva&#x2019;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Teva uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For finance leases, Teva recognizes interest on the lease liability separately from amortization of the ROU assets in the statement of comprehensive income. For operating leases, lease expenses are recognized on a straight-line basis over the lease term. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The new standard also provides practical expedients for an entity&#x2019;s ongoing accounting. Teva elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, Teva does not recognize ROU assets or lease liabilities, including ROU assets or lease liabilities for existing short-term leases of assets in transition, but recognizes lease expenses over the lease term on a straight line basis. Teva also elected the practical expedient to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for all of Teva&#x2019;s leases, other than leases of real estate. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease terms will include options to extend or terminate the lease when it is reasonably certain that Teva will either exercise or not exercise the option to renew or terminate the lease. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s lease agreements have remaining lease terms ranging from 1 year to 78 years. Some of these agreements include options to extend the leases for up to &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; years and some include options to terminate the leases immediately. Certain leases also include options to purchase the leased property. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Some of Teva&#x2019;s vehicle lease agreements include rental payments based on the actual usage of the vehicles and other lease agreements include rental payments adjusted periodically for inflation. Teva&#x2019;s lease agreements do not contain any material residual value guarantees. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The new lease standard has no impact on Teva&#x2019;s debt-covenant compliance under its RCF. &lt;/div&gt;&lt;/div&gt; </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">175000000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="P01_01_2020To12_31_2020">Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva&#x2019;s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.</us-gaap:LesseeOperatingLeaseDescription>
    <teva:OperatingLeaseRemainingLeaseTerm contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">P1Y</teva:OperatingLeaseRemainingLeaseTerm>
    <teva:OperatingLeaseRemainingLeaseTerm contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">P78Y</teva:OperatingLeaseRemainingLeaseTerm>
    <teva:CertainTransactionsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2&#x2014;Certain transactions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Business acquisitions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actavis Generics and Anda acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;2, 2016, Teva consummated its acquisition of Allergan plc&#x2019;s (&#x201c;Allergan&#x201d;) worldwide generic pharmaceuticals business (&#x201c;Actavis Generics&#x201d;). At closing, Teva transferred to Allergan consideration of approximately $33.4 billion in cash and approximately 100.3&#160;million Teva shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;3, 2016, Teva consummated the acquisition of Anda Inc. (&#x201c;Anda&#x201d;), a medicines distribution business in the United States, from Allergan, for cash consideration of $500 million. This transaction was related to the Actavis Generics acquisition and, as such, the purchase price accounting and related disclosures were treated on a combined basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The final cash consideration for the Actavis Generics acquisition was subject to certain net working capital adjustments. On January&#160;31, 2018, Teva and Allergan entered into a settlement agreement and mutual releases for which Allergan made a one-time payment of $703 million to Teva to settle the working capital adjustments under the Master Purchase Agreement, dated July&#160;26, 2015. As the measurement period has ended, this amount was recorded as a gain under legal settlements and loss contingencies in the first quarter of 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rimsa &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;3, 2016, Teva completed the acquisition of Representaciones e Investigaciones M&#xe9;dicas, S.A. de C.V. (&#x201c;Rimsa&#x201d;), a pharmaceutical manufacturing and distribution company in Mexico, for $2.3&#160;billion, in a cash free, debt free set of transactions. Teva financed the transaction using cash on hand. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the closing of the acquisition, Teva identified issues concerning Rimsa&#x2019;s pre-acquisition quality, manufacturing and other practices, at which point Teva began an assessment of the extent and cost of remediation required to return its products to the market. In September 2016, two lawsuits were filed: a pre-emptive suit by the Rimsa sellers against Teva and Teva&#x2019;s lawsuit alleging fraud and breach of contract against the Rimsa sellers. The Rimsa sellers subsequently dismissed their lawsuit and the dismissal was approved by court order on December&#160;20, 2016. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On February&#160;15, 2018, Teva and the Rimsa sellers entered into a settlement agreement and mutual releases with respect to Teva&#x2019;s breach of contract claim, pursuant to which the Rimsa sellers made a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; payment to Teva. Teva&#x2019;s breach of contract claim was subsequently dismissed by the court. As the measurement period has ended, this payment was recorded as a gain under legal settlements and loss contingencies in the first quarter of 2018. &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other significant agreements: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#x2019;s most significant agreements of this nature are summarized below. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Alvotech Partnership &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, Teva entered into a partnership agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this partnership contains biosimilar candidates addressing multiple therapeutic areas. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva paid an upfront payment in the third quarter of 2020 that w&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;as&lt;/div&gt;&#160;recorded as R&amp;amp;D expenses. During the fourth quarter of 2020, Teva accrued additional amounts due to the high probability that additional milestone payments will be paid in 2021. Additional development and commercial milestone payments of up &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;to&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; $450 million, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilar&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;s.&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eli Lilly and Alder BioPharmaceuticals &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2018, Teva entered into an agreeme&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;n&lt;/div&gt;t with Eli Lilly, resolving the European Patent Office opposition they had filed against Teva&#x2019;s AJOVY&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; patents. The settlement agreement with Lilly also resolved Lilly&#x2019;s action to revoke the patent protecting AJOVY in the United Kingdom. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;8, 2018, Teva signed a global license agreement with Alder BioPharmaceuticals (&#x201c;Alder&#x201d;). The agreement validates Teva&#x2019;s intellectual property and resolves Alder&#x2019;s opposition to Teva&#x2019;s European patent with respect to anti-calcitonin gene-related peptide (CGRP) antibodies, including the withdrawal of Alder&#x2019;s appeal before&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;the European Patent Office. Under the terms of the agreement, Alder will receive a non-exclusive license to Teva&#x2019;s anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the United States and worldwide, excluding Japan and Korea. Teva received a&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; $25 million &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;upfront payment that was recognized as revenue during the first quarter of 2018, and a&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$25 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million milestone payment in March 2020 that was recognized as revenue in the first quarter of 2020. The agreement stipulates additional commercial milestone payments to Teva of up to&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; $150 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, as well as future royalties.&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;PGT Healthcare Partnership &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2018, Teva terminated its joint venture with the Procter&#160;&amp;amp; Gamble Company (&#x201c;P&amp;amp;G&#x201d;), PGT Healthcare partnership (&#x201c;PGT&#x201d;), which the two companies established in 2011 to market OTC medicines. Teva will continue to maintain its OTC business on an independent basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the separation, Teva transferred to P&amp;amp;G the shares it held in New Chapter Inc. and ownership rights in an OTC plant located in India. Teva provides certain services to P&amp;amp;G after the separation for a transition period.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the first quarter of 2018, Teva classified the plant in India as an asset held for sale and recorded an impairment of&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$64&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million under other assets impairments, restructuring and other items. In addition, Teva recorded a write-down of&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$94&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of its investment in New Chapter Inc. under share in losses of associated companies.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;During September 2018, Teva and P&amp;amp;G completed the final net asset distribution as part of the dissolution and Teva recorded a gain of&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; $50&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million to reflect the cash payment received from P&amp;amp;G under the dissolution agreement.&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUSTEDO&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;19, 2017, Teva entered into a partnership agreement with Nuvelution Pharma, Inc. (&#x201c;Nuvelution&#x201d;) for development of AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States. There are no further plans in this indication following clinical trial results received in February 2020, which failed to meet their primary endpoints. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Otsuka &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#x201c;Otsuka&#x201d;), providing Otsuka with an exclusive license to conduct phase 2 and 3 clinical trials for AJOVY in Japan and, if approved, to commercialize the product in Japan. Otsuka paid Teva an upfront payment of $50&#160;million in consideration for the transaction. Results for these trials were received in January 2020 indicating that primary and secondary endpoints were achieved and that no clinically significant adverse events were observed in subjects. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15&#160;million, which was recognized as revenue in the third quarter of 2020. Teva may receive additional milestone payments upon achievement of certain commercial and revenue targets. Otsuka will also pay Teva royalties on AJOVY sales in Japan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Celltrion &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2016, Teva and Celltrion, Inc. (&#x201c;Celltrion&#x201d;) entered into a collaborative agreement to commercialize TRUXIMA&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; and HERZUMA&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;, two biosimilar products for the U.S. and Canadian markets. Teva paid Celltrion $160&#160;million, of which Teva received an aggregate credit of $60&#160;million as of December&#160;31, 2020. Teva and Celltrion share the profit from the commercialization of these products. These two products, TRUXIMA and HERZUMA, were approved by the FDA in November and December 2018, respectively and were launched in the United States in November 2019 and March 2020, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Regeneron &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (&#x201c;Regeneron&#x201d;) entered into a collaborative agreement to develop and commercialize Regeneron&#x2019;s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&amp;amp;D costs of approximately $1&#160;billion. Teva made an upfront payment of $250&#160;million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of $120&#160;million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $2,230&#160;million, as well as future royalties. &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and Liabilities Held For Sale: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain assets of Teva&#x2019;s business venture in Japan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva operates its business in Japan, which is part of Teva&#x2019;s International Market segment, through a business venture with The Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), in which Teva owns a&lt;/div&gt; 51% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;stake and Takeda owns the remaining&lt;/div&gt; 49%. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2020, Teva and Takeda entered into a purchase agreement to sell the majority of the business venture&#x2019;s generic and operational assets. This transaction was completed on February&#160;1, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva is accounting for the business venture assets and liabilities under the purchase agreement as held for sale and determined that the fair value less cost to sell did not exceed the carrying value, resulting in an impairment charge of&lt;/div&gt;&#160;$247 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in other assets impairments, restructuring and other items recognized in 2020&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva determined that the sale of this portion of the Teva-Takeda business venture does not constitute a strategic shift for Teva, and does not and will not have a major effect on its operations and financial results. Accordingly, the operations associated with the transactions are not reported as discontinued operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets held for sale include the Teva-Takeda business venture assets that are held for sale, the anticipated sale of certain OTC assets and other manufacturing assets that are expected to be sold within the next year. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below summarizes all Teva assets included as held for sale as of December&#160;31, 2020 and December&#160;31, 2019: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 76%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 0pt;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:13%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:13%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment, net and others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;312&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments of assets held for sale to fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;(296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets of the disposal group classified as held for sale in the consolidated balance sheets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:CertainTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P08_02_2016To08_02_2016_ActavisMemberusgaapBusinessAcquisitionAxis"
      decimals="-8"
      unitRef="Unit_USD">33400000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P08_02_2016To08_02_2016_ActavisMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_shares">100300000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P10_03_2016To10_03_2016_AndaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">500000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <teva:OneTimeMilestonePaymentReceived
      contextRef="P01_31_2018To01_31_2018_AllerganPlcMembersrtCounterpartyNameAxis"
      decimals="-6"
      unitRef="Unit_USD">703000000</teva:OneTimeMilestonePaymentReceived>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P03_03_2016To03_03_2016_RimsaMemberusgaapBusinessAcquisitionAxis"
      decimals="-8"
      unitRef="Unit_USD">2300000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <teva:NumberOfLawsuitsFiled
      contextRef="P09_01_2016To09_30_2016_RimsaMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_Lawsuit">2</teva:NumberOfLawsuitsFiled>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_01_2020To12_31_2020_AlvotechMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">450000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:UpfrontPayments
      contextRef="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</teva:UpfrontPayments>
    <teva:MilestonePayment
      contextRef="P01_01_2020To03_31_2020_AlderMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</teva:MilestonePayment>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_08_2018To01_08_2018_AlderMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2018To03_31_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">64000000</teva:ImpairmentsRestructuringAndOthers>
    <us-gaap:GainLossOnInvestments
      contextRef="P01_01_2018To03_31_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">94000000</us-gaap:GainLossOnInvestments>
    <teva:ProfitFromSaleOfLongLivedAssetsAndInvestment
      contextRef="P09_01_2018To09_30_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">-50000000</teva:ProfitFromSaleOfLongLivedAssetsAndInvestment>
    <teva:UpfrontPayments
      contextRef="P05_12_2017To05_12_2017_OtsukaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">50000000</teva:UpfrontPayments>
    <teva:MilestonePayment
      contextRef="P07_01_2020To09_30_2020_OtsukaMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">15000000</teva:MilestonePayment>
    <teva:TotalAssociatedCost
      contextRef="PAsOn09_30_2020_CelltrionMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">160000000</teva:TotalAssociatedCost>
    <teva:RefundablePayment
      contextRef="PAsOn09_30_2020_CelltrionMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">60000000</teva:RefundablePayment>
    <teva:ResearchAndDevelopmentCosts
      contextRef="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-9"
      unitRef="Unit_USD">1000000000</teva:ResearchAndDevelopmentCosts>
    <teva:UpfrontPayments
      contextRef="P07_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</teva:UpfrontPayments>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_01_2017To12_31_2017_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">120000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P01_01_2018To12_31_2018_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">120000000</teva:CollaborativeAgreementMilestonePayments>
    <teva:CollaborativeAgreementMilestonePayments
      contextRef="P09_01_2016To09_30_2016_RegeneronMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">2230000000</teva:CollaborativeAgreementMilestonePayments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn11_30_2015_TevaMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn11_30_2015_TevaMembersrtOwnershipAxis"
      decimals="2"
      unitRef="Unit_pure">0.49</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="P04_01_2020To06_30_2020"
      decimals="-6"
      unitRef="Unit_USD">247000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below summarizes all Teva assets included as held for sale as of December&#160;31, 2020 and December&#160;31, 2019: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 76%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 0pt;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:13%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:13%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment, net and others&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;312&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjustments of assets held for sale to fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;(296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets of the disposal group classified as held for sale in the consolidated balance sheets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;width:5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">146000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">312000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">98000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">27000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-296000000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-11000000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">189000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3&#x2014;Revenue from contracts with customers: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disaggregation of revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table disaggregates Teva&#x2019;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,902&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,736&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,946&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;772&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,354&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;84&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;32&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;129&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,462&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,495&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(14&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;169&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;527&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;680&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,447&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,757&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,154&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,302&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,659&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,941&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,770&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;545&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,304&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,887&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,838&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,153&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,297&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $1&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable consideration mainly includes SR&amp;amp;A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. For description of the nature of each deduction and how provisions are estimated see note 1. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SR&amp;amp;A to U.S. customers comprised approximately 79% of the Company&#x2019;s total SR&amp;amp;A as of December&#160;31, 2020, with the remaining balance primarily in Canada and Germany. The changes in SR&amp;amp;A for third-party sales for the period ended December&#160;31, 2019 and 2020 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 39%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="26" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales Reserves and Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt; included in&lt;br/&gt; Accounts&lt;br/&gt; Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt; other&lt;br/&gt; governmental&lt;br/&gt; allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; reserves&lt;br/&gt; included in&lt;br/&gt; Sales&lt;br/&gt; Reserves&lt;br/&gt; and&lt;br/&gt; Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at January 1, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;638 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,886&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in current year period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;976&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;9,565&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;281 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;16,767&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;17,150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(17&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credits and payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(5,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,076&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(9,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(17,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(17,605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at December 31, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%; border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;2,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1,342&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;6,159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;6,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in current year period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;4,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;8,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;14,415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;14,806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 39%; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credits and payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(5,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(8,614&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(15,309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(15,707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at December 31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,054&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;828&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;4,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;4,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table disaggregates Teva&#x2019;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,902&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,736&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,946&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;772&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,354&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;84&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;32&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;129&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,462&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,495&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(14&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;169&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;527&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;680&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,447&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,757&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,154&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,302&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,659&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,941&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,770&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xa7;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;545&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,304&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,887&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0pt; width: 0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,838&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,153&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Licensing arrangements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Distribution&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,297&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#xa7;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $1&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">6902000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">4736000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1946000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">772000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">14354000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">-14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">8447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">4757000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">16659000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">6941000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">4770000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">2045000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">754000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">14510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">-6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">545000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">716000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">8542000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">4795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">16887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">7838000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">5153000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">2151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">739000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_ProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">15881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_LicenseMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_DistributionServiceMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">9297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">5186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_OtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">18271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <teva:SalesReservesAndAllowancesCurrentTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SR&amp;amp;A to U.S. customers comprised approximately 79% of the Company&#x2019;s total SR&amp;amp;A as of December&#160;31, 2020, with the remaining balance primarily in Canada and Germany. The changes in SR&amp;amp;A for third-party sales for the period ended December&#160;31, 2019 and 2020 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 39%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="26" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sales Reserves and Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reserves&lt;br/&gt; included in&lt;br/&gt; Accounts&lt;br/&gt; Receivable,&#160;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid and&lt;br/&gt; other&lt;br/&gt; governmental&lt;br/&gt; allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Returns&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; reserves&lt;br/&gt; included in&lt;br/&gt; Sales&lt;br/&gt; Reserves&lt;br/&gt; and&lt;br/&gt; Allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="30" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at January 1, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,361&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;638 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,886&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in current year period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;976&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;9,565&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;281 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;16,767&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;17,150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(17&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credits and payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(5,570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,076&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(9,736&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(392&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(17,134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(17,605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at December 31, 2019&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%; border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;2,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;1,342&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;6,159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;6,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in current year period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;4,703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;744&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;8,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;14,415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;14,806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 39%; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions related to sales made in prior periods&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(184&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credits and payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(5,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(8,614&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(15,309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(15,707&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at December 31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,054&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;828&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;4,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;4,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 39%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:SalesReservesAndAllowancesCurrentTableTextBlock>
    <teva:SalesReservesAndAllowancesToCustomersPercentage
      contextRef="P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.79</teva:SalesReservesAndAllowancesToCustomersPercentage>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">175000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3006000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1361000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1530000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">638000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">176000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">6711000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">6886000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2019To12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">383000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">5552000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">976000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">9565000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">281000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">394000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">16767000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">17150000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-92000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-151000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-17000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">77000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-6000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-189000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-189000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">471000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">5570000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1076000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">9736000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">360000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">392000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">17134000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">17605000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2019To12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2019To12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2019To12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2019To12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2019To12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2019To12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2895000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1109000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1342000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">637000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">176000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">6159000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6246000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2020To12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">391000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4703000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">744000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">8438000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">459000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">71000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">14415000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">14806000000</teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-219000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-184000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-65000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-28000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-497000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-497000000</teva:ValuationAllowancesAndReservesRelatedToPriorPeriodSales>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">398000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">5360000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">849000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">8614000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">386000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">15309000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">15707000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2020To12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">35000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2020To12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">8000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2020To12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2020To12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2020To12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2020To12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">56000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <teva:ValuationAllowancesAndReservesForeignCurrencyTranslation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">56000000</teva:ValuationAllowancesAndReservesForeignCurrencyTranslation>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_ReservesIncludedInAccountsReceivableNetMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">80000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_RebatesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2054000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_MedicaidAndOtherGovernmentalAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">828000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_ChargebacksMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1108000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_ReturnsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">686000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_OtherSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">148000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_TotalReservesIncludedInSalesReservesAndAllowancesMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4824000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4904000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4&#x2014;Inventories: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories, net of reserves, consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$2,378 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$2,504 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw and packaging materials&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Products in process&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;583&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Materials in transit and payments on account&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-size: 10pt;;text-align:right;"&gt;$4,403 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$4,422 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories, net of reserves, consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finished products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$2,378 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$2,504 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Raw and packaging materials&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,231&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Products in process&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;583&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Materials in transit and payments on account&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;189&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-size: 10pt;;text-align:right;"&gt;$4,403 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$4,422 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2378000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2504000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1231000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1183000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">605000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">583000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:OtherInventoryInTransit
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">189000000</us-gaap:OtherInventoryInTransit>
    <us-gaap:OtherInventoryInTransit
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">151000000</us-gaap:OtherInventoryInTransit>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4403000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4422000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5&#x2014;Property, plant and equipment: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment, net, consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Machinery and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;5,245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;5,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;"&gt;2,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;2,197&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets under construction and payments on account&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;"&gt;933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;672&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Land&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;11,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;11,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less&#x2014;accumulated depreciatio&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;n&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;"&gt;(5,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(4,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;$6,296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;$6,436 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expenses were $537 million, $609 million and $676 million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. During the years ended December&#160;31, 2020, 2019 and 2018, Teva had impairments of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;property&lt;/div&gt;, plant and equipment in the amount of $416 million, $139 million and $500 million, respectively. &lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;See note &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment, net, consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Machinery and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;5,245&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;5,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;"&gt;2,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and other assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;2,197&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets under construction and payments on account&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;"&gt;933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;672&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Land&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;323&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;11,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;11,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less&#x2014;accumulated depreciatio&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;n&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;"&gt;(5,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(4,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;"&gt;$6,296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;$6,436 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">5245000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">5385000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2720000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2839000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2197000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2131000000</us-gaap:PropertyPlantAndEquipmentOther>
    <teva:AssetsUnderConstructionAndPaymentsOnAccount
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">933000000</teva:AssetsUnderConstructionAndPaymentsOnAccount>
    <teva:AssetsUnderConstructionAndPaymentsOnAccount
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">672000000</teva:AssetsUnderConstructionAndPaymentsOnAccount>
    <us-gaap:Land
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">292000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">323000000</us-gaap:Land>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">11388000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">11350000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">5092000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4914000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">6296000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6436000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">537000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">609000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">676000000</us-gaap:Depreciation>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">416000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">139000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">500000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6&#x2014;Identifiable intangible assets: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable intangible assets consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 53%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;carrying&#160;amount&lt;br/&gt; net of impairment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;carrying&#160;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product rights&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;19,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,094&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,640&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,556&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade names&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-process research and development (IPR&amp;amp;D)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;1,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;21,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,923&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product rights and trade names &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately 10 years. Amortization of intangible assets amounted to $1,020 million, $1,113 million and $1,166 million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the estimated aggregate amortization of intangible assets for the years 2021 to 2025 is as follows: 2021&#x2014;$812 million; 2022&#x2014;$764 million; 2023&#x2014;$744 million; 2024&#x2014;$705 million&#160;and 2025&#x2014;$723 million. These estimates do not include the impact of IPR&amp;amp;D that is expected to be successfully completed and reclassified to product rights.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s IPR&amp;amp;D are assets that have not yet been approved in major markets. Teva&#x2019;s IPR&amp;amp;D is comprised mainly of various generic products from the Actavis Generics acquisition of $877&#160;million. IPR&amp;amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets impairment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of identifiable intangible assets amounted to $1,502 million, $1,639 million and $1,991 million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. These amounts are recorded&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in the statement of income (loss) under intangible assets impairment.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments in 2020 mainly consisted of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D assets of $797&#160;million, mainly due to: (i) $300&#160;million related to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States; (ii) $262&#160;million related to lenalidomide (generic equivalent of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revlimid&#xae;),&#160;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;due to modified competition assumptions as a result of settlements between the innovator and other generic filers; (iii) $211&#160;million related to AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the United States following clinical trial results, received in February 2020, which failed to meet their primary endpoints; and&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable product rights of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$705 &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, mainly due to: (i) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$398 &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States; (ii) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$165 &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in Japan in connection with ongoing regulatory pricing reductions and generic competition; and (iii) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$110 &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million related to a change in the assumptions regarding competition for the expected relaunch of metformin tablets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments in 2019 mainly consisted of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable product rights of $958 million, mainly due to: (i) $647 million due to updated market assumptions regarding price and volume of certain products acquired from Actavis Generics and primarily marketed in the United States, (ii) $128 million related to a decrease in future expected sales in Japan as a result of generic competition, and (iii) $123 million related to the discontinuation of certain products from Actavis Generics&#x2019; portfolio in several international markets; and&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D assets of $681&#160;million, due to: (i) $497&#160;million related to various generic pipeline products acquired from Actavis Generics due to development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date or discount rate) in the United States (ii) $125&#160;million related to lenalidomide (generic equivalent of REVLIMID&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;), due to modified competition assumptions as a result of settlements between the innovator and other generic filers, and (iii) $59&#160;million related to a change in assumptions concerning the future European market share of a number of pipeline products acquired from Actavis Generics. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments in 2018 mainly consisted of: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable product rights of $1,068&#160;million, mainly due to: (i) $412&#160;million in connection with updated market assumptions regarding price and volume of products acquired from Actavis Generics currently marketed in the United States and supply constraints; (ii) $290&#160;million in certain international markets, due to a loss of several tenders and termination of products manufacturing lines; and (iii) $222&#160;million in Japan in connection with ongoing regulatory pricing reductions and generic competition. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IPR&amp;amp;D assets of $923&#160;million, mainly related to revaluation of generic products acquired from Actavis Generics due to development progress and changes in other key valuation indications (e.g., market size, legal landscape, launch date or discount rate). &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value measurement of the impaired intangible assets in 2020&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; is&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; based&lt;/div&gt; on significant unobservable inputs in the market and thus represents a Level&#160;3&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; measurement within the fair value hierarchy. The discount rate applied ranged from 7.5% to 9%. A probability of success factor of 80% was used in the&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;majority of &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value calculation&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; to reflect&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; inherent regulatory and commercial risk of IPR&amp;amp;D. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Identifiable intangible assets consisted of the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 53%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;carrying&#160;amount&lt;br/&gt; net of impairment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;carrying&#160;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product rights&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,650&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;19,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,094&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,640&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,556&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade names&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;456&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-process research and development (IPR&amp;amp;D)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;1,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,735&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;"&gt;21,998&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,923&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 2%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;width:1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">19650000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">19663000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">12094000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">10640000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">7556000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">9023000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">621000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">600000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">126000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">456000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">474000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">911000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1735000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">911000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1735000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">21182000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">21998000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">12259000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">10766000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">8923000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">11232000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2020To12_31_2020">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1020000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1113000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1166000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">812000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">764000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">744000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">705000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">723000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="PAsOn12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">877000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1502000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1639000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1991000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">797000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_LenalidomideProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">300000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020_LenalidomideProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">262000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020_AustedoMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">211000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">705000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">398000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">110000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">958000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">647000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019_JPsrtStatementGeographicalAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">128000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019_DiscontinuedBusinessMemberTEVADiscontinuationOfBusinessAxis_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">123000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">681000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_LenalidomideProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">497000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019_LenalidomideProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">125000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">59000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1068000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_ProductRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">412000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">290000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2018To12_31_2018_ActavisMemberusgaapBusinessAcquisitionAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_JPsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">222000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2018To12_31_2018_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-6"
      unitRef="Unit_USD">923000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MinimumMembersrtRangeAxis"
      decimals="1"
      unitRef="Unit_pure">7.5</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_pure">9</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="0"
      unitRef="Unit_pure">80</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7&#x2014;Goodwill: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 201&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;11,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;8,653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,687&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;24,917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes during the period:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwil&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;l &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;disposal&lt;/div&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(23&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%; padding-bottom: 0.45pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:3%;"&gt;(112&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%; border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019 (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;11,091&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;8,536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,687&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;24,846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes during the period:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill reclassified as assets held for sale&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(4,628&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(4,628&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255); white-space: nowrap; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:3%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;, 2020 (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;6,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;9,102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,687&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;20,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 0.5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated goodwill impairment as of December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018 was approximately $25.6&#160;billion, $21.0&#160;billion and $21.0&#160;billion, respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva&#x2019;s production and sale of APIs to third parties (&#x201c;Teva API&#x201d;) and an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. The Teva API and Medis reporting units are included under &#x201c;Other&#x201d; in the above table. See note 19 for additional segment information. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#x2019;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#x201c;WACC&#x201d;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#x2019;s assumptions, Teva may recognize an impairment of goodwill allocated to its reporting units in the future. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;First Quarter Developments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During the first quarter of 2020, management assessed developments that occurred during the quarter, including expected effects of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on its business, to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. As part of this assessment, management also considered the sensitivity of its conclusions as they relate to changes in the estimates and assumptions used in the latest forecast available for each period. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of March&#160;31, 2020 and, therefore, no quantitative assessment was performed. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Second Quarter Developments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to Company policy, the Company has historically performed its annual goodwill assessment during the fourth quarter of each year. During the second quarter of 2020, the Company changed its annual impairment assessment date from October&#160;1 to June&#160;30 to more closely align the impairment assessment date with the Company&#x2019;s long-term planning and forecasting process. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the second quarter of 2020, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test and utilized the assistance of an independent valuation expert. No goodwill impairment charge was recorded during the second quarter of 2020.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the aforementioned analysis, Teva analyzed the aggregated fair value of its reporting units compared to its market capitalization as part of its annual goodwill impairment test, in order to assess the reasonableness of the results of its cash flow projections used for its goodwill impairment analysis. Management noted differences between the market capitalization and management&#x2019;s internal projections as of the end of the second quarter. As of June&#160;30, 2020, those differences were believed to be attributable to the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management noted a portion of the difference can be attributed to sales projections of AJOVY and AUSTEDO in the International Markets reporting unit. Management continues to believe that the majority of analysts do not focus on these brands in preparing their financial models and, as a result, have not attributed value to the launch potential in this reporting unit. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management noted an additional difference can be attributed to sales projections of AUSTEDO in the North America reporting unit, resulting in higher fair value as analyzed by management compared to Teva&#x2019;s market capitalization. Management continues to believe that it has more accurate information based on its knowledge of the market and its growth and therefore no adjustment was incorporated to the fair value. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management noted that market concerns regarding the uncertainty related to the opioid and price fixing litigation risks are impacting its market capitalization. Management believes that these concerns led to an acute reaction, which resulted in a decline in Teva&#x2019;s share price. Management believed developments in the opioids case would clarify the outlook with regards to the opioid litigation, when the proposed settlement framework is finalized, which was expected in the near term. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Even if management was to adjust the fair value of the North America reporting unit for any one of the uncertainties noted, the estimated fair value would still exceed its carrying amount. Management also noted that negative results related to all the uncertainties noted may lead to a material goodwill impairment charge. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Third Quarter Developments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the third quarter of 2020, Teva&#x2019;s share price experienced further decline. Teva analyzed its aggregated internal valuation of its reporting units compared to its market capitalization as part of its goodwill impairment test. Management believed there are similar reconciling factors to those referenced in the second quarter with additional declines occurring due to increased uncertainty related to certain litigation actions in the third quarter and the related uncertainties it added to the existing concerns around financial strength. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the third quarter of 2020, management noted the following factors that led to an assessment of the North America reporting unit for impairment: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; padding-top: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company noted a 25% reduction in its market capitalization from the second quarter of 2020 to the third quarter of 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;With respect to the opioids litigation, as discussions continue with the group of Attorneys General regarding the nationwide framework and trial dates are postponed largely due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic, a resolution of this matter is taking longer than anticipated. Accordingly, the Company was and is currently unable to predict the timing of any final settlement or whether the settlement will be finalized based upon the current settlement framework. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;25, 2020, the Company was indicted by the U.S. Department of Justice for alleged violations of the Sherman Act. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;18, 2020, the Company was sued by the U.S. Department of Justice alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is committed to its projected cash flow targets and management&#x2019;s views on the litigation exposures have not changed. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, the developments indicated&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;the timeframe for resolution will take significantly longer than previously expected which introduces greater uncertainty to a favorable resolution. In addition, management &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;believed&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;that analysts &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;were&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;unlikely to modify their projections until the Company &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;could&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; demonstrate progression on the resolution with respect to some or all of the above legal matters. As such, for purposes of testing the goodwill in the North America reporting unit under ASC 350&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, management incorporated these factors into its valuation of the North America reporting unit, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;which resulted&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in an impairment charge of $4,628 million. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fourth Quarter Developments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the fourth quarter of 2020, management assessed developments during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of December&#160;31, 2020 and, therefore, no quantitative assessment was performed. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the goodwill impairment charge recorded in the third quarter of 2020 to the North America reporting unit, the carrying value of the North America reporting unit equaled its fair value as of September&#160;30, 2020. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to the North America reporting unit in the future. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The other reporting units all have fair value in excess of 10% over their book values as of December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td style="width: 0.5%;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&lt;br/&gt; America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&lt;br/&gt; Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 201&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;11,098&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;8,653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,687&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;24,917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes during the period:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwil&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;l &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;disposal&lt;/div&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(23&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(28&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%; padding-bottom: 0.45pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:3%;"&gt;(112&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%; border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019 (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;11,091&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;8,536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,532&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,687&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;24,846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes during the period:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill reclassified as assets held for sale&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;(8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(4,628&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(4,628&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Translation differences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;574&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 58%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255); white-space: nowrap; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:3%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;, 2020 (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;6,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;9,102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,687&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;20,624&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 58%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 0.5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated goodwill impairment as of December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018 was approximately $25.6&#160;billion, $21.0&#160;billion and $21.0&#160;billion, respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2018_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17702679"
      unitRef="Unit_USD">11098000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2018_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17702680"
      unitRef="Unit_USD">8653000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2018_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17702681"
      unitRef="Unit_USD">2479000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2018_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17702682"
      unitRef="Unit_USD">2687000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      id="Fact_17702683"
      unitRef="Unit_USD">24917000000</us-gaap:Goodwill>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">28000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2019To12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-16000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2019To12_31_2019_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">112000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-53000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">43000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17703192"
      unitRef="Unit_USD">11091000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17703191"
      unitRef="Unit_USD">8536000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17703190"
      unitRef="Unit_USD">2532000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17703189"
      unitRef="Unit_USD">2687000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      id="Fact_17703188"
      unitRef="Unit_USD">24846000000</us-gaap:Goodwill>
    <teva:GoodwillReclassification
      contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-8000000</teva:GoodwillReclassification>
    <teva:GoodwillReclassification
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-19000000</teva:GoodwillReclassification>
    <teva:GoodwillReclassification
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-27000000</teva:GoodwillReclassification>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">4628000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4628000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-10000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2020To12_31_2020_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">-574000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">151000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-433000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17702690"
      unitRef="Unit_USD">6473000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17702691"
      unitRef="Unit_USD">9102000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_InternationalMarketsMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17702692"
      unitRef="Unit_USD">2362000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      id="Fact_17702693"
      unitRef="Unit_USD">2687000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      id="Fact_17702694"
      unitRef="Unit_USD">20624000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn12_31_2020"
      decimals="-8"
      unitRef="Unit_USD">25600000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn12_31_2019"
      decimals="-8"
      unitRef="Unit_USD">21000000000.0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="PAsOn12_31_2018"
      decimals="-8"
      unitRef="Unit_USD">21000000000.0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <teva:PercentageDecreaseInTheMarketCapitalization
      contextRef="P01_01_2020To09_30_2020_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</teva:PercentageDecreaseInTheMarketCapitalization>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2020To12_31_2020_NorthAmericaMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">4628000000</us-gaap:GoodwillImpairmentLoss>
    <teva:PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill
      contextRef="PAsOn12_31_2020_OtherMembersrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</teva:PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8&#x2014;Leases: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva adopted the new accounting standard ASC 842 &#x201c;Leases&#x201d; and all the related amendments on January&#160;1, 2019 and used the effective date as Teva&#x2019;s date of initial application. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of operating lease cost for the year ended December&#160;31, 2020 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed payments and variable payments that depend on an index or rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease payments not included in the lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%; padding-bottom: 0.45pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;$155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;$178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental cash flow information related to operating leases was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets obtained in exchange for lease obligations &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(non-cash):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%; padding-bottom: 2.2pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%; padding-bottom: 2.2pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 2.5pt double black;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;"&gt;211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 2.2pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 2.5pt double black;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental balance sheet information related to operating leases was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 18%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease ROU assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;116&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;595&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;7.5&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;7.5&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of operating lease liabilities were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025 and thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;302 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;722 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;595 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the end of the third quarter of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;2020&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, after obtaining the right to use the building, Teva began transitioning its corporate headquarters to a consolidated site in Tel-Aviv, Israel. Teva has an operating lease for the office space in Tel Aviv for an initial term of twelve and a half years, with an option for three extensions. Teva estimates that the reasonably certain holding period of the lease for accounting purposes is twelve and a half years. As of September 30,&#160;&lt;/div&gt;2020&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon initial recognition,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;Teva booked&#160;&#160;$&lt;/div&gt;74 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million as operating lease right-of-use and $&lt;/div&gt;66 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million as operating lease liability.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December 31, 2020, Teva&#x2019;s total finance lease assets and finance lease liabilities were&lt;/div&gt;&#160;$29 million and $21 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively. The difference between those amounts is mainly due to prepaid payments.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <teva:ComponentsOfLeaseExpenseTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of operating lease cost for the year ended December&#160;31, 2020 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed payments and variable payments that depend on an index or rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease payments not included in the lease liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 60%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%; padding-bottom: 0.45pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;$155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;$178&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:ComponentsOfLeaseExpenseTableTextBlock>
    <teva:FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">148000000</teva:FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate>
    <teva:FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">166000000</teva:FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">155000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">178000000</us-gaap:LeaseCost>
    <teva:SupplementalCashFlowInformationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental cash flow information related to operating leases was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%;"/&gt;
&lt;td style="vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 60%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets obtained in exchange for lease obligations &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(non-cash):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 60%; padding-bottom: 2.2pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 16%; padding-bottom: 2.2pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 2.5pt double black;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;"&gt;211&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 2.2pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 2.2pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 2.5pt double black;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:SupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">151000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">169000000</us-gaap:OperatingLeasePayments>
    <teva:OperatingLeasesNonCash
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">211000000</teva:OperatingLeasesNonCash>
    <teva:OperatingLeasesNonCash
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">142000000</teva:OperatingLeasesNonCash>
    <teva:SupplementalBalanceSheetInformationRelatedToLeasesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental balance sheet information related to operating leases was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 18%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease ROU assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;559&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;116&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;595&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;553&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 18%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 17%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;7.5&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;7.5&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:SupplementalBalanceSheetInformationRelatedToLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">559000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">514000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <teva:OperatingLeaseLiabilityOther
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">116000000</teva:OperatingLeaseLiabilityOther>
    <teva:OperatingLeaseLiabilityOther
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">118000000</teva:OperatingLeaseLiabilityOther>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">479000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">435000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">595000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">553000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020">P7Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2019">P7Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.052</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of operating lease liabilities were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;91 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025 and thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;302 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;722 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 82%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;595 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 82%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">137000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">119000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">91000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">73000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <teva:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">302000000</teva:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">722000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <teva:OperatingLeasesImputedInterest
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">127000000</teva:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">595000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2020_MinimumMembersrtRangeAxis"
      decimals="-6"
      unitRef="Unit_USD">74000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn09_30_2020_MaximumMembersrtRangeAxis"
      decimals="-6"
      unitRef="Unit_USD">66000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">21000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 9&#x2014;Debt obligations: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term debt: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td colspan="3" style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; interest rate as of&lt;br/&gt; December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible debentures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 7%; text-align: center;"&gt;0.25%&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td colspan="5" style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current maturities of long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,674 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,831 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="5" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td colspan="5" style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total short term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;3,188 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,345 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="5" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible senior debentures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva 0.25% convertible senior debentures, due 2026, principal amount as of December&#160;31, 2020 and 2019 were $514 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. These convertible senior debentures include a &#x201c;net share settlement&#x201d; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#x201c;net share settlement&#x201d; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. Holders of the convertible debentures were able to cause Teva to redeem the debentures on February 1, 2021, and $491 million of the convertible debentures were redeemed on such date.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 100%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 0pt;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; interest rate as of&lt;br/&gt; December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,010&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million (1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;0.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,500&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;1.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,839 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,673&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,300&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,595&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 900&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 750&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;1.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;916 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;833 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 700&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;3.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;861 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 700&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;860&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;782&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,000&#160;million&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,120&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,000&#160;million&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;7.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 3,500&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;3.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;3,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;3,494 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,475&#160;million&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;2.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 3,000&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;2,996&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;2,995&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 2,000&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;4.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,985&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;6.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 844&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;2.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;853 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 789&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;6.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;783 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;782&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 700&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million (2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;2.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 613&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;3.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;616&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;618 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 588&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;3.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;586&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;587 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;397 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;361 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%; padding-bottom: 0.45pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right; padding-bottom: 0.45pt;;width:6%;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;;width:4%;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;"&gt;398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;"&gt;362 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total senior notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;25,490 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;26,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;1.08 &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;1 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less current maturities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;(2,674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;(1,831&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less debt issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;(86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;(103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total senior notes and loans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;22,731&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;24,562 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July&#160;&lt;/div&gt;2020&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Teva repaid at maturity &#x20ac;&lt;/div&gt;1,010 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of its&lt;/div&gt;&#160;0.375% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;senior notes.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March&#160;&lt;/div&gt;2020&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Teva repaid at maturity $&lt;/div&gt;700&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of its&lt;/div&gt;&#160;2.25% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;senior notes.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts (as defined), if any. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term debt as of December&#160;31, 2020 is effectively denominated in the following currencies: U.S. dollar 60%, euro 37% and Swiss franc 3%. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $2.3 billion&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;unsecured syndicated&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;revolving credit facility&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;entered into in April 2019&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(&#x201c;RCF&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The RCF agreement provides for two separate tranches, a&lt;/div&gt; $1.15 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion tranche A and a&lt;/div&gt;&#160;$1.15 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion tranche B. Loans and letters of credit will be available from time to time under each tranche for Teva&#x2019;s general corporate purposes. Tranche A has a maturity date of April 8, 2022, with two one-year extension options, of which $1.065 billion was extended to April 8, 2023. Tranche B has a maturity date of April 8, 2024.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time.&lt;/div&gt; The net debt to EBITDA ratio limit was 5.75x through December 31, 2020, gradually declines to 5.50x in the first and second quarters of 2021, 5.00x in the third and fourth quarters of 2021, and continues to gradually decline over the remaining term of the RCF. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The RCF can be used for general corporate purposes, including repaying existing debt. As of December&#160;31, 2020, and as of the date of this Annual Report on Form 10-K, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date these financial statements are issued. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes is outstanding, could lead to an event of default under the Company&#x2019;s senior notes due to cross acceleration provisions.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that these financial statements are issued.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the required annual principal payments of long-term debt, excluding debt issuance cost, including convertible senior debentures, starting from the year 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;, are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4,591&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,089&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,735 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;2026 and thereafter *&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;9,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23,330 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 2%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Including $514&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million convertible notes. See note 9a. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term debt: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td colspan="3" style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; interest rate as of&lt;br/&gt; December&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible debentures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 7%; text-align: center;"&gt;0.25%&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td colspan="5" style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current maturities of long-term liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,674 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,831 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="5" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td colspan="5" style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total short term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;3,188 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,345 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td colspan="5" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis">2026</teva:DebtInstrumentMaturityYear>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">514000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn12_31_2019_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">514000000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2674000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1831000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">3188000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2345000000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0025</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2020_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">514000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2019_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">514000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn02_01_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">491000000</us-gaap:DebtInstrumentCarryingAmount>
    <teva:LongTermDebtExcludingConvertibleDebtTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 100%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 0pt;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; interest rate as of&lt;br/&gt; December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,010&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million (1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;0.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,500&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;1.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,839 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,673&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,300&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;1.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,595&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,451&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 900&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;4.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 750&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;1.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;916 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;833 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 700&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;3.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;861 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 700&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;1.88&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;860&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;782&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes EUR 1,000&#160;million&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;1,230&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,120&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,000&#160;million&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;7.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,000&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 3,500&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;3.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;3,495&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;3,494 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,475&#160;million&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;"&gt;2.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"&gt;1,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 3,000&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;2.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;"&gt;2023&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;2,996&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"&gt;2,995&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 2,000&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;4.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,985&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2024&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 1,250&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;6.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2028&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;1,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 844&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;2.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;853 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 789&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;6.15&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2036&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;783 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;782&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 700&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million (2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;2.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2020&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 613&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;3.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;616&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;618 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes USD 588&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;3.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;586&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;587 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;397 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;361 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%; padding-bottom: 0.45pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes CHF 350&#160;million&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right; padding-bottom: 0.45pt;;width:6%;"&gt;1.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;;width:4%;"&gt;2025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;"&gt;398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;"&gt;362 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total senior notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;25,490 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;26,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other long-term debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;1.08 &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;"&gt;2026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;1 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less current maturities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;(2,674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;(1,831&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less debt issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;(86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;"&gt;(103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total senior notes and loans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;22,731&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;"&gt;24,562 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July&#160;&lt;/div&gt;2020&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Teva repaid at maturity &#x20ac;&lt;/div&gt;1,010 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of its&lt;/div&gt;&#160;0.375% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;senior notes.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March&#160;&lt;/div&gt;2020&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Teva repaid at maturity $&lt;/div&gt;700&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of its&lt;/div&gt;&#160;2.25% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;senior notes.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:LongTermDebtExcludingConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1010000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_17703224"
      unitRef="Unit_pure">0.0038</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis"
      id="Fact_17702857">2020</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_17702859"
      unitRef="Unit_USD">1131000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0113</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis">2024</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1839000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2024MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1673000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis">2023</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1595000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2023OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1451000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0450</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1107000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1008000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0163</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis">2028</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">916000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2028MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">833000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0325</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis">2022</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">861000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">784000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0188</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis">2027</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">860000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2027MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">782000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_EUR">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0600</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1230000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1120000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0713</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0315</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis">2026</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3495000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2026OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3494000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1475000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0220</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis">2021</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1472000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1474000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0280</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis">2023</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">2996000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2023TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">2995000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0410</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis">2046</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1986000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2046MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1985000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0600</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis">2024</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2024OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis">2028</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2028OneMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1250000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">844000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0295</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis">2022</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">853000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">856000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">789000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0615</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis">2036</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">783000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2036MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">782000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="Fact_17703207"
      unitRef="Unit_pure">0.0225</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear
      contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis"
      id="Fact_17702929">2020</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2020TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="Fact_17702931"
      unitRef="Unit_USD">700000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">613000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0365</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis">2021</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">616000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">618000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">588000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0365</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis">2021</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">586000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">587000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_CHF">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0050</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis">2022</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">397000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2022ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">361000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_CHF">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0100</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis">2025</teva:DebtInstrumentMaturityYear>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">398000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2025ThreeMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">362000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">25490000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">26496000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0108</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:DebtInstrumentMaturityYear contextRef="P01_01_2020To12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis">2026</teva:DebtInstrumentMaturityYear>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2020_OtherDebentures2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2019_OtherDebentures2026MemberusgaapDebtInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2674000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1831000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">86000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">103000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">22731000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:LongTermNotesAndLoans
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">24562000000</us-gaap:LongTermNotesAndLoans>
    <us-gaap:SeniorNotes
      contextRef="PAsOn07_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_EUR">1010000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn07_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="5"
      unitRef="Unit_pure">0.00375</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn03_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0225</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <teva:LongTermDebtCurrencyPortionUSD
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.60</teva:LongTermDebtCurrencyPortionUSD>
    <teva:LongTermDebtCurrencyPortionEUR
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.37</teva:LongTermDebtCurrencyPortionEUR>
    <teva:LongTermDebtCurrencyPortionCHF
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.03</teva:LongTermDebtCurrencyPortionCHF>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-8"
      unitRef="Unit_USD">2300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LinesOfCreditCurrent
      contextRef="PAsOn04_30_2019"
      decimals="-7"
      unitRef="Unit_USD">1150000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="PAsOn11_30_2015"
      decimals="-7"
      unitRef="Unit_USD">1150000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="PAsOn04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheAExtensionMemberusgaapLineOfCreditFacilityAxis_TracheAMemberTEVATrancheAxis"
      decimals="-6"
      unitRef="Unit_USD">1065000000.000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="P04_01_2019To04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheAExtensionMemberusgaapLineOfCreditFacilityAxis_TracheAMemberTEVATrancheAxis">2023-04-08</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="P04_01_2019To04_30_2019_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TracheBMemberTEVATrancheAxis">2024-04-08</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:DebtInstrumentCovenantDescription contextRef="P01_01_2020To12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">The net debt to EBITDA ratio limit was 5.75x through December 31, 2020, gradually declines to 5.50x in the first and second quarters of 2021, 5.00x in the third and fourth quarters of 2021, and continues to gradually decline over the remaining term of the RCF.</us-gaap:DebtInstrumentCovenantDescription>
    <us-gaap:LineOfCredit
      contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the required annual principal payments of long-term debt, excluding debt issuance cost, including convertible senior debentures, starting from the year 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;, are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4,591&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,089&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,735 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;2026 and thereafter *&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;9,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23,330 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 2%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Including $514&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million convertible notes. See note 9a. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2111000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4591000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">3089000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">3735000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <teva:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      id="Fact_17703057"
      unitRef="Unit_USD">9804000000</teva:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter>
    <teva:LongTermDebtaExcludeIssuanceCost
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">23330000000</teva:LongTermDebtaExcludeIssuanceCost>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2020_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">514000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="/* background-color: rgb(255, 255, 255); */letter-spacing: 0px;top: 0px;;display:inline;"&gt;NOTE 10&#x2014;Derivative instruments and hedging &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;activities&lt;/div&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign exchange risk management: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2020, approximately 48% of Teva&#x2019;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;subject &lt;/div&gt;to significant foreign currency risks. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company enters into forward exchange contracts, purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: the euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar, the Polish zloty, the Indian rupee and other European and Latin American currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#x201c;net investment hedge&#x201d;) and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest risk management: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company raises capital through various debt instruments, including straight notes that bear a fixed or variable interest rate, bank loans and convertible debentures. In some cases, the Company has swapped from a fixed to a floating interest rate (&#x201c;fair value hedge&#x201d;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#x201c;cash flow hedge&#x201d;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative instrument disclosure: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cross-currency swap&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net investment hedge&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative instrument outstanding: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the classification and fair values of derivative instruments: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Not designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; padding: 0pt; white-space: nowrap;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Cross-currency swaps&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;, &lt;/div&gt;net investment&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;hedge&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(22)&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The table below provides information regarding the location and amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; (gains) losses from derivatives designated in fair value or cash flow hedging relationships: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other comprehensive&lt;br/&gt; income&#160;(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2020&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2019&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2018**&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2020&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2019&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2018**&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;834 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;822&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(585&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Cross-currency swaps&#x2014;cash flow hedge (1)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Cross-currency swaps&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net investment hedge (2)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Interest rate swaps&#x2014;fair value hedge (3)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;**&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comparative figures are based on prior hedge accounting standard. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The table below provides information regarding the location and amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; (gains) losses from derivatives not designated as hedging instruments: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2020&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2019&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2018&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;822&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,887&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts (4)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&#160; (5)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588&#160;million in cross-currency swap agreements against its &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500&#160;&lt;/div&gt; million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva&#x2019;s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;float-for-float&lt;/div&gt;&lt;/div&gt; interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3&#160;million. &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500&#160;million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(4)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(5)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. During 2019 and 2020, Teva entered into hedging instruments to hedge part of the projected 2020 operating results. In 2020, Teva recognized a gain of $27&#160;million in relation with the 2020 hedging program. During the second half of 2020, Teva entered into hedging instruments to hedge part of the projected operating results for 2021. As part of the economic hedge treatment, Teva recorded a loss of $27&#160;million in relation to the 2021 hedging instruments in the second half of 2020, while the positive foreign exchange impact on the underlying revenues and expenses, may occur upon their maturity in 2021. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortizations due to terminated derivative instruments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward starting interest rate swaps and treasury lock agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;margin-left: 0%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position of $493&#160;million, which was recorded in other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to these forward starting interest rate swaps and treasury lock agreements, losses of &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$31 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $29 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million and &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $28 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million were recognized under financial expenses, net for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value hedge &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its 2.95% senior notes due 2022 with respect to $844&#160;million notional amount and its 3.65% senior notes due 2021 with respect to $450&#160;million notional amount. Settlement of these transactions resulted in a gain position of $41&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the third quarter of 2019, Teva terminated $500&#160;million interest rate swap agreements designated as a fair value hedge relating to its 2.8% senior notes due 2023 with respect to $3,000&#160;million notional amount. Settlement of these transactions resulted in cash proceeds of $10&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash flow hedge &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;margin-left: 0%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the fourth quarter of 2019, Teva terminated $588 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million cross-currency swap agreements against its &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;outstanding 3.65% &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;senior notes maturing in November 2021. Settlement of these transactions resulted in cash proceeds of &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$95 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to the interest rate swap and cross-currency swap agreements,&#160;gains of &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$3 million, $6 million and $6 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million were recognized under financial expenses, net for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;f.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Securitization: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2011, Teva established a trade receivables securitization program to sell trade receivables to BNP Paribas Bank (&#x201c;BNP&#x201d;). Under the program Teva (on a consolidated basis) receives an initial cash purchase price and the right to receive a deferred purchase price (&#x201c;DPP&#x201d;), according to the purchase price for the receivables sold by it. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On an individual seller basis, each Teva subsidiary sells receivables to BNP for an amount equal to their nominal amount. BNP then immediately &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-sells&lt;/div&gt; such receivables to a bankruptcy-remote special-purpose entity (&#x201c;SPE&#x201d;), for an amount equal to the nominal amount of such trade receivables. The SPE then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-sells&lt;/div&gt; such receivables to a conduit sponsored by BNP (&#x201c;the conduit&#x201d;) for an initial cash purchase price (equal to the nominal amount of such receivables less a discount) and the right to receive a DPP. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The SPE is a VIE for which Teva is considered to be the primary beneficiary. The SPE&#x2019;s sole business consists of the purchase of receivables from Teva subsidiaries and the subsequent transfer of such receivables to the conduit. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Although the SPE is included in Teva&#x2019;s consolidated financial statements, it is a separate legal entity with separate creditors. The conduit and other designated creditors of the SPE are entitled, both before and upon the SPE&#x2019;s liquidation, to be paid out of the SPE&#x2019;s assets prior to the DPP payable to Teva. The assets of the SPE are not available to pay creditors of Teva or its subsidiaries.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This program expires on August&#160;21, 2021 but can be renewed with consent from the parties to the program up to August&#160;20, 2022 or any other date agreed between the parties. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Once sold to BNP, the relevant Teva subsidiary as seller has no retained interests in the receivables sold and they are unavailable to the relevant seller should the relevant seller become insolvent. The conduit has all the rights in the securitized trade receivables, including the right to pledge or dispose of such receivables. Consequently, receivables sold under this agreement are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;de-recognized&lt;/div&gt; from Teva&#x2019;s consolidated balance sheet. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The portion of the purchase price for the receivables which is not paid in cash by the conduit is a DPP asset. The conduit pays the SPE the DPP from collections received by the conduit from the securitized trade receivables (after paying senior costs and expenses, including the conduit&#x2019;s debt service obligations), which the SPE then pays to Teva.The DPP asset represents a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The DPP asset is included in other current assets on Teva&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva has collection and administrative responsibilities for the sold receivables. The fair value of these servicing arrangements as well as the fees earned was immaterial. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;DPP asset as of December&#160;31, 2020 and 2019 was &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$266 million and $250 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020 and 2019, the balance of Teva&#x2019;s securitized assets sold were &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$734 million and $690 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the sold receivables outstanding balance net of DPP asset under the outstanding securitization program: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 0pt;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;and&#160;for&#160;the&#160;year&#160;ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sold receivables at the beginning of the year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Proceeds from sale of receivables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash collections (remitted to the owner of the receivables)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of currency exchange rate changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sold receivables at the end of the year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;734&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <teva:RevenuesOtherThanUsd
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.48</teva:RevenuesOtherThanUsd>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cross-currency swap&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net investment hedge&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the classification and fair values of derivative instruments: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 54%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Not designated as hedging&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability derivatives:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 39%; padding: 0pt; white-space: nowrap;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Cross-currency swaps&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;, &lt;/div&gt;net investment&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;hedge&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(22)&lt;/div&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 54%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn12_31_2020_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">24000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="PAsOn12_31_2019_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn12_31_2020_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis_SwapMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">22000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn12_31_2020_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">79000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn12_31_2019_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_NondesignatedMemberusgaapHedgingDesignationAxis_SeniorNotesAndLoansMemberusgaapBalanceSheetLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">41000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The table below provides information regarding the location and amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; (gains) losses from derivatives designated in fair value or cash flow hedging relationships: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other comprehensive&lt;br/&gt; income&#160;(loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2020&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2019&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2018**&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2020&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2019&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2018**&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;834 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;822&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(585&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Cross-currency swaps&#x2014;cash flow hedge (1)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Cross-currency swaps&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;net investment hedge (2)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Interest rate swaps&#x2014;fair value hedge (3)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;**&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comparative figures are based on prior hedge accounting standard. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">834000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">822000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2017To12_31_2017_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="Fact_17704207"
      unitRef="Unit_USD">959000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-30000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">160000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704198"
      unitRef="Unit_USD">-585000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="Fact_17704362"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="Fact_17704218"
      unitRef="Unit_USD">-2000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2017To12_31_2017_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="Fact_17704206"
      unitRef="Unit_USD">-2000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704361"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704217"
      unitRef="Unit_USD">-33000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704197"
      unitRef="Unit_USD">-35000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis"
      decimals="-6"
      id="Fact_17704212"
      unitRef="Unit_USD">-2000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis"
      decimals="-6"
      id="Fact_17704216"
      unitRef="Unit_USD">-29000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2017To12_31_2017_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis"
      decimals="-6"
      id="Fact_17704205"
      unitRef="Unit_USD">-31000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704211"
      unitRef="Unit_USD">-21000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704215"
      unitRef="Unit_USD">-22000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704196"
      unitRef="Unit_USD">-51000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="Fact_17704360"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_FinancialExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      id="Fact_17704359"
      unitRef="Unit_USD">2000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704358"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704357"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_FairValueHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis"
      decimals="-6"
      id="Fact_17704356"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetRevenuesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The table below provides information regarding the location and amount of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-tax&lt;/div&gt; (gains) losses from derivatives not designated as hedging instruments: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2020&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2019&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2018&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported under&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Line items in which effects of hedges are recorded&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;822&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,887&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts (4)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option and forward contracts&#160; (5)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Represents an amount less than $0.5&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588&#160;million in cross-currency swap agreements against its &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500&#160;&lt;/div&gt; million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva&#x2019;s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;float-for-float&lt;/div&gt;&lt;/div&gt; interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3&#160;million. &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500&#160;million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(4)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(5)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. During 2019 and 2020, Teva entered into hedging instruments to hedge part of the projected 2020 operating results. In 2020, Teva recognized a gain of $27&#160;million in relation with the 2020 hedging program. During the second half of 2020, Teva entered into hedging instruments to hedge part of the projected operating results for 2021. As part of the economic hedge treatment, Teva recorded a loss of $27&#160;million in relation to the 2021 hedging instruments in the second half of 2020, while the positive foreign exchange impact on the underlying revenues and expenses, may occur upon their maturity in 2021. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">834000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">822000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">959000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">16659000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">16887000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      unitRef="Unit_USD">18271000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_17704950"
      unitRef="Unit_USD">130000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_17704949"
      unitRef="Unit_USD">-51000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentTradingMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_17704944"
      unitRef="Unit_USD">-12000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_17704867"
      unitRef="Unit_USD">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2019To12_31_2019_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_17704947"
      unitRef="Unit_USD">14000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2018To12_31_2018_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-6"
      id="Fact_17705120"
      unitRef="Unit_USD">-4000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NotDesignatedAsHedgingInstrumentEconomicHedgeMemberusgaapHedgingDesignationAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">588000000</teva:NotionalAmountHedgeDebt>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0365</teva:PreviouslyHedgeDebtRate>
    <teva:CashReceivedOnSettlementOfPosition
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">95000000</teva:CashReceivedOnSettlementOfPosition>
    <teva:CashReceivedOnSettlementOfPosition
      contextRef="PAsOn12_31_2020_SeniorNotesDue2020MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">500000000</teva:CashReceivedOnSettlementOfPosition>
    <teva:CashReceivedOnSettlementOfPosition
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">3000000</teva:CashReceivedOnSettlementOfPosition>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn12_31_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="3"
      unitRef="Unit_pure">0.028</teva:PreviouslyHedgeDebtRate>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn12_31_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">500000000</teva:NotionalAmountHedgeDebt>
    <teva:SettlementGainPosition
      contextRef="PAsOn12_31_2020_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</teva:SettlementGainPosition>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2020To12_31_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">27000000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2020To12_31_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis_HedgingOfRevenuesTwoThousandAndTwentyOneMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis"
      decimals="-6"
      unitRef="Unit_USD">27000000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">493000000</us-gaap:DerivativeLossOnDerivative>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">31000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">29000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">28000000</teva:ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0295</teva:PreviouslyHedgeDebtRate>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn09_30_2016_SeniorNotesDue2022MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">844000000</teva:NotionalAmountHedgeDebt>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0365</teva:PreviouslyHedgeDebtRate>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn09_30_2016_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">450000000</teva:NotionalAmountHedgeDebt>
    <us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss
      contextRef="P07_01_2016To09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">41000000</us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">500000000</teva:NotionalAmountHedgeDebt>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="3"
      unitRef="Unit_pure">0.028</teva:PreviouslyHedgeDebtRate>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn09_30_2016_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000000</teva:NotionalAmountHedgeDebt>
    <teva:CashReceivedOnSettlementOfPosition
      contextRef="PAsOn09_30_2019_SeniorNotesDue2023TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</teva:CashReceivedOnSettlementOfPosition>
    <teva:NotionalAmountHedgeDebt
      contextRef="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">588000000</teva:NotionalAmountHedgeDebt>
    <teva:PreviouslyHedgeDebtRate
      contextRef="PAsOn12_31_2019_SubsidiarySeniorNotesDue2021TwoMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0365</teva:PreviouslyHedgeDebtRate>
    <teva:CashReceivedOnSettlementOfPosition
      contextRef="PAsOn12_31_2019_SeniorNotesDue2021MemberusgaapDerivativeInstrumentRiskAxis"
      decimals="-6"
      unitRef="Unit_USD">95000000</teva:CashReceivedOnSettlementOfPosition>
    <teva:InterestRateSwapGain
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">3000000</teva:InterestRateSwapGain>
    <teva:InterestRateSwapGain
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6000000</teva:InterestRateSwapGain>
    <teva:InterestRateSwapGain
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">6000000</teva:InterestRateSwapGain>
    <teva:DeferredPurchaseAsset
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">266000000</teva:DeferredPurchaseAsset>
    <teva:DeferredPurchaseAsset
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">250000000</teva:DeferredPurchaseAsset>
    <us-gaap:AccountsReceivableFromSecuritization
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">734000000</us-gaap:AccountsReceivableFromSecuritization>
    <us-gaap:AccountsReceivableFromSecuritization
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">690000000</us-gaap:AccountsReceivableFromSecuritization>
    <teva:ScheduleOfAccountReceivableFromSecuritization contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the sold receivables outstanding balance net of DPP asset under the outstanding securitization program: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 0pt;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;and&#160;for&#160;the&#160;year&#160;ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sold receivables at the beginning of the year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Proceeds from sale of receivables&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash collections (remitted to the owner of the receivables)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of currency exchange rate changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sold receivables at the end of the year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;734&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfAccountReceivableFromSecuritization>
    <us-gaap:AccountsReceivableFromSecuritization
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">690000000</us-gaap:AccountsReceivableFromSecuritization>
    <us-gaap:AccountsReceivableFromSecuritization
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">686000000</us-gaap:AccountsReceivableFromSecuritization>
    <us-gaap:ProceedsFromAccountsReceivableSecuritization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4606000000</us-gaap:ProceedsFromAccountsReceivableSecuritization>
    <us-gaap:ProceedsFromAccountsReceivableSecuritization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4852000000</us-gaap:ProceedsFromAccountsReceivableSecuritization>
    <us-gaap:RepaymentsOfAccountsReceivableSecuritization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4607000000</us-gaap:RepaymentsOfAccountsReceivableSecuritization>
    <us-gaap:RepaymentsOfAccountsReceivableSecuritization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4849000000</us-gaap:RepaymentsOfAccountsReceivableSecuritization>
    <teva:EffectOfExchangeRateOnAccountsReceivableFromSecuritization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">45000000</teva:EffectOfExchangeRateOnAccountsReceivableFromSecuritization>
    <teva:EffectOfExchangeRateOnAccountsReceivableFromSecuritization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1000000</teva:EffectOfExchangeRateOnAccountsReceivableFromSecuritization>
    <us-gaap:AccountsReceivableFromSecuritization
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">734000000</us-gaap:AccountsReceivableFromSecuritization>
    <us-gaap:AccountsReceivableFromSecuritization
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">690000000</us-gaap:AccountsReceivableFromSecuritization>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 11&#x2014;Legal settlements and loss contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal settlements and loss contingencies for 2020 amounted to expenses of $60&#160;million, compared to expenses of $1,178&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;in 2019&#160;&lt;/div&gt;&lt;/div&gt;and an income of $1,208&#160;million in &#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018.&lt;/div&gt;&#160;The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). The expenses in 2019 were mainly related to an estimated provision recorded in connection with potential settlement of the opioid cases. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020 and 2019, Teva&#x2019;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $1,625&#160;million and $1,580&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">60000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1178000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1208000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <teva:RestructuringExpenseAndIncome contextRef="P01_01_2020To12_31_2020_SettlementOnAccountOfProductLiabilityMembersrtLitigationCaseAxis_USsrtStatementGeographicalAxis">The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). The expenses in 2019 were mainly related to an estimated provision recorded in connection with potential settlement of the opioid cases.</teva:RestructuringExpenseAndIncome>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1625000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1580000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 12&#x2014;Commitments and contingencies:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalty commitments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company is committed to pay royalties to owners of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how,&lt;/div&gt; partners in alliances and other certain arrangements and to parties that financed research and development, at a wide range of rates as a percentage of sales or of the gross margin of certain products, as defined in the underlying agreements. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Until September&#160;30, 2018, royalty expenses were reported in cost of goods sold if related to the acquisition of a product, and if not, such expenses were included in S&amp;amp;M expenses. Commencing October&#160;1, 2018, royalty expenses are retroactively reported entirely under cost of goods sold. Royalty expenses in each of the years ended December&#160;31, 2020, 2019 and 2018 were $505 million, $403 million and $536 million, respectively. &lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone commitments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva has committed to make potential future milestone payments to third parties under various agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events,&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;it is unclear when, if ever, Teva may be required to pay such amounts. As of December&#160;31, 2020, if all milestones and targets, for compounds in phase 2 and more advanced stages of development, are achieved, the total contingent payments could reach an aggregate amount of up to $509&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of the cases described below, management&#x2019;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#x2019;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters that the Company has determined no longer meet the materiality threshold for disclosure. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#x2019;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA (formerly IMS Health Inc.) data. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intellectual Property Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, Teva seeks to develop generic versions of patent-protected pharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#x2019;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#x2019;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic version even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act. For example, Teva could be sued for patent infringement after commencing sales of a product. In addition, for biosimilar products, Teva could be sued according to the &#x201c;patent dance&#x201d; procedures of the Biologics Price Competition and Innovation Act (BPCIA). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#x2019;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#x2019;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In July 2014, GlaxoSmithKline (&#x201c;GSK&#x201d;) sued Teva in Delaware federal court for infringement of a patent expiring in June 2015 directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#x2019;s Coreg&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#x2019;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $235.5&#160;million, not including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-&lt;/div&gt; or post-judgment interest or a multiplier for willfulness. Following post-trial motions filed by the parties, on March&#160;28, 2018, the district court issued an opinion overturning the jury verdict and instead found no induced infringement by Teva, thereby finding that Teva did not owe any damages; the district court also denied Teva&#x2019;s motion seeking to overturn the jury verdict with respect to invalidity. The provision that was originally included in the financial statements following the damages verdict in this matter in 2017 was reversed in 2018, following the opinion overturning the verdict as the exposure was no longer considered probable. On October&#160;2, 2020, the Court of Appeals for the Federal Circuit overturned the lower court&#x2019;s ruling and reinstated the jury verdict in a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-to-one&lt;/div&gt;&lt;/div&gt; decision. On December&#160;2, 2020, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva filed a request for panel and en banc review. On February 9, 2021, the Federal Circuit granted panel rehearing. In its February 9, 2021 order, the Court vacated the October 2, 2020 judgment and scheduled oral argument for February 23, 2021. The Court will hear oral argument only on the issue of whether there is enough evidence to support the jury&#x2019;s verdict of induced infringement during the time period from January 8, 2008 through April 30, 2011 (the &#x201c;skinny label&#x201d; period). If further appeals are decided against Teva, the case would be remanded to the district court for it to consider Teva&#x2019;s other legal and equitable defenses that have not yet been considered by the district court.&#160;&lt;/div&gt; &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2014, Teva Canada succeeded in its challenge of the bortezomib (the generic equivalent of Velcade&#xae;) product and mannitol ester patents under the Patented Medicines (Notice Of Compliance) Regulations (&#x201c;PM (NOC)&#x201d;). At the time of Teva&#x2019;s launch in 2015, annual sales of Velcade were approximately&lt;/div&gt;&lt;/div&gt;&#160;94&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million Canadian dollars. Additionally, Teva commenced an action under Section 8 of PM (NOC) to recover damages for being kept off of the market during the PM (NOC) proceedings. Janssen and Millennium filed a counterclaim for infringement of the same two patents as well as a patent covering a process to prepare bortezomib. The product patent expired in October 2015; the other patents expire in January 2022 and March 2025. In 2017, Teva entered into an agreement with Janssen and Millennium which limited the damages payable by either party depending on the outcome of the infringement/impeachment action. As a result, the most Janssen and Millennium could have recovered is&lt;/div&gt; 200&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million Canadian dollars plus post-judgment interest. In June 2018, the court ruled that Janssen and Millennium pay Teva&lt;/div&gt; 5&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million Canadian dollars in Section 8 damages. Janssen and&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Millennium filed an appeal, which was denied by the appellate court on November&#160;4, 2019. On January&#160;3, 2020, Janssen and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Millennium applied for leave to appeal to the Canadian Supreme Court. On May&#160;8, 2020, the Canadian Supreme Court denied Janssen and Millennium&#x2019;s application. This matter is now closed.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product Liability Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both approaches, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (API) supplied by multiple API manufacturers. Teva&#x2019;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#x201c;MDL&#x201d;) pending in the United States District Courts. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring claims. Defendants&#x2019; motions to dismiss in the valsartan, losartan and irbesartan MDL were denied in part and granted in part, allowing plaintiffs to file amended complaints.&#160;On December&#160;31, 2020, the court in the ranitidine MDL granted the generic defendants&#x2019; motion to dismiss on the grounds of preemption and deficient pleading, allowing plaintiffs to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-plead&lt;/div&gt; certain claims. Certain plaintiffs appealed the decision. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#x2019;s, as well as other generic manufacturers&#x2019; metformin products. A motion to dismiss in that consolidated action is pending. Similar lawsuits are pending in Canada and Germany.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Competition Matters &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#x2019;s patent challenges have resulted in litigation relating to Teva&#x2019;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva and its subsidiaries have increasingly been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases, which are usually direct and indirect purchasers of pharmaceutical products, and often assert claims on behalf of classes of all direct and indirect purchasers, typically allege that (1)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (2)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These class action cases seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;what the generic price allegedly would have been and disgorgement of profits, which are automatically tripled under the relevant statutes, plus attorneys&#x2019; fees and costs. The alleged damages generally depend on the size of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the branded market and the length of the alleged delay, and can be substantial&#x2014;potentially measured in multiples of the annual brand sales&#x2014;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#x2019;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#x201c;FTC&#x201d;) v. Actavis, Inc. (the &#x201c;AndroGel case&#x201d;), that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva&#x2019;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#x2019;s currently pending antitrust litigations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning in April 2006, certain subsidiaries of Teva were named in a class action lawsuit filed in the U.S. District Court for the Eastern District of Pennsylvania with allegations that the settlement agreements entered into between Cephalon, Inc., now a Teva subsidiary (&#x201c;Cephalon&#x201d;), and various generic pharmaceutical companies in late 2005 and early 2006 to resolve patent litigation involving certain finished modafinil products (marketed as PROVIGIL&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;) were unlawful because they had the effect of excluding generic competition. The cases also allege that Cephalon improperly asserted its PROVIGIL patent against the generic pharmaceutical companies. Separately, Apotex challenged Cephalon&#x2019;s PROVIGIL patent and, in October 2011, the court found the patent to be invalid and unenforceable based on inequitable conduct. Teva has either settled or reached agreements in principle to settle with all plaintiffs in such cases, except for an action brought by the State of Louisiana. The settlement with the State of California that was reached in 2019 received final court approval in June 2020. All settlements entered into in connection with the above proceeding are covered by the settlement fund explained below. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 12pt;margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2015, Cephalon entered into a consent decree with the FTC (the &#x201c;Modafinil Consent Decree&#x201d;) under which the FTC dismissed its claims against Cephalon in the FTC Modafinil Action in exchange for payment of&lt;/div&gt;&#160;$1.2&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion (less set-offs for prior settlements) by Cephalon and Teva into a settlement fund. Under the Modafinil Consent Decree, Teva also agreed to certain injunctive relief with respect to the types of settlement agreements Teva may enter into to resolve patent litigation in the United States for a period of ten years. The remaining balance of the settlement fund after consideration of the settlement with the State of California noted above is approximately&lt;/div&gt;&#160;$19&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. In February 2019, in connection with the settlement of other unrelated FTC antitrust lawsuits, as described below, Teva and the FTC agreed to amend certain non-financial provisions of the Modafinil Consent Decree and to restart its ten-year term.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, the European Commission issued a Statement of Objections and a Supplementary Statement of Objection in July 2017 and June 2020, respectively, and a final decision against both Cephalon and Teva in November 2020, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling &#x20ac;60.5&#160;million on Teva and Cephalon. Teva and Cephalon&#160;filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva and its affiliates have been named as defendants in lawsuits that allege that multiple patent litigation settlement agreements relating to AndroGel&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; 1% (testosterone gel) violate the antitrust laws. The first of these lawsuits (the &#x201c;Georgia AndroGel Litigation&#x201d;) was filed in January 2009 in California federal court, and later transferred to Georgia federal court, with the FTC and the State of California, and later private plaintiffs, &lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0);font-family: 'Times New Roman';font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: left;text-indent: 0px;text-transform: none;white-space: normal;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;/* background-color: rgb(255, 255, 255); */text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;margin-top: 0pt;margin-bottom: 0pt;font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;challenging a September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#x201c;Watson&#x201d;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#x201c;Solvay&#x201d;). The second lawsuit (the &#x201c;Philadelphia AndroGel Litigation&#x201d;) was filed by the F&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;T&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;&#160;in September 2014 in federal court in Philadelphia, challenging Teva&#x2019;s December 2011 patent litigation settlement with AbbVie. The FTC stipulated to dismiss Teva from both litigations, in exchange for Teva&#x2019;s agreement to amend the Modafinil Consent Decree, as described above. On July 16, 2018, the direct purchaser plaintiffs&#x2019; motion for class certification in the Georgia AndroGel Litigation was denied and Teva later settled with most of the retailer plaintiffs in the Georgia AndroGel Litigation as well as the three direct purchasers that had sought class certification. These settlement amounts were paid in full. In addition, on January 7, 2021, Teva settled all claims with the remaining retailer plaintiff in the Georgia AndroGel Litigation and thus no claims remain in the Georgia AndroGel Litigation. In August 2019, certain other direct-purchaser plaintiffs (who would have been members of the direct purchaser class in the Georgia AndroGel Litigation, had it been certified) filed their own claims in the federal court in Philadelphia (where the Philadelphia AndroGel Litigation has been pending), challenging (in one complaint) both the September 2006 settlement between Watson and Solvay, and the December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AndroGel&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; 1% were approximately&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $350&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million at the time of the earlier Watson/Solvay settlement and approximately&lt;/div&gt; $140&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million at the time Actavis launched its generic version of AndroGel&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; 1% in November 2015. A provision for these matters was included in the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving extended release venlafaxine (generic Effexor XR&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;) entered into in November 2005. The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In October 2014, the court granted Teva&#x2019;s motion to dismiss in the direct purchaser cases, after which the parties agreed that the court&#x2019;s reasoning applied equally to the indirect purchaser cases. Plaintiffs appealed and, in August 2017, the Third Circuit reversed the district court&#x2019;s decision and remanded for further proceedings. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; were approximately&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $2.6&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion at the time of settlement and at the time Teva launched its generic version of Effexor XR&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; in July 2010. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;) entered into in February 2005. The plaintiffs claim that the settlement agreement unlawfully delayed generic entry and seek unspecified damages. In December 2012, the court dismissed the case, but in June 2015, the U.S. Court of Appeals for the Third Circuit reversed and remanded for further proceedings. In December 2018, the district court granted the direct-purchaser plaintiffs&#x2019; motion for class certification, but on April&#160;22, 2020, the Third Circuit reversed that ruling and remanded for further class certification proceedings. The district court&#x2019;s decision on the direct purchaser plaintiffs&#x2019; renewed motion for class certification remains pending. Annual sales of Lamictal&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; were approximately&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$950&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million at the time of the settlement and approximately&lt;/div&gt;&#160;$2.3&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion at the time Teva launched its generic version of Lamictal&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; in July 2008. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; (extended release niacin) sued Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005, to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#x2019; class. In August 2019, the district court certified the direct-purchaser class, but in June 2020, the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;court denied the indirect purchasers&#x2019; motion for class certification without prejudice. On September&#160;4, 2020, the indirect purchasers filed a renewed motion for class certification, which remains pending. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, which has since been amended, alleging violations of state law. Defendants moved to strike the District Attorney&#x2019;s claims for restitution and civil penalties to the extent not limited to alleged activity occurring in Orange County. The Superior Court denied that motion. The Court of Appeals subsequently reversed the decision and in June 2020, the California Supreme Court reversed the Court of Appeals&#x2019; decision, allowing the District Attorney&#x2019;s claims to proceed. Annual sales of Niaspan&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; were approximately&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $416&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million at the time of the settlement and approximately&#160;&lt;/div&gt;$1.1&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion at the time Teva launched its generic version of Niaspan&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; in September 2013.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning in 2013, several putative class actions were filed against Actavis, Inc. and certain of its affiliates, alleging that Watson&#x2019;s 2012 patent lawsuit settlement with Endo Pharmaceuticals Inc. relating to Lidoderm&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; (lidocaine transdermal patches) violated the antitrust laws. The cases were consolidated as a multidistrict litigation in federal court in California and were settled in 2018. The FTC also filed suit to challenge the Lidoderm&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; settlement, although in February&#160;2019, the FTC dismissed its claims against Actavis and Allergan, in exchange for Teva&#x2019;s agreement to amend the Modafinil Consent Decree, as described above. In July 2019, Teva also settled a complaint brought by the State of California. On September&#160;16, 2019, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payers&lt;/div&gt; Blue Cross Blue Shield of Michigan and Blue Care Network of Michigan (collectively &#x201c;BCBSM&#x201d;) filed their own lawsuit against Watson, and other defendants, in Michigan state court relating to the Lidoderm&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; settlement. Defendants moved to dismiss that lawsuit on June&#160;5, 2020, and those motions were granted in part and denied in part on October&#160;16, 2020. In January 2021, Watson and BCBSM reached an agreement in principle to settle the lawsuit. On January&#160;24, 2020, the State of Mississippi filed a complaint against Teva and Watson in Mississippi state court relating to the Lidoderm&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; settlement, which it subsequently amended on June&#160;12, 2020. Teva and Watson have moved to dismiss that amended complaint, and their motion remains pending. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payers&lt;/div&gt; for, and direct-purchasers of, Actos&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payers&#x2019;&lt;/div&gt; lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#x2019; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#x2019;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#x2019; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#x2019;s settlement, annual sales of Actos&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; and Actoplus Met were approximately&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$&lt;/div&gt;3.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion and approximately&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$&lt;/div&gt;500&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively. At the time Teva launched its authorized generic version of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actos&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actoplus Met in August 2012, annual sales of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actos&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; and &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actoplus Met were approximately&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; $&lt;/div&gt;2.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion and approximately&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$&lt;/div&gt;430&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2015, a purported class of end payers for Namenda IR&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; (memantine hydrochloride) filed a lawsuit against Forest Laboratories, LLC (&#x201c;Forest&#x201d;), the innovator, and several generic manufacturers, including Teva, alleging, among other things, that the settlement agreements between Forest and the generic manufacturers to resolve patent litigation over Namenda IR&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; violated the antitrust laws. Teva reached a settlement agreement with these plaintiffs in July 2020, which received preliminary approval on October&#160;13, 2020 and is awaiting final court approval. Annual sales of Namenda IR&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; at the time of the patent litigation settlement were approximately&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;1.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;billion and approximately&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;$&lt;/div&gt;550&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million at the time other manufacturers first launched generic versions of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Namenda IR&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; in July&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2015.&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;In January 2019, generic manufacturer Cipla Limited filed a lawsuit against Amgen, which was later amended to include Teva as a defendant, in Delaware federal court, alleging, among other things, that a January&#160;2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;), violated the antitrust laws. On August&#160;14, 2020, Cipla Limited agreed to dismiss its claims against Teva, with prejudice, and those claims have since been dismissed. Putative classes of direct-purchaser and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;end-payer&lt;/div&gt; plaintiffs have also filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva related to the January&#160;2, 2019 settlement. On July&#160;22, 2020, a magistrate judge recommended that plaintiffs&#x2019; claims be dismissed and on November&#160;30, 2020, the district court overruled the magistrate judge&#x2019;s recommendation, denied Teva&#x2019;s motion to dismiss in part, and instructed plaintiffs to file an amended complaint. Annual sales of Sensipar&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $1.4 billion at the time Teva launched its generic version of Sensipar&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; in December 2018, and at the time of the January&#160;2, 2019 settlement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;16, 2016, the U.K. Competition and Markets Authority (&#x201c;CMA&#x201d;) issued a statement of objections (a provisional finding of breach of the Competition Act) in respect of certain allegations against Allergan, Actavis UK and certain Auden Mckenzie entities alleging competition law breaches in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. On March&#160;3, 2017 and February&#160;28, 2019, the CMA issued second and third statements of objections in respect of certain additional allegations relating to the same products and covering part of the same time periods as in the first statement of objections. On February&#160;12, 2020, the CMA issued a Supplementary Statement of Objections effectively combining the three previously issued statements referenced above and a Statement of Draft Penalty Calculation was issued on October&#160;28, 2020. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to the December&#160;16, 2016 and March&#160;3, 2017 statements of objections, and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. A liability for this matter has been recorded in the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2019, the European Commission commenced an inspection of Teva and subsequently requested information for purposes of investigating whether Teva may have abused a dominant position in the Multiple Sclerosis field, dating back to at least 2014. No formal proceedings have been initiated. Annual sales of COPAXONE&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; in the European Economic Area for the past year were approximately $431&#160;million. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; retailer purchasers of Bystolic&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; violated the antitrust laws. The cases have been coordinated and remain in their preliminary stages, pending a decision regarding potential transfer. Annual sales of Bystolic&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; in the United States were approximately $700&#160;million at the time of Watson&#x2019;s 2013 settlement with Forest. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government Investigations and Litigation Relating to Pricing and Marketing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#x201c;DOJ&#x201d;) Antitrust Division seeking documents and other information relating to the marketing and &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three count indictment charging T&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;e&lt;/div&gt;va USA with criminal felony Sherman Act violations. See No. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20-cr-200&lt;/div&gt;&lt;/div&gt; (E.D. Pa.). The indictment alleges Teva USA participated in a conspiracy with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs, including Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;E-Cream,&lt;/div&gt; Gel, and Ointment), Warfarin, Etodolac (IR), Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. A tentative trial date is yet to be scheduled. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#x2019;s busi&lt;div style="display:inline;"&gt;n&lt;/div&gt;ess, including monetary penalties and debarment from federally funded health care programs. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#x2019;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed yet another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA in a similar complaint relating to dermatological generics products. In the various complaints described above, the states seek a finding that the defendants&#x2019; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#x201c;Pennsylvania MDL&#x201d;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#x2019; general November&#160;1, 2019 complaint, referenced above, along with three complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. Teva moved the court to reconsider that ruling, and the motion was granted on February&#160;9, 2021. As a result, the attorneys&#x2019; general November&#160;1, 2019 amended complaint is not expected to be among the bellwether complaints in the Pennsylvania MDL. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;opt-out&lt;/div&gt; plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva and Actavis. The plaintiffs generally &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;court &lt;/div&gt;denied certain of the defendants&#x2019; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#x2019; motions to dismiss as to certain state law claims. On July&#160;18, 2019, and again on May&#160;6, 2020, certain individual plaintiffs commenced a civil action in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaint has been filed in either action and the July&#160;18, 2019 case has been placed in deferred status. On November&#160;13, 2019, and again on August&#160;24, 2020, certain counties in New York commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. On December&#160;15, 2020, several additional New York counties filed suit in New York state court raising similar allegations. On March&#160;1, 2020, Harris County in Texas filed a complaint against several generic manufacturers including Teva and Actavis in the District Court for the Southern District of Texas, which has been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2017, Teva received a subpoena from the U.S. Attorney&#x2019;s office in Boston, Massachusetts requesting documents related to Teva&#x2019;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#x2019;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. It is alleged that Teva caused the submission of false claims to Medicare through Teva&#x2019;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On October&#160;19, 2020, Teva filed a motion to dismiss the complaint, which remains pending. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2016, Teva resolved certain claims under the U.S. Foreign Corrupt Practices Act (&#x201c;FCPA&#x201d;) with the SEC and the DOJ. The settlement included a fine, disgorgement and prejudgment interest, a three-year deferred prosecution agreement (&#x201c;DPA&#x201d;) for Teva and the retention of an independent compliance monitor for a period of three years. In February 2020 the term of the monitorship provided for by the DPA and Teva&#x2019;s consent judgement with the SEC expired and on March&#160;4, 2020, following Teva&#x2019;s certification to the SEC and the DOJ confirming that Teva had complied with its disclosure obligations under the DPA, the DOJ filed a motion to dismiss the information filed against Teva at the time the DPA was entered into. On July&#160;21, 2020, the information was dismissed. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Opioids Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Since May 2014, more than 3,000 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#x201c;MDL Opioid Proceeding&#x201d;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were recently transferred back to federal district court for additional discovery, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-trial&lt;/div&gt; proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., No. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14-cv-04361&lt;/div&gt;&lt;/div&gt; (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., No. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;18-cv-07591-CRB&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law, generally contend that the defendants &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;allegedly engaged in improper marketing and distribution of opioids, including ACTIQ&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; and FENTORA&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;. The complaints also assert claims related to Teva&#x2019;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#x2019; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-economic&lt;/div&gt; damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Absent resolutions, trials are expected to proceed in several states in 2021, unless postponed as a result of the COVID-19 pandemic. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2019, Teva settled the Oklahoma litigation brought by the Oklahoma Attorney General (State of Oklahoma, ex. rel. Mike Hunter, Attorney General of Oklahoma vs. Purdue Pharma L.P., et. al.) for&lt;/div&gt; $85&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. The settlement did not include any admission of violation of law for any of the claims or allegations made. As the Company demonstrated a willingness to settle part of the litigation, for accounting purposes, management considered a portion of opioid-related cases as probable and, as such, recorded an estimated provision in the second quarter of 2019. Given the relatively early stage of the cases, management viewed no amount within the range to be the most likely outcome. Therefore, management recorded a provision for the reasonably estimable minimum amount in the assessed range for such opioid-related cases in accordance with Accounting Standards Codification 450 &#x201c;Accounting for Contingencies.&#x201d;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;21, 2019, Teva reached a settlement with the two plaintiffs in the MDL Opioid Proceeding that was scheduled for trial for the Track One case, Cuyahoga and Summit Counties of Ohio. Under the terms of the settlement, Teva will provide the two counties with opioid treatment medication, buprenorphine naloxone (sublingual tablets), known by the brand name Suboxone&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;, with a value of $25&#160;million at wholesale acquisition cost and distributed over three years to help in the care and treatment of people suffering from addiction, and a cash payment in the amount of $20&#160;million, to be paid in four payments over three years. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 12pt;margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Also on October 21, 2019, Teva and certain other defendants reached an agreement in principle with a group of Attorneys General from North Carolina, Pennsylvania, Tennessee and Texas for a nationwide settlement framework (the &#x201c;framework&#x201d;). The framework is designed to provide a mechanism by which the Company attempts to seek resolution of remaining potential and pending opioid claims by both the U.S. states and political subdivisions (i.e., counties, tribes and other plaintiffs) thereof. Under this framework, Teva would provide buprenorphine naloxone (sublingual tablets) with an estimated value of up to approximately&lt;/div&gt;&#160;$23&#160;billion at wholesale acquisition cost over a ten year period. In addition, Teva would also provide cash payments of up to $250&#160;million over a ten year period.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of January 2021, the Company continues to negotiate the terms and conditions of the framework. The Company cannot predict if the framework will be finalized with its current terms and obligations. The Company considered a range of potential settlement outcomes. The current provision remains a reasonable estimate of the ultimate costs if the nationwide settlement framework is finalized based on recent discussions. However, if not finalized for the entirety of the cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and adverse effect on Teva&#x2019;s reputation, business, results of operations and cash flows.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Separately, on April&#160;27, 2018, Teva received subpoena requests from the United States Attorney&#x2019;s office in the Western District of Virginia and the Civil Division seeking documents relating to the manufacture, marketing and sale of branded opioids. In August 2019, Teva received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Teva received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. Following a Statement of Changes and Notice of Hearing filed by the NYDFS, a hearing is currently scheduled to take place in June 2021. Currently, Teva cannot predict how the nationwide settlement framework agreement (if finalized) will affect these investigations and administrative actions. In addition, a number of state attorneys general, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids. Other states are conducting their own investigations outside of the multistate group. Teva is cooperating with these ongoing investigations and cannot predict their outcome at this time. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, several jurisdictions and consumers in Canada have initiated litigation regarding opioids alleging similar claims as those in the United States. The cases in Canada may be consolidated and are in their early stages. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shareholder Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#x201c;Ontario Teachers Securities Litigation&#x201d;). On December&#160;13, 2019, the lead plaintiff in that action filed an amended complaint, purportedly on behalf of purchasers of Teva&#x2019;s securities between February&#160;6, 2014 and May&#160;10, 2019. The amended complaint asserts that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#x2019;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. The amended complaint seeks unspecified damages, legal fees, interest, and costs. In July 2017, August 2017, and June 2019, other putative securities class actions were filed in other federal courts based on similar allegations, and those cases have been transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and October 2020, twenty complaints were filed against Teva and certain of its current and former officers and directors seeking unspecified compensatory damages, legal fees, costs and expenses. The similar claims in these complaints have been brought on behalf of plaintiffs, in various forums across the country, who have indicated that they intend to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; of the plaintiffs&#x2019; class if one is certified in the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; cases for pretrial purposes. The case is now in discovery. Pursuant to that consolidation order, plaintiffs in several of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; cases filed amended complaints on May&#160;28, 2020. On January&#160;22, 2021, the Court dismissed the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;opt-out&#x201d;&lt;/div&gt; plaintiffs&#x2019; claims arising from statements made prior to the five year statute of repose, but denied Teva&#x2019;s motion to dismiss their claims under Israeli laws. The Ontario Teachers Securities Litigation plaintiffs filed a Motion for Class&#160;Certification and Appointment of Class&#160;Representatives and Class&#160;Counsel on June&#160;19, 2020, which the defendants opposed. That motion is pending. Motions to approve securities class actions were also filed in the Tel Aviv District Court in Israel with similar allegations to those made in the Ontario Teachers Securities Litigation. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers alleging, among other things, violations of &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Section&#160;10(b) of the Securities and Exchange Act of 1934 and SEC Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10b-5.&lt;/div&gt; The complaint, purportedly filed on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020, alleges that Teva and certain of its former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had caused the submission of false claims to Medicare through Teva&#x2019;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#x2019;s commercial success and the sustainability of its revenues and resulted in the above referenced August 2020 False Claims Act complaint filed by the DOJ. The securities class action complaint seeks unspecified damages, legal fees, interest, and costs. The case is in its preliminary stages. Motions for the appointment of lead plaintiff and selection of counsel were filed in late November 2020 and remain pending. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Motions to approve derivative actions against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness with respect to the acquisition of the Rimsa business, the acquisition of Actavis Generics and the patent settlement relating to Lidoderm&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;. Motions for document disclosure prior to initiating derivative actions were filed with respect to several U.S. and EU settlement agreements, opioids, the U.S. price-fixing investigations and allegations related to the DOJ&#x2019;s complaint regarding Copaxone patient assistance program in the U.S. In October 2020, Teva filed a notice with the Tel Aviv District Court to settle the derivative proceeding with regard to the acquisition of Actavis Generics and two related actions, including the derivative proceedings related to allegations in connection with the Lidoderm&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; patent settlement agreement. Various motions were filed in Israel to approve a derivative action, discovery and a class action related to claims regarding Teva&#x2019;s above-mentioned FCPA resolution with the SEC and DOJ. The parties have reached a settlement which was approved by the Tel Aviv District Court on April&#160;6, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Environmental Matters &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#x2019;s facilities or former facilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#x2019;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; and natural resource damages have not yet been determined, and for others Teva&#x2019;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;clean-up&lt;/div&gt; costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#x2019;s facilities may result in the imposition of significant penalties (in amounts not &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;expected to materially adversely affect Teva&#x2019;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implem&lt;div style="display:inline;"&gt;e&lt;/div&gt;nted. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Matters &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#x2019;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt; (reslizumab) for the treatment of eosinophilic esophagitis (&#x201c;EE&#x201d;). The plaintiffs claim damages of at least $200&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). Defendants moved to dismiss the complaint and on December&#160;28, 2018, the court granted the motion in part and dismissed all of plaintiffs&#x2019; claims, except for their claim against Cephalon for breach of contract.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Trial in this matter is currently scheduled for October 2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">505000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">403000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">536000000</us-gaap:RoyaltyExpense>
    <teva:MilestoneContingentPayments
      contextRef="PAsOn12_31_2020_MaximumMembersrtRangeAxis"
      decimals="-6"
      unitRef="Unit_USD">509000000</teva:MilestoneContingentPayments>
    <teva:DamagesAssessment
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">235500000</teva:DamagesAssessment>
    <teva:AnnualSalesOfVelcade
      contextRef="P01_01_2014To12_31_2014"
      decimals="-6"
      unitRef="Unit_CAD">94000000</teva:AnnualSalesOfVelcade>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="PAsOn12_31_2020_JanssenAndMillenniumMembersrtCounterpartyNameAxis"
      decimals="-6"
      unitRef="Unit_CAD">200000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="P06_27_2018To06_27_2018_JanssenAndMillenniumMembersrtCounterpartyNameAxis"
      decimals="-6"
      unitRef="Unit_CAD">5000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <teva:ModafinilPayment
      contextRef="PAsOn05_31_2015"
      decimals="-8"
      unitRef="Unit_USD">1200000000</teva:ModafinilPayment>
    <teva:ModafinilPaymentRemainingBalance
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">19000000</teva:ModafinilPaymentRemainingBalance>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2020_ModafinilSettlementAgreementMembersrtLitigationCaseAxis"
      decimals="-5"
      unitRef="Unit_USD">60500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn01_31_2009"
      decimals="-6"
      unitRef="Unit_USD">350000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn01_31_2009_AndroGelRateAtOnePercentageMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">140000000</teva:AnnualSalesAtTimeOfSettlement>
    <teva:AnnualSalesOfEffexor
      contextRef="P08_21_2017To08_21_2017"
      decimals="-8"
      unitRef="Unit_USD">2600000000</teva:AnnualSalesOfEffexor>
    <teva:AnnualSalesOfLamictal
      contextRef="PAsOn02_28_2005"
      decimals="-6"
      unitRef="Unit_USD">950000000</teva:AnnualSalesOfLamictal>
    <teva:AnnualSalesOfLamictal
      contextRef="PAsOn07_31_2008"
      decimals="-8"
      unitRef="Unit_USD">2300000000</teva:AnnualSalesOfLamictal>
    <teva:AnnualSalesOfNiaspan
      contextRef="P04_01_2013To04_30_2013"
      decimals="-6"
      unitRef="Unit_USD">416000000</teva:AnnualSalesOfNiaspan>
    <teva:AnnualSalesOfNiaspan
      contextRef="P09_01_2013To09_30_2013"
      decimals="-8"
      unitRef="Unit_USD">1100000000</teva:AnnualSalesOfNiaspan>
    <teva:AnnualSalesOfActos
      contextRef="P12_01_2010To12_31_2010"
      decimals="-8"
      unitRef="Unit_USD">3700000000</teva:AnnualSalesOfActos>
    <teva:AnnualSalesOfActoplus
      contextRef="P12_01_2010To12_31_2010"
      decimals="-6"
      unitRef="Unit_USD">500000000</teva:AnnualSalesOfActoplus>
    <teva:AnnualSalesOfActos
      contextRef="P08_01_2012To08_31_2012"
      decimals="-8"
      unitRef="Unit_USD">2800000000</teva:AnnualSalesOfActos>
    <teva:AnnualSalesOfActoplus
      contextRef="P08_01_2012To08_31_2012"
      decimals="-6"
      unitRef="Unit_USD">430000000</teva:AnnualSalesOfActoplus>
    <teva:AnnualSalesOfNamenda
      contextRef="P11_01_2009To11_30_2009"
      decimals="-8"
      unitRef="Unit_USD">1100000000</teva:AnnualSalesOfNamenda>
    <teva:AnnualSalesOfNamenda
      contextRef="P07_01_2015To07_31_2015"
      decimals="-6"
      unitRef="Unit_USD">550000000</teva:AnnualSalesOfNamenda>
    <teva:AnnualSalesOfSensipar
      contextRef="P01_01_2019To12_31_2019"
      decimals="-8"
      unitRef="Unit_USD">1400000000</teva:AnnualSalesOfSensipar>
    <teva:AnnualSalesOfCopaxone
      contextRef="P01_01_2014To12_31_2014"
      decimals="-6"
      unitRef="Unit_USD">431000000</teva:AnnualSalesOfCopaxone>
    <teva:AnnualSalesAtTimeOfSettlement
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">700000000</teva:AnnualSalesAtTimeOfSettlement>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P05_01_2019To05_31_2019_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">85000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">25000000</us-gaap:LossContingencyDamagesPaidValue>
    <teva:LitigationSettlementAmountAwardedDistributionPeriod contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis">P3Y</teva:LitigationSettlementAmountAwardedDistributionPeriod>
    <teva:LitigationSettlementAmountAwardedCashAmount
      contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:LitigationSettlementAmountAwardedCashAmount>
    <teva:LitigationSettlementAmountAwardedNumberOfInstallments
      contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis"
      decimals="0"
      unitRef="Unit_Number">4</teva:LitigationSettlementAmountAwardedNumberOfInstallments>
    <teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod contextRef="P10_21_2019To10_21_2019_OpioidLitigationMembersrtLitigationCaseAxis">P3Y</teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis"
      decimals="-9"
      unitRef="Unit_USD">23000000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <teva:LitigationSettlementAmountAwardedDistributionPeriod contextRef="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis">P10Y</teva:LitigationSettlementAmountAwardedDistributionPeriod>
    <teva:LitigationSettlementAmountAwardedCashAmount
      contextRef="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</teva:LitigationSettlementAmountAwardedCashAmount>
    <teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod contextRef="P10_21_2019To10_21_2019_NationwideSettlementMembersrtLitigationCaseAxis">P10Y</teva:LitigationSettlementAmountAwardedCashAmountDistributionPeriod>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis"
      decimals="-6"
      unitRef="Unit_USD">200000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_USsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">150000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P01_01_2018To12_31_2018_EosinophilicEsophagitisMemberusgaapLossContingenciesByNatureOfContingencyAxis_EuropeMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">50000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 13&#x2014;Income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income (loss) before income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 8pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent Company and its Israeli subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;947&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Israeli subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,406&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In Israel&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outside Israel&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;885&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income (Loss) before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(4,406&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(2,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statutory tax rate in Israel&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Theoretical provision for income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(1,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase (decrease) in the provision for income taxes due to:&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-left: 0in; text-indent: 0in; width: 66%;"&gt;&lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Parent Company and its Israeli subsidiaries - Mainly tax benefits arising from reduced tax rates under benefit programs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Israeli subsidiaries, including impairments *&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;381&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. Tax Cuts and Jobs Act effect&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase (decrease) in other uncertain tax positions&#x2014;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(341&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective consolidated income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;In 2020 and 2018, income before income taxes includes goodwill impairment in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-Israeli&lt;/div&gt; subsidiaries that did&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;not have a corresponding tax effect. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The effective tax rate is the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-Israeli&lt;/div&gt; subsidiaries that have tax rates different than Teva&#x2019;s average tax rates, the impact of impairment, restructuring and legal settlement charges and adjustments to valuation allowances on deferred tax assets on such subsidiaries. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2020, Teva released a valuation allowance on its deferred tax assets in one jurisdiction and recorded a valuation allowance in another jurisdiction, with both adjustments reflecting changes in the business forecasts of profitability in these jurisdictions. The net effect of these adjustments did not materially impact Teva&#x2019;s effective tax rate for 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Long-term deferred tax assets (liabilities), net:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory related&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales reserves and allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision for legal settlements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets (*)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(1,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(1,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carryforward losses and deductions and credits (**)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;527&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions for employee related obligations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&#x2014;in respect of carryforward losses and deductions that may not be utilized&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(2,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,974&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(*)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The decrease in deferred tax liability is mainly due to impairment and amortization. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(**)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amounts are shown after reduction for unrecognized tax benefits of $ 63&#160;million and $115 million as of December&#160;31, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt; and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;, respectively. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 0%;line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703734"&gt;2021&lt;/span&gt;&lt;/div&gt;-&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703735"&gt;2022&lt;/span&gt;&lt;/div&gt;&#x2014;$79 million; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703736"&gt;2023&lt;/span&gt;&lt;/div&gt;-&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703738"&gt;2029&lt;/span&gt;&lt;/div&gt;&#x2014;$663 million; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703737"&gt;2030&lt;/span&gt; &lt;/div&gt;and thereafter&#x2014;$171 million. The remaining balance&#x2014;$1,327 million&#x2014;can be utilized with no expiration date. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The deferred income taxes are reflected in the balance sheets among: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term assets&#x2014;deferred income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;695&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term liabilities&#x2014;deferred income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Uncertain tax positions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity of Teva&#x2019;s gross unrecognized tax benefits: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at the beginning of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(decrease)&#160;&lt;/div&gt;related to prior year tax positions, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase related to current year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at the end of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;888&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Uncertain tax positions, mainly of a long-term nature, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;include&lt;/div&gt; accrued potential penalties and interest of $173 million, $164 million and $131&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million as of December&#160;31, 2020, 2019 and 2018, respectively. The total amount of interest and penalties reflected in the consolidated statements of income was a net increase of $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9 million, $&lt;/div&gt;33 million &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and $19 million&#160;&lt;/div&gt;for the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;years&lt;/div&gt; ended December&#160;31, 2020,&#160;2019 and 2018&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively&lt;/div&gt;. Substantially all the above uncertain tax benefits, if recognized, would reduce Teva&#x2019;s annual effective tax rate. Teva does not expect uncertain tax positions to change significantly over the next 12 months, except in the case of settlements with tax authorities, the likelihood and timing of which is difficult to estimate. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax assessments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva files income tax returns in various jurisdictions with varying statutes of limitations. Teva and its subsidiaries in Israel have received final tax assessments through tax year 2007. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2013, Teva settled the 2005-2007 income tax assessment with the Israeli tax authorities, paying $213 million. No further taxes are due in relation to these years. Certain guidelines which were set pursuant to the agreement reached in relation to the 2005-2007 assessment have been implemented in the audit of tax years &lt;span style="-sec-ix-hidden:hidden17703740"&gt;2008-2011&lt;/span&gt;, and are reflected in the provisions. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Israeli tax authorities issued tax assessment decrees for 2008-2012 and 2013-2016, challenging the Company&#x2019;s positions on several issues. Teva has protested the 2008-2012 and 2013-2016 decrees before the Central District Court in Israel. The Company believes it has adequately provided for these items, however, adverse results could be material. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the United States, Teva has one tax issue in dispute for the 2009-2011 audit cycle, which is currently in litigation. The 2012-2014 audit cycle is ongoing, with an assessment report expected to be received in 2021. Additionally, Teva&#x2019;s U.S. subsidiaries have multiple audit cycles open. The Company believes it has adequately provided for these items and that any adverse results would have an immaterial impact on Teva&#x2019;s financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;March 2021&lt;/div&gt;. A final and binding decision against Teva in this case may lead to an impairment in the amount of $141 million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s subsidiaries in Europe have received final tax assessments mainly through tax year 2014. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;f.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of taxation: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company and its subsidiaries are subject to tax in many jurisdictions, and estimation is required in recording the assets and liabilities related to income taxes. The Company believes that its accruals for tax liabilities are adequate for all open years. The Company considers various factors in making these assessments, including past history, recent interpretations of tax law, and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these assessments can involve a series of complex judgments regarding future events. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Incentives Applicable until 2013 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the incentives regime applicable to the Company until 2013, industrial projects of Teva and certain of its Israeli subsidiaries were eligible for &#x201c;Approved Enterprise&#x201d; status. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of the projects in Israel have been granted Approved Enterprise status under the &#x201c;alternative&#x201d; tax benefit track which offered tax exemption on undistributed income for a period of two to ten years, depending on the location of the enterprise. Upon distribution of such exempt income, the distributing company is subject to corporate tax at the rate ordinarily applicable to the Approved Enterprise&#x2019;s income. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amendment 69 to the Investment Law &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to Amendment 69 to the Investment Law (&#x201c;Amendment 69&#x201d;), a company that elected by November&#160;11, 2013 to pay a corporate tax rate as set forth in that amendment (rather than the tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company up until December&#160;31, 2011 is entitled to distribute a dividend from such income without being required to pay additional corporate tax with respect to such dividend. A company that has so elected must make certain qualified investments in Israel over the five-year period commencing in 2013. Teva invested the entire required amount in 2013. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During 2013, Teva applied the provisions of Amendment 69 to certain exempt profits Teva accrued prior to 2012. Consequently, Teva paid $577 million in corporate tax on exempt income of $9.4 billion. Part of this income was distributed as dividends during 2013-2018, while the remainder is available to be distributed as dividends in future years with no additional corporate tax liability. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Incentives Applicable starting 2014: The Incentives Regime &#x2013; Amendment 68 to the Investment Law &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under Amendment 68 to the Investment Law, which Teva started applying in 2014, upon an irrevocable election made by a company, a uniform corporate tax rate will apply to all qualifying industrial income of such company (&#x201c;Preferred Enterprise&#x201d;), as opposed to the previous law&#x2019;s incentives, which were limited to income from Approved&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Enterprises during the benefits period. Under the law, when the election is made, the uniform tax rate for 2014 until 2016 was 9% in areas in Israel designated as Development Zone A and 16% elsewhere in Israel. The uniform tax rate for Development Zone A, as of January&#160;1, 2017, is 7.5% (as part of changes enacted in Amendment 73, as described below). The profits of these &#x201c;Preferred Enterprise&#x201d; will be freely distributable as dividends, subject to a 20% or lower withholding tax, under an applicable tax treaty. Certain &#x201c;Special Preferred Enterprises&#x201d;&#160;that meet more stringent criteria (significant investment, R&amp;amp;D or employment thresholds) will enjoy further reduced tax rates of 5% in Zone A and 8% elsewhere. In order to be classified as a &#x201c;Special Preferred Enterprises,&#x201d; the approval of three governmental authorities in Israel is required. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The New Technological Enterprise Incentives Regime &#x2013; Amendment 73 to the Investment Law &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since 2017, a portion of the Company&#x2019;s taxable income in Israel is entitled to a preferred 6% tax rate under Amendment 73 to the Investment Law as it pertains to Special Preferred Technological Enterprises. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The new incentives regime applies to &#x201c;Preferred Technological Enterprises&#x201d; or &#x201c;Special Preferred Technological Enterprises.&#x201d; A &#x201c;Preferred Technological Enterprise&#x201d; is an enterprise that meet certain conditions, including, inter alia: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;a.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment of at least 7% of income, or at least NIS 75&#160;million (approximately $22 million) in R&amp;amp;D activities; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;b.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;One of the following: &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;a.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At least 20% of the workforce (or at least 200 employees) are employed in R&amp;amp;D; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;b.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A venture capital investment approximately equivalent to at least $2 million was previously made in the company; or &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;c.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Growth in sales or workforce by an average of 25% over the three years preceding the tax year. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A &#x201c;Special Preferred Technological Enterprise&#x201d; is an enterprise that meets, inter alia conditions 1 and 2 above, and in addition has total annual consolidated revenues above NIS 10 billion (approximately $2.9 billion). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Preferred Technological Enterprises are subject to a corporate tax rate of 7.5% on their income derived from intellectual property in areas in Israel designated as Zone A and 12% elsewhere, while Special Preferred Technological Enterprises are subject to 6% on such income. The withholding tax on dividends from these enterprises is 4% to foreign companies (or a lower rate under a tax treaty, if applicable). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income not eligible for Preferred Technological Enterprise benefits is taxed at the regular corporate tax rate, which is 23%, or the preferred tax rate, as the case may be. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Parent Company and its Israeli subsidiaries elected to compute their taxable income in accordance with Income Tax Regulations (Rules for Accounting for Foreign Investors Companies and Certain Partnerships and Setting their Taxable Income), 1986. Accordingly, the taxable income or loss is calculated in U.S. dollars. Applying these regulations reduces the effect of U.S. dollar&#x2014;NIS exchange rate on the Company&#x2019;s Israeli taxable income&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Israeli&lt;/div&gt; subsidiaries are taxed according to the tax laws in their respective country of residence. Certain manufacturing subsidiaries operate in several jurisdictions outside Israel, some of which benefit from tax incentives such as reduced tax rates, investment tax credits and accelerated deductions. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;U.S. Tax reform &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the &#x201c;Act&#x201d;), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January&#160;1, 2018, and imposed a one-time deemed repatriation tax based on the post-1986 earnings and profits of the Company&#x2019;s U.S. owned foreign subsidiaries. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The one-time deemed repatriation tax is based on the post-1986 earnings and profits for which the Company has previously deferred from U.S. income taxes and is payable over 8 years. The year ended December&#160;31, 2017 included a $112 million provisional estimate for Teva&#x2019;s one-time deemed repatriation taxes liability. During 2018, Teva completed its analysis of the impacts of the Act and recorded an additional expense of $97 million, pursuant to guidance issued by the U.S. Department of Treasury and revisions to the Company&#x2019;s estimates since the assessment date. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income (loss) before income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 8pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Parent Company and its Israeli subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;947&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 67%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Israeli subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,406&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 67%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">947000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">542000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1022000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-5353000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1807000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-3618000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4406000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1265000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2596000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <teva:DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In Israel&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outside Israel&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;885&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">60000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">107000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">131000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-228000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-385000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-326000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-168000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-278000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-195000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">182000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">885000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">700000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-350000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1163000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-895000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-168000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-278000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-195000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income (Loss) before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(4,406&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(1,265&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(2,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statutory tax rate in Israel&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;23.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Theoretical provision for income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(1,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase (decrease) in the provision for income taxes due to:&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-left: 0in; text-indent: 0in; width: 66%;"&gt;&lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Parent Company and its Israeli subsidiaries - Mainly tax benefits arising from reduced tax rates under benefit programs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Israeli subsidiaries, including impairments *&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;381&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. Tax Cuts and Jobs Act effect&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase (decrease) in other uncertain tax positions&#x2014;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(341&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective consolidated income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(168&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;In 2020 and 2018, income before income taxes includes goodwill impairment in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-Israeli&lt;/div&gt; subsidiaries that did&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;not have a corresponding tax effect. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1265000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2596000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.230</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.230</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">0.230</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-1013000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-291000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-597000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-183000000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-44000000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-134000000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_17703660"
      unitRef="Unit_USD">1369000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      id="Fact_17703661"
      unitRef="Unit_USD">-115000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      id="Fact_17703662"
      unitRef="Unit_USD">381000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <teva:Ustaxcutsandjobsacteffect
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">97000000</teva:Ustaxcutsandjobsacteffect>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-341000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">172000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">58000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-168000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-278000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-195000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2018To12_31_2018"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Long-term deferred tax assets (liabilities), net:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory related&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;212&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;144&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales reserves and allowances&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;198&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision for legal settlements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets (*)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(1,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(1,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carryforward losses and deductions and credits (**)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;527&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions for employee related obligations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&#x2014;in respect of carryforward losses and deductions that may not be utilized&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(2,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1,974&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(*)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The decrease in deferred tax liability is mainly due to impairment and amortization. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(**)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amounts are shown after reduction for unrecognized tax benefits of $ 63&#160;million and $115 million as of December&#160;31, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt; and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;, respectively. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 0%;line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703734"&gt;2021&lt;/span&gt;&lt;/div&gt;-&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703735"&gt;2022&lt;/span&gt;&lt;/div&gt;&#x2014;$79 million; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703736"&gt;2023&lt;/span&gt;&lt;/div&gt;-&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703738"&gt;2029&lt;/span&gt;&lt;/div&gt;&#x2014;$663 million; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden17703737"&gt;2030&lt;/span&gt; &lt;/div&gt;and thereafter&#x2014;$171 million. The remaining balance&#x2014;$1,327 million&#x2014;can be utilized with no expiration date. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">212000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">144000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">173000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">198000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">235000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">260000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      id="Fact_17703679"
      unitRef="Unit_USD">1064000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      id="Fact_17703680"
      unitRef="Unit_USD">1733000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <teva:DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      id="Fact_17703681"
      unitRef="Unit_USD">2176000000</teva:DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent>
    <teva:DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      id="Fact_17703682"
      unitRef="Unit_USD">1689000000</teva:DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">142000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">170000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <teva:DeferredTaxAssetsDeferredInterest
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">527000000</teva:DeferredTaxAssetsDeferredInterest>
    <teva:DeferredTaxAssetsDeferredInterest
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">648000000</teva:DeferredTaxAssetsDeferredInterest>
    <teva:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">107000000</teva:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent>
    <teva:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">106000000</teva:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent>
    <teva:DeferredTaxAssetsLiabilitiesOtherNetNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-54000000</teva:DeferredTaxAssetsLiabilitiesOtherNetNoncurrent>
    <teva:DeferredTaxAssetsLiabilitiesOtherNetNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-122000000</teva:DeferredTaxAssetsLiabilitiesOtherNetNoncurrent>
    <teva:DeferredTaxAssetsLiabilitiesGrossNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-2278000000</teva:DeferredTaxAssetsLiabilitiesGrossNoncurrent>
    <teva:DeferredTaxAssetsLiabilitiesGrossNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1264000000</teva:DeferredTaxAssetsLiabilitiesGrossNoncurrent>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2547000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1974000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">269000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">710000000</us-gaap:DeferredTaxLiabilities>
    <teva:DeferredTaxAssetUnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">63000000</teva:DeferredTaxAssetUnrecognizedTaxBenefits>
    <teva:DeferredTaxAssetUnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">115000000</teva:DeferredTaxAssetUnrecognizedTaxBenefits>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsExpirationPeriodOneMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-6"
      unitRef="Unit_USD">79000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-6"
      unitRef="Unit_USD">663000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsNoExpirationMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-6"
      unitRef="Unit_USD">171000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2020_TaxCarryforwardsAndDeductionsIndefiniteMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-6"
      unitRef="Unit_USD">1327000000</us-gaap:TaxCreditCarryforwardAmount>
    <teva:ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The deferred income taxes are reflected in the balance sheets among: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term assets&#x2014;deferred income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;695&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term liabilities&#x2014;deferred income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </teva:ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">695000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">386000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">964000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1096000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">269000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">710000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Uncertain tax positions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity of Teva&#x2019;s gross unrecognized tax benefits: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at the beginning of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(decrease)&#160;&lt;/div&gt;related to prior year tax positions, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase related to current year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at the end of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;888&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1223000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1072000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2017"
      decimals="-6"
      unitRef="Unit_USD">1034000000</us-gaap:UnrecognizedTaxBenefits>
    <teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-238000000</teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">23000000</teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">76000000</teva:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">246000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">11000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">105000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">118000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">49000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <teva:UnrecognizedTaxBenefitsIncreasesDecreasesOther
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-2000000</teva:UnrecognizedTaxBenefitsIncreasesDecreasesOther>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">888000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1223000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1072000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">173000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">164000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">131000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">33000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">19000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2019To12_31_2019_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_TaxYear2005To2007MemberusgaapTaxPeriodAxis"
      decimals="-6"
      unitRef="Unit_USD">213000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <teva:ExpectedImpairmentOfIncomeTaxBenefit
      contextRef="P07_01_2020To07_31_2020"
      decimals="-6"
      unitRef="Unit_USD">141000000</teva:ExpectedImpairmentOfIncomeTaxBenefit>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2020To12_31_2020_Amendment69ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-6"
      unitRef="Unit_USD">577000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:DividendIncomeSecuritiesOperatingTaxExempt
      contextRef="P01_01_2020To12_31_2020_Amendment69ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-8"
      unitRef="Unit_USD">9400000000</us-gaap:DividendIncomeSecuritiesOperatingTaxExempt>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2016To12_31_2016_Amendment68ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0.09</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2016To12_31_2016_Amendment68ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0.16</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2017To01_01_2017_Amendment73ToInvestmentLawMemberusgaapTaxCreditCarryforwardAxis_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="INF"
      unitRef="Unit_pure">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <teva:WithholdingTaxPercentageOnDividends
      contextRef="P01_01_2016To12_31_2016_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredEnterpriseMemberusgaapTaxCreditCarryforwardAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</teva:WithholdingTaxPercentageOnDividends>
    <teva:WithholdingTaxPercentageOnDividends
      contextRef="P01_01_2016To12_31_2016_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredEnterpriseMemberusgaapTaxCreditCarryforwardAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</teva:WithholdingTaxPercentageOnDividends>
    <teva:WithholdingTaxPercentageOnDividends
      contextRef="P01_01_2016To12_31_2016_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</teva:WithholdingTaxPercentageOnDividends>
    <teva:MinimumPercentageOfInvestmentIncome
      contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"
      decimals="INF"
      unitRef="Unit_pure">0.07</teva:MinimumPercentageOfInvestmentIncome>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"
      decimals="-6"
      unitRef="Unit_ILS">75000000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"
      decimals="-6"
      unitRef="Unit_USD">22000000</us-gaap:InvestmentIncomeNet>
    <teva:MinimumPercentageOfWorkforce
      contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"
      decimals="INF"
      unitRef="Unit_pure">0.20</teva:MinimumPercentageOfWorkforce>
    <teva:MinimumNumberOfEmployeesEmployed
      contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"
      decimals="INF"
      unitRef="Unit_Employee">200</teva:MinimumNumberOfEmployeesEmployed>
    <teva:VentureCapitalInvestments
      contextRef="PAsOn12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</teva:VentureCapitalInvestments>
    <teva:AverageGrowthRateInSalesOrWorkforce
      contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</teva:AverageGrowthRateInSalesOrWorkforce>
    <teva:AverageGrowthPrecedingPeriodInSalesOrWorkforce contextRef="P01_01_2020To12_31_2020_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis">P3Y</teva:AverageGrowthPrecedingPeriodInSalesOrWorkforce>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-9"
      unitRef="Unit_ILS">10000000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-8"
      unitRef="Unit_USD">2900000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_DevelopmentZoneaMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis"
      decimals="INF"
      unitRef="Unit_pure">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_PreferredTechnologicalEnterprisesMemberusgaapTaxCreditCarryforwardAxis"
      decimals="INF"
      unitRef="Unit_pure">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis"
      decimals="INF"
      unitRef="Unit_pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <teva:WithholdingTaxPercentageOnDividends
      contextRef="P01_01_2020To12_31_2020_IsraelTaxAuthorityMemberusgaapIncomeTaxAuthorityNameAxis_SpecialPreferredTechnologicalEnterpriseMemberusgaapTaxCreditCarryforwardAxis"
      decimals="2"
      unitRef="Unit_pure">0.04</teva:WithholdingTaxPercentageOnDividends>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2017To12_31_2017"
      decimals="INF"
      unitRef="Unit_pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="INF"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit
      contextRef="P01_01_2017To12_31_2017"
      decimals="-6"
      unitRef="Unit_USD">112000000</us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">97000000</us-gaap:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 14&#x2014;Equity: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares and ADSs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020 and 2019, Teva had approximately 1.2&#160;billion ordinary shares issued. Teva ordinary shares are traded on the Tel-Aviv Stock Exchange and on the New York Stock Exchange, in the form of American Depositary Shares (&#x201c;ADSs&#x201d;), each of which represents one ordinary share&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mandatory convertible preferred shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;17, 2018, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s&lt;/div&gt; &lt;/div&gt;mandatory convertible preferred shares automatically converted into ordinary shares at a ratio of 1 mandatory convertible preferred share to 16 ADSs, and all of the accumulated and unpaid dividends on the mandatory convertible preferred shares were paid in ADSs, at a ratio of 3.0262 ADSs per mandatory convertible preferred share, all in accordance with the conversion mechanism set forth in the terms of the mandatory convertible preferred shares.&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;As a result of this conversion, Teva issued 70.6 million ADSs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation plans are comprised of stock options, RSUs, PSUs, and other equity-based awards to employees, officers, directors and consultants of the Company and its affiliates. The purpose of the plans is to (a)&#160;attract, retain, motivate, and reward such individuals, and (b)&#160;promote the creation of long-term value for shareholders of the Company by closely aligning the interests of such individuals with those of the shareholders. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;29, 2010, the Teva 2010 Long-Term Equity-Based Incentive Plan was approved by Teva&#x2019;s shareholders, under which 70&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. The 2010 Plan expired on June&#160;28, 2015 (except with respect to awards outstanding on that date), and no additional awards under the 2010&#160;Plan may be made.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;3, 2015, the Teva 2015 Long-Term Equity-Based Incentive Plan was approved by Teva&#x2019;s shareholders, under which 43.7&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April&#160;18, 2016, Teva&#x2019;s shareholders approved an increase of an additional 33.3&#160;million equivalent share units to the share reserve of Teva&#x2019;s 2015 Long-Term Equity-Based Incentive Plan, so that 77&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, are approved for grant. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;13, 2017, Teva&#x2019;s shareholders approved an increase of an additional 65&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million equivalent share units to the share reserve of Teva&#x2019;s 2015 Long-Term Equity-Based Incentive Plan, so &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;that 142&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, are approved for grant.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The 2015 Plan expired on June&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;, 2020 (except with respect to awards outstanding on that date), and no additional awards under the 2015&#160;Plan may be made. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;11, 2020, the Teva 2020 Long-Term Equity-Based Incentive Plan was approved by Teva&#x2019;s shareholders and became effective on July&#160;1, 2020. Under the plan, 68&#160;million shares, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, 74 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares remain available for future awards under the 2020 Long-Term Equity-Based Incentive Plan. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the past, Teva had various employee stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards granted under such prior plans continue in accordance with the terms of the respective plans. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The vesting period of the outstanding options and RSUs is generally from 1 to 4 years from the date of grant. The vesting period of PSUs is generally 3 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for ten years. &lt;/div&gt;&lt;/div&gt; Status of options &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of the status of the options granted by Teva as of December&#160;31, 2020, 2019 and 2018, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 43%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance outstanding at beginning of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,121&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44.32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes during the year:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,401&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49.35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance outstanding at end of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance exercisable at end of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,601&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43.41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average fair value of options granted during &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;these&lt;/div&gt; years was generally estimated by using the Black-Scholes option-pricing model as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of these options was estimated on the date of grant, based on the following weighted average assumptions: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;5 years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected term was estimated based on the weighted average period for which the options granted are expected to be outstanding, taking into consideration the current vesting of options and the historical exercise patterns of existing options. The expected volatility assumption used is based on a blend of the historical and implied volatility of the Company&#x2019;s stock. The risk-free interest rate used is based on the yield of U.S. Treasuries with a maturity closest to the expected term of the options granted.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables summarize information as of December&#160;31, 2020 regarding the number of ordinary shares issuable upon (1)&#160;outstanding options and (2)&#160;vested options: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1) Number of ordinary shares issuable upon exercise of outstanding options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Range of exercise prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;end&#160;of&lt;br/&gt; period&#160;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; remaining life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lower than $15.01&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$15.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $25.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$25.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $35.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,221&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$35.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $45.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,216&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$45.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $55.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$55.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $65.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2) Number of ordinary shares issuable upon exercise of vested options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Range of exercise prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;end&#160;of&lt;br/&gt; period&#160;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; remaining life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lower than $15.01&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$15.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $25.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$25.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $35.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,423&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$35.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $45.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,216&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$45.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $55.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$55.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $65.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,197&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company&#x2019;s closing stock price of $ 9.65&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;on December&#160;31, 2020, less the weighted average exercise price in each range. This represents the potential amount receivable by the option holders had all option holders exercised their options as of such date. As of December&#160;31, 2020, there were no exercisable options that were &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-the-money.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total intrinsic value of options exercised during the years ended December&#160;31,&#160;2019 and 2018 was immaterial, based on the Company&#x2019;s average stock price of&#160;$11.50 and $20.92, for the years then ended, respectively.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;No options were exercised during 2020.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; Status of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; RSUs and PSUs&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes information about the number of RSUs and PSUs &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;granted&lt;/div&gt;&#160;and outstanding: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 43%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; grant&#160;date&lt;br/&gt; fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; grant&#160;date&lt;br/&gt; fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; grant&#160;date&lt;br/&gt; fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance outstanding at beginning of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,977&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; padding: 0px; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16.49&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,848&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11.42&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,900&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19.49&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18.18&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,294&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18.74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance outstanding at end of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.81&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,977&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expenses compensation costs are based on the grant-date fair value. For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded stock-based compensation costs as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSUs and PSUs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax effect on stock-based compensation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net effect&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020, the total unrecognized compensation cost before tax on employee stock options and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSUs&lt;/div&gt;/PSUs amounted to $20&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million and $164&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million, respectively. This cost is expected to be recognized over a weighted average period of approximately 1.1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;years and 2.5 years, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva has not paid dividends on Teva ordinary shares or ADSs since December 2017. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated other comprehensive los&lt;div style="display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of accumulated other comprehensive loss attributable to Teva are presented in the table below: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 53%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net Unrealized Gains/(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available-&lt;/div&gt;&lt;br/&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for-sale&lt;/div&gt;&lt;br/&gt; securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&lt;br/&gt; gains/(losses)&lt;br/&gt; and prior&lt;br/&gt; service&lt;br/&gt; (costs)/credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 53%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,853&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cumulative effect of new accounting standard**&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income/(loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(729&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(729&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; text-align: right;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(10&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(611&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,878&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(504&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(78&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income/(loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,794&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(420&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,312&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income/(loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;65&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(1,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(363&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(2,399&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $56 million gain in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;, $14 million gain in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt; and $26&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million gain in 2018. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;**&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the adoption of ASU 2016-01, the Company recorded a $5&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million opening balance reclassification from accumulated other comprehensive income to retained earnings. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="-8"
      unitRef="Unit_shares">1200000000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="-8"
      unitRef="Unit_shares">1200000000</us-gaap:SharesOutstanding>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="P12_17_2018To12_17_2018">1 mandatory convertible preferred share to 16 ADSs, and all of the accumulated and unpaid dividends on the mandatory convertible preferred shares were paid in ADSs, at a ratio of 3.0262</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P12_17_2018To12_17_2018"
      decimals="-5"
      unitRef="Unit_shares">70600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn06_29_2010_TwoThousandTenPlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_shares">70000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn09_03_2015_TwoThousandFifteenPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">43700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="P04_18_2016To04_18_2016_TwoThousandFifteenPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">33300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn04_18_2016_TwoThousandFifteenPlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_shares">77000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="P07_13_2017To07_13_2017_TwoThousandFifteenPlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_shares">65000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn07_13_2017_TwoThousandFifteenPlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_shares">142000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn06_11_2020_TwoThousandTwentyPlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_shares">68000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">74000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2020To12_31_2020">The vesting period of the outstanding options and RSUs is generally from 1 to 4 years from the date of grant. The vesting period of PSUs is generally 3 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for ten years.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of the status of the options granted by Teva as of December&#160;31, 2020, 2019 and 2018, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 43%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance outstanding at beginning of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,121&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44.32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes during the year:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,401&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,040&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expired&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49.35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance outstanding at end of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance exercisable at end of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,601&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43.41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">40064000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">37.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">48393000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2017"
      decimals="-3"
      unitRef="Unit_shares">43121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2017"
      decimals="2"
      unitRef="Unit_USD_per_Share">44.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">12401000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">19.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">11000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">84000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">17.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">3610000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">40.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">8318000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">42.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">7040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">39.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">1220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">49.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="P01_01_2018To12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">50.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">35234000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">37.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">40064000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">37.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">48393000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">28556000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">40.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">26601000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">43.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">24086000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">46.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average fair value of options granted during &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;these&lt;/div&gt; years was generally estimated by using the Black-Scholes option-pricing model as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2018To12_31_2018"
      decimals="INF"
      unitRef="Unit_USD_per_Share">7.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2020To12_31_2020"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of these options was estimated on the date of grant, based on the following weighted average assumptions: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;5 years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_pure">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2018To12_31_2018"
      decimals="3"
      unitRef="Unit_pure">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2018To12_31_2018">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables summarize information as of December&#160;31, 2020 regarding the number of ordinary shares issuable upon (1)&#160;outstanding options and (2)&#160;vested options: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1) Number of ordinary shares issuable upon exercise of outstanding options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Range of exercise prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;end&#160;of&lt;br/&gt; period&#160;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; remaining life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lower than $15.01&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$15.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $25.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$25.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $35.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,221&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$35.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $45.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,216&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$45.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $55.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$55.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $65.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,223&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">592000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">11.40</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">6.84</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">25.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">10087000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">18.93</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">7.12</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">25.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">35.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">7221000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">34.61</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">6.16</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">35.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">45.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">5216000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">40.66</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">1.46</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">45.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">55.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">7895000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">51.06</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">4.10</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">55.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">65.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">4223000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">59.26</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">4.30</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">35234000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">37.27</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010 contextRef="PAsOn12_31_2020" decimals="2" unitRef="Unit_Y">5.07</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 45%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2) Number of ordinary shares issuable upon exercise of vested options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Range of exercise prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;end&#160;of&lt;br/&gt; period&#160;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;average&lt;br/&gt; remaining life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lower than $15.01&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;394&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$15.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $25.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18.81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.09&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$25.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $35.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,423&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;34.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$35.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $45.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,216&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$45.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $55.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,895&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$55.01 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;- $65.00&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,197&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;59.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 45%;"&gt; &lt;div style="text-indent: -1em;font-family: &amp;quot;Times New Roman&amp;quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 45%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">394000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">11.40</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">6.84</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">25.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">5431000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">18.81</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">7.09</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">25.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">35.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">5423000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">34.61</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">6.16</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">35.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">45.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">5216000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">40.66</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFourMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">1.46</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">45.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">55.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">7895000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">51.06</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeFiveMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">4.10</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">55.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="P01_01_2020To12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">65.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">4197000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">59.28</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010
      contextRef="PAsOn12_31_2020_ExercisePriceRangeSixMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"
      decimals="2"
      unitRef="Unit_Y">4.30</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">28556000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">40.56</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010>
    <teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010 contextRef="PAsOn12_31_2020" decimals="2" unitRef="Unit_Y">4.65</teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.65</us-gaap:SharePrice>
    <teva:AverageSharePrice
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">11.50</teva:AverageSharePrice>
    <teva:AverageSharePrice
      contextRef="PAsOn12_31_2018"
      decimals="INF"
      unitRef="Unit_USD_per_Share">20.92</teva:AverageSharePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes information about the number of RSUs and PSUs &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;granted&lt;/div&gt;&#160;and outstanding: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 43%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; grant&#160;date&lt;br/&gt; fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; grant&#160;date&lt;br/&gt; fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; grant&#160;date&lt;br/&gt; fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance outstanding at beginning of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,977&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; padding: 0px; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16.49&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,848&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11.42&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,900&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18.80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19.49&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;37.30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18.18&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,294&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18.74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 43%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance outstanding at end of year&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,720&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.81&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,977&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,403&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 43%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">15977000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">10403000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">20.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2017_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">7468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2017_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">27.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">10848000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">9303000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">4324000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">19.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">2435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">30.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">1638000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">37.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">1781000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">1294000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">1327000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">32.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">20720000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">15977000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_shares">10403000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">20.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expenses compensation costs are based on the grant-date fair value. For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded stock-based compensation costs as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee stock options&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSUs and PSUs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;99&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax effect on stock-based compensation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net effect&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_StockOptionsPlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">30000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_StockOptionsPlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">46000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_StockOptionsPlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">74000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">99000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">73000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_RestrictedStockUnitsMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">81000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">129000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">119000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2018To12_31_2018_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">155000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2020To12_31_2020_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2019To12_31_2019_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P01_01_2018To12_31_2018_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">18000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="P01_01_2020To12_31_2020_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">115000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="P01_01_2019To12_31_2019_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">105000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="P01_01_2018To12_31_2018_OmnibusLongTermShareIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-6"
      unitRef="Unit_USD">137000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <teva:UnrecognizedCompensationCostOptions
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:UnrecognizedCompensationCostOptions>
    <teva:UnrecognizedCompensationCostRsus
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">164000000</teva:UnrecognizedCompensationCostRsus>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020">P1Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2020To12_31_2020">P2Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="P01_01_2020To12_31_2020">The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 53%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net Unrealized Gains/(Losses)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Benefit&#160;Plans&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Foreign&lt;br/&gt; currency&lt;br/&gt; translation&lt;br/&gt; adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available-&lt;/div&gt;&lt;br/&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for-sale&lt;/div&gt;&lt;br/&gt; securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Derivative&lt;br/&gt; financial&lt;br/&gt; instruments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Actuarial&lt;br/&gt; gains/(losses)&lt;br/&gt; and prior&lt;br/&gt; service&lt;br/&gt; (costs)/credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="18" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 53%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January&#160;1, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,853&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cumulative effect of new accounting standard**&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income/(loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(729&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(639&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(729&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; text-align: right;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(10&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(611&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,878&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(504&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(78&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income/(loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(16&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;147&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,794&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(420&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,312&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other comprehensive income/(loss) before reclassifications&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts reclassified to the statements of income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;"&gt;&#160;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) before tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(190&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(152&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corresponding income tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;65&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 53%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net other comprehensive income/(loss) after tax*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance as of December&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(1,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(363&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(117&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(2,399&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 53%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $56 million gain in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;, $14 million gain in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt; and $26&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million gain in 2018. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;**&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the adoption of ASU 2016-01, the Company recorded a $5&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million opening balance reclassification from accumulated other comprehensive income to retained earnings. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2017_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1139000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2017_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-4000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2017_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-619000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2017_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-91000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2017_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1853000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning
      contextRef="P01_01_2018To12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704338"
      unitRef="Unit_USD">5000000</teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning>
    <teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704339"
      unitRef="Unit_USD">5000000</teva:ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-729000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">87000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-639000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-28000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-13000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-42000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-729000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">115000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">17000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-597000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704555"
      unitRef="Unit_USD">-739000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704556"
      unitRef="Unit_USD">115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704557"
      unitRef="Unit_USD">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704558"
      unitRef="Unit_USD">-611000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1878000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2018_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2018_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-504000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2018_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-78000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2459000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">54000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">142000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-30000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-20000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">84000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-21000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">162000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">16000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">15000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704559"
      unitRef="Unit_USD">84000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedNetUnrealizedInvestmentGainLossMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704560"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704561"
      unitRef="Unit_USD">84000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704562"
      unitRef="Unit_USD">-20000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2019To12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704366"
      unitRef="Unit_USD">147000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1794000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-420000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-98000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2312000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-190000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">22000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-175000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-35000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-23000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-190000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-19000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-152000000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-65000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-66000000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704367"
      unitRef="Unit_USD">-125000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704368"
      unitRef="Unit_USD">57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704369"
      unitRef="Unit_USD">-18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2020To12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      id="Fact_17704370"
      unitRef="Unit_USD">-86000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-1919000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_AccumulatedGainLossNetCashFlowHedgeParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-363000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_AccumulatedDefinedBenefitPlansAdjustmentMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-117000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-2399000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2018To12_31_2018_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2017To12_31_2017_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-26000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <teva:OtherExpensesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 15&#x2014;Other assets impairments, restructuring and other items: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of long-lived tangible assets &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;416&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration (see note 2)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;26&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;423&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;987&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Including impairments related to exit and disposal activities. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Following Teva&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-year&lt;/div&gt; restructuring plan, described below, and its ongoing plant rationalization efforts, the Company may change its current plans with respect to any given asset and/or the assumptions underlying such plans. Consequently, additional impairments may be recorded in the future. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairments of tangible assets for the years ended December&#160;31, 2020, 2019 and 2018 were &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$416 million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; $139 million&#160;and $500 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively. The impairment for the year ended December&#160;31, 2020 was mainly related to the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;sale of&#160;&lt;/div&gt; certain assets from Teva&#x2019;s business venture in Japan&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, which was completed on February 1, 2021, as well as&#160;&lt;/div&gt;plant rationalization. See note 2. &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2020, Teva recorded an income of &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$81 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million for contingent consideration, compared to an expense of &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$59 million and $57 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in 2019 and 2018 respectively. The income in 2020 was mainly related to a change in the future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;), which was part of the Actavis Generics acquisition, partially offset by the change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;expense&lt;/div&gt; in 2019 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;was&lt;/div&gt; mainly related to a change in the estimated future royalty payments from Eagle in connection with bendamustine sales and an increase in the expected future royalty payments to Eagle due to the orphan drug status granted to BENDEKA&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;, offset by the change in future royalty payments in connection with lenalidomide (generic equivalent of Revlimid&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;&#xae;&lt;/div&gt;), which was part of the Actavis Generics acquisition. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restructuring &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2020, Teva recorded $120 &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of restructuring expenses, compared to &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$199 million in 2019 and $488 million in 2018. The expenses in 2020 were primarily related to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;residual expenses&lt;/div&gt;&#160;of the restructuring plan announced in 2017&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and other network consolidation impacts.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2017, Teva announced a comprehensive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-year&lt;/div&gt; restructuring plan intended to reduce its cost base by $3&#160;billion, unify and simplify its organization and improve business performance, profitability, cash flow generation and productivity. This plan achieved its goals, including a total cost base reduction of $3&#160;billion by the end of 2019. Teva is continuing to evaluate opportunities to further optimize its manufacturing and supply network to achieve additional operational efficiencies. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables provide the components of costs associated with Teva&#x2019;s restructuring plan, including other costs associated with Teva&#x2019;s restructuring plan and recorded under different items: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2018&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee termination&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;410 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;199 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;488 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides the components of and changes in the Company&#x2019;s restructuring accruals: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&lt;br/&gt; termination&#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions )&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January 1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and other*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;217&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;(208&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;(215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(71&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"&gt;(49&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(120&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and other&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;164&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;49&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;213&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(115&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(122&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Includes adjustments for foreign currency translation. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant regulatory and other events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2018, the FDA completed an inspection of Teva&#x2019;s manufacturing plant in Davie, Florida in the United States, and issued a Form FDA-483 to the site. In October 2018, the FDA notified Teva that the inspection of the site is classified as &#x201c;official action indicated&#x201d; (OAI). On February 5, 2019, Teva received a warning letter from the FDA that contained four additional enumerated concerns related to production, quality control and investigations at this site. Teva has been working diligently to address the FDA&#x2019;s concerns in a manner consistent with current good manufacturing practice (cGMP) requirements as quickly and as thoroughly as possible. An FDA follow up inspection occurred in January 2020, resulting in some follow up findings and Teva received a letter from the FDA dated April 24, 2020 notifying it that the site continues to be classified as OAI. If Teva is unable to remediate the findings to the FDA&#x2019;s satisfaction, Teva may face additional consequences. These would potentially include delays in FDA approval for future products from the site, financial implications due to loss of revenues, impairments, inventory write-offs, customer penalties, idle capacity charges, costs of additional remediation and possible FDA enforcement action. Teva expects to generate approximately&lt;/div&gt; $190 &#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in revenues from this site in 2021, assuming remediation or enforcement does not cause any unscheduled slowdown or stoppage at the facility, however, delays in FDA approvals of future products from the site may occur.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#x201c;Huahai&#x201d;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#x2019;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the second quarter of 2020, Teva&#x2019;s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva has completed partial remediation of this issue and has restarted limited supply from its Goa facilities. The impact to Teva&#x2019;s financial results for the twelve months ended December&#160;31, 2020 was immaterial, however, if the full remediation takes longer than expected there may be further loss of sales, customer penalties or impairments to related assets. &lt;/div&gt;&lt;/div&gt; </teva:OtherExpensesTextBlock>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of long-lived tangible assets &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;416&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration (see note 2)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(81&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;26&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;479&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;423&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;987&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Including impairments related to exit and disposal activities. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_17703138"
      unitRef="Unit_USD">416000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      id="Fact_17703225"
      unitRef="Unit_USD">139000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      id="Fact_17703133"
      unitRef="Unit_USD">500000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-81000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">59000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">120000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">199000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">488000000</us-gaap:RestructuringCharges>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">24000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">26000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-58000000</teva:LegalSettlementsLossContingenciesImpairmentsOtherExpenses>
    <teva:ImpairmentAndRestructuring
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">479000000</teva:ImpairmentAndRestructuring>
    <teva:ImpairmentAndRestructuring
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">423000000</teva:ImpairmentAndRestructuring>
    <teva:ImpairmentAndRestructuring
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">987000000</teva:ImpairmentAndRestructuring>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">416000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">139000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">500000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-81000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">59000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">57000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">120000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">199000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">488000000</us-gaap:RestructuringCharges>
    <teva:RestructuringPlanCostReduction
      contextRef="P01_01_2017To12_31_2017"
      decimals="-9"
      unitRef="Unit_USD">3000000000</teva:RestructuringPlanCostReduction>
    <teva:RestructuringPlanCostReduction
      contextRef="P01_01_2017To12_31_2017"
      decimals="-9"
      unitRef="Unit_USD">3000000000</teva:RestructuringPlanCostReduction>
    <teva:ScheduleOfRestructuringChargesTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables provide the components of costs associated with Teva&#x2019;s restructuring plan, including other costs associated with Teva&#x2019;s restructuring plan and recorded under different items: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2018&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee termination&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;410 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;199 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;488 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfRestructuringChargesTableTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">71000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">159000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">410000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">49000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">40000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis"
      decimals="-6"
      unitRef="Unit_USD">78000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">120000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">199000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">488000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides the components of and changes in the Company&#x2019;s restructuring accruals: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee&lt;br/&gt; termination&#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions )&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of January 1, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and other*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;217&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 66%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;(208&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;"&gt;(215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(71&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"&gt;(49&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(120&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Utilization and other&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;164&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;49&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;213&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance as of December 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(115&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(122&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 66%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Includes adjustments for foreign currency translation. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2018_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">204000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2018_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">29000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">233000000</us-gaap:RestructuringReserve>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2019To12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">159000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2019To12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">40000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">199000000</teva:RestructuringAccrualProvision>
    <teva:UtilizationAndOther
      contextRef="P01_01_2019To12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_17703264"
      unitRef="Unit_USD">155000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2019To12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_17703265"
      unitRef="Unit_USD">62000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      id="Fact_17703266"
      unitRef="Unit_USD">217000000</teva:UtilizationAndOther>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2019_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">208000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2019_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">215000000</us-gaap:RestructuringReserve>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2020To12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">71000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2020To12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">49000000</teva:RestructuringAccrualProvision>
    <teva:RestructuringAccrualProvision
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">120000000</teva:RestructuringAccrualProvision>
    <teva:UtilizationAndOther
      contextRef="P01_01_2020To12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_17704583"
      unitRef="Unit_USD">164000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2020To12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      id="Fact_17704584"
      unitRef="Unit_USD">49000000</teva:UtilizationAndOther>
    <teva:UtilizationAndOther
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_17704585"
      unitRef="Unit_USD">213000000</teva:UtilizationAndOther>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020_EmployeeTerminationMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">115000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020_OtherExitAndDisposalMemberTEVAExitAndDisposalAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">122000000</us-gaap:RestructuringReserve>
    <teva:ExpectedRevenueFromFacility
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">190000000</teva:ExpectedRevenueFromFacility>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 16&#x2014;Other income: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 4.5%;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 4.5%; vertical-align: bottom;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 4.5%;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 5.5%; vertical-align: bottom;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 4.5%;"/&gt;
&lt;td style="width: 0.5%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on divestitures, net of divestitures related costs (1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&#160;8 and similar payments (2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain (loss) on sale of assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mainly related to the divestment of several activities in the International Markets segment. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <teva:ScheduleOfOtherIncomeTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 4.5%;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 4.5%; vertical-align: bottom;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 4.5%;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 5.5%; vertical-align: bottom;"/&gt;
&lt;td style="width: 1%;"/&gt;
&lt;td style="width: 4.5%;"/&gt;
&lt;td style="width: 0.5%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on divestitures, net of divestitures related costs (1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&#160;8 and similar payments (2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain (loss) on sale of assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 65%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="white-space: nowrap; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="width: 0.5%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mainly related to the divestment of several activities in the International Markets segment. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfOtherIncomeTableTextBlock>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_17703027"
      unitRef="Unit_USD">8000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      id="Fact_17703028"
      unitRef="Unit_USD">50000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      id="Fact_17703029"
      unitRef="Unit_USD">67000000</us-gaap:GainLossOnSaleOfBusiness>
    <teva:PatentedMedicinesRegulationsAndSimilarPayments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      id="Fact_17705017"
      unitRef="Unit_USD">5000000</teva:PatentedMedicinesRegulationsAndSimilarPayments>
    <teva:PatentedMedicinesRegulationsAndSimilarPayments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      id="Fact_17705018"
      unitRef="Unit_USD">195000000</teva:PatentedMedicinesRegulationsAndSimilarPayments>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">11000000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1000000</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">9000000</us-gaap:GainsLossesOnSalesOfAssets>
    <teva:OtherOperatingIncomeNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:OtherOperatingIncomeNet>
    <teva:OtherOperatingIncomeNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">22000000</teva:OtherOperatingIncomeNet>
    <teva:OtherOperatingIncomeNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">20000000</teva:OtherOperatingIncomeNet>
    <us-gaap:OtherIncome
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">40000000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">76000000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">291000000</us-gaap:OtherIncome>
    <teva:FinancialExpensesNetTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 17&#x2014;Financial expenses, net: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width:0.5%;"/&gt;
&lt;td style="width:3%;"/&gt;
&lt;td style="width:1%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width:0.5%;"/&gt;
&lt;td style="width:3%;"/&gt;
&lt;td style="width:1%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width:0.5%;"/&gt;
&lt;td style="width:3%;"/&gt;
&lt;td style="width:0.5%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December,&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expenses and other bank charges&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;920&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from investments (1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;(104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;(39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Foreign exchange (gains) losses, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;(26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;(15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, net (2)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;;width:3%;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total finance expense, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;822&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2020, Income from investments comprised mainly of revaluation gain of Teva&#x2019;s investment in American Well Corporation (&#x201c;American Well&#x201d;). See note 20. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2018, Other, net comprised mainly of a make-whole payment of $46 million following early redemption of senior notes during 2018. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:FinancialExpensesNetTextBlock>
    <teva:FinancialExpensesNetTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width:0.5%;"/&gt;
&lt;td style="width:3%;"/&gt;
&lt;td style="width:1%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width:0.5%;"/&gt;
&lt;td style="width:3%;"/&gt;
&lt;td style="width:1%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td style="width:0.5%;"/&gt;
&lt;td style="width:3%;"/&gt;
&lt;td style="width:0.5%;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;ended&#160;December,&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expenses and other bank charges&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;920&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from investments (1)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;(104&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;(39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Foreign exchange (gains) losses, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;(26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;(15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, net (2)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;;width:3%;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total finance expense, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;822&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"&gt;959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2020, Income from investments comprised mainly of revaluation gain of Teva&#x2019;s investment in American Well Corporation (&#x201c;American Well&#x201d;). See note 20. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2018, Other, net comprised mainly of a make-whole payment of $46 million following early redemption of senior notes during 2018. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:FinancialExpensesNetTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">963000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">881000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">920000000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      id="Fact_17703578"
      unitRef="Unit_USD">104000000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      id="Fact_17703579"
      unitRef="Unit_USD">41000000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      id="Fact_17703580"
      unitRef="Unit_USD">39000000</us-gaap:InvestmentIncomeNonoperating>
    <teva:ForeignCurrencyTransactionGainLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">26000000</teva:ForeignCurrencyTransactionGainLoss>
    <teva:ForeignCurrencyTransactionGainLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">15000000</teva:ForeignCurrencyTransactionGainLoss>
    <teva:ForeignCurrencyTransactionGainLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-13000000</teva:ForeignCurrencyTransactionGainLoss>
    <teva:OtherFinancialIncomeExpenseNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      id="Fact_17703585"
      unitRef="Unit_USD">4000000</teva:OtherFinancialIncomeExpenseNet>
    <teva:OtherFinancialIncomeExpenseNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      id="Fact_17703586"
      unitRef="Unit_USD">-65000000</teva:OtherFinancialIncomeExpenseNet>
    <teva:FinanceIncomeExpensesNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-834000000</teva:FinanceIncomeExpensesNet>
    <teva:FinanceIncomeExpensesNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-822000000</teva:FinanceIncomeExpensesNet>
    <teva:FinanceIncomeExpensesNet
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-959000000</teva:FinanceIncomeExpensesNet>
    <teva:PaymentForRedemptionOfSeniorNotes
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">46000000</teva:PaymentForRedemptionOfSeniorNotes>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 18&#x2014;Earnings (loss) per share: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December&#160;31, 2020, 2019 and 2018 are as follows: &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December, 31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions,&#160;except&#160;share&#160;data)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) used for the computation of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;basic and&#160;&lt;/div&gt;diluted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings (loss)&lt;/div&gt; per share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(999&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(2,399&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of shares used in the computation of basic&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings (loss)&lt;/div&gt; per share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;1,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;1,091&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;1,021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of shares used in the computation of diluted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings (loss)&lt;/div&gt; per share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;1,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;1,091&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;1,021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#x2019;s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested restricted share units (&#x201c;RSUs&#x201d;)) during the period, net of treasury shares. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In computing diluted loss per share for the years ended December 31, 2020, 2019 and 2018, no account was taken of the potential dilution that could occur upon the exercise of employee stock options, RSUs and PSUs, amounting to&lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;104&#160;million, 113&#160;million and 51&#160;million weighted average shares, respectively, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, in computing diluted loss per share for the period between January 1, 2018 and December 17, 2018, no account was taken of the potential dilution of the mandatory convertible preferred shares amounting to&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; 74&#160;million&#160;since they had an anti-dilutive effect on loss per share. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted loss per share was $3.64 for the year ended December&#160;31, 2020, compared to basic and diluted loss per share of $0.91 and $2.35 for the years ended December&#160;31, 2019 and December&#160;31, 2018, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December&#160;31, 2020, 2019 and 2018 are as follows: &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December, 31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions,&#160;except&#160;share&#160;data)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) used for the computation of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;basic and&#160;&lt;/div&gt;diluted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings (loss)&lt;/div&gt; per share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(3,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(999&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(2,399&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of shares used in the computation of basic&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings (loss)&lt;/div&gt; per share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;1,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;1,091&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;1,021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of shares used in the computation of diluted &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;earnings (loss)&lt;/div&gt; per share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;1,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;1,091&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;1,021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-3990000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-999000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2399000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">1095000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_shares">1091000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_shares">1021000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_shares">1095000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_shares">1091000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_shares">1021000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-6"
      unitRef="Unit_shares">104000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-6"
      unitRef="Unit_shares">113000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2018To12_31_2018_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-6"
      unitRef="Unit_shares">51000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2018To12_17_2018_ConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-6"
      unitRef="Unit_shares">74000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.64</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.91</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2018To12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 19&#x2014;Segments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva operates its business and reports its financial results in three segments: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America segment, which includes the United States and Canada. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(b)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe segment, which includes the European Union and certain other European countries. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(c)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets segment, which includes all countries other than those in the North America and Europe segments. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In addition to these three segments, Teva has other sources of revenues included in other activities, primarily the sale of APIs to third parties, certain contract manufacturing services and an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-licensing&lt;/div&gt; platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;), who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;performance&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit is comprised of gross profit for the segment less R&amp;amp;D expenses, S&amp;amp;M expenses, G&amp;amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#x2019;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva&#x2019;s CEO may review its strategy and organizational structure. Any changes in strategy may lead to a reevaluation of the Company&#x2019;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 7. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment information: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;622&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;247&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;427&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"&gt;2,421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"&gt;1,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-top: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"&gt;474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,542&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,795&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,246&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,350&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,704&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,167&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;652&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;262&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;88&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;890&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;481&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;439&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;239&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;138&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(14&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,252&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,318&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;464&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,297&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,186&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,422&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,979&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,884&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,254&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;713&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;283&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;96&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,154&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,003&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;518&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;484&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;325&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;153&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(209&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,837&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,273&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,421&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,252&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,837&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,331&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,318&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,273&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;474&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;464&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total reportable segments profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,225&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,608&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profit (loss) of other activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;163&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;108&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total segments profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,388&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,142&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,723&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts not allocated to segments:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,113&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,166&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; white-space: nowrap; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Other asset impairments, restructuring and other items&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;479&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;987&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,628&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible asset impairments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,502&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,639&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,991&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on divestitures, net of divestitures related costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Other R&amp;amp;D expenses (income)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs related to regulatory actions taken in facilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;45&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal settlements and loss contingencies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,178&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,208&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other unallocated amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;219&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;366&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated operating income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,572&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,637&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;834&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;822&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;959&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated income (loss) before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,406&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,265&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,596&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment revenues by major products and activities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following tables present revenues by major products and activities for each segment for the year ended December&#160;31, 2020, 2019 and 2018: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America segment: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUSTEDO&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BENDEKA/TREANDA&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;884&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProAir*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;241&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;QVAR&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anda&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,462&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;708&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,297&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Does not include revenues from the ProAir authorized generic, which are included under generic products. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe segment: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,593&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; padding: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;656&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4,757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets segment: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,792&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva revenues from external customers attributed to Israel were less than 5% of the consolidated revenues in the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental data&#x2014;major customers: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents the percentage of consolidated third party net sales to Teva&#x2019;s major customers during the years ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage&#160;of&#160;Third&#160;Party&#160;Net&#160;Sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;McKesson Corporation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AmerisourceBergen Corporation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of Teva&#x2019;s revenues from these customers were in the North America segment. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment&#x2014;by geographical location were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Israel&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,611&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;864&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Croatia&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;539&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Germany&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Czech republic&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hungary&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ireland&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;267&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,501&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,776&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property, plant and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_Segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;622&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;247&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;70&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;427&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;136&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"&gt;2,421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"&gt;1,331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-top: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;"&gt;474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,542&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,795&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,246&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,350&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,704&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,167&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;652&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;262&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;88&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;890&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;481&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;439&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;239&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;138&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(14&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,252&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,318&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;464&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;North&#160;America&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Europe&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;International&#160;Markets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,297&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,186&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,422&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,979&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,884&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,254&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;713&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;283&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;96&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&amp;amp;M expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,154&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,003&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;518&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;484&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;325&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;153&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(209&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(11&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 52%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segment profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,837&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,273&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">8447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4757000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4489000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2666000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1096000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">622000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">247000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">70000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1013000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">830000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">427000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">443000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">261000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">136000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-10000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-3000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2421000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1331000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">474000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">8542000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4350000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2704000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1167000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">652000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">262000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">88000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1021000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">890000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">481000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">439000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">239000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">138000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-14000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-5000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-3000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2252000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1318000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">464000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">9297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">5186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4979000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2884000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1254000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">713000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">283000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">96000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1154000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1003000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">518000000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">484000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">325000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">153000000</us-gaap:GeneralAndAdministrativeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-209000000</teva:OtherOperatingIncomeExpense>
    <teva:OtherOperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</teva:OtherOperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2837000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1273000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">498000000</us-gaap:OperatingIncomeLoss>
    <teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.$ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,421&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,252&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,837&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,331&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,318&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,273&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;474&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;464&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total reportable segments profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,225&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,034&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,608&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Profit (loss) of other activities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;163&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;108&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total segments profit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,388&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,142&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,723&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amounts not allocated to segments:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,113&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,166&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; white-space: nowrap; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Other asset impairments, restructuring and other items&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;479&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;423&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;987&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill impairment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,628&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014; &#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible asset impairments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,502&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,639&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,991&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on divestitures, net of divestitures related costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(66&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Other R&amp;amp;D expenses (income)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;37&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(15&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;83&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs related to regulatory actions taken in facilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;45&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Legal settlements and loss contingencies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,178&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,208&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other unallocated amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;219&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;366&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated operating income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3,572&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(443&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,637&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial expenses, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;834&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;822&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;959&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated income (loss) before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,406&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,265&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,596&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2421000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2252000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2837000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1331000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1318000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1273000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">474000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">464000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">498000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4225000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4034000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_CorporateMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4608000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">163000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">108000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_AllOtherSegmentsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">115000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4388000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4142000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018_SegmentsAndOtherActivitiesMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4723000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1020000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1113000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1166000000</us-gaap:AdjustmentForAmortization>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">479000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">423000000</teva:ImpairmentsRestructuringAndOthers>
    <teva:ImpairmentsRestructuringAndOthers
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">987000000</teva:ImpairmentsRestructuringAndOthers>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4628000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">3027000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">1502000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1639000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">1991000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-8000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-50000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-66000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <teva:PurchaseOfResearchAndDevelopmentInProcess
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">37000000</teva:PurchaseOfResearchAndDevelopmentInProcess>
    <teva:PurchaseOfResearchAndDevelopmentInProcess
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-15000000</teva:PurchaseOfResearchAndDevelopmentInProcess>
    <teva:PurchaseOfResearchAndDevelopmentInProcess
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">83000000</teva:PurchaseOfResearchAndDevelopmentInProcess>
    <teva:CostsRelatedToRegulatoryActionsTakenInFacilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">23000000</teva:CostsRelatedToRegulatoryActionsTakenInFacilities>
    <teva:CostsRelatedToRegulatoryActionsTakenInFacilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">45000000</teva:CostsRelatedToRegulatoryActionsTakenInFacilities>
    <teva:CostsRelatedToRegulatoryActionsTakenInFacilities
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">14000000</teva:CostsRelatedToRegulatoryActionsTakenInFacilities>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">60000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1178000000</teva:LegalSettlementsAndLossContingencies>
    <teva:LegalSettlementsAndLossContingencies
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-1208000000</teva:LegalSettlementsAndLossContingencies>
    <teva:OtherUnallocatedAmounts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">219000000</teva:OtherUnallocatedAmounts>
    <teva:OtherUnallocatedAmounts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">252000000</teva:OtherUnallocatedAmounts>
    <teva:OtherUnallocatedAmounts
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">366000000</teva:OtherUnallocatedAmounts>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-3572000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-443000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-1637000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-834000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-822000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-959000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-4406000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-1265000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2018To12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">-2596000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;North America segment: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,010&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,963&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUSTEDO&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BENDEKA/TREANDA&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;884&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,017&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProAir*&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;241&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;274&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;QVAR&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anda&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,462&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;485&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;546&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;708&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,542&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,297&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Does not include revenues from the ProAir authorized generic, which are included under generic products. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Europe segment: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,470&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,593&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;AJOVY&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;31&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: right; padding: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;535&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;353&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;402&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;536&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;656&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4,757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;4,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;International Markets segment: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Generic products&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,792&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COPAXONE&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;328&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,246&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4010000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4056000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">93000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_AjovyMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_AustedoMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_BendekaAndTreandaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">884000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1017000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_ProAirMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_QVARMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1492000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_AndaMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">546000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">708000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">8447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">8542000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">9297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_GenericsMediciansMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">3593000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_AjovyMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">432000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">354000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_RespiratoryProductMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">536000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">656000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4757000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">4795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_EuropeSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">5186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1792000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">1893000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_GenericsMediciansMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_COPAXONEMembersrtProductOrServiceAxis_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis_OtherProductsMembersrtProductOrServiceAxis"
      decimals="-6"
      unitRef="Unit_USD">328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To12_31_2019_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2018To12_31_2018_InternationalMarketsMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">2422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2018To12_31_2018_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ILsrtStatementGeographicalAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <teva:SalesPercentageByTherapeuticCategoryTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table represents the percentage of consolidated third party net sales to Teva&#x2019;s major customers during the years ended December&#160;31, 2020, 2019 and 2018. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage&#160;of&#160;Third&#160;Party&#160;Net&#160;Sales&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;McKesson Corporation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AmerisourceBergen Corporation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:SalesPercentageByTherapeuticCategoryTableTextBlock>
    <teva:NetSalesPresent
      contextRef="PAsOn12_31_2020_Customer1MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</teva:NetSalesPresent>
    <teva:NetSalesPresent
      contextRef="PAsOn12_31_2019_Customer1MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.13</teva:NetSalesPresent>
    <teva:NetSalesPresent
      contextRef="PAsOn12_31_2018_Customer1MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</teva:NetSalesPresent>
    <teva:NetSalesPresent
      contextRef="PAsOn12_31_2020_Customer2MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</teva:NetSalesPresent>
    <teva:NetSalesPresent
      contextRef="PAsOn12_31_2019_Customer2MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</teva:NetSalesPresent>
    <teva:NetSalesPresent
      contextRef="PAsOn12_31_2018_Customer2MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.14</teva:NetSalesPresent>
    <teva:PropertyPlantAndEquipmentByGeographicAreaTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment&#x2014;by geographical location were as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Israel&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,611&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;864&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Croatia&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;539&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Germany&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;933&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Czech republic&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;343&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hungary&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;330&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ireland&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;267&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,501&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,776&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property, plant and equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,296&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,436&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:PropertyPlantAndEquipmentByGeographicAreaTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_ILsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1611000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_ILsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1670000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_USsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">790000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_USsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">864000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_HRsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">539000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_HRsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">517000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_DEsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">933000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_DEsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">665000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_CZsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">330000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_CZsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">343000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_HUsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">325000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_HUsrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">330000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_IEMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">267000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_IEMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">271000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1501000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019_OtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-6"
      unitRef="Unit_USD">1776000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">6296000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">6436000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 20 &#x2014;Fair value measurement: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial items carried at fair value as of December&#160;31, 2020 and 2019 are classified in the tables below in one of the three categories described in note 1f: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Equity securities*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;259&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, mainly debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Asset derivatives&#x2014;options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Liabilities derivatives&#x2014;options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Contingent consideration**&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,153&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, mainly debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Asset derivatives&#x2014;options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Liability derivatives&#x2014;options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Liabilities derivatives&#x2014;interest rate and cross-currency swaps&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Contingent consideration**&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(460&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(460&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(31&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the third quarter of 2020, Teva recorded a gain of $134&#160;million under share in profits of associated companies, net, reflecting the difference between the book value of Teva&#x2019;s investment in American Well&#160;and its fair value as of the date it completed its initial public offering in September 2020. The investment was reclassified from &#x201c;investment in associated companies&#x201d; to &#x201c;investment in marketable securities,&#x201d; since Teva no longer ha&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&#160;significant influence in American Well. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;This represented a transfer into Level 3 measurement within fair value hierarchy. By&#160;&lt;/div&gt;December&#160;31,&#160;2020,&#160;Teva recorded an&#160;additional&#160;gain&#160;of&#160;$80&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million under financial expenses, net, reflecting the revaluation gain of this security as of December 31, 2020 and transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to management&#x2019;s intention and ability to sell this security in the next twelve months, the balance as of December&#160;31, 2020 was reclassified to short term investments. &lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;**&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor ranging from 80% to 100% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;amp;D. The discount rate applied ranged from 7.5% to 8.0%. The weighted average discount rate, calculated based on the relative fair value of Teva&#x2019;s contingent consideration liabilities, was 7.7%. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value measurement of the investment in equity securities is based on a discount rate for fair value measurement, related to restriction of sale of shares, and thus represents a Level 2 measurement within the fair value hierarchy. The discount rate applied for the fair value measurement at December 31, 2020 was&lt;/div&gt;&#160;4%.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the beginning of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transfer into Level 3- equity securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;179 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revaluation of equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;80&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revaluation of debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassification to Level 2- equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt; &lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(259&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;Adjustments to provisions for contingent consideration:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Actavis Generics transaction&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;156 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transactio&lt;div style="display:inline;"&gt;n&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(75&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(151&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;Settlement of contingent consideration:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Eagle transaction&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;111 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the end of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Teva&#x2019;s financial instruments consist mainly of cash and cash equivalents, investments in securities, current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; receivables, short-term credit, accounts payable and accruals, loans and senior notes, convertible senior debentures and derivatives. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The fair value of the financial instruments included in working capital and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; receivables approximates their carrying value. The fair value of long-term bank loans mostly approximates their carrying value, since they bear interest at rates close to the prevailing market rates.&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments not measured at fair value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured on a basis other than fair value consist of senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value:&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated fair value*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes included under long-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,686 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and convertible senior debentures included under short-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the end of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,891&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,004 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; margin-left: 13%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value was estimated based on quoted market prices. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial items carried at fair value as of December&#160;31, 2020 and 2019 are classified in the tables below in one of the three categories described in note 1f: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,810&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Equity securities*&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;259&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, mainly debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Asset derivatives&#x2014;options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Liabilities derivatives&#x2014;options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Contingent consideration**&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;204&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;2,153&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money markets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;577&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, deposits and other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;1,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in securities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other, mainly debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivatives:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Asset derivatives&#x2014;options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Liability derivatives&#x2014;options and forward contracts&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(41&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Liabilities derivatives&#x2014;interest rate and cross-currency swaps&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Contingent consideration**&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(460&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"&gt;(460&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;2,019&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(31&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;(448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"&gt;1,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the third quarter of 2020, Teva recorded a gain of $134&#160;million under share in profits of associated companies, net, reflecting the difference between the book value of Teva&#x2019;s investment in American Well&#160;and its fair value as of the date it completed its initial public offering in September 2020. The investment was reclassified from &#x201c;investment in associated companies&#x201d; to &#x201c;investment in marketable securities,&#x201d; since Teva no longer ha&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&#160;significant influence in American Well. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;This represented a transfer into Level 3 measurement within fair value hierarchy. By&#160;&lt;/div&gt;December&#160;31,&#160;2020,&#160;Teva recorded an&#160;additional&#160;gain&#160;of&#160;$80&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million under financial expenses, net, reflecting the revaluation gain of this security as of December 31, 2020 and transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to management&#x2019;s intention and ability to sell this security in the next twelve months, the balance as of December&#160;31, 2020 was reclassified to short term investments. &lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;**&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">367000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">367000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">1810000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_DemandDepositsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1810000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="Fact_17702405"
      unitRef="Unit_USD">25000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="Fact_17704579"
      unitRef="Unit_USD">259000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      id="Fact_17702408"
      unitRef="Unit_USD">284000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">15000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">24000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn12_31_2020_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">24000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">79000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">79000000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="Fact_17702754"
      unitRef="Unit_USD">268000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      id="Fact_17702755"
      unitRef="Unit_USD">268000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">2207000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">204000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-258000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2153000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">577000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">577000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_DemandDepositsMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">1398000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_DemandDepositsMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">1398000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">42000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_EquitySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">42000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_OtherDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="PAsOn12_31_2019_InterestRateSwapMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">32000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">41000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2019_OptionsAndForwardContractsDerivativeLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-6"
      unitRef="Unit_USD">41000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">22000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">22000000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      id="Fact_17702766"
      unitRef="Unit_USD">460000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      id="Fact_17702767"
      unitRef="Unit_USD">460000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">2019000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-31000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-6"
      unitRef="Unit_USD">-448000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1540000000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:GainLossOnSaleOfEquityInvestments
      contextRef="P01_01_2020To09_30_2020"
      decimals="-6"
      unitRef="Unit_USD">134000000</us-gaap:GainLossOnSaleOfEquityInvestments>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="P01_01_2020To12_31_2020_RevaluationOfAssetsMemberusgaapFreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis"
      decimals="-6"
      unitRef="Unit_USD">80000000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.80</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MaximumMembersrtRangeAxis_MeasurementInputProbabilityOfSuccessMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.075</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_WeightedAverageMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.077</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.04</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the beginning of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transfer into Level 3- equity securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;179 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revaluation of equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;80&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revaluation of debt securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reclassification to Level 2- equity securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt; &lt;div style="line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(259&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;Adjustments to provisions for contingent consideration:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Actavis Generics transaction&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;156 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eagle transactio&lt;div style="display:inline;"&gt;n&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(75&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(151&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"&gt;Settlement of contingent consideration:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Eagle transaction&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;111 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the end of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">448000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2018"
      decimals="-6"
      unitRef="Unit_USD">497000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">179000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">80000000</us-gaap:FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">-2000000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">259000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod
      contextRef="P01_01_2020To12_31_2020_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">156000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod
      contextRef="P01_01_2019To12_31_2019_ActavisGenericsMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">92000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease
      contextRef="P01_01_2020To12_31_2020_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-75000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease>
    <teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease
      contextRef="P01_01_2019To12_31_2019_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">-151000000</teva:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2020To12_31_2020_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">111000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P01_01_2019To12_31_2019_EagleTransactionMemberusgaapIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">106000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">258000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">448000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured on a basis other than fair value consist of senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value:&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated fair value*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S. $ in millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes included under long-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,684&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22,686 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Senior notes and convertible senior debentures included under short-term liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value at the end of the period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,891&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,004 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; margin-left: 13%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;*&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value was estimated based on quoted market prices. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2020_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">22684000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2019_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">22686000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2020_SeniornotesandconvertibleseniordebenturesmemberMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">3207000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2019_SeniornotesandconvertibleseniordebenturesmemberMemberusgaapLongtermDebtTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2318000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">25891000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">25004000000</us-gaap:DebtInstrumentFairValue>
    <teva:LongTermEmployeeRelatedObligationsTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 21&#x2014;Long-term employee-related obligations: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term employee-related obligations consisted of the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued severance obligations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;82 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined benefit plans&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;192 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;165 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;241 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2020 and 2019, Teva had $86 million and $82 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively, deposited in funds managed by financial institutions and earmarked by management to cover severance pay liability. Such deposits are not considered to be &#x201c;plan assets&#x201d; and are therefore included in other non-current assets.&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Most of the change resulted from actuarial updates, as well as from exiting from several defined benefit plans in several countries. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects to expense an approximate contribution of $116 million in 2021 to pension funds and insurance companies in connection with its severance and pension pay obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The main terms of the different arrangements with employees are described in below. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Terms of arrangements: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Israel &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Parent Company and its Israeli subsidiaries make ongoing deposits into employee pension plans to fund their severance liabilities. Generally, employees that joined the Company after 2005, have signed an arrangement, pursuant to which such deposits are made in lieu of the Company&#x2019;s severance liability. Therefore, no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who were employed by the Parent Company and its Israeli subsidiaries prior to that date, as well as employees who have special contractual arrangements, are provided for in the financial statements based upon the number of years of service and the latest monthly salary of such employees. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Europe &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Many of the employees in the Company&#x2019;s European subsidiaries are entitled to a retirement grant when they leave the Company. In the consolidated financial statements, the liability of the European subsidiaries is accrued, based on the length of service and remuneration of each employee at the balance sheet date. Other employees in Europe are entitled to a pension according to a defined benefit scheme providing benefits based on final or average pensionable pay or according to a hybrid pension scheme that provides retirement benefits on a defined benefit and a defined contribution basis. Independent certified actuaries value these schemes and determine the rates of contribution payable. Pension costs for the defined benefit section of the scheme are accounted for on the basis of charging the expected cost of providing pensions over the period during which the subsidiaries benefit from the employees&#x2019; services. The Company uses December&#160;31 as the measurement date for defined benefit plans. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;North America &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s North American subsidiaries mainly provide various defined contribution plans for the benefit of their employees. Under these plans, contributions are based on specified percentages of pay. Additionally, a multi-employer plan is maintained in accordance with various union agreements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Latin America &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The majority of the employees in Latin America are entitled to severance under local law. The severance payments are calculated based on service term and employee remuneration, and accruals are maintained to reflect these amounts. In some Latin American countries it is Teva&#x2019;s practice to offer retirement health benefits to qualifying employees. Based on the specific plan requirements, benefits accruals are maintained to reflect the estimated amounts or adjusted if future plans are modified. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects to pay the following future minimum benefits to its employees: $13 million in 2021; $12 million in 2022; $12 million in 2023; $11 million in 2024; $12 million in 2025 and $65 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in the aggregate between 2026 to 2030. These amounts do not include amounts that may be paid to employees who cease working with the Company before their normal retirement age.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </teva:LongTermEmployeeRelatedObligationsTextBlock>
    <teva:LongTermEmployeeRelatedObligationsTableTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term employee-related obligations consisted of the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(U.S.&#160;$&#160;in&#160;millions)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued severance obligations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;82 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined benefit plans&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;192 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;165 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;241 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:LongTermEmployeeRelatedObligationsTableTextBlock>
    <teva:AccruedSeverancePayNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">82000000</teva:AccruedSeverancePayNoncurrent>
    <teva:AccruedSeverancePayNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">76000000</teva:AccruedSeverancePayNoncurrent>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">192000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">165000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <teva:EmployeeRelatedObligationsNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">275000000</teva:EmployeeRelatedObligationsNoncurrent>
    <teva:EmployeeRelatedObligationsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">241000000</teva:EmployeeRelatedObligationsNoncurrent>
    <teva:LongTermInvestmentsEarmarkedForDomesticSeveranceObligations
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">86000000</teva:LongTermInvestmentsEarmarkedForDomesticSeveranceObligations>
    <teva:LongTermInvestmentsEarmarkedForDomesticSeveranceObligations
      contextRef="PAsOn12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">82000000</teva:LongTermInvestmentsEarmarkedForDomesticSeveranceObligations>
    <teva:DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">116000000</teva:DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear>
    <teva:FutureExpectedDomesticMinimumBenefitPaymentsYearOne
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">13000000</teva:FutureExpectedDomesticMinimumBenefitPaymentsYearOne>
    <teva:FutureExpectedDomesticMinimumBenefitPaymentsYearTwo
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">12000000</teva:FutureExpectedDomesticMinimumBenefitPaymentsYearTwo>
    <teva:FutureExpectedDomesticMinimumBenefitPaymentsYearThree
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">12000000</teva:FutureExpectedDomesticMinimumBenefitPaymentsYearThree>
    <teva:FutureExpectedDomesticMinimumBenefitPaymentsYearFour
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">11000000</teva:FutureExpectedDomesticMinimumBenefitPaymentsYearFour>
    <teva:FutureExpectedDomesticMinimumBenefitPaymentsYearFive
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">12000000</teva:FutureExpectedDomesticMinimumBenefitPaymentsYearFive>
    <teva:FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen
      contextRef="PAsOn12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">65000000</teva:FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen>
    <teva:SelectedQuarterlyFinancialDataTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 22&#x2014;Selected quarterly financial data (unaudited): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents selected unaudited quarterly financial data for 2020 and 2019:&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;4th&#160;quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;3rd&#160;quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2nd&#160;quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;1st&#160;quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;U.S $ in millions (except per share amounts)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,870 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,357&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,048&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,763&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,340&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to Teva&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to ordinary shareholders&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share attributable to ordinary shareholders:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;0.14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;0.14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;4th quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;3rd quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2nd quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;1st quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;U.S $ in millions (except per share amounts)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,149&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(307&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to Teva&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(314&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to ordinary shareholders&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(314&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share attributable to ordinary shareholders:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:SelectedQuarterlyFinancialDataTextBlock>
    <teva:SelectedQuarterlyFinancialDataTableTextBlock contextRef="P01_01_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents selected unaudited quarterly financial data for 2020 and 2019:&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;4th&#160;quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;3rd&#160;quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2nd&#160;quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;1st&#160;quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;U.S $ in millions (except per share amounts)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,870 &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,357&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,048&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,852&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,763&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,340&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to Teva&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to ordinary shareholders&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share attributable to ordinary shareholders:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;0.14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;0.14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;4th quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;3rd quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;2nd quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;1st quarter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;U.S $ in millions (except per share amounts)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenues&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,093&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,177&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,149&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,856&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(307&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to Teva&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(314&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) attributable to ordinary shareholders&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(314&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(105&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Earnings per share attributable to ordinary shareholders:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </teva:SelectedQuarterlyFinancialDataTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P10_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2020To09_30_2020"
      decimals="-6"
      unitRef="Unit_USD">3978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-6"
      unitRef="Unit_USD">3870000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-6"
      unitRef="Unit_USD">4357000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P10_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2048000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P07_01_2020To09_30_2020"
      decimals="-6"
      unitRef="Unit_USD">1852000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P04_01_2020To06_30_2020"
      decimals="-6"
      unitRef="Unit_USD">1763000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2020To03_31_2020"
      decimals="-6"
      unitRef="Unit_USD">2063000000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="P10_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">162000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-6"
      unitRef="Unit_USD">-4340000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-6"
      unitRef="Unit_USD">53000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-6"
      unitRef="Unit_USD">25000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">150000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2020To09_30_2020"
      decimals="-6"
      unitRef="Unit_USD">-4349000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-6"
      unitRef="Unit_USD">140000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P10_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">150000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2020To09_30_2020"
      decimals="-6"
      unitRef="Unit_USD">-4349000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P04_01_2020To06_30_2020"
      decimals="-6"
      unitRef="Unit_USD">140000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To03_31_2020"
      decimals="-6"
      unitRef="Unit_USD">69000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P10_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2020To09_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P10_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2019To09_30_2019"
      decimals="-6"
      unitRef="Unit_USD">4093000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2019To06_30_2019"
      decimals="-6"
      unitRef="Unit_USD">4177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-6"
      unitRef="Unit_USD">4149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="P10_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1958000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P07_01_2019To09_30_2019"
      decimals="-6"
      unitRef="Unit_USD">1830000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P04_01_2019To06_30_2019"
      decimals="-6"
      unitRef="Unit_USD">1893000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2019To03_31_2019"
      decimals="-6"
      unitRef="Unit_USD">1856000000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="P10_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">75000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P07_01_2019To09_30_2019"
      decimals="-6"
      unitRef="Unit_USD">-307000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2019To06_30_2019"
      decimals="-6"
      unitRef="Unit_USD">-671000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-97000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P10_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">110000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2019To09_30_2019"
      decimals="-6"
      unitRef="Unit_USD">-314000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To06_30_2019"
      decimals="-6"
      unitRef="Unit_USD">-689000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-105000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P10_01_2019To12_31_2019"
      decimals="-6"
      unitRef="Unit_USD">110000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2019To09_30_2019"
      decimals="-6"
      unitRef="Unit_USD">-314000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P04_01_2019To06_30_2019"
      decimals="-6"
      unitRef="Unit_USD">-689000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To03_31_2019"
      decimals="-6"
      unitRef="Unit_USD">-105000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P10_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P10_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2019To09_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareDiluted>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="P01_01_2020To12_31_2020">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 50%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Column A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Column&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Column C&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Column D&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Column&#160;E&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&lt;br/&gt;beginning&lt;br/&gt;of period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Charged&#160;to&#160;costs&lt;br/&gt;and&#160;expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Charged&#160;to&#160;other&lt;br/&gt;accounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deductions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;at&#160;end&lt;br/&gt;of&#160;period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for doubtful accounts:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;209&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December&#160;31, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance in respect of carryforward tax losses and deductions that may not be utilized:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,974&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;670&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,974&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year ended December&#160;31, 2018&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;407&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,633&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">209000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="P01_01_2020To12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-11000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="P01_01_2020To12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">200000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">232000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="P01_01_2019To12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-16000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">209000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2017_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">232000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="P01_01_2018To12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="P01_01_2018To12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">-9000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2018To12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">232000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1974000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="P01_01_2020To12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">670000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2020To12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">97000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2020_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">2547000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1633000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="P01_01_2019To12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">555000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2019To12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">214000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2019_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1974000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2017_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1504000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="P01_01_2018To12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">407000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="P01_01_2018To12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="P01_01_2018To12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">283000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="PAsOn12_31_2018_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMemberusgaapValuationAllowancesAndReservesTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">1633000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_17701953"
          xlink:label="Fact_17701953"
          xlink:type="locator"/>
        <link:footnote id="FN_64427" xlink:label="FN_64427" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount less than 0.5 million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17701953"
          xlink:to="FN_64427"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17701954"
          xlink:label="Fact_17701954"
          xlink:type="locator"/>
        <link:footnote id="FN_64429" xlink:label="FN_64429" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mainly MCPS conversion.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17701954"
          xlink:to="FN_64429"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17701975"
          xlink:label="Fact_17701975"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17701975"
          xlink:to="FN_64429"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17701976"
          xlink:label="Fact_17701976"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17701976"
          xlink:to="FN_64429"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17701977"
          xlink:label="Fact_17701977"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17701977"
          xlink:to="FN_64429"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17701992"
          xlink:label="Fact_17701992"
          xlink:type="locator"/>
        <link:footnote id="FN_64453" xlink:label="FN_64453" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Following the adoption of ASU 2016-01, the Company recorded a $ 5 million opening balance reclassification from accumulated other comprehensive income to retained earnings. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17701992"
          xlink:to="FN_64453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17701993"
          xlink:label="Fact_17701993"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17701993"
          xlink:to="FN_64453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17701996"
          xlink:label="Fact_17701996"
          xlink:type="locator"/>
        <link:footnote id="FN_64426" xlink:label="FN_64426" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mandatory convertible preferred shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17701996"
          xlink:to="FN_64426"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702197"
          xlink:label="Fact_17702197"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702197"
          xlink:to="FN_64426"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702257"
          xlink:label="Fact_17702257"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702257"
          xlink:to="FN_64426"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702405"
          xlink:label="Fact_17702405"
          xlink:type="locator"/>
        <link:footnote id="FN_64452" xlink:label="FN_64452" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the third quarter of 2020, Teva recorded a gain of $134 million under share in profits of associated companies, net, reflecting the difference between the book value of Teva&#x2019;s investment in American Well and its fair value as of the date it completed its initial public offering in September 2020. The investment was reclassified from &#x201c;investment in associated companies&#x201d; to &#x201c;investment in marketable securities,&#x201d; since Teva no longer had significant influence in American Well. This represented a transfer into Level 3 measurement within fair value hierarchy. By December 31, 2020, Teva recorded an additional gain of $80 million under financial expenses, net, reflecting the revaluation gain of this security as of December 31, 2020 and transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate. Due to management&#x2019;s intention and ability to sell this security in the next twelve months, the balance as of December 31, 2020 was reclassified to short term investments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702405"
          xlink:to="FN_64452"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702408"
          xlink:label="Fact_17702408"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702408"
          xlink:to="FN_64452"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702679"
          xlink:label="Fact_17702679"
          xlink:type="locator"/>
        <link:footnote id="FN_64451" xlink:label="FN_64451" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Accumulated goodwill impairment as of December 31, 2020, December 31, 2019 and December 31, 2018 was approximately $25.6 billion, $21.0 billion and $21.0 billion, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702679"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702680"
          xlink:label="Fact_17702680"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702680"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702681"
          xlink:label="Fact_17702681"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702681"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702682"
          xlink:label="Fact_17702682"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702682"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702683"
          xlink:label="Fact_17702683"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702683"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702690"
          xlink:label="Fact_17702690"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702690"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702691"
          xlink:label="Fact_17702691"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702691"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702692"
          xlink:label="Fact_17702692"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702692"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702693"
          xlink:label="Fact_17702693"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702693"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702694"
          xlink:label="Fact_17702694"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702694"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702754"
          xlink:label="Fact_17702754"
          xlink:type="locator"/>
        <link:footnote id="FN_64423" xlink:label="FN_64423" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702754"
          xlink:to="FN_64423"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702755"
          xlink:label="Fact_17702755"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702755"
          xlink:to="FN_64423"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702766"
          xlink:label="Fact_17702766"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702766"
          xlink:to="FN_64423"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702767"
          xlink:label="Fact_17702767"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702767"
          xlink:to="FN_64423"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702857"
          xlink:label="Fact_17702857"
          xlink:type="locator"/>
        <link:footnote id="FN_64449" xlink:label="FN_64449" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In July 2020, Teva repaid at maturity &#x20ac;1,010 million of its 0.375% senior notes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702857"
          xlink:to="FN_64449"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702859"
          xlink:label="Fact_17702859"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702859"
          xlink:to="FN_64449"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702929"
          xlink:label="Fact_17702929"
          xlink:type="locator"/>
        <link:footnote id="FN_64450" xlink:label="FN_64450" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In March 2020, Teva repaid at maturity $700 million of its 2.25% senior notes. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702929"
          xlink:to="FN_64450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17702931"
          xlink:label="Fact_17702931"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17702931"
          xlink:to="FN_64450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703027"
          xlink:label="Fact_17703027"
          xlink:type="locator"/>
        <link:footnote id="FN_64437" xlink:label="FN_64437" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mainly related to the divestment of several activities in our International Markets segment. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703027"
          xlink:to="FN_64437"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703028"
          xlink:label="Fact_17703028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703028"
          xlink:to="FN_64437"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703029"
          xlink:label="Fact_17703029"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703029"
          xlink:to="FN_64437"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703057"
          xlink:label="Fact_17703057"
          xlink:type="locator"/>
        <link:footnote id="FN_64461" xlink:label="FN_64461" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Including $514 million convertible notes. See note 9a.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703057"
          xlink:to="FN_64461"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703133"
          xlink:label="Fact_17703133"
          xlink:type="locator"/>
        <link:footnote id="FN_64439" xlink:label="FN_64439" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Including impairments related to exit and disposal activities </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703133"
          xlink:to="FN_64439"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703138"
          xlink:label="Fact_17703138"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703138"
          xlink:to="FN_64439"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703188"
          xlink:label="Fact_17703188"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703188"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703189"
          xlink:label="Fact_17703189"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703189"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703190"
          xlink:label="Fact_17703190"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703190"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703191"
          xlink:label="Fact_17703191"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703191"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703192"
          xlink:label="Fact_17703192"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703192"
          xlink:to="FN_64451"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703207"
          xlink:label="Fact_17703207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703207"
          xlink:to="FN_64450"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703224"
          xlink:label="Fact_17703224"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703224"
          xlink:to="FN_64449"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703225"
          xlink:label="Fact_17703225"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703225"
          xlink:to="FN_64439"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703264"
          xlink:label="Fact_17703264"
          xlink:type="locator"/>
        <link:footnote id="FN_64455" xlink:label="FN_64455" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes adjustments for foreign currency translation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703264"
          xlink:to="FN_64455"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703265"
          xlink:label="Fact_17703265"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703265"
          xlink:to="FN_64455"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703266"
          xlink:label="Fact_17703266"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703266"
          xlink:to="FN_64455"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703578"
          xlink:label="Fact_17703578"
          xlink:type="locator"/>
        <link:footnote id="FN_64456" xlink:label="FN_64456" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2020, Income from investments comprised mainly of revaluation gain of Teva&#x2019;s investment in American Well Corporation (&#x201c;American Well&#x201d;). See note 20. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703578"
          xlink:to="FN_64456"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703579"
          xlink:label="Fact_17703579"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703579"
          xlink:to="FN_64456"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703580"
          xlink:label="Fact_17703580"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703580"
          xlink:to="FN_64456"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703585"
          xlink:label="Fact_17703585"
          xlink:type="locator"/>
        <link:footnote id="FN_64436" xlink:label="FN_64436" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2018, Other, net comprised mainly of a make-whole payment of $46 million following early redemption of senior notes during 2018. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703585"
          xlink:to="FN_64436"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703586"
          xlink:label="Fact_17703586"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703586"
          xlink:to="FN_64436"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703660"
          xlink:label="Fact_17703660"
          xlink:type="locator"/>
        <link:footnote id="FN_64458" xlink:label="FN_64458" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2020 and 2018, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703660"
          xlink:to="FN_64458"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703661"
          xlink:label="Fact_17703661"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703661"
          xlink:to="FN_64458"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703662"
          xlink:label="Fact_17703662"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703662"
          xlink:to="FN_64458"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703679"
          xlink:label="Fact_17703679"
          xlink:type="locator"/>
        <link:footnote id="FN_64441" xlink:label="FN_64441" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The decrease in deferred tax liability is mainly due to impairment and amortization.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703679"
          xlink:to="FN_64441"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703680"
          xlink:label="Fact_17703680"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703680"
          xlink:to="FN_64441"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703681"
          xlink:label="Fact_17703681"
          xlink:type="locator"/>
        <link:footnote id="FN_64459" xlink:label="FN_64459" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amounts are shown after reduction for unrecognized tax benefits of $ 63 million and $115 million as of December 31, 2020 and 2019, respectively. This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: 2021-2022&#x2014;$79 million; 2023-2029&#x2014;$663 million; 2030 and thereafter&#x2014;$171 million. The remaining balance&#x2014;$1,327 million&#x2014;can be utilized with no expiration date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703681"
          xlink:to="FN_64459"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17703682"
          xlink:label="Fact_17703682"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17703682"
          xlink:to="FN_64459"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704196"
          xlink:label="Fact_17704196"
          xlink:type="locator"/>
        <link:footnote id="FN_64425" xlink:label="FN_64425" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Comparative figures are based on prior hedge accounting standard.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704196"
          xlink:to="FN_64425"
          xlink:type="arc"/>
        <link:footnote id="FN_64430" xlink:label="FN_64430" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva&#x2019;s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3 million. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704196"
          xlink:to="FN_64430"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704197"
          xlink:label="Fact_17704197"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704197"
          xlink:to="FN_64425"
          xlink:type="arc"/>
        <link:footnote id="FN_64428" xlink:label="FN_64428" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588 million in cross-currency swap agreements against its outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704197"
          xlink:to="FN_64428"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704198"
          xlink:label="Fact_17704198"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704198"
          xlink:to="FN_64425"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704205"
          xlink:label="Fact_17704205"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704205"
          xlink:to="FN_64425"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704205"
          xlink:to="FN_64430"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704206"
          xlink:label="Fact_17704206"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704206"
          xlink:to="FN_64425"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704206"
          xlink:to="FN_64428"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704207"
          xlink:label="Fact_17704207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704207"
          xlink:to="FN_64425"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704211"
          xlink:label="Fact_17704211"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704211"
          xlink:to="FN_64430"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704212"
          xlink:label="Fact_17704212"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704212"
          xlink:to="FN_64430"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704215"
          xlink:label="Fact_17704215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704215"
          xlink:to="FN_64430"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704216"
          xlink:label="Fact_17704216"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704216"
          xlink:to="FN_64430"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704217"
          xlink:label="Fact_17704217"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704217"
          xlink:to="FN_64428"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704218"
          xlink:label="Fact_17704218"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704218"
          xlink:to="FN_64428"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704338"
          xlink:label="Fact_17704338"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704338"
          xlink:to="FN_64453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704339"
          xlink:label="Fact_17704339"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704339"
          xlink:to="FN_64453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704356"
          xlink:label="Fact_17704356"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704356"
          xlink:to="FN_64425"
          xlink:type="arc"/>
        <link:footnote id="FN_64431" xlink:label="FN_64431" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500 million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704356"
          xlink:to="FN_64431"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704357"
          xlink:label="Fact_17704357"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704357"
          xlink:to="FN_64431"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704358"
          xlink:label="Fact_17704358"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704358"
          xlink:to="FN_64431"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704359"
          xlink:label="Fact_17704359"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704359"
          xlink:to="FN_64431"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704360"
          xlink:label="Fact_17704360"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704360"
          xlink:to="FN_64431"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704361"
          xlink:label="Fact_17704361"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704361"
          xlink:to="FN_64428"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704362"
          xlink:label="Fact_17704362"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704362"
          xlink:to="FN_64428"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704366"
          xlink:label="Fact_17704366"
          xlink:type="locator"/>
        <link:footnote id="FN_64457" xlink:label="FN_64457" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $56 million gain in 2020, $14 million gain in 2019 and $26 million gain in 2018. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704366"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704367"
          xlink:label="Fact_17704367"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704367"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704368"
          xlink:label="Fact_17704368"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704368"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704369"
          xlink:label="Fact_17704369"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704369"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704370"
          xlink:label="Fact_17704370"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704370"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704555"
          xlink:label="Fact_17704555"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704555"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704556"
          xlink:label="Fact_17704556"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704556"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704557"
          xlink:label="Fact_17704557"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704557"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704558"
          xlink:label="Fact_17704558"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704558"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704559"
          xlink:label="Fact_17704559"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704559"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704560"
          xlink:label="Fact_17704560"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704560"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704561"
          xlink:label="Fact_17704561"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704561"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704562"
          xlink:label="Fact_17704562"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704562"
          xlink:to="FN_64457"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704579"
          xlink:label="Fact_17704579"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704579"
          xlink:to="FN_64452"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704583"
          xlink:label="Fact_17704583"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704583"
          xlink:to="FN_64455"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704584"
          xlink:label="Fact_17704584"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704584"
          xlink:to="FN_64455"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704585"
          xlink:label="Fact_17704585"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704585"
          xlink:to="FN_64455"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704867"
          xlink:label="Fact_17704867"
          xlink:type="locator"/>
        <link:footnote id="FN_64433" xlink:label="FN_64433" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the British pound, the Russian ruble and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. [The [positive] impact from these derivatives recognized under revenues was $1 million, $14 million and ($4) million, partially offset by $0 million, $X million and $X million negative impact recognized under cost of sales in the years ended December 31, 2020, 2019 and 2018, respectively]. [To be updated] The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704867"
          xlink:to="FN_64433"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704944"
          xlink:label="Fact_17704944"
          xlink:type="locator"/>
        <link:footnote id="FN_64432" xlink:label="FN_64432" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704944"
          xlink:to="FN_64432"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704947"
          xlink:label="Fact_17704947"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704947"
          xlink:to="FN_64433"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704949"
          xlink:label="Fact_17704949"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704949"
          xlink:to="FN_64432"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17704950"
          xlink:label="Fact_17704950"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17704950"
          xlink:to="FN_64432"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17705017"
          xlink:label="Fact_17705017"
          xlink:type="locator"/>
        <link:footnote id="FN_64438" xlink:label="FN_64438" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17705017"
          xlink:to="FN_64438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17705018"
          xlink:label="Fact_17705018"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17705018"
          xlink:to="FN_64438"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17705078"
          xlink:label="Fact_17705078"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17705078"
          xlink:to="FN_64429"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17705079"
          xlink:label="Fact_17705079"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17705079"
          xlink:to="FN_64426"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17705080"
          xlink:label="Fact_17705080"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17705080"
          xlink:to="FN_64429"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17705081"
          xlink:label="Fact_17705081"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17705081"
          xlink:to="FN_64429"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17705082"
          xlink:label="Fact_17705082"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17705082"
          xlink:to="FN_64429"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_17705120"
          xlink:label="Fact_17705120"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_17705120"
          xlink:to="FN_64433"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489019432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TEVA PHARMACEUTICAL INDUSTRIES LIMITED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">1,096,511,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TEVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Basel Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Petach Tikva<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4951033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972 (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">914-8213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487116472">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables, net of allowance for credit losses of $126 million and $135 million as of December 31, 2020 and December 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,581<span></span>
</td>
<td class="nump">5,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">945<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">710<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">189<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,005<span></span>
</td>
<td class="nump">13,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">695<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other&#160;non-current&#160;assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">538<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,296<span></span>
</td>
<td class="nump">6,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">559<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Identifiable intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,923<span></span>
</td>
<td class="nump">11,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,624<span></span>
</td>
<td class="nump">24,846<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,640<span></span>
</td>
<td class="nump">57,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,188<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SalesReservesAndAllowances', window );">Sales reserves and allowances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,824<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">1,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">685<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,780<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">933<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,164<span></span>
</td>
<td class="nump">13,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">964<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other taxes and long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,240<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,731<span></span>
</td>
<td class="nump">24,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">479<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,414<span></span>
</td>
<td class="nump">28,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies, see note 12</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,579<span></span>
</td>
<td class="nump">42,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Teva shareholders' equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.10 par value per share; December 31, 2020 and December 31, 2019: authorized 2,495 million shares; issued 1,202 million shares and 1,198 million shares, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,443<span></span>
</td>
<td class="nump">27,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,946)<span></span>
</td>
<td class="num">(6,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,399)<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury shares as of December 31, 2020 and December 31, 2019: 106 million ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,128)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to Teva shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,026<span></span>
</td>
<td class="nump">13,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,061<span></span>
</td>
<td class="nump">15,063<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50,640<span></span>
</td>
<td class="nump">$ 57,470<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accumulated goodwill impairment as of December 31, 2020, December 31, 2019 and December 31, 2018 was approximately $25.6 billion, $21.0 billion and $21.0 billion, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesAndLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesAndLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642665164728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit losses | $</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized</a></td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">1,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury shares</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489778456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income (Loss) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 16,659<span></span>
</td>
<td class="nump">$ 16,887<span></span>
</td>
<td class="nump">$ 18,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">8,933<span></span>
</td>
<td class="nump">9,351<span></span>
</td>
<td class="nump">9,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">7,726<span></span>
</td>
<td class="nump">7,537<span></span>
</td>
<td class="nump">8,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="nump">2,498<span></span>
</td>
<td class="nump">2,614<span></span>
</td>
<td class="nump">2,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IntangibleAssetsImpairments', window );">Intangible assets impairments</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">4,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ImpairmentsRestructuringAndOthers', window );">Other asset impairments, restructuring and other items</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LegalSettlementsAndLossContingencies', window );">Legal settlements and loss contingencies</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="num">(3,572)<span></span>
</td>
<td class="num">(443)<span></span>
</td>
<td class="num">(1,637)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(4,406)<span></span>
</td>
<td class="num">(1,265)<span></span>
</td>
<td class="num">(2,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (benefit)</a></td>
<td class="num">(168)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in (profits) losses of associated companies, net</a></td>
<td class="num">(138)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(4,099)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(2,472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Teva</a></td>
<td class="num">(3,990)<span></span>
</td>
<td class="num">(999)<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Accrued dividends on preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to ordinary shareholders</a></td>
<td class="num">$ (3,990)<span></span>
</td>
<td class="num">$ (999)<span></span>
</td>
<td class="num">$ (2,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to ordinary shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (3.64)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (2.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (3.64)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (2.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares (in millions):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentsRestructuringAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairments restructuring and others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentsRestructuringAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IntangibleAssetsImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Impairments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IntangibleAssetsImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsAndLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsAndLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488560776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (4,099)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">$ (2,472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax', window );">Unrealized gain (loss) on derivative financial instruments, net</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on&#160;available-for-sale&#160;securities, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax', window );">Unrealized gain (loss) on defined benefit plans, net</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="num">(585)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income (loss)</a></td>
<td class="num">(4,129)<span></span>
</td>
<td class="num">(840)<span></span>
</td>
<td class="num">(3,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to non-controlling interests</a></td>
<td class="num">(53)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Teva</a></td>
<td class="num">$ (4,076)<span></span>
</td>
<td class="num">$ (852)<span></span>
</td>
<td class="num">$ (2,761)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487720296">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th" colspan="2"><div>Ordinary Shares [Member]</div></th>
<th class="th"><div>MCPS [Member]</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th" colspan="2"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Treasury Shares [Member]</div></th>
<th class="th"><div>Total Teva Shareholders' Equity [Member]</div></th>
<th class="th"><div>Non-controlling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18,745<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="nump">$ 3,631<span></span>
</td>
<td class="nump">$ 23,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3,803)<span></span>
</td>
<td class="num">$ (1,853)<span></span>
</td>
<td class="num">$ (4,149)<span></span>
</td>
<td class="nump">$ 17,359<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning', window );">Cumulative effect of new accounting standard</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,472)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(585)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(611)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Shares, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(52)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td colspan="2" class="num">(3,880)<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Issuance of Treasury Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividends to preferred shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="nump">249<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_TransactionsWithNonControllingInterests', window );">Transactions with non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,794<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">27,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,958)<span></span>
</td>
<td class="num">(2,459)<span></span>
</td>
<td class="num">(4,142)<span></span>
</td>
<td class="nump">14,707<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(999)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Issuance of Treasury Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_TransactionsWithNonControllingInterests', window );">Transactions with non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherEquity', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,063<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">27,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,956)<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
<td class="num">(4,128)<span></span>
</td>
<td class="nump">13,972<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,198<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,099)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,990)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Shares, value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">129<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_TransactionsWithNonControllingInterests', window );">Transactions with non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,061<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,443<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (10,946)<span></span>
</td>
<td class="num">$ (2,399)<span></span>
</td>
<td class="num">$ (4,128)<span></span>
</td>
<td class="nump">$ 10,026<span></span>
</td>
<td class="nump">$ 1,035<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Mandatory convertible preferred shares.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Following the adoption of ASU 2016-01, the Company recorded a $ 5 million opening balance reclassification from accumulated other comprehensive income to retained earnings.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Mainly MCPS conversion.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than 0.5 million.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification From Accumulated Other Comprehensive Income To Retained Earning</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_TransactionsWithNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transactions With Non Controlling Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_TransactionsWithNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489073560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options by employees and vested RSUs</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488851832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (4,099)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">$ (2,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of goodwill, long-lived assets and assets held for sale</a></td>
<td class="nump">6,546<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">5,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">1,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Net change in operating assets and liabilities</a></td>
<td class="num">(2,188)<span></span>
</td>
<td class="num">(896)<span></span>
</td>
<td class="num">(1,823)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions', window );">Deferred income taxes, net and uncertain tax positions</a></td>
<td class="num">(696)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
<td class="num">(837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other items</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development in process</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment', window );">Net loss (gain) from investments and from sale of long lived assets</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="nump">2,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables', window );">Beneficial interest collected in exchange for securitized trade receivables</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales of long-lived assets and investments</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(578)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets', window );">Purchases of investments and other assets</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of senior notes and loans and other long-term liabilities</a></td>
<td class="num">(1,871)<span></span>
</td>
<td class="num">(3,944)<span></span>
</td>
<td class="num">(7,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from senior notes and loans, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short term debt</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short term debt</a></td>
<td class="num">(559)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend', window );">Tax withholding payments made on shares and dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,885)<span></span>
</td>
<td class="num">(1,926)<span></span>
</td>
<td class="num">(3,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Translation adjustment on cash and cash equivalents</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Balance of cash and cash equivalents at beginning of year</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Balance of cash and cash equivalents at end of year</a></td>
<td class="nump">2,177<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Non-cash&#160;financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables', window );">Beneficial interest obtained in exchange for securitized trade receivables</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of mandatory convertible preferred shares into ordinary shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashPaidDuringTheYearForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes, net of refunds</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(1,473)<span></span>
</td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(1,437)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt', window );">Trade payables, accrued expenses, employee-related obligations and other liabilities</a></td>
<td class="num">(463)<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories', window );">Trade receivables net of sales reserves and allowances</a></td>
<td class="num">(293)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation', window );">Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information</a></td>
<td class="num">$ (2,188)<span></span>
</td>
<td class="num">$ (896)<span></span>
</td>
<td class="num">$ (1,823)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Interest Obtained in Exchange for Securitized Trade Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CashPaidDuringTheYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid during the year for.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CashPaidDuringTheYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredIncomeTaxesNetAndUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred income taxes net and uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredIncomeTaxesNetAndUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the period in accounts receivable and current assets not separately reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the period in sales reserves and allowances, accounts payable, and other current liabilities not separately reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the amounts of the current assets and current liabilities that are reported in the supplemental disclosure of information section of the Consolidated Statements of Cash Flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchase of available for sales securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy income tax withholding obligation for shares and dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from beneficial interest in exchange for securitized trade receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit from sale of long lived assets and investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProfitFromSaleOfLongLivedAssetsAndInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642480066952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1&#8212;Significant accounting policies: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva Pharmaceutical Industries Limited (the &#8220;Parent Company&#8221;), headquartered in Israel, together with its subsidiaries and associated companies (the &#8220;Company,&#8221; &#8220;Teva&#8221; or the &#8220;Group&#8221;), is engaged in the development, manufacturing, marketing and distribution of generics, specialty medicines and biopharmaceuticals. The majority of the Group&#8217;s revenues are in the United States and Europe. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of presentation and use of estimate<div style="display:inline;">s</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In preparing the Company&#8217;s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of intangible assets and goodwill; assessing sales reserves and allowances in the United States, and contingent consideration; assessing compliance with debt covenants; uncertain tax positions, valuation allowances, contingencies, inventory valuation and restructuring. The inputs into Teva&#8217;s judgments and estimates also consider the economic implications of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&amp;D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva&#8217;s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic within its financial statements may change in future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Functional currency </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A major part of the Group&#8217;s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income (loss) in the consolidated statements of comprehensive income (loss). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of consolidation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and VIEs for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders&#8217; interests are shown as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, are carried on the equity basis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated. </div></div>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New accounting pronouncements </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently adopted accounting pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-04</div> &#8220;Reference Rate Reform (Topic 848)&#8212;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no impact to the Company&#8217;s consolidated financial statements for the period ended December&#160;31, 2020 as a result of adopting this standard update. The Company is continuing to evaluate the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities and has started initial negotiations to transform the facility base rate of its securitization program. However, it is not expected to have a material impact on the consolidated financial results. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In April 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-04</div> &#8220;Codification Improvements to Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825).&#8221; This ASU provides clarifications of three topics related to financial instruments accounting. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> &#8220;Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606.&#8221; The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i)&#160;addresses when the participant should be considered a customer in the context of a unit of account, (ii)&#160;adds <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">unit-of-account</div></div> guidance in ASC 808 to align with guidance in ASC 606 and (iii)&#160;precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> &#8220;Intangibles&#8212;Goodwill and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other&#8212;Internal-use</div> software (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40):</div> Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.&#8221; This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software. Teva applied the guidance prospectively to all implementation costs incurred after the date of adoption. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> &#8220;Fair Value Measurement (Topic 820)&#8212;Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement.&#8221; This guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level&#160;3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. Certain disclosures required by this guidance must be applied on a retrospective basis and others on a prospective basis. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Upon adoption of the standard, there was no immediate impact to the Company&#8217;s financial position, results of operations or cash flows. On an ongoing basis, the Company will contemplate forward-looking economic conditions in recording lifetime expected credit losses for the Company&#8217;s financial assets measured at cost, such as the Company&#8217;s trade receivables and certain short-term investments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> &#8220;Debt &#8211; Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> &#8220;Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes&#8221; (the &#8220;update&#8221;). The amendments in this update simplify the accounting for income taxes by removing the following exceptions in ASC 740: (1) exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items; (2)&#160;exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment; (3)&#160;exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary; and (4)&#160;exception to the general methodology for calculating income taxes in an interim period when a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss exceeds the anticipated loss for the year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the update also simplifies the accounting for income taxes in certain topics as follows: (1)&#160;requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-income-based</div> tax; (2)&#160;requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; (3)&#160;specifying that an entity can elect (rather than be required to) allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; and (4)&#160;requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2020. The </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company reviewed the above topics, noting that Items (1)&#160;and (4) of this paragraph are expected to be relevant, but not material. The adoption of this guidance will not have a significant impact on the Company&#8217;s consolidated financial statements. </div></div>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s consolidated financial statements include the operations of acquired businesses from the date of the acquisition&#8217;s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> at each reporting period, with any adjustments in fair value recognized in earnings under other assets impairments, restructuring and other items. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative arrangements: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative agreements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues are recorded on a net basis. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity investments: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-01</div> &#8220;Financial Instruments&#8212;Recognition and Measurement of Financial Assets and Financial Liabilities&#8221; to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">f.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurement: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. </div></div>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">g.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in debt securities: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Investment in securities consists of debt securities classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s investment in debt securities accounting policy until December&#160;31, 2019, prior to the adoption of the new Current Expected Credit Losses (&#8220;CECL&#8221;) standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gains of available for sale debt securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for debt securities are included in financial expenses, net. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s investment in debt securities accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unrealized gains and losses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are excluded from earnings and reported net of the related tax effect in the accumulated other comprehensive income component of shareholders&#8217; equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The CECL methodology, which became effective January&#160;1, 2020, requires the Company to estimate lifetime expected credit losses for all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Comparative information continues to be reported in accordance with the methodology in effect for prior periods. When estimating a security&#8217;s probability of default and the recovery rate, the Company assesses the security&#8217;s credit indicators, including credit ratings. If the assessment indicates that an expected credit loss exists, the Company determines the portion of the unrealized loss attributable to credit deterioration and records an allowance for the expected credit loss through the Consolidated Statements of Income. Unrealized gains and any portion of a security&#8217;s unrealized loss attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">h.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">i.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s accounts receivables accounting policy until December&#160;31, 2019, prior to the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables are stated at their net realizable value. The allowance against gross accounts receivables reflects the best estimate of losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. An allowance for doubtful debts is reflected in net accounts receivables. Accounts receivables are written off after all reasonable means to collect the full amount have been exhausted. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s accounts receivables accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Write-off</div> activity and recoveries for the periods presented were not material. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">j.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of credit risks: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of Teva&#8217;s cash and cash equivalents (which, along with investment in securities, totaled $2,478&#160;million at December&#160;31, 2020) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 48% of Teva&#8217;s consolidated revenues in 2020. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. </div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">k.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Inventories acquired in a business combination are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stepped-up</div> to their estimated fair value and amortized to cost of sales as that inventory is sold. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">l.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva&#8217;s long-lived, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are comprised mainly of goodwill, identifiable intangible assets, property, plant and equipment, and operating lease ROU assets. All long-lived assets are monitored for impairment indicators throughout the year. Impairment testing for goodwill and all indefinite-lived intangible assets is performed at least annually. When necessary, charges for impairments of long-lived assets, other than goodwill, are recorded for the amount by which the fair value is less than the carrying value of these assets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the acquiree, over the assigned fair values of the identifiable net assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has historically performed its annual goodwill assessment during the fourth quarter of each year. During the second quarter of 2020, the Company decided to change the date of its annual impairment assessment from October&#160;1 to June 30. The change was made to more closely align the impairment assessment date with the Company&#8217;s long-term planning and forecasting process. See note 7. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The goodwill impairment test is performed according to the following principles: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value is recognized. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company&#8217;s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company&#8217;s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Identifiable intangible assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (&#8220;S&amp;M&#8221;) expenses when separable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite life intangible assets are mainly comprised of IPR&amp;D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. Teva determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset&#8217;s estimated life, calculates the undiscounted value of the asset&#8217;s or asset group&#8217;s cash flows and compares such value against the asset&#8217;s or asset group&#8217;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company&#8217;s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i)&#160;for IPR&amp;D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii)&#160;for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, plant and equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly between 15 to 20 years; and other assets, between 5 to 10 years. </div>&#160;</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For property, plant and equipment and lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, whenever impairment indicators are identified, Teva reconsiders the asset&#8217;s estimated life, calculates the undiscounted value of the asset&#8217;s cash flows and compares such value against the asset&#8217;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See note 8 and note 1 cc for further discussion. </div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">m.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treasury shares: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treasury shares are presented as a reduction of Teva shareholders&#8217; equity and carried at their cost to Teva, under treasury shares. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">o.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (&#8220;RSUs&#8221;) and performance share units (&#8220;PSUs&#8221;). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">p.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Deferred income taxes are determined utilizing the &#8220;asset and liability&#8221; method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax has not been provided on the following items: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company&#8217;s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amounts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> income generated from the Company&#8217;s current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 13 f. </div> </td> </tr> </table>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">q.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncertain tax positions: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> its tax positions based on developments in its tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of Teva&#8217;s ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">r.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives and hedging: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company&#8217;s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative instruments are recognized on the balance sheet at their fair value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net in the statements of income in the period that the changes in fair value occur. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For derivative instruments that are designated as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-investment</div> hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income. The effective portion is determined by looking into changes in spot exchange rate. The change in fair value attributable to changes other than those due to fluctuations in the spot exchange rate are excluded from the assessment of hedge effectiveness and are recognized in the statement of income under financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative instruments that do not qualify for hedge accounting are recognized on the Balance Sheet at their fair value, with changes in the fair value recognized as a component of financial expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">s.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (&#8220;SR&amp;A&#8221;) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&amp;A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&amp;A components and how they are estimated, see &#8220;Variable Consideration&#8221; below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&amp;M expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> year or less, based on the practical expedient. The Company&#8217;s credit terms to customers are, on average, between <span style="-sec-ix-hidden:hidden17702468">thirty</span> and ninety days. </div>&#160;</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&amp;M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of revenue streams </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements performance obligations generally include intellectual property (&#8220;IP&#8221;) rights, certain R&amp;D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct&#8212;i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company&#8217;s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s IP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Revenues from licensing arrangements included royalty income of $129 million, $147 million and $165 million for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specifies goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenues are primarily comprised of contract manufacturing services, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets and liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities are mainly comprised of deferred revenues which were immaterial as of December&#160;31, 2020 and 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration mainly includes SR&amp;A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rebates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-established</div> volumes or the attainment of revenue milestones for a specified period, the customer receives a rebate. Since rebates are contractually agreed upon, they are estimated based on the specific terms in each agreement based on historical trends and expected sales. Externally obtained inventory levels and expected sales usage by contract are evaluated in relation to estimates made for rebates payable to indirect customers and managed care agreements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid and Other Governmental Rebates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer&#8217;s price for generic products dispensed and &#8220;best price&#8221; for specialty products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chargebacks </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva&#8217;s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva&#8217;s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a &#8220;chargeback&#8221;) to the wholesaler for the difference between the invoice price to the wholesaler and the customer&#8217;s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers and, therefore, will not necessarily fluctuate in proportion to an increase or decrease in sales. Provisions for estimating chargebacks are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Teva considers current and expected price competition when evaluating the provision for chargebacks. Chargeback provisions are compared to externally obtained distribution channel reports for reasonableness. The Company regularly monitors the provision for chargebacks and makes adjustments when the Company believes that actual chargebacks may differ from estimated provisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Promotional Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other promotional or incentive arrangements are periodically offered to customers, specifically related to the launch of products or other targeted promotions. Provisions are made in the period for which the Company can estimate the incentive earned by the customer, in accordance with the contractual terms. The Company regularly monitors the provision for other promotional arrangements and makes adjustments when it believes that the actual provision may differ from the estimated provisions. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shelf Stock Adjustments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers&#8217; existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. Teva regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns primarily relate to customer returns of expired products which, the customer has the right to return up to one year following the expiration date. Such returned products are destroyed and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recoded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, The Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies or packaging and any changes to customer terms, for determining the overall expected levels of returns. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prompt Pay Discounts </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prompt pay discounts are offered to most customers to encourage timely payment. Discounts are estimated at the time of invoice based on historical discounts in relation to sales. Prompt pay discounts are almost always utilized by customers. As a result, the actual discounts do not vary significantly from the estimated amount. </div></div>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">t.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses are charged to statement of income (loss) as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Upfront fees received in connection with cooperation agreements are deferred and recognized over the period of the applicable agreements as a reduction of research and development expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are delivered or the services are performed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">u.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs, which are included in S&amp;M expenses, were $124 million, $138 million and $159 million for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, respectively. </div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">v.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs are expensed as incurred. Advertising costs for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> were $225 million, $213&#160;million and $256 million, respectively. </div> </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">w.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual termination benefits are provided to employees when employment is terminated due to an event specified in the provisions of an existing plan or agreement. A liability is recorded and the expense is recognized when it is probable that employees will be entitled to the benefits and the amount is reasonably estimable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Special termination benefits arise when the Company offers, for a short period of time, to provide certain additional benefits to employees electing voluntary termination. A liability is recorded and the expense is recognized in the period the employees irrevocably accept the offer and the amount of the termination liability is reasonably estimable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">x.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment reporting: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s business includes three reporting segments based on three geographical areas: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment, which includes the United States and Canada. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment, which includes the European Union and certain other European countries. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment, which includes all countries in which Teva operates other than those in the North America and Europe segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each business segment manages the entire product portfolio in its region, including generics, specialty and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> (&#8220;OTC&#8221;) products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">y.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share are computed by dividing the net income attributable to ordinary shareholders by the weighted average number of ordinary shares (including fully vested RSUs and PSUs) outstanding during the year, net of treasury shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans and one series of convertible senior debentures, using the treasury stock method; (ii)&#160;the conversion of the remaining convertible senior debentures using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;if-converted&#8221;</div> method, by </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">adding to net income interest expense on the debentures and amortization of issuance costs, net of tax benefits, and by adding the weighted average number of shares issuable upon assumed conversion of the debentures; and (iii)&#160;until December&#160;17, 2018, the conversion of the mandatory convertible preferred shares (&#8220;MCPS&#8221;) using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;if-converted&#8221;</div> method by adding to net income attributable to ordinary shareholders the dividends on the preferred shares and by adding the weighted average number of shares issuable upon assumed conversion of the mandatory convertible preferred shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;17</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, the mandatory convertible preferred shares automatically converted into ordinary shares. As a result of this conversion, Teva issued 70.6&#160;million ADSs. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">See note 14</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div></div>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">z.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securitization </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva accounts for transfers of certain of its trade receivable as sales when it has surrendered control over the related assets in accordance with ASC Topic 860 &#8220;Transfer and Servicing&#8221; of Financial Assets. Whether control has been relinquished requires, among other things, an evaluation of relevant legal considerations and an assessment of the nature and extent of the Company&#8217;s continuing involvement with the assets transferred. Assets obtained and liabilities incurred in connection with transfers reported as sales are initially recognized in the balance sheet at fair value. Refer to note 10 f. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">aa.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Divestitures </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company nets the proceeds on the divestitures of products with the carrying amount of the related assets and records gain or loss on sale within other income. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when it is probable that a significant reversal of income will not occur, or in the case of a business, when such payments are realizable. For divestures of businesses, including divestitures of products that qualify as a business, the Company reflects the relative fair value of goodwill associated with the businesses in the determination of gain or loss on sale. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">bb.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt instruments </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Debt instruments are initially recognized at the fair value of the consideration received. Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liability. They are subsequently recognized at amortized cost using the effective interest method. Debt may be considered extinguished when it has been modified and the terms of the new debt instruments and old debt instruments are &#8220;substantially different&#8221; (as defined in the debt modification guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div> &#8220;Debt&#8212;Modifications and Extinguishments&#8221;). The Company classifies the current portion of long term debt as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities on the Balance Sheet when it has the intent and ability to refinance the obligation on a long-term basis, in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div> &#8220;Debt&#8221;. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">cc.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s lease accounting policy until December&#160;31, 2018, prior to the adoption of the new lease standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva leases real estate, cars and equipment for use in its operations, which are classified as operating leases. In addition to rent, the leases may require Teva to pay directly for fees, insurance, maintenance and other operating expenses. Rental expense for the year ended December&#160;31, 2018 was $175&#160;million. The Company also has capital leases for properties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s lease accounting policy from January&#160;1, 2019, following the adoption of the new lease standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva adopted the new accounting standard ASC 842 &#8220;Leases&#8221; and all the related amendments on January&#160;1, 2019 and used the effective date as Teva&#8217;s date of initial application. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">842-10-25-2.</div></div></div> If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva&#8217;s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets, other current liabilities and operating lease liabilities in the consolidated balance sheets. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated balance sheets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets represent Teva&#8217;s right to use an underlying asset for the lease term and lease liabilities represent Teva&#8217;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Teva uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For finance leases, Teva recognizes interest on the lease liability separately from amortization of the ROU assets in the statement of comprehensive income. For operating leases, lease expenses are recognized on a straight-line basis over the lease term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The new standard also provides practical expedients for an entity&#8217;s ongoing accounting. Teva elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, Teva does not recognize ROU assets or lease liabilities, including ROU assets or lease liabilities for existing short-term leases of assets in transition, but recognizes lease expenses over the lease term on a straight line basis. Teva also elected the practical expedient to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for all of Teva&#8217;s leases, other than leases of real estate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease terms will include options to extend or terminate the lease when it is reasonably certain that Teva will either exercise or not exercise the option to renew or terminate the lease. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s lease agreements have remaining lease terms ranging from 1 year to 78 years. Some of these agreements include options to extend the leases for up to </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> years and some include options to terminate the leases immediately. Certain leases also include options to purchase the leased property. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of Teva&#8217;s vehicle lease agreements include rental payments based on the actual usage of the vehicles and other lease agreements include rental payments adjusted periodically for inflation. Teva&#8217;s lease agreements do not contain any material residual value guarantees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The new lease standard has no impact on Teva&#8217;s debt-covenant compliance under its RCF. </div></div> Teva rents out or subleases certain assets to third parties, which has an immaterial impact on Teva&#8217;s consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478790696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CertainTransactionsDisclosureTextBlock', window );">Certain transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2&#8212;Certain transactions: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business acquisitions: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actavis Generics and Anda acquisitions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;2, 2016, Teva consummated its acquisition of Allergan plc&#8217;s (&#8220;Allergan&#8221;) worldwide generic pharmaceuticals business (&#8220;Actavis Generics&#8221;). At closing, Teva transferred to Allergan consideration of approximately $33.4 billion in cash and approximately 100.3&#160;million Teva shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;3, 2016, Teva consummated the acquisition of Anda Inc. (&#8220;Anda&#8221;), a medicines distribution business in the United States, from Allergan, for cash consideration of $500 million. This transaction was related to the Actavis Generics acquisition and, as such, the purchase price accounting and related disclosures were treated on a combined basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The final cash consideration for the Actavis Generics acquisition was subject to certain net working capital adjustments. On January&#160;31, 2018, Teva and Allergan entered into a settlement agreement and mutual releases for which Allergan made a one-time payment of $703 million to Teva to settle the working capital adjustments under the Master Purchase Agreement, dated July&#160;26, 2015. As the measurement period has ended, this amount was recorded as a gain under legal settlements and loss contingencies in the first quarter of 2018. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rimsa </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;3, 2016, Teva completed the acquisition of Representaciones e Investigaciones M&#233;dicas, S.A. de C.V. (&#8220;Rimsa&#8221;), a pharmaceutical manufacturing and distribution company in Mexico, for $2.3&#160;billion, in a cash free, debt free set of transactions. Teva financed the transaction using cash on hand. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the closing of the acquisition, Teva identified issues concerning Rimsa&#8217;s pre-acquisition quality, manufacturing and other practices, at which point Teva began an assessment of the extent and cost of remediation required to return its products to the market. In September 2016, two lawsuits were filed: a pre-emptive suit by the Rimsa sellers against Teva and Teva&#8217;s lawsuit alleging fraud and breach of contract against the Rimsa sellers. The Rimsa sellers subsequently dismissed their lawsuit and the dismissal was approved by court order on December&#160;20, 2016. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On February&#160;15, 2018, Teva and the Rimsa sellers entered into a settlement agreement and mutual releases with respect to Teva&#8217;s breach of contract claim, pursuant to which the Rimsa sellers made a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> payment to Teva. Teva&#8217;s breach of contract claim was subsequently dismissed by the court. As the measurement period has ended, this payment was recorded as a gain under legal settlements and loss contingencies in the first quarter of 2018. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other significant agreements: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company&#8217;s most significant agreements of this nature are summarized below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alvotech Partnership </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, Teva entered into a partnership agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this partnership contains biosimilar candidates addressing multiple therapeutic areas. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva paid an upfront payment in the third quarter of 2020 that w<div style="letter-spacing: 0px; top: 0px;;display:inline;">as</div>&#160;recorded as R&amp;D expenses. During the fourth quarter of 2020, Teva accrued additional amounts due to the high probability that additional milestone payments will be paid in 2021. Additional development and commercial milestone payments of up <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">to</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $450 million, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilar</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">s.&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eli Lilly and Alder BioPharmaceuticals </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, Teva entered into an agreeme<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div>t with Eli Lilly, resolving the European Patent Office opposition they had filed against Teva&#8217;s AJOVY<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> patents. The settlement agreement with Lilly also resolved Lilly&#8217;s action to revoke the patent protecting AJOVY in the United Kingdom. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;8, 2018, Teva signed a global license agreement with Alder BioPharmaceuticals (&#8220;Alder&#8221;). The agreement validates Teva&#8217;s intellectual property and resolves Alder&#8217;s opposition to Teva&#8217;s European patent with respect to anti-calcitonin gene-related peptide (CGRP) antibodies, including the withdrawal of Alder&#8217;s appeal before&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">the European Patent Office. Under the terms of the agreement, Alder will receive a non-exclusive license to Teva&#8217;s anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the United States and worldwide, excluding Japan and Korea. Teva received a</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $25 million </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">upfront payment that was recognized as revenue during the first quarter of 2018, and a&#160;</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$25 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million milestone payment in March 2020 that was recognized as revenue in the first quarter of 2020. The agreement stipulates additional commercial milestone payments to Teva of up to</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $150 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million, as well as future royalties.</div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PGT Healthcare Partnership </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Teva terminated its joint venture with the Procter&#160;&amp; Gamble Company (&#8220;P&amp;G&#8221;), PGT Healthcare partnership (&#8220;PGT&#8221;), which the two companies established in 2011 to market OTC medicines. Teva will continue to maintain its OTC business on an independent basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the separation, Teva transferred to P&amp;G the shares it held in New Chapter Inc. and ownership rights in an OTC plant located in India. Teva provides certain services to P&amp;G after the separation for a transition period.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the first quarter of 2018, Teva classified the plant in India as an asset held for sale and recorded an impairment of</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$64&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million under other assets impairments, restructuring and other items. In addition, Teva recorded a write-down of</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$94&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million of its investment in New Chapter Inc. under share in losses of associated companies.&#160;</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">During September 2018, Teva and P&amp;G completed the final net asset distribution as part of the dissolution and Teva recorded a gain of&#160;</div></div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> $50&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million to reflect the cash payment received from P&amp;G under the dissolution agreement.&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;19, 2017, Teva entered into a partnership agreement with Nuvelution Pharma, Inc. (&#8220;Nuvelution&#8221;) for development of AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States. There are no further plans in this indication following clinical trial results received in February 2020, which failed to meet their primary endpoints. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Otsuka </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (&#8220;Otsuka&#8221;), providing Otsuka with an exclusive license to conduct phase 2 and 3 clinical trials for AJOVY in Japan and, if approved, to commercialize the product in Japan. Otsuka paid Teva an upfront payment of $50&#160;million in consideration for the transaction. Results for these trials were received in January 2020 indicating that primary and secondary endpoints were achieved and that no clinically significant adverse events were observed in subjects. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15&#160;million, which was recognized as revenue in the third quarter of 2020. Teva may receive additional milestone payments upon achievement of certain commercial and revenue targets. Otsuka will also pay Teva royalties on AJOVY sales in Japan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Celltrion </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2016, Teva and Celltrion, Inc. (&#8220;Celltrion&#8221;) entered into a collaborative agreement to commercialize TRUXIMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and HERZUMA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, two biosimilar products for the U.S. and Canadian markets. Teva paid Celltrion $160&#160;million, of which Teva received an aggregate credit of $60&#160;million as of December&#160;31, 2020. Teva and Celltrion share the profit from the commercialization of these products. These two products, TRUXIMA and HERZUMA, were approved by the FDA in November and December 2018, respectively and were launched in the United States in November 2019 and March 2020, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regeneron </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2016, Teva and Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;) entered into a collaborative agreement to develop and commercialize Regeneron&#8217;s pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&amp;D costs of approximately $1&#160;billion. Teva made an upfront payment of $250&#160;million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of $120&#160;million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to $2,230&#160;million, as well as future royalties. </div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and Liabilities Held For Sale: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain assets of Teva&#8217;s business venture in Japan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva operates its business in Japan, which is part of Teva&#8217;s International Market segment, through a business venture with The Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), in which Teva owns a</div> 51% <div style="letter-spacing: 0px; top: 0px;;display:inline;">stake and Takeda owns the remaining</div> 49%. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2020, Teva and Takeda entered into a purchase agreement to sell the majority of the business venture&#8217;s generic and operational assets. This transaction was completed on February&#160;1, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is accounting for the business venture assets and liabilities under the purchase agreement as held for sale and determined that the fair value less cost to sell did not exceed the carrying value, resulting in an impairment charge of</div>&#160;$247 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million in other assets impairments, restructuring and other items recognized in 2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determined that the sale of this portion of the Teva-Takeda business venture does not constitute a strategic shift for Teva, and does not and will not have a major effect on its operations and financial results. Accordingly, the operations associated with the transactions are not reported as discontinued operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale include the Teva-Takeda business venture assets that are held for sale, the anticipated sale of certain OTC assets and other manufacturing assets that are expected to be sold within the next year. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below summarizes all Teva assets included as held for sale as of December&#160;31, 2020 and December&#160;31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 76%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">146</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net and others</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">312</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">98</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments of assets held for sale to fair value</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">(296</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">189</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CertainTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CertainTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478790136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from contracts with customers</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3&#8212;Revenue from contracts with customers: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregation of revenue </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;activities</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,902</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,736</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,946</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">772</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,354</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">84</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">32</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">129</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,462</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,495</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(14</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">169</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">527</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">680</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,447</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,757</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,154</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,302</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,659</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div> </td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">activities</div></div></div> </td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,941</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,770</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,045</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">754</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,492</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">545</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">716</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,542</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,795</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,246</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,304</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,887</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 2%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 2%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 2%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 2%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">activities</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,838</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,153</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,151</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">739</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,347</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">618</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,297</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,186</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,422</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,366</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $1&#160;million. </div></div> </td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration mainly includes SR&amp;A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. For description of the nature of each deduction and how provisions are estimated see note 1. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR&amp;A to U.S. customers comprised approximately 79% of the Company&#8217;s total SR&amp;A as of December&#160;31, 2020, with the remaining balance primarily in Canada and Germany. The changes in SR&amp;A for third-party sales for the period ended December&#160;31, 2019 and 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="26" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> reserves<br/> included in<br/> Sales<br/> Reserves<br/> and<br/> Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at January 1, 2019</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,006</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,361</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,530</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">638 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6,711</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6,886</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year period</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">383</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">5,552</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">976</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">9,565</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">281 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">16,767</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">17,150</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(92</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(151</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(17</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(189</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(189</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(471</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(5,570</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,076</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(9,736</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(360</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(392</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(17,134</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(17,605</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2019</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%; border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">2,895</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,109</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,342</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">6,159</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">6,246</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year period</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">391</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">4,703</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">744</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">8,438</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">459</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">14,415</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">14,806</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(219</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(184</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(65</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(28</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(497</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(497</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(398</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(5,360</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(849</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(8,614</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(386</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(100</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(15,309</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(15,707</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 39%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2020</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,054</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">828</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,108</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">686</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">4,824</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">4,904</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 39%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478748840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4&#8212;Inventories: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories, net of reserves, consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$2,378 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$2,504 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw and packaging materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Products in process</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials in transit and payments on account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">189</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-size: 10pt;;text-align:right;">$4,403 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$4,422 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478761384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5&#8212;Property, plant and equipment: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net, consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">5,245</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">5,385</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;">2,720</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,839</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and other assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">2,197</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,131</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets under construction and payments on account</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;">933</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">672</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Land</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">292</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">323</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">11,388</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">11,350</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less&#8212;accumulated depreciatio<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;">(5,092</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(4,914</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">$6,296</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">$6,436 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expenses were $537 million, $609 million and $676 million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. During the years ended December&#160;31, 2020, 2019 and 2018, Teva had impairments of <div style="letter-spacing: 0px; top: 0px;;display:inline;">property</div>, plant and equipment in the amount of $416 million, $139 million and $500 million, respectively. <div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">See note </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">15</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642480091368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6&#8212;Identifiable intangible assets: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount<br/> net of impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Product rights</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,650</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;">19,663</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,094</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,640</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">7,556</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,023</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trade names</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">621</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;">600</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">456</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">In-process research and development (IPR&amp;D)</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">911</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;">1,735</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160; </div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">911</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,735</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,182</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;">21,998</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,259</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,766</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,923</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,232</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product rights and trade names </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately 10 years. Amortization of intangible assets amounted to $1,020 million, $1,113 million and $1,166 million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the estimated aggregate amortization of intangible assets for the years 2021 to 2025 is as follows: 2021&#8212;$812 million; 2022&#8212;$764 million; 2023&#8212;$744 million; 2024&#8212;$705 million&#160;and 2025&#8212;$723 million. These estimates do not include the impact of IPR&amp;D that is expected to be successfully completed and reclassified to product rights.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s IPR&amp;D are assets that have not yet been approved in major markets. Teva&#8217;s IPR&amp;D is comprised mainly of various generic products from the Actavis Generics acquisition of $877&#160;million. IPR&amp;D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets impairment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Impairment of identifiable intangible assets amounted to $1,502 million, $1,639 million and $1,991 million in the years ended December&#160;31, 2020, 2019 and 2018, respectively. These amounts are recorded<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">in the statement of income (loss) under intangible assets impairment.&#160;</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in 2020 mainly consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $797&#160;million, mainly due to: (i) $300&#160;million related to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States; (ii) $262&#160;million related to lenalidomide (generic equivalent of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revlimid&#174;),&#160;</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">due to modified competition assumptions as a result of settlements between the innovator and other generic filers; (iii) $211&#160;million related to AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the United States following clinical trial results, received in February 2020, which failed to meet their primary endpoints; and&#160;</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$705 </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million, mainly due to: (i) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$398 </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States; (ii) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$165 </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million in Japan in connection with ongoing regulatory pricing reductions and generic competition; and (iii) </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$110 </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">million related to a change in the assumptions regarding competition for the expected relaunch of metformin tablets. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in 2019 mainly consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $958 million, mainly due to: (i) $647 million due to updated market assumptions regarding price and volume of certain products acquired from Actavis Generics and primarily marketed in the United States, (ii) $128 million related to a decrease in future expected sales in Japan as a result of generic competition, and (iii) $123 million related to the discontinuation of certain products from Actavis Generics&#8217; portfolio in several international markets; and</div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $681&#160;million, due to: (i) $497&#160;million related to various generic pipeline products acquired from Actavis Generics due to development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date or discount rate) in the United States (ii) $125&#160;million related to lenalidomide (generic equivalent of REVLIMID<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), due to modified competition assumptions as a result of settlements between the innovator and other generic filers, and (iii) $59&#160;million related to a change in assumptions concerning the future European market share of a number of pipeline products acquired from Actavis Generics. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairments in 2018 mainly consisted of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable product rights of $1,068&#160;million, mainly due to: (i) $412&#160;million in connection with updated market assumptions regarding price and volume of products acquired from Actavis Generics currently marketed in the United States and supply constraints; (ii) $290&#160;million in certain international markets, due to a loss of several tenders and termination of products manufacturing lines; and (iii) $222&#160;million in Japan in connection with ongoing regulatory pricing reductions and generic competition. </div></div> </td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D assets of $923&#160;million, mainly related to revaluation of generic products acquired from Actavis Generics due to development progress and changes in other key valuation indications (e.g., market size, legal landscape, launch date or discount rate). </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value measurement of the impaired intangible assets in 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> is<div style="letter-spacing: 0px; top: 0px;;display:inline;"> based</div> on significant unobservable inputs in the market and thus represents a Level&#160;3</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> measurement within the fair value hierarchy. The discount rate applied ranged from 7.5% to 9%. A probability of success factor of 80% was used in the</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">majority of </div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">fair value calculation</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">s</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> to reflect</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> inherent regulatory and commercial risk of IPR&amp;D. </div></div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489153128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7&#8212;Goodwill: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td style="width: 0.5%;"/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 201</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(1)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">11,098</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">8,653</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,479</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,687</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">24,917</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwil</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">l </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">disposal</div><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(23</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:3%;">(112</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019 (1)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">11,091</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">8,536</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,532</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,687</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">24,846</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwill reclassified as assets held for sale</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(27</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(4,628</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(4,628</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">574</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(151</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">433</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:3%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of <div style="letter-spacing: 0px; top: 0px;;display:inline;">December </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">31</div>, 2020 (1)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">6,473</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">9,102</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,362</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,687</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">20,624</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accumulated goodwill impairment as of December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018 was approximately $25.6&#160;billion, $21.0&#160;billion and $21.0&#160;billion, respectively. </div></div></div></div></td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva&#8217;s production and sale of APIs to third parties (&#8220;Teva API&#8221;) and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. The Teva API and Medis reporting units are included under &#8220;Other&#8221; in the above table. See note 19 for additional segment information. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva&#8217;s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (&#8220;WACC&#8221;), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva&#8217;s assumptions, Teva may recognize an impairment of goodwill allocated to its reporting units in the future. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">First Quarter Developments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the first quarter of 2020, management assessed developments that occurred during the quarter, including expected effects of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its business, to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. As part of this assessment, management also considered the sensitivity of its conclusions as they relate to changes in the estimates and assumptions used in the latest forecast available for each period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of March&#160;31, 2020 and, therefore, no quantitative assessment was performed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Second Quarter Developments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Company policy, the Company has historically performed its annual goodwill assessment during the fourth quarter of each year. During the second quarter of 2020, the Company changed its annual impairment assessment date from October&#160;1 to June&#160;30 to more closely align the impairment assessment date with the Company&#8217;s long-term planning and forecasting process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the second quarter of 2020, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test and utilized the assistance of an independent valuation expert. No goodwill impairment charge was recorded during the second quarter of 2020.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the aforementioned analysis, Teva analyzed the aggregated fair value of its reporting units compared to its market capitalization as part of its annual goodwill impairment test, in order to assess the reasonableness of the results of its cash flow projections used for its goodwill impairment analysis. Management noted differences between the market capitalization and management&#8217;s internal projections as of the end of the second quarter. As of June&#160;30, 2020, those differences were believed to be attributable to the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management noted a portion of the difference can be attributed to sales projections of AJOVY and AUSTEDO in the International Markets reporting unit. Management continues to believe that the majority of analysts do not focus on these brands in preparing their financial models and, as a result, have not attributed value to the launch potential in this reporting unit. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management noted an additional difference can be attributed to sales projections of AUSTEDO in the North America reporting unit, resulting in higher fair value as analyzed by management compared to Teva&#8217;s market capitalization. Management continues to believe that it has more accurate information based on its knowledge of the market and its growth and therefore no adjustment was incorporated to the fair value. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management noted that market concerns regarding the uncertainty related to the opioid and price fixing litigation risks are impacting its market capitalization. Management believes that these concerns led to an acute reaction, which resulted in a decline in Teva&#8217;s share price. Management believed developments in the opioids case would clarify the outlook with regards to the opioid litigation, when the proposed settlement framework is finalized, which was expected in the near term. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if management was to adjust the fair value of the North America reporting unit for any one of the uncertainties noted, the estimated fair value would still exceed its carrying amount. Management also noted that negative results related to all the uncertainties noted may lead to a material goodwill impairment charge. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third Quarter Developments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of 2020, Teva&#8217;s share price experienced further decline. Teva analyzed its aggregated internal valuation of its reporting units compared to its market capitalization as part of its goodwill impairment test. Management believed there are similar reconciling factors to those referenced in the second quarter with additional declines occurring due to increased uncertainty related to certain litigation actions in the third quarter and the related uncertainties it added to the existing concerns around financial strength. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of 2020, management noted the following factors that led to an assessment of the North America reporting unit for impairment: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; padding-top: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company noted a 25% reduction in its market capitalization from the second quarter of 2020 to the third quarter of 2020. </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">With respect to the opioids litigation, as discussions continue with the group of Attorneys General regarding the nationwide framework and trial dates are postponed largely due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, a resolution of this matter is taking longer than anticipated. Accordingly, the Company was and is currently unable to predict the timing of any final settlement or whether the settlement will be finalized based upon the current settlement framework. </div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;25, 2020, the Company was indicted by the U.S. Department of Justice for alleged violations of the Sherman Act. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;18, 2020, the Company was sued by the U.S. Department of Justice alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is committed to its projected cash flow targets and management&#8217;s views on the litigation exposures have not changed. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">However, the developments indicated&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">the timeframe for resolution will take significantly longer than previously expected which introduces greater uncertainty to a favorable resolution. In addition, management </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">believed&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">that analysts </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">were&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">unlikely to modify their projections until the Company </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">could&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> demonstrate progression on the resolution with respect to some or all of the above legal matters. As such, for purposes of testing the goodwill in the North America reporting unit under ASC 350</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, management incorporated these factors into its valuation of the North America reporting unit, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">which resulted&#160;</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in an impairment charge of $4,628 million. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fourth Quarter Developments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the fourth quarter of 2020, management assessed developments during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of December&#160;31, 2020 and, therefore, no quantitative assessment was performed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the goodwill impairment charge recorded in the third quarter of 2020 to the North America reporting unit, the carrying value of the North America reporting unit equaled its fair value as of September&#160;30, 2020. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to the North America reporting unit in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">The other reporting units all have fair value in excess of 10% over their book values as of December&#160;31, 2020. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2144439<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642480080104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8&#8212;Leases: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva adopted the new accounting standard ASC 842 &#8220;Leases&#8221; and all the related amendments on January&#160;1, 2019 and used the effective date as Teva&#8217;s date of initial application. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease cost for the year ended December&#160;31, 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 16%;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost:</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed payments and variable payments that depend on an index or rate</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease payments not included in the lease liability</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 16%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$155</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$178</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to operating leases was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 16%;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">169</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for lease obligations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-cash):</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%; padding-bottom: 2.2pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom; width: 16%; padding-bottom: 2.2pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;">211</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 2.2pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;">142</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;">&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental balance sheet information related to operating leases was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease ROU assets</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">559</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">116</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">479</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">595</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">7.5&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">7.5&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">5.2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2025 and thereafter</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">302 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease payments</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">722 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">595 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At the end of the third quarter of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, after obtaining the right to use the building, Teva began transitioning its corporate headquarters to a consolidated site in Tel-Aviv, Israel. Teva has an operating lease for the office space in Tel Aviv for an initial term of twelve and a half years, with an option for three extensions. Teva estimates that the reasonably certain holding period of the lease for accounting purposes is twelve and a half years. As of September 30,&#160;</div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, <div style="letter-spacing: 0px; top: 0px;;display:inline;">upon initial recognition,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>Teva booked&#160;&#160;$</div>74 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million as operating lease right-of-use and $</div>66 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million as operating lease liability.&#160;</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2020, Teva&#8217;s total finance lease assets and finance lease liabilities were</div>&#160;$29 million and $21 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. The difference between those amounts is mainly due to prepaid payments.</div> </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478692392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt obligations</a></td>
<td class="text"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9&#8212;Debt obligations: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term debt: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> interest rate as of<br/> December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible debentures</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 7%; text-align: center;">0.25%</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2026</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">514</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">514</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="5" style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current maturities of long-term liabilities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,674 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,831 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td colspan="5" style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total short term debt</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">3,188 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,345 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible senior debentures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva 0.25% convertible senior debentures, due 2026, principal amount as of December&#160;31, 2020 and 2019 were $514 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. These convertible senior debentures include a &#8220;net share settlement&#8221; feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the &#8220;net share settlement&#8221; feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. Holders of the convertible debentures were able to cause Teva to redeem the debentures on February 1, 2021, and $491 million of the convertible debentures were redeemed on such date.</div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 100%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:57%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> interest rate as of<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,010&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million (1)</div></div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">0.38</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,131</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,500&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">1.13</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2024</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,839 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,673</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,300&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">1.25</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2023</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,595</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,451</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 900&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">4.50</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,107</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,008</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 750&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">1.63</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2028</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">916 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">833 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 700&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">3.25</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">861 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">784</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 700&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">1.88</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2027</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">860</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">782</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,000&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">6.00</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,230</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,120</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,000&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">7.13</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 3,500&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">3.15</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2026</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">3,495</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">3,494 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,475&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">2.20</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,472</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,474</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 3,000&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">2.80</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2023</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">2,996</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">2,995</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 2,000&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">4.10</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2046</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">1,986</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">1,985</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,250&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">6.00</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2024</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,250&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">6.75</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2028</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 844&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">2.95</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">853 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">856</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 789&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">6.15</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2036</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">783 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">782</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 700&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million (2)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">2.25</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">700</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 613&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">3.65</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">616</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">618 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 588&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">3.65</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">586</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">587 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF 350&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">0.50</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">397 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">361 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF 350&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right; padding-bottom: 0.45pt;;width:6%;">1.00</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;;width:4%;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;">398</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;">362 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">25,490 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">26,496</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term debt</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">1.08 </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2026</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">1 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current maturities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">(2,674</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">(1,831</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less debt issuance costs</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">(103</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes and loans</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">22,731</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">24,562 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In July&#160;</div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, Teva repaid at maturity &#8364;</div>1,010 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million of its</div>&#160;0.375% <div style="letter-spacing: 0px; top: 0px;;display:inline;">senior notes.</div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March&#160;</div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, Teva repaid at maturity $</div>700&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of its</div>&#160;2.25% <div style="letter-spacing: 0px; top: 0px;;display:inline;">senior notes.&#160;</div> </div></div></td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts (as defined), if any. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term debt as of December&#160;31, 2020 is effectively denominated in the following currencies: U.S. dollar 60%, euro 37% and Swiss franc 3%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $2.3 billion<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">unsecured syndicated</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;revolving credit facility</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">entered into in April 2019</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;(&#8220;RCF&#8221;).</div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The RCF agreement provides for two separate tranches, a</div> $1.15 <div style="letter-spacing: 0px; top: 0px;;display:inline;">billion tranche A and a</div>&#160;$1.15 <div style="letter-spacing: 0px; top: 0px;;display:inline;">billion tranche B. Loans and letters of credit will be available from time to time under each tranche for Teva&#8217;s general corporate purposes. Tranche A has a maturity date of April 8, 2022, with two one-year extension options, of which $1.065 billion was extended to April 8, 2023. Tranche B has a maturity date of April 8, 2024.&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time.</div> The net debt to EBITDA ratio limit was 5.75x through December 31, 2020, gradually declines to 5.50x in the first and second quarters of 2021, 5.00x in the third and fourth quarters of 2021, and continues to gradually decline over the remaining term of the RCF. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The RCF can be used for general corporate purposes, including repaying existing debt. As of December&#160;31, 2020, and as of the date of this Annual Report on Form 10-K, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date these financial statements are issued. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes is outstanding, could lead to an event of default under the Company&#8217;s senior notes due to cross acceleration provisions.&#160;</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that these financial statements are issued.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the required annual principal payments of long-term debt, excluding debt issuance cost, including convertible senior debentures, starting from the year 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>, are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">2,111</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">4,591</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,089</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">202<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,735 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">2026 and thereafter *</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">9,804</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">23,330 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including $514<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million convertible notes. See note 9a. </div></div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478771512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="/* background-color: rgb(255, 255, 255); */letter-spacing: 0px;top: 0px;;display:inline;">NOTE 10&#8212;Derivative instruments and hedging <div style="letter-spacing: 0px; top: 0px;;display:inline;">activities</div>:</div></div></div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign exchange risk management: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, approximately 48% of Teva&#8217;s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is <div style="letter-spacing: 0px; top: 0px;;display:inline;">subject </div>to significant foreign currency risks. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company enters into forward exchange contracts, purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: the euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar, the Polish zloty, the Indian rupee and other European and Latin American currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (&#8220;net investment hedge&#8221;) and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest risk management: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company raises capital through various debt instruments, including straight notes that bear a fixed or variable interest rate, bank loans and convertible debentures. In some cases, the Company has swapped from a fixed to a floating interest rate (&#8220;fair value hedge&#8221;) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (&#8220;cash flow hedge&#8221;), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative instrument disclosure: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-currency swap<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net investment hedge</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative instrument outstanding: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification and fair values of derivative instruments: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">$</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; padding: 0pt; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal; text-align: left; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Cross-currency swaps<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">, </div>net investment<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>hedge</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(22)</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(79</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives designated in fair value or cash flow hedging relationships: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other comprehensive<br/> income&#160;(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018**&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018**&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">834 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">822</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">959</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;">160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(585</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cross-currency swaps&#8212;cash flow hedge (1)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cross-currency swaps<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net investment hedge (2)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Interest rate swaps&#8212;fair value hedge (3)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparative figures are based on prior hedge accounting standard. </div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">834</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">822</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">959</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,887</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (4)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">130</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts&#160; (5)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588&#160;million in cross-currency swap agreements against its </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500&#160;</div> million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva&#8217;s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">float-for-float</div></div> interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3&#160;million. <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500&#160;million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. During 2019 and 2020, Teva entered into hedging instruments to hedge part of the projected 2020 operating results. In 2020, Teva recognized a gain of $27&#160;million in relation with the 2020 hedging program. During the second half of 2020, Teva entered into hedging instruments to hedge part of the projected operating results for 2021. As part of the economic hedge treatment, Teva recorded a loss of $27&#160;million in relation to the 2021 hedging instruments in the second half of 2020, while the positive foreign exchange impact on the underlying revenues and expenses, may occur upon their maturity in 2021. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div></div> </td> </tr> </table>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortizations due to terminated derivative instruments: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward starting interest rate swaps and treasury lock agreements </div></div></div> <div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;margin-left: 0%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position of $493&#160;million, which was recorded in other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to these forward starting interest rate swaps and treasury lock agreements, losses of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$31 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million, </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $29 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million and </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $28 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million were recognized under financial expenses, net for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value hedge </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its 2.95% senior notes due 2022 with respect to $844&#160;million notional amount and its 3.65% senior notes due 2021 with respect to $450&#160;million notional amount. Settlement of these transactions resulted in a gain position of $41&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the third quarter of 2019, Teva terminated $500&#160;million interest rate swap agreements designated as a fair value hedge relating to its 2.8% senior notes due 2023 with respect to $3,000&#160;million notional amount. Settlement of these transactions resulted in cash proceeds of $10&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow hedge </div></div></div> <div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;margin-left: 0%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fourth quarter of 2019, Teva terminated $588 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million cross-currency swap agreements against its </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outstanding 3.65% </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">senior notes maturing in November 2021. Settlement of these transactions resulted in cash proceeds of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$95 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">With respect to the interest rate swap and cross-currency swap agreements,&#160;gains of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$3 million, $6 million and $6 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million were recognized under financial expenses, net for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">f.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securitization: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2011, Teva established a trade receivables securitization program to sell trade receivables to BNP Paribas Bank (&#8220;BNP&#8221;). Under the program Teva (on a consolidated basis) receives an initial cash purchase price and the right to receive a deferred purchase price (&#8220;DPP&#8221;), according to the purchase price for the receivables sold by it. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On an individual seller basis, each Teva subsidiary sells receivables to BNP for an amount equal to their nominal amount. BNP then immediately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-sells</div> such receivables to a bankruptcy-remote special-purpose entity (&#8220;SPE&#8221;), for an amount equal to the nominal amount of such trade receivables. The SPE then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-sells</div> such receivables to a conduit sponsored by BNP (&#8220;the conduit&#8221;) for an initial cash purchase price (equal to the nominal amount of such receivables less a discount) and the right to receive a DPP. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The SPE is a VIE for which Teva is considered to be the primary beneficiary. The SPE&#8217;s sole business consists of the purchase of receivables from Teva subsidiaries and the subsequent transfer of such receivables to the conduit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the SPE is included in Teva&#8217;s consolidated financial statements, it is a separate legal entity with separate creditors. The conduit and other designated creditors of the SPE are entitled, both before and upon the SPE&#8217;s liquidation, to be paid out of the SPE&#8217;s assets prior to the DPP payable to Teva. The assets of the SPE are not available to pay creditors of Teva or its subsidiaries.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This program expires on August&#160;21, 2021 but can be renewed with consent from the parties to the program up to August&#160;20, 2022 or any other date agreed between the parties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Once sold to BNP, the relevant Teva subsidiary as seller has no retained interests in the receivables sold and they are unavailable to the relevant seller should the relevant seller become insolvent. The conduit has all the rights in the securitized trade receivables, including the right to pledge or dispose of such receivables. Consequently, receivables sold under this agreement are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-recognized</div> from Teva&#8217;s consolidated balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The portion of the purchase price for the receivables which is not paid in cash by the conduit is a DPP asset. The conduit pays the SPE the DPP from collections received by the conduit from the securitized trade receivables (after paying senior costs and expenses, including the conduit&#8217;s debt service obligations), which the SPE then pays to Teva.The DPP asset represents a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The DPP asset is included in other current assets on Teva&#8217;s consolidated balance sheet. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva has collection and administrative responsibilities for the sold receivables. The fair value of these servicing arrangements as well as the fees earned was immaterial. </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">DPP asset as of December&#160;31, 2020 and 2019 was </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$266 million and $250 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, the balance of Teva&#8217;s securitized assets sold were </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$734 million and $690 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the sold receivables outstanding balance net of DPP asset under the outstanding securitization program: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;and&#160;for&#160;the&#160;year&#160;ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sold receivables at the beginning of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash collections (remitted to the owner of the receivables)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of currency exchange rate changes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sold receivables at the end of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">734</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td> </tr> </table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478814696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Settlements and Loss Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Settlements and Loss Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11&#8212;Legal settlements and loss contingencies: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies for 2020 amounted to expenses of $60&#160;million, compared to expenses of $1,178&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">in 2019&#160;</div></div>and an income of $1,208&#160;million in &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">2018.</div>&#160;The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). The expenses in 2019 were mainly related to an estimated provision recorded in connection with potential settlement of the opioid cases. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, Teva&#8217;s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $1,625&#160;million and $1,580&#160;million, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489692472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 12&#8212;Commitments and contingencies:</div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalty commitments: </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company is committed to pay royalties to owners of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> partners in alliances and other certain arrangements and to parties that financed research and development, at a wide range of rates as a percentage of sales or of the gross margin of certain products, as defined in the underlying agreements. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until September&#160;30, 2018, royalty expenses were reported in cost of goods sold if related to the acquisition of a product, and if not, such expenses were included in S&amp;M expenses. Commencing October&#160;1, 2018, royalty expenses are retroactively reported entirely under cost of goods sold. Royalty expenses in each of the years ended December&#160;31, 2020, 2019 and 2018 were $505 million, $403 million and $536 million, respectively. </div>&#160;</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone commitments: </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva has committed to make potential future milestone payments to third parties under various agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events,</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is unclear when, if ever, Teva may be required to pay such amounts. As of December&#160;31, 2020, if all milestones and targets, for compounds in phase 2 and more advanced stages of development, are achieved, the total contingent payments could reach an aggregate amount of up to $509&#160;million. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of the cases described below, management&#8217;s assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management&#8217;s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters that the Company has determined no longer meet the materiality threshold for disclosure. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva&#8217;s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA (formerly IMS Health Inc.) data. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property Litigation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, Teva seeks to develop generic versions of patent-protected pharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator&#8217;s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator&#8217;s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic version even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act. For example, Teva could be sued for patent infringement after commencing sales of a product. In addition, for biosimilar products, Teva could be sued according to the &#8220;patent dance&#8221; procedures of the Biologics Price Competition and Innovation Act (BPCIA). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva&#8217;s product. The amount of lost profits would generally be based on the lost sales of the patentee&#8217;s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In July 2014, GlaxoSmithKline (&#8220;GSK&#8221;) sued Teva in Delaware federal court for infringement of a patent expiring in June 2015 directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK&#8217;s Coreg<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) in September 2007. A jury trial was held and the jury returned a verdict in GSK&#8217;s favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of $235.5&#160;million, not including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> or post-judgment interest or a multiplier for willfulness. Following post-trial motions filed by the parties, on March&#160;28, 2018, the district court issued an opinion overturning the jury verdict and instead found no induced infringement by Teva, thereby finding that Teva did not owe any damages; the district court also denied Teva&#8217;s motion seeking to overturn the jury verdict with respect to invalidity. The provision that was originally included in the financial statements following the damages verdict in this matter in 2017 was reversed in 2018, following the opinion overturning the verdict as the exposure was no longer considered probable. On October&#160;2, 2020, the Court of Appeals for the Federal Circuit overturned the lower court&#8217;s ruling and reinstated the jury verdict in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-to-one</div></div> decision. On December&#160;2, 2020, <div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva filed a request for panel and en banc review. On February 9, 2021, the Federal Circuit granted panel rehearing. In its February 9, 2021 order, the Court vacated the October 2, 2020 judgment and scheduled oral argument for February 23, 2021. The Court will hear oral argument only on the issue of whether there is enough evidence to support the jury&#8217;s verdict of induced infringement during the time period from January 8, 2008 through April 30, 2011 (the &#8220;skinny label&#8221; period). If further appeals are decided against Teva, the case would be remanded to the district court for it to consider Teva&#8217;s other legal and equitable defenses that have not yet been considered by the district court.&#160;</div> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">In 2014, Teva Canada succeeded in its challenge of the bortezomib (the generic equivalent of Velcade&#174;) product and mannitol ester patents under the Patented Medicines (Notice Of Compliance) Regulations (&#8220;PM (NOC)&#8221;). At the time of Teva&#8217;s launch in 2015, annual sales of Velcade were approximately</div></div>&#160;94&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million Canadian dollars. Additionally, Teva commenced an action under Section 8 of PM (NOC) to recover damages for being kept off of the market during the PM (NOC) proceedings. Janssen and Millennium filed a counterclaim for infringement of the same two patents as well as a patent covering a process to prepare bortezomib. The product patent expired in October 2015; the other patents expire in January 2022 and March 2025. In 2017, Teva entered into an agreement with Janssen and Millennium which limited the damages payable by either party depending on the outcome of the infringement/impeachment action. As a result, the most Janssen and Millennium could have recovered is</div> 200&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million Canadian dollars plus post-judgment interest. In June 2018, the court ruled that Janssen and Millennium pay Teva</div> 5&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million Canadian dollars in Section 8 damages. Janssen and</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Millennium filed an appeal, which was denied by the appellate court on November&#160;4, 2019. On January&#160;3, 2020, Janssen and </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Millennium applied for leave to appeal to the Canadian Supreme Court. On May&#160;8, 2020, the Canadian Supreme Court denied Janssen and Millennium&#8217;s application. This matter is now closed.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Liability Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both approaches, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (API) supplied by multiple API manufacturers. Teva&#8217;s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (&#8220;MDL&#8221;) pending in the United States District Courts. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring claims. Defendants&#8217; motions to dismiss in the valsartan, losartan and irbesartan MDL were denied in part and granted in part, allowing plaintiffs to file amended complaints.&#160;On December&#160;31, 2020, the court in the ranitidine MDL granted the generic defendants&#8217; motion to dismiss on the grounds of preemption and deficient pleading, allowing plaintiffs to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-plead</div> certain claims. Certain plaintiffs appealed the decision. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva&#8217;s, as well as other generic manufacturers&#8217; metformin products. A motion to dismiss in that consolidated action is pending. Similar lawsuits are pending in Canada and Germany.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition Matters </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva&#8217;s patent challenges have resulted in litigation relating to Teva&#8217;s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva and its subsidiaries have increasingly been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases, which are usually direct and indirect purchasers of pharmaceutical products, and often assert claims on behalf of classes of all direct and indirect purchasers, typically allege that (1)&#160;Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (2)&#160;significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These class action cases seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">what the generic price allegedly would have been and disgorgement of profits, which are automatically tripled under the relevant statutes, plus attorneys&#8217; fees and costs. The alleged damages generally depend on the size of </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the branded market and the length of the alleged delay, and can be substantial&#8212;potentially measured in multiples of the annual brand sales&#8212;particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva&#8217;s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (&#8220;FTC&#8221;) v. Actavis, Inc. (the &#8220;AndroGel case&#8221;), that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva&#8217;s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva&#8217;s currently pending antitrust litigations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning in April 2006, certain subsidiaries of Teva were named in a class action lawsuit filed in the U.S. District Court for the Eastern District of Pennsylvania with allegations that the settlement agreements entered into between Cephalon, Inc., now a Teva subsidiary (&#8220;Cephalon&#8221;), and various generic pharmaceutical companies in late 2005 and early 2006 to resolve patent litigation involving certain finished modafinil products (marketed as PROVIGIL<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) were unlawful because they had the effect of excluding generic competition. The cases also allege that Cephalon improperly asserted its PROVIGIL patent against the generic pharmaceutical companies. Separately, Apotex challenged Cephalon&#8217;s PROVIGIL patent and, in October 2011, the court found the patent to be invalid and unenforceable based on inequitable conduct. Teva has either settled or reached agreements in principle to settle with all plaintiffs in such cases, except for an action brought by the State of Louisiana. The settlement with the State of California that was reached in 2019 received final court approval in June 2020. All settlements entered into in connection with the above proceeding are covered by the settlement fund explained below. </div></div><div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 12pt;margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In May 2015, Cephalon entered into a consent decree with the FTC (the &#8220;Modafinil Consent Decree&#8221;) under which the FTC dismissed its claims against Cephalon in the FTC Modafinil Action in exchange for payment of</div>&#160;$1.2&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">billion (less set-offs for prior settlements) by Cephalon and Teva into a settlement fund. Under the Modafinil Consent Decree, Teva also agreed to certain injunctive relief with respect to the types of settlement agreements Teva may enter into to resolve patent litigation in the United States for a period of ten years. The remaining balance of the settlement fund after consideration of the settlement with the State of California noted above is approximately</div>&#160;$19&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million. In February 2019, in connection with the settlement of other unrelated FTC antitrust lawsuits, as described below, Teva and the FTC agreed to amend certain non-financial provisions of the Modafinil Consent Decree and to restart its ten-year term.&#160;</div> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the European Commission issued a Statement of Objections and a Supplementary Statement of Objection in July 2017 and June 2020, respectively, and a final decision against both Cephalon and Teva in November 2020, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling &#8364;60.5&#160;million on Teva and Cephalon. Teva and Cephalon&#160;filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva and its affiliates have been named as defendants in lawsuits that allege that multiple patent litigation settlement agreements relating to AndroGel<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> 1% (testosterone gel) violate the antitrust laws. The first of these lawsuits (the &#8220;Georgia AndroGel Litigation&#8221;) was filed in January 2009 in California federal court, and later transferred to Georgia federal court, with the FTC and the State of California, and later private plaintiffs, </div></div><div style="color: rgb(0, 0, 0);font-family: 'Times New Roman';font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: left;text-indent: 0px;text-transform: none;white-space: normal;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;/* background-color: rgb(255, 255, 255); */text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;margin-top: 0pt;margin-bottom: 0pt;font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">challenging a September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. (&#8220;Watson&#8221;), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. (&#8220;Solvay&#8221;). The second lawsuit (the &#8220;Philadelphia AndroGel Litigation&#8221;) was filed by the F</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">T<div style="letter-spacing: 0px; top: 0px;;display:inline;">C</div>&#160;in September 2014 in federal court in Philadelphia, challenging Teva&#8217;s December 2011 patent litigation settlement with AbbVie. The FTC stipulated to dismiss Teva from both litigations, in exchange for Teva&#8217;s agreement to amend the Modafinil Consent Decree, as described above. On July 16, 2018, the direct purchaser plaintiffs&#8217; motion for class certification in the Georgia AndroGel Litigation was denied and Teva later settled with most of the retailer plaintiffs in the Georgia AndroGel Litigation as well as the three direct purchasers that had sought class certification. These settlement amounts were paid in full. In addition, on January 7, 2021, Teva settled all claims with the remaining retailer plaintiff in the Georgia AndroGel Litigation and thus no claims remain in the Georgia AndroGel Litigation. In August 2019, certain other direct-purchaser plaintiffs (who would have been members of the direct purchaser class in the Georgia AndroGel Litigation, had it been certified) filed their own claims in the federal court in Philadelphia (where the Philadelphia AndroGel Litigation has been pending), challenging (in one complaint) both the September 2006 settlement between Watson and Solvay, and the December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AndroGel<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> 1% were approximately<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $350&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million at the time of the earlier Watson/Solvay settlement and approximately</div> $140&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million at the time Actavis launched its generic version of AndroGel<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> 1% in November 2015. A provision for these matters was included in the financial statements. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving extended release venlafaxine (generic Effexor XR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) entered into in November 2005. The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In October 2014, the court granted Teva&#8217;s motion to dismiss in the direct purchaser cases, after which the parties agreed that the court&#8217;s reasoning applied equally to the indirect purchaser cases. Plaintiffs appealed and, in August 2017, the Third Circuit reversed the district court&#8217;s decision and remanded for further proceedings. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> were approximately</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $2.6&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion at the time of settlement and at the time Teva launched its generic version of Effexor XR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in July 2010. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>) entered into in February 2005. The plaintiffs claim that the settlement agreement unlawfully delayed generic entry and seek unspecified damages. In December 2012, the court dismissed the case, but in June 2015, the U.S. Court of Appeals for the Third Circuit reversed and remanded for further proceedings. In December 2018, the district court granted the direct-purchaser plaintiffs&#8217; motion for class certification, but on April&#160;22, 2020, the Third Circuit reversed that ruling and remanded for further class certification proceedings. The district court&#8217;s decision on the direct purchaser plaintiffs&#8217; renewed motion for class certification remains pending. Annual sales of Lamictal<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> were approximately<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$950&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million at the time of the settlement and approximately</div>&#160;$2.3&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion at the time Teva launched its generic version of Lamictal<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in July 2008. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (extended release niacin) sued Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005, to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers&#8217; class. In August 2019, the district court certified the direct-purchaser class, but in June 2020, the </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">court denied the indirect purchasers&#8217; motion for class certification without prejudice. On September&#160;4, 2020, the indirect purchasers filed a renewed motion for class certification, which remains pending. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, which has since been amended, alleging violations of state law. Defendants moved to strike the District Attorney&#8217;s claims for restitution and civil penalties to the extent not limited to alleged activity occurring in Orange County. The Superior Court denied that motion. The Court of Appeals subsequently reversed the decision and in June 2020, the California Supreme Court reversed the Court of Appeals&#8217; decision, allowing the District Attorney&#8217;s claims to proceed. Annual sales of Niaspan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> were approximately</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $416&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million at the time of the settlement and approximately&#160;</div>$1.1&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion at the time Teva launched its generic version of Niaspan<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in September 2013.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Beginning in 2013, several putative class actions were filed against Actavis, Inc. and certain of its affiliates, alleging that Watson&#8217;s 2012 patent lawsuit settlement with Endo Pharmaceuticals Inc. relating to Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (lidocaine transdermal patches) violated the antitrust laws. The cases were consolidated as a multidistrict litigation in federal court in California and were settled in 2018. The FTC also filed suit to challenge the Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> settlement, although in February&#160;2019, the FTC dismissed its claims against Actavis and Allergan, in exchange for Teva&#8217;s agreement to amend the Modafinil Consent Decree, as described above. In July 2019, Teva also settled a complaint brought by the State of California. On September&#160;16, 2019, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers</div> Blue Cross Blue Shield of Michigan and Blue Care Network of Michigan (collectively &#8220;BCBSM&#8221;) filed their own lawsuit against Watson, and other defendants, in Michigan state court relating to the Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> settlement. Defendants moved to dismiss that lawsuit on June&#160;5, 2020, and those motions were granted in part and denied in part on October&#160;16, 2020. In January 2021, Watson and BCBSM reached an agreement in principle to settle the lawsuit. On January&#160;24, 2020, the State of Mississippi filed a complaint against Teva and Watson in Mississippi state court relating to the Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> settlement, which it subsequently amended on June&#160;12, 2020. Teva and Watson have moved to dismiss that amended complaint, and their motion remains pending. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers</div> for, and direct-purchasers of, Actos<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payers&#8217;</div> lawsuits against all defendants in September 2015. On February&#160;8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers&#8217; case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit&#8217;s decision, but on October&#160;8, 2019, the district court dismissed, with prejudice, the direct purchasers&#8217; claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva&#8217;s settlement, annual sales of Actos<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and Actoplus Met were approximately</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div>3.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion and approximately</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div>500<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. At the time Teva launched its authorized generic version of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actos<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actoplus Met in August 2012, annual sales of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actos<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actoplus Met were approximately&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> $</div>2.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion and approximately</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div>430<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2015, a purported class of end payers for Namenda IR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (memantine hydrochloride) filed a lawsuit against Forest Laboratories, LLC (&#8220;Forest&#8221;), the innovator, and several generic manufacturers, including Teva, alleging, among other things, that the settlement agreements between Forest and the generic manufacturers to resolve patent litigation over Namenda IR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> violated the antitrust laws. Teva reached a settlement agreement with these plaintiffs in July 2020, which received preliminary approval on October&#160;13, 2020 and is awaiting final court approval. Annual sales of Namenda IR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> at the time of the patent litigation settlement were approximately<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>1.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">billion and approximately</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;$</div>550<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million at the time other manufacturers first launched generic versions of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Namenda IR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in July<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2015.&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">In January 2019, generic manufacturer Cipla Limited filed a lawsuit against Amgen, which was later amended to include Teva as a defendant, in Delaware federal court, alleging, among other things, that a January&#160;2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), violated the antitrust laws. On August&#160;14, 2020, Cipla Limited agreed to dismiss its claims against Teva, with prejudice, and those claims have since been dismissed. Putative classes of direct-purchaser and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-payer</div> plaintiffs have also filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva related to the January&#160;2, 2019 settlement. On July&#160;22, 2020, a magistrate judge recommended that plaintiffs&#8217; claims be dismissed and on November&#160;30, 2020, the district court overruled the magistrate judge&#8217;s recommendation, denied Teva&#8217;s motion to dismiss in part, and instructed plaintiffs to file an amended complaint. Annual sales of Sensipar<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in the United States were approximately $1.4 billion at the time Teva launched its generic version of Sensipar<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in December 2018, and at the time of the January&#160;2, 2019 settlement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;16, 2016, the U.K. Competition and Markets Authority (&#8220;CMA&#8221;) issued a statement of objections (a provisional finding of breach of the Competition Act) in respect of certain allegations against Allergan, Actavis UK and certain Auden Mckenzie entities alleging competition law breaches in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. On March&#160;3, 2017 and February&#160;28, 2019, the CMA issued second and third statements of objections in respect of certain additional allegations relating to the same products and covering part of the same time periods as in the first statement of objections. On February&#160;12, 2020, the CMA issued a Supplementary Statement of Objections effectively combining the three previously issued statements referenced above and a Statement of Draft Penalty Calculation was issued on October&#160;28, 2020. On January&#160;9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to the December&#160;16, 2016 and March&#160;3, 2017 statements of objections, and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. A liability for this matter has been recorded in the financial statements. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the European Commission commenced an inspection of Teva and subsequently requested information for purposes of investigating whether Teva may have abused a dominant position in the Multiple Sclerosis field, dating back to at least 2014. No formal proceedings have been initiated. Annual sales of COPAXONE<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in the European Economic Area for the past year were approximately $431&#160;million. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Between September&#160;1, 2020 and December&#160;20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> retailer purchasers of Bystolic<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> violated the antitrust laws. The cases have been coordinated and remain in their preliminary stages, pending a decision regarding potential transfer. Annual sales of Bystolic<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> in the United States were approximately $700&#160;million at the time of Watson&#8217;s 2013 settlement with Forest. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Investigations and Litigation Relating to Pricing and Marketing </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (&#8220;DOJ&#8221;) Antitrust Division seeking documents and other information relating to the marketing and </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">pricing of certain Teva USA generic products and communications with competitors about such products. On August&#160;25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three count indictment charging T<div style="letter-spacing: 0px; top: 0px;;display:inline;">e</div>va USA with criminal felony Sherman Act violations. See No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-cr-200</div></div> (E.D. Pa.). The indictment alleges Teva USA participated in a conspiracy with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs, including Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-Cream,</div> Gel, and Ointment), Warfarin, Etodolac (IR), Nadolol, Temozolomide, and Tobramycin. On September&#160;8, 2020, Teva USA pled not guilty to all counts. A tentative trial date is yet to be scheduled. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company&#8217;s busi<div style="display:inline;">n</div>ess, including monetary penalties and debarment from federally funded health care programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January&#160;1, 2009 relevant to the Civil Division&#8217;s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December&#160;15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June&#160;18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May&#160;10, 2019, most (though not all) of these attorneys general filed yet another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November&#160;1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June&#160;10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA in a similar complaint relating to dermatological generics products. In the various complaints described above, the states seek a finding that the defendants&#8217; actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (&#8220;Pennsylvania MDL&#8221;). On July&#160;13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys&#8217; general November&#160;1, 2019 complaint, referenced above, along with three complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. Teva moved the court to reconsider that ruling, and the motion was granted on February&#160;9, 2021. As a result, the attorneys&#8217; general November&#160;1, 2019 amended complaint is not expected to be among the bellwether complaints in the Pennsylvania MDL. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Beginning on March&#160;2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva and Actavis. The plaintiffs generally </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October&#160;16, 2018, the <div style="letter-spacing: 0px; top: 0px;;display:inline;">court </div>denied certain of the defendants&#8217; motions to dismiss as to certain federal claims, pending as of that date, and on February&#160;15, 2019, the court granted in part and denied in part defendants&#8217; motions to dismiss as to certain state law claims. On July&#160;18, 2019, and again on May&#160;6, 2020, certain individual plaintiffs commenced a civil action in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaint has been filed in either action and the July&#160;18, 2019 case has been placed in deferred status. On November&#160;13, 2019, and again on August&#160;24, 2020, certain counties in New York commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been transferred to the Pennsylvania MDL. On December&#160;15, 2020, several additional New York counties filed suit in New York state court raising similar allegations. On March&#160;1, 2020, Harris County in Texas filed a complaint against several generic manufacturers including Teva and Actavis in the District Court for the Southern District of Texas, which has been transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2017, Teva received a subpoena from the U.S. Attorney&#8217;s office in Boston, Massachusetts requesting documents related to Teva&#8217;s donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney&#8217;s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. It is alleged that Teva caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On October&#160;19, 2020, Teva filed a motion to dismiss the complaint, which remains pending. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2016, Teva resolved certain claims under the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) with the SEC and the DOJ. The settlement included a fine, disgorgement and prejudgment interest, a three-year deferred prosecution agreement (&#8220;DPA&#8221;) for Teva and the retention of an independent compliance monitor for a period of three years. In February 2020 the term of the monitorship provided for by the DPA and Teva&#8217;s consent judgement with the SEC expired and on March&#160;4, 2020, following Teva&#8217;s certification to the SEC and the DOJ confirming that Teva had complied with its disclosure obligations under the DPA, the DOJ filed a motion to dismiss the information filed against Teva at the time the DPA was entered into. On July&#160;21, 2020, the information was dismissed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opioids Litigation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Since May 2014, more than 3,000 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio (&#8220;MDL Opioid Proceeding&#8221;) and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were recently transferred back to federal district court for additional discovery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-trial</div> proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14-cv-04361</div></div> (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">18-cv-07591-CRB</div></div></div> (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law, generally contend that the defendants </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">allegedly engaged in improper marketing and distribution of opioids, including ACTIQ<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> and FENTORA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>. The complaints also assert claims related to Teva&#8217;s generic opioid products. In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding.&#160;Furthermore, approximately 700 complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages,&#160;attorneys&#8217; fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-economic</div> damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Absent resolutions, trials are expected to proceed in several states in 2021, unless postponed as a result of the COVID-19 pandemic. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Teva settled the Oklahoma litigation brought by the Oklahoma Attorney General (State of Oklahoma, ex. rel. Mike Hunter, Attorney General of Oklahoma vs. Purdue Pharma L.P., et. al.) for</div> $85&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million. The settlement did not include any admission of violation of law for any of the claims or allegations made. As the Company demonstrated a willingness to settle part of the litigation, for accounting purposes, management considered a portion of opioid-related cases as probable and, as such, recorded an estimated provision in the second quarter of 2019. Given the relatively early stage of the cases, management viewed no amount within the range to be the most likely outcome. Therefore, management recorded a provision for the reasonably estimable minimum amount in the assessed range for such opioid-related cases in accordance with Accounting Standards Codification 450 &#8220;Accounting for Contingencies.&#8221;&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;21, 2019, Teva reached a settlement with the two plaintiffs in the MDL Opioid Proceeding that was scheduled for trial for the Track One case, Cuyahoga and Summit Counties of Ohio. Under the terms of the settlement, Teva will provide the two counties with opioid treatment medication, buprenorphine naloxone (sublingual tablets), known by the brand name Suboxone<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, with a value of $25&#160;million at wholesale acquisition cost and distributed over three years to help in the care and treatment of people suffering from addiction, and a cash payment in the amount of $20&#160;million, to be paid in four payments over three years. </div></div> <div style="text-indent: 4%;font-family: Times New Roman;font-size: 10pt;margin-top: 12pt;margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Also on October 21, 2019, Teva and certain other defendants reached an agreement in principle with a group of Attorneys General from North Carolina, Pennsylvania, Tennessee and Texas for a nationwide settlement framework (the &#8220;framework&#8221;). The framework is designed to provide a mechanism by which the Company attempts to seek resolution of remaining potential and pending opioid claims by both the U.S. states and political subdivisions (i.e., counties, tribes and other plaintiffs) thereof. Under this framework, Teva would provide buprenorphine naloxone (sublingual tablets) with an estimated value of up to approximately</div>&#160;$23&#160;billion at wholesale acquisition cost over a ten year period. In addition, Teva would also provide cash payments of up to $250&#160;million over a ten year period.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of January 2021, the Company continues to negotiate the terms and conditions of the framework. The Company cannot predict if the framework will be finalized with its current terms and obligations. The Company considered a range of potential settlement outcomes. The current provision remains a reasonable estimate of the ultimate costs if the nationwide settlement framework is finalized based on recent discussions. However, if not finalized for the entirety of the cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and adverse effect on Teva&#8217;s reputation, business, results of operations and cash flows.</div></div></div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Separately, on April&#160;27, 2018, Teva received subpoena requests from the United States Attorney&#8217;s office in the Western District of Virginia and the Civil Division seeking documents relating to the manufacture, marketing and sale of branded opioids. In August 2019, Teva received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. In September 2019, Teva received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. Following a Statement of Changes and Notice of Hearing filed by the NYDFS, a hearing is currently scheduled to take place in June 2021. Currently, Teva cannot predict how the nationwide settlement framework agreement (if finalized) will affect these investigations and administrative actions. In addition, a number of state attorneys general, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids. Other states are conducting their own investigations outside of the multistate group. Teva is cooperating with these ongoing investigations and cannot predict their outcome at this time. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, several jurisdictions and consumers in Canada have initiated litigation regarding opioids alleging similar claims as those in the United States. The cases in Canada may be consolidated and are in their early stages. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder Litigation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On November&#160;6, 2016 and December&#160;27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits were consolidated and transferred to the U.S. District Court for the District of Connecticut (the &#8220;Ontario Teachers Securities Litigation&#8221;). On December&#160;13, 2019, the lead plaintiff in that action filed an amended complaint, purportedly on behalf of purchasers of Teva&#8217;s securities between February&#160;6, 2014 and May&#160;10, 2019. The amended complaint asserts that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva&#8217;s alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. The amended complaint seeks unspecified damages, legal fees, interest, and costs. In July 2017, August 2017, and June 2019, other putative securities class actions were filed in other federal courts based on similar allegations, and those cases have been transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and October 2020, twenty complaints were filed against Teva and certain of its current and former officers and directors seeking unspecified compensatory damages, legal fees, costs and expenses. The similar claims in these complaints have been brought on behalf of plaintiffs, in various forums across the country, who have indicated that they intend to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> of the plaintiffs&#8217; class if one is certified in the Ontario Teachers Securities Litigation. On March&#160;10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the above-referenced putative class actions for all purposes and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases for pretrial purposes. The case is now in discovery. Pursuant to that consolidation order, plaintiffs in several of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> cases filed amended complaints on May&#160;28, 2020. On January&#160;22, 2021, the Court dismissed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;opt-out&#8221;</div> plaintiffs&#8217; claims arising from statements made prior to the five year statute of repose, but denied Teva&#8217;s motion to dismiss their claims under Israeli laws. The Ontario Teachers Securities Litigation plaintiffs filed a Motion for Class&#160;Certification and Appointment of Class&#160;Representatives and Class&#160;Counsel on June&#160;19, 2020, which the defendants opposed. That motion is pending. Motions to approve securities class actions were also filed in the Tel Aviv District Court in Israel with similar allegations to those made in the Ontario Teachers Securities Litigation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers alleging, among other things, violations of </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Section&#160;10(b) of the Securities and Exchange Act of 1934 and SEC Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b-5.</div> The complaint, purportedly filed on behalf of persons who purchased or otherwise acquired Teva securities between October&#160;29, 2015 and August&#160;18, 2020, alleges that Teva and certain of its former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had caused the submission of false claims to Medicare through Teva&#8217;s donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE&#8217;s commercial success and the sustainability of its revenues and resulted in the above referenced August 2020 False Claims Act complaint filed by the DOJ. The securities class action complaint seeks unspecified damages, legal fees, interest, and costs. The case is in its preliminary stages. Motions for the appointment of lead plaintiff and selection of counsel were filed in late November 2020 and remain pending. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Motions to approve derivative actions against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness with respect to the acquisition of the Rimsa business, the acquisition of Actavis Generics and the patent settlement relating to Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>. Motions for document disclosure prior to initiating derivative actions were filed with respect to several U.S. and EU settlement agreements, opioids, the U.S. price-fixing investigations and allegations related to the DOJ&#8217;s complaint regarding Copaxone patient assistance program in the U.S. In October 2020, Teva filed a notice with the Tel Aviv District Court to settle the derivative proceeding with regard to the acquisition of Actavis Generics and two related actions, including the derivative proceedings related to allegations in connection with the Lidoderm<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> patent settlement agreement. Various motions were filed in Israel to approve a derivative action, discovery and a class action related to claims regarding Teva&#8217;s above-mentioned FCPA resolution with the SEC and DOJ. The parties have reached a settlement which was approved by the Tel Aviv District Court on April&#160;6, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Environmental Matters </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva&#8217;s facilities or former facilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva&#8217;s potential liability varies greatly at each of the sites; for some sites the costs of the investigation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> and natural resource damages have not yet been determined, and for others Teva&#8217;s allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">clean-up</div> costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva&#8217;s facilities may result in the imposition of significant penalties (in amounts not </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expected to materially adversely affect Teva&#8217;s results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implem<div style="display:inline;">e</div>nted. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Matters </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon&#8217;s acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery.&#160;Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (reslizumab) for the treatment of eosinophilic esophagitis (&#8220;EE&#8221;). The plaintiffs claim damages of at least $200&#160;million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States ($150 million) and Europe ($50 million). Defendants moved to dismiss the complaint and on December&#160;28, 2018, the court granted the motion in part and dismissed all of plaintiffs&#8217; claims, except for their claim against Cephalon for breach of contract.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;Trial in this matter is currently scheduled for October 2021<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489514328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 13&#8212;Income taxes: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 8pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent Company and its Israeli subsidiaries</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">947</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-Israeli subsidiaries</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,353</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,807</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In Israel</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outside Israel</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(385</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(326</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(278</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">885</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(350</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(895</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(278</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (Loss) before income taxes</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(4,406</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,265</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(2,596</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory tax rate in Israel</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">23.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">23.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">23.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Theoretical provision for income taxes</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,013</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(291</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(597</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Increase (decrease) in the provision for income taxes due to:</div> </div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-left: 0in; text-indent: 0in; width: 66%;"><div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">The Parent Company and its Israeli subsidiaries - Mainly tax benefits arising from reduced tax rates under benefit programs</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(183</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(44</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Non-Israeli subsidiaries, including impairments *</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,369</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(115</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">381</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Tax Cuts and Jobs Act effect</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">97</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase (decrease) in other uncertain tax positions&#8212;net</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(341</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">172</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective consolidated income taxes</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(278</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(195</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In 2020 and 2018, income before income taxes includes goodwill impairment in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Israeli</div> subsidiaries that did<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>not have a corresponding tax effect. </div></td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The effective tax rate is the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Israeli</div> subsidiaries that have tax rates different than Teva&#8217;s average tax rates, the impact of impairment, restructuring and legal settlement charges and adjustments to valuation allowances on deferred tax assets on such subsidiaries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Teva released a valuation allowance on its deferred tax assets in one jurisdiction and recorded a valuation allowance in another jurisdiction, with both adjustments reflecting changes in the business forecasts of profitability in these jurisdictions. The net effect of these adjustments did not materially impact Teva&#8217;s effective tax rate for 2020. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Long-term deferred tax assets (liabilities), net:</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory related</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">144</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales reserves and allowances</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">198</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for legal settlements</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">235</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">260</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets (*)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(1,064</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,733</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carryforward losses and deductions and credits (**)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,176</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,689</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(142</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(170</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred interest</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">527</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">648</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for employee related obligations</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">122</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,278</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,264</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance&#8212;in respect of carryforward losses and deductions that may not be utilized&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(2,547</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,974</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(269</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(710</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(*)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The decrease in deferred tax liability is mainly due to impairment and amortization. </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(**)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts are shown after reduction for unrecognized tax benefits of $ 63&#160;million and $115 million as of December&#160;31, <div style="letter-spacing: 0px; top: 0px;;display:inline;">2020</div> and <div style="letter-spacing: 0px; top: 0px;;display:inline;">2019</div>, respectively. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 0%;line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703734">2021</span></div>-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703735">2022</span></div>&#8212;$79 million; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703736">2023</span></div>-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703738">2029</span></div>&#8212;$663 million; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703737">2030</span> </div>and thereafter&#8212;$171 million. The remaining balance&#8212;$1,327 million&#8212;can be utilized with no expiration date. </div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The deferred income taxes are reflected in the balance sheets among: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term assets&#8212;deferred income taxes</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">695</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term liabilities&#8212;deferred income taxes</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(964</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(269</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(710</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table>  <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncertain tax positions: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity of Teva&#8217;s gross unrecognized tax benefits: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at the beginning of the year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,223</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase <div style="letter-spacing: 0px; top: 0px;;display:inline;">(decrease)&#160;</div>related to prior year tax positions, net</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to current year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(118</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 70%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at the end of the year</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">888</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,223</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,072</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncertain tax positions, mainly of a long-term nature, <div style="letter-spacing: 0px; top: 0px;;display:inline;">include</div> accrued potential penalties and interest of $173 million, $164 million and $131<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million as of December&#160;31, 2020, 2019 and 2018, respectively. The total amount of interest and penalties reflected in the consolidated statements of income was a net increase of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">9 million, $</div>33 million <div style="letter-spacing: 0px; top: 0px;;display:inline;">and $19 million&#160;</div>for the <div style="letter-spacing: 0px; top: 0px;;display:inline;">years</div> ended December&#160;31, 2020,&#160;2019 and 2018<div style="letter-spacing: 0px; top: 0px;;display:inline;">, respectively</div>. Substantially all the above uncertain tax benefits, if recognized, would reduce Teva&#8217;s annual effective tax rate. Teva does not expect uncertain tax positions to change significantly over the next 12 months, except in the case of settlements with tax authorities, the likelihood and timing of which is difficult to estimate. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax assessments: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva files income tax returns in various jurisdictions with varying statutes of limitations. Teva and its subsidiaries in Israel have received final tax assessments through tax year 2007. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2013, Teva settled the 2005-2007 income tax assessment with the Israeli tax authorities, paying $213 million. No further taxes are due in relation to these years. Certain guidelines which were set pursuant to the agreement reached in relation to the 2005-2007 assessment have been implemented in the audit of tax years <span style="-sec-ix-hidden:hidden17703740">2008-2011</span>, and are reflected in the provisions. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Israeli tax authorities issued tax assessment decrees for 2008-2012 and 2013-2016, challenging the Company&#8217;s positions on several issues. Teva has protested the 2008-2012 and 2013-2016 decrees before the Central District Court in Israel. The Company believes it has adequately provided for these items, however, adverse results could be material. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, Teva has one tax issue in dispute for the 2009-2011 audit cycle, which is currently in litigation. The 2012-2014 audit cycle is ongoing, with an assessment report expected to be received in 2021. Additionally, Teva&#8217;s U.S. subsidiaries have multiple audit cycles open. The Company believes it has adequately provided for these items and that any adverse results would have an immaterial impact on Teva&#8217;s financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin in <div style="letter-spacing: 0px; top: 0px;;display:inline;">March 2021</div>. A final and binding decision against Teva in this case may lead to an impairment in the amount of $141 million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s subsidiaries in Europe have received final tax assessments mainly through tax year 2014. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">f.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of taxation: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and its subsidiaries are subject to tax in many jurisdictions, and estimation is required in recording the assets and liabilities related to income taxes. The Company believes that its accruals for tax liabilities are adequate for all open years. The Company considers various factors in making these assessments, including past history, recent interpretations of tax law, and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these assessments can involve a series of complex judgments regarding future events. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentives Applicable until 2013 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the incentives regime applicable to the Company until 2013, industrial projects of Teva and certain of its Israeli subsidiaries were eligible for &#8220;Approved Enterprise&#8221; status. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the projects in Israel have been granted Approved Enterprise status under the &#8220;alternative&#8221; tax benefit track which offered tax exemption on undistributed income for a period of two to ten years, depending on the location of the enterprise. Upon distribution of such exempt income, the distributing company is subject to corporate tax at the rate ordinarily applicable to the Approved Enterprise&#8217;s income. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment 69 to the Investment Law </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Amendment 69 to the Investment Law (&#8220;Amendment 69&#8221;), a company that elected by November&#160;11, 2013 to pay a corporate tax rate as set forth in that amendment (rather than the tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company up until December&#160;31, 2011 is entitled to distribute a dividend from such income without being required to pay additional corporate tax with respect to such dividend. A company that has so elected must make certain qualified investments in Israel over the five-year period commencing in 2013. Teva invested the entire required amount in 2013. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During 2013, Teva applied the provisions of Amendment 69 to certain exempt profits Teva accrued prior to 2012. Consequently, Teva paid $577 million in corporate tax on exempt income of $9.4 billion. Part of this income was distributed as dividends during 2013-2018, while the remainder is available to be distributed as dividends in future years with no additional corporate tax liability. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentives Applicable starting 2014: The Incentives Regime &#8211; Amendment 68 to the Investment Law </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Amendment 68 to the Investment Law, which Teva started applying in 2014, upon an irrevocable election made by a company, a uniform corporate tax rate will apply to all qualifying industrial income of such company (&#8220;Preferred Enterprise&#8221;), as opposed to the previous law&#8217;s incentives, which were limited to income from Approved<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Enterprises during the benefits period. Under the law, when the election is made, the uniform tax rate for 2014 until 2016 was 9% in areas in Israel designated as Development Zone A and 16% elsewhere in Israel. The uniform tax rate for Development Zone A, as of January&#160;1, 2017, is 7.5% (as part of changes enacted in Amendment 73, as described below). The profits of these &#8220;Preferred Enterprise&#8221; will be freely distributable as dividends, subject to a 20% or lower withholding tax, under an applicable tax treaty. Certain &#8220;Special Preferred Enterprises&#8221;&#160;that meet more stringent criteria (significant investment, R&amp;D or employment thresholds) will enjoy further reduced tax rates of 5% in Zone A and 8% elsewhere. In order to be classified as a &#8220;Special Preferred Enterprises,&#8221; the approval of three governmental authorities in Israel is required. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The New Technological Enterprise Incentives Regime &#8211; Amendment 73 to the Investment Law </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since 2017, a portion of the Company&#8217;s taxable income in Israel is entitled to a preferred 6% tax rate under Amendment 73 to the Investment Law as it pertains to Special Preferred Technological Enterprises. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The new incentives regime applies to &#8220;Preferred Technological Enterprises&#8221; or &#8220;Special Preferred Technological Enterprises.&#8221; A &#8220;Preferred Technological Enterprise&#8221; is an enterprise that meet certain conditions, including, inter alia: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of at least 7% of income, or at least NIS 75&#160;million (approximately $22 million) in R&amp;D activities; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the following: </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At least 20% of the workforce (or at least 200 employees) are employed in R&amp;D; </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A venture capital investment approximately equivalent to at least $2 million was previously made in the company; or </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">c.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Growth in sales or workforce by an average of 25% over the three years preceding the tax year. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A &#8220;Special Preferred Technological Enterprise&#8221; is an enterprise that meets, inter alia conditions 1 and 2 above, and in addition has total annual consolidated revenues above NIS 10 billion (approximately $2.9 billion). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Technological Enterprises are subject to a corporate tax rate of 7.5% on their income derived from intellectual property in areas in Israel designated as Zone A and 12% elsewhere, while Special Preferred Technological Enterprises are subject to 6% on such income. The withholding tax on dividends from these enterprises is 4% to foreign companies (or a lower rate under a tax treaty, if applicable). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income not eligible for Preferred Technological Enterprise benefits is taxed at the regular corporate tax rate, which is 23%, or the preferred tax rate, as the case may be. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Parent Company and its Israeli subsidiaries elected to compute their taxable income in accordance with Income Tax Regulations (Rules for Accounting for Foreign Investors Companies and Certain Partnerships and Setting their Taxable Income), 1986. Accordingly, the taxable income or loss is calculated in U.S. dollars. Applying these regulations reduces the effect of U.S. dollar&#8212;NIS exchange rate on the Company&#8217;s Israeli taxable income<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Israeli</div> subsidiaries are taxed according to the tax laws in their respective country of residence. Certain manufacturing subsidiaries operate in several jurisdictions outside Israel, some of which benefit from tax incentives such as reduced tax rates, investment tax credits and accelerated deductions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Tax reform </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the &#8220;Act&#8221;), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January&#160;1, 2018, and imposed a one-time deemed repatriation tax based on the post-1986 earnings and profits of the Company&#8217;s U.S. owned foreign subsidiaries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The one-time deemed repatriation tax is based on the post-1986 earnings and profits for which the Company has previously deferred from U.S. income taxes and is payable over 8 years. The year ended December&#160;31, 2017 included a $112 million provisional estimate for Teva&#8217;s one-time deemed repatriation taxes liability. During 2018, Teva completed its analysis of the impacts of the Act and recorded an additional expense of $97 million, pursuant to guidance issued by the U.S. Department of Treasury and revisions to the Company&#8217;s estimates since the assessment date. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489717432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 14&#8212;Equity: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares and ADSs </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, Teva had approximately 1.2&#160;billion ordinary shares issued. Teva ordinary shares are traded on the Tel-Aviv Stock Exchange and on the New York Stock Exchange, in the form of American Depositary Shares (&#8220;ADSs&#8221;), each of which represents one ordinary share<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatory convertible preferred shares </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;17, 2018, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s</div> </div>mandatory convertible preferred shares automatically converted into ordinary shares at a ratio of 1 mandatory convertible preferred share to 16 ADSs, and all of the accumulated and unpaid dividends on the mandatory convertible preferred shares were paid in ADSs, at a ratio of 3.0262 ADSs per mandatory convertible preferred share, all in accordance with the conversion mechanism set forth in the terms of the mandatory convertible preferred shares.</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>As a result of this conversion, Teva issued 70.6 million ADSs. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation plans </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation plans are comprised of stock options, RSUs, PSUs, and other equity-based awards to employees, officers, directors and consultants of the Company and its affiliates. The purpose of the plans is to (a)&#160;attract, retain, motivate, and reward such individuals, and (b)&#160;promote the creation of long-term value for shareholders of the Company by closely aligning the interests of such individuals with those of the shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;29, 2010, the Teva 2010 Long-Term Equity-Based Incentive Plan was approved by Teva&#8217;s shareholders, under which 70&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. The 2010 Plan expired on June&#160;28, 2015 (except with respect to awards outstanding on that date), and no additional awards under the 2010&#160;Plan may be made.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;3, 2015, the Teva 2015 Long-Term Equity-Based Incentive Plan was approved by Teva&#8217;s shareholders, under which 43.7&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;18, 2016, Teva&#8217;s shareholders approved an increase of an additional 33.3&#160;million equivalent share units to the share reserve of Teva&#8217;s 2015 Long-Term Equity-Based Incentive Plan, so that 77&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, are approved for grant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;13, 2017, Teva&#8217;s shareholders approved an increase of an additional 65&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million equivalent share units to the share reserve of Teva&#8217;s 2015 Long-Term Equity-Based Incentive Plan, so </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that 142&#160;million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, are approved for grant.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2015 Plan expired on June&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div>, 2020 (except with respect to awards outstanding on that date), and no additional awards under the 2015&#160;Plan may be made. </div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;11, 2020, the Teva 2020 Long-Term Equity-Based Incentive Plan was approved by Teva&#8217;s shareholders and became effective on July&#160;1, 2020. Under the plan, 68&#160;million shares, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, 74 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares remain available for future awards under the 2020 Long-Term Equity-Based Incentive Plan. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the past, Teva had various employee stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards granted under such prior plans continue in accordance with the terms of the respective plans. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The vesting period of the outstanding options and RSUs is generally from 1 to 4 years from the date of grant. The vesting period of PSUs is generally 3 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for ten years. </div></div> Status of options <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the status of the options granted by Teva as of December&#160;31, 2020, 2019 and 2018, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44.32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes during the year:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(84</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance exercisable at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,601</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43.41</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average fair value of options granted during <div style="letter-spacing: 0px; top: 0px;;display:inline;">these</div> years was generally estimated by using the Black-Scholes option-pricing model as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of these options was estimated on the date of grant, based on the following weighted average assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2.6</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">5 years</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected term was estimated based on the weighted average period for which the options granted are expected to be outstanding, taking into consideration the current vesting of options and the historical exercise patterns of existing options. The expected volatility assumption used is based on a blend of the historical and implied volatility of the Company&#8217;s stock. The risk-free interest rate used is based on the yield of U.S. Treasuries with a maturity closest to the expected term of the options granted.</div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables summarize information as of December&#160;31, 2020 regarding the number of ordinary shares issuable upon (1)&#160;outstanding options and (2)&#160;vested options: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(1) Number of ordinary shares issuable upon exercise of outstanding options</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of exercise prices</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;end&#160;of<br/> period&#160;(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> remaining life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lower than $15.01</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$15.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $25.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$25.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $35.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$35.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $45.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$45.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $55.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$55.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $65.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,223</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(2) Number of ordinary shares issuable upon exercise of vested options</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of exercise prices</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;end&#160;of<br/> period&#160;(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> remaining life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lower than $15.01</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$15.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $25.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$25.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $35.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,423</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$35.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $45.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$45.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $55.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$55.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $65.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company&#8217;s closing stock price of $ 9.65<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>on December&#160;31, 2020, less the weighted average exercise price in each range. This represents the potential amount receivable by the option holders had all option holders exercised their options as of such date. As of December&#160;31, 2020, there were no exercisable options that were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-the-money.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total intrinsic value of options exercised during the years ended December&#160;31,&#160;2019 and 2018 was immaterial, based on the Company&#8217;s average stock price of&#160;$11.50 and $20.92, for the years then ended, respectively.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;No options were exercised during 2020.</div> </div></div> Status of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes information about the number of RSUs and PSUs <div style="letter-spacing: 0px; top: 0px;;display:inline;">granted</div>&#160;and outstanding: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,977</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; padding: 0px; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11.42</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,900</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19.49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18.18</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,294</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13.81</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,977</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses compensation costs are based on the grant-date fair value. For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded stock-based compensation costs as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee stock options</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs and PSUs</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax effect on stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net effect</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the total unrecognized compensation cost before tax on employee stock options and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div>/PSUs amounted to $20<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million and $164<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million, respectively. This cost is expected to be recognized over a weighted average period of approximately 1.1<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>years and 2.5 years, respectively. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva has not paid dividends on Teva ordinary shares or ADSs since December 2017. </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive los<div style="display:inline;">s</div></div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of accumulated other comprehensive loss attributable to Teva are presented in the table below: </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Unrealized Gains/(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-</div><br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-sale</div><br/> securities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial<br/> gains/(losses)<br/> and prior<br/> service<br/> (costs)/credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 53%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(619</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Cumulative effect of new accounting standard**</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(729</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(639</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(729</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">115</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">(10</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(739</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(611</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(1,878</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(504</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(78</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">142</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,794</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(420</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(98</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,312</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(190</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(190</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(152</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">65</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(1,919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(363</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(2,399</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $56 million gain in <div style="letter-spacing: 0px; top: 0px;;display:inline;">2020</div>, $14 million gain in <div style="letter-spacing: 0px; top: 0px;;display:inline;">2019</div> and $26<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million gain in 2018. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the adoption of ASU 2016-01, the Company recorded a $5<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million opening balance reclassification from accumulated other comprehensive income to retained earnings. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478746760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherExpensesTextBlock', window );">Other assets impairments, restructuring and other items</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 15&#8212;Other assets impairments, restructuring and other items: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of long-lived tangible assets <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">416</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration (see note 2)</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(81</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">59</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">57</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">488</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(58</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">479</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">423</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">987</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including impairments related to exit and disposal activities. </div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following Teva&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> restructuring plan, described below, and its ongoing plant rationalization efforts, the Company may change its current plans with respect to any given asset and/or the assumptions underlying such plans. Consequently, additional impairments may be recorded in the future. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Impairments of tangible assets for the years ended December&#160;31, 2020, 2019 and 2018 were </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$416 million<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> $139 million&#160;and $500 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively. The impairment for the year ended December&#160;31, 2020 was mainly related to the <div style="letter-spacing: 0px; top: 0px;;display:inline;">sale of&#160;</div> certain assets from Teva&#8217;s business venture in Japan<div style="letter-spacing: 0px; top: 0px;;display:inline;">, which was completed on February 1, 2021, as well as&#160;</div>plant rationalization. See note 2. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingent consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Teva recorded an income of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$81 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million for contingent consideration, compared to an expense of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$59 million and $57 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million in 2019 and 2018 respectively. The income in 2020 was mainly related to a change in the future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), which was part of the Actavis Generics acquisition, partially offset by the change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The <div style="letter-spacing: 0px; top: 0px;;display:inline;">expense</div> in 2019 <div style="letter-spacing: 0px; top: 0px;;display:inline;">was</div> mainly related to a change in the estimated future royalty payments from Eagle in connection with bendamustine sales and an increase in the expected future royalty payments to Eagle due to the orphan drug status granted to BENDEKA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, offset by the change in future royalty payments in connection with lenalidomide (generic equivalent of Revlimid<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>), which was part of the Actavis Generics acquisition. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restructuring </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Teva recorded $120 </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million of restructuring expenses, compared to </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$199 million in 2019 and $488 million in 2018. The expenses in 2020 were primarily related to <div style="letter-spacing: 0px; top: 0px;;display:inline;">residual expenses</div>&#160;of the restructuring plan announced in 2017<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">and other network consolidation impacts.</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2017, Teva announced a comprehensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> restructuring plan intended to reduce its cost base by $3&#160;billion, unify and simplify its organization and improve business performance, profitability, cash flow generation and productivity. This plan achieved its goals, including a total cost base reduction of $3&#160;billion by the end of 2019. Teva is continuing to evaluate opportunities to further optimize its manufacturing and supply network to achieve additional operational efficiencies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide the components of costs associated with Teva&#8217;s restructuring plan, including other costs associated with Teva&#8217;s restructuring plan and recorded under different items: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2020</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2019</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2018</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">488 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee<br/> termination&#160;costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions )</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January 1, 2019</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(204</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(29</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(233</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(159</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(40</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(199</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">155</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">62</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">217</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(208</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(215</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(71</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;">(49</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(120</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr>
<td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">164</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">49</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">213</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December 31, 2020</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(115</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(7</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(122</div></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes adjustments for foreign currency translation. </div></div> </td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant regulatory and other events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, the FDA completed an inspection of Teva&#8217;s manufacturing plant in Davie, Florida in the United States, and issued a Form FDA-483 to the site. In October 2018, the FDA notified Teva that the inspection of the site is classified as &#8220;official action indicated&#8221; (OAI). On February 5, 2019, Teva received a warning letter from the FDA that contained four additional enumerated concerns related to production, quality control and investigations at this site. Teva has been working diligently to address the FDA&#8217;s concerns in a manner consistent with current good manufacturing practice (cGMP) requirements as quickly and as thoroughly as possible. An FDA follow up inspection occurred in January 2020, resulting in some follow up findings and Teva received a letter from the FDA dated April 24, 2020 notifying it that the site continues to be classified as OAI. If Teva is unable to remediate the findings to the FDA&#8217;s satisfaction, Teva may face additional consequences. These would potentially include delays in FDA approval for future products from the site, financial implications due to loss of revenues, impairments, inventory write-offs, customer penalties, idle capacity charges, costs of additional remediation and possible FDA enforcement action. Teva expects to generate approximately</div> $190 &#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million in revenues from this site in 2021, assuming remediation or enforcement does not cause any unscheduled slowdown or stoppage at the facility, however, delays in FDA approvals of future products from the site may occur.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. (&#8220;Huahai&#8221;). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva&#8217;s claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the second quarter of 2020, Teva&#8217;s operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva has completed partial remediation of this issue and has restarted limited supply from its Goa facilities. The impact to Teva&#8217;s financial results for the twelve months ended December&#160;31, 2020 was immaterial, however, if the full remediation takes longer than expected there may be further loss of sales, customer penalties or impairments to related assets. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489792664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock', window );">Other income</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 16&#8212;Other income: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td style="width: 1%;"/>
<td style="width: 4.5%;"/>
<td style="width: 1%;"/>
<td style="width: 4.5%; vertical-align: bottom;"/>
<td style="width: 1%;"/>
<td style="width: 4.5%;"/>
<td style="width: 1%;"/>
<td style="width: 5.5%; vertical-align: bottom;"/>
<td style="width: 1%;"/>
<td style="width: 4.5%;"/>
<td style="width: 0.5%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on divestitures, net of divestitures related costs (1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;8 and similar payments (2)</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap; width: 4.5%;;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212; </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">195</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain (loss) on sale of assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">291</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mainly related to the divestment of several activities in the International Markets segment. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other operating income and other operating expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642659580936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial expenses, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FinancialExpensesNetTextBlock', window );">Financial expenses, net</a></td>
<td class="text"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 17&#8212;Financial expenses, net: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width:0.5%;"/>
<td style="width:3%;"/>
<td style="width:1%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width:0.5%;"/>
<td style="width:3%;"/>
<td style="width:1%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width:0.5%;"/>
<td style="width:3%;"/>
<td style="width:0.5%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December,&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses and other bank charges</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">963</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">881</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">920</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from investments (1)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(104</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(39</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Foreign exchange (gains) losses, net</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(26</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net (2)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;;width:3%;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">65</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total finance expense, net</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">834</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">822</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">959</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Income from investments comprised mainly of revaluation gain of Teva&#8217;s investment in American Well Corporation (&#8220;American Well&#8221;). See note 20. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2018, Other, net comprised mainly of a make-whole payment of $46 million following early redemption of senior notes during 2018. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FinancialExpensesNetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Expenses Net [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FinancialExpensesNetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489595416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 18&#8212;Earnings (loss) per share: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December&#160;31, 2020, 2019 and 2018 are as follows: </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December, 31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions,&#160;except&#160;share&#160;data)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) used for the computation of <div style="letter-spacing: 0px; top: 0px;;display:inline;">basic and&#160;</div>diluted <div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(999</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(2,399</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares used in the computation of basic<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">1,095</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">1,091</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">1,021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares used in the computation of diluted <div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;">1,095</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;">1,091</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;">1,021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings and loss per share are computed by dividing net income (loss) attributable to Teva&#8217;s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested restricted share units (&#8220;RSUs&#8221;)) during the period, net of treasury shares. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In computing diluted loss per share for the years ended December 31, 2020, 2019 and 2018, no account was taken of the potential dilution that could occur upon the exercise of employee stock options, RSUs and PSUs, amounting to</div>&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104&#160;million, 113&#160;million and 51&#160;million weighted average shares, respectively, and convertible senior debentures, since they had an anti-dilutive effect on loss per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in computing diluted loss per share for the period between January 1, 2018 and December 17, 2018, no account was taken of the potential dilution of the mandatory convertible preferred shares amounting to</div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> 74&#160;million&#160;since they had an anti-dilutive effect on loss per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss per share was $3.64 for the year ended December&#160;31, 2020, compared to basic and diluted loss per share of $0.91 and $2.35 for the years ended December&#160;31, 2019 and December&#160;31, 2018, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478692392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 19&#8212;Segments: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva operates its business and reports its financial results in three segments: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment, which includes the United States and Canada. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment, which includes the European Union and certain other European countries. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment, which includes all countries other than those in the North America and Europe segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to these three segments, Teva has other sources of revenues included in other activities, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their <div style="letter-spacing: 0px; top: 0px;;display:inline;">performance</div>. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit is comprised of gross profit for the segment less R&amp;D expenses, S&amp;M expenses, G&amp;A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva&#8217;s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s CEO may review its strategy and organizational structure. Any changes in strategy may lead to a reevaluation of the Company&#8217;s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 7. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment information: </div></div></div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">247</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">427</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 52%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A <div style="letter-spacing: 0px; top: 0px;;display:inline;">expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">2,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">1,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,542</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,795</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,246</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,350</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,704</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,167</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">652</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">262</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">88</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">890</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">481</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">439</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">239</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">138</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(14</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,252</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,318</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">464</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,297</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,186</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,422</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,979</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,884</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,254</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">713</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">283</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">96</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,154</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,003</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">518</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">484</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">325</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(209</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,837</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,273</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,421</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,252</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,837</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,331</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,318</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,273</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">474</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">464</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,225</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,034</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,608</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit (loss) of other activities</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">163</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">108</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">115</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,388</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,142</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,723</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,020</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,113</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,166</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; white-space: nowrap; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Other asset impairments, restructuring and other items</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">479</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">987</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">4,628</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212; &#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">3,027</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible asset impairments</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1,502</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1,639</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1,991</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on divestitures, net of divestitures related costs</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(50</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(66</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other R&amp;D expenses (income)</div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">37</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(15</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">83</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs related to regulatory actions taken in facilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">23</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">45</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">14</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">60</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1,178</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(1,208</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">219</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">252</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">366</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(3,572</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(443</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(1,637</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">834</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">822</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">959</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(4,406</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(1,265</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2,596</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment revenues by major products and activities:</div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present revenues by major products and activities for each segment for the year ended December&#160;31, 2020, 2019 and 2018: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">642</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">884</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProAir*</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">241</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QVAR</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">708</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,297</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Does not include revenues from the ProAir authorized generic, which are included under generic products. </div></div> </td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,513</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,470</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,593</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;">&#160;<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">31</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;">&#160;<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">3</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; text-align: right; padding: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">400</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">432</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">535</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">353</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">354</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">402</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">459</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">536</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">656</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 70%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4,757</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4,795</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">5,186</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 70%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,792</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">309</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">291</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">328</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,154</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,246</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,422</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva revenues from external customers attributed to Israel were less than 5% of the consolidated revenues in the years ended December&#160;31, 2020, 2019 and 2018, respectively. </div></div>  <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental data&#8212;major customers: </div></div></div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the percentage of consolidated third party net sales to Teva&#8217;s major customers during the years ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage&#160;of&#160;Third&#160;Party&#160;Net&#160;Sales</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">McKesson Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AmerisourceBergen Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of Teva&#8217;s revenues from these customers were in the North America segment. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment&#8212;by geographical location were as follows: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Israel</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,611</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">864</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Croatia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">539</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Germany</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">665</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Czech republic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hungary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ireland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">267</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property, plant and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,436</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489818168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurement</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 20 &#8212;Fair value measurement: </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial items carried at fair value as of December&#160;31, 2020 and 2019 are classified in the tables below in one of the three categories described in note 1f: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Equity securities*</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">259</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, mainly debt securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Asset derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liabilities derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(79</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(79</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Contingent consideration**</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(268</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(268</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,207</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(258</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,153</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,398</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,398</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, mainly debt securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Asset derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liability derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liabilities derivatives&#8212;interest rate and cross-currency swaps</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(22</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(22</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Contingent consideration**</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(460</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(460</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,019</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(31</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(448</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,540</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of 2020, Teva recorded a gain of $134&#160;million under share in profits of associated companies, net, reflecting the difference between the book value of Teva&#8217;s investment in American Well&#160;and its fair value as of the date it completed its initial public offering in September 2020. The investment was reclassified from &#8220;investment in associated companies&#8221; to &#8220;investment in marketable securities,&#8221; since Teva no longer ha<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div>&#160;significant influence in American Well. <div style="letter-spacing: 0px; top: 0px;;display:inline;">This represented a transfer into Level 3 measurement within fair value hierarchy. By&#160;</div>December&#160;31,&#160;2020,&#160;Teva recorded an&#160;additional&#160;gain&#160;of&#160;$80&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million under financial expenses, net, reflecting the revaluation gain of this security as of December 31, 2020 and transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate.&#160;</div></div></div></div> </td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Due to management&#8217;s intention and ability to sell this security in the next twelve months, the balance as of December&#160;31, 2020 was reclassified to short term investments. </div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">**</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></div> </td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor ranging from 80% to 100% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&amp;D. The discount rate applied ranged from 7.5% to 8.0%. The weighted average discount rate, calculated based on the relative fair value of Teva&#8217;s contingent consideration liabilities, was 7.7%. <div style="letter-spacing: 0px; top: 0px;;display:inline;">The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities.&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The fair value measurement of the investment in equity securities is based on a discount rate for fair value measurement, related to restriction of sale of shares, and thus represents a Level 2 measurement within the fair value hierarchy. The discount rate applied for the fair value measurement at December 31, 2020 was</div>&#160;4%.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(448</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(497</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Transfer into Level 3- equity securities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">179 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revaluation of equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">80</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revaluation of debt securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Reclassification to Level 2- equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(259</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;">Adjustments to provisions for contingent consideration:</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Actavis Generics transaction</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">156 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Eagle transactio<div style="display:inline;">n</div></div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(75</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(151</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;">Settlement of contingent consideration:</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Eagle transaction</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">111 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(258</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(448</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Teva&#8217;s financial instruments consist mainly of cash and cash equivalents, investments in securities, current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> receivables, short-term credit, accounts payable and accruals, loans and senior notes, convertible senior debentures and derivatives. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The fair value of the financial instruments included in working capital and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> receivables approximates their carrying value. The fair value of long-term bank loans mostly approximates their carrying value, since they bear interest at rates close to the prevailing market rates.</div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments not measured at fair value </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value consist of senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value:&#160;&#160;&#160;&#160; </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes included under long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,684</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,686 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,891</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,004 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; margin-left: 13%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489783032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Employee-related Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermEmployeeRelatedObligationsTextBlock', window );">Long-term Employee-related Obligations</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 21&#8212;Long-term employee-related obligations: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term employee-related obligations consisted of the following: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued severance obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined benefit plans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">241 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020 and 2019, Teva had $86 million and $82 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, deposited in funds managed by financial institutions and earmarked by management to cover severance pay liability. Such deposits are not considered to be &#8220;plan assets&#8221; and are therefore included in other non-current assets.&#160;</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of the change resulted from actuarial updates, as well as from exiting from several defined benefit plans in several countries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to expense an approximate contribution of $116 million in 2021 to pension funds and insurance companies in connection with its severance and pension pay obligations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The main terms of the different arrangements with employees are described in below. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Terms of arrangements: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Israel </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Parent Company and its Israeli subsidiaries make ongoing deposits into employee pension plans to fund their severance liabilities. Generally, employees that joined the Company after 2005, have signed an arrangement, pursuant to which such deposits are made in lieu of the Company&#8217;s severance liability. Therefore, no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who were employed by the Parent Company and its Israeli subsidiaries prior to that date, as well as employees who have special contractual arrangements, are provided for in the financial statements based upon the number of years of service and the latest monthly salary of such employees. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Europe </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of the employees in the Company&#8217;s European subsidiaries are entitled to a retirement grant when they leave the Company. In the consolidated financial statements, the liability of the European subsidiaries is accrued, based on the length of service and remuneration of each employee at the balance sheet date. Other employees in Europe are entitled to a pension according to a defined benefit scheme providing benefits based on final or average pensionable pay or according to a hybrid pension scheme that provides retirement benefits on a defined benefit and a defined contribution basis. Independent certified actuaries value these schemes and determine the rates of contribution payable. Pension costs for the defined benefit section of the scheme are accounted for on the basis of charging the expected cost of providing pensions over the period during which the subsidiaries benefit from the employees&#8217; services. The Company uses December&#160;31 as the measurement date for defined benefit plans. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">North America </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s North American subsidiaries mainly provide various defined contribution plans for the benefit of their employees. Under these plans, contributions are based on specified percentages of pay. Additionally, a multi-employer plan is maintained in accordance with various union agreements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Latin America </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The majority of the employees in Latin America are entitled to severance under local law. The severance payments are calculated based on service term and employee remuneration, and accruals are maintained to reflect these amounts. In some Latin American countries it is Teva&#8217;s practice to offer retirement health benefits to qualifying employees. Based on the specific plan requirements, benefits accruals are maintained to reflect the estimated amounts or adjusted if future plans are modified. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to pay the following future minimum benefits to its employees: $13 million in 2021; $12 million in 2022; $12 million in 2023; $11 million in 2024; $12 million in 2025 and $65 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million in the aggregate between 2026 to 2030. These amounts do not include amounts that may be paid to employees who cease working with the Company before their normal retirement age.</div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermEmployeeRelatedObligationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Employee Related Obligations [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermEmployeeRelatedObligationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489595416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SelectedQuarterlyFinancialDataTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 22&#8212;Selected quarterly financial data (unaudited): </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents selected unaudited quarterly financial data for 2020 and 2019:</div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2020</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">4th&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">3rd&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2nd&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">1st&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">U.S $ in millions (except per share amounts)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,978</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,870 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,357</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,048</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,763</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,340</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">0.14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">0.14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2019</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">4th quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">3rd quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2nd quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">1st quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">U.S $ in millions (except per share amounts)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,149</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(307</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(671</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(97</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(314</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(689</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(314</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(689</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SelectedQuarterlyFinancialDataTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selected Quarterly Financial Data [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SelectedQuarterlyFinancialDataTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478753096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule of Valuation and Qualifying Accounts</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Column A</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Column&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Column C</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Column D</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Column&#160;E</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at<br/>beginning<br/>of period</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charged&#160;to&#160;costs<br/>and&#160;expenses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Charged&#160;to&#160;other<br/>accounts</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;end<br/>of&#160;period</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for doubtful accounts:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">232</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(16</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">232</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">232</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance in respect of carryforward tax losses and deductions that may not be utilized:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(97</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(214</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ended December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">407</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(283</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,633</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490700808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_GeneralOptionsAccountingPolicyPolicyTextBlock', window );">General</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva Pharmaceutical Industries Limited (the &#8220;Parent Company&#8221;), headquartered in Israel, together with its subsidiaries and associated companies (the &#8220;Company,&#8221; &#8220;Teva&#8221; or the &#8220;Group&#8221;), is engaged in the development, manufacturing, marketing and distribution of generics, specialty medicines and biopharmaceuticals. The majority of the Group&#8217;s revenues are in the United States and Europe. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of presentation and use of estimate<div style="display:inline;">s</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In preparing the Company&#8217;s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and recoverability of intangible assets and goodwill; assessing sales reserves and allowances in the United States, and contingent consideration; assessing compliance with debt covenants; uncertain tax positions, valuation allowances, contingencies, inventory valuation and restructuring. The inputs into Teva&#8217;s judgments and estimates also consider the economic implications of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&amp;D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva&#8217;s employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic within its financial statements may change in future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Functional currency </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A major part of the Group&#8217;s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (&#8220;dollar&#8221; or &#8220;$&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year. Differences resulting from translation are presented as other comprehensive income (loss) in the consolidated statements of comprehensive income (loss). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of consolidation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and VIEs for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders&#8217; interests are shown as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interests<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, are carried on the equity basis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New accounting pronouncements </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently adopted accounting pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-04</div> &#8220;Reference Rate Reform (Topic 848)&#8212;Facilitation of the Effects of Reference Rate Reform on Financial Reporting.&#8221; This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March&#160;12, 2020 through December&#160;31, 2022. There was no impact to the Company&#8217;s consolidated financial statements for the period ended December&#160;31, 2020 as a result of adopting this standard update. The Company is continuing to evaluate the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities and has started initial negotiations to transform the facility base rate of its securitization program. However, it is not expected to have a material impact on the consolidated financial results. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In April 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-04</div> &#8220;Codification Improvements to Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 825).&#8221; This ASU provides clarifications of three topics related to financial instruments accounting. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> &#8220;Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606.&#8221; The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i)&#160;addresses when the participant should be considered a customer in the context of a unit of account, (ii)&#160;adds <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">unit-of-account</div></div> guidance in ASC 808 to align with guidance in ASC 606 and (iii)&#160;precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> &#8220;Intangibles&#8212;Goodwill and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other&#8212;Internal-use</div> software (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40):</div> Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.&#8221; This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software. Teva applied the guidance prospectively to all implementation costs incurred after the date of adoption. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> &#8220;Fair Value Measurement (Topic 820)&#8212;Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement.&#8221; This guidance removes certain disclosure requirements related to the fair value hierarchy, modifies existing disclosure requirements related to measurement uncertainty and adds new disclosure requirements. The new disclosure requirements include disclosing the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level&#160;3 fair value measurements held at the end of the reporting period and the range and weighted average of significant unobservable inputs used to develop Level&#160;3 fair value measurements. Certain disclosures required by this guidance must be applied on a retrospective basis and others on a prospective basis. Teva adopted the provisions of this update as of January&#160;1, 2020 with no material impact on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> &#8220;Financial Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Upon adoption of the standard, there was no immediate impact to the Company&#8217;s financial position, results of operations or cash flows. On an ongoing basis, the Company will contemplate forward-looking economic conditions in recording lifetime expected credit losses for the Company&#8217;s financial assets measured at cost, such as the Company&#8217;s trade receivables and certain short-term investments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently issued accounting pronouncements, not yet adopted </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> &#8220;Debt &#8211; Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> &#8220;Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes&#8221; (the &#8220;update&#8221;). The amendments in this update simplify the accounting for income taxes by removing the following exceptions in ASC 740: (1) exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items; (2)&#160;exception to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment; (3)&#160;exception to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary; and (4)&#160;exception to the general methodology for calculating income taxes in an interim period when a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss exceeds the anticipated loss for the year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the update also simplifies the accounting for income taxes in certain topics as follows: (1)&#160;requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-income-based</div> tax; (2)&#160;requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; (3)&#160;specifying that an entity can elect (rather than be required to) allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; and (4)&#160;requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2020. The </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company reviewed the above topics, noting that Items (1)&#160;and (4) of this paragraph are expected to be relevant, but not material. The adoption of this guidance will not have a significant impact on the Company&#8217;s consolidated financial statements. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s consolidated financial statements include the operations of acquired businesses from the date of the acquisition&#8217;s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired in process research and development (&#8220;IPR&amp;D&#8221;) be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> at each reporting period, with any adjustments in fair value recognized in earnings under other assets impairments, restructuring and other items. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative arrangements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative arrangements: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborative agreements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues are recorded on a net basis. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_EquityAndCostMethodInvestmentPolicyTextBlock', window );">Equity investments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">e.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity investments: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative prescribed within ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-01</div> &#8220;Financial Instruments&#8212;Recognition and Measurement of Financial Assets and Financial Liabilities&#8221; to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">f.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurement: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investment in debt securities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">g.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in debt securities: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Investment in securities consists of debt securities classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and recorded at fair value. The fair value of quoted securities is based on current market value. When debt securities do not have an active market, fair value is determined using a valuation model. This model is based on reference to other instruments with similar characteristics, or a discounted cash flow analysis, or other pricing models making use of market inputs and relying as little as possible on entity-specific inputs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s investment in debt securities accounting policy until December&#160;31, 2019, prior to the adoption of the new Current Expected Credit Losses (&#8220;CECL&#8221;) standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gains of available for sale debt securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for debt securities are included in financial expenses, net. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s investment in debt securities accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unrealized gains and losses for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are excluded from earnings and reported net of the related tax effect in the accumulated other comprehensive income component of shareholders&#8217; equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The CECL methodology, which became effective January&#160;1, 2020, requires the Company to estimate lifetime expected credit losses for all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities in an unrealized loss position. </div>Comparative information continues to be reported in accordance with the methodology in effect for prior periods. When estimating a security&#8217;s probability of default and the recovery rate, the Company assesses the security&#8217;s credit indicators, including credit ratings. If the assessment indicates that an expected credit loss exists, the Company determines the portion of the unrealized loss attributable to credit deterioration and records an allowance for the expected credit loss through the Consolidated Statements of Income. Unrealized gains and any portion of a security&#8217;s unrealized loss attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-credit</div> losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">h.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AccountsReceivablesPolicyTextBlock', window );">Accounts receivables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">i.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s accounts receivables accounting policy until December&#160;31, 2019, prior to the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables are stated at their net realizable value. The allowance against gross accounts receivables reflects the best estimate of losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. An allowance for doubtful debts is reflected in net accounts receivables. Accounts receivables are written off after all reasonable means to collect the full amount have been exhausted. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s accounts receivables accounting policy from January&#160;1, 2020, following the adoption of the new CECL standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Write-off</div> activity and recoveries for the periods presented were not material. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">j.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of credit risks: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of Teva&#8217;s cash and cash equivalents (which, along with investment in securities, totaled $2,478&#160;million at December&#160;31, 2020) were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pharmaceutical industry, particularly in the United States, has been significantly affected by consolidation among managed care providers, large pharmacy chains, wholesaling organizations and other buyer groups. The U.S. market constituted approximately 48% of Teva&#8217;s consolidated revenues in 2020. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">k.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Inventories acquired in a business combination are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stepped-up</div> to their estimated fair value and amortized to cost of sales as that inventory is sold. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">l.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva&#8217;s long-lived, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets are comprised mainly of goodwill, identifiable intangible assets, property, plant and equipment, and operating lease ROU assets. All long-lived assets are monitored for impairment indicators throughout the year. Impairment testing for goodwill and all indefinite-lived intangible assets is performed at least annually. When necessary, charges for impairments of long-lived assets, other than goodwill, are recorded for the amount by which the fair value is less than the carrying value of these assets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest in the acquiree, over the assigned fair values of the identifiable net assets acquired. Goodwill is not amortized, and is assigned to reporting units and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has historically performed its annual goodwill assessment during the fourth quarter of each year. During the second quarter of 2020, the Company decided to change the date of its annual impairment assessment from October&#160;1 to June 30. The change was made to more closely align the impairment assessment date with the Company&#8217;s long-term planning and forecasting process. See note 7. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The goodwill impairment test is performed according to the following principles: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value is recognized. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company&#8217;s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company&#8217;s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Identifiable intangible assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (&#8220;S&amp;M&#8221;) expenses when separable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite life intangible assets are mainly comprised of IPR&amp;D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. Teva determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IPR&amp;D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset&#8217;s estimated life, calculates the undiscounted value of the asset&#8217;s or asset group&#8217;s cash flows and compares such value against the asset&#8217;s or asset group&#8217;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company&#8217;s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i)&#160;for IPR&amp;D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii)&#160;for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, plant and equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly between 15 to 20 years; and other assets, between 5 to 10 years. </div>&#160;</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For property, plant and equipment and lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, whenever impairment indicators are identified, Teva reconsiders the asset&#8217;s estimated life, calculates the undiscounted value of the asset&#8217;s cash flows and compares such value against the asset&#8217;s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See note 8 and note 1 cc for further discussion. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">m.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingencies: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. Legal costs are expensed as incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_TreasurySharesPolicyTextBlock', window );">Treasury shares</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">n.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treasury shares: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treasury shares are presented as a reduction of Teva shareholders&#8217; equity and carried at their cost to Teva, under treasury shares. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">o.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (&#8220;RSUs&#8221;) and performance share units (&#8220;PSUs&#8221;). The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva measures compensation expense for the RSUs and PSUs based on the market value of the underlying stock at the date of grant, less an estimate of dividends that will not accrue to the RSU and PSU holders prior to vesting. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Deferred income taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">p.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Deferred income taxes are determined utilizing the &#8220;asset and liability&#8221; method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax has not been provided on the following items: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company&#8217;s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Amounts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> income generated from the Company&#8217;s current Approved Enterprises and unremitted earnings from foreign subsidiaries retained for reinvestment in the Group. See note 13 f. </div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxesUncertaintiesPolicyTextBlock', window );">Uncertain tax positions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">q.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncertain tax positions: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> its tax positions based on developments in its tax audits, statute of limitations expirations, changes in tax laws and new information that can affect the technical merits and change the assessment of Teva&#8217;s ability to sustain the tax benefit. In addition, the Company classifies interest and penalties recognized in the financial statements relating to uncertain tax position under the income taxes line item. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives and hedging</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">r.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives and hedging: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company&#8217;s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative instruments are recognized on the balance sheet at their fair value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net in the statements of income in the period that the changes in fair value occur. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For derivative instruments that are designated as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-investment</div> hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income. The effective portion is determined by looking into changes in spot exchange rate. The change in fair value attributable to changes other than those due to fluctuations in the spot exchange rate are excluded from the assessment of hedge effectiveness and are recognized in the statement of income under financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. </div></div>Derivative instruments that do not qualify for hedge accounting are recognized on the Balance Sheet at their fair value, with changes in the fair value recognized as a component of financial expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">s.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognition: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (&#8220;SR&amp;A&#8221;) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&amp;A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&amp;A components and how they are estimated, see &#8220;Variable Consideration&#8221; below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&amp;M expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> year or less, based on the practical expedient. The Company&#8217;s credit terms to customers are, on average, between <span style="-sec-ix-hidden:hidden17702468">thirty</span> and ninety days. </div>&#160;</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&amp;M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of revenue streams </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements performance obligations generally include intellectual property (&#8220;IP&#8221;) rights, certain R&amp;D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct&#8212;i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company&#8217;s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s IP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Revenues from licensing arrangements included royalty income of $129 million, $147 million and $165 million for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specifies goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenues are primarily comprised of contract manufacturing services, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets and liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contract liabilities are mainly comprised of deferred revenues which were immaterial as of December&#160;31, 2020 and 2019. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable consideration mainly includes SR&amp;A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rebates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-established</div> volumes or the attainment of revenue milestones for a specified period, the customer receives a rebate. Since rebates are contractually agreed upon, they are estimated based on the specific terms in each agreement based on historical trends and expected sales. Externally obtained inventory levels and expected sales usage by contract are evaluated in relation to estimates made for rebates payable to indirect customers and managed care agreements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medicaid and Other Governmental Rebates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer&#8217;s price for generic products dispensed and &#8220;best price&#8221; for specialty products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chargebacks </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva&#8217;s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva&#8217;s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a &#8220;chargeback&#8221;) to the wholesaler for the difference between the invoice price to the wholesaler and the customer&#8217;s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers and, therefore, will not necessarily fluctuate in proportion to an increase or decrease in sales. Provisions for estimating chargebacks are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Teva considers current and expected price competition when evaluating the provision for chargebacks. Chargeback provisions are compared to externally obtained distribution channel reports for reasonableness. The Company regularly monitors the provision for chargebacks and makes adjustments when the Company believes that actual chargebacks may differ from estimated provisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Promotional Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other promotional or incentive arrangements are periodically offered to customers, specifically related to the launch of products or other targeted promotions. Provisions are made in the period for which the Company can estimate the incentive earned by the customer, in accordance with the contractual terms. The Company regularly monitors the provision for other promotional arrangements and makes adjustments when it believes that the actual provision may differ from the estimated provisions. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shelf Stock Adjustments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers&#8217; existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. Teva regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Returns primarily relate to customer returns of expired products which, the customer has the right to return up to one year following the expiration date. Such returned products are destroyed and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recoded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, The Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies or packaging and any changes to customer terms, for determining the overall expected levels of returns. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prompt Pay Discounts </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prompt pay discounts are offered to most customers to encourage timely payment. Discounts are estimated at the time of invoice based on historical discounts in relation to sales. Prompt pay discounts are almost always utilized by customers. As a result, the actual discounts do not vary significantly from the estimated amount. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">t.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses are charged to statement of income (loss) as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Upfront fees received in connection with cooperation agreements are deferred and recognized over the period of the applicable agreements as a reduction of research and development expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are delivered or the services are performed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CostOfShippingAndHandlingPolicyTextBlock', window );">Shipping and handling costs</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">u.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs, which are included in S&amp;M expenses, were $124 million, $138 million and $159 million for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, respectively. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising costs</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">v.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advertising costs are expensed as incurred. Advertising costs for the years ended December&#160;31</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2020</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2019</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> and 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> were $225 million, $213&#160;million and $256 million, respectively. </div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringTextBlock', window );">Restructuring</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">w.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual termination benefits are provided to employees when employment is terminated due to an event specified in the provisions of an existing plan or agreement. A liability is recorded and the expense is recognized when it is probable that employees will be entitled to the benefits and the amount is reasonably estimable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Special termination benefits arise when the Company offers, for a short period of time, to provide certain additional benefits to employees electing voluntary termination. A liability is recorded and the expense is recognized in the period the employees irrevocably accept the offer and the amount of the termination liability is reasonably estimable. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">x.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment reporting: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s business includes three reporting segments based on three geographical areas: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment, which includes the United States and Canada. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment, which includes the European Union and certain other European countries. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment, which includes all countries in which Teva operates other than those in the North America and Europe segments. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each business segment manages the entire product portfolio in its region, including generics, specialty and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> (&#8220;OTC&#8221;) products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licensing</div> platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">y.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic earnings per share are computed by dividing the net income attributable to ordinary shareholders by the weighted average number of ordinary shares (including fully vested RSUs and PSUs) outstanding during the year, net of treasury shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> RSUs and PSUs granted under employee stock compensation plans and one series of convertible senior debentures, using the treasury stock method; (ii)&#160;the conversion of the remaining convertible senior debentures using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;if-converted&#8221;</div> method, by </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">adding to net income interest expense on the debentures and amortization of issuance costs, net of tax benefits, and by adding the weighted average number of shares issuable upon assumed conversion of the debentures; and (iii)&#160;until December&#160;17, 2018, the conversion of the mandatory convertible preferred shares (&#8220;MCPS&#8221;) using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;if-converted&#8221;</div> method by adding to net income attributable to ordinary shareholders the dividends on the preferred shares and by adding the weighted average number of shares issuable upon assumed conversion of the mandatory convertible preferred shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;17</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, 2018</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">, the mandatory convertible preferred shares automatically converted into ordinary shares. As a result of this conversion, Teva issued 70.6&#160;million ADSs. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">See note 14</div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SecuritizationTextBlock', window );">Securitization</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">z.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securitization </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva accounts for transfers of certain of its trade receivable as sales when it has surrendered control over the related assets in accordance with ASC Topic 860 &#8220;Transfer and Servicing&#8221; of Financial Assets. Whether control has been relinquished requires, among other things, an evaluation of relevant legal considerations and an assessment of the nature and extent of the Company&#8217;s continuing involvement with the assets transferred. Assets obtained and liabilities incurred in connection with transfers reported as sales are initially recognized in the balance sheet at fair value. Refer to note 10 f. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DivestituresTextBlock', window );">Divestitures</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">aa.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Divestitures </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company nets the proceeds on the divestitures of products with the carrying amount of the related assets and records gain or loss on sale within other income. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when it is probable that a significant reversal of income will not occur, or in the case of a business, when such payments are realizable. For divestures of businesses, including divestitures of products that qualify as a business, the Company reflects the relative fair value of goodwill associated with the businesses in the determination of gain or loss on sale. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt instruments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">bb.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt instruments </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Debt instruments are initially recognized at the fair value of the consideration received. Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liability. They are subsequently recognized at amortized cost using the effective interest method. Debt may be considered extinguished when it has been modified and the terms of the new debt instruments and old debt instruments are &#8220;substantially different&#8221; (as defined in the debt modification guidance in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div> &#8220;Debt&#8212;Modifications and Extinguishments&#8221;). The Company classifies the current portion of long term debt as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities on the Balance Sheet when it has the intent and ability to refinance the obligation on a long-term basis, in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div> &#8220;Debt&#8221;. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">cc.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s lease accounting policy until December&#160;31, 2018, prior to the adoption of the new lease standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva leases real estate, cars and equipment for use in its operations, which are classified as operating leases. In addition to rent, the leases may require Teva to pay directly for fees, insurance, maintenance and other operating expenses. Rental expense for the year ended December&#160;31, 2018 was $175&#160;million. The Company also has capital leases for properties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Company&#8217;s lease accounting policy from January&#160;1, 2019, following the adoption of the new lease standard </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva adopted the new accounting standard ASC 842 &#8220;Leases&#8221; and all the related amendments on January&#160;1, 2019 and used the effective date as Teva&#8217;s date of initial application. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">842-10-25-2.</div></div></div> If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva&#8217;s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets, other current liabilities and operating lease liabilities in the consolidated balance sheets. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated balance sheets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets represent Teva&#8217;s right to use an underlying asset for the lease term and lease liabilities represent Teva&#8217;s obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Teva uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For finance leases, Teva recognizes interest on the lease liability separately from amortization of the ROU assets in the statement of comprehensive income. For operating leases, lease expenses are recognized on a straight-line basis over the lease term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The new standard also provides practical expedients for an entity&#8217;s ongoing accounting. Teva elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, Teva does not recognize ROU assets or lease liabilities, including ROU assets or lease liabilities for existing short-term leases of assets in transition, but recognizes lease expenses over the lease term on a straight line basis. Teva also elected the practical expedient to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for all of Teva&#8217;s leases, other than leases of real estate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease terms will include options to extend or terminate the lease when it is reasonably certain that Teva will either exercise or not exercise the option to renew or terminate the lease. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Teva&#8217;s lease agreements have remaining lease terms ranging from 1 year to 78 years. Some of these agreements include options to extend the leases for up to </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> years and some include options to terminate the leases immediately. Certain leases also include options to purchase the leased property. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of Teva&#8217;s vehicle lease agreements include rental payments based on the actual usage of the vehicles and other lease agreements include rental payments adjusted periodically for inflation. Teva&#8217;s lease agreements do not contain any material residual value guarantees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The new lease standard has no impact on Teva&#8217;s debt-covenant compliance under its RCF. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AccountsReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivables [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AccountsReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CostOfShippingAndHandlingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of shipping and handling policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CostOfShippingAndHandlingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DivestituresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DivestituresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_EquityAndCostMethodInvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element describes an entity's application of the equity method of accounting to investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The description provided may include a description of how equity method or cost investments are assessed for impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_EquityAndCostMethodInvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_GeneralOptionsAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General options accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_GeneralOptionsAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncomeTaxesUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an entity's accounting policy for tax positions taken in the Company's tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of contingencies related to income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncomeTaxesUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SecuritizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securitization [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SecuritizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_TreasurySharesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes how the entity's previously issued shares that were reacquired by the entity are presented in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_TreasurySharesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for whether provision for loss for performance obligation was determined at contract or performance obligation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -Section 25<br> -Paragraph 47<br> -URI http://asc.fasb.org/extlink&amp;oid=108311418&amp;loc=d3e55442-111641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489784456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock', window );">Summary of Major Classes of Assets and Liabilities Included as Held for Sale</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below summarizes all Teva assets included as held for sale as of December&#160;31, 2020 and December&#160;31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 76%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">146</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net and others</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">312</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">98</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments of assets held for sale to fair value</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">(296</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">189</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;;width:5%;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;;width:1%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;;width:1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;;width:5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width:1%;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Assets And Liabilities Held For Sale [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489975640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from contracts with customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of disaggregates revenues by major revenue streams</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table disaggregates Teva&#8217;s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;activities</div></div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6,902</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,736</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,946</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">772</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14,354</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">84</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">32</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">129</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,462</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,495</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(14</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">169</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">527</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">680</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,447</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,757</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,154</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,302</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16,659</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div> </td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">activities</div></div></div> </td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); padding: 0pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding: 0pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,941</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,770</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,045</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">754</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,492</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#167;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">545</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">716</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,542</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,795</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,246</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,304</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,887</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0pt; width: 0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 2%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 2%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 2%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 2%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;America</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">activities</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of goods</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,838</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,153</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,151</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">739</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Licensing arrangements</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,347</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">230</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">618</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,297</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,186</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,422</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,366</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#167;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $1&#160;million. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SalesReservesAndAllowancesCurrentTableTextBlock', window );">Summary of Sales Reserves and Allowances</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR&amp;A to U.S. customers comprised approximately 79% of the Company&#8217;s total SR&amp;A as of December&#160;31, 2020, with the remaining balance primarily in Canada and Germany. The changes in SR&amp;A for third-party sales for the period ended December&#160;31, 2019 and 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="26" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sales Reserves and Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reserves<br/> included in<br/> Accounts<br/> Receivable,&#160;net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Rebates</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Medicaid and<br/> other<br/> governmental<br/> allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Chargebacks</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Returns</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> reserves<br/> included in<br/> Sales<br/> Reserves<br/> and<br/> Allowances</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="30" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at January 1, 2019</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,006</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,361</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,530</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">638 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6,711</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6,886</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year period</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">383</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">5,552</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">976</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">9,565</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">281 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">16,767</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">17,150</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(92</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(151</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(17</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(189</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(189</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(471</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(5,570</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,076</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(9,736</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(360</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(392</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(17,134</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(17,605</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2019</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%; border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">2,895</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,109</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">1,342</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">176</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">6,159</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">6,246</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in current year period</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">391</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">4,703</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">744</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">8,438</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">459</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">14,415</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">14,806</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:2%;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"/> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions related to sales made in prior periods</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(219</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(184</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(65</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(28</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(497</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(497</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credits and payments</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(398</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(5,360</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(849</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(8,614</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(386</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(100</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(15,309</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(15,707</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">56</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 39%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2020</div> </td>
<td style="vertical-align: bottom; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,054</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">828</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,108</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">686</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">4,824</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">4,904</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 39%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 2%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowancesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of sales reserves and allowances current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowancesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478797304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories, net of reserves, consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished products</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$2,378 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$2,504 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw and packaging materials</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Products in process</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials in transit and payments on account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">189</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-size: 10pt;;text-align:right;">$4,403 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$4,422 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489605080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property, Plant and Equipment, Net</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment, net, consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and equipment</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">5,245</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">5,385</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;">2,720</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,839</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and other assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">2,197</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,131</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets under construction and payments on account</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;">933</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">672</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Land</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">292</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">323</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">11,388</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">11,350</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less&#8212;accumulated depreciatio<div style="letter-spacing: 0px; top: 0px;;display:inline;">n</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 3%;;text-align:right;">(5,092</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(4,914</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 3%;;text-align:right;">$6,296</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">$6,436 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 84%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478797304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Identifiable Intangible Assets</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable intangible assets consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;carrying&#160;amount<br/> net of impairment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;carrying&#160;amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2019&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="22" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Product rights</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,650</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;">19,663</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,094</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,640</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">7,556</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,023</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Trade names</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">621</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;">600</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">126</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">456</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">474</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">In-process research and development (IPR&amp;D)</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">911</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;">1,735</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160; </div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">911</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,735</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,182</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;;text-align:right;">21,998</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,259</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,766</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,923</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,232</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 2%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 2%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;width:1%;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642602123992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of Changes in the Carrying Amount of Goodwill by Segment</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 0.5%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td style="width: 0.5%;"/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North<br/> America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International<br/> Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 201</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(1)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">11,098</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">8,653</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,479</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,687</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">24,917</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwil</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">l </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">disposal</div><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(23</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(28</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:3%;">(112</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%; padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">(43</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019 (1)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">11,091</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">8,536</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,532</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,687</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">24,846</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Changes during the period:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwill reclassified as assets held for sale</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(27</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(4,628</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(4,628</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Translation differences</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">574</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(151</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> </div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">433</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:3%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0pt; width: 0.5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgb(204, 238, 255); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of <div style="letter-spacing: 0px; top: 0px;;display:inline;">December </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">31</div>, 2020 (1)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">6,473</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">9,102</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,362</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,687</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">20,624</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 58%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap; width: 0.5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 0.5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accumulated goodwill impairment as of December&#160;31, 2020, December&#160;31, 2019 and December&#160;31, 2018 was approximately $25.6&#160;billion, $21.0&#160;billion and $21.0&#160;billion, respectively. </div></div></div></div></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642720678200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ComponentsOfLeaseExpenseTableTextBlock', window );">Components Of Lease Expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease cost for the year ended December&#160;31, 2020 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 16%;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost:</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed payments and variable payments that depend on an index or rate</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease payments not included in the lease liability</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;">&#160;</td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; width: 16%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$155</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$178</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SupplementalCashFlowInformationTableTextBlock', window );">Supplemental cash flow information related to leases</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to operating leases was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 16%;"/>
<td style="vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended<br/> December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">169</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for lease obligations <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-cash):</div></div></td>
<td style="vertical-align: bottom; width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 60%; padding-bottom: 2.2pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom; width: 16%; padding-bottom: 2.2pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;">211</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 16%; padding-bottom: 2.2pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2.2pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 2.5pt double black;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2.5pt double black;;text-align:right;">142</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock', window );">Supplemental Balance Sheet Information Related To Leases</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental balance sheet information related to operating leases was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease ROU assets</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">559</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">116</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">479</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">595</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">553</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 18%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="width: 17%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">7.5&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">7.5&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">5.2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Maturities of lease liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2025 and thereafter</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">302 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease payments</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">722 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">595 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 15%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ComponentsOfLeaseExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ComponentsOfLeaseExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486612296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term debt: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> interest rate as of<br/> December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible debentures</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap; width: 7%; text-align: center;">0.25%</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2026</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">514</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">514</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="5" style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current maturities of long-term liabilities</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,674 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,831 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td colspan="5" style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total short term debt</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">3,188 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,345 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock', window );">Schedule of Senior Notes and Loans</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 100%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:57%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> interest rate as of<br/> December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Maturity</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,010&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million (1)</div></div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">0.38</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,131</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,500&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">1.13</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2024</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,839 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,673</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,300&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">1.25</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2023</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,595</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,451</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 900&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">4.50</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,107</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,008</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 750&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">1.63</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2028</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">916 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">833 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 700&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">3.25</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">861 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">784</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 700&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">1.88</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2027</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">860</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">782</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes EUR 1,000&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">6.00</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">1,230</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,120</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,000&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">7.13</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 3,500&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">3.15</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2026</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">3,495</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">3,494 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,475&#160;million&#160;</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);;width:6%;">2.20</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:4%;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,472</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;width:5%;">1,474</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 3,000&#160;million</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0);;width:6%;">2.80</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:4%;">2023</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">2,996</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;;width:5%;">2,995</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 2,000&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">4.10</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2046</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">1,986</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">1,985</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,250&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">6.00</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2024</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 1,250&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">6.75</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2028</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">1,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 844&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">2.95</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">853 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">856</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 789&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">6.15</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2036</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">783 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">782</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 700&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million (2)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">2.25</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">700</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 613&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">3.65</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">616</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">618 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes USD 588&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">3.65</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">586</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">587 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF 350&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">0.50</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:4%;">2022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">397 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">361 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%; padding-bottom: 0.45pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes CHF 350&#160;million</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right; padding-bottom: 0.45pt;;width:6%;">1.00</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; padding-bottom: 0.45pt;;text-align:right;;width:4%;">2025</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;">398</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;;width:5%;">362 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.45pt;;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">25,490 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">26,496</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term debt</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">1.08 </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:4%;">2026</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">1 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less current maturities</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">(2,674</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">(1,831</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less debt issuance costs</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:5%;">(103</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:1%;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total senior notes and loans</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); text-align: right;;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">22,731</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:1%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:5%;">24,562 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 57%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:1%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:5%;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In July&#160;</div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, Teva repaid at maturity &#8364;</div>1,010 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million of its</div>&#160;0.375% <div style="letter-spacing: 0px; top: 0px;;display:inline;">senior notes.</div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March&#160;</div>2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, Teva repaid at maturity $</div>700&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of its</div>&#160;2.25% <div style="letter-spacing: 0px; top: 0px;;display:inline;">senior notes.&#160;</div> </div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the required annual principal payments of long-term debt, excluding debt issuance cost, including convertible senior debentures, starting from the year 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div>, are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">2,111</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">4,591</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3,089</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">202<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,735 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">2026 and thereafter *</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">9,804</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">23,330 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 16%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including $514<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million convertible notes. See note 9a. </div></div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtExcludingConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtExcludingConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642479061864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-currency swap<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net investment hedge</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Values of Derivative Instruments</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification and fair values of derivative instruments: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not designated as hedging</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset derivatives:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">$</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability derivatives:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%; padding: 0pt 4pt 0pt 0pt;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 39%; padding: 0pt; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal; text-align: left; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Cross-currency swaps<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">, </div>net investment<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>hedge</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(22)</div>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 54%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts</div></div> </td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(79</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives designated in fair value or cash flow hedging relationships: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other comprehensive<br/> income&#160;(loss)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018**&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018**&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">834 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">822</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">959</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;">160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(585</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cross-currency swaps&#8212;cash flow hedge (1)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cross-currency swaps<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>net investment hedge (2)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Interest rate swaps&#8212;fair value hedge (3)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparative figures are based on prior hedge accounting standard. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The table below provides information regarding the location and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> (gains) losses from derivatives not designated as hedging instruments: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Financial expenses, net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2019&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2018&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reported under</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Line items in which effects of hedges are recorded</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">834</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">822</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">959</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,887</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts (4)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">130</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option and forward contracts&#160; (5)</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 3%; padding: 0pt 4pt 0pt 0pt;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents an amount less than $0.5&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588&#160;million in cross-currency swap agreements against its </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500&#160;</div> million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva&#8217;s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">float-for-float</div></div> interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3&#160;million. <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500&#160;million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10&#160;million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense. </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. During 2019 and 2020, Teva entered into hedging instruments to hedge part of the projected 2020 operating results. In 2020, Teva recognized a gain of $27&#160;million in relation with the 2020 hedging program. During the second half of 2020, Teva entered into hedging instruments to hedge part of the projected operating results for 2021. As part of the economic hedge treatment, Teva recorded a loss of $27&#160;million in relation to the 2021 hedging instruments in the second half of 2020, while the positive foreign exchange impact on the underlying revenues and expenses, may occur upon their maturity in 2021. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfAccountReceivableFromSecuritization', window );">Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the sold receivables outstanding balance net of DPP asset under the outstanding securitization program: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 0pt;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;and&#160;for&#160;the&#160;year&#160;ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sold receivables at the beginning of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of receivables</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash collections (remitted to the owner of the receivables)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,607</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of currency exchange rate changes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sold receivables at the end of the year</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">734</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfAccountReceivableFromSecuritization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of account receivable from securitization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfAccountReceivableFromSecuritization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642479050856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) before income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 8pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parent Company and its Israeli subsidiaries</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">947</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-Israeli subsidiaries</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,353</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,807</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,265</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of the Provision for Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">b.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In Israel</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outside Israel</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(385</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(326</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(278</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">885</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 57%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(350</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(895</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(278</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(195</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Accumulated Other Comprehensive Income/(Loss) (Net of Tax)</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (Loss) before income taxes</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(4,406</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,265</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(2,596</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory tax rate in Israel</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">23.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">23.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">23.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Theoretical provision for income taxes</div></div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,013</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(291</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(597</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Increase (decrease) in the provision for income taxes due to:</div> </div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-left: 0in; text-indent: 0in; width: 66%;"><div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">The Parent Company and its Israeli subsidiaries - Mainly tax benefits arising from reduced tax rates under benefit programs</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(183</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(44</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Non-Israeli subsidiaries, including impairments *</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,369</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(115</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">381</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Tax Cuts and Jobs Act effect</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">97</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase (decrease) in other uncertain tax positions&#8212;net</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(341</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">172</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective consolidated income taxes</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(168</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(278</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(195</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In 2020 and 2018, income before income taxes includes goodwill impairment in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Israeli</div> subsidiaries that did<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>not have a corresponding tax effect. </div></td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">c.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Long-term deferred tax assets (liabilities), net:</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory related</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">212</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">144</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales reserves and allowances</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">198</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for legal settlements</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">235</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">260</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets (*)</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(1,064</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(1,733</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carryforward losses and deductions and credits (**)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,176</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,689</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(142</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(170</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred interest</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">527</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">648</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provisions for employee related obligations</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">122</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,278</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,264</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance&#8212;in respect of carryforward losses and deductions that may not be utilized&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(2,547</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1,974</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(269</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(710</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 78%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(*)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The decrease in deferred tax liability is mainly due to impairment and amortization. </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(**)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts are shown after reduction for unrecognized tax benefits of $ 63&#160;million and $115 million as of December&#160;31, <div style="letter-spacing: 0px; top: 0px;;display:inline;">2020</div> and <div style="letter-spacing: 0px; top: 0px;;display:inline;">2019</div>, respectively. </div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 0%;line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703734">2021</span></div>-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703735">2022</span></div>&#8212;$79 million; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703736">2023</span></div>-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703738">2029</span></div>&#8212;$663 million; <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden17703737">2030</span> </div>and thereafter&#8212;$171 million. The remaining balance&#8212;$1,327 million&#8212;can be utilized with no expiration date. </div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities By Report Caption</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The deferred income taxes are reflected in the balance sheets among: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term assets&#8212;deferred income taxes</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">695</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term liabilities&#8212;deferred income taxes</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(964</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(269</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(710</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncertain tax positions: </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity of Teva&#8217;s gross unrecognized tax benefits: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto;border: 0px currentcolor;width: 84%;font-family: &quot;Times New Roman&quot;;font-size: 10pt;border-collapse: collapse;border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at the beginning of the year</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,223</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase <div style="letter-spacing: 0px; top: 0px;;display:inline;">(decrease)&#160;</div>related to prior year tax positions, net</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to current year tax positions</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(118</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 70%; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at the end of the year</div></div></td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">888</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,223</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,072</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Domestic And Foreign Income Tax Expense Benefit Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of deferred tax assets and liabilities by report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642479007608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the status of the options granted by Teva as of December&#160;31, 2020, 2019 and 2018, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> exercise<br/> price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,121</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44.32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes during the year:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(84</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expired</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance exercisable at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,601</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43.41</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Summary of Weighted Average Fair Value of Options Granted</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average fair value of options granted during <div style="letter-spacing: 0px; top: 0px;;display:inline;">these</div> years was generally estimated by using the Black-Scholes option-pricing model as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average fair value</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of these options was estimated on the date of grant, based on the following weighted average assumptions: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">%&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2.6</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">%&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">&#8212;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">5 years</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Ordinary Shares Issued Upon Outstanding Options</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 2pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables summarize information as of December&#160;31, 2020 regarding the number of ordinary shares issuable upon (1)&#160;outstanding options and (2)&#160;vested options: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(1) Number of ordinary shares issuable upon exercise of outstanding options</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of exercise prices</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;end&#160;of<br/> period&#160;(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> remaining life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lower than $15.01</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$15.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $25.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,087</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$25.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $35.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$35.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $45.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$45.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $55.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$55.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $65.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,223</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,234</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock', window );">Schedule of Ordinary Shares Issued Upon Vested Options</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 13%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="13" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(2) Number of ordinary shares issuable upon exercise of vested options</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of exercise prices</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;end&#160;of<br/> period&#160;(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> exercise price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;average<br/> remaining life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lower than $15.01</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$15.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $25.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.09</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$25.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $35.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,423</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$35.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $45.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$45.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $55.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 3em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$55.01 <div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>- $65.00</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">59.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 45%;"> <div style="text-indent: -1em;font-family: &quot;Times New Roman&quot;;font-size: 10pt;margin-top: 0pt;margin-bottom: 0pt;margin-left: 5em;line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 45%;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of the Number of RSUs Issued and Outstanding</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes information about the number of RSUs and PSUs <div style="letter-spacing: 0px; top: 0px;;display:inline;">granted</div>&#160;and outstanding: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> average<br/> grant&#160;date<br/> fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at beginning of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,977</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; padding: 0px; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,848</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11.42</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,900</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19.49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">18.18</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,294</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance outstanding at end of year</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13.81</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,977</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses compensation costs are based on the grant-date fair value. For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded stock-based compensation costs as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee stock options</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs and PSUs</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">155</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax effect on stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net effect</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Accumulated Other Comprehensive Income/(Loss) (Net of Tax)</a></td>
<td class="text">The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net Unrealized Gains/(Losses)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Benefit&#160;Plans</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign<br/> currency<br/> translation<br/> adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-</div><br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-sale</div><br/> securities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Derivative<br/> financial<br/> instruments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actuarial<br/> gains/(losses)<br/> and prior<br/> service<br/> (costs)/credits</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 53%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(619</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(91</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,853</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Cumulative effect of new accounting standard**</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(729</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(639</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(729</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212; </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">115</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">(10</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(739</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(611</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2018</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(1,878</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(504</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(78</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">142</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(16</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,794</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(420</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(98</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,312</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income/(loss) before reclassifications</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(190</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified to the statements of income</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; text-align: right; width: 6%; padding: 0pt 5pt 0pt 0pt;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; text-align: right;">&#160;&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) before tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(190</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(152</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Corresponding income tax</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">65</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 53%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Net other comprehensive income/(loss) after tax*</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December&#160;31, 2020</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(1,919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(363</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(2,399</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 53%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $56 million gain in <div style="letter-spacing: 0px; top: 0px;;display:inline;">2020</div>, $14 million gain in <div style="letter-spacing: 0px; top: 0px;;display:inline;">2019</div> and $26<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">million gain in 2018. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the adoption of ASU 2016-01, the Company recorded a $5<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million opening balance reclassification from accumulated other comprehensive income to retained earnings. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488887720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Other Assets Impairments, Restructuring and Other Items</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of long-lived tangible assets <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">416</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">139</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration (see note 2)</div></div> </td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(81</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">59</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 4%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">57</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">488</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(58</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">479</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">423</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">987</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Including impairments related to exit and disposal activities. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfRestructuringChargesTableTextBlock', window );">Summary of Restructuring Plan Including Costs Related to Exit and Disposal</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide the components of costs associated with Teva&#8217;s restructuring plan, including other costs associated with Teva&#8217;s restructuring plan and recorded under different items: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2020</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2019</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2018</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restructuring</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee termination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">488 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring Accruals</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides the components of and changes in the Company&#8217;s restructuring accruals: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee<br/> termination&#160;costs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions )</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January 1, 2019</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(204</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(29</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(233</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(159</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(40</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(199</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other*</div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">155</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">62</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">217</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 66%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(208</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 2.5pt double black;;text-align:right;">(215</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 2.2pt; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr>
<td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Provision</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(71</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;">(49</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;(120</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1.2pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td> </tr>
<tr>
<td style="vertical-align: top; padding-left: 0.26in; width: 66%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Utilization and other</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">164</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">49</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 7%; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">213</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; width: 66%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December 31, 2020</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(115</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(7</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap; text-align: right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(122</div></div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; width: 7%; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes adjustments for foreign currency translation. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfRestructuringChargesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Restructuring Charges [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfRestructuringChargesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642575644664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfOtherIncomeTableTextBlock', window );">Schedule of Other Income</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td style="width: 1%;"/>
<td style="width: 4.5%;"/>
<td style="width: 1%;"/>
<td style="width: 4.5%; vertical-align: bottom;"/>
<td style="width: 1%;"/>
<td style="width: 4.5%;"/>
<td style="width: 1%;"/>
<td style="width: 5.5%; vertical-align: bottom;"/>
<td style="width: 1%;"/>
<td style="width: 4.5%;"/>
<td style="width: 0.5%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on divestitures, net of divestitures related costs (1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;8 and similar payments (2)</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding: 0pt 5pt 0pt 0pt; white-space: nowrap; width: 4.5%;;text-align:right;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212; </div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">195</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain (loss) on sale of assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">9</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 65%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income</div></div></div> </td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;;text-align:right;">291</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="white-space: nowrap; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 5.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; width: 1%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 4.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="width: 0.5%;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mainly related to the divestment of several activities in the International Markets segment. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfOtherIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Other Income Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfOtherIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489595416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial expenses-net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FinancialExpensesNetTableTextBlock', window );">Schedule of Financial Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width:0.5%;"/>
<td style="width:3%;"/>
<td style="width:1%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width:0.5%;"/>
<td style="width:3%;"/>
<td style="width:1%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td style="width:0.5%;"/>
<td style="width:3%;"/>
<td style="width:0.5%;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;ended&#160;December,&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expenses and other bank charges</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">963</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">881</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">920</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from investments (1)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(104</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(39</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Foreign exchange (gains) losses, net</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(26</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">(15</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">13</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, net (2)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding: 0pt 5pt 0pt 0pt; white-space: nowrap;;text-align:right;;width:3%;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:1%;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;;width:3%;">65</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total finance expense, net</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">834</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">822</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;width:0.5%;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;;width:3%;">959</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;width:0.5%;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 76%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:1%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:0.5%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;width:3%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);;width:0.5%;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, Income from investments comprised mainly of revaluation gain of Teva&#8217;s investment in American Well Corporation (&#8220;American Well&#8221;). See note 20. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2018, Other, net comprised mainly of a make-whole payment of $46 million following early redemption of senior notes during 2018. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FinancialExpensesNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Expenses Net Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FinancialExpensesNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490644360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings per Share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December&#160;31, 2020, 2019 and 2018 are as follows: </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December, 31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions,&#160;except&#160;share&#160;data)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) used for the computation of <div style="letter-spacing: 0px; top: 0px;;display:inline;">basic and&#160;</div>diluted <div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(3,990</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(999</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(2,399</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares used in the computation of basic<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">1,095</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">1,091</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">1,021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares used in the computation of diluted <div style="letter-spacing: 0px; top: 0px;;display:inline;">earnings (loss)</div> per share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;">1,095</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;">1,091</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;">1,021</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 66%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487955384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Summary of Segment Profit</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">247</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">427</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 52%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;; white-space: nowrap;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A <div style="letter-spacing: 0px; top: 0px;;display:inline;">expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">2,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">1,331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-top: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-top: 0.75pt solid black;;text-align:right;">474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8,542</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,795</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,246</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,350</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,704</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,167</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">652</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">262</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">88</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">890</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">481</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">439</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">239</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">138</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(14</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,252</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,318</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">464</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table>  <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">North&#160;America</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Europe</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">International&#160;Markets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,297</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5,186</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,422</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,979</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,884</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,254</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">713</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">283</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">96</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">S&amp;M expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,154</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,003</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">518</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">484</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">325</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(209</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 52%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segment profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,837</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,273</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 10%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock', window );">Schedule Of Consolidated Income Before Income Tax</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.$ in millions)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,421</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,252</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,837</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,331</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,318</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,273</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">474</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">464</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total reportable segments profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,225</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,034</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,608</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Profit (loss) of other activities</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">163</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">108</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">115</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total segments profit</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,388</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,142</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,723</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts not allocated to segments:</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,020</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,113</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,166</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; white-space: nowrap; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Other asset impairments, restructuring and other items</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">479</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">423</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">987</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill impairment</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">4,628</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#8212; &#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">3,027</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible asset impairments</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1,502</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1,639</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1,991</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on divestitures, net of divestitures related costs</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(8</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(50</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(66</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Other R&amp;D expenses (income)</div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">37</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(15</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">83</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs related to regulatory actions taken in facilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">23</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">45</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">14</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal settlements and loss contingencies</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">60</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">1,178</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(1,208</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated amounts</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">219</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">252</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">366</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated operating income (loss)</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(3,572</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(443</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(1,637</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial expenses, net</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">834</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">822</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">959</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated income (loss) before income taxes</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(4,406</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(1,265</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">(2,596</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Net Sales by Product Line</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,963</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">134</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AUSTEDO</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENDEKA/TREANDA</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">642</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">884</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProAir*</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">241</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">397</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QVAR</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">182</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anda</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">546</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">708</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,297</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Does not include revenues from the ProAir authorized generic, which are included under generic products. </div></div> </td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,513</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,470</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,593</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">AJOVY</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;">&#160;<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">31</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: right; white-space: nowrap;">&#160;<div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">3</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; text-align: right; padding: 0px; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">400</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">432</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">535</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Respiratory products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">353</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">354</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">402</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">459</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">536</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">656</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 70%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4,757</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">4,795</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">5,186</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); width: 70%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International Markets segment: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generic products</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,792</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,022</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COPAXONE</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">63</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">309</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">291</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">328</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,154</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,246</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,422</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SalesPercentageByTherapeuticCategoryTableTextBlock', window );">Schedule of Sales Percentage by Therapeutic Category</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the percentage of consolidated third party net sales to Teva&#8217;s major customers during the years ended December&#160;31, 2020, 2019 and 2018. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage&#160;of&#160;Third&#160;Party&#160;Net&#160;Sales</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">McKesson Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AmerisourceBergen Corporation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock', window );">Schedule of Property, Plant and Equipment by Geographic Location</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">d.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment&#8212;by geographical location were as follows: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Israel</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,611</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">864</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Croatia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">539</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Germany</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">665</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Czech republic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hungary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ireland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">267</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,501</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property, plant and equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,436</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A schedule indicating where long-lived tangible assets are located.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesPercentageByTherapeuticCategoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A schedule of net sales by therapeutic category, stated as a percentage of total sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesPercentageByTherapeuticCategoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of consolidated income before income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489376312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Items Carried at Fair Value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial items carried at fair value as of December&#160;31, 2020 and 2019 are classified in the tables below in one of the three categories described in note 1f: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Equity securities*</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">259</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, mainly debt securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Asset derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liabilities derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(79</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(79</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Contingent consideration**</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(268</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(268</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,207</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">204</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(258</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">2,153</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money markets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">577</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, deposits and other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,398</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">1,398</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in securities:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">42</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other, mainly debt securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">12</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivatives:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Asset derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liability derivatives&#8212;options and forward contracts</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Liabilities derivatives&#8212;interest rate and cross-currency swaps</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(22</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(22</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Contingent consideration**</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(460</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;;text-align:right;">(460</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">2,019</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(31</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">(448</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;;text-align:right;">1,540</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of 2020, Teva recorded a gain of $134&#160;million under share in profits of associated companies, net, reflecting the difference between the book value of Teva&#8217;s investment in American Well&#160;and its fair value as of the date it completed its initial public offering in September 2020. The investment was reclassified from &#8220;investment in associated companies&#8221; to &#8220;investment in marketable securities,&#8221; since Teva no longer ha<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div>&#160;significant influence in American Well. <div style="letter-spacing: 0px; top: 0px;;display:inline;">This represented a transfer into Level 3 measurement within fair value hierarchy. By&#160;</div>December&#160;31,&#160;2020,&#160;Teva recorded an&#160;additional&#160;gain&#160;of&#160;$80&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million under financial expenses, net, reflecting the revaluation gain of this security as of December 31, 2020 and transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate.&#160;</div></div></div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Due to management&#8217;s intention and ability to sell this security in the next twelve months, the balance as of December&#160;31, 2020 was reclassified to short term investments. </div></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">**</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. </div></div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level&#160;3 inputs. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the beginning of the period</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(448</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(497</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Transfer into Level 3- equity securities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">179 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revaluation of equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">80</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revaluation of debt securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Reclassification to Level 2- equity securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(259</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;">Adjustments to provisions for contingent consideration:</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Actavis Generics transaction</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">156 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Eagle transactio<div style="display:inline;">n</div></div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(75</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; text-align: right; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(151</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;">Settlement of contingent consideration:</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Eagle transaction</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">111 </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(258</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(448</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Instrument Measured on a Basis Other Than Fair Value</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured on a basis other than fair value consist of senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value:&#160;&#160;&#160;&#160; </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated fair value*</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S. $ in millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes included under long-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,684</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,686 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior notes and convertible senior debentures included under short-term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value at the end of the period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,891</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,004 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; margin-left: 13%; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value was estimated based on quoted market prices. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489986952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Employee-related Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermEmployeeRelatedObligationsTableTextBlock', window );">Schedule of Long Term Employee Related Obligation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">a.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term employee-related obligations consisted of the following: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(U.S.&#160;$&#160;in&#160;millions)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued severance obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined benefit plans</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">241 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermEmployeeRelatedObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Employee Related Obligations Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermEmployeeRelatedObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489153128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SelectedQuarterlyFinancialDataTableTextBlock', window );">Selected Quarterly Financial Data</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents selected unaudited quarterly financial data for 2020 and 2019:</div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2020</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">4th&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">3rd&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2nd&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">1st&#160;quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">U.S $ in millions (except per share amounts)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,978</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,870 </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,357</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,048</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,763</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,340</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">0.14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">0.14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2019</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">4th quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">3rd quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">2nd quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">1st quarter</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">U.S $ in millions (except per share amounts)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,177</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,149</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross profit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(307</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(671</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(97</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to Teva</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(314</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(689</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) attributable to ordinary shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(314</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(689</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(105</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share attributable to ordinary shareholders:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.29</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SelectedQuarterlyFinancialDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selected Quarterly Financial Data Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SelectedQuarterlyFinancialDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489368824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional information (Detail) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 17, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions', window );">Cash deposited with financially sound European us and Israeli banks and financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PercentageOfConsolidatedSalesInNorthAmerica', window );">Percentage of consolidated sales in North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShippingHandlingAndTransportationCost', window );">Shipping and handling costs, which are included in selling and marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Ordinary shares issued upon mandatory conversion of preferred shares</a></td>
<td class="nump">70.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating leases rent expense net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva&#8217;s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CreditTermsToCustomers', window );">Credit terms to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OperatingLeaseRemainingLeaseTerm', window );">Operating Lease Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Other Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Other Capitalized Property Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CreditTermsToCustomers', window );">Credit terms to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OperatingLeaseRemainingLeaseTerm', window );">Operating Lease Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">78 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Other Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Other Capitalized Property Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash deposited with financially sound european us and israeli banks and financial institutions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CreditTermsToCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit terms to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CreditTermsToCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PercentageOfConsolidatedSalesInNorthAmerica">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage that sales to external customers in North America are to consolidated net sales for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PercentageOfConsolidatedSalesInNorthAmerica</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ShippingHandlingAndTransportationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shipping, handling and transportation cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ShippingHandlingAndTransportationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478802440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Transactions - Business Transactions - Additional Information (Detail) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Oct. 03, 2016</div></th>
<th class="th"><div>Aug. 02, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=teva_AllerganPlcMember', window );">Allergan plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OneTimeMilestonePaymentReceived', window );">Allergan one time payment to Teva</a></td>
<td class="nump">$ 703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember', window );">Actavis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued as consideration for the acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_AndaMember', window );">Anda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OneTimeMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One Time Milestone Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OneTimeMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=teva_AllerganPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=teva_AllerganPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_ActavisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_AndaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_AndaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486679896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Transactions - Other Transactions - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 08, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 12, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 03, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>Lawsuit</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ImpairmentsRestructuringAndOthers', window );">Other asset impairments, restructuring and other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment', window );">Net (gain) loss from sale of long-lived assets and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=teva_PgtMember', window );">PGT Healthcare Partnership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ImpairmentsRestructuringAndOthers', window );">Other asset impairments, restructuring and other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Write-down of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment', window );">Net (gain) loss from sale of long-lived assets and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_RimsaMember', window );">Rimsa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NumberOfLawsuitsFiled', window );">Number of lawsuits filed | Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_AlderMember', window );">Alder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember', window );">Otsuka [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_CelltrionMember', window );">Celltrion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RefundablePayment', window );">Refundable payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_TotalAssociatedCost', window );">Total associated cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_RegeneronMember', window );">Regeneron [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ResearchAndDevelopmentCosts', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember', window );">Alvotech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems', window );"><strong>Noncash or Part Noncash Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CollaborativeAgreementMilestonePayments', window );">Collaborative agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CollaborativeAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CollaborativeAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentsRestructuringAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairments restructuring and others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentsRestructuringAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_NumberOfLawsuitsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Lawsuits Filed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_NumberOfLawsuitsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ProfitFromSaleOfLongLivedAssetsAndInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit from sale of long lived assets and investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ProfitFromSaleOfLongLivedAssetsAndInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refundable Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_TotalAssociatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Associated Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_TotalAssociatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=teva_PgtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=teva_PgtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_RimsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_RimsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_AlderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_AlderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_CelltrionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_CelltrionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488438968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Transactions - Assets and Liabilities Held For Sale - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charge</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=teva_TevaMember', window );">Teva [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority Interest Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=teva_TevaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=teva_TevaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642480407608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventories</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property, plant and equipment, net and others</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent', window );">Goodwill</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Adjustments of assets held for sale to fair value</a></td>
<td class="num">(296)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total assets of the disposal group classified as held for sale in the consolidated balance sheets</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488490744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SalesReservesAndAllowancesToCustomersPercentage', window );">Percentage sales reserves and allowances to U.S. customers</a></td>
<td class="nump">79.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SalesReservesAndAllowancesToCustomersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales reserves and allowances to customers percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SalesReservesAndAllowancesToCustomersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487478920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 4,454<span></span>
</td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
<td class="nump">$ 4,357<span></span>
</td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 16,659<span></span>
</td>
<td class="nump">$ 16,887<span></span>
</td>
<td class="nump">$ 18,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,354<span></span>
</td>
<td class="nump">14,510<span></span>
</td>
<td class="nump">15,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember', window );">Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">2,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="nump">754<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember', window );">Other activities [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,447<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
<td class="nump">9,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,902<span></span>
</td>
<td class="nump">6,941<span></span>
</td>
<td class="nump">7,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,757<span></span>
</td>
<td class="nump">4,795<span></span>
</td>
<td class="nump">5,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Sale of Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,736<span></span>
</td>
<td class="nump">4,770<span></span>
</td>
<td class="nump">5,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Licensing Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Distribution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_DistributionServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_OtherActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490710488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 6,246<span></span>
</td>
<td class="nump">$ 6,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">14,806<span></span>
</td>
<td class="nump">17,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(497)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(15,707)<span></span>
</td>
<td class="num">(17,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">4,904<span></span>
</td>
<td class="nump">6,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember', window );">Reserves Included in Accounts Receivable, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(398)<span></span>
</td>
<td class="num">(471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember', window );">Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">2,895<span></span>
</td>
<td class="nump">3,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">4,703<span></span>
</td>
<td class="nump">5,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(5,360)<span></span>
</td>
<td class="num">(5,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember', window );">Medicaid and Other Governmental Allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(849)<span></span>
</td>
<td class="num">(1,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember', window );">Chargebacks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">8,438<span></span>
</td>
<td class="nump">9,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(8,614)<span></span>
</td>
<td class="num">(9,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember', window );">Returns [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(386)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember', window );">Total Reserves Included in Sales Reserves and Allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">6,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales', window );">Provisions related to sales made in current year period</a></td>
<td class="nump">14,415<span></span>
</td>
<td class="nump">16,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales', window );">Provisions related to sales made in prior periods</a></td>
<td class="num">(497)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits and payments</a></td>
<td class="num">(15,309)<span></span>
</td>
<td class="num">(17,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation', window );">Translation differences</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 4,824<span></span>
</td>
<td class="nump">$ 6,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves related to current period sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves related to prior period sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReservesIncludedInAccountsReceivableNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_RebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_MedicaidAndOtherGovernmentalAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_OtherSalesReservesAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_TotalReservesIncludedInSalesReservesAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642480358120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_InventoriesLineItems', window );"><strong>Inventories [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="nump">$ 2,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw and packaging materials</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Products in process</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryInTransit', window );">Materials in transit and payments on account</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 4,403<span></span>
</td>
<td class="nump">$ 4,422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_InventoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_InventoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489782712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">$ 5,245<span></span>
</td>
<td class="nump">$ 5,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">2,720<span></span>
</td>
<td class="nump">2,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Computer equipment and other assets</a></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AssetsUnderConstructionAndPaymentsOnAccount', window );">Assets under construction and payments on account</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">11,388<span></span>
</td>
<td class="nump">11,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;accumulated depreciation</a></td>
<td class="num">(5,092)<span></span>
</td>
<td class="num">(4,914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net, Total</a></td>
<td class="nump">$ 6,296<span></span>
</td>
<td class="nump">$ 6,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AssetsUnderConstructionAndPaymentsOnAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets under construction and payments on account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AssetsUnderConstructionAndPaymentsOnAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486972632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense for the year</a></td>
<td class="nump">$ 537<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment charge during the year on property, plant and equipment</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642495254888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">$ 21,182<span></span>
</td>
<td class="nump">$ 21,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">12,259<span></span>
</td>
<td class="nump">10,766<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">8,923<span></span>
</td>
<td class="nump">11,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember', window );">Identifiable product rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">19,650<span></span>
</td>
<td class="nump">19,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">12,094<span></span>
</td>
<td class="nump">10,640<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">7,556<span></span>
</td>
<td class="nump">9,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development (IPR&amp;D) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount net of impairment</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">$ 1,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489321512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization of intangible assets useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="nump">$ 1,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_LenalidomideProductMember', window );">Lenalidomide Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember', window );">Identifiable product rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember', window );">Actavis [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business combination recognized identifiable assets</a></td>
<td class="nump">877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember', window );">Actavis [Member] | In Process Research and Development [Member] | Lenalidomide Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember', window );">Actavis [Member] | Identifiable product rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=teva_AustedoMember', window );">AUSTEDO [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Discontinued business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember', window );">International Markets [Member] | Actavis [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member] | Identifiable product rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member] | Actavis [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_LenalidomideProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_LenalidomideProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_ActavisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_ActavisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=teva_AustedoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=teva_AustedoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DiscontinuationOfBusinessAxis=teva_DiscontinuedBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DiscontinuationOfBusinessAxis=teva_DiscontinuedBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489151256">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 24,846<span></span>
</td>
<td class="nump">$ 24,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_GoodwillReclassification', window );">Goodwill reclassified as assets to held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">433<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,624<span></span>
</td>
<td class="nump">24,846<span></span>
</td>
<td class="nump">24,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,091<span></span>
</td>
<td class="nump">11,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,473<span></span>
</td>
<td class="nump">11,091<span></span>
</td>
<td class="nump">11,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,536<span></span>
</td>
<td class="nump">8,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_GoodwillReclassification', window );">Goodwill reclassified as assets to held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">574<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,102<span></span>
</td>
<td class="nump">8,536<span></span>
</td>
<td class="nump">8,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,532<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_GoodwillReclassification', window );">Goodwill reclassified as assets to held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(151)<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,362<span></span>
</td>
<td class="nump">2,532<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,687<span></span>
</td>
<td class="nump">2,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,687<span></span>
</td>
<td class="nump">$ 2,687<span></span>
</td>
<td class="nump">$ 2,687<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accumulated goodwill impairment as of December 31, 2020, December 31, 2019 and December 31, 2018 was approximately $25.6 billion, $21.0 billion and $21.0 billion, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_GoodwillReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill reclassification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_GoodwillReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488653192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment</a></td>
<td class="nump">$ 25.6<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642496795496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,628<span></span>
</td>
<td class="nump">$ 3,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PercentageDecreaseInTheMarketCapitalization', window );">Reduction in its market capitalization</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill', window );">Percentage difference between fair value and carrying value in respect of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PercentageDecreaseInTheMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage decrease in the market capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PercentageDecreaseInTheMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference In the value of goodwill in percentage terms between the carrying value and the faitr value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478973992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OperatingLeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate', window );">Fixed payments and variable payments that depend on an index or rate</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease payments not included in the lease liability</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fixed payments and variable payments depend on an index or rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OperatingLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OperatingLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488576184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental cash flow information related to leases (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations (non-cash):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OperatingLeasesNonCash', window );">Operating leases</a></td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OperatingLeasesNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of operating leases non cash amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OperatingLeasesNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642575667128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information Related To Leases (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OperatingLeasesAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OperatingLeaseLiabilityOther', window );">Other current liabilities</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 595<span></span>
</td>
<td class="nump">$ 553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term Operating leases</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate Operating leases</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent<span></span>
</td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OperatingLeaseLiabilityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent of operating other current liabilties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OperatingLeaseLiabilityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642485235592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases -  Maturities of lease liabilities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter', window );">2025 and thereafter</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OperatingLeasesImputedInterest', window );">Less: imputed interest</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 595<span></span>
</td>
<td class="nump">$ 553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OperatingLeasesImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents imputed interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OperatingLeasesImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489604760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance Lease, Liability</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487607864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Short-term Debt (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term liabilities</a></td>
<td class="nump">$ 2,674<span></span>
</td>
<td class="nump">$ 1,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total short term debt</a></td>
<td class="nump">$ 3,188<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member', window );">Convertible senior debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term borrowings</a></td>
<td class="nump">$ 514<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Maturity Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_ShortCreditAgreement2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642485535752">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Senior Notes and Loans (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25,490<span></span>
</td>
<td class="nump">$ 26,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,674)<span></span>
</td>
<td class="num">(1,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Less debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Total senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,731<span></span>
</td>
<td class="nump">24,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member', window );">Other Debentures [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoans', window );">Total senior notes and loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020OneMember', window );">Senior notes EUR 1,010 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member', window );">Senior notes EUR 1,500 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,839<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember', window );">Senior notes EUR 1,300 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member', window );">Senior notes EUR 900 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,107<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member', window );">Senior notes EUR 750 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember', window );">Senior notes USD 3,500 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,495<span></span>
</td>
<td class="nump">3,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember', window );">Senior notes USD 3,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,996<span></span>
</td>
<td class="nump">2,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member', window );">Senior notes USD 2,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember', window );">Senior notes EUR 1,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,230<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember', window );">Senior notes USD 1,000 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021OneMember', window );">Senior notes USD 1,475 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember', window );">Senior notes USD 844 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member', window );">Senior notes USD 789 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 783<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020TwoMember', window );">Senior notes USD 700 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021TwoMember', window );">Senior notes USD 613 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021ThreeMember', window );">Senior notes USD 588 million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DebtInstrumentMaturityYear', window );">Maturity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Total senior notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In July 2020, Teva repaid at maturity &#8364;1,010 million of its 0.375% senior notes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">In March 2020, Teva repaid at maturity $700 million of its 2.25% senior notes.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DebtInstrumentMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Maturity Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DebtInstrumentMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesAndLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesAndLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_OtherDebentures2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486289096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) - Dec. 31, 2020<br> &#8364; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020OneMember', window );">Senior notes EUR 1,010 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">&#8364; 1,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member', window );">Senior notes EUR 1,500 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember', window );">Senior notes EUR 1,300 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member', window );">Senior notes EUR 900 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member', window );">Senior notes EUR 750 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member', window );">Senior notes EUR 700 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember', window );">Senior notes EUR 1,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | &#8364;</a></td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember', window );">Senior notes USD 1,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember', window );">Senior notes USD 3,500 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021OneMember', window );">Senior notes USD 1,475 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember', window );">Senior notes USD 3,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member', window );">Senior notes USD 2,000 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember', window );">Senior notes USD 1,250 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember', window );">Senior notes USD 844 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member', window );">Senior notes USD 789 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020TwoMember', window );">Senior notes USD 700 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021TwoMember', window );">Senior notes USD 613 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021ThreeMember', window );">Senior notes USD 588 million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember', window );">Senior notes CHF 350 Million [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2026OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2023TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2024OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2028OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2020TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2021ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2022ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=teva_SubsidiarySeniorNotesDue2025ThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478997288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtMaturityLineItems', window );"><strong>Long Term Debt Maturity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">4,591<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">3,089<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">3,735<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter', window );">2026 and thereafter</a></td>
<td class="nump">9,804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtaExcludeIssuanceCost', window );">Total</a></td>
<td class="nump">$ 23,330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Including $514 million convertible notes. See note 9a.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtMaturityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Maturity [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtMaturityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtaExcludeIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debta Exclude Issuance Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtaExcludeIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487108696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount currently outstanding on the debt instruments</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642495308392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations - Additional Information (Detail)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Revolving credit facility</a></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionUSD', window );">Long term debt currency portion USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionEUR', window );">Long term debt currency portion EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermDebtCurrencyPortionCHF', window );">Long term debt currency portion CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount currently outstanding on the debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
<td class="nump">$ 491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Debt Instrument, Covenant Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The net debt to EBITDA ratio limit was 5.75x through December 31, 2020, gradually declines to 5.50x in the first and second quarters of 2021, 5.00x in the third and fourth quarters of 2021, and continues to gradually decline over the remaining term of the RCF.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long Term Debt Payable Under Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Trache A [Member] | Trache A Extension [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Revolving credit facility</a></td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit facility, expiration date</a></td>
<td class="text">Apr.  08,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Trache B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit facility, expiration date</a></td>
<td class="text">Apr.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionCHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion C H F.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionCHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionEUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion E U R.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionEUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermDebtCurrencyPortionUSD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt currency portion U S D.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermDebtCurrencyPortionUSD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_TrancheAxis=teva_TracheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_TrancheAxis=teva_TracheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=teva_TracheAExtensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=teva_TracheAExtensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_TrancheAxis=teva_TracheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_TrancheAxis=teva_TracheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642480441816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amounts of hedge</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642485508520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Non-current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Swap [Member] | Other Current Liabilities [Member] | Net Investment Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member] | Net Investment Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=teva_SeniorNotesAndLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=teva_SeniorNotesAndLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_SwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_SwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489506328">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details) - Designated as Hedging Instrument [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember', window );">Other Comprehensive Income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (30)<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td colspan="2" class="num">$ (585)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember', window );">Other Comprehensive Income | Cash Flow Hedging [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td colspan="2" class="num">(35)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember', window );">Other Comprehensive Income | Net Investment Hedging [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td colspan="2" class="num">(51)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember', window );">Other Comprehensive Income | Fair Value Hedging [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">$ 0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">834<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Cash Flow Hedging [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Net Investment Hedging [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">$ (31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Fair Value Hedging [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Comparative figures are based on prior hedge accounting standard.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">With respect to cross-currency swap agreements, Teva recognized gains which mainly reflect the differences between the fixed interest rate and the floating interest rate. In the fourth quarter of 2019, Teva terminated $588 million in cross-currency swap agreements against its outstanding 3.65% senior notes maturing in November 2021. The settlement of these transactions resulted in cash proceeds of $95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of $500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva&#8217;s foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these cross-currency swap agreements expired. The settlement of these transactions resulted in cash proceeds of $3 million.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">In the fourth quarter of 2016, Teva entered into an interest rate swap agreement designated as fair value hedge relating to its 2.8% senior notes due 2023 with respect to $500 million notional amount of outstanding debt. With respect to this interest rate swap agreement, Teva recognized a loss which mainly reflects the differences between the fixed interest rate and the floating interest rate. In the third quarter of 2019, Teva terminated this interest rate swap agreement. The settlement of these transactions resulted in a gain position of $10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLocationAxis=us-gaap_OtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487712040">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,659.0<span></span>
</td>
<td class="nump">$ 16,887.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18,271.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">834.0<span></span>
</td>
<td class="nump">822.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">959.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">130.0<span></span>
</td>
<td class="num">$ (51.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (12.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember', window );">Financial expenses [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the British pound, the Russian ruble and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. [The [positive] impact from these derivatives recognized under revenues was $1 million, $14 million and ($4) million, partially offset by $0 million, $X million and $X million negative impact recognized under cost of sales in the years ended December 31, 2020, 2019 and 2018, respectively]. [To be updated] The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_FinancialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentTradingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentTradingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642495367512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableFromSecuritization', window );">Sold receivables at the beginning of the year</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromAccountsReceivableSecuritization', window );">Proceeds from sale of receivables</a></td>
<td class="nump">4,606<span></span>
</td>
<td class="nump">4,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfAccountsReceivableSecuritization', window );">Cash collections (remitted to the owner of the receivables)</a></td>
<td class="num">(4,607)<span></span>
</td>
<td class="num">(4,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization', window );">Effect of currency exchange rate changes</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableFromSecuritization', window );">Sold receivables at the end of the year</a></td>
<td class="nump">$ 734<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of exchange rate on accounts receivable from securitization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableFromSecuritization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount owed to the reporting entity by counterparties in securitized loan transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableFromSecuritization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromAccountsReceivableSecuritization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromAccountsReceivableSecuritization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfAccountsReceivableSecuritization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfAccountsReceivableSecuritization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486697128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RevenuesOtherThanUsd', window );">Revenues other than USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Teva other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 493.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses', window );">Forward starting interest rate swaps and treasury lock agreements losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_InterestRateSwapGain', window );">Interest Rate Swap Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredPurchaseAsset', window );">Deferred purchase asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266.0<span></span>
</td>
<td class="nump">250.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableFromSecuritization', window );">Sold receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734.0<span></span>
</td>
<td class="nump">690.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">686.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashReceivedOnSettlementOfPosition', window );">Cash received on settlement of position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales [Member] | Hedging Of Revenues 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Teva other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember', window );">Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (4.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2023TwoMember', window );">Senior Notes Due 2023 Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NotionalAmountHedgeDebt', window );">Notional amount hedge debt</a></td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PreviouslyHedgeDebtRate', window );">Previously hedge debt rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SettlementGainPosition', window );">Settlement gain position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashReceivedOnSettlementOfPosition', window );">Cash received on settlement of position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss', window );">Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2022Member', window );">Senior Notes Due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NotionalAmountHedgeDebt', window );">Notional amount hedge debt</a></td>
<td class="nump">$ 844.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PreviouslyHedgeDebtRate', window );">Previously hedge debt rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2021Member', window );">Senior Notes Due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NotionalAmountHedgeDebt', window );">Notional amount hedge debt</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 588.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PreviouslyHedgeDebtRate', window );">Previously hedge debt rate</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashReceivedOnSettlementOfPosition', window );">Cash received on settlement of position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2020Member', window );">Senior Notes Due 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashReceivedOnSettlementOfPosition', window );">Cash received on settlement of position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SubsidiarySeniorNotesDue2021TwoMember', window );">Senior Notes Due 2021 Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PreviouslyHedgeDebtRate', window );">Previously hedge debt rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CashReceivedOnSettlementOfPosition', window );">Cash received on settlement of position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the British pound, the Russian ruble and some other currencies during the period for which such instruments are transacted. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. [The [positive] impact from these derivatives recognized under revenues was $1 million, $14 million and ($4) million, partially offset by $0 million, $X million and $X million negative impact recognized under cost of sales in the years ended December 31, 2020, 2019 and 2018, respectively]. [To be updated] The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CashReceivedOnSettlementOfPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notional amount hedge debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CashReceivedOnSettlementOfPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredPurchaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Purchase Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredPurchaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forward starting interest rate swaps and treasury lock agreements losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_InterestRateSwapGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate swap gain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_InterestRateSwapGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_NotionalAmountHedgeDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notional amount hedge debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_NotionalAmountHedgeDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PreviouslyHedgeDebtRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Previously hedge debt rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PreviouslyHedgeDebtRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RevenuesOtherThanUsd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues other than US Dollar.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RevenuesOtherThanUsd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SettlementGainPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement gain position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SettlementGainPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableFromSecuritization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount owed to the reporting entity by counterparties in securitized loan transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableFromSecuritization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on derivative instrument designated and qualifying as fair value hedge included in assessment of hedge effectiveness, recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_NetRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2023TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2023TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_SeniorNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=teva_SubsidiarySeniorNotesDue2021TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=teva_SubsidiarySeniorNotesDue2021TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490751160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Settlements and Loss Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Legal settlements and loss contingencies, expense</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 1,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Legal settlements, income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued amount for legal settlements and loss contingencies</a></td>
<td class="nump">$ 1,625<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_SettlementOnAccountOfProductLiabilityMember', window );">Settlement On Account Of Product Liability [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringExpenseAndIncome', window );">Restructuring expense and income</a></td>
<td class="text">The expenses in 2020 were mainly related to a fine imposed by the European Commission in relation to a 2005 patent settlement agreement and an increase of a reserve for certain product liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics). The expenses in 2019 were mainly related to an estimated provision recorded in connection with potential settlement of the opioid cases.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringExpenseAndIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring expense and income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringExpenseAndIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_SettlementOnAccountOfProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_SettlementOnAccountOfProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642485529416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Commitments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MilestoneContingentPayments', window );">Milestone contingent expense</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_MilestoneContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_MilestoneContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487401272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingencies - Additional Information (Detail)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 21, 2019 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Jun. 27, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Aug. 21, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2009 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2009 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2005 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DamagesAssessment', window );">Damages assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfVelcade', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ModafinilPayment', window );">Modafinil payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfEffexor', window );">Annual sales of Effexor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfLamictal', window );">Annual sales of Lamictal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="nump">$ 950.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfNiaspan', window );">Annual sales of Niaspan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="nump">$ 416.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfActos', window );">Annual sales of Actos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800.0<span></span>
</td>
<td class="nump">$ 3,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfActoplus', window );">Annual sales of Acto plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430.0<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfNamenda', window );">Annual sales of Namenda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss contingency payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfSensipar', window );">Annual Sales Of Sensipar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ModafinilPaymentRemainingBalance', window );">Modafinil payment remaining balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesOfCopaxone', window );">Annual sales of Copaxone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Generic modafinil, and imposed fines amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,580.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_OpioidLitigationMember', window );">Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedDistributionPeriod', window );">Litigation settlement amount awarded distribution period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedCashAmount', window );">Litigation settlement amount awarded cash amount</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedNumberOfInstallments', window );">Litigation settlement amount awarded number of installments | Number</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod', window );">Litigation settlement amount awarded cash amount distribution period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_NationwideSettlementMember', window );">Nationwide Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement amount</a></td>
<td class="nump">$ 23,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedDistributionPeriod', window );">Litigation settlement amount awarded distribution period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedCashAmount', window );">Litigation settlement amount awarded cash amount</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod', window );">Litigation settlement amount awarded cash amount distribution period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=teva_ModafinilSettlementAgreementMember', window );">Modafinil Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Generic modafinil, and imposed fines amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember', window );">Eosinophilic Esophagitis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember', window );">Eosinophilic Esophagitis [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember', window );">Eosinophilic Esophagitis [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damage claimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=teva_JanssenAndMillenniumMember', window );">Janssen and Millennium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Maximum damages payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Litigation settlement awarded from other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember', window );">AndroGel Rate at 1% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AnnualSalesAtTimeOfSettlement', window );">Annual sales at the time of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesAtTimeOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales at time of settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesAtTimeOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfActoplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Acto plus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfActoplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfActos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Actos.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfActos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfCopaxone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Sales Of Copaxone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfCopaxone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfEffexor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of effexor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfEffexor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfLamictal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Lamictal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfLamictal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfNamenda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Namenda.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfNamenda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfNiaspan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales of Niaspan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfNiaspan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfSensipar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents Annual Sales Of Sensipar.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfSensipar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AnnualSalesOfVelcade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Sales Of Velcade</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AnnualSalesOfVelcade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DamagesAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Damages assessment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DamagesAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountAwardedCashAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded cash amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountAwardedCashAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded cash amount distribution period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountAwardedDistributionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded distribution period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountAwardedDistributionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LitigationSettlementAmountAwardedNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount awarded number of installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LitigationSettlementAmountAwardedNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ModafinilPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modafinil payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ModafinilPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ModafinilPaymentRemainingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modafinil payment remaining balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ModafinilPaymentRemainingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_OpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_OpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_NationwideSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_NationwideSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=teva_ModafinilSettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=teva_ModafinilSettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=teva_JanssenAndMillenniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=teva_JanssenAndMillenniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642483029352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Before Income Taxes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems', window );"><strong>Income Before Income Taxes And Income Tax Expense Benefit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Parent Company and its Israeli subsidiaries</a></td>
<td class="nump">$ 947<span></span>
</td>
<td class="nump">$ 542<span></span>
</td>
<td class="nump">$ 1,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-Israeli subsidiaries</a></td>
<td class="num">(5,353)<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
<td class="num">(3,618)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">$ (4,406)<span></span>
</td>
<td class="num">$ (1,265)<span></span>
</td>
<td class="num">$ (2,596)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income before income taxes and income tax expense benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489125720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of the Provision for Income Taxes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems', window );"><strong>Income Before Income Taxes And Income Tax Expense Benefit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">In Israel</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Outside Israel</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(385)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective consolidated income taxes</a></td>
<td class="num">(168)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">885<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(350)<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (168)<span></span>
</td>
<td class="num">$ (278)<span></span>
</td>
<td class="num">$ (195)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income before income taxes and income tax expense benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642664550088">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems', window );"><strong>Income Before Income Taxes And Income Tax Expense Benefit [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (Loss) before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,406)<span></span>
</td>
<td class="num">$ (1,265)<span></span>
</td>
<td class="num">$ (2,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical provision for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,013)<span></span>
</td>
<td class="num">$ (291)<span></span>
</td>
<td class="num">$ (597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract', window );"><strong>Increase (decrease) in the provision for income taxes due to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">The Parent Company and its Israeli subsidiaries- Mainly tax benefits arising from reduced tax rates under benefit programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Non-Israeli subsidiaries, including impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,369<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_Ustaxcutsandjobsacteffect', window );">U.S. Tax Cuts and Jobs Act effect</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Increase (decrease) in other uncertain tax positions-net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(341)<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective consolidated income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (168)<span></span>
</td>
<td class="num">$ (278)<span></span>
</td>
<td class="num">$ (195)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2020 and 2018, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income before income taxes and income tax expense benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_Ustaxcutsandjobsacteffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>US tax cuts and jobs act effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_Ustaxcutsandjobsacteffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489692472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems', window );"><strong>Income Before Income Taxes And Income Tax Expense Benefit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Income before income taxes includes goodwill impairment tax effect</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income before income taxes and income tax expense benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642496612664">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Defered Income Taxes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetsLiabilitiesNetLineItems', window );"><strong>Deferred Tax Assets Liabilities Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory related</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances', window );">Sales reserves and allowances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">173<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements', window );">Provision for legal settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">235<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,064)<span></span>
</td>
<td class="num">(1,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent', window );">Carryforward losses and deductions and credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">1,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetsDeferredInterest', window );">Deferred interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">527<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent', window );">Provisions for employee related obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent', window );">Long-term deferred tax assets (liabilities)-gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,278<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance&#8212;in respect of carryforward losses and deductions that may not be utilized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,547)<span></span>
</td>
<td class="num">(1,974)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax assets liabilities net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (269)<span></span>
</td>
<td class="num">$ (710)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The decrease in deferred tax liability is mainly due to impairment and amortization.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The amounts are shown after reduction for unrecognized tax benefits of $ 63 million and $115 million as of December 31, 2020 and 2019, respectively. This amount represents the tax effect of gross carryforward losses and deductions with the following expirations: 2021-2022&#8212;$79 million; 2023-2029&#8212;$663 million; 2030 and thereafter&#8212;$171 million. The remaining balance&#8212;$1,327 million&#8212;can be utilized with no expiration date.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets carryforward losses and deductions noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetsDeferredInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Deferred Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetsDeferredInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets liabilities gross noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetsLiabilitiesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Liabilities Net [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetsLiabilitiesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities other net noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Non Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478694744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetsLiabilitiesNetLineItems', window );"><strong>Deferred Tax Assets Liabilities Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetUnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Unrecognized Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetsLiabilitiesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Liabilities Net [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetsLiabilitiesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642496394392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail)<br> &#8362; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ILS (&#8362;) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Balance of accrued potential penalties and interest in unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Annual revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,454<span></span>
</td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
<td class="nump">$ 4,357<span></span>
</td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 16,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,887<span></span>
</td>
<td class="nump">$ 18,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExpectedImpairmentOfIncomeTaxBenefit', window );">Expected impairment of income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit', window );">Provisional estimate for one-time deemed repatriation tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Income tax audit period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2008 2009 2010 2011<span></span>
</td>
<td class="text">2008 2009 2010 2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_WithholdingTaxPercentageOnDividends', window );">Withholding tax percentage on dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member] | Tax Year 2005 To 2007 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember', window );">Tax Carryforwards And Deductions Expiration Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax effect of unspecified carryforward losses and deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember', window );">Tax Carryforwards And Deductions Expiration Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax effect of unspecified carryforward losses and deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsNoExpirationMember', window );">Tax Carryforwards And Deductions No Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax effect of unspecified carryforward losses and deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsIndefiniteMember', window );">Tax Carryforwards And Deductions Indefinite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax effect of unspecified carryforward losses and deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_Amendment69ToInvestmentLawMember', window );">Amendment 69 to Investment Law [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Payment of corporate tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt', window );">Exempt Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_Amendment68ToInvestmentLawMember', window );">Amendment 68 to Investment Law [Member] | Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_Amendment68ToInvestmentLawMember', window );">Amendment 68 to Investment Law [Member] | Israel Tax Authority [Member] | Development Zonea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_Amendment73ToInvestmentLawMember', window );">Amendment 73 to Investment Law [Member] | Israel Tax Authority [Member] | Development Zonea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_PreferredEnterpriseMember', window );">Preferred Enterprise [Member] | Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_WithholdingTaxPercentageOnDividends', window );">Withholding tax percentage on dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_PreferredEnterpriseMember', window );">Preferred Enterprise [Member] | Israel Tax Authority [Member] | Development Zonea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_WithholdingTaxPercentageOnDividends', window );">Withholding tax percentage on dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_PreferredTechnologicalEnterprisesMember', window );">Preferred Technological Enterprises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_VentureCapitalInvestments', window );">Venture capital investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AverageGrowthRateInSalesOrWorkforce', window );">Average growth rate in sales or workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce', window );">Average growth preceding period in sales or workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_PreferredTechnologicalEnterprisesMember', window );">Preferred Technological Enterprises [Member] | Research and Development Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MinimumPercentageOfInvestmentIncome', window );">Minimum percentage of investment income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Minimum investment income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">&#8362; 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MinimumPercentageOfWorkforce', window );">Minimum percentage of workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_MinimumNumberOfEmployeesEmployed', window );">Minimum number of employees employed | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_PreferredTechnologicalEnterprisesMember', window );">Preferred Technological Enterprises [Member] | Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_PreferredTechnologicalEnterprisesMember', window );">Preferred Technological Enterprises [Member] | Israel Tax Authority [Member] | Development Zonea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_SpecialPreferredTechnologicalEnterpriseMember', window );">Special Preferred Technological Enterprise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Annual revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">&#8362; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=teva_SpecialPreferredTechnologicalEnterpriseMember', window );">Special Preferred Technological Enterprise [Member] | Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_WithholdingTaxPercentageOnDividends', window );">Withholding tax percentage on dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Tax Carryforwards And Deductions Expiration Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Tax Carryforwards And Deductions Expiration Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Tax Carryforwards And Deductions No Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2030<span></span>
</td>
<td class="text">Dec. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Tax Carryforwards And Deductions Expiration Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Tax Carryforwards And Deductions Expiration Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average growth preceding period in sales or workforce.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AverageGrowthRateInSalesOrWorkforce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average growth rate in sales or workforce.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AverageGrowthRateInSalesOrWorkforce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExpectedImpairmentOfIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected impairment of income tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExpectedImpairmentOfIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_MinimumNumberOfEmployeesEmployed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of employees employed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_MinimumNumberOfEmployeesEmployed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_MinimumPercentageOfInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of investment income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_MinimumPercentageOfInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_MinimumPercentageOfWorkforce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of workforce.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_MinimumPercentageOfWorkforce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_VentureCapitalInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Venture Capital Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_VentureCapitalInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_WithholdingTaxPercentageOnDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Withholding tax percentage on dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_WithholdingTaxPercentageOnDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendIncomeSecuritiesOperatingTaxExempt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating dividend income on securities exempt from state, federal and other income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendIncomeSecuritiesOperatingTaxExempt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax benefit for remeasurement of deferred tax liability from change in tax rate pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=teva_TaxYear2005To2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=teva_TaxYear2005To2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsNoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsNoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsIndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_TaxCarryforwardsAndDeductionsIndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_Amendment69ToInvestmentLawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_Amendment69ToInvestmentLawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_Amendment68ToInvestmentLawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_Amendment68ToInvestmentLawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=teva_DevelopmentZoneaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=teva_DevelopmentZoneaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_Amendment73ToInvestmentLawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_Amendment73ToInvestmentLawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_PreferredEnterpriseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_PreferredEnterpriseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_PreferredTechnologicalEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_PreferredTechnologicalEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=teva_SpecialPreferredTechnologicalEnterpriseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=teva_SpecialPreferredTechnologicalEnterpriseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488875288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DeferredTaxAssetsLiabilitiesNetLineItems', window );"><strong>Deferred Tax Assets Liabilities Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Long-term assets-deferred income taxes</a></td>
<td class="nump">$ 695<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Long-term liabilities-deferred income taxes</a></td>
<td class="num">(964)<span></span>
</td>
<td class="num">(1,096)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax assets liabilities net</a></td>
<td class="num">$ (269)<span></span>
</td>
<td class="num">$ (710)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DeferredTaxAssetsLiabilitiesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Liabilities Net [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DeferredTaxAssetsLiabilitiesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642479147512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems', window );"><strong>Schedule Of Unrecognized Tax Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 1,223<span></span>
</td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increase (decrease) related to prior year tax positions, net</a></td>
<td class="num">(238)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther', window );">Other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the year</a></td>
<td class="nump">$ 888<span></span>
</td>
<td class="nump">$ 1,223<span></span>
</td>
<td class="nump">$ 1,072<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ScheduleOfUnrecognizedTaxBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Unrecognized Tax Benefits [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ScheduleOfUnrecognizedTaxBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increases decreases other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490496488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 17, 2018</div></th>
<th class="th"><div>Jul. 13, 2017</div></th>
<th class="th"><div>Apr. 18, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 03, 2015</div></th>
<th class="th"><div>Jun. 29, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ordinary shares issuance ADSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Share issued due to conversion of convertible preferred shares</a></td>
<td class="nump">70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible preferred stock terms of conversion</a></td>
<td class="text">1 mandatory convertible preferred share to 16 ADSs, and all of the accumulated and unpaid dividends on the mandatory convertible preferred shares were paid in ADSs, at a ratio of 3.0262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for future awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting period, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The vesting period of the outstanding options and RSUs is generally from 1 to 4 years from the date of grant. The vesting period of PSUs is generally 3 years from the date of grant. The rights of the ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of the other ordinary shares of the Company. The contractual term of these options is primarily for ten years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AverageSharePrice', window );">Company average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">$ 20.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UnrecognizedCompensationCostOptions', window );">Total unrecognized compensation cost before tax on employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UnrecognizedCompensationCostRsus', window );">Total unrecognized compensation cost before tax on employee stock RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share based compensation arrangements expected over weighted average period for options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share based compensation arrangements expected over weighted average period for RSU/PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=teva_TwoThousandTenPlanMember', window );">2010 Long-Term Equity-Based Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=teva_TwoThousandFifteenPlanMember', window );">2015 Long-Term Equity-Based Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=teva_TwoThousandTwentyPlanMember', window );">2020 Long-Term Equity-Based Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AverageSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AverageSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UnrecognizedCompensationCostOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation cost options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UnrecognizedCompensationCostOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UnrecognizedCompensationCostRsus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation cost rsus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UnrecognizedCompensationCostRsus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=teva_TwoThousandTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=teva_TwoThousandTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=teva_TwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=teva_TwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=teva_TwoThousandTwentyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=teva_TwoThousandTwentyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490066552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Stock Option Activity (Detail) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at begining of year</a></td>
<td class="nump">40,064<span></span>
</td>
<td class="nump">48,393<span></span>
</td>
<td class="nump">43,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(3,610)<span></span>
</td>
<td class="num">(8,318)<span></span>
</td>
<td class="num">(7,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="num">(1,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance outstanding at end of year</a></td>
<td class="nump">35,234<span></span>
</td>
<td class="nump">40,064<span></span>
</td>
<td class="nump">48,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Balance exercisable at end of year</a></td>
<td class="nump">28,556<span></span>
</td>
<td class="nump">26,601<span></span>
</td>
<td class="nump">24,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at begining of year</a></td>
<td class="nump">$ 37.90<span></span>
</td>
<td class="nump">$ 38.62<span></span>
</td>
<td class="nump">$ 44.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.99<span></span>
</td>
<td class="nump">17.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">40.24<span></span>
</td>
<td class="nump">42.12<span></span>
</td>
<td class="nump">39.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="nump">49.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance outstanding at end of year</a></td>
<td class="nump">37.27<span></span>
</td>
<td class="nump">37.90<span></span>
</td>
<td class="nump">38.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Balance exercisable at end of year</a></td>
<td class="nump">$ 40.56<span></span>
</td>
<td class="nump">$ 43.41<span></span>
</td>
<td class="nump">$ 46.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490831736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Weighted Average Fair Value of Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489029512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487878152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Ordinary Shares Issued Upon Outstanding Options (Detail)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>yr </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">35,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 37.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">5.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeOneMember', window );">Lower than $15.01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 11.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">6.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 15.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeTwoMember', window );">$15.01 - $25.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">10,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">7.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 15.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 25.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeThreeMember', window );">$25.01 - $35.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">7,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 34.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">6.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 25.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 35.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFourMember', window );">$35.01 - $45.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">5,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 40.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 35.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 45.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFiveMember', window );">$45.01 - $55.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">7,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 51.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">4.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 45.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 55.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeSixMember', window );">$55.01 - $65.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">4,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 59.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">4.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 55.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 65.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average period remaining as of the balance-sheet date until option expiration pertaining to the outstanding stock options for all option plans in the customized range of exercise prices, which may be expressed in a variety of ways (for example, years, months).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642492316920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>yr </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">28,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 40.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">4.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeOneMember', window );">Lower than $15.01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 11.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">6.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 15.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeTwoMember', window );">$15.01 - $25.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">5,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">7.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 15.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 25.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeThreeMember', window );">$25.01 - $35.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">5,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 34.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">6.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 25.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 35.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFourMember', window );">$35.01 - $45.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">5,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 40.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 35.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 45.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFiveMember', window );">$45.01 - $55.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">7,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 51.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">4.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 45.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 55.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeSixMember', window );">$55.01 - $65.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Balance at end of period (in thousands) Number of shares | shares</a></td>
<td class="nump">4,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010', window );">Weighted average exercise price</a></td>
<td class="nump">$ 59.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010', window );">Weighted average remaining life Years | yr</a></td>
<td class="nump">4.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower limit</a></td>
<td class="nump">$ 55.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper limit</a></td>
<td class="nump">$ 65.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining life of the exercisable stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=teva_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489198872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Number of RSUs Issued and Outstanding (Detail) - Restricted Stock Units [Member] - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance outstanding at beginning of year</a></td>
<td class="nump">15,977<span></span>
</td>
<td class="nump">10,403<span></span>
</td>
<td class="nump">7,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">10,848<span></span>
</td>
<td class="nump">9,303<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(4,324)<span></span>
</td>
<td class="num">(2,435)<span></span>
</td>
<td class="num">(1,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(1,781)<span></span>
</td>
<td class="num">(1,294)<span></span>
</td>
<td class="num">(1,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance outstanding at end of year</a></td>
<td class="nump">20,720<span></span>
</td>
<td class="nump">15,977<span></span>
</td>
<td class="nump">10,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share - RSUs at beginning year</a></td>
<td class="nump">$ 16.49<span></span>
</td>
<td class="nump">$ 20.93<span></span>
</td>
<td class="nump">$ 27.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">11.42<span></span>
</td>
<td class="nump">15.36<span></span>
</td>
<td class="nump">18.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">19.49<span></span>
</td>
<td class="nump">30.24<span></span>
</td>
<td class="nump">37.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="nump">18.18<span></span>
</td>
<td class="nump">18.74<span></span>
</td>
<td class="nump">32.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share - RSUs at end of year</a></td>
<td class="nump">$ 13.81<span></span>
</td>
<td class="nump">$ 16.49<span></span>
</td>
<td class="nump">$ 20.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=teva_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=teva_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486500296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=teva_StockOptionsPlanMember', window );">Stock Options Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=teva_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=teva_OmnibusLongTermShareIncentivePlanMember', window );">Omnibus Long Term Share Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax effect on stock-based compensation expense</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Net effect</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=teva_StockOptionsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=teva_StockOptionsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=teva_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=teva_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=teva_OmnibusLongTermShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=teva_OmnibusLongTermShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486333416">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,399)<span></span>
</td>
<td class="num">$ (2,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,794)<span></span>
</td>
<td class="num">(1,878)<span></span>
</td>
<td class="num">$ (1,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income/(loss) before reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(190)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(190)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Corresponding income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="num">(739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,919)<span></span>
</td>
<td class="num">(1,794)<span></span>
</td>
<td class="num">(1,878)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-for-sale Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning', window );">Cumulative effect of new accounting standard</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income/(loss) before reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="num">(619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income/(loss) before reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(363)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="num">(504)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Benefit Plans [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income/(loss) before reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Corresponding income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,312)<span></span>
</td>
<td class="num">(2,459)<span></span>
</td>
<td class="num">(1,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning', window );">Cumulative effect of new accounting standard</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income/(loss) before reclassifications</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(175)<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="num">(639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Amounts reclassified to the statements of income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(152)<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="num">(597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Corresponding income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive income (loss) after tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="num">(611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,399)<span></span>
</td>
<td class="num">$ (2,312)<span></span>
</td>
<td class="num">$ (2,459)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $56 million gain in 2020, $14 million gain in 2019 and $26 million gain in 2018.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Following the adoption of ASU 2016-01, the Company recorded a $ 5 million opening balance reclassification from accumulated other comprehensive income to retained earnings.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification From Accumulated Other Comprehensive Income To Retained Earning</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490306520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation attributable to non-controlling interests</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488547624">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAndImpairmentCostsLineItems', window );"><strong>Restructuring and Impairment Costs [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairments of long-lived tangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration (see note 2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">120<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ImpairmentAndRestructuring', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Including impairments related to exit and disposal activities</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentAndRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment and restructuring.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentAndRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements loss contingencies impairments other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAndImpairmentCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and impairment costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAndImpairmentCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486883064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAndImpairmentCostsLineItems', window );"><strong>Restructuring and Impairment Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairments of property, plant and equipment</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business combination contingent consideration arrangements change in amount of contingent consideration liability</a></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExpectedRevenueFromFacility', window );">Expected revenue from Florida manufacturing plant in 2020</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringPlanCostReduction', window );">Restructuring plan cost reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExpectedRevenueFromFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Revenue From Facility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExpectedRevenueFromFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAndImpairmentCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and impairment costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAndImpairmentCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringPlanCostReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Plan Cost Reduction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringPlanCostReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490450952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642595487784">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (215)<span></span>
</td>
<td class="num">$ (233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">213<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember', window );">Employee termination costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">164<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember', window );">Other Exit and Disposal [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_RestructuringAccrualProvision', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_UtilizationAndOther', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes adjustments for foreign currency translation.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_RestructuringAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Accrual Provision</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_RestructuringAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_UtilizationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Utilization and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_UtilizationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExitAndDisposalAxis=teva_EmployeeTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExitAndDisposalAxis=teva_OtherExitAndDisposalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642575735672">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other Income - Schedule of Other Income (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherincomeLineItems', window );"><strong>Other Income [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on divestitures, net of divestitures related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PatentedMedicinesRegulationsAndSimilarPayments', window );">Section 8 and similar payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain (loss) on sale of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherOperatingIncomeNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Total other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Mainly related to the divestment of several activities in our International Markets segment.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Section 8 of the Patented Medicines (Notice of Compliance) Regulation relates to recoveries of lost revenue related to patent infringement proceedings in Canada.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherOperatingIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherOperatingIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherincomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherincomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PatentedMedicinesRegulationsAndSimilarPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patented Medicines Regulations and Similar Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PatentedMedicinesRegulationsAndSimilarPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642478936520">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial expenses, net - Schedule of Financial Expenses (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExpensesLineItems', window );"><strong>Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses and other bank charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 963<span></span>
</td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Income from investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ForeignCurrencyTransactionGainLoss', window );">Foreign exchange (gains) losses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherFinancialIncomeExpenseNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FinanceIncomeExpensesNet', window );">Total finance expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="nump">$ 959<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2020, Income from investments comprised mainly of revaluation gain of Teva&#8217;s investment in American Well Corporation (&#8220;American Well&#8221;). See note 20.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">In 2018, Other, net comprised mainly of a make-whole payment of $46 million following early redemption of senior notes during 2018.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FinanceIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance income expenses net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FinanceIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ForeignCurrencyTransactionGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of net unrealized foreign currency transaction gains (losses) and net realized foreign currency transaction gains (losses) relating to debt repayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ForeignCurrencyTransactionGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherFinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other financial income expense net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherFinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642601569304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial expenses, net - Schedule of Financial Expenses (Parenthetical) (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ExpensesLineItems', window );"><strong>Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PaymentForRedemptionOfSeniorNotes', window );">Payment for redemption of senior notes</a></td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PaymentForRedemptionOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for redemption of senior notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PaymentForRedemptionOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642483005560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share - Schedule of Earnings per Share (Detail) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) used for the computation of basic and diluted earnings (loss) per share</a></td>
<td class="num">$ (3,990)<span></span>
</td>
<td class="num">$ (999)<span></span>
</td>
<td class="num">$ (2,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in the computation of basic earnings (loss) per share</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in the computation of diluted earnings (loss) per share</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490081880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share - Additional Information (Detail) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
<td class="nump">$ 3.64<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember', window );">Stock Option Restricted Stock Units And Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average shares with anti-dilutive effect on earnings per share</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average shares with anti-dilutive effect on earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642483696520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Summary of Segment Profit (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 4,454<span></span>
</td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
<td class="nump">$ 4,357<span></span>
</td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 16,659<span></span>
</td>
<td class="nump">$ 16,887<span></span>
</td>
<td class="nump">$ 18,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 2,048<span></span>
</td>
<td class="nump">$ 1,852<span></span>
</td>
<td class="nump">$ 1,763<span></span>
</td>
<td class="nump">$ 2,063<span></span>
</td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="nump">$ 1,830<span></span>
</td>
<td class="nump">$ 1,893<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
<td class="nump">7,726<span></span>
</td>
<td class="nump">7,537<span></span>
</td>
<td class="nump">8,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">997<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,498<span></span>
</td>
<td class="nump">2,614<span></span>
</td>
<td class="nump">2,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,572)<span></span>
</td>
<td class="num">(443)<span></span>
</td>
<td class="num">(1,637)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,447<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
<td class="nump">9,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,489<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherOperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,421<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,757<span></span>
</td>
<td class="nump">4,795<span></span>
</td>
<td class="nump">5,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">2,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherOperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,331<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">S&amp;M expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherOperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642587203768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="num">$ (3,572)<span></span>
</td>
<td class="num">$ (443)<span></span>
</td>
<td class="num">$ (1,637)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_ImpairmentsRestructuringAndOthers', window );">Other asset impairments, restructuring and other items</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">4,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Gain on divestitures, net of divestitures related costs</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_PurchaseOfResearchAndDevelopmentInProcess', window );">Other R&amp;D expenses (income)</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_CostsRelatedToRegulatoryActionsTakenInFacilities', window );">Costs related to regulatory actions taken in facilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LegalSettlementsAndLossContingencies', window );">Legal settlements and loss contingencies</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_OtherUnallocatedAmounts', window );">Other unallocated amounts</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="num">(3,572)<span></span>
</td>
<td class="num">(443)<span></span>
</td>
<td class="num">(1,637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(4,406)<span></span>
</td>
<td class="num">(1,265)<span></span>
</td>
<td class="num">(2,596)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">2,421<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">2,421<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">1,331<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">1,331<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">4,225<span></span>
</td>
<td class="nump">4,034<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">4,225<span></span>
</td>
<td class="nump">4,034<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember', window );">Segments and Other Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsAllocatedToSegmentsAbstract', window );"><strong>Amounts allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segments profit</a></td>
<td class="nump">4,388<span></span>
</td>
<td class="nump">4,142<span></span>
</td>
<td class="nump">4,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AmountsNotAllocatedToSegmentsAbstract', window );"><strong>Amounts not allocated to segments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Consolidated operating income (loss)</a></td>
<td class="nump">$ 4,388<span></span>
</td>
<td class="nump">$ 4,142<span></span>
</td>
<td class="nump">$ 4,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AmountsAllocatedToSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AmountsAllocatedToSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AmountsNotAllocatedToSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AmountsNotAllocatedToSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_CostsRelatedToRegulatoryActionsTakenInFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs related to regulatory actions taken in facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_CostsRelatedToRegulatoryActionsTakenInFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_ImpairmentsRestructuringAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairments restructuring and others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_ImpairmentsRestructuringAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LegalSettlementsAndLossContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LegalSettlementsAndLossContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_OtherUnallocatedAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other unallocated amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_OtherUnallocatedAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_PurchaseOfResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of research and development in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_PurchaseOfResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_SegmentsAndOtherActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642487198488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 4,454<span></span>
</td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
<td class="nump">$ 4,357<span></span>
</td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 16,659<span></span>
</td>
<td class="nump">$ 16,887<span></span>
</td>
<td class="nump">$ 18,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember', window );">North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,447<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
<td class="nump">9,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,757<span></span>
</td>
<td class="nump">4,795<span></span>
</td>
<td class="nump">5,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember', window );">International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,010<span></span>
</td>
<td class="nump">3,963<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,513<span></span>
</td>
<td class="nump">3,470<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember', window );">Generic products [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
<td class="nump">1,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_COPAXONEMember', window );">COPAXONE [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember', window );">BENDEKA and TREANDA [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_ProAirMember', window );">ProAir [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_QVARMember', window );">QVAR [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AjovyMember', window );">AJOVY [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AjovyMember', window );">AJOVY [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AustedoMember', window );">AUSTEDO [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_RespiratoryProductMember', window );">Respiratory Product [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_AndaMember', window );">Anda [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | North America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=teva_OtherProductsMember', window );">Other [Member] | International Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_NorthAmericaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_GenericsMediciansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_GenericsMediciansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_COPAXONEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_COPAXONEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_ProAirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_ProAirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_QVARMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_QVARMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AjovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AjovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AustedoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AustedoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_RespiratoryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_RespiratoryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_AndaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_AndaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=teva_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=teva_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488507256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=teva_Customer1Member', window );">McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NetSalesPresent', window );">Third party net sales present</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=teva_Customer2Member', window );">AmerisourceBergen Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_NetSalesPresent', window );">Third party net sales present</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_NetSalesPresent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net sales present.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_NetSalesPresent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=teva_Customer1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=teva_Customer1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=teva_Customer2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=teva_Customer2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642489432376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 6,296<span></span>
</td>
<td class="nump">$ 6,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,611<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HR', window );">Croatia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CZ', window );">Czech republic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HU', window );">Hungary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_IEMember', window );">Ireland [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="nump">$ 1,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CZ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CZ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_IEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_IEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=teva_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=teva_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642479017656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Additional Information (Detail) - Segment<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenues from external customers</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642486483144">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (268)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember', window );">Asset Derivatives - Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember', window );">Liabilities Derivatives Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(79)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">367<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember', window );">Cash, Deposits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other, Mainly Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,207<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">367<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Cash, Deposits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Other, Mainly Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Asset Derivatives - Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Liabilities Derivatives Options and Forward Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(79)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(268)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(258)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Other, Mainly Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">During the third quarter of 2020, Teva recorded a gain of $134 million under share in profits of associated companies, net, reflecting the difference between the book value of Teva&#8217;s investment in American Well and its fair value as of the date it completed its initial public offering in September 2020. The investment was reclassified from &#8220;investment in associated companies&#8221; to &#8220;investment in marketable securities,&#8221; since Teva no longer had significant influence in American Well. This represented a transfer into Level 3 measurement within fair value hierarchy. By December 31, 2020, Teva recorded an additional gain of $80 million under financial expenses, net, reflecting the revaluation gain of this security as of December 31, 2020 and transferred it to Level 2 measurement within fair value hierarchy due to a change in discount rate. Due to management&#8217;s intention and ability to sell this security in the next twelve months, the balance as of December 31, 2020 was reclassified to short term investments.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=teva_OptionsAndForwardContractsDerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642488136056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurement - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Gain&#160;under share&#160;in&#160;profits&#160;of&#160;associated&#160;companies</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_RevaluationOfAssetsMember', window );">Revaluation of Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Gain under financial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement input probability of success [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement input probability of success [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement input, discount rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_RevaluationOfAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis=us-gaap_RevaluationOfAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=teva_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642490606440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the beginning of the period</a></td>
<td class="num">$ (448)<span></span>
</td>
<td class="num">$ (497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfer into Level&#160;3- equity securities</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Revaluation of equity securities</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Revaluation of debt securities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Reclassification to Level&#160;2- equity securities</a></td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at the end of the period</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember', window );">Actavis Generics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod', window );">Actavis Generics transaction</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember', window );">Eagle Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease', window );">Adjustments to provisions for contingent consideration</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlement of contingent consideration</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_ActavisGenericsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=teva_EagleTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642480160504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">$ 25,891<span></span>
</td>
<td class="nump">$ 25,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">22,684<span></span>
</td>
<td class="nump">22,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesmemberMember', window );">Senior Notes and Convertible Senior Debentures Included Under Short-Term Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total</a></td>
<td class="nump">$ 3,207<span></span>
</td>
<td class="nump">$ 2,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesmemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=teva_SeniornotesandconvertibleseniordebenturesmemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642583131176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_AccruedSeverancePayNoncurrent', window );">Accrued severance obligations</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Defined benefit plans</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_EmployeeRelatedObligationsNoncurrent', window );">Total</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_AccruedSeverancePayNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued severance pay non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_AccruedSeverancePayNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_EmployeeRelatedObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee related obligations non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_EmployeeRelatedObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642480306344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Employee-related Obligations - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations', window );">Long-term investments earmarked for severance pay liabilities in Israel</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear', window );">Expected contributions to pension funds</a></td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne', window );">2021</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo', window );">2022</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree', window );">2023</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour', window );">2024</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive', window );">2025</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen', window );">2026 to 2030</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan estimated future discretionary employer contributions in next fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future expected domestic minimum benefit payments year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future expected domestic minimum benefit payments year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future expected domestic minimum benefit payments year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future expected domestic minimum benefit payments year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future expected domestic minimum benefit payments year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future expected domestic minimum benefit payments years six through ten.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term investments earmarked for domestic severance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642601591880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_teva_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 4,454<span></span>
</td>
<td class="nump">$ 3,978<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
<td class="nump">$ 4,357<span></span>
</td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 16,659<span></span>
</td>
<td class="nump">$ 16,887<span></span>
</td>
<td class="nump">$ 18,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,048<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">7,726<span></span>
</td>
<td class="nump">7,537<span></span>
</td>
<td class="nump">8,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">162<span></span>
</td>
<td class="num">(4,340)<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="num">(307)<span></span>
</td>
<td class="num">(671)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(4,099)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(2,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Teva</a></td>
<td class="nump">150<span></span>
</td>
<td class="num">(4,349)<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="num">(689)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(3,990)<span></span>
</td>
<td class="num">(999)<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to ordinary shareholders</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="num">$ (4,349)<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="num">$ (314)<span></span>
</td>
<td class="num">$ (689)<span></span>
</td>
<td class="num">$ (105)<span></span>
</td>
<td class="num">$ (3,990)<span></span>
</td>
<td class="num">$ (999)<span></span>
</td>
<td class="num">$ (2,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to ordinary shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="num">$ (3.97)<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (3.64)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (2.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="nump">$ 0.14<span></span>
</td>
<td class="num">$ (3.97)<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (3.64)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (2.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_teva_SelectedQuarterlyFinancialInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selected Quarterly Financial Information [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">teva_SelectedQuarterlyFinancialInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>teva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140642497668168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II Valuation and Qualifying Accounts (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 6,246<span></span>
</td>
<td class="nump">$ 6,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(15,707)<span></span>
</td>
<td class="num">(17,605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">4,904<span></span>
</td>
<td class="nump">6,246<span></span>
</td>
<td class="nump">$ 6,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance For Doubtful Accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember', window );">Valuation Allowance in Tax Carryforward Losses And Deductions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 2,547<span></span>
</td>
<td class="nump">$ 1,974<span></span>
</td>
<td class="nump">$ 1,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>148
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MQ+.=B*M-GQ D:AFSLYI!N7&< M3Y#JP14C+%.I">V"]%A2:Q"M0;@&P#;2:
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MY#MG\9E-G[.PEK7';PXNH,)X]!]7W9\H=1BLUONS,B0K((*NNE-T;Q2X=$.
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M^BXR_M;A)X.=ZJR)R>1)B&=C?$UGCF<$ 8=$&P:*KRW,@7-#A#)^-YQ.&](
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M(CCTGT.(A,Z26[W2+T)"7X!\COPT#N,G;5 ^GS!P/IR0*RG3\'$C_<=($)F
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M:6X I.MQ'K?#U1**X7D_\*M-[59U4P]*N4 <9=.%L2>< Z"('X0B>Y"'K@@
MV?OY+8 13P&1R ,>\I]!/@;X48T1:_&E@W<]4-PUT#,,#^0!L@*1.#8(+RRU
M+]9]MX.7NF!0 V_ X/L]L RW:CSB#H8-#R"=!<V_Z\)0!,.(3B.]]PU2)LQ0
M>> 7(&%T$3>N&1,I][[L;H"\")-T;&J@]'93(WQF5S9=5]W63?.2+H: HP6'
MY(F'H[]1$!K0!I"@PRR-+N@ALX>X\+H29FG'1B8%&QR/1N57^#1L$*P[O"Q&
MN-,/#B=QGX$+AYK6O;#+B[ LTI3(JX%9M3#0T/6'(VP (QJ%2S%'J=O]..!J
M )7*#.G(_#%6FT139B>:T,5U$0H Q6VWJ\NBWM'6\PX)E;[Y^?=WWY]??#/W
MAZQ0250P^@ ^DS/\MD.X=NZ ?Q6N @:V![(FZ@#^V%:TV.NF*4!LE<CI-O#\
MUMWX8N5]6P![+<>&AAII<\:67DNG9UG\ !N"ZP) RK$'^54>BFMFQP7PG6&>
M(7=)3@)/*5T/\JHJ0,<L5@?+ITX0$\L_IBG!54=RD-@HRC[>P_4,< P/GDZ@
M#.(A=> YD'U67=.X/K)4_FGDH%S_6V*Q=\RCL#U,*#,8=5\T76D&DAGFMIN6
MTA$;T4%8P)7-6"5I\1 FT[LV\$X3P1M<$/.:9](PEWD16#&RQW,/C[WCF9&O
M$@4XX(XW>%0&8>>N /L#-&R#G,-">"T/I_<C0G4JMAZ8\R((R+W[@&\@YT7Q
M!/P,U@!HZ'8@SG^8#N0_EUO@=+[8P.;(LCID0$?8:\&(XF&*Q_@(;/>'))]9
M*@EJ$:J'*0,R 2U6!']B"D+V"!.J<ZK6G'>W+8QG"6E1_-'!7A6(8D JK^/W
M=V\#8JZXW=;E-C])(3(GSZ(05 VTV^"LMQ[D"FX!82L2E5E)/"RW<,P\*[<
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M_N6S\R^>/;EBU.O5AP_]')_][Q$H%'Y_=?+)K_#)B&^Y=Q+=:=-U9RQ =V_
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M$<CJ*>^D+ME=1J(2"+SJW2WP47(P>Y$8N;*99@8F)/%?I@"F>T[.&D;-B&/
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MF;/-?C=ZWV*(!<-ZI(PJ1B*'0D'G@3/DS^$$G?U!82%,)TBH,WX0X,X_H64
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M)9G^&+H]#EFLN@&HFO[<>N 2/3X ]]<=D+?\P ENN_X3@??Z_P!02P,$%
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MEA DHPI@?HI?*4]0>0''N'7_0:YKN2+=(*CIKS5;6?EM(NDH 6WAA?2#).T
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M@&'+CFT5H$P3:EZ\NQ*_P/O\NB 4VDFBH7WK8YZ\#EU!FNA\X:H:0C+56(:
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MR*B6CZ&_<FH5!A%^;4VW0OK>9X+3.JGZ2GY5Y8$Z(72*'W3-)52*Z;"Z+Q?
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MO:GYXUJA9K*T ,^7QOCTA0[([[.^_ ]02P,$%     @ G8!*4@U#91G5!@
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M^WQ??.=YH\VCK1 =/-=2V454.;>;Q;'-*ZRY'>D=*HJ4VM3<D6FVL=T9Y$4
MU3)F27(:UURH:#D/OK59SO7>2:%P;<#NZYJ;EQ5*W2RB-#HX[L2V<MX1+^<[
MOL5[= ^[M2$K[ED*4:.R0BLP6"ZBBW2VRGQ^2/@AL+%'>_!*-EH_>N.F6$2)
M+P@EYLXS<%J>\!*E]$14QJ^.,^J/],#C_8'].F@G+1MN\5++GZ)PU2*:1E!@
MR??2W>GF"W9Z)IXOU]*&+S1M;II%D.^MTW4'I@IJH=J5/W?_X0@P35X!L [
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M&?B%L7_=4GS4D#6:;1@["X&E[<W>VT_V1=O0?]+;9^&6&Y)F06))T&1T-HG
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M0N.ZZ!O.0U,.-1>69K84%G+"EG!MHJ$>R)] H0!":JAPX)M$<RCP;EK;5\U
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M 9[/# !CO* #FB^^SO\#4$L#!!0    ( )V 2E(XI1H">P4  $4-   9
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M&]G>O'A3AXORW'BZ=H<AIP=:WD#KA3%^\\('M%].I_\ 4$L#!!0    ( )V
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MMTO604O%?)J(V7S\-$$RFC?ZFX$@!D%Z4NT]DNDH[DF29C')D\:'9-]NW_Y
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ML70H;/@Q(#QXL^4#^*7QWFSX=HVP4)86X/O*P,^;!]J@^T7F\G]02P,$%
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M)RII$S@#KQ7#T\CPR^E!BJ_5<B1FDZ&8CJ?C _1FE0)F3._\<06\[2C@NZ"
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MV+3)XQ[_J#3_A7]*CG""6U2D9H+.9-SVT#V;_B5<%%L7*[BDNC'M-EX;6U,
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M2P_@]]2@% U?:('J_Y O_@-02P,$%     @ G8!*4FA; +:2 @  S04  !D
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M9#!W]"GK:^(:EC-BE\):4'U_+VRG:?6J=&"[2-KJF-@J[J"5.C#A2U'C\[!
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M<\3&2!C0*S(ZF^\DGF:!<'/+HVRU5.Q):4F>[]IT=*[TYS/'Z=_H48"W9'R
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MTW%LVZY)#,4ZS'B,W[DCBQPQ[?UBNFJGHLND %Z5".H@$WN ED],UOH9UCD
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M<Q:S#]GE'G6_>O+L-+3'I\4W+ V")B@-'^N6XE.$>!^LM8E'T_A"2WC4I!]
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MW.,!^G[1DN.C?V "<!$O[X?_!5!+ P04    " "=@$I2OX11M^P1  !_,
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MUWF-33'\QJQN <^6.X)Y6<(^C/)92)9!WVW2TCB\063&B(1BHN_F>E,;*+'
M!N9&QM':)=)S!7LS/)*GJUK ^_29,8$< Y,D)=Y5ULTQ(-2C]=<*.M;XEVA6
MRQ76; .>862LFO"O54W@.]%W50X0N$34R(0T>IC:QUG?$H# 8 I>9NP=MP/P
M?=_QOR 3Z;5W$M'F+*(T6OO^\-NB*HQ)1/\3.-5Q-']J*",:6XJ^'<QI^-V@
ME('W/;%LPT9X.&SX;A]395NHC!S7^]-C*K-\K>=JK85>+#07YX8?TKCAP1$?
M^IBS832GLQ[$#H"_TI^/%'&VB((=/F KU ()=:/2C%<F,HNF;HCT?@"]+Z(.
M[HW\JJH'->.-*M.BJ?KJHBU1N%SH"9BJ8!@A1X7,H'9A(<:E"X/".%#%>77_
MB>V<=EU.[HB)0,.P@V*G3O.&5(.>; [=*##<Y7R4'$"DKR/:S-4+8PSY!I4#
M*7R#FK1(NK&CG#9@E)6-TFBI<UVJ#.:U0'4C)/EZ(#YI!6OD)T2$DB 1'+C-
M_FIO]RCZ]Z!34H/82[9;O1?75*B1^74D6C-F,J/2$W,-"^3L:4+*GB.X<>@:
MU$Q&07OKC HTPQFIA,K%AJAH4_!C$)%J<82PT"':]I3@P_JUSHW(<)*NH^^+
MM5K5S5;0ED1G%FU4$.J8;U%WU+5),U./F*:D$DE3=A6DP5OG?;M#DA/J%!*(
M6VXW:#W:>! 3FI,WO-06SU%?L@/4.(IL:RB JHO%F6/]"QRT# REL-BY60@2
MP'IM%IUP0P67A3S5F?B-MPLP]9M>6\]4QMXSM'TDFVN]3',NMB$K(24"UW:G
M@3@5?N3$K@AFMA_[=#MSIAX*)UMZ$K=!X/B>]?PPW ^M'UH=MGWPT?_2LP-7
M"AD[TK->MG:\/VTBI3@3<NK$L9C, KJ.'%=:KXIRH5-::.+;4]2:9^#?\0(,
MLGTYHUL/E,4DLMV WOJQX\^PD,EJ$VFC'Z51>!SNKQKB5>@ZT_ 8?#I/>N#\
MT/;\@&#SH@[%$8:,8$]I:#4[E%";A^&4),&O-[6G0 @5:R"%%]CN#&^FSBRV
MR"%O._4K-,(*'?M"I67;<@VLMW.IK9XJ?5^S_.TS2^PB=BHB)^!(,>9C'",H
M]U.HI'V,?G]A% =M81)%T>TM9'!-XGQ/7E4AIABZ#^\K$=0/!\6@FR)#PYHA
MI>Y) FOYN_4NK3Z>+TJ];4-%26SN#O:<*4;W9#DR[HX)VT#TG@/V<.08CI'@
M>^*VJ84"J\G3AP(G1?OM$@7U70.[1;VF/A*67/'0C@(R0VD:=^[BF[*D@K/+
M9@,SH@A+0U8IRH.2<TF?>S:JAC0YQVI]E[9SS41G+/4 ]JWZ1$-R(R#W "@!
MW\C[K#U8E(L7U#/IF-@X8VVK2:I(NLQZ6*%[:W,D2W7&JW]PKC"=.@6XCVYW
M'11Z6=1LM"YO7%1UUQ*,M7LXN1EVMG9=4QRHVOR8_H?X,_OHO"%]9(>PU$M5
M)EW@'>2L YN!'&>:#:A-Y-G1"FCBG;'>"83.J6C\ZWO2'E4B^VM8[WA7D2VD
M,QMH%&2ZJ+B-A'MA9_>!M66JY>544 "HK)^+6RZ?T6:<RA!Y0H2QAW[%@5,C
M<@96^U0B2,\BM. .HG-$&>C4XQ<1TH(4?N!,)2;(J77J&S*V)SDN3Z<"U/ \
M:,?/XE"$TG'QUI&N=1KR\P!T?"SN>/3<=ZWW14V=^C!38&!D$>Y?@_%85]\-
M7C\.#L ;VH$O"=T9$'+<N$,7SX'*GX&NC"-&=S9$=Y0] TK>Y&IJN21WJ=GS
MD02K=-ZFIT%EQUT%$\&C\UK=[0[>R4N[D88" 9F[:9X8>\+O5,1@ [3.,>E\
M7>2Z+:?-6KL,#0*N[BNB(P7M3E 8U,.<5M(U)94R5=D7..^L8)=S:#4T1Q&G
MZ+)CSS8U?<\%KG+#BCUHP3+(][K8YGM=ZGU13-^>%_EY:\4'(N(V(%;CB'B-
MZ+(3]4:M>A=G_[]J;QG:<13!7E#I!C'%I\"EVIN@1X2R@^F,[E!4AGV%C4&S
M8,;NYXG8]C$![N=/X4ZQZ[+[N=:O!N%)8/L>5\\QT9^@^/:IQO5-S2SMJ4\U
M,P(3O&E06TL[FG$!/G-@6%0UQX&YC7B:CSB&:1YLY3Z5,GJW".A+GR)#*_-(
M8I:7W;8['J"<FB/)C@]AY@4=#%"Y,S)NUOTY%Y3;,M01KT:6>]!_#G25PT.*
M4M,N!!TQ'3L6:CFJ6D.^?TTZX2+CE!K(=K^H.K->CO=L.G\ZI6TXM&!3JK<#
M:VSXZ) B7\QD&PV/<MHBB@X,L(,+&2)0(N*9/3:"\LM3 _Z#]^BZFP?;E2']
MNOSK1];1K;%MM&UR0G:9P\\/X E'@>=C++BCU0^#TFW@6*BM7M !$3"ONFVP
M"G&F1HF:(OKT[T#KX/$HS(0/9BO:']LR3AO+C@4[NIS/FW63F>:%MT[X"%"O
MZ N$&RV0!$35;I>LD;%U>UJGOCROXO.X]+HQT0\%I=D!*?5@GZ(]<#5#>-/B
M(6O@ U!4&6/X@T)"N9C\#(H:D>B9SO4BK7F?L"+'1F3*Q66W WE.0?V\4AE)
M6]+I'[%S2=L\E#H$6])A"^T+"Y;P)Y4W!*3)112K$!RD'R,XX#(P_Z:RO8^E
M^2_M6>B+,^NY08?6[HQP(7)]RYM_35Z;S$J'OV7RX,&@L=IKM:PW!^"%-HNU
MOI@0S&>=3<'N,O0@Z0)]A;&C2>01?Q-B#L4AXMN4!+ NU\1#-9AAFJMN'TNO
M.SV;A;9;'*A(X @B\%A+AS1_D#4R]Y:9GA1<2T9B$J+N 5Y%22FW,#&V795G
M\4;(WFY&P&+A]YY\J$5-=9ZZ>P ^_#T^?%(E4-JQ@=V*A//%+**\(L&YRUSP
M+:6?D*#]!FU)I#A651ATFT3 ^:MUU?WWW19$S_WC2NMYFH$GSVQ<>9_3UO2
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MTBK1)0W ^T51U-T-+=!_7OGTOU!+ P04    " "=@$I20%>M%-4*  !1&@
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M#D\G,=BNW74+;]K08AZ,IX85IA7]0Z!E!]HO#6G>+3C X3]G]3]02P,$%
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MKE>"S"\K:7"0>W:3+KL65!-LRT2:9CI\ZY)68?DNAF/CDY7H-JK*1B6T[0+
M?Y%%0XXRFJ6L-U0G PB6$+!1&?)1EC]IM2J12UH\O?E0F4TSE;*-4&9RAU<"
MZBM(02P6S0(/C<J*)=127[*D]0XL1AK\>XX!)#&\)54UI\(W%9NM,KE@%X\R
M:2@QL>O% A,5&]$,;K^975SK)^?-,2%<LLPX,='K# E):"J33*?(M?@\7'Y]
M?KE=#R@HGPU8F14FH]-*I',8"'R(%&1:5>99*HALR'@9S!9)4JXWHLAHZ(FE
M62662R67>LY0E)C#Y"WRFF($539O:.I&E8NL)A%DBG%EEL*1V8)$FP 2\WSH
MX$*L)9RSPY=Q1Q;:X" [Q^0\@J0'J.J5ZSB"&7-)="T3;8CA6+^U<6)547AC
M/%,,H&M3BT2R-BMT)L$[!)'**L)QP9:JQ++V)18-);.<1-[^*-:;-^=,/J+"
M5D2N.SUR.1AYKT>F_8A6R5 8I"[7$M;D!W2?[*N7EEA<E'47"TRL@6?VM?7:
MLTR 3+-&!.K@@KVHSR:M$1RXM40A2CQU'"'I<.S6<8C)-;T'&H.E(!JK5H9N
MBF2@JBUSF4[VP@/\W6H-JC6Y4*"!8;(1ML.\^=,!^I!E8P(&M;Y4LLT6 [&T
MX,\*V]?PXAKV]1J1B55-E6'Y9-RDE@B8KQTO\:ZA-"$G; I0$B1$#6JQ7472
M<G16Y$P!N=@M;XQ"P)#<.S.0]SKL4'59ENE#AN3;,KI-F\802A4-"HCQRX.D
M:<@' JRF74"(VD2IMAC+R)Z]I<0J2<!)%DXLL279 +K7UF]2*":I)V"HZ'(]
M!YU0U2VJZM9NUF^#^&  6Z./D[L)>T4(K6$51?"Q==MEEE<L&GM>B+LW#GVZ
M\['C>];[8=QY8R^*\2(( N:,[3BP]H..!9PS#CFA;>V''RUQ7!:Y-O-X:#V+
M1<]S&0\<YKB!=3V,R9%CLV,V<NGB..S8V@M&TM7C#N[.V'7I[H7>"[@Y\??%
MS?>XP2WVM2[<"_9Q<WT;+T+;@XI.$![ S0=N 6=1=! W6!?%P"UR#N#FPB?X
M<]QH'S>/(/-;\ [!QGUN8',B,B%X$;;H>\(6CWE,-//'3A2T+N3[L,4AT2V*
M"#8.-CZ#+02A>.0R4/$ ;" P@6>[S(?RSX&#7)?[S/'=/>"X'0.TME_]-NDB
M-]3H\= E].)H@)[U+%@9,8]I'#4X>]CL8ON,VIVO]*Y6"WT[R]#>>%%K8QWN
M,#M<0X]<K16^+VO=4S]K%+9.X(#(&]LN%HP#.[)NS(M1#E<=4R;=[P&9$[C,
ML:&+X[<;/)?J1A&N#D('@<-=:[JF%M?4D9T68MO>3X<UEH+")A^# 1137<YH
MBP_R>J;:PHD.I2T6E'H')9^*,M"(D8] H0@YJ4OYV_5D-(]Z+KC8-B1X46XR
MPNO9?M#&MSFN <7D.(X1LKH1*-#G?8$J&54M*O!8!_2&@WW[D905)(TB';\Z
M^R'E'K<F/HN"D>'M,0,?1P[%>^1:,RUBT,^8HE^7ZDG[BCJX&@U=031$RYWE
MQGF PD-,>-8_T8^2Y^HZE]NJ2%[7/2BPE.A]*7=I/X01]AYSN+W3LRFVCA2M
M>SF% (CLPF&S86>\[<"[(#3\&KEC/^2$ -4'J@  -L0>/_>]][:_(T@C$!5]
M.HO]>'>'7;ESW<%T@[5XU%EIA!)G VEZA#&!;Q[YV(\)__FV1O<]^9P:C=_1
M>X':*5C6]KE]-."8BTYC40**!S)/AQD% DY??T6.[GJEP,FP:\:Z-OCI<,K6
MY_ZQR3HDBC+/Z\/GXY>[C/W$M9_5W\N"I&T5IV)HHVB_0KC$@6O^]P-K^H_K
M3[^A3GDL=AE"_N/=_<7Y-2-_>@[JG^U9[RZNSB]^G9[<WUY,K\ZG&$?R ?:!
MQZW9]<WT/]=7%\P4!-L)<0WA9F2D::9^0N/A,([DYL:A]:]/TUOF4/U _#@1
MMZ9%*C#?"R@VO9BNKA>V5/4BG_E>@+:E2XG;AJ@K\+IB63^Q\_W>OW?A0I5K
M[1&C$!,-CN@J^PI0EP:C[G O#/7,,;H![*J;T:,XV3O ?W<?(; <5]^]T/C*
MC]W61R@G;I?SMKA[-EH0ES/?]5'*JTVF3#KIA;H^_(JBZ]F\ ]:/,1W^@_L[
M8+L.L^N8= OPC9+U_S(>Q(E-ZQ/%KBZK-A\P#': MV%GA8M^@,? A&_IH?OC
MKM_K&QA](-HEA'S4AN7M]T>IJOYP8!+SATH)F>,0 5+DYG0L"N;_T)U2=KX@
M#+["],%?_<GHUZ5P(_67V_QI8B5(9\UF8]([%,0.HG6Z246]Q@>3&+4-)HN9
M3RG(X D)6NHO/CM:;S_[/.DD39^%] >#G2/@WJ8L-17[KYHYL6YV-+G7F]_H
MS:^P^1UMOD^<R^170(\B/2L5FJ&VR>#L!^0KNN#)TEG3?.UX)Q4"]L!D??%P
MN43]U;L/+7R6*BHYL%<SX.#WO.[(;.%<?T-9 ;:,V287YDS.Y!]-MJ$9K?M0
M3):R7"JQ0;J!9_L#K-Z"3JK:E6BJ#@?3X3AJB4I1$SCFO!7@H+?[(37$.27"
M06*F2FPI$$K(  YZ*ZGTYXO816P%OC7[*I$(0:%FGB,V71P+7<^U?FF*I4!.
MH<8<8]8'ZF#(L4&(W.ZT 4D]%G6\8=BEE<U+J$#5 -D[T'?/#0Y]#3\9?/5?
MDW?IMXW*?'DU/P#TH_W/)U/SJ\%VNOGM!<EKF:&]RN4"2^U)Z!\Q97[/,/_4
MY4;_AC O:[A>/ZZD0!6@"7B_*,NZ^X<VZ']4.OLO4$L#!!0    ( )V 2E(F
ML)X<RPD  'L;   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;+59;7/;
M-A+^KE^!T:4=QZ/((B79\NM,7GN9::^9.+U^ADA(0D,"# !:47_]/0M0%"13
M3MJ[F_%8? %V%[O//KL ;];:?+8K(1S[6A;*WO97SE579V<V6XF2VZ&NA,*;
MA38E=[@URS-;&<%S/ZDLSM+1Z/RLY%+U[V[\LP_F[D;7KI!*?##,UF7)S>:5
M*/3ZMI_TMP\^RN7*T8.SNYN*+\6]<+]5'PSNSEHIN2R%LE(K9L3BMO\RN7HU
MIO%^P+^E6-OHFM%*YEI_IIOW^6U_1 :)0F2.)'#\/(C7HBA($,SXTLCLMRII
M8GR]E?[.KQUKF7,K7NOB=YF[U6U_UF>Y6/"Z<!_U^I^B6<^4Y&6ZL/X_6X>Q
MZ;C/LMHZ73:384$I5?CE7QL_1!-FHR,3TF9"ZNT.BKR5;[CC=S=&KYFAT9!&
M%WZI?C:,DXJ"<N\,WDK,<W?ON#3L@1>U8*7@MC8"'G<W9PZR:<19ULAY%>2D
M1^0D*?M%*[>R[*W*1;XOX Q&M9:E6\M>I4]*?".R(1LG Y:.TM$3\L;M2L=>
MWN2_7NF3<BA+KFS%,W';1QI881Y$_^Y?OWYZ"T/9C_^8I4EZW:WKBKV3BJM,
M\H)))TK+,FZ,%#GCCBUV4[AE>L&P?E'.A6E]P+C*<9%<,FX$RPINK5S0;*F8
M6PGF^+P0ELTIT>B95H+D^%<K(S"%.['44&B!6YL9.0^3E7:")8NKWB.5O9_%
M@RA8PL)OVOR.V2?M>-$[^6UX/V3/2$8IBP)99I_W7G.[\J9F="&^U!*KPNKM
M50\($1N@UWP6SF+>^/P"_QN?[5WAC1<T@*65MA+#2:3&8@Q+!K.D=77[ZY_V
MWJL'81UYFZRR(JN-=%CQ5>\M+'&;Z-$I2Z?XNVPEI+-)[U?2,&!$9\4&RN<N
MFL&F.VTCEDSA,(/5$:] P4MK0:+Y[E$S5E?$/V$!8-$U-_ -<L6 D>Q.^22Z
M[/TL^5P60>G?E7AR<<F>[]_U7F.45$MR#R98"=F<9)V>/O+G27H^P_SPT_,!
M1V#203JBH*6C"?Z?I%,:0X^3Z?@0/\GE_QD_TXMC^,&;I_ SOIQUX =/_PI^
MV"1])&22?@-!NRE@S&3ROT30.(TN6P1M_CY^)DF,'[K[!BZE<@*4Z!A )4(,
MC;;V!59OA,K@O#6O(@5I&BN@N[\$T,GYB #J?R* $D,"FN/$(_-D,@D030;3
MR:AWRMX@%&K9T*+$RK_4W,!NXDKBO '[)!XX&HY,FYRXF2TYL>F"/4O&DRU0
M68TRA^9F15R,UY71"T(9AH&7-3C>"7)J67$%9PV8$FY 78QO1QK]N5PL!'E&
M@+7=6HA Y-3#-*4 XL@:O^2+:PM-,3Q?E@A!QA7['5V-]S>9\*B2>%44$>F\
M184@VVBH5 @EW%;5\T)F& MSR#C(OA>5"\E,3AFR3RL1:U]#-%RT*T(+HTL?
MFG1TO6]EES_\P.2:.=T])^0X%;0H>0;;65:2RWR8E&:%!EX,6W&6PTI)=OG"
MK)R/'E"M+-8%L="V):"H+*/C A!4[+>5!.Q,MMH,V:O-0<@7;0T77]$:VV/!
M-8)D>?"V"')D7K.@S9-U?FNU\9%BK>7I]UK.<MQA&F?9BL-!Y-5<VDS7*N3G
ML/<FC"BY0OM-\B*8.=SZKAFV;(D$8RT!;7\53?>AQ%>8N1;% WH>WPD. IAY
MP2E:QQ;["$BD9:4-A E31I"SPQY(X!@_[()N61&1U"Z-]UHL&(WIJMD:D!NQ
M/P#!HU(0,PX#N')!-J#_R_U2HOE-5L6:0*3^67;,0MH\H 3!I\06\\:K+]9^
MXX WV^B(IO0MJ(]#;(J-E601>7W1V5@RO&FE6[E4\"1HP0&Q>DX=JD\DJ:K:
MY[PW,V18P-JJMK'_^%-9<N"(*%,^=;KHJ#OV;(8^@XQ:H !I ^38.D-$[%40
ML?6&)<?]@:!M^8;>8F@FK$=7K7B%$0]XC9^\SJ 3"Y1$?O;:CXX\3S.BR8]G
M#."KK*ASRF@C[6<;4YG'3 UD&X?DAC0CEJBC-)9G\,I#\!KYM^(;?PTEH!+
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MMD'%L[O,'I\_$3N)=6\T@VIFH0=2O$&1_P/YT!;XP>:V[&C8[#', C"4J(#
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MDI8H[W;^>T)AT=#A18#0+D#L&AFM<+0"M%($ RW.-C/O%G(=FTDAT)TEQB?
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M9$]:6E#@6-Q#,H=+":R>Q:QV$04<<>SQ*9,Z21=D[X@:^F\BLI!6&H0*'@.
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MGA&V[MZ4N9L(THL,W-B2[L>EQ(9VW;E-HN/Y\*N**N<3<.3?F2XR ZAP[%-
MTY+,B47Q%\O5[.\EF"WGZ9BG<'F4>7G38:>:R>B78&,JWY8[A6)]*&=_LKJ&
MYNPE*TG2_M%BJ_(U=_RC=$A"G76\Q @55E<3DQ='G#!(@&XOO2R:=16C53Y6
M@':0I7A1]0*UJ8J7-&G&YDW>QG8V% 0 J#"KE5(S$ W49$V:"[D.MNJ"]$Y"
M!TZ\LVH,5LS)[U/A)OXT=4Y] A"K,3*[M+/GFO.Z71.:J9,S"1#Y.O51"8NV
M]7'=:A"]?<4GSO2#!?#-\S5"I1*%D)#1W*C=9AJHD@LQ9B#TJV)OB:+N*,!'
M-E'\(]J94$)];5.-05[A<.)AT(MT+-B34;O"V[S:1JDQ:HJ*&=K<+Q558RE1
M?VB=I( ?6>"=W/^2EG^W8<VUM5SAL,Y!R4*G?#^T2<'K\IU+EF?*N2,Q WE"
M4PVZVPBVM-XS5I3:;ZN)KA'#H]2/K_8_;%/7AW?P[$J O0<A;:F<5^-((7QN
MUW7,M"T6<AM=#H3A6^LY88("'<O=-C?+XQ@AS02%YPYDVE>>+YN9A&B1(H;=
MP/6[ELKDM"ESL1'*HE/13+K^,*ML'$<*LI+P^\"+CW'"[\W#=!RE24?'V38@
M%D^P;B#(($U+PO3 N[*@WLJQ._#CZ5E?APH#,IVOPG:A"U*#GR!S69M3S)T#
M3BQU!K;I>K0Z)7;*Q,N-HF"?HB^3VWX<HD-ZQ=:F;I'4\$3+M$$5G0E9E#C:
M*XF-.__DJ 'E#SZ!A=J$6D</A=.#3V8B:!46'O8 !G.[_U,W\+7?0/6\4_')
M:79]6^[WZAX'!EI4?)$:)1QP)I/R2/6/2/H)2J<1U\\= YUV\F<+9JBV0,Y<
MET5=^$5!&*7$2]*[Z:":P:TF';=(58!VE,A^C,-:9#/&$-*#*;:*W"#'!D%7
MUILP)WM6G.DE,AK?VNN5(#'.B'OO(Q+::,G+G@3V6>W BR0[55;2;D_V^<'G
ML1Q3-*(/%;DI)FB1U40]/T8]?]E]R8>Z*,DQ[ SK:))SO3P?;ZP(C1*AQ2J1
M.E9,1V24V%[4F^D1KI$WT=\ZPID5U BUEYXLSM7 \3F)!L:=RWUM1BQEZ2T[
M;D;$]=(D7%Q9I-!ZR[:;8$\#U9,6Y,<H^9KO::D.JQ%1:S_G-* ZU"R5T.X\
M)H]P]R,^2 ( 7[ZA+%;CF+Z)S701_[#,5N5O';IO=IV9#&0DL2Z!T5$D,R^I
MK4.\%;U,N_:9[#+BY?WLCG 9"7@[TN5*1QK'BG3X-K 2*]:S9GQL;XGOB'N1
M#06R0;A_D.0?8O(.J5H<X".7AN_!CQB[!QAP%IJ.P8YJ151V?X0C5U-,/[DZ
MX-C.Q:5IHSGT;9&J.7 V'B5/NEL_3#_3G%EU[%KNKUR720PJN4/76,)"3_>W
M[WQ!G/$0KC.B/BC<II-%C]I8<J%4>0KBS#_WG_F<<:(E:6Y !K;J1*/;$J0E
M:&Q7E-=IA 'C.,*X, GOGEQ!? !H=-1NAM;L%<FFHG[T,;(XL5A^F1A,)44C
MFPWWI!9N=@17GIN2@2NZ'76Q.,&V0,%JOKCK=[3+J49"#=<X?MF-I.E"5KH(
M%5P5IYB0&D1D&8Z&9N=<KCH07Y0G 4"T0/00<0]RL@8 5"Y"T6>8LLL/EFI:
M4\AAD,3LLVTG%9AY,>$#BZ(H(8\+D-P=FO [?X_GW@MY;B%"N(^O4Y8+2,K#
M;HT=U^+7QI-ITD\9YS3EDRE(HYMF1$^@.QB1\%&D$TL;<4$C!-D]VHE/L+2%
M5;M5C3*E[+H>WL#81G*.#-Z^&P],G)XIT.PS*71K#GE%1K"I-F/C/+?54.7A
M7!(7XF+%M30K4>*E(#Y:+MR.6CL-S7+72$P=>G&EK:G@EA8A>4H,]2'VJ+*C
M3AUP3?XZ5P8AHIKG]=;;6<<5-S+,_-?SBR^UR=<*_GK^,K;\ O3]]?R+%_:#
MZJV42T\WN12^*5C&7<$R;DQ)G^-%?-G*>=2P9.Q-4H/J73'DR0S%2+"3+^.$
MV\#/E#WWB>!@[<M)_!5=KG6D"UAV5^;9%1P?">+H9;SX\S6<J1U ^&.X*QD9
MWU=='^#?/_: ^,?7/W[_Q$H*1[W%/$R3>V08D"Z] 4C5Z9;;+VM6L:H^X]MC
M)!/![NB<T=VUD;,>SYB^S<\G9_6M+G\6_OPF]N?\#-CM&AN!G%,Y2,-L@X8<
MK&E0%$1VY9\8[Z&;VA,K:PD=K\0VC<E2(/!^V)+="WMD^=I%WC039PI&_O+O
MJ8O=_W-]\=]6%W\6+<4=RXB[I$C[ 95N%4_P+M!5LUB[17L:/8% L!M0//(Z
M8$4):5[_'^/^M6+T2"K@Y/F1\OEIVSZY%&&I8^VHOW1GCF:8OI+@9_10%BI[
MS<9VX(_+2>9@-"^5D1I/3^T?RYVV?9-+XR:])U6\?'F:_7/>,7CD9X'%5JD.
MK54*GKBRL\?1GOR)J+@L'/G&VB8VC;!BT>HYNR</.L*193>BE;F9NMM0;34'
MF!Q+Q&>?Z $9I=+@*/O>J-+FYZ+T0%$NJQ >D\;1(A#F\_LXU:A'-ZD[Y"TC
M"*4XO-0+_OBR.B$A3HR-44W7T,/&EWMO+(M/[R<:Z^44;8O5C.I\](!Z%^2E
M.63-,9NP-%?(*_6=)?5>M008.K*4UTLO865PT@:8]Q!K;TFWTLXG3$!6QFK6
M"EI]JY@8F_?(##05:8\94ZYS7D)RS)G_YDE.E_0N[8/JFB(2OVNZD#(\*D^*
M',BF41)FJS3>%>%,+5X691N@'MM3S3)QR= BWO(;M9[*5MUM"4#.FM-P)+%H
ML L,1DS(E'(E6+AX&M9RX]$FJ,^8\JU0+R"E=OKU:?83J0ZLZW$L&"]'QKN1
M274)W/:X4J_>>-/(1!?]/8S0RG+ & 5;%=:BK^D<!MGQM@T%-06M\OOTT,5$
MVMZ13C<;UNA;RO)W' HSM)/H%C:,B!?J:0-:<OBK=B1]E%GIW6!H(9!&503]
MHZRUH<QK%\/X92P;O19(3@XM#DT"D"OKHY)TSYWVPRVP%Q&N-5@#W6,ZH3J9
MQ@UPH_3_UVU)<:^INDHBJ0B)1]Q,"'%KN\AA\B=U!)%[+X%]=($"VKG',[$Y
M,TX.KJMKHIU<Q5L#T?6J"XH#<4,PERSFXE,QE23"2;^-NP%K4%/%N^%3K1**
M,WB,VCF*]I6'27@!9N)2:2-[/!R"Q8LL-]IVV 9!/?./6Q^;0JXA9SO*R1CM
M;493Q^YA5F:1["!F'R)'D2L")Y^/=]9CB?46]7V-Y*N/XDDAM#NS7A,6^D25
M#ST:%ZNSLS/'>;&=$O:<WU=A[!VWWQVJ_SP@0X?<=HU<";:RTEBX^#7K K@1
M0$G]IN-Y/?C@A3]B\S#]<NNT@@E8DAA0UN)E9*>'XT<:KMN5']/N"N16T39+
MD56)UN$I$-Y>17MS%>/1VF,6Y?JV&E 'Z8-,JA4D2'BU<3W/]!S/&^%=<$QX
M&D5TK=6+=DEPO#J^.XI&/Z76A-I(*KXE;'E+;9+O4\+QF7J*-D'KZ;A,15O*
M4AV)SL/'PK>M(D/(7=/5+^VL%P1C94M:TA1<6$=<C>PM-722KF,(=$WU@7OJ
MV[3EZB*YTZ*V %94236=W+?_6B!![EKV =6WJ#M'\W$2SF<_O'1K=N,@\_6*
MZ[S2REK9.Z?(7WE9\_-$S^?6 ZQA3N42>SZEN:Y3.QV;US0&"5&:^LI^R:$&
MGDVJI! /=G%FCSHN3<!G:%)*-[$HGC)QPLY[VC:^ %&"H[(FS/B<6K<K:H5
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MMR$'$/$%>+YMFE[_P GNF_8#@??M_P%02P,$%     @ G8!*4HQ<T4W8 @
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MCI=K_/8SCA;@\Z7%M\7AAASLOR;/_P%02P,$%     @ G8!*4EU9TOUO @
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M\I@.[MB%4&O[)8&+2M:E;J[;_=O^8^6BN:._F3=?.EB\ZPP72BY6"/5Q8YV
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M]^+S4H!UBL A/UBR?8@>^2N\8?$Z+T7E-5&77E3I15TO1<ZLYKGA+A+@72V
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MWXK47O<I4MQK56C(_*7@<+TF'Q(@@F08P6['!=;>>#HM=277MVN&6]+$ BK
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MC;>NL08!3?F/73<K:F![N@%0&R@&TAA(Z3?L8T"Z<>H".4MCU\)"( );5VF
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M1I9VN&(4=K0X ;XOI#3= RKH?X"=_P-02P,$%     @ G8!*4M^:N&9W"0
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M)N[C'X[[-N8GRDR! 0[+%/ZW4$@NU<K"H#.DJSD\L"T-[-R%#OV'S5).U?$
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M96.D*EW@Q4%[6HQQ3/U<%T2A&PLFX4"!4U:*8]"9T=A2(AJ11 (T7<I4LGY
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M&<WE.O<?S>;?5-H3%,Q,[L)_L8EG+R[:(EL[;XJ2&!H42L=?^:WT0X-@W#]
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MDB0<Q@?P?FZ@=;E@ =77P9O_ E!+ P04    " "=@$I2Q/Z915H"  #H!
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M+ N@;(U5S0E,'C1<=CU[.>7A C"+;@"2$R#Q?G<'>2_OF&7KI59'T,Z:V-S
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M<_H.!.X(&DT**D6Z*U;=Q*J#+Q!;9:G<^&%-]1VU,Z#]G5+V/'$']'\,ZW\
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MUN3JB:L-LH?8Y5M+G$A<5OQ(H0L.?+ZSELY&(&B?O<D?4$L#!!0    ( )V
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MHN\T!HAU62FG1FZG?E*KYT8$2'DL\@=62'DM<@>93RL4M,86Z]N1 8/T$-F
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ML;U2OOU2YNOZ6N]M7I9Y6G]<\6C!1060O]_E>?GXI:I@=[%_\A]02P,$%
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M1&@#N+_D7#TO]!1MOYK&?P%02P,$%     @ G8!*4LOMYB69 @  QP8  !D
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MEP:U ]#]3"F[VK@ [;=K^!=02P,$%     @ G8!*4K)B4;", P  Z@T  !D
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M_<5B/U&\*,_F2Z[T2;\<;O1E#(0QT-]7G*N'B3GNU]>[Z1]02P,$%     @
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MH!OV>KM)MI2G)@EK][!D#\LXB[A8@[64T<XPVMDVV&H;]#VT-P!<I0(<[HT
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M1L8%%"W2#CZ0*(B"0PXUPZ<0(SP\"I^^&AX.&J)IUSEM.[[V2SF]_88[Y,I
MKG\W\'9JWH[C[;S$R_*",H6WWQS2JB3I.1);=C;C3B_"N#;[BOQ_J!U$_?K0
M$_^ZM7_=1O^^2V4R,LE!L9B2VQGD2U!-@?=JXMZ;"MJO>?MO(6B_6= GI@>U
MZ4&CZ6M(UF7EQ:O,C,::HNZPS<2T8(9R]M==_D-WNYDWZK:"X'V#-F>U@V>-
M1#],!NHU20R#QU(7O&D:P[TB&C8Z.P<58_*P49*$I2DH$#&0)9@M@" IYI9L
M*%\#H2)!B95Z8&)5+3';/W6!?9#(E*PJ'P]6Q68GPN"8]/Y>?\#;L7)]5I-8
MKH4IBV2]6O?RB>M@S]8O;8]W?>>1IGP@S*A:,:$)AQ0I@U8?KZHJ>VXY,;)P
M76@I#?8T-\SPG0+*'L#]5$JSFU@#]<MG_ ]02P,$%     @ G8!*4H]B+.&_
M @  00<  !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULC55M;]HP$/XK
M5K0/K;0V$"#I*D JT&J35JTJ:_?9) >QZMB9?;STW^_L0$HAH'U)[,O=<\]S
MYYS[:VW>; Z ;%-(90=!CEC>AJ%-<RBXO=8E*/HRUZ;@2%NS"&UI@&<^J)!A
MU&K%8<&%"H9];WLRP[Y>HA0*G@RSRZ+@YGT$4J\'03O8&9[%(D=G"(?]DB]@
M"OA2/AG:A35*)@I05FC%#,P'P5W[=IPX?^_P*F!M]];,*9EI_>8V/[)!T'*$
M0$**#H'3:P5CD-(!$8V_6\R@3ND"]]<[] >OG;3,N(6QEG]$AOD@N E8!G.^
ME/BLU]]AJZ?G\%(MK7^R=>6;M *6+BWJ8AM,# JAJC??;.NP%]".3P1$VX#H
M,*![(J"S#>AXH14S+VO"D0_[1J^9<=Z$YA:^-CZ:U CENCA%0U\%Q>'P)U -
M++MB8UV46H%"R_2<>3.[W]!AH??%!) +>4EN+],)N_ARR;XPH=BCD))Z8?LA
M$A4'&*;;M*,J;70B;3MBCUIA;MF]RB#[#!"2AEI(M!,RBLXB3B"]9IWV5Q:U
MHE8#H?%_A[>_G:'3J>O:\7B=$WB_2C <A5HPZ4N9:HNW9W"[-6[7XW9/X#Z(
M#62LY.^%;Q57&5MQ(_A,PH<5<XYTEJEY&7._BJ)F9;!AVC B!4WMJK+&/JO[
M\U?#=O>F'Z[V*]C@$\>USR<YO5I.[ZR<UQWWJDJU J61.*=R28?#G33,=RZ2
M_(44^-ZDHDK6VV/8/=!P['%"05PKB,\JF.;:X!6"*?8ZW<0M/LK<.>!V['&"
M6U)S2\YR^ZV12Z8;CF(3P>2XO;W> <4&G^3F@&2X-XT*, L_I"VE72JL_N?:
M6M\#=W[\'=A'=#]4X_P#IKI<'KE9"&5)T)P@6]<)%<U4 [O:H"[]S)MII GJ
MESG=<6"< WV?:XV[C4M0WYK#?U!+ P04    " "=@$I2/T2QS+$"  "7!@
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M89/\_Z/X!YW.WC+W7*]%92B(@E3!M>W+NNW<[015W32_I4)JI<UP0Y<=:&M
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MIBK%Y3#!&F<#*39(VMF&S39<F YMRB?<+OM,2S-*#$YG#V!"4^@*C8J"V)7
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M[J15]P]I*"?:YA=Q0C.,TR&%R;O#XW P>*.P,DKVW8B[R6&%O49AKSVR4FQ
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ME,7=C\N7L(-CHN_"%2?6RO<D$M "TZC5OHFU\CT99^E[8JU]3X:&="@CG8J
MP:V%[,GIG [%!BY@<6*M2D^&0/5+%IO5HK.>Z*45/VC5L[8-)]8Z]"02UURI
M.&-:Z]"3<8!MUPD-7R@4R!@TYD&IT#^I%0HBU&M,NUHHNES(+:A[/<L[TT38
M42C$E>PQIETK%%,L-/_I1T1Y\E+4^E7&M&N%1BH6LJN%ABX7FH<R)H&%P-@N
M_3F]]F<>B@W<96&[CF>(0I[Y2Y:#Y1WI\6I@[*C<H:*O<,>NW(DIW3G)F!8Q
MQRG=P5;M#AZ\>">4$0>&Z;%5OH/_0?U.*#8P-(JM"AX\2 D/=M3PT%0=&]/5
MJJ^Z%[<U/$<?66#;U=KT7N8ZB]HN0F'OUNA_F^67MES_-?I5/V6HU(]9;DRR
M+QC_@O[]+T4%^\]A$6=QA_*Z0LF42O[-P1:;>O>%1=) -8[[TOTB%&;Z=)65
MMP^!3KVR;U=WG6EOOL)]F5F/?ECI\KY]A$:%;HO-NFYT69_NG]-QT3Z<HO,Y
MH6_FS:[O?M?LN^8[YOZ.-]^U#]:8@83M@T-,[^_S=866^L[(2:;-9%NY?13'
M]DU=/+8/I[@IZKI8M2\?=+;09=/ ?']7F*[OWC0_L'\BROG_ 5!+ P04
M" "=@$I2=_6#1Q0%  !U(0  &0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6RUFFMOVS84AO\*X15#"J21>)/MSC&PQ@L:H&F#&-D^%/L@VW0L5!=/HN,6
MV(\?*2DZRG2!J91?8DG6.>1Y2+WA*WIV3-)OV4X(B;Y'89Q=CG92[M\[3K;>
MB<C/+I*]B-4WVR2-?*E.TT<GVZ?"W^1!4>@0U_6<R _BT7R67[M+Y[/D(,,@
M%G<IR@Y1Y*<_/H@P.5Z.\.CYPGWPN)/Z@C.?[?U'L13R87^7JC.GRK()(A%G
M01*C5&PO1[_C]PMOK /R._X,Q#&K'2-=RBI)ONF3F\WER-4]$J%82YW"5Q]/
MXDJ$H<ZD^O%/F714M:D#Z\?/V:_SXE4Q*S\35TGX5["1N\O19(0V8NL?0GF?
M'#^*LB"N\ZV3,,O_HF-YKSM"ZT,FDZ@,5CV(@KCX]+^7(&H!F'8$D#* G!I
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MEIZL-VN:PJA= .TOE+)OCGNWF[F>_@-02P,$%     @ G8!*4B\F2S&1!0
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ME:YY-:QY)=P6'&,+PBLND1U<(DN;4]S&MMH_KRYW+;A^K[?BY#J-[-6E@QL
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MX^$HF(PP_5$08>/A.)B,,?UQ$&'C(>T%$]K#+$ 2H9*04K#!T+FA%C84-\K
M!D/Z!B01*@DI@$U1M$$2H9*0 N 411PD$2H)*8!.4=1!$J&2D +P%$4>)!$J
M"2F 3U'T01*ADI " 2C* )!$J"2D0 **L@ D$2H)&?" H3P 281*0@8\8"@/
M0!*ADI !#QC* Y!$J"1DP .&\@ D$2H)&?" H3P 281*0@8\8"@/0!*ADI !
M#QC* Y!$J.2"#8,;AJ$-+]0@P3"%UU608,C!P3ZX\3!\X" #DNK'.TTUKGY+
M](ZKF3U#IF(*E;EW,O0[<(YU/\^I/IABX7[L<5<84V3N<2XX=!*K /)I 5VG
M_F G6/U(ZOP_4$L#!!0    ( )V 2E(Q_PC:T@8  +P7   9    >&PO=V]R
M:W-H965T<R]S:&5E=#@R+GAM;+U86T_C.!3^*U;% T@=FJ17$"!!.S!(PPR"
MF=V5$ ]NXC3>2>R,[;1TM3]^SW'2)"UI858P+VULG_MWSO'E9"'5#QTQ9LA3
M$@M]VHJ,28\['>U'+*'Z4*9,P$HH54(-#-6LHU/%:&"9DKCC.<Z@DU N6F<G
M=NY6G9W(S,1<L%M%=)8D5"TO6"P7IRVWM9JXX[/(X$3G["2E,W;/S/?T5L&H
M4TH)>,*$YE(0Q<+3UKE[?.4YR& I_N!LH6O?!%V92OD#!]?!:<M!BUC,?(,B
M*/S-V9C%,4H".WX60ENE3F2L?Z^D7UKGP9DIU6PLXS]Y8*+3UJA% A;2+#9W
M<O&)%0[U49XO8VU_R:*@=5K$S[212<$,%B1<Y/_TJ0C$:QB\@L';8' '6QBZ
M!4-WDZ&WA:%7,/0V&;I;&/H%0_^U&@8%P^"U&H8%P]""E4?70C.AAIZ=*+D@
M"JE!&GY8?"TW(,(%IN*]4;#*@<^<39CB<XKI0*Z%-BJ#-#.:4!&03RR8<3$C
MYY@MW'"FR0=R#[409#$C7T/RU41,D4J")E^D@;'F,T$-"\BY+H74A=\;6,T_
MOX:77%#A<QJ36Z9L:0F?D7/07UN1FMO$_2Q]:C_V)\Q0'NL#,.G[_83L[QV0
M/<(%N>%Q# 3ZI&,@.NACQR\B,<XCX6V)A.N1&RE,I,E'$;!@74 'PEK&UEO%
M=NSME#AA_B'INFWB.9[38-#DU>SN40/[Y>O91SN\Z9:9TK7R>EOD?8&^>,?F
M3&0 ],,-2Z9,/9)_-S&G39B7]#OLZ)5V]*P=W9<S]N$SK)%K2":]2W*_E-S?
MZ>$5=&ZR_UEJ2"O(L>;2:!,(1)O<*DC IZ8LRW4,K [<".9G[F#0!P#G=>B;
MJ$:CX3K590/5R!NZ)=6:FX/2S<&[ =DF'WTI9,)]N\A> ^RPM&OXQL".2LFC
MWP!LKL-U:F@XA_T-7'.B?AVQWCK)Q]VV/KB/3;7^7.Z'#;E7ORAW+9)'922/
M=DJI>C)[@M.0?I]6X#K5[N6\<<ZXM9W1_0U94RBI(S?J;D W:2+RO(UFT$!T
M5.LKZUYZE9?>.R/:)M\4#7#N-=!6VXW;?6MHJRW$[;T_M!<O*'GPFBIY7'"M
MM8BNLYD0O6>=_T/?W4R(!B+7VY(0U2;H[MX%WR(A?GV3<*O=RQV\=5Y4.Y [
M_!UYL5M)<X<?%UQU-)TM6.*^MSY3]6]W=P-O5G[Q M<W-J<$?&<*,.?"2"+3
M_"8)YW0XM"^H"@A@;A1<+35<!3%!@!0(8YYP0^"F@.DD=:88D2'RP"51P)P?
M40$I$L:9;S)[N-<8^E3)O^&V"C+4ZJB"NLJ45,R7*K#6$)8IV;8J+A3<$W1$
M4IF)()^ZR[3F%*[-V11N+2A#RP1LL'<7/U.*0;*#P"!3F,7(D@+LTOI%%A'W
M([BGPP^O7X_ "_!5:(HF'I)O$=,,W"[3I4X<2"*@:A)\6$#Q/A@)E-0JB&R!
M4-\'BPT8T":17(#'REJ_M)J*59:;1#$2A*TJS K8;4&[<".A2YCVXRQ@ELWZ
M6WAAXTYG%-E(F!G$Z04,VM8X!&(F^#] !;"A?U,:VSM<_I1"K=-<D9#"SYS&
M&4-"2GYF5$$<XB4^)?#<2$ ()3S+#IZD8.-* 6"+?&A^<W*@H]('<#$[=#;5
M[&>&1X]"I3XD8RM7X[I56+,MM#-;L-SPN&#7%#(*:X8 LDDY6UUS02@$'O,.
MT-MPH2R+*<.AQ1-2Z@$0)0^IO?G.V>,J!*&2"4I8 UO7;;*BJ\ L0..>2Y+\
M7MR&[]YJ8(.VO]<[J%93"!"T?@!%AJ$&^*9+LN?4N/]:8ZX-!9L5X<H-?6:1
M+R&S(!":QE7@EXPJ#9T%*QDNK':;**_,^<W7*L([;!MDZI39MZMX^8@ADA T
MDJ4![D6/6 /$IU#^82P7@)76$O8QS-\%-U%#U'(TPSA/<@A4C=L&6D(KH%B6
M^9-9_@A2F X%J&7,K>X-K"LQA[N>$:I3KN?\CY/$Q0M<MFEG6 _/ZJEJU?OX
M7(EP[^CG!]C'\T:U7MN8[46DBDZZ+--YU9)VZ,;P8V<,ULX3J\Y4+SO;]\H>
M2=),@1(&=7PM4)XHWC5K,&]7"\=5#$R9GYK8KD= 10P;/\,"I6:5_X@TU!*T
MAOSAJ6@/37&@L9;5OI0G??CL,-6&2C&-:=&IO>(E3,WL RWD)'J=WZ++V?(1
M^,(^?6[,C]WC*[=A?N(=?VRBO_2.KYKFS]W1\24<-IZOP'D!5HZ:5CSG^#)_
MF>Y43N3OVC=4S3#2,0O!(>=P" =1E3\5YP,C4_M2.97&R,1^1HQ"')$ UD,I
MS6J "LH'^[/_ %!+ P04    " "=@$I2!SV\M#$#  !X"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970X,RYX;6R=5DUOVS@0_2L#H8<$V$:V;,M.81N([18-
MT.P:,=(>BCW0TL@B2I$N2<7)_OH=4HJJV(J[V(O$CYFG]V:&'$T/2O\P.:*%
MIT)(,PMR:_<?PM D.1;,7*D]2MK)E"Z8I:G>A6:OD:7>J1!AU.O%8<&X#.93
MO[;6\ZDJK> 2UQI,611,/R]0J,,LZ <O"_=\EUNW$,ZG>[;##=J'_5K3+&Q0
M4EZ@-%Q)T)C-@IO^A^7$V7N#KQP/IC4&IV2KU \WN4UG0<\10H&)=0B,7H^X
M1"$<$-'X66,&S2>=8WO\@O[):R<M6V9PJ<0WGMI\%DP"2#%CI;#WZO 9:STC
MAY<H8?P3#K5M+X"D-%85M3,Q*+BLWNRICD/+H1^_X1#5#M&QP_ -AT'M,/!"
M*V9>UHI9-I]J=0#MK G-#7QLO#>IX=)E<6,U[7+RL_,5:O[(7"CA5AJK2\J0
M-<!D"I\QW7&Y@QL7:6XY&G@/FRK;H#+8*)'"/29( %M!NW^5UECR=$X+)IA,
M$/ZD0B3;U7H--\;0I)0IZE>F&TQ*3?C_,)_8M58[S0JX6*%E7%S21Q\V*[AX
M=PGO@$NXXT*0G9F&EO0[%6%2:UU46J,WM/8CN%/2Y@8^$HGT-4!(@6NB%[U$
M;Q&=15QA<@6#_A\0]:)>!Z'E?W;O7Y^A,VB2.?!X@]\G\_L7VH-;BX7Y^PSR
ML$$>>N3A&\@^U[J5:V;!Y@A;I!*1+HN49+?PC$QW9::"CSV\NUD>Y_$U1>RQ
M':P.FTG<V+SB/6IXC\[RIF)*$%,#F58%&";0$6T)Z>):08Y:/(9Q+SXBVV$T
M&47=;..&;7R6[9*9'.A$UW><@0N-!;<64[#*AU<=))V>.M8M&9==.N(3BN])
MR/A(2)?59'C=K63<*!F?5?(QRTB#(TIG6Z-,G@&?DIS)'=%F%J$:=X9_?!K9
MT1'G4Y-^-]])PW?RO^H;Z1[\365/3JIV/!@>\3VU:5=_Q3AL7>(%ZIWO;8;*
MH92VNI&:U:9]WOBN<;2^H+9:=<%?,%5/OF.:CJL!@1E!]J[&%$%=];EJ8M7>
MMXJMLM1X_#"G7P/4SH#V,Z7LR\1]H/G9F/\+4$L#!!0    ( )V 2E)FNFMV
MN@@  #HD   9    >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;+5:;6_;.!+^
M*X21 UK :^O-CATD 9(X;0)L]XJDNW= D ^T1%FZ2J)+4G&SN!]_0TH6;8FF
ME;WLE\22.,-G7OC,B-3YAK+O/"%$H)]Y5O"+02+$^FP\YF%"<LQ'=$T*>!)3
MEF,!EVPUYFM&<*2$\FSL.<YTG..T&%R>JWM?V>4Y+466%N0K0[S,<\Q>KTE&
M-Q<#=["]\9"N$B%OC"_/UWA%'HGX??V5P=6XT1*E.2EX2@O$2'PQN'+/[H-3
M*:!&_)&2#=_YC:0I2TJ_RXO[Z&+@2$0D(Z&0*C#\>R$W),ND)L#QHU8Z:.:4
M@KN_M]H_*>/!F"7FY(9F_THCD5P,9@,4D1B7F7B@FSM2&S21^D*:<?47;>JQ
MS@"%)1<TKX4!09X6U7_\LW9$'P&O%O!: N[T@(!?"_AM@>" 0% +!&T!_X#
MI!:8])UA6@M,^\YP6@N<]IUA5@O,^@K,:X&Y2H<J?BKX"RSPY3FC&\3D:- F
M?Z@,4M(0\[20R?XH&#Q-04Y<+@A+7[!,.'1?<,%*2&3!$2XB=$>B55JLT)7,
MQU2DA*-?T%44I3)+<0;CJ[4F<_;#@@B<9A]AQ.^/"_3AY",Z06F!OJ19!L_Y
M^5@ 6#GE.*R!75? O / ?/2%%B+AZ+:(2&20O['+NYY%P1B\U+C*V[KJVK-J
M?"3K$?*=(?(<=VH"9!=?D!#$72GN.0;Q16]Q=VX0_]1??&80O^MONVGV^_ZS
M3RVA\)NL]94^_WC6/OT*S]"](#E_MF@.&LV!TAP<T/Q 7DA10JI3D1"&1((+
MF=&F<-L5!;.1X_S#@FC2()I8%7TC+[A&$](<*EHB2PU8GE%N6E<WE;JI4B=K
MW<ME,/?/QR\&#-,&P]2* >K*!K,(<8&9D)R0%H(PP@5B6!#$-WA=<8: @LM+
M]@K@PN\(KQ@A%:%(L,0(MYIYL@/7=QNTU<J8=BSRYOM#/AF&S,PVGS8VGUIM
MOM^:^"!-? 03T6=H'DPFG'9-:%G0'3%M&6 ;L8=_UN"?6?$O2$P8(Q%:ERQ,
MH!] &$(@3/AGG;F]:0O?PC!FXI@1SAN$<RO"1YI%T#"%!-;R,C-GQ[PS[:D?
MM*!UQTSG3LN]AC&S PYV'5T[':L!-Y@GM0'@9RB#X%^1J8Q'-$9KRE6M-!8O
MQY(S^W!V2KEKAT.YFI=C<"9Z^D+R)6$V4G0]K=I[9\)U-9>[_I%$W>H>JA4F
M':GO&9WG=Y/Q](#W-/&[=L(V>P_]M^F#_AFCICI #7=[>5BSO#MY;P]K]G;M
M]/WF$N)V2?F@@S6?NG9"_0U>W1H'[OAW07BZ*H!D(V"HQMNZ&^WE9\V*[NR]
M_:SYS+43FLK>#[^"4S_N)_%N;SU$X(@A^LJ@8_YI:N3J221#--YW1A.S^SU-
M5IZ=K ZY_S<JCH9@B&Y#6M \#=5#TB<DGN8MSWWGD'B:N#SO[P_)33W)P9#4
M#;S7635NJU;='H'[Y#X;>WNOT][\TM+\^:V:]QVJV=JSL_4C*5+*9-9 &BU*
M(JG01]\VM%=.:#;V@O?."4VUGKVC!NS5&RS.:0G\DJB4CLC2U!Q=>]U^VG><
M5G]Q9Q@U:0^Z/S)HWQS-[IZ=W2%M7U):\NQUQQ+5F!O?\^S*O-&L_=928W^S
MW+XYNDQX]C+QJ'NHE5R\MB[*ZW;-[B%_Z@KAV1OGO][5W=6:IWWPZ*KBV:O*
M;G_T":<,_8$S6'>*B(= 8V%61@ 47'4;QT1M'A:$\[J9JKC/F-C=GCAPS6!]
M765\>Y4QT8/7AQI\72[\]RX7OBX7OITEWT8-?I>69T%PP(4[>QMVAGW3>KX^
MHLP;S2>V=>EK1O;M_;$ILKUZ8%\3L__>/;"O6=*W$]0;(]O=3P@F+3I?& 9-
M9@=V'7S-?[Z=_]X8?KLR?S1MA[_&_F:Y?7,TF_I_%YLN_"Z;S@^TP;YF4__(
MIH,AC9T^:1QH#@R<]]Z=U.07''G'_^M;#K7F7MU'H!DSL#.FF19Z]H.!)L7@
MW7=\=[9\[<SVIA6W.*+LV,H)-!L&]C;U_U@Y0;?1/+1R LF@^W<T505VEC"_
MK5P?D5*[$43MKLJN15!$U]7!9Q&AN-YIAM=-P7 H. 1#OIO"4!B8I7DJD$@(
M(C_!_I(1Z0F0(3 $[H4)+B!^<5:&HE0G4UPZ;LWH?Z Q(G*WL7X!EG.!#E)P
MN  G4U;W4*1D=*BFN&;@7PC!&NI%5-UZ*#E/<8%8N<R(TL%I3K9;*R5CI CE
M.5E4,OD"+476D+A4V84V21HFB)?P)]T]:P,KP-:"8PEQA+XEA,L<;!)^=W!$
M40$O[+D\!Y?J0P )([&:H,I>'(:RP@& (4KH!BQF"OVKFJE^2BI(6'H"D>W+
MO5)@1S"LS<CQ*]Q6O:<24_;65BB_8]F]<X'B4L@X'8G!4(&3@5@5Z9]5ODO[
MECC#14A0=?*/E='0 L>R#WY1?;!,'/2CQ S\ "MXB7E:@80(20V=[$CS-6#<
M3@"QE7(2OCDYI*$TA.#*[.#EDI,?I5R"]91\A&Z47BZ?JPEWL,7JSH%8MBRN
MQ3F&C))K!D%D\^:N #JJQ$ I.%[F'42O94*S+)9$7JIX0DH]04314\48+^1Y
MZX*8T5QJV LVW\6D5&O';&#&$Q?EU:GN$'X'VPOEM \GP4?]="T/BW &0:%Q
M#.2%EJ_HQ-F1_O>>\,YE05:UNRJ@'43AWF9M[:-7@AD'9I$K>0&\*:M/<^):
M'5VJB>01Z!!T\G7UMI2]/DL747 :*M>1W 9[EFL A9*!XXQNN#P[H6&J=L@V
MJ4@,7JNB&6=5DH.C=J25HRE0 5:G9UB?J-?080%RFJ5J[E:LM9J1J:R,=\[^
M<\)6ZL,1F%PN\NJ K[G;?)QRI3[):-V_<<\^NX;["^_LUC3^DW?VV73_*IB>
MW0=3PQ,H#-OO8L8::O55S1?,@$(XRD@,L)W1*50P5GVH4ET(NE9?,2RI$#17
M/Q."(0!R #R/*70@]86<H/E<Z/)_4$L#!!0    ( )V 2E*V?NGF% 0  -@*
M   9    >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;+56VV[;.!#]E8'1AP3(
M6K9\B5/8!AR[W0TV08.DZ3X4?:"ID4V4(E62LI/%?OP.*5FQXPNR#_MBZS)G
MYIR9$6>&:VU^VB6B@^=,*CMJ+)W+/T:1Y4O,F&WJ'!6]2;7)F*-;LXAL;I E
M 93)*&ZU^E'&A&J,A^'9O1D/=>&D4'AOP!99QLS+-4J]'C7:C<V#![%8.O\@
M&@]SML!'=$_YO:&[J/:2B R5%5J!P734F+0_SJZ\?3#X)G!MMZ[!*YEK_=/?
MW"2C1LL30HG<>0^,_E8X12F](Z+QJ_+9J$-ZX/;UQOOGH)VTS)G%J99_B<0M
M1XU! Q),62'=@U[_@96>GO?'M;3A%]:5;:L!O+!.9Q68&&1"E?_LN<K#>P!Q
M!8C? -K=(X!.!>B\%]"M -V0F5)*R,.,.38>&KT&XZW)F[\(R0QHDB^4+_NC
M,_16$,Z-;W'!)%!UG42JIK/ 5 *WVEJ8:N6$6J#B BW\!I,D$;Y69'^CRH;S
ME3N;H6-"GI/%T^,,SCZ<PP<0"NZ$E/3>#B-'/'VTB%><KDM.\1%.[1CN*/;2
MPB>58++K("*!M<IXH_(Z/NEQAKP)G?8%Q*VX=8#0]-WP]M4!^.S]\,$)-9VZ
M9IW@KW.L9OO5^7Y+-G#C,+,_3D3HUA&Z(4+W9%?8-UTA?5R^'?<"\)D.((N'
MBER&Z(<0_O19C?N4^]5VVO=-VNW+06VTP[U7<^_]-^X7U(U<9X<XSGK[!.+6
M$0+]FD#_)($)YZ; !%BF"^6 OA20[\SGH33V]RGVX]Z;1!XPZ@U:AW5<UCHN
M3^IX/13@BP)2%>1\2>'>Z*3@#FX%FPLIW M\O\-LCN8'_ -/2C@2_^B8\WU9
MO3C1DX.:SN!_ZOJK.L+52<$/:)TA886A$)O.#I4ZVD#7ISU^7>+&C_5GHC]^
M8(T&P4]D^4*#4S*?+J>!0>K5B"S7EI[,7\ 1^E-A:,0S1<JS3-@P;84J<?XZ
M &G&]R G1U2?UR8#MC!879$&YH&<5@/2I%-"&;1H5A@:E*.A0UQ!7I56UJ7E
MDHDLD/=T=JI[03&-$TR2$)VF%-FS)A<<,;'DGR/-](0"2-HN?$[9-CTBX5U^
MGMY/:%(;L6)^!=C@R3Q$O;&&H0P*=K&L7!HH!W.C"YKNI)<D6!>\TF8AT5AO
M."D2I''$_T3UMT X"\!?A;!AFE$E$O2\)]RQE;#P.RHBP^UY$_;+U[XZ6CX%
MU#XB"_>D@5R5FQ'7AH:8A].GKJIU9RW<$G+M*R9V3H9-5G0NM$B 4[5L\U!O
M1ULS/T.S"+N3/T[H(RT'8_VT7L\F82MY\_R:UK9RRWIU4^Y\=\PL**%T>J7D
MLM6\I-/2E'M4>>-T'C:+N7:TIX3+):V>:+P!O4\U*:QN?(!ZF1W_"U!+ P04
M    " "=@$I2<,$KZI("   3!P  &0   'AL+W=O<FMS:&5E=',O<VAE970X
M-BYX;6RU5=M.VT 0_965Q0-(!3MV+H <2[FT*A*1$(CV ?5A8T_B%7M)=S<D
M_'UGUXX;('%YZ4N\ESEGSLS$Q^E&Z6=3 EBR%5R:85!:N[H.0Y.7(*BY4"N0
M>+-06E"+6[T,S4H#+3Q(\#".HGXH*)-!EOJS.YVE:FTYDW"GB5D+0?7K&+C:
M#(-.L#NX9\O2NH,P2U=T"0]@'U=W&G=APU(P =(P)8F&Q3 8=:ZG Q?O WXP
MV)B]-7&5S)5Z=IN;8AA$3A!PR*UCH/AX@0EP[HA0QN^:,VA2.N#^>L?^S=>.
MM<RI@8GB/UEARV%P&9 "%G3-[;W:?(>ZGI[CRQ4W_I=LZM@H(/G:6"5J,"H0
M3%9/NJW[L ?H](\ XAH0OP=TCP"2&I!\%M"M 5W?F:H4WX<IM31+M=H0[:*1
MS2U\,ST:RV?2C?W!:KQEB+/91 G!+,[1&D)E029*6B:7(',&AIR3_?MS,BH*
MYL9%.;F1U7_.#>]T"I8R?H81CP]3<GIR1DX(DV3&.,=[DX86I;J$85[+&E>R
MXB.R.C&9H9+2D*^R@.(M08@U-H7&NT+'<2OC%/(+DG2^D#B*HP.")I^&=ZX.
MP*>?AU^V5),T8TL\7_+/L9'1AZD]W6(TN;$@S*^67-TF5]?GZA[)=:]>*;>O
M!+;H-08.#;,BZ'L"9S0O62_JI>'+?G\_QG2CY&W,] !/TF]BWJCO->I[K>IG
M=,O$6I"G&8@YZ+:&]!O*_G]O_J#)-6B7SSB@"2!EODMCVR8Q.#")JW<=#/?L
M0H!>>MLUF& M;?5"-:>-LX^\H;T['Z/C5P;]EZ;Z7,RH7C)I"(<%4D87 QR2
MKBRXVEBU\J8T5Q8MSB]+_&J!=@%XOU#*[C8N0?,=S/X 4$L#!!0    ( )V
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M)#>PR7@8#G9&\WW9ZD7N>L;!I)<":%\+[E+*:01NU#%XL3G\?AN3_$AJV_=
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M%N( $VN<;21.2,6;:\0@3KZUOOEKY ;.WRV<6;<X2?AW^7?6U]6WYT/&IR7
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M@7$ ^K[6&I\GSD'7ZBW^!5!+ P04    " "=@$I283_[7^,%  !E%@  &0
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MYK@W[9&$KUB1VJ]J^XE[A\:H+U:I<;]DZV6#'HD+8U7FP< @$[+\S^Y\(+H
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M.,F:BNV3JJIN8 R1D+B5"I\_3HWWYZAT!E;247!%!W:%%3%,->".W:A2WEF
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MV5N-M"?\,:?%#,89T'VF-1X$%Z!;]8L_4$L#!!0    ( )V 2E*^9[\?4P4
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MT[G4(8CZNJ:O:)[K2$K']R;HH.U3-^P>;Z/_9@:O!G-%!'W%\B]9*E<G@V0
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MDY(5YG!%B2)7/Z#N+QB3VQ/=0;N'.OL74$L#!!0    ( )V 2E*\KGJA^0,
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M[<"U>[*&*$VZQ!K41;I<R(I:6=%565_5/0OI#3X %7T#VLK40"GF@#8XH^B
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M BH!XO\-(?P\D1NT'U^+?P%02P,$%     @ G8!*4NMM$(=M P  O L  !H
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M7V88O)S@P9]A:UBY5,+?9&P!7/4DC.K6-@6%M:!)4U"[W6QO&+THBTXK8T^
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MC(&^OY)2/7\Q#6S/?%[] U!+ P04    " "=@$I2BGO=00(#  #+"   &@
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MU]^AYC.P_A+)M?LEZ]HV\$A2:B/S&HP9Y$Q4__2MUF$+$ [W *(:$.T"^GL
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M+W] +:CC^%(MK7^R91T;!2Q=6-1%#:89%$)5;_Y<%V(%$'<_ "0U(-D$M#\
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MI$?+PE1'>-5!7?I#[4$C'9&^F=.U!XP+H.\SK?&UXQ(T%ZGQ?U!+ P04
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M=?*1*.ERPI4+JU:^Y\^5I0GB'S/Z*$#M '2^4,IN%NX%]6?&Z!=02P,$%
M  @ G8!*4M/;ZN\] P  / H  !H   !X;"]W;W)K<VAE971S+W-H965T,3$U
M+GAM;,U6VX[;-A#]%4+H0P(TULVW#6P#OA5=((L::Z1Y"/I 2R.+6(I427J]
M^?L.*9FQO;;AM^9%XF7.\)R9D8:CO50ON@0PY*WB0H^#TICZ<QCJK(2*ZHZL
M0>!.(55%#4[5-M2U IH[4,7#)(KZ8469""8CM[92DY'<&<X$K!31NZJBZL<,
MN-R/@S@X+#RS;6GL0C@9U70+:S!?ZY7"6>B]Y*P"H9D41$$Q#J;QYV4<68"S
M^)O!7A^-B96RD?+%3A[S<1!91L A,]8%Q=<KS(%SZPEY_-LZ#?R9%G@\/GC_
MPXE',1NJ82[Y-Y:;<AP, Y)#07?</,O]G] *ZEE_F>3:/<F^M8T"DNVTD54+
M1@85$\V;OK6!. +$_2N I 4DYX#N%4#: M)[ =T6T+T7T&L!3GK8:'>!6U!#
M)R,E]T19:_1F!R[Z#HWQ8L(6RMHHW&6(,Y,E58*)K28?ODBM/Y(:%%F75 'Y
M1*9YSFPV*2>/HJE)F]L/"S"4\8]H\1L)B;;6^O!B@CPQSM%.CT*#!.TQ8=:2
MF35DDBMDXH0\26%*398BA_S408C*O+SD(&^6W/2X@*Q#TOAWDD1)=('0_&YX
M_' !OK@?/KP 7]X!CP>7X"?!2'VN4^<OO>)O*@S+&=_93Y.L(=LI3"_F;/F6
M\1W&FQ1*5F0NJWIGFE3+@O@"6?G*^/X%'9-' Y7^YP:MKJ?5=;2Z5VC-J&89
MH2(GCASRX%B*KA)=45VJH\;CT'FT_\+72=KI=T?AZW%NWQM%G8?XU&CQWBCI
MI#UO=**HYQ7U;BI:&YF]D+]J%\-GT$:QS.IJUK\*9C29HEX,J?NL1 8G>]^?
MH-J NA7<OJ?2_Y5R/O"T!C<C],W]P/%X^@H*&]+A][%GIL12,.R3)PU%@4V%
M(#,XT+I9&LW!O:.$QM%Y95RPB=.SPGAOTXLOE\70BQ[>%#V7 M4:MN% 5M@/
M02E?%'>D_,$?\_ KI3R.?K::Z']*^K(]^3A;@^Y9ML*C+EF!VKKKB2:9W G3
M=!2_ZJ] 4]?XS]9G]FKDNN]/-\V]ZHFJ+1.:<"C09=09("'57%6:B9&UZ\4;
M:;"SNV&)USM0U@#W"RG-86(/\!?&R7]02P,$%     @ G8!*4OD--*Z<!@
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MJL.LBWP2N/ HN_4HN^94_B-,-G_>(/9#WAWD8$I/7*W>(%#:-M4UV,)*I\X
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M#2?)D;OL'H A.MODK8D:!"#2  .(*'$Z8F@@2<R0[ \8H@/N5"4EI.EJ8L-
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M"H'\?<FYV)\4%=2?N%S\#U!+ P04    " "=@$I2WKH%%'\&  #V(   &@
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M\'35$]-.GK^(-4]-'= Z%:XG2F51F%S,M?$\89JC%F(T6%#L&SJ P7CL;S\
M=81)-&EAYTHW[J[=55KN<E?T>%4*03HLC!/VG1L"C8A/)P31UCWFBC@>O9*2
MC1[4W",I7H8'55L,O2]C!F^T42@NT)Y L+ _@5#M#0IVS0/N[AZ^)#DWB69R
M\=D\K%&"?,+Z/Z',9P. 2!"G$#0=35NHN$X"=[<2E\V H+OJ+F$?)5W>)8"D
MPG)OU(]BGQ8 PR0.K * D=&T+05=_X"[&XA?38NW0>>94,F"H[^N1'8GU-\=
MS2-VQ1Q/^^GCB2O'I+L<']#)D[ Z$D:P%P4(%;H A)JT[13B2BW!_37SQ!5
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M"E<9XLQL"06*:#0Y(4MLJ:SA0&1.EI2#)@M0*2ZB_&2U(7<E*%I#8UA*YM1
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MC M(>F30OR!A$ 8G!,U?#>]_. %?O!Y^V1'-H*W"P/$-NJM 5K"5RC"1/ZO
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MAZS0LQ6C 2CPE9D?0^E4: )$BCS5:*@F1^FK*02IW3 #1^<K1NM0$-@*] !
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MTO!V_7#;\/IHF3\_9,W&9AS@C"[![\A2%YX,UNRJ-@T!ZL;IJD_D$1Q,76M
MRE06YPD<2^DQJ"ZS:RN&3F%,?9&9P9B2<P[/A:],V0,<+%*B+2#,[CH>W&S6
MR<Z%U6CXB,9[ 7[Z#RKEKRS7*=!R,)AF.43IEH.Q5,N!NB#+04RW',0TR\&Y
MT"T'@^F6 QA@N7&R;Y40OBEV8S.T9/M4E%^L]=5ZQ_=+L>^E7!]8MS,+N#[/
M=XB+?;*?X<OM9?G-OZ%IAF*REJG,;B"71E[NV)8G@NV*7;-7)@1+BL,MP?)Q
ME0/R]S5CXGB2)ZCWS?L_ %!+ P04    " "=@$I2YYQ(\!$$  !H$   &@
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MUE8WDAW+16_+I%H;R\L#D!AX 5#O=XS)EYO"0///A=7_4$L#!!0    ( )V
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M&QOV3& IJ)! Z<.GR[DFDC[:M&L]<RX+#B-<R+RVK6!_%T7WO<36,P()I:5
M#]K 9)P@I;#D4^WDG?/@LQ0H[/DFT0HCB3:NUX?5@+S1119"!EB695RX#4W&
M%(=&CB11;%HE$L<DE1),&P%!D> HU[ =41@:N\24SLQ+ZUNXPUZ'M77+]QDO
M32VH,"W&.H9?IUEV'3MX$1<D9"74QTP_#L]]L\WPO<0A6>?^.BP%--'=9CI*
M$KKY0$G$&;8/?W+!R1AMQX%82/*HJYFMLM0!+"%88:G(LA[Y(5$RQVNUW4[K
ML%FSUT+-_W>>(\RQ1+0N6N_]<Y[E%RON#5]+<OY6V1=\4&-Q$SEWD?TVB!RT
M060K]N1-&T2.6B!R^&IOS7\1Z9Z_R%XK5ML[2Y%.<:>L75QWKJUE%)C/ Q]^
M-1\;M"H*%AFABO#"BTD08/[L]JKQ"BWTA_P.7_</<(@RJN9ETH>5_04')&.C
MLM>]F8BB5V5_-H^GK\*F8/5OP>0/4$L#!!0    ( )V 2E*7BKL<P    !,"
M   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8
M$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*N
MU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I
M2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3
MZ:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ G8!*4M61
M]@>Z"   G%0   \   !X;"]W;W)K8F]O:RYX;6S%G%UOVS84AO\*X:L.:!;)
MMF2Y: ID2;H9Z!JOSKK+@9%IFZA$>924C_WZ45*<'+KRV]T<YZJU[,B/29$/
M#S_.^_O"?KLMBF_B(<],>3;85-7VW>EIF6Y4+LN?BZTR[IU587-9N9=V?5IN
MK9++<J-4E6>GPR"(3W.IS>##^]V]YO:4OB@JE5:Z,.YB<^&K5O?ER_O-2W&G
M2WVK,UT]G@W:_V=J(')M=*[_5<NS03 0Y::X_ZVP^M_"5#);I+;(LK-!V+WQ
M5=E*I]]=7C20-_*V;*]4\O:+="!G@SAP-UQI6U;M)]K[2\=XI]R'NU=U57S4
M6:7LI:S4K[:HM]JLF]NX7W%*?D9;#KM_NT)\9_]/,1:KE4[599'6N3)55XY6
M90V@*3=Z6PZ$D;DZ&UP4=\J*N5RKYD>Y;YDMNQ]8.3)27/:==F_8V;)EY.0Q
M99'II?OVI?A%9M*D2K3E6!+ (0 <OAJ@>#.7!'($($='A%PT$,T?E*)8B9E)
M"P(Y!I#C5X.\*/(M@8P 9/1ZD!MI"&0,(.-7A/Q[2" G '+R>I"RW!#(!$ F
MO) +O3;:?5::2IRG:5&;RO7,8N[ 4ZUH%S0%D%/FDG0^<DX4E96FE*W]*%D8
MH.X[X&7[HNZ4J958V2(7J;.I=8"EN-?51J2UAPDMPZR9F7&8E1.^5Z<A\DK(
M+!8WE-FZBGU\*^99\_A)LQ17_]1ZV_P=A41>"9G%,ENZ]UT#D>YKG4HJ:=8-
M@3@O2]_0(1)+R&R67XMB>:^SC/(@AX3,$OFD9.D_:$@6(;,M+M5M)8K;3*_E
M=UT'\D/(+(A+9?6=;,;)0INRLG7GAZ8=;-1R33&1(4)F17Q2:YF)A:JJ3+T0
M?BK*T@U;_):*'!%R2Z+(<UV] #9]L5.9,GL>&R);#)EMT0Q&<^5BIP>?":EA
MR*R&IL^M'BD-C#:8K7!=;5Q\)MON5>A\*[5MZ_2ML,JU$8J)O#!D]D*'J=OJ
MI$S( D-F"WS4Q@5GVC56]>!NXWK@M\(HVD"'2 I#9BE<26M<@W118]-W_"2<
M_%T<*:U7?L@30V9/+-2Z?=0H#_+#D-D/']VS+^YDYD:7N1-J;=7>R&B(M##D
MUD)AUB>5LKFXRK=9\:C42?LY%^Q<.]=23*2%(;,6%BI3:0/U1RVMP\T>Q4L[
MN?2F+Y 81LQB6+A[+&LWL'31X5=7Y>TG6H\Y;J\T1\@5(V97P'#1"[Q'2"(C
M[CFKGH!1O+EI!O'E3Q023EDQ*P1&CGY9(JN,F*U"(L?>(D1*&3$K!8:0X@W%
M1&(9,8L%!Y&"8B+?C)A]LXLB>ZL9J6;$'H$TX60O%E++B%DM^W%E'^ 8267,
M+!488'H]S!A)9<P^-]4&13=-4-1;AD@E8V:5=-%1+Q:2Q_@H\<>!,,FO6KCB
MP2P/&B;UEB&RQYC9'M_'2R<N7.K%1/88,]OC8-S4D5),9(\QLSUVT5-O^2%[
MC)GMT8917]LPZO>7,*H7$]EDS&P3&$]Y+3I"3HFX Q443_F8R"G1JP8J(XJ)
M[!(=*5"YH8'*B?BE+K51)9V)B)!M(N[E]7[,KG>_H9-R$;)-Q+W WH_Y-,RF
ML7X$5]BYE]A1I?M-"'DG8O:.%Y]>^/'IA=^$D'<B9N]@S#'%1!:*F"V$,2.*
MB2P4,5N(1OLG8E'GN;2/W3::.W_R,486BIDMA /_$XJ)+!0S6PAB>BT]1A:*
MF2T$YR=\3&2A^#77XKT.*486BH^T&.^WGV;SU-HU*CJ5&R,+Q<P6@IA^I<.=
M7LP6(ICGRZ5NWG<#S9GI;N:5)K)0S&RAIRFJDW8G7V%V&[W:R^+J@6(B"\7'
MF4EKJGR[[9;S76FFLMR(55;<4TQDH9@[%NK%?-Y\2O?W(0M-F"WTC"E^EU5M
MW<.IVEK/VEJGD?D$66C";*%GS+X&5- MG1-DH0FSA=KIU&LRG>JJGZR*44QD
MH0FSA2"FO_<466C";"&,264Y01::,%MH#Y-2?E'_U!0366ARC"UDAS#]2H<[
MCMEWE'U7Z;3-4TQDH0FSA<BZQ&QO7>(WY3^;R$(3]O4=A$DCRP19*#G>*D\/
M)HTL$V2AA-E"&#.FF,A"";N%$.:$8B(+)>P60I@)Q4062I@M!/>.>OUF@BR4
ML!]Z\?>.7M"]H]YT0H(LE+ ?>P&8?FDB"R7,%O+6<_U!W-YAK 2>?&&V$,"L
M-HJ.-Q-DH81]1L[#/$_=7]1/ZT*.DV!.D86FQ]G9W(_I/9M39*'I,?<:^)5^
MJ59>:2(+3;EGY!"F7YK(0E/N&;F]2M^++RDFLM"4?0L;*DTZWIPB"TV9+00P
M_S3>-NDILM"4>S]"MR/F?TPG3)&%ILP6>L8DLYN+JDB_B>NM^S#%1!::,ENH
M#_,OI=>;IN<\OZ.8\ 0FLX7Z,,G&"H(9!O@X)K.'7D!)\[FV2VT:ZH4'"@]D
M!D<Y=G, U.OBPP >TPR.LP/.!_U<Y[?*[LW+A0$\JADPVZCO&6VFXZ5Y%%</
M6P\4GM8,F'WTTH/N#>;L?B* ,(#'. /N(SL(=.\9A2<\ V8GX>V0(P\4'OD,
MF*V$0<<>*#ST&3!["8-&'B@\]ADPFPF#TGFE$"<*X,X4T($^#?+VNGT_D M_
MD"J V4P'SA'NF#U0:";N# (0U.^><!(![BP"A[?PMJ@>*#03=R(!!.J&^QXH
M-!-WAH'GW<;^^+Z[*N8>*#03=_*!?M"Y+5:Z$K>/'B@T$W<V @I*NJ:G?6M>
MT@2<CH ['\$!T(7,7-@\]_M1:";NC 0'0#^[KVM@*2A,2A!R9R4@H#_88Q/"
M3 4A=ZJ" UOY=TW+ \6I;;C-U'MT^[E\/5!H)NX\!K!$?87"W 8A>W(#".J-
M\&&6@Y [S0$^Q^&#0C-QISO H%XH M,@A-QY$/"1$[]$H9FX4R(\]_*SV0\.
M\8<P)T+8)44X;3]>?GB_5"MMU/*S^Y+274]EELZM:/YY:IA1([I5G647[MJU
M^53(Y2ZYYBXQZ(?_ %!+ P04    " "=@$I2V#['%X,#  "H2P  &@   'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=M+3AM!%(7AK2 O(%VWWA4!HTR8
M1MF !<U# 6RY.TJR^Z P@'.502:H_Y'5MEP^HT^6W?_YU_EQOSX<GI?[A^-R
M]NOI\7FYV-VOZ_'S-"W7]_/3?OET.,[/+Z_<'DY/^_7E\G0W'??7W_=W\Q1#
MJ-/I_1F[R_/W9YY]^WV<_^?$P^WMP_7\Y7#]XVE^7O]Q\/3S</J^W,_SNCO[
MMC_=S>O%;OKU^/;T,OU]L$\O)^_.KFXN=J>K&]M-6P^*,BAN/RC)H+3]H"R#
M\O:#B@PJVP^J,JAN/ZC)H+;]H"Z#^O:#A@P:VP^RH#(&P"2'-4!K4ZX-X+4I
MV 80VY1L YAMBK8!U#9EVP!NF\)M +E-Z3: W:9X&T#OJ'I'@-Y1]8X O:/[
ML@W0.ZK>$:!W5+TC0.^H>D> WE'UC@"]H^H= 7I'U3L"](ZJ=P3HG53O!- [
MJ=X)H'=2O1- [^1^+ 'HG53O!- [J=X)H'=2O1- [Z1Z)X#>2?5. +V3ZIT
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ME;F^O'=^^_R_EZ]/.JY?0\SI_8SE\@]02P,$%     @ G8!*4AT+?RZU @
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MHLA:462M*+)6%%DKBJP51=:*(FM%D544A591%%M%47 51=%5%(57411?15&
M%4415A2%6%$88T%Q+(RQG$ 6)Y'%B61Q,EF<4!8GE<6)96%R68()9@DFF268
M:)9@LEF""6<))ITEF'B68/)9@@EHR7]-:'T?Q\,_;G^ZQGW=#B_]DZ6HN_D)
M4$L! A0#%     @ G8!*4@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "=@$I26\9V7>X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" "=@$I2F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( )V 2E+@PVPHJ 4  *X7   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" "=@$I2YE,?*MP'  "D(   &               @('K#0  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ G8!*4KQ&'@"P @  X0<  !@
M             ("!_14  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( )V 2E*MJ!;1.08  '@9   8              " @>,8  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "=@$I27JL<OLT#  #G
M#   &               @(%2'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ G8!*4FD:5!SA"   -2L  !@              ("!52,
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )V 2E*C/ECZ
MQ0(  /4&   8              " @6PL  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " "=@$I2:H=CR/@(   3)P  &
M@(%G+P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ G8!*
M4C0?VAZ>*0  $(8  !@              ("!E3@  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( )V 2E)J DCAY@\  -LJ   9
M      " @6EB  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ G8!*4@U#91G5!@  _0\  !D              ("!AG(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "=@$I2GKAI0W$"  #[!
M&0              @(&2>0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( )V 2E*UQ42S*0,  * &   9              " @3I\  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ G8!*4OD%-6"I
M"   MQ@  !D              ("!FG\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " "=@$I2*7E")7P-  #])0  &0
M@(%ZB   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )V
M2E(XI1H">P4  $4-   9              " @2V6  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ G8!*4K>0MR M"@  G1D  !D
M         ("!WYL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " "=@$I299L-Q^X0   ;.0  &0              @(%#I@  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )V 2E)H6P"VD@(  ,T%
M   9              " @6BW  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ G8!*4LG.&\;2+   [X8  !D              ("!,;H
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "=@$I2OX11
MM^P1  !_,   &0              @($ZYP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( )V 2E+MQI$CI T  &HI   9
M  " @5WY  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MG8!*4D!7K135"@  41H  !D              ("!. <! 'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " "=@$I24BHPO04#   A!@  &0
M            @(%$$@$ >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( )V 2E*/=+7:* ,  '\&   9              " @8 5 0!X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ G8!*4C,4'I-7!
M40L  !D              ("!WQ@! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " "=@$I2:B8[P'X*  !@&@  &0              @(%M
M'0$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )V 2E(F
ML)X<RPD  'L;   9              " @2(H 0!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ G8!*4D>1<SL/"   *!0  !D
M     ("!)#(! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M" "=@$I2.H5.[%<#  !]"   &0              @(%J.@$ >&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( )V 2E(N@&F*SP(  (8&   9
M              " @?@] 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!
M A0#%     @ G8!*4IQ#+64X.@  XL@  !D              ("!_D ! 'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "=@$I2C%S13=@"
M  #;!0  &0              @(%M>P$ >&PO=V]R:W-H965T<R]S:&5E=#,S
M+GAM;%!+ 0(4 Q0    ( )V 2E+E="4K"P8  %D.   9              "
M@7Q^ 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ G8!*
M4EU9TOUO @  ]00  !D              ("!OH0! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " "=@$I2VX-?&+<"  "%!0  &0
M        @(%DAP$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( )V 2E+*L>$HS0(  +4%   9              " @5** 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ G8!*4J;-:8Z$ P  P0<
M !D              ("!5HT! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " "=@$I2<=4C1C($  "N"P  &0              @($1D0$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( )V 2E+#.O43
M0 4  ,X-   9              " @7J5 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ G8!*4G$U"-<1"@  EA\  !D
M ("!\9H! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "=
M@$I2SNCUNS4'   ,$P  &0              @($YI0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( )V 2E+?FKAF=PD   8=   9
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M970T-RYX;6Q02P$"% ,4    " "=@$I2(.QM"!H(  #[$P  &0
M    @(%TQ $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M )V 2E**5D1]7P<  "D4   9              " @<7, 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ G8!*4L3^F45: @  Z 0  !D
M             ("!6]0! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " "=@$I2:;_!/$P#   ]"   &0              @('LU@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( )V 2E*),]#L(08
M $@9   9              " @6_: 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ G8!*4H58[\'& @  7 @  !D              ("!
MQ^ ! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "=@$I2
MQ'*'CTH%  !1&0  &0              @('$XP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( )V 2E+)ON7-CP(  #\&   9
M      " @47I 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ G8!*4CGU'L0W P  5 @  !D              ("!"^P! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "=@$I2_E% >D$"   "!0
M&0              @(%Y[P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( )V 2E(JC92C70<  .0O   9              " @?'Q 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ G8!*4D=F3G,O
M!P  ^2D  !D              ("!A?D! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " "=@$I2NTV39X\"  #Z!@  &0
M@('K  ( >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( )V
M2E*$A:WT$0,  $$)   9              " @;$# @!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ G8!*4LOMYB69 @  QP8  !D
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M=#8V+GAM;%!+ 0(4 Q0    ( )V 2E(%&P 7]P(   4)   9
M  " @8\; @!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
MG8!*4H]B+.&_ @  00<  !D              ("!O1X" 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    " "=@$I2/T2QS+$"  "7!@  &0
M            @(&S(0( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( )V 2E(R1*'A$0,  *0)   9              " @9LD @!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ G8!*4E0A3.R) @
M2@<  !D              ("!XR<" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    " "=@$I2![(+2),"  #B!P  &0              @(&C
M*@( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( )V 2E)M
MDG!W]0(  $@(   9              " @6TM @!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ G8!*4BU$;+\W"0  '44  !D
M     ("!F3 " 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )V 2E(1:B<58P(   H%   9              "
M@0%+ @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ G8!*
M4AJD"^E@ P  ?0T  !D              ("!FTT" 'AL+W=O<FMS:&5E=',O
M<VAE970X,"YX;6Q02P$"% ,4    " "=@$I22Q&1&( (   P)0  &0
M        @($R40( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0
M   ( )V 2E(Q_PC:T@8  +P7   9              " @>E9 @!X;"]W;W)K
M<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ G8!*4@<]O+0Q P  > @
M !D              ("!\F " 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q0
M2P$"% ,4    " "=@$I29KIK=KH(   Z)   &0              @(%:9 (
M>&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( )V 2E*V?NGF
M% 0  -@*   9              " @4MM @!X;"]W;W)K<VAE971S+W-H965T
M.#4N>&UL4$L! A0#%     @ G8!*4G#!*^J2 @  $P<  !D
M ("!EG$" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " "=
M@$I2W7[,F0P'  !M)0  &0              @(%?= ( >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( )V 2E*Z7Q_?R@(  )\'   9
M          " @:)[ @!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#
M%     @ G8!*4IL\9_<= P  L D  !D              ("!HWX" 'AL+W=O
M<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4    " "=@$I2^N^^ 8D$  "!
M#@  &0              @('W@0( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM
M;%!+ 0(4 Q0    ( )V 2E)E#!B2= (  ) %   9              " @;>&
M @!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ G8!*4B\2
M;*0Q!0  ?!   !D              ("!8HD" 'AL+W=O<FMS:&5E=',O<VAE
M970Y,BYX;6Q02P$"% ,4    " "=@$I23(C%Z2L"  "C!   &0
M    @('*C@( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (
M )V 2E)&='Y?X0D  /$]   9              " @2R1 @!X;"]W;W)K<VAE
M971S+W-H965T.30N>&UL4$L! A0#%     @ G8!*4CS WGYR @  *P8  !D
M             ("!1)L" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"
M% ,4    " "=@$I29I4<6U<#  #V"0  &0              @('MG0( >&PO
M=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( )V 2E)A/_M?XP4
M &46   9              " @7NA @!X;"]W;W)K<VAE971S+W-H965T.3<N
M>&UL4$L! A0#%     @ G8!*4DH<L $"!   &0\  !D              ("!
ME:<" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " "=@$I2
M NVZ4T$"  "R!   &0              @('.JP( >&PO=V]R:W-H965T<R]S
M:&5E=#DY+GAM;%!+ 0(4 Q0    ( )V 2E) %&JU?0(  /8%   :
M      " @4:N @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0
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M965T,3 T+GAM;%!+ 0(4 Q0    ( )V 2E*UFS$"O <  /\I   :
M      " @>3# @!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0
M   ( )V 2E**>]U! @,  ,L(   :              " @=C+ @!X;"]W;W)K
M<VAE971S+W-H965T,3 V+GAM;%!+ 0(4 Q0    ( )V 2E+MW8(?:P,  ( *
M   :              " @1+/ @!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM
M;%!+ 0(4 Q0    ( )V 2E*#\Q^N3 ,  'D)   :              " @;72
M @!X;"]W;W)K<VAE971S+W-H965T,3 X+GAM;%!+ 0(4 Q0    ( )V 2E*I
MM#Q%!0,  %0)   :              " @3G6 @!X;"]W;W)K<VAE971S+W-H
M965T,3 Y+GAM;%!+ 0(4 Q0    ( )V 2E(K368G" 0  ) /   :
M      " @7;9 @!X;"]W;W)K<VAE971S+W-H965T,3$P+GAM;%!+ 0(4 Q0
M   ( )V 2E(W'GOCQ ,  )@+   :              " @;;= @!X;"]W;W)K
M<VAE971S+W-H965T,3$Q+GAM;%!+ 0(4 Q0    ( )V 2E)F&"&"V0,  -H+
M   :              " @;+A @!X;"]W;W)K<VAE971S+W-H965T,3$R+GAM
M;%!+ 0(4 Q0    ( )V 2E(^'T==" (   <$   :              " @</E
M @!X;"]W;W)K<VAE971S+W-H965T,3$S+GAM;%!+ 0(4 Q0    ( )V 2E+>
MD=.[_0(  '((   :              " @0/H @!X;"]W;W)K<VAE971S+W-H
M965T,3$T+GAM;%!+ 0(4 Q0    ( )V 2E+3V^KO/0,  #P*   :
M      " @3CK @!X;"]W;W)K<VAE971S+W-H965T,3$U+GAM;%!+ 0(4 Q0
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M965T,3$Y+GAM;%!+ 0(4 Q0    ( )V 2E+JT%M!PP,  &41   :
M      " @04& P!X;"]W;W)K<VAE971S+W-H965T,3(P+GAM;%!+ 0(4 Q0
M   ( )V 2E)L'G@$H0(  '$'   :              " @0 * P!X;"]W;W)K
M<VAE971S+W-H965T,3(Q+GAM;%!+ 0(4 Q0    ( )V 2E(<=&$&4P@  *\M
M   :              " @=D, P!X;"]W;W)K<VAE971S+W-H965T,3(R+GAM
M;%!+ 0(4 Q0    ( )V 2E(T-3_HZ0,  !@2   :              " @605
M P!X;"]W;W)K<VAE971S+W-H965T,3(S+GAM;%!+ 0(4 Q0    ( )V 2E+W
MU@SGS@,  -T,   :              " @849 P!X;"]W;W)K<VAE971S+W-H
M965T,3(T+GAM;%!+ 0(4 Q0    ( )V 2E)6,@$3Q@(  #\(   :
M      " @8L= P!X;"]W;W)K<VAE971S+W-H965T,3(U+GAM;%!+ 0(4 Q0
M   ( )V 2E*9YP[M:0(  .T%   :              " @8D@ P!X;"]W;W)K
M<VAE971S+W-H965T,3(V+GAM;%!+ 0(4 Q0    ( )V 2E*+A-+^S (  .('
M   :              " @2HC P!X;"]W;W)K<VAE971S+W-H965T,3(W+GAM
M;%!+ 0(4 Q0    ( )V 2E(@)0*V$@4  $,7   :              " @2XF
M P!X;"]W;W)K<VAE971S+W-H965T,3(X+GAM;%!+ 0(4 Q0    ( )V 2E+G
MG$CP$00  &@0   :              " @7@K P!X;"]W;W)K<VAE971S+W-H
M965T,3(Y+GAM;%!+ 0(4 Q0    ( )V 2E+I*IM;F0(  #H0   -
M      "  <$O P!X;"]S='EL97,N>&UL4$L! A0#%     @ G8!*4I>*NQS
M    $P(   L              ( !A3(# %]R96QS+RYR96QS4$L! A0#%
M  @ G8!*4M61]@>Z"   G%0   \              ( !;C,# 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( )V 2E+8/L<7@P,  *A+   :
M  "  54\ P!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M )V 2E(="W\NM0(  &5(   3              "  1!  P!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    ") (D U"4  /9" P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>676</ContextCount>
  <ElementCount>639</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>193</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss</Role>
      <ShortName>Consolidated Statements of Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Certain transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactions</Role>
      <ShortName>Certain transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Revenue from contracts with customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomers</Role>
      <ShortName>Revenue from contracts with customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Identifiable Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssets</Role>
      <ShortName>Identifiable Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Debt obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligations</Role>
      <ShortName>Debt obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Derivative instruments and hedging activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities</Role>
      <ShortName>Derivative instruments and hedging activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Legal Settlements and Loss Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies</Role>
      <ShortName>Legal Settlements and Loss Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Other assets impairments, restructuring and other items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems</Role>
      <ShortName>Other assets impairments, restructuring and other items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherIncome</Role>
      <ShortName>Other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Financial expenses, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FinancialExpensesNet</Role>
      <ShortName>Financial expenses, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Earnings (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Fair value measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurement</Role>
      <ShortName>Fair value measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Long-term Employee-related Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations</Role>
      <ShortName>Long-term Employee-related Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Schedule of Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts</Role>
      <ShortName>Schedule of Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Certain transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsTables</Role>
      <ShortName>Certain transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/CertainTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Revenue from contracts with customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables</Role>
      <ShortName>Revenue from contracts with customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/RevenueFromContractsWithCustomers</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Inventories</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Identifiable Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables</Role>
      <ShortName>Identifiable Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/IdentifiableIntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Goodwill</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Leases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Debt obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsTables</Role>
      <ShortName>Debt obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/DebtObligations</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Derivative instruments and hedging activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables</Role>
      <ShortName>Derivative instruments and hedging activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Equity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Other assets impairments, restructuring and other items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables</Role>
      <ShortName>Other assets impairments, restructuring and other items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Other income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherIncomeTables</Role>
      <ShortName>Other income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/OtherIncome</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Financial expenses-net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FinancialExpensesNetTables</Role>
      <ShortName>Financial expenses-net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/FinancialExpensesNet</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Earnings (Loss) per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/EarningsLossPerShare</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/Segments</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Long-term Employee-related Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables</Role>
      <ShortName>Long-term Employee-related Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Significant Accounting Policies - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Policies - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Certain Transactions - Business Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail</Role>
      <ShortName>Certain Transactions - Business Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail</Role>
      <ShortName>Certain Transactions - Other Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Certain Transactions - Assets and Liabilities Held For Sale - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail</Role>
      <ShortName>Certain Transactions - Assets and Liabilities Held For Sale - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail</Role>
      <ShortName>Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail</Role>
      <ShortName>Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Inventories - Summary of Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail</Role>
      <ShortName>Inventories - Summary of Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail</Role>
      <ShortName>Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail</Role>
      <ShortName>Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Identifiable Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail</Role>
      <ShortName>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail</Role>
      <ShortName>Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Goodwill - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail</Role>
      <ShortName>Goodwill - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Leases - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Leases - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Leases - Supplemental cash flow information related to leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Supplemental cash flow information related to leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Leases - Supplemental Balance Sheet Information Related To Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information Related To Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Leases -  Maturities of lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail</Role>
      <ShortName>Leases -  Maturities of lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail</Role>
      <ShortName>Debt Obligations - Schedule of Short-term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail</Role>
      <ShortName>Debt Obligations - Schedule of Senior Notes and Loans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail</Role>
      <ShortName>Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail</Role>
      <ShortName>Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail</Role>
      <ShortName>Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Debt Obligations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail</Role>
      <ShortName>Debt Obligations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail</Role>
      <ShortName>Derivative Instruments and Hedging Activities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail</Role>
      <ShortName>Legal Settlements and Loss Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Commitments and Contingencies - Commitments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Commitments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Income Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Income Taxes - Schedule of the Provision for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of the Provision for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail</Role>
      <ShortName>Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail</Role>
      <ShortName>Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Income Taxes - Schedule of Defered Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Defered Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail</Role>
      <ShortName>Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquityAdditionalInformationDetail</Role>
      <ShortName>Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Equity - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail</Role>
      <ShortName>Equity - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Equity - Summary of Weighted Average Fair Value of Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail</Role>
      <ShortName>Equity - Summary of Weighted Average Fair Value of Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>1100 - Disclosure - Equity - Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail</Role>
      <ShortName>Equity - Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>1101 - Disclosure - Equity - Schedule of Ordinary Shares Issued Upon Outstanding Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail</Role>
      <ShortName>Equity - Schedule of Ordinary Shares Issued Upon Outstanding Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>1102 - Disclosure - Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail</Role>
      <ShortName>Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>1103 - Disclosure - Equity - Schedule of Number of RSUs Issued and Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail</Role>
      <ShortName>Equity - Schedule of Number of RSUs Issued and Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>1104 - Disclosure - Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail</Role>
      <ShortName>Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>1105 - Disclosure - Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail</Role>
      <ShortName>Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>1106 - Disclosure - Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail</Role>
      <ShortName>Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>1107 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>1108 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>1109 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>1110 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail</Role>
      <ShortName>Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>1111 - Disclosure - Other Income - Schedule of Other Income (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail</Role>
      <ShortName>Other Income - Schedule of Other Income (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>1112 - Disclosure - Financial expenses, net - Schedule of Financial Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail</Role>
      <ShortName>Financial expenses, net - Schedule of Financial Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>1113 - Disclosure - Financial expenses, net - Schedule of Financial Expenses (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail</Role>
      <ShortName>Financial expenses, net - Schedule of Financial Expenses (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>1114 - Disclosure - Earnings (Loss) per Share - Schedule of Earnings per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail</Role>
      <ShortName>Earnings (Loss) per Share - Schedule of Earnings per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>1115 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Earnings (Loss) per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>1116 - Disclosure - Segments - Summary of Segment Profit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail</Role>
      <ShortName>Segments - Summary of Segment Profit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>1117 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail</Role>
      <ShortName>Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>1118 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail</Role>
      <ShortName>Segments - Schedule of Revenues by Major Products and Activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>1119 - Disclosure - Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail</Role>
      <ShortName>Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>1120 - Disclosure - Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail</Role>
      <ShortName>Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>1121 - Disclosure - Segments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail</Role>
      <ShortName>Segments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>1122 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>1123 - Disclosure - Fair value measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Fair value measurement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>1124 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>1125 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>1126 - Disclosure - Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail</Role>
      <ShortName>Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>1127 - Disclosure - Long-term Employee-related Obligations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail</Role>
      <ShortName>Long-term Employee-related Obligations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>1128 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="d102112d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>1129 - Disclosure - Schedule II Valuation and Qualifying Accounts (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail</Role>
      <ShortName>Schedule II Valuation and Qualifying Accounts (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="d102112d10k.htm">d102112d10k.htm</File>
    <File>d102112dex107.htm</File>
    <File>d102112dex108.htm</File>
    <File>d102112dex109.htm</File>
    <File>d102112dex21.htm</File>
    <File>d102112dex23.htm</File>
    <File>d102112dex311.htm</File>
    <File>d102112dex312.htm</File>
    <File>d102112dex32.htm</File>
    <File>teva-20201231.xsd</File>
    <File>teva-20201231_cal.xml</File>
    <File>teva-20201231_def.xml</File>
    <File>teva-20201231_lab.xml</File>
    <File>teva-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g102112g01r43.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>154
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d102112d10k.htm": {
   "axisCustom": 3,
   "axisStandard": 43,
   "contextCount": 676,
   "dts": {
    "calculationLink": {
     "local": [
      "teva-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "teva-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d102112d10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "teva-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "teva-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "teva-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 1025,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 8,
    "http://www.tevapharm.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 14
   },
   "keyCustom": 162,
   "keyStandard": 477,
   "memberCustom": 115,
   "memberStandard": 73,
   "nsprefix": "teva",
   "nsuri": "http://www.tevapharm.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.tevapharm.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:CertainTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Certain transactions",
     "role": "http://www.tevapharm.com/role/CertainTransactions",
     "shortName": "Certain transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:CertainTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1100 - Disclosure - Equity - Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions (Detail)",
     "role": "http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail",
     "shortName": "Equity - Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1101 - Disclosure - Equity - Schedule of Ordinary Shares Issued Upon Outstanding Options (Detail)",
     "role": "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
     "shortName": "Equity - Schedule of Ordinary Shares Issued Upon Outstanding Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1102 - Disclosure - Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail)",
     "role": "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail",
     "shortName": "Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "lang": null,
      "name": "teva:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019_RestrictedStockUnitsMemberusgaapPlanNameAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1103 - Disclosure - Equity - Schedule of Number of RSUs Issued and Outstanding (Detail)",
     "role": "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail",
     "shortName": "Equity - Schedule of Number of RSUs Issued and Outstanding (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2017_RestrictedStockUnitsMemberusgaapPlanNameAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_StockOptionsPlanMemberusgaapPlanNameAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1104 - Disclosure - Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail)",
     "role": "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail",
     "shortName": "Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_StockOptionsPlanMemberusgaapPlanNameAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1105 - Disclosure - Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)",
     "role": "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
     "shortName": "Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2017_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1106 - Disclosure - Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
     "shortName": "Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_AccountingStandardsUpdate201601MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1107 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
     "shortName": "Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1108 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
     "shortName": "Other assets impairments, restructuring and other items - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "teva:ExpectedRevenueFromFacility",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1109 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
     "shortName": "Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfRestructuringChargesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Revenue from contracts with customers",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
     "shortName": "Revenue from contracts with customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1110 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
     "shortName": "Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfOtherIncomeTableTextBlock",
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1111 - Disclosure - Other Income - Schedule of Other Income (Detail)",
     "role": "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail",
     "shortName": "Other Income - Schedule of Other Income (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfOtherIncomeTableTextBlock",
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:FinancialExpensesNetTableTextBlock",
       "teva:FinancialExpensesNetTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1112 - Disclosure - Financial expenses, net - Schedule of Financial Expenses (Detail)",
     "role": "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail",
     "shortName": "Financial expenses, net - Schedule of Financial Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:FinancialExpensesNetTableTextBlock",
       "teva:FinancialExpensesNetTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "teva:FinancialExpensesNetTableTextBlock",
       "teva:FinancialExpensesNetTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:PaymentForRedemptionOfSeniorNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1113 - Disclosure - Financial expenses, net - Schedule of Financial Expenses (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail",
     "shortName": "Financial expenses, net - Schedule of Financial Expenses (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "teva:FinancialExpensesNetTableTextBlock",
       "teva:FinancialExpensesNetTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:PaymentForRedemptionOfSeniorNotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1114 - Disclosure - Earnings (Loss) per Share - Schedule of Earnings per Share (Detail)",
     "role": "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail",
     "shortName": "Earnings (Loss) per Share - Schedule of Earnings per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1115 - Disclosure - Earnings (Loss) per Share - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
     "shortName": "Earnings (Loss) per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SelectedQuarterlyFinancialDataTableTextBlock",
       "teva:SelectedQuarterlyFinancialDataTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P10_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1116 - Disclosure - Segments - Summary of Segment Profit (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
     "shortName": "Segments - Summary of Segment Profit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1117 - Disclosure - Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
     "shortName": "Segments - Summary of Profit by Segments and Reconciliation of Segments Profit to Consolidated Income Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SelectedQuarterlyFinancialDataTableTextBlock",
       "teva:SelectedQuarterlyFinancialDataTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P10_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1118 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
     "shortName": "Segments - Schedule of Revenues by Major Products and Activities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_GenericsMediciansMembersrtProductOrServiceAxis_NorthAmericaSegmentMemberusgaapStatementBusinessSegmentsAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SalesPercentageByTherapeuticCategoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020_Customer1MembersrtMajorCustomersAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:NetSalesPresent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1119 - Disclosure - Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail",
     "shortName": "Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SalesPercentageByTherapeuticCategoryTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020_Customer1MembersrtMajorCustomersAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:NetSalesPresent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Inventories",
     "role": "http://www.tevapharm.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1120 - Disclosure - Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail",
     "shortName": "Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:PropertyPlantAndEquipmentByGeographicAreaTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020_ILsrtStatementGeographicalAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1121 - Disclosure - Segments - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
     "shortName": "Segments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1122 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
     "shortName": "Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnSaleOfEquityInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1123 - Disclosure - Fair value measurement - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
     "shortName": "Fair value measurement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To09_30_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnSaleOfEquityInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1124 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
     "shortName": "Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1125 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
     "shortName": "Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:LongTermEmployeeRelatedObligationsTableTextBlock",
       "teva:LongTermEmployeeRelatedObligationsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:AccruedSeverancePayNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1126 - Disclosure - Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail)",
     "role": "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail",
     "shortName": "Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:LongTermEmployeeRelatedObligationsTableTextBlock",
       "teva:LongTermEmployeeRelatedObligationsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:AccruedSeverancePayNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "teva:LongTermEmployeeRelatedObligationsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:LongTermInvestmentsEarmarkedForDomesticSeveranceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1127 - Disclosure - Long-term Employee-related Obligations - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail",
     "shortName": "Long-term Employee-related Obligations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "teva:LongTermEmployeeRelatedObligationsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:LongTermInvestmentsEarmarkedForDomesticSeveranceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SelectedQuarterlyFinancialDataTableTextBlock",
       "teva:SelectedQuarterlyFinancialDataTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P10_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1128 - Disclosure - Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Detail)",
     "role": "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail",
     "shortName": "Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SelectedQuarterlyFinancialDataTableTextBlock",
       "teva:SelectedQuarterlyFinancialDataTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P07_01_2020To09_30_2020",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SalesReservesAndAllowancesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1129 - Disclosure - Schedule II Valuation and Qualifying Accounts (Detail)",
     "role": "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail",
     "shortName": "Schedule II Valuation and Qualifying Accounts (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2017_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.tevapharm.com/role/PropertyPlantAndEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Identifiable Intangible Assets",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
     "shortName": "Identifiable Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Goodwill",
     "role": "http://www.tevapharm.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Leases",
     "role": "http://www.tevapharm.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Debt obligations",
     "role": "http://www.tevapharm.com/role/DebtObligations",
     "shortName": "Debt obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Derivative instruments and hedging activities",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
     "shortName": "Derivative instruments and hedging activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Legal Settlements and Loss Contingencies",
     "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
     "shortName": "Legal Settlements and Loss Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Commitments and contingencies",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Income taxes",
     "role": "http://www.tevapharm.com/role/IncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Equity",
     "role": "http://www.tevapharm.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:OtherExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Other assets impairments, restructuring and other items",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
     "shortName": "Other assets impairments, restructuring and other items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:OtherExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Other income",
     "role": "http://www.tevapharm.com/role/OtherIncome",
     "shortName": "Other income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:FinancialExpensesNetTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Financial expenses, net",
     "role": "http://www.tevapharm.com/role/FinancialExpensesNet",
     "shortName": "Financial expenses, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:FinancialExpensesNetTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Earnings (Loss) per Share",
     "role": "http://www.tevapharm.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Segments",
     "role": "http://www.tevapharm.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Fair value measurement",
     "role": "http://www.tevapharm.com/role/FairValueMeasurement",
     "shortName": "Fair value measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:LongTermEmployeeRelatedObligationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Long-term Employee-related Obligations",
     "role": "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations",
     "shortName": "Long-term Employee-related Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:LongTermEmployeeRelatedObligationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:SelectedQuarterlyFinancialDataTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Selected Quarterly Financial Data (Unaudited)",
     "role": "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited",
     "shortName": "Selected Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:SelectedQuarterlyFinancialDataTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Schedule of Valuation and Qualifying Accounts",
     "role": "http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts",
     "shortName": "Schedule of Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:GeneralOptionsAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:GeneralOptionsAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Certain transactions (Tables)",
     "role": "http://www.tevapharm.com/role/CertainTransactionsTables",
     "shortName": "Certain transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Revenue from contracts with customers (Tables)",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
     "shortName": "Revenue from contracts with customers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Inventories (Tables)",
     "role": "http://www.tevapharm.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Identifiable Intangible Assets (Tables)",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
     "shortName": "Identifiable Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Goodwill (Tables)",
     "role": "http://www.tevapharm.com/role/GoodwillTables",
     "shortName": "Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ComponentsOfLeaseExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Leases (Tables)",
     "role": "http://www.tevapharm.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ComponentsOfLeaseExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Income (Loss)",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
     "shortName": "Consolidated Statements of Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Debt obligations (Tables)",
     "role": "http://www.tevapharm.com/role/DebtObligationsTables",
     "shortName": "Debt obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Derivative instruments and hedging activities (Tables)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
     "shortName": "Derivative instruments and hedging activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Equity (Tables)",
     "role": "http://www.tevapharm.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Other assets impairments, restructuring and other items (Tables)",
     "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
     "shortName": "Other assets impairments, restructuring and other items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "teva:OtherExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ScheduleOfOtherIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Other income (Tables)",
     "role": "http://www.tevapharm.com/role/OtherIncomeTables",
     "shortName": "Other income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:ScheduleOfOtherIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "teva:FinancialExpensesNetTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:FinancialExpensesNetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Financial expenses-net (Tables)",
     "role": "http://www.tevapharm.com/role/FinancialExpensesNetTables",
     "shortName": "Financial expenses-net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "teva:FinancialExpensesNetTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:FinancialExpensesNetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Earnings (Loss) per Share (Tables)",
     "role": "http://www.tevapharm.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Segments (Tables)",
     "role": "http://www.tevapharm.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.tevapharm.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "teva:LongTermEmployeeRelatedObligationsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:LongTermEmployeeRelatedObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Long-term Employee-related Obligations (Tables)",
     "role": "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables",
     "shortName": "Long-term Employee-related Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "teva:LongTermEmployeeRelatedObligationsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:LongTermEmployeeRelatedObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "teva:SelectedQuarterlyFinancialDataTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:SelectedQuarterlyFinancialDataTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "teva:SelectedQuarterlyFinancialDataTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "teva:SelectedQuarterlyFinancialDataTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Significant Accounting Policies - Additional information (Detail)",
     "role": "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Significant Accounting Policies - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "teva:CertainTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_31_2018To01_31_2018_AllerganPlcMembersrtCounterpartyNameAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:OneTimeMilestonePaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Certain Transactions - Business Transactions - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
     "shortName": "Certain Transactions - Business Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "teva:CertainTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_31_2018To01_31_2018_AllerganPlcMembersrtCounterpartyNameAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:OneTimeMilestonePaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:ImpairmentsRestructuringAndOthers",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
     "shortName": "Certain Transactions - Other Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2018To03_31_2018_PgtMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-6",
      "lang": null,
      "name": "teva:ImpairmentsRestructuringAndOthers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Certain Transactions - Assets and Liabilities Held For Sale - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail",
     "shortName": "Certain Transactions - Assets and Liabilities Held For Sale - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)",
     "role": "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail",
     "shortName": "Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "teva:SalesReservesAndAllowancesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:SalesReservesAndAllowancesToCustomersPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
     "shortName": "Revenue from Contracts with Customers - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "teva:SalesReservesAndAllowancesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:SalesReservesAndAllowancesToCustomersPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SelectedQuarterlyFinancialDataTableTextBlock",
       "teva:SelectedQuarterlyFinancialDataTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P10_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
     "shortName": "Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_ProductMembersrtProductOrServiceAxis",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SalesReservesAndAllowancesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)",
     "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
     "shortName": "Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SalesReservesAndAllowancesCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "teva:ValuationAllowancesAndReservesRelatedToCurrentPeriodSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Changes in Equity",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Inventories - Summary of Inventories (Detail)",
     "role": "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
     "shortName": "Inventories - Summary of Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail)",
     "role": "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail",
     "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
     "shortName": "Property, Plant and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail",
     "shortName": "Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Identifiable Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)",
     "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
     "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "teva:GoodwillReclassification",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
     "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Goodwill - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
     "shortName": "Goodwill - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To09_30_2020_NorthAmericaMembersrtStatementGeographicalAxis",
      "decimals": "2",
      "lang": null,
      "name": "teva:PercentageDecreaseInTheMarketCapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ComponentsOfLeaseExpenseTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Leases - Components of Lease Expense (Detail)",
     "role": "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail",
     "shortName": "Leases - Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ComponentsOfLeaseExpenseTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SupplementalCashFlowInformationTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Leases - Supplemental cash flow information related to leases (Detail)",
     "role": "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail",
     "shortName": "Leases - Supplemental cash flow information related to leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SupplementalCashFlowInformationTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
     "shortName": "Consolidated Statements of Changes in Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2018To12_31_2018_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Leases - Supplemental Balance Sheet Information Related To Leases (Detail)",
     "role": "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail",
     "shortName": "Leases - Supplemental Balance Sheet Information Related To Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:SupplementalBalanceSheetInformationRelatedToLeasesTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "teva:OperatingLeaseLiabilityOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Leases -  Maturities of lease liabilities (Detail)",
     "role": "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail",
     "shortName": "Leases -  Maturities of lease liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
     "shortName": "Debt Obligations - Schedule of Short-term Debt (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020_ShortCreditAgreement2026MemberusgaapDebtInstrumentAxis",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeniorNotes",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
     "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
     "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020_SubsidiarySeniorNotesDue2020OneMemberusgaapDebtInstrumentAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_EUR",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail",
     "shortName": "Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn02_01_2021_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail",
     "shortName": "Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn04_30_2019",
      "decimals": "-7",
      "first": true,
      "lang": null,
      "name": "us-gaap:LinesOfCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Debt Obligations - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
     "shortName": "Debt Obligations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn04_30_2019",
      "decimals": "-7",
      "first": true,
      "lang": null,
      "name": "us-gaap:LinesOfCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting (Detail)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail",
     "shortName": "Derivative Instruments and Hedging Activities - Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_NetInvestmentHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
     "shortName": "Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
     "shortName": "Derivative Instruments and Hedging Activities - Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_OtherComprehensiveIncomeMemberusgaapOtherComprehensiveIncomeLocationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure - Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
     "shortName": "Derivative Instruments and Hedging Activities - Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020_NetRevenuesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableFromSecuritization",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail",
     "shortName": "Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfAccountReceivableFromSecuritization",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ProceedsFromAccountsReceivableSecuritization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:RevenuesOtherThanUsd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1084 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
     "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "teva:RevenuesOtherThanUsd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1085 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
     "shortName": "Legal Settlements and Loss Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1086 - Disclosure - Commitments and Contingencies - Commitments - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Commitments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "teva:DamagesAssessment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1087 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "teva:DamagesAssessment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1088 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail",
     "shortName": "Income Taxes - Schedule of Income Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1089 - Disclosure - Income Taxes - Schedule of the Provision for Income Taxes (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail",
     "shortName": "Income Taxes - Schedule of the Provision for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Significant Accounting Policies",
     "role": "http://www.tevapharm.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1090 - Disclosure - Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
     "shortName": "Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationOtherAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1091 - Disclosure - Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
     "shortName": "Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationOtherAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1092 - Disclosure - Income Taxes - Schedule of Defered Income Taxes (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail",
     "shortName": "Income Taxes - Schedule of Defered Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:DeferredTaxAssetUnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1093 - Disclosure - Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail",
     "shortName": "Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "teva:DeferredTaxAssetUnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1094 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1095 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "teva:ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1096 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)",
     "role": "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SharesOutstanding",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1097 - Disclosure - Equity - Additional Information (Detail)",
     "role": "http://www.tevapharm.com/role/EquityAdditionalInformationDetail",
     "shortName": "Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SharesOutstanding",
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1098 - Disclosure - Equity - Summary of Stock Option Activity (Detail)",
     "role": "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail",
     "shortName": "Equity - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "PAsOn12_31_2017",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1099 - Disclosure - Equity - Summary of Weighted Average Fair Value of Options Granted (Detail)",
     "role": "http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail",
     "shortName": "Equity - Summary of Weighted Average Fair Value of Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d102112d10k.htm",
      "contextRef": "P01_01_2018To12_31_2018",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 193,
   "tag": {
    "country_CZ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CZECH REPUBLIC",
        "terseLabel": "Czech republic [Member]"
       }
      }
     },
     "localname": "CZ",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany [Member]"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CROATIA",
        "terseLabel": "Croatia [Member]"
       }
      }
     },
     "localname": "HR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HUNGARY",
        "terseLabel": "Hungary [Member]"
       }
      }
     },
     "localname": "HU",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL",
        "terseLabel": "Israel [Member]",
        "verboseLabel": "Israel [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan [Member]"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
      "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail",
      "http://www.tevapharm.com/role/EarningsLossPerShareTables",
      "http://www.tevapharm.com/role/Equity",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail",
      "http://www.tevapharm.com/role/EquityTables",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/FinancialExpensesNet",
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail",
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail",
      "http://www.tevapharm.com/role/FinancialExpensesNetTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail",
      "http://www.tevapharm.com/role/IncomeTaxesTables",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/Leases",
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail",
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.tevapharm.com/role/LeasesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/OtherIncome",
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail",
      "http://www.tevapharm.com/role/OtherIncomeTables",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipment",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail",
      "http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
      "http://www.tevapharm.com/role/SegmentsTables",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
      "http://www.tevapharm.com/role/SignificantAccountingPolicies",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail",
      "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail",
      "http://www.tevapharm.com/role/EarningsLossPerShareTables",
      "http://www.tevapharm.com/role/Equity",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail",
      "http://www.tevapharm.com/role/EquityTables",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/FinancialExpensesNet",
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail",
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail",
      "http://www.tevapharm.com/role/FinancialExpensesNetTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail",
      "http://www.tevapharm.com/role/IncomeTaxesTables",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/Leases",
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail",
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.tevapharm.com/role/LeasesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/OtherIncome",
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail",
      "http://www.tevapharm.com/role/OtherIncomeTables",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipment",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail",
      "http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
      "http://www.tevapharm.com/role/SegmentsTables",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
      "http://www.tevapharm.com/role/SignificantAccountingPolicies",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r215",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r241",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r215",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r241",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r80",
      "r152",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by currency.",
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continent of Europe.",
        "label": "Europe [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r251",
      "r384",
      "r388",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r411",
      "r414",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r661",
      "r726",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r411",
      "r414",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r661",
      "r726",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r251",
      "r384",
      "r388",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continent of North America.",
        "label": "North America [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r247",
      "r384",
      "r386",
      "r662",
      "r725",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r247",
      "r384",
      "r386",
      "r662",
      "r725",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r394",
      "r411",
      "r414",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r661",
      "r726",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r394",
      "r411",
      "r414",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r661",
      "r726",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r167",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule of Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r248",
      "r249",
      "r384",
      "r387",
      "r728",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r384",
      "r387",
      "r728",
      "r747",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r340",
      "r412",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r253",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r167",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r636",
      "r638",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance.",
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AccountsReceivablesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivables [Text Block]",
        "label": "Accounts Receivables [Policy Text Block]",
        "terseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "AccountsReceivablesPolicyTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_AccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses.",
        "label": "Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpenses",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AccruedSeverancePayNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail": {
       "order": 1.0,
       "parentTag": "teva_EmployeeRelatedObligationsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued severance pay non-current.",
        "label": "Accrued Severance Pay Noncurrent",
        "terseLabel": "Accrued severance obligations"
       }
      }
     },
     "localname": "AccruedSeverancePayNoncurrent",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AcquisitionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition [Text Block]",
        "label": "Acquisition [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AcquisitionTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ActavisGenericsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actavis Generics [Member]",
        "label": "Actavis Generics [Member]",
        "terseLabel": "Actavis Generics [Member]"
       }
      }
     },
     "localname": "ActavisGenericsMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ActavisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actavis [Member]",
        "label": "Actavis [Member]",
        "terseLabel": "Actavis [Member]"
       }
      }
     },
     "localname": "ActavisMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AjovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AJOVY [Member]"
       }
      }
     },
     "localname": "AjovyMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AlderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alder [Member]",
        "label": "Alder [Member]",
        "terseLabel": "Alder [Member]"
       }
      }
     },
     "localname": "AlderMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AllerganPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allergan Plc.",
        "label": "Allergan Plc [Member]",
        "terseLabel": "Allergan plc [Member]"
       }
      }
     },
     "localname": "AllerganPlcMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AlvotechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alvotech.",
        "label": "Alvotech [Member]",
        "terseLabel": "Alvotech [Member]"
       }
      }
     },
     "localname": "AlvotechMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_Amendment68ToInvestmentLawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment 68 to Investment Law [Member]",
        "label": "Amendment 68 to Investment Law [Member]",
        "terseLabel": "Amendment 68 to Investment Law [Member]"
       }
      }
     },
     "localname": "Amendment68ToInvestmentLawMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_Amendment69ToInvestmentLawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment 69 to Investment Law [Member]",
        "label": "Amendment 69 to Investment Law [Member]",
        "terseLabel": "Amendment 69 to Investment Law [Member]"
       }
      }
     },
     "localname": "Amendment69ToInvestmentLawMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_Amendment73ToInvestmentLawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment 73 to Investment Law [Member]",
        "label": "Amendment 73 to Investment Law [Member]",
        "terseLabel": "Amendment 73 to Investment Law [Member]"
       }
      }
     },
     "localname": "Amendment73ToInvestmentLawMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AmountsAllocatedToSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts allocated to segments.",
        "label": "Amounts Allocated To Segments [Abstract]",
        "terseLabel": "Amounts allocated to segments:"
       }
      }
     },
     "localname": "AmountsAllocatedToSegmentsAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_AmountsNotAllocatedToSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts not allocated to segments.",
        "label": "Amounts Not Allocated To Segments [Abstract]",
        "terseLabel": "Amounts not allocated to segments:"
       }
      }
     },
     "localname": "AmountsNotAllocatedToSegmentsAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_AndaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anda [Member]",
        "label": "Anda [Member]",
        "terseLabel": "Anda [Member]"
       }
      }
     },
     "localname": "AndaMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AndroGelRateAtOnePercentageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Andro gel rate at one percentage.",
        "label": "Andro Gel Rate At One Percentage [Member]",
        "terseLabel": "AndroGel Rate at 1% [Member]"
       }
      }
     },
     "localname": "AndroGelRateAtOnePercentageMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AnnualSalesAtTimeOfSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales at time of settlement.",
        "label": "Annual Sales At Time Of Settlement",
        "terseLabel": "Annual sales at the time of settlement"
       }
      }
     },
     "localname": "AnnualSalesAtTimeOfSettlement",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfActoplus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Acto plus.",
        "label": "Annual Sales Of Actoplus",
        "terseLabel": "Annual sales of Acto plus"
       }
      }
     },
     "localname": "AnnualSalesOfActoplus",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfActos": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Actos.",
        "label": "Annual Sales Of Actos",
        "terseLabel": "Annual sales of Actos"
       }
      }
     },
     "localname": "AnnualSalesOfActos",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfCopaxone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Sales Of Copaxone.",
        "label": "Annual Sales Of Copaxone",
        "terseLabel": "Annual sales of Copaxone"
       }
      }
     },
     "localname": "AnnualSalesOfCopaxone",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfEffexor": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of effexor.",
        "label": "Annual Sales Of Effexor",
        "terseLabel": "Annual sales of Effexor"
       }
      }
     },
     "localname": "AnnualSalesOfEffexor",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfLamictal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Lamictal.",
        "label": "Annual Sales Of Lamictal",
        "terseLabel": "Annual sales of Lamictal"
       }
      }
     },
     "localname": "AnnualSalesOfLamictal",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfNamenda": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Namenda.",
        "label": "Annual Sales Of Namenda",
        "terseLabel": "Annual sales of Namenda"
       }
      }
     },
     "localname": "AnnualSalesOfNamenda",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfNiaspan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual sales of Niaspan.",
        "label": "Annual Sales Of Niaspan",
        "terseLabel": "Annual sales of Niaspan"
       }
      }
     },
     "localname": "AnnualSalesOfNiaspan",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfSensipar": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Annual Sales Of Sensipar.",
        "label": "Annual Sales Of Sensipar"
       }
      }
     },
     "localname": "AnnualSalesOfSensipar",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AnnualSalesOfVelcade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Sales Of Velcade",
        "label": "Annual Sales Of Velcade",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "AnnualSalesOfVelcade",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AssetsUnderConstructionAndPaymentsOnAccount": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets under construction and payments on account.",
        "label": "Assets Under Construction And Payments On Account",
        "terseLabel": "Assets under construction and payments on account"
       }
      }
     },
     "localname": "AssetsUnderConstructionAndPaymentsOnAccount",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_AustedoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Austedo [Member]",
        "label": "Austedo [Member]",
        "terseLabel": "AUSTEDO [Member]"
       }
      }
     },
     "localname": "AustedoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_AverageGrowthPrecedingPeriodInSalesOrWorkforce": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average growth preceding period in sales or workforce.",
        "label": "Average growth preceding period in sales or workforce",
        "terseLabel": "Average growth preceding period in sales or workforce"
       }
      }
     },
     "localname": "AverageGrowthPrecedingPeriodInSalesOrWorkforce",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_AverageGrowthRateInSalesOrWorkforce": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average growth rate in sales or workforce.",
        "label": "Average growth rate in sales or workforce",
        "terseLabel": "Average growth rate in sales or workforce"
       }
      }
     },
     "localname": "AverageGrowthRateInSalesOrWorkforce",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_AverageSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average share price.",
        "label": "Average Share Price",
        "terseLabel": "Company average share price"
       }
      }
     },
     "localname": "AverageSharePrice",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "teva_BendekaAndTreandaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENDEKA and TREANDA.",
        "label": "BENDEKA and TREANDA [Member]",
        "verboseLabel": "BENDEKA and TREANDA [Member]"
       }
      }
     },
     "localname": "BendekaAndTreandaMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Interest Obtained in Exchange for Securitized Trade Receivables",
        "label": "Beneficial Interest Obtained in Exchange for Securitized Trade Receivables",
        "terseLabel": "Beneficial interest obtained in exchange for securitized trade receivables"
       }
      }
     },
     "localname": "BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_COPAXONEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COPAXONE.",
        "label": "COPAXONE [Member]",
        "terseLabel": "COPAXONE [Member]"
       }
      }
     },
     "localname": "COPAXONEMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash deposited with financially sound european us and israeli banks and financial institutions.",
        "label": "Cash Deposited With Financially Sound European Us And Israeli Banks And Financial Institutions",
        "terseLabel": "Cash deposited with financially sound European us and Israeli banks and financial institutions"
       }
      }
     },
     "localname": "CashDepositedWithFinanciallySoundEuropeanUsAndIsraeliBanksAndFinancialInstitutions",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_CashPaidDuringTheYearForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid during the year for.",
        "label": "Cash paid during the year for [Abstract]",
        "terseLabel": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringTheYearForAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid for Amounts Measurement of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_CashReceivedOnSettlementOfPosition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notional amount hedge debt.",
        "label": "Cash Received On Settlement Of Position",
        "terseLabel": "Cash received on settlement of position"
       }
      }
     },
     "localname": "CashReceivedOnSettlementOfPosition",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_CelltrionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Celltrion [Member]",
        "label": "Celltrion [Member]",
        "terseLabel": "Celltrion [Member]"
       }
      }
     },
     "localname": "CelltrionMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_CertainTransactionsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Certain Transactions Disclosure [Text Block]",
        "terseLabel": "Certain transactions"
       }
      }
     },
     "localname": "CertainTransactionsDisclosureTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks.",
        "label": "Chargebacks [Member]",
        "terseLabel": "Chargebacks [Member]"
       }
      }
     },
     "localname": "ChargebacksMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_CollaborativeAgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone Payments",
        "label": "Collaborative Agreement Milestone Payments",
        "terseLabel": "Collaborative agreement milestone payments"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestonePayments",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_CommitmentAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Line Items]",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_CommitmentAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Table]",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ComponentsOfLeaseExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Components Of Lease Expense [Table Text Block]",
        "terseLabel": "Components Of Lease Expense"
       }
      }
     },
     "localname": "ComponentsOfLeaseExpenseTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_CostOfShippingAndHandlingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of shipping and handling policy.",
        "label": "Cost of Shipping and Handling [Policy Text Block]",
        "terseLabel": "Shipping and handling costs"
       }
      }
     },
     "localname": "CostOfShippingAndHandlingPolicyTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_CostsRelatedToRegulatoryActionsTakenInFacilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs related to regulatory actions taken in facilities.",
        "label": "Costs Related To Regulatory Actions Taken In Facilities",
        "terseLabel": "Costs related to regulatory actions taken in facilities"
       }
      }
     },
     "localname": "CostsRelatedToRegulatoryActionsTakenInFacilities",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_CreditTermsToCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit terms to customers.",
        "label": "Credit Terms to Customers",
        "terseLabel": "Credit terms to customers"
       }
      }
     },
     "localname": "CreditTermsToCustomers",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_Customer1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 1.",
        "label": "Customer 1 [Member]",
        "terseLabel": "McKesson Corporation [Member]"
       }
      }
     },
     "localname": "Customer1Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_Customer2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 2.",
        "label": "Customer 2 [Member]",
        "terseLabel": "AmerisourceBergen Corporation [Member]"
       }
      }
     },
     "localname": "Customer2Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DamagesAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Damages assessment.",
        "label": "Damages Assessment",
        "terseLabel": "Damages assessment"
       }
      }
     },
     "localname": "DamagesAssessment",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DebtInstrumentMaturityYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Maturity Year",
        "label": "Debt Instrument Maturity Year",
        "terseLabel": "Maturity"
       }
      }
     },
     "localname": "DebtInstrumentMaturityYear",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "teva_DeferredIncomeTaxesNetAndUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred income taxes net and uncertain tax positions.",
        "label": "Deferred Income Taxes Net And Uncertain Tax Positions",
        "terseLabel": "Deferred income taxes, net and uncertain tax positions"
       }
      }
     },
     "localname": "DeferredIncomeTaxesNetAndUncertainTaxPositions",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DeferredPurchaseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Purchase Asset",
        "label": "Deferred Purchase Asset",
        "terseLabel": "Deferred purchase asset"
       }
      }
     },
     "localname": "DeferredPurchaseAsset",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DeferredTaxAssetUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset Unrecognized Tax Benefits",
        "label": "Deferred Tax Asset Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetUnrecognizedTaxBenefits",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 6.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets carryforward losses and deductions noncurrent.",
        "label": "Deferred Tax Assets Carryforward Losses And Deductions Noncurrent",
        "terseLabel": "Carryforward losses and deductions and credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsCarryforwardLossesAndDeductionsNoncurrent",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DeferredTaxAssetsDeferredInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 8.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Deferred Interest",
        "label": "Deferred Tax Assets Deferred Interest",
        "terseLabel": "Deferred interest"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredInterest",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax assets liabilities gross noncurrent.",
        "label": "Deferred Tax Assets Liabilities Gross Noncurrent",
        "negatedTotalLabel": "Long-term deferred tax assets (liabilities)-gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesGrossNoncurrent",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DeferredTaxAssetsLiabilitiesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Liabilities Net [Line Items]",
        "label": "Deferred Tax Assets Liabilities Net [Line Items]",
        "terseLabel": "Deferred Tax Assets Liabilities Net [Line Items]"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, net, noncurrent, classification.",
        "label": "Deferred Tax Assets Liabilities Net Noncurrent [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrentAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "xbrltype": "stringItemType"
    },
    "teva_DeferredTaxAssetsLiabilitiesOtherNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 10.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets liabilities other net noncurrent.",
        "label": "Deferred Tax Assets Liabilities Other Net Noncurrent",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesOtherNetNoncurrent",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 9.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Non Current",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Non Current",
        "terseLabel": "Provisions for employee related obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsNonCurrent",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan estimated future discretionary employer contributions in next fiscal year.",
        "label": "Defined Benefit Plan Estimated Future Discretionary Employer Contributions In Next Fiscal Year",
        "terseLabel": "Expected contributions to pension funds"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureDiscretionaryEmployerContributionsInNextFiscalYear",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_DevelopmentZoneaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Zone A.",
        "label": "Development Zone A [Member]",
        "terseLabel": "Development Zonea [Member]"
       }
      }
     },
     "localname": "DevelopmentZoneaMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DiscontinuationOfBusinessAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinuation Of Business [Axis]"
       }
      }
     },
     "localname": "DiscontinuationOfBusinessAxis",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_DiscontinuationOfBusinessDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinuation Of Business [Domain]"
       }
      }
     },
     "localname": "DiscontinuationOfBusinessDomain",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DiscontinuedBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Business [Member]",
        "terseLabel": "Discontinued business [Member]"
       }
      }
     },
     "localname": "DiscontinuedBusinessMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_DivestituresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestitures [Text Block]",
        "label": "Divestitures [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DivestituresTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic And Foreign Income Tax Expense Benefit Table [Text Block]",
        "label": "Domestic And Foreign Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of the Provision for Income Taxes"
       }
      }
     },
     "localname": "DomesticAndForeignIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_EagleTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eagle transaction.",
        "label": "Eagle Transaction [Member]",
        "terseLabel": "Eagle Transaction [Member]"
       }
      }
     },
     "localname": "EagleTransactionMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EffectOfExchangeRateOnAccountsReceivableFromSecuritization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of exchange rate on accounts receivable from securitization.",
        "label": "Effect Of Exchange Rate On Accounts Receivable From Securitization",
        "terseLabel": "Effect of currency exchange rate changes"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnAccountsReceivableFromSecuritization",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_EmployeeRelatedObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee related obligations non-current.",
        "label": "Employee Related Obligations Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EmployeeRelatedObligationsNoncurrent",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_EmployeeRelatedObligationsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee related obligations non-current.",
        "label": "Employee Related Obligations Noncurrent [Abstract]"
       }
      }
     },
     "localname": "EmployeeRelatedObligationsNoncurrentAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "xbrltype": "stringItemType"
    },
    "teva_EmployeeTerminationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee termination.",
        "label": "Employee Termination [Member]",
        "terseLabel": "Employee termination costs [Member]"
       }
      }
     },
     "localname": "EmployeeTerminationMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EosinophilicEsophagitisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eosinophilic Esophagitis [Member]",
        "label": "Eosinophilic Esophagitis [Member]",
        "terseLabel": "Eosinophilic Esophagitis [Member]"
       }
      }
     },
     "localname": "EosinophilicEsophagitisMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_EquityAndCostMethodInvestmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element describes an entity's application of the equity method of accounting to investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The description provided may include a description of how equity method or cost investments are assessed for impairment.",
        "label": "Equity And Cost Method Investment Policy [Text Block]",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquityAndCostMethodInvestmentPolicyTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_EuropeSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe segment.",
        "label": "Europe Segment [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeSegmentMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$45.01 - $55.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$35.01 - $45.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "Lower than $15.01 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExercisePriceRangeSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sixth range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.",
        "label": "Exercise Price Range Six [Member]",
        "terseLabel": "$55.01 - $65.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeSixMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$25.01 - $35.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second range of exercise prices set forth in stock option grants that remain outstanding as of the balance sheet date.",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$15.01 - $25.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExitAndDisposalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit And Disposal [Axis]",
        "label": "Exit And Disposal [Axis]",
        "terseLabel": "Exit And Disposal [Axis]"
       }
      }
     },
     "localname": "ExitAndDisposalAxis",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ExitAndDisposalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit And Disposal [Domain]",
        "label": "Exit And Disposal [Domain]",
        "terseLabel": "Exit And Disposal [Domain]"
       }
      }
     },
     "localname": "ExitAndDisposalDomain",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ExpectedImpairmentOfIncomeTaxBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected impairment of income tax benefit.",
        "label": "Expected Impairment OF Income Tax Benefit",
        "terseLabel": "Expected impairment of income tax benefit"
       }
      }
     },
     "localname": "ExpectedImpairmentOfIncomeTaxBenefit",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ExpectedRevenueFromFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Revenue From Facility",
        "label": "Expected Revenue From Facility",
        "terseLabel": "Expected revenue from Florida manufacturing plant in 2020"
       }
      }
     },
     "localname": "ExpectedRevenueFromFacility",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses [Line Items]",
        "label": "Expenses [Line Items]",
        "terseLabel": "Expenses [Line Items]"
       }
      }
     },
     "localname": "ExpensesLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail",
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses [Table]",
        "label": "Expenses [Table]",
        "terseLabel": "Expenses [Table]"
       }
      }
     },
     "localname": "ExpensesTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail",
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration arising during period.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Arising During Period",
        "terseLabel": "Actavis Generics transaction"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationArisingDuringPeriod",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease",
        "terseLabel": "Adjustments to provisions for contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FinanceIncomeExpensesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance income expenses net.",
        "label": "Finance Income Expenses Net",
        "negatedTotalLabel": "Total finance expense, net"
       }
      }
     },
     "localname": "FinanceIncomeExpensesNet",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FinancialExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial expenses [Member]",
        "terseLabel": "Financial expenses [Member]"
       }
      }
     },
     "localname": "FinancialExpensesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_FinancialExpensesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Expenses Net [Abstract]",
        "label": "Financial Expenses Net [Abstract]"
       }
      }
     },
     "localname": "FinancialExpensesNetAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "xbrltype": "stringItemType"
    },
    "teva_FinancialExpensesNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Expenses Net Table [Text Block]",
        "label": "Financial Expenses Net Table [Text Block]",
        "terseLabel": "Schedule of Financial Expenses"
       }
      }
     },
     "localname": "FinancialExpensesNetTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_FinancialExpensesNetTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Expenses Net [Text Block]",
        "label": "Financial Expenses Net [Text Block]",
        "terseLabel": "Financial expenses, net"
       }
      }
     },
     "localname": "FinancialExpensesNetTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of fixed payments and variable payments depend on an index or rate.",
        "label": "Fixed Payments And Variable Payments Depend On An Index Or Rate",
        "verboseLabel": "Fixed payments and variable payments that depend on an index or rate"
       }
      }
     },
     "localname": "FixedPaymentsAndVariablePaymentsDependOnAnIndexOrRate",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ForeignCurrencyTransactionGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail": {
       "order": 3.0,
       "parentTag": "teva_FinanceIncomeExpensesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate of net unrealized foreign currency transaction gains (losses) and net realized foreign currency transaction gains (losses) relating to debt repayments.",
        "label": "Foreign Currency Transaction Gain Loss",
        "negatedLabel": "Foreign exchange (gains) losses, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLoss",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward starting interest rate swaps and treasury lock agreements losses.",
        "label": "Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses",
        "terseLabel": "Forward starting interest rate swaps and treasury lock agreements losses"
       }
      }
     },
     "localname": "ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future expected domestic minimum benefit payments year five.",
        "label": "Future Expected Domestic Minimum Benefit Payments Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FutureExpectedDomesticMinimumBenefitPaymentsYearFive",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FutureExpectedDomesticMinimumBenefitPaymentsYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future expected domestic minimum benefit payments year four.",
        "label": "Future Expected Domestic Minimum Benefit Payments Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FutureExpectedDomesticMinimumBenefitPaymentsYearFour",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FutureExpectedDomesticMinimumBenefitPaymentsYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future expected domestic minimum benefit payments year one.",
        "label": "Future Expected Domestic Minimum Benefit Payments Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FutureExpectedDomesticMinimumBenefitPaymentsYearOne",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FutureExpectedDomesticMinimumBenefitPaymentsYearThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future expected domestic minimum benefit payments year three.",
        "label": "Future Expected Domestic Minimum Benefit Payments Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FutureExpectedDomesticMinimumBenefitPaymentsYearThree",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FutureExpectedDomesticMinimumBenefitPaymentsYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future expected domestic minimum benefit payments year two.",
        "label": "Future Expected Domestic Minimum Benefit Payments Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FutureExpectedDomesticMinimumBenefitPaymentsYearTwo",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future expected domestic minimum benefit payments years six through ten.",
        "label": "Future Expected Domestic Minimum Benefit Payments Years Six Through Ten",
        "terseLabel": "2026 to 2030"
       }
      }
     },
     "localname": "FutureExpectedDomesticMinimumBenefitPaymentsYearsSixThroughTen",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_GeneralOptionsAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General options accounting policy.",
        "label": "General Options Accounting Policy [Policy Text Block]",
        "terseLabel": "General"
       }
      }
     },
     "localname": "GeneralOptionsAccountingPolicyPolicyTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_GenericsMediciansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generics Medicians.",
        "label": "Generics Medicians [Member]",
        "terseLabel": "Generic products [Member]"
       }
      }
     },
     "localname": "GenericsMediciansMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_GoodwillReclassification": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill reclassification.",
        "label": "Goodwill Reclassification",
        "terseLabel": "Goodwill reclassified as assets to held for sale"
       }
      }
     },
     "localname": "GoodwillReclassification",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_HedgingOfRevenuesTwoThousandAndTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging Of Revenues Two Thousand And Twenty One [Member]",
        "terseLabel": "Hedging Of Revenues 2021 [Member]"
       }
      }
     },
     "localname": "HedgingOfRevenuesTwoThousandAndTwentyOneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_IEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ireland.",
        "label": "I E [Member]",
        "terseLabel": "Ireland [Member]"
       }
      }
     },
     "localname": "IEMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ImpairmentAndRestructuring": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment and restructuring.",
        "label": "Impairment And Restructuring",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ImpairmentAndRestructuring",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Intangible Assets Reasons For Impairment.",
        "label": "Impairment Of Intangible Assets Reasons For Impairment [Axis]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Intangible Assets Reasons For Impairment.",
        "label": "Impairment Of Intangible Assets Reasons For Impairment [Domain]"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ImpairmentsRestructuringAndOthers": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 16.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairments restructuring and others.",
        "label": "Impairments Restructuring And Others",
        "terseLabel": "Other asset impairments, restructuring and other items",
        "verboseLabel": "Other asset impairments, restructuring and other items"
       }
      }
     },
     "localname": "ImpairmentsRestructuringAndOthers",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income before income taxes and income tax expense benefit.",
        "label": "Income Before Income Taxes And Income Tax Expense Benefit [Line Items]",
        "terseLabel": "Income Before Income Taxes And Income Tax Expense Benefit [Line Items]"
       }
      }
     },
     "localname": "IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Before Income Taxes And Income Tax Expense Benefit [Table]",
        "label": "Income Before Income Taxes And Income Tax Expense Benefit [Table]",
        "terseLabel": "Income Before Income Taxes And Income Tax Expense Benefit [Table]"
       }
      }
     },
     "localname": "IncomeBeforeIncomeTaxesAndIncomeTaxExpenseBenefitTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_IncomeTaxesUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes an entity's accounting policy for tax positions taken in the Company's tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of contingencies related to income taxes.",
        "label": "Income Taxes Uncertainties Policy [Text Block]",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxesUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the period in accounts receivable and current assets not separately reported.",
        "label": "Increase Decrease In Certain Current Assets Excluding Inventories",
        "terseLabel": "Trade receivables net of sales reserves and allowances"
       }
      }
     },
     "localname": "IncreaseDecreaseInCertainCurrentAssetsExcludingInventories",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the period in sales reserves and allowances, accounts payable, and other current liabilities not separately reported.",
        "label": "Increase Decrease In Certain Current Liabilities Excluding Debt",
        "terseLabel": "Trade payables, accrued expenses, employee-related obligations and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_IntangibleAssetsImpairments": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets Impairments",
        "label": "Intangible Assets Impairments",
        "terseLabel": "Intangible assets impairments"
       }
      }
     },
     "localname": "IntangibleAssetsImpairments",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_InterestRateSwapGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate swap gain.",
        "label": "Interest Rate Swap Gain"
       }
      }
     },
     "localname": "InterestRateSwapGain",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_InternationalMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International markets.",
        "label": "International Markets [Member]",
        "terseLabel": "International Markets [Member]"
       }
      }
     },
     "localname": "InternationalMarketsMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_InventoriesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories [Line Items]",
        "label": "Inventories [Line Items]",
        "terseLabel": "Inventories [Line Items]"
       }
      }
     },
     "localname": "InventoriesLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_InventoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories [Table]",
        "label": "Inventories [Table]",
        "terseLabel": "Inventories [Table]"
       }
      }
     },
     "localname": "InventoriesTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_JanssenAndMillenniumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen and Millennium [Member]",
        "label": "Janssen and Millennium [Member]",
        "terseLabel": "Janssen and Millennium [Member]"
       }
      }
     },
     "localname": "JanssenAndMillenniumMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_LegalSettlementsAndLossContingencies": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 14.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items).",
        "label": "Legal Settlements And Loss Contingencies",
        "terseLabel": "Legal settlements and loss contingencies"
       }
      }
     },
     "localname": "LegalSettlementsAndLossContingencies",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements loss contingencies impairments other expenses.",
        "label": "Legal Settlements Loss Contingencies Impairments Other Expenses",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "LegalSettlementsLossContingenciesImpairmentsOtherExpenses",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LenalidomideProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lenalidomide Product [Member]"
       }
      }
     },
     "localname": "LenalidomideProductMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year five and thereafter.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And Thereafter",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LitigationSettlementAmountAwardedCashAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount awarded cash amount.",
        "label": "Litigation Settlement Amount Awarded Cash Amount",
        "terseLabel": "Litigation settlement amount awarded cash amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedCashAmount",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LitigationSettlementAmountAwardedCashAmountDistributionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount awarded cash amount distribution period.",
        "label": "Litigation Settlement Amount Awarded Cash Amount Distribution Period",
        "terseLabel": "Litigation settlement amount awarded cash amount distribution period"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedCashAmountDistributionPeriod",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_LitigationSettlementAmountAwardedDistributionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount awarded distribution period.",
        "label": "Litigation Settlement Amount Awarded Distribution Period",
        "terseLabel": "Litigation settlement amount awarded distribution period"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedDistributionPeriod",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_LitigationSettlementAmountAwardedNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount awarded number of installments.",
        "label": "Litigation Settlement Amount Awarded Number Of Installments",
        "terseLabel": "Litigation settlement amount awarded number of installments"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedNumberOfInstallments",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "teva_LongTermDebtCurrencyPortionCHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion C H F.",
        "label": "Long Term Debt Currency Portion C H F",
        "terseLabel": "Long term debt currency portion CHF"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionCHF",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtCurrencyPortionEUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion E U R.",
        "label": "Long Term Debt Currency Portion E U R",
        "terseLabel": "Long term debt currency portion EUR"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionEUR",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtCurrencyPortionUSD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt currency portion U S D.",
        "label": "Long Term Debt Currency Portion U S D",
        "terseLabel": "Long term debt currency portion USD"
       }
      }
     },
     "localname": "LongTermDebtCurrencyPortionUSD",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_LongTermDebtExcludingConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Long Term Debt Excluding Convertible Debt Table [Text Block]",
        "terseLabel": "Schedule of Senior Notes and Loans"
       }
      }
     },
     "localname": "LongTermDebtExcludingConvertibleDebtTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail": {
       "order": 4.0,
       "parentTag": "teva_LongTermDebtaExcludeIssuanceCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LongTermDebtMaturityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Maturity [Line Items]",
        "label": "Long Term Debt Maturity [Line Items]",
        "terseLabel": "Long Term Debt Maturity [Line Items]"
       }
      }
     },
     "localname": "LongTermDebtMaturityLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_LongTermDebtMaturityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Maturity [Table]",
        "label": "Long Term Debt Maturity [Table]",
        "terseLabel": "Long Term Debt Maturity [Table]"
       }
      }
     },
     "localname": "LongTermDebtMaturityTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_LongTermDebtaExcludeIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debta Exclude Issuance Cost",
        "label": "Long Term Debta Exclude Issuance Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtaExcludeIssuanceCost",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_LongTermEmployeeRelatedObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Employee Related Obligations Table [Text Block]",
        "label": "Long Term Employee Related Obligations Table [Text Block]",
        "terseLabel": "Schedule of Long Term Employee Related Obligation"
       }
      }
     },
     "localname": "LongTermEmployeeRelatedObligationsTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_LongTermEmployeeRelatedObligationsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Employee Related Obligations [Text Block]",
        "label": "Long Term Employee Related Obligations [Text Block]",
        "terseLabel": "Long-term Employee-related Obligations"
       }
      }
     },
     "localname": "LongTermEmployeeRelatedObligationsTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_LongTermInvestmentsEarmarkedForDomesticSeveranceObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term investments earmarked for domestic severance obligations.",
        "label": "Long Term Investments Earmarked For Domestic Severance Obligations",
        "terseLabel": "Long-term investments earmarked for severance pay liabilities in Israel"
       }
      }
     },
     "localname": "LongTermInvestmentsEarmarkedForDomesticSeveranceObligations",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_MeasurementInputProbabilityOfSuccessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input probability of success.",
        "label": "Measurement Input Probability Of Success [Member]",
        "terseLabel": "Measurement input probability of success [Member]"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MedicaidAndOtherGovernmentalAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid and other governmental allowances.",
        "label": "Medicaid And Other Governmental Allowances [Member]",
        "terseLabel": "Medicaid and Other Governmental Allowances [Member]"
       }
      }
     },
     "localname": "MedicaidAndOtherGovernmentalAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_MilestoneContingentPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Contingent Payments",
        "label": "Milestone Contingent Payments",
        "terseLabel": "Milestone contingent expense"
       }
      }
     },
     "localname": "MilestoneContingentPayments",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_MinimumNumberOfEmployeesEmployed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of employees employed.",
        "label": "Minimum number of employees employed",
        "terseLabel": "Minimum number of employees employed"
       }
      }
     },
     "localname": "MinimumNumberOfEmployeesEmployed",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "teva_MinimumPercentageOfInvestmentIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of investment income.",
        "label": "Minimum percentage of investment income",
        "terseLabel": "Minimum percentage of investment income"
       }
      }
     },
     "localname": "MinimumPercentageOfInvestmentIncome",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_MinimumPercentageOfWorkforce": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of workforce.",
        "label": "Minimum percentage of workforce",
        "terseLabel": "Minimum percentage of workforce"
       }
      }
     },
     "localname": "MinimumPercentageOfWorkforce",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_ModafinilPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modafinil payment.",
        "label": "Modafinil Payment",
        "terseLabel": "Modafinil payment"
       }
      }
     },
     "localname": "ModafinilPayment",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ModafinilPaymentRemainingBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modafinil payment remaining balance.",
        "label": "Modafinil payment Remaining Balance",
        "terseLabel": "Modafinil payment remaining balance"
       }
      }
     },
     "localname": "ModafinilPaymentRemainingBalance",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ModafinilSettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modafinil settlement agreement.",
        "label": "Modafinil Settlement Agreement [Member]"
       }
      }
     },
     "localname": "ModafinilSettlementAgreementMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NationwideSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nationwide Settlement [Member]"
       }
      }
     },
     "localname": "NationwideSettlementMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in the amounts of the current assets and current liabilities that are reported in the supplemental disclosure of information section of the Consolidated Statements of Cash Flows.",
        "label": "Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information",
        "totalLabel": "Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information"
       }
      }
     },
     "localname": "NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_NetRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenues [Member]",
        "terseLabel": "Net Revenues [Member]"
       }
      }
     },
     "localname": "NetRevenuesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NetSalesPresent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales present.",
        "label": "Net Sales Present",
        "terseLabel": "Third party net sales present"
       }
      }
     },
     "localname": "NetSalesPresent",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_NorthAmericaSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "North America segment.",
        "label": "North America Segment [Member]",
        "terseLabel": "North America [Member]"
       }
      }
     },
     "localname": "NorthAmericaSegmentMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_NotionalAmountHedgeDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notional amount hedge debt.",
        "label": "Notional Amount Hedge Debt",
        "terseLabel": "Notional amount hedge debt"
       }
      }
     },
     "localname": "NotionalAmountHedgeDebt",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_NumberOfLawsuitsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Lawsuits Filed",
        "label": "Number Of Lawsuits Filed",
        "terseLabel": "Number of lawsuits filed"
       }
      }
     },
     "localname": "NumberOfLawsuitsFiled",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "teva_OmnibusLongTermShareIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Long Term Share Incentive Plan [Member]",
        "label": "Omnibus Long Term Share Incentive Plan [Member]",
        "terseLabel": "Omnibus Long Term Share Incentive Plan [Member]"
       }
      }
     },
     "localname": "OmnibusLongTermShareIncentivePlanMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OneTimeMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Milestone Payment Received",
        "label": "One Time Milestone Payment Received",
        "terseLabel": "Allergan one time payment to Teva"
       }
      }
     },
     "localname": "OneTimeMilestonePaymentReceived",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OperatingLeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Cost [Abstract]",
        "verboseLabel": "Operating lease cost:"
       }
      }
     },
     "localname": "OperatingLeaseCostAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_OperatingLeaseLiabilityOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent of operating other current liabilties",
        "label": "Operating Lease Liability Other",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityOther",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "teva_OperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "OperatingLeasesAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_OperatingLeasesImputedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents imputed interest.",
        "label": "Operating Leases Imputed Interest",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "OperatingLeasesImputedInterest",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OperatingLeasesNonCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of operating leases non cash amount.",
        "label": "Operating Leases Non Cash",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeasesNonCash",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Opioid Litigation [Member]"
       }
      }
     },
     "localname": "OpioidLitigationMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OptionsAndForwardContractsDerivativeLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and forward contracts derivative liabilities.",
        "label": "Options And Forward Contracts Derivative Liabilities [Member]",
        "terseLabel": "Liabilities Derivatives Options and Forward Contracts [Member]"
       }
      }
     },
     "localname": "OptionsAndForwardContractsDerivativeLiabilitiesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Activities [Member]",
        "label": "Other Activities [Member]",
        "terseLabel": "Other activities [Member]"
       }
      }
     },
     "localname": "OtherActivitiesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other countries.",
        "label": "Other Countries [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherDebentures2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other debentures 2026.",
        "label": "Other Debentures 2026 [Member]",
        "terseLabel": "Other Debentures [Member]"
       }
      }
     },
     "localname": "OtherDebentures2026Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity",
        "label": "Other Equity",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherEquity",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtherExitAndDisposalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other exit and disposal.",
        "label": "Other Exit And Disposal [Member]",
        "terseLabel": "Other Exit and Disposal [Member]"
       }
      }
     },
     "localname": "OtherExitAndDisposalMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses [Text Block]",
        "label": "Other Expenses [Text Block]",
        "terseLabel": "Other assets impairments, restructuring and other items"
       }
      }
     },
     "localname": "OtherExpensesTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_OtherFinancialIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail": {
       "order": 4.0,
       "parentTag": "teva_FinanceIncomeExpensesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other financial income expense net.",
        "label": "Other Financial Income Expense Net",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherFinancialIncomeExpenseNet",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtherIncomeExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense [Table]",
        "label": "Other Income Expense [Table]",
        "terseLabel": "Other Income Expense [Table]"
       }
      }
     },
     "localname": "OtherIncomeExpenseTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member].",
        "label": "Other [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherOperatingIncomeExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Operating Income (Expense)",
        "label": "Other Operating Income (Expense)",
        "verboseLabel": "Other (income) expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpense",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtherOperatingIncomeNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Operating Income Net",
        "label": "Other Operating Income Net",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeNet",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products [Member]",
        "label": "Other Products [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherSalesReservesAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other sales reserves and allowances.",
        "label": "Other Sales Reserves And Allowances [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherSalesReservesAndAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_OtherUnallocatedAmounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other unallocated amounts.",
        "label": "Other Unallocated Amounts",
        "terseLabel": "Other unallocated amounts"
       }
      }
     },
     "localname": "OtherUnallocatedAmounts",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_OtherincomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income.",
        "label": "Otherincome [Line Items]",
        "terseLabel": "Other Income [Line Items]"
       }
      }
     },
     "localname": "OtherincomeLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_OtsukaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otsuka [Member]",
        "label": "Otsuka [Member]",
        "terseLabel": "Otsuka [Member]"
       }
      }
     },
     "localname": "OtsukaMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PatentedMedicinesRegulationsAndSimilarPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patented Medicines Regulations and Similar Payments",
        "label": "Patented Medicines Regulations And Similar Payments",
        "verboseLabel": "Section 8 and similar payments"
       }
      }
     },
     "localname": "PatentedMedicinesRegulationsAndSimilarPayments",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_PaymentForRedemptionOfSeniorNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for redemption of senior notes.",
        "label": "Payment For Redemption Of Senior Notes",
        "terseLabel": "Payment for redemption of senior notes"
       }
      }
     },
     "localname": "PaymentForRedemptionOfSeniorNotes",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchase of available for sales securities and other assets.",
        "label": "Payment To Acquire Marketable Securities And Other Assets",
        "negatedLabel": "Purchases of investments and other assets"
       }
      }
     },
     "localname": "PaymentToAcquireMarketableSecuritiesAndOtherAssets",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_PaymentsRelatedToTaxWithholdingForSharesAndDividend": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy income tax withholding obligation for shares and dividends.",
        "label": "Payments Related To Tax Withholding For Shares And Dividend",
        "negatedLabel": "Tax withholding payments made on shares and dividends"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForSharesAndDividend",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_PercentageDecreaseInTheMarketCapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage decrease in the market capitalization.",
        "label": "Percentage Decrease In The Market Capitalization",
        "terseLabel": "Reduction in its market capitalization"
       }
      }
     },
     "localname": "PercentageDecreaseInTheMarketCapitalization",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Percentage difference between fair value and carrying value in respect of goodwill",
        "documentation": "Difference In the value of goodwill in percentage terms between the carrying value and the faitr value",
        "label": "Percentage Difference Between Fair Value And Carrying Value In Respect Of Goodwill"
       }
      }
     },
     "localname": "PercentageDifferenceBetweenFairValueAndCarryingValueInRespectOfGoodwill",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_PercentageOfConsolidatedSalesInNorthAmerica": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage that sales to external customers in North America are to consolidated net sales for the reporting period.",
        "label": "Percentage Of Consolidated Sales In North America",
        "terseLabel": "Percentage of consolidated sales in North America"
       }
      }
     },
     "localname": "PercentageOfConsolidatedSalesInNorthAmerica",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_PgtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pgt [Member]",
        "label": "Pgt [Member]",
        "terseLabel": "PGT Healthcare Partnership [Member]"
       }
      }
     },
     "localname": "PgtMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PreferredEnterpriseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Enterprise [Member]",
        "label": "Preferred Enterprise [Member]",
        "terseLabel": "Preferred Enterprise [Member]"
       }
      }
     },
     "localname": "PreferredEnterpriseMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PreferredTechnologicalEnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Technological Enterprises [Member]",
        "label": "Preferred Technological Enterprises [Member]",
        "terseLabel": "Preferred Technological Enterprises [Member]"
       }
      }
     },
     "localname": "PreferredTechnologicalEnterprisesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_PreviouslyHedgeDebtRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously hedge debt rate.",
        "label": "Previously Hedge Debt Rate",
        "terseLabel": "Previously hedge debt rate"
       }
      }
     },
     "localname": "PreviouslyHedgeDebtRate",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_ProAirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pro air.",
        "label": "Pro Air [Member]",
        "terseLabel": "ProAir [Member]"
       }
      }
     },
     "localname": "ProAirMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from beneficial interest in exchange for securitized trade receivables",
        "label": "Proceeds from beneficial interest in exchange for securitized trade receivables",
        "terseLabel": "Beneficial interest collected in exchange for securitized trade receivables"
       }
      }
     },
     "localname": "ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Rights [Member]",
        "label": "Product Rights [Member]",
        "terseLabel": "Identifiable product rights [Member]"
       }
      }
     },
     "localname": "ProductRightsMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ProfitFromSaleOfLongLivedAssetsAndInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit from sale of long lived assets and investment.",
        "label": "Profit From Sale Of Long Lived Assets And Investment",
        "negatedLabel": "Net loss (gain) from investments and from sale of long lived assets",
        "negatedTerseLabel": "Net (gain) loss from sale of long-lived assets and investments"
       }
      }
     },
     "localname": "ProfitFromSaleOfLongLivedAssetsAndInvestment",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule indicating where long-lived tangible assets are located.",
        "label": "Property Plant And Equipment By Geographic Area Table [Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment by Geographic Location"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByGeographicAreaTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_PurchaseOfResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of research and development in process.",
        "label": "Purchase Of Research And Development In Process",
        "verboseLabel": "Other R&amp;D expenses (income)"
       }
      }
     },
     "localname": "PurchaseOfResearchAndDevelopmentInProcess",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_QVARMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "QVAR.",
        "label": "QVAR [Member]",
        "terseLabel": "QVAR [Member]"
       }
      }
     },
     "localname": "QVARMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates.",
        "label": "Rebates [Member]",
        "terseLabel": "Rebates [Member]"
       }
      }
     },
     "localname": "RebatesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification From Accumulated Other Comprehensive Income To Retained Earning",
        "label": "Reclassification From Accumulated Other Comprehensive Income To Retained Earning",
        "terseLabel": "Cumulative effect of new accounting standard",
        "verboseLabel": "Cumulative effect of new accounting standard"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeToRetainedEarning",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_RefundablePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refundable Payment",
        "label": "Refundable Payment",
        "terseLabel": "Refundable payment"
       }
      }
     },
     "localname": "RefundablePayment",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_RegeneronMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron [Member]",
        "label": "Regeneron [Member]",
        "terseLabel": "Regeneron [Member]"
       }
      }
     },
     "localname": "RegeneronMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Costs",
        "label": "Research And Development Costs",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCosts",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ReservesIncludedInAccountsReceivableNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserves included in accounts receivable net.",
        "label": "Reserves Included In Accounts Receivable Net [Member]",
        "terseLabel": "Reserves Included in Accounts Receivable, Net [Member]"
       }
      }
     },
     "localname": "ReservesIncludedInAccountsReceivableNetMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RespiratoryProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Respiratory product.",
        "label": "Respiratory Product [Member]",
        "terseLabel": "Respiratory Product [Member]"
       }
      }
     },
     "localname": "RespiratoryProductMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement under which unregistered shares are granted and issuable to employees, and which vest pursuant to terms of the arrangements.",
        "label": "Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RestructuringAccrualProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Accrual Provision",
        "label": "Restructuring Accrual Provision",
        "negatedLabel": "Provision"
       }
      }
     },
     "localname": "RestructuringAccrualProvision",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_RestructuringAndImpairmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and impairment.",
        "label": "Restructuring And Impairment [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringAndImpairmentCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and impairment costs.",
        "label": "Restructuring And Impairment Costs [Line Items]",
        "terseLabel": "Restructuring and Impairment Costs [Line Items]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentCostsLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringAndImpairmentCostsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Impairment Costs [Table]",
        "label": "Restructuring And Impairment Costs [Table]",
        "terseLabel": "Restructuring And Impairment Costs [Table]"
       }
      }
     },
     "localname": "RestructuringAndImpairmentCostsTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringExpenseAndIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring expense and income",
        "label": "Restructuring expense and income",
        "terseLabel": "Restructuring expense and income"
       }
      }
     },
     "localname": "RestructuringExpenseAndIncome",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RestructuringPlanCostReduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Plan Cost Reduction.",
        "label": "Restructuring Plan Cost Reduction",
        "terseLabel": "Restructuring plan cost reduction"
       }
      }
     },
     "localname": "RestructuringPlanCostReduction",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_RestructuringTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring [Text Block]",
        "label": "Restructuring [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Returns.",
        "label": "Returns [Member]",
        "terseLabel": "Returns [Member]"
       }
      }
     },
     "localname": "ReturnsMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RevenueRecognitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition [Line Items]",
        "label": "Revenue Recognition [Line Items]",
        "terseLabel": "Revenue Recognition [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueRecognitionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition [Table]",
        "label": "Revenue Recognition [Table]",
        "terseLabel": "Revenue Recognition [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Type [Axis]"
       }
      }
     },
     "localname": "RevenueTypeAxis",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RevenueTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Type [Domain]"
       }
      }
     },
     "localname": "RevenueTypeDomain",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_RevenuesOtherThanUsd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues other than US Dollar.",
        "label": "Revenues Other Than Usd",
        "terseLabel": "Revenues other than USD"
       }
      }
     },
     "localname": "RevenuesOtherThanUsd",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations Noncash [Abstract]",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease obligations (non-cash):"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsNoncashAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_RimsaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rimsa [Member]",
        "label": "Rimsa [Member]",
        "terseLabel": "Rimsa [Member]"
       }
      }
     },
     "localname": "RimsaMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SalesPercentageByTherapeuticCategoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule of net sales by therapeutic category, stated as a percentage of total sales.",
        "label": "Sales Percentage By Therapeutic Category Table [Text Block]",
        "terseLabel": "Schedule of Sales Percentage by Therapeutic Category"
       }
      }
     },
     "localname": "SalesPercentageByTherapeuticCategoryTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SalesReservesAndAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection.",
        "label": "Sales Reserves And Allowances",
        "terseLabel": "Sales reserves and allowances"
       }
      }
     },
     "localname": "SalesReservesAndAllowances",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_SalesReservesAndAllowancesCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of sales reserves and allowances current.",
        "label": "Sales Reserves And Allowances Current [Table Text Block]",
        "terseLabel": "Summary of Sales Reserves and Allowances"
       }
      }
     },
     "localname": "SalesReservesAndAllowancesCurrentTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SalesReservesAndAllowancesToCustomersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales reserves and allowances to customers percentage.",
        "label": "Sales Reserves and Allowances to Customers Percentage",
        "terseLabel": "Percentage sales reserves and allowances to U.S. customers"
       }
      }
     },
     "localname": "SalesReservesAndAllowancesToCustomersPercentage",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "teva_ScheduleOfAccountReceivableFromSecuritization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of account receivable from securitization.",
        "label": "Schedule Of Account Receivable From Securitization",
        "terseLabel": "Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program"
       }
      }
     },
     "localname": "ScheduleOfAccountReceivableFromSecuritization",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]",
        "label": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]",
        "terseLabel": "Summary of Major Classes of Assets and Liabilities Included as Held for Sale"
       }
      }
     },
     "localname": "ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Computation Of Deferred Tax Assets Liabilities Net [Table]",
        "label": "Schedule Of Computation Of Deferred Tax Assets Liabilities Net [Table]",
        "terseLabel": "Schedule Of Computation Of Deferred Tax Assets Liabilities Net [Table]"
       }
      }
     },
     "localname": "ScheduleOfComputationOfDeferredTaxAssetsLiabilitiesNetTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesParentheticalDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of consolidated income before income tax.",
        "label": "Schedule Of Consolidated Income Before Income Tax [Table Text Block]",
        "terseLabel": "Schedule Of Consolidated Income Before Income Tax"
       }
      }
     },
     "localname": "ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred tax assets and liabilities by report caption.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities By Report Caption [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities By Report Caption"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfOtherIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Income Table [Text Block]",
        "label": "Schedule Of Other Income Table [Text Block]",
        "terseLabel": "Schedule of Other Income"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfRestructuringChargesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Restructuring Charges [Table Text Block]",
        "label": "Schedule of Restructuring Charges [Table Text Block]",
        "terseLabel": "Summary of Restructuring Plan Including Costs Related to Exit and Disposal"
       }
      }
     },
     "localname": "ScheduleOfRestructuringChargesTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_ScheduleOfUnrecognizedTaxBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Unrecognized Tax Benefits [Line Items]",
        "label": "Schedule Of Unrecognized Tax Benefits [Line Items]",
        "terseLabel": "Schedule Of Unrecognized Tax Benefits [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_ScheduleOfUnrecognizedTaxBenefitsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Unrecognized Tax Benefits [Table]",
        "label": "Schedule Of Unrecognized Tax Benefits [Table]",
        "terseLabel": "Schedule Of Unrecognized Tax Benefits [Table]"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_SecuritizationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securitization [Text Block]",
        "label": "Securitization [Text Block]",
        "terseLabel": "Securitization"
       }
      }
     },
     "localname": "SecuritizationTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SegmentsAndOtherActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segments and other activities.",
        "label": "Segments And Other Activities [Member]",
        "terseLabel": "Segments and Other Activities [Member]"
       }
      }
     },
     "localname": "SegmentsAndOtherActivitiesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SelectedQuarterlyFinancialDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected Quarterly Financial Data Table [Text Block]",
        "label": "Selected Quarterly Financial Data Table [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialDataTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SelectedQuarterlyFinancialDataTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected Quarterly Financial Data [Text Block]",
        "label": "Selected Quarterly Financial Data [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialDataTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SelectedQuarterlyFinancialInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected Quarterly Financial Information [Line Items]",
        "label": "Selected Quarterly Financial Information [Line Items]",
        "terseLabel": "Selected Quarterly Financial Information [Line Items]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_SelectedQuarterlyFinancialInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected Quarterly Financial Information [Table]",
        "label": "Selected Quarterly Financial Information [Table]",
        "terseLabel": "Selected Quarterly Financial Information [Table]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationTable",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_SeniorNotesAndLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes and loans.",
        "label": "Senior Notes And Loans [Member]",
        "terseLabel": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "SeniorNotesAndLoansMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2020",
        "label": "Senior Notes Due 2020 [Member]",
        "terseLabel": "Senior Notes Due 2020 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2020Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2021 [Member]",
        "label": "Senior Notes Due 2021 [Member]",
        "terseLabel": "Senior Notes Due 2021 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2021Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes due 2022.",
        "label": "Senior Notes Due 2022 [Member]",
        "terseLabel": "Senior Notes Due 2022 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2022Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniorNotesDue2023TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes due 2023 two.",
        "label": "Senior Notes Due 2023 Two [Member]",
        "terseLabel": "Senior Notes Due 2023 Two [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2023TwoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SeniornotesandconvertibleseniordebenturesmemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior notes and convertible senior debentures.",
        "label": "Seniornotesandconvertibleseniordebenturesmember [Member]",
        "terseLabel": "Senior Notes and Convertible Senior Debentures Included Under Short-Term Liabilities [Member]"
       }
      }
     },
     "localname": "SeniornotesandconvertibleseniordebenturesmemberMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SettlementGainPosition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement gain position.",
        "label": "Settlement Gain Position",
        "terseLabel": "Settlement gain position"
       }
      }
     },
     "localname": "SettlementGainPosition",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_SettlementOnAccountOfProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement On Account Of Product Liability.",
        "label": "Settlement On Account Of Product Liability [Member]"
       }
      }
     },
     "localname": "SettlementOnAccountOfProductLiabilityMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price 2010",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2010",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average remaining life of the exercisable stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term 2010",
        "terseLabel": "Weighted average remaining life Years"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2010",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance 2010",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance2010",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "teva_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average period remaining as of the balance-sheet date until option expiration pertaining to the outstanding stock options for all option plans in the customized range of exercise prices, which may be expressed in a variety of ways (for example, years, months).",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term 2010",
        "terseLabel": "Weighted average remaining life Years"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2010",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "teva_ShippingHandlingAndTransportationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shipping, handling and transportation cost.",
        "label": "Shipping, Handling and Transportation Cost",
        "terseLabel": "Shipping and handling costs, which are included in selling and marketing expenses"
       }
      }
     },
     "localname": "ShippingHandlingAndTransportationCost",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ShortCreditAgreement2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short credit agreement 2026.",
        "label": "Short Credit Agreement 2026 [Member]",
        "terseLabel": "Convertible senior debentures [Member]"
       }
      }
     },
     "localname": "ShortCreditAgreement2026Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Line Items]",
        "label": "Significant Accounting Policies [Line Items]",
        "verboseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_SpecialPreferredTechnologicalEnterpriseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Preferred Technological Enterprise [Member]",
        "label": "Special Preferred Technological Enterprise [Member]",
        "terseLabel": "Special Preferred Technological Enterprise [Member]"
       }
      }
     },
     "localname": "SpecialPreferredTechnologicalEnterpriseMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option restricted stock units and performance stock units.",
        "label": "Stock Option Restricted Stock Units And Performance Stock Units [Member]",
        "terseLabel": "Stock Option Restricted Stock Units And Performance Stock Units [Member]"
       }
      }
     },
     "localname": "StockOptionRestrictedStockUnitsAndPerformanceStockUnitsMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_StockOptionsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options Plan [Member]",
        "label": "Stock Options Plan [Member]",
        "terseLabel": "Stock Options Plan [Member]"
       }
      }
     },
     "localname": "StockOptionsPlanMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2020OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Senior notes EUR 1,010 million [Member]",
        "documentation": "Subsidiary senior notes due 2020 one.",
        "label": "Subsidiary Senior Notes Due 2020 One [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2020OneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2020TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2020 two.",
        "label": "Subsidiary Senior Notes Due 2020 Two [Member]",
        "terseLabel": "Senior notes USD 700 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2020TwoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2021OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2021 one.",
        "label": "Subsidiary Senior Notes Due 2021 One [Member]",
        "verboseLabel": "Senior notes USD 1,475 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2021OneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2021ThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2021 three.",
        "label": "Subsidiary Senior Notes Due 2021 Three [Member]",
        "terseLabel": "Senior notes USD 588 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2021ThreeMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2021TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2021 two.",
        "label": "Subsidiary Senior Notes Due 2021 Two [Member]",
        "terseLabel": "Senior notes USD 613 million [Member]",
        "verboseLabel": "Senior Notes Due 2021 Two [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2021TwoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2022OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2022 one.",
        "label": "Subsidiary Senior Notes Due 2022 One [Member]",
        "terseLabel": "Senior notes EUR 700 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2022OneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2022ThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2022 Three [Member]",
        "label": "Subsidiary Senior Notes Due 2022 Three [Member]",
        "terseLabel": "Senior notes CHF 350 Million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2022ThreeMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2022TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2022 two.",
        "label": "Subsidiary Senior Notes Due 2022 Two [Member]",
        "terseLabel": "Senior notes USD 844 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2022TwoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2023OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2023 one.",
        "label": "Subsidiary Senior Notes Due 2023 One [Member]",
        "terseLabel": "Senior notes EUR 1,300 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2023OneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2023TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2023 two.",
        "label": "Subsidiary Senior Notes Due 2023 Two [Member]",
        "terseLabel": "Senior notes USD 3,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2023TwoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2024.",
        "label": "Subsidiary Senior Notes Due 2024 [Member]",
        "terseLabel": "Senior notes EUR 1,500 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2024Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2024OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2024 One [Member]",
        "label": "Subsidiary Senior Notes Due 2024 One [Member]",
        "terseLabel": "Senior notes USD 1,250 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2024OneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2025 Member",
        "label": "Subsidiary Senior Notes Due 2025 [Member]",
        "terseLabel": "Senior notes EUR 900 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2025 One [Member]",
        "label": "Subsidiary Senior Notes Due 2025 One [Member]",
        "terseLabel": "Senior notes EUR 1,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025OneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025ThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2025 three.",
        "label": "Subsidiary Senior Notes Due 2025 Three [Member]",
        "terseLabel": "Senior notes CHF 350 Million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025ThreeMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2025TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2025 two.",
        "label": "Subsidiary Senior Notes Due 2025 Two [Member]",
        "terseLabel": "Senior notes USD 1,000 million [Member]",
        "verboseLabel": "Senior notes USD 1,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2025TwoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2026OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2026 one.",
        "label": "Subsidiary Senior Notes Due 2026 One [Member]",
        "terseLabel": "Senior notes USD 3,500 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2026OneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2027.",
        "label": "Subsidiary Senior Notes Due 2027 [Member]",
        "terseLabel": "Senior notes EUR 700 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2027Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2028.",
        "label": "Subsidiary Senior Notes Due 2028 [Member]",
        "terseLabel": "Senior notes EUR 750 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2028Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2028OneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Senior Notes Due 2028 One [Member]",
        "label": "Subsidiary Senior Notes Due 2028 One [Member]",
        "terseLabel": "Senior notes USD 1,250 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2028OneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2036.",
        "label": "Subsidiary Senior Notes Due 2036 [Member]",
        "terseLabel": "Senior notes USD 789 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2036Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SubsidiarySeniorNotesDue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary senior notes due 2046.",
        "label": "Subsidiary Senior Notes Due 2046 [Member]",
        "terseLabel": "Senior notes USD 2,000 million [Member]"
       }
      }
     },
     "localname": "SubsidiarySeniorNotesDue2046Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_SupplementalBalanceSheetInformationRelatedToLeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental balance sheet information related to leases.",
        "label": "Supplemental Balance Sheet Information Related To Leases Text Block",
        "terseLabel": "Supplemental Balance Sheet Information Related To Leases"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationRelatedToLeasesTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_SupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Supplemental cash flow information related to leases",
        "terseLabel": "Supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_TaxCarryforwardsAndDeductionsExpirationPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax carryforwards and deductions expiration period one.",
        "label": "Tax Carryforwards And Deductions Expiration Period One [Member]",
        "terseLabel": "Tax Carryforwards And Deductions Expiration Period One [Member]"
       }
      }
     },
     "localname": "TaxCarryforwardsAndDeductionsExpirationPeriodOneMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax carryforwards and deductions expiration period two.",
        "label": "Tax Carryforwards And Deductions Expiration Period Two [Member]",
        "terseLabel": "Tax Carryforwards And Deductions Expiration Period Two [Member]"
       }
      }
     },
     "localname": "TaxCarryforwardsAndDeductionsExpirationPeriodTwoMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TaxCarryforwardsAndDeductionsIndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax carryforwards and deductions indefinite.",
        "label": "Tax Carryforwards And Deductions Indefinite [Member]",
        "terseLabel": "Tax Carryforwards And Deductions Indefinite [Member]"
       }
      }
     },
     "localname": "TaxCarryforwardsAndDeductionsIndefiniteMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TaxCarryforwardsAndDeductionsNoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax carryforwards and deductions no expiration.",
        "label": "Tax Carryforwards And Deductions No Expiration [Member]",
        "terseLabel": "Tax Carryforwards And Deductions No Expiration [Member]"
       }
      }
     },
     "localname": "TaxCarryforwardsAndDeductionsNoExpirationMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TaxYear2005To2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year 2005 to 2007.",
        "label": "Tax Year 2005 To 2007 [Member]",
        "terseLabel": "Tax Year 2005 To 2007 [Member]"
       }
      }
     },
     "localname": "TaxYear2005To2007Member",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teva Member",
        "label": "Teva [Member]",
        "terseLabel": "Teva [Member]"
       }
      }
     },
     "localname": "TevaMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TotalAssociatedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Associated Cost",
        "label": "Total Associated Cost",
        "terseLabel": "Total associated cost"
       }
      }
     },
     "localname": "TotalAssociatedCost",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_TotalReservesIncludedInSalesReservesAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total reserves included in sales reserves and allowances.",
        "label": "Total Reserves Included In Sales Reserves And Allowances [Member]",
        "terseLabel": "Total Reserves Included in Sales Reserves and Allowances [Member]"
       }
      }
     },
     "localname": "TotalReservesIncludedInSalesReservesAndAllowancesMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TracheAExtensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trache A Extension [Member]"
       }
      }
     },
     "localname": "TracheAExtensionMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TracheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trache A.",
        "label": "Trache A [Member]",
        "terseLabel": "Trache A [Member]"
       }
      }
     },
     "localname": "TracheAMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TracheBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trache B.",
        "label": "Trache B [Member]",
        "terseLabel": "Trache B [Member]"
       }
      }
     },
     "localname": "TracheBMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche.",
        "label": "Tranche [Axis]"
       }
      }
     },
     "localname": "TrancheAxis",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "teva_TrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche.",
        "label": "Tranche [Domain]"
       }
      }
     },
     "localname": "TrancheDomain",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TransactionsWithNonControllingInterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transactions With Non Controlling Interests",
        "label": "Transactions With Non Controlling Interests",
        "terseLabel": "Transactions with non-controlling interests"
       }
      }
     },
     "localname": "TransactionsWithNonControllingInterests",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_TreasurySharesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes how the entity's previously issued shares that were reacquired by the entity are presented in the balance sheet.",
        "label": "Treasury Shares [Policy Text Block]",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasurySharesPolicyTextBlock",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "teva_TwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen plan.",
        "label": "Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2015 Long-Term Equity-Based Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenPlanMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TwoThousandTenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand ten plan.",
        "label": "Two Thousand Ten Plan [Member]",
        "terseLabel": "2010 Long-Term Equity-Based Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTenPlanMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_TwoThousandTwentyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty plan.",
        "label": "Two Thousand Twenty Plan [Member]",
        "terseLabel": "2020 Long-Term Equity-Based Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyPlanMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_UnrecognizedCompensationCostOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized compensation cost options.",
        "label": "Unrecognized Compensation Cost Options",
        "terseLabel": "Total unrecognized compensation cost before tax on employee stock options"
       }
      }
     },
     "localname": "UnrecognizedCompensationCostOptions",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UnrecognizedCompensationCostRsus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized compensation cost rsus.",
        "label": "Unrecognized Compensation Cost Rsus",
        "terseLabel": "Total unrecognized compensation cost before tax on employee stock RSUs"
       }
      }
     },
     "localname": "UnrecognizedCompensationCostRsus",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UnrecognizedTaxBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits [Abstract]",
        "label": "Unrecognized Tax Benefits [Abstract]"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsAbstract",
     "nsuri": "http://www.tevapharm.com/20201231",
     "xbrltype": "stringItemType"
    },
    "teva_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Increase (decrease) related to prior year tax positions, net"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UnrecognizedTaxBenefitsIncreasesDecreasesOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increases decreases other.",
        "label": "Unrecognized Tax Benefits Increases Decreases Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesOther",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments",
        "label": "Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_Ustaxcutsandjobsacteffect": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US tax cuts and jobs act effect.",
        "label": "US Tax Cuts and Jobs Act Effect",
        "terseLabel": "U.S. Tax Cuts and Jobs Act effect"
       }
      }
     },
     "localname": "Ustaxcutsandjobsacteffect",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_UtilizationAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Utilization and other.",
        "label": "Utilization And Other",
        "terseLabel": "Utilization and other"
       }
      }
     },
     "localname": "UtilizationAndOther",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance tax carryforward losses and deductions.",
        "label": "Valuation Allowance Tax Carryforward Losses And Deductions [Member]",
        "terseLabel": "Valuation Allowance in Tax Carryforward Losses And Deductions [Member]"
       }
      }
     },
     "localname": "ValuationAllowanceTaxCarryforwardLossesAndDeductionsMember",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "teva_ValuationAllowancesAndReservesForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves foreign currency translation.",
        "label": "Valuation Allowances And Reserves Foreign Currency Translation",
        "terseLabel": "Translation differences"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesForeignCurrencyTranslation",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves related to current period sales.",
        "label": "Valuation Allowances And Reserves Related To Current Period Sales",
        "terseLabel": "Provisions related to sales made in current year period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesRelatedToCurrentPeriodSales",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves related to prior period sales.",
        "label": "Valuation Allowances And Reserves Related To Prior Period Sales",
        "terseLabel": "Provisions related to sales made in prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesRelatedToPriorPeriodSales",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_VentureCapitalInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Venture Capital Investments",
        "label": "Venture Capital Investments",
        "terseLabel": "Venture capital investment"
       }
      }
     },
     "localname": "VentureCapitalInvestments",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "teva_WithholdingTaxPercentageOnDividends": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Withholding tax percentage on dividends.",
        "label": "Withholding tax percentage on dividends",
        "terseLabel": "Withholding tax percentage on dividends"
       }
      }
     },
     "localname": "WithholdingTaxPercentageOnDividends",
     "nsuri": "http://www.tevapharm.com/20201231",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r18",
      "r56"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "verboseLabel": "Accounts payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableFromSecuritization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount owed to the reporting entity by counterparties in securitized loan transactions.",
        "label": "Accounts Receivable from Securitization",
        "periodEndLabel": "Sold receivables at the end of the year",
        "periodStartLabel": "Sold receivables at the beginning of the year",
        "terseLabel": "Sold receivables"
       }
      }
     },
     "localname": "AccountsReceivableFromSecuritization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r38",
      "r254",
      "r255"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivables, net of allowance for credit losses of $126 million and $135 million as of December 31, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r88",
      "r93",
      "r95",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Benefit Plans [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r54",
      "r317"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less\u2014accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r83",
      "r93",
      "r529",
      "r590",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r93",
      "r103",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r93",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Available-for-sale Securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r41",
      "r90",
      "r92",
      "r93",
      "r709",
      "r738",
      "r742"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 33.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r89",
      "r93",
      "r95",
      "r169",
      "r170",
      "r171",
      "r529",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r83",
      "r93",
      "r95",
      "r529",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r39",
      "r452"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional\u00a0paid-in\u00a0capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r137",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r491",
      "r492",
      "r493",
      "r494",
      "r664",
      "r665",
      "r666",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r415",
      "r416",
      "r455",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs, Policy [Policy Text Block]",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other Segments [Member]"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r416",
      "r443",
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Allocated Share-based Compensation Expense, Net of Tax",
        "terseLabel": "Net effect"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Allowance For Doubtful Accounts [Member]"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r45",
      "r256",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r137",
      "r301",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average shares with anti-dilutive effect on earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r137",
      "r313"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of goodwill, long-lived assets and assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r149",
      "r223",
      "r236",
      "r243",
      "r265",
      "r523",
      "r532",
      "r587",
      "r681",
      "r707"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r13",
      "r76",
      "r149",
      "r265",
      "r523",
      "r532",
      "r587"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.",
        "label": "Assets, Fair Value Adjustment",
        "terseLabel": "Adjustments of assets held for sale to fair value"
       }
      }
     },
     "localname": "AssetsFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r4",
      "r5",
      "r6",
      "r314",
      "r321"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets held for sale",
        "verboseLabel": "Total assets of the disposal group classified as held for sale in the consolidated balance sheets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r549",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r15",
      "r316"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r410",
      "r413",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Shares issued as consideration for the acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r136",
      "r516"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 2.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "positiveLabel": "Business combination contingent consideration arrangements change in amount of contingent consideration liability",
        "verboseLabel": "Contingent consideration (see note 2)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r511",
      "r512",
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "negatedLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business combination recognized identifiable assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r52",
      "r139"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r140",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r132",
      "r139",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Balance of cash and cash equivalents at end of year",
        "periodStartLabel": "Balance of cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r132",
      "r589"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r147",
      "r149",
      "r187",
      "r188",
      "r189",
      "r192",
      "r194",
      "r203",
      "r204",
      "r205",
      "r265",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r66",
      "r339",
      "r688",
      "r714"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies, see note 12"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r353",
      "r748",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares available for future awards"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Ordinary shares of NIS 0.10 par value per share; December 31, 2020 and December 31, 2019: authorized 2,495 million shares; issued 1,202 million shares and 1,198 million shares, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r98",
      "r100",
      "r101",
      "r111",
      "r694",
      "r721"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Teva"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r98",
      "r100",
      "r110",
      "r521",
      "r522",
      "r536",
      "r693",
      "r720"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r98",
      "r100",
      "r109",
      "r520",
      "r536",
      "r692",
      "r719"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r251",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r251",
      "r585",
      "r586",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r251",
      "r585",
      "r586",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r206",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r208",
      "r209",
      "r251",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Revenues from external customers"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r251",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r142",
      "r143",
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of mandatory convertible preferred shares into ordinary shares"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r35",
      "r36",
      "r364",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.",
        "label": "Convertible Preferred Stock, Terms of Conversion",
        "terseLabel": "Convertible preferred stock terms of conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Corporate Segment [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r114",
      "r662"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r395",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]",
        "verboseLabel": "Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r151",
      "r487",
      "r497",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r207",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Total short term debt",
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt obligations"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r28",
      "r30",
      "r31",
      "r682",
      "r684",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r31",
      "r357",
      "r684",
      "r705"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount currently outstanding on the debt instruments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "auth_ref": [
      "r31",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
        "label": "Debt Instrument, Covenant Description"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r600",
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r63",
      "r358",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r64",
      "r153",
      "r364",
      "r367",
      "r368",
      "r369",
      "r599",
      "r600",
      "r602",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt instruments"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Gain under financial expenses"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r55",
      "r601"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedLabel": "Less debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r464",
      "r465"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r137",
      "r151",
      "r488",
      "r497",
      "r498",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r33",
      "r34",
      "r477",
      "r683",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Long-term liabilities-deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Long-term assets-deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory related"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 4.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements",
        "terseLabel": "Provision for legal settlements"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances",
        "terseLabel": "Sales reserves and allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance\u2014in respect of carryforward losses and deductions that may not be utilized"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r465",
      "r480"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred tax assets liabilities net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesByReportCaptionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 5.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail": {
       "order": 7.0,
       "parentTag": "teva_DeferredTaxAssetsLiabilitiesGrossNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfDeferedIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail": {
       "order": 2.0,
       "parentTag": "teva_EmployeeRelatedObligationsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Defined benefit plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Demand Deposits [Member]",
        "terseLabel": "Cash, Deposits and Other [Member]"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r137",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense for the year"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r137",
      "r315"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r78",
      "r79",
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on derivative instrument designated and qualifying as fair value hedge included in assessment of hedge effectiveness, recognized in earnings.",
        "label": "Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)",
        "terseLabel": "Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)"
       }
      }
     },
     "localname": "DerivativeFairValueHedgeIncludedInEffectivenessGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r77",
      "r81",
      "r552",
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Asset derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r77",
      "r81",
      "r552",
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "negatedLabel": "Liability derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r550",
      "r553",
      "r558",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r547",
      "r550",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r78",
      "r79",
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "negatedLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Teva other comprehensive loss"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r539",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amounts of hedge"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r538",
      "r540",
      "r541",
      "r547",
      "r548",
      "r555",
      "r558",
      "r566",
      "r568",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r156",
      "r538",
      "r540",
      "r547",
      "r548",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives and hedging"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of disaggregates revenues by major revenue streams"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r417",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r4",
      "r314",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r4",
      "r314",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r4",
      "r314",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Property, plant and equipment, net and others"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DistributionServiceMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution assistance, including, but not limited to, marketing and selling fund shares, advertising, printing and mailing of prospectus and sale literature to investor.",
        "label": "Distribution Service [Member]",
        "terseLabel": "Distribution [Member]"
       }
      }
     },
     "localname": "DistributionServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendIncomeSecuritiesOperatingTaxExempt": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating dividend income on securities exempt from state, federal and other income tax.",
        "label": "Dividend Income, Securities, Operating, Tax Exempt",
        "terseLabel": "Exempt Income"
       }
      }
     },
     "localname": "DividendIncomeSecuritiesOperatingTaxExempt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r370",
      "r700"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "negatedTerseLabel": "Dividends to preferred shareholders"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share attributable to ordinary shareholders:",
        "verboseLabel": "Earnings per share attributable to ordinary shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r112",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r184",
      "r187",
      "r192",
      "r193",
      "r194",
      "r198",
      "r199",
      "r695",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r112",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r187",
      "r192",
      "r193",
      "r194",
      "r198",
      "r199",
      "r695",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r589"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Translation adjustment on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r467",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate in Israel"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r467",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee-related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense",
        "terseLabel": "Tax effect on stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee termination [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r173",
      "r181",
      "r183",
      "r202",
      "r269",
      "r363",
      "r370",
      "r449",
      "r450",
      "r451",
      "r493",
      "r494",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r24",
      "r29",
      "r262",
      "r706",
      "r744",
      "r745",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r573",
      "r574",
      "r575",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Instrument Measured on a Basis Other Than Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "terseLabel": "Revaluation of equity securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r573",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r409",
      "r574",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r395",
      "r396",
      "r401",
      "r409",
      "r574",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r395",
      "r396",
      "r401",
      "r409",
      "r574",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r409",
      "r574",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held.",
        "label": "Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)",
        "terseLabel": "Revaluation of debt securities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r578",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Transfer into Level\u00a03- equity securities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "negatedLabel": "Reclassification to Level\u00a02- equity securities"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Settlement of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "negatedPeriodEndLabel": "Fair value at the end of the period",
        "negatedPeriodStartLabel": "Fair value at the beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r409",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalHomeLoanBanksAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Home Loan Banks [Abstract]"
       }
      }
     },
     "localname": "FederalHomeLoanBanksAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r150",
      "r466"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "In Israel"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r607",
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization of intangible assets useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r305",
      "r308",
      "r663",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r305",
      "r667"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount net of impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r302",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r305",
      "r663"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Identifiable intangible assets, net",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r395",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Outside Israel"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis": {
     "auth_ref": [
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of adjustment following bankruptcy and reorganization.",
        "label": "Fresh-Start Adjustments [Axis]",
        "terseLabel": "Fresh-Start Adjustments [Axis]"
       }
      }
     },
     "localname": "FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r118",
      "r137",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Write-down of investment"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r137",
      "r530"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain on divestitures, net of divestitures related costs"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.",
        "label": "Gain (Loss) on Sale of Equity Investments",
        "terseLabel": "Gain\u00a0under share\u00a0in\u00a0profits\u00a0of\u00a0associated\u00a0companies"
       }
      }
     },
     "localname": "GainLossOnSaleOfEquityInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Legal settlements, income"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnSalesOfAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.",
        "label": "Gain (Loss) on Disposition of Assets for Financial Service Operations",
        "terseLabel": "Gain (loss) on sale of assets"
       }
      }
     },
     "localname": "GainsLossesOnSalesOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "G&amp;A expenses",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r289",
      "r291",
      "r680"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill.",
        "label": "Goodwill Disclosure [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedLabel": "Translation differences"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r292",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r137",
      "r290",
      "r294",
      "r298"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 15.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Goodwill impairment",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedLabel": "Goodwill disposal"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r113",
      "r149",
      "r223",
      "r235",
      "r239",
      "r242",
      "r245",
      "r265",
      "r587"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r547",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r137",
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets excluding goodwill",
        "verboseLabel": "Intangible asset impairments"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r137",
      "r313",
      "r319"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 1.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairments of long-lived tangible assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r137",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r311",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development [Member]",
        "verboseLabel": "In Process Research and Development (IPR&amp;D) [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r154",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Parent Company and its Israeli subsidiaries"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r154",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Non-Israeli subsidiaries"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r154",
      "r223",
      "r235",
      "r239",
      "r242",
      "r245"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes",
        "verboseLabel": "Income (Loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r106",
      "r137",
      "r220",
      "r263",
      "r689",
      "r716"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 18.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Share in (profits) losses of associated companies, net"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r468",
      "r475",
      "r482",
      "r495",
      "r502",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax settlement amount"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year being audited in the income tax examination, in CCYY format.",
        "label": "Income Tax Examination, Year under Examination",
        "terseLabel": "Income tax audit period"
       }
      }
     },
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r151",
      "r182",
      "r183",
      "r221",
      "r466",
      "r496",
      "r503",
      "r723"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 17.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income taxes (benefit)",
        "totalLabel": "Effective consolidated income taxes",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfTheProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r146",
      "r462",
      "r463",
      "r475",
      "r476",
      "r481",
      "r489",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r461",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "The Parent Company and its Israeli subsidiaries- Mainly tax benefits arising from reduced tax rates under benefit programs"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Non-Israeli subsidiaries, including impairments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Theoretical provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Income before income taxes includes goodwill impairment tax effect"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Increase (decrease) in other uncertain tax positions-net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract]",
        "terseLabel": "Increase (decrease) in the provision for income taxes due to:"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r134",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Payment of corporate tax"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes, net of refunds"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Net change in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r104",
      "r217",
      "r598",
      "r601",
      "r697"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail": {
       "order": 1.0,
       "parentTag": "teva_FinanceIncomeExpensesNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expenses and other bank charges"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r130",
      "r133",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Asset Derivatives - Options and Forward Contracts [Member]"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r46",
      "r285"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r73"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r19",
      "r74",
      "r146",
      "r201",
      "r283",
      "r284",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r48",
      "r285"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw and packaging materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r47",
      "r285"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Products in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r117",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Minimum investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail": {
       "order": 2.0,
       "parentTag": "teva_FinanceIncomeExpensesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "negatedLabel": "Income from investments"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FinancialExpensesNetScheduleOfFinancialExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investment in securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Israel.",
        "label": "Israel Tax Authority [Member]",
        "terseLabel": "Israel Tax Authority [Member]"
       }
      }
     },
     "localname": "IsraelTaxAuthorityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r14",
      "r53"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r618",
      "r620"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Settlements and Loss Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating Lease description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r60",
      "r149",
      "r237",
      "r265",
      "r524",
      "r532",
      "r533",
      "r587"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r44",
      "r149",
      "r265",
      "r587",
      "r686",
      "r712"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r62",
      "r149",
      "r265",
      "r524",
      "r532",
      "r533",
      "r587"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r31",
      "r32",
      "r149",
      "r265",
      "r524",
      "r532",
      "r533",
      "r587"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing Arrangements [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r31",
      "r684",
      "r705"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Long Term Debt Payable Under Revolving Credit Facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r57",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility terminates, in CCYY-MM-DD format.",
        "label": "Line of Credit Facility, Expiration Date",
        "terseLabel": "Line of credit facility, expiration date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r28",
      "r682"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Litigation settlement awarded from other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Legal settlements and loss contingencies, expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less current maturities",
        "terseLabel": "Current maturities of long-term liabilities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r158",
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r158",
      "r354"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail": {
       "order": 3.0,
       "parentTag": "teva_LongTermDebtaExcludeIssuanceCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r158",
      "r354"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail": {
       "order": 2.0,
       "parentTag": "teva_LongTermDebtaExcludeIssuanceCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r158",
      "r354"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail": {
       "order": 1.0,
       "parentTag": "teva_LongTermDebtaExcludeIssuanceCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesAndLoans": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes and Loans, Noncurrent",
        "terseLabel": "Senior notes and loans",
        "verboseLabel": "Total senior notes and loans"
       }
      }
     },
     "localname": "LongTermNotesAndLoans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r64",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r349",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r349",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Accrued amount for legal settlements and loss contingencies",
        "verboseLabel": "Generic modafinil, and imposed fines amount"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r339",
      "r342",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Paid, Value",
        "terseLabel": "Loss contingency payment"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r339",
      "r342",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damage claimed"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r343",
      "r348",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Maximum damages payable"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r349",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r15",
      "r316"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investment in debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement input, discount rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r72",
      "r149",
      "r265",
      "r587",
      "r685",
      "r711"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 35.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Minority Interest Ownership Percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Markets [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r132",
      "r135",
      "r138"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r6",
      "r96",
      "r99",
      "r107",
      "r138",
      "r149",
      "r172",
      "r176",
      "r177",
      "r178",
      "r179",
      "r182",
      "r183",
      "r190",
      "r223",
      "r235",
      "r239",
      "r242",
      "r245",
      "r265",
      "r587",
      "r690",
      "r717"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to Teva",
        "totalLabel": "Net income (loss) attributable to Teva"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r99",
      "r182",
      "r183",
      "r526",
      "r535"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 19.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r179",
      "r184",
      "r185",
      "r191",
      "r194",
      "r223",
      "r235",
      "r239",
      "r242",
      "r245"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income (loss) attributable to ordinary shareholders",
        "totalLabel": "Net income (loss) attributable to ordinary shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r186",
      "r191",
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income (loss) used for the computation of basic and diluted earnings (loss) per share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedge [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfNotionalAmountsForHedgedItemsDesignatedAsHedgeAccountingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "New accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncash or Part Noncash Acquisitions [Line Items]",
        "terseLabel": "Noncash or Part Noncash Acquisitions [Line Items]"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionsTable": {
     "auth_ref": [
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The process of acquiring assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisitions [Table]",
        "terseLabel": "Noncash or Part Noncash Acquisitions [Table]"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r370",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Financial expenses, net",
        "negatedTerseLabel": "Financial expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used as economic hedge for exposure to risk.",
        "label": "Not Designated as Hedging Instrument, Economic Hedge [Member]",
        "terseLabel": "Not Designated as Hedging Instrument, Economic Hedge [Member]"
       }
      }
     },
     "localname": "NotDesignatedAsHedgingInstrumentEconomicHedgeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotDesignatedAsHedgingInstrumentTradingMember": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used for trading purposes for exposure to risk.",
        "label": "Not Designated as Hedging Instrument, Trading [Member]",
        "terseLabel": "Not Designated as Hedging Instrument, Trading [Member]"
       }
      }
     },
     "localname": "NotDesignatedAsHedgingInstrumentTradingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "verboseLabel": "Other comprehensive income/(loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r223",
      "r235",
      "r239",
      "r242",
      "r245"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "presentationGuidance": "Segments profit",
        "terseLabel": "Segment profit",
        "totalLabel": "Operating (loss) income",
        "verboseLabel": "Consolidated operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r607"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "presentationGuidance": "Total operating lease liabilities",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r607"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "verboseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r609",
      "r615"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r606"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r617",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r616",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Operating leases rent expense net"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other\u00a0non-current\u00a0assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.",
        "label": "Other Capitalized Property Plant and Equipment [Member]",
        "terseLabel": "Other Capitalized Property Plant and Equipment [Member]"
       }
      }
     },
     "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in other comprehensive income.",
        "label": "Other Comprehensive Income Location [Axis]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in other comprehensive income.",
        "label": "Other Comprehensive Income Location [Domain]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r520",
      "r521",
      "r528"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "totalLabel": "Net other comprehensive income (loss) before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax": {
     "auth_ref": [
      "r90",
      "r94",
      "r403"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax",
        "verboseLabel": "Unrealized gain (loss) on defined benefit plans, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r97",
      "r100",
      "r103",
      "r108",
      "r363",
      "r590",
      "r595",
      "r596",
      "r691",
      "r718"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r97",
      "r100",
      "r520",
      "r521",
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Foreign currency translation attributable to non-controlling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r97",
      "r100",
      "r520",
      "r521",
      "r528"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Net other comprehensive income (loss) after tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r520",
      "r521",
      "r528"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedLabel": "Corresponding income tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included.",
        "label": "Other Comprehensive Income (Loss) [Member]",
        "terseLabel": "Other Comprehensive Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesInformationRegardingTheLocationAndAmountOfPretaxGainsLossesOfDerivativesDesignatedInFairValueOrCashFlowHedgingRelationshipsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax": {
     "auth_ref": [
      "r84",
      "r91"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax",
        "negatedLabel": "Unrealized gain (loss) on derivative financial instruments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r85",
      "r90"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "verboseLabel": "Unrealized gain (loss) on\u00a0available-for-sale\u00a0securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r549",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r261",
      "r278",
      "r395",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other, Mainly Debt Securities [Member]"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncomeScheduleOfOtherIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInventoryInTransit": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.",
        "label": "Other Inventory, in Transit, Gross",
        "terseLabel": "Materials in transit and payments on account"
       }
      }
     },
     "localname": "OtherInventoryInTransit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r61"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other taxes and long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Other Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Non-current Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other items"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other operating income and other operating expense items.",
        "label": "Other Operating Income and Expense [Text Block]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherOperatingIncomeAndExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 13.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Teva Shareholders' Equity [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r122",
      "r125",
      "r157"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r123",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r417",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 20.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "terseLabel": "Accrued dividends on preferred shares"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "MCPS [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromAccountsReceivableSecuritization": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.",
        "label": "Proceeds from Accounts Receivable Securitization",
        "terseLabel": "Proceeds from sale of receivables"
       }
      }
     },
     "localname": "ProceedsFromAccountsReceivableSecuritization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from senior notes and loans, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "verboseLabel": "Gain on divestitures, net of divestitures related costs"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r127",
      "r129",
      "r157"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales of long-lived assets and investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from short term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Sale of Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r96",
      "r99",
      "r131",
      "r149",
      "r172",
      "r182",
      "r183",
      "r223",
      "r235",
      "r239",
      "r242",
      "r245",
      "r265",
      "r520",
      "r525",
      "r527",
      "r535",
      "r536",
      "r587",
      "r698"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r54",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r324",
      "r751",
      "r752",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r53",
      "r316"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r25",
      "r26",
      "r318",
      "r713"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Other, Gross",
        "terseLabel": "Computer equipment and other assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r25",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r25",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Property plant and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Amounts reclassified to the statements of income"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Summary of Segment Profit"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r404",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r404",
      "r621",
      "r624",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfAccountsReceivableSecuritization": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.",
        "label": "Repayments of Accounts Receivable Securitization",
        "negatedLabel": "Cash collections (remitted to the owner of the receivables)"
       }
      }
     },
     "localname": "RepaymentsOfAccountsReceivableSecuritization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfSoldReceivablesOutstandingBalanceNetOfDppAssetUnderOutstandingSecuritizationProgramDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of senior notes and loans and other long-term liabilities"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayment of short term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research and Development Arrangement [Member]",
        "terseLabel": "Research and Development Arrangement [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "R&amp;D expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r146",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Research and development in process"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r137",
      "r325",
      "r330",
      "r334"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": {
       "order": 3.0,
       "parentTag": "teva_ImpairmentAndRestructuring",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "positiveLabel": "Restructuring costs",
        "terseLabel": "Restructuring",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r326",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r40",
      "r370",
      "r452",
      "r710",
      "r737",
      "r742"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r173",
      "r181",
      "r183",
      "r269",
      "r449",
      "r450",
      "r451",
      "r493",
      "r494",
      "r733",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevaluationOfAssetsMember": {
     "auth_ref": [
      "r625",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The revaluation of an entity's assets to take into account the increase (decrease) in value subject to the plan of bankruptcy.",
        "label": "Revaluation of Assets [Member]",
        "terseLabel": "Revaluation of Assets [Member]"
       }
      }
     },
     "localname": "RevaluationOfAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r214",
      "r215",
      "r234",
      "r240",
      "r241",
      "r247",
      "r248",
      "r251",
      "r383",
      "r384",
      "r662"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "positiveLabel": "Revenues",
        "positiveTerseLabel": "Total revenue",
        "terseLabel": "Annual revenue",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedSelectedQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election for whether provision for loss for performance obligation was determined at contract or performance obligation level.",
        "label": "Revenue, Remaining Performance Obligation, Provision for Loss [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationProvisionForLossPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesCommitmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalty income"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r208",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue, Net [Member]",
        "terseLabel": "Sales Revenue, Net [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r93",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss) (Net of Tax)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Information Regarding The Location And Amount Of Pretax (Gains) Losses Of Derivatives Designated In Fair Value Or Cash Flow Hedging Relationships"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsScheduleOfLongTermEmployeeRelatedObligationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Values of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r538",
      "r540",
      "r541",
      "r547",
      "r548",
      "r555",
      "r558",
      "r566",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Summary of Notional Amounts for Hedged Items, Designated as Hedge Accounting"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r187",
      "r188",
      "r192",
      "r194",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss) (Net of Tax)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Net Sales by Product Line"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Items Carried at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r302",
      "r304",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r302",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Maturities of lease liabilities"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of Changes in the Carrying Amount of Goodwill by Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r19",
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r557",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r54",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentNetDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r328",
      "r329",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring Accruals"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r326",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Other Assets Impairments, Restructuring and Other Items"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r105",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsScheduleOfNetSalesByProductLineScheduleOfPropertyPlantAndEquipmentByGeographicLocationDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfSalesPercentageByTherapeuticCategoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r223",
      "r226",
      "r238",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r417",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "terseLabel": "Schedule of the Number of RSUs Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of Ordinary Shares Issued Upon Outstanding Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r420",
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Options Estimated on Date of Grant Based on Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Debt"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r67",
      "r147",
      "r203",
      "r204",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r474",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r251",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r212",
      "r213",
      "r223",
      "r227",
      "r239",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments, Geographical Areas [Abstract]"
       }
      }
     },
     "localname": "SegmentsGeographicalAreasAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SelectedQuarterlyFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selected Quarterly Financial Information [Abstract]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "S&amp;M expenses",
        "verboseLabel": "Selling and marketing expenses"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r687",
      "r715"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "terseLabel": "Senior notes",
        "verboseLabel": "Total senior notes"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting period, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balance outstanding at end of year",
        "periodStartLabel": "Balance outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant date fair value per share - RSUs at end of year",
        "periodStartLabel": "Weighted-average grant date fair value per share - RSUs at beginning year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Share based compensation arrangements expected over weighted average period for RSU/PSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfNumberOfRsusIssuedAndOutstandingDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfCompanyExpensesCompensationCostsBasedOnGrantDateFairValueDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail",
      "http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Balance at end of period (in thousands) Number of shares",
        "verboseLabel": "Number of shares exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Balance exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfWeightedAverageFairValueOfOptionsGrantedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Fair Value of Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r422",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance outstanding at end of year",
        "periodStartLabel": "Balance outstanding at begining of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance outstanding at end of year",
        "periodStartLabel": "Balance outstanding at begining of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Balance exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]",
        "terseLabel": "Schedule of Ordinary Shares Issued Upon Vested Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r146",
      "r417",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of exercise prices, lower limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "terseLabel": "Balance at end of period (in thousands) Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of exercise prices, upper limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponOutstandingOptionsDetail",
      "http://www.tevapharm.com/role/EquityScheduleOfOrdinarySharesIssuedUponVestedOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r439",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfFairValueOfOptionsEstimatedOnDateOfGrantBasedOnWeightedAverageAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Share based compensation arrangements expected over weighted average period for options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "terseLabel": "Ordinary shares issuance ADSs"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r27",
      "r682",
      "r708"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Short-term borrowings"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationScheduleRequiredAnnualPrincipalPaymentsOfLongTermDebtExcludingDebtIssuanceCostParentheticalDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r613",
      "r620"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "verboseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r3",
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r251",
      "r297",
      "r322",
      "r327",
      "r335",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/GoodwillAdditionalInformationDetail",
      "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail",
      "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfProfitBySegmentsAndReconciliationOfSegmentsProfitToConsolidatedIncomeBeforeIncomeTaxesDetail",
      "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r147",
      "r149",
      "r187",
      "r188",
      "r189",
      "r192",
      "r194",
      "r203",
      "r204",
      "r205",
      "r265",
      "r363",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r71",
      "r169",
      "r170",
      "r171",
      "r173",
      "r181",
      "r183",
      "r202",
      "r269",
      "r363",
      "r370",
      "r449",
      "r450",
      "r451",
      "r493",
      "r494",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxDetail",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/EarningsLossPerShareTables",
      "http://www.tevapharm.com/role/Equity",
      "http://www.tevapharm.com/role/EquityTables",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/FinancialExpensesNet",
      "http://www.tevapharm.com/role/FinancialExpensesNetTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/IncomeTaxesTables",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/Leases",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail",
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.tevapharm.com/role/LeasesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/OtherIncome",
      "http://www.tevapharm.com/role/OtherIncomeTables",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipment",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsTables",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
      "http://www.tevapharm.com/role/SignificantAccountingPolicies",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r202",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactions",
      "http://www.tevapharm.com/role/CertainTransactionsAssetsAndLiabilitiesHeldForSaleAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CertainTransactionsTables",
      "http://www.tevapharm.com/role/CommitmentsAndContingencies",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/DebtObligations",
      "http://www.tevapharm.com/role/DebtObligationsTables",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities",
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables",
      "http://www.tevapharm.com/role/EarningsLossPerShare",
      "http://www.tevapharm.com/role/EarningsLossPerShareTables",
      "http://www.tevapharm.com/role/Equity",
      "http://www.tevapharm.com/role/EquityTables",
      "http://www.tevapharm.com/role/FairValueMeasurement",
      "http://www.tevapharm.com/role/FairValueMeasurementTables",
      "http://www.tevapharm.com/role/FinancialExpensesNet",
      "http://www.tevapharm.com/role/FinancialExpensesNetTables",
      "http://www.tevapharm.com/role/Goodwill",
      "http://www.tevapharm.com/role/GoodwillTables",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssets",
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables",
      "http://www.tevapharm.com/role/IncomeTaxes",
      "http://www.tevapharm.com/role/IncomeTaxesTables",
      "http://www.tevapharm.com/role/Inventories",
      "http://www.tevapharm.com/role/InventoriesTables",
      "http://www.tevapharm.com/role/Leases",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail",
      "http://www.tevapharm.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.tevapharm.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.tevapharm.com/role/LeasesTables",
      "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligations",
      "http://www.tevapharm.com/role/LongTermEmployeeRelatedObligationsTables",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems",
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables",
      "http://www.tevapharm.com/role/OtherIncome",
      "http://www.tevapharm.com/role/OtherIncomeTables",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipment",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentTables",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers",
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables",
      "http://www.tevapharm.com/role/ScheduleOfValuationAndQualifyingAccounts",
      "http://www.tevapharm.com/role/Segments",
      "http://www.tevapharm.com/role/SegmentsTables",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnaudited",
      "http://www.tevapharm.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
      "http://www.tevapharm.com/role/SignificantAccountingPolicies",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r70",
      "r363",
      "r364",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Ordinary shares issued upon mandatory conversion of preferred shares",
        "verboseLabel": "Share issued due to conversion of convertible preferred shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquityAdditionalInformationDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r36",
      "r37",
      "r363",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r37",
      "r363",
      "r370",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/EquitySummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r36",
      "r37",
      "r363",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r363",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options by employees and vested RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r37",
      "r42",
      "r43",
      "r149",
      "r257",
      "r265",
      "r587"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Stockholders' equity attributable to Teva shareholders"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Teva shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r149",
      "r169",
      "r170",
      "r171",
      "r173",
      "r181",
      "r265",
      "r269",
      "r370",
      "r449",
      "r450",
      "r451",
      "r493",
      "r494",
      "r518",
      "r519",
      "r534",
      "r587",
      "r590",
      "r591",
      "r596",
      "r734",
      "r735"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets",
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r370",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r597",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r597",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/CertainTransactionsBusinessTransactionsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.tevapharm.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Non-cash\u00a0financing and investing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SwapMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A forward-based contract in which two parties agree to swap streams of payments over a specified period. The payment streams are based on an agreed-upon (or notional) principal amount. The term notional is used because swap contracts generally involve no exchange of principal at either inception or maturity. Rather, the notional amount serves as a basis for calculation of the payment streams to be exchanged.",
        "label": "Swap [Member]",
        "terseLabel": "Swap [Member]"
       }
      }
     },
     "localname": "SwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r2",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment charge during the year on property, plant and equipment",
        "verboseLabel": "Impairments of property, plant and equipment"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail",
      "http://www.tevapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax effect of unspecified carryforward losses and deductions"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in CCYY-MM-DD format.",
        "label": "Tax Credit Carryforward, Expiration Date",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax benefit for remeasurement of deferred tax liability from change in tax rate pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Liability, Income Tax Benefit",
        "terseLabel": "Provisional estimate for one-time deemed repatriation tax liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r259",
      "r260",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r69",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Shares [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r69",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r69",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": {
       "order": 34.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury shares as of December 31, 2020 and December 31, 2019: 106 million ordinary shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r363",
      "r370",
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Issuance of Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r491",
      "r492",
      "r493",
      "r494",
      "r664",
      "r665",
      "r666",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical",
      "http://www.tevapharm.com/role/EquityAccumulatedOtherComprehensiveIncomeLossNetOfTaxParentheticalDetail",
      "http://www.tevapharm.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfFreshStartAdjustmentDomain": {
     "auth_ref": [
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The types of fresh-start entries made to preconfirmation balance sheet to arrive at postconfirmation balance sheet. These adjustments may include, but are not limited to: discharge of debt, exchange of stock, revaluation of assets and revaluation of liabilities.",
        "label": "Type of Fresh-Start Adjustment [Domain]",
        "terseLabel": "Type of Fresh-Start Adjustment [Domain]"
       }
      }
     },
     "localname": "TypeOfFreshStartAdjustmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r460",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at the beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Balance of accrued potential penalties and interest in unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r159",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Charged to other accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Credits and payments",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail",
      "http://www.tevapharm.com/role/ScheduleIiValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r614",
      "r620"
     ],
     "calculation": {
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "verboseLabel": "Variable lease payments not included in the lease liability"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/LeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail",
      "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r186",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "verboseLabel": "Weighted average number of shares used in the computation of diluted earnings (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of shares (in millions):"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r184",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average number of shares used in the computation of basic earnings (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss",
      "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 16
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(ColumnA))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/subtopic&trid=2144439"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "47",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "35",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=108311418&loc=d3e55442-111641"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121636179&loc=d3e34841-113949"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL75039408-165497"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=120604989&loc=SL2890621-112765"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=120604989&loc=SL2890621-112765"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.2)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r763": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r764": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r765": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r766": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r767": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r768": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r769": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r770": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r771": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r772": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r773": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r774": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>155
<FILENAME>0001193125-21-036239-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-036239-xbrl.zip
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M/B&CJ,T+X<^"U\&#C&^\67,D^L_K&"H]E\T1)#R-ALW<] C@QRQ0O>5UV43
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MMZ":9<U@LS*83\#FN&^^^8HRY7EHJ'S)^)"//9[R'SQ:&'-" &BGQ<@P-@S
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ME,+V:+,1RLF41Z$]*B^/"MLC?'?C]DCPZ+CT/"IJC_#=C=LCP:-VV75MF6S
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M0UR/T=N7Z<^3TH-A*3+\0B3S>*- LB)(GAX?*I>4W3F&%HZHZ++,XX,"ZJI
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MMG9[KS6/?C1^TFXOM=YO%UK,"XX\X$ZWAX^;9^W#+)\-!0O_P<R%T,<$O3H
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M74VN$>V56M;^=PA!;8U3PH%1!CS@'F: "=<,_]8TW M[[T% ==@X"A$90S.
M\R#O8,&"!;9_P/?_CI]_"+Y^)3Y><);Y%U[;D[1UR1&(L\1Y0[MQ4B\??IY?
M%4$ZA-B."[_\Z9EHJL!"B:,53)Q*XW-,5QOWT"1_$J>9IM8L%S @TPRQK BO
MWQW+L]&7Q.,3K.@)3=QGMQ!5\@+E=4#%=K09M/S8_,EGT  ,!^+$T(AE16")
MH^B9!B] QQG 26 E9F="_P;Q@X_%R3<#GD)$@*]"@*!3$;LW6YHXYLNU'Z$_
M<*$T[D$,P0<.[N4/3V.Y ^+.4O%*>!KPHG% R$\?Q"+SCZT8M<_@C<%+SW\
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M3#%676LU/N,N'V)//H@_FY_#GU_I["^.Q\)?,/,8_-JC8Q+^++Z!W>./VMV
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M<1_A@?;@#*E&AKAX(6HCN ,0/@, ,A>D.0'J78T8AN:--,,3O0D7#49QH'7
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MWX$N?@@8(I0-@.SCVE<-P]$]OQP+3%+AN1*A@I&MB_3A'8:,UC"P(2 4]DI
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MFJ#C17MUF,']SQ >3JM\@,3..J$^CV=_1:;BG@ WY:13F!:&&;^#H]>GJ7X
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M,>[J)I <95"6M)H_].+B I:#W23Q!=*&4: ^1/\O,E7'^82#X$V7R^9/,S*
M&P5J<("?S80BSZ#W86/%,?X1FQ 59RQ0_*!&+VR=&=-P1K>+P@ND[QD>9*Y)
MG#7@C$!=G9/MDT]A0C1T_& 6N2&>.L0/AOC!-RU4D9N33.;(9&=5K]0S]]BD
MA?"[]:(7TS0O.L&7\DU6YC[1S^X3#62FB-/HMJX\R^N*G1#V#R7I.=E^L01=
MMP%*EMV8Q",^SLBE22"KQ=L?*XBG6N:TE<FO9YB]QT"MR66)H*0<LX _U51%
M9PE@P:8AEB B&/?;L[!!F!G2#UE-7RH5NQ2G.O%$53$P>>:58KY2EH#\!'*R
MBDGL5%ZD.29NZA )F '$V@H<%4G>EP[X459=-/!_D!HBU9$\4&C/R[?_4%C/
MPR2K26OA7<G]K6?B1I_.': VC#L[RRNEFB+3N8*5B$ .;0\=$32%Y.G@J2,
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M\&BG. [ %<.H*N8UJN*X!=1ZL"TT)=(X'\]=:I&)E5?1#DU^E,'O&Q;XQ]W
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M[[R_>'/JG7<!WB%[CK)'P$ ,%EJ5&5?EW>NUH*GJK8*JXYL@E $(4RA &:C
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MC[Y!X\JFJIN_ZQ"O&3?_DMZ1W^ZZ"QSH55YVUPP?NJFWD0*^>E&5W\P"D;M
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MY,OYJJ&#HFT"LWE5-<YF %^67K.N:4$>3^-L)&^(E_3E/KS)V'WDD^J4PQ%
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M]OM^[V-&$YV77CQJTV7ZBT6Z=T#%XX8I(3R^-=;^+WIM,N++K[3HC18!1H_
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MP%?2H:FLN+4G4\37U;DTKE#N]_WDA)E_N;VS:] # ]R'I'/U&]K/ND?5&XU
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ML,!/Z&AQYFB&I"UE#<):Z?U0*XMMP_TMI,<+.MWPZP4J\P2-\BP26GLJ;E4
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MR8.,&2CZ8PRS?=N'@AS*XVX&[_WHX/!I>-&N8:05-H("2(1@A%-<C67"?9C
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M6*M<S?^B@TXFM51L=Q(Q0G<62V74[X=98 B,D66KF-\+J9+%:H\O:Q DGW]
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M(173^I>7#O,?Q5$W.:,W">78HZM4$#P,;XU3T6[;7GEBPL>Y,E'/SCH7*.0
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MW5'?0$G,[.$E$IH[_9TB.Q->%7%IX["'X6XIJ[!2KU0*"$CA@GU92.!':$@
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M1WWA,V:9R''W)WFQJ9JJYSJKL\A/$]RL!__HHR4$9/IJ!I6=Z6U0N\O,*J+
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M=0N,GC*37]I>2D?S"L8@UG6(N.%2TMA%N<[USY1XQX. O2QY&!J'C,$,VAV
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M3@"QV8OL!UYOGV@RK//^@K.NB;@':QV!&6PU 6UN<QBLA=+#.AEYBRX!WBI
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M(#!JO@U^8Q=,K07D;7>>-V($>,&YTQWR*\-TX\\F0AS=WKRW>8>L_M/Y:@C
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M^&16HJUP:=HC%./3CN^S-?H*I.4P$:OTMTUJ66W'$K&^TQCQN^_.93:DJ%G
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MN^L1!)IQJ92.1@AN19%22)6@%@U*/%+FNF9%9J6^/Z,D!LYM(4P^*12YVJL
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M)$ E&BA[V"6^CRYBEQ*8\9$+Z2E&#3$G!W/)=Z[+(4](E0C,*U+RHB/E<BV
M(BO\8VM_/ GVEG3LE*(WTE8O!$ 6P$P[A4[OJE\P]<V3W>JV2JG>D 2\*-:;
MH;BB.\997ZD4)W)'.4B-%5DB56ZQ\-[(TM%Q>%7^7>A#?\SH1)@6, )-)"8^
MRGG7H<A9#KP:KE[J&K%OE2I8P-XO!BED>J?JZZ$R"3A+?1&)L#L%M4H=S*YM
M>(I2M;"K""KL*65PZ+:.,KO)3,53_D[#M-'/H_X9CM[EWS>R3F374@IE)D)F
MB+_E1@DXV'40Z<Q'\H\2M*L/NK]LRD7=UV1H3.'ATE7'-EL,VIS*?%.$;]6@
M*=-D-F3U!>@ O9&8_(F]>$U,+5T,@OGE#4Y?(ZW=S3->S%27E-JV+A!PBSD0
MJ9EEFC3X4D&0!9E3A9:K;Z3,.9COP4D->Z) # NU*B9WQ)@X6A@X'PX\4D4$
MK/SS_)4Q6WN65IP'N /,#X)?.:<N*8.EY-FV*"W-6#,#_)9T DF3BSH[4);P
MO72BY&WY\JT(4&]/L8R5"2PR=IF;G6D2(4+2>MY<^S@82=;E2.-4FEJE^*2J
M M$^S0K6PZ;P<RPT&__<OM!1IVWCGS;^N87PN.M5V1^ Y%3N, 3WS&'Q2#0K
M>('K4 =X9I'J**F;IE/4LK)I:EYEH#QAAB\N-M V684H8$N@IT0%-&3S507H
M3JJCN*7,,%F^82T&G6!86=F9BT/SV#"8KD^NV&&4![C6A3,<"RF$[_+<^D13
M4,.YE#YH*@HL ?S*:DH\VESPLD-  52EJK:0[ G00RAE*LHXD#!*_-F0W=U2
MZ4(-1GGO=)T8T?)$ !$-@<_>!$9YZ,3_*E.]!GIS-$VGHK@H0[%#>A,<P]0Q
M$9EO2&'K/&2M&YOP5U0Y9'X7M!(B\2L>@I?2<#;Y(<@LT%& 3F@=KBY6&-R9
M :R%2B'?=MJ7$>O7OM0E[\9Q* @VA%/27+,U*VJG*:F.DD$8;9,KZ(KTTG*M
M:]DKI), C!I#3"=521[%#&;R;,IL\F,$.?UG,/B*_93(+SC+Y,DHJX%\<YSZ
MS%4J.1-3HWR +1;.">O@6/="KF'.RO7OJA"?4 ?67M-A',G9<90LH"L$F\1U
MN9JJ9!HIK<IL04E5-=@J0S!?Y!"#:Q"-@>Q8D<QZ<"WN8YE5HDE",\X0])6A
M#ER\51BL3*\Z?8:]!.H8W?P #4K2RZBJFP&U&2ZL:D-:Z Z$92</0/WDW(GJ
MH$M]DG-\TB!-9T+F.LB:@9]R>CF?KX'+\9ZPY:#.3/ALX)U^5,AGST*$4LA\
MZ!LA2M/7X1HN,'F/&3.46B3)(@I78104$\/#./XJ34A"&8I5KQ"S_E8%MR@S
MQ[A<.CG)NC.7U8TN"R"DNM%D"4Y9YGNS\U\G=S/TV7P%)15TY/=S0?79%FDM
M9-^KJ"C')@C>K5!V?U?5("A2:V+%(_=H4*ZS_A3K6/1>8,4@NYA2#61 %YR*
MD[#4[9O\8>5) XEXQX.[<J^I*1,&(!BMSPA?W\0(VFLXR4:(/C*F2OAX:,3-
MX<?CS^?D&AU\]6\8'EM_5.P]*E-D!F.\I&_1X9#<Z@[QF1B,(U19[LOYB[PS
MO'E4)Y3**EQ>C-I%C00N)M=PS+$<5\#'\024*4/C+A318R&%ZANM,CFTFTS6
MJF&E%GIKL(SP+A)#U912HE!@Q;31XUF-HK_\5GJ]9'7EG9]A046@\.,8K#R^
M'P!9Y@!N!]A.DM4\L%<DSS^1&X!?4\5DO'I5/@8J5:YZ+GZ<RSU+H#+G:>*+
M4(OVCXQ929DC'XCW"T-=N4IHIO?Z\0OTG9' ^P"[ )S!.>8F8?*=SL'%A^.3
MM\80IP(W1.&XG;#?5BBRH4=R )5(PHE.T?3F-%CU63RJ1&F<*VFKSF-Z8)-8
MC>+0>ZZG^K)UX5R[*K-X-\U0EL(IW!O8]O"-XD6BE\(%*D/W&-U%^265,.3S
M\ (/K&7-< -&KD&IK$1IJ 8X$2L'_E*$&T0Y[JQL$J$@7[!827<Y4SK@ N >
M<L/>1)S1H) 2RUT!%D_#?0 N026&O>/K3L( E1.?HE0'"N%[#HM5FQY)^M:H
M=53-%631D@ ;;#0'R:";&5?:P'-(([D-2KNBI?4\^,%#+(0(1=>C?A<> BL>
MST<8M%K>P_V,'F]*,]\$8HZ,B(L23NT#596EZ-6C4!;U]%G-HUI4PY(Q#KW*
MLS+.2#<HT:TF\N]1&=U83-#I48#]4M_)<T;*4&\&[H).@BX$S8O-'U7;I&+"
M$NMO!0ZO>\$4)DGE?_ :;I920),CW93J]=G2UIAR"BB,NX-RGJBA<IK--CD=
M:4RYOEA!"PK5+)/%W3+WVMC1A_IU+4:.6V :2-B#B01@TU4#!8U:"27%?G6J
M%S,&(Z>GR"$56@=60RN@'+25"8+,K$/0K@X4#[[T!(W]/_QD2#7G)A+B_(84
M"SHXS:O()60)-NHB,HF)_@3D*,N,.#-#AJJ-P21MR+X7.='"M?(5Z%X:<^LK
MAUN%W^$9-T#30%5!9?%*.!Y] F::HAI;V!CE]L8H.S9&:6.4.T[$.=<B534K
M W%*%DF,D/V]H:PS48G;"MLS'^4.\V)\"MV .<']M*_O\^ ?HE%RXP_X8,;H
M*".5LBN-P]WU@J[GW([SP(+1'LWV2WVJ?:%2P'4YG)&Q7_2$FA[58ML7E6@N
MY7@Y(YZO@01@O7=&X0P](;GKNN#1,U/+L(0V4\ESUNPXCV1Y-.4P?J.28MCD
M3O\-.Q&H(@.W#X%7!#I.61?#*"!O/OG;,IWMKGUY0U"N_:24+3>/5F1&#$;2
M3:B/E8[)5.$3,?4109A88N&,S4HN9<482)%8.,(2740J>9+I0D(88=[N1#5W
M/XY,+QB!"B5Y(:8DTU+V+[SX9]2SG>,)EA3XKG,"(R<R2__,1Z]JE%?(YZ86
M>?S2P'=E2BCZ3WB'N;U$OL]*_RYF/K-9DZ>LPAR'XM8/9^IBC>\QYYCBVC+9
M1'R3CC*RU<S+TW#."I]-XEMIL VY$!:IQ9$]</T$B^[9(&HUO2/SI,9B2,Y_
M]O/ +(R69NP<0$\X-?P)<SJ#._VZW99]U+A\C!U"S"<8?PVS*@Y"L&3>TO/=
M7N%Y3HF@U(I G1E%[G5<@.O9BQY_*7"-B$>)&/&DI),#K:SEW%IFDTWR>]0V
M=?L\,FX+4+IRRG(FZW\8W4'>K@@A&K4@R(^>&^Q0D:B^(Y0T"^_X2B:>6V8_
MKO(NRE0NQ5E<+ED$4J8:<?HS%FZ:DBK/UIV;PM+,KZ:G7>#Y!=G,*&<Y@\$0
M1':GHA#&KNJT9O*.R]Y*B7E8&CE$[_>3',Z58.H2K')&AM*U'W(S@3'BVP?4
M4* D RN8A/)?5WBM:TL/_^)R&Z/):KX[6-22S#2ZH0IL2OFA,E$H&AP@=J5L
M<DRN)72"%0ZI4E8@/]'(<^C'4^K%8C&8)]G_!VN7YT]9DV?>#0.19>ZPA9W+
M'9W"4-M[\P!X0:JJ+63I+4Y4A'EOCJ62;?+NL!1Q^GV&7%0)/E?7=7#E'Z@Q
M&6O.JI1H3M]2TV.7+8.M,@LU]^^!;7L*U,M3A./6&ZCK#^!@%51T0\Y<G\/J
MC(&:5_Y@GF)9Q4;5*T@*Z)Q<@[U5QM"_5%P@H=H]2C=%D@GCZ.9=2+T^><V%
M!KLX*5@G^;GF=L>E^#I51TGS4C7N#GV9XXOW1S8_H3)"O54-YR?SN_Y ^I1Q
M'S!\CYF1P:CBI65C)Q]2KRHB@ ON 7,-]H:*_(*9@JV&<]9A?)=@S'T.$Q.P
M-S4M:3@7G%=>WB1I5^#[! ]MP/%&:C2-3FJ\2,M3V>M$YAOGFI':4_>1W7]\
MSQ57*/"\(G.7-7U4- DGI* JZ3B8Y1F C9@LXU_'B?3!:03=AG,B6^51^C'A
M@6L!;7X_?\I [XEG&:8DXM)93< YJ7NF>WLNOF-SB;[Y^6*Z5:IS7^;)F_0C
MV26>&AB:CQ?!BFA[><^__,F?3-^?$GJURL4;PWQ_GX$V7L3OC#E=AZ#261LR
M%V<DW1KK:S@?)*S1K9"^QSP#O?!U7$]A9V1NM$Y,IJB<K%R31%,H3N3OHKR4
MT1U_^)]9JEIK854H8TL(A#E \C=245\$;@<;[T@.::ZK#(KFJZ240()&8--?
M<1,,X/)0@%+'Q]F(ER8ZGXF$XIGKLZ4,9_W=0M@2*URJF?X3L=@>1%=+G1Y1
MSZ%:V1+J"F%.Y2FZ-+:Y>91^5,4[-//.<X?0J1$/;<+'DOI"YG\KP*5H)!>"
MOI(&+)J^V$ \0U:_10K!UB1EX"XJ;.-"<J%4XXU;]Y_9\(;%=9J'H:G+&J9_
M,;N2T2!NY2W!"\AFH::U#>?GX*O O(I*G/<9>K(QMPSF9"+W5\Z/9 ]9"S;X
MO:UQPT[7!K]M\'O'B9C8D@SG%1N 44 :I9#1.4"&]W0=H?3KS7,TU?Z@F-&-
M7X<9D'I/<0@%9':=J@Q@LT8Q*Q@O*L2(O)8X,[''X@LX$5FOY9TJ"S$-BIHZ
M]<S$:HEJPJZBE)&)RQ G[D+<8G9B$=T4BA7+>(U(*8C(00A K%W/"U!N]ZX"
M?\MINH^C U.QB>ZT6=LS1^O_&LUOD<1&/QO"54O'P8AL%-7#Z,>SSY>ZB1$\
M1(H+72CL%!$I^+B+Y,:/@C_XG/$$SU2%SDFL[0YZT6G>GU:_Y.+LY%2_)#]Q
M><S4"0<9P8 =Q_&\(LPN#9RKGB,ZT3!]GXA8.0+,%FBE<BZ?&HX!S4PI+&RD
M&Q2>P:X]$7J_4]T3*15J?)<=,_XPGF8*!&PHF["8$>URHK4!$/B0(GFENZ/<
MD3]GQ"O&2!HV31HJMS?&8V3U&3NC9:*%CE8CFU3EZ(75<>:EBLK@L9"36W=2
MNHN3K[)L03M*(C@!B@=(6]]LZBBM9@57\]"6$UXZ^P#2(F2/B9@^\4$WSS#G
M6"9&*1X@&1!F "0SJLJQ#NH5---E*\?(.< F?4H/J$9/8/:MZX05Y%;!?Y)G
M/3]P%91_A(\8 TXX+D=IK%FKW $:,E+=VAPF;W[CX,-1R/&C9?T]18\MG@F7
MP!LXY5R9H%VM@SB9QO2VG'UQG-BM]LLJSJ/NM%(3"PRK'*FC:LU\'*.:P9D$
MWQP)"$L_CJIJ(KC<+%-HJ&:C0")<%=3+F9_\P%4N00."FVLL@TIDD6+/3O-J
MR 9Z&OITX"?)O>G(5M@7$_214H-V7&E"8 _4_Q#>>1,4P<J(#:HWE*L?: R9
M)J->0H#B,HU?NEI'_BT<((T+TZ5*9^4$0<6!W;=W='-+B&D,W"\=[86UYABY
M<QG]HUEY8Q3$@VR".&PX>5HG]H9*<U"6M-04E:\ ZY[%,;&X0L- $AHRR5B?
MP>C@\;P8U"AIY%?H48@#BGE(B-IJD\?</)/!F77GL4H/=5%?7\S>_[*4>ZOW
M;/=6;T7NK?_Z/W_-B*@&H#%.,<@2W?SM5?,5_2X'IM_E%*[I"M,+%'LA]\Q[
MI^"_><8A\AO>4?QLFL*?U4_ZH\)Z7_$:M!O)<#J!-A8,T>ET&P=#]>"PY$CI
MOC$V)AM6/]1>!(YO^%_(_8)#@2W0>V L;\%8#\QBR5<O]"2Q9^B%4=@P"TZ\
M4XX[J>=M[&H3EZT29-+A0[#@G*K G3M+&%E:[A=TB/=E_R@>%?R;T+_XQ>(A
M#$)@QG^APG3<LV]Z>VCZB)+$I62X7ZSF6K9AV89E&QMC&WGAYBQ2NI96/ OU
MPR.)N (<1,;%?Y]A^UWN:T3LIT*WPU1#,TNBD*- .!MQ6F@Z6E #[\S.T%*_
MM"S)LB3+DO:8)579B293R/F5-A#]3+:;4\[+$!W7J645EE585K''K(+<844_
MMV^4/>5>0*GF2 >8Z8GCIRD#BZ!.5<-"9#YH)IE*#G]H,"/I]",'2CP:I5)O
M4CH-Q3QP=J0PY5][CP-;UF19DV5->\N:%B'BD/]<@4BP51/?1/"BDI;#7<K0
M#SYB#$6*(91!YPA), NF,YG3K2,%91?WVOC+-H=DUW/R9UP51MWYTG$PM8 6
M3P]G7XZ!\L<P,Y&8;:-E)_1 YU138#,U'L8+PUY0$U UP)"E*N;GA"9.K$"O
MA0YYX.@$*ZI;ECWT:LQBR%],OU-EK(:XMX%O3DMX9!,)@2[?0XHV(9XE@LS3
M!J=SATH]GE$B2417/TWC09"G+17/7:/A/3 /IHF7(PD.LNNT\$)E?H%^<361
MGKU*?J1N!,YPQCVM$><1,5CC>(C!8@21I#9:F+E!6*&X=7"*$:](?,->; 2L
M,0XHY6-<O%53D6"KUM(#9N.5++[SDV%:Z%Z<A\_--;NJ<VR"_3("">SO7\_*
M[Y]26VD-@TAC&M57+J:-8O*2K/5'Z#["$+B-N45,IKH^8U,"(3*)U%O<?^IW
M0557JFS7YN)O:QISIV=S\6TN_HX3L8^IG1PO(<ARR=@T0OL"J>46>Y-6?(]S
M\]%*( [G#/PIZDXN\#XL)E-0T$9AKIG7S3#8!.BJ0+/9*D&N65"?$)3JU@]+
MA;-%&74WCJF2^0XGHMIL(M I]F>67:N)NU/;),Y*Y-X51@IZ<<C;F)/$<-.F
MTSA0K5>XM[8,5>.?=;FN+-[$PDU,=12#&:6E<$UM6;"8 A21AOP@H2).EFOF
MDQ*' =>G,HVP.2,UXBDD)'&#'7P/)5@CB(VN&HY\KEU&Y08;;M)K9=/S"47<
MS6Y"[.SF1&(-W9O_19F1NK2#+4G9RLJH$C8%-AZ^67L(DO 1':M0^FNT#)\P
MN"WV:'A<M;'9NLN9-Y_STS42$HG&))C-(O66ZF_@5F--O[P=V/3"_RJ,/&RL
M*\U9 0XQ2_/G=7ZOA/O%QA#XVCF\,*Z>'C/B06![8Q.LEM;,5=XLGII$HT93
MI8"-,,IO5\+H6X++F]@"I9H9YM^N<A.EJIFUYL4<>B\P[R"ZC</;O'5RC -(
MUD<:MED6.Z^>Y]-E]5HIR;HDX%KD[0PX3I]R5UWF6<94$(^ R@<FA%RCM@==
M69BM' Q5&3N-2W2:(S"81%I8WRR"Q0L_E(D&#+Z*P"I2>&C"E,MB$ /QS<<B
MBN(L\'CPU:J.=UZ4*72=M&#]E-@CY3CPCR2@-9)/SO]DM3+_S#JGA$@/3'<=
MMQ^3L"(R%7-NK HQ4&(4W\D(.(U<6ELF'O@CW,%E!!/&)QJ**37K8+!;V7)&
MGTE]B[4*.M-#7)R0A@T 3>.8]1VDH\0^WTQ'1HV-A,,AIJ[LVO((]/M0R+#5
M($1UA?KC7<>H\2!DI>(<,EO'9W[_H_K\5']."8'8_0Z)!!A7HK301=H*Y1(7
M"WZ(5,E&3U@G)-73+#51Q":E%9';M6P^KA2K>(JX@K,(_:OZ1BJ5A)P.E"*$
M0<!$3(+9A%DGI08H7U+>?U 5L*C1F92YAR8R&KZI"O0'P3 4J+_/KR>2!\TS
MD75M5OU9'AWC^/128N%4./NHC1@IG7GUJ<2*E=0:E)O\\N%AF8=M<3*WS[)6
M1D1J9RN;1J58+^EX1_V6PM; WUM-KZ4 6W&*O\4)MCJ-!U]SY-H#_%#6AW[Z
M[?),U8>Z6I\MGW(^H[S!&PYR=7QYIB?2]1K4\8BA!4O737XC%9HRL,@UQ2S#
M 3&4G'0,&,&#6-->3F?PL %JF2Z<=/$KN!E*(E^.Q5<1IG+!P$#REV=TN =Y
MI1=Y1(N?.W_$$59<&7^5RQYB%TYNMJ(^FL[ T!N@/1?0IPL;@/'DWI80H:F(
M2X[.#7:U]*[8V^PNUOO+M?_D*!\RX!T_(S&3RCZ#"!4468HFYUA4%@JOH_9]
MH]*)FGU/_+G1"JM8N BMX^*0ED<ORZ//M250T#UD5QTXC1>!^)+W21Z/!O11
M^)DS"7.A31UU4[4R8]F^!E'"@DYII!*_XKW-,=KDA9GSG2E^8ZJ'M.FS#.TY
MQHU06A%ZBX"S$!BA#N<56)%DB06DYQ*ZNP$[1JX^_C7WCE$W(WX?@>6AN)"3
MF7M= 4@UJ"!BTH@CK=QQR3/6Q1&;X'>13Q&FBM"))M%K,M1?PCG&QAR#J!B_
MFV'?5.4JPU\T35-QID9"#VZ#T.@)6+3[-.JRZAAN,#FLQ:5R?$+H0Z3TN2O+
M2KCL]2IQ6 ;4_R0J[7"5*"F7<ZYX3XLKQQ4Q LQ#Z^7*V@ N'#D1V&? />D-
M.E\FU.<]/];GK2K85\-,N& (K#@>>,V6Y[7^7_?57#AN^;0W\W2>+1H?%,SG
M5V<?^?B\'QM%.;/?B7/;F&SURZ<O9Y<7/_]Z=NI<7AU_^."<7'S\>/;IZK(R
MWVH=67![K5I\0IQU732Z'(^UZ10;2:<XM.D4]4JG* K3WJL5&[9/H/!M%!2Y
MU&XUG,]?+CZ??;DZ/ZL6$W7AYF HQG>DF%-O6J??<XJXYHL S:GW(;GSBUW,
M6MU&J]A+*D7<<P&*//I>CLF:.14#@=@M_&#;<QUNB(:6X#*O)SM0]64L]+M.
MQ8T$#TPEODFZ'#Q)(93TG69 :T-F $^2S0!F$8\:!H>]C=H%QGC&Q^4RE=[1
M4R;YJDK[?LB,X$-][AMV]]MV;PK?9J-@GDR7X?2DGBY=]K5HLRM]J/+^Y]K-
M=,Y<_*Y[O+1.KBZT,0&',.A(A0.NC?][^]Y1G,TAWO4.>=66V)7?93S\J$3*
M)8N4A<;D4D=;?8K,^^=K[H"9PCRCO[UJO7ILX,+AO#-TZ_Q@BH^H6S]WLBJZ
M0&=;<%%HU75]'I9/LUP_B$=_O4Y^^)\/6OP_T>.RS!G8HWRQH[PD_8]WY@,H
M@873PX-=WU0.@HCG@2C:*>B6Z=L7HZ7GB!/6L1;*$\,-99))J]D!1;K=AW^Z
MW;>/2ATN^%ULZKPC3\!+.QX+QBR]<:MJ>#_%2396[86_D_DO9@[?H0]\!\.J
M&L;D">1<@(&]H[7/;5>VINMZK>Y*I_>"[,%>_%64<%/3\#V_\>V6O?&+F&'+
M;3>;NW+EK4:PQ@QOLRG"1TY3VW<^L5K9MT];<^@>]E:K-RUB$Y)H*]RE+^.\
M6_'!O%H<<GS,\\3!ONFW2K?3X\QA%6'CVBUS;1=V7S:L)LNT1LQ"7:6]=;K*
MO^(D'-YADNQ5G)&VLBBV6NU<W4-5IM^SJLR"K6EU7>^H\P*ZS$XDVFUU+:F"
M2B\F1Q@)$=C;899B1H1_'=\*"7<:<(VI[J''Z?U89)1F27 ]TW!9=U1$.>-*
MGCS)@F$'Q]@\"!C)YHMZ_R6,]DNI$%^ID=)=M'3BB.OXJH,FUG>ZJJ$= UV\
M4--ZS&.7>T:U"[)U-98R8,X-[.O%$\\%<\\R+)R3WZ_=U9#U+=A(,<@D'(HB
M=SK],%25)5/TXR6JI2TAILD.E]3X2*)E2E"$J1\D>4/%TIY3@TDXFQ!!>#9_
M&3;'E;B\PI7;*R_07!61ZB&F4#+&PA]B*)!P)K!,6[9T4/4\5!3Y663^8/SN
M*OAZZ^.A7HG0.;X-;M_]PQ^-?+@I%>5*=+"%+^9WRYE%<& ZX0SSS#R^6;)]
MG!\9Y, Y<+)@7([N$ ? 5Q3GDE>\!%30A"!'5*D#9$+C8L73V ]U=[([ANF#
MU^FNJ]D8>R@#N8@H?00^9^^)JA!I6X*V$NY\3$5"!=)"8H -#Z:,<(&3_0=V
MJ[RGZE3VZR\W/HQT/$EAT*$_<67U,Y8SA1@YKNU9:=Z;-X+!RQ+=Q/@SPAH+
M"6($A#Y1388E-YX7TNEL.@4^$(D,N]4J1!+9@2K$UK&#,$YG$KCA!P2/"#1\
M"HQ:'!$;S&3+J2[%9.G#52=+[SJ&<9XMW6XL*LKH+BK.*HWV/O_24:,S_?9*
M52'\?/;3\<^8BWUR=G9Z_NFG>B=CGV-!Y(3ORY1+="7<2"ANN&?O0 C,.TF=
M@8\(0Q(9'!B5A%XXS\3$Z1-H8.O]!]T?]E+WAY4??8HSF9+CM:X;\H\G=*5O
M&"=! C@PL&Q:+"6^1KE-6 0#E.N)"*+';UC?WK!%-ZS3<#Z>?SIS+H\_G%W]
MYIR>7Y[\?''YRY>:%R<L76KV:"77]Q-9J[/;1/;Y^,N5<WZ^D(Z*=_1HY7?T
M">K+-FX?WE&G"]?S^,L_SZZ<#Q=?G*N_GV&)Z>?C3[])<-9+*CF]^.2<_>\O
MYU>_N<Z7LY^/KZ@>]>+DGW^_^/GT[ N,<'5U]N72.?YTZIQ?7OX"?_K\RY>3
MOQ]?PBV_^""_ZUR>G?SRY7R9NJ05G="+M0M84S]C-A@B,/$(9@^Q>BX9J^=
MRD3$^E%P1+7FIPH,2BG93\>$ND-@7'^8.UWHBQH;RD^'_N_PGT)R!(YZ,<AB
M-+]AE$-I?L- B <B?I^Q(R '_#*&^BF,KU%]$2'B5WR4 #X7$?QX+Y73)A:/
M>30W1I"4\'34A2E(%2J\!GV2GM2GXE@1J$@.&V6KGK>VZKEOJY[K5?7\?9'G
MK29B'(><ET/!OLCT?@*'HAC3U=FOQPUEH)T$67#M1U]=YU/CN$$@/X+J7X>Y
M1%0N3>1?#>?,!^8//Z+#&P0EXS8A^%H![*ZV#JY?_22@:!FW-B'YD",$T]'
MWB;!+6%EI]K715!-42YIECJ]W06C6Y/.HFA2*G5UU]^61M&4P8HY_481X7&N
MVQ30-BU!/GP(?Y=8PW4F1%2%(ZK01'4 ^Q<F0[.[!*O)V3S.@X3?:+::_-.=
MG\H_N8>=P]I*G,?V<PZ%]BE;Z_6[=F.K-C9()0(C]1 FV,E!-@-S,_^&>C01
M-\A=$^:OA#@2QU_I( A^?8@!;L+,C&$=B(BI@E?&*>;- R0/3K-$@'T<^9/<
MW1XKL$1LUP&ZN^P@B0DC.7H\_&9V7<$OL;)"Z(J4ZH 'RG#OV-&.P1/O'=V)
M0%K&J<Z:8*^^5!GC!.WQ69HM:F5H!</\:T\#A-N/AO46#?^2>15X!Z9^@"BR
M:EODS2DSLUBJRZR$&)D:WD,"P1(=@Q]&!FNZ]&6C"=E_]C+'3$7>]$M*UOMG
MCB+6FTP_@;UKJ>O1X!&W!?7Q8OZ4^--QK6GF4A#,<38&>RN,[Z@!GNJ<2EMT
M0UM$(C-1>3&#V00;+6%J448Y^(G(9DGD'( XGTTX8\;H!T1=623#?.N6VQ*X
MVI$S@*L>#?V$D\L<["DUK(15\WKT[R']VZ=_CX@;2,2UD?/::S8E;C.K-Y7#
M=%5PX*34EY #"OC))3; \Y.AS';'W%OG<QPG^M$NO.@<9OI-9UB>PC;^ QL?
MT#+YBY]!+$S\@9A16DG*WU@2RWF+0-P6C/\<WZ,QPAJ" LM-\K_^SU^#"2;<
M9G][]<I)D\'?7MUP,/FFZ26==N,_TYLRJ'.OB56,VC_>\M#'_>H'B0:S,R=<
M0[3NXCFVEL?F_O.>(6,_@6FR SG&AJ3 R&2JE>YRO9C]-YCS"<SU"@<S;N,:
MOT"-P@3V98S1($G78!0':5Y4L(Y"'ALUW734],A&3>L5-2TF?GE-"Q:](#FS
MUW NSWX^.\&$K@_GGXX_G9P?_^R<'E\=/\D:>M=ZGFQ?QC0J'C>\<$<V^T)7
MX)SZF;]4XMONJX/?@=J\:06Q8(4LAFWVB/ 6 @ZW%^,-%[ZVS,]VZ+4,O7EL
MY,V"MWK]NJ*W?I .)_0S+7(S;26&ZCZ076TQ@\V=,?_-P]OS_VXO*K0]V^7.
MUCNR9[NW9]NW9[NW9WMHSW9OS[:W]K/=N-:W2HBO)Y@0&Z:!@SP$*\/-_(OJ
MF2#[>:4RTU!\&XAIQC]3)@__Z$<R_CM5!H+YX22>1=GW-EVP:,KK1%/>1C_A
M>32()R)',R!WX5\D52P(!GT_1L6!_W;>$[D^8,2E]_4IZ+V[-.IW2/P=6IW=
MLVT9U>Z9W;/GCFJ1D+>[:\,G(5751-R*:+9VF..GWY?*IB0]M]?=7)>F#2RW
MWS^LSW+[;NO0J\UR6Y[;[[;KM-Q.[R70M:T)O-NBZ21.*?$SQ>J=G11+??>H
M79^+?.2VN_7ATD?NT>'FNC^M701[;JM='XWCR.U[JR7E12+)-J_:BNX]-5GF
M6B[@?FQ5399I*<)2A*4(2Q&6(BQ%V&:'>^E'^2F)TQ1[)(R";"?=*(?N86MS
MW0G7O]INC2SMOMLZJL_9>DVWY]7*:]1;<23#NO;W021]$:GPD\&8H0'%K0CC
M*>6MB6]3$:4[ZNX_.JH/W_;<IM>LT6I;7GT".9Y[>-BOS6I;;O-PM??6&D3;
M+7TN11BJ+HL3:IV"O^VTZ&FYG:,Z7=F>M]J,D>U>[9%7'Q.I[;:/ZF,AM=UN
MWQI(5D3-^>Q$)!(_Y&[9PTD0!6F6,%KJ3LLIS_4.ZZ1(>T>M&JVV52,=Q',[
M-<IV\T JK];<MT;2=DN@\RCSHYL <=O\-!59Z@23J1\DZ*;;4='3;=:)&??:
M-2J(<8^.ZL.,VRYHV[59;;>_6CJV!M(^B*>?XGAX%X3AKDNECMMK[<)=7M&+
M*X>IVA<)!_]]1[/C'*_M-ELUBB0>NEZS/J'$HQ6OU=I1VRVH+JC_()E0AJQ*
M72<1:9;,!MDL4;$H;E4(!S[93>=>Y[ ^%D>G51\WYE&=L ;<?KL^P;9^>V>$
MD;6MUB:R?A8W?NB P,I"0I/C+IDA9I$/8&P80T2#8$<C4+WZJ)H8;-L%VW(U
MJSWPW%;S^<M]NROK[=;(:.H?[8P/T$J@E1E-C&JZDU+FH//\R[DSG.C@\/D:
M\^XLMK6"2-/NK!936)[/>W=GO8>]%:]VD:BQP"];4<E<DV6N1=/;CZVJR3(M
M15B*L!1A*<)2A*6([0-^L=[^#?28#KB+S %Z^M_NIMNE[78/GY_DNSOF:J?S
M_##T[JP6DYJ?'XK>H?4>NIW^\PM==V;!+=?K[@P2O!4^*Q ^'X+(CP:!'^JR
M1M>)Q&ZF\O;;]:E)[[?J4TIS5*/.,OT:U=Y[;GM-Z4_6U[\5QFM-EFF]-I8B
M+$58BK 482G"4H2E".OKM^Z68I]X]O [UV(4)T*Y_3/_VXZF]!]TW$ZS3BF(
MGMOJ/=].WYWUMMSN"D#B=V>]7M]MKZ"6<F<6W&]9KW\-Q1!)'.?@6D1B%&0[
M&G'V>C6J.3IHK:"@;'=6ZZW &[Y#JUU)M^*=66^WM9X.K]9"VB71=#GVR21R
M#KAA%IA):"S!N^(1HGC$@\#/Q- ! 3;UHV"7X]4'W@I0Y';FNM>H?\=AC: 0
M:[/2@Q7?51NKWFKG:TV6::,.EB(L15B*L!1A*<)2A*6(;8]56Q_+"GPLGQ *
M=?=KS3INLU;0*)[;7 'DV.ZLM^5V:E5+Z/7<3J=&!-WV; !@BX73G)1P_"Q+
M@NM9YF-3HBPN+*3J>)XLF*(X>H<(ITE,#6*E0 HB&$2D6;IK LIKUN@V']2)
M5;=74'ZW.ZOUZE0##:NUCOX:6:XU6:9UV5B*L!1A*<)2A*4(2Q&6(JRCOXZ.
M_CD7SI6X]7?3^]]VCU;0$7UWS-*C6L4Z$(FL3J?K]>I54MANK:>AC'6R;(76
M4)-E6G794H2E"$L1EB(L15B*L!2Q[4Z6.J:U;,@5<SP8)#,Q=.#M< #1,'7B
MR)DF8B22!/Z<8MGKNM%_5E215SE,E='WI__NM[S6^XU.=D7+L[OT(FZ!U@KR
M'W=FK37JA-WJK2?5T[I[MD)_J<DRK>)N*<)2A*4(2Q&6(BQ%6(K8=G>/=>2L
M):<&*"R(_.2>G3KC. 2"VU%@9YMDL\^K;;GM6JW7Z[G=5HV2;%: C&N=+H]J
M$6W0(H;Q#)G_7FM+6[/.'5"@MV:OZK).2Q.6)BQ-6)JP-&%I8EO=+S;;9FU.
MFC,_B>#!5+EHIB)A;\QRSIJ_K#L1YT4,HET:]3OR:79H=7;/MF54NV=VSYX[
MJHW0F,*_O77"_T<_#0;.P>L=A35M-WIU@MMJ-HZ>GQNX.\MM-=HUBD <>+U&
MJT:=0YN-YJ&-N=3(=U"7=5J_F:4)2Q.6)BQ-6)JP-&%IPL9<K-NE=."G03C#
MSKS6\;(3IJIUO.SU<JWCQ3I>]EF!J,LZK?)L:<+2A*4)2Q.6)BQ-6)K8%<?+
M#KI4MB^-]5\T#S&$/14)[+03S2;7(G'BD02,<PZ"R(&9A$$<I6]MVNJFS+!-
MSV.71K5[9O?,[ME>I:W:*,MZDUMW,K[BN<VCYWO@=\4AC:M=+>;EEJ^V5:O5
M>L^/K>S*:H^ZJ[VU-K*RW1Z"NJS3>L<L35B:L#1A:<+2A*4)2Q,VLE(C-XI,
M5K6.E*TW/ZTC9:]76R='BFV"4RN%H"[KM,JPI0E+$Y8F+$U8FK T86EB5QPI
M>YNULGV)K*>RZS$!L18A5]>=LVJ[^=I=6IED>?T\CT"ST=T-9\\SU^DUVKOA
MYMFV=;+T@W\1KKHH9 :A\!,::XSL_YOF]<2+<]&&(Q,/5BS6&.,N&&9CX.G>
MFY*\Z"\C>%J&!L%_,\5HKC\4'U'OI%D6/J%)_84[\JU>P< 3(=#O@0C#J3\$
M&73SMU?-5_2[')A^EZ_DN=$+G,$L24"8T^K@V.0*FLTWSQ+L<O4P:NA/4_BS
M^DE_5%COJY(:M'2 2,ZW [.M4EY,0D;] ;Y_X+]=@HP7?'E>%9+/T^<OK@EM
ME=[S(4X<WX$_#V9I&L015N[ G9^D3C;V,\<?C<0 ZWNR,=!E/)GZB7\=A$%V
MCP\F(IV%60JS2.B!>[CPJ=-JMIJ.#ZI4J^D=N?#0"%2J+'90A+::[\]A=.=0
MRM./?@1$,@'2I3\<OD^=TWPN.,AQY(?W:9#B^SZ 5A8- C]T3N)H&&3JF2]R
M'O#(!>AO/GZ0-NA]WGNG0G][8:YEG,I2? K_5D$!Q@BKL%\6$/T -E\D);)_
MW&CYSC6MAZJ[S?*I%_ZSP @EJZ2\#/R;P<BN!1 [,K+PSK]/C>,?)V691=Q7
M44\;9VP('Z_;=AWU#]AP/RRD(*_=:/7QVX6I-GJ'%;.5?\[_'L:#KR"V_"2;
M_PY])I"2U=?HK7=RQM=Q2$+.=\9PA?_VZK^S>/#J?ZY(0L%%@QN8 >6D?_W!
M7Y+"7E6*]GZC&P!]S;-A.<V$9^//LKAD1-*?7E7LV\OQ[@J"EMM%NS5'AQLK
MP0B!3PKG<BQ$YISZF5^X#@]S+*_U;);%0VQ )>))LDK$%+/U2I(QGO%Q637J
M==]4AS;5*BI4)VTSF)ZK)7ZV0Z]EZ.?X#?O/RK]2UIV\4+GTF&;?XT)Y:)CY
MP>!VP'V(_O;*Z[]Z;.3O-]WF[+Z"Z6;:!%HX/<>:>YI4.$X=4*U/Q4!@K3QO
M4=MSBRQZ)=MO*0TIK5570D-+[,6HRI[8BYR8=V1/;,=.K+^])V;/JG16A_:L
M=N:L>ONK$7U_L.A9&O6&S_3@E\9EPQFB?9RDC@D,]7TGO;I#M8D86Q.0T#Y^
M/TU%ECH' S\=NP[^ZXC?9\&M'Z+?D1S_070KT@S#!TA-J1C,DB +1+IN?/=U
M9R.TW,YA?V/QZNW?G6:[;7=GP>YX;K^S"[D.Z]^79J]I]Z5B7XXZ1VLI"ZIG
MZ>GVB>!SW(M@%%#D)8@R/[H)\$<6R*X3B6S/Y6O?/6I9";*0(WANJ]VRV[-H
M>SINL[D+Y<]KWYA#M]>Q(K9"8?7<3G\]W6&L,;Q+DOBG.![>!6&XY^*VU71[
MK>=W-MM7@=+J;-1DVX'M.?)6RSWW1*STW8ZWN6NUO1O3Z;B=IK5IZR1)_Q4G
M7^%!9^!/@\P/G8.8$\7A3]+// FB60J3YOSV&CB1>SUKPRW:FT.KC2S:F@.O
MOQ-M.]>^+^W^3C3G7?>^M)NK]:19RW8?Y/%5G.D0[Y[+V6YSHVZOK=^>0[=S
M:+=GH98&U-/?7"QB>S?F$#;&LV[V"A3'MMOL[HPW>0>EZ?:!!5^.XR1[!U^9
M.$-QG;E.$ W"V9 ,7BYZ@Q5D,CEJS\5MV_7Z-C=J<6Y4N[,YIKG]N]/:";C?
M]=^IGLT9J]R7UN%+X.E8ZW:WY?'/<71CBN-(9(B94#M9W&JYA^W- 8AM_?9T
MW*YUPB_>GIY[V+3Y0I6!W7YKM?'+_=B8=LOMKCB19)% KGD/ U@XUPGN-^3P
MMBQS;3Q^7S:L)LNT=&'I8D=1Z[=EJVJR3$L1EB)L.\@=SY= ;]*^NXRZ[I&W
M.=MVZ[>GYQXU;7CK <_(D8W@5'M&.H<V6Z)B8[IN?\5.1AO#V1^)BX@SV?V>
MRUP/L2]LF&;A]G1A>RP<P /;<WADR\PJ-J;O'FXPV69[-Z;=<8^.7J(JX*^V
MHT>TIQT]/-O1HUX=/8(AO#,>>,V6Y[7^G^>]6@'5[5&/C_.KLX_,$PX;SL?C
M3\<_G7T\^W0EVRA=.J?GER>_7%Z>7WQRCC^=PO^/?_[M\OS2N?C@?#C_=/SI
MY/SX9^?DXM/I^95ZYLO9Y2\_7]$C%Y_/OASC!Y=+=0YY_FGT=OLT?IRE\$.:
M.A<@PFX#&/^1;2O86YUR!Y*G,>LG[-V:BJV%XR?P?^<FC*_!B)J.?;#E!F)&
MPIW[B$7W+OXP"3)J+Q8#7PVGF+ ^];.  3Y)*E-CL;LX">DA?S# 7?9'P+.'
MQ+@F8A@,<.\)$/1:1&(49,XHB2=.$$7Q+3<#P^\&DVD2WPH<,$C@=7Z8C1O.
MQ2QQ)@'W&POHN6MCYJ Z#$6"X*(W,'(2#%+72:<"\4FS^_*[@[BX4'B6WXG+
MPF6$P:V@+F5JC0UG+012:.FS+13"!?CR;$%T"->Y"[(Q'LSP]QG(-\$8P>=I
MXHN0=MAW4A GP0@V-\J<:2)2@6V.X"'<W5^B $GI,H-18>O/9@F\@KX',[]W
M0/V#DX1-^"HJB(L)X:NXA\U(1'23C5-91 $SA4_HH7=(#GB8DA@, A#?IJB[
MIOS":9QDHS@,8A>V:C!+85I55*,?HR])D@NB4>+#)&:#;);P<"D0DZ@MK5R)
M6]^Y\^D\X@3VS,=CSBD#+NX'<9T R=RS0/10!SOJ=!@B.*5#3F?$.6+J1.@[
MT0Q;K^!5Y$$"1PV-W,*EKX!\$2GE[8+Y,1C3%. /P'6"=,PS\(Z:W@/GLB+9
MZ/5W6SCBS=("\E+<3(B]UUQ *O:'S.5:;4XV!K9T,\;_"J!9N55_<3X!HQ@[
MQQ-D.GZ!M9VC(AX1V0+O^,C<K>&<^4"P>E@Y$/)!L'M2>B="? )[ ?$T!$YC
ML"(@ZP".)Q$W,*99258E 7$*%U<G:AAX\]48;ES.OD2$4IK^$B/6"MH#-!>&
M[\[$#=\YD+K9G1"1W!>^A:@?B(3 P'DZ\+<O?_(GT_>G]'U<A^2:S-<)SL7D
MO\YH%@TR6D@\S8))\ <^@M]3"P^#D1C<#Q#>=)#$= 8P@2F)<-1B_"T0TN>1
M@RT-:)^ ?<$,4U&B$1">PAG[H-ZPG/-AU;=48N#"4@,8%J;$G-!G<^_X\SD/
M%B2P82!OZ=D!2#$?2&  4TU@$*29V<C'P\2=2U&['4B%QX^*YE^%D^;)-R.>
M9>]">$,$I'LC=QR>@--,)C#KD:!I^,8)HSHEJ0_7P\NOU#AA@?J&(0F %AF$
M 5["CR"2]3EO-0N_@A-<^::?7/QZ?OI.=1YR/L/AB@F0?SV9,[9G<[2F][ %
M0[H)J?A#5 +3%-DJLB.MXP%)JBX7IN8_;]T(L!SOG:%_WV MYH*85!!SH1 P
MP G>2Z5.QJSSLA5#M_%.A.&[:T'\;<0L?C(-XWLA;ROV=H8_@M(\A;D$LHLS
M3 ^O>A#-!/XLET)/%M: +XN$GP 3:36;/$.YKGQ-=^/8&8JIX+?-4F--FV:A
M&U1]8'$S$'_WR,?ND;8&>*1(1DD<@M5#O'<P"VESAY+/SD!^#\9^&((M0N8C
M3K#A2,OZ3J*9D<%T T9M$K%2!2<U!/TV#/' [AVPDU""TRM >*?C8,K?B8UY
MN42C/@)]2TMJ".<6QE,<TE7,E61H.IM.0Y;ZL-0L":YGF6P:/@:FY8#=1E25
MDPZV!L_I0YEZ:ID9*@NS""RY@4 *$-H*DH0-6Y4&#TG@E^;/10=EZ\WS=6[Z
M68>WGTQ1"\9#4+M@\(!CZH1O.9[.O.9=-Q9_118AT3)<,FP= [^ 1J&40_0#
M:*6"7*K>^USK=;4JS!WJ09%2SS"73AVXS#<"1I]%J.,FR6P*M.TRG\;[YP\%
MW)4LU[^QDTV4Q< EI!J*TXA )X:;WG".I?8'%_O>9>9[[4LQ #I]> ^7A*1+
MG$D!E((*!3I?S(JA+#R%"9&*:+P,)I2((4@B/QH0AXK(Z0(_#$@@@-Z9(/D8
M(R/6Q AF@NZM$8QPK]G2((Q37/4DC@(87KF]Q&T<D@\L#;(9:_M!I/>YJ&"&
M\4!Z['!JA@&@'3<I23K\KWE*O+?D=1R *8^R&QG5T)_J0]7FT""_"K1@V%\8
M$!^!>4CP1YBXGZ&P!)DW&+O&+(%C4S(O,N[!5S=GA-+U(R6H9O(@KX'@427'
M3YD5&GIT8IZ.LE9HYX I8_MN4,7PF\A(J_2+ H.5VBTHT:9G:].REY2DL4_\
M_RNZP@+TVA%EL,Q#L0C4FZU!MYTJW1:V5UYZ1Z W.:,IF+(4=UV*(7U<J"[-
MDFN::@ ZX"!3$[\-DEG*7D1MDIJ$+>\R[<,U&KIH?H-EG.*QYTH=]["29BSZ
M_<@EKD4PO@T#V<1TB"R"B+U10[AZDAKT5<W ?,VD8H#D?"?8XH?;;]!2C%[1
M>_Z[\6?4!?#[ZA;#K9$FJ-0#2;F[&^.8=,+#&":@+EF#_X;@Y04%D_9@3FU1
MSH#<DQ$G-V"P_:&\]Q5T73A!N%\WO,MBB+IRZ,NH FD8K$6XZ,<#VW<8XY,T
M>_@4MQ?X+34X07X7ID6-6(H)Y ZW?IH5#<^"BEQVZML$@FT2^=V632"H5P+!
M>M(%=MU ,/VIN",_^Z"#C$65?WYC5L*_D&G#AF049@.9ZR.$"FC@**:D%&:%
M,HYNB+L/8'5L8DL-#L7;3>)/4J6DL?-7+=9'NQR>G879NC418 CQ'4JCW(5+
MP<0 8YM#A"4/)E3Z0]X#=,VJM66X 2G8TB2H,+S%RC4(]#2,[]X-XSMV.H%Y
MG8"Z2WYW0U^$U<V&@70/I;,4'3<"[8&;&<A/- _ E,']9L][/@/C"7^*>@-.
M ]X3P4EKLTE."ZT+7,? QWT"E1O>O_*M3<0[Y2ICE4'N,:T]GRN8;0.UWGPU
M*Y_-%*:36RYR*DQJAE^>K"94O/+3!OT_(?>UFAQ3HM99E5[">IX/2MRWC,\,
M1XB'1+IPYZ1!,Y)&Y-T\O1.9D1H*JM'7=XC#FZ(&JJW*V116@#>IJ,6RO5A%
M'QOQGN\Z\\6N!'"4</*?0:4<L#W^4?@IF)E;Q8$WZ#XUO-CL&?')^D>Z2Q6-
M:],>S>G4'P&%^N0#4):+LO?E\_DME*YSML/-="3#(\0)0\I*9"-BX--]P'O(
M'\,-3,ER,5SR.),L=X^("-^+MPB9)C L= !-U&G#.T6$/\HHW4B8[M8L\>&N
MH:TCEU#,/0)S4+I 6( 8:0KZ!6A@$;/(WX0#I<#Q='@A!AG@X@['=SC165KP
M#9M;78S$%KE$'L.EM=.4E!R@0(+.OIB*>$I-)N?<+[$,'3MI3/X?=+-@8^CH
MIN'\>"^-. KD@B:;"QIG.KY/23K"%G\+)C+&$4?HG:'8((M9C)]3KA<2)#Z;
MH5Y!*@2(8B2Q.W4W>5]!,PA0Z0CO74E4D\DLXLG"]&6*".=X;=[ELKG0V1U'
M)XQ4!C# "]Y\]D@:)C9YZ9@6,\R)N+FG>Y4(("?E"INE,_0*:,)R_(P8@>DG
MH'R]6Q&2.B=NR;,@0QFN,XLPD>]F%@S9HQ( +4U#:;D;QY^S$B)K)*$_1/DU
MRB%S&\@<"& .<!M!AM\K+T,:3(!D_$C$,W3QT(7CT#5=;=PC<K+:V,9W2\^K
M!/B9%9,ZWS;-T-NFS"12*5F#DZ92KO(N"/!5!O9R00-W$C[$6 ;=0,FTS3A*
M:A@S(=AB<.,(!1.N!XGK@1_A]*[1"XG#HJSU,^81J+BR-(YGX="((U-$<B;3
MA$BLX@ND-"_HQ[X,J(.T@R7@_33DZW26%2(;E.$2AY3LQ$9DPSGGMXV"),T<
MF82*;VDU6TUB6Z9E!AP$TX-PBPT?O4J@T=OF4LB"UG0MI &+_EK%#J2WF'DC
M+PG^&R%$J"#QF?IW&#2.)[ A*?MC>3_9CPJBFBR&Q3/(HZV8+X1^W/+:9+"%
MU20,U(1XZ^%4"X-+BRZD>!")V<#G$QG'*;?5\A531#M5SD.F;CF+YR?#SG)N
M8S\<J8FA)9.-29!$+,6!A!3Q@+E$.6;&VDMY&GETB,-'SO ^@ALY(%JF5PY0
M$4#"5@0F:6H41*AM^)QXS$E%*AY/89N #I[RS$T:=(&>,.<T]RFSXWW>$YX*
MX=S".*3DR"7 1L"J/1>D$'U)>CWR )$/WP>YA8JCX0.)Q(U/Q%YTAN!0QD+8
MO:$-<TIQE>X2E>4B%V%36A_CN'^'*=$=J7<>ZZ61CC_.MT1Q%9E /_S+(_3$
M4^@MZW)=&!?IK2@N@C6I="T'(@RGF'H9W?SM5?,5_2X'IM_E%!C=B5Z@[BKY
M]=\[!<?_,PY&XD?!J*$_3>'/ZB?]46&]KTKP$TMC,\GY=M\\5/XK'VK#DJJ0
M)<R*7_+;XU#]5JOWP%C>@K&>4(2\X-4+0Q <4GCIZ$ UI,4%)>*!A3)CZ4>W
MA:*SK[V>V^L>%1+L0(,  4'*!L59O#?X'0H#_]*X;("4 %K@_ ),GP@E#0[N
M2?GB/&JPDMGR;S6](Y=,>LHV8P,,A\>9LG-7SHMDFQ+6<804?6,F7)Q<?#[^
M]\6G,U8>M+ '32!A[V#^**6X8?(*IO"F((>O[XE?B*3TNN-?+J_.3B_8I_&/
MBU]_PX1R43D]+,>@:*U/RA Z+^^UEZ%"'=*.:9:#!>E=#.6OR_.?NTS77,)N
M.:WEM#7BM(7J&5T,0SE\E":B60K<_]=]M],Y+.8WRX@AUI7B$RVWT_**3T@6
MWG"^J*$4OR:N! S[&2Q8\5G7^?'LT^G9/X]_N/IR=OSI]+C >-E$R2MSOI_Y
MNLQY=84-R1B=\9@G^"S>6LQQ,BWE-)Y(![#V'-S&X6PBGF12&E;LNC@T&V)C
M)6DJK'_![I2'I(V1BR3RE"PDI9=>QH;$BTUPVDB"4]LF.-4FP:GV>M/1@WK3
MDAH+N=R 1Z?WDRG04DH.8%5IR6$^/Z^3 I8^B67%+B955,I:76J9RU M5G7J
M+YL;K!N41-]MD.*,X(.\4@SMNN)3E"OK2VEZS=FI6->9RC!T),*&\YE5%B6H
MZ&V';\J*A]0$;BBT+K4<)CEI4*(#6(5Z40!&J:!D#VNRU/3J69/EY4T66>'_
MB*W2<0^[#]LJGMMN/]56P?H6IT4^IBIWTJ.F#/# @7;9<*H:IV:6/$CEI$L%
MJD*1KBS0X;Z"::2=3GHC5/HC?XN"&< Y$Y]*;@8B,ZJL%AA#!,W#Z7E8%\]N
MIR\%TTC-3<^=G'4C>)-;:<$-XT$6)T5#IH*UYZXH+.T5=Y2*(M)!$L@8ZWSD
MSHR.F:&<]9E$55N(\K"T1SK9D%UX:ROL&?B,MV.$)D8AHE'XVOC4)5GPG\%7
MWF!=8")CO93/,XG3+%^G0% -MK-AR2M?T#T(3-1-&ZH,OT)^>W/RFP7T)0GH
MCP4!;5V+5DY;.?VR<KH2?N<QL=URO6[G0;'=.>P\26AW6&BC/'J"V&:XM9(G
M$!,S@.OI>EOF?;H*D-D-VQKPZ#_\J:\,A536&IAR<XB(=V3I2+>A,##=C-44
M8F#D:S-MI&6B.B1J>2W&8Q(-1HO_+8K]S)F::Y.0:(>&3 @OJ;0PP59)L=8B
M*W0A%>:F:%G25>LC561J9:*5B58FOJQ,W&"=2%'PE%'0RED6;KO9*B59D/0L
M2TGBT]59%<D"^[F</6>YC>4VEMOL$;<Y!Q81)(Q< 6IC@+F=P8@3>;%2*KJA
MS%\LJE2>(F XW1+#(9T&_MYK'\WI^J@.HCL@=;ABZU0,!)9,\8-MS\VSMEF5
MQ[0K00GOX7W#N10"\X:%TZ/:)V". ]#+L.4D&2-Y2G"*WK%)%1*U95J6:5FF
MM4=,ZU^8@8/(6%ARX]S$\9 J$@+-R["\(;D1,K#0:_6+7,G(8XGG$G\2H6IE
ML232Y& /,C"#4QU:3F4YE>54EE,5.97R\DBO:$E3RCU\I&L9S(Q=?1*%7 %7
M\*,!\!%M#A9SXXMO:[4K?+!H$6JFY74MU[)<RW(MR[4(HU]7">>*5J1X"K&4
M7G..HX3B!OD$O"P4.18B!5.X6%1B%A49%9B-WF'_4?;D6?9DV9-E3Y8]O?J?
M"T9.(83EE(OG7K?=[F&K,LY<Y#:^[LJBOD[Z46>1?H3I/F9Y1.G+VA,/<RA&
M 1=;I0^&^0AR.=7)/9C^RG 6C(^P-(<UH*5E/'*J@I<5-J\,\EO.:3FGY9Q[
MS#D_:'5)FX?LTN^WJY-T2JH:'.("/EDQ<B%**9DCCI8$A,LXXLQ_;$M7L%6/
M>NU2,+.*6]Y0:P+RY=WZH<J'1(@?RK)@M#7"'Z>(*55#=HMS/TB5<@F37%:Y
M?&MR5I^FP7E0O;*+L9"<@V./Q?!&F>]P88-;PCE)"S":B[;1.WKJ-O;[Q5QI
MR]LM;[>\?1V\O6P]WT0P+@8J,O^;;NI+!0V]?HG3Q0FG/T;P](M ^<(4%(:O
MUGW=3K-78A7GD4JK?&0)K<.*);1:ZUZ#Y[9ZW=(:,(\&ITN=*=&[JA5UUK2S
ML:_E5SF%KT)YEVTGAL&08*P(!Q21S!)N0L8 K? ZAC.S^7F6SUH^NY<Z]-DW
M,./!T&;&,HEOI25N9 J;G6:5UB=A(UTVZU&G#E)EUC,+4LAWP(9TPKC.RP.5
M]W6[Y*2@.)#V1V!'Z8EP#I IOJ7GNV6VOE$-T"(I; 1)H6.1%"R2@A6Y5N3N
ML,@])BV_.N_*)=_*4%QG' AH==TCKXPY6'!BM7KN4;,4</07OH&# $&>&5_A
MZT]%%("!@;XD+"D"DX&@H">(>XR &R3D!WXZ-JKHC&IHS"VK]G*)@JYAEOY:
M=XXU,RS/VV.>=X+L8A3&=P;/8%>RUOB-BB!B?9[;\GK+N/$/.XOR+8C3Z7CG
M/*=;/I98K)RTS,HR*\NL]I99G9J^CSM18%E"L.I#O$Q"!GC-DH*F6PX-Q0@K
MN/U4Q;APW 6<;? 4%NGB*)UF=VX4=F</N$VPC*3A)6 <YB#*E3!T(JN8(KG#
M!P/@0E1%/A#!+5YL3LAXW3N<>PVPS $U]*498C4W]8Q":*0$V[!C]^Z,^^_\
M/@NHG8EJ)5PLPJK6%%]W*W+H:(,(089@!GPN@\>.Z6DF4^7*^2WD))^'5^!P
M)G;@8G% BY#"X(G'4)G[0JW,BPJRWB=2S64!FH&,4+F<#<D9VT3B.+S%OE-C
MYS,<+QQA.@ZFM6XG<1XYQ[.;69KE7)&</\13"*UB:NR4?P-\DNX\V8K705SJ
M_D)7,KIW]#[+;GW(G<)9B@U3\C:=LKF7JETBT&.X0R-\"H9. ]@ 7T.)8!N:
M(:4\:'X04-?T:3 5A*?![\).,,:4,>&,DC",$?.1$ \$F :Q;VP>AOW)<#*)
M/Z4E89,G'][W"[4RH\'U'KCY*@."Z)B"P4L<4"VZT/,)>_)0LS7=4TFV.6<4
ME <73,_GW=WU9G*.A=Y.[F.H\5G4OL(^P7%>9KQU_\+..0$E2L^FP+W@,*?^
M/1VJ_ (L,YGO5\1==?S42+5.*U J3W.'P2C&WJJ539U )B4S'$+"L2#H](2E
ME &PABP4EW.M(4%Q#L9W8+^ J6*/(KF$E#?H6JY1-O=I.,?Y=XQ#D3V8U 96
M#0>3GDW)&NETR]J D6*3Q/<,2RJ_AY':>Y[&/6G2(#WH_+#5(3=D!*Z"4"Y<
M=-S@3PF[5!$5K20=8YLQ:<AH )WY.\14E)IT-"=GK#B8Z\0M^S/![EWD?0ZW
M0AY0#XX@'<Q23+-ERA_%V"4T54U^4MFC3,;H9)?2)%^3V;L1$W"#W[$7H^R?
MJ!03>!Z^-I"PD2-X)?R1*^$+%>\-YP,B%3WIC7EJ&@(I,KYDQ5N\(_66ODM-
MNLA>:KX_S\3$.<1?O-;[CWX$5AS>+OK#X?O4.<WWAVX.7.][V=$MSU [T6_&
M9RI/G%[GO5?KH0D=1Q&VO_PBN -LA*N?K#Y3Q&N^^Z<KB6P4($0425:\Y)=G
M)_1><9T ![UGYM/2=;SV5B_:TTOIVCF/1FAPTMD_<J=7M'-/4.^V<>.*'C*U
MC5O!#C>T(U>DQJC>S.P40^0UB<K&60]NGM)J@ HJ$-YJMZ-2$:<^J-[97<R\
M<+FN;84FQ-_G*>0A-N JY$FRJY!#Q(\Z#X]:&_4=&N,9'Y<=>+T^]?)=Z.#K
M5#CX^*2*7UOFY_4-7>7BW*Y9L]MD_L"6X3\DYI9V#2^8K".)/D_IF&9/<=LN
M,\S\8$#"0+31WUYYG5>/C2R)G']]9Z2T@"F&_WM;?D3YI(W+(S^A-_W%H=J#
M@K-99XR8_.;9O:@?E)&_/0!U4A19*SD#2VY(;KVZ4AOJW"]&52L=QIX5VF_[
MRP&>3CHK$2,;/M,#] [S E[S?X*HX(Y+^;<?^#]O^#_QB/\K31G^12%@O_T^
M&ED=.;!ZNI >C,B.>3=;S8[KM-I]^*?;??LHU7 4>;'%]HZ2:%\Z#%S( Z4W
M;E5@6)%$15SN>1?LL>^]7OYA\P)2CBU\G3IG/H&]5;FL5LE/5LVYJM;L-9O/
M7O&;EY_Z"LZVVVG5[VP;*S[=%V30EO6N@/7^9'3!6SO[707-=MQ._ZAF][3;
M;GB[P817<\+M[O.YTHZ=<+/Q?*)>%R.VFO+Z-.52PL=.LNQ>JVZ*U6&C4Q]^
MW>O6[WA[.\.L+1M>18I#J2773K)ASVUZ[9K=5*^U:@-WFSDQG'#K^89"W4_8
M:L[[P+)_(I9]O-LLN].I&\/N-IZO3.X,O^ZT:^?)6K4CRVK.V\V&+Z@CR0'#
M4+U5W'@GF?&!]WQ%X^UN75<<X_ I63.KY5'K/^'GNVWL"2]BR9*-5"3U+GK7
MTGRJ,A5XY?N]$!AM(7.625M<YC']QOE:I92OQ]GU*L#M:K?,-2I&^[%A-5GF
M6H31?FQ5399I.86EBT?IPCH%]\$:5366G/_TYUW+/VVYG=KY]UO]QO-3;G<A
M ;7EMFH72&_U5ITH88W/2IG:!IDZC&=8.;S7NL/6K'-GE,JMV;&ZK','#-"M
MV:NZK--R"TL92QNA?[5M6:(];<O2M6U9-MN6Y;$%+ >\C']9Z6*NDQ\VW$2F
M8E /4;0+ZUZ*:[3FT0R> H7P[4$HA)6S8F3"M<9F;RT/N_[G)>2SA4U_HI,2
MU!!X"S:7E#"4B-P*>_I'CFP[@#VFCL.4:Q-D8K(VS&M[/9[2E6#)5 M[1Y9
MD-"P@'XDL8P9+YX:N#8;W3?["/M>E,VM-U4'\#2D2RD]Y7D^^1P6C(=(M\'@
M,<1+!0-2 7FY,>#+BX40DAH%> [DFYCPB1_Y0[^1+TIW>%\TG,.MA[&!^VM"
M%F'U(\>[SIN+88.,HV[I\SAQO#=N15N&8G,>&H8 VX,H[QQ*LSNY^'S\[XM/
M9Z[SX]FGT[-_'O]P]>7L^-/I<8582:<"\7T1=%L"GE<W;9!]&(HO.O[E\NKL
M],)UCO]Q\>MOW*(4=H8@Z*FW0S!(G>M9"K-,4V[27+UK8S^E'-(D$-$ UIQB
M<U-8/,R'4)!ANK=Q.(,_RM433YB.[U/LY<'B<ARG#,4L^T_<FUW75HXX?'+Q
MZ_GI.X60!5L&%#P)!BXLEY?CAVE<6)/9> .>)6!G;-0ACT/CS2<BI)88$KT]
M@R]1PPNDEI=>!O4@@3FD]Y,IW)Z4FH,KI'B7YJ-!Y&.<\B3.!)UY!%>TDI:2
M "XDW&6#1C39X#Y="Q'E+7!5>Y#\:&^#%&=TC:CP62!%P[#\%#5S\26UP+,X
M)6XG @>0QE$DPHU@/>\Z9_]BM"3^Z/\'Z/6SHE,ZR;PIV18Q^VU&.7X$T!BV
M>4+;/#6WV>C]9A&/ET8\[L\1V#8B'K<?1CSNOQQV\/8/_9SL+(L3N\/8HXA*
MS/M"T,3\X_KPB7F8)+[C8V@]>@S?>;XP\!->LJ=G_5DD^%:XJ87S)-_XVB9Q
M0DW_-C@!-/'>/02/O")JM(RUUI?-W!GS7Z2\19]M+V"W/>&GG+!WM/83WCB?
M>1&8[T?5LFU ^79>HZ-)P7JO!*5[1=OWZ-5\;IVP+>K8AZ*.G]B!K#TA:Z[J
M6)"5_H1J@,H1JI%1FRO (%A7KN$:-Z;M'O5V!REG1:]?>G<LY$JM^"'%3W82
M8<5K/[\::+<*H(YVAVNM"/*JNS/,R*IPZV-9'.C=2:;5:]>M)4S'JUN=:G=W
MN);E1RO@1Z5TJ)WD2QWO^42[6[>T<_1\6/;=6O&!MP(@^K=6G]HW_J42.W>2
M<?7[=;,"$9F_;DKDP0IZ$:R-=5FFM *F]#F)CX-D_:!+*P&JZ=0.=^FP;ESX
M8 5FK56F]H]O_>^OQU]VDFEYAW5K+]"J7>/(@U9_=YB694>K\)5'0W\WV9';
MZ=7-<0QK/JK;F@^L&F7YUH).,#O)N#K]NGG2NYWZ>=)7D"6U%->J.1+MMJ"[
MUV29.X,LN2T;5I-EKB_9]46XU[:,:HWE[58ZK^+,#_>W((!@@W9&4UOKQG0[
MNV-WK[L@X,#JNFL1]EN#(EV7=>Z,MKLU.U:7=5I]=X7Z[E]?"C_3(DM;Z%R+
M+/UBUM!I&4JZB-*)<'&<I(7(:>,X@5<-%3ZGBXK@8.SXB5!?'SIPG46BGM %
MV)M WETE8& !_LX\S75B,Y2KV@M[JL\-X5D78@0>\#DAR.!U$*<![(6?I&\U
M]*P"&B4T3>\-(G6^IA)SYE8::/8QA-E*R->K+[_\^_SCL7. 5)6_'I__$F2S
M;WZTJ'%(=Q%?*.W1^_Q+1XW.]!MQV<..Y+)O7=J9A?1,>(D(1EJB7B?T9]%@
M+!; VX;QW=Q2&2!WT2W8-)FN,S5A$DL8W4F<9DX*1Q>,X!B!%LN[X]P)%*R(
M=ENBW@(PLJ0BU_'#ZQG,)0Z==!:._ R9T-@/)0@^? "#.0?YB:^>N.1QSE,2
M4)J89/!# +P-<9:1LC(1Q:/X%D@/!HYAU=^"T!G-X+1P[L0$81/H<JBM$;_/
M@EL_E B^5\GLUA_Z+WY)Q!0>FXX3!HC^CQBP4@+;.:.]?6"*9]/@LWCA:TR;
MR2]R_I$T7G@[&#$X&,8#'_<C2_PH!0D'0AM!A4'Z/; ;/\/7\%GG,S[YPA,M
MB]C:L)@/<0+,A720$6I31*,Q2\$RCW&=2@'H@H 4SI_^N]]J-=^?9V+B>/B+
MUWK_HT0@E[]>S#2*L?,9>-0(#(&82$0]Z%R,1@*QP^4WE-#^*(; #N")!KW&
M>U_7XSIG9NXBNP]1@T#L_ +J.\SVJR X_ Q]]02$/$B"*2-T*R%=^"N,%H#
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MY<J9%.<<3[%#V0RN#O8F2H0T2>GHG=>'_<)FXTVCHV2Q_]T'6GUHFVY,1M/
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M-C\'Q=2D$!+8&]=G/H;:[)@5/M0/41X HT.6#-=-MI5,Q&T VX72*2IHBBB
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M'$\VK_UQE@98F2!_O8!A/LLO?XZ3; 0<+R9;6#WH7(Q&(H&)RF]<ZI=^!.I
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MHW3:CPVKR3(M75BZ>)0NK,-S'^S5(I+ G[?#W_D2N;^>VVY;9^=2_KS^'F0
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MJLDR=Z;*>ELVK";+7!\C?Q'NM2VC6L-]NU7>JSCSP^U0>?>U^?>V;HSM:?V
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M\J':L=/#UN)MY]DJXRQ("&UDU-@W )4I1(T*^[W9?A!*BJU;)+Y7UR!];^'
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M!_9KQ>/N(EU-S'L/^7G%O[,B_].=]GOT%V2G<!Q21/ =4#J>A/C/*X61AG=
MSC!EV_"03_H?LH1M*AB40*#\TUHF,BG3H4W5L*2J(*J&%E67:@ZU5YP-+E=4
MCV :69QD<.&9"KS SA(=A[&(4<U$AT_&64L.\J"YL>&S4Y?Q<) 9#QNZC![
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M3>'^^>'9W[(D0*L?A0N<B]?P+,-QB/W3+Q_ T$V\&MZ$48XW*VE)"M24#%B
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MC05A(!,+[66U<+,9AO1#BGJ96Q,WLN/=FTQ4JRNC?\-&7W&\]R,E/2"G_Y0
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MIBUI9CC41;]_=L=8O15C/<"P7O'JE4HF*XU/K/^MB(%?BS0D!AM)>,.(Q'@
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MC*U98"@<?:Q&-A1"Y6:*"66S/,K".1P+,H+$DN<H,V4H96STH)&O\U!0/Z(
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M() W83:EU\.N39.4 . Z5%*O.Q2-0H1LR[&Q"$QT)/$J"6/3XPC1X306W$S
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M 3[CRJZ_<KBQD<*X;^7*Z K0IRN@]\/$04SAU+#,0K$XP_I$.CRHS@*-]&C
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MP%.MH90HD#A=,XI>""@'8_0!L\/ FCI:MHP+ZE<#MNR *.%,BRAM)"<<*0_
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MY;JTIZRT7!:K(W@$;9N2G<DFQ&*$"6;L)2EI"Y2S3T%'RWJ$BQXT3BPG0 8
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ME1MA;"GZB$K;K9A B:>> SF]Z)Z9O-**UT3#)_EP*3@(0/%9=\ DT<,[>=P
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MX3JFQ1K\5.6%P*MOP,;F$U'T)_B4'RA3U_<MR@>/]LP(9CK[K (+/(8 ]Q,
M9Y9M_Z/BP,HZA_L[^EJ[]9&^9#G/Q \F %W^$/:6]O'X1+ET0*.!UE,,W2?S
MK<SH*Q[L(#2FC#?%?P%C1]$=DV[@1?=H_ZH3>+H1^"?*^<P#4"CMEM9G:S!F
M)"8\.' 5/6LI.*='"-V2"K +S_Z3QG7* U>K5 2X,R_SI&3FN0K0BSNQ'#V
M1\V/'IU*>;0\ .3?,Y!,@ !8K-UJ@Y4;'GC=GGR%O$XM.,&B9L]?#&B#HN1
M.=1]R5 -<+X%-"BWEO]#^:8[H,P8N369[_\$9O8(I=[_$".@5&Y%L/(HK#P*
M*TKE0.)S#N4\%KX,GH7GOL#3@*C_I*Q) 9NUC,4I7G\""GZ"5U7JKE+AX1HS
MG[)F])S)A  GP=?H4]A"T0NV]?<,N"QX U8BIK^&\O/$FM86$&V>;C&1.*5*
M#P +QOC36'D& >3.?) Z#U2D^H$WXPBS',.>40]5 ??!<CU0O0%AKD*@/("E
M#Q+PT7H%&05OT468>9-"HJKX;Z /#";)'G3GAV*[NK-BB4=X+Z!/2],!12B(
M9.;YT0? -F%W,R]S)TR.9Z[#I*?O3F*5H-,3^X9G/="]$=M]82)^K#\3)C6G
M\/*CYT[BM9G(7[')2"L]ZA:%!?6L4AI)C9>*OL]78PLOGS?CN1F??+&",7P<
M9+H!WALP4/BU6/B#'P8*@KEV3&_,'"-T_N*/1!L'H(SIYEX6]PW*8F8P3@,,
MZ+8]WP.H$N( *"GNZ)?HARC3^E1?N8;%D,[VF-YV4O$WEAN!&"/+*6VB,/"K
M5/"]C%WJ+E A"EZ4!P9%9$,!Y%T?. #DL,6D8(AX?TH,Z]$R%+!?'%]GR 86
MG!EC3NV4OWU_ICL&G,DC-L,0)2]'T0V0DCZSW.@CV6?!=0$CQ*$'4I6'-V[]
MA+3OQN92+'!C!#.;([:BZ =^A24?J/G%"&G:;-3? ROR(""3.DH<GDEI.E!K
M 3B?#I._#!T P)!MJ2M"P3[100X"SNB?/C4$SXE!)@_$X^9F1U.9:?AA@[$7
M'J9]@">77**","G?) ^3<F]7^,!I8KW$VTOATITVF=E''J[4S@B\1BF PQX@
M[[<1- @:! V"!D&#H!'SVP@:!$WA0WX&!_5'K*LC44+;?9YDFRZEY_<RP;=.
M#:>K.]@&>&W'0GE(Y)5PS^P]]3,$F;*X5P[[+(SO'#1D<07V5M49Q7,_VT>;
M%MZ_7F>IV"=5KY,L!8DSIX>4\.R&ZWLWT.U_/GB_?AI-W)D3I*&?"]@+6";&
MVVE3\9;*]3#\W=)XJB\9_AK+=^U66T-<28.K-N)*&EQU$%?2X*J+N)(&5SW$
ME32X.E7^1Y],/S+#D&;4B?X(#RP,@96[\GEV7<4$U.ENHJ"*$?WN^\G=B6+2
M))['"A+#(GC_>#],8Z]MTV^Z^,)J=JA/B9==5+,JCH)'F"',Q%P5888P0YB)
MN2K"#&%VZ*H%>CP2^C(=X>8&L=%W$LX-TD[5]B#?2QJ*#8H<=MSV2;MU\&%_
MEN6T_1/M\'%]TIRVK9[VJYMQ7/9I!Q6.GBP?L\-A<V24IK9[APLI>4[;:C7G
MM'VUEX-(QE!XW<S'BYGG2FD_#M1N*]\YJB*S;^ND<_AAI3&H3D]RD,PEG+9N
M$P)%IHG!:7532,LW37K#ZNX0*?^T@PJO2"O?I>ATJKM8MGS<]OMX$V>3#$I9
M[^7J-TCBMDYR\/.EL28UM";1FEPX>V<H@PY&BD HB<8W,L1<ZD81&&JM@V7\
M_>Y\Q03$7Z2TF'M:<Y*>K9/VX>Z!-!:S+*>MFYQ'*"&4$$H(I69 24PK9)6M
M'5I^?/!1ZEF1?<DFO.]9M1OW5\[;*W%97+9YRV)ZIU:ML]&8?.R>K6Y5[&A!
MF"',Q%P5888P0YB)N2K"#&%VZ*J8N:M#YNZ:C@OSI4S2-:AH6I(RK[SZB>4X
M+8;"$4H()8020DE&*(EH@VQ*T"U?PE>)![0[J%-&^"Z7HO +,J>OF3>B;#:D
M<[CHL7G'+$-$">+#5L]+5>]#IE7W$?+U8,F&'+,4M5\/4#7DF$@12!%($4@1
M2!%($4@12!&Y4 068NY;B%E.3I)=4OI!RIQD^U1MM63H'93)[Q<EFB#3Z42!
MV=&GGP[D*&DF$!]\4$V3HZ3AP(-VU=ZP$0?MJ*V!'-/?#CYHOR/'B*D##SI4
M!SEK=TSY">TW-.28:' *:3S)=#I18'8H2W: )4UW1J?8U%KT"'-."8)UPL"J
M*>=$FD":0)I FD":0)I FD":D"7]5]O&1?&2A%^)[],YHX%B^?Y,=PRB&*X?
MR-G*^"Z'ZT*/,88C8CQ"IM,AS$19%6&&,$.8B;DJP@QA=NBJF/85.A_:D&-B
MVA=%GY"K(LP09@@S,5=%F"',$&;BN S8M21&0J*BKJ5#NPYZZE"3XN)#0=@0
M!:),JR+,$&8(,S%719@AS!!FXC@2#<\]"%.LUI1SHM. PD_(51%F"#.$F9BK
M(LP09@BSJIP&^*F#X9BV0 V;Z!Y;>DRMS]?8AF3FX;PC@AJ5_,;6T!1,K/%B
MF<$8G _MYP4[=+!->J"=L''Y:\GNB[F%F_Y(]$RVR]0[;%,?>(E._B8P11"%
MHF(0VY[JI@D+_7;4.F)_APNSO\-'\KVQ!RC&S/.($[#3?52B$[1:/Q^4?@E/
M#ZO:^M2'EZ/?XK=2YSU:\!ZWSBN%^VW#;K-23,G\!,WRP/=_V8*F5WQU.5T5
M?IZ]7WBV2JC<U)FM^[[U:!%3 48D@+FQZP7O88T)ZZ$Y43*<M()9/G&HK9B\
MQ>ZG7[="'N[I"IHQ@.F(MT UFS.N>YZI'*(8=!>QGOIG18R!)5X7CT%?2TB!
M!_+H>E0*V"_ZFY] _]A;%/A,=$74TZ$[3DANK==1E>C'\<>C7U=2D-8Y:0_H
MMU-;/3GM9^PV?'G^NNT:/T#FZUZP_!WV'J&4''V-/36\D5QA5Y+#^71E[)''
MWX[^$;C&T:=[)M[=1^4,/@N4X__S5WU+"CO*U(N#DYX%]+4LQ<)M>GPW^BQP
M%_+D[*5H4<N$9[J&UFIK6OLOK7.4 ]7M2>(B7NE^>7_QC<N$P8GRY?)J='5V
M.?JJW-V/X(V+J_L[971UKMQ]O[GYROX>W?Y;.1_=CU)LM(\@V1_B6EMND-]?
M_#%2;GX?W7X;G5U\O[\\ WA?7IU_O[N_O;RX4[Y>?@.DG%<(8,E)^NSZZN[Z
MZR50*4 QDZ01M'N"]LOUK7+_^X7R[XO1K7)Q=0X /K\XN_CV^>*6"Y&.IBKM
M5KNU"<3)G;0/MH3X$A6X*7R3W$WABDAXQR6Q7BLC[17N<MC[.=NY#M_O9+@S
M<10AF>]8__LA]7V#@\K[HJ! B.2YH30-]HF#K%MF>3' &.#(^>VH?;1IX?T]
M_*7P0,K#3SJ/L1EVB-._F_RZ ;RE140NH,:JT<.J1D74.0D_XS6TXGNMHT^W
M9 KN/'4X+@&V4\( K-R2)\N'Y<'IOYD]V):AC P#O/( 'J5\L;S)W"N1<FA&
M#C,S=IG$&RP1?$1#I]-=XDEI51*+O^Y1/LLBP]>)X<]<A^DH/0 N_F(YNF-8
MNJW<!?#"A$86/E3"P*)D);#3HG@6Z@C7:9&E!;6C3Y]UFXV!NAL3D@RY2:;6
MAJU2U!H2L[C$W#[Z-)?PW*PSW E1WGUU??]87LHNY[9TI&QQ*;NS2-EG[F3J
MD3$!\#^3NM!Y&^F\X73>7:+SL>X\P>,M1[GX>V8%;_)2=P>IN^'4W5NB;MT?
M*U]L]T5BL[N<>YV0K,4EZ].C3U=N (\+7&5CX$5>0B\B;(I58K6M$NMAE5@#
MJ\02Z24L!=G$([<7-]>W]\KU%UJ[='%#BT&N[I7;BW]=WMU?W%Z<*S??/W^]
M/%-&9V?7WZ_N+Z_^I7RYO/VV56'(?F)DE[JPLL;C*,&8*)]=W3,IT9];'C$"
MU_,5W3&5N['ND3'@E'C,H-RC+FPUZ XHKQL419AA 4)H!NUNOF2O9P7 G\;R
MQZ^GEF.!1:.X#L-"ED'#\'!)V=J!UZE,\EQ;<<$R2'R<9YII GF9=O.EX-.5
MD/^3*&/]F8#0,BUJG=$#Z8;A3J:Z\T:W9B1MMX<P*^"SK "C+?*L*S= <!.P
M:F;,[*%Y\YD?>!9L\*LU8<M2<%CP#7_V -:WI=,WRRL*2<'W'3WB__QCT&ZW
M/I[Q<[*_M(_'BL[.=$X,,GD 5,5%9W3[[98V5"O:,WT^W;9';(:'%%+\E/=H
MA5$_FT;]5/J*D8H*9KP_CZ80%DUAQZ5O4$?TD3JB0%V>0G1C3%^F&PE ]Q+E
M#4Q2]CWZTI1XEFLJM%["7 :A2A]LSVB!3>HD#O,1Z -]8TS,&5?BS[H]TP-@
M,O;.WS-@Q$=&C3HONLAA0XH^G<*GZ:*\B^,2@ A&SSO]6'E'*]] H *\[#?8
MZB/Q:.$'>#) ( GR2:'A,>;K.4(BPCK),O&*T4C T+KMN\M<G:!UK?^10BF4
M3D92.LU/X<72:057J" .?%@<L&1X\!C/TA7B4]?% OE@4C14+*F7!/![)I.?
M/.Z(>OJ$O+C>CY3$?0=\WCEF]^!0@?<6P0[D6$ 8<=Y-*=H9Y5Q[3[IC_9>1
MJA^1XCT8Y"98X?Q;OD_)^-W9]=UUF61PZ2CNS%-<KJM4MK$DN58DR+*8),U@
M#T"&"L@KGU9=/>J69[]1V0%$;<-)&951VO2GP)\^/]=\T:GK6TQLA*@(:7ZC
M7"\/&NH*N>[/[%!^TW] =(4T%2G./&5Q1;B'O0$%PNXG5,>\6,$X$N>4E:;
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M]GLU9J[B_8*FV"*Q52B[.;)]+&X5SG8_<(:W'ETEQ2[8?*:)0/@TO7. 7Y'
MI[KQ(4D>H47QM.":MT;_M%ZZQ#/AOKC>N3M["!YG=O2XV_AIH4=3B@K7VJ<9
M,F8Q39L;M$LEB55"*'5-4CD(RU$M=+*4PF:$"07X5%MIG !3XLMILMY:#)[O
MZ^;7P4W9T_(KWYQ:YI4K$I0IW[IJ;Z#5V(I"%T6$_4K#6/GIH9YZVL\R'>K"
M6!A0Q8#J[FM=AG-\+-+8$*HT(C3"U1M(SI)LD6ZK4V.1B;:("/L5EI'RLSV
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M8.28Z54N_I[!V]](,';AG6?X2$%3);:*-*K=%M:5U)F "G93-;5]6NQU;4A
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MN^2)WI-G'9W.3&.SJHE7PR&&"ZM%<<'NXA#C_54CN.B0L-8KD8?1'3S(XNJ
MQ66Z,ZH0);8;=SI%@YT$Q#9B&[$MA%.([E[.[M[(,+P9,15X.H#9,7T%K*.I
M1QZ)Y\'+/FU-:5**,;QU.XF-)9@E^6+K#^X$-\'*^/$Z=,G]GTWE,"&[WP6N
M\>,\D@3<);H+](!=UT;O635*ON2EBR/_)/&(,)#>' L9<8VX1EQ7[@MA@DS0
M!!E0GN7HWAOWGL:N#80HB@_UDSB!]M&S;MF\+.O,G4Q<AYF?(;@^Z[YE8#HM
M=VU0!_QCKJW1V"\Z$=<I$__H=F*P'E,SB&W$-F);)N<3W<J<W<H+W7/@@W[D
M5$Z)Q_W'[=S+#Q7ZESM;'ON)I7T>LX&A1#OB09(7T8!HD 4-&!8]3']UA--?
MS&7'(*<^_1!I\AOBL<FN!X4R_P([X"^V3#*LT8ZC&JTM8YHGI\7>B=G8H-8N
MV-X8N,P)VZV38;$#)1';VV![4Z R)VRW3SH"#!;'@"4&-3"$A=A&;".V,6#9
M (?OW+)G 3'1Y<LP"T/8H-/7$#=@/;[1[6L8OM'Q0\</C4-T!1#;B&W$-K9)
M-+&>Y4^V#V("%H@'N%' >'D@'KW2D#>5*^\L1X&=V/1Z[F.L7Q$\8X^%$X@&
M1 ,&*N4+5(I4F5+]L(=(+X^X6KYB6OGZD44C_.M9X >Z8P)<]Z]:X>I]OUMO
MU5;!EV0W><Y''JA?'\L\$/7EW8**J-\#]6O#FH>AOHT7X&(<LR&Q#HQL(;81
MV_7$-L8QZ^8]BE7F(JPE&8)IR:!$#[(!;L2.R$<?LLG(1R\2O<CR+4W!-BR&
M3!$*)-)M&'$H_X;7BW?X28=NI+=LV$3WV-'&=+NO\4/Y7F,GC>Z">1#1TQ?=
MK!!&!J&WT.;F9VGM%8Y6A@?UPG?^X-KFLN-3U84$$P!>X,,)W@" @:*;IC*;
M*N:,S3YAD(5U3I2D0U8NA%=ZLBD29'B0!.;W8Z+HAN%.IKKS1B^7!\##@]CP
M&8?=-/_DZ;8RU;V UN\$\/%'R]$=PX)7_6A O+\1*8F-#K:%:@90$BOL>M*D
M/-B':C;';W8_TZYGH"Y.*AB1^F>%<&6AG,6MT-<2\:8' N8UC3?9+_J;GY!<
M8V]!7FHMZE9$I-ZA&TZ$I+1>1U6B'\<?CWY=205:YZ0]2(A]OM63TW[&;L.7
MYZ_;KO'C/5"?%RQ_A[U'J!".OI9D/H5Q'YQ/5\8>]3W^$;@&L &;L 0$?D8=
M%R#H?_ZJ)ZED(ZTL*+<06(.3G@64DOP\#7;%F_7XGO19X"Y$P]A+61&Z$A]K
MF?#,5PU\*_#:>IVC"@7LT?K;5N00M1=_C)2;WT>WWT9G%]_O+\]&7Y7+J_/O
M=_>WEQ=WRM?+;Y?W%^?*V?75W?77R_,1_6-9JHJA\.J C[M[ /&WBZO[.^7Z
M"X#]V\WMQ>\75W>7?UP 7N#O"^7=U^N[NV/$0H%8>/?]Y.X$['K;UCU?2=8%
MKP'[2KV7W$[[8#N#+Y&#H4$=#Z9A#&+;4[!K82'6ZT7_#A?FO5])]<T>$$II
M[@CQ5XR9YP&!,;4[=R>97CX <:&KE3KFT>HX5^+M19>J?_HSLR!6N5QMV.@*
M=S'UM6U^EV[I0]*$@X.J1R.//*2_.0N<]*?!/K&(]0LM+P<$"]3E_':DS2E]
MU=HA-<86X#3(NL8C&<F.+:)##.S=1.:_B>XI8&H24SDG!J%!<7[JCJ:FQ59.
M,$42BDBH70\*HBG0 BDEYX7J!WUMB-"O$/H#0:5D:?4X@M7@B-=+N'3ETI[5
M./LF/G<</Y'/S(D;SWVT GI52C77('755OX7H>PQ0V1W<2HFN@J^M4A36ZW<
M;ZUJ,KJ*OF:HVV\7C*Z*FQ11K6U0:]?!F'@*3;MY9$P OL\DK>94Q2$\XZ:_
M[ML@7WQ7?+$-N"5W_.XCOD3:#8(608M.3QT:#\Y8@-]X4P)/=WQ;9T:,;OYG
MY@>TVJ)T%VC7;^QAE#&%>);4A_/[(K^X'B#&B:!R3X'"%QDYYOT<1*,80N U
M7C_>ZZ_5N$^GLOI.>>!9(#0?X':MNR.VGS]V94&N2$Q<L)?6USKHHS5:"W]W
M +(V+& J3[KE1+?S =6;Q+.>@5J?D\60@(' F[%J2.:\":^E<^H-6L7T<_#]
M"Z!'1<"U<QX#SA]YE@]H.)]Y\/,&7G?-RA1VKR$B72*,%QPR'>0^'1TQ?BC&
MB]7GFI9[;S"ZWDU2^OJS;MFTB.\]4-E['VA/\8D!I!U81!J-STO9NC_'*72&
M%:4'_[?X_^6)C-]=F^Y@+CGN8G!F"([B7/JDT/@O\5Q3]\<4MH.VUOXHHYK8
M]<')QK4,N9(@%=I5D$D>"SN)MY[1E,*6X?^?M%HMC9)<LG::DU?VQ):4(#B#
M+SQXEJKXX#R^]X%*'G<@WA45OXP#MI4W\&C^U/52)GM3RY700C%4T3GK#,9:
M+SU+IM)E(DU29!9!1O0X)\=RR6R9HN)PPT%Z"372?@RTOSV[FT;:J1N[2C,6
M#=2"HU*/\!%3>2 ._!8H\#U'&L,TG]*>M0%HRZ%P8T'FZ\<;^C:+/5^Y3OC'
MC>L''@DLC_4TWP#X_M#M&?M"M0DE6B?;B(22['10L-'4EK7*3["P5>%DD(_J
M7Y0"!22D*IYKM3\M[?Z]PX;/P/&S6BCR'I93P$S477:^XTC44D+>B#?$&^)M
M&6^8;ZA#(?B]&^BVXFXJ!T</#J!0K1/60>,[-^.[DL(]@(*,V1PI>;'@9'YO
M4$ RO^HKK]$9JH]QAD8UX@WQ5@MG"-V<'-R<Y&-7.)>]'O,KHW3^(4_8SPG;
MTOUJC"N68?E%5A_\9<]HJOS&]5C31A!XUL.,S;B[=Z]<AQJ%GFL#?)\NZ6 9
MX@=5C;+0VDUIQY(+\857>*._+B3:B_4,.VJKB&Z.LAJW,/):7I/U:G6OZ GZ
MIG</ "V]3Y XFXM/:=Q'8T!_%5?Y]XINX91.!52!Y(*BN06,4)(:M94P<-&C
MLH:G&.?%.*^X<2>,%R+>$&\8YT6G2H8X[RXNWSUYUBL-^U8P&76-C5C9(.)^
MT19@4:I "OP5'83M%3WHMMG8*WI0<?\T]VNUT?\2[8I>078I@7V.^$!\B(&/
M?Y9^275%%YR6?#=VL3?>2'>OMAC77&Z\7;N66"OP9NY"[N<^& FYWNTMR@W?
MRU=XM]==9;KI?M/R!#/>+5[6W>+U5;IK6&05H7_:")%"B-U<NNZ\*\YUY^*J
MJ.UN-,]00)73GPS@3=T$OW!;^>^CJW\!B"^OE(O_^_WR_M\;@"SFO=C4KSGH
M6NR5MV(G%<K6&$O=;AU\S+X0>U6H:OZNF99.G>[/X?W0ZYS-T-?D7VFGOK'Q
M5UP2EZS_DBSDL5_FM[\A\;M5?'F+.V?S72>^[[=3D^O2:4I5\<?@P8[A?>+Y
M;*)A_Z-"_IY9P=O27<""HV7S-<RE[ZW>9VRN!#BMAP"X]N#<NO?&A8"/#"_,
M.GA&/".>49QU\(QX1C2DJD"#%(;4U6SR0#Q^3/?QGP_>KY]"FTIY9SG\;\"E
M;;G.XO"".K"*%#BZHRE8D^/B6;=G!/%0"1Z^G=W<_?(+ K\2X(_@W+1J5+<Y
M(Z22=QG5H3LG%::Z98(2XH T]*D5P*,R"AX0XR5A_)8$.KV&@N.;Z)X##_'Y
M7^]TPYA-9O9<,-([*PPK0!U5$7LNXH,-HN6_IL8A\9?6S$1"E)451 >SVY]Y
M;TFC#U%1#2K8V##6*%:,<F/8?9].EH18YM*UIGD3*;"?.[:O7.=]$KN)*0R1
M^,V8.H,8+Y??2^&\B@,T.]/$0<C/XVG[;Z_3W;2_BJGNW?>3NQ/%!$&@>S[(
M@ ,#.WG164Z#S-9NF;;<1S=$=KH_+X NK^[[K>O=]V^^+[:Z<*^2^<^ZK3L&
M4?1 ^5_=F>G>&Z<+#5#3HA?.[>]#AQAK_[P GT%\Z>E\WT7V 6R[WXV;3)Q(
MDOWF,@[LCCD7E[X_(^9"!_+(OW;BSN/^7V?N9.(Z=X%K_/A&:&AZYM,5[J(N
ME NF+FF#L^O0"OC1J^4OMBMS5V:_66"JUNYF-RIO1["9YEO=J"*LN-,DV:X4
MF\PFG3EA[,%TE(E"EX^S30[#5PM@UWWG]O7*9U0I* FY4UP]6 )+WGCDD7@>
M,2OA2M;[] 4._Y?6[[>TX?"43E(^[:R8_H&\BKS:8%Z=)S5O=,N\=,YXVK%T
M5=KNJ-W^BLL-D$6112MCT0V#KLK@T2@-?1$FH(MASNUN)!BT5LPAEX9)CY%+
MD4N+T*3S^H-5ETU6Q[B:.EAU@0 R+C)NHQDWJD(IT%O=\G:OKNP&,+)H#5FT
M>@Z]T>DTC-)]4JVO=GJRLR1RI#0PE8@CL[]3/H>JG<&*F>K(H,B@S670W!AL
MH/:[O;IQ6'&E8E@$5ED1V-E8=YY@87/FP>=9X=>')E5^;0]IV:J!<CU9YC4.
M-3NC4-B3S%+)$1$U.\ZF^K":'5>$XR#OU.0X3= [(AP'&:8FQT&&08:I/_21
M8:1#&3),38Z##(,,4W_H(\-(AS)DF)H<!QD&&:;^T$>&D0YER# U.0XRC,"U
M(#@VJ/P:$-Z!8ST3A3P^$H/=)NS 4^CEPS,GH(4A?J [INZ9O_RR[R1EK RI
M8;JW":)4,.RA&5*3XV!E"/).HZ"/>D<ZE"'#U.0XR##(,-AAM*)O/B#/^H=;
M8MBZ[UN/L 7ZWA?/G6PQG>+>71@TL]!AU-+^:K'NHL&]&W<:#<293K,T^*US
M]$GVUB5LJ*\A[PK#NI6-K-F!B=OR,W$C>+AFU@\:K-*A3#*&J0=,MU9ZN][,
MLZ_@WO4Y.U%-[HL7L"1BI&2,;&WV[9$257D"6E5\XEF/NW-]OA)DT-;:'SEX
MTN)DQ_RIB#;9 74 @[5E )C@SS'!?T6"/&[N3*:F=F7W[0];TE,RK4LA3U7@
MMLJ&<#G(;3*$13J*2'MI,EB+,\XVS*&]\=Q'*_@*&D>RH/BGMJKU6CD'T!)Q
M:60@J1@(P=ILN53D)-T:2R-I\%OF7-:M+@QIMQ';16&[ .[L]HO%%W9;U"@8
MPW+&0*B)I'&^P9G*@X(-+]#')*C,V),L'UJS;#2V5\B,/>2=FARG"7I'A.-(
MQC#U@"EX0Z8YWX!HA1\20% LJJR93$ Q+AW*D&'*.,X\5)49I$J(=<M9(=87
M(!)'+I.'X-$CM@K__Z35:FGT. FEH'"MD!E82L/W#+[PX%FJXNN._SXL2-N[
M^"T!W.V+X;:J@LO>TQ**-L1B5S5$T.CL%0FN'^_U5\&[++8)^9YJ6D; =UW8
MKESB7:;=)*%FT6E$IG,J+97Z-O9PH4 63R"C!5,;E$G&,/6 :5X)T/R4;M6%
M#MEZM6B/^U@"6A&+_VHF_?)46!E.0O$Z++G6SM\M2;8(<OEQ.^OFXWULS)KQ
M@&02J!XP%<X"R%VC]P95S"$H5J,75XZ%A58Y%EI=^OY,=PQ"I]G> [#]F?>F
MW(W!Q/6QQ$KN(IWB(PS%E?'+!FO)#(.:F645N"9%T]\!OLJ>H\=K1A/(D34Y
M#D:WD6'J WW,OU>??X_\G+O -7[\H=LS,C+^GED>,<]<&FP+QJZY9?X=D$D?
MH-LWNF5>.F?ZU ITN\*FN!WC=IA1;W!&72C!6)^A9!+ 3"PZE%25H^U;&Y0A
MP]3D.-5DE@^/V91EL*96*CVMW,>L<@VD3SU@>N!(_?Q9L\BRLC4\V<4)^.*S
M7,T$'EK(TJ%,,H:I!TQ%TU&H<THO=L+94Z671#$V>?^@^\1D$ZB(X[,+DQ3R
M2G\G6!<E=ZT.6A\R8T\R0Z1F9F#1O",8L=4,>Y+Q3CU@BI-TD"K%VV1.KN7(
M_,_,#VB,TK]W5U3#L&X"9DZ?):SI6P(NJ ][N"/>LV60&^)9KGE+#/?)8:LP
M1U7 ,IPU?JW6P_M$D8-1KT@"0;&HLF:V)GK9TJ$,&:8FQT&&08:IK]U3(\\%
M'8]&,6#-Q!]J+.E0)AG#U .FJ+$:H;$.* (9K*T!P>J.@@;>^&S.S2^_[#DQ
MX9![N@_Z;B[BA)6Y4&@0\WSF >RX5."S?P#L[*TM[X8$83-QG<.:"C@R]A$F
MBF7^=O0%#OF7UN^WM&&O>_0I]\L&2[V</J<P[7S+N9$'TQ054,>>>B9-&KU6
M?W#T*?]K*.4@ASU&YN5(!#<>>22>1\P"Z6"+#ODE@A@>?>JH@P'>'%R%9! D
M<;M(%(,6(XK,*:AB2XKM;;LBI[?5[A)V!"N"51ZPUL!<*%KM#[2C3ST)[X]'
MCD&.J8ACVH5S#'91U2C.=FX] P(<TX</*=/(^>,AM[%KF\3# =.2M^)@_D]F
M[$F6"JQ9(A8;J63&'O).38Y3SWEAL>V5#KJ?Z?Y8XF!]6QOVCSZUNT.<(E8#
MF50/F.85!SB88P7)I*Q@3YGJ>HZ1_>1A/^R!JQ55UDPE8X!$.I0AP]3D.,@P
MR#"-L'L"I0?_M_C_N]A @[;61B,(211-<S$AB%2)@A.;E00IHKCW=,?G\2P?
M]A^,E>2^LU&\(XX<UWE/0WV>:\,K3QQ9BN7 (L0/_%UYX9 .HQU*P<IY2LG7
M3Y?9ZR-N25\YR&TRA$4ZBD!%D]FYDH \ZQ^2<OA/$,-7KG,VEYF7D;"4+&F"
M?2;(4@A6!*M<8)5? 51TYY9\\K[T!HG\<0U?-I:_+-95W0>%%,+0QMR_/>GV
M6"!!XD[DLJ@C=^QJE6"WN Z:;<(Z6S79R!C\68K$O?!//+BVF5&;64F_S6?=
M9F-M]$ Y)P:3:IPP.AI 'D@\72197,_-MKU6^X<WMT-N:J.,NLN+,F_'"0^N
M9\(I^3%.^C0:[;NV92H/-GP_KQ+^ND K4RIN .$>PRW8%"+>D;F@.4;^M2/,
MS*-/FJH-\YY/D1^ND'+GT,@GCU<38&SB6 31?I+N\%E?85,N%UN7CF'/J+UY
MXWKT"Z,@\*R'6: _V.3>S7:EBA>7^_K;/5$%)5([2D>4CM78@6$=!S],.65'
M*!10**!0$%DH5&\G"9.3[JMM+>^IF"@B442BB)1;1&XST:Q@&7E+ AV@8E[H
MG@-?\JM+XO7486^ 0G(-T1?53HU2$J4D2LFUEJ1AS"8S&\2A>1V,B4=%H4?&
MQ/&M9P*/<R>D.L'95KN]\B=%H.!$P8F"$P7G>L%Y[Q'=GWEOU0Z_^M15M6[N
MM]CD)B*/&T_R*")11#8T2%E1W;365?NMOK BL?$4CA(1)6)#)6*9W05KJP);
M Q20PA(\"D@4D,T4D/G=&ZWVAUV4<+M0[(:NH&W;4GB'4*[-0?H[@!L#7OBC
MA0U"134(G8UUYPD6-MD]4[0E:/BAVIZ@+.P+RD*E3Z_<F5TD[[6H"'8YSPAM
M*!1K08$Y0J0>9GXEQ(0 RT.&U80ED0)1AB$%U1]@:(<UG>Q0<"$%20@P%%Q-
M)SL47$A!$@(,!5?3R0X%%U*0A !#P=5TLD/!A10D(<!0<#6=[%!P(05)"# 4
M7$TG.Q1<2$$2 @P%5]/)#@474I"$ $/!56.R*^SBW6U;5&IY/6\U+157)% L
M-DA)>6>[OG]\:">%H'?:[O(4O*D7;^JM(81%.HI(>VDR6$N_]B[JU[WQW$<K
M^ H:9]7E=L/$Y79#@>:E#H=Y#_TKX7I#9!\$JSQ@E48J%3E$JK:R2!KLBG;=
M;OYW+B.N0USG?WFNVFKE??7$3A?EXD@,22,R;- UT&QBTG6^$9H&1"C%#>EB
M6S,F%:J&8BTH$!.C(A 3 @QG72 %H@Q#"FH0P- .:SK9H>!""I(08"BXFDYV
M*+B* TB]P3#537.^\<-$3E8^(X\\"6(3N1RYO!0P;,W7Z].4JVXUI8G+*Q)<
M/][KK]LEJRN[*G7M95>B7.2"E%QS"8>6L P 0P>LZ62'@@M-LZ:99I5=-8K6
ME_#$BD(,Z4(*(2;*[:"B7)R'M(LR#>E":IF6FTPZS;O2OP'$AT,DZM.R<.G[
M,]TQB.(^*G=C\';\\J=('/3=7.02NX*8@H*8Y^R"TAOB6:[) 0(P9V]MV7H&
MXFWB.FS%O4TLGSUX+XF6=Z?9R@+772GMEQU)JJ*&M<1Y,^GHP#8P;&L6X2@B
M[07!BF!%L")8$:P(5@2K\& MSD7Y)4?;$B<,U-]=OP>T^#/O+2>_O0&!*W'K
M0K"-%"N3JH9B+2@0<V$B$!,"C/^=L/(4;N;5=-S UG'A_)[\RWX&#_(#2E1Q
M!$0C* BM0FFA*#/ 4'!A690H95$;1IY&H1Q6-?"';L_(R/A[9GG$/'-II68P
M=LTM>PE-TZ(/T.T;W3(OG3-]:@6Z7=WDVX&$]56#3&J+IG<BX==%(*)*E0%@
M:,DUG>Q0<"$%20@P%%Q-)SL47$A!AP%LZ_KVO4^XO-.R?-742F*T(R(UHSR4
M%" (ACP[%?.3<A6-D#B5,.[6,%*MAPA#)2@#P- 7;3K9H>!"VZMAMA?:4C+.
MB.!-)RN'1.S=>;(X1P*[3K8-"#%&?/^@^\1DMUL2Q]<9WY)7^CNIJO5D>3*(
MD+Q0I!A>1=2B%0B+9MTMPZUF]G&>>J>F1)83-!IM#==)!(LA=&K"7$7*'YGA
M@D('A8YX0@<AV!!R0_&#XJ<0MS.7R-_(_,_,#VAJU+]W5[0RL&D7+!9QE@A%
MW)*_9Y8/>[@CWK-E$#[ \988[I/#5F%Q1 %[*%:''17+_.WH"\#I+ZW?AWWU
M>T>?-&TH2"P2F:"F0A'5J<C 0NNMR>2&@@HI1Q)@H:!J,KFAH$+*D018**B:
M3&XHJ# >AO$P$3L8EL)?IQC^$IKFZR$#47N*#"PTUII,;BBHT%A#8ZV,EH<E
MXZN/QE>9/1!LXP>U0$C8W'#OZ< 0C+!\V'\P5I+[SB:@'3L9@';?)^["YLA2
MK/!*;'_G(L<#;J[<'N@E/:7<FWH..95(%P@=".%RD-MD"(MT%)'V@F!%L")8
M$:P(5@1KGF M[H+$%4/4 _*L?TCZ#G^"ZW#E.F=S._\R,O"W2WC EXWE+]=G
MAOK1IV.D@EPC*=5CL=J!"XEH0S%!'>&B%@QHZP-/VVY057SB68_E1:JN@S'Q
M<&B#A-F;FC0'8]Y00@C6@O(PA8C)9TF 5>?I$$AY*+.0<NH'++2SFDQN**BP
M/JO*^JQUH4$6\^#16@&G0,ATD^8RA1XWGD3K(;)0V8D,++2MFDQN**B0<B0!
M%@JJ)I,;"BJD'$F A8*JR>2&@@JC5;6)5A4YHP&#4W)3)$JHFD@H-)"D@Z#,
MP$+Q@^*G+@92@PP>$0CL>(G"5O0GA!T(\/ -;0:[2_ =KBU-SDK8M6]EY\?L
MU>J]WU.2I)#&[6L&;N&U!]<S@3[8AP IBN_:ELG(K 6K\P=D#V_83Z3D>7]U
MH0?<T*>7?6K!2*/0I6M.:M6P5;%4AZ0F)*DA?2%](7U5301(7TA?2%](7TA?
M2%](7TA?2%](7TA?2%](7_6DKPWSD[:=+\1G*54X1FDS2<HX2JFLO-6:/7QD
M?[_P[S^XMKG%M[>K-"CI;)]U6W<,HNB!<DX,5BG&Z;^C :FTZ'3WY$2H:J9#
M;2;?W4BCXMSW3AFZ&IPLEXL4V"4)_J7OSXBYD-P?^==.HNKQS)U,7.<N<(T?
M>Y<^^NQI^UR2\$E3M:$H=0#-HK1\:HH$/%C-CK,IE[J'<*#,/@;U2SR?L_>E
M8]@S$^!QXWKT"Z,@\*R'6: _V.3>S9[E6KQ8V?/BE4^]4X$%2LVH4RPIT@3D
M%7W&3'F2ZZD';:W]D1]>3!"(@.;:\BCBJ6C;OP3U7NIDGS6JOMU7.UH;U3V*
M$L337J)D18- F;+DE@0ZG-R\T#T'ON17UX%YJ@X;Y#LL-QB@-!$2494?1TD(
M#H5+CA5I)0'$R<@P9I.9#7+#9!U.5&9X9$P<WWHF\#AW0JJ3,.U&F2LH85#"
MU,]>N?>([L^\MP*#F]N(DJZJM47.G* HD83W:G8<B:(H14Z<69=S[:C#?G.L
MD,HI$B6'',?9WLVI7G24>;_FVO*-UE!#28*2!/$DIPV2FR#HJ:W33G,EP;SV
M>8L:Y9UN"^0C582N/HYKZ9.[W!6D2^A94R<<BL%6BX+F;*P[3W!4<^;!@Y1V
MJ]WZ<$@%[F%W.6;5[B\5^.?9B7#@-)\&'6S;1HS=C[A7DT7C$+K'\"W9B:Y>
MI]EKK$^]N E9J&$01RU4!RS*L,=Z01SYI@Y8E&&/]8(X\DT=L(A[S&>/>P8
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M.)+@ZG=;9TP<VU80YZO(.7+5N%R"V4H9E(D.5^W$8PV/A!*_GA*_S/%_VV@
MK36LL_Q'82\PY%'8H["OL[ O8')\:XCB6DYQ/>^@2.U^KY:%!X_H/]Y;CF^9
M\)+^[%HF/!_'5QX(UEW)A]U2 X(@<4W-NBZ+XL981B0GPJ#"RO>RMA-+1@AM
MV?I5\1$KW\#F&8?204@.P%>^ 3%Y'M&-Z$9T([H+1G=!RQ;9A+_']7"K+H2D
MOO@5":X?[_77[0*P0M\R.<C]$MLMR>-8$+*KG$M1>*'PVEEXY1F3*DT05EU[
MD"GKRIN4(HK$JPL+E$2U@ER?EO]M\W*15TVHMBQAFW_A5E;55MEB<T-*8\%"
M6<;E5'\B[W/.9:P>,H6YC'5FQZ7OSW3'((K[J-R-P33PRQD.E9OHR?$)1:;C
M][Q+D**'F.?LHK0;XEFNR9$$=,#>VK+Z"&39Q'4.N__<9P_>1VLJEOG;T1<X
MY%]:O]_2AKW.T:=N27)L#7D4EE'>2$:[KOY+@3Q9$",6QM_KDSV;O+1R+B;=
MGT"%P4;.S3&5;T"4@(R@Z!:.I[,8^1?D0.3 RL$B![0KWP"B6^QS(;J%4X0U
M]5C_T.T9V=%A+3))L:XKIA*O5!ARJIS[4"C50"CM-RYB2XPN]Z24)Y5J)&6P
M*Z%VD7Q&Y^\?=)^8K#>!.+[.V(&\TM\)-B5@%5!A61C!RJ\JWP V)4ASKD;P
MO##HKDD!R7J3<V3^9^8'U%GU[]V1:5KT,[I]HUOFI7.F3ZU MUD>EVGKLX2R
MOB7@W?JPASOB/5L&X;;J+3'<)X>MPLS6+2N>LQ]<OE/=SNI=;E#15.6\C"(.
MT8WHE@/:E6\ T8T&C!@&3%5) +174**)"!:YED6)5EP"000)A5T 1>0.[CT=
MZ(ZAU(?]!V,EN>_LU-J.B0*@FO>)7BJ>$5"LL*7*%Z_R/_>LL$A[$4,UE=VG
M4?D1*]^ @!D"0>L)*C]7(W@>T8WH1G0CNA'=B&YAH5WY!A#=8I\+T5V# N*R
MNQI63 ,)R+/^(1F/^=,*QE>N<[8\AT;22T#:%14BYS6#">FW5/JM)?VM"&-S
M9&G3UTWAZ(*+='GLNI"43O%UP"O';2Q= )%U2\2#ZYG$XQ\"1"B^:ULF>TQ+
M5>A_BY=1Q$'T_:8V'))++.UP&RR2[!,+0@Z%+5MCTJJ&A8JC,B0M84@+Z0GI
M">D)Z0GI">D)Z0GI">D)Z0GI">D)Z0GI">D)Z:G^])33%!RM=<@8G$2@/Z^>
M"<&+W1F\]AN3H_*^ E7QB6<]'C:G>^%H']G?+WR/#ZYM'G1O]%9P6H;*\C,_
MZS:;SZ\'RCDQ6*J84W!' VRWVJVL:\!W'%<=AYB+(<"RD+N?0,RM3VG=:/F2
M2?LPR%4$OWQF4+);"OBXMX6D]LB_=H2Y$^&3IL(N\LY_(RT+0<L?.?PT!)]$
MVN,0H/TDGNC<="G&YIF98["!B.=S.7CI&/;,I-,S78]^810$GO4P"_0'F]R[
MV85MQ<O?O:]QZPLJ>>4C?0'D!8I;I#DA9*Z8@O;&(X_$\XA9DJS]+_%<4_?'
M"_=^M=N]/D7=H*VU/RZ+7RE)\!!"1#4B&$NC&FD8S0EHM8NI0429)-KNJ]UN
M!TWW^@@-E+D-HSE)9.Z&"\++$+JW)-#AU.:%[CGP);^Z-D&MI0Z[N5]\WU@6
M.!9 <*#<;1C1H=S=VM@UC-ED9H. -:^#,?&H</7(F#B^]4S@<>Z$5-BQK7:&
MN<]^;"Q3H"1&28R26%A)?.\1W9]Y;P7&K;>1N5U5:P]0YJ+,%0)^ H!//J!)
M(G.K%[E57;G04EMMC##42$:@B&T8S:&(W5+$ECD$;FW]<:O30XE;'Y&!$K=A
M-(<2=SN)FYO$!)%YJJ'(+);GA9G'N.XNH4(&C19_ZTI^P^0ZTU?%=&? DN6W
M*B].\Q3G((*@N;!EQ8%T'=E KB''S2(9D0Z"="(NG10Q.&.GT^4Y.0,I2@"*
M$ND@2"=()T@GE8.W-@=!.A&73M"208JJ[T&03I!.BJ$3%K^&'S1=D3J(81/=
M8Z 8TT.\QEOA)X@?1/?&@^M\3XDEPKB5IF5.:MLT<J[-D@D<4ORUY)GF<$I_
M)'IF LSA.VQ3'_A,Q]QS 10+%(2*06Q[JILT(?3;4>N(_1VNR_Z.$,6VQM97
MC)E'JYC8X>)@G]9J_7S(X,/P[*DC':43%5/]B;S?8@QDN",Z\#%K(F0RB49'
M*,+7?]G,8BN^N30(,OPX>[OH.9#9'+=/HFIY [N2V"V9>L2G512*[BCZ!%@M
M@$5\7PG&\,(664H^5.Y\YM'<)/$LU_Q#MV>$O7<]93>L7;P2S[#\I=%ST7UJ
MVG!^GYHVW&L$TE_?]%=K,IOP+_A><*L[3V2;RI#>EGG.DD Q2(!BT&A0+-P2
M*28H6B=9U4*;7N""'=C;AK].DD-3DC^5["QPCEH4U4E*G: ^.5B??-,=4P]<
M[XWR- ,>):]I-&M)X:-!D>2%(7FD^1QH'GY]4[Z=W=R%5.^C6!>*QFM%Y%]<
MVW9? (Y@HA-%-UUF3BGNHS*Z^ZZD'./,RKH=J1OLT-/W+4WEI,6>28TLW7E3
M/&)0Q)J*KORTP558U3/^U?7]*Q)</][KK_M7-JZPGBOK65\W8W6],:BX4T+G
MF@!S\P'W &-;]WWK$8B5P?71<R>*/C^9XM*C 3P29U,L=CA *WR?STM12#@P
MY40I4/*L8A>#4,3MR3!::Y%CM/8*ELE0 5M?77# WG;EJ1'SLWTXP1O +P F
M-I795#%G'&44L+#.R8*F*!' JT22)/"]IX+1,+B8HMP$0(8'@>E)HQP6@.K)
MTVUEJGL!E9M4ICU:#O";!:_ZD1CP-R%@'Z&^]K*- ^]VV)E %N"?'U&4@^;A
M(<'5SNH;0A;AF!(]]-Z612#0UQ(&S ,!!4 -&/M%?_/GPG'L+5@QW*Z*1&N'
M[C@1>]9Z'56)?AQ_//IU%>EHG9/V()$$X!L].>UG[#5\>?ZZ[1H_W@/->\'R
M=]A[A$KYZ&M)EE<8S\/I=&7L4<7XC\ U@/F8Z0EL=495-+#1/W_5MR/.HZRP
M_N"D9P%E+AM?X28]OA=]%K@+5^RPEU:;<.6)S!4DQFRU"F%"YQ 'KUJKK8'-
MU.L=H5[9J%<N_A@I-[^/;K^-SBZ^WU^>C;XJEU?GW^_N;R\O[I2OE]\N[R_.
M46WO"=ZSZZN[ZZ^7YR,*Q+M[^.?;Q=7]G7+]13D;W?VN?/EZ_><=0G=/Z+[[
M?G)WHIC@2.F>#T:0$KH<_O'V9D[*\-[/SN%+E)\*Y7OD00XN&(L,>X27WVV.
M>R2^,W]W,=K1/V4]&4M!C,0592MJ"Y+?VOBK-,MNN*%PG5G+S.QM@TVK"C9"
M<IL3_$F?D?RN%2SKUUE:#:@32,GY[4B;D_7*FI)D40(M5 BRKIE,1KPR#8Z#
M;Q)<*PG_371/ ?N2F,NW^.W7QKL%9II./.UZT,[R)8\YTDB^Z]0/]-H005\5
MZ =E2\:HR3Q8E'!1X.(T[L_?QDQ*&3(Q?KI'C5OU $7$S<N5FFC;X0@;,V)*
MV@!=]+-RN#YY>S=KT_W)J[/ (GICUU/BZ0&-3=,TT+,56,3_D!4IVGJ,QE+_
M_*Y"=>O3AS-U]FK5WX%)!%KZD.$$<IX8@5GYTL7IA[I*_BL21*GO=[;K^\>E
M"U$V?^J0R4=[#)V^\=Q'*Z"5%%M5TA8P";J5^_3]Q$3D$L0*Q5IN?1JB83]=
M79__-3AJJ]5"[ N+_51)5 $W;W3[[4*QCUY225Y22:5/YG]F?L#*:WAY&E"M
M8=E$<4!W4YU-7Z6_&[H_5J:>^VS1\/##&ZV,\U@)W**?U%0/:4,KN !VK^R6
M/D*XUA!&!VM7I7$YF>J61Z4W+? ZQ&IZ<EWSQ;)M=;G>X! #S':=I_>V]4R+
MTGV?L+;6^-<QL4UJS"@^F#BE:X]#=$(^4X5'% QS%)Z- >ND *=QC;UXJO9R
MOS.S5*DI!>X.</G6>GK]?MXW/B'N<G38UK6=J*?MO(=TEZ1+T4VKP$T[IW,A
M#(NW'#$5.J'=6?]E+U3D?E6O0)-0&3GF* &34K6HIO9Z?93$92"P,%7:7@Z;
M*8C!(C!8B$+5U$$W_\ G.J?RJ4J:=#3&=+ ,+:IWYW4=<__3MO0'RV8U'C76
MG1M2%9>.06^N)>>$_WOIQ#4P9_K4"H"KRM2A;54;Y._-E)NWD@V3Q2C3P3#_
MB +B<2T>BU*I[0[F$E'S;N^DAE.EHG$7^BLHV ,BR6K8"4?SCU1OSQP#4*2#
M6H>EE:GK6RS_V#P='I!G_4,$;CXYY9X"&VP?,,*_1V!B0UQ"(%53BW2*NJ J
MS!9<9S0<Y'TO*V)V6\P66T,TZ.0?RRI'ZZ,^SU6?L^&N[Q_ $C79/"OB^,V.
M-]_1:9F?*3S.$N H-]3<SK^TMQ92-T?,%11CUA!SA6.N&$>XMVSJY)D;0#>X
M5FJ3S;94 .>3.GNF6\P7C:-7H[BE\DSWQU]L]R6>[5FN\BR@,Z(!(OA09!:C
M3]M8^[1/D/E@9!;K?&J=8L,*Z'Q*HD5OB4]TSQBSP*])GHGM3EFAL^70-A2#
M^,W5KA%L1HYY/H?,I7/#X5*J3AV@2BT-@SDITO\2SS5!W-/##]I:^^.*&>AY
M@ :Q640KZ-HP0U?.,JAF^ZI74;OENR?=<H[YM0*6\TRBYDRJ!MF+M%F&=OO0
MUAHEV5I32T6X+IG"FZV_ %#N ";7CU\!(E\I0%B!OP_<>!D#L-Q:)JW8N@EY
MY6C!Z"PH<HMU:=5@LQ@%6>QLE!4*,AK:MS12.(>6W:2Z.YRN#E "!]V(#+#)
M&O"8Z\W.!=P6O\NV=[HLOES#&5&'J$/4I5&'L<):COJ\6C/-)C7_L]+QG]5'
M&0%.-"EP$T+I\]MWGQ:N9>0.2FZV;&LXLJ *?!;C7?6[R^X5=EZ6@<Y"W*NV
MVBUVH@@Z6&CJH96.J$/428^Z#:(<+[C "R[0Z\W)Z^71=KS@0LS1ET4K,1PN
MBA N^BC_/WM?VMPVDFS[5Q"^2]@1E*Y66^Z^,Q%JV>[1/+OE9\DS\3YU@$!1
M1!L$V"A ,OO7O]QJ 0A*I,5-$B+NG;8D$J@E*RN7DR>[<.DC@5;^HC(U2*(D
M3(,$.Z;!O8"V1JJBDHKW _5="'2(G%5%50'7Q5_PM[((8X4DX2JYP6:OSP^"
M:7+;D5*QQNRV6\QS6<OS[+VLWX>\N'2K=X6+]\6MW9JCID=[JZUB>FIQMM7O
M]*JX[(Y..C+"[=KH%?'SO%E!L42']7RJU[X1<0<CU09'.DW1[D%/G]T=[S7S
ML3H!06RG6?PI+/'L3RX&G\+BFZ*.]T8?K)NZO5/R&]S3U=S=AT?+!PYWFSK_
MIJ[DGCYY.UTB]3CH [H+>+D7<%6 $:GYVAT7"#DJ)[T /I0QOYWZLTJH=.@)
M7[GW-= +)V1T7.6G$:Q&H3[+.GW&58*#_=ZLT5HOV^,5=-IXTC4 2]O/U5RT
MQP<=>]V&]G,E=^SKX^5W4UF -F"Q>^-'K]JYG.;N0O[!"[E9;)D3C4^]M'*Q
M^WBA_7I 'G6N]SSD;I]S(LNH&F/U8K5+F_$.2H9(3+B0;+UFP+)OC7D#80O?
M+3\J>TM^P[.0M171Z'>BUHG:NC@CEET3^R/"MMDX1NN PY<P3AJL_,]>9V#]
M !5B"_1LB1;579NT;*NJ[5U+MZS:)[2<2*FX;Q_RP@^:TCY9A. J"[OFX8 [
M6#:#S?S+O-(=7/8-N/8);)$(KKB[P?%ZK*].!!^S"*Z8"7/9$:T?W,'UU]O]
MH"FVSF.S%F-BZ^N.'G9NM[5"R8QH.Q3>>C1V)VJ=J'6BUHG:@D; )F,S3S/Q
MM8VE@ZV$.?<'=;IDV1*BRC_$ ;*62,Y=J8O7RX8Q;C@%\-1S%RN6LE45NAQN
M+!_;R=E6RMFJ^F"_GF8T>B""]P?VJPO$=(&8SF7IO.-.U#I1ZT3MF8K:/49
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MLP+7117<HOI<%Z%*>_#Z:T7EP+=).0P2,*!TU0?]F(3T#JI.TCH'*PM?Q9$
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M*B(ZDG4(*47I*%(^&A-]#$SM%@:ZD^;Y-R(&,=02\-\XD2KJC *[!?%KI,E
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M-:7$.$6, HZP%A-%CK!IEC61)N2-:#)5]6"?3V SEZHWK,E4Z%M[A-#>6?Y
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M[3\4DK)O@'SY"TQ#^EN>65CTG,A=[/=*G_@*__C]Z^6[%Z#CHF04IOIO+W;
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MZ5B63;:;A:3R@3IXQL1BL6HT0@F0F,X,#\=_,6:K^/=(GI\-TDJ9"B@3)\*
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MN0FG-Z\(<(3G'JX2J?[:]5:U#DALF%HF3=R&O''C:"0P75ZP?<AA2B/E\%L
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M"'0*6K.6GM[1*OHIK@K,LF,FL@G7H^P[B-O*1QM^7WBT;TY:APO*^1(K8FP
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M0RX0J"W'W:O1,NCW\*]R<BXX)LUM""Z*<VFU\1OUX+@8<#,"_NNJU^P!S0G
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M?954+B9;7>[6SI(83/08P0!H4IA)>PY"#SYPC8FFT& TP*P?CU/#A'GWA&V
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M^CNB_V%H!0G-_"ZD8%G^TM7.9]AO F" LS)PT]%'UBD*89/(B/GDR2H<;".
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M1S*=0.5(>RBFP(%%TVE-J?ODB:4I &TVQT\2A[4JDDI!HAF[))XC'!(.:YR
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M?4L+Z+O>I/\J2;M LAOW:JUV/2@PH&JB?\HPA^%HF<CYHIA!8H"&:]B>)2:
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M/^IDG(_SI1".G?+%]BA%Y.M0V 8[F7*)D!3&\OL1;'3+/1-[+,O?RUDZ3]7
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M/#!%XE^?__I?+G'.OUW?7+[['-B]J>D<B42-CS$[C[O1/"$TN !96W,/QG]
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MW+Y""'YVOP+\,OJXBDF*U(?)E,CF2<N6HUX_6Z->/RL,]>-QP:@GE;*]-T-
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MN<(+LZXS[&K_A L2V^/(-C&SU*0^.>44/X2CS0QLX<$/#?]RV9RQ!_YPY $
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MN3W_X!CVGLA3;O%]K/*;S-RCND<BUMW1'X6(5?&*1XKJ--)8^\ \3YNM7!=
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M90[;7TDD8EA3K^_!\G6]J)L.46*Z^;T)$G94.N! 'F3;F;,9I!B/G0[<R^W
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M%U]OJ]C>9^]HW3*S2'V'0Q\4?<,)5+*'-)G[OQ8"-PZ'< X/8"W@E&5V3"^
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M32.6=.=3^$A#='"T30?IZF*849^6#:4<9#]63A*Y0<QWBW'?IGY"&\GINO$
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MV]>/VZJ1]Y-!F#XP:XVLM%!!42@SUSXG=PYFOES&N-& HX9E)58CEV(EOGI
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MCZSXT7'#P?]_6+Q$!Y\LM*Q\0T_ZFT.^:0X/:L(SF\.P7L<\*V&?_PO*A_^
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M3B$<A/,V!#D9-[1NPBOTIQZ5<9"!!4?(2'7Y(PD=<;3&(&I",4C,B*QRAFS
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MS#(U/:]'2P#GNX-P*1&HGZO&2:<>Z%I/=)N1<YX),F[$<= O4!X]:1@IAV?
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MXU%I.AB8/LDHCW7&@5T!I&./4FCMT'_4$ S6E$@JYY'1U7%]!O#W*[6/[A;
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M>G,2BI2ZY<F]^99S_)C&?YT^8.B0TVY:BW)FC2?PJ$I(G .D 2D6-0PYCF]
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M;9 UQN!VP*J9VZC1DUT5,6K_WK[$B-',$KAY S]7FXZ\S8ZQS2ZVFGNZ+B3
M=KDZX^_D-1A_<YEW&U(*F7%W?/D"C+O;C$,"F5VFF%=Y=N*&S?"/'X&4-IQ/
MG@M/#M:\! >E$%/@X>L>LK%GI[M@GKB3"MMR4O54L.,Z4CO*G!K%4M<<68OA
MVT!;8UJ1*3K6'+O@,#DU*<#*$7.:5G&-8]E?QV?RB!70<.#Y34P 84H!C#/A
M?[:*,C##'Z/-0/7Z/=VFI62WK+SA1CA*CF!8LJ26G<D1N*QA29E+)&!J#@_W
M%9%$4'P'4YH3<LC& "&A+F>P*XPXDS^N-N/H1D4#5%MDFRPH65&KV%45H^Q&
M2<J>''7+E;-<U!S.=5%+7?%0LRN_F@6J6[=OK"[A?)&ZA(NZ=7LEYMUNI5Z=
M?YP7-XLF,-KPHTC]D?:\+D-T#6J0U_W4C@I6I9^%?F#.,)QFE"Y%X_+IW_-&
M/B]]+232=-N[B$#*-XB%'3=R-=EZ,+'T7S,&?Z%(G-DE=<DWC0C=I=CC#BG(
MBLT]#AOL(Z 3EX_<\QW T[/;-,++/S+B&L?]356_1,9)F34\1FX6+TD-D+8+
M/A/VM0Q<7S>S)4C7=W()L7<PM346FAC)+5"/5B2_#+M(=RELCKGI,A2CBEB:
M;O+2A$0$8<;(5PIW9]UF_7$A1VTGH\O.BS7U>7K3W$V*S]-RK&]N-6Z<:V*I
MU2_%G<O1WLT$%?8\]2R35$P]G_Y^3.GFDZ\A_'UR3'^O*EA[VIJ8>MY\L-8^
M^Y:=M2MKUJ[FG;7Y6=Y:TV.VFR>BWY,#]=FAX<UHD&)5T4ES#B=AMZ/#.:YA
MCA#K8.$HA6,5F?ML)N$<B$ZS&^79O5V+)DTZ8&:\/-893D=<5L]'AP7FA$VL
M5>KJBN55[X)>6*S6XR?;/#P?O%[84]%PW9%J<%+"+K*1,J<-/A+G#KM0JM@P
M\O0F4O)8R,1\(UN8M<GQY*IJ-NM<YY:>D3(U1KRXEUE-&O$U\BK2)"-GHZ;:
MI;%N:/ZRQ;78^RVD@N3#31!W)GVH1EQ3>@#>)WK -MSK+ZB[S2!!5S8GIJGR
MLNS?2>2]V0I66?]2J@=W7WFH'E[YB+,\LBQOL./C313"OJ<_[P<><M_#&#^"
M?0Y2R,8E7X:4O9]4\A1&WW)7''1#W]?,>;HR]LW-F_N/IORU6+FE][Q>358/
MTA"3J\^,@4^K:AYF>1$Y/; 56:[V0S0VEA2??M.0[7->XC/MX''E%R8\=)=Y
MVLZ%SO#24SW70#XTOILM-4C/?&MGA; *T:HXHU7):*N#?$ZLBK@:YU7>@:M)
M^=:R7W.>JI'OC\C<"/]_-/*,=YCM"KWF)KLGXZ-5SGZX4PNM'58\IFQ_3#S6
M_.JVVGHIBJ](M9+5<J+O9.;)E 7"EA'_ON3 [[%!<D]NOY6^!%$*L.,\<OP;
MPKJLN'3NC@;W88H*)"@![/\']1:HXLK,^/I5+:75&:V=3T%R$A[.LS!>LSS3
M60G/H1YA'U7B'(R\\ ',#?<_6,]*?6GM#^BZH4K0!\*DO-FY[C?5<W5X2KH$
M-P02R$:E82&%!>Z#29E&5&.1M<S%K='(G>*\1]AT,0+ 89:&=#?GHX$:%L>-
MZ0C&."N:I=&:(MO*D<UAOU5@%]<H-&*TR,)ETR$K0(V@<S27.8?EC%1UWK:Z
M;%B5#Q-!E??,=:%!B&C01\.L)@)?GOL!F'/IT>VR(6M#$ZLOK^($+YAUO%@:
MKC@I^8]($=,<6LHF=(L90G*D-EVW<+2*[C!(%TV\J@6CHLIG:)I?>79<DRG&
MA1:$G-=^: ?)\I-8PED:)&CN +_45E\%AL&(G7!EFNAQ-9V#C9*P)W>R^!],
MV)@-:V<>-IWK?"0G9UWG+/Q"X&\KRFUB''!"HN99D0R-*339F7F"530=A5!5
MJRVAJN.OH>9-;LTD<)\W5'72O"B%JM8P#VN88!,JJL9T[L9BHLRM9#WG#=B>
M'9?1M?NQGA(4SM.MYS5+.1(HC<C^8U4A6$'!O47(;D@M;@3KONP\&+6=*]1L
ME\^2>K5G'(*;6:;RZ;HVE>&LX'@]OA1UW*;235;'[=6A]R_W5!WOZ_'ZO/6<
M.Q]ZLI'CM?HLW..@SO8*3+-.9Y4<#OGR!N<3>7:N<[ON N*#(7K$"::-!N->
M%'8'/M@Q/75HXJ+%2/C[$&$IS@>W@T2C843TE1\^W&0==^D"NX/NLD$8G:E;
M*LHBXYX>99E=:+&QE9D>\$$+U$3)JVM(=)5PK ILA9(>PJBXQEU);\41]D8;
M>@%&/$UOQ5(@_X2CQXSJ =OWR?4H]EW5F;$"8[.I":Q =4RGS-Q.#>9RE94+
M'54R]45'L,4GU?$5.((MQJ#,)CA;!H-26QXKL3RJE_/X0@R/,S \+N9M'#FW
M7U]1-;L?RUD)]J*#)'\$<&LBX]T7W/G]]O VIGOEE-EY!4JIB*HGU;V97FIO
MILNZC*TN8]MXE=3.5CI1*=JJCK)%?ULH@5L59;/='XIN-J6@KA:2+93#66]1
M]V9:3V^FW>RZM&#=H:,ET9G3]%GX=O/'+V>(X3.W?#:VRJ$O/((9;SC]:14_
MGF0E+5SF>;%(F>?E(@NS#FNV*H)K00&O&I7Q0^?&@U\Y'Z0(;U($]7H(/]:Q
M-Z2UEEY!&LP3:IYK@6<B -]@J0AL_%;!/1'M7.QK.SM0ZA8 L@SJF4[;2P,V
MK(8-"9%BR&]"D!1DR@4'LHL(/CU1]RJ(O9$;K9EJL#$]<'JGD[<2RS3XX/S2
M:?I?BT>XC/#GR2CBG3+$M%Q.$%&KB-1@I9K.YUQERP2&24J9VO;Q2H%\958<
M&J]5EI&?0F[3K*MC\V_6#>&<@J479'BI,$2+[6%^*V1\F02CYGG'Q9LAJ:9Y
M4)&KT(5=^8  -01HP[H\8!^;;C@T:#G8!V7*0%FNCK) E 3WSXB\^4$GQS:H
MO("$0_F/4BDF*(W#8I"6\4@!M(#G9Y-9(TZQ(06U<.>TB_-EK5["RT;0^2)B
MNQR,W\RF-*CH@#8768MQ1;Q]_AI4/>YB[%-"V:TK"].TPE#V:2GVZ3R[4G!S
M4U_@$2TR&DMN9.9FVZ&T[P9=GV7\T+ML[G.54^>:/?;?R!X['*G$,S7^']WH
M&W8(O&9$63(V>=6;C]>F7 F40<J9/^UYX3*&G3^4%$<>N%DS#=CP?8^QQW!1
MA]*&>M7MQU]WDT.4%PV ADM,VT*+$\WH;E/4ID'RO_X[5W-Y#29,X'SL?E/!
M?SS$-2<><^OKPLNN]7 X&61H:A+=L1.GHQ%H"1A7ZWC(7+-M_(,SUR'LE1BK
M I#83B56CX-_TTE!1/>BP1EJ3G<H%/CE4,XPY7JJ!4S-ISO2X&8=1PI3/V$&
MI0\;+(8]F<7"H1@4GB;RXZH#(LYG6RLR?>CH,MJ]Q-G0BQTW:S-&"8P)@E&!
MNV_E.'ZM5R9:AA%O?S1\[^U;WF4OK/I]4UP'2]KA?G&):70'QA'89&F,1'HR
MF=G<4?L !2:$%#"R>LH_ZVWD]A.D&W1]V \W8%BF?M;"3^Y93%/S2F*14[$H
M[$H7&I">IM-1:7L13T8!A&N1AI6Y[H)T]9Q_*JP,[:+A+89BHTI4K2Z@3W Z
M($&*&@9>?UQQ'P1[C$(THCW>IBC]PU$89XTX<45@4GZ"*X6^&E/N44\W#Y&$
M>Z'L% 9.@B@3)>)5K8ZTXBENCTDBWI!:BABK@C'QC\TC<7ND"/(G#A%3/!'&
M>$5/"N_T%!=:$[*?8VQN:\)$QYC7@_NAG>Q&7FR>#/LQUK42NH;B443'#<:@
M-F Y>&JS.4263-V!=2S5)=EM#$TFVFG1_G4<VBRVR>+H$<7Y+HW"D8)U@_,%
M+5<4039XNUS6Z04,*&-;R)0A%KADX*^8G0DVRS2'$ &HQ%_R@D>DR7E@-?HT
M4.3STAV'[EB\F4Y*UKS3"Q'= J(!/_?L/J$?492QL/2^"Q('7V(B6/FPP7M\
M8^SC3&79((/*9?#O:1,\ [88?9O,W*H*Y%A94D4V<W/W^?K_WGUZMQG;VZS(
M.]BH, M=YQI.6U-6-<)7&BLW6LHLOPE'[G<X@B>9Y:>667ZZ.BSD))832?EO
MW71](W&48AV]A:/**^:V\3!C!<<^*D_+Q1/XH%@-D8+SE5@!1A.C">(O5K>)
M6C/?;M8WUJXG==Z,XR3TO>ZZ\8V!ZGB/H1_ZU?A&,[\6"_#2-;SZL'I>K:E=
MTK8D]I'1?]50QUQ+#K);*I&=R&=2PG#.ADEN:'GG9#7)]+$=HM(%H:89L1?E
M$) Q-J&$*="%FVY&:!:! 1_1AYGQQED=%94U_88F8\51EKDZ>6IUWEY9Y=A%
M1>583IT7@Q=EYIZ3$E4/BW:S KFUH@1OZW*"]L]#$^",V9.4[R^XC0.:P=O,
MPB+_'[:-U8OZB^7!?@8UH[O <" #_[4YZ_A\UXQC[@(52QLF=B,>LIGURC-K
M*=*"DX/19#VEQ(0 'X?:@L8@XRA'195%$:KTPM9MHNUY*Z8[ 4?B;(8'6JY?
M[Z\="I'912\91AY<E%&H G 0S;JPI8"61*)#%O^"8\CK*A.\>WOW+Q.\NS;G
MU%M/VMUBHRKRD\-NRD=W1C1D.S_%<%%>(FH(X^N ,%[5$,:-0QB=&>+Y0_Z*
M58$89SVV!J@MG:5A!"0M\F1*_F4>(.A#+4>E_5JO\39 B,XDC?1,.OX%H6WS
MG(C.XC"KRT5@5E<_5,S"JD_8D?@$5B[,F%DZ,E%(> V'X$IVQ2@F_TUG"D.,
M6760GYZ"^OIW)5Q/.R,P-# 4Y"SL.7^DX-GKF.B,IE88NTJC@"+'G,KJ(E\Z
M1=*Z;.IU!_3.#\[7932$XO666>$WCB@,X</P_3 8._<#)'2E)*U%.M]T[F%4
MG\+FZJ-X*[]A^_BH&QVUT;VW1/S@7?-MT_GL-@\Y8&/-+5.KQ9FX4'/VKC?2
M ".7F&I'7N1VQS)KFNZ7+&<M7KTH?2@7^F+@AU.S 6+UOF/FJBO$P&&78H(@
M3^&08G69.6YX]8T5'_;[*L P$XP&!F"RGSJ7: \C%_;['+F/+N:1O  [%D0=
M=^C^1XU@NN"?/G;KA7^'/OSK71+V8,V[SL'M%QK+NR^'#>>]GX8P]V'@]<#3
MN $#;KAZ.7AW1#=NR'K]HGR>C3N8/5RF0^3OC/K@K ;Y<<(7G]P>AEXQP3<,
MX4W"(8R4?_XU[$3N< QCJ**8O=3;-UM[C-9BBX.'U,,L,'<XX U)R3RTUSC\
M#?.&?>5P!<&O&RNB<NO >B <!Z%93>>_!YY0AR(  I.$<&4:D/D'%Z-3CL$R
M[&!!5+VPBIAYY- 37(JQIP;+WZ,G::Q PJUFYY)N(+%(_9XDHC#!J&A\;H^:
M'&"VU^TFNK6M#,=$LSII[$T%I@:\+BK.2=8P#!3E[+-F$4S1VG$CVEODNXIF
M!.^VGQ)2;$"):8<RTZ!;06,.3:2@;*6\Y""!T#5<-C0P4;Q_5YIP6)&;1VQT
M,20EH@,"X.T[-W2=]O"IWV6<NH'A%=3'TGO7!RFX8? A:/?&A&" '0;@<P^#
M$39)J955.KZBAI6/UO/RXS$"E@M!V1K,1JE0FL$<UODPTXRDA@H>W =6UQRL
MT.I5 YY(ZQZ!_J6'FMP%3)CKP<]H%#[&Z5-XO* ER4QP*:?;I^G+>GO@/D\[
M0R^1,\*<E1I^4)QO#->;S5CD9LP0 9A+UK!LPA(TLKW5L& !L$A]Y>%L:&-F
MY'LNKA(")#PYM:>;_S6'REHB=ZZ)W64[]4:P.]W4ZB?T"THZ)G">$97+\D',
M#YU+2N4M-POKT$#]7P#GG&FLH-8YDJU!S%.!N-V5D0O0%$D[0'J?X-9C'D8>
MM$X39?.P\"MUZ>RALR*.%2>896/A\1 9E95_)P/GHYWLR$ZV[)X9@>BOJ%PR
M[M+*@@BW!X<_B)1^F9AR5C;PF<CPGQ28!/BE>LI#%@/KYS1H?J^&!GA;W-@,
M +QL3)[8TRL]#B(;^YS"7(7.%Z\;&G89VZ.X 8TR[( WD3&-V^T5BB#MR@8"
MPH.3O6%IQ23!STUU8P$\ZB/A6(,:AR'<^$"Z&Z U!;-T*)HQKGI='C/:4&X@
M]J]9_(E#UH NLUDFCK-1D!YS#L!EY>.B2,]K82J+LD83D(?MMVQDIVS.">];
M!9YOP*:#H1EH8YC Y4%*P&J80".)1D91%%04>9Q)Q_&>G;*/4['FXNK00<O(
M03?6B4X. Q&:S79X9#=-.)9ADF&-HK'@O6E#V_<WBX- I^^J9[R?R'O \[KC
M]61[:'>HE_E#]OK$ [06BTM3 7O-+8VUX0S6!863J8=%,ALYN"O/:R.# ^M[
MZZLH#?.;A\>=<QO[,,8X:_[&H-U<Z[?R1LW. E O)="%W?'!2+H>KM&KY)>6
M6\W99P3U9DG '7J@I9(5C*T9NN71874JTLU;X)1"OP]+FF,ZKS#@(6!O P[)
M!JYK770/'8.?F*#:@U[I&&.K)HB1"A]'G B,#S$7.17E!7^D 1W"^/*>ZC>P
MCN4A!)^(29@UFA5^W%$#U^_C(NA7UH_M6?E2&%\&(K>& <\MML;CKV-R#6$X
M%"VR9C$#A&C41I25'>7#!E,ZW\P50](9P-R'']]^T.G 0A639M?BA<UJBF!M
MM>HIW@D<32PWRYU7>J&U7JM4A;9R*^*P43.CZ,MNX^"7F3_>5=BK(/(>\_ T
M0@<)&%*PZ#)5=FH;X;6^_Z3,\< W%F8SZ4!A)H#P1KC:7H_ 3R#74>KS!I43
M5U+AJ#9U<Y*PB'0GX'>[!2(14V]*Q"\WGC-O904.YS1J ?4=%2"+4D>)]L '
M5+ZMGICB@E8!BK?A)60]N<)<^43;6*:\"3'<S,))9JE=<(2";+IF5&[ ?-^,
M''8IIQB>@6[$CIP%"![M::UG<^I*7YE9)]-OOV[<9+:CR&B([?VGBX?9;*A2
M]+;?;6P&,4.R6*>N*S 1S]R97F7"9^NF71!M^VG%G2N(SC=)LB,#F@X?3U&V
MBBR$J^P^<-Y,TJR(9IB4OMD9.,-B6;U]QS,L$U X/:Y2=_G_K![2X"R/:9B8
M0JQ!#36H80] #9-ID>H5JB$)JX(D7"T"26@=;P*3L"5Q(?^\Y!9S9DY\X2F!
MUD;%A7EOV5"<5#1>U!'-990*.V,L"$)88?77K8XTZ+:1%HN%&]L1(L,2(A%9
M4VT1\TW!M,5M94*UA>+E,SNJQP.<HSGE,\99C!T7_793.$XQLP>:%"L&>Z[=
M>GT_R\^P+%^K2#(?]:]R%4V3-*RRA&L^8V4B!2 &GN_VE#\:\%68!]!V^A"S
MW:7EFN2*3C/;=?#+<H--W:SQZI3'4>.N2?@1V41IWG3/-/D]W*_+-\ Q4G0&
M%R"M#.R>5$Y]#@]T6IQ^ @YXS#5@"K>RV;?G/E[+W.FIF#<J50X2E.DESK*R
M079FK?"K]9+RYE;797L2<GU-72Y!T/%,*ZE2Y%1HZ6?_TXTB+]9B1W"O[VX\
MI<_JU#*Y*7-8BN'.4:-'8]'NLY&VN:8;?-2($"7$C81$$^4HKW:*J0MVX&(/
M2MM3CS?@JN<B'/IM>@K!1+HF/FL[8<)W[CB,Q _7"H?F%^M*E!OYNAINMU+7
MF\:$@+ [%G7$U,PR92-T2MG +<)^'Y.D,+-OPCA!+,-'6 JW.TBQ9"W6->_Y
MK+-%BY4CB.K!QC:GU@C^)-0<=BA."'&007CRN6:[@Y6.-#]ON"8(5'E83:N@
MM3=E_IXF(Y@ER[7.U;8"5M <_=OK?J.J?+2R4VTA6*EK!(C03V54;#)-P]Y8
M"0\XZ)O.;<+[G1%_6?),L"?,2=/1! ?PI"(:Y:/J>82FTJ'1R>O7"5%Z$,F'
M>PBM((TOY80'LY8AIT_/IJ&PECL3@C@':D'F,=K[C&&A2C1M1U9G3G(VZA#>
M0579E5<YD)[6[V76LMPIE_4<F=(J^G7I%9N?Z]RHEI@+!HV]8@,QS.;"NE;P
MRV%O15$Z2A!1B@E,Q=)L.O+<?,ZHHTSZ]/[=3897N/L7*W^K<%;03CW.**I\
M]DZ@6\K(ED?EY)C %:ST$;%)&.L-)#=6789690R3ICS.&B!J"'/4X^ B19 :
MWF'$'6+MCPQ?!18PYMJE^2WS(K'BP.05CH83J]J!(.'E7+Z*AEK%R%WB@3?2
MNZU'MQ2H#8S4(#+,1L9C&T=#''^YYCLTR^H[G.D9FZ!E-!FS-.O/F[\QZK*^
M8.'U85Y8.'PZ-D$V*5^:/.P^S),##Z;1X%$.2XB4/(A."SN^*3S-I I>KV%N
M/'U+YTA9^$H;8V17:>N)P^R<S3M09'!LV;E/^_[X0XLW<WK0I*[F+C/1C;S0
MZ\5VW?8&4XR3R[+O";\J8-M3A(#060F;_*1Q?'P\+6-81)R$](I"NL!M[-'"
MZ&B5D\]2L8B"=>-[C"JQLMUY5%P!5V.@3 UFW\H00%V/L:#:OVH8Q(I4(]@X
M!CA[@RY=A&.4$9>3Z7;?:SWT?"+4^*A$A62 543D!W,]L( 4.3Y6T(4?PS@I
M6E9EO@PKL$E4(>Y,2,2G,"H[7G<#+S3J'D$++))P8FG:)', ,+@H\[1Y3":B
M8/NGV4#!GF#00%C@G=5 D?Q;$.=3U2C@&'P*Y9&D38E PYR%FBZJZJ=\*3H%
M1%]E.Y6:/4H/K4 :2T=6YJJCED9A 5-]Y4EF.+./J$!"IYDMVBHZ5/ [M 6(
MP=AELC5XW@W2I&&H":PW]R%T'I&]..JEX"G3!G$^-#\W'<+K-1M[4I'4.CWJ
M/AX=GYZ<M_(U29^P)NG6]YLLC/3N] ?'-)"]%534^PAM<%BJ%S$9JY_=2YK=
MB[.KUM'-ES<5YPW/\PU,$J*@&!Q#$B>L/#H4C#!^.]#-=EP<#M&WB;RXYVE>
M0L)Y@:T :^<%(8;9=%BKD8OH-#@ZA$57H!<"MZ$#0[\F[H#YEY *B<&$>'D^
M"LR[MJ@K"U$D1 $&#[Z^&H\60S.4 =1S=XS'<:*&W +49BJ"3<M%3=9N9>I8
M.1PG +9U@,I0P0IJID]8KR1S=1L6Y((X?H)>9:BJAF/L1:)I.3C&,C]NE;=Y
M#>BH 1TU7," ,FHX1@W'V"8<HW6\$!ZCM0D\AD38P?BP<F'><(24M5&!Y"KG
MUB,M-8<V[&3K]<W7V_^S9K)%HHY_]^GKW9?K]3Y)>"PM6P_3CVSP:6MO4H)(
MYP0E-I*K+\G8MXFP\^KL&&.F,3F@&/_'XG$+U/_,.$1#ZMYIN&C)%AZ!T_@4
MA<%#/P6_5[E8?<[OY F3Z'DN#-1P DY'8O$_/$JRJY$J^OA3/'S>1N]3BE)@
MQ*E1(,B\J(@\<;WA=8 I7>1$=0ZR\C8CDJ$IC;(RV(=91HM,:KR'TW<IG$'%
M0(_*#T><=QD*W;[Q!.(4,W"4V$-B= S'(2]ZG,8C^!B7 >G)&>M>6&4=HB<J
M="IR0!9LV4-6(Y(<DXK0K^OE@_D-'9WK&I)?H@EHP0'&MQ*BA"$ENGS#S T.
M<1;$DKHD%!S%[K/.*MERA=D#+TE9)@M9J4+R@3+78=]+*'ZFT!S2^2Q>W%(]
M1U]5I;80?@5^E/AV5MA-MI=Q@8;*Y:!YWP"P/(Z"XX)$\E:<Z(K9'PN[Q/O-
M(478;/!ZL:[@X97(E!=G!GCY<%]F8)EN>6SH.:(,##5EN;2@8=\N],'A,] (
M]^$!J6HQ )CE,0T#ON9;T3"DB=O?Z?-FX95<>:0@"(,C);3DHE[-&&\#.Q:H
M8U*-W&)%RI1J_Q%ZDIS245S3,X%J<5!M9/[LKG!;[$D)_G6'LEP920*'KU%/
MX!K8Q4^Z  Q#)K(04J3H!52$U7#2P(<M@4S\R2@DDJ6L*LNTI[G[[?;M4>L*
MW#_L">%U=Z4T:@\AX1FKR94DF3G9RXG$NV^^.X"QVO'\ LN N:1$E'! EC6%
M^>6:!DA#$S5LT_GH?5/./U-T5!KEGUJ_<1[CJC@JW"II8B254L.RY!,XK-/X
MZ,%U1W_+\EP9>_7U$*.WU]PZY6M(\<;/X)6/B]T*SK(F8O"W-!'[G>V([,8?
M*6<?1TGVT0VHINOO7KPJ*NS+LPE,V,N(@6F*4$CW]SSF5](D)ZATW9Z%;<DQ
MJ2 .EK(65IJ&[;8PAQ*$W=-35'!IDRW!5@X#[HN'^67LD@-CQ^ZTJ#MX4+E^
M1YE0-OBQ7<ZR(6^ 6!P-/"=<,1!TK2C=GIHEV,["D;:7);]!E=<=BJJ FJ&J
M0#2*&EGW%S!V-"=4+XNFZE-6>D/]F<*(.1>($M-T?@$K(Q (@^\*'8F%ILLE
MN'+C?_34$_%=X;&5!G;T6!BIN,"4$0N(#X=-AJVQT@0,5R5@Q3[9MM9ML_>Q
M7D(CLB*P<4*DP!K+N^)\#+W &Z9#/0QM5F !)EJ%/!:\ UF1E=.+!?'4]XA0
M&F0.76?+!YH#SN*HAX#17@9U. 5W1)*%UL7X(';9)7W:E*1A!9OP:SL:BO"L
MMN&[$$"12]T(W1(W/J$TGD+;HIJ:Y>2L*.X1S:?&(A0)_1']]&N$&<^[@(6[
MX=RD8]#Q#PSJN4^'0R_A;)K'$#U,#S>=7PT.!2$Y!O:7C;AAM=726#@]?H-K
MIK<2:QJ\ Y?9!-E#81722<$O"K!W-\P='!U^B%UKG(,X[: B0F-8FL@=-IQO
M8-8&^@SL$(DD'C:(J:2?K=?]%[X+])[\E#3&K*,OC.-LCXS?LOG[V?5ZO^$=
M)K7FN;1:\URNZ@!K3SK K%8.X&&"'8A4B6[WS]23MDSH1N7#/5C0C_$ >?M/
M6%3N=>W>%3,/_;=6Z.@SX<,*L]$Z_KUM^H>:OQ<[^JWI.(*#X6^]-,+V[6 Y
M__ /"XJF)T;>XQ^HT ?*'^F]1ZA13LAK"4:O5X7H\6%4@)L"$MS8N(P"@<4]
M-T!,MR#S6&>S!I\L0//-(;SH@#]8P]RM2.IF-!!IR.')!'.!L\QT?"+XSUW_
M%LP9,'LHN+SVB>&'VG-S;*;FN"R!,#U& OMA&I6;V(JHQ$OOL$PZ=GFO+0 V
MGFHB%,_LDH&P2_;!,C[#-5>\9(W^\K:%':@J4B5EAH>-^\6(%NBO+L6OY(![
M &]S1+TW#2N7=A))RQ&LS$)LY/$<7^%?:),J0>=2R1$A@1EC_X2F@F7Z]",0
MZR>L=SI [2BVIODT8^=!-RF[V",&)CC+39B#;! 7S(ON $82#]%2X*BT[?$@
MB>1PE(A_H[X5F"89\)+O)T7A6T' B#6C6Y2/&=IG8. 6Y=@H1%\)0[%@S/0\
M#?LX\)JJ:6,3+=BAX!R-^7>(-XY4V,\,,FR'J.= VV#$:JLG8 &+2M;;]JB,
M;0,"@,@9.QK/FY05^!J]_@GJZ),1GNR62QQA5W.V&F^?3#C".G,93J3&W6V8
M2@O/UU05#MXS*O"2K<3@_JHFLBR5E"+3HFD;0W$F9!NU@E8L1O/;W[-ZJ2TO
M*<L?^1N5F56%W1'1BR=6T#O*($7N0?L,:W#-_QP?+IGEW_G17M.6$@9JB>S;
M!Y^&&M#)%ZB'D-KA6CZ^X+.%&MG@T?5IPP>PN9L;8(P2SAKT>!RO<#$'!CI<
M'^>#L625OG33B#"/V5.M"IC"4^SHH2& MYA],S-" FZZVZ0\(PNNZ3(W-PNO
MJ8Q>7EX6$WE#1H%B\E#>:I;=0BV*]6MVW)@9[QA^3A#RE$*W,+1_AD^8@VG@
MG7'ZLI_I<$TIB\D1R=RHTQ&",1 92C7$>6)\69@.E1HK+$;BEL<3F+5S&3VD
MK4AQB<*HV!'/KECTD4V_@MF^D=4R2HTT&S2H)4B>S$\H=!,&1^8#BX!C DD_
MNM/R!MSF'N<XA[&(% ,A.*X4(S4XLJA2&DO2\L);+K*.QU'?#Y_BYO0V7GN/
MLBT]_WMQD-\+-ZE!NG.#=-LUQ+:&V-80T!IB6T-L=P]BVUH(8MNNVMTKRE/.
M-VU[@C^ZQQ:[%!2B?AG7H\CS)=EYH3G.\L0LAI9%>%7LIKTYJN$IS"=X,5:#
M%2M:=7&8J<7/=]BIZ!Y2[MYK8**- LI9]PZC?*/2X$#&PQGN%BNY:XAHK"YW
M%9PTT]_YCM]9.P55U.:&)0HOJF2HL9P_<V/DL3O*0*<8H^QJKA%"BH$'7U6U
M+8VM)?J997 )-^H\:72F]MNHZ W)4'JQ2?%$0GG4B4*WIPH.!M<"Y]"ZAB'?
M'DL863QQQ _!'2N87H>N!3<@Y J\C$P!55\4^I@A1P(>8FF1GD.W5LNSRI6L
M:#-MYI[15OF&TY8*5M$C48 <?/J?M^_O#PG?HN<A,(TACIZ8:^;/U*..B+)T
MVLNQX,34<6 D[KE%%";=PL"]32/A&U)#+T6^H?>&SL+-C@0N'T:WD:<,SA(4
M-_CTG\KE;*:FE:?7Q=&C#SJ0;SWCQ". QH /<.#N-\64<2@7V%O"8:+W&WU]
M0Q/WY.('@_!I+E?;(BP!%]JXSX<<;W!YRMB9K6CICBBJP".X$\*.!2A?B%[:
M3 (3FI/88&DW5Q]*4&#^%:P?R*' [N&QB2> ^-RP:+DSJH1,]XP,@0R1I4ER
M!S=A1I8P@7HAUC6\.AO!H'R$E0ONV8.W>PK^'WMOVMRV<O2/OK]5]SN@E'.>
MOY2B:(*[;,=5M"PG2GF[DGR>F_O&!9$C"3D0P "@EGSZVSTSV B !(EM $XJ
M1Y:X (/IGM[[U^MKL58N1EM\ );@66A&B(\$0.);W)4.QA+@CEOFO<6ZA&,[
MOT9NO@06LHG,\A.QK+0A2CG"Q5ZM;Z0M.SJK(\#&6^?14.4I%JW;H<Q7"!7,
M!]UCN3 $Z:18!6G#I4A0AL9OBT&EV[6&$7I.;>\JP"7IH'<2=B:[P8;@A ^P
M(I *HD'/Q&!$&4SNF+)"%%>36Y?P 5HGY_4](9X5!V>+MD!1')#H7(L-2'CG
M\)QX9B*CB$#!P/O4NHR *ID1R-UP7)LBO%CV(U4A:,?9GD&%<RLXNJ,5#K?2
M9<9.00(69E8<O_  I7!6_;OI8L\8/ *6 L"ZKH.="]@B,A!G#=AT$$;Y-8@6
MFOS&MAB$.4_C;9K@16N%L0\-2V6CPT7"0T,B\=T0E6^)^XQ #U$(8L8W0[IY
ML9%KJ0._$@=R[4O:^!RGT*KY&,I'/J.)PXR:?&P35:21!_;:A+!%#7N>&.P7
MPH81Q1OFS6JW[RF*K!7 4-,)QQYL:!20%+;]#OB,C<@#"^]1^].?,DKIP: 3
MX6*/NH,49K?QH@ETU?[N\.(W+TSOI.TRNF"(A<%:IO2@]ZFCL+&BV!;6"6/7
M!6.C+ADRF<+P/@.?:\(^Q8U,Y$E>/[&C6.!)B@@F4Y#&20#<]2"# V">C7C!
M>QS:KO*1<WCH<>E=_<(?AL[&)DN&6B1#CU:8O/(=Z##]Z"!XT]'@ Z_)Q.0-
M>' E[$<R'<\*6+,;=']<<Q+$F-?Y$A42D798G^GA(59HB,QMRP>[7)ET]!YV
M3W(CA[JN)$!5H2X7A5FQBF^HXW*7#Q3B@I5K6FYF!P_C>;:,6<&_P<(=W<<>
M#)18-C$>PX7NA4']&!]&E$[V2_/*(=;YR_HH08.?AD:7I?0DW[&F%+]7Q _9
M5+KS',?,LD-X/GZ[K&>HLDEBSQ3YW(,!HUU1H>'16G@':9P$>X [:Q7\/HS=
M76V/R@3"NEAV(L#X?3[KG6%!AB=9]_N=2$$!<HX/ EG],R6>&.J"V PDG09J
M0BH+6Y]08Z+0Y3._D34I+JK#,(M9[1^R  /3YV,*(OHX$7U3MZ-(3Y>.K1%#
MYR,@;K(?J7"3+X?[_,IN2)MM\!@Q:IQ'H$@I#/MRB=VV?F@G^.P5P:@1(AWB
M863'+7PID(\.,=8&[_IPPD'U9*B,U%KB+BWXN&"^)WH(/_AK,,"!U@]NU<2T
M2"QBI=_ FF9/P%)K:I/.$\7]Y?B0<=W,"(R:F1)]1X$I1KRAVEXE/_K)S[H_
M]E+;:DG1YJ/,[M76 9W;#):8D<(C$='AL-B>=P^&012TO%7U'*TOR,B%?#:0
M!1FR($,6#,B"#%F0(5Y!1G^G@HQ!%9AGU^SFGI-\?'OB>6K7T=C=Q<N<)DWI
M2 ?XB'HV8,%&G -PM3)*<(/4WNWIB)>G1N''HC%49H1%@R041(@!1WE1U87B
M%>4^ZPYO5[&YFY,47XWVL5._0!TQER,TTTN=^B9C>+A25C-N4\B4QDEO7T/1
M21ZN9$%*FC)-C%(&>2L6!WJ$6])C"-M"NQ9,EO ^__YC]O]^_W;1H:T6F)Z^
M?:4!5UX=X@=<UP8ZB#YW)CKN"C=.?P2FPVWV'CDT-,/?'6<UGR/XAQ>6<8#(
M0#KM%C:$%:7K='.?".TD8/466& =N  T%!2>8A^:<!2?\Q.$B",E!Z$Q*,F>
M1S&AY7"LAP?+EUB*_@B/; =)1\^C]3P9+>IOKZ5!&.85%VET'@'WLJ-A9^1Y
M/_'%=H=M9QAQNZO,0F$'SYW6-CID<7<ZEMA:\Z9C8]C@P5])T/3H>W9A])?=
M/'#&%>O4+L!K/$"G/2'  H(3)U:$JEI\;]H'KM,<?UB0PSI3O/@^[<'QQ/'Z
M> ^?2W1&F5 %@$GNP1+$4\Y9=_XG(HE1^*#UTA3*!*'V2*YBKT 0:*%VC82/
M>4,&_\[26(%P EE'$1J#0J%P7=\7?6'!MCR6#0H:%@Y>'5YXO(\?=^3U%;02
M,4ZND'!8WSHO?DR/"35$?H8?VJ^)P@$G'@:K?ZSHT,+3._TEI3(G?'+7B@=!
M"(=U!#^Y@68]MY8:;2Y.GW@7.>&7YEKZ*C*NS&1%:#X23EH,,,"E8H%)?R>7
MH?D?; =QH2F\E\Q4SY:_!YHWR2 H]4J]7V3GPAN:D.'%BU3#F@GGPV>5KO('
M3YIYXW:CRHE'62,Z)\:TG2 QXL&=A'51:$]\=%R/=:)Y;IH\>F2CQ=!G.O\Q
M"[>IQ0:E^=8!5E/J7OXU&5B)*C:J%MF#^"9&&G]%ZYG'7DY$EASMJ*4NS"?=
MMKPQ2U\1=\%VQ*@XJBL"@^(.6RM=A+6[=?2%CD"\K$ 36?F532L)ZD])9 ]#
M J>#U^%<S^N4O;'=@;R*C]F\7J'[ Z]3V,"@09.]W6'>!7,K+-NK?L5/6XAC
M@<Y8!_T(BV;9#-US"^X\J$&*E&<&HP#I,CU++EKPS6U=>!P?RA $!M'XI- '
M[;\@*NB@F:!@FU<J8)7P"A\'901XMB0 J?T:Z6=='ZG$Q1"%_7 MVHJ@VTR/
ML,I>:@U%[OZ,YB<=>4>S7K1TVZ63%770+91HI]8S2BW0+>QYW0>/FJC#L8,9
M(Z8, H4_8NH34A_/]]0T?E%J/'B;1_BC$(UC'NHNK=:ASM\K_F83_?%VA9VR
ME+Q.  N(DOF)3T<+^(2"2=.6 (XQ&AV0M@)K/A0%P1WV1+L'Z8L=Y6LT<7BY
M<!*_)S,NCG9$LY.Z#5IP(&*TC,R(8X](H2*QU(QSH4]."DW.:!@,$0M3DP+F
M$:;R74;64W9K^C7^672-=39"SEZ'QPW=UB,O34"C9;1>PW8'HL)@>\E.!D9"
M@A?K'[XZ,X#:&*<(3C=+KKD4F#+@9ZYZ.US*^--1=1M,8,[.':_"-P8&W4DZ
MH6B V-YPY&#PJF/YM3K>T&TN, H/M]%3=;I:AD8+, G):YG\G? ,#YO<H:/O
M\.TQ>,T+MIOPUAD?2,'["K='Z;$-P2U0^U/[D_"6 (ZKZI6TT9E2M!5"\TI(
MPVP5("($9'MB9^T>F1MA^ET%[2,?R1&Y^1V3#%B#3__FL3+']1<=D=DE#,%+
MV/ TX<[1_RU7>24NDQ0!PD''UPU<Y*T74@+7(-?Z0]J#?<*@!T-,B%P19W#S
MW><GGP?_'$HFDQY[#E]O&33.X0T%8+X"K0[$O>QX)(<3S"< O+(2=_9YW<.[
M#=!>O8#,PHH@ =N$]G!XWF9 =823A7/%(3S+IA+C$"KC:,L1E;\HFA[9Q-Z.
M)]B8:@+M:%-QQYI&+/X'8VSO$8S7).FRUII#<!#MG!GV,>^+N_V>*(ZF_WT+
MA]HT'5Z&^\SZIF US,#A!@&+(,.!H2=C@PA'Z<;U /=SF7'DR2>$)Z.5.KA>
M?Z[W,>+P4IP>QGBR*.$ BA*&LBA!U**$,FH29,J\@)*$/.>-ES-$CECDIR10
M]34-XI<T[%'1,-A G8:KO/ <&:_%!UT)AL.%O[&&ZS48K@3 K1,_:<--51JE
M\9U&OU,DS?CO\.[HUU#0AA;?VS:?WJN%6ER)^:#1U',0B?(&1V&"DT_W"F]J
M_-$9/X P6*PUG<K0[_:J8FK;IX=\#R;B^WV]15'UT%$\#RGHRZ4GYIQ0> <Z
M-41;DI6KSQTVYJY#D088O(8_^,$OX+EE&1BX))O9B"*;+!\P3L;F/&'SCY^)
M]-X*'.10<@PNA>>YXQ5DV%[8@$8UX)B%PB+^?!'>?\%3SB$H$.XV_[R>L=Z#
MT*)HBA$N\(R^,,^],%R*.;;:L V;)51V1[NFN,?'-L6__JV7#7+79UC@7GC[
M?.I_GNZ<'<*7B)8!D1<LD''"E4348PV0)"G:@[,^1S#X.'"1<G[Y[?^975Z5
MG/8[!BD'MUL]:K<G?O ],KR 8 #?6C[ X\T5D+2P!S@_$%Q3WG9S<1&%W0[M
M-B6U'Y-AX7 ,>KK[C<.XINU]V0=B_+H(K?TB6#J#J5TY>*OHG<#E_OCZ#?4*
M^7X76D"Q@PZV3CK0/*>?QW\8T\*>HSY[@GN8?ID$?(<XKF42A(MYI>SEM2UM
MEAK\4+%!DSYKTY W@H/<4F5KD_N5P=HV64J4#XNYN$A$;E".&TA7(*1CN[YU
M^G>"Q0AP;:!ED617$U"=%4YQ9O%<K'!R;C/WD*W=QW\N?3<W;687-(7?@?9(
MT_C1-KQP1[])*V'7D".FGN;E?<&@;1"AR^M[]?K83(;0Q$&G>(<C;W1-ZSO$
M$7MS.(*>L/5: GU]Z!]%_$!<H>:"PF:/=T.;6.GYU3$NB==(@VG"183J<'*A
MGVY SEV/9B8BFWL'X!*3QN1&>_GD%TZAU_41HT$IO-_O!;S?[QV!'IN#Q00&
MI>T=E^0B<^:ZC<?3PJS"3+9\0TSW;]]O+A1UP-UY1A;%U5Z(\W:')H5Q;H=^
M7&"+0BK77?,S@5.#\$$_TC!JP(N()P[6V,Q<?(;7P1ZC<<9<C/GA__Z_WM/Y
M&^#\&L82<QOF/1T6A'_S)V5CA#A@/&TIIT_LG68:L'VG1"*Z.5B$W0'AZ UM
MZ<#+WF_^6Q$"L$?PX\JA*+1.P=K?*MJ3I2_XYQ9KD=5AFHT;"L+14&O!$%P;
MSYJV)L;<173M>RPX'CHN.:*HX+.<>H%]$]6LT12AP\7,,0+8GR@LF8%)SXVR
MAY()?MCX T]45!IASM)^2\?SX'Z]^%M#%Q.,8<"]8L_>F+:K744(6R03(30_
MD2I3O/3'^KRM3>1?2RNF2Y,,PB1TK>#==1$RGM! 6.R4;I PC#Z1;VW]M3&7
MI6<@OHU90FC46,DJP5.6J7 .#-)]]!!X?+M-EF:Y2NQ:P%/ 1N;?CM2 R],N
MS-F._1D:NG+<ZR@]-FHE^A%/KX9T(W^'WNFM0C,A$060F$LL5V?]"\%+&)Y+
MU-,9J)W=M%EF.AXRH_4/E<_0ABV)GR2YRB"7>B;)U21R3=LIK7=FG2*4?<W4
M/*9M;K]A'(X'+IV3O:A;%"&9.Y9*225Q&MUQOS?L*/W!E ZC.]E&;W2&E:AI
MGI;>/:6U;&4[PI&D.;UC1M>X&F?WAT91-_UYM!S5W>NQ#3=*["<9 L\B]4AM
MX[[?=KA;0H%Q^!C24CG<[8T)$!8!P.3$9]MZY$5$L)W?_0J2M=@<<;SH7,8H
M7#$YBK/A)):DR+=7NZM825]_=*F7^CHK+ >%X]PD?46@;R2U65C&MM/KETKA
M\I2U5,,%E[::IT+IW)W%1,:#>USXR>7)L.(5+_;+P&N;)71G,(K/9,][@D]J
M$-)M(7@.39R%X&IGVBO>Z)($ST'P_55S%H(/.F,,BI1(\!0ES=5)//&4=J?L
MZBJBF&M@O;3FLO HZ,AX:!XR8S4MRQ<6+5L+N"7K\VC",A_1*EOV%L,N^5F$
M,?<E=25U)76+I6X3HJ[-T3\E!"2*MWJ^ZB8"W;Q><JC0F;F(7N7B/RMX^RMQ
M'RQX!Y$Q:.]C/8[0L#/LC5MA%Q\B<Y3N-/7'(\D<366.<AVL?F=T5J[DD [6
M3M;. *R=A;7"DLY&66D[K?N C7!)7TE?2=]T-RLHX'\3:==)K\;/#X&E%H:!
ME=1AY)(G[6V\?\@W&2[81-2/Q"1WNBO;BEK95G0KVXI$:"N2'43-Z2"BA*Z]
MA6A<3J^/N)<]Y,X.V4(D6XADDX-L(9+DDBU$#267;"&2+41M:2$:R=KE#(XM
M;Q?*5:P\%BLKMSDI]YD!^*<$T)*2=)7V!8WCV&4UM8T<)E7+Z0922R@\EF3=
MA:SE- $-U-:W $DUF@&=>>7B[M:M2VMJ"]B<DJI&HV:J5NF7VPP@R5RZBLW4
M]3$5IU[MH,E<<G-/OZ659Z,\E6=Y&$ZV!XA>ER2I*ZDKJ2L.=9L0#6V._JFK
M0#]FY-3CGJCC=K@GHI.Q9/>C/Y%DK(2,Y;H7ZEFY7J1T+V1AO#1!)7TE?25]
M91:H%5F@<U:^?CBE%/R!*_.B-IEK4V'@-MM/PG)J)*8EY&TD"2NMAY@D3"]M
M1#V$+#ZL05_B($Y@W<6AU4MXSRU4]'&0,#2UB6&K1M&T=.P>=2P.PNWA4+7<
MR.141B9%BFS(Y&F;XU:2NI*ZDKJ"Q22;HUE$3Z+*DH96D%&6-+2#C+*DX8 <
M!YD2;;=Q605]15BB),SA'+SW&T$VLX)NYL?<+ QR,P41D>-U*#MZ-7L^4S7I
M%G68!WQD%$<]C (AIG V33NM;P-YC'B MQ0%'3Q XUE[==YY^(?O'WQ#(@(E
MZG'Z )<<RM:IHT%'\7Z<O#MZDXI^..CVIZ$3QQ;:'4\2ULI?#EY'8-53Q]5L
M-_X=^AY!($?O:V&<%H4"M<#3:<J#C6;=7UQK?O2!8K8JUIV"O76(Y?[^C9:P
MJ0GL&64E#S"Q.]*!-^/XGGR1-EL+!5^,9@CI2^DHH8EGHOBL94,@06\N_I@I
M/_XQN_HZ.[_X>7-Y/ONB7'[[]//ZYNKRXEKY<OGU\N;B4Q)6J-S>3$,U7;BN
M:^&AH*$NS24+Y;-N:N9<UPSEVH47Z.2#__G+M*_VWQWSSE2R.-FRZ6(BJ:(?
M.6>/0+MJ%7WQMR-$<KXF!J&^VB]U,ND-Q^,I\Q[IL\[<M0_-EN!G+OR/_E+]
MZI$HK+3GH%[/'\AB99#O=Q=W=WB)IV :Q15L\16!>\UU0Z>+J@%>.@88JVP%
MG$;(V/KPIK/!QHXWPL9.A,5W+>FR.>+)$LVSN7B#XJ)Y2D(U!,=3$DHB>&[Z
M0CJ72 3/_&9]SJX2-(.REM[*6MH,$RJ.<4S<B<("*L XP=B*7$6VD^QDVBN@
MZXF?V$2,S!RQZW[]5D0\-]M"$].&?.9F^7?/E6G=C>C9[Y#QLCGSM3G((_Q<
MQ^8-_93L>L#LVKPQI/NPJQ"=NNDVE78,:Z8+YS]ZTJ[:9B=@G'GE6O8K6E$*
M'!>TJHK >4TUJ9*IM)]9M?,-RC@S2??;O<LQ2WAZYG*\:)]JD0_O50.Y7-DD
M+)T&OG Z[6\62H-NT1U5N]#S]Z+5:#%L(SDR T=NMNXD1TJ.K)PC-QIP;>#(
MVHI7=[77]CQ%HMD;C>S;$?(!"ZOTJX +Q9'EDO\D_TG^D_R7G_]D0JV-@9^;
M!V+9A&ZTLK2M)]U!>QMLV09EU5H1MT;').+!I/34E1'\*2"1TE.+1F"1B90V
M,V39K;QG14^LD^S8:G8L-W,W.BMZ+J;,VPENOD6,LO!75'6T0]U^1W&(K=_M
M52D%A'*(<@Q<2'\[P92>^T VV'G*8@6_66_7&M]$C,%E)WR)CO .4="* P'B
MKJR:$(5DCX:N3+*' $2H965"!)@RF55^&P$S"WI^([)GF]!7HCUP&\V8S ^Z
M_ISK-DR""1.Q8 9PLST,F-*ME1LP2WYHV..HG%N/2\U\531SH>BNPXN0=,59
MW0(Q=<W6X;ZGRE<-OLS*E6Z9Y>\H\)X#MU/N;.M1L<EB-2<+OZ#) :,>' /O
MTV@%W=O:XYZQK6Q\$AA$)<>V2KELX>A040?N_$$S[\FE>6'"M\BBW@#6M#'A
MJYTX;[P/8I3DN4IB5,.A9#G)<M5"XPU$X+EZXU"9C=-=#+AJXU"#/>-0I9MQ
MWRSS-,E>ZV"4R5BAS:SH8-[I-FVC4/Y:H/&UB81%&V 5EU$4-$$G14!]MFS@
M(C,2)O^DW]T1-,=U$!L5#KBB<#"?8?44VF4P'O<PN3@8G]58/EDB68O6F*+R
MY7Z:<T_&+-=LBW&H"ARJ5M-%F$S>8LRYPV;02OFSC)ED,;;L'WT83*M)@K<I
MLM<*FZ^:TC$*VP%LKYRO,/9F+I1_6K>.,IN["J$=&F)'UG*F /([IP4OH*#1
MD&*NJK$1"#&W,X\G?S"D*S9XE&QAN.1)>_O3<;67.0A1D*'_!A&*<2(J0"L=
M:EI;B9*,#+792DBI0[+<!V(#Y\Z!$!K6)8$=L;0<G>)T<*Q;DQ1I0LCXT+Y^
M.+S T%3N";Q(TM!/RI[<.JS3FY%.=DU.=D;F*V=6NSKIB^%!2Y83D.5*,<-&
M1<\@*S9F4R)0P)[F5^FGI!KC0/A&V7R'4_1&V;Q/UWA9+?E/\I_D/\E_^?E/
M9GO:"!3@@VZA,1R,*LJ/$B!8)?4.7;#U5!>V<^!U^VM7V\%8C1O!+1FK(8S5
MM*'@!58^RZ"*B$Y%)?.3:_4JRI^T+-U:R8&2 R4'2@XL+K3RWI]+'WKNN4$T
MFV[I S[SB[_RM4E3>%TVHRT^&=X;_J?^OO;TF0;9]^,S T-FT=:!@R_K[]!%
M>0,'\TW!BM*'/C=2:)?YO%NG\;*9[;6-X\U:^,17.TR898MQL["93\>I'WWX
MZ_:#G/+-M!'@;$Y[V?&T9 EU:2H8$:'ERNAH=+P(5L(L.=ZT!K_<6];B63>,
M4/,:%C%%#D^2B[ KHYI!_QSGTPCJ@?N@N<I"7Q1V%O;)CG_'RJW9XM^KS;.0
M=HI ]7QWKA?QXDX=,D=/[AD.@$/,/?/Y&5>\DP>:><6FE>!WKKW@*@_:$U$T
M6!=(%F=IF;13$FOB6"%H-PS%M:8$WD3FGD<E>B2,'1L7OKV<,GS0(D/DPR>-
MH7<0/SX<3!!R*-P8/-'*<!7K#A[P"1G9?<4_[N#A+3O2&HJ?OB<(R[%\T.?*
MH_Y"SZG[NB3XC:5M+59SUT&=L% 6*]O[SBOHO@X<#-YZD[ 61]&62P-D%HI\
MUZKGY%(B!RL*U@OOFLH->=)HX>/D':P61"Q(].#3'?J@*'[F="L#0=3!#79M
MV!BV(;AC!KG7#,6!9S (%5;S!Z ;85T:6G 2<"N>-&-%CXFB&8;UK)ES^!S\
MM2"P.IL#J&@.7(R^[*SF#Y%G\WBS#L8K=$AM5?6P5 %U*+V!= :6Q"[HT8C1
M ?<;<6V22($UM"91_@U$=Q8ZDX9(71M$'U@+:5?4\5.L^#;\U0Z8,>X#-1\C
M_&&3.P./$O#5G.(8.!Z(X.W*@0=R'!1^9*XYR!WTB-[I()E ],(I9Q]UHJL$
MAD%Y81+OG.+WV,?"=P8U!X?1!;K#]NKP *\>]T<.2H+805!#W.) :(;LOIJH
MGG1&PA?-9&''>3YVB0(LX_<1?;*F8:_G#V2Q,LCWNT^<)T';SBA'SLS%%YU1
M'J3"#4K:&Y "'PUK_F=&&X& 2EVB]+!7'"!#-U=D,0/5BI>Z)I07+9/V. ['
MDSXS;J4=OZLU7NY [WEWMTQP@]R'W3:B)F'C'<V(,_,V01I6$%,(/TP_OY#K
M%R3D=A4;;)%,;&@KU_+.\@9!,HV9/57*D=#E@G?7I<=D2NM>8@<TA,&9$K,+
M?VOKK\5?-D>?V#1/FY@7L?3P'SVF52G3[AK$W725V+6 ^D!ODR4\M\13]P["
MQ2)XD2!<6$;/"8Y,KE2M?")S\GA+;+8U [6S7[W15MH=,G/U#Y6YT  MB9\D
MN<H@EWK6SN._,^L4H#%J)N8Q11+Y#<,%L,<&Q@A.]B)N0\N0&U-Z_,6"@P.,
M\)@8D3HV O?_I(,!GK>EU *+"_CBG[C15KG<-O29AAR]C25I4]&Z $1$<WB"
MS;#L5XQ<8P- 10 -XTK*!?-6TI;8JAP+M_J46(NMSISO9N&PG!_Z:ML;X3<6
MWTB>R\QS!8(O5 20GA>^L Y4HM3^**G#MNJP:^ ]S&PZQ'[R4N)^YKN"'K:B
M=5DSD,Y2A0K\XKW&&T6N.&EFYF(VG]LK$!M7Q%W9)GW%)U4EBD^=U#48I.Q^
MI/(5GF3,,K7C65V=<M+1.P E^2,R(W2]GJQ(-5F_VR<Z3-5^DND+TNPZ(%DU
M?N*@3B3\-ON)!\^DQ:G._K@G!I-*Q[)5.O/2=#7S7L>R(B\E\M?]$EG2H=P!
M9R D>4(%J'_G+3L@; *Z,,E4A29<G\<Q.<-!1KVQ"//7#M:=W'\#:V;+PG3?
M.EM.Z7RMR4"$Z:?2F6RK8CS7;/L5F/)9LQ>*80&WL[#K D<TTYX0^N<<3HM.
MM6:A:E,ZF!NG3\0,]S"UOE!B@;#ZY)/JFV7R>N<Z].A4!?N]HT[&8ECPTLUL
M/*N6IUO[J%O'4T%F5TIGLU4Z]8=M+6&C7SL*O&ZZ5(&2_ZST)<91I--9C]/I
M$>4'D@1$T85'D&IRE<-JBG2D=]DF_BMR6DHU<57I1AZFR@OUM<+WB%/5=##I
M),8M;^^%2TZ*2A3<J%_-C$+I]K6&^8K3;N.AV).9I"/73*WF5]I0*!V%/"X-
MZY40K\%"L6YA]RF,CRQ.+:L&,%G,Q"L8SJU'_)=2 \QKCFB.<:;SZD*B']2>
M *-ZI9O7<'XLT._K51.-EZ6H!ZD@*7RG=/5JL[9#\25*BF_$+2,'F&6*QTB0
MCC#I_S62(TL86*3V!6F,3=%_(HV68<JNRH$*HHY5D/,J!1JJT#IA+EFS+:Q9
M;ZBO8(B8$M2 C&+M9"S]W;:<4NKW,HUV[-0WW%'&K1K'@678ZIU^;?T7,E)U
M #.R_X@/7*"#"OKO=!,!1Y9\VL%\>ST\'1CRJ+W2&0BW1%FY<(+^2Q9Q+.O&
M>U+E=?$DW2]?K143:#Z=?<R':IJK.Z-AG040Q53Y">HTM9P+"\SV=,XF=89A
M&S9/60:]9&1!P,A"Z^2W9,VVL*8,>HD:],J+55IM,T0U-OFXFO:^ ^FY:0V'
M%6=O3U2!NVJDI2VB.;/33/M&VC,[/6'=!HVTM25S"LN<[TL=_^A-DU)_7WOZ
M3 -O^_$A5"%]M76"U<OZ.W11W@2K?!..XG'XG6=*'NXH6@J+M^TH-WDJ;#7I
M)ARC#6:BC1/$<7A69"B3-XSI5=$=>!3XTJNR6!&<^![,CF?@]X\6[/Q_:2AY
M?69V7$"\B8R'_D#_YI.:Z152Q[_F'W%=V(3K%!;BH\_RS*K?X9FJX1%UF$?*
MC9,FJ(=?2E&3-#6[O@WX6DBFW!*<' \RQ7C67AU??;Q_L->5!Q6#WJ$;X))#
M6D =#3J*]P.,DS>ILX,'W?XTI+[90KOC2<):^<O!ZSC$'-2'9KOQ[]#W".I!
M[VOAD7<*G7D'3Z<I#S8Z@W]QK3F<7:HIK#OE'#U(BJBM)6QJ GM&6<D;-MP=
MZ<";<8'(%VFSM;#1Q9$L.GTI7:PFGHGB!6M#)FO?7/PQ4W[\8W;U=79^\?/F
M\GSV1;G\]NGG]<W5Y<6U\N7RZ^7-Q:>D2=MR>S-L[S?+A>N"AH)#08TTV@#[
M63<U<ZYKAG+MP@L4)YJ751R?,\U#%B=;-EW,.>3OUY0GA1"[ ?ZX)@:AH9[9
M<@FBA2**#<?CZ2^5Q9SH,\_<+1_N'V6X __X!#XL3=@=3%AIPQ9EPX(!NH(S
MK6@V49P'Z]E4M#NXB&)[Y5"T,7YEVF1NW9M8!44MW%O>[8I:]#=EAX+$GZ$K
MP6M>UVPU*!)QI%TF%OCD6VJ1_U;NPTP+*P51X],>%/]!*&%B0]N5//9H,*6;
M[E.^2WD3I#M>:9[^1(S7[1Y0 2$2*6>SRMG=8ID9Y&WF/5K?HG79FB!:(X8U
M$"0B::G-4*.<U1TN:('=ESC]#D6N"^(792FYN^.UJ?=8H9VE0O59=Q_H]^\L
MK#^#52CD9:G;#*KD;:[#^1['*'M?/G7(_%2'LZ4O%L1\R_ZA$*N3P9#*!/7]
M&_P"/UVGE=QY1._<C]R96Z4IXMO+)8*4/J=(UV'TVADES<:4]2_\8N@K4:S;
M"W_O?Q!;MQ;?3?*52MZ5@W=-ONF+[A26IHSGP3U5\*X:7AA3B@QJX(4IO?.9
ML+QP\VQ5R@OC!"NG8F:8($D&/4X2KM-1@F&_.*'V99T4^F8%-*J4-.I$325-
M5T%KW"88+49Q?JL9H1:&6O;ITER .0L/7*TP4SN#!*A!;Y_XALR!$T.=&4PA
MFE9("RH8P,@64H^$T-]'8NQAZ_]Z_@![8Y#O=[%R<-BW4&G*Q]<KLK1LV*$E
M7I*&&]'M_XC1RC6"]-1?/4:,&RM<(45@KY9X9WM%-K3^#-<MS]U"YI%PC! Q
M<Y97\;%&Y]8C-9((\U!M<H>1$_H6M7_X,0'7E>#,)S"R\":I&0<Q(U$[NR1L
MD<PE86'EK4[*9+ROCS+-[Z*$KA:\N^Z8\":WF)\1*KE(J3@(?VOKK\5?-D?-
M[#1/R:Q7;\$9)DB@+-UWN]? ;+I*[%I ?=3MK/MS2S7(WB4$L?J#2 E!V-5,
MS,[L;-[L%*6/Q5;V:PO<2KM#9J[^H3)7$&HKG)\DN<H@EQ?.;-OQWYEU"M 8
M-1/S^&?WNJO\A@8F=SF<_0:B5=17D[6@?'OWC00;R,Q27\#-.(5O//)AL]PK
M371<]I,,N0O>B^FJ+F 6-84=J:0?:'Q6] #T/3;Q8.A67%YV,"T:PUB@GD8I
M5?>0JD803#LHT9JQ$^Z2[D$-'9=GA6,X[=%+>7#T*Q(_I'=6O*RMMU<Q5P=B
M ;PD//A!$R$-A#'&)'7KH&X3W.7F2*@=&OLE*(0H)DH#B"8RSH*T2D1O$V]D
M\W<[[!))WWR626I';FJQ2?X&7+6P#MRD B=/!P0U3BF]#5>687QF15\%U#7)
M6ORLM?C5)< 6W=W":DWNLQ*Q$?.G.8<=UK# 37M1EI:C>T7]\2;+\D%$BJPV
M'(M8;!AT4#!)Y*P>88EP4=:@@<;H$R(Y6'?*#7G2:#AZ\L[AO1JIC7$'6(28
M*IR]/GE@G[T[@-+E<F'UA[V-]8=)LKJ ^D-Q+WO(E6=J[U!KF?X%*D,A(.\7
M\?;1=M8XR9HY6>(HR55?B:,D5RGDFK936I=0D;I=V<N2U)I+4GNR>&H;2WWD
MG7":RQKC""R6=I*"XXHOO()AEZM>:BA6,FMS+JM.F!FUT^_'>[!K*D1M.]6*
MP]/I]"9%CQ.75$NAVJ1 J@V*+TD4KGA8ZK^M^N_2Y&"\>>RR8P_2]R0<(+6)
M0<$074M9VKIE4UT:C<YW%).XM:G7BLM9*1I"RJGWR/");^05<5:&"YO_V;8>
M?^#N<5@4[>6'MWD94X=%ST0>%#T1>?]"(1&)7ROMU;. ]L599NTPR]I)\&F(
MX(49=9.&-A9)#[I."R*D[WD>,T'CMT[9[V7D>WOF1([^.=NU*C3])M^@^)K2
MUDO[2LA=DG(?EBKL);WWIW<INEV-@^DU0K=+K5VHUO9LS[#6=N :!AM6P*%R
M-5JC]&#9M*>!PNG2ZB&,CFO+I0$4H,5?KN:N< X"O&SHC[JKM5/7;^D$29$&
MWE9'I<%UL-G_"WL-GX<W9L%F5ZSSBX> :)-3+P#AR]'^JBJC.:(3OA0S8%AN
MNY\P=D#6D("T%C99"]\1@CJO.L]*BKU$P&X7+_BR560& J%"B5%3\%^ L=Y"
M<5V>AZKN7DFLR &"&O#84H"(1;7ZNL)3]7GRS.^B.6W370IABQ)&EU>!I5+K
MY/+245<*'%PNN5!RH>1"R862"[=&"':$'R@K4+"="V6P8$M)/3$711;3"R6.
M=B@:SG=TJB@O+BZ=,)T6'54^0+._5;PE=IN(Y*Z&<Y?0[2Q[<I<,LS3(M:@$
M&JY6WZ)\$#GIXDH^E'PH^5#R83G!EO>9X#?;/2<W!26PH^  :8/"U6F*X0]4
M,35W99-.KN9(W9P;JP7A<'':?&ZOR )N[<(.ZYJA+(FI&7YYI8XP&<1Q<25;
MQE>G%PRP*1D_O O/S,4EO^R,W;Z2*( Z21^IWJGGX0IT0Q-&NG@/1PE9S_,5
MYP@-$NK$<YR"L*CSMXD6#,?PTA1D0ORIGM&=Q,?J*+ !2X*HDL1X95/?7<N%
MXZ/1>>UX(?_HX)>"4Q4;?@V[1X/DM.P92Y=YR3.]!)V2] PKT[ U&5]@9=+T
M..:!KBF<&RY>X!D=4FF=<+QH,'R@F1ZK^$'+J8L=I(NN7,J@),FP98O*:21)
M9X;P88<KT%.79]<P;\"["=) %IG08']&)$>>^T:E#EM 5[E>W8+4H,H;+ ;X
MP1!O;ZTG EL;MB\\5-N.HM\I 54[RK.U,A;PRF(U)U%\7,TT5R#5R-T=NRV]
MC@TRJDL_!R8GB#33<A7R@@M;NZ%OT- FS ?-O">TKD^_ _O9=-'  6.:KM<$
M-@$#37D$CGF %9*7.5FZOHSD,F];2TB'?MK0_R2&_F!9"[KMKO[($93 ,)T_
M*+JC+/0[6,+*<'%AP+# 0OA(F<!^!0*!1_M< J^+!;Q.)/!ZK<#K-R@1'(<X
M#A43$G"]A"U&R7^G&W#Q8(XGJ ]P3DU\27G2;-U:.<J_5[;N+/0YTP%48,-;
MKRB-4WKTN%JAKB?(> =TF[[0X7+T7LJE8VO$4!ZT)^P4G!/02 M8"5@@3!,$
M= =% $2Z9QJ"]OWW>[W)!A'?[D##I8G6QZ##MI>IT055EK MHU/<FS M@XWD
M:A8^R/9>CZO<I48INL6.] W&BQ=X8I.2.Z]Y_8NM"8<=\P6]?J5VV,K!>_JW
M]-_]!DN:O>C.+W@1,;+QX6\L?/KP]ZA5BUW1^-'"&MO5=!N^JWRSE+N5C9T4
M;":NHME$6:P(,CUMB<4-!5L%/N&PPA4X*N?<U+I?@:I$0CO<PGF&G40B*\N5
M[:S TN)?5;1[FU#S"2ZJX9"8A.N'."+$!O3(W1)B*OKCDIE@@0NKK18Z]7F]
MP^8H[Q&5U6/T4X?,3W40I/H"SM=;]H\ZF?0&DV$/<6Y[4[@AMH+CM\#.Q?./
M.Q!SEI>V]:0[3%)$CS+N+;*,#@8KV]P4ZRN__5;8#)\4'<_!:?-(H!V>J1H!
MI [SF&"3N!*/ZO64T#FM1EO?!O(8Z>>[)7!JT=(TGK57QU?G[Q_L-7.3&<>>
M,3# )8=:%-012%?OQ\F[HS>IUO^@VY^&0OILH=WQ)&&M_.7@=9S1= JZTW;C
MWZ'O$;1+O*^%C32%6FGP=)KR8*,T^XMKS=%<0O\!CNXYBEM0G._?: F;FL">
M45;RIH-T1SKP9MQBY8NTV5KHI)%HX2!]*=WN33P3Q5N^33%R+_Z8*3_^,;OZ
M.CN_^'ES>3[[HEQ^^_3S^N;J\N):^7+Y]?+FXE.2Z2NW-\/V?K/0,@5U>!Z.
MS7X&J\6<8X[DVH_2\@:HXW.F><CB9,NFBSDVZ/V:\E3TQ=^.<"C<-4']"Z_,
MEF"6+7ZATAZ.Q]-??6:@T6>>N5L^/#@JS]863M/=I-O*BNXX*SYB*F1;4;A2
M>!=CDYXMU/<BA@/\:]S!\)EA$/.>SKB"6YQ;CV KO?J1NB#6!N1SR!.Q@5'I
M_3RGZD%ST'X"UG8#VS_I9OZ"F&IDMX.%XA4_Z8YK@T<']P=[-?#)6 Z$+PJ^
M:.BP!'A@E]Y66Y#_ &<1XY59<!@SY9%8,&=U.$S@1SQ8S[ALL/X6\ _%@D&X
M @<8#<.3MT3!*)T-!_"0W3@D!CHBL(-4##F=@+J6R=PW2G:D#5X O&QOKY'@
M9]32YB;[_'5ND$X0%^5!02 3?!DG!]]3<<"(BXR"7QZ&OXS?LLQ["Y;?8;ZB
M9H9YVR9+R_;"PPS7YS;DN^OHE_;5KC);+"C[8A"[$XU!T[D)D4@ =48>$<H"
M7)'P:F M('ER\R(+&S]HF+M[C;$CBY;3-6CH#GE<B9X1.'9X_B+KO_/U1I#=
M.U@.]F-'X. I<T/3'T%8D3\]J0:6Z8HU:" O/8!1P&;ZH4N\U/2%YZ->FL +
M9ER^TC!''QB $02/"[(UI@_@7X?/1>5L")N"'\GCF'S5;#@YR,)>.F;&XU'(
M0K= 1EP_!@$<FF*^!W_=<=F)C:SN47N%O=3HRBA7P=/:] 1Y/K:?6$X)M%#4
MA@M^SB[][W^_\\,@/'>W'EJ9!"E:^+WHJHMA/'$?A#T.]1 DZ._U4.?%R@99
MEBG4R8N%$B*>ZE FM612*W]2ZTXFM6IU2#]JCN[P "NUR&1:JU2IG)R PH@T
MO/!O+'1 .P0M;1,> 3X?R72Q^#4O*Z#>-)9]_6>EVU[ ?0YBPS-Y4)*[',Q2
MUVYU0^=U8CX09I"8H;Y<DFU+C55<,"WH!!7-3%I88?B:^ ">^4L_@-4B:#%[
M&87PM;$N#:25[?CIO#O0WY;ML(?V3#:'A'511V'UI?CF4@-+!PP<^,YKA^HP
M:LT 398VX?D^+VE@:,\=;G7#'H,-@R4B]%W,4Z#C!U_K*A_)7%LY7K[Q?F7P
MJZQ1)GH3=EVZ%9Y#@Q31S0?"G1V_:J43?R(PS]!*?+(,M/?!6*6L  L#FH#W
M\0*D7]RS3\**-$;7NQ46ZBI FLVV?D$B+Z*^TWNSA^LXM'O(._I[4$B>6^VP
MZ^DN:()Y(I@[EB4CA\\"?%>P@W6#ABL2I>!A2:V?\%S,N=>#S0).A-N%,7&Y
MW^0=[F +\<0N5AC4P>)OV\(SY'ASTNG1\2JZL" 5WO)B6Q'12#..\.J]CC=#
MT8*&;;_W#L@&3C;(L0MV)G6'T'?4=ZP$X' ]X:\6*ZOG:4VV[VLU#C3A>F]K
M--F:L)5\#X&<'A/P;=<,^ @FV9_\[0Y5 "HNN&)_\K"/=7=';!Z4)"_D<4D%
M)/P?+DJ#?;<KEH"E2HAJ#65)T^-T]<\6Y2U/AW3 2<3@+ZVX8YZK8<V9T.4/
M2_SE=Y6?2XM&J=AM^(><%2R++87?EM7U!9^#B\\Y)^M.6/*#8EU:6)_(G"0&
M^4#_IAH7F!5K)&/'(H5+J6/&5B"%^-Y"? ;:<4%#&>.S('X#8LJE+W[1GJ48
M__ C5*F18<../?$:^B@_Z"<=C*SQTT'M0L)K*&Y?E6_ Y4&ALDH+E4&-XDPT
M[95^+WQ^Z"^:0TM)X."[#RP8A7%1_[['\"%:MO*@L>,>?#%RS)*D%SM:)RQN
MS&N;\;-1R1.1!&C@KAY7S#:^?>4=%%RI+;E>2RK'5E44%:@@71X #.X!#PY4
M!V,7M-V=;3TR">1U7\#BK)4+LA/%CF_'>UOFQZW7]F[]F>@EO;M@F#!"(@Q,
M.Y9/J4=0R&AC$U_Y@LUN@$U,!;''"6%UX1=2WX'(/Z7A'RZDX3[P8>1"'AX=
M=+WXXU.0"L*-H04W_/%XN-'_QH$JZ4_@U\'&A6KG*%?S30NJD5!MK1];CW2<
M?^'#6'S/K^+UW=%)A/!A%K;&?#-0@'HE_'XTZIVUMHXX/^#CF7IP?OG+'9_=
M6(%X >FR5@MW#OR@N^>:;;^"$'@&%Z?(NKC19)+>VP*[%SU5EKDF#K;W)7[B
M9XYMTC69KUBRX#N<#PU-"5J3B-<48M^F_KZ=;>Y]ZB9T_-UZ@?4?FLV-2]TO
MTL4VLK!<I7^RO8'? D8_91UN8!T:A"=E,,*,%B9<3'O2=,,3ZK<D_8I .^X&
MLXI *A!-*UUB>I&*5UG:UZB"AWRE?5-9VB=+^V3MF2SMDZ5]@I3V#78I[1L>
ME1(,R08VVKQ82') FTI];GX-W](L3.B#5RR82_E1?1=V,Z8RG+(Q*KY]J[S:
M-]86A61 ,Q8H\QKXR\..LEK2-)*BVS9YLAC1O!,!S[T@&(KPHRX8@ $C'XWW
MI(#*,QCI[!ZTV ?^8,X]OZ4?C \\'!H[\.(%7NCG!ZAZ8MM)H74, 6$IW-)R
MB%\RM82ETS2>H3V'@YN<S3KAWB':D1=)/M*PB!?#*0IY(UBX[X#@2KT^=1[!
MZ"I!CL-@)",LU.230'<H%5B8V-MZ?\-97:TZ#+(>8^H,;?8;+[R>=]^[OH*+
M71&0C7-P4Z@PG;F?R0(K;:]I.Z-EOT8^G-;$-@XUL8U##N5T'X?RUR?R1 QK
MB=_Y_RR3:.%O?;' OR7VXX^5/7_0'')N/0)E\:,?7\]AA?>PY.]WEZ#RO$^P
M:^[;6+?NW2[!_PN[MY??/OO^[6E_1W"/W_% :@B $@I\+0@B"FC<_0SMA8*;
MH<QH"JLEE!: *FI\/._O< X=\HS9]/5Z\,2C&*=1AV/O_%,#(\5^Y<%I&K6=
M=/!PUT:_R8T5_![0;S*0)S7@B4DW/J[S=^48VPUX&(IA?V#X7?.Z.0/=/!E0
M^L-!GMOZ+8;U89.>3Q@'>5%3ECMT_ 3G!NW'%.PMZBR"5=Y^A(JJ[7",JA-.
M'6HI7$;K:O\WJ$9FW<&H-K5[\MWTPHNI\Q*C(F#OCF7_@8/GW2O>N$[G?E8J
M]^.#V']7X#@#K4 YKY5K=WA*&IL!0FD@$ ,NR&\,\7G-RYR>UUCS T9/$ET=
M3E@F%VB^Y)$0^('-*4A;X"W@(^ >6HBO'(<P9D+IDHYR]3_:X_+=)UPU>5P:
MUBOE/_?!)@ZNW3EAK$/,?UNO?C\V@\59^#*,\F(5K"*2M*B?_9)$#+#/5B4O
MQO$M;!OBDPQ"ZK<+WHU"*Y)Y<'YN:([#TH840R[+8>OX!2,/-(<+%C]\E,I?
MD*?*/68:3>0T;'*(]EYPDRQ4[BC+)O8.%:#VPZVX(?,'TS*L>RRP#F?/LX0(
M)@,9(D@AQS7ZOMS$U!3L4@O5**UW9V#=-6HP[@U'>#U<4Z"AF\W/U/CWP.Y=
MK<4C4NFBT3ZU)5..-% 9/ZQI''&XM70W%$'N.:T$DD5\8Y9CZCYZ$C H8]R%
M"-ZW9]GOZ'T%\ZMFJ$!."8P=KYH M-3"0PGV:ZT[K.19 4FBO<W4\3/.': >
MRWZ?@OI]TC':^6=&V7N"M&Z[NW.JZK/VA3)"<+O8FNFXFRS,K[JI/ZX>0Z;E
M77 19A=F*R_QA45$5H3D2[90PQ7XRMB;.C,7(3]B9MOHB..O!7@31880DGS+
M.[_Z%XN./2)\N[S>$@]:W_AO)&-I3X/W_O++]5[E5Y.X7\6$D5>"=4Q=@!>*
MD&J\;J]$.[RMWQL1+C[9R2M\.T$+TXM6X'M/U,=ZQ_S<:GO^I-'0>J/A5AH-
M!1@-WTWBN8]W0'OKF7Y+GM:#/ZUG&4[K#FW_TL0OXK3.]C/J_]>R_P2=/I?6
M_,ZI(B8:G[T-5([#5OUV*GQ;X2-^O[N@F1M"'/Y+QG:'!E/">^(T:O2V$"-.
M#9[^@DT\H;WS_,]%R.Q\)S67U%P%:RYI9Q:BN12$E<#&FKFVQ.Q1*,>M1+UU
MS,(]@8Q@?:6^L-V$(/8'N_8YNW3@SV\>U5Z0>"W,M4YO*7NF*)BL%!)VB!9O
M^I.X:-*'QOVW";]83U*&JG!QQ-K6_H_()XIJ "E"W//U[US4/MREJ'UTU K)
MKV05_4H6V9_XH1V$_[R;<)F,WTUEV ,4_W^WK6?6B>]H%/'4#MG46(9N EV)
M#=3>4J@T8Y]BU\,BR$OS&J_XW:[%R2FN4"VI5,COCW\?&3:;NA\_$*\*SSR;
M!%+WUH0>%X=IO%VL;"#ZPB'FT0=6E\.'TJV-TEUZC^%#,^#G8@VV>"ZI@E,:
M 1TG7@'";/="@>TY?R><U@\E_A65X76S(7\=/JC7;ZRF8!)\&BD;WQ<9,6HC
M*MD*T>#HB,#MZ;0K]H7/MO6(O7#X(:RG.U\YL._$OGCA10@S"II&IT1F.QQ\
MK[:=D;VDQWH^["QC6[V:X"S?[I4*:^2V[8M&T.\FC-_D^W9RL&5)&:J%UJ$+
M$R%X4O5X^1T0:[PG9DURJ79'[D8(!H.FVU[Q(!"!@3EC2QT*> /=D!6#W\/*
MO]?M?4X"]#:M<49[J*C&HP>A&FL/&&6'BL#U,]YTBI6I@'+0+:DS#6>A!%A>
MK*5HK55%H0B$'FH-/92LTXB$*)C:@Y:SO:")),GLB,4!BGY']D=,%A!E/-R&
MQ;DT$\0;B4+ETEJH88C.K Y:B0[7IF!,P&9NA_%6M\NAH*]:IP7MJ$DX0":%
M4K833(_0;)C:>C C(S\+8\[:'F<:>IQIXQ\G*L"*B^'$AZ5N?^%W6BC*L0[X
M80@8&9UB;Y0\3ENYW83IVFX9@EKPAX8AZAC@?2*ZLP=+20%V'^E$*6;1QMMB
MM#EBVVO86D,!W[BXPJG<5R' ]N.KE<$GGLW@&PC,@+#I\.=GKAU8Y@GAYL]]
M/8&+]/I&$>'.)+;SH"_9&]>P"3S0!2N[X2MC]S_I*.K9=-RE-Z,0[8BOR$-B
MX2>@_:P.E9# IW..,PJWHT.H%AAP1YS\F8<0PBR%,!0]:Q=EO$;HL4/W+?1U
MCBN$<1?RPAJCN9=G)K8>A6;)A5::!X)C;9C'IDR\0(AZFU$ )<C>IF^?I8+L
M*0GT+PAF3\F/LY<ZKZ@I0'LB9%HE&%SA6'MR?^L VTN5!N*@[>U1F3"J?3@N
MN'@NH4]-N]N?;6VY#ZW-4VZJ\*V(S4[B/N?<GWYD^5E)0WMV>!F.;GNPZ>"O
M*-0VM%]1NL*K&$N9DP \!'9@A5.)&'98Y(86A7>F-JDW#3<RI$FQ5BY>C]M7
M'<7A8&O,X?4F9;!X$)WTY+<6TXB2YL2103KA2BQ\=4X#+,P^A><&%K#I$5C@
M-^DRNDD*6$(C;(9&H-;T#9T!1>&E))C!=W-MZ$&_[\%GT8'!N&$>^!*^@)MW
MON*<^4_KU@'/R%6.0Q-DX.\ 39"=">W1PJDN%!4G@+[O!.? NU-""HN>H_Q!
MBG/J+UV:%^Q9MJ-W^:&628&1YD%2FJ>0P/YNS[=3*&F7^OWXS-;?.]R;1:&<
M@-,VY64(CPQS4L-9U*>N3M-=H.*Q[&"I(:XEW1@ZBP@3@)[3"]]R3]%%5XAF
MF\#RC#.CZ%\QUY@RF_5LL@G.-&P0U@$''=_9NO^ZLQ,),#;#Q$!XCMA#M)IV
MX87=Z'&GY D/+V0L@K!PK\QEPJ*L:7CX(!U< N817")QB,N$8UY0%MM2@($)
M#A!Q,W.! @[DV?<[O()WQ/C9^N1E3+27+]X @FT3DS/)E[TG)B?D'_WJ95_L
M@CG#!TRR\']DXO@VV@,E0L,6@ADG4SYSA(TVI)$OJB(TX]6;/XISYNB8<_]/
M5!Q(5S;5$@ECAF<\X.1WT\DRJ*-\>FV4E_O2ZRQ]?DE'68;&.MVO=!88U1UG
M%4POHJ?D$T&H1 ]PX@9S_RO[E>^K-V,F.L//I[;'!V"84D@C;Z@H&V"IH-.5
M8:)&4EFD1YEKUYK_B0E.8CL7_UEAXA$\NT^Z,S<L6"=!_^8CADXR)@D(;.P2
MI;"](IOJLJF3-%+/S@J3I)G,XZ9XU]]O+A1UR%UG1I>DN<"RRTKX6GLAAWYK
M\:'?+2[>%_&$?V<S*U\5YT&SN?DT^W3M)![RIA5Q"^=#SZA)DV1V]GNLX+JG
MGG$+Z4%;K+7:;;9MKBD!OX-YXVIT..J&;KIXD0,C_UZ%N<4M*Y[=S[$LM1LW
M<E. B+SJ:VOM,# KBL\R7'^3AAMM;1&X-S?$.)T] 6-18T:Y\%*O2%C^$62I
M?UGVGVL?Z7C]@336Q ;]V0@NC%:;Y>@NWI?M9#"7$TYI$#ZA,\S]T")8X_!1
MC'JCH;ZV](KRNFK^Q*Y:5&97:G\1M?^MU/XU:_^O()HTK,-"F4QW&P])4-K$
M19VT!:J(IV,DG45(BCJ".P?U0A&>2.W&8S8^P=( 4,=X9 W_H[2XR;7B^M-5
M- S<ZU:H^20Y.' >W-2O0:4*%'M!G.]W['V,8*P9%V!8J),@+,-_!]M R?1$
M& Y1Q]0>9K%GG*3$8U+A(='XULJD8W2#,F^N\3-N'9V)1*^ @RO8#2,;-.CV
M^N-^K/N2VNI+8F>[3X<^04(-'<,F\'91>21HE^C.X_I<;M@2W')O$[(]G"?F
MBU0LU9S1HJ90S1 9'W9B900C<X/MY@8_C]EM,:>1[2_I)UE0E34/,]LP. ?>
MF: $"0829SL>VVWP45;HSUXWWC+A1YJ1=[N[%&%(BU):E!O-J+FT*&N6F%0^
MG;*L'^9XB.FPG!!\S)269!U[CH8,OHP-.@LZZY'&'JPEA_B_NOX)/W_0GS14
M0:LO" WV\ZMJV+A%LT,^JEL'KG2GST'==,#HL<F<%M+C]Q$* !2=9L:RZGX+
M@ 9?Q7($PG.RRY6-27WOXVS=.KWAL7;"Q*_FT@9WK 7!PJR.\FBY^A/KNZ Y
M+%RCUXI'S; 5*"OVYO$MO\C2MN!K+($UQZXO/I##L,S[4S1ME"?-6+%\)]5[
M/"6U_B"W8/$8L&(P<ZED\. O*)@"<=B3KZ_%,[5"3QJ^Q\'6$H G],^527A5
MT1GU@GH='E(#PPC_5+#U^Q3M?86EH4X_4L[T)]0H/X!I*/26QD>((I$B.>OP
M9GO3PUB\+$,(D][N/'2Z0H",'U^#C_S0Z,BO&7+C=W;$+EZ(/=<=E&P,83(A
M!-H;_^J?H?G5^W7S;-T\6"L'&/>&F/A8X9Y*_#MMY%."I989I#T.2A$%:0_A
MO#'?"&\='A#B"12%!(^;Z/DQB4//)1,ZU/?QJ89'[QZVUF6B@1*?TI:\+''>
M$SI6(7:94G89*<?D94Z6+CMCO+J3HATPT64% 6CFF6DL;7W"!(1IA0L*^'=6
M_DQ87 2['UT)Z^VBP&Y=D<YL0[PJ.._70*IP#H01,7KF1ZT_\V>_>@,\\Z/P
MF?^LW[DD][G/ZJ$-!]UX<4G])[^![6.QT,Q!]8[E$4.CGNP=D[UCM?4VE1N2
M:%K?F8C=9ZVD4,&=:[OWK[TD[/S+FFK+T&P65%!F@[_%C_Y2=^I(*SO$1G>G
M3G-XMK1U@V<!F4,S[J3;L8'%!-8O6&%8RDL%?+0LNB0#UQN2,//OQ)(/'#'H
MO_%I"<-?ZI3/.0Y^K\_D'0RZ<>B/+":O5QW-7L("&_N)[GN$4MD]%VP(9)ZH
M +Y(B83)'(.HT1/1,C@B=;OW58?D#*_]:N U^K5&)$U^J0/>7A/\7A_GC]-&
M).;/G-<@TE(F%%3#N:+(4P&X2AW&*V#K%J@BR=/"PJ7_9VUY_Z>@!DMZ[M)C
MWWF>9<!C+KSVO.SH^2@E>IZ<$(X-/MD%\8+[%SLX(_T2X3':P(J1_)S*VQ4B
ML?I^X?DYRE>W9 Y2,=05;D7,$K:0KO+3Y[0E54$"2/_Q+Y7CK8:S><]PJ=>J
M3(KI%MGOR>T2P_@5PF6(9T)OZO79QJ.(:VZ9M*Z#3\EB!NT5,] 6GRW[\PIG
M:&$E(%9QYFVJR>RBQ0%W<U4K<V8LJLXR;4+6KM?D1;DV>40((.U)TPW-0\&]
MHQN?I.6R2L%NO1;RH?JTEQR$0G/<4(O=DV8CLH1?V,2KH]C $X]JK" IG#V.
MU%"%RJ8HYT2KIJATI (1>\FNLW^1?X??EU83+6&Q-E^.9^"DU7-'*K5#>%?T
MVP<;V=B,0K"O;4!__($P">;]%0:5LZ&Q,S/_B7T/R_AU:^%1+&)SA]B%ZEX=
MN(.8"#EFO#(D%!7-]2$#.O$AYJF1CA<,%=3$[_8C=L5!ANO0+)_/7^O='=8M
M%NEY,"T4J999%?0RD=I#1,2E2T"7$9LG:(4NBTR$2N78,8G=)U*7QU:&&X_:
M">==T)H^]B&\%-]'!(BQ0:/9.FX?(CH3DV/$Q-/X.T#$"E:74&J]PX8,?9WS
M'O/GC-+J>V.0=MF22!MRCVP7:-5![8!WN_O8_5U\[ &6*6ONR@D=_Z3#E)K7
MW"BVYP]DL3+(][MD 4YU+G??9J@$P3*C51&Y4&7VV++!+ELV+#$LD:V&O2'U
MA#.PC1X?-0;A2:/9/J=1Q<&%OF=.\; #PFMN<- 0),&#9.#(<ZQ7WU$6#,W*
MY6!B#D<3HX$Q5%@+#M1)<<NP"Q]O2@SKF:$?FC1J$#H'D7;]-?T6]<6#T!S.
M";+N3G9JGQ((PW;7]BFV2-8^Q;1!90U5&[NF0E\*O1WKE1I0 9\ZXG:0T$O%
MZ!']6I;?Y:6;?FG6"A5GLRR2GMIVF5OY4A:K\ ,9R(3NA$J%U%'-^UTH?CDX
MP7#<S+\=]?M'VZ[-CZ=?1[ET%5I&16LU08#C_T\BS7V^*5I=;=F_-H!-[MBJ
MN MQ) O10&8;. BMD1(Y1=(@$PW4,TF#VFDPE1*S7*6[&Z><AGHC?"Y9^XAG
MBX?L:?X.CVY01GNG),V'J)GA6'(WPG*W]IM\Z:[=5G"LFXQ:+D\@.R=B2R')
M55MI^K_T3;)@O*3AU)![PO[P N3LKZ6MSXG8Y)9$EZ)$BA(I2J0HD:)$8-Z2
M7-4<49+'#6-1^U0_+(04%:9FOS?L*/T!=MV-1B=;O34$#%,B8?WT'-TI[4XO
MNY,QDI6F=\P('U9-<NZC9M"RI' YB^8JMP0636&3K#N:14O !,O$54'L/5V7
M;+[$'@)GVQ&F=0M!L5%)E<@A4/742N2=$-\'?A7H8#-H2*_3&\<K07-NX#YT
MB!%_%[+_UF2*>R)[QH0UKTHG/U! [\0'/Z\__5H2^Q>]<9@=^CXW]#;WTTZZ
M9W'T*!&804J") [( O":61),.X.S>#>U",27DF"+)$@:3Y93$DR[XZ2A&_4S
M@Y0$21P0&RB81Q(,.FK"4$\1B"\EP19)D#18,I\D& Z[@Y(E08FNHG0""W8"
MSY,K)]_6Y_1EI\@>(BC[SA8D\RJ_81XA>Z!;7XL=<Z![+=F\A5LO"2!Y7^RM
ME[F,(LW8@7!F[-]9!U&C4A4\ZT8W6!G!?SWV7W;WE<./[O2D]8N@@]\JN6&2
MMQK,6V($UZC$=RY--F4OI4N8C\\K/KNB]CO#7O-CJJ+2WMF)^#L$5[,Q1NX@
MJWK6566055JGW#KU./) [=/62T5I0I2D1HYSC-P-0XOX!S!-'9R%U$&1]5AJ
M"3;"B>C'01 CP2-Z+CMA(V/DMQ/&W;,S(:U(@=BD,B%0EK,P+:$@4PJ!"H5
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M7"M?+K]>WEQ\2CAA"627%"J#0M\L%Z[K6GCH:+!<PYF6GW53,^>Z9BC7+KR
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M/D-^>SHKS.%J/R4'5%MRY^:!*+BWFOFJD!?<8KC-/+39\(?C.@KLL7*+FZS
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MUDD5Q?DE<5&"..VD<HRD/-3?X9FJH;XZRB-*!XDG,O)/BK-+\UWK&T$>(VE
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M=W!]? ]!6#.(Q1OKBK@:*ML+S<9&TFSP.'5[%.GBEM;4?8;]8?5Q@\'TZ(-
MT$I%:FUY!.6&-73#1!1DU5J..TBPL](EF(S&M]3(_)Y0-*]3KF;I]1,/1<=>
M.W5YAT,WR.#<XJA^G^L?Z1ZM"R:'O0S.Z2S4@7!CL0C7SN)'L-#]I(RQ7E5'
M9-O.,\)&\QL?**MMUD95K%-'?'[3N.J2T4X/Q(*NFHMJ"-17FT-L-0\)HL7$
M"]F/2Z]:D '[QOE2,XK9Z81<)8;#B)W%CH^%@5%\YF$UWX/: =@[J6LB#*/
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M$-I-0K2;"$Z[3'&BA#JS'#0+6PC\9ZV='>O\B">NJR18416J*B6A?63=;"S
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M.X@<Z*'P$,R5%BQ8TZ&,4Q])I5K"<E-9D$Q0P?%0-XF3*)'3@82$,B$A)9C
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MVH00%\V.>M%B;W;(E!@O=!:OFF,A(1@3E)EC/Z^&2P>(01(-"*\#JWU'P;4
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M8PF@IRT>@/SWQ&2K_V0!;H/.#E^,+L;?U+/=-J2;>6UCC^"QN/&)MJ6;0$7
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M+;PM6G%,H27'8'Z:,G=0[7_R[.G9.UI?F!7RMK "M_O';UI*&3U+Q.;C]L
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MR1"C+I&H^@J($(!DU*DL&I$X@W>2Z,:9$XDS5F4331-UW=*9FL+GP Y4!T:
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MS >.>ZT_$KQ6^.[1=G08-+T(2*BXMFGH=!NYTU+P_^='-4F,SN8H5[!:T^'
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M$ER6[)*Y^N9K^[ZM_*P8E@)T-G$+\OPT+O-C9W$9K#$_HHH)JP6ZR7\2BX9
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M%#^0=1O>4TL.YYSCE7%[FD/&A!R!Y'$31E#?F<D1U'EFG$=0?'ENCNE?I9X
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MI0A($6BP",A@:8V"I>A$><L(9I11TD+]V35T/]Z)9;R[7[&NDL'1?E<$7U@
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M]I9$\ #Z>^X[$H?W'XX5H+**]OH.7*=X<P+_&8ZN_,?7''B"8L^4;J<+"O5
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M'=?7F'_W.C? @W.WW+AG3:?]<$R#^"&2"-ZSZF&Z/>8E)1QSY%J@@1%8IAC
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M,ZV)C?WYMF >!TUJ%EW%3;Q2O42TB0/.'3MMY6&L@=6HTX"]%)I[@>>[> I
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M7(>_9$/]B2##BG#^Q;\5"?1I.AQALS"L$WK\@'N/2?L_@>F_?/BL>? ;^%N
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M"G[1:N@TK8:N1*NAPK0:$E7S&:_O%E7SV9FJJ)H71;.B:E[0_]CT%U7S!0?
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M^Q95ZYE;N+D>1_PE\OE<%)P6ZA9L='JU)Z./,*]<I1>"F-:':9)PD27>9)3
M I"0<YJ01+\32PYV$4>Q$>U$9^HRB7[)R_,D'P[>4:-P@4_Z0!Q--)-$%PC
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M@.T#$J72ER.4M;RB2G)-?Q43\19]A'L1=G7"U21\:OA[[D,T]9=!6&]'JK@
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MZQYKJ)Y# @DWH*6(M:3/"LVRBM^'(P;[^T*AES2;4 ,N,,$2'_X5%)N24^*
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M">J<A;J3:/H\^V0Q\;\M1-%M_&#] V;_6QI5#K;XD@A9\' 1)[$];6+4&3B
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MI2!MH=ILXGKA1&IR9>$S3P2RX],ZQ0.-$]DX]FOB5_N7L0C&/TTXYO?'M]W
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MC#@,BH@D1'T,1%%AV @(T- <:6Y4Y@I9N;DB498C.L;!5$0"5J*IY(V0RV\
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MJPL70#8O:5&TM27WVHOS:5J"S[:K+5:IKH9+2S=R0T)KWB4WI#7J;T$9.^$
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MP 7QA[EB[ TI8@]<QE%%RM$^_!$Q8K;/JT)CVF8E9#;-)Q@?4\)-DB*EQ'J
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MYBIDB#L@\#]2]2.6CD0WDL(*6!<T HBF2H#["_DOB>04'7BED#(ML!H1COO
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MB\CU$X,@OT#^!*;T<A'WHF-&]9N<=+M5P3FG'%354"=X5]:>TU0WEHB67+W
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M;6_:2!#^CL1_&/G4JI$P?DL"(L828)-8=< "M[E^7,R"5V=[K?5"FOOU-VM
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M[*X#7SYZAL+CAD]IOI8BN)R&57HC$0%AB5:>='ADS!QC.26G.@>"24II@GE
M:F)-:9[9S+3)"4VP4UK F@B1E3K-.%ALQQZG (U)&0O6Z2)Z),EG/FG&M[&
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ME\)CUYLM8&25:1$M&?E;=3#'.#1?6O7T54>+ICJ]$XE&\RKE?P!02P,$%
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M?YXG2W+GG-^Y]]@]9_8.;T^_O9Q472(0"Y)*E2I=*EXJGI3T]HJDDPO# ND
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M4!T4MT/L0)52-&2PP^\^B@$-1C>!::7Q6)88/ACTOPLW.!B W],&B0 %!L0
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M?/TQ6 QHU":B,2[>1L7<,;/3@<8,7+<!4RK(K'"('I&'P+B 'Z11/1Y'B$3
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MY#&2R88R@9!& H1PO3'9]* ==X(HB>MGL00FP,VGN("8)V:@D"":E6$@QOT
MC.G9 -6L@M%(,.0B@S2OF Z$9(22MB+(@X/.L"<* XH$G15U4+0Q@I>>8*HP
M/C,<D4:(Q)C!)/#%W;C1+1 )#%( ?A1?$0'5.9B8+4+10"H"GMU=/*BD:&>8
MV%; Y.8 4:[8*R^:&P]@BU@"O-:!?4P50>YWX]0$#]L>$XA5OK@CZA 8.!;,
M!&AYB!44&RF!H$9"#Z!QFK 8,$SA1L@.*Y[ #5$?(G3)0UJ"E.!+.-P)4Y'3
M"2(V7T1*M_$9#G;(S";C@@(F%1[Y#+HG0/%XO3862$#B=CI+3"BI'&*&*)%
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MR6-G@]&MQ>3$L,>(8C:%F!G#*W%W'-2[_&:2+JA%5!@YAIE -\$ >>E>.QZ
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MZ-$H$@1V^U@UH/_J[9[X%1G+]A7QP#"Y&B2@)7TN(H1)'WVS9YS7:WMW(-^
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M7#*=M0\KG/VA'53WA%B]-?S#=5;^+<;Q0+A61<52%G>F;]8,Y>E(NT7%*CW
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M60CF>M.1D0;A+0QU#9ZF*[-['FWGD\CF5*AC5M3Q5!B7Z>1EK/=%[-B-Q('
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MG0JE<Z.$C=<T?>FLBH?Y2@Z8-M49UI$GGBZG'MR</:FMYR_! 8-E$Y$]/LB
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M1KJ[.Z6[NX92NH;N(08D!1%U]]V;=^_V"_P_P/D]=^?B.:<Z:VV(,^C4%RR
M\D)B":B"6K:-BIO4KEFTR9@:4<^8?\"_=]OL-H8*5&1.;$9-"DF]9/QY0[?A
MN(%/#5M4N!'?=\=B=/0;%+EX5XW -MRR@\[&*7Z]!S8^7)F2U,NZHK[#5L;0
MUD@XUCF!:+CV I@1V&A>%50^VZ#H3<4FT\Q6OQ4=Z/<\G-)=ZJ<)0&@YC(L?
M-ZH$8[L(UA3=Y9'%.Q5^?R2!0=NF$DN<9@YWU#>I,A<>6_ ;'%(+B[]9N)ID
M>:&"^B!NT*^=[$+=!&GBCW8I"E^%V>Q;5A5R<=O*GT61BE=:35BE;8>_)&?&
M]2';ZC66NJ]Q#IXUBC-?O:-Z"50(BM#NZA06.+R;Q<WH*E(UM].2RYQ=GZN5
M:VA4=5UEF:B50":^I THF,ZK&O;([7&U^%$J?F#7E5FO(F2UVCF5P>>L&X+'
M2\U?DJKJ.;PYEEP2])J:THS$!E^7(I^.R&R:(T]"@\5WD>=,7N]6"T.N>6(\
MC6:-6\M4# &C03@0,QFIHU82:L^X,4I H$<Y\6291/ '8UBQWN>_><85QO4;
MCMS=BP@;\U%X:J:?3ERA1W39) "_M&>>\)^",BP\.M%HP&X6Z@P3T50JSE5R
M\ZFA$<& G,#CYYDQR(J[+"@C"0L+K(>4#V#S"M]\]/CPK:UC[#F01$^_ '\4
M@\,I]FPL0VMHN6RX$C'>7#*"5O'&&T\2)(DA"]^9_[U:LS]CG$?&V8%<-""0
ML<V%I3W8%LFDR*BJOH&C%/V-U6$F^R0THBN.09?C!(:*C9EWVN?J%X@/NM>-
MD\%WLW$SX&KA@>5EOO\\Q!_#X"I?NFVZ=#II];3N,"$]YQ87W.N,M-/T!"F;
M3B/]FP9<6?H$88#UL>Y$F[DY'B@"%.(8I8M2Q :6R.*7'#^5O6=8;<TFB&1*
M\008\4FCL6V]1=#/G),FO+1@]8ZT@^L,A9U99Y0;I7"*EK?66&IUO86Y+WC>
M-/VO!2U08G6J6K8%_V36J6'&GU/.2,>_"!0Y0IVO;I).4YG3GD5^N5.+V]JC
MBO) 0'Y(9,*>Q@S5=EW"ML*:A>5$?WRJ)I8+5$<F>V3 N'LCO-OZ^L BE4,1
MZ#&W-W5#()A\.MLQ(=H%M0(N)NA]Q:.O PARXRY$$;_Y]E&7)$>/)1H! OLE
M8N[20WU048[F>6>1)N>C+;0^_10(>+V>(3Q)[]8.7R""!^9R@M!WTJR Q (U
M;2\5G_^B;*<><:>''*?@>]KL!Z_HW;O/[CG@+<V$;ZC&=,5=K!^M.1GHP&PF
MPH'VY,*M3X3KQK%9Y+M$#87-ZU4]PCM.B3@YM&?**;FR1,P\.</!4T._=[Z;
MW?/%M'%\<7_<ZD>V#%:_>#[CR:&4E0MK:0)M)G?$?9GHM.A<2^ES!OL=4:$[
M-.5Z>BK1D+-J$S+YD^NV>(;TKUUH8Q533E>"#R=*LZ-EZ]I1?RG&O;.+E/Z(
MN- 3[2LF?W=GUT3T=!L=S-Q.;VJ0BBX4\:<\RU//,57YH?S+D_=^BNXNJ_3$
MS&(IJC^A@91#LZ BZ)/'">^NI2,RG/)K-;8G2R<OS4BE<MEDQTX)X>04[_AS
M_YZ#6>(]<3REOCYC@+Y1=M.2BQ<7GFQ1+W>F\U%[(]!TY5JTFE&M0Z7!Z-"P
M5,N3^Y@9,8M&0CAND7G*[0MITNE"4H:QW.WK'UT;S=X;*J"2@\KV\A"B-7LN
M=UFL)L\1]A>=#LG%G^F]33=#YMG'C2]$5!_(HW^QC*F/Y4C*:-7G)!%Z1Z^5
M>>XRL>HVE;.6U(* [" IX65N0%0V,\<H(>P=+[L7KW#C^4<>!8UGC*Z'&Z]I
M7H99>0F87F4UQ^)G[HAI.)PG-A6CT6W2@TAE7,++NER)!_AUJR%BB%)08@:E
ML8@%$W^"5'R=:/@:430T?8?!3(4X#CS[B'$[9L3MY<NC9S.,PJ+[P6_=FOBH
M'U>PM W5@$ 0F]64NQ_%/\WV1'03NE0EAL8VS/E5G@>[W@ :E!E>=.*.W+H@
M>I5%V,KMU?M0A'JA#XVV8I7JW4Q]IB*+2/$1Y^C;62'HN&5OC24(_!8X/;M[
M[Q(NA*2B\&22,P*8\@R*8\\_K@4)Z?_D238.SLXS3?A:WLPJE62(MM@W%#X
MM4SZB](QW,*P&E18OLFSJUAJ#C)T\"KXO?K5S=GS^UM#%%V:\L!<YTBR6.@8
MPQ<JZ5<\0%R;[L&2YXGB:D0Q/))4BJW])?16:=NL8J:%QYSV+CMXB?.#CEM_
MIR6I<S[M\@4JAKG?6E5\Z9%M'-S#T,1-OGJ!4,XC>LY#]M* M(RS<',:Y5P8
M1G=?3:_64'=G5:=0IF?1O?WK8+EYJRLHG'I7KXRKN-4X$4\*#+[PNK8E.IEM
M\*#F$?LB<*J4AD02G:]V8'?[5GTDSWWBHMW$K0JR(\M:+&X7(#-=HV1XY8G7
M-\@<Z<=6;R+4_4G<2L;OV'J9QFG%9D1,RI>]O6B$_*1_SUGE"V<2]U8A7$@0
MF/[N;43N447PB!I4=.[JY>4=QYB#VZN#C2-6B[.P<J_'B+-)/*D53@9R( YS
M&J%SQ>%:-H=EB,,AE6PS@6R)L49<7&3(^2V&%W"SC8 ,XTT=79N'CI3T53ET
M8O'GD7D3$4[BI4+YHIGG_6*L7^/[(4D0AUE-3H[70J/L"2B+.=_:7S!F? <F
M#'@WQ\1VBIU[=#AEJM(\^P78H1X9W$U+84QZ!(].553'Y.ZT"[RY0U]O9GM!
M0AURG:\Q<E0W>:RW3<>7XLEMO?KLY@+S^BY]W*I378H_('KZZ<M-H$28,58*
MW\ZKJQ'Z$7EFB'0J S]0NE'?QS_O" TGI9?(!%@;TXC&@5B@NA>_K=&E>6HI
M (QA.>VFO*(A1ZJZ3C,5V$&V76XZNEE*KD/K&L5JK%SC_2;BLE)/;H5R;)H*
M*5;5J3F:I^=V&M4EV<97P3$"Q^DPS'J_Z(RL2RN'VIR'/MZ30T*U_B'LFSVS
M<DGCG].OTAP$_,] >_\#T@S7V/Z'T(//$OKVM-@^1,V+?7X8___TA&;9K/R3
M*"=5R:>NM3@=UX3>=:WE^$D"1_^<.I\Z]:)+^:4JF_=D^IYG <1W.['-+I[:
MEV11'46G@#KW(<ZUFQ"1+4D[ZS5[:J/NANUJ5Z$UG.O.7V0NJ_,Q5D6]O.TH
M ;%$K02Y9WN>2!6M=+);;G2KV3L@+,4W$%)HUWI_'M)2Y6;4LG-'^Q@&\ HR
MEJ5 MR9Z!92Q5#G#G*_:C-K$RMY2Q<WC-8C1D-.AC;3 (08AAA?>ME5P9EZC
M-?IVZ7&UO^X^U^:$(R(KC^<OR,:XQ^MF4'&@D6UNE7;?,&,AD]([4](T%69(
M.K%6SR6?Q"NU9IW-Y=FWC]=L3&:18G?)D$P:_;),&FC2&+./\=MU..EJ.:%'
M13.YSNAY44!&Q'@DG96W5R!./$X0H2)*XW@*[)@HP.7PVC=_%WA2M)#3XY>,
MWV6<M'FV@VGPZ%*@YU\>@TN()D>(MORZ:3$D'60W\#LDW982G4(]VF=_=!FP
M 1ZCRKDY*<4U<_D9BMW2OUB9!_<ERI!@L;U6SKQ'&)$2Y8_8;9)QB:HN=A)8
M/#Z<$3YUXY1:84I'UUZB +,=]?5^<I7..#)JREA6?NQ]UI533L\[?H0IR>$3
M3FL,'G]_F5)JK*H:%M"ZJ(A)UDATY3+9*%-.HL,Z5G.%_BA3_YT3R;*]\]:N
M[_XS!'L'*S6EF"ME8O6!&XJ.MLG/155/;2'__9Y%,7,\WS0V]RY"L$[55XOC
MS(5GTIGIKL3O/H4J_9M75M_;_>G K,C!=7"^"&/$?U=8ZEO%U]D+R5XVY[4O
MT_@4B0GEL;K7<(VDZA_>4PR/V/P]_7FMMH#)$.J^3/CF@FHVX'0?M79V^.:8
M# YVS-RNV#E>C4:J3Z8FJ>ZA>_/-(V,\P$N@0O#EB+/_O"2']C&69LSL18*6
M_%:G9<Q%?&=*[[?,"-R5ZGV1R68&S4+6':^+@@P% \6]W/#Q\P>OTH<YX:^J
M<HO8*O(P$N[SF40WP,>]!+MI%.+:?&3N 3^G_F=9^B4\[VVFC"C*QA(R7)'9
M5ZXQ#%18=U.(IIBCNO/[\4DCIKVJG )ZW6+&VO&8=\*MK( 4=01!F[]LF.^.
M]P%W%^2RG\?N,<WRM?OQ)L;3@4,O\%&]*^42:L^\Z/4:96SDXTXE55] <Q0C
M7@S'V4XR6E//WP5GC:=M55#W%>.AJ>8ONJ!(*YN8D0#)9F94_9AB>4K-P7>;
M"B8*'\PN_U8*L/!=>QY3R/\T5^I#.OF!897))#$E4T?ON:[6X-[XC7L21$P
MMG G"/U"14D@O7I)02]8><^6HO? ,DWE%+WO;UM>>YZ<);5^ "G^4V3VZ]6?
M*G0ND 0M]C9W!\]J,16 *A;0P)L#K-ZP-4_#DG79$!?I,"#Y)!P11F1-LOS
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MR_4P76"Q(GTB7""_BE@?%;8V-6BQXC9OT"($V^=(I$_\H,F2)L]\/UDF:5)
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MCD+LE;>ZHNR:&O16\7<65U^Q O"]1W&\H<+BJ]QI<E!D%VT8-\<CP#&HN.(
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M2JU@;/@(X]')3X-(Z#@J:>CCP:C5E"2&+3\^PB]P?0+%$5M?B=_=R=&A?"J
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M3B8%(_K^G$R9O*JCRDGLJ/>T$&$S8Z>1R=I&:D>L=:'$PO[R.SQUM0]_PV$
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M"VY7_7X0=4,Z?PL&EUV].RGVD5<Y;)F:=98&!*7A/;*L:I"6.>"%S;DY61E
MWM9&ANR!TT1^':AP,10*N'SG1M!$SVC;O2:L,J"J- +O7!!U)&U/%N*/[)E:
M9<#P+/Z78YGHDFK1(=/ [E)"5H1NJR,]4);6&/VG?):AWHEDC+2,%\NIEJ%N
MMP@%PN%+?P'+_9*^C-3"$?*$&9IC\?%SO !'A*J+-6%_C=@W,7469RU;3(C?
MB8J!S-T*"Q9#%IVG[DHSG]OUL?:ER28FB9)ELLS\UI^6JS!:8\S5'VY*G+<3
M8<U8X24#I_R36,S -^4 P"W::B<J1F'.90]L1M^?G3^P3#RHBED4 G(S?35@
M'VO"^BN)%XLHA,XKQF!-;O22/)$ TX [4%LG*BP<_B]084/L%DKU?M1\HR9_
M1S<1.U$RWA+L"8?1"I[\'\$0<E@4S(#9XJ8U>H%\&*=OW[Z?1N)?A[DKC:@M
MIFX(/H/?/WV81D4'_H*>'9[/M-(PA*^/KX O$PT#^/KYW>[Y,M+0GR^Q0E/[
M07"<K!CA#@\(&Y /X&2*_06-PFA.?!06D)U6"NU(BH5_6DP7!(5M&!Q>A^E'
MD-5XK[LYRQY.,7V2E,1TA^'T)K M95N6@=-KZ[:4C2P#**\%Y[_Q:U%_E:"1
M.;Z)"NF^$I[K2+(X7*UWQ3D\:&RE8,BQH@&X^Q/$9D*&N M;<;AT(_8A9C1C
M%3LX6?:29_4O^5C5O.S-UTC3:.<B+8@SO'>8)R%<YH/L.K>"-:9F!['!5[>[
M'=TP&97@\6Y^I1[4^P5B6&"KN,?DB[%O;U1Q#NL,^KD29/B\XZ/<7FOGI)V(
ML9PI39@FJ[',>!C'.1UC,:TEN[DBLQAC>BO:.%R -.*W6&,5\*8[Y&4Z)A\R
M ]'N6*F@M_'/BB6&V#7*H>A.5H@E3PZ7]LWX1^$G2AQ6%V_&/P8_]^1EE^QH
MZ,?@QG$1CQ8"QN#(J6.D$?TH^G'IXFA$;[$5A#76N5A6EB9K^92?)?$B8C"1
M/]! K/3BR/^63N$PGO(:N28Q+ _@?$Q-]7_%4&T;!VI%5VIRCN>$:A<\3]^>
MO'6PN'QU'+]VI>47<2'K"8@_02'DWM;UI:(XL$^6*/QOK;!F;G>L*_4$Q-3!
MW/X[=B@;#E^[4OZE.M! ;BU3D!&(2I#$/5 2.SP\:\)N<<5N2<ECPK/J!6EO
MI!!%(A;T;O=(G4FQZ%V%$7&W3)DP#TQ\!Q>W\H@8AZ[_+D2,R1KX:)SY_KN1
M,<3SWX+!I=^_.RD6]T(+JZ!!"9&C]+P-^$=+[('G2+M-*Y,;E_(*%D2D!PE9
MO0-':3[LR1M+0B7!P]@G7<S9::@;,;31,-JA1!:GJ)(HPTG(%?)EKE.W@9*U
M!(S()H$^=4GX*N(H=%2;J!;KD!I%&P#=U2HR(+;P^:B >E@I$>HXRJ$!N<4*
M-!U]2G)QN.ALP#YT(>/[+('(K^B)\-V,>%42QCO,CL78\L_L7IS+X_LZQ*.Q
M)>&E >9J1G2U^C1B'K+@E$")!.IR<5F/UB)F%<7B!PZ^"GWY A"_P_,DE-@A
MM.J>+$F(V(@9E[L$K_:D:5S3G AJ45IV Z1[XZKPB1'Y:.Q5"H,)\ YWMLWH
M[:[0 !A7P\<&OB&#1@;*Y8A1@].VK!TN#:+<61<Q8Q^OCT0,DSG-ZHM.&:*0
MW0; BJ41[/&<E0!JI6/<<2_OGB7QNAW^&F@8C5DU;P@!BUTJ7DK'H<Q+FE4,
M<Q(RU8&*T<K\%0[2.L^VF%%O,9M%; F =N%O'TB@Q<R1L&B%[_$<GCG<U-6A
MM<@_&+%X<;84N'WDG(<&Y)8;TXTEC^KSNUMSY02,%TXK\[GRLS",?+&T#::1
MDIS+*P5=B+"YE"BABA'K57#71H=-Z2 .Y5C#%*+:B$1L?99>.)FB;YA>4^4'
M)*Y\S_VI&JV<ERK+",4G.4;BA[R DU^MOJ:W+/*QJV52#W+&DH <,QXHRNQ,
MF9[# :L.^6B+A:S/*,</6-23M"&7]<W::.C?CS]C"G,63WT*3NN*&U%;C$:3
MV[._36X^N2-^$V-_FG__X^S.';TZ-BOOLKP^*(9254_/:=2) ;?EPDI!<6CI
MM6AM[M%'9\1A;'H9G\4BZ._1D\/RCR5T_:D]QS3 WY"J(4P#ARE8C*AM>JH\
MA 74CHY(*QB''(]JP-P=C=8@M9B"$AZ+71([<3@';:*TI_K4/=6G W;Z.);I
MZFZ96-P6&3NW5S.W@M B,LGAXN1ZP+)$10R*L4A56\]"5_FE(.()04BDEL[5
M96$$*\(L\N')"O(XW2:MDEA,@X^J>/!D=I_XL&UR6#^A!S46YQ:(L#]0F& -
M#61V>Z#1(\?L"4B2:,6NVH\H[)M1ZH^$Y+WR]@8G/"^N7-2"%7]Q$N"4O3-&
MN'A\F<9"X6I9H:V=%NR.O?%.7ISPL'FS_E])/U7>QHM*0_,0:X=0#IWF!LP6
MRW0_1D^$%]MQ9POV>L060?;R>(C"\9!8/0M#><(L)@(EER\"_(AE5DZ^E"A<
M>FRL"+,/RE.^S\ECJ,H':3GG';J=^Y%C8[*^0!C<8[AF(_KH+5H[3G'?0L%X
M TP'23IAN!LA8V;R)Q1G6>\A?OJ3 +P$U%<)=)E+PD5SP"-X5<0QN214M0'Y
M-;W!+_&5^ Z%D!S45?KZ\>D>RXF=4I#%:XN]+A9@?96 .2-9A8\!9DBMX$1J
M=H3M3"Q1XL:8[ C;E5@FHQ30'%\JD_[5-<<3"K\G+].%0#A?3/$8@=CCRV>3
MQ%V)2F;6>)424I3M3##/T>L4"] UVJTV=?E62YG_";$E8M\P.'PR:O(%E[8
M<2*<0?2-=PH=2MW\GB 68Q:NM<! &0@&")PEK.Q!S*"DE5WP.$U<V9,@BQH6
M*$Q2UU(81L]@%1OI76M*RKG;U0ZAKHLLCKF_P$OTE_\"4$L#!!0    ( )V
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MFT3$62A415^U]T<5C#*75].5NU)H4^%7WD H<R!1;+?.EQ*%^EUC76%?<#&
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M, <4$\ON$_8PR5=XZ9,-X0V=>J_)I2)^!E2"QW'@=6!3J"1*$3HH>ZN6\"2
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M17NL#A(4<++H3\^IE)Q[C-884'ML=5SZX23"IR'-4^;<$=<+$7?$,-NS[:E
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M">74]%L8+"D'TR]Q-,.,E:E@)L8F:42'MLJI5E;6#NQGG/M&01NXJ"LIU(0
MLE34E.E#ZYQ,)XJT>59+]>X2:@/7>8YPR&>>_6".R<\C[M-"P9"]E?!02R1
MJ6P=5APNG^5.S?AZ2Z\N3C#1'N<3[W!C$)P0[ XY,'?KLZX\V&J'!*NMH)#&
M+-(4B!WKFZY%FKW6)'0;M$AKN^LT99'&^_4$0BEHC@3D%ND] $-F!ON64D*O
MJRS>(@;*#*1[N@U9#1KB,TB+M [#91;IYLJIE6^D-W[H1S/TND(H^X"WTJN)
MD6B9<\U;S]9_IDA<N=%_%)@DOW"4<(")ZC\G].(>IJRG7O2CYY>;RME*W%=1
M1WF0[-T5S[]_K#!) [+4ULMYGYQD**\M,BFHPP%ZN3M2F]?=4U\\EQUSH$Z<
M*(VM'BXF,)<Z#KWZ4LNA07D:JRFN(QA;<?\UY?0'(MLRFE^_X]\NT0LB_#G\
MD;PE=90%*!^*,J/?;LEJH 3S4BU$<!>D,V*!(H_L>U_1JB)G#$69X:94N2V1
MBU"">0,7GQY'W7NZ> @B?.D*_/ Y3JED[LE=+B6%OI\"X3.MJ4]XX^[58.0T
MQD'Y+F(-.Y@'^AJVV:N)G0C4"K99@>@X=!NTS=I/L%_--DNAVO%KJ6F;S24@
MM<T> )A*ZF#=:$@)=I7U3<1!B:WP0+>I# \-,1JB=5:+X^;3/=0_$(ZA7C<[
M:KBY):48)"DJN7UR10E".5B5/4@=CK4B<-7%E3M^[)^5Y]/H!<VP=H)5EAL_
M#=*O4?PM1<D[0?\8;;89_G.,%94PH#;W(E!I9D5;G\RYZRJKA;KP)9/&%E=,
M9<[X7W.NS%W7)PGPR:><3:2I9\3/?K9-J*M,V7FFO0^&?0?FP3KWO[Z=MY$J
M][\^]S#GT/T31(M2J! RYW DH'3_ZW.-)?"B12F]D$H''ABH<!GA&[#A18OF
M]+H^LVLSO/EHT?1QC0]]XA:>H00QK;T*O2CY0X"!"(Q30 <.T">[FD^K5T,G
M#W"5SVL9%#"O;$\(*\N(0^XQMG6+OF#]XNT["M_19ZQLK$1Z8=4A*7,&3OR%
M*LNY-E8P;V^J2/X3^<G;]]B _/<CY:QPFI?(FM@O(8)Y,-,"@#\LNE-ICY6S
M ^+;J2&)GX&TE3;=JLP?XBW+V[#J4#DSVG6$5\9HXJ&/HPAKT12\DT1W;RNL
M'_J+C.\]6FO0'+63O /5U&@S:*UED;>VJ@VLYEQ[_9@*VA&;Y VS*=LPH&*3
M!HS"O;Z#\ZZ&4;C7=U!B4L Z5:,PI=NE4=AV<1>,L=\#&:F9L_Y,3FS2;16$
MM%!_A)+L*DR3S3T.AR\(MA4<8HW'KLW U9D-I'SC9\RO]78M9/M9FYQ\)U<2
MWJPMLYM-L=-JC)_]'W)&%]OD9#NY[6LPFDFQVPJ+Y@J2=@970P@%EE4/33D4
MIU45#=:^Q'!&EBY4=6N2[CG-D(X4CBTSIQ/I0#B:;8A)=G"[N+%MOZ7HWUM,
M]?T[V2;P]V1EY=D]<HCP<HRSMSQ5,-;*0IH0E+R4.:]/CL]5?G)5YBN+[ (4
M'$NA#:&YWASM2@]B9(.=5!WCJ\G(DEVEEF578/U2 P0HQH$&52)-L0EZ>?U.
M]ZK3+J&IP $4(E"@5L6!B=D^QP70T4Q13&4@UHIQ.O0QH_M%NX0D@R(ISVG_
M)>L.?<L*F7I/M4>/.=])"S>/6N3+CU&:)5O5ERU.#V\X=N"_<T[,P0F4)'>X
M7RS0+ O>#UD>_*7HZ4MK'&]H*59><84()<!>(Q7PV<O1?4[,/OIG1QP->*X9
M_!Z8UG%+9*&$Q-:K6*65)<_=56CEC:Z<ZF 55\49]6"2J9V#D3W<,UKCV63'
MGBI\NJ^],Q5H-_A\[T!E/H<EL=Z5&V..V<D\H66UX\M&090G&&!",<X)_.*O
MY88?7A?/6H$(94L=C]TJPKD$ B8.P["(H-CES,E*9HO3>OOC*&CT7G*;H'F0
M72\31'=>W&K(?>Q6Z(4/6*=^S^+YS]#45." B6/(Z7SP9_3J*SENRHV]P56_
MW[>C2-L\<01(P#SFG=,HW<U8S7-0KL\; ;-5I',!!<XCGCD!03EM3$I*^O;3
MD&]L?D^;\?:VRR9X6P>0+$]Q.V,3;^JMK13!/]M_*F?ZX:=+IA]^[UV'X9XX
MDH^%MSQ$S3$>5XF@V*P]9[^<=%.O9S!$X7J;,B$3Z;:D?>=O*(_+$$*!)<5]
MB4N_J9<OZ\E%1E>N-AXN[\HL+E,L>;("Q5_7NTD-1DLW$0?Y!PXENLG;C.0>
M=]D4PP;@ZJ=YA6.#X,C#P<VZ2)_T;E!NC.&X]NAC<U@NC2( CCP<7*<-R,/U
MCF5.,+(-K.O@.OT41\N#3X/\ 9'1&N_,3F.K*SQB<5%PQ.+"Z_7@:W(3)TG\
M/8B60G_R<FL\WYR6G*L@%BX*CEB:"V[GNP2A*(B3+W&&TNMH_A3[D:,4J.8<
M@T9#+9-%$TXC(TLQ$36G,N44XRE"A@1,_40W[E@C2T%]YJ59 Q\HQZ!ZKBDC
M2TD,*[FF*$NI0+M!UQ3GOD7ZKBFC(5 +5BX;!5&>8 #U%ZKG]S :NKYR\MBM
M(IQ+(!_2>P@C@W(+-2<KV6U4RWS)<TW9?DN#>> GNX*F?+=%I.4TXJ<;4>_L
MC<: E,/+U<#0#C506709$A#Q]CVN+I=C9V\,R2Q04RX7J SX$>G+I5-GO70*
M,\O2BY8#N5RB,N!$I"^7<66AC(]KW5+9NN8E<@;)8D91$0EUULFX.*,^CE0N
M4)EP#=(63$_FCRKMB8D'9#FH)9)S2"9<A[3ET:\LC_Z)>)@^POKR.(=DPG^(
M5Q,D6Z$$$XX)WB8HE;MI<SMXXTZ[N"]!8L(QJ()61;.>5]>K"MVQ;OAA;B)E
M7"9\B/3%,ZHLF=%1$_DH9\8Y)!,^1_KR&-11KDZ=O<&HVP4:8%)!, Q@)CR4
M*HBGWFY6[$Z0#&SY 3L0$0N:";>E*D*J86 Y=28HAE=.RY&8%5 )F DOIBH:
M00WQ=(J6HH]C9[E 9<)[25\PW3IG3[=H6@64@J*>8"Y1F?!?JB"8>J=.]US7
M_#!:01F7Q(_)FGAJ;&BGSOAJ_''6S04JCF!,7/@%5/3J;&B]XM+_,&OF$A5'
M,):- OW*4ND?B?\PBMD9)(X\+%L!^G462K]H_'9:\<NH5"Y0<01CVQQ0_1YS
MG%4?1B1GD#CRL'S_']99*,/BE/HP;_>7J#B"L7SG[]71P4Z=O>&HUW5;@M3H
M:5\&QA&/=N120^'!HZ$="YD-YTHN_1Q75^U@).OAJ^,.I/!@RKLRB\L4<_BK
M[?#?!']=NSG68+3,G[&G=<]V'QX\&@)-B2)PW&:#X,C#@3-]W7#4T="24U#U
M\&#*8;DTB@ X\G#@1V] 'JYW+'."D6Y@#=7*T\W=-+)47-G&1L4FGL/O^@D\
MFD\8-!JX2CS'9NTY^^6D<T2AG=H#ABA<;TXF9"+=EIP4$E@@3.E\7_'C-DZS
M]$L<Y5"R+\+:--*^WF@,R/SQI!;[J(2)(T '>4$,I)T8 7J.4A(2%P4GK-%A
M-I"SC 8*@CEKC^<:(-<'+=$P<'"$XR(GR,E^)A!)H16>78 <N)0$4:*>PWZ8
MN3^>?;*H5RBC94M;G@AD["(=4?UT!>.C/P6 = 64A[PCFT.[P70%SG.*Z*<K
M&'< E/SFRT9!E"<80). U(N%'W<M'>YUTA50=JL(YQ((T#0?M47D^N)I7E:R
M:ZAEGR!3WJ=CM_5JQ:OA7"JZJ RD_G#L?-J'&?);138E7$Z2?)CR/1WW/\ZJ
MN4#E),F'*=?3<??#K)A+5$Z2?)CR$QKW %W\:\KE I63)!_&@H+Z,%VU*\CE
M$I6;;!_U7;7'79@>J!5$<@;)29(/8Z[:XQ[,L.TJ4KE Y23;A]'0X+&EVG,.
MA%/&93'YAU5/^G'WPZR8,TAN\H*8\J0?]V!Z:U>0RB6JMF8$&1\=05LODC-(
M;C*"U$]_-^X!\K:H)X\S2&Y2@)A*?S?N?QRI7*!RD_;#5+[;<??#7.TO4;E)
M^&$LX6W_PQSUEZC<)/PPE?%VW/LX1I<+5&X2?AA-FM?_,-M9&9>3A!\&$JV.
M^Q]%13Z'Y"3/AX%$J^/>1WEF.8?D)KV'T22&'\<25@;F)MN'P?QXW<Z'N<0P
M@)G(^6'#>>G!GZ'K=;P5NO3SNF#> -+6GO0].2^A2#*!-.W ?/!??D'_W@8)
MFE]'T=8/GY,@F@4;_ ]_1T"DTT4Q6N'^QRS<SH-H2:&FZ?809*+KX\S9#8K?
M.M3+>Q*X+LL[>>.AXV*J>Y("E+Z@S9&K1T8_1J0@(-48!:NDVH 8O!.E6E4L
M[&54!ZL!]V>%J>GGZP 55X#*[&3UPW0[41VJR4@#$ABG9^WY]!!O62I'K?$P
M3YRX%S2\%$]0P3A4ZV\GWV.C._'W&'/$B2[3]#Y\0&K/,9L%AA<<).Z *;7C
M2LJ,#S*TVS(0&(P2TDXKT5!RK;&E5 9*H4!*,CB3&A>" <_K9M(_#2U9_2JE
MUZ*L*W.X3+$!!^JFV.LZ*J<&GV7A-R9>3_75CN =74?SMQ5*D+_(^!:C^B-C
M'CBQP9H]02J!-N!Q[4JCQX",:O1X/&]\-1Z[,?LVK=07T4K<N]MMQ@(0M_^Z
MBI/L0*C(]B7NX(T[P_Y0^_ S0/\I+T*1,%D$OZA;CJ5!;5V1M>SEI82DW;']
MY\#PUR3A_<SV.2_L:)I:0?YJ F/+6@@,C 6L1*8TI)S3(X=FR;U).>Y?S'5%
M25T  F.N,BTKUU<->T(SF@C C/!NX^@=)5F =PZJ7?%>KX7M<WA.O:%DJX4M
M+C$:0S8GTX_4MWZ2[+ JJ/E0?=XM!^G4!:22KJ*$26RV:CSQUO5\'N2T/$:+
M.%G3W[8]Q]9(SQ<0[D(800JJN>!OA34P$@34N!;8([X[)"C-2/+H^\4"S3)\
M3W_&>B_^F[]43Y<F&0?S )!G;@61*N$#HZO73WPWLN0X52GQG;*4"K0;O!P[
M4.!O$X0/J =_%H3\9RY^8V\$-?%=+ANVYL>! 4<Q/R-0>J5B-<?X+3F1*E]\
M>6Q6$4H1!!A5W)!8H-QQS<A'=J]UX-?[@M[C\!VK1><T2^^WPGX8J],;$W]]
ML.6E ,;0$[3[[*LC2\D];1Y"/!@&WJGAI?8<=5U;87GL5A'.)1 P+\N&103E
M8#(G*]GAI)?GJ\D*C9;"Y6WL:%SZ3>3R:L3':30 5:&Q*R\<2"DVD9*K*?ZZ
MWEMJ,%JZB4!X=ZOTICVRE$30IMXD0&(BYQ:T9]&1K52U-=^O*</UWD%'_/RT
M>NFW ,K(]?9F0UC2?<_!U=[,D_5HX#1YJG"!<*PO?!PF$G:9<W3-U,\D5G.O
M?S7N0G"STCR5A%A,9.ZR(R'IEL?ND".S%"2F?# )>:XFI@LX)C)Y0104E-/)
MM,1D)Y2+4F"%%!C2TZG4-L?E]'"2+!&.%L$%8C'5UUOB1[,5[Y2Y;.(-Q]W>
MV(X9TL;)PJ7?8G:N_>>XFTVY44Z5JY. RR,^*R_(MIA:JS(S7>_6=;DJW95-
MA%;C#Q/RQ!F7SAKEU+G+,,*>@&R>,JBVF-4J_^"-"B]OBE2Y2Q&AR<M+JN&D
MH"*IL]"_M_@@N'\GIX&")8_=P^L/AT-+^?:LFO,D<"1YJ-R*2FXQXO7)\5ER
M*% W[4F8KRRR"U <H3FX\-H0FNOSV:[TI*>WB]MP$*'I0LM5D=>%G 'C20L-
M3#(\'(]2%^GD&*0^D3B*1&[%D'3-T;KV)9'*0EV$3' <43IPX;<O2BB;J5V9
MRC;5GJ';.[DWW).@)0):Z6YTT3JGUVDJ4^5EPK\Z\4!QF%___3Y-LL*BPC]=
M+BC\*^_%CY8\[?[L[]YH..A92C!OXXQB$\]A=OW7>'5F<U? 18N<9DO76>FQ
MPF8?A\47!'.87/\YW1J376_XU;DMW<0=V _(9ID>=LO;;9(@83 DJSE>T8!*
M\#VIQ&+Q87 DX\)<<'H247L!\D:0BNXIR:%$/8?]IK.LY2*?[9[CA'SJ]I\/
M/"U'W,L;02K0+F2Y,AJ."$Q4HQ)\_O[K2P41X%Z8:$#%#FJ)X(B&$T=HHNZ4
MX/-?7^\JB #WPDNW+0> ,AJ.")Q'P=<K,M&;7 ULJ:D-A;<ST'!DY3R:_39^
M1Y$?97<HG24!I4]9:(R^N7T59)40]7P3 E@<,;K(H5ZP("A:J'(4;<L<P43
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MR1%.,"L>:2K=*>B1G:N?Q;--"QJ8, 89U=*=4FT "GQLR?%=^=C3$E$U*5_
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MES@3SN;T^)*83A>+PQ/A,TJH VPT0R3G]_'7<9J#.Q@_6^RK.G";'+^"K^K
M4A&^*KZJ Y5:;>>4M]M7U8I[U<!2Q?"Z-XH!OV2;"B(PCJK67',&E@JW&7.O
M&O!KN*F! ^.J:E.&4*X<=H5IU%F5XUZ%E:<7](ZBK<RQJM30ZU\-QV.GB5#4
M5L2Y "1@#'B8VG5DPX1.+)5AMLUU&20PGJ'&;(]D4@',D2S6%"1@P.2T-FK)
M(N!<>UY+&*]KP-I# N,>:EY>4-0 &X*3'?X.;/WU0]P)M F$9T[^<N&\<@K
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M4:3:H+D.3M;;&K$TF"MVM)5ZMCW!.Z,<#9@;M)T(# S2DJIB)(8FEX&6[,Z
M@;D?VY.>:_.C?3'*;)0.O)]OXS2;+E[]4*'^<ZFM1X)3ND[O=2IKARTN/AH#
MGLWFPYK&G=%XY-1*I,]J"10X'LJBZ@Z:?HG'HA"8(7;N6]9T" 4X<+R,;90<
MP1A=UY%4D(%,>%Q@$#V$S0H/B@IA3XI2?T$MZP;GF'I%41 G7^(,I7=;A/_>
M$9]6O/:8XHDEEUU=.P5W43!.+ D<$]ZXJHSO:C*^>Z(4R(MA+<:?PS'A(:O*
M^-[;]UB3]Z<NA%X@]KE:["\A,I'IE">![;<TF =^LBLO/[DL5#I[@W%G:*D
ME5VY:*$SD=94=95<:2Z1JT*R,TM5%9M=(9> X"0JA1*$A7EIYR1J]!JD#!1<
M"E1#H3J=U@9?Y7)ABUJ&%UQ^5(/2A'Q7LBI6L\E3.4?EGH3IXF#[P@?UVRK>
MIGXT)X_7WS'*W33BQS]7&(4:UFQ5K*J;_SM?4(PSM2)&.'E23:7E&0S&PP'
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MV\E"%)2'\$;=JRLWB1B5%H/0)/?_M_>M38TCR[8_Z6)L@_WE1A@:>G.B!W.
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M2?PA=O'9?V0V'J $"BAT][H"ZH+;*#SH//AI/$!)GZ9-\;'(S@H+*G7D*F7
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MN6:_D%="Y>5!%JA6TA* XEUS.M*M&F97I6>TE7M+Z)>AFA536M:*(="W_LN
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ME0/S)RI6TX3=W%RZYW?:0YVK,6RG1^#]B?J<SL,K\AHGY)',ET&:AJ_AO.C
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MG95Z@!\:)FL"XJ)$(6&H39$,;^S*7TE$Q5S2-6"R6%'5T)-* $N0/!)0TA*
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M>TJ53<48Q2?!V;:R"-T3?AHAX?,P=:$6!%(<4IP-OP"2K6RU3M9,078,A5;
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MTDM2;7OSEN!C:!^7@,,2A-E3>'T0=]H[@7&7XC%(5"D*O(#R<I2[@?, 5N2
M'@#*VD\<R;?S(+E-(_SM?V*UG2JTM?N04:!4]MJ/-42T)2)-G3U67(QBRP\2
MAS$Q\ 9Q&!#K!=.QU[^M\E>GLI$WMQ5D)Z=7B&BK,FCPF[*[I#8K$6XM,&\$
M)YT@O1&0K*Q__XR3Y'^FV=?T"0=%EN+HMBC.(Z^QI'VLZF,YY1(M!QW>_ (]
M4-T%L3ZN%/2*+-C5V",H$C7W"(36CJDZ!DGR_ES$*2[4V9QZ+>U&5?6HE,4J
M03-4MW,65S5"+/T=YUR&)B^"40:1,!!>-02#E4'Z<-XF<?@QR0)U<IM..ZL
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MQLT6,$8D.RV%'<>,^P..UIG%&33OR0$QU\7G4&.+(!VDM0\"VL@/'X<!O?Z
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MROL=6($T[RW.7^(0%T]9HKY.E'>R>J.HH%V\5"SH$TS:G/H$Z@X(>KBZ5YS
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M\X@),7%8X@A^N$JC[A^XELSC>IN&< N);S#[WR;1^(=OX0%4]"-A^ ,-;%8
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M+-,<H]/#FNQ+(%^N8:!$@T:$DO8(-D]!VEP)YPN^_L-@$1+GP4#3F?N<I6]
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M])52RZU+#%)ZQ,<M0T6 ]GEV/I$604EF#!+)!<!_02R^B*XO?#;'9'K2OC0
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MV.EO4:/ L>@1PWL0\D=\RG):'5>C!*VTBTU_EYQNP;W%FJ*FK2>'A+&I%QQ
M(_/N#C2&#E2=W@ZAI.DT%5#EE[-T#E-NRR/H@VM,0ORXP@KB_$]!<N9<M5I7
M6,IN-J^PU/0+%AYICFA[3B!\\<OHK(5P@Z6Q$&[1I*-T1_HYQI/RR" !E',5
M.XF1%\K($0?0W'4.)2TPZ<C#DEZ5NRS=/^/\^.%X2K(+QH\L[?9]^X!NU,=B
M-(0MCXL97T)@+>F-H#NJ^Z-J ,2-X-H?,Y_'-R7/XYM<Y-&9LV8",#NN&U>H
MU'+D.$7G#&WQA!,<DN_\QSG("7222^-AN@G*8%13:'>WI27T^1%M=]83-5U1
MZVV#SJZ5PYJLO?J2!N<H)FU>.],/AE#LZ 87.-32"R[P.-F:+O*2LZ3)O_I6
M-/G3W\!VH2Q?I<!5$N\N]($?K:6G.IF9=+:@+HQX$1;GPS5Z"@\X.B=X@][]
M].;'WVU0,QJ]TFS'JPLHNC[%F:]>+6/F2[<N!NNIO]^IJ=)SK,T>T1):YW&M
M!>'Z#Y!2:1S.7GCL5I@9DTEP)<@+B  OW0O@?X85>M66QQLU.8?;VK(O)92*
MY:>;9J[-1G.*W1T153CHV'NK@T#+N%L0#!9+P$<O."]C*&1YG15E06L?7W1\
MH*,];1:#'^5"6(6V!Z)=-JR:]07]M?I?YQ[1>4R%T,5I97L]9 GE[?5@9?$Q
M>% <X%4L^1]X*/ 2)'"GIR\GFOUM/OW6Y$AX!4TZL*?>\!]<5_]D9S:+(?P'
M;KLZ?>1M@D#A;;<)_&RF6$@(E5E.DP1=Y3D4#*5%6IAE2:2?D:@2+.TAK*95
MT.9+3#+ =45<WPUJ>_LG:4LQ'+1]':=4,$.FF$S!#)9>I#4QV,X,!O$CG8F&
MUE>E,O%P<YO'J_^I2W2W-F,HVI0U,@E0-Q3.>8]Q\<MUCJ.XA/]2"I>BEU5I
M4E$_ *FV-8)&&\0Z5/_P3X"FLP>5U!EO.6GN6()&,2:*S"C 9CCNFFP7N/A"
MOI.709R66KN+67=;[CU]?N2I5W"!.GT;87#K!YS.6M,<,K*@4^;:2V@(NH[C
MT 7BM'R)TY?G!A=A'F\Q6#((:DR5E]^0_VX/$">&OUV6=Q>0_.L7G")8UP,F
M)M#Q%*30%1KEN#SG*=K%"8X0=,S0%E?_A(&^'N+P@(A.C MTS'*,DO@7G%S(
M2(2(-"OA/THZ+O])1$L5P<]DL.)< )-DP/.)_(2_!<<X92IW>X%N]$W^N3QD
M.4L>_"I^B]]NT'D8CJ^Y]_NP5K0L2"=M&ZJCH0@S,9=BZ*T;1VRSXOJFN+R+
MBYQ4)DK1/Y/ @(T;O,,YV38[J/$B,96FW3R&FQD6 +AL[W=/A_AT@FO"-/HC
M$<.D.?..F@#Z_6W9  8<B89C48+:J3NSY-]5=_?0G\M>AZU#S9:S>X=)^.M8
M T[ IV4.+ #"8G"UF#'@:,N#>BCZN]U@:\OE=70VAVWIW^ZF3SO9U)J$_:Y+
MZVAN9PI@N'OQKH_KT9X.7[^/8T9\ ^\?^F=P!2_B"]]>Q&O*A2:P9EA[+'$>
M];T6Y2=,SF;1;?J""^J3U;3XS,:P9?49<C:<(!%=T;L$LO^R$5 [A"=>H&78
MC)LN[@R_*5#L&'_.<*AE ,Y<J.=#7"#,BDB@:-A#=#J141H?-_AJ,%O>(P,O
M^2/G1:).DV;9P6M$SI1'TK> Q)K@(ZIR)Z8$A:09- F3<P1]S^3\F1:$Z(CZ
M7R)R&"W*.$3%>5O$41SD]-8MS/(3W*)B])\9&06]D _!Z\@-2C,8H"2S1VU8
M_A,HQY".J"BA7]LCB8_PF@6=@KQ,B5006YC\%2SA^I<D#K9Q NR&U/-%2'B+
MKJ*(>I.")+ELR)0,3B*=*<4LPH&HGD,R:UB0F:')HOXR2"@#WK'.;)'&U3)4
MOK=S&H&/2[U>;]$S:<"(/E'J3GGV$D=DC&-PJ=8&HZ#3A(QPR+[VA\T91SP#
M0"@DU"3_C]'4IM5T=+1HGM5^:M\&,S'1-\P,QG#QX%N#,\7C;ZZW?P;;;![]
M?!>NBT7I&W%=(,XPZ7[&*608OZ<:H.C'K&C:=(:#V#+J3'GK0ZOJCZH!?(S*
M6I)/9[;<) QVC#EW -2RYI8"8E8!4;C=<W6'U6S[]_E-7)RR@C"Y@^?L=_$+
MCJYHSFV#^ZU)P]F\^YK&KW OU@P#UE4]$)A?-(<#'0NQP?S;JQ>: \II0CEE
MJ=F=7JC-P+%PV38#Q/8D]Q&3P](9/^)C$(/3Z 'GQ(X_!F2ZVI03#W!D*,A_
M?,QR2!BI+\G+#&]1LA>:CS[*JV$WJ!D8<2-SV3V(G->#TP,5K?GHC<RO.SOD
M#!]F^Y2>O%UJ@25EHJ\5EA0(%\72#61?U<E)H7.M(*JFL7\[[E1.V,TOJ\#M
M1\%Q76D9A]",$^\-#%O&Y5CN/U5C6R=8&:W"JG/M7-\Q3*'9V=%3"8;.$7-]
M)&@=)1=%A,6<QW A^3XH< 2!IC@M*)/L0'R51K<T2IV0_$"8*$9? DX:S69.
MY$G<BO%69)0W6Q@&\>-L*H<4U>_-6(@.YMWFM=!4P"53-14A-X[33,O3(2UD
M7IZ.9YL!RW"_EN4&-RKR+E8#EJ5TBP'+55/_C, )7#A^[S>&%S%*60T6>TC_
M%.2_X#+8)O@)AV?V_&!T3U)ULHAV)>U]I+2-4=O:/^P;\<3%W,0IBB#$L6AZ
MN92'<53U)6(<4O9DXC/^RMU;Y%F:P4.<8YM;0G]7,!_*HOQ,X+./0#)$YZJP
M,XA5Z8KP+F9^M9_/<03.IO4YY^^F.H.XE+VIZ.U+Y%3HVG3L%YA,#J2 N<$O
M.,E.0%U5+FQT$]/J;=4MK\.-Z%=FO>@!B>M75TWS;X=;@,^H[>?6B:Z-/]%'
MK@V^&>Z_1[[H\ZC_3];:E@-02NT %KA:UHY=@-.H=N8$5$.BXP6T@ <M-^#"
MN)A50H"9IO\(M/*W2IO;*Q$@HU=,P<ZW="U34^EVF-!?"8Q> O_U4:&9L']A
M=+@K*VAZ+-/L[["TH.XQ1"@NZ)_!-Y>UO.[H4ZU!HZ.4$=QF[$_/.0VBOE ?
MNVYFHI%.MO:J,=J%9S]5>_8PTX, HGE<T(>8[NZ&M9#3V<;LP49K,S.=^#:5
M$#P#ZKQS.N7X)<[.17)!<5&<<50M#GNX]!7G$,450*9S2)0""7R:WO2U$.E?
M8/J$J<HWM T2&@)7'#!V]6CH#AXPX3LR22;Q3<I>%G='-?5"O"UMO4&LO7O-
M,)4+:.=RS]/ 3'^GTP#,K.(9K#3'(PYQ_ *7!;J;G$Y/>X4U-+@0*RM4E6BX
M7NZ1O0 _>=O+83$.75SU2G-8!95FH8[%P+6"_Z0IO<.>!ERET5WU-CG&Q1]Q
M$GW,\J<@P<] PKA_9>IPUOPOD_F5%FJZWU6O96@"!FXT!,,A,AZ" <GJT:MN
MQWZ<Y?@_'X\!,9.S'?H4_"=A\CJAC[+A#]5\!+WYN&7OON'-#9N;734W[KQ$
M\^#?]2)Y@'T]+Y.O,F#Q:4%<!/M]CMG+A_M=]4!B5,D9]K?YX$"3(S%2E^\'
MPEN_BW&MK^9RQBFHJ!V"9F*E Q1P4#Q2U57]!14E.48>W68B,T&F\'+!!)9S
MK 8BRP5<F.8O&-3'59)D7^% 75R?\YSH'TUKP708:U:",7\"^& $5 ]!M6([
M"*I&<2YB2S';2EJ/[Z##M[MM?AI>N]N[0[#J;>NSUY$T."=!#NJR+JT*J3SI
MDN;\D@8ME$,VMB,?6FO*-/&[NAK(? B;=T_Z?*D*R'(1Y;ZHG"4X;-6-)\'F
MIC 4;J,,,6A/P![R[(3S\@)O/TJB5" S' V,TA$MG<X6A4J+ES[8ZDX;^L*I
MI.JOZ>B--$UBC9,C)9<;]!D[C>K3!V%?L/01Z&+/^@CAT9@FYK@EFWNZCPF8
MV#EZPO9E,)J3G<R$6]6FQL:I\M2T(]4."%]$<B'&N;TN@AO-74S9$_CV8_LS
M1K1\)S2&LPL)_CG+(B@K8R:I [V<2.00]2K)J]M[*&-:K+2R='V .IE%4WXH
MR/,+1*A>'>'6I</K]H*J8"$_1$P*.;DH2?$VQP5T/IU8<MH@><^B*9X@F.(V
MI9EE:,$W5O'H.6.7S^/NH#E#6G,-S>);A&0[&JJ&0W0\Q V(JA'1<U9'4+2B
MY\)CY,4<N/,FS8=^U[/D">[UO$R+KKW$X\0CHA.J111VBPBNHEI"OV3LA-+0
M;5#)_&.2?>7XTW1NFPWB0G_I\*:45EJV?D=&4*^+8Q7EBDTG"DD;KU(59!>L
MQDIGRFJFP4*: 1*D9"D\N+W?4>U6O0_44PFZO>T5F]/D9J"">=41;OYIU_IU
MJ_.SP6J<.:PR9P*Z7HTYZXC3K# W<7W,)7EQI]T9LII]BM/X>#X^4I7T$%SH
M(_R/67Y_PE#M.MU7ML\$-]Z<\=TX]F;-B-+51T=&U="(C8WJP6GX6#-\$UON
MG6]BV?GY%)15,A:8(6IY-.5DO+D&6T!(%)[!^1(RPP2 7-K/.#]"'< /WZHB
M0]=9^H+S$ER4\'<]<V#*2+9,@TE<#F591S *HK4>FW$0-Q#[B<FLXS?.B_#,
MJZ\GG,9$17W.RBINXBX+'):NGX[<CDWA&+9:]L4B2WF%"FXQHZ ,Z"+R9\ 3
M*P9?E2A+H*I U"MK2DMHY3GXFZL43+B1@Y"3@XB6<J4/VJKZ6 6*JRN?L,J\
M23!\) /L<%!5&@NS! ZA4)TCQ_3Y6U4BJZE&SU.;XA 7!;C ";$!VD'MHNII
M'&W@/(CGZ9#E9;UN9F:3K*L3BTC*AU);0*<W9:,N_3-DEF#+#_M$#32YZ:%&
MF0N1:<U!5N:C(<[\Y*$[E!.1TN93A<6N[4R+P/@L;Y-Y?L354^BK-#W#B2DG
M6TI\XL]. O\;SCZC\W%;%&?J>8<BH'Z(K1G8Y6)LAG078EU[.?_("BC<MO;$
M$Q0;/3+7R<<X)2L4D_-/6]#C*HW:/V<%S;]XEX5Z-Q>N"'&B4BS-L4HA 0D(
M:$ 5$8BC8H-:.JK )_;)3A4?,/6X7RIJ-JBFQT.]YFCBN[?)^R"GN@XJU39S
M1=]IL!B0>XB*Q&7P#;WZF9CXQ6M:%0E3OS!?YN0&%_$^I3=!MRGB:I[>YP/+
M2^]&H8H>U 3V0ZG:5#5RE6Q3S[A0Z/=P&N-P\SDK6^1<%<[UO%/ZG*A_MRNB
MJIQ$*.'5"GTM+>P.'NKU[WQ&_5#''B@*N9;V0$NX4-XMQQQKMVG#',];Q413
M1=M,#2_T)2<*=:E94AG,[3<ZNC!.6UNY9RHW!C%GFOFG.E>;.R[F&?)S-,YD
M=FYHIJ203ZX?:G%1$90KN$7ESQM5M8 .\E*YS-0:WXD:T)1OLA<3-!*5QPZP
M+#P"=F0XF1+T%IL!$PASM4(\%O2Y$KSHRX<V?0Z;NC9%UT?"5S<SLS0ZV&P0
M!^FQM'A3)@1B(W 9S!",@=0)PBW<\\]FDDMWD251)T7;_;DL2K*UPM&B?LOP
M&5.;Y.;A@;W50^<TPGFG:2^=]T.>[?/@Z$-:+'V(RY)A6<:W:0JL>3@GZUJ5
M'.+2)B*8SJ;NUS^FW:W+Z@=G1ZBL&L+!*<LQ4>>W:4C^]AQ\JV(HW^,4[V+-
M&*3)PUFK03R97\$?4(U$G;S56(@-ALAH30!S-9X?,4G+L<]#%MX\-N7>J9W0
MSH/+<LCSL-TMF.P!L/5**GL*\$4LI!N\PWF.(_+YH5R#[R\L ?]U<#)X6+70
MZ/9MJIFSH3*VZJ'I0DM2,;Z_5#4I4/4%YP<@2_.3#<]//SVI,#\>V%]+")#$
M,/-&>@PMMA51$M4H@6O?H$4)%U\/^0!8^1,4LB\XCYH<F9 )EX&&(SIR")EQ
M/5<[N-:5EF; M2&X$+Q5_J$)V'8AUA]V.QPR/U9E#SX&)28'53*!A-BI%_U3
MAG4BX)/X5V&\&9 WBF%,U!W40U%?9"ZN0K+/GMFC=7J1B^ 99HX/Y%30SLH/
MKR#.Z35Z5;FMR+=>^Z$(I@N$7!M,EP8W24Z!R/>8G-A;@L4#Y*3<IY-&=I02
M==HLJ#.E4HVPI8-R^F&#FE-UP)VJ_=,0*T[*^_ZD^&(9S!('50[6&;+@0BU\
M27.BL/9I_ ]JUE3^G>(Q2Q)"Z]<@CR9H!/-!G2B#";RK(,\/1^V#>D $(Z)J
M2 _EW]8\^"'Y4Q$O%_JI<'?S3#+(\?N@P!$8<,1ZJ])N%64>A\2Z>RH)@5]2
M0OX5$'X%!DY<7B8H@86^Y.@1YC*SI'[<2+[Q9@L?0?Q7-JC]#J(?0O1+B'X*
MU=_R4(_8F#6X?OI\/F[)"03JS3Q]*>AC,XA*(386=R_NA[)95-Q4;TL7E#5_
MU!(K_WIU+@]9#LKU"P0_4%[NJ?L44G,7[R\?ON$\C O\0)C%C_!:?@E-M<3'
M/5)>B\SE-'U6U71NOUU%L3#EQCY/D\<7&W"1UR0@2@.B1'PWVF[U:;Z'IV=!
M6RF[TGY?3F0.^; @]CE/;*ZUQ=M4,RXGVU;KSE5Y3F5<77&I0MY?VC;5PVVJ
M^G4TX^)?LEO+;N%9&JAZQ^6;E6D]Q'^&)@+G&E:?JBPZ7U3;^E/'OR@@PP;I
MI0XL*;J3!VD#"D3'1N2?/^=06.0&W.WMLP/'E?;6D,6!FGQK"*); X\GC5.Y
M!2PJXXGL:$?VMUG'SCD?<FRXS9HC72.MHX4V'6N,&&+-IQ#W+6]TU?J3UJHJ
M[O$7V%_53'PHROA([\/(%%'5!)4?J*)J]-:?<;P_0).K%YP'\&"BI< WPVR^
M6.H88?-ETJ+R&M.X,H5;\43!4-RF#SB/LZC&0@4%^B/ IGT"IJWKW-)E4S4Z
M7@%!*6@8>TI;;]/J5T8;O#YEU&U$;3%H]OBC@GU;G%9C"S,YK,+I1W#D5!/[
MH&,$Q>V#@OE^]/R?< 'LI1&<94):O03^5#D/*'.V5+LY*=^1-I\PSVLJ<$8.
M*W=9$02Y4>'/&\01]?\;A;W$_&LZ,JNY]<&'Z4@Y+*V3IVH&%[X"+MB0QAIV
M0@U95 W$&4YP#DP<V8DW8.HLJ&1.+XP356&<WBBNQ>?D>P]GG24A\G/Z+/'P
MZ-J8<RPL'L"B,[A/U[XZ<Z%K)@E.PN\N&&7:='!)&_@KZWH /W3"7%DPOD/5
M%@07FH'&OIQ#R-6<[HG94Q66I!=+9FI <R0G,J_+I9CDF^M'CS!UB51V\^:?
M.$_EE)/=+M-DK\O/0>*)']X(KG))-<+J(J_T.U^\)HIBK_%J=,(8]E_<:W&F
M,K:[>*M&<"Y:BW I$RJ(FP'CN:G5!,KDL2UV^N%;7%)U<Q,7IZP($@^>R>LC
M6/(8WC)\#9^\.X&Q\QV?_ /G+_C]Y9D0<+\#(,[8]=6CN=_Y1[C57]UJ('"!
MPE L4*?PL;[)4ORSTW_U;O_V> KBO"J@(-I(K"W-A^BAU: #>4W+00?OBU@/
M=$;K=W)F1H.BJWU;0<6'*O5.A:CZ=:0'2<-F\I1U>?)@>Q^%F&17MX,OP\W<
M LYFR'63WK@.ZOR,-5,)ZO2T)=5:7/0GNTT:W@2T@M/8"Y&>Q! OT2)SSN1:
M'V(=L;:,+RVIMH<S)QEH@AQ*FQ8/.*_=A_0!_$V<G.'V<4+R&;,1W>2=,>1:
MF7*F&@OBP]@=^0;1\:H#-!W10\M\E3DXU7/@A^$]"=V*3#)3H#UCHW[(,Z@^
M? %W30DQ 7\_QR<61/ SAO31IP/Y?HX#O=U[\G"VMO3I_/;!68]$/5TE39/9
M# 9)(-OA$(SGAP&P'/N\;-:C;JJY"#ISL>W,Q5U5EL>9W3 3\1UCP@>X:UD8
MRZT[5\X\3B-:!B;=HZ_D4(%9Y?(D?J&I+],]+4A>Y[^D/X?@_764Z;*;C8L<
MH,B$4.+)W.SB$J(96-+V/:OUD%UG:9$E<00TZ]@G2WW HKFRV)R(MXJ=5'@T
MTKH:&K&QZ\BB'2OFP#X %P/\)[RQ:5:;*#Z@@'6NYL>E=;.LJ/2-G67E9([S
M,4@P&%HA:,\]^#B)%@M.^%S&X37YV#[+QX.%)H]DS34YA4L!IC (:D<! X<;
M!]4#^6'E+,,R_U:RS_YVF'UW3L[)4.[Z/-WB6,\%NL3B<E8,6=X4EZB@2TS6
MM>36-:S&VZ"BK.M=!7 "K7$ :8BR,DA8]Z6JL[3'05[U#284-+TK,1[0_@V*
M.<\J?W?'G)"EHG1N9[B? @_N9R:"77)KXQ+IAG<Y"RXW44@AO]QQ)R-M]:\R
M^.:\W,"'M(S+RY_CB'!)R_BR-&4O.#W3XED?OA&!28/D^ER4A.:\>'\A]F%T
M#FFJ]2><O\0A-HS?7/R;;CS+B\^<>'JC@[&S63T<:L:#7;(>D?IZZC&=JU$7
MD\6+'ES /-6&1#4.NHM37WS5Z\B<PIN]CL#9TU?-RV06%O0)!Y"")[HG3(3G
MO JM_9Q!UE?V3_#7ZS]'6V9XBUIHH?D0[C*;1_F;.@"K'AJ2IS2#4VW##T^O
MP?S1.RM-#Y^!IKGU;>O2=N8JJ*:$Q7D\'X+4DT192XI27^,L*4<.E M7.&:
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MT>D[1@.8]>-V###F0&P>@Z^? K**<9"82XVBLPNA4?&BD!G2#37]?!,9$YZ
M$?9T.?PEV$/J@V/=U0O9&<6:5'1&@>9 <OZ<Y;_<0E%U<L8R%QU5;Q>RH^1&
M(3S0#XZ@54_?Q,>(K2I5<,$>F= N7LC-.-*D@C,.,WN20X-6&LIN4_H&-U:5
M.9/VL"@A<JJ'@W(XV2 PJEIOT,]Y)J+)CC#H<]#H6""]9,TZR3!0UMR7NI2,
M$23UI6$$1E93U9]P7EX>R*Q#^OP/?S_')YA8(ID:5?_TNMM-;*_#SX">I=TV
MB':D"&NZ5K$47A0"-%FO@;SSVHOE 0)53BN3SCZ@3^6]4&+/@T)HEIGR0IJD
MSC%SX-F3I*LP/!_/](GJ#3[E.(RI<XW\=X+I*YTTNCIF>1G_@_Y=RH)"WI;[
MA$6I7'!>^C#GAD;\V)!TK!J=77IRXV]03S@V7>EPE:5LQ6FZ(Z;^K__I7W]Z
M]],? F[&(NXS+M7 TH+35Q9+2XT]E?+^'"=1G.[A0OCV2$Z@+ZP:&CT[*/3$
M2#^+PC_&@9#?LFY/A9+OX?3$-)D-EW*EA9Z^L&A!QV+510(#!=#9SS9K+#)Z
M! U+_NRHG*(^03:QQZ^;4"&16S1[2/H4A =B'.877J6/*5)5)XNH4](N^FRJ
MQOUCM$/].8,!+#/,;,)Y'#Q]D(\CQX,S_AC\QSKZ<+:7H6C$I[22,$!(WN03
MO8R5I_.6#NSE65TI!7H \D 2J$=XBB14'7V0A)H'0TF@W9SN#L8<76?'TYD,
MW6X.7%*#H"BPV]@0/91IRTH'8C,B$J_HQ'Q)(YQ?9VE1YBQ5-OG40W6;<U\_
MGQN0!/,A;,4OFO$E^)!H;T2[([X_?2Q0CX#NFW>>#N(=%^'P3#D,>0X]NLF;
MBM!.V*0K>&I%4UI>1$<)$7D/FV(_[3:SN'OVZ!.+),A]HG8V0P,"$?YVPFF!
M(?DX(IL$3=KL<N,;6OS^-C>T\O;@^4SF,MXFF(K3[?$4Q#D(#GO.ISH*C76T
M".%1'H2'0E4'1'N@M@NJ^KA!NC$?'.$A;82B<PY1C37V0?V=&FOWU%B[4A_"
M;$9?<+[-5F6UH$6>3)BR*?%Z\M37 7K"9#.$L^0I@KBX#]_@-1T!%P1G?XV3
M1",<QVP8JT&=1OP-5 SN:) JJ/-5,P:J!WGM29S.E 450R;-5],>9.M\I_<[
M>$50XKOX!9Z1=DF6/<N<,HA%N!KQ)CC+JLZ@-EGW-[0_$E#LYKVG)TS:E$9S
MK/9ET1RH]B110=&=1@R=7G>+TJ?)S]#K+!4,[UP'TMGGRZ:,F:"P+UTF$/1"
MKL;NK<:[^B%/L@L?->:<^NHG<$/_CL(@SR]@*P:TF#!D5(/=*VZL?T^E1WF_
MI0LT+Z2&BX/CX]VFR9%T,#\D2\ZKJ:SQ,:;\4-Z)GS[+/$N!@B5/)' $MP8R
M.0):+Z3T_>53\)]9?IT$13%2.\AH%#_D<H [0X-K>T%T"$3'<%HWR#V?GDBH
M#+,&HBD#K!<RV9+V.3CBT1I"QB/Y(9L2+DTW3!ZU,)#CFD(>,>R)M*K0;""Q
M*BC/B%*IWMP_QOM#.9+B<K"IK:B383HE&000:^8RX:0>O;<1.8G%NY@FO:[R
M[*!<3;RU\! %-#IA(&OC0BO<8S%\6+P<SX,(@S#+Y4[>U.8%N$BG<.4-3:@V
M=B5T"Q-K]5)7@@/A&E<" IL7MU4F$TAB0K@\7*71#7[!249OQD=AK-G?ZE6M
M'D?B'6V=<0?5/6F4 -=W/4'0C()8D[=7MP^/OPZ.IS_<O'8L\"Y6T.[=NH',
MB9?J!@(W)];Y7)0XRM3V8Z^1M7CE'FV">X[][M)8'"7QR]/SAYM[]R;AX#IW
M8X)76V2]J-\9BVWSH7D1IT0JK[/C-DXI0X\XS/9I_ ]R\./.!+4?]>_G.,=0
MB?*._#E.XC+&!?F-S$?$FB@VW34^9O5)^PIS)3X@9Q]!W%<VJ/T.ZAS4*I=A
M_2FZ;7 ?0]77-E5#5V_H;<Y;V'X%ZCC5TQ;ST^;^I=!Z<B>^ZU]+Z+SPT/+7
M.1]85/QG_*U\_HJ3%_PI2\O#Q(L4K8']\-_JS8'Q_2<W*JJ&A?C/;R5B(R,V
MM'?>W6G30:#WSE._K0'&3>Y$]0%N,9<61]3]KD^R0I+'.MK,>S7&@V *\I*6
M[41A="-BL_F(6S[<[[AZR!)22&G!RM>=\"_DI/V1M%UL!VP']';GXWA>9L>#
M 1&,^#UL= KN":+^^?O9X/K0G;>Q]7'KM< 2'"TKL'1 OP66\;RDP)(1OQN!
M'>:>(.J_?F<"RT%W 8'E<.N#P'XI\.Z<W,6[:?LIW]T+8>SP8R1Z&\3Z(NCL
MFY0IV1HU4=&9<98,<.:'\(DPU!<U$8,6KVR;@'_1D!;>5ZJN;LW&L7F%:\BA
MXIG[T"EP\-VMHZO.13D5A1 WC.ZK09Q=7<_EM,<;]^[%;4F9*=(H7.I.$44?
MMG*9R?'\-5O4]*;C>;'9JSE>T/ F _IF$9CQ3L#TDY\[OP9JYUO='&2]EE3R
M^67]6M6(?DMKQ?62\@I#?C<2*^&?P.JWWYG,\OA=0&IY\#H-'[G.TI+L^I#5
M)TN+.,(Y_7-]F7SYA(/BG-/<\K?IZ:Q*J[/(Z&X#1";,AEY$2#LPZHR\:>(_
M+AO$C8[H\-X$@"PY+R$_+V$[+V%W7I)V7H[<O,1#\^(X%&2J#&G$?DP5H!DA
MF3=QP5;E7%VCU61)7KGJ=+(5LCE&NY"EL=L>W>]0@U-W+SGUEZ$30:FU!FL
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MPZ%9[42IP#$:T5F:M]!,_M5',OG5/XHHT4IF@?DB#A KD$L<;US!F-GI\KG
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M.+^*7W"64VJ6<FGWXU65'&)?*7L?/:0P:DJC"DRP>_53-<!>;-[K,=0G@!Y
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MZCED@DZ#/I18^>KE&=0.J<-Z,?/KX9(51KCJ$\,(5!,N,[;2")W$Z^LDB.5
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M-/.'#%70!+E/]D_/^3B*=.J"DZ2KB3E-BGH>$D6M4%$(K:(@W&+N]4!X@@B
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M04]N$=XB&&@]WC8((NVL7/L#7EJ)$;TB.\RTH#-[M%]3,Q 2.Q*F8%FO+1'
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MD+BS^H12D*ZK <SZKJD!QH!I0ASA,&46XUQ]$-2H-C1M.&V,Z=/41.>"DXV
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M@7-!NN)0(0ET436_'O"<4*]_3"#ED!=9&N"H+8W6_9)7<<D'N=P<AEC1+H:
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MB BU]-+M'.("LO+H\8!8#9BC!ZZT<(EZ SSU*6  )G=\8-\N)5'MRFO*.^2
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M-C[L8>:ZFM47UH6"G25D?I3='!I0%YX"'4T&D8#5A+D8!*.3!]SF<6?([IE
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M>&G>UD0GZ&WX6:X2"E52O=D9SJ#[VW&>/*%1?C+9L0NGFR256H(W/O')C 3
MK#>KA?!HRC.U%$[GN["R%.M2*JAW8$8.0289 ]:6*I _S_> ;X/9Z#'52>?/
M?5#JIZ]%?_YJ93HJFITKWU'A55[$VL1'3GNR8'>0H_P9(QRO:7B(_KBSO!(5
M]04+8?K;&X_X*8QC"A1EGT!?V[-FEDRN]UFS2?Z;<HD6]SC/(ZP[/S_G1X_
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M>TNA7#Y>&W!(@'L.T.6RI>1V,DLN6(1GG%QD&4ESB4LBP. *WJC3[S5!_=2
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M>86Z&H6-;^=4?5S]PJH,L5,CG.Y 5O/(10^O[L5FU#Q4Y9BLY5I ].@2 -V
MM/R@FN4O40H:=58_"GQK>2'<'(''&W&:(G;%REMWA.G#M96A CG9/B2(:J.%
MBL:5Z]"Z(R&'8BUI!?[[>WL^!J]^-"?I;;1^B1'/MP!^.E'/HT#R]&+G?-@@
M/X*>*U<N:IGJ>0_T7,CR;I'07!)LQ8@C-HL YP*M>E0ZKL3L%]A2\ H#07=
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M!,=C)),^+'65(LB[_%,19()P+:/(X>12]M]%15"^V6LZ:QFTP43ARH&YS(]
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MQ#.\-FCT-+DG'4X/24S_F;T_A'Z4T8G.%+#\<L7F\%)]A4K>D5121QQN>D)
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M#_OA#K:<-I,VJ"20G1-JL6H.%=5G"'I9D1[WYW1\3OY2,'M0D&)"=EZH11^
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MRR1^X]E04Q7ITGI4.LA^YO5XUP#7 AL4*"-^4*^R\/.*5#[(_N7UR-=!YV+
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MO=MHN<J>Z0<5ERU0E5PDK?!.4$($6$>RKUAA77EE E?*Q8)\K:;D3)_J$BJ
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M9*<(F3C%DP6$8>E6J?HZ>*)8F 'V*P @ _N$@7VW=,=T0J(^&0;##,^0@BE
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M .\#9PU)G3JSME-<LIRZVJ[':QD70*JQ14GPJL6Q;$IU9NRN,H7?)IM2"1=
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M39.L,%WI3^6I2G_E/?K1'%+C]_[N#0?]<[?RLH)KK+CCMG)SGIH=<*:52N1
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M7$A0"5(5,3%=NXJ@L-9*@$ BD3E?'84]LCB/H@NG#%+3KO\Z2OP<W,J'VMF
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MJ:.HQ/QK.,1.\8"I;CG$>D0N2YQUI4.LA_HJ6^H0LY>/FMNW,SX3?,090.F
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MX*-E D9OG%STAH.V[%YL846,IU4^J4,F5<Y/-UIF(\;@$*.H[\$Z3.J7/!G
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MSGXHM* CIN)0\-1U].']CD*]Z*G5PT4AE;:N_N20$,G:Y:0[2,&G/+R^A9^
M:B@1NS!VR7VR^#6B2*9;U$!Z\7ZSY'GZSF99P. #!W]YQ>91S+8>H,F=N^[
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M=@Z[2ZNZO/O$AQKFVNBXO/OHL46W7-Y4*VN<=:7+&U\PTZ8TVSW$%0\B[%%
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MO,R1RO>+YK5(' CZ.&! S&A$L>]Q/"!F0'4UKPEUFPN(&>#7 3L8$#,XZ4!
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MOGL)AR"^>+*^8((M(+1? #Q05LJMN9 PQ8GH;>SSM*PWW!/B*Z&@@/_$WK(
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MSD1-6.HL,27HT),^#S00.1P4RJ RHB!<O V7I^[QI\D/-O/YESY4Q*$CCP-
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M=;2V;HN(ROM1!;,^>P%+'ED\A=]Y8U=?+^\L]CY8EOK3:[X3>XOBKS_!K+*
MR<$IP>9^+Q@YC\/^G:\0@Y4I%S?6PK?OW-9F11(#_4C7*B\&-HAG!9NJ(FX&
M&Q0=3XSL@#KOJ VYRI:  SV& -J!4[4I!L+P9D&76QI FU\QV5@I'CZ[_R
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M7DN*+]WM>VB5,[VB)8PFUS[Q>PHBRFLAHSUD;L9M;YBT2Z<YL$5=Q]GRM\
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MBGB?:FP/%?!UX=[T'9?G_3GUXO1R]J]L>> ,9(WGHG]2!6J;OVUR<=X?G'7
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M,3 R,3$R9#$P:RYH=&U02P$"% ,4    " "=@$I2#+7:HA1:   U.@( $0
M            @ %B*P4 9#$P,C$Q,F1E>#$P-RYH=&U02P$"% ,4    " "=
M@$I2><3:C=Q"  !62@$ $0              @ &EA04 9#$P,C$Q,F1E>#$P
M."YH=&U02P$"% ,4    " "=@$I2[RBKF P<  ";H   $0
M@ &PR 4 9#$P,C$Q,F1E>#$P.2YH=&U02P$"% ,4    " "=@$I2.#<[38L$
M  #=&P  $               @ 'KY 4 9#$P,C$Q,F1E>#(Q+FAT;5!+ 0(4
M Q0    ( )V 2E(J3IQ_@0,  ,4)   0              "  :3I!0!D,3 R
M,3$R9&5X,C,N:'1M4$L! A0#%     @ G8!*4I/S,__^!P  T"D  !$
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M,#(P,3(S,2YX<V102P$"% ,4    " "=@$I2<,B4EN\4  !@* $ %0
M        @ 'ASP8 =&5V82TR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @
MG8!*4CF2:$X.Q@  42@- !4              ( ! ^4& '1E=F$M,C R,#$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( )V 2E(*TP+!)O8  / V#@ 5
M      "  42K!P!T979A+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "=
M@$I2*F[[ID[+   ;1PX %0              @ &=H0@ =&5V82TR,#(P,3(S
?,5]P<F4N>&UL4$L%!@     /  \ O ,  !YM"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
